<SEC-DOCUMENT>0001140361-22-014764.txt : 20220415
<SEC-HEADER>0001140361-22-014764.hdr.sgml : 20220415
<ACCEPTANCE-DATETIME>20220415170729
ACCESSION NUMBER:		0001140361-22-014764
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220415
DATE AS OF CHANGE:		20220415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Brooklyn ImmunoTherapeutics, Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		22830564

	BUSINESS ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALROY INDUSTRIES INC
		DATE OF NAME CHANGE:	19850411
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>brhc10036185_10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:btx="http://brooklynitx.com/20211231" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="background-color: #ffffff; color: #000000;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_0aeff87ffc6c40578b41a362360fa3bb" contextRef="c20210101to20211231" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="Fact_cf57cd4aa0524f5a95cee76898f58e27" contextRef="c20210101to20211231" format="ixt:datemonthday">12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="Fact_8359db28ff634441b860c33e1c52f466" contextRef="c20210101to20211231">2021</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="Fact_c8e22448b87c4502a0c0e7993ecb862d" contextRef="c20210101to20211231">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_b75e69355dfb40b7bfe444fe530ec6dc" contextRef="c20210101to20211231">0000748592</ix:nonNumeric><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Fact_8f4da43a33f64403a03756802f5c0aae" contextRef="c20210325to20210325" unitRef="U004" decimals="INF">0.5</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Fact_565a5991ac0445a8b9e9f14506915bfe" contextRef="c20210325to20210325" unitRef="U004" decimals="INF">0.5</ix:nonFraction><ix:nonNumeric name="us-gaap:OpenTaxYear" id="Fact_145d916fadf245a7a67bdeb44d432d49" contextRef="c20210101to20211231">2018 2019 2020 2021</ix:nonNumeric><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Fact_2d5f06641c0a4e39b73cdc701f6abe8c" contextRef="c20220306to20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember">P5Y6M</ix:nonNumeric><ix:nonNumeric name="dei:AuditorFirmId" id="Fact_10926fb50ef84807b40df791d25443c8" contextRef="c20210101to20211231">688</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="btx-20211231.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20210101to20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementClassOfStockAxis_CommonClassCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementClassOfStockAxis_CommonClassCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementClassOfStockAxis_CommonUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:CommonUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementClassOfStockAxis_CommonClassAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementClassOfStockAxis_CommonClassBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementClassOfStockAxis_CommonUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:CommonUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementClassOfStockAxis_CommonClassBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementClassOfStockAxis_CommonClassAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200101to20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:CommonUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:CommonUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:CommonUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:CommonUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20201231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:CommonUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NoveCiteINCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210426to20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:FirstPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-26</xbrli:startDate><xbrli:endDate>2021-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210526to20210526_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:SecondPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-26</xbrli:startDate><xbrli:endDate>2021-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:SecondPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:FirstPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-16</xbrli:startDate><xbrli:endDate>2021-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220309to20220309_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-09</xbrli:startDate><xbrli:endDate>2022-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210325to20210325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryAndManufacturingEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">btx:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325to20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">btx:PurchasePriceAllocationProFormaAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">btx:ProFormaFairValueAdjustmentToAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">btx:ProFormaFairValueAdjustmentToAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">btx:ProFormaFairValueAdjustmentToAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">btx:PurchasePriceAllocationProFormaAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">btx:PurchasePriceAllocationProFormaAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210301to20210331_BusinessAcquisitionAxis_NTNBuzztimeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">btx:NTNBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-26</xbrli:startDate><xbrli:endDate>2021-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">btx:NTNBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">btx:NTNBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">btx:NTNBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember_RelatedPartyTransactionsByRelatedPartyAxis_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-16</xbrli:startDate><xbrli:endDate>2021-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-16</xbrli:startDate><xbrli:endDate>2021-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210930_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NoveCiteINCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember_OwnershipAxis_CitiusPharmaceuticalsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">btx:CitiusPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NoveCiteINCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210716to20210716_BusinessAcquisitionAxis_NoveCiteINCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NoveCiteINCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-16</xbrli:startDate><xbrli:endDate>2021-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">btx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">btx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">btx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">btx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">btx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">btx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">btx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-04-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190418to20190418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-18</xbrli:startDate><xbrli:endDate>2019-04-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_DebtInstrumentAxis_PaycheckProtectionProgramLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btx:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_DebtInstrumentAxis_PaycheckProtectionProgramLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btx:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_DebtInstrumentAxis_PaycheckProtectionProgramLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btx:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200504_DebtInstrumentAxis_PaycheckProtectionProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btx:PaycheckProtectionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_DebtInstrumentAxis_PaycheckProtectionProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btx:PaycheckProtectionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_LegalEntityAxis_NTNBuzztimeIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210205to20210205_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:DheshGovenderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-15</xbrli:startDate><xbrli:endDate>2021-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211215to20211215_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:DheshGovenderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-15</xbrli:startDate><xbrli:endDate>2021-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210205to20210205_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-05</xbrli:startDate><xbrli:endDate>2021-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210315_LegalEntityAxis_NTNBuzztimeIncMember_RelatedPartyTransactionsByRelatedPartyAxis_RobertGarfieldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:RobertGarfieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210316_LegalEntityAxis_NTNBuzztimeIncMember_RelatedPartyTransactionsByRelatedPartyAxis_RobertGarfieldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:RobertGarfieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_LegalEntityAxis_UniversityOfSouthFloridaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:UniversityOfSouthFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210413to20210413_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-13</xbrli:startDate><xbrli:endDate>2021-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210430to20210430_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-30</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210415to20210415_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-15</xbrli:startDate><xbrli:endDate>2021-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210426_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember_StatementScenarioAxis_ScenarioForecastMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_RelatedPartyTransactionsByRelatedPartyAxis_NoveCiteMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NoveCiteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210322to20210322_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:InvestorRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-22</xbrli:startDate><xbrli:endDate>2021-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180622to20180622_TypeOfArrangementAxis_CollaboratorRoyaltyAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:CollaboratorRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-22</xbrli:startDate><xbrli:endDate>2018-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20120501to20120501_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:InvestorRoyaltyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-05-01</xbrli:startDate><xbrli:endDate>2012-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210903_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_PlanNameAxis_EquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210315_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210903_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210531_PlanNameAxis_InducementPlan2021Member_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:InducementPlan2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210903_PlanNameAxis_EquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AwardTypeAxis_NonQualifiedStockOptionMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btx:NonQualifiedStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btx:IncentiveStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_InducementPlan2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:InducementPlan2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_InducementPlan2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:InducementPlan2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200101to20201231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20201231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AwardTypeAxis_PerformanceBasedNonqualifiedStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btx:PerformanceBasedNonqualifiedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AwardTypeAxis_TimeBasedNonQualifiedStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btx:TimeBasedNonQualifiedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AwardTypeAxis_TimeBasedNonQualifiedStockOptionMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btx:TimeBasedNonQualifiedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200101to20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210426to20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:FirstPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-26</xbrli:startDate><xbrli:endDate>2021-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210526to20210526_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:SecondPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-26</xbrli:startDate><xbrli:endDate>2021-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:SecondPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:SecondPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_PurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:PurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_TypeOfArrangementAxis_SecondPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:SecondPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210325_StatementClassOfStockAxis_CommonClassCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_StatementClassOfStockAxis_CommonClassAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325_StatementClassOfStockAxis_CommonClassBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210325to20210325_StatementClassOfStockAxis_CommonClassAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210325to20210325_StatementClassOfStockAxis_CommonClassBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210325to20210325_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210325to20210325_StatementClassOfStockAxis_CommonClassCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-25</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-16</xbrli:startDate><xbrli:endDate>2021-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember_RelatedPartyTransactionsByRelatedPartyAxis_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-16</xbrli:startDate><xbrli:endDate>2021-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-16</xbrli:startDate><xbrli:endDate>2021-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_IncomeTaxAuthorityAxis_DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_IncomeTaxAuthorityAxis_DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_IncomeTaxAuthorityAxis_ForeignCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_IncomeTaxAuthorityAxis_ForeignCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220306_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">btx:PIPEInvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">btx:PIPEInvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btx:CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">btx:PIPEInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btx:CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220306to20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btx:CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-06</xbrli:startDate><xbrli:endDate>2022-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220306to20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btx:CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">btx:PIPEInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-06</xbrli:startDate><xbrli:endDate>2022-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220103to20220103_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220305_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331to20220331_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-31</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U001"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U002"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U003"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U004"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U005"><xbrli:measure>btx:Segments</xbrli:measure></xbrli:unit><xbrli:unit id="U006"><xbrli:measure>btx:BoardMember</xbrli:measure></xbrli:unit><xbrli:unit id="U007"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U008"><xbrli:measure>btx:Squarefeet</xbrli:measure></xbrli:unit><xbrli:unit id="U009"><xbrli:measure>btx:Claim</xbrli:measure></xbrli:unit><xbrli:unit id="U010"><xbrli:measure>btx:Defendant</xbrli:measure></xbrli:unit><xbrli:unit id="U011"><xbrli:measure>btx:Patents</xbrli:measure></xbrli:unit><xbrli:unit id="U012"><xbrli:measure>btx:Grant</xbrli:measure></xbrli:unit><xbrli:unit id="U013"><xbrli:measure>btx:Installment</xbrli:measure></xbrli:unit><xbrli:unit id="U014"><xbrli:measure>btx:Employee</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold; font-family: 'Times New Roman';">UNITED STATES<br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold; font-family: 'Times New Roman';">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 12pt; font-weight: bold; font-family: 'Times New Roman';">Washington, D.C. 20549</div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

        <div>
          <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 15%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 18pt; font-weight: bold; font-family: 'Times New Roman';">Form <ix:nonNumeric name="dei:DocumentType" id="Fact_40786e39032143f49ec1c5c715117f0a" contextRef="c20210101to20211231">10-K</ix:nonNumeric></div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

        <div>
          <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 15%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">(Mark One)<br />
        </div>

      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal;"><ix:nonNumeric name="dei:DocumentAnnualReport" id="Fact_a3ee7509a9b84b79bb335d4941a56686" contextRef="c20210101to20211231" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></span><br />
                </div>
              </td>

    <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
              </td>

  </tr>


</table>
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">
<div>For the Fiscal Year Ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_5fe75f530ac642b1a89755b1beddfec1" contextRef="c20210101to20211231" format="ixt:datemonthdayyearen">December 31, 2021</ix:nonNumeric></div>

        <div><br />
        </div>

        <div>OR<br />
        </div>

        <div> <br />
        </div>

      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-weight: normal;"><ix:nonNumeric name="dei:DocumentTransitionReport" id="Fact_984a68efdb7e4e3d9deff87993ad97ab" contextRef="c20210101to20211231" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></span><br />
                </div>
              </td>

    <td style="align: left; vertical-align: top; width: auto;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OFTHE SECURITIES EXCHANGE ACT OF 1934</div>
              </td>

  </tr>


</table>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br />
        </div>

        <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">For the transition period from ________ to ________</div>

        <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br />
        </div>

      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Commission File Number <ix:nonNumeric name="dei:EntityFileNumber" id="Fact_9352634f284e4ab582e4e58276c9ac88" contextRef="c20210101to20211231">1-11460</ix:nonNumeric></div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

        <div>
          <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 15%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

        <div style="text-align: center; margin-right: 216pt; margin-left: 216pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_cd3f96f5e576403d8b2314703c5947ea" contextRef="c20210101to20211231">Brooklyn ImmunoTherapeutics, Inc.</ix:nonNumeric><br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(Exact name of registrant as specified in its charter)</div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

        <div>
          <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 15%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_7c1ae00d7a2b4a9b9b131acd59a9fa12" contextRef="c20210101to20211231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_01a81c45a70f438a982f0c57c3544d12" contextRef="c20210101to20211231">31-1103425</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(State or Other Jurisdiction of </div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Incorporation or Organization)</div>
            </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(I.R.S. Employer </div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_29b3a7f1b50b47ba8505adb0ca504e6d" contextRef="c20210101to20211231">10355 Science Center Drive, Suite 150,</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_e689722e864d445cb322e8a8d5416b09" contextRef="c20210101to20211231">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_2b95c81f98e44857bef87641b2a2d6e4" contextRef="c20210101to20211231" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></div>
            </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_ac4231873cc14ac889408eed5578a137" contextRef="c20210101to20211231">92121</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Address of Principal Executive Offices)</div>
            </td>

    <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Zip Code)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_e071081b1b404701ac38e202ae2338a3" contextRef="c20210101to20211231">212</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_cc44cd3c5a5647e79fec2c6d9875f11d" contextRef="c20210101to20211231">582-1199</ix:nonNumeric></div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(Registrant&#8217;s telephone number, including Area Code)</div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

        <div>
          <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 15%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

        <div style="text-align: center; margin-right: 216pt; margin-left: 216pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Title of Each Class</div>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Trading Symbol(s)</div>
              </div>
            </td>

    <td style="width: 1%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Name of Each Exchange on Which Registered</div>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_184666d9ce5f454aa0dc67f625e9d859" contextRef="c20210101to20211231">Common Stock, $0.005 par value</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 32%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_99b1b6df09964b38a368e6e5456ecbba" contextRef="c20210101to20211231">BTX</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_6f8352c1c5e8469aad9a0da165511810" contextRef="c20210101to20211231" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>

      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160; &#9744; <ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" id="Fact_b973370f7f964c6fb1c51dc351d928d2" contextRef="c20210101to20211231">No</ix:nonNumeric>&#160; &#9746;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.&#160; Yes&#160; &#9744;&#160; <ix:nonNumeric name="dei:EntityVoluntaryFilers" id="Fact_a408b42577244608a79da17e4befd01f" contextRef="c20210101to20211231">No</ix:nonNumeric>&#160; &#9746;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act
        of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days.&#160; &#160; <ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="Fact_388b14146b9e4e2b8b31c69b50c35574" contextRef="c20210101to20211231">Yes</ix:nonNumeric>&#160; &#9746;&#160; &#160; No&#160; &#9744;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
        405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; &#160; <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="Fact_063fb241572848a1958206b715d9bfe1" contextRef="c20210101to20211231">Yes</ix:nonNumeric>&#160; &#9746;&#160; &#160; No&#160; &#9744;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
        company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>

      <div style="margin-left: 27pt;">
        <table cellspacing="0" cellpadding="0" border="0" style="border-collapse: collapse; width: 100%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">


  <tr>

    <td style="width: 50%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Large accelerated filer&#160; &#9744;</div>
              </td>

    <td style="width: 50%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Accelerated filer&#160; &#9744;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:EntityFilerCategory" id="Fact_4b2280f0cdc8430f8af4a80b9e36f752" contextRef="c20210101to20211231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric>&#160; &#9746;</div>
              </td>

    <td style="width: 50%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Smaller reporting company&#160; <ix:nonNumeric name="dei:EntitySmallBusiness" id="Fact_2ef58c1927ab4b16ab194ea6e62f0f0b" contextRef="c20210101to20211231" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>
              </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 50%; vertical-align: bottom; text-align: center;" rowspan="1">Emerging growth company&#160; <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_182ace3705764c1199c04c57b56fed72" contextRef="c20210101to20211231" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

  </tr>


</table>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
        any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; &#9744;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its
        internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" id="Fact_e1b25788fee748ffbd3a697076b098b3" contextRef="c20210101to20211231" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is a shell compan<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">y (as defined in Rule 12b-2 of the Act).&#160; </span>&#160; Yes&#160; <ix:nonNumeric name="dei:EntityShellCompany" id="Fact_7a66746e02e94e67949571889dfc59a6" contextRef="c20210101to20211231" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160; &#160; No&#160; &#9746;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The aggregate market value of the common stock held by non-affiliates of the registrant as of the last business day of the registrant&#8217;s most
        recently completed second fiscal quarter (June 30, 2021), computed by reference to the closing sale price of the common stock on the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) on such date, was approximately $<ix:nonFraction name="dei:EntityPublicFloat" id="Fact_d87dab6a29e44ad2b9e9554bbeb4dcda" contextRef="c20210630" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">694</ix:nonFraction> million. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For purposes of this determination shares beneficially owned by executive officers, directors and ten percent stockholders have been excluded, which does not represent an admission by the registrant as
          to the affiliate status of such person</span>.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">As of April 12, 2022, the registrant had <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" id="Fact_cd0cc4324667410886a80322400d1f81" contextRef="c20220412" unitRef="U002" decimals="INF" scale="0" format="ixt:numdotdecimal">57,451,937</ix:nonFraction>
        shares of common stock outstanding.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Documents Incorporated by Reference.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 32.9333px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Portions of the registrant&#8217;s definitive proxy statement for its 2022 Annual Meeting of Stockholders are incorporated by reference in Items 10, 11, 12, 13, and 14 of Part III of this Annual Report on Form 10-K. Such proxy statement
          will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December 31, 2021.</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
<div><br /></div>

      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><a id="TABLE"><!--Anchor--></a>TABLE OF CONTENTS</div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 5%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-weight: bold;">Item</div>
              </td>

    <td style="width: 90%; vertical-align: bottom; padding-bottom: 2px;"><br />
              </td>

    <td style="width: 5%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Page</div>
              </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;"><br />
              </td>

    <td style="width: 90%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Part I</div>
              </td>

    <td style="width: 5%; vertical-align: bottom;"><br />
              </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: middle;">&#160;</td>

    <td style="width: 90%; vertical-align: middle;">&#160;</td>

    <td style="width: 5%; vertical-align: middle; text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">1.</div>
              </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM1">Business</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;"><span style="color: rgb(0, 0, 0);">1</span>&#160; <br />
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">1A.</div>
              </td>

    <td style="width: 90%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM1A.">Risk Factors</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; text-align: center; white-space: nowrap;">28</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">1B.</div>
              </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM1B">Unresolved Staff Comments</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center; white-space: nowrap;">57</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">2.</div>
              </td>

    <td style="width: 90%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM2">Properties</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; white-space: nowrap;">
                <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;"><span style="color: rgb(0, 0, 0);">57</span><br />
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">3.</div>
              </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM3.">Legal Proceedings</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center; white-space: nowrap;">57</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">4.</div>
              </td>

    <td style="width: 90%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM4">Mine Safety Disclosures</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; text-align: center; white-space: nowrap;">59</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 5%; vertical-align: middle; background-color: rgb(204, 238, 255); text-align: right;"><br />
              </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;"><br />
              </td>

    <td style="width: 90%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Part II</div>
              </td>

    <td style="width: 5%; vertical-align: bottom;"><br />
              </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 5%; vertical-align: middle; background-color: rgb(204, 238, 255); text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">5.</div>
              </td>

    <td style="width: 90%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM5.">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; text-align: center; white-space: nowrap;">60</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">6.</div>
              </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM6">[Reserved]</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center; white-space: nowrap;">60</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">7.</div>
              </td>

    <td style="width: 90%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM7">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; text-align: center; white-space: nowrap;">60</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">7A.</div>
              </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM7A">Quantitative and Qualitative Disclosures About Market Risk</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center; white-space: nowrap;">70</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">8.</div>
              </td>

    <td style="width: 90%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM8">Financial Statements and Supplementary Data</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; text-align: center; white-space: nowrap;">70</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">9.</div>
              </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM9">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center; white-space: nowrap;">70</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">9A.</div>
              </td>

    <td style="width: 90%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM9A">Controls and Procedures</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; text-align: center; white-space: nowrap;">70</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">9B.</div>
              </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM9B">Other Information</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center; white-space: nowrap;">71</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">9C.</div>
              </td>

    <td style="width: 90%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM9C">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; text-align: center; white-space: nowrap;">71<br />
              </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 5%; vertical-align: middle; background-color: rgb(204, 238, 255); text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;"><br />
              </td>

    <td style="width: 90%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Part III</div>
              </td>

    <td style="width: 5%; vertical-align: bottom;"><br />
              </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 5%; vertical-align: middle; background-color: rgb(204, 238, 255); text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">10.</div>
              </td>

    <td style="width: 90%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#PARTIII">Directors, Executive Officers and Corporate Governance</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; text-align: center; white-space: nowrap;">72</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">11.</div>
              </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#PARTIII">Executive Compensation</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center; white-space: nowrap;">72</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">12.</div>
              </td>

    <td style="width: 90%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#PARTIII">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; text-align: center; white-space: nowrap;">72</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">13.</div>
              </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#PARTIII">Certain Relationships and Related Transactions, and Director Independence</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center; white-space: nowrap;">72</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">14.</div>
              </td>

    <td style="width: 90%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#PARTIII">Principal Accountant Fees and Services</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; text-align: center; white-space: nowrap;">72</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 5%; vertical-align: middle; background-color: rgb(204, 238, 255); text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;"><br />
              </td>

    <td style="width: 90%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Part IV</div>
              </td>

    <td style="width: 5%; vertical-align: bottom;"><br />
              </td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 90%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 5%; vertical-align: middle; background-color: rgb(204, 238, 255); text-align: center;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">15.</div>
              </td>

    <td style="width: 90%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM15">Exhibits and Financial Statement Schedules</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; text-align: center; white-space: nowrap;">73</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">16.</div>
              </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#ITEM16">Form 10-K Summary</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center; white-space: nowrap;">75</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;"><br />
              </td>

    <td style="width: 90%; vertical-align: top;">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#SIGNATURES">Signatures</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; text-align: center; white-space: nowrap;">76</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);"><a href="#INDEX">Index to Financial Statements and Schedule</a></div>
              </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: center;"><span style="color: rgb(0, 0, 0);">F-1</span></div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">i</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">This Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; as that term is defined under the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;), Section 27A of the Securities
          Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Forward-looking statements include statements related to future events, results, performance, prospects and
          opportunities, including statements related to our strategic plans and targets, revenue generation, product availability and offerings, capital needs, capital expenditures, industry trends and our financial position. Forward-looking statements
          are based on information currently available to us, on our current expectations, estimates, forecasts, and projections about the industries in which we operate and on the beliefs and assumptions of management. Forward looking statements often
          contain words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;could,&#8221; &#8220;targets,&#8221; &#8220;projects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions. In addition, any statements that refer to projections of our
          future financial performance, our anticipated growth and trends in our business, and other characterizations of future events or circumstances, are forward-looking statements. Forward-looking statements by their nature address matters that are,
          to different degrees, subject to risks and uncertainties that could cause actual results to differ materially and adversely from those expressed in any forward-looking statements. For us, particular factors that might cause or contribute to such
          differences include those identified in the &#8220;Summary of Principal Risk Factors&#8221; below and the other risks and uncertainties described in Part I, Item 1A &#8220;Risk Factors&#8221; of this Annual Report on Form 10-K and described in other documents we file
          from time to time with the Securities and Exchange Commission, or SEC, including our Quarterly Reports on Form 10-Q.</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Readers are urged not to place undue reliance on the forward-looking statements in this Annual Report on Form 10-K, which speak only as of the date of this Annual Report on Form 10-K. We are
          including this cautionary note to make applicable, and take advantage of, the safe harbor provisions of the PSLRA. Except as required by law, we do not undertake, and expressly disclaim any obligation, to disseminate, after the date hereof, any
          updates or revisions to any such forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which any such statements are based.</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We believe that the expectations reflected in forward-looking statements in this Annual Report on Form 10-K are based upon reasonable assumptions at the time made. However, given the risks and
          uncertainties, you should not rely on any forward- looking statements as a prediction of actual results, developments or other outcomes. You should read these forward-looking statements with the understanding that we may be unable to achieve
          projected results, developments or other outcomes and that actual results, developments or other outcomes may be materially different from what we expect.</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Unless otherwise indicated in this Annual Report on Form 10-K, &#8220;Brooklyn&#8221; refers to Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (formerly known as NTN Buzztime, Inc.), and
          &#8220;Brooklyn LLC&#8221; refers to Brooklyn ImmunoTherapeutics LLC, a wholly owned subsidiary of Brooklyn. All references to &#8220;our company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; mean Brooklyn and its subsidiaries, including Brooklyn LLC, unless stated otherwise or the
          context otherwise requires.</div>

        <div><br />
        </div>

        <div style="text-align: center; margin-left: 0.05pt; color: rgb(0, 0, 0); font-weight: bold;">SUMMARY OF PRINCIPAL RISK FACTORS</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">You should carefully consider the summary of principal risk factors below, together with the more detailed risk factors related to our business and industry described under &#8220;Risk Factors&#8221;
          contained in Item 1A of this Annual Report on Form 10-K. The occurrence of any of the events discussed below could significantly and adversely affect our business, prospects, results of operations, financial condition, and cash flows, which could
          result in a decline in the market price of our common stock.</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">We will require substantial additional capital to fund our operations, and if we fail to obtain the necessary financing, we may not be able to complete the development and commercialization of any of our
                  product candidates.</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">ii</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">We face business disruption and related risks resulting from the pandemic of the novel coronavirus (COVID-19), which could have a material adverse effect on our business plan.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Our business and operations would suffer in the event of system failures, cyber-attacks or a deficiency in our cyber-security.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">We are substantially dependent on the success of our internal development programs and our product pipeline candidates may not successfully complete clinical trials, receive regulatory approval or be
                  successfully commercialized.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Our current or future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs that could
                  halt their clinical development, prevent their marketing approval, limit their commercial potential or result in significant negative consequences.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will
                  be negatively impacted.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">We rely, and expect to continue to rely, on third parties to conduct our clinical studies, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of
                  such studies.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">If we are unable to obtain and maintain patent and other intellectual property protection for our products and product candidates, or if the scope of the patent and other intellectual property protection
                  obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products and product candidates may be adversely affected.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">iii</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <!--PROfilePageNumberReset%Num%1%%%-->
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PART I</div>

        <div>&#160;</div>

        <a id="ITEM1"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 46.1pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 1.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Business</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Background</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On March 25, 2021, BIT Merger Sub, Inc., a wholly owned subsidiary of Brooklyn (then known as NTN Buzztime, Inc.) merged with and into Brooklyn LLC, with Brooklyn LLC surviving as a wholly
          owned subsidiary of Brooklyn. This transaction, which we refer to as the Merger, was completed in accordance with the terms of an agreement and plan of merger and reorganization dated August 12, 2020 among Brooklyn (then known as NTN Buzztime,
          Inc.), BIT Merger Sub, Inc. and Brooklyn LLC. In accordance with such agreement and plan of merger, on March 25, 2021, Brooklyn amended its restated certificate of incorporation in order to effect:</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">prior to the Merger, a reverse stock split of its common stock, par value $0.005 per share, at a ratio of one-for-two; and</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">following the Merger, a change in its corporate name from &#8220;NTN Buzztime, Inc.&#8221; to &#8220;Brooklyn ImmunoTherapeutics, Inc.&#8221;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On March 26, 2021, we sold the rights, title and interest in and to the assets relating to the business operated under the name &#8220;NTN Buzztime, Inc.&#8221; prior to the Merger to eGames.com Holdings
          LLC, or eGames.com, in exchange for eGames.com&#8217;s payment of a purchase price of $2.0 million and assumption of specified liabilities relating to such pre-Merger business. This transaction, which we refer to as the Disposition, was completed in
          accordance with the terms of an asset purchase agreement dated September 18, 2020, as amended, between us and eGames.com.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The Merger has been accounted for as a reverse acquisition in accordance with United States generally accepted accounting principles, or GAAP. Under this method of accounting, Brooklyn LLC was
          deemed the &#8220;acquiring&#8221; company and Brooklyn (then known as NTN Buzztime, Inc.) was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Operations prior to the Merger are those of Brooklyn LLC, and the historical financial
          statements of Brooklyn LLC became the historical financial statements of Brooklyn with respect to periods prior to the completion of the Merger.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">
          <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Our principal executive offices are located at 10355 Science Center Drive, Suite 150, San Diego, CA 92121 and our phone number is <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">(212) 582-1199. </span>We maintain a website at www.brooklynitx.com. Information contained on, or accessible through, our website is not a part of and is not incorporated by
            reference into this Annual Report on Form 10-K.</div>

        </div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Overview</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We are a clinical-stage biopharmaceutical company focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer, both as a single
          agent and in combination with other anti-cancer therapies. We are seeking to develop IRX-2, a novel cytokine-based therapy, to treat patients with cancer. We also are exploring opportunities to advance oncology, blood disorder, and monogenic
          disease therapies using gene-editing and cell therapy technology through a license with Factor Bioscience Limited, or Factor, and through our acquisition of Novellus, Inc. and Novellus, Ltd. in July 2021, which we refer to as the Acquisition.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"><span style="text-decoration: underline;">IRX-2</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2, or IL2, and other key cytokines. Together, these cytokines are believed to signal,
          enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells, unlike many existing cancer therapies, which rely on targeting the cancer directly. IRX-2 is prepared from the supernatant of
          pooled allogeneic peripheral blood mononuclear cells, known as PBMCs, that have been stimulated using a proprietary process employing a specific population of cells and a specific mitogen.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">1</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">While IRX-2 is a cytokine mixture, one of its active components is IL2, a cytokine-signaling molecule with pleiotropic effects on the immune system. IL2 is a protein that regulates the
          activities of white blood cells (leukocytes, including lymphocytes) that are responsible for immunity. IL2 is part of the body&#8217;s natural response to microbial infection, and in discriminating between foreign, or non-self and &#8220;self,&#8221; IL2 mediates
          its effects by binding to IL2 receptors, which are expressed by lymphocytes. The major sources of IL2 are activated CD4<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">+</sup> T lymphocytes and activated CD8<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">+</sup> T lymphocytes.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Unlike existing recombinant IL2 therapies, IRX-2 is derived from human blood cells. We believe this may promote better tolerance, broader targeting and a natural molecular conformation leading
          to greater activity, and may permit low physiologic dosing, rather than the high doses needed in other existing IL2 therapies.</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0);">Regarding IRX-2 development, our strategy is:</div>

        <div style="color: rgb(0, 0, 0);"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 13.5pt;"><br />
              </td>

    <td style="width: 22.5pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-style: italic;">Advance our product candidate IRX-2 through clinical development.</span> IRX-2 is a human blood cell-derived cytokine therapy being studied for multiple types of cancer,
                  including squamous cell cancer of the head and neck. Enrollment in the ongoing Phase 2b INSPIRE trial, or the INSPIRE trial, has been completed, with top-line data estimated to be available by the third quarter of 2022.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 13.5pt;"><br />
              </td>

    <td style="width: 22.5pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-style: italic;">Advance additional studies.</span> Once INSPIRE trial data are released, we plan to use those results as a catalyst in addition to data from the other clinical trials in
                  the program, see &#8220;&#8212;Clinical Program&#8221; below, with multiple data read-outs anticipated in 2022 and later.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 13.5pt;"><br />
              </td>

    <td style="width: 22.5pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-style: italic;">Pursue partnerships to advance the IRX-2 clinical program</span>. We are pursuing partnership opportunities with certain leading biopharmaceutical companies for the
                  development and commercialization of IRX-2.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 13.5pt;"><br />
              </td>

    <td style="width: 22.5pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-style: italic;">Regulatory strategy.</span> We believe that our assets may present opportunities for potential breakthroughs in the treatment of cancer and other indications. We will
                  endeavor to seek breakthrough therapy designation with regulatory agencies for IRX-2 for one or more indications.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 13.5pt;"><br />
              </td>

    <td style="width: 22.5pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-style: italic;">Intellectual Property</span>. We continue to pursue additional intellectual property based on data from our IRX-2 clinical studies.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Pre-Clinical Results</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our findings to date from our nonclinical studies of IRX-2 include murine acute toxicology as well as acute and chronic toxicology in non-human primates. These studies detected circulating
          associated cytokines yet were associated with benign toxicological findings.</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Clinical Program</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">IRX2 currently remains under development and has not yet been approved for marketing authorization in any jurisdiction. The ongoing company sponsored development program is investigating use of
          IRX2 as an immunotherapeutic neoadjuvant (pre-surgical) and adjuvant (post-operative) treatment for advanced head and neck squamous cell carcinoma, or (&#8220;HNSCC&#8221;).&#160; Studies in other indications and combinations are being pursued in the investigator
          sponsored study program.</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0);"><span style="text-decoration: underline;">HNSCC</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The HNSCC development program is being conducted under U.S. Food and Drug Administration (&#8220;FDA&#8221;)&#160; Investigational New Drug (IND) 11137 filed on June 30, 2003 and is ongoing. The HNSCC program
          has received fast track designation, approved November 7, 2003, and orphan drug designation, conferred on July 7, 2005, from the FDA. We have not submitted a request for orphan drug designation in the European Union, although we may seek such
          designation in the future.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">2</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Clinical studies in humans with HNSCC involving IRX&#8209;2 show immune marker activation in patients treated with IRX&#8209;2. In a prior Phase 2a clinical trial, a correlation was shown between marker
          activation and disease-free survival in head and neck cancer. Results from this study were used to support the initiation of the INSPIRE trial involving 105 patients with HNSCC. Details of this trial can be found at <span style="font-style: italic;">clinicaltrials.gov</span> (NCT02609386). The trial study schema can be found below.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Historical Background of the Inspire Study</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The IRX-2 regimen has been studied in patients HNSCC in two previous open-label, multi-center studies. Also, a phase 1 trial evaluated the IRX-2 regimen as a therapy for advanced disease, which
          reported that the IRX-2 regimen was well tolerated.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In 2011, results were reported for a Phase 2a trial of IRX-2. This trial was an open-label study involving 27 patients, 26 of whom completed the study. The primary endpoint of the study was to
          further evaluate the safety and efficacy of the immunotherapy regimen including IRX-2 in the neoadjuvant setting in previously untreated patients with advanced (Stage II to IVa) HNSCC. The primary study objective was to demonstrate the safety of
          this immunotherapy regimen based on adverse events (&#8220;AEs&#8221;), changes in clinical laboratory measures (hematology, chemistry, and urinalysis), vital signs, and physical examinations. Secondary objectives were clinical, pathologic, and radiographic
          tumor response; and patient disease-free survival (&#8220;DFS&#8221;) and overall survival (&#8220;OS&#8221;).</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Most recombinant cytokines, such as IL-2, are tested in the same manner as traditional oncology drugs, where the maximum tolerated dose is sought. Typical cytokine therapies in cancer treatment
          use extremely high doses, in the millions of units per administration. Thus, AEs such as fever, hypotension, malaise, anemia, leukopenia, and hepatic and renal dysfunction are commonly reported, and often lead to discontinuation of the treatment.
          IV administration of cytokines is frequently associated with an acute phase reaction characterized by rigors, fever, an increase in neutrophils, a decrease in lymphocytes, and changes in hormone levels. By contrast, the IRX-2 regimen, which
          contains physiologic quantities of cytokines, showed greatly improved tolerability over typical recombinant cytokine therapies.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The results of the Phase 2a study were published in December 2011 in the journal Head and Neck. The article reported that IRX-2 showed an immunologically mediated antitumor effect, suggested by
          pronounced lymphocytic infiltration. Lymphocytic infiltration was measured by a 100-mm Visual Analog Scale (&#8220;VAS&#8221;) score, in which 100 mm signified lymphocyte infiltration of the entire primary tumor section and 0 mm signified no lymphocyte
          infiltration in the tumor specimen. The mean VAS score for all 24 patients was 22.6 mm on the samples obtained at surgery. Patients were grouped into a low VAS score (below the overall mean) and high VAS score (above the overall mean) cohorts.
          There were 14 patients in the low VAS score cohort with scores between 2 and 21 (median of 9.5), and there were 10 patients in the high VAS score cohort with scores between 27 and 66 (median of 37.0). Patients in the high-LI group included fewer
          oral cavity patients (50% in high LI vs 60% in low LI) but were similar with respect to tumor sites. Seventy percent of high-LI patients were stage IV, whereas only 60% of low LI were stage IV. The LI score was used to determine whether the
          degree of LI correlated with survival. Patients with a high-LI score had an improved survival trend compared to those with low LI, and superior to the survival rate for the combined overall group. (See below.)</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">3</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: center; color: rgb(0, 0, 0);"> <img src="image00003.jpg" alt="graphic" /></div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Interestingly, LI in resected tumor specimens was considered high in 40% of the patients. The 10 patients with a high-LI score showed an improved survival trend in comparison to the low-LI
          group (n = 15) and to the entire study population (n = 26). It is difficult to directly compare these subgroups, because there was some imbalance, with a slightly higher per-centage of oral cavity patients in the low-LI group. However, in the
          absence of a randomized control, it is impossible to directly attribute the LI to the immuno-therapy regimen. In addition, tumor reductions were observed at the end of the 21-day regimen in 11 patients, and a 75% reduction of glycolytic activity
          in the tumor and lymph nodes on posttreatment PET scans in one patient.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">With regard to the primary endpoint, eight serious adverse events (SAEs) were reported during treatment and the 30-day postoperative period in 7 patients, including 3 patients with aspiration
          pneumonia, 1 patient with asthma exacerbation secondary to upper respiratory infection, 1 patient with a postoperative wound infection, 1 patient with a neck abscess, and 1 patient with an episode of alcohol withdrawal. Only 1 case of aspiration
          pneumonia was deemed life threatening (grade 4). None of the SAEs was considered related to treatment except for the postoperative wound infection, which was considered possibly related. Other minor (grade 1 or 2) AEs included headache (30%),
          injection-site pain (22%), nausea (22%), constipation (15%), dizziness (15%), fatigue (11%), and myalgia (7%).</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">After over more than 36 months of follow-up, 11 of the 27 patients enrolled in the Phase 2a study had experienced tumor relapse (n = 1) or death (n = 10). The pattern of first HNSCC relapse
          included 3 patients with primary site recurrence, 2 with recurrences in the neck, and 2 with distant metastases. Of the 10 patients who died, 6 died of cancer (1 from a new primary) and 4 died of other causes. The 1-year, 2-year, and 3-year DFS
          probabilities after surgery were 72%, 64%, and 62%, respectively. Of the 26 patients whose primary tumor was resected surgically, 2 patients died during the first year and 5 patients died during the second year after surgery. The probability of
          surviving after surgery was 92% the first year, 73% the second year, and 69% the third year, which was considered to be an encouraging survival rate compared to historical norms in patients with HNSCC.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">A second finding of the study was that some tumors showed some decrease in overall size after the immunotherapy regimen. Overall tumor shrinkage was modest, although in 4 patients, independent,
          objective imaging documented a greater than 10% decrease in tumor size. This was unexpected and encouraging after only 3 weeks of presurgical neoadjuvant immunotherapy. No patient achieved a true partial response by modified Response Evaluation
          Criteria in Solid Tumors (RECIST) criteria. Increases in tumor measurements were also seen in some patients, but most patients showed negligible change in tumor dimensions. We believe that these findings suggest the safety of the neoadjuvant
          regimen, although final decisions on whether a drug product is safe and effective can only be made by the FDA.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">4</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The phase 2a trial did not include a randomized control cohort. However, the manuscript published in Head &amp; Neck in December 2011 stated the authors&#8217; belief that the safety results and
          feasibility of this immunotherapy regimen were intriguing enough to warrant further study and appropriate comparison in a randomized trial.</div>

        <div><br />
        </div>

        <div style="text-align: center;"><img src="image00004.jpg" alt="graphic" /></div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The INSPIRE study is an open label, randomized, multi-center, multi-national Phase 2b clinical trial intended for patients with Stage II, III or IVA untreated SCC of the oral cavity who are
          candidates for resection with curative intent. Subjects were randomized 2:1 to either Regimen 1 or Regimen 2 and treated for 21 days prior to surgery and then postoperatively with a booster regimen given every three months for one year (a total
          of four times.)</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Regimen 1: IRX-2 Regimen with cyclophosphamide, indomethacin, zinc-containing multivitamins, omeprazole and IRX-2 as neoadjuvant and adjuvant therapy.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Regimen 2: Regimen 1 with cyclophosphamide, indomethacin, zinc-containing multivitamins, omeprazole but without IRX-2 as neoadjuvant and adjuvant therapy.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Treatments were allocated to study subjects using minimization with a stochastic algorithm based on the range method. Minimization will account for the major prognostic factors for SCC of the
          oral cavity (T and N stage) and study center to avoid imbalances in treatment allocation within centers.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Postoperatively, subjects first received standard adjuvant radiation or chemoradiation therapy as determined by the investigators per NCCN guidelines, and then also received Booster Regimen 1
          or 2 as determined in the prior randomization.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Subjects will be followed for the Primary, Secondary and Exploratory endpoints. Protocol mandated follow-up will end four years after randomization of the last patient.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The Neoadjuvant IRX-2 Regimen is a 21-day pre-operative regimen of cyclophosphamide on Day 1, indomethacin, zinc-containing multivitamins and omeprazole on Days 1-21, and subcutaneous IRX-2
          injections in bilateral mastoid insertion regions for 10 days between Days 4 and 21, as shown in the table below:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">5</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 24.01%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Agent</div>
              </td>

    <td style="width: 2.01%; vertical-align: bottom;"><br />
              </td>

    <td style="width: 24%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Dose</div>
              </td>

    <td style="width: 2%; vertical-align: bottom;"><br />
              </td>

    <td style="width: 24%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Route of Administration</div>
              </td>

    <td style="width: 2%; vertical-align: bottom;"><br />
              </td>

    <td style="width: 22%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Treatment Days</div>
              </td>

  </tr>

  <tr>

    <td style="width: 24.01%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Cyclophosphamide</div>
              </td>

    <td style="width: 2.01%; vertical-align: bottom; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">300 mg/m2</div>
              </td>

    <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">IV</div>
              </td>

    <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 22%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">1</div>
              </td>

  </tr>

  <tr>

    <td style="width: 24.01%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0);">IRX-2</div>
              </td>

    <td style="width: 2.01%; vertical-align: bottom;"><br />
              </td>

    <td style="width: 24%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0);">230 units daily (Bilateral injections of 115 units)</div>
              </td>

    <td style="width: 2%; vertical-align: bottom;"><br />
              </td>

    <td style="width: 24%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Subcutaneous at or near the mastoid insertion of both sternocleidomastoid muscles</div>
              </td>

    <td style="width: 2%; vertical-align: bottom;"><br />
              </td>

    <td style="width: 22%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Any 10 days between Days 4 and 21</div>
              </td>

  </tr>

  <tr>

    <td style="width: 24.01%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Indomethacin</div>
              </td>

    <td style="width: 2.01%; vertical-align: bottom; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">25 mg TID</div>
              </td>

    <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Oral</div>
              </td>

    <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 22%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">1-21</div>
              </td>

  </tr>

  <tr>

    <td style="width: 24.01%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Zinc-Containing Multivitamins</div>
              </td>

    <td style="width: 2.01%; vertical-align: bottom;"><br />
              </td>

    <td style="width: 24%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0);">1 tablet containing 15-30 mg of zinc</div>
              </td>

    <td style="width: 2%; vertical-align: bottom;"><br />
              </td>

    <td style="width: 24%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Oral</div>
              </td>

    <td style="width: 2%; vertical-align: bottom;"><br />
              </td>

    <td style="width: 22%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0);">1-21</div>
              </td>

  </tr>

  <tr>

    <td style="width: 24.01%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Omeprazole</div>
              </td>

    <td style="width: 2.01%; vertical-align: bottom; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">20 mg</div>
              </td>

    <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Oral</div>
              </td>

    <td style="width: 2%; vertical-align: bottom; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 22%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">1-21</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The Booster IRX-2 Regimen is given at 3, 6, 9 and 12 months (-14 to +28 days) after surgical resection. It is a 10- day post-operative regimen of cyclophosphamide on Day 1, indomethacin,
          zinc-containing multivitamins and omeprazole on Days 1-10 and subcutaneous IRX-2 injections in bilateral deltoid regions for 5 days between Days 4 and 10 as shown in the table below:</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 24.01%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Agent</div>
              </td>

    <td style="width: 2.01%; vertical-align: bottom;"><br />
              </td>

    <td style="width: 24%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Dose</div>
              </td>

    <td style="width: 2%; vertical-align: bottom;"><br />
              </td>

    <td style="width: 24%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Route of Administration</div>
              </td>

    <td style="width: 2%; vertical-align: bottom;"><br />
              </td>

    <td style="width: 22%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Treatment Days</div>
              </td>

  </tr>

  <tr>

    <td style="width: 24.01%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">
                <div style="color: rgb(0, 0, 0);">Cyclophosphamide</div>
              </td>

    <td style="width: 2.01%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;"><br />
              </td>

    <td style="width: 24%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">
                <div style="color: rgb(0, 0, 0);">300 mg/m2</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;"><br />
              </td>

    <td style="width: 24%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">
                <div style="color: rgb(0, 0, 0);">IV</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;"><br />
              </td>

    <td style="width: 22%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">
                <div style="color: rgb(0, 0, 0);">1</div>
                <div style="color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0);">Every 3 months.</span> </div>
              </td>

  </tr>

  <tr>

    <td style="width: 24.01%; vertical-align: top; text-align: center;">
                <div style="color: rgb(0, 0, 0);">IRX-2</div>
              </td>

    <td style="width: 2.01%; vertical-align: top; text-align: center;"><br />
              </td>

    <td style="width: 24%; vertical-align: top; text-align: center;">
                <div style="color: rgb(0, 0, 0);">230 units daily (Bilateral injections of 115 units)</div>
              </td>

    <td style="width: 2%; vertical-align: top; text-align: center;"><br />
              </td>

    <td style="width: 24%; vertical-align: top; text-align: center;">
                <div style="color: rgb(0, 0, 0);">Subcutaneous into bilateral deltoid regions</div>
              </td>

    <td style="width: 2%; vertical-align: top; text-align: center;"><br />
              </td>

    <td style="width: 22%; vertical-align: top; text-align: center;">
                <div style="color: rgb(0, 0, 0);">Any 5 days between Days 4 and 10</div>
                <div style="color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0);">Every 3 months.</span> </div>
              </td>

  </tr>

  <tr>

    <td style="width: 24.01%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">
                <div style="color: rgb(0, 0, 0);">Indomethacin</div>
              </td>

    <td style="width: 2.01%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;"><br />
              </td>

    <td style="width: 24%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">
                <div style="color: rgb(0, 0, 0);">25 mg TID</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;"><br />
              </td>

    <td style="width: 24%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">
                <div style="color: rgb(0, 0, 0);">Oral</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;"><br />
              </td>

    <td style="width: 22%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">
                <div style="color: rgb(0, 0, 0);">Days 1-10</div>
                <div style="color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0);">Every 3 months.</span> </div>
              </td>

  </tr>

  <tr>

    <td style="width: 24.01%; vertical-align: top; text-align: center;">
                <div style="color: rgb(0, 0, 0);">Zinc-Containing Multivitamins</div>
              </td>

    <td style="width: 2.01%; vertical-align: top; text-align: center;"><br />
              </td>

    <td style="width: 24%; vertical-align: top; text-align: center;">
                <div style="color: rgb(0, 0, 0);">1 tablet containing 15-30 mg of zinc</div>
              </td>

    <td style="width: 2%; vertical-align: top; text-align: center;"><br />
              </td>

    <td style="width: 24%; vertical-align: top; text-align: center;">
                <div style="color: rgb(0, 0, 0);">Oral</div>
              </td>

    <td style="width: 2%; vertical-align: top; text-align: center;"><br />
              </td>

    <td style="width: 22%; vertical-align: top; text-align: center;">
                <div style="color: rgb(0, 0, 0);">Days 1-10</div>
                <div style="color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0);">Every 3 months.</span> </div>
              </td>

  </tr>

  <tr>

    <td style="width: 24.01%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">
                <div style="color: rgb(0, 0, 0);">Omeprazole</div>
              </td>

    <td style="width: 2.01%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;"><br />
              </td>

    <td style="width: 24%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">
                <div style="color: rgb(0, 0, 0);">20 mg daily</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;"><br />
              </td>

    <td style="width: 24%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">
                <div style="color: rgb(0, 0, 0);">Oral</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;"><br />
              </td>

    <td style="width: 22%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: center;">
                <div style="color: rgb(0, 0, 0);">Days 1-10</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Regimen 2, the control arm of the study, is identical, except that subjects will not receive IRX-2.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The primary objective of the study is to determine if the event-free survival (EFS) of subjects treated with Regimen 1 is longer than for subjects treated with Regimen 2. The secondary
          objections of the study are (i) to determine if OS of subjects treated with Regimen 1 is longer than for subjects treated with Regimen 2, (ii) to compare the safety of each Regimen, and (iii) to compare the feasibility of each booster regimen.</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0);"><span style="text-decoration: underline;">Other Indications</span></div>

        <div style="color: rgb(0, 0, 0);"><span style="text-decoration: underline;"> <br />
          </span></div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Other than the phase 2b INSPIRE trial, all clinical studies using IRX-2 are investigator-sponsored studies for which we are providing IRX&#8209;2 as the study drug and financial support to conduct
          the trial. These studies include:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Monotherapy studies:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">BR-101 - A study involving 16 patients with neoadjuvant breast cancer performed at the Providence Portland Medical Center. Details of this trial can be found at <span style="font-style: italic;">clinicaltrials.gov</span>
                  (NCT02950259).</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">CIN-201 - An open label single arm Phase 2 trial of the IRX&#8209;2 regimen in women with cervical squamous intraepithelial neoplasia 3 or squamous vulvar intraepithelial neoplasia 3. Details of this trial can be
                  found at <span style="font-style: italic;">clinicaltrials.gov</span> (NCT03267680).</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">6</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Combination studies:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><span style="color: rgb(0, 0, 0);">BAS-104 - A basket study originally intended to enroll 100 patients with metastatic bladder, renal, non-small cell lung cancer, or NSCLC, melanoma, and head and neck cancer being held at the Moffitt
                    Cancer Center, using IRX&#8209;2 in conjunction with Opdivo</span><span style="color: rgb(77, 81, 86);">&#174;</span><span style="color: rgb(0, 0, 0);"> (Nivolumab), an immunotherapy cancer treatment marketed by Bristol-Myers Squibb Company. This
                    trial was discontinued after 11 subjects were enrolled due to insurance reimbursement challenges. Details of this trial can be found on </span><span style="font-style: italic; color: rgb(0, 0, 0);">clinicaltrials.gov</span><span style="color: rgb(0, 0, 0);"> (NCT03758781).</span></div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><span style="color: rgb(0, 0, 0);">HCC-107 - A study involving 28 patients with metastatic hepatocellular carcinoma, or HCC, being held at City of Hope Medical Center, HonorHealth Research Institute, and Texas Oncology at Baylor
                    Charles A. Simmons Cancer Center using IRX&#8209;2 in conjunction with Opdivo</span><span style="color: rgb(77, 81, 86);">&#174;</span><span style="color: rgb(0, 0, 0);">, a cancer treatment marketed by Bristol-Myers Squibb Company. Details of
                    this trial can be found at </span><span style="font-style: italic; color: rgb(0, 0, 0);">clinicaltrials.gov</span><span style="color: rgb(0, 0, 0);"> (NCT03655002).</span></div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><span style="color: rgb(0, 0, 0);">GI-106 - A study involving 20 patients with metastatic gastric and gastroesophageal junction cancers (GI) being held at City of Hope Medical Center, HonorHealth Research Institute, and Texas Oncology
                    at Baylor Charles A. Simmons Cancer Center using IRX&#8209;2 in conjunction with Keytruda</span><span style="color: rgb(77, 81, 86);">&#174;</span><span style="color: rgb(0, 0, 0);"> (Pembrolizumab), an immunotherapy cancer treatment marketed by
                    Merck. Details of this trial can be found at </span><span style="font-style: italic; color: rgb(0, 0, 0);">clinicaltrials.gov</span><span style="color: rgb(0, 0, 0);"> (NCT03918499).</span></div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">MHN-102 - A study involving 15 patients with metastatic head and neck cancer being held at the H. Lee Moffitt Cancer Center and Research Institute and University of Michigan Health System using IRX&#8209;2 in
                  conjunction with Imfinzi (Durvalumab), a cancer treatment marketed by AstraZeneca plc. Details of this trial can be found at <span style="font-style: italic;">clinicaltrials.gov</span> (NCT03381183).</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">BR-202 - A study involving 30 patients with neoadjuvant triple negative breast cancer, held at the Providence Portland Medical Center using IRX&#8209;2 in conjunction with a programmed cell death protein 1, or
                  PD1, and chemotherapy treatments. Details of this trial can be found at <span style="font-style: italic;">clinicaltrials.gov</span> (NCT04373031).</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"><span style="text-decoration: underline;">Impact of COVID-19 Pandemic</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The development of our product candidates has been, and could continue to be, disrupted and materially adversely affected by past and continuing impacts of the COVID-19 pandemic. This is
          largely a result of measures imposed by the governments and hospitals in affected regions, businesses and schools were suspended due to quarantines intended to contain this outbreak. The spread of COVID-19 from China to other countries resulted
          in the Director General of the World Health Organization declaring COVID-19 a pandemic in March 2020. While the constraints of the pandemic are being lifted, we are still assessing the longer-term impact of the COVID-19 pandemic on our
          development plans, and on the ability to conduct our clinical trials. COVID-19 could continue to disrupt production and cause delays in the supply and delivery of products used in our operations, may affect our operations, including the conduct
          of clinical studies, or the ability of regulatory bodies to grant approvals or supervise our candidates and products, may further divert the attention and efforts of the medical community to coping with the COVID-19 and disrupt the marketplace in
          which we operate and may have a material adverse effects on our operations. COVID-19 may also affect our employees and employees and operations at suppliers that may result in delays or disruptions in supply. In addition, a recession or market
          correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. Additionally, if the COVID-19 pandemic has a significant impact on our business and financial results for an extended period
          of time, our liquidity and cash resources could be negatively impacted. The extent to which the COVID-19 pandemic and ongoing global efforts to contain its spread will impact our operations will depend on future developments, which are highly
          uncertain, and include the duration, severity and scope of the pandemic and the actions taken to contain or treat the COVID-19 pandemic. Further, the specific clinical outcomes, or future pandemic related impacts of emerging COVID-19 variants
          cannot be reliably predicted.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The patients in our clinical trials have conditions that make them especially vulnerable to COVID-19, and as a result we have seen slowdowns in enrollment in our clinical trials. While our
          INSPIRE trial in patients with squamous cell carcinoma of the oral cavity is fully populated, our other clinical studies are likely to continue to encounter delays in enrollment as a result of the pandemic.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">7</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-weight: bold;"><span style="text-decoration: underline;">Engineered Cellular and Genetic Medicines</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We are advancing our gene-editing and cell therapy technology in oncology, blood disorders and monogenic disorders through a license with Factor and through the Acquisition of Novellus, Inc.
          and Novellus, Ltd. in July 2021. We expect that the first generation product candidates resulting from the Acquisition will be derived from unedited (that is, not gene modified), induced pluripotent stem cells (&#8220;iPSC&#8221;)-derived allogeneic
          mesenchymal stem cells (&#8220;iMSC&#8221;). We expect to begin preclinical development of iMSC for clinical indications for which inhibiting inflammation and/or supporting recovery of bone marrow stromal cells is required. The prior work of Novellus and
          NoveCite with iMSC shows evidence for preclinical efficacy in inflammatory conditions (for example, acute respiratory distress syndrome, or ARDS). Interactions with the FDA provided guidance on Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;), and
          manufacturing plans, which will be undertaken in a similar manner for additional iMSC applications. We expect that second generation iMSC products will involve gene editing, for which we anticipate using the stepwise addition of genes provided by
          the in-licensed Factor Bioscience gene editing machinery, NoveSlice, to efficiently place genes and regulatory sequences into safe harbor locations. Development of processes to advance CMC and manufacturing will follow the experience from first
          generation iMSC products. We expect clinical indications for gene-modified iMSC will include solid tumors and other conditions associated with episodic and/or chronic inflammation.&#160; We are also exploring opportunities to advance in vivo gene
          therapies for monogenic and other diseases by combining the NoveSlice gene editing technology in combination with ToRNAdo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup>, the in-licensed lipid nanoparticle (or
          &#8220;LNP&#8221;) technology.</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Pluripotent Stem Cell-Derived MSC</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">MSC, also known as mesenchymal stromal cells, were originally discovered and isolated from bone marrow in the 1970s and have been isolated from various tissue sources including muscle,
          umbilical cord, liver, placenta, skin, amniotic fluid, synovial membrane, and tooth root. MSC have been intensely investigated for clinical applications within the last decades with a very strong record of safety and tolerability. However, the
          majority of registered clinical trials applying MSC therapy for diverse human diseases have fallen short of expectations, despite the encouraging pre-clinical outcomes in varied animal disease models. This can be attributable to inconsistent
          properties of MSC across studies as a result of variations in tissue source, donor variability, as well as isolation and manufacturing methodologies.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The generation of MSC from an iPSC source eliminates many of the sources of variability attributable to tissue derived MSC. Sources of reduced variability include the use a single tissue source
          and single donor as well as the ability to make larger cell banks due to the more extensive proliferation capacity of iMSC. Moreover, development of iMSC products can leverage decades of valuable manufacturing, preclinical and clinical experience
          with MSC. Brooklyn plans to create &#8220;off-the-shelf&#8221; iMSC products in clinical indications that harness their anti-inflammatory and tumor homing properties.&#160; Further, gene editing of iPSC can produce a stable source for iMSC that are endowed with
          additional therapeutically beneficial properties that are not present in tissue derived MSC or native iMSC.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Bone Marrow Transplant and Inflammatory Diseases</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Brooklyn is exploring the use of iMSC to address primary graft failure or poor graft function after bone marrow or hematopoietic stem cell transplantation, or BM/HSCT in addition to potential
          applications in the prevention and/or treatment of graft vs host disease.&#160; Preclinical studies will be conducted to demonstrate the ability of iMSC to target the bone marrow and influence the microenvironment. In addition, we have assembled an
          advisory board of world class experts in BM/HSCT to guide the clinical trial design and selection of clinical populations that are most likely to show benefit of a secondary transplant after treatment with iMSC.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Tumor Localized Delivery of Immune Stimulating Cytokines</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The ability of MSC to migrate and navigate to sites of inflammation, including tumors, makes MSC attractive for delivery of oncology therapeutics. We intend to use gene editing of iPSC to
          produce a cell line with expression of the immune stimulatory cytokines, which then can be used to generate iMSC that express both IL-7 and IL-15.&#160; Following systemic delivery of the gene edited iMSC, we believe that migration and homing to tumor
          sites will result in a localized and more sustained delivery of these potent cytokines in the tumor microenvironment without producing the side effects that occur with high dose systemic administration of these cytokines.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">8</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Precision In vivo Genetic Medicines</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We believe that&#160; the ability to engineer target site-specific DNA endonucleases with high fidelity (gene editing) has opened a new therapeutic arena for addressing the underlying genetic basis
          of disease. Gene editing systems that possess both high specificity (low off-target editing) and high efficiency for on-target editing enable the in vivo use of the gene editing machinery to specifically modify patient DNA in target tissues and
          thus address the genetic underpinnings of numerous disease states. Brooklyn&#8217;s in-licensed technologies are being leveraged to develop genetic medicines that can achieve precision in vivo gene editing to address disorders that occur primarily as a
          result of mutations in a single gene.&#160; The initial disease and gene targets being pursued include familial transthyretin amyloidosis (<span style="font-style: italic;">TTR</span> gene mutations) and Stargardt disease (<span style="font-style: italic;">ABC4A</span> gene mutation).</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Autologous and Allogeneic Cell Therapy</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Cellular reprogramming refers to the process of generating pluripotent stem cells from non-pluripotent somatic cells (e.g., dermal fibroblasts obtained through a skin biopsy) by the forced
          expression of key genes and factors important for maintaining the defining properties of pluripotent cells.&#160; We believe the in-licensed technology for mRNA-based cellular reprogramming is highly efficient and safer than methods that utilize viral
          vectors or plasmid DNA for expression of reprogramming factors because it eliminates the chance of DNA integration and potential for creating mutations in genomic DNA. Also, our proprietary reprogramming process utilizes daily repeated
          transfection of mRNA for expression of reprogramming factors and can achieve a rapid generation of iPSC clones (in 2 weeks) from patient tissue biopsy. This rapid and efficient process therefore reduces the potential negative impact of low
          quantity biopsy material and enhances reproducibility of autologous iPSC generation. Furthermore, by delivering mRNA for a gene editing nuclease, genomic modifications, including correction of mutations, can be simultaneously performed thus
          streamlining overall manufacturing time to produce gene-corrected autologous cells. We expect that this approach, leveraging the proprietary in licensed technologies, can be employed to produce cell therapies addressing genetic diseases (e.g.,
          sickle cell disease) of infectious diseases (e.g. HIV). In addition, we have the potential to generate off-the-shelf (allogeneic) iPSC derived cell therapies for truly personalized cell therapy application in patients with genetic diseases.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Recent Developments</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"><span style="text-decoration: underline;">Listing on The Nasdaq Global Market</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We transferred the listing of our common stock to The Nasdaq Global Market effective October 25, 2021, after voluntarily withdrawing the listing from the NYSE American stock exchange. The
          common stock continues to trade under the stock symbol &#8220;BTX.&#8221;</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-weight: bold;"><span style="text-decoration: underline;">PIPE Transaction</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On March 6, 2022, we entered into a Securities Purchase Agreement with an investor (the &#8220;PIPE Investor&#8221;) providing for the private placement (the &#8220;PIPE Transaction&#8221;) to the PIPE Investor of
          approximately 6,857,000 units (the &#8220;Units&#8221;), each of&#160; which consisted of (i) one share of our common stock (or, in lieu thereof, one pre-funded warrant (the &#8220;Pre-Funded Warrants&#8221;) to purchase one share of common stock) and (ii) one warrant (the
          &#8220;Common Warrants&#8221;) to purchase one share of common stock, for an aggregate purchase price of approximately $12.0 million. The PIPE Transaction closed on March 9, 2022.</div>

        <div><br />
        </div>

        <div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">Each Pre-Funded Warrant has an exercise price of $0.005 per share of common stock, was immediately exercisable and may be exercised at any time and has no expiration date and is subject to
            customary adjustments. The Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 9.99% immediately after exercise thereof.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">Each Common Warrant has an exercise price of $1.91 per share, becomes exercisable six months following the closing of the PIPE Transaction, expires five-and-one-half years from the date of
            issuance, and is subject to customary adjustments. The Common Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 4.99% immediately after exercise thereof,
            subject to increase to 9.99% at the option of the holder.</div>

        </div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In connection with the PIPE Transaction, we and the PIPE Investor also entered into a registration rights agreement, dated March 6, 2022, pursuant to which we agreed to prepare and file a
          registration statement with the Securities and Exchange Commission (the &#8220;SEC&#8221;) to register the resale of the shares of common stock included in the Units and the shares of common stock issuable upon exercise of the Pre-Funded Warrants and the
          Common Warrants. We agreed to use our best efforts to have such registration statement declared effective as promptly as possible after the filing thereof, subject to certain specified penalties if timely effectiveness is not achieved.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">9</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"><span style="text-decoration: underline;">Purchase Agreements</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On April 26, 2021, we and Lincoln Park Capital Fund, LLC, or Lincoln Park, executed a purchase&#160;agreement, or the First Purchase Agreement. Pursuant to the First Purchase Agreement, we had the
          right, but not the obligation, to sell to Lincoln Park, and Lincoln Park would be obligated to purchase, up to $20.0 million of shares of our common stock. Sales of common stock by us were subject to certain limitations, and could occur from time
          to time, at our sole discretion. In consideration for Lincoln Park&#8217;s entry into the First Purchase Agreement, we issued Lincoln Park approximately 56,000 shares of common stock. As of December 31, 2021, we had issued and sold to Lincoln Park
          approximately 1,128,000 shares of common stock under the First Purchase Agreement for gross proceeds of $20.0 million, and no further shares may be sold to Lincoln Park under the First Purchase Agreement.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify;"><span style="color: rgb(0, 0, 0);">On May 26, 2021, we and Lincoln Park executed a second purchase agreement, or the Second Purchase Agreement, and together with the First Purchase Agreement, the Purchase
            Agreements. Pursuant to the Second Purchase Agreement,</span><span style="color: rgb(0, 176, 240);">&#160;</span><span style="color: rgb(0, 0, 0);">we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park would be
            obligated to purchase, up to $40.0 million of shares of our common stock. Sales of common stock by us are subject to certain limitations, and may occur from time to time, at our sole discretion. In consideration of Lincoln Park&#8217;s entry into the
            Second Purchase Agreement, we issued to Lincoln Park 50,000 shares of common stock.</span></div>

        <div style="text-align: justify;"><span style="color: rgb(0, 0, 0);"> <br />
          </span></div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Under the Second Purchase Agreement, we may direct Lincoln Park to purchase up to 60,000 shares of common stock on any business day, which we refer to as a Regular Purchase, which amount may be
          increased up to 120,000 shares based on the closing price of the common stock, provided that Lincoln Park&#8217;s maximum commitment in any single Regular Purchase may not exceed $2.0 million. The purchase price per share for each such Regular Purchase
          is based off of the common stock&#8217;s market immediately preceding the time of sale.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The Second Purchase Agreement also prohibits us from directing Lincoln Park to purchase any shares of common stock if those shares, when aggregated with all other shares of common stock then
          beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership, at any single point in time, of more than 4.99% of the then total outstanding shares of common stock. We have the
          right to terminate the Second Purchase Agreement at any time, at no cost or penalty.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Actual sales of shares of common stock to Lincoln Park under the Second Purchase Agreements depend on a variety of factors to be determined by us from time to time, including, among others,
          market conditions, the trading price of the common stock and determinations by us as to the appropriate sources of funding for us and our operations.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">As of December 31, 2021, we had issued and sold approximately 2,424,000 shares of common stock under the Second Purchase Agreement for total gross proceeds of $34.1 million.&#160; Pursuant to the
          securities purchase agreement in respect of the PIPE Transaction, we are prohibited from issuing additional shares under the Second Purchase Agreement for a period of one -year immediately following the closing of the PIPE Transaction.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"><span style="text-decoration: underline;">Acquisition of Novellus</span></div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"><span style="text-decoration: underline;"> <br />
          </span></div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On July 16, 2021, Brooklyn and its newly formed, wholly owned subsidiary Brooklyn Acquisition Sub, Inc. entered into an agreement and plan of acquisition, or the Acquisition Agreement, with (a)
          Novellus LLC, (b) Novellus, Inc., the sole equity holder of Novellus, Ltd. and, prior to the closing under the Acquisition Agreement, a wholly owned subsidiary of Novellus, LLC, and (c) a seller representative. Novellus, Ltd. is a pre-clinical
          stage biotechnology company organized under the laws of Ireland that is developing engineered cellular medicines using its licensed, patented non-immunogenic mRNA, high-specificity gene editing, mutation-free and footprint-free cell reprogramming
          and serum-insensitive mRNA lipid delivery technologies. The Acquisition closed contemporaneously with the execution and delivery of the Acquisition Agreement.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We delivered consideration for the Acquisition totaling approximately $124.0 million, which consisted of (a) $22.8 million in cash and (b) approximately 7,022,000 shares of common stock, which
          under the terms of the Acquisition Agreement were valued at a total of $102.0 million, based on a price of $14.5253 per share.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">10</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We expect the Acquisition will advance our evolution into a platform company with a pipeline of next generation engineered cellular, gene editing and cytokine programs. The completion of the
          Acquisition relieves Brooklyn LLC from potential obligations to pay Novellus, Ltd. certain upfront fees, clinical development milestone fees and post-registration royalties under the License Agreement. The agreement with Factor under the License
          Agreement, which grants Brooklyn LLC exclusive rights to develop certain next-generation mRNA gene editing and cell therapy products, remains unchanged.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">License and Royalty Agreements</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"><span style="text-decoration: underline;">Cell and Gene Therapy</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On April 26, 2021, Brooklyn LLC entered into an exclusive license agreement, or the License Agreement, with Novellus, Ltd. and Factor, or the Licensors, to license the Licensors&#8217; intellectual
          property and mRNA cell reprogramming and gene editing technology for use in the development of certain cell-based therapies to be evaluated and developed for treating human diseases, including certain types of cancer, sickle cell disease, and
          beta thalassemia. Through the License Agreement, Brooklyn LLC acquired an exclusive worldwide license to develop and commercialize certain cell-based therapies to treat cancer and rare blood disorders, including sickle cell disease, based on
          patented technology and know-how of Novellus, Ltd.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The License Agreement provides that Brooklyn LLC pay the Licensors a total of $4.0 million in connection with the execution of the License Agreement, all of which has been paid. Brooklyn LLC
          was obligated to pay to the Licensors additional fees of $5.0 million in October 2021 and $7.0 million in October 2022.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The completion of our July 16, 2021 acquisition of Novellus, Inc., the sole equity holder of Novellus, Ltd., relieves us from potential obligations to pay Novellus, Ltd. certain upfront fees,
          clinical development milestone fees and post-registration royalties under the License Agreement. The agreements with Factor under the License Agreement remain unchanged. Brooklyn LLC is obligated to pay Factor $2.5 million in October 2021, which
          has been paid, and $3.5 million in October 2022.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Under the terms of the License Agreement, Brooklyn LLC is required to use commercially reasonably efforts to achieve certain delineated milestones, including specified clinical development and
          regulatory milestones and specified commercialization milestones. In general, upon its achievement of these milestones, Brooklyn LLC will be obligated, in the case of development and regulatory milestones, to make milestone payments to Licensor
          in specified amounts and, in the case of commercialization milestones, to specified royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers. In the event Brooklyn LLC fails to timely achieve certain
          delineated milestones, the Licensors may have the right to terminate the rights of Brooklyn LLC under provisions of the License Agreement relating to those milestones.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The Licensors are responsible for preparing, filing, prosecuting and maintaining all patent applications and patents under the License Agreement. If, however, the Licensors determine not to
          maintain a particular licensed patent or not to prepare, file and prosecute a licensed patent, Brooklyn LLC will have the right, but not the obligation, to assume those responsibilities in the territory at its expense.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Novellus, Ltd. is a pre-clinical development, manufacturing, and technology licensing entity focused on engineered cellular medicines. Novellus, Ltd. has developed mRNA-based cell reprogramming
          and gene editing technologies to create engineered cellular medicines. The synthetic mRNA is non-immunogenic&#8212;it is capable of successfully evading the cellular innate immune system and then is capable of expressing high levels of proteins for
          cell reprogramming and gene editing. The mRNA may be formulated for injection into target tissues for cellular uptake and therapeutic treatment.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The synthetic mRNA technology may be used to edit gene mutations or expressed gene-editing proteins to treat genetic and rare diseases. It may also be used to reprogram human non-pluripotent
          cells into induced pluripotent stem cells )(iPSC). The iPSC may then be differentiated into populations of varying therapeutic cell types. The reprogramming technology offers a rapid and patient specific therapy using the engineered stem cells
          created from iPSC that may avoid the cost, complexity and safety issues associated with viral vector gene editing approaches.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">11</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Novellus, Ltd. also has licenses from Factor to use over 70 granted patents throughout the world covering synthetic mRNA, RNA-based gene editing, and RNA-based cell reprogramming, in addition
          to specific patents covering methods for treating specific diseases. There are also more than 60 pending patent applications throughout the world focused on these and other aspects of the technology. The patent coverage includes granted patents
          and pending patent applications in the United States, Europe, and Japan, along with other major life sciences markets.</div>

        <div>
          <div><br />
          </div>

          <div style="text-align: justify; color: rgb(0, 0, 0);">Novellus, Ltd. is required to use commercially reasonably efforts to achieve certain delineated milestones, including specified clinical development and regulatory milestones and specified
            commercialization milestones. In general, upon its achievement of these milestones, Novellus, Ltd. will be obligated, in the case of development and regulatory milestones, to make milestone payments of up to $51 million in aggregate to Factor
            and, in the case of commercialization milestones, specified royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers. In the event Novellus, Ltd. fails to timely achieve certain delineated milestones,
            Factor may have the right to terminate Novellus, Ltd.&#8217;s rights under provisions of the License Agreement relating to those milestones.</div>

        </div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">There can be no assurance that Brooklyn LLC can successfully develop and commercialize the technology licensed under the License Agreement.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"><span style="text-decoration: underline;">IRX-2</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Unless otherwise stated below, each royalty to be paid under these license and royalty agreements is payable until the last patent for IRX-2 expires and runs in perpetuity
          unless earlier terminated pursuant to the terms described below. There are no milestone payments due under any of these agreements.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">License Agreement with the University of South Florida Research Association</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On June 28, 2000, IRX Therapeutics, a predecessor of Brooklyn LLC, entered into a series of License Agreements (collectively, the &#8220;USF License Agreement&#8221;) with the University of South Florida
          Research Association, Inc. (&#8220;Research Association&#8221;). Pursuant to the USF License Agreement, as amended, the Research Association licensed to IRX Therapeutics the exclusive worldwide rights to certain patents on IRX-2 in exchange for royalties
          equal to 7% of the gross product sales of IRX-2 (as defined in the USF License Agreement). The USF License Agreement was assigned to Brooklyn LLC in connection with the sale of the assets of IRX Therapeutics to Brooklyn in November 2018. The
          Research Association has the right to terminate the USF License Agreement (i) upon Brooklyn LLC&#8217;s entering into bankruptcy or insolvency on a voluntary or involuntary basis, (ii) upon the failure to pay royalties due and payable upon thirty days&#8217;
          notice, or (iii) upon a material breach or default of the Agreement by Brooklyn LLC, unless such breach or default is cured within a thirty-day notice period. Brooklyn may terminate the USF License Agreement for any reason upon six months&#8217; notice
          to the Research Association.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Royalty Agreement with certain former IRX Therapeutics investors</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On May 1, 2012, IRX Therapeutics entered into a royalty agreement (the &#8220;IRX Investor Royalty Agreement&#8221;) with certain investors who participated in a financing transaction. The IRX Investor
          Royalty Agreement was assigned to Brooklyn LLC in November 2018 when Brooklyn LLC acquired the assets of IRX Therapeutics. Pursuant to the IRX Investor Royalty Agreement, if and when Brooklyn LLC becomes obligated to pay royalties to the Research
          Association under the USF License Agreement, it will pay an additional royalty of 1% of gross sales to an entity organized by the investors who participated in such financing transaction. There are no termination provisions in the IRX Investor
          Royalty Agreement.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Collaborator License Agreement</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Effective June 28, 2018, IRX Therapeutics terminated its Research, Development and Option Facilitation Agreement (the &#8220;Termination Agreement&#8221;) and its Options Agreement with a collaborative
          partner (the &#8220;Collaborator&#8221;), pursuant to a Termination Agreement. In connection with the Termination Agreement, all of the rights granted to the Collaborator under the RDO and Option Agreements were terminated, and IRX Therapeutics had no
          obligation to refund any payments received from the Collaborator. The Termination Agreement was assigned to Brooklyn LLC in connection with the sale of the assets of IRX Therapeutics to Brooklyn in November 2018.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">12</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">As consideration for entering into the Termination Agreement, the Collaborator will receive a royalty equal to 6% of revenues from the sale of IRX-2, for the period of time beginning with the
          first sale of IRX-2 through the later of (i) the twelfth anniversary of the first sale of IRX-2, or (ii) the expiration of the last IRX patent or other exclusivity of IRX-2, all as more particularly set forth in the Termination Agreement. Each
          party under the Termination Agreement may terminate the agreement (i) upon a material breach of the Termination Agreement by the other party that is not cured within sixty days (or thirty days if such breach is due to Brooklyn LLC&#8217;s non-payment
          of royalties), or (ii) upon the other party entering into bankruptcy on a voluntary or involuntary basis where such petition is not dismissed, discharged, bonded or stayed within ninety days.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Investor Royalty Agreement</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On November 6, 2018, Brooklyn LLC entered into a royalty agreement (the &#8220;Brooklyn Investor Royalty Agreement&#8221;) with Brooklyn Immunotherapeutics Investors LP (&#8220;Investors LP&#8221;) and Brooklyn
          Immunotherapeutics Investors GP (&#8220;Investors GP&#8221;), which entities provided the financing required by Brooklyn LLC in connection with Brooklyn LLC&#8217;s acquisition of the assets of IRX Therapeutics. Under the Brooklyn Investor Royalty Agreement,
          Brooklyn LLC is required to pay compensatory royalties equal to 4% of gross sales of IRX-2 on an annual basis, 3% of which is to be paid to Investors LP and 1% of which is to be paid to Investors GP (all as more particularly set forth in the
          Royalty Agreement). This royalty continues in perpetuity.</div>

        <div>
          <div><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">In anticipation of the Merger, on March 22, 2021, Brooklyn LLC entered into an Amended and Restated Royalty Agreement and Distribution Agreement, or the Amended Royalty Agreement, with
            Investors GP, Investors LP, and certain beneficial holders of GP and LP. Pursuant to the Amended Royalty Agreement, among other things, we are required to pay compensatory royalties equal to 4% of net revenues of IRX-2, on an annual basis, of
            which 3% is to be paid to certain beneficial holders of LP and 1% is to be paid to certain beneficial holders of GP. The royalty continues in perpetuity.</div>

          <div><br />
          </div>

          <div style="text-align: justify; color: rgb(0, 0, 0);">The Royalty Agreement specifies royalty payments to certain beneficial holders, including:</div>

          <div><br />
          </div>

        </div>

        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0);">Charles Cherington, one of our directors and stockholders has a right to receive 4.20% of the Specified Royalty;</div>
                </td>

  </tr>


</table>
          <div>&#160;</div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0);">entities affiliated with George P. Denny III (Denny Family Partners II, LLC, the George P. Denny Trust, and the R. Breck Denny Trust), a former director and current stockholder have a right to receive a
                    total of 4.39% of the Specified Royalty;</div>
                </td>

  </tr>


</table>
          <div>&#160;</div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0);">an entity affiliated with Nicholas J. Singer (PCI BI LLC), a former director and current stockholder, has a right to receive a total of 2.10% of the Specified Royalty</div>
                </td>

  </tr>


</table>
          <div><br />
          </div>

        </div>

        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0);">entities affiliated with Yiannis Monovoukas (The Yiannis Monovoukas Family 2013 Revocable Trust FBO Alexi Monovoukas, The Yiannis Monovoukas Family 2013 Revocable Trust FBO Aresti Monovoukas, and The
                    Yiannis Monovoukas Family 2013 Revocable Trust FBO Christian Monovoukas), a former director and stockholder have a right to receive a total of 1.40% of the Specified Royalty; and;</div>
                </td>

  </tr>


</table>
          <div>&#160;</div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0);">an entity affiliated with John D. Halpern (The John D. Halpern Revocable Trust), one of our stockholders, has a right to receive 3.50% of the Specified Royalty.</div>
                </td>

  </tr>


</table>
          <div>&#160;</div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">13</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-weight: bold;">Patent Portfolio</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">
          <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">As of April 12, 2022, we owned or controlled approximately 9 patent families filed in the United States and other major markets worldwide,
            including 99 granted, 10 pending and 11 published patent applications, directed to novel compounds, formulations, methods of treatments and platform technologies. Patent protection for IRX-2 includes:</div>

        </div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 46%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>&#160;</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Summary Description of Patent or Patent Application</div>
              </td>

    <td style="width: 2%; vertical-align: bottom;"><br />
              </td>

    <td style="width: 25%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0);">United States or Foreign </div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Jurisdiction</div>
              </td>

    <td style="width: 2%; vertical-align: bottom;"><br />
              </td>

    <td style="width: 25%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Earliest Effective Date</div>
                <div style="text-align: center; color: rgb(0, 0, 0);"> of Patent Application</div>
              </td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top;"><br />
              </td>

    <td style="width: 2%; vertical-align: top;"><br />
              </td>

    <td style="width: 25%; vertical-align: top;"><br />
              </td>

    <td style="width: 2%; vertical-align: top;"><br />
              </td>

    <td style="width: 25%; vertical-align: top;"><br />
              </td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">IRX-2 Modified Manufacturing Process</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Granted: </span>US (No. 8,470,562), EP (BE, CH, DE, DK, ES, FI, FR, GB, IT, LI, NL, SW), AU, CA, JP, MX, TR</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">US: 4/14/2009</div>
                <div>&#160;</div>
                <div style="color: rgb(0, 0, 0);">EP: 4/14/2009</div>
              </td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Method of Reversing Immune Suppression of Langerhans Cells</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Granted</span>: US (Nos. 9,333,238 and 9,931,378), EP (BE, CH, DE, DK, ES, FI, FR, GB, LI, NL), AU, CA</div>
                <div>&#160;</div>
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Published: </span>CN, HK</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">US: 6/8/2012 (No. 9,333,238), 4/13/2016 (No. 9,931,378)</div>
                <div>&#160;</div>
                <div style="color: rgb(0, 0, 0);">EP: 12/8/2010</div>
              </td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Method of Increasing Immunological Effect</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Granted</span>: US (Nos. 7,993,660 and 8,591,956), EP (BE, CH, DE, DK, ES, FI, FR, GB, IT, LI, NL), AU, CA, JP</div>
                <div>&#160;</div>
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Published</span>: HK</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">US: 8/9/2011 (No. 7,993,660), 11/26/2013 (No. 8,591,956)</div>
                <div>&#160;</div>
                <div style="color: rgb(0, 0, 0);">EP: 11/26/2008</div>
              </td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Vaccine Immunotherapy</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Granted: </span>US (Nos. 6,162,778, 9,492,517, 9,492,519, 9,539,320 and 9,566,331), EP (BE, CH, DE, DK, ES, FI, FR, GB, IT, LI, NL), AU, CA, HK, JP</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">US: 7/24/2007 (No. 6,162,778), 10/8/2009 (No. 9,492,517), 11/15/2011 (No. 9,539,230), 2/20/2013 (No. 9,566,331), 7/12/2013 (No. 9,492,519)</div>
                <div>&#160;</div>
                <div style="color: rgb(0, 0, 0);">EP: 5/17/2010</div>
              </td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Immunotherapy for Reversing Immune Suppression</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Granted</span>: US (No. 7,731,945), AU</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0); font-size: 12pt;"><span style="font-size: 10pt;">US: 10/26/2002</span></div>
              </td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Vaccine Immunotherapy for Immune Suppressed Patients</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Granted</span>: US (Patent Nos.&#160;&#160;6,977,072, 7,153,499, 8,784,796, 9,789,172 and 9,789,173), CA, JP</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">US: 10/26/2001 (No. 6,977,072), 5/5/2003 (No. 7,153,499), 7/12/2013 (No. 8,784,796), 6/4/2014 (Nos. 9,789,172 and 9,789,173)</div>
              </td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Immunotherapy for Immune Suppressed Patients</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Granted</span>: EP (BE, CH, DE, ES, FR, GB, IT, NL, LI)</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">EP:&#160;&#160;3/9/2007</div>
              </td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Composition for the Treatment of Advanced Prostate Cancer</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Granted</span>: CA</div>
                <div>&#160;</div>
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Published</span>: EP, HK</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 25%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Uses of PD-1/PD-L1 Inhibitors and/or CTLA-4 Inhibitors with a Biologic Containing Multiple Cytokine Components</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Pending</span>: AU, CA, EP, IL, JP, KR, NZ, PH, SG, US</div>
                <div>&#160;</div>
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Published</span>: BR, CN, EA, IN, MX, ZA</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: middle; background-color: rgb(204, 238, 255);"><br />
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">14</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br />
              </td>

    <td style="width: 2%; vertical-align: top;"><br />
              </td>

    <td style="width: 25%; vertical-align: top;"><br />
              </td>

    <td style="width: 2%; vertical-align: top;"><br />
              </td>

    <td style="width: 25%; vertical-align: middle;"><br />
              </td>

  </tr>

  <tr>

    <td style="width: 46%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">US &#8211; United States of America</div>
                <div style="color: rgb(0, 0, 0);">EP &#8211; European Patent Convention</div>
                <div style="color: rgb(0, 0, 0);">BE &#8211; Belgium</div>
                <div style="color: rgb(0, 0, 0);">CH &#8211; Switzerland</div>
                <div style="color: rgb(0, 0, 0);">DE &#8211; Germany</div>
                <div style="color: rgb(0, 0, 0);">DK &#8211; Denmark</div>
                <div style="color: rgb(0, 0, 0);">ES &#8211; Spain</div>
                <div style="color: rgb(0, 0, 0);">FI &#8211; Finland</div>
                <div style="color: rgb(0, 0, 0);">GB &#8211; Great Britain</div>
                <div style="color: rgb(0, 0, 0);">IT &#8211; Italy</div>
                <div style="color: rgb(0, 0, 0);">LI &#8211; Lichtenstein</div>
                <div style="color: rgb(0, 0, 0);">NL &#8211; Netherlands</div>
                <div style="color: rgb(0, 0, 0);">SW &#8211; Sweden</div>
                <div style="color: rgb(0, 0, 0);">AU &#8211; Australia</div>
                <div style="color: rgb(0, 0, 0);">BR - Brazil</div>
                <div style="color: rgb(0, 0, 0);">CA &#8211; Canada</div>
                <div style="color: rgb(0, 0, 0);">CN &#8211; Peoples&#8217; Republic of China</div>
                <div style="color: rgb(0, 0, 0);">EA &#8211; Eurasian Patent Organization</div>
                <div style="color: rgb(0, 0, 0);">HK &#8211; Hong Kong</div>
                <div style="color: rgb(0, 0, 0);">IL &#8211; Israel</div>
                <div style="color: rgb(0, 0, 0);">IN - India</div>
                <div style="color: rgb(0, 0, 0);">JP &#8211; Japan</div>
                <div style="color: rgb(0, 0, 0);">KR &#8211; Republic of Korea (South Korea)</div>
                <div style="color: rgb(0, 0, 0);">MX &#8211; Mexico</div>
                <div style="color: rgb(0, 0, 0);">PH &#8211; Philippines</div>
                <div style="color: rgb(0, 0, 0);">SG - Singapore</div>
                <div style="color: rgb(0, 0, 0);">TR &#8211; Turkey</div>
                <div style="color: rgb(0, 0, 0);">ZA &#8211; South Africa</div>
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 25%; vertical-align: middle; background-color: rgb(204, 238, 255);"><br />
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Patent Families</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0);">Descriptions of our patent families with issued patents in the United States or European Union are as follows:</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">IRX-2 Modified Manufacturing Process - A method of making a primary cell derived biologic, including the steps of: (a) removing contaminating cells from mononuclear cells (&#8220;MNCs&#8221;) by loading leukocytes onto
                  lymphocyte separation medium (&#8220;LSM&#8221;), and washing and centrifuging the medium with an automated cell processing and washing system; (b) storing the MNCs overnight in a closed sterile bag system; (c) stimulating the MNCs with a mitogen and
                  ciprofloxacin in a disposable cell culture system to produce cytokines; (d) removing the mitogen from the mononuclear cells by filtering; (e) incubating the filtered MNCs in a culture medium; (f) producing a clarified supernatant by
                  filtering the MNCs from the culture medium; (g) producing a chromatographed supernatant by removing DNA from the clarified supernatant by anion exchange chromatography; and (h) removing viruses from the chromatographed supernatant by
                  filtering with dual 15 nanometer filters in series, thereby producing a primary cell derived biologic, wherein the primary cell derived biologic comprises IL-1.beta., IL-2, and IFN-.gamma.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Method of Reversing Immune Suppression of Langerhans Cells - A method of treating human papillomavirus (&#8220;HPV&#8221;), by administering a therapeutically effective amount of a primary cell-derived biologic to a
                  patient infected with HPV and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (&#8220;LC&#8221;), by administering a therapeutically effective amount of a primary cell-derived biologic to
                  a patient infected with HPV and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC,
                  and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and
                  preventing new lesions from developing.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">15</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Method of Increasing Immunological Effect - A method of increasing immunological effect in a patient by administering an effective amount of a primary cell derived biologic to the patient, inducing immune
                  production, blocking immune destruction, and increasing immunological effect in the patient. Methods of treating an immune target, treating a tumor, immune prophylaxis, and preventing tumor escape.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Vaccine Immunotherapy/Composition for the Treatment of Advanced Prostate Cancer &#8211; A method providing compositions and methods of immunotherapy to treat cancer or other antigen-producing diseases or lesions.
                  According to one embodiment of the invention, a composition is provided for eliciting an immune response to at least one antigen in a patient having an antigen-producing disease or lesion, the composition comprising an effective amount of
                  a cytokine mixture, preferably comprising IL-1, IL-2, IL-6, IL-8, IFN-gamma. (gamma) and TNF- alpha (alpha). The cytokine mixture acts as an adjuvant with the antigen associated with the antigen-producing disease or lesion to enhance the
                  immune response of the patient to the antigen. Methods are therefore also provided for eliciting an immune response to at least one antigen in a patient having an antigen-producing disease or lesion utilizing the cytokine mixture of the
                  invention. The compositions and methods are useful in the treatment of antigen-producing diseases such as cancer, infectious diseases or persistent lesions.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Immunotherapy for Reversing Immune Suppression - A method for overcoming immune suppression including the steps of inducing production of na&#239;ve T-cells and restoring T cell immunity.&#160; A method
          of vaccine immunotherapy includes the steps of inducing production of na&#239;ve T cells and exposing the na&#239;ve T cells to endogenous or exogenous antigens at an appropriate site.&#160; Additionally, a method for unblocking immunization at a regional lymph
          node includes the steps of promoting differentiation and maturation of immature dendritic cells, thus, for example, exposing tumor peptides to T cells to gain immunization of the T cells.&#160; Further, a method of treating cancer and other persistent
          lesions includes the steps of administering an effective amount of a natural cytokine mixtures an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions; preferably the natural cytokine mixture is
          administered with thymosin.</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Vaccine Immunotherapy for Immune Suppressed Patients - A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A
                  method of vaccine immunotherapy includes the steps of inducing production of naive T-cells and exposing the naive T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a
                  regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for
                  example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an
                  adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Immunotherapy for Immune Suppressed Patients &#8211; A method providing compositions of a natural cytokine mixture (&#8220;NCM&#8221;) for treating a cellular immunodeficiency characterized by T lymphocytopenia, one or more
                  dendritic cell functional defects such as those associated with lymph node sinus histiocytosis, and/or one or more monocyte functional defects such as those associated with a negative skin test to NCM. The invention includes methods of
                  treating these cellular immunodeficiences using the NCM of the invention. The compositions and methods are useful in the treatment of diseases associated with cellular immunodeficiencies such as cancer. Also provided are compositions and
                  methods for reversing tumor-induced immune suppression comprising a chemical inhibitor and a non-steroidal anti-inflammatory drug (&#8220;NSAID&#8221;). The invention also provides a diagnostic skin test comprising NCM for predicting treatment
                  outcome in cancer patients.</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">16</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Patent Term and Term Extensions</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Individual patents have terms for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in
          which they are obtained. Generally, utility patents issued for applications filed in the United States and the European Union are granted a term of 20 years from the earliest effective filing date of a non-provisional patent application. In
          addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark Office, or the USPTO, delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA
          regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the restoration period cannot extend the patent term beyond 14 years from FDA approval. The duration of foreign patents varies
          in accordance with provisions of applicable local law, but typically are also 20 years from the earliest effective filing date. All taxes or annuities for a patent, as required by the USPTO and various foreign jurisdictions, must be timely paid
          in order for the patent to remain in force during this period of time.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The actual protection afforded by a patent may vary on a product-by-product basis, from country to country, and can depend upon many factors, including the type of patent, the scope of its
          coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our patents and patent applications may be subject to procedural or legal challenges by others. We may be unable to obtain, maintain and protect the intellectual property rights necessary to
          conduct our business, and we may be subject to claims that we infringe or otherwise violate the intellectual property rights of others, which could materially harm our business. For more information, see the section titled &#8220;Risk Factors-Risks
          Related to Our Intellectual Property.&#8221;</div>

        <div style="text-align: justify;"><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Supply and Manufacturing</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Brooklyn has considerable experience in manufacturing the investigational active pharmaceutical ingredient (&#8220;API&#8221;) currently in the clinic. In recent years, we maintained internal API
          manufacturing capabilities. We are currently investigating the option of outsourcing API manufacturing to an experienced contract manufacturing organization (&#8220;CMO&#8221;), as we had historically done, to mitigate the overhead costs of internal
          manufacturing and leverage process development expertise to streamline and eliminate some of the more manual processes, thereby reducing risk of product microbial contamination.&#160; The CMO selected will have the capability to produce high quality
          product to meet both the investigational and anticipated commercial demands. There will be technology transfer and process validation costs, which will be carefully considered in any decision.&#160; We have established long-standing contract
          manufacturing relationships for fill/finish and packaging of the clinical supplies of IRX-2.&#160; As with any supply program, obtaining raw materials of the correct quality, and the performance of our contract manufacturing sites cannot be
          guaranteed.&#160; Due to the current demand for CMO services and supply chain issues in the COVID-19 pandemic environment we cannot ensure that we will be successful in obtaining such raw materials on terms acceptable to us, if at all.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We expect to similarly rely on contract manufacturing relationships for any products that we may in-license or acquire in the future. However, there can be no assurance that we will be able to
          successfully contract with such manufacturers on terms acceptable to us, or at all.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Contract manufacturers are subject to ongoing periodic and unannounced inspections by the FDA, the Drug Enforcement Administration (&#8220;DEA&#8221;) and corresponding state agencies to ensure strict
          compliance with current good manufacturing practices (&#8220;cGMPs&#8221;) and other state and federal regulations. Our contractors, if any, in Europe face similar challenges from the numerous European Union and member state regulatory agencies and
          authorized bodies. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards, other than through contractual obligations. If our contractors are deemed out of compliance with cGMPs, product recalls
          could result, inventory could be destroyed, production could be stopped, and supplies could be delayed or otherwise disrupted, which could have a materially adverse effect on our business.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">If we need to change manufacturers after commercialization, the FDA and corresponding foreign regulatory agencies must approve these new manufacturers in advance, which will involve testing and
          additional inspections and associated regulatory submissions to ensure compliance with FDA regulations and standards, which collectively may result in significant lead times, delay and cost. Furthermore, switching manufacturers may be difficult
          because the number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer quickly or on terms acceptable to us, or at all.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">17</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Regulatory Matters</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Government regulation and product approval</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing,
          manufacture, labeling, record-keeping, promotion, storage, advertising, distribution, marketing and export and import of products such as those we are developing. Drugs and biologics must be approved by the FDA through the New Drug Application,
          (NDA) process or the Biologic License Application (BLA) process before they may be legally marketed in the United States. Henceforth, we will use the term &#8220;marketing application&#8221; or MA to apply to both.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">There are two centers within the FDA that are responsible for the review and approval of drug marketing applications and general regulatory oversight: the Center for Drug Evaluation and
          Research, or CDER, and the Center for Biologics Evaluation and Research, or CBER. While all conventional drug products are regulated by CDER, biologic products can be regulated by either CDER or CBER, depending on the product&#8217;s classification.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The majority of BLA submissions are assigned to CBER; however, BLAs for certain biologic product categories are reviewed by CDER. These product categories include monoclonal antibodies for in
          vivo use, most proteins for therapeutic use, and categories such as cytokines, enzymes, and other novel proteins. Based on this, it is likely that a BLA submission for IRX-2 would fall under the jurisdiction of CDER. Regardless of the category,
          NDAs for all drug products fall under the jurisdiction of CDER.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In the United States, drugs are subject to rigorous regulation by the FDA under the federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations, and biologics under the FDCA,
          the Public Health Services Act (PHSA), and their implementing regulations. Additionally, drugs and biologics are subject to other federal and state statutes. The process of obtaining regulatory approvals and the subsequent compliance with
          appropriate federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the product
          development process, approval process, or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, license suspension or revocation,
          withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. Any agency or judicial
          enforcement action could have a material adverse effect on us. The process required by the FDA before a drug or biologics may be marketed in the United States generally involves the following:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">completion of pre-clinical laboratory tests, animal studies and formulation studies according to the FDA&#8217;s good laboratory practice, or GLP, regulations;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">submission of an investigational new drug application, or IND, which must become effective before human clinical trials may begin and which must include approval by an institutional review board, or IRB, at
                  each clinical site before the trials are initiated;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug for its intended use conducted in compliance with federal regulations and good
                  clinical practice, or GCP, an international standard meant to protect the rights and health of human clinical trial subjects and to define the roles of clinical trial sponsors, administrators, and monitors;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">submission to, and acceptance by, the FDA of a MA;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">satisfactory completion of an FDA inspection of our manufacturing facility or other facilities at which the drug or biologic is produced to assess compliance with current good manufacturing practice, or
                  cGMP, regulations to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">potential FDA audit of the non-clinical and clinical trial sites that generated the data in support of the MA: and</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">FDA review and approval of the MA.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The testing and approval process require substantial time, effort and financial resources, and the receipt and timing of any approval is uncertain.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">18</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">United States drug development process</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Once a pharmaceutical candidate is identified for development it enters the pre-clinical testing stage. Pre-clinical tests include laboratory evaluations of product chemistry, toxicity and
          formulation, as well as animal studies. Prior to beginning human clinical trials, a sponsor must submit an Investigational New Drug Application (&#8220;IND&#8221;) to the FDA, which includes the results of the pre-clinical tests, together with manufacturing
          information and analytical data. Some pre-clinical or non-clinical testing may continue even after the IND is submitted. In addition to including the results of the pre-clinical studies, the IND will also include a protocol detailing, among other
          things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated, if the trial lends itself to an efficacy evaluation. The IND automatically becomes effective 30 days
          after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the trial. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can
          begin. The FDA may, at any time, impose a clinical hold on ongoing clinical trials. If the FDA imposes a clinical hold, clinical trials cannot commence or recommence without FDA authorization and then only under terms authorized by the FDA.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Clinical trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of one or more qualified investigators in accordance with
          federal regulations and GCP.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Clinical trials must be conducted under protocols detailing the objectives of the trial and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as
          part of the IND. Further, an Institutional Review Board, or IRB, affiliated with each institution participating in the clinical trial must review and approve each protocol before any clinical trial commences at that institution. All research
          subjects must provide informed consent, and informed consent information must be submitted to the IRB for approval prior to initiation of the trial. Progress reports detailing the results of the clinical trials must be submitted at least annually
          to the FDA and more frequently if adverse events or other certain types of other changes occur.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Human clinical trials are typically conducted in three phases. A fourth, or post-approval, phase may include additional clinical studies. These phases generally include the following, and may
          be sequential, or may overlap or be combined:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Phase 1 clinical trials involve the initial introduction of the drug or biologic into human subjects. These studies are designed to determine the safety of usually single doses of the compound and determine
                  any dose limiting intolerance, as well as evidence of the metabolism and pharmacokinetics of the drug in humans. For some products for severe or life-threatening diseases, especially if the product may be too toxic to administer to
                  healthy humans, the initial clinical trials may be conducted in individuals having a specific disease for which use the tested product is indicated.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Phase 2 clinical trials usually involve studies in a limited patient population to evaluate the safety and efficacy of the drug or biologic for specific, targeted indications, to determine dosage tolerance
                  and optimal dosage, and to identify possible adverse effects and safety risks.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">In Phase 3, if a compound is found to be potentially effective and to have an acceptable safety profile in Phase 2 (or occasionally Phase 1) studies, the Phase 3 studies will be conducted to further confirm
                  clinical efficacy, optimal dosage and safety within an expanded population which may involve geographically diverse clinical trial sites. Generally, but not always, two adequate and well-controlled Phase 3 clinical trials are required by
                  the FDA for approval of a marketing application.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Phase 4 clinical trials are studies required of or agreed to by a sponsor that are conducted after the FDA has approved a product for marketing. These studies are used to gain additional experience from the
                  treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical
                  trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement. Failure to promptly conduct Phase 4 clinical trials where
                  necessary could result in withdrawal of approval for products approved under accelerated approval regulations.</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">19</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">While Phase 1, Phase 2, and Phase 3 studies are generally required for approval of a marketing application, certain drugs and biologics may not require one or more steps in the process
          depending on other testing and the situation involved. Additionally, the FDA, an IRB, or the sponsor may stop testing at any time if results show patients being exposed to unnecessary health risks or overly dangerous side effects.&#160; Prior to the
          initiation of a clinical trial or at any time during the conduct of studies with human subjects, the FDA may place a study on clinical hold where patients may not be enrolled until questions around potential safety issues with investigational
          products are addressed.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In addition, the manufacturer of an investigational drug in a Phase 2 or Phase 3 clinical trial for a serious or life-threatening disease is required to make available, such as by posting on
          its website, its policy on evaluating and responding to requests for expanded access to such investigational drug.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the mechanism of action and physical characteristics of
          the drug and finalize a process for manufacturing the product in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other requirements, the manufacturer
          must develop methods for testing the identity, strength, quality, potency, and purity of the final product. Additionally, appropriate packaging must be selected and validated, and stability studies must be conducted to demonstrate that the
          product does not undergo unacceptable deterioration over its shelf life.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">United States drug review and approval process</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Following completion of clinical studies, the results are evaluated and, depending on the outcome, submitted to the FDA in the form of an NDA or BLA in order to obtain FDA approval of the
          product and authorization to commence commercial marketing. In responding to an NDA, the FDA may require additional testing or information, may require that the product labeling be modified, may impose a post-approval study and other commitments
          or reporting requirements or other restrictions on product distribution, or may deny the application.&#160; The timing of final FDA review and action varies greatly but can take years in some cases and may involve the input of an FDA advisory
          committee of outside experts. Product sales in the United States may commence only when an NDA or BLA is approved.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">FDA approval of a marketing application is required before marketing of the product may begin in the United States. The MA must include the results of product development, pre-clinical studies
          and clinical studies, together with other detailed information, including information on the chemistry, manufacture and controls utilized in manufacture of the product. In addition, a MA must also demonstrate purity, specifically in terms of
          showing that the final product does not contain extraneous material. The FDA has 60 days from its receipt of the MA to review the application to ensure that it is sufficiently complete for substantive review before accepting it for filing. The
          FDA may request additional information rather than accept an MA for filing. In this event, the MA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing.
          Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The submission of an MA is also subject to the payment of a substantial application fee (for FDA fiscal year 2022 this fee may exceed 3 million dollars,
          although a waiver of such fee may be obtained under certain limited circumstances, including when the drug that is subject of the application has received Orphan Drug Designation for the indication sought). Further, the sponsor of an approved MA
          is subject to an annual program fee, which for FDA fiscal year 2022 is $369,413 per prescription drug product. User fees typically increase annually. The approval process is lengthy and complex, and the FDA may refuse to approve an MA if the
          applicable regulatory criteria are not satisfied or may require additional clinical or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy the criteria for
          approval. The FDA may also refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review,
          evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee. The FDA reviews an application to determine, among other things, whether a product is safe and
          effective for its intended use. Before approving an MA, the FDA will inspect the facility or facilities where the product is manufactured to determine whether its manufacturing is cGMP&#8211;compliant to assure and preserve the product&#8217;s identity,
          potency, quality, purity and stability.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">If the FDA&#8217;s evaluation of the marketing submission or manufacturing facilities is not favorable, the FDA will issue a complete response letter. The complete response letter outlines the
          deficiencies in the submission and often requires additional testing or information in order for the FDA to reconsider the application. Even after submitting this additional information, the FDA ultimately may decide that the application does not
          satisfy the regulatory criteria for approval. With limited exceptions, the FDA may withhold approval of a MA regardless of prior advice it may have provided or commitments it may have made to the sponsor.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">20</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Once an MA is approved, changes to the conditions of approval, including additional indications, are made by the submission of a supplement to the MA The supplemental NDA, or sNDA, or the
          supplemental BLA, or sBLA must contain all of the information necessary to support the change. In the case of a new indication, that information usually consists of at least one clinical trial, and often more. Like an MA, FDA determines whether
          the supplemental application is sufficiently complete to permit review before it is filed. FDA then reviews the supplemental application. The FDA can either approve or issue a complete response letter outlining the deficiencies.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Manufacturing Readiness</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">As part of the approval process, the FDA must inspect and approve each manufacturing facility. Among the conditions of approval is the requirement that a manufacturer&#8217;s quality control and
          manufacturing procedures conform to cGMP. Manufacturers must expend significant time, money and effort to ensure continued compliance, and the FDA conducts periodic inspections to verify compliance.&#160; If we, or our contract manufacturers, fail to
          comply or cannot remedy regulator identified deficiencies, then we may be prohibited from marketing product.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">If the FDA grants approval, the approval will be limited to those conditions and patient populations for which the product is safe and effective, as demonstrated through clinical studies.
          Further, a product may be marketed only in those dosage forms and for those indications approved in the MA. Certain changes to an approved MA, including, with certain exceptions, any significant changes to labeling, require approval of a
          supplemental application before the drug may be marketed as changed. Any products that we manufacture or distribute pursuant to FDA approvals are subject to continuing monitoring and regulation by the FDA, including compliance with cGMP and the
          reporting of adverse experiences with the drugs. The nature of marketing claims that the FDA will permit us to make in the labeling and advertising of our products will generally be limited to those specified in FDA approved labeling, and the
          advertising of our products will be subject to comprehensive monitoring and regulation by the FDA. Products whose review was accelerated may carry additional restrictions on marketing activities, including the requirement that all promotional
          materials are pre-submitted to the FDA. Claims exceeding those contained in approved labeling will constitute a violation of the FDCA. Violations of the FDCA or regulatory requirements at any time during the product development process, approval
          process, or marketing and sale following approval may result in agency enforcement actions, including corrective advertising, cessation of violative promotion, withdrawal of approval, recall, seizure of products, warning letters, injunctions,
          fines and/or civil or criminal penalties. Any agency enforcement action could have a material adverse effect on our business.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Failure to comply with applicable federal, state and foreign laws and regulations would likely have a material adverse effect on our business. In addition, federal, state and foreign laws and
          regulations regarding the manufacture and sale of new drugs are subject to future changes.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Post-approval requirements and consideration</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Once a MA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs and biologics,
          including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. As a condition of MA approval, the FDA may
          also require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug or biologic outweigh the potential risks. REMS can include medication guides, communication plans for the healthcare professionals, and
          other Elements to Assure Safe Use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient
          registries. The requirement for a REMS can materially affect the potential market and profitability of the drug or biologic.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Drugs and biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an
          approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new MA supplement before the change can be implemented. An MA supplement for a new indication
          typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing MA supplements as it does in reviewing MAs.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">21</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Adverse event reporting and submission of periodic reports is required following FDA approval of an MA. The FDA also may require post-marketing testing, known as Phase 4 testing, and
          surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control as well as drug manufacture, packaging, and labeling procedures
          must continue to conform to cGMPs after approval. Drug and biologic manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced
          inspections by the FDA during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain
          compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized
          problems are subsequently discovered.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Foreign regulatory requirements</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In addition to regulation by the FDA and certain state regulatory agencies, we are also subject to a variety of foreign regulations governing clinical trials and the marketing of other
          products. Outside of the United States, our ability to market a product depends upon receiving a marketing authorization from the appropriate regulatory agencies. The requirements governing the conduct of clinical trials, marketing authorization,
          pricing and reimbursement vary widely from country to country. In any country, however, we will only be permitted to commercialize our products if the appropriate regulatory agency is satisfied that we have presented adequate evidence of safety,
          quality and efficacy. Whether or not FDA approval has been obtained, approval of a product by the comparable regulatory authorities of foreign countries must be obtained prior to the commencement of marketing of the product in those countries.
          The regulatory approval and oversight process in other countries includes all of the risks associated with regulation by the FDA and certain state regulatory agencies as described above.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Under the European Union regulatory system, applications for drug approval may be submitted either in a centralized or decentralized manner. Under the centralized procedure, a single
          application to the European Medicines Agency may lead to an approval granted by the European Commission which permits marketing of the product throughout the European Union. The decentralized procedure provides for mutual recognition of
          nationally approved decisions and is used for products that do not comply with requirements for the centralized procedure. Under the decentralized procedure, the holders of national marketing authorization in one of the countries within the
          European Union may submit further applications to other countries within the European Union, who will be requested to recognize the original authorization based on an assessment report provided by the country in which marketing authorization is
          held.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Pharmaceutical pricing and reimbursement</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In both United States and foreign markets, our ability to commercialize our products successfully, and to attract commercialization partners for our products, depends in significant part on the
          availability of adequate financial coverage and reimbursement from third-party payors, including, in the United States, governmental payors such as Medicare and Medicaid, managed care organizations, private commercial health insurers and pharmacy
          benefit managers, or PBMs. Third party payors are increasingly challenging the prices charged for medicines and examining their cost effectiveness, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic or
          other studies in order to further demonstrate the value of our products. Even with the availability of such studies, our products may be considered less safe, less effective or less cost-effective than alternative products, and third-party payors
          may not provide coverage and reimbursement for our product candidates, in whole or in part.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Political, economic and regulatory influences are subjecting the health care industry in the United States to fundamental changes. There have been, and we expect there will continue to be,
          legislative and regulatory proposals to change the healthcare system in ways that could significantly affect our business, including the Patient Protection and Affordable Care Act of 2010 (the &#8220;Affordable Care Act&#8221;).</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We anticipate that in the United States, Congress, state legislatures, and private sector entities will continue to consider and may adopt healthcare policies intended to curb rising healthcare
          costs. These cost containment measures could include:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">22</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">controls on government-funded reimbursement for drugs;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">mandatory rebates or additional charges to manufacturers for their products to be covered on Medicare Part D formularies;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">controls on healthcare providers;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">controls on pricing of pharmaceutical products, including the possible reference of the pricing of United States drugs to non-United States drug pricing for the same product;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">challenges to the pricing of drugs or limits or prohibitions on reimbursement for specific products through other means;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">reform of drug importation laws;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">entering into contractual agreements with payors; and</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">expansion of use of managed-care systems in which healthcare providers contract to provide comprehensive healthcare for a fixed cost per person</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We are unable to predict what additional legislation, regulations or policies, if any, relating to the healthcare industry or third-party coverage and reimbursement may be enacted in the future
          or what effect such legislation, regulations or policies would have on our business. Any cost containment measures, including those listed above, or other healthcare system reforms that are adopted may have a material adverse effect on our
          business prospects.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Further, the pricing of pharmaceutical products generally, and particularly the pricing of orphan drugs, has recently received scrutiny from the press and from members of Congress in both
          parties. Some members of the medical community have also made statements in the press on the pricing of orphan drugs. The impact of this scrutiny on the pricing of orphan drugs and other pharmaceutical products generally cannot be determined with
          any certainty at this time.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The Biologics Price Competition and Innovation Act of 2009, which was included in the Affordable Care Act, authorized the FDA to approve similar versions of innovative biologics, commonly known
          as biosimilars. Under the Affordable Care Act, a manufacturer may submit an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biologic product or &#8220;reference product.&#8221;
          Manufacturers may not submit an application for a biosimilar to the FDA until four years following approval of the reference product, and the FDA may not approve a biosimilar product until 12 years from the date on which the reference product was
          approved. Even if IRX-2 or any other biologic product we may acquire or in-license, if approved, are deemed to be reference products eligible for exclusivity, another company could market a competing version of that product if the FDA approves a
          full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Orphan Drug Exclusivity</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Some jurisdictions, including the United States and Europe, may designate drugs or biologic products for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983
          (ODA), the FDA may grant orphan drug designation to drugs or biologic products intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States
          and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. In the United
          States, orphan drug designation must be requested before submitting an application for marketing approval. An orphan drug designation does not shorten the duration of the regulatory review and approval process. The grant of an orphan drug
          designation request does not alter the standard regulatory requirements and process for obtaining marketing approval. Safety and efficacy of a product candidate must be established through adequate and well-controlled studies. If a product which
          has been granted orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the product is entitled to an orphan drug exclusivity period, which means the FDA may not approve any
          other application to market the same drug for the same disease or condition for a period of seven years, except in limited circumstances, such as where an alternative product demonstrates clinical superiority to the product with orphan
          exclusivity. In addition, holders of exclusivity for orphan drugs are expected to assure the availability of sufficient quantities of their orphan drugs to meet the needs of patients. Failure to do so could result in the withdrawal of marketing
          exclusivity for the drug.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">23</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The orphan drug exclusivity contained in the ODA has been the subject of recent scrutiny from the press, from some members of Congress and from some in the medical community. There can be no
          assurance that the exclusivity granted in ODA to orphan drugs approved by the FDA will not be modified in the future, and as to how any such change might affect our products.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The European Orphan Drug Regulation is considered for drugs intended to diagnose, prevent or treat a life-threatening or very serious condition afflicting five or fewer per 10,000 people in the
          EU, including compounds that for serious and chronic conditions would likely not be marketed without incentives due to low market return on the sponsor&#8217;s development investment. The medicinal product considered should be of significant benefit to
          those affected by the condition. Benefits of being granted Orphan Medicinal Product Designation are significant, including ten years of marketing exclusivity and a potential two-year extension. The EU Community and Member States may not accept or
          grant for ten years a new marketing authorization or application for another drug for the same therapeutic indication as the orphan drug, although the ten-year period can be reduced to six years if, after the end of the fifth year, available
          evidence establishes that the product is sufficiently profitable not to justify maintenance of the marketing exclusivity. A supplementary protection certificate may extend the protection six months beyond patent expiration if that is later than
          the orphan drug exclusivity period. To apply for the supplementary protection, a pediatric investigation plan, or PIP, must be included in the market application. In Europe all drugs now seeking marketing authorization need to have a PIP agreed
          with the European Medicines Agency (EMA) before it can be approved, even if it is a drug being developed specifically for a pediatric indication. If a product is developed solely for use in the pediatric population, then a Pediatric Use Marketing
          Authorization, or PUMA, may provide eight years of data exclusivity and ten years of marketing exclusivity.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Fast Track Designation and Accelerated Approval</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The FDA is required to facilitate the development, and expedite the review, of drugs or biologics that are intended for the treatment of a serious or life-threatening disease or condition for
          which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under the fast-track program, the sponsor of a new product candidate may request that FDA designate the product candidate
          for a specific indication as a fast-track drug concurrent with, or after, the filing of the IND for the product candidate. FDA must determine if the product qualifies for fast-track designation within 60 days of receipt of the sponsor&#8217;s request.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Under the fast track program and FDA&#8217;s accelerated approval regulations, FDA may approve a product for a serious or life-threatening illness that provides meaningful therapeutic benefit to
          patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to
          predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions,
          or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A product approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or
          post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow FDA to withdraw the product from the market
          on an expedited basis. All promotional materials for products approved under accelerated regulations are subject to prior review by FDA.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In addition to other benefits such as the ability to use surrogate endpoints and engage in more frequent interactions with FDA, FDA may initiate review of sections of a fast-track drug&#8217;s MA
          before the application is complete. This rolling review is available if the applicant provides, and FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, FDA&#8217;s time period
          goal for reviewing an application does not begin until the last section of the MA is submitted. Additionally, the fast-track designation may be withdrawn by the FDA if they believe that the designation is no longer supported by data emerging in
          the clinical trial process.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">24</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Priority Review</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Under FDA policies, a product candidate is eligible for priority review, or review within a six to eight-month time frame from the time a complete MA is submitted, if the product candidate is
          intended for the treatment, diagnosis, or prevention of a serious or life-threatening condition, demonstrates the potential to address an unmet medical need, or provides a significant improvement compared to marketed drugs.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Disclosure of clinical trial information</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Sponsors of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial information. Information related to the product, patient
          population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after
          completion. Disclosure of results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the clinical trial. Competitors may use this publicly available information to gain knowledge regarding
          the progress of development programs. Finally, there can be no assurance that fast track designation will result in a faster review process.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Anti-Kickback, False Claims Laws, Stark Law &amp; the Prescription Drug Marketing Act</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In addition to FDA restrictions on marketing of pharmaceutical products, other state and federal laws have been applied to restrict certain marketing practices in the pharmaceutical industry in
          recent years. These laws include anti-kickback prohibition, statutes and false claims statutes. The federal healthcare program Anti-Kickback Statute, or Anti-Kickback Statute, prohibits, among other things, knowingly and willfully offering,
          paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally
          financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and patients, prescribers, purchasers and formulary managers on the other. Violations of the
          Anti-Kickback Statute are punishable by imprisonment, criminal fines, civil monetary penalties, and exclusion from participation in federal healthcare programs. Although there are a number of statutory exceptions and regulatory safe harbors
          protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be
          subject to scrutiny if they do not qualify for an exemption or safe harbor.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Federal false claims laws prohibit, among other things, any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly
          making, or causing to be made, a false statement to have a false claim paid. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing
          services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In
          addition, certain marketing practices, including off-label promotion, may also violate false claims laws. The majority of states also have statutes or regulations similar to the Anti-Kickback Statute and false claims laws, which apply to items
          and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Federal law includes a provision commonly known as the &#8220;Stark Law.&#8221; This law prohibits a physician (defined to include a doctor of medicine or osteopathy, a doctor of dental surgery or dental
          medicine, a doctor of podiatric medicine, a doctor of optometry, or a chiropractor) from referring Medicare and Medicaid patients to certain types of entities with which the physician or any of the physician&#8217;s immediate family members have a
          financial relationship, unless an exception to the law&#8217;s prohibition is met. Subject to adherence to their respective criteria requirements, the self-referral prohibition contains a number of exceptions, including exceptions covering employment
          or independent contractor arrangements, space and equipment leases, and recruitment agreements.&#160; Sanctions within the Stark Law include significant civil penalties including over $25,000 for each violation, over $169,000 for schemes to circumvent
          the Stark Law restrictions, and up to $10,000 for each day an entity fails to report required information and exclusion from the federal healthcare programs.&#160; Violations of the Stark Law may also result in payment denials, false claim recoveries,
          civil monetary penalties, and/or federal program exclusion.&#160; Further, several states have enacted statutes similar in scope and purpose to the Stark Law. These state laws may mirror the federal Stark Law or may be different in scope. The
          available guidance and enforcement activity associated with such state laws varies considerably.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">25</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The Physician Payments Sunshine Act, created under the ACA, and its implementing regulations require manufacturers of approved prescription drugs, devices, biologics, and medical supplies, for
          which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually collect and report information on payments or transfers of value to physicians and teaching hospitals, as well
          as investment interests held by physicians and their immediate family members. The information reported each year is made publicly available on a searchable website. Failure to submit required information may result in civil monetary penalties.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In addition, several states now require prescription drug companies to report expenses relating to the marketing and promotion of drug products and to report gifts and payments to individual
          physicians in these states. Other states prohibit various other marketing-related activities. Still other states require the posting of information relating to clinical studies and their outcomes. In addition, California, Connecticut, Nevada, and
          Massachusetts require pharmaceutical companies to implement compliance programs and/or marketing codes. Several additional states are considering similar proposals. Compliance with these laws is difficult and time consuming, and companies that do
          not comply with these state laws face civil penalties.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Prescription drug advertising is subject to federal, state and foreign regulations. In the United States, the FDA regulates prescription drug promotion, including direct-to-consumer
          advertising. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Any distribution of prescription drug products and pharmaceutical samples must comply with the United States Prescription Drug
          Marketing Act, or PDMA, a part of the FDCA. In addition, Title II of the Federal Drug Quality and Security Act of 2013, known as the Drug Supply Chain Security Act, or DSCSA, has imposed new &#8220;track and trace&#8221; requirements on the distribution of
          prescription drug products by manufacturers, distributors, and other entities in the drug supply chain. The DSCSA requires product identifiers (i.e., serialization) on prescription drug products in order to eventually establish an electronic
          interoperable prescription product system to identify and trace certain prescription drugs distributed in the United States and preempts existing state drug pedigree laws and regulations on this topic. The DSCSA also establishes new requirements
          for the licensing of wholesale distributors and third-party logistic providers. The FDA is the process of finalizing regulations addressing wholesale distributors and third-party logistics providers. We serialize our product at both the package
          and homogeneous case level, pass serialization and required transaction information to our customers, and believe that we comply with all such requirements.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, sets standards governing the
          conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information that is stored or transmitted electronically.&#160; These include standards for common healthcare transactions, such as: claims
          information, plan eligibility, payment information and the use of electronic signatures; unique identifiers for providers, employers, health plans and individuals; and security, privacy, breach notification and enforcement.&#160; HIPAA transaction
          regulations establish form, format and data content requirements for most electronic healthcare transactions, such as healthcare claims that are submitted electronically. The HIPAA privacy regulations establish comprehensive requirements relating
          to the use and disclosure of protected health information. The HIPAA security regulations establish minimum standards for the protection of protected health information that is stored or transmitted electronically. The HIPAA breach notification
          regulations establish the applicable requirements for notifying individuals, the HHS, and the media in the event of a data breach affecting protected health information. Violations of the privacy, security and breach notification regulations are
          punishable by civil and criminal penalties.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In addition to the federal HIPAA regulations, most states also have laws that regulate the collection, storage, use, retention, security, disclosure, transfer and other processing of health
          information and other confidential, sensitive and personal data. Certain of these laws grant individuals rights with respect to their information, and we may be required to expend significant resources to comply with these laws. For example,
          various states, such as California and Massachusetts, have implemented privacy laws and regulations, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of
          personally identifiable information, including protected health information. These laws in many cases are more restrictive than, and may not be preempted by, the HIPAA rules and may be subject to varying interpretations by courts and government
          agencies.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">26</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Competition</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical
          companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, product development, technical and human resources than we do. Large pharmaceutical companies, in
          particular, have extensive experience in clinical testing, obtaining marketing approvals, recruiting patients and manufacturing pharmaceutical products. Some of these companies also have significantly greater research and marketing capabilities
          than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may
          also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Mergers and acquisitions in the pharmaceutical and biotechnology
          industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or marketing approval or discovering,
          developing and commercializing products in our field before we do.</div>

        <div style="text-align: justify;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist both of small
          molecule drug products, such as traditional chemotherapy, as well as novel immunotherapies. Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have
          fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain FDA, European Medicines Agency
          (&#8220;EMA&#8221;) or other marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if the product
          candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Human Capital Resources</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Employees</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">
          <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">We perform in a highly competitive industry and recognize that our continued success relies upon our ability to attract, develop and retain
            a diverse team of talented individuals. We place high value on the satisfaction and well-being of our employees and operate with fair labor standards and industry-competitive compensation and benefits. As of April 12, 2022, we have <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">ten </span>full-time employees, which includes five research and development positions and <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">five </span>administrative




            positions. None of our employees are covered by collective bargaining agreements.</div>

        </div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Compensation, Benefits and Development</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our approach to employee compensation and benefits is designed to deliver cash, equity and benefit programs that are competitive with those offered by leading companies in the biotechnology and
          pharmaceutical industries to attract, motivate and retain talent with a focus on encouraging performance, promoting accountability and adherence to our values and alignment with the interests of our stockholders.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our base pay program aims to compensate staff members relative to the value of the contributions of their role, which takes into account the skills, knowledge and abilities required to perform
          each position, as well as the experience brought to the job. We may also provide our employees with opportunities to earn cash and equity incentive compensation to reward the achievement of company-wide goals that are established annually and
          designed to drive aspects of our strategic priorities that support and advance our strategy across our company. Our employees are also eligible for the grant of equity awards under our long-term incentive program that are designed to align
          interests of our employees with that of our stockholders.&#160; All employees also participate in a regular performance measurement process through which staff receive performance and development feedback, which is taken into account in determining
          annual compensation.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our benefit programs are generally broad-based, promote health and overall well-being and emphasize saving for retirement. All employees are eligible to participate in the same health and
          retirement savings plans.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">27</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Code of Business Conduct and Ethics</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We are committed to conducting business in accordance with the highest ethical standards. Our Code of Conduct and Ethics emphasizes the importance of integrity, honesty, forthrightness, respect
          and fairness.&#160; Our Code of Conduct and Ethics applies to all our employees, including those who are integrated into the Company through acquisitions.</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Health, Safety and Well-Being</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We actively promote the safety, health and well-being of our employees. We have continued to focus on employee safety throughout the COVID-19 pandemic by implementing extensive safety measures,
          including without limitation, on-site COVID-19 testing protocols and flexible remote working options for most of our employees.</div>

        <div><br />
        </div>

        <div>
          <a id="ITEM1A."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45pt; vertical-align: top;"><span style="font-weight: bold; color: rgb(0, 0, 0);">ITEM 1A</span><span style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">.</span></td>

    <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Risk Factors</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our business, financial condition and operating results can be affected by many factors, whether currently known or unknown, many of which are not exclusively within our control, including but
          not limited to those described below, any one or more of which could, directly or indirectly, cause our financial condition and operating results to differ materially from historical or anticipated future financial condition and operating
          results. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and stock price. We urge investors to carefully consider the risk factors described below in evaluating
          our stock and the information in this Annual Report on Form 10-K, including the consolidated financial statements and the notes thereto and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Risks Related to Ownership of our Common Stock</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We have a limited operating history and have never generated any product revenue.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We are a clinical-stage biopharmaceutical company with a limited operating history. We were formed on September 27, 2018, for the purpose of consummating a business combination with IRX
          Therapeutics, Inc., which business combination was consummated on November 6, 2018. Since inception, we have incurred significant net losses. As of December 31, 2021, we had an accumulated deficit of approximately $159.7 million. Since inception,
          we have financed our operations with capital contributions from the former beneficial holders of Brooklyn LLC&#8217;s Class A membership interests, as well as through the sale of our securities under the Purchase Agreements with Lincoln Capital and in
          connection with the PIPE Transaction.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our ability to generate product revenue and become profitable depends upon our ability to successfully complete the development of, and obtain the necessary regulatory approvals for, our
          product candidates in development, including IRX-2. We have never been profitable, have no products approved for commercial sale, and have not generated any product revenue. It is possible that none of our product candidates will be approved for
          marketing. Failure to obtain regulatory approvals, or delays in obtaining regulatory approvals, may adversely affect the successful commercialization of any drugs or biologics that Brooklyn or its partners develop, may impose additional costs on
          us or our collaborators, may diminish any competitive advantages that we or our partners may attain, and/or may adversely affect our receipt of revenues or royalties.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses, or when or if we will be able to
          achieve or maintain profitability. Neither will we be able to predict the state of market competition which would adversely affect our potential revenues from product sales. Our expenses could increase beyond expectations if we are required by
          the FDA or comparable non-U.S. regulatory authorities to perform studies or clinical trials in addition to those that we currently anticipate. Even if any of our product candidates is approved for commercial sale, we anticipate incurring
          significant costs associated with their commercial launch. If we cannot successfully execute any one of the foregoing, our business may not succeed, and your investment will be negatively impacted.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">28</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Furthermore, we sometimes estimate for planning purposes the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones
          may include our expectations regarding the commencement or completion of scientific studies, clinical trials, the submission of regulatory filings or commercialization objectives. From time to time, we may publicly announce the expected timing of
          some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, the receipt of marketing approval or a commercial launch of a product. The achievement of many of these milestones may be
          outside of our control. All of these milestones are based on a variety of assumptions, which may cause the timing of achievement of the milestones to vary considerably from our estimates. If we fail to achieve milestones in the timeframes we
          expect, the commercialization of our product candidates may be delayed, we may not be entitled to receive certain contractual payments, which could have a material adverse effect on our business, financial position, results of operations and
          future growth prospects.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We may not be successful in our efforts to identify and acquire or in-license additional product candidates, or to enter into collaborations or strategic
          alliances for the development and commercialization of any such future product candidates.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We may seek to identify and acquire or in-license novel product candidates. The process by which we identify them may fail to yield product candidates for clinical development for a number of
          reasons, including those discussed in these risk factors and also:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">potential product candidates may, upon further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval
                  and achieve market acceptance;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">potential product candidates may not be effective in treating their targeted diseases; or</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the acquisition or in-licensing transactions can entail numerous operational and functional risks, including exposure to unknown liabilities, disruption of our business, or incurrence of substantial debt or
                  dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected acquisition or integration costs.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. We also cannot be certain that, following an acquisition or
          in-licensing transaction, we will achieve the revenue or specific net income that justifies such transaction. Further, time and resources spent identifying, acquiring and developing potential product candidates may distract management&#8217;s attention
          from our primary business or other development programs. Additional product candidates will require additional, time-consuming development efforts prior to commercial sale, including preclinical studies, clinical trials and approval by the FDA
          and/or applicable foreign regulatory authorities. All product candidates are prone to the risks of failure that are inherent in pharmaceutical product development. If we are unable to identify and acquire suitable product candidates for clinical
          development, this would adversely impact our business strategy, financial position and share price.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications
          that may be more profitable or for which there is a greater likelihood of success.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Because we have limited financial and managerial resources, we intend to focus on developing product candidates for specific indications that we identify as most likely to succeed, in terms of
          both their potential for marketing approval and commercialization, and there can be no assurance that the products we focus on will succeed. Because we must decide where to focus our resources, we may forego or delay pursuit of opportunities with
          other product candidates or for other indications that may later prove to have greater commercial potential.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and
          development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may
          relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to the
          product candidate.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">29</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">International expansion of our business exposes us to business, legal, regulatory, political, operational, financial and economic risks associated with
          conducting business outside of the United States.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Part of our business strategy involves potential expansion internationally with third-party collaborators to seek regulatory approval for our product candidates outside the United States. Doing
          business internationally involves a number of risks, including but not limited to:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">multiple conflicting and changing laws and regulations such as tax laws, export and import restrictions, employment laws, anti-bribery and anti-corruption laws, regulatory requirements and other
                  governmental approvals, permits and licenses;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">failure by us or our collaborators to obtain appropriate licenses or regulatory approvals for the sale or use of IRX-2 or any other product candidate we may acquire or in license;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">difficulties in managing foreign operations;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">complexities associated with managing multiple payor-reimbursement regimes or self-pay systems;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">financial risks, such as longer payment cycles, difficulty enforcing contracts and collecting accounts receivable and exposure to foreign currency exchange rate fluctuations;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">reduced protection for intellectual property rights;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">failure to comply with the United States Foreign Corrupt Practices Act, or FCPA, including its books and records provisions and its anti-bribery provisions, the United Kingdom Bribery Act 2010, or U.K.
                  Bribery Act, and similar anti-bribery and anti-corruption laws in other jurisdictions, for example by failing to maintain accurate information and control over sales or distributors&#8217; activities.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Any of these risks, if encountered, could significantly harm our future international expansion and operations and consequently, negatively impact its financial condition, results of operations
          and cash flows.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our ability to compete in the highly competitive pharmaceuticals industry depends in large part upon the ability to attract highly qualified managerial, scientific and medical personnel. In
          order to induce valuable employees to remain with us, we intend to provide employees with stock options that vest over time. The value to employees of stock options that vest over time will be significantly affected by movements in the price of
          the common stock that it will not be able to control and may at any time be insufficient to counteract more lucrative offers from other companies.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our management team has expertise in many different aspects of drug development. However, we will need to hire additional personnel as we continue to develop our product candidates. Competition
          for skilled personnel in the pharmaceutical industry is intense and competition for experienced scientists may limit our ability to hire and retain highly qualified personnel on acceptable terms. Despite our efforts to retain valuable employees,
          members of our management, scientific and medical teams may terminate their employment with us on short notice. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level, and senior
          managers as well as junior, mid-level, and senior scientific and medical personnel.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Other pharmaceutical companies with which we compete for qualified personnel have greater financial and other resources, different risk profiles, and a longer history in the industry than we
          do. Other pharmaceutical companies also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what Brooklyn has to offer. If we are
          unable to continue to attract and retain high-quality personnel, the rate and success at which we can develop and commercialize product candidates would be limited.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">30</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Risks Related to our Financial Position and Capital Requirements</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We expect to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to
          gain regulatory approval or fail to become commercially viable. We have never generated any product revenue, and we cannot estimate with precision the extent of our future losses. We do not currently have any products that are available for
          commercial sale, and we may never generate product revenue or achieve profitability.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We expect that our research and development expenses in connection with our development programs for product candidates will continue to be significant. In addition, as we prepare for and if we
          obtain regulatory approval for any of our product candidates, we expect to incur increased sales, marketing and manufacturing expenses. As a result, we expect to continue to incur significant and increasing operating losses and negative cash
          flows for the foreseeable future. These losses have harmed and will continue to harm our results of operations, financial position and working capital.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">There can be no assurance that we will be profitable even if we successfully commercialize IRX - 2 or any other product candidate we may acquire or in-license (including any products that may
          be developed from the licensed technology with Factor and Novellus, Ltd.). If we do successfully obtain regulatory approval to market any of our product candidates, our revenue will be dependent upon, in part and among other things, the size of
          the markets in the territories for which we gain regulatory approval, the number of competitors in such markets, the accepted price for any such product candidate and whether we own the commercial rights for those territories. If the indication
          approved by regulatory authorities is narrower than we expect, or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of any of our product candidates,
          even if approved. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Failure to become and remain profitable may adversely impact the market price of the common stock and
          our ability to raise capital and continue operations.</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We own only a 25% interest in NoveCite, Inc., and that interest may be diluted unless we invest additional funds.</div>

        <div>&#160; <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In July 2021, we acquired 25% of the outstanding common stock of NoveCite, Inc. As a result, we will only be entitled to a portion of any benefits that flow from the development by NoveCite,
          Inc. of any product candidates. In the event that NoveCite, Inc. issues additional equity securities in the future, our percentage ownership would be diluted unless we were to invest additional funds. Dilution of our equity ownership would
          decrease our portion of any benefit that might be derived from a NoveCite, Inc. product candidate&#8217;s successful development. If we were to determine that it would be in the best interests of our company and stockholders to invest additional
          amounts in NoveCite, Inc. to prevent dilution of our interests, the required funds may not be available to us on reasonable terms, or at all.</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We may not generate the expected benefits of our Acquisition and it could disrupt our ongoing business, distract our management and increase our expenses.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We entered into the Acquisition Agreement to acquire all the outstanding equity interests of Novellus, Inc. and Novellus, Ltd., which we collectively refer to as Novellus, with the expectation
          that the Acquisition will result in various benefits, including accelerating our research and development efforts in the gene editing and mRNA spaces. Achieving the anticipated benefits of the Acquisition is subject to a number of uncertainties,
          including whether our business and the business of Novellus can be integrated in an efficient and effective manner. We cannot assure you that we will be able to accurately forecast the performance or ultimate impact of the Acquisition.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">It is possible that the integration process following the Acquisition could take longer than anticipated and could result in unforeseen expenses, the disruption of our ongoing business,
          processes and systems, or inconsistencies in standards, controls, procedures, practices, policies and compensation arrangements, any of which could adversely affect our ability to achieve the anticipated benefits of the Acquisition. There may be
          increased risk due to integrating financial reporting and internal control systems. The integration process is subject to a number of uncertainties, and no assurance can be given that the anticipated benefits, expense savings and synergies of the
          Acquisition will be realized or, if realized, the timing of their realization. Failure to achieve these anticipated benefits could result in increased costs or decreases in the amount of expected revenues and could adversely affect our future
          business, financial condition, operating results and prospects.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">31</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We have incurred and will continue to incur non-recurring expenses in connection with the Acquisition, including legal, accounting and other expenses. Additional unanticipated costs may be
          incurred following consummation of the Acquisition during the integration of the business of Novellus into our business. We cannot be certain that the realization of efficiencies related to the integration of Novellus will offset in the near
          term, or at all, the transaction and integration costs of the Acquisition and any losses from undiscovered liabilities not covered by indemnification provisions from the sellers of Novellus under the Acquisition Agreement or otherwise.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We may acquire businesses, assets or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We may acquire additional businesses, assets or products, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business.
          If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may
          encounter numerous difficulties in developing, manufacturing and marketing any new acquisition. Difficulties may prevent us from realizing its expected benefits or enhancing our business. We cannot assure you that, following any such acquisition,
          we will achieve the expected synergies to justify the transaction.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We will require substantial additional capital to fund our operations, and if we fail to obtain the necessary financing, we may not be able to complete
          the development and commercialization of any of our product candidates.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Brooklyn expects to spend substantial capital to complete the development of, seek regulatory approvals for and commercialize IRX-2, perhaps with development partners, as well as any of other
          product candidate it may develop. We will require additional capital to complete the development and potential commercialization of our product candidates. Because the length of time and activities associated with successful development of our
          product candidates are highly uncertain, we are unable to estimate with certainty the actual funds we will require for development and any approved marketing and commercialization activities. Our future funding requirements, both near- and
          long-term, will depend on many factors, including, but not limited to:</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">the timing, progress, costs and results of our INSPIRE trial for the treatment of squamous cell cancer of the head and neck;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">the costs of any other clinical trials we may initiate, including the costs to conduct the study and to produce the supply of product that may be required for our own studies or for investigator-sponsored
                  studies;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the cost of filing, prosecuting, defending and enforcing its patent claims and other intellectual property rights;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against it or any of its current or future product candidates;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the effect of competing market developments;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the cost and timing of completion of commercial-scale manufacturing activities;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the cost of establishing sales, marketing and distribution capabilities for our products in regions where we choose to commercialize our products on our own; and</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the initiation, progress, timing and results of the commercialization of our product candidates, if approved for commercial sale.</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">32</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Based on currently available information and our ongoing operations, we believe that our existing cash, inclusive of the funding committed by certain beneficial holders of Brooklyn LLC&#8217;s Class
          A membership interests and received under the Purchase Agreements with Lincoln Capital and in connection with the PIPE Transactions, will not be sufficient for us to fund our operating expenses and capital expenditure requirements through the
          twelve-month period subsequent to the issuance date of this report.&#160; We intend to raise additional sources of capital, which could be in the form of debt, grants or equity.&#160; We cannot be certain that additional capital will be available on
          acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of any product
          candidate, or potentially discontinue operations altogether. In addition, attempting to secure additional capital may divert the time and attention of our management from day-to-day activities and harm its product candidate development efforts.
          Because of the numerous risks and uncertainties associated with the development and potential commercialization of its product candidates, we are unable to estimate the amounts of increased capital outlays, operating expenditures and capital
          requirements associated with its current product development programs.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Raising additional funds by issuing equity securities may cause dilution to existing holders, raising additional funds through debt financings may involve
          restrictive covenants, and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We expect that significant additional capital will be needed in the future to continue our planned operations. Until such time, if ever, that we can generate substantial product revenue, we
          expect to finance our cash needs through a combination of equity offerings, debt financings, strategic alliances and license and development agreements or other collaborations. To the extent that we raise additional capital by issuing equity
          securities, existing stockholder ownership may experience substantial dilution, and the securities may include preferred shares with liquidation or other preferences that could harm the rights of a common stockholder.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to
          its technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or
          terminate its product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market themselves.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Risks Related to our Business and Industry</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We face business disruption and related risks resulting from the pandemic of the novel coronavirus (COVID-19), which could have a material adverse effect
          on our business plan.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The development of our product candidates has been, and could continue to be, disrupted and materially adversely affected by past and continuing impacts of the COVID-19 pandemic. This is
          largely a result of measures imposed by the governments and hospitals in affected regions, businesses and schools were suspended due to quarantines intended to contain this outbreak. The spread of COVID-19 from China to other countries resulted
          in the Director General of the World Health Organization declaring COVID-19 a pandemic in March 2020. While the constraints of the pandemic are being lifted, we are still assessing the longer-term impact of the COVID-19 pandemic on our
          development plans, and on the ability to conduct our clinical trials. COVID-19 could continue to disrupt production and cause delays in the supply and delivery of products used in our operations, may affect our operations, including the conduct
          of clinical studies, or the ability of regulatory bodies to grant approvals or supervise our candidates and products, may further divert the attention and efforts of the medical community to coping with the COVID-19 and disrupt the marketplace in
          which we operate and may have a material adverse effects on our operations. COVID-19 may also affect our employees and employees and operations at suppliers that may result in delays or disruptions in supply. In addition, a recession or market
          correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. Additionally, if the COVID-19 pandemic has a significant impact on our business and financial results for an extended period
          of time, our liquidity and cash resources could be negatively impacted. The extent to which the COVID-19 pandemic and ongoing global efforts to contain its spread will impact our operations will depend on future developments, which are highly
          uncertain, and include the duration, severity and scope of the pandemic and the actions taken to contain or treat the COVID-19 pandemic. Further, the specific clinical outcomes, or future pandemic related impacts of emerging COVID-19 variants
          cannot be reliably predicted.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">33</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Our business and operations would suffer in the event of system failures, cyber-attacks or a deficiency in our cyber-security.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our computer systems, as well as those of various third parties on which it relies, may sustain damage from computer viruses, unauthorized access, data breaches, phishing attacks,
          cybercriminals, natural disasters (including hurricanes and earthquakes), terrorism, war and telecommunication and electrical failures. We rely on our third-party providers to implement effective security measures and identify and correct for any
          such failures, deficiencies or breaches. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the
          number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug
          development and other programs. For example, the loss of nonclinical or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
          reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability
          and the further development of any product candidate could be delayed.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We are substantially dependent on the success of our internal development programs and our product pipeline candidates may not successfully complete
          clinical trials, receive regulatory approval or be successfully commercialized.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our future success will depend heavily on the success of our development of IRX-2, successful clinical development of our in-licensed cell and gene therapy technologies and any other products
          we may acquire, license or develop (including any products that may be developed from the licensed technology if Brooklyn exercises its option to license certain technology from Novellus). We expect to continue our efforts and expenditures
          related to the continued clinical evaluation of our lead product candidate, IRX-2, and the monotherapy and combination studies related thereto. We expect to continue our efforts towards the commercialization of such product candidates following
          regulatory approval, if received. Additionally, we expect to devote substantial resources and efforts to the preclinical and clinical evaluation of new cell and gene therapy product platforms that we may acquire or in-license (including any
          products that may be developed from the licensed technology with Factor and Novellus, Ltd.). Accordingly, our business currently depends heavily on the successful completion of our clinical trials for its product candidates and subsequent
          regulatory approval and commercialization of such product candidates. Our ability to successfully commercialize IRX-2 and any other product we may acquire, license or develop, will depend on, among other things, our ability to:</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">successfully complete pre-clinical studies and clinical trials deemed adequate by regulatory authorities and obtain and maintain regulatory approval for the marketing of our product candidates;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">receive regulatory approvals from the FDA, the EMA and other similar regulatory authorities;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">establish and maintain collaborations with third parties for the development and/or commercialization of our product candidates, or otherwise build and maintain strong development, sales, distribution and
                  marketing capabilities that are sufficient to develop products and launch commercial sales of any approved products, including establishing sales, marketing and distribution systems for our product candidates;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">obtain coverage and adequate reimbursement from payors such as government health care systems, pharmacy benefit managers, and insurance companies and achieve commercially attractive levels of pricing;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">secure acceptance of our product candidates from physicians, health care payors, patients and the medical community;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">produce, through a validated process, in manufacturing facilities inspected and approved by regulatory authorities, including the FDA, sufficiently large quantities of our product candidates to permit
                  successful commercialization;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">manage our spending as expenses increase due to government mandated post-approval clinical trials and commercialization;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">obtain and enforce sufficient intellectual property rights for any approved products and product candidates, maintain, expand and protect our intellectual property portfolio;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">add operational, financial, and management information systems; personnel, including personnel to support its clinical, manufacturing and planned future commercialization efforts and operations as a public
                  company;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">conduct internal or contract manufacturing meeting specifications and in compliance with applicable cGMPs; and</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">34</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">initiate and continue relationships with third-party suppliers and manufacturers or continue to further develop our own manufacturing capabilities and have commercial quantities of our product candidates
                  manufactured at acceptable cost and quality levels and in compliance with the FDA and other regulatory requirements.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"><span style="font-weight: bold;">Conducting pre-clinical studies in animals and clinical studies in humans is a lengthy, time-consuming, and expensive process. In order to
            obtain FDA approval to market a new pharmaceutical product, we must demonstrate proof of safety and efficacy of the product.</span>&#160;<span style="font-weight: bold;">We cannot be certain that our clinical trials for our product candidates will
            be successful or that any of our product candidates will receive approval from the FDA, the EMA or any other comparable regulatory authority.</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of products are, and will remain, subject to extensive regulation by the FDA and other regulatory
          authorities in the United States and in other countries that each have differing regulations. While we have submitted an IND in the United States and comparable drug approval filings with certain foreign regulatory authorities, the timing of the
          filing for marketing approval in the United States or comparable filing in other nations is unknown. We must provide these regulatory authorities with data from preclinical studies and clinical trials that demonstrate our product candidates are
          safe and effective for specific indications before they can be approved for commercial distribution. Securing regulatory approval requires the submission of extensive preclinical, nonclinical and clinical data and other supporting information for
          each proposed therapeutic indication, in order to establish the product&#8217;s safety and efficacy for each intended use. In the case of biologics the data must also include potency and purity for each product.&#160; There are risks associated with this
          process that may include:</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">preclinical studies and clinical trials are long, expensive and unpredictable processes that can be subject to extensive delays;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">we cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">it may take several years and require significant expenditures to complete the preclinical studies and clinical trials necessary to commercialize a product candidate, and delays or failure are inherently
                  unpredictable and can occur at any stage.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">we may also be required to conduct additional clinical trials or other testing of our product candidates beyond the trials and testing that we contemplate, which may lead to us incurring additional
                  unplanned costs or result in delays in clinical development;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">we may be required to redesign or otherwise modify our plans with respect to an ongoing or planned clinical trial and changing the design of a clinical trial can be expensive and time consuming; and</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">an unfavorable outcome in one or more trials would be a major setback for our product candidates and for us. It may require us to delay, reduce the scope of or eliminate one or more product development
                  programs, which could have a material adverse effect on our business, financial position, results of operations and future growth prospects.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In order to obtain FDA approval to market a new pharmaceutical product, we must demonstrate proof of safety and efficacy of the product in humans. To meet these requirements, we must conduct
          &#8220;adequate and well controlled&#8221; clinical studies.&#160; The length of time to complete these studies may vary substantially according to the type, complexity, novelty, and intended use of the product candidate, and often can be several years or more
          per study. We cannot be certain that our clinical trials for our product candidates will be successful or that any of our product candidates will receive approval from the FDA, the EMA or any other comparable regulatory authority. Of the large
          number of drugs in development in the pharmaceutical industry, only a small percentage result in the submission of a new drug marketing application to the FDA and even fewer are approved for commercialization. The FDA or other foreign regulatory
          authorities may delay, limit or deny approval of any of our product candidates for many reasons, including:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">We may not be able to demonstrate that any product candidate is safe or effective as a treatment for any of our currently or future targeted indications to the satisfaction of the FDA or other relevant
                  regulatory authorities.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">The relevant regulatory authorities may require additional pre-approval studies or clinical trials which would increase our costs and prolong development timelines or could grant conditional approval with a
                  requirement to perform additional studies at a significant cost.</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">35</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">The results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA or other relevant regulatory authorities for marketing approval.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">The FDA or other relevant regulatory authorities may disagree with the number, design, size, conduct or implementation of our clinical trials, including the design of its future pivotal Phase 3 clinical
                  trials.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Contract Research Organizations (&#8220;CROs&#8221;) that we may retain to conduct clinical trials may take actions outside of our control, or otherwise commit errors or violations of protocols, that adversely impact
                  our clinical trials and ability to obtain market approvals.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">The FDA or other relevant regulatory authorities may not find the data from nonclinical studies or clinical trials sufficient to demonstrate that the clinical and other benefits of these products outweigh
                  their safety risks.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">The FDA or other relevant regulatory authorities may disagree with our interpretation of data or significance of results from the nonclinical studies and clinical trials of IRX - 2 or any other product
                  candidate we may acquire or in-license or may require that it conduct additional studies.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">The FDA or other relevant regulatory authorities may not accept data generated from our clinical trial sites.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">If our MA or other foreign application is reviewed by an advisory committee, the FDA or other relevant regulatory authority, may have difficulties scheduling an advisory committee meeting in a timely manner
                  or the advisory committee may recommend against approval of such application or may recommend that the FDA or other relevant regulatory authority require, as a condition of approval, additional nonclinical studies or clinical trials,
                  limitations on approved labeling or distribution and use restrictions.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">The FDA or other relevant regulatory authorities may require development of a REMS, or its equivalent, as a condition of approval.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">The FDA or other relevant regulatory authorities may require additional post-marketing studies and/or a patient registry, which would be costly.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">The FDA or other relevant regulatory authorities may find the chemistry, manufacturing and controls data insufficient to support the quality of IRX - 2 or any other product candidate we may acquire or
                  in-license.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">The FDA or other relevant regulatory authorities may identify deficiencies in the manufacturing processes or facilities of our third-party manufacturer or our own manufacturing processes or facilities.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">The FDA or other relevant regulatory authorities may change their approval policies or adopt new regulations.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Many of the factors that cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval for our product candidates.
          The FDA, EMA or any other comparable regulatory authority may disagree with our clinical trial design and our interpretation of data from clinical trials or may change the requirements for approval even after it has reviewed and commented on the
          design for our clinical trials. In connection with clinical trials of our product candidates, we face a number of risks, including risks that:</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">a product candidate is ineffective or inferior to existing approved products for the same indications;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">patients may die or suffer adverse effects for reasons that may or may not be related to the product candidate being tested;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">a product candidate causes or is associated with unacceptable toxicity or has unacceptable side effects;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">the results may not confirm the positive results of earlier trials;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">we are unable to manufacture sufficient quantities of stable and qualified materials under cGMP for use in clinical studies;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">we fail to recruit a sufficient number of patients or we have slower than expected rates of patient recruitment;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">modification of clinical study protocols is necessary;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">there may be changes in regulatory requirements for clinical studies;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">there is a lack of effectiveness during clinical studies;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">there is an emergence of unforeseen safety issues;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">there may be delays, suspension, or termination of the clinical studies due to the IRB responsible for overseeing the study at a particular study site;</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">36</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">there could be government or regulatory delays or &#8220;clinical holds&#8221; requiring suspension or termination of the studies; and</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">our collaborators may be unable or unwilling to perform under their contracts.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Delays associated with products for which we are directly conducting clinical studies may cause us to incur additional operating expenses.&#160; An unfavorable outcome in one or more trials would be
          a major setback for our product candidates and for us. It may require us to delay, reduce the scope of or eliminate one or more product development programs, which could have a material adverse effect on our business, financial position, results
          of operations and future growth prospects.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Furthermore, even if we do receive regulatory approval to market our product candidates, any such approval may be subject to limitations on the indicated uses or patient populations for which
          we may market the product.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The failure of clinical studies to demonstrate safety and effectiveness for the desired indications could harm the development of that product candidate and other product candidates. This
          failure could cause us to abandon a product candidate and could delay development of other product candidates. Any delay in, or termination of, our clinical studies would delay the filing of its marketing application with the FDA and, ultimately,
          our ability to commercialize its product candidates and generate product revenues. Any change in, or termination of, our clinical studies could materially harm our business, financial condition, and results of operations. Any of these events
          could harm our business and operations and could negatively impact the price of our common stock.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of clinical trials do not necessarily predict
          success in the results of completed clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and
          we could face similar setbacks. For example, results from the INSPIRE trial of IRX-2 may not be positive or replicated at clinical trial sites in a later stage clinical trial conducted by us or our collaborators. The design of a clinical trial
          can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to design and execute a clinical trial to support
          marketing approval.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical
          studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we, or any collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the
          FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes
          in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants.
          If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and
          financial prospects would be negatively impacted.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">37</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Clinical studies required for our product candidates may involve combination with other products which may result in unpredictable outcomes</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In some cases, IRX-2 and any other product we may acquire or in-license (including any products that may be developed from the licensed technology if Brooklyn exercises its option to
          exclusively license certain technology from Novellus) may be expected to be used in combination with approved therapies that may have significant adverse event profiles. During the course of treatment, these patients could suffer adverse medical
          events or die for reasons that may or may not be related to our product candidates. We cannot ensure that safety issues will not arise with respect to our product candidates in clinical development. In addition, several of our IRX-2 studies focus
          on IRX-2 in conjunction with current preferred treatments for certain types of cancer, including head and neck cancers. If the drugs being studied in conjunction with IRX-2 are found to be faulty in any way, or if they fall out of favor as a
          preferred treatment, our clinical studies may be adversely effected, as we may have to restart such studies with the newer, preferred treatment in conjunction with IRX-2. Any delay in obtaining or failure to obtain required approvals could
          negatively impact our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact the price of our common stock.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product
          candidates.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on our ability to recruit
          patients to participate as well as the completion of required follow-up periods. Patients may be unwilling to participate in our clinical trials because of negative publicity from adverse events related to novel therapeutic approaches,
          competitive clinical trials for similar patient populations, the existence of current treatments or for other reasons. Enrollment risks are heightened with respect to certain indications that we may target for one or more of our product
          candidates that may be rare diseases, which may limit the pool of patients that may be enrolled in our planned clinical trials. The timeline for recruiting patients, conducting trials and obtaining regulatory approval of our product candidates
          may be delayed, including as a result of the ongoing effects of the COVID-19 pandemic, which could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination
          of the clinical trials altogether.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with the required or desired characteristics, to complete our clinical trials in a timely manner.
          For example, due to the nature of the indications that we are initially targeting, patients with advanced disease progression may not be suitable candidates for treatment with our product candidates and may be ineligible for enrollment in our
          clinical trials. Therefore, early diagnosis in patients with our target diseases is critical to our success. Patient enrollment and trial completion is affected by factors including the:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">size of the patient population and process for identifying subjects;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">design of the trial protocol;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">eligibility and exclusion criteria;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">safety profile, to date, of the product candidate under study;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">perceived risks and benefits of the product candidate under study;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">perceived risks and benefits of our approach to treatment of diseases;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">availability of competing therapies and clinical trials;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">severity of the disease under investigation;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">degree of progression of the subject&#8217;s disease at the time of enrollment;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">proximity and availability of clinical trial sites for prospective subjects;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">ability to obtain and maintain subject consent;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">risks that enrolled patients will drop out before completion of the trial;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">patient referral services of physicians; and</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">ability to monitor subjects adequately during and after treatment.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of
          which would have an adverse effect on our business, financial condition, results of operations and prospects.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product
          candidates.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We face a potential risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize our product candidates. For
          example, we may be sued if any product we develop or any materials that we use in our products allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability
          claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer
          protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require
          significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">38</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">decreased demand for our product candidates;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">injury to our reputation;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">withdrawal of clinical trial participants;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">costs to defend the related litigation;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">a diversion of management&#8217;s time and its resources;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">substantial monetary awards to trial participants or patients;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">product recalls, withdrawals or labeling, marketing or promotional restrictions;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the inability to commercialize our product candidates; and</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">a decline in the value of the common stock.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Any inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the
          commercialization of products we develop. We intend to obtain product liability insurance covering our clinical trials. Although we will maintain such insurance, any claim that may be brought against us could result in a court judgment or
          settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability
          claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed its coverage limitations or that are not covered by its insurance, and we may not have, or be able to obtain,
          sufficient capital to pay such amounts.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Our current or future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved
          products or investigational new drugs that could halt their clinical development, prevent their marketing approval, limit their commercial potential or result in significant negative consequences.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Undesirable or clinically unmanageable side effects could occur and cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label
          or the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">If unacceptable side effects arise in the development of our product candidates, we, the FDA or comparable foreign regulatory authorities, IRBs, or independent ethics committees at the
          institutions in which our studies are conducted, or the Data Safety Monitoring Board, or DSMB, could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny
          approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability
          claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We may be required to train medical personnel using our product candidates to understand the side effect profiles for our
          clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences
          may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Moreover, clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our
          clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of a product candidate,
          we, or others, discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following consequences could occur:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">39</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">regulatory authorities may withdraw their approval of the product or seize the product;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">we, or any collaborators, may need to recall the product, or be required to change the way the product is administered or conduct additional clinical trials;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the&#160; product;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">regulatory authorities may require the addition of labeling statements, such as a boxed warning or a contraindication;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">we, or any collaborators, may be required to create a medication guide outlining the risks of the previously unidentified side effects for distribution to patients;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">we, or any collaborators, could be sued and held liable for harm caused to patients;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the product may become less competitive; and</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">our reputation may suffer.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Risks Related to New, Cutting Edge Technologies</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Because our gene-editing and cell therapy product candidates are based on novel technologies, we cannot assure that we will be successful, or predict the
          related cost and time we will spend, in initiating, conducting and completing clinical development, and obtaining the necessary regulatory and reimbursement approvals, required for commercialization.</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Cellular immunotherapies, stem cell therapies, gene-edited, and iPSC-derived cell therapies represent relatively new therapeutic areas, and the FDA has cautioned consumers about potential
          safety risks associated with them. To date, there are relatively few approved cell therapies. As a result, the regulatory approval process for a gene-editing or cellular therapy product candidates are uncertain and may be more expensive and take
          longer than the approval process for product candidates based on other, better known or more extensively studied technologies and therapeutic approaches. For example, there are no new FDA approved products with a label designation that supports
          the use of a product to treat and reduce the severity of ARDS in patients with COVID-19, which makes it difficult to determine the clinical endpoints and data required to support an application or regulatory approval, and the time and cost
          required to obtain regulatory approval in the United States for our product candidate.</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Cell reprogramming technology and cell therapy products using allogenic MSCs derived from iPSCs represent novel therapeutic approaches, and to our knowledge no iPSC-derived cell products are
          currently approved for commercial sale anywhere in the world. As such, it is difficult to accurately predict the type and scope of challenges that we will incur during development of our respective product candidates. We thus face uncertainties
          associated with the preclinical and clinical development, manufacture, and regulatory compliance for the initiation and conduct of clinical trials, regulatory approval, and reimbursement required for successful commercialization of product
          candidates. In addition, because the iPSC-derived cell product candidates are in the pre-clinical stage, no human data are yet available to assess the effects of treatment. Animal models and assays may not accurately predict the safety and
          efficacy of our product candidates in our target patient populations, and appropriate models and assays may need to be developed for demonstrating the safety, efficacy and purity of the product candidates, as required by the FDA and other
          regulatory authorities for ongoing clinical development and regulatory approval.</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Regulatory processes in the United States governing cell therapy products have changed frequently and the FDA or other regulatory bodies may change the requirements, or identify different
          regulatory pathways, for approval of these product candidates. For example, within the FDA, the Center for Biologics Evaluation and Research, CBER, restructured and created a new Office of Tissues and Advanced Therapies, OTAT, to better align its
          oversight activities with FDA Centers for Drugs and Medical Devices. It is possible that over time new or different divisions may be established or be granted the authority for regulating cell and/or gene therapy products, including iPSC-derived
          cell products. As a result, we may be required to change regulatory strategies or to modify applications for regulatory approval, which could delay and impair our ability to complete the pre-clinical and clinical development and manufacture of,
          and obtain regulatory approval for, our product candidates. Changes in regulatory authorities and advisory groups, or any new requirements or guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional
          studies, increase development and manufacturing costs, lead to changes in regulatory pathways, positions and interpretations, delay or prevent approval and commercialization of the product candidates or lead to significant post-approval
          limitations or restrictions. As we advance our product candidates, we will be required to consult with the FDA and other regulatory authorities, and our product candidates will likely be reviewed by an FDA advisory committee. We also must comply
          with applicable requirements, and if we fail to do so, we may be required to delay or discontinue development of our product candidates. Delays or unexpected costs in obtaining, or the failure to obtain, the regulatory approval necessary to bring
          the product candidates to market could impair our ability to generate sufficient product revenues to maintain our respective businesses.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">40</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The pre-clinical and clinical development, manufacture, and regulatory requirements for approval of the product candidates may be more expensive and take longer than for other more well-known
          or extensively studied pharmaceutical or biopharmaceutical product candidates, due to a lack of prior experiences on the side of both developers and regulatory agencies. Additionally,&#160; we may be required to modify or change pre-clinical and
          clinical development plans or manufacturing activities and plans or be required to meet stricter regulatory requirements for approval. Any such modifications or changes could delay or prevent our ability to develop, manufacture, obtain regulatory
          approval or commercialize the product candidates, which would adversely affect our business, financial condition and results of operations.</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Gene editing product candidates we may develop based on our license agreements with Factor and Novellus are based on new technology, which makes it
          difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if we are able to obtain such approval.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Gene editing product candidates we may develop based on our license agreements with Factor and Novellus are based on new technology, which makes it difficult to predict the time and cost of
          development and of subsequently obtaining regulatory approval, if we are able to obtain such approval<span style="font-style: italic;">. </span>Gene editing technology is relatively new, and no products based on such technology have been
          approved in the U.S. or the E.U. to date, and only a limited number of clinical trials of product candidates based on gene-editing technologies have been commenced. As such, it is difficult to accurately predict the developmental challenges we
          may incur if we exclusively license the technology from Factor, as we proceed through product discovery or identification, preclinical studies and clinical trials. There may be long-term effects from treatment with any such product candidates
          that we may develop that we cannot predict at this time. Any product candidates we may develop may interact with genetic material (RNA/DNA) and because animal genetic materials differ from human genetic material, past testing of any such product
          candidates in animal models may not be predictive of results in human clinical trials for safety or efficacy. As a result of these factors, it is more difficult to predict the time and cost of such product candidate development, and we cannot
          predict whether the application of gene editing technology, or other similar or competitive gene editing technologies, will result in the identification, development and regulatory approval of any products. There can be no assurance that any
          development problems we may experience related to such gene editing technology or any of our research programs that use such technology will not cause significant delays or anticipated costs, or that such development problems can be solved. Any
          of these factors may prevent us from completing preclinical studies or clinical trials based on such technology or from commercializing any such product candidates on a timely or profitable basis, if at all.</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary
          substantially according to the type, complexity, novelty and intended use and market of the product candidate. No products based on gene-editing technologies have been approved by regulators to date. As a result, the regulatory approval process
          for product candidates using such technology is uncertain and may be more expensive and take longer than the approval process for product candidates based on other, better known or more extensively studied technologies. It is difficult to
          determine how long it will take or how much it will cost to obtain regulatory approvals for product candidates using this technology in either the United States or the E.U. or how long it will take to commercialize any product candidates. Delay
          or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product candidate to market could decrease our ability to generate sufficient product revenue, and our business, financial condition,
          results of operations and prospects may be harmed.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">41</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Regulatory requirements in the United States and in other jurisdictions governing gene therapy products have changed frequently and may continue to change in the future. In January 2020, the
          FDA issued several new guidance documents on gene therapy products. The FDA established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research to consolidate the review of gene therapy and related
          products, and established the Cellular, Tissue and Gene Therapies Advisory Committee to advise this review. In addition to the government regulators, the IBC and IRB of each institution at which we conduct clinical trials of our product
          candidates, or a central IRB if appropriate, would need to review the proposed clinical trial to assess the safety of the trial. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA
          or other oversight bodies to change the requirements for approval of any of our product candidates. Similarly, the EMA governs the development of gene therapies in the EU and may issue new guidelines concerning the development and marketing
          authorization for gene therapy products and require that we comply with these new guidelines. These regulatory review agencies and committees and the new requirements or guidelines they promulgate may lengthen the regulatory review process,
          require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of any product candidates we may develop if we
          exercise our option agreements with Novellus or lead to significant post-approval limitations or restrictions. As we advance any such product candidates, we will be required to consult with these regulatory agencies and committees and comply with
          applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we
          otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our or our collaborators&#8217;
          ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Risks Related to Regulatory Requirements</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We are subject to extensive and costly government regulation.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Product candidates employing medical technology are subject to extensive and rigorous domestic government regulation including regulation by the FDA, the Centers for Medicare and Medicaid
          Services, or CMS, other divisions of the United States Department of Health and Human Services, the United States Department of Justice, state and local governments, and their respective foreign equivalents. If products employing our technologies
          are marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not they have obtained FDA approval for a given product and its uses. Such foreign regulation may be equally or more demanding than
          corresponding United States regulation.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Government regulation substantially increases the cost and risk of researching, developing, manufacturing, and selling our products. Even if we are able to obtain regulatory approval for a
          particular product, the approval may limit the indicated medical uses for the product, may otherwise limit our ability to promote, sell, and distribute the product, may require that we conduct costly post-marketing surveillance, and/or may
          require that we conduct ongoing post-marketing studies. Material changes to an approved product, such as, for example, manufacturing changes or revised labeling, may require further regulatory review and approval. Once obtained, any approvals may
          be withdrawn, including, for example, if there is a later discovery of previously unknown problems with the product, such as a previously unknown safety issue.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. For example, regulatory
          agencies may approve a product candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. Regulators may approve a product candidate for a smaller patient population,
          a different drug formulation or a different manufacturing process, than we are seeking. If we are unable to obtain necessary regulatory approvals, or more limited regulatory approvals than we expect, our business, prospects, financial condition
          and results of operations may suffer.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services.
          Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authority. The FDA or other regulatory authority may conclude that a financial relationship between us and a principal
          investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or other regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the
          utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of
          marketing approval of one or more of our product candidates.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">42</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or
          guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require
          additional preclinical, clinical or other studies. Varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. We cannot commercialize a product until
          the appropriate regulatory authorities have reviewed and approved the product candidate. Even if our product candidates demonstrate safety and efficacy in clinical trials, the regulatory agencies may not complete their review processes in a
          timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays
          or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process. Any marketing
          approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product commercially unviable.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities.
          The FDA or other regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our
          obtaining marketing approval or prevent or limit commercial use. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could
          harm our business.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and wastes generated
          in our manufacturing facility. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from the use of hazardous materials, we could be held liable for any resulting damages,
          and the amount of the liability could exceed our resources. We could also incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">If we, our collaborators, or our contract manufacturing organizations fail to comply with applicable regulatory requirements at any stage during the regulatory process, such noncompliance could
          result in, among other things delays in the approval of applications or supplements to approved applications; refusal of a regulatory authority, including the FDA, to review pending market approval applications or supplements to approved
          applications; warning letters; fines; import and/or export restrictions; product recalls or seizures; injunctions; total or partial suspension of production; civil penalties; withdrawals of previously approved marketing applications or licenses;
          recommendations by the FDA or other regulatory authorities against governmental contracts; and/or criminal prosecutions.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Any fast-track designation or grant of priority review status by the FDA may not actually lead to a faster development or regulatory review or approval
          process, nor will it assure FDA approval of our product candidates. Additionally, our product candidates may treat indications that do not qualify for priority review vouchers.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our product candidate, IRX-2, has received fast track designation in head and neck cancers. If a drug or biologic is intended for the treatment of a serious or life-threatening condition and
          the drug or biologic demonstrates the potential to address unmet medical needs for this condition, the drug or biologic sponsor may apply for FDA fast track designation. If a product candidate offers major advances in treatment, the FDA may
          designate it eligible for a priority review. The FDA has broad discretion to grant these designations, so even if we believe a particular product candidate is eligible for these designations, we cannot assure you that the FDA would decide to
          grant them. We may also seek fast track designation for IRX-2 in the other indications or for future products we may seek to develop. Even if we are granted fast track designation or priority review, we may not experience a faster development
          process, review or approval compared to conventional FDA procedures. The FDA may also withdraw fast track designation if it believes that the designation is no longer supported by data from Brooklyn&#8217;s clinical development program.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">43</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Orphan Drug Designation and Fast Track Designation may not actually lead to a faster review process.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Under the Prescription Drug User Fee Act, the FDA has a goal of responding to NDAs or BLAs for new molecular entities within 10 months of the date that it is filed for standard review, but the
          timeframe is also often extended. We have in the past sought and we may in the future seek approval of IRX-2 or any other product candidate we may acquire or license under programs designed to accelerate the FDA&#8217;s review and approval of NDAs or
          BLAs. For example, fast track designation is a process designed to facilitate the development and expedite the review of drugs and biologics to treat serious conditions that fill an unmet clinical need. The purpose is to get important new drugs
          and biologics to the patient earlier. In our case, IRX-2 has been granted fast track designation for the treatment of head and neck cancer. In the future, we may request fast track designation from the FDA for other diseases or for other products
          we may acquire or in-license, but we cannot assure that we will obtain such designations. Further, even if we obtain fast track designation, the designation does not guarantee FDA approval of any NDA or BLA that we file, that the development
          program or review timeline will ultimately be shorter than if we had not obtained the designations, or that the FDA will not request additional information, including requesting additional clinical studies (although potentially a post-marketing
          requirement), during its review. Any request for additional information or clinical data could delay the FDA&#8217;s timely review of any NDA or BLA that we submit.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not mean that we will be successful in
          obtaining marketing approval of our current and future product candidates in other jurisdictions.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain marketing approval in
          any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing approval process in others. For example, even if the FDA grants marketing approval of a product
          candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve
          requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by
          regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we
          intend to charge for our products is also subject to approval. We do not have experience in obtaining reimbursement or pricing approvals in international markets. Further, pricing obtained in other jurisdictions may impact pricing realized in the
          United States and in other jurisdictions where the product is approved.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Obtaining marketing approvals and compliance with regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our
          products in certain countries outside of the United States. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize
          the full market potential of our product candidates will be harmed.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Healthcare legislative reform measures and constraints on national budget social security systems may have a material adverse effect on our business and
          results of operations.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Payors, whether domestic or foreign, or governmental or private, are developing increasingly sophisticated or complex methods of controlling healthcare costs and those methods are not always
          specifically adapted for new technologies such as those we are developing. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our
          ability to sell our products profitably. In particular, in the United States, the Affordable Care Act, among other things, subjects biologic products to potential competition by lower-cost biosimilars; addresses a new methodology by which rebates
          owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increases the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate
          Program; extends the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjects manufacturers to new annual fees and taxes for certain branded prescription drugs; and
          provides incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">44</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. In August 2011, the Budget Control Act of 2011, among other
          things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.5 trillion for the years 2013 through 2021, was unable to reach
          required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013, and due to
          subsequent legislative amendments, including the BBA, will remain in effect through 2027 unless additional Congressional action is taken. The CARES Act, the Consolidated Appropriations Act of 2021, and the Act to Prevent Across-the-Board Direct
          Spending Cuts suspended the 2% sequestration mandated by the Budget Control Act of 2011 and the American Relief Act of 2011 through December 31, 2021. In December 2021, Congress extended the suspension of the automatic 2% reduction through March
          2022 and reduced the sequestration adjustment to 1% beginning on April 1, 2022 through June 30, 2022, with the full 2% reduction for sequestration resuming thereafter. In January 2013, the American Taxpayer Relief Act of 2012, was signed into
          law, which, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from
          three to five years. We cannot anticipate whether Congress will further extend the sequestration and when the sequestration reimbursement will return.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Also, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional
          inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program
          reimbursement methodologies for drug products. For example, in November 2018, CMS issued a proposed rule for comment that would, among other things, provide Medicare prescription drug plans under Part D more transparency in pricing and greater
          flexibility to negotiate discounts for, and in certain circumstances exclude, drugs in the six &#8220;protected&#8221; formulary classes and allow Medicare Advantage plans to use certain drug management tools such as step therapy for physician-administered
          drugs. Although a number of these, and other proposed measures will require authorization through additional legislation to become effective, Congress and the Biden administration has each indicated that it will continue to seek new legislative
          and/or administrative measures to control drug costs.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and
          containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of these governments and other payors to contain or reduce costs of healthcare and/or impose price controls
          may adversely affect:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the demand for our product candidates, if we obtain regulatory approval;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">our ability to set a price that we believe is fair for our products;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">our ability to generate revenue and achieve or maintain profitability;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the level of taxes that we are required to pay; and</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the availability of capital.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Any denial in coverage or reduction in reimbursement from Medicare or any other government programs may result in a similar denial or reduction in payments from private payors, which may
          adversely affect our future profitability.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Risks Related to the Commercialization of Brooklyn&#8217;s Product Candidates</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We may be unable to successfully scale up manufacturing of IRX-2 or newer gene editing or cellular products in sufficient quality and quantity, which may
          delay or prevent us from commercializing the product even if approved for marketing by the FDA or other regulatory agencies.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">45</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In order to commercialize IRX -2 or any other product candidate we may acquire or in-license (including any products that may be developed from the licensed technology from Factor or via the
          Novellus acquisition), we will need to manufacture them in large quantities. We would need to scale up the manufacturing process to enable production of commercial quantities of IRX-2, likely at a qualified contract manufacturer, if approved, and
          we are currently exploring options for implementing scale-up activities in anticipation of study completion and submitting applications for marketing approval, if supported by study data. However, we may be unable to successfully increase
          manufacturing capability in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Further, in order to release and demonstrate stability of product candidates for future commercial use, our analytical methods must be validated in accordance with regulatory guidelines. We may
          not be able to successfully validate or maintain validation of analytical methods during scale-up or demonstrate adequate purity, stability or comparability of the biological product candidates in a timely or cost-effective manner, or at all.
          Even if we believe our manufacturing processes meet all the regulatory manufacturing requirements, the FDA will review those processes and the manufacturing facility as part of the review of any future MA for IRX-2, if submitted after completion
          of the INSPIRE trial. If we are unable to successfully scale up the manufacture of IRX-2 in sufficient quality and quantity, or if we encounter validation issues, the development, testing, and clinical trials of future product candidates, may be
          delayed or infeasible, and regulatory approval or commercial launch of any resulting product, including IRX-2, may be delayed or may not be successfully achieved.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Even if we are able to commercialize any product candidate that we may develop, the product may become subject to unfavorable pricing regulations,
          third-party payor reimbursement practices or healthcare reform initiatives that could harm our business.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The commercial success of our current or future product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of its product candidates will be
          paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities (such as Medicare and Medicaid), private health coverage insurers and other
          third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our products. Even if coverage is provided, the approved reimbursement amount may not be high enough
          to allow us to establish and maintain pricing sufficient to realize a meaningful return on our investment.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new drug products vary
          widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some non-U.S.
          markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to
          price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenues it is able to generate from the sale of the product in that country. Adverse pricing limitations may hinder
          our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our ability to successfully commercialize our product candidate will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available
          from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they
          will cover and establish reimbursement levels. The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and third-party payors have attempted to control costs by limiting
          coverage and the amount of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may
          not be available to our customers, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives could cause us to decrease the price we might establish for products, which could result in
          lower than anticipated product revenues. If the prices for our products, if any, decrease or if governmental and other third-party payors do not provide adequate coverage or reimbursement, our prospects for revenue and profitability will suffer.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">46</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">There may also be delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications for which the drug is approved by the FDA or
          comparable non-U.S. regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and
          distribution. Reimbursement rates may vary, by way of example, according to the use of the drug and the clinical setting in which it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost drugs or may be
          incorporated into existing payments for other services.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. We cannot
          be sure that coverage will be available for any product candidate that we may commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions
          if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded
          and private payors for any of our product candidates for which we obtain marketing approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial
          condition.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">If we are unable to develop our sales, marketing and distribution capability on our own or through collaborations with marketing partners, we will not be
          successful in commercializing our product candidates.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We currently have no marketing, sales or distribution capabilities and have limited sales or marketing experience within our organization. If one or more of our product candidates is approved,
          we intend either to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize that product candidate, or to outsource this function to a third party. There are risks involved
          with either establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Recruiting and training an internal commercial organization is expensive and time consuming and could delay any product launch. Some or all of these costs may be incurred in advance of any
          approval of any of our product candidates. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or
          unnecessarily incurred these commercialization expenses. This may be costly and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. In addition, we may not be able to hire a sales force in the United
          States or other target market that is sufficient in size or has adequate expertise in the medical markets that we intend to target.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future product that we may develop;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the lack of complementary treatments to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability to us from these revenue streams is likely to be
          lower than if we were to market and sell any product candidates that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so
          on terms that are favorable to us. We likely will have little control over such third parties and any of them may fail to devote the necessary resources and attention to sell and market our product candidates effectively. If we do not establish
          sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing our product candidates.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">47</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">The market opportunities for any current or future product candidate we develop, if and when approved, may be limited to those patients who are ineligible
          for established therapies or for whom prior therapies have failed, and therefore may be small.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Cancer therapies are sometimes characterized as first-line, second-line, or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early
          enough, first-line therapy, usually chemotherapy, hormone therapy, surgery, radiation therapy, immunotherapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are
          administered to patients when prior therapy is not effective. We may initially seek approval of IRX-2 and any other product candidates we develop as a therapy for patients who have received one or more prior treatments. Subsequently, for those
          products that prove to be sufficiently beneficial, if any, we would expect to seek approval potentially as a first-line therapy, but there is no guarantee that product candidates we develop, even if approved, would be approved for first-line
          therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The number of patients who have the cancers we are targeting may turn out to be lower than we expect or may change as we develop the product candidate (e.g., lower rates of smoking around the
          globe may lead to lower incidence levels of head and neck cancer at the time of approval). Additionally, the potentially addressable patient population for our current programs or future product candidates, if and when approved, may be limited.
          Even if we obtain significant market share for any product candidate, if and when approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications,
          including use as first- or second-line therapy.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than the product
          candidates we develop, our commercial opportunities will be negatively impacted.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The life sciences industry is highly competitive. We are currently developing therapeutics that will compete, if approved, with other products and therapies that currently exist, are being
          developed or will in the future be developed, some of which we may not currently be aware. Competitors who are developing products in the same fields or that target the same indications as us with products that have a similar mechanism of action
          may experience problems with its products that could identify problems that would potentially harm our business.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical
          companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, product development, technical and human resources than we do. Large pharmaceutical companies, in
          particular, have extensive experience in clinical testing, obtaining marketing approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we
          do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also
          invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Mergers and acquisitions in the pharmaceutical and biotechnology
          industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or marketing approval or discovering,
          developing and commercializing products in our field before we do.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. These treatments consist both of small
          molecule drug products, such as traditional chemotherapy, as well as novel immunotherapies. Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have
          fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain FDA, EMA or other marketing
          approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if the product candidate we develop achieve
          marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">48</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Smaller and other early-stage companies may also prove to be significant competitors. These third parties compete with us in recruiting and retaining qualified scientific and management
          personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by
          rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our product candidates obsolete, less
          competitive or not economical.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">If we fail to maintain orphan drug exclusivity for IRX-2 or we fail to obtain or maintain such exclusivity for any future product candidate we may
          license, our competitors may sell products to treat the same conditions, and our revenues would be significantly adversely affected.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In July 2005 the FDA granted orphan drug designation for IRX-2 for head or neck cancer. In the U.S., orphan drug designation entitles a party to financial incentives such as opportunities for
          grant funding towards clinical trial costs, tax advantages and user-fee waivers. The company that first obtains FDA approval for a designated orphan drug for a given rare disease receives marketing exclusivity for use of that drug for the stated
          disease or condition for a period of seven years, with an additional six months if for a pediatric indication. Orphan drug exclusive marketing rights may be lost if the FDA later determines that the request for designation was materially
          defective, a subsequent product is deemed clinically superior, or if the manufacturer is unable to deliver sufficient quantity of the drug.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In the E.U., the EMA&#8217;s Committee for Orphan Medicinal Products, or COMP, grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or
          treatment of life-threatening or chronically debilitating conditions affecting not more than five in 10,000 persons in the EU Community and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the
          product would be a significant benefit to those affected). Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and
          when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the medicinal product. An EU orphan drug designation entitles a party to financial incentives such as
          reduction of fees or fee waivers and 10 years of market exclusivity is granted following medicinal product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown
          that the product is sufficiently profitable not to justify maintenance of market exclusivity. Orphan drug designation must be requested before submitting an application for marketing approval. Orphan drug designation does not convey any advantage
          in, or shorten the duration of, the regulatory review and approval process.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Because the extent and scope of patent protection for IRX-2 may be particularly limited, orphan drug designation is especially important. We plan to rely on the orphan exclusivity period to
          maintain a competitive position. However, if we cannot maintain orphan exclusivity for our IRX-2, our competitors may then sell the same drug to treat the same condition and our revenues will be reduced. Also, without strong patent protection,
          competitors may sell a generic version upon the expiration of orphan exclusivity, if our patent position is not upheld.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Even if we obtain orphan drug designation for our future product candidates, we may not fulfill the criteria for exclusivity, or we may not be the first to obtain marketing approval for any
          orphan indication. Further, even if we obtain orphan drug exclusivity for a particular product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after
          an orphan drug is approved, the FDA can subsequently approve a drug for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. The FDA can discontinue Orphan Drug
          exclusivity after it has been granted if the orphan drug cannot be manufactured in sufficient quantities to meet demand.</div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">49</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;"> The commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, payors and
          others in the medical community.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We have never commercialized a product, and even if we obtain any regulatory approval for our product candidates, the commercial success of our product candidates will depend in part on the
          medical community, patients, and payors accepting our product candidates as effective, safe and cost-effective. Any product that we bring to the market may not gain market acceptance by physicians, patients, payors and others in the medical
          community. Physicians are often reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are
          currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The degree of market acceptance of these product candidates, if approved for commercial sale, will depend on a number of factors, including:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the potential efficacy and potential advantages over alternative treatments;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the frequency and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the frequency and severity of any side effects resulting from follow-up requirements for the administration of our product candidates;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the relative convenience and ease of administration;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">the strength of marketing and distribution support and timing of market introduction of competitive products;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">formulary acceptance;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">publicity concerning our products or competing products and treatments; and</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">sufficient third-party insurance coverage and adequate reimbursement.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Even if a product candidate displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product, if approved for commercial sale, will
          not be known until after it is commercially launched. Our efforts to educate the medical community and payors on the benefits of our product candidates may require significant resources and may never be successful. Such efforts to educate the
          marketplace may require more resources than are required by the conventional technologies marketed by our competitors. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not
          become profitable.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Risks Related to Brooklyn&#8217;s Dependence on Third Parties</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We or our affiliates&#8217; employees, independent contractors, principal investigators, consultants, commercial collaborators, service providers and other
          vendors or potential collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm the results of our operations.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We are exposed to the risk that our employees or affiliates&#8217; employees and contractors, including any prospective or current principal investigators, CROs, consultants, commercial
          collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or other unauthorized activities that violate the laws and
          regulations of the FDA or other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing and the FDA&#8217;s GCP or cGMP standards; federal, state and
          foreign healthcare fraud and abuse laws and data privacy; or laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and other business arrangements in the healthcare industry
          are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing, bribery, corruption, antitrust violations and other abusive practices. These laws may restrict or prohibit a wide range of business activities, including research,
          manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">50</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Activities subject to these laws also involve the improper use or misrepresentation of information obtained during clinical trials, creating fraudulent data in our nonclinical studies or
          clinical trials or illegal misappropriation of drug product, which could result in data being eliminated from the final analysis of studies, regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter
          employee or third-party misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting them from governmental investigations or other actions
          or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person, including any person who may have engaged in any fraud or misconduct, or government agency could allege such
          fraud or other misconduct, even if none occurred. Furthermore, we rely on our CROs and clinical trial sites to adequately report data from ongoing clinical trials. Any failure by such parties to adequately report safety events to us in a timely
          manner from any such trials may also affect the approvability of our product candidates or cause delays and disruptions for the approval of any of our product candidates, if at all. If we or our affiliates&#8217; employees, independent contractors,
          principal investigators, consultants, commercial collaborators, service providers or other vendors are alleged or found to be in violation of any such regulatory standards or requirements, or become subject to a corporate integrity agreement or
          similar agreement and curtailment of our operations, it could have a significant impact on our business and financial results, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines,
          suspension or delay in Brooklyn&#8217;s clinical trials, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs or formulary and pharmacy benefit management programs, FDA debarment, contractual damages,
          reputational harm, diminished profits and future earnings, and additional reporting requirements and oversight, any of which could harm our ability to operate our business and results of operations.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We rely, and expect to continue to rely, on third parties to conduct our clinical studies, and those third parties may not perform satisfactorily,
          including failing to meet deadlines for the completion of such studies.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Outside of the INSPIRE trial, each of the trials involving IRX-2 that are currently being performed are investigator-sponsored trials. Outside our providing study drug and financial support for
          these studies, we have less involvement and less control of these studies than we would if these were our studies. Negative results from these studies could have material adverse effects on our business despite our lack of control.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We may seek to enter into collaborations with third parties for the development and commercialization of our product candidates. If we fail to enter into
          such collaborations, or such collaborations are not successful, we may not be able to capitalize on the market potential of IRX-2 or any other product we may acquire or in-license.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We may seek third-party collaborators for development and commercialization of IRX-2 or any other product we may acquire or in-license. Our likely collaborators for any marketing, distribution,
          development, licensing or broader collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, non-profit organizations, government agencies, and biotechnology companies. We will
          face significant competition in seeking appropriate collaborators. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because such product candidates may be
          deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. We are currently party to a limited number of
          such arrangements and have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will
          depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. If and when we collaborate with a third party for development and commercialization of a product candidate, we can expect to
          relinquish some or all of the control over the future success of that product candidate to the third party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon assessment of the collaborator&#8217;s
          resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Collaborations involving our product candidates currently pose, and will continue to pose, the following risks to it:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on preclinical or clinical
                  study results, changes in the collaborators&#8217; strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">51</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">collaborators may delay clinical studies, provide insufficient funding for a clinical study program, stop a clinical study or abandon a product candidate, repeat or conduct new clinical studies or require a
                  new formulation of a product candidate for clinical testing;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are
                  more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate its
                  intellectual property or proprietary information or expose it to potential litigation;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or
                  arbitration that diverts management attention and resources; and</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#9679;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a
          business combination, the continued pursuit and emphasis on its product development or commercialization program could be delayed, diminished or terminated.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Risks Relating to Brooklyn&#8217;s Intellectual Property</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">If we are unable to obtain and maintain patent and other intellectual property protection for our products and product candidates, or if the scope of the
          patent and other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products and product
          candidates may be adversely affected.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">
          <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Our ability to compete effectively will depend, in part, on our ability to maintain the proprietary nature of our technology and
            manufacturing processes. We rely on research, manufacturing and other know-how, patents, trade secrets, license agreements and contractual provisions to establish our intellectual property rights and protect our products and product candidates.
            These legal means, however, afford only limited protection and may not adequately protect our rights. As of April 12, 2022, our intellectual property portfolio included 16 patents in the United States and an additional 92 patents around the
            world.</div>

        </div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In certain situations, and as considered appropriate, we have sought, and we intend to continue to seek to protect our proprietary position by filing patent applications in the United States
          and, in at least some cases, one or more countries outside the United States relating to current and future products and product candidates that are important to our business. However, we cannot predict whether the patent applications currently
          being pursued will issue as patents, or whether the claims of any resulting patents will provide us with a competitive advantage or whether we will be able to successfully pursue patent applications in the future relating to our current or future
          products and product candidates. Moreover, the patent application and approval processes are expensive and time-consuming. We may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely
          manner. Furthermore, we, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent
          protection on them. Therefore, we may miss potential opportunities to seek additional patent protection. It is possible that defects of form in the preparation or filing of patent applications may exist, or may arise in the future, for example
          with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or
          eliminated. If there are material defects in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable
          patents.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">52</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Even if they are unchallenged, our patents and patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims
          by developing similar or alternative technologies or therapeutics in a non-infringing manner. For example, a third party may develop a competitive therapy that provides benefits similar to one or more of our product candidates but that falls
          outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our product candidates is not sufficiently broad to impede such competition, our ability to
          successfully commercialize our product candidates could be negatively affected.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Other parties, many of whom have substantially greater resources and have made significant investments in competing technologies, have developed or may develop technologies that may be related
          or competitive with our approach, and may have filed or may file patent applications and may have been issued or may be issued patents with claims that overlap or conflict with our patent applications, either by claiming the same compositions,
          formulations or methods or by claiming subject matter that could dominate our patent position. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. As a result, any patents we
          may obtain in the future may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar to our products and product candidates.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical
          patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds commonly involves complex legal and factual questions, which has in recent
          years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our competitors may also seek approval to market their own products similar to
          or otherwise competitive with our products. Alternatively, our competitors may seek to market generic versions of any approved products by submitting ANDAs or ABLAs to the FDA in which they claim that our patents are invalid, unenforceable or not
          infringed. In these circumstances, we may need to defend or assert our patents, or both, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our
          patents invalid or unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes
          sufficient to achieve our business objectives.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In addition to patent protection, we expect to rely heavily on trade secrets, know-how and other unpatented technology, which are difficult to protect. Although we seek such protection in part
          by entering into confidentiality agreements with our vendors, employees, consultants and others who may have access to proprietary information, we cannot be certain that these agreements will not be breached, adequate remedies for any breach
          would be available, or our trade secrets, know-how and other unpatented proprietary technology will not otherwise become known to or be independently developed by our competitors. If we are unsuccessful in protecting our intellectual property
          rights, sales of our products may suffer and our ability to generate revenue could be severely impacted.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Issued patents covering our products and product candidates could be found invalid or unenforceable if challenged in court or in administrative
          proceedings. We may not be able to protect our trade secrets in court.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">If we initiate legal proceedings against a third-party to enforce a patent covering one of our products or product candidates, the defendant could counterclaim that the patent covering our
          product or product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to
          meet any of several statutory requirements, including lack of novelty, obviousness, written description or non- enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent
          withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context
          of litigation. Such mechanisms include re- examination, post grant review, inter partes review and equivalent proceedings in foreign jurisdictions. An adverse determination in any of the foregoing proceedings could result in the revocation or
          cancellation of, or amendment to, our patents in such a way that they no longer cover our products or product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity
          question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we were unaware during prosecution. If a defendant or third party were to prevail on a legal assertion of invalidity or
          unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our products and product candidates. Such a loss of patent protection could have a material adverse impact on our business.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">53</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In addition, our trade secrets may otherwise become known or be independently discovered by competitors. Competitors and other third parties could purchase our products and product candidates
          and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe, misappropriate or otherwise violate our intellectual property rights, design around our protected technology or develop
          their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent
          them, or those to whom they communicate it, from using that technology or information to compete with us. If our trade secrets are not adequately protected or sufficient to provide an advantage over our competitors, our competitive position could
          be adversely affected, as could our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed
          by governmental patent agencies, and our patent protection could be reduced or eliminated for non- compliance with these requirements.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid to the USPTO and various governmental patent
          agencies outside of the United States in several stages over the lifetime of the patents and applications. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedurals, documentary, fee payment and
          other similar provisions during the patent application process and after a patent has issued. There are situations in which non- compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete
          loss of patent rights in the relevant jurisdiction. The terms of one or more licenses that we enter into the future may not provide us with the ability to maintain or prosecute patents in the portfolio and must therefore rely on third parties to
          do so. If we fail to obtain and maintain the patents and patent applications covering our products or procedures, we may not be able to stop a competitor from marketing products that are the same as our product candidates, which could have a
          material adverse effect on our business.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">If we do not obtain patent term extension and data exclusivity for our products and product candidates, our business may be materially harmed.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional
          filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may
          be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such
          candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In the future, if we obtain an issued patent covering one of our present or future product candidates, depending upon the timing, duration and specifics of any FDA marketing approval of such
          product candidates, such patent may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of
          up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may
          be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. A patent may only be extended once and only based on a single approved product. However, we may not be granted
          an extension because of, for example, failure to obtain a granted patent before approval of a product candidate, failure to exercise due diligence during the testing phase or regulatory review process, failure to apply within applicable
          deadlines, failure to apply prior to expiration of relevant patents or otherwise our failure to satisfy applicable requirements. A patent licensed to us by a third party may not be available for patent term extension. Moreover, the applicable
          time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing
          products following our patent expiration, and our revenue could be reduced, possibly materially.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">54</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to
          protect our products and product candidates.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Changes in either the patent laws or the interpretation of the patent laws in the United States or other jurisdictions could increase the uncertainties and costs surrounding the prosecution of
          patent applications and the enforcement or defense of issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. When implemented, the Leahy-Smith Act included several significant
          changes to U.S. patent law that impacted how patent rights could be prosecuted, enforced and defended. In particular, the Leahy-Smith Act also included provisions that switched the United States from a &#8220;first-to-invent&#8221; system to a
          &#8220;first-to-file&#8221; system, allowed third- party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings. Under a
          first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the
          invention earlier. The USPTO developed new regulations and procedures governing the administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file
          provisions, only became effective on March 16, 2013. Some of the Company&#8217;s patents and patent applications have effective dates later than March 16, 2013 and thus will be subject to the provisions of the Leahy-Smith Act.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent rulings from the U.S. Court of
          Appeals for the Federal Circuit and the U.S. Supreme Court have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created
          uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable
          ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We may not be able to protect our intellectual property rights throughout the world.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Filing, prosecuting, maintaining, defending and enforcing patents on products and product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual
          property rights in some countries outside the United States could be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly in developing countries; thus, even in countries
          where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover our products. There can be no assurance that we will obtain or maintain patent rights in or outside the United States under any
          future license agreements. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties
          from utilizing our inventions in all countries outside the United States, even in jurisdictions where we pursue patent protection, or from selling or importing products made using our inventions in and into the United States or other
          jurisdictions. Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent
          protection, but enforcement is not as strong as that in the United States. These products may compete with our products and product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent
          them from competing.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">55</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly
          certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to
          stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third
          parties. Proceedings to enforce our patent rights, even if obtained, in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being
          invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if
          any, may not be commercially meaningful. While we intend to protect our intellectual property rights in major markets for our products, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we
          may wish to market our products. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of
          what we regard as our own intellectual property.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Many of our current and former employees, including our senior management, were previously employed at universities or at other biotechnology or pharmaceutical companies, including some which
          may be competitors or potential competitors. Some of these employees may be subject to proprietary rights, non-disclosure and non- competition agreements, or similar agreements, in connection with such previous employment. Although we try to
          ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other
          proprietary information, of any such third party. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or
          personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available
          on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such
          intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such
          intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims,
          litigation could result in substantial costs and be a distraction to our senior management and scientific personnel.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and
          unsuccessful.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which
          can be expensive and time consuming and divert the time and attention of our management and scientific personnel. In addition, our patents may become, involved in inventorship, priority, or validity disputes. To counter or defend against such
          claims can be expensive and time-consuming, and our adversaries may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. Any claims we assert against perceived infringers could provoke these
          parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In an infringement proceeding, a court may decide that a patent is invalid or unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our
          patents do not cover the technology in question. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating intellectual property rights we own or control. An adverse result in any
          litigation proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted narrowly. Further, because of the substantial amount of discovery required in connection with intellectual property
          litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">56</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Even if resolved in our favor, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate
          remedy. Litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public
          announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common
          stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or
          proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other
          proceedings could have a material adverse effect on our ability to compete in the marketplace.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our marks of interest and our
          business may be adversely affected.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We rely on both registration and common law
          protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of
          interest. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, with the USPTO and with
          comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our
          trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</div>

        <div>&#160;</div>

        <a id="ITEM1B"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45.05pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 1B.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Unresolved Staff Comments</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0);">We do not have any unresolved comments issued by the SEC Staff.</div>

        <div>&#160;</div>

        <a id="ITEM2"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45.05pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 2.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Properties</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0);">We currently lease approximately 9,000 square feet of office and laboratory space in New York,&#160; Massachusetts and California. The terms of our leases expire from December 2026 through June 2028. We believe that our
          leased property meets our current needs.</div>

        <div>&#160;</div>

        <a id="ITEM3."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45.05pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 3.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Legal Proceedings</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">From time to time, we become involved in litigation and arbitrations in the ordinary course of business. Legal fees and other costs associated with such actions are expensed as incurred. In
          addition, we assess the need to record a liability for litigation and contingencies. We reserve for costs relating to these matters when a loss is probable, and the amount can be reasonably estimated.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">57</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"><span style="text-decoration: underline;">Merger-Related Shareholder Litigation</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Brooklyn (then known as NTN Buzztime, Inc.) and its former directors were named as defendants in ten substantially similar actions arising out of the Merger that were brought by purported
          pre-Merger stockholders of Brooklyn: Henson v. NTN Buzztime, Inc., et al., No. 1:20-cv-08663-LGS (S.D.N.Y.); Monsour v. NTN Buzztime, Inc., et al., No. 1:20-cv-08755-LGS (S.D.N.Y.); Amanfo v. NTN Buzztime, Inc., et al., No. 1:20-cv-08747-LGS
          (S.D.N.Y.); Carlson v. NTN Buzztime, Inc., et al., No. 1:21-cv-00047-LGS (S.D.N.Y.); Finger v. NTN Buzztime, Inc., et al., No. 1:21-cv-00728-LGS (S.D.N.Y.); Falikman v. NTN Buzztime, Inc., et al., No. 1:20-cv-05106-EK-SJB (E.D.N.Y.); Haas v. NTN
          Buzztime, Inc., et al., No. 3:20-cv-02123-BAS-JLB (S.D. Cal.); Gallo v. NTN Buzztime, Inc., et al., No. 3:21-cv-00157-WQH-AGS (S.D. Cal.); Chinta v. NTN Buzztime, Inc., et al., No. 1:20-cv-01401-CFC (D. Del.); and Nicosia v. NTN Buzztime, Inc.,
          et al., No. 1:21-cv-00125-CFC (D. Del.) (collectively, the &#8220;Stockholder Actions&#8221;).&#160; Only two of the Stockholder Actions (the Chinta and Nicosia cases) also named Brooklyn LLC. These actions asserted claims alleging violations of Sections 14(a)
          and 20(a) of the Exchange Act and Rule 14a-9 promulgated thereunder and both the Chinta and Nicosia cases alleged that Brooklyn LLC is a controlling person of Brooklyn. The complaints generally alleged that the defendants failed to disclose
          allegedly material information in a Registration Statement on Form S-4 filed on October 2, 2020, including: (1) certain details regarding any projections or forecasts of Brooklyn or Brooklyn LLC may have made, and the analyses performed by
          Brooklyn&#8217;s financial advisor, Newbridge Securities Corporation; (2) conflicts concerning the sales process; and (3) disclosures regarding whether or not Brooklyn entered into any confidentiality agreements with standstill and/or &#8220;don&#8217;t ask, don&#8217;t
          waive&#8221; provisions. The complaints generally alleged that these purported failures to disclose rendered such Registration Statement on Form S-4 false and misleading. The complaints requested: preliminary and permanent injunction of the Merger;
          rescission of the Merger if executed and/or rescissory damages in unspecified amounts; direction to the individual directors to disseminate a compliant Registration Statement on Form S-4; an accounting by Brooklyn for all alleged damages
          suffered; a declaration that certain federal securities laws had been violated; and reimbursement of costs, including attorneys&#8217; and expert fees and expenses. On or about February 26, 2021, in order to render moot certain of the disclosure claims
          asserted in the Stockholder Actions, to avoid nuisance, potential expense, and delay, and to provide additional information to Brooklyn&#8217;s stockholders, Brooklyn determined to voluntarily supplement the Form S-4 with certain additional
          disclosures. In exchange for those disclosures, the plaintiffs in each of the Stockholder Actions agreed to voluntarily dismiss their claims. As of the date of this Annual Report on Form 10-K all ten actions have been dismissed. Following the
          dismissal the parties amicably resolved plaintiffs&#8217; counsel&#8217;s request for an award of attorneys&#8217; fees and expenses based on the purported benefit contented to be conferred on Brooklyn&#8217;s stockholders as a result of the supplemental disclosures.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"><span style="text-decoration: underline;">Dhesh Govender v. Brooklyn Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021)</span></div>

        <div><br />
        </div>

        <div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">
            <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">On or about February 5, 2021, Dhesh Govender, a former short-term consultant of Brooklyn LLC, filed a complaint against Brooklyn LLC and
              certain individuals that plaintiff alleges were directors of Brooklyn LLC. The complaint is captioned, Dhesh Govender v. Brooklyn Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021). Plaintiff alleges that
              Brooklyn LLC and certain of its officers engaged in unlawful and discriminatory conduct based on race, national origin and hostile work environment. Plaintiff also asserts various breach of contract, fraud and quantum meruit claims based on
              an alleged oral agreement pursuant to which he alleges Brooklyn LLC agreed to hire him as an executive once the Merger was completed. In particular, plaintiff alleges that, in exchange for transferring an opportunity to obtain an agreement to
              acquire a license from Novellus for its mRNA-based gene editing and cell reprogramming technology to Brooklyn LLC, he was promised a $500,000 salary and 7% of the equity of Brooklyn LLC. Based on these and other allegations, plaintiff seeks
              damages of not less than $10 million, a permanent injunction enjoining Brooklyn LLC from exercising the option to acquire such license from Novellus or completing the proposed Merger. On or about February 19, 2021, an amended complaint was
              filed asserting the same causes of action but withdrawing the request for injunctive relief. On June 6, 2021, <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">defendants </span>filed a motion to compel arbitration or,
              in the alternative, for partial dismissal of the complaint for failure to state viable fraud, quantum meruit and employment discrimination claims. After obtaining extensions of time to respond, plaintiff opposed the defendants&#8217; motion on
              August 9, 2021. The defendants filed their reply on September 3, 2021. The Court heard oral argument on the motion to compel arbitration and/or dismiss and the motion to seal on October 13, 2021<span style="font-family: 'Times New Roman', serif; font-size: 10pt;">. By Order dated November 10, 2021, the Court granted defendants&#8217; motion to compel Govender to arbitrate all of his claims against them, based on the arbitration clause of his consulting agreement with Brooklyn
                LLC.&#160; Govender thereafter filed his Statement of Claim (the &#8220;Demand&#8221;) with the American Arbitration Association (&#8220;AAA&#8221;), Case No. 01-21-0017-9417, on December 15, 2021 against the same defendants, and served it on defendants&#8217; counsel on
                February 3, 2022.&#160; In his Demand, Govender continues to assert statutory discrimination claims against all defendants, claims against Brooklyn LLC premised on the breach of an alleged oral promise to issue Govender 7% of the equity of
                Brooklyn LLC and to employ Govender at a $500,000 annual salary in exchange for allegedly arranging and negotiating the Novellus license, common law fraud claims against the Company and Cherington based on the breach of these same promises
                and a claim for quantum meruit against the Brooklyn LLC.&#160; In his Demand, Govender now claims that the fair and reasonable value of his services on the quantum meruit claim exceeded $100 million and is seeking damages in an amount to be
                determined at the hearing.&#160; Defendants filed an answering statement to the Demand on February 28, 2022 and the parties are in the process of conferring on the selection of a three-member arbitration panel. </span>At this stage in the
              litigation, the Company is not able to predict the probability of a favorable or unfavorable outcome.</div>

          </div>

          <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
          </div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">58</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"><span style="text-decoration: underline;">Carlson v. Allen Wolff, Michael Gottlieb, Richard Simtob, Susan Miller, and NTN Buzztime, Inc., C.A. No. 2021-0193-KSJM (Del. Ch. Ct.)</span></div>

        <div><br />
        </div>

        <div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">
            <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">On or about March 12, 2021, Douglas Carlson, a purported stockholder of Brooklyn (then known as NTN Buzztime, Inc.), filed a verified
              class action complaint against Brooklyn and its then current members of the board of directors, for allegedly breaching their fiduciary duties and violating Section 211(c) of the Delaware General Corporation Law.&#160; In particular, plaintiff
              seeks to compel the defendants to hold an annual stockholder meeting.&#160; Plaintiff also moved for summary judgment at the same time that he filed his complaint.&#160; In order to moot the claim addressed in the complaint, Brooklyn agreed to hold its
              annual meeting on June 29, 2021, which date was subsequently rescheduled to August 20, 2021.&#160; On or about May 6, 2021, the parties entered into a stipulation, which was &#8220;so ordered&#8221; by the court, extending defendants&#8217; time to respond to the
              complaint and to file their answering brief in opposition to plaintiff&#8217;s motion for summary judgment on or before July 16, 2021 and providing that plaintiff&#8217;s reply brief in support of his motion for summary judgment is due on or before
              August 20, 2021. On or about July 12, 2021, the parties entered in a further amended scheduling order, which provided that defendants were to respond to the complaint and file their answering brief in opposition to plaintiff&#8217;s motion for
              summary judgment on or before September 16, 2021 and plaintiff was to file its reply brief in support of his motion for summary judgment on or before October 20, 2021.&#160; On August 20, 2021, Brooklyn convened its 2021 annual meeting. Due to the
              lack of a required quorum, the meeting was adjourned to September 3, 2021. Thereafter, Brooklyn obtained a quorum, and the annual meeting was held on September 3, 2021. On September 10, 2021, Brooklyn filed a report on Form 8-K with the SEC
              announcing the results of the annual meeting. On September 16, 2021, the parties filed a stipulation seeking voluntary dismissal of the complaint as moot. The Court entered the dismissal on September 16, 2021 with prejudice as to the named
              plaintiff and without prejudice as to other members of the purported class and retained jurisdiction for the purpose of determining any fee application to the extent it cannot be resolved amicably the parties. <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">Thereafter, on or about November 12, 2022, the parties resolved plaintiff&#8217;s counsel&#8217;s request for an award of fees and expenses for the purported benefit that Carlson contended was received by
                stockholders as a result of his action.&#160; </span></div>

          </div>

          <div><br />
          </div>

        </div>

        <div>
          <div style="color: rgb(0, 0, 0);"><span style="text-decoration: underline;">Edmund Truell Matter</span></div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">&#160;</div>

        </div>

        <div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">On May 14, 2021, Edmund Truell, a stockholder of Brooklyn, alleged that he sustained a loss because he was unable to sell shares of common stock timely due to a delay caused by Brooklyn&#8217;s
            issuance of stock certificates in lieu of electronic book entry.</div>

          <div><br />
          </div>

        </div>

        <div>
          <div style="color: rgb(0, 0, 0);"><span style="text-decoration: underline;">Emerald Private Equity Fund, LLC Matter</span></div>

        </div>

        <div>
          <div><br />
          </div>

          <div style="text-align: justify; color: rgb(0, 0, 0);">
            <div>
              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">By a letter dated July 7, 2021, Emerald Private Equity Fund, LLC (&#8220;Emerald&#8221;), a stockholder of Brooklyn, made a demand pursuant to 8
                Del. C. 220 to inspect certain books and records of Brooklyn. The stated purpose of the demand is to investigate possible wrongdoing by persons responsible for the implementation of the Merger and the issuance of paper stock certificates,
                including investigating&#160; whether: (i) Brooklyn&#8217;s stock certificates were issued in accordance with the Merger Agreement; (ii) certain restrictions on the sale of Brooklyn common stock following the Merger were proper and applied without
                favor; (iii) anyone received priority in post-Merger issuances of Brooklyn&#8217;s stock certificates that allowed them to benefit from an increase in the trading price of Brooklyn&#8217;s common stock; and (iv) it should pursue remedial measures
                and/or report alleged misconduct to the SEC. Brooklyn has responded to the demand letter and has produced certain information to Emerald in connection with the demand, which is subject to the terms of a confidentiality agreement entered
                into among the parties, including certain additional stockholders who have subsequent joined as parties to such agreement.&#160; In October 2021, Emerald requested that Brooklyn produce additional information related to the authority, purpose
                and justification for the restriction imposed on the sale of Brooklyn common stock following the Merger and the timing of share delivery to Brooklyn stockholders, following which request Brooklyn agreed to produce certain additional
                information and emails relating to these topics.<br />
              </div>

              <div><br />
              </div>

              <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">On March 30, 2022, counsel to Emerald advised the Company that it was prepared to file suit against the Company, certain current and
                former directors of the Company, and the Company&#8217;s financial advisor in connection with the Merger, on behalf of Emerald and a class of similarly situated stockholders with respect to some or all of the foregoing matters, alleging claims
                for breach of fiduciary duty, conversion and aiding and abetting breach of fiduciary duty.&#160; Emerald&#8217;s counsel has expressed a willingness to engage in private pre-suit early resolution discussions with the Company and its financial advisor
                on behalf of individual stockholders whom counsel represents in addition to Emerald; and the Company has agreed to respond to Emerald&#8217;s counsel by April 22, 2022.&#160; The Company can provide no assurance that such pre-suit early resolution
                discussions will be successful or that suit will not ultimately be filed against the Company, nor can the Company currently predict the outcome of any such suit, if filed.&#160; The Company intends to defend itself vigorously against any and all
                claims.&#160; Additionally, on April 7, 2022, the Company received a demand for indemnification from its financial advisor as it relates to the aforementioned potential lawsuit.</div>

            </div>

          </div>

          <div><br />
          </div>

        </div>

        <div>
          <div style="color: rgb(0, 0, 0);"><span style="text-decoration: underline;">John Westman v. Novellus, Inc., Christopher Rohde, and Matthew Angel, Civil Action No. 2181CV01949 (Middlesex County (Massachusetts) Superior Court)</span></div>

        </div>

        <div>
          <div><br />
          </div>

          <div style="text-align: justify; color: rgb(0, 0, 0);">
            <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">On or about September 7, 2021, John Westman, a former employee of Novellus, Inc. filed a Complaint in Middlesex County (Massachusetts)
              Superior Court against Novellus, Inc. and the company&#8217;s founders and former executives, Christopher Rohde and Matthew Angel (collectively, &#8220;Defendants&#8221;).&#160; Brooklyn acquired Novellus, Inc. on July 16, 2021.&#160; Mr. Westman&#8217;s claims relate to
              alleged conduct that took place before Brooklyn acquired Novellus, Inc.&#160; Pursuant to the July 16, 2021 Agreement and Plan of Acquisition, as well as a separate agreement among Brooklyn, Novellus, Inc., Mr. Rohde, and Mr. Angel, Mr. Rohde and
              Mr. Angel are essentially assuming the defense of and paying the fees associated with defending against these claims.&#160; To that end, on September 10, 2021, Morgan Lewis accepted service on behalf of all defendants. On December 24, 2021,
              Westman dismissed the case without prejudice so the parties could mediate the matter. The parties&#8217; February 2022 mediation was unsuccessful, but Mr. Westman has not refiled suit.</div>

            <div>&#160;</div>

          </div>

        </div>

        <a id="ITEM4"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45.05pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 4.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Mine Safety Disclosures</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0);">Not Applicable.</div>

        <div style="color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">59</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PART II</div>

        <div>&#160;</div>

        <a id="ITEM5."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45.05pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 5.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our common stock is listed on The Nasdaq Global Market under the symbol &#8220;BTX.&#8221;</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">
          <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">As of April <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">12</span>, 2022, there were approximately <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">421</span> stockholders of record based on the actual number of holders registered on our books at such date.</div>

        </div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We have 156,112 shares of Series A Preferred Stock issued and outstanding. The Series A Preferred Stock provides for a cumulative annual dividend of 10 cents per share, payable in semi-annual
          installments in June and December. Dividends may be paid in cash or in shares of our common stock. In 2021, we paid approximately $8,000 in cash dividends and issued 202 shares of common stock in stock dividends to the holders of our Series A
          Preferred Stock.&#160; We expect to pay the dividends on our Series A Preferred Stock in accordance with its terms, though we may elect to pay the dividend in shares of our common stock in the future.</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We have not declared or paid any cash dividends on our common stock. No cash dividends have been previously paid on our common stock and none are anticipated in 2022.</div>

        <div>&#160;</div>

        <a id="ITEM6"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45.05pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 6.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">[Reserved]</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <a id="ITEM7"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45.05pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 7.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;), Section 27A of the Securities Act of
          1933, as amended, (the &#8220;Securities Act&#8221;), and Section 21E of the Exchange Act, about our expectations, beliefs, or intentions regarding our product development efforts, business, financial condition, results of operations, strategies and
          prospects. You can identify forward-looking statements by the fact that these statements do not relate to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as
          of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any
          future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include
          those contained in &#8220;Item 1A &#8212; Risk Factors&#8221; of this Annual Report on Form 10-K. We do not undertake any obligation to update forward-looking statements except as required by applicable law. We intend that all forward-looking statements be subject
          to the safe harbor provisions of PSLRA. These forward-looking statements reflect our views only as of the date they are made.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Overview</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0);">We are a clinical-stage biopharmaceutical company focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer, both as a single agent and in combination
          with other anti-cancer therapies. We are seeking to develop IRX-2, a novel cytokine-based therapy, to treat patients with cancer. We also are exploring opportunities to advance oncology, blood disorder, and monogenic disease therapies using
          gene-editing and cell therapy technology through a license with Factor Bioscience Limited, or Factor, and through our acquisition of Novellus, Inc. and Novellus, Ltd. in July 2021, or the Acquisition.</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-weight: bold;">Recent Developments</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Acquisition of Novellus</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On July 16, 2021, we acquired Novellus, Inc. and Novellus, Inc.&#8217;s wholly owned subsidiary, Novellus, Ltd. Brooklyn also acquired 25.0% of the total outstanding equity interests of NoveCite,
          Inc.&#160; Total consideration was $124.0 million, which consisted of (a) $22.8 million in cash and approximately and (b) approximately 7,022,000 shares of common stock, which under the terms of the Acquisition Agreement were valued at a total of
          $102.0 million, based on a price of $14.5253 per share.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">60</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Merger with NTN Buzztime, Inc.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On March 25, 2021, we completed the Merger with NTN Buzztime, Inc. In accordance with the Merger Agreement, on March 25, 2021, Brooklyn amended its restated certificate of incorporation in
          order to effect:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">prior to the Merger, a reverse stock split of its common stock, par value $0.005 per share, at a ratio of one-for-two; and</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">following the Merger, a change in its corporate name from &#8220;NTN Buzztime, Inc.&#8221; to &#8220;Brooklyn ImmunoTherapeutics, Inc.&#8221;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On March 26, 2021, we sold the rights, title and interest in and to the assets relating to the business operated under the name &#8220;NTN Buzztime, Inc.&#8221; prior to the Merger to eGames.com Holdings
          LLC, or eGames.com, in exchange for eGames.com&#8217;s payment of a purchase price of $2.0 million and assumption of specified liabilities relating to such pre-Merger business. This transaction, which we refer to as the Disposition, was completed in
          accordance with the terms of an asset purchase agreement dated September 18, 2020, as amended, between us and eGames.com.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The Merger has been accounted for as a reverse acquisition in accordance with U.S. generally accepted accounting principles, or GAAP. Under this method of accounting, Brooklyn LLC was deemed
          the &#8220;acquiring&#8221; company and Brooklyn (then known as NTN Buzztime, Inc.) was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Operations prior to the Merger are those of Brooklyn LLC, and the historical financial statements of
          Brooklyn LLC became the historical financial statements of Brooklyn with respect to periods prior to the completion of the Merger.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Impact of COVID-19 Pandemic</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The development of our product candidates has been, and could continue to be, disrupted and materially adversely affected by past and continuing impacts of the COVID-19 pandemic. This is
          largely a result of measures imposed by the governments and hospitals in affected regions, businesses and schools were suspended due to quarantines intended to contain this outbreak. The spread of COVID-19 from China to other countries resulted
          in the Director General of the World Health Organization declaring COVID-19 a pandemic in March 2020. While the constraints of the pandemic are being lifted, we are still assessing the longer-term impact of the COVID-19 pandemic on our
          development plans, and on the ability to conduct our clinical trials. COVID-19 could continue to disrupt production and cause delays in the supply and delivery of products used in our operations, may affect our operations, including the conduct
          of clinical studies, or the ability of regulatory bodies to grant approvals or supervise our candidates and products, may further divert the attention and efforts of the medical community to coping with the COVID-19 and disrupt the marketplace in
          which we operate and may have a material adverse effects on our operations. COVID-19 may also affect our employees and employees and operations at suppliers that may result in delays or disruptions in supply. In addition, a recession or market
          correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. Additionally, if the COVID-19 pandemic has a significant impact on our business and financial results for an extended period
          of time, our liquidity and cash resources could be negatively impacted. The extent to which the COVID-19 pandemic and ongoing global efforts to contain its spread will impact our operations will depend on future developments, which are highly
          uncertain, and include the duration, severity and scope of the pandemic and the actions taken to contain or treat the COVID-19 pandemic. Further, the specific clinical outcomes, or future pandemic related impacts of emerging COVID-19 variants
          cannot be reliably predicted.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The patients in our clinical trials have conditions that make them especially vulnerable to COVID-19, and as a result we have seen slowdowns in enrollment in our clinical trials. While our
          INSPIRE trial in patients with squamous cell carcinoma of the oral cavity&#160; is fully populated, our other clinical studies are likely to continue to encounter delays in enrollment as a result of the pandemic.</div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">61</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-weight: bold;">Basis of Presentation</div>

        <div style="color: rgb(0, 0, 0); font-weight: bold;"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Revenues</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We are a development stage company and have had no revenues from product sales to date. We will not have revenues from product sales until such time as we receive regulatory approval of our
          product candidates, successfully commercialize our products or enter into a licensing agreement which may include up-front licensing fees, of which there can be no assurance.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Research and Development Expenses</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We expense our research and development costs as incurred. Our research and development expenses consist of costs incurred for company-sponsored research and development activities, as well as
          support for selected investigator-sponsored research. Upfront payments and milestone payments for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to
          have any alternative future uses other than the specific research and development project for which it was intended. In-Process Research and Development (&#8220;IPR&amp;D&#8221;) that is acquired through an asset acquisition and has no alternative future
          uses and, therefore, no separate economic values, is expensed to research and development costs at the time the costs are incurred.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The major components of research and development costs include preclinical study costs, clinical manufacturing costs, clinical study and trial expenses, insurance coverage for clinical trials,
          expensed licensed technology, consulting, scientific advisors and other third-party costs, salaries and employee benefits, stock-based compensation expense, supplies and materials and allocations of various overhead costs related to our product
          development efforts.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In the normal course of our business, we contract with third parties to perform various clinical study and trial activities in the on-going development and testing of potential products. The
          financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events or milestones, the
          successful enrollment of patients, the allocation of responsibilities among the parties to the agreement, and the completion of portions of the clinical study or trial or similar conditions. Preclinical and clinical study and trial associated
          activities such as production and testing of clinical material require significant up-front expenditures. We anticipate paying significant portions of a study&#8217;s or trial&#8217;s cost before such begins and incurring additional expenditures as the study
          or trial progresses and reaches certain milestones.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">General and Administrative Expenses</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our general and administrative expenses consist primarily of salaries, benefits and other costs, including equity-based compensation, for our executive and administrative personnel, legal and
          other professional fees, travel, insurance, and other corporate costs.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">62</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Comparison of the Years Ended December 31, 2021 and 2020</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;"></td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Years Ended December 31,</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="2" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;
                <div style="text-align: center; font-weight: bold;">Change</div>
              </td>

    <td valign="bottom" rowspan="2" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;&#160;</td>

    <td valign="bottom" rowspan="2" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;&#160;</td>

    <td valign="bottom" rowspan="2" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;
                <div style="text-align: center; font-weight: bold;">% Change</div>
              </td>

    <td valign="bottom" rowspan="2" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> 2021</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2020</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Operating expenses:</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Research and development</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">$<br />
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>12,705,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">$<br />
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>3,951,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">$ <br />
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>8,754,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">$ <br />
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>222</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Acquired in-process research and development</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>80,538,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>80,538,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>N/A</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">General and administrative</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>14,724,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>3,297,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>11,427,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>347</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Transaction costs</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>5,765,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>5,765,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>N/A</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Change in fair value of contingent consideration</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(180,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>19,240,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(19,420,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>-101</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total operating expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>113,552,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>26,488,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>87,064,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;">
                <div>329</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Loss from operations</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(113,552,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(26,488,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(87,064,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>329</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other expenses:</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Loss on sale of NTN assets</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(9,648,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(9,648,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>N/A</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other income (expense), net</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>899,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(43,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>942,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>-2191</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total other expense</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>(8,749,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>(43,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-top: 2px solid rgb(0, 0, 0); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>(8,706,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div>20247</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Loss before income taxes</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(122,301,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(26,531,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(95,770,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>361</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Provision for income taxes</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>(5,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>(5,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div>N/A</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net loss</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(122,306,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(26,531,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(95,775,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>361</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Series A preferred stock dividend</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(16,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(16,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>N/A</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net loss attributable to common stockholders</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(122,322,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(26,531,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(95,791,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>361</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Research and Development Expenses</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Years Ended December 31<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div>&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> 2021</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2020</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Change</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">% Change</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">License fees</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>6,500,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>6,500,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>N/A</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock-based compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>1,597,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>1,597,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>N/A</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Clinical trials</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>1,292,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>412,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>880,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>214</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Payroll-related</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>2,342,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>1,985,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>357,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>18</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other expenses, net</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>974,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>1,554,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>(580,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div>-37</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total research and development expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>12,705,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>3,951,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>8,754,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;">
                <div>222</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">
          <div style="text-align: justify; font-family: 'Times New Roman', serif; font-size: 10pt;">For the year ended December 31, 2021, our research and development expenses increased by approximately $8.75 million from the year ended December 31, 2020
            due to upfront payments associated with licensed technology, which were expensed because there is no future alternative use for the licensed technology other than for the intended purpose, increased clinical trial expenses, increased headcount
            and increased stock-based compensation when compared to 2020.</div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Acquired IPR&amp;D</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">During the year ended December 31, 2021, we expensed the approximately $80.5 million fair value of the IPR&amp;D acquired in the Acquisition because there is no future alternative use for the
          IPR&amp;D other than for its intended purpose.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">General and Administrative Expenses</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Years Ended December 31<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> 2021</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2020</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Change</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">% Change</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Professional fees</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>7,351,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>2,352,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>4,999,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>213</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stock-based compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>3,638,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>91,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>3,547,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>3898</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Payroll-related</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>1,299,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(98,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>1,397,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>-1426</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Insurance</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>1,134,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>122,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>1,012,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>830</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other expenses, net</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>1,302,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>830,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>472,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div>57</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total general and administrative expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>14,724,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>3,297,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>11,427,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;">
                <div>347</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">63</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The $11.42 million increase in general and administrative expense for the year ended December 31, 2021 from the year ended December 31, 2020 was primarily related to increased professional fees
          such as legal, accounting and consulting fees associated with merger and acquisition activity, including the Merger and the Acquisition, as well as costs associated with becoming a publicly traded company, increased stock-based compensation
          resulting from the issuance of equity awards, increased payroll-related expense due to an increase in our headcount and increased insurance expenses when compared to 2020.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Transaction Costs</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">For the year ended December 31, 2021, we incurred approximately $5.8 million in transaction costs related to the issuance of common stock to Brooklyn LLC&#8217;s financial advisor upon consummation
          of the Merger, and there were no comparable transaction costs for the year ended December 31, 2020.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Change in Fair Value of Contingent Consideration</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">As of December 31, 2020, our contingent consideration liability was approximately $20.1 million and&#160; related to royalties we would be obligated to pay under certain IRX-2 license agreements
          based on future revenues from any future IRX-2 product sales. During the year ended December 31, 2021, the change in fair value of the contingent consideration was a decrease to the liability of $180,000, based on our third-party valuation
          analysis.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Loss on Sales of NTN Assets</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The approximately $9.6 million loss on the sale of NTN assets during the year ended December 31, 2021 was incurred upon completion of the Disposition, and there was no comparable loss on sale
          for the year ended December 31, 2020.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Other Income (Expense), Net</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;"></td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Years Ended December 31<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> 2021</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2020</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Change</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">% Change</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Employer retention tax credit</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF; white-space: nowrap;">
                <div>664,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF; white-space: nowrap;">
                <div>664,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF; white-space: nowrap;">
                <div>N/A</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Income from Brooklyn PPP loan forgiveness</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>310,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>310,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>N/A</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other expenses, net</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(1,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(1,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>N/A</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Interest expense, net</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>(74,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>(43,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>(31,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;">
                <div>72</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Total other income (expense), net</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>899,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(43,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>942,000</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>-2191</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">During the year ended December 31, 2021, we recognized an increase in other income, net of expense of $899,000, as compared to other expense of $43,000 for the year ended December 31, 2020,
          primarily as a result of a withholding tax refund related to the employer retention tax credit under the Coronavirus Aid, Relief, and Economic Security Act administered by the U.S. Small Business Administration, or the CARES Act, and the
          forgiveness of Brooklyn LLC&#8217;s Paycheck Protection Program loan, or the PPP Loan, which was primarily offset by interest accrued on notes payable that we assumed as part of the acquisition of the assets of IRX Therapeutics, LLC in 2018. Such notes
          bore interest at the rate of 14% and matured on December 31, 2021, on which date the Company repaid such notes in full, including all accrued and unpaid interest thereon.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Provision for Income Taxes</div>

        <div><br />
        </div>

        <div style="text-align: justify; margin-right: 0.2pt; color: rgb(0, 0, 0);">
          <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our income tax provision is for state income tax related to our U.S. operations.&#160; At December 31, 2021 and 2020 we had available net
            operating loss (&#8220;NOL&#8221;) carryforwards of approximately $20,679,000 and $0 for federal income tax purposes, respectively, of which $20,679,000 can be carried forward indefinitely. We have available $1,397,000 and $747,000 state NOLs for the years
            ended December 31, 2021 and 2020, respectively.&#160; We also have foreign NOL carryforwards of $4,759,000 and $0 for the years ended December 31, 2021 and 2020, respectively, which carry forward indefinitely. Section 382 of the Internal Revenue
            Code (&#8220;IRC&#8221;) imposes limits on the ability to use NOL carryforwards that existed prior to a change in control to offset future taxable income. Such limitations would reduce, potentially significantly, the gross deferred tax assets disclosed in
            the table above related to the NOL carryforwards.&#160; We continue to disclose the NOL carryforwards at their original amount in the table above as no potential limitation has been quantified. We have also established a full valuation allowance for
            all deferred tax assets, including the NOL carryforwards, since we could not conclude that we were more likely than not able to generate future taxable income to realize these assets.</div>

        </div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">64</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Liquidity and Capital Resources</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">
          <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">At December 31, 2021, we had cash and cash equivalents of approximately $17.0 million. During the second quarter of 2021, we entered into
            Purchase Agreements with Lincoln Park, pursuant to which we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to an aggregate of $60.0 million in shares of our common stock. Future
            sales of common stock by us, if any, are subject to certain limitations, and may occur from time to time, at our sole discretion. As of April <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">12</span>, 2022, we had issued
            and sold approximately 3,552,000 shares of common stock for total gross proceeds of $54.1 million and net proceeds of $52.0 million. For further information, see &#8220;&#8212;Recent Developments&#8212;Purchase Agreements.&#8221; On March 9, 2022, we consummated the
            PIPE Transaction, resulting in net proceeds of approximately $11&#160;million. see &#8220;&#8212;Recent Developments&#8212;PIPE Transaction.&#8221;&#160;&#160; Pursuant to the purchase agreement entered into in respect of the PIPE Transaction, we are prohibited from issuing equity
            under the Purchase Agreements for a period of one-year following consummation of the PIPE Transaction.</div>

        </div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We have to date incurred operating losses, and we expect these losses to increase in the future as we expand our product development programs and operate as a publicly traded company.&#160;
          Developing product candidates, conducting clinical trials and commercializing products are expensive, and we will need to raise substantial additional funds to achieve our strategic objectives. It will likely be some years before we obtain the
          necessary regulatory approvals to commercialize one or more of our product candidates. Based on our current financial condition and forecasts of available cash, including as mentioned above, we believe we do not have sufficient funds to fund our
          operations for the next twelve months from the filing of the financial statements contained in this Annual Report on Form 10-K. There can be no assurance that we will ever be in a position to commercialize IRX-2 or any other product candidate we
          may acquire, or that we will obtain any additional financing that we require in the future or, even if such financing is available, that it will be obtainable on terms acceptable to us.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In that regard, our future funding requirements will depend on many factors, including:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">the scope, rate of progress and cost of our clinical trials and other product development activities;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">future clinical trial results;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">the terms and timing of any collaborative, licensing and other agreements that we may establish;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">the cost and timing of regulatory approvals;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">the cost and delays in product development as a result of any changes in regulatory oversight applicable to our products;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">the cost and timing of establishing sales, marketing and distribution capabilities;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">the effect of competition and market developments; and</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">the cost of filing and potentially prosecuting, defending and enforcing any patent claims and other intellectual property rights.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We plan to raise additional funds to support our product development activities and working capital requirements through the remaining availability under the Second Purchase Agreement (to the
          extent we are permitted to use such agreement), public or private equity offerings, debt financings, corporate collaborations or other means. We may also seek governmental grants to support our clinical trials and preclinical trials. Further, we
          may seek to raise capital to fund additional product development efforts even if we have sufficient funds for our planned operations. Any sale by us of additional equity or convertible debt securities could result in dilution to our stockholders.
          There can be no assurance that any such required additional funding will be available to us at all or available on terms acceptable to us.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">65</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Further, to the extent that we raise additional funds through collaborative arrangements, it may be necessary to relinquish some rights to our technologies or grant sublicenses on terms that
          are not favorable to us. If we are not able to secure additional funding when needed, we may have to delay the commercialize of our products, reduce the scope of or eliminate one or more research and development programs, which could have an
          adverse effect on our business.</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Sources of Funds</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"><span style="text-decoration: underline;">Equity Securities</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On March 6, 2022, we entered into a Securities Purchase Agreement with the PIPE Investor providing for the private placement (the &#8220;PIPE Transaction&#8221;) to the PIPE Investor of approximately
          6,857,000 Units, each of which consisted of (i) one share of our common stock (or, in lieu thereof, one Pre-Funded Warrant) and (ii) one Common Warrant, resulting in net proceeds of approximately $11 million. The PIPE Transaction closed on March
          9, 2022. see &#8220;&#8212;Recent Developments&#8212;PIPE Transaction.&#8221;</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On April 26, 2021, we and Lincoln Park Capital Fund, LLC, or Lincoln Park, executed the First Purchase Agreement, pursuant to which we had the right, but not the obligation, to sell to Lincoln
          Park, and Lincoln Park would be obligated to purchase, up to $20.0 million of shares of Brooklyn&#8217;s common stock, subject to certain limitations. In consideration for Lincoln Park&#8217;s entry into the First Purchase Agreement, we issued Lincoln Park
          approximately 56,000 shares of common stock. As of December 31, 2021, we issued and sold to Lincoln Park approximately 1,128,000 shares of common stock under the First Purchase Agreement for gross proceeds of $20.0 million, and no further shares
          may be sold to Lincoln Park under the First Purchase Agreement.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">
          <div style="text-align: justify; font-family: 'Times New Roman', serif; font-size: 10pt;">On May 26, 2021, we and Lincoln Park executed the Second Purchase Agreement, pursuant to which we have the right from time to time, but not the obligation,
            to sell to Lincoln Park, and Lincoln Park would be obligated to purchase, up to $40.0 million of shares of Brooklyn&#8217;s common stock, subject to certain limitations. In consideration of Lincoln Park&#8217;s entry into the Second Purchase Agreement, we
            issued to Lincoln Park 50,000 shares of common stock. As of December 31, 2021, Brooklyn had issued and sold approximately 2,424,000 shares of common stock under the Second Purchase Agreement for total gross proceeds of $34.1 million.&#160;&#160; Pursuant
            to the Securities Purchase Agreement in respect of the PIPE Transaction, we may not effect transactions under the Second Purchase Agreement for a period of one year immediately following closing of the PIPE Transaction.</div>

        </div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">For further information on the Purchase Agreements, see &#8220;&#8212;Recent Developments&#8212;Purchase Agreements.&#8221;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">As a condition to the closing of the Merger, Brooklyn LLC was required to have at least $10.0 million in cash and cash equivalents at the effective time of the Merger. In furtherance of, and
          prior to, the Merger, certain of its members entered into agreements pursuant to which those members purchased additional units of Brooklyn LLC for an aggregate purchase price of $10.5 million.</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0);"><span style="text-decoration: underline;">Disposition</span>.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On March 26, 2021, we completed the Disposition, in which we sold to eGames.com our rights, title and interest in and to the assets relating to the business we operated prior to the Merger
          under the name &#8220;NTN Buzztime, Inc.&#8221; in exchange for eGames.com&#8217;s payment of a purchase price of $2.0 million and assumption of specified liabilities relating to such pre-Merger business.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="color: rgb(0, 0, 0);"><span style="text-decoration: underline;">Brooklyn LLC PPP Loan</span>.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On May 4, 2020, Brooklyn LLC issued a note in the principal amount of approximately $310,000 to Silicon Valley Bank evidencing the loan, or the Brooklyn LLC PPP Loan, Brooklyn LLC received
          under the Paycheck Protection Program, or PPP, of the CARES Act administered by the U.S. Small Business Administration. Brooklyn LLC PPP Loan had an interest rate of 1.0% per annum.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">66</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">
          <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Under the terms of the CARES Act, certain amounts of the Brooklyn LLC PPP Loan could be forgiven if they were used for qualifying expenses
            as described in the CARES Act. In June 202<span style="font-family: 'Times New Roman', serif; font-size: 10pt;">1</span>, Brooklyn LLC submitted its loan forgiveness application for the Brooklyn LLC PPP Loan, and in September 202<span style="font-family: 'Times New Roman', serif; font-size: 10pt;">1</span>, the lender informed Brooklyn LLC that the U.S Small Business Administration had approved the forgiveness of 100% of the outstanding principal and interest of the
            Brooklyn LLC PPP Loan. As of December 31, 2021, there was no outstanding principal balance under the Brooklyn LLC PPP Loan.</div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Uses of Funds</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"><span style="text-decoration: underline;">Net Cash Used in Operating Activities</span><span style="font-style: italic;">.</span></div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our operations used $23.5 million during the year ended December 31, 2021. Our cash use for operating activities is influenced by the level of our net loss and the amount of cash we invest in
          personnel and technology development to support anticipated growth in our business.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"><span style="text-decoration: underline;">License Obligations</span>.</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0);">We are obligated to pay certain amounts to Factor pursuant to the license agreement we entered into in April 2021, including $2.5 million in October 2021, which was paid, and $3.5 million in October 2022.&#160; The
          license agreement also provides for milestone payments and royalties on the net sale of product developed under the license agreement.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"><span style="text-decoration: underline;">Lease Obligations</span>.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">
          <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">We are obligated to pay approximately $750,000 per year for our facilities leases, subject to annual increases and to a sharing of common
            area expenses with other tenants in the building. The leases expire at varying times between December 202<span style="font-family: 'Times New Roman', serif; font-size: 10pt;">6</span> and June 2028.</div>

        </div>

        <div style="color: rgb(0, 0, 0);"><span style="text-decoration: underline;"> <br />
          </span></div>

        <div style="color: rgb(0, 0, 0);"><span style="text-decoration: underline;">Acquisition</span>.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On July 16, 2021, we used approximately $22,882,000 of cash as partial consideration for the Acquisition, and we issued common stock valued at a total of $102.0 million, based on a price of
          $14.5253 per share, for the remaining portion of the Acquisition&#8217;s purchase price.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"><span style="text-decoration: underline;">Brooklyn PPP Loan</span>.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">On April 18, 2020, Brooklyn (then known as NTN Buzztime, Inc.) was granted a loan, which we refer to as the Brooklyn PPP Loan, in the aggregate amount of $1,625,000, pursuant to the PPP under
          the CARES Act. Under the terms of the PPP, certain amounts of the Brooklyn PPP Loan could be forgiven if they were used for qualifying expenses as described in the CARES Act. In October 2020 the U.S. Small Business Administration approved the
          forgiveness of $1,093,000 of the $1,625,000 principal amount of the Brooklyn PPP Loan, leaving a principal balance of approximately $532,000, all of which, plus accrued and unpaid interest, was due and, in accordance with the terms of the Merger
          Agreement, paid by Brooklyn upon the closing of the Merger.</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-weight: bold;">Critical Accounting Estimates</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The
          preparation of these consolidated financial statements requires us to make judgments, estimates, and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the
          consolidated financial statements, as well as the reported revenue and expenses during the reporting periods. We continually evaluate our judgments, estimates and assumptions. We base our estimates on the terms of underlying agreements, our
          expected course of development, historical experience and other factors we believe are reasonable based on the circumstances, the results of which form our management&#8217;s basis for making judgments about the carrying value of assets and liabilities
          that are not readily apparent from other sources. Actual results may differ from these estimates. We believe the following critical accounting estimates affect our more significant judgments and estimates used in the preparation of our
          consolidated financial statements.<br />
          <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">67</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Use of Estimates</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (a) the reported amounts of assets and
          liabilities; (b) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; (c) the reported amounts of revenues and expenses during the reporting period and (d) the reported amount of the fair value of
          assets acquired in connection with business combinations. Actual results could differ from those estimates. Our significant estimates and assumptions include the recoverability and useful lives of long-lived assets and the contingent
          consideration liability.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Goodwill</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in the acquisition of IRX Therapeutics, Inc. in November 2018 (the &#8220;IRX
          Acquisition&#8221;), which was accounted for as a business combination. Goodwill is not amortized but is tested for impairment annually, or if events occur or circumstances change that would reduce the fair value of a reporting unit below its carrying
          value. Since management evaluates Brooklyn as a single reporting unit, goodwill is tested for impairment at the entity level by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the
          entity is less than its carrying value. Such qualitative factors include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant events.&#160; If the entity does not pass the
          qualitative assessment, then the entity&#8217;s carrying value is compared to its fair value. Goodwill is considered impaired if the carrying value of the entity exceeds its fair value.</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Impairment of Long-Lived Assets</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We review long-lived assets and certain identifiable assets for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be
          recovered. An impairment exists when the carrying value of the long-lived asset is not recoverable and exceeds its fair value.</div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">68</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Fair Value of Financial Instruments</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between willing market participants. A fair value
          hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows:</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Level 1 Inputs &#8211; Valued based on quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Level 2 Inputs &#8211; Valued based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for
                  similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest
                  rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Level 3 Inputs &#8211; Valued based on inputs for which there is little or no market value, which require the reporting entity to develop its own assumptions.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The carrying amounts reported on the balance sheet for cash and cash equivalents, accounts receivable, prepaid assets and other current assets, accounts payable and accrued expenses, other
          current liabilities and other liabilities approximate fair value based due to their short maturities. The carrying value of loans payable approximates its fair market value because the effective yield on this debt, which includes contractual
          interest rates as well as other finance charges, is comparable to rates of returns for instruments of similar credit risk.</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Commitment and Contingencies</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We follow ASC No.450-20, <span style="font-style: italic;">Loss Contingencies</span>, to report accounting for contingencies. Liabilities for loss contingencies arising from claims,
          assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Stock-Based Compensation</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The Company recognizes stock-based compensation expense for equity awards granted to employees, directors and certain consultants. The Company estimates the fair value of stock options using
          the Black-Scholes option pricing model. The fair value of stock options granted is recognized as expense over the requisite service period. Stock-based compensation expense for share-based payment awards is recognized using the straight-line
          single-option method.</div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-weight: bold;">Recent Accounting Pronouncements</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In May 2021, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) <span style="font-style: italic;">2021-04, Earnings Per Share (Topic 260),
            Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of
            Freestanding Equity-Classified Written Call Options</span>. ASU 2021-04 addresses the accounting for certain modifications or exchanges of freestanding equity-classified written call options. ASU 2021-04 is effective for fiscal years beginning
          after December 15, 2021 (January 1, 2022 for us) and interim periods within those fiscal years, with early adoption permitted. We do not expect the adoption of this update to have a significant impact on our financial statements.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In July 2021, the FASB issued ASU 2021-05, <span style="font-style: italic;">Leases (Topic 842) &#8211; Lessors - Certain Leases with Variable Lease Payments,</span> which amends the lessor
          classification guidance to introduce additional criteria when classifying leases with variable lease payments that do not depend on a reference index or a rate. This guidance is effective for annual periods beginning after December 15, 2021
          (January 1, 2022 for us), with early adoption permitted. We do not expect the adoption of this update to have a significant impact on its financial statements.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">69</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <a id="ITEM7A"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45.05pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 7A.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Quantitative and Qualitative Disclosures about Market Risk</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0);">Under SEC rules and regulations, as a smaller reporting company we are not required to provide the information otherwise required by this item.</div>

        <div><br />
        </div>

        <a id="ITEM8"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45.05pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 8.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Financial Statements and Supplementary Data</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0);">See &#8220;Index to Consolidated Financial Statements&#8221; on page F-1 for a listing of the Consolidated Financial Statements filed with this Annual Report on Form 10-K.</div>

        <div>&#160;</div>

        <a id="ITEM9"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45.05pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 9.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</div>
              </td>

  </tr>


</table>
        <div>
          <div><br />
          </div>

          <div style="text-align: justify; color: rgb(0, 0, 0);">None.</div>

        </div>

        <div>&#160;</div>

        <a id="ITEM9A"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45.05pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 9A.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Controls and Procedures</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Disclosure Controls and Procedures</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act, designed to ensure that information required to be disclosed
          in our reports filed pursuant to the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management,
          including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosures.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">In designing and evaluating the disclosure controls and procedures, we recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable
          assurance of achieving the desired control objectives, and we were required to apply our judgment in evaluating the cost-benefit relationship of possible controls and procedures. We have carried out an evaluation as of the end of the period
          covered by this Annual Report on Form 10-K under the supervision, and with the participation, of our management, including our Chief Executive Officer and President (who serves as our principal executive officer) and our Vice President of Finance
          (who serves as our principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures.</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Based on that evaluation, our Chief Executive Officer and Vice President of Finance concluded that our disclosure controls and procedures were not effective as of the end of the period covered
          by this Annual Report on Form 10-K in providing reasonable assurance of achieving the desired control objectives due primarily to a material weakness discussed below.</div>

        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Management&#8217;s Report on Internal Control over Financial Reporting</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide
          reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Under the supervision and with the participation of our management, including our Chief Executive Officer and our Vice President of Finance, we conduct an annual evaluation of the effectiveness
          of our internal control over financial reporting based on the guidelines established by the 2013 <span style="font-style: italic;">Internal Control&#8212;Integrated Framework</span> issued by the Committee of Sponsoring Organizations of the Treadway
          Commission. If management identifies any material weakness in the course of that evaluation, management cannot conclude that our internal controls over financial reporting are effective.&#160; A material weakness is a deficiency, or a combination of
          deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Upon completion of the Merger in March 2021 and the resulting change in our business model and strategy, we experienced a complete turnover of our employees, including all of the members of our
          executive management team, which resulted in, among other things, our having insufficient accounting staff available to enable and ensure adequate segregation of duties and our lacking appropriate and complete documentation of policies and
          procedures critical to the accomplishment of financial reporting objectives. The accounting personnel and documentation deficiencies each increase the risk that a material misstatement of our financial statements will not be prevented or detected
          on a timely basis. Based on this evaluation, our Chief Executive Officer and President and our Vice President of Finance concluded that, as of December 31, 2021, our disclosure controls and procedures were not effective and did not provide
          reasonable assurance of achieving the desired control objectives.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">70</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Management&#8217;s Plan for Material Weakness in Internal Control over Financial Reporting</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">Management plans to implement measures designed to ensure that the deficiencies contributing to the ineffectiveness of our disclosure controls and procedures are promptly remediated, such that
          the controls and procedures are designed, implemented and operating effectively. The remediation actions planned include:</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">hiring additional accounting personnel in a number, and with experience, to allow for proper segregation of duties; and</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">developing and implementing, and then monitoring the effectiveness of, written policies and procedures required to achieve our financial reporting objectives in a timely manner, including policies and
                  procedures relating to internal control over financial reporting.</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">We are committed to developing a strong internal control environment, and we believe the remediation efforts that we will implement will result in significant improvements in our control
          environment. We hired our Vice President of Finance in the second quarter of 2021 to oversee all accounting and financial reporting matters, including implementing a framework for internal controls over financial reporting, and we hired a
          full-time controller at the beginning of 2022. Also, during the fourth quarter of 2021, we engaged a third-party consulting firm with expertise in implementing the framework for internal controls over financial reporting, and we currently
          developing this framework. Our management will continue to monitor and evaluate the relevance of our risk-based approach and the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and is committed
          to taking further action and implementing additional enhancements or improvements, as necessary.</div>

        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Changes in Internal Control over Financial Reporting</div>

        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0);">Other than described above, there was no change in our internal control over financial reporting during the most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our
          internal control over financial reporting.</div>

        <div>&#160;</div>

        <a id="ITEM9B"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45.05pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 9B.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Other Information</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0);">Not Applicable.</div>

        <div>&#160;</div>

        <a id="ITEM9C"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45.05pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 9C.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0);">Not Applicable.</div>

        <div style="color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">71</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><a id="PARTIII"><!--Anchor--></a>PART III</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0);">The information required in Item 10 (Directors, Executive Officers and Corporate Governance), Item 11 (Executive Compensation), Item 12 (Security Ownership of Certain Beneficial Owners and
          Management and Related Stockholder Matters), Item 13 (Certain Relationships and Related Transactions, and Director Independence), and Item 14 (Principal Accounting Fees and Services) is incorporated by reference to the Company&#8217;s definitive proxy
          statement for the 2022 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of December 31, 2021.</div>

        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">72</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PART IV</div>

        <div>&#160;</div>

        <a id="ITEM15"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45.05pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 15.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Exhibits, Financial Statement Schedules</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-indent: 27pt; color: rgb(0, 0, 0);">(a) The following documents are filed as a part of this Annual Report on Form 10-K:</div>

        <div>&#160;</div>

        <div style="text-indent: 27pt;"><span style="font-style: italic; color: rgb(0, 0, 0);">(1)</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="color: rgb(0, 0, 0);"><span style="font-style: italic;">Consolidated Financial Statements.</span> The consolidated financial
            statements of the Company and its consolidated subsidiaries are set forth in the &#8220;Index to Consolidated Financial Statements&#8221; on page F-1.</span></div>

        <div>&#160;</div>

        <div style="text-indent: 27pt;"><span style="font-style: italic; color: rgb(0, 0, 0);">(2)</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="color: rgb(0, 0, 0);"><span style="font-style: italic;">Financial Statement Schedules. </span>None</span></div>

        <div>&#160;</div>

        <div style="text-indent: 27pt;"><span style="font-style: italic; color: rgb(0, 0, 0);">(3)</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="color: rgb(0, 0, 0);"><span style="font-style: italic;">Exhibits. </span>The following exhibits are submitted with this Annual
            Report on Form 10-K or, where indicated, incorporated by reference to other filings.</span></div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 9%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="color: rgb(0, 0, 0); font-weight: bold;">Exhibit</div>
              </td>

    <td style="width: 0.52%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td style="width: 64.48%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="color: rgb(0, 0, 0); font-weight: bold;">Description</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="color: rgb(0, 0, 0); font-weight: bold;">Incorporated By Reference</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000149315221001359/forms-4a.htm">2.1(b)</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Agreement and Plan of Merger and Reorganization, dated August 12, 2020, among NTN Buzztime, Inc., BIT Merger Sub, Inc. and Brooklyn Immunotherapeutics LLC</div>
                <div>&#160;</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Annex A to the proxy statement/prospectus/consent solicitation statement forming a part of the S-4 Registration Statement filed on January 20, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121024732/brhc10026994_ex10-1.htm">2.2(b)</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;">&#160;</td>

    <td style="width: 64.48%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Agreement and Plan of Acquisition, dated as of July 16, 2021, by and among Brooklyn ImmunoTherapeutics, Inc., Brooklyn Acquisition Sub, Inc., Novellus LLC, Novellus, Inc., and the Sellers&#8217; Representative.</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Exhibit to Form 8-K filed on July 19, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="https://www.sec.gov/Archives/edgar/data/748592/000101968713003135/ntn_10q-ex0301.htm">3.1</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Restated Certificate of Incorporation</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form 10-Q filed on August 14, 2013</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315216010919/ex3-1.htm">3.2</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;">&#160;</td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Certificate of Amendment to the Restated Certificate of Incorporation (reverse/forward split)</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Exhibit to Form 8-K filed on June 17, 2016</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315217003784/ex3-1.htm">3.3</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Certificate of Decrease of the Series A Convertible Preferred Stock</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form 8-K filed on April 12, 2017</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315217006434/ex3-1.htm">3.4</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;">&#160;</td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Certificate of Amendment to the Restated Certificate of Incorporation (decrease in authorized capital stock)</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Exhibit to Form 8-K filed on June 9, 2017</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121011095/brhc10022537_ex3-1.htm">3.5</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Certificate of Amendment to Restated Certificate of Amendment, dated March 25, 2021 (Reverse Stock Split)</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form 8-K filed on March 31, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121011095/brhc10022537_ex3-2.htm">3.6</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;">&#160;</td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Certificate of Amendment to Restated Certificate of Amendment, dated March 25, 2021 (Authorized Share Increase)</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Exhibit to Form 8-K filed on March 31, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121011095/brhc10022537_ex3-3.htm">3.7</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Certificate of Amendment to Restated Certificate of Amendment, dated March 25, 2021 (Name Change)</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form 8-K filed on March 31, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121030987/brhc10028852_ex3-1.htm">3.8</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;">&#160;</td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Certificate of Validation of Brooklyn ImmunoTherapeutics, Inc., as filed with the Secretary of State of the State of Delaware on September 3, 2021</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Exhibit to Form 8-K filed on September 13, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a style="font-family: 'Times New Roman', serif; font-size: 10pt;" href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121032255/brhc10029142_ex3-2.htm">3.9</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Amended and Restated Bylaws of Brooklyn ImmunoTherapeutics, Inc.</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form 8-K filed on September 23, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);"><a href="brhc10036185_ex4-1.htm">4.1</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;">&#160;</td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</div>
                </div>
              </td>

    <td style="width: 0.6%; vertical-align: top;">&#160;</td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121015275/nt10023650x2_ex10-2.htm">10.1</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Registration Rights Agreement, dated as of April 26, 2021, between<span style="background-color: rgb(204, 238, 255);">&#160;</span>Brooklyn ImmunoTherapeutics, Inc. and Lincoln Park Capital Fund, LLC</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form 8-K filed on April 30, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121018871/brhc10025183_ex10-2.htm">10.2</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;">&#160;</td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Registration Rights Agreement, dated as of May 26, 2021, between Brooklyn&#160;ImmunoTherapeutics, Inc. and Lincoln Park Capital Fund, LLC</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;">&#160;</td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Exhibit to Form 8-K filed on May 26, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121024732/brhc10026994_ex10-2.htm">10.3</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Registration Rights Agreement, dated as of July 16, 2021, by and among Brooklyn ImmunoTherapeutics, Inc. and the individuals and entities named therein.</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form 8-K filed on July 19, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121011095/brhc10022537_ex10-1.htm">10.4</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;">&#160;</td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Amended and Restated Royalty Agreement and Distribution Agreement, dated March 22, 2021.</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Exhibit to Form 8-K filed on March 31, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121011095/brhc10022537_ex10-3.htm">10.5</a><span style="color: rgb(0, 0, 0);">(a)</span></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Assignment and<span style="background-color: rgb(204, 238, 255);">&#160;</span>Assumption of Employment Agreement dated March 30, 2021 among Brooklyn ImmunoTherapeutics, LLC, Brooklyn ImmunoTherapeutics, Inc. and Ronald Guido<span style="background-color: rgb(204, 238, 255);">.</span></div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form 8-K filed<span style="background-color: rgb(204, 238, 255);">&#160;</span>on March 31, 2021</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">73</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121011095/brhc10022537_ex10-4.htm">10.6</a><span style="color: rgb(0, 0, 0);">(a)</span></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Assignment and Assumption of Employment Agreement dated March 30, 2021 among Brooklyn ImmunoTherapeutics, LLC, Brooklyn ImmunoTherapeutics, Inc. and Lynn Sadowski Mason.</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form 8-K filed<span style="background-color: rgb(204, 238, 255);">&#160;</span>on March 31, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121012036/brhc10022864_ex10-1.htm">10.7</a><span style="color: rgb(0, 0, 0);">(a)</span></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Executive Employment Agreement, dated as of April 1, 2021 and effective as&#160;of April 16, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Howard&#160;J. Federoff.</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Exhibit to Form 8-K filed<span style="background-color: rgb(204, 238, 255);">&#160;</span>on April 7, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121020543/brhc10025686_ex10-1.htm">10.8</a><span style="color: rgb(0, 0, 0);">(a)</span></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Executive Employment Agreement, dated as of June 5, 2021 and effective as of June 28, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Kevin D&#8217;Amour.</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form 8-K filed on June 10, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121021741/brhc10026052_ex10-1.htm">10.9</a>(a)</div>
              </td>

    <td style="width: 0.52%; vertical-align: top;"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Executive Employment Agreement, dated as of June 16, 2021 and effective&#160;as of June 21, 2021, between Brooklyn ImmunoTherapeutics, Inc. and&#160;Sandra Gurrola.</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Exhibit to Form 8-K filed<span style="background-color: rgb(204, 238, 255);">&#160;</span>on June 21, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121024792/brhc10027031_ex10-1.htm">10.10</a>(a)</div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Executive Employment Agreement, dated as of July 6, 2021 and effective as of July 15, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Jay Sial.</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form 8-K filed on July 19, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121032255/brhc10029142_ex10-1.htm">10.11</a>(a)</div>
              </td>

    <td style="width: 0.52%; vertical-align: top;"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Executive Employment Agreement, effective as of September 20, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Roger Sidhu.</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Exhibit to Form 8-K filed on September 23, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121013151/brhc10023212_ex10-1.htm">10.12</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Form of Indemnification Agreement</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form 8-K filed on April 16, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121015275/nt10023650x2_ex10-1.htm">10.13</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Purchase Agreement, dated as of April 26, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Lincoln Park Capital Fund, LLC</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Exhibit to Form 8-K filed on April 30, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121018871/brhc10025183_ex10-1.htm">10.14</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Purchase Agreement, dated as of May 26, 2021, between Brooklyn ImmunoTherapeutics, Inc. and Lincoln Park Capital Fund, LLC</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form 8-K filed on May 26, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div style="font-size: 12pt;"><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121015275/nt10023650x2_ex10-3.htm"><span style="font-size: 10pt;">10.15</span></a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Exclusive License Agreement, dated as of April 26, 2021, between Factor Bioscience Limited, Novellus Therapeutics Limited and Brooklyn ImmunoTherapeutics LLC</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Exhibit to Form 8-K filed on April 30, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="font-size: 12pt;"><span style="font-size: 10pt;"><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000114036121018871/brhc10025183_ex10-3.htm">10.16</a>(a)</span></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Brooklyn ImmunoTherapeutics, Inc. 2021 Inducement Stock<span style="background-color: rgb(204, 238, 255);">&#160;</span>Incentive Plan</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form 8-K filed<span style="background-color: rgb(204, 238, 255);">&#160;</span>on May 26, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div style="font-size: 12pt;"><span style="font-size: 10pt;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000114036121030987/brhc10028852_ex99-1.htm">10.17</a>(a)</span></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Brooklyn ImmunoTherapeutics, Inc. Restated 2020 Stock Incentive Plan</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Exhibit to Form 8-K filed on September 13, 2021</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="font-size: 12pt;"><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000149315220022484/ex10-23a.htm"><span style="font-size: 10pt;">10.18</span></a><span style="font-size: 10pt;">(c)</span></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Lease Agreement, made as of September 28, 2015, between Biobat, Inc. and IRX Therapeutics, LLC</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form S-4/A filed on November 25, 2020</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000149315220022484/ex10-23b.htm">10.19</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>First Amendment to Lease Agreement, dated September 28, 2015</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Exhibit to Form S-4/A filed on November 25, 2020</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="font-size: 12pt;"><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000149315220022484/ex10-23c.htm"><span style="font-size: 10pt;">10.20</span></a><span style="font-size: 10pt;">(c)</span></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Assignment and Assumption of Lease, made by and between IRX Therapeutics, LLC and Brooklyn, and consented to by Biobat, Inc., as landlord</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form S-4/A filed on November 25, 2020</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000149315220022484/ex10-23d.htm">10.21</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;">&#160;</td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Second Amendment to Lease Agreement, dated July 24, 2019</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;">&#160;</td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Exhibit to Form S-4/A filed on November 25, 2020</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="font-size: 12pt;"><a href="https://www.sec.gov/Archives/edgar/data/748592/000149315220022484/ex10-24a.htm"><span style="font-size: 10pt;">10.22</span></a><span style="font-size: 10pt;">(c)</span></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Sublease Agreement, dated April 18, 2019, between Brooklyn and Nezu Asia Capital Management, LLC</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form S-4/A filed on November 25, 2020</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000149315220022484/ex10-24b.htm">10.23</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;">&#160;</td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Consent to Sublease and Agreement, dated as of May 18, 2019, among 654 Madison Avenue Associates LP, Brooklyn, and Nezu Asia <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">Capital </span>Management, LLC</div>
                </div>
              </td>

    <td style="width: 0.6%; vertical-align: top;">&#160;</td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Exhibit to Form S-4/A filed on November 25, 2020</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="https://www.sec.gov/Archives/edgar/data/0000748592/000149315220022484/ex10-24c.htm">10.24</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Commencement Date Confirmation Agreement, made as of June 27, 2019, among Brooklyn and Nezu Asia Capital Management, LLC.<br />
                </div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Exhibit to Form S-4/A filed on November 25, 2020</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div style="font-size: 12pt;"><a href="brhc10036185_ex10-26.htm"><span style="font-size: 10pt;">10.25</span></a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;">&#160;</td>

    <td style="width: 64.48%; vertical-align: top;">
                <div><span style="color: rgb(0, 0, 0);">Lease Agreement dated June 15, 2021 between Brooklyn ImmunoTherapeutics, Inc. and Fairlane Columbia, LLC<br />
                  </span></div>
              </td>

    <td style="width: 0.6%; vertical-align: top;">&#160;</td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);"><a href="brhc10036185_ex21-1.htm">21.1</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Subsidiaries of the Company.</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Filed herewith.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);"><a href="brhc10036185_ex23-1.htm">23.1</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;">&#160;</td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Consent of the Independent Registered Accounting Firm.</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;">&#160;</td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Filed herewith</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">74</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="brhc10036185_ex31-1.htm">31.1</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div><a href="brhc10036185_ex31-2.htm">31.2</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="brhc10036185_ex32-1.htm">32.1</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Furnished herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div><a href="brhc10036185_ex32-2.htm">32.2</a></div>
              </td>

    <td style="width: 0.52%; vertical-align: top;"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Furnished herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>101.INS</div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div>101.SCH</div>
              </td>

    <td style="width: 0.52%; vertical-align: top;"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Inline XBRL Taxonomy Extension Schema Document</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>101.CAL</div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Inline XBRL Taxonomy Extension Calculation Linkbase Document</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div>101.DEF</div>
              </td>

    <td style="width: 0.52%; vertical-align: top;"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Inline XBRL Taxonomy Extension Definition Linkbase Document</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>101.LAB</div>
              </td>

    <td style="width: 0.52%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Inline XBRL Taxonomy Extension Label Linkbase Document</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
                <div>101.PRE</div>
              </td>

    <td style="width: 0.52%; vertical-align: top;"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top;">
                <div>Inline XBRL Taxonomy Extension Presentation Linkbase Document</div>
              </td>

    <td style="width: 0.6%; vertical-align: top;"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top;">
                <div>Filed herewith</div>
              </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>104</div>
              </td>

    <td style="width: 0.52%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 64.48%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).</div>
              </td>

    <td style="width: 0.6%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);"><br />
              </td>

    <td style="width: 24.71%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(a)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Indicates management contract or compensatory plan.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(b)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Pursuant to Item 601(b)(2) of Regulation S-K, portions of this exhibit have been omitted because the Company customarily and actually treats the omitted portions as private or confidential, and such
                  portions are not material and would likely cause competitive harm to the Company if publicly disclosed. The Company will supplementally provide a copy of an unredacted copy of this exhibit to the U.S. Securities and Exchange Commission or
                  its staff upon request.</div>
              </td>

  </tr>


</table>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 27pt; vertical-align: top; color: rgb(0, 0, 0);">(c)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <a id="ITEM16"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45.05pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 16.</td>

    <td style="vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Form 10-K Summary</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-indent: 27pt; color: rgb(0, 0, 0);">None.</div>

        <div style="text-indent: 27pt; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">75</span></div>

          <div style="page-break-after:always;" class="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><a id="SIGNATURES"><!--Anchor--></a>SIGNATURES</div>

        <div>&#160;</div>

        <div style="text-indent: 24.5pt; color: rgb(0, 0, 0);">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned,
          thereunto duly authorized<span style="font-weight: bold;">.</span></div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: middle;">&#160;</td>

    <td style="width: 3%; vertical-align: bottom;">&#160;</td>

    <td style="width: 47%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt;"><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">Date: A</span><span style="font-family: 'Times New Roman',serif; font-size: 10pt;">pril </span><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">15, 2022</span></div>
                </div>
              </td>

    <td style="width: 3%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">By:</div>
              </td>

    <td style="width: 47%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; font-style: italic;">/s/ Howard J. Federoff</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">&#160;</td>

    <td style="width: 3%; vertical-align: middle;">&#160;</td>

    <td style="width: 47%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Howard J. Federoff</div>
              </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">&#160;</td>

    <td style="width: 3%; vertical-align: bottom;">&#160;</td>

    <td style="width: 47%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Chief Executive Officer and President</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Principal Executive Officer)</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-indent: 24.5pt; color: rgb(0, 0, 0);">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on
          the dates indicated.</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32.69%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Name</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Title</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Date</div>
              </td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; font-style: italic;">/s/ Howard J. Federoff</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#160;Chief Executive Officer, President and Member of the Board (Principal Executive Officer)</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt;"><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">A</span><span style="font-family: 'Times New Roman',serif; font-size: 10pt;">pril </span><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">15, 2022</span></div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Howard J. Federoff</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom; text-align: center;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; font-style: italic;">/s/ Sandra Gurrola</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#160;Vice President of Finance (Principal Financial and Accounting Officer)</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0);">
                    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt;"><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">A</span><span style="font-family: 'Times New Roman',serif; font-size: 10pt;">pril </span><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">15, 2022</span></div>
                  </div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Sandra Gurrola</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom; text-align: center;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; font-style: italic;">/s/ Charles Cherington</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#160;Chairman of the Board</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0);">
                    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt;"><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">A</span><span style="font-family: 'Times New Roman',serif; font-size: 10pt;">pril </span><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">15, 2022</span></div>
                  </div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Charles Cherington</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom; text-align: center;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; font-style: italic;">/s/ Dennis H. Langer</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#160;Member of the Board</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0);">
                    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt;"><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">A</span><span style="font-family: 'Times New Roman',serif; font-size: 10pt;">pril </span><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">15, 2022</span></div>
                  </div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Dennis H. Langer</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom; text-align: center;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; font-style: italic;">/s/ Erich Mohr</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#160;Member of the Board</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0);">
                    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt;"><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">A</span><span style="font-family: 'Times New Roman',serif; font-size: 10pt;">pril </span><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">15, 2022</span></div>
                  </div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Erich Mohr</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom; text-align: center;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; font-style: italic;">/s/ Heather B. Redman</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#160;Member of the Board</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0);">
                    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt;"><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">A</span><span style="font-family: 'Times New Roman',serif; font-size: 10pt;">pril </span><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">15, 2022</span></div>
                  </div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Heather B. Redman</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom; text-align: center;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center; font-style: italic;">/s/ Erin S. Enright</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#160;Member of the Board</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">
                  <div style="color: rgb(0, 0, 0);">
                    <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 12pt;"><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">A</span><span style="font-family: 'Times New Roman',serif; font-size: 10pt;">pril </span><span style="font-family: 'Times New Roman', serif; font-size: 10pt;">15, 2022</span></div>
                  </div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 32.69%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Erin S. Enright</div>
              </td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 43.88%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1.01%; vertical-align: bottom;">&#160;</td>

    <td style="width: 21.4%; vertical-align: bottom;">&#160;</td>

  </tr>


</table>
        <div><br />
        </div>

      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">76</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

      <!--PROfilePageNumberReset%Num%1%F-%%--> </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><br />
        BROOKLYN IMMUNOTHERAPEUTICS, INC. AND SUBSIDIARIES</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><a id="INDEX"><!--Anchor--></a>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 92%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td style="width: 8%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Page</div>
            </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: rgb(0, 0, 0);"><a href="#REPORT">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID: <span style="-sec-ix-hidden:Fact_10926fb50ef84807b40df791d25443c8">688</span>)<br />
              </div>
            </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: right; color: rgb(0, 0, 0);">F-2</div>
            </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: middle;">&#160;</td>

    <td style="width: 8%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: rgb(0, 0, 0);">Consolidated Financial Statements:</div>
            </td>

    <td style="width: 8%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: middle;">
              <div style="margin-left: 18pt;">&#160;</div>
            </td>

    <td style="width: 8%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: rgb(0, 0, 0); margin-left: 18pt;"><a href="#BALANCESHEETS">Consolidated Balance Sheets as of December 31, 2021 and 2020</a></div>
            </td>

    <td style="width: 8%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: right; color: rgb(0, 0, 0);">F-3</div>
            </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: middle;">
              <div style="margin-left: 18pt;">&#160;</div>
            </td>

    <td style="width: 8%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: rgb(0, 0, 0); margin-left: 18pt;"><a href="#OPERATIONS">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2021 and 2020</a></div>
            </td>

    <td style="width: 8%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: right; color: rgb(0, 0, 0);">F-4</div>
            </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: middle;">
              <div style="margin-left: 18pt;">&#160;</div>
            </td>

    <td style="width: 8%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: rgb(0, 0, 0); margin-left: 18pt;"><a href="#EQUITY">Consolidated Statements of Shareholders&#8217; Equity for the years ended December 31, 2021 and 2020</a></div>
            </td>

    <td style="width: 8%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: right; color: rgb(0, 0, 0);">F-5</div>
            </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: middle;">&#160;</td>

    <td style="width: 8%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: rgb(0, 0, 0); margin-left: 18pt;"><a href="#CASHFLOW">Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020</a></div>
            </td>

    <td style="width: 8%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: right; color: rgb(0, 0, 0);">F-6</div>
            </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: middle;">&#160;</td>

    <td style="width: 8%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: rgb(0, 0, 0);"><a href="#NOTES">Notes to the Consolidated Financial Statements</a></div>
            </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-align: right; color: rgb(0, 0, 0);">F-7</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-1</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

      <!--PROfilePageNumberReset%Num%3%F-%%--> </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><a id="REPORT"><!--Anchor--></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">To the Stockholders, Members and Board of Directors of</div>

        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Brooklyn ImmunoTherapeutics, Inc.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Opinion on the Financial Statements</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have audited the accompanying consolidated balance sheets of Brooklyn ImmunoTherapeutics, Inc. (the &#8220;Company&#8221;) as of December 31,
          2021 and 2020, the related consolidated<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span>statements of operations, stockholders&#8217; and members&#8217; equity (deficit) and cash flows for each of the
          two years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).&#160; In our opinion, the financial statements present fairly, in all material respects, the financial position of the
          Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of
          America.</div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
          <div><br />
          </div>

          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><a id="z_Hlk100901172"></a>Explanatory Paragraph &#8211; Going Concern</div>

          <div>&#160;</div>

          <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.
            As more fully described in Note 2, the Company has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company's ability to
            continue as a going concern. Management's plans in regard to these matters are also described in Note <span style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;">2</span>. The consolidated financial statements do not include any
            adjustments that might result from the outcome of this uncertainty.</div>

          <div>&#160;</div>
<div>
          Change in Accounting Principle</div>
</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">As discussed in Notes 3 and 7 to the financial statements, the Company has changed its method of accounting for leases in 2020 due
          to the adoption of the guidance in ASC Topic 842, Leases (&#8220;Topic 842&#8221;).</div>

        <div><br />
        </div>

        <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Basis for Opinion</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the
          Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in
          accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to
          obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over
          financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over
          financial reporting. Accordingly, we express no such opinion.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
          error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the
          accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</div>

        <div><br />
        </div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Critical Audit Matters</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that were
          communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The
          communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit
          matter or on the accounts or disclosures to which it relates.</div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-2</span></div>

          <div style="page-break-after: always;" class="DSPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        </div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value of Contingent Consideration</div>

        <div><br />
        </div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Description of the Matter</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As discussed in Note 5 to the financial statements, contingent consideration is recorded at fair value at the transaction date and
          subsequently revalued each reporting period, with changes in the fair value recognized within the statement of operations. As of and for the year ended December 31, 2021, management recorded a contingent consideration liability of $19.9 million
          and change in fair value of $0.2 million.&#160; Management utilized a third-party valuation specialist to assist in estimating the contingent consideration fair value using the income approach, and the discounted cash flows were used to estimate the
          expected royalty payments to third parties.</div>

        <div><br />
        </div>

        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Auditing management&#8217;s estimated fair value of contingent consideration is highly subjective and judgmental as the assumptions used in
          the fair value measurement, including the discount rate, the amount and timing of cash flows, and the forecast of future product sales, are all based on significant inputs not observable in the market.&#160; This in turn led to a high degree of
          auditor judgment, subjectivity and effort in performing procedures related to the fair value of contingent consideration and the audit effort involved the use of professionals with specialized skill and knowledge to assist in evaluating the audit
          evidence obtained.</div>

        <div><br />
        </div>

        <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">How we Addressed the Matter in Our Audit</div>

        <div>
          <div><br />
          </div>

          <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">With the assistance of our valuation specialists, our audit procedures included, amongst others:</div>

          <div><br />
          </div>

          <div>
            <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 18pt;">
                    <div>&#8226;</div>
                  </td>

    <td style="align: left; vertical-align: top; width: auto;">
                    <div style="text-align: justify;">We obtained an understanding of management&#8217;s process in regards to the methodology used and the factors considered around the inputs, sources of data used and assumptions and estimates made in
                      determining the fair value of contingent consideration, including those over management&#8217;s review of its third-party specialist valuation report.</div>
                  </td>

  </tr>


</table>
          </div>

          <div>
            <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 18pt;">
                    <div>&#8226;</div>
                  </td>

    <td style="align: left; vertical-align: top; width: auto;">
                    <div style="text-align: justify;">We tested the completeness and accuracy of the data used in the discounted cash flow model.</div>
                  </td>

  </tr>


</table>
          </div>

          <div>
            <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 18pt;">
                    <div>&#8226;</div>
                  </td>

    <td style="align: left; vertical-align: top; width: auto;">
                    <div style="text-align: justify;">We evaluated the appropriateness of the discounted cash flow model.</div>
                  </td>

  </tr>


</table>
          </div>

          <div>
            <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 18pt;">
                    <div>&#8226;</div>
                  </td>

    <td style="align: left; vertical-align: top; width: auto;">
                    <div style="text-align: justify;">We performed a sensitivity analysis on the discount rate used in the discounted cash flow model to determine the impact rate changes could have on the fair value.</div>
                  </td>

  </tr>


</table>
          </div>

          <div><br />
          </div>

        </div>

        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Marcum <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-variant: small-caps;">llp</span></div>

        <div><br />
        </div>

        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:AuditorName" id="Fact_3c04b56a4cac4e488afbc65aa6a80bc6" contextRef="c20210101to20211231">Marcum LLP</ix:nonNumeric><br />
        </div>

        <div><br />
        </div>

        <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are uncertain as to the year we began serving consecutively as the auditor of the Company&#8217;s financial statements; however, we are aware that we have
          been the Company&#8217;s auditor consecutively since at least 2013.</div>

        <div><br />
        </div>

        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:AuditorLocation" id="Fact_f34c495b19774ce6a91361494f7884ff" contextRef="c20210101to20211231">New York, NY</ix:nonNumeric><br />
        </div>

        <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">April 15, 2022</div>

        <div><br />
        </div>

      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-2</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">BROOKLYN IMMUNOTHERAPEUTICS, INC. AND SUBSDIARIES</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">CONSOLIDATED <a id="BALANCESHEETS"><!--Anchor--></a>BALANCE SHEETS</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(In thousands, except par value amount)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">December 31,</div>
              <div style="text-align: center; font-weight: bold;">2021<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; font-weight: bold;">December 31,</div>
              <div style="text-align: center; font-weight: bold;">2020<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
              <div style="font-weight: bold;">ASSETS</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
              <div style="margin-left: 9pt;">Current assets:</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Cash</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:Cash" id="Fact_3105dd9ccc1b48719f8176a107ccd4f9" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">16,985</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:Cash" id="Fact_673c5e1322154cf49ed662c412f4516e" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,630</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">Accounts receivable</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" id="Fact_1f71e7118a9c4118a047f2a3cf9ece25" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">684</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" id="Fact_dd5037cb9c19485ab72c3eb387cbc862" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Prepaid expenses and other current assets</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_47f0d14df958408e80f2c1a0ffb1c76e" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,097</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_766fa37f6a864ccb965af4dcd9857f0a" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">102</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 18pt;">Total current assets</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_19ecdd8cc8014c38a47e22bd9230caa6" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">18,766</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_ec8ec10327b44638b5afea22b2522071" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,732</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Property and equipment, net</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_2b7d2f29bbcd4894a3aedfcdf2e257b8" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">670</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_f2408597d21546f8a2eb36eb09327d25" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">594</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">Right-of-use assets - operating leases</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_ef93195bea7f44f88df1378682c2c431" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,567</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_5764aa5646744e69b1d38aa65921f0d0" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,093</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Goodwill</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:Goodwill" id="Fact_4a4a467136da4654b2cfeb7570353b05" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,044</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:Goodwill" id="Fact_5d5560f56a1d4f2aacda2fa27f118819" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,044</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">In-process research and development</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" id="Fact_deafd1da7f164ab3aa3df12c7e4a01f2" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,860</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" id="Fact_799857ffe05e4240a7ab761fcb2f79e6" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,860</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Investment in minority interest</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:EquityMethodInvestments" id="Fact_f67cb2ff7e3144f7b5d8c9399bc0e38d" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:EquityMethodInvestments" id="Fact_16950d0c24294fbe9f3ab2f983b65702" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
              <div style="margin-left: 9pt;">Security deposits and other assets</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:DepositAssets" id="Fact_7a2c3d2392b648ebaf56d7a1f442b234" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">522</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:DepositAssets" id="Fact_d3cf4ecfdc0a42ba87ade4f7685ef059" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">453</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 18pt;">Total assets</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:Assets" id="Fact_e31cc62ef317439291eb1b61998b9664" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">32,429</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:Assets" id="Fact_a61df61a01094ffebbc7e7ba7ec52c31" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">13,776</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-weight: bold;">LIABILITIES AND STOCKHOLDERS&#8217; AND MEMBERS&#8217; EQUITY (DEFICIT)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">Current liabilities:</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Accounts payable</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_b760e19c944a493abbe5191e772372a4" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,755</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_f0056ea2db3f4ecb9b6c8dd61714d03f" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,275</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">Accrued expenses</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_2fc4cf671ba1465cb1f1758cba8dcf9b" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,249</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_fd56bb147e664534b60ca33c582f7434" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,051</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Loans payable</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:LoansPayableCurrent" id="Fact_f3c48df9f2724b13a3e91a8b1608fc3f" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:LoansPayableCurrent" id="Fact_87f71a6ebf544bd8bda1c917271fe023" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">410</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">PPP loan, current</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:PaycheckProtectionProgramLoanCurrent" id="Fact_6a206d85fcab437baaa5cb6a867b0d8e" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:PaycheckProtectionProgramLoanCurrent" id="Fact_9c841795ba3b4169875c788672e8f092" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">116</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Operating lease liabilities, current</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_d4ddc7eeaf824fe5bae613c8190ade70" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">426</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_c81c16e3ba1e4aa1b69980bc8f9aeb91" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">273</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
              <div style="margin-left: 9pt;">Other current liabilities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" id="Fact_f96ab1f0b0524b49a055eba77a2db23e" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">247</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" id="Fact_c1c95cfe984d4911984927197e8a1e68" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 18pt;">Total current liabilities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_0c7086dc3d4b4afc82f8c47423757476" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,677</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_a71671ee0bc0489dbfef42e7552650c2" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,125</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">Contingent consideration</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" id="Fact_d913d3d63ec24dc1b04a453dbc16f225" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">19,930</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" id="Fact_d3f4c963a49d4b40a1bd15e5a7145f7f" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">20,110</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Operating lease liabilities, non-current</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_4cfd1290738e4a558803aeb3e9f91c3c" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,297</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_018badadaf0c497297297d85b2f0c1c6" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,905</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">PPP loan, non-current</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:PaycheckProtectionProgramLoanNonCurrent" id="Fact_c4a272273dfa48a882f3819cd5c17c72" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:PaycheckProtectionProgramLoanNonCurrent" id="Fact_88cac281a1e044dc900ea5e6032ea42f" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">194</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Other liabilities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_ce4df0ca62d34750aed114a1ccd220d2" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_313f3ea5530945b693fb4893f851ddf4" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 18pt;">Total liabilities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_4532e8cedd7a4953a92798b7990cf61d" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">25,927</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_81e90baa7a744ef6bdb15cb617cf6e3a" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">25,357</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div>Stockholders&#8217; and members&#8217; equity (deficit):</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Class A membership units</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:MembersCapital" id="Fact_f4ec78d7ac71448b80665aa2405f006e" contextRef="c20211231_StatementClassOfStockAxis_CommonClassAMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:MembersCapital" id="Fact_e01d28cfefc24008802683a7776a6b79" contextRef="c20201231_StatementClassOfStockAxis_CommonClassAMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">23,202</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">Class B membership units</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:MembersCapital" id="Fact_66ea54ebda6346eb9a4a4adf65bab5cf" contextRef="c20211231_StatementClassOfStockAxis_CommonClassBMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:MembersCapital" id="Fact_703249fc98cc4c3fbbd3f949bf4f60ea" contextRef="c20201231_StatementClassOfStockAxis_CommonClassBMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,400</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Class C membership units</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:MembersCapital" id="Fact_86628241612c4437ba88eef0cc26b938" contextRef="c20211231_StatementClassOfStockAxis_CommonClassCMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:MembersCapital" id="Fact_d9e046812df34de7903cc80ce5504010" contextRef="c20201231_StatementClassOfStockAxis_CommonClassCMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">Common units</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:MembersCapital" id="Fact_5373217751c445eb9195986880a81886" contextRef="c20211231_StatementClassOfStockAxis_CommonUnitsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:MembersCapital" id="Fact_9eda8889c61b47019aeba69999904d5f" contextRef="c20201231_StatementClassOfStockAxis_CommonUnitsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">198</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
              <div style="margin-left: 9pt;">Series A preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_513d7a7c3c20471d9937a97ca1595e49" contextRef="c20201231" unitRef="U003" decimals="3" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_d69a1f197156427fb86ed00abb8bb991" contextRef="c20211231" unitRef="U003" decimals="3" scale="0" format="ixt:numdotdecimal">0.005</ix:nonFraction></ix:nonFraction> par value, $<ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" id="Fact_31acc6e1a27b4b879d7c6e77c5d2eebb" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" id="Fact_0062360134ea426e9aa6231f32db350e" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">156</ix:nonFraction></ix:nonFraction> liquidation preference, <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_27828cf010684758b488d7e640ff8cd4" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_ac25dadae31641299c8277d1d79a752e" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_4a23f9a7c9fd49babb28fea919462fc5" contextRef="c20201231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_7809838da624439daee5a2a3004d3d27" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">156</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares
                authorized, issued and outstanding at December 31, 2021; <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_b0cd673f6d2b4219ae74f9ab038d11b2" contextRef="c20201231" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_5c5017f43fdf44898c4327bc317edf68" contextRef="c20201231" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding at&#160;December 31, 2020.</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_3c06de5a37354e65a8849492f19661e5" contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_da8e4aba74cf471cb2da0d377787e0c8" contextRef="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
              <div style="margin-left: 18pt; text-indent: -9pt;">Common stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_1f122b9d571d4b7394ab907a1165ff63" contextRef="c20201231" unitRef="U003" decimals="3" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_68444d60f8f34faab3139f302ed53368" contextRef="c20211231" unitRef="U003" decimals="3" scale="0" format="ixt:numdotdecimal">0.005</ix:nonFraction></ix:nonFraction></span> par value, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_121619fbcb214cd5b9cebb3d97d19a41" contextRef="c20201231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_0368c0b5a4c84bd29017461f7d3e964b" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">100,000</ix:nonFraction></ix:nonFraction></span> shares authorized, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_3aa720625143427ba2468ae58c992ebd" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_cdea0190c7dd4d4b852276540bf1e534" contextRef="c20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">52,021</ix:nonFraction></ix:nonFraction></span> issued and
                outstanding at <span style="text-indent: 0pt;">December 31, 2021</span>; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_624457c789d54559a2ce380257b624c1" contextRef="c20201231" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_4fb31baabbd94c719c361d1191b50e17" contextRef="c20201231" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span> shares issued and outstanding at <span style="text-indent: 0pt;">December 31, 2020</span>.</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_acfd183b334c4b448746386881a5f1a3" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">260</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_689d2db27711499684fb0c7b75a0d459" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Additional paid-in capital</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_a7869b86b66f4b18baaf6bfaf956911f" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">165,944</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_4c0e2532c384417fb65f5e588fa602f5" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
              <div style="margin-left: 9pt;">Accumulated deficit</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_21eec3385f8c478985cc0ecea2b3377d" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">159,703</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_02187ad3624844fb89dae0473c890707" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">37,381</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 18pt;">Total stockholders&#8217; and members&#8217; equity (deficit)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_cc15f6d34c78426e9bc1b08534e7519f" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,502</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_560b70cfced84ddcbbe71cfd32cd058b" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,581</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
              <div style="margin-left: 18pt;">Total liabilities and stockholders&#8217; and members&#8217; equity (deficit)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_a554beb328b9406880844da48fcaa972" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">32,429</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_93fc25e31f83417cbdef29d6cc256591" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">13,776</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The accompanying notes are an integral part of these consolidated financial statements.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-3</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">BROOKLYN IMMUNOTHERAPEUTICS, INC. AND SUBSIDIARIES</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">CONSOLIDATED STATEMENTS OF <a id="OPERATIONS"><!--Anchor--></a>OPERATIONS</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(In thousands, except per share amounts)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Years ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">2021<br />
              </div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">2020<br />
              </div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: normal; white-space: nowrap;">
              <div>Operating expenses:</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div>Research and development</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" id="Fact_01cd1add88fc4750bcad235a94efb490" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">12,705</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" id="Fact_9f60c4da0eb34485b5f77e418d695d40" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,951</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div>Acquired in-process research and development</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="btx:ResearchAndDevelopmentInProcessAssetAcquisition" id="Fact_22e1533394354721bfd3abd9fc9d0425" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">80,538</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="btx:ResearchAndDevelopmentInProcessAssetAcquisition" id="Fact_0e4ca1d6a16742dd8ec80d2ffe8f4c20" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div>General and administrative</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_9bb7d355128b41cd8f3e64942a0a7ce9" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">14,724</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_a7e884621bb742aeaec523854e3e0f5a" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,297</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div>Transaction costs</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" id="Fact_4fe9decad0074dfc8114f574e8770623" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5,765</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" id="Fact_831740ad530b4513831620344ebd3983" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>Change in fair value of contingent consideration</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" id="Fact_0639037200664749bb955b54de4293b6" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">180</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" id="Fact_706c088d09204051b8bf41833881a5c0" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">19,240</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
              <div style="margin-left: 9pt;">Total operating expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_ee22632000d94bda8131d30d5e89ffa1" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">113,552</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_35a371f5fdc747be869f455cf3b0ed4d" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">26,488</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div>Loss from operations</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_ee01a084a17d4894a5fee901f69edc19" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">113,552</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_db49d649e544483796aa161f552a936e" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">26,488</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-weight: normal; white-space: nowrap;">
              <div>Other expenses:</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div>Loss on sale of NTN assets</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" id="Fact_0f14b415dd394bf7bea9e9fdc05424d1" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,648</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" id="Fact_b4846047e43c42fd96a854db46f53b44" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
              <div>Other income (expense), net</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_51930577dcaa4e00929941d47c4b39c4" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">899</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_44c8c72a12214b1b98fce1c598d7771b" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">43</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Total other expenses, net</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_16e365f1d7a84174b23759e28903f827" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,749</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_818ae173b43748fab7a4de732249c7ff" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">43</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div>Loss before income taxes <br />
              </div>
            </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_6b46aff3e03f4087ab8344ddf3b8ea6a" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">122,301</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_fd1efe4c0a1d42d2ac5958537b1b0dce" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">26,531</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>Provision for income taxes <br />
              </div>
            </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_b2a816c57e9545d089a175b99825d599" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_f7b434f713f4481c8ccb3955f1be9c0a" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; font-weight: normal; white-space: nowrap;">
              <div>Net loss</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_1d9f8c5ef15643feb8c324bcf4f3a1fa" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">122,306</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_640000860a8a4a5da53a913a6fb3b5d0" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">26,531</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>Series A preferred stock dividend</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" id="Fact_e7f3e3d50a764e9583536993e4f46de9" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">16</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" id="Fact_a57c8da9484e400aba9b04f47ca24bbf" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
              <div>Net loss attributable to common stockholders</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_21643c30732c41a4bcf8387cda6802c7" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">122,322</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_6c5e251e213a4c4e8572d941f2e28915" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">26,531</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
              <div>Net loss per common share - basic and diluted</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_da70584682314fee83ccae881b51b51b" contextRef="c20210101to20211231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_258879fa819845759e6dac5588b1dc7d" contextRef="c20210101to20211231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">2.82</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_fa1f379cf4a24dcb891cc244a449dca8" contextRef="c20200101to20201231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_bfb2c250f973450592b49220f9770750" contextRef="c20200101to20201231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">1.51</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div>Weighted average shares outstanding - basic and diluted</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_ac65a98d7d7646d598e85f0d0209de36" contextRef="c20210101to20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_1275f61f6b24471e8ce4b9dd21adf2da" contextRef="c20210101to20211231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">43,306</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_e1a4aed506e44770a46a04fd4c0020cc" contextRef="c20200101to20201231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_665f926370474d579ecdfac1f9e4eab3" contextRef="c20200101to20201231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">17,588</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The accompanying notes are an integral part of these consolidated financial statements.</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-4</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">BROOKLYN IMMUNOTHERAPEUTICS, INC. AND SUBSIDIARIES</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; AND MEMBERS&#8217; <a id="EQUITY"><!--Anchor--></a>EQUITY (DEFICIT)</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">For the years ended December 31, 2021 and 2020</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(In thousands)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="14">
              <div style="text-align: center; font-weight: bold;"> Membership Equity</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; font-weight: bold;"> Common Stock</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
              <div style="text-align: center; font-weight: bold;"> Series A</div>
              <div style="text-align: center; font-weight: bold;">Preferred Stock</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> Additional<br />
                Paid-in</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> Accumulated</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> Class A</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> Class B</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> Class C</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Common</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> Shares</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Amount</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Shares</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Amount</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Capital</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> Deficit</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;">Total</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-weight: bold;">Balances at January 1, 2021</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e9057aef406f4540a8e10bd6d2ebc88a" contextRef="c20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">23,202</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_11bb31ea454e41c7b767dafaab4e2e24" contextRef="c20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,400</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c15ab3d0fd9247198a9038caeff059c1" contextRef="c20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_677524bbd5bd48bc93e964949e78f09f" contextRef="c20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">198</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_e0ed04c4c8b7411288b1d8d0388a9b9d" contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_48530363e3db402197a6653f468b5ab2" contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_de4636764472463bbcd85abeb451bb5e" contextRef="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_209a8d62e661439699b167019f1d405e" contextRef="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_17b3294ce6bb4ad4ab94641a2016e5c7" contextRef="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_04d4529069fa462e879e5827688231a0" contextRef="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">37,381</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_2058f28807d84e4990c750ebdb33c397" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,581</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; white-space: nowrap;">
              <div style="text-indent: -18pt; margin-left: 18pt;">Brooklyn rights offerings membership units</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_6bc2fea3802e44f7a1553a513a38f90a" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10,500</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_0eb4ff0e670344149b893025f2ae5f7c" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_44b44c32a08747a9910d73a91036fc03" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_ee6591acb2de4d4d91421e59f269928f" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div>-</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_9f89fb60ae534e9494c52ec79088b037" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div>-</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_713537546d5c4f2bb5ec4f26247fd47f" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_043fbfcf5f5f4025a1da4272070787aa" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_1ec00c3ab32740f2b753d802bd3f0db1" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="Fact_8661018aeb94457eb60b4a27468f26f7" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10,500</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -18pt; margin-left: 18pt;">Elimination of Brooklyn&#8217;s historical members&#8217; equity</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_5901af5b6b76452f99fcb8ded3621b9a" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">33,702</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_e980d155fca84712867132f44492d443" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,400</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_47a6e2c1a0a648239f1ddd75e4d8e2b0" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_d4b46b7208374d4890f99ddd6476da09" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">198</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>-</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_e689c2d8413c4de6bf583465a62db3fe" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>-</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_4db05f4df22b4cbeb16439fd5f090d9f" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_4ac1323a1637498ea3640a61d567a123" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">36,300</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_864ceb5fd7b4495993478ab1e0a25324" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="Fact_f1af653d24b94c7c86f7bdc3dfbb0c68" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; white-space: nowrap;">
              <div style="text-indent: -18pt; margin-left: 18pt;">Common stock to be retained by NTN stockholders</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_ebd7c994101f45ee97b5d18edb16c2ca" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_926807bedaa44b0ea00c6ee53c5fbf50" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_51fc73cc811747c0b24ce37f2198c98c" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_b629c00a1a8544e38d50d1276ddab65d" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodSharesAcquisitions1" id="Fact_3917805bcfa349639a6050eb86f8f288" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">1,514</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_126aec1ff9f2432a94b78fc63345bd3a" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodSharesAcquisitions1" id="Fact_16a626c199c045309964472161e7be22" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_8f479cd4e89d4a4e8ff8b097135ce5cc" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_f7bc19ebf16a47189c60f74ca109a691" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8,170</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_1dae332b93a64c1a8646fcb94a00a4cb" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions1" id="Fact_09c895144f9644609faf73b14f54f859" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8,178</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: #CCEEFF; white-space: nowrap;">
              <div>
                <div>Issuance of Series A preferred stock retained</div>
                <div style="text-indent: 9pt;">by NTN stockholders</div>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_f8c93cff5d304c7084a5dcdd46ece524" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_bc864b87117648f88be5154d0dea86d8" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_a6ec911f141f4244bc3c99155c1a36ff" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_6da7696f6cfb42c0b274087a58765c7c" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_29f38d6177cc461bbbf8a1a528e43650" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_675a51144a6b49ff8c9fccf14c7cff7f" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_5049635531e64128a0269997ebcf6229" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">156</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_f067c95e1f2a4f189cfd80ae49b13b64" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_ba27fbb9b1b34ce7949f6b3a874cc7c7" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_a6abaee3a9f14e90afa571710c15eb68" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="Fact_95fa6183824e4a418a73497c39865254" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; white-space: nowrap;">
              <div style="text-indent: -18pt; margin-left: 18pt;">Issuance of common stock to Brooklyn members</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_f4d9d7d8c54647bcb622f2e4a6185d86" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_3539a6f3621649b199d3fc1ba795186e" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_1072e0e076724101880bbd4eb9872aa1" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_815c65ccf11249e8a766c33529566ae7" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PartnersCapitalAccountUnitsAcquisitions" id="Fact_04688469418443cbb52bd82a9acbe208" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">38,924</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_fa5e598c32bc4b1092e053cc378a01ec" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">195</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PartnersCapitalAccountUnitsAcquisitions" id="Fact_9da31cc18816403ba2f7bff0d434af59" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_245e48f5fdbd46118ec1e105138e9bc4" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_a4ebf914dfbc454a8167a0184da78958" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">195</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_0ff82ca853cc49878d47fd9cd08ad923" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PartnersCapitalAccountAcquisitions" id="Fact_48783773751346db8e7e2096e4c65163" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: #CCEEFF; white-space: nowrap;">
              <div>
                <div style="text-indent: -9pt; margin-left: 9pt;">Issuance of common stock to Financial Advisor upon</div>
                <div style="text-indent: -9pt; margin-left: 18pt;">consummation of merger</div>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_853246f6590849d098d682b9eb8882f0" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_517c643fe2ed40b5a71d6f25f4953e74" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_17a56d1b47c64deaa5a7666b222a7080" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_ea23653c04ef47579ff656013b87f95f" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" id="Fact_131cb9d8ec8b440facc1f0c60184e52c" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">1,068</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_81c23dac0bd048ad8d28fd653360f807" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" id="Fact_00285ff385534fd99a343e8d68e7b4de" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_06585f5d02844239bfefc7113e0c0814" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_a9803d0cdd8e4e9297a3d3c27b0f9c25" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5,760</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_f45887c71ab140a19bc987f0accc36f8" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_d3ffbb0c6e014a05be9e07347cc06f43" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5,765</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; white-space: nowrap;">
              <div>
                <div>Issuance of common stock from the exercise of</div>
                <div style="text-indent: 9pt;">stock options</div>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_cfe9179d72a84b1ab3ff67c8971eb684" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_b8a4f20ebb4640bfaca3ade33e077548" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_cc1058827ae44ff89a185af64bb3624e" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_b48f037fd9ea4598b6a8707ce340f68e" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_b124eb9af3934f718bbdad0c73988eab" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_a5173ee1e7294a5e924cebf7d6b6148f" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_62803e9961e14483b0a0c7cf504ca913" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_6622e18e245f4fc290bc40d173f9a44a" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_f845426fe01d40469c842517ec63e7d3" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_741cc1b93cbf4735aca9306bf65d86d8" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_6e7c4f5952df43c6982f2d12349e907c" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: #CCEEFF; white-space: nowrap;">
              <div>
                <div>Issuance of common stock related to stock purchase</div>
                <div style="margin-left: 9pt;">agreement with Lincoln Park Capital Fund, LLC, net</div>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_b239475f51314747bcdffd54c714443e" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_4f8a8fe506304ca39e8ab0dd1c6b8eae" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_580ee6871bb04e2abbf869b40e3dba73" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_f0724c3ef06a4237a32f0eea858fb8c0" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodSharesStockPurchaseAgreement" id="Fact_1e4294a6e7fc481f99859dcd1e883abc" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">3,552</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_42bc1ff1f0354f4b958f8a3daa54b899" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodSharesStockPurchaseAgreement" id="Fact_6dae6c55d2d047d496bb426e7f5ac50d" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_472e21b517cd4d8993f47f4577f2b544" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_0a91299e538a4ec1ac595f78bad9704e" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">52,008</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_b10c51f8b9694942bbad8a65b664067f" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueStockPurchaseAgreement" id="Fact_1023cdca45e2443e9a9684960c4593da" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">52,025</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; white-space: nowrap;">
              <div>
                <div>Issuance of common stock in connection with</div>
                <div style="text-indent: 9pt;">the acquisition of Novellus, Inc.</div>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_04eceb648cfc42b2bf01fcabb794f405" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_6c0788d7ae974aea9a9db1abbe1e9dca" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_9a6e041c235e4771ac11464280b205b6" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_42584bd8e9464c4d99f86665073720ed" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodSharesAcquisitions2" id="Fact_6a0b4d8d75c04b619d6c9852ece19219" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">7,022</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_f14c50061bfe4359b8ed347fd2d14579" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">35</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodSharesAcquisitions2" id="Fact_71d094568ead401e80c873182235050d" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_fb002ffc514f44209b06fd0f1b22d821" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_eef41400da1f437f89ef18c59bcabe28" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">58,649</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_c86675cb978e43c9b54e4dcd3395a527" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueAcquisitions2" id="Fact_f3c50affb624422bba231a1faeb244ce" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">58,684</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -18pt; margin-left: 18pt;">Cash dividends to Series A preferred stockholders</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:DividendsPreferredStockCash" id="Fact_cfecafce884649fb867fb3f908782630" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:DividendsPreferredStockCash" id="Fact_b73b141de6ca42a696e1a1685798d781" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:DividendsPreferredStockCash" id="Fact_b726225040f8497d82bfc79582f1811c" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:DividendsPreferredStockCash" id="Fact_df27285e62344f56bc6a0798fcc77a0d" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PreferredStockDividendsShares" id="Fact_b117bb6ef03048c6bd792d71c22c1837" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:DividendsPreferredStockCash" id="Fact_4672708f17234c5182ba3fe33ec86100" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:PreferredStockDividendsShares" id="Fact_13f72c35c0b94ab78a9e9cc36cc03451" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:DividendsPreferredStockCash" id="Fact_cd68cc42636b4dceb270c6ccf54169ab" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:DividendsPreferredStockCash" id="Fact_03f5cfc183154ba3919d6f6530ff674c" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:DividendsPreferredStockCash" id="Fact_adb24a6c1447451bb72f3cc2978ad49d" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:DividendsPreferredStockCash" id="Fact_5967bd4cb4ec4e9da5d1b9beea186909" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; white-space: nowrap;">
              <div>
                <div>Issuance of common stock in lieu of cash</div>
                <div style="text-indent: 9pt;">dividend to Series A preferred stockholders</div>
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_37b6bad68e80472dacf15558212a9ecc" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_57582479cb4a41898ba4b08a0fa01b4b" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_d4ff0eceaab646f3b9986daa49caf661" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_e751749c47254a72aee368eb9c253fec" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodSharesInLieuOfDividends" id="Fact_5268bc771142419ba9a34c8428576e82" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_ae04d87e3a8b4312ba9bdc16c4749bd1" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodSharesInLieuOfDividends" id="Fact_46e4bc7190d946e4ad915678162eb657" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_d6cef9d2fffd4134b047539349e9eec3" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_3852e81fd8224922bc428de3ac4372f3" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="btx:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_8235e431edf74adca64fd35efea92bb0" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueInLieuOfDividends" id="Fact_760d49d64e33409bbf03cb7aa6e2f1a4" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -18pt; margin-left: 18pt;">Forfeiture of unvested restricted stock</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_e8b3d1916d7e40e297555c0fd0e6db32" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_1f4fc4733a254b638dba757f6f36d93b" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_6af14035cc93498aa39f110ad971f82d" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_81c7607d22644842a86429fef4b12fb6" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="btx:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" id="Fact_7c6ccd089e23448f8a7c1a409925adaa" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">60</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_efd06e62aa8f412baf0a0e9e7021c620" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" id="Fact_13cbb9b313ce45878ac7f391f4ac9b53" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_835869427fe244d9b8885a5bf58aeaca" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_bb7d32fef0894d11ba5f5ec4a0165e08" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_6bc62ca1f67d45518f559e7f9934a39b" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="Fact_4682e55e3f074e6daf356a206796d219" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; white-space: nowrap;">
              <div style="text-indent: -18pt; margin-left: 18pt;">Stock based compensation</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_854bd3bcab5740069958bba69a76bd1b" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_2b263290fcf44891b3b24a3a3dd7f2cc" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_3b8d6539abda400aa7c8f2bf28b96c4f" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_bb775edc05c5464f8fd0548b68455ed6" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div>-</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_b024b986296d4b19b6a003ce86be796d" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div>-</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_3b29c5b9c98b42719209638e556da009" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_3367ce3a27e44e4f882b5b94b0ccbc80" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5,235</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_cfa4a7dbfa5e412fba93a4a36d5beec1" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_dc97804095124bb1934388736d4c687b" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5,235</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); text-indent: -18pt; margin-left: 18pt;">Net loss</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_5af966f6036a444e9cdc4b9cd5beb98e" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_9f1818df4db948fea4666adcbea8ce77" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_b5138ee5964741b3bc285c28d3764790" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_97c9dcb0984d4a7eb949c527216bfd78" contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>-</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_d87331a16bfd445c916833ffb69d001e" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>-</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_68217bd9e8b04e03b023d27b071f9f75" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_4b67c649fac642c3bde8f3c375cce62c" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_15a678e02208445185ef7dfc60ca5251" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">122,306</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_0fedf8022c694e169df2d0b89ad74e3d" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">122,306</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 12%; padding-bottom: 4px; white-space: nowrap;">
              <div style="font-weight: bold; text-indent: -18pt; margin-left: 18pt;">Balances at <span style="text-indent: 0pt;">December 31, 2021</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c38614db0b004fdcb28fa11c5b88ff29" contextRef="c20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_157eb086e8914fb588ce9eb92799bf35" contextRef="c20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_3cb6af10e2a94d7b9b25e24a6eb49cca" contextRef="c20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e835fc162478430db8e38577092cd16a" contextRef="c20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_c679a78fdcdf43388c793bb2725da0eb" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">52,021</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_11a1429d21ea4a02bcebe80e44bff3a1" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">260</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_9a7798b5d24042b8832fe30619710036" contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">156</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c7fb04cb885044c985bc449e25a2ca8f" contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_cdeda3a4c74f425f9c98f21d779d6833" contextRef="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">165,944</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e8a81bf47e6e48bcbe8b52769fc5e646" contextRef="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">159,703</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 5%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_86c1cd5d9446415dacfc49a9924bba76" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,502</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="14">
              <div style="text-align: center; font-weight: bold;"> Membership Equity</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> Accumulated</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> Class A</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> Class B</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> Class C</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> Common</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> Deficit</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;"> Total</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="font-weight: bold;">Balances at January 1, 2020</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e61085ac93ff4e33833533f8f979ad36" contextRef="c20191231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">18,178</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_acfb0d963fa64ad0834405af1c885cf8" contextRef="c20191231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,400</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_9c37ea46b5884cc9abb7d795898e15ae" contextRef="c20191231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_50c9af9ff8004ef2b3d76c217c7c6075" contextRef="c20191231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">107</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_869a039101154f7c90a83f6bd701bd87" contextRef="c20191231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,942</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_765f4e447ee44887869eec456f9d8167" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">9,743</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; white-space: nowrap;">
              <div>Implementation of new accounting principle</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:EffectOfImplementationOfNewAccountingPrincipal" id="Fact_9f64c0f8a9fe4b68a3c44dac33097b21" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:EffectOfImplementationOfNewAccountingPrincipal" id="Fact_121aaf0e589c4cb380eb7d4c3419318a" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:EffectOfImplementationOfNewAccountingPrincipal" id="Fact_e4a364d03c594175848b1bfc73ef959c" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:EffectOfImplementationOfNewAccountingPrincipal" id="Fact_8b9531da695f4a01b0f955886d67a31b" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:EffectOfImplementationOfNewAccountingPrincipal" id="Fact_b75f465ff15244589e2b9eab35d557cf" contextRef="c20200101to20201231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">92</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="btx:EffectOfImplementationOfNewAccountingPrincipal" id="Fact_021c6f9679ff4756af8a98bcadedc21f" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">92</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF; white-space: nowrap;">
              <div>Stock based compensation</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_48cf4e7453e1463a8a972ab555f77bd1" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_fcec746ba92149049b615d97134a3ea8" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_aa650e32a4634d288a57676f14d789b0" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_e1ef2f80d8f54351aae2f62cb5d56729" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">91</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_860206aca5cb47ccafc9d9d1acf7f134" contextRef="c20200101to20201231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_060150b54d364a82a955df68b58ec6ba" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">91</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; white-space: nowrap;">
              <div>Sale of members&#8217; equity</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquityOther" id="Fact_77ad941c1ab9462c8fa39fba562f4485" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5,024</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquityOther" id="Fact_e62ce40ed66d4f5c9ef8338e82f06bfc" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquityOther" id="Fact_93d5b119ff7644f28c781bbfd813d1a2" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquityOther" id="Fact_673bba027f9b41db8d376a75d8d131ba" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquityOther" id="Fact_5b42f611ee2746b081fbe18a3f0565cc" contextRef="c20200101to20201231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquityOther" id="Fact_282a5e122595460abf02a44344d39430" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5,024</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>Net loss</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e54f148b86554d98ba526e272cc61179" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_15afae84120149489f462a4afc07f092" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_5e3dc1198f0f4838a889911694e8a6a2" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c4add3e2730c4f468e7a1d5cf752f612" contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e1b7ca3040ce4e34a07bd1caa4e53663" contextRef="c20200101to20201231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">26,531</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_d3081d26b3074761b84753e82d4b174b" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">26,531</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; padding-bottom: 4px; white-space: nowrap;">
              <div style="font-weight: bold;">Balances at December 31, 2020</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e92545ba44f24f4ab74c1ad41ba57152" contextRef="c20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">23,202</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_27b3dd870326470bafb8565998f83635" contextRef="c20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,400</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_aacf393ba30f40e49ab18935b397938f" contextRef="c20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c9b4d6e388ce4585980595a008fd2c93" contextRef="c20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">198</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_080f0947c35548d69de0bead320bd64b" contextRef="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">37,381</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_62aac37538bc441db7e935c52d308ce8" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,581</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
              <div>)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The accompanying notes are an integral part of these consolidated financial statements.</div>

      <div><br /></div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-5</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">BROOKLYN IMMUNOTHERAPEUTICS, INC. AND SUBSIDIARIES</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">CONSOLIDATED STATEMENTS OF <a id="CASHFLOW"><!--Anchor--></a>CASH FLOWS</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(In thousands)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; font-weight: bold;">For years ended</div>
              <div style="text-align: center; font-weight: bold;">December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;"> 2021<br />
              </div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">2020<br />
              </div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
              <div>Cash flows used in operating activities:</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Net loss</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_0b5a3c432d8046b5a37eb98349d4b4fa" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">122,306</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a830814c69f0449f9a50e3237e031012" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">26,531</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 18pt;">Depreciation and amortization</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_5c33e67354b047eb91ef682500baf574" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">117</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_745109199f584e128dd8269e4568b6c1" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">98</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 18pt;">Stock-based compensation</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_b0b555adf57241a39b3680277f385d9d" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5,235</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_2c4c574744be420390b191ec9a594c03" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">91</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 18pt;">Amortization of right-to-use asset</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_9d819258e20942c9bcea05d188e2823a" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">342</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_bd4feec8d43c4448a99c5096ce2fa278" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 18pt;">Transaction costs - shares to Financial Advisor</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" id="Fact_cf3b5a1f6ec0429785154b0b72af6030" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5,765</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:NoncashMergerRelatedCosts" id="Fact_b477b5a11ec34b11a1521532f338439e" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 18pt;">Loss on sale of NTN assets</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" id="Fact_437a2d49a9c64dc7a8b3108c0e5c8e28" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,648</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" id="Fact_927b253ade6042c99d2843f31ebba262" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 18pt;">Loss on disposal of fixed assets</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="btx:GainLossOnDisposalOfFixedAssets" id="Fact_947dc1dd675b4ec7a423300cc67bf0ce" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">13</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="btx:GainLossOnDisposalOfFixedAssets" id="Fact_433e8ae312d5472b86725ea1e2954526" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 18pt;">Gain on forgiveness of PPP loan</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="btx:GainLossOnForgivenessOfPaycheckProtectionProgramLoan" id="Fact_35154077e8e842f9a4ce01ac27a2907c" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">310</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="btx:GainLossOnForgivenessOfPaycheckProtectionProgramLoan" id="Fact_47b9bb25d7234c6bba835062f1bca494" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 18pt;">Acquired in-process research and development</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="btx:ResearchAndDevelopmentInProcessAssetAcquisition" id="Fact_9ac6c1f2c82140b38fa46b768a733273" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">80,538</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="btx:ResearchAndDevelopmentInProcessAssetAcquisition" id="Fact_56ace37820ff4e8188bbb016ec3d5c5e" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 18pt;">Change in fair value of contingent consideration</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" id="Fact_33d98d08cb93459f846b7b6c1c72f1ed" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">180</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" id="Fact_76a7f792ac2a4bc5b145dec30f064c25" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">19,240</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 18pt;">Changes in operating assets and liabilities:</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 27pt;">Account receivable</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" id="Fact_225670abf0f149bab9d448907897cdf8" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">659</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" id="Fact_a7120e5d33544c8497d564d3a4e17db2" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 27pt;">Prepaid expenses and other current assets</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_1919aa5855084332859a3b6ec5a8534b" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">850</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_8d6744c712d2414184a0cce3cf622d88" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">16</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 27pt;">Security deposits and other non-current assets</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="btx:IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" id="Fact_6b3d30abb5e648d0be311ef5d83adfbe" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="btx:IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" id="Fact_02e845cc15fa43c88b4ace796ee9a892" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">90</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 27pt;">Accounts payable and accrued expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" id="Fact_8ed44ef49a5a4bc0b1d1ad6cfec04dd4" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">485</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" id="Fact_ad0781da627945d8b9d7983777bdecfa" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">930</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 27pt;">Operating lease liability</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="btx:IncreaseDecreaseInOperatingLeaseLiabilities" id="Fact_e8965267f06441ebacef418a75c25652" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">322</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="btx:IncreaseDecreaseInOperatingLeaseLiabilities" id="Fact_34e1931ddb4d40ac80fa693a24171bc4" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
              <div style="margin-left: 27pt;">Other liabilities</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" id="Fact_95e16e6ba5814878b8a9622f6b75ea2f" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" id="Fact_a822f9dd0c1f49e5873248b30300ec58" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 36pt;">Net cash used in operating activities</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_cad32201fde649a6b8af981f82a16314" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,488</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_3a97e2b36294497a95725561054f3476" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,101</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div>Cash flows used in investing activities:</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Purchase of property and equipment</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_9a4de66d7e454d93a2f47c0127451f37" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">154</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_ce093a2bc3b6483aa6b20dbdcc32e373" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">39</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">Purchase of NTN, net of cash acquired</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ProceedsFromSalesOfAssetsInvestingActivities" id="Fact_df0cf657cbe24d2e814da5f01ab58bfb" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">147</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ProceedsFromSalesOfAssetsInvestingActivities" id="Fact_cb443ea34d104be1a8be76127daa0f45" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Purchase of Novellus, net of common stock issued and cash acquired</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="btx:PaymentsToAcquireProductiveAssetsNet" id="Fact_4801b1c9ede24365b749275403f2585a" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">22,854</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="btx:PaymentsToAcquireProductiveAssetsNet" id="Fact_b418fe559f6847618d36fb6359f2ad66" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
              <div style="margin-left: 9pt;">Proceeds from the sale of NTN assets, net of cash disposed</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" id="Fact_6b9ebb63bdef4aa1b9ae71bb8ba10a49" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">119</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" id="Fact_fe636a160af94989ad796574fd0b4f49" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 18pt;">Net cash used in investing activities</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_daaed406ad5c47a8b49a120f48459289" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22,742</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_16fc34fd977e4fdcb858e4eeb19e43ee" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">39</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div>Cash flows provided by financing activities:</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Net proceeds of common stock issued to Lincoln Park</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_693083d516654772b696f0633cd762a8" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">52,025</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_a797e2b32d174cdcb0ec3fa07ffb675d" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">Proceeds from sale of members&#8217; equity</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" id="Fact_14ceec9784594ad69e4d3c641b936e9a" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10,500</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" id="Fact_4dbf15a8123d4a29b43cfec805c988e4" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,359</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Proceeds from the exercise of stock options</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_9078d1b9c8b741ed929dcfb8af4825af" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_2d6ca4567e5149fe9b4d408ae2dff3c0" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">Proceeds from loans payable</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" id="Fact_6cec81fcf11042fc925d45f5e898996f" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" id="Fact_e1d5f4dfd91a434e9533d0de5f4cd770" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">310</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Repayment of <span style="font-style: normal;">NTN&#8217;s</span> PPP loan</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="btx:PaymentsOfPaycheckProtectionProgramLoan" id="Fact_7b6a035e4e024ef4957de51997f60208" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">532</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="btx:PaymentsOfPaycheckProtectionProgramLoan" id="Fact_3b931b5857e3475797f1b368997f4841" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">Principal payments on notes payable</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" id="Fact_887c514171964ede9b1c8d46a859f1b4" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">410</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" id="Fact_088360d5490d437095487aaed3cb7e4f" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Dividends paid to Series A preferred shareholders</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" id="Fact_00eb0da2c53e4a6180362bcf26acd1b4" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock" id="Fact_388f28b03fc04aba8ef8027d49609d5b" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
              <div style="margin-left: 18pt;">Net cash provided by financing activities</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_c56ff05c922e4a04b1eee06c6665ebeb" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">61,585</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_62c78fd7f2b04480b22e0d21655cb3ac" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,669</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div>Net increase (decrease) in cash and cash equivalents</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_dd05c41e92814513b3c7b369969a5ad0" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">15,355</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_364c734ec0bb4ea4bd38678cd2b09a83" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,471</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
              <div>Cash and cash equivalents at beginning of period</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_0562eb194f60409e9defa1ffcbaceda3" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,630</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_a411d5c8a44d402d8e796ed63b49090f" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5,101</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Cash and cash equivalents at end of period</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_2614eb5fd066456194afe3dc9dcba2be" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">16,985</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_bb4ac44cb0ef4b3199f512e94fb09fcf" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,630</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div>Supplemental disclosures of cash flow information:</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="margin-left: 9pt;">Cash paid during the period for:</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 18pt;">Interest</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_99b54c3ea1b94232823600d4284cabbb" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">225</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_e9cac12a2b6b439d8272f12ed679c001" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
              <div style="margin-left: 18pt;">Income taxes</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" id="Fact_96344efcd6ae43f3a2eb442c4ccd8b30" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" id="Fact_f750be35366c4f038277a6ec0178f484" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div>Supplemental disclosure of non-cash investing and financing activities:</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Issuance of common stock for Series A preferred stock dividend</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="btx:IssuanceOfCommonStockForSeriesAPreferredStockDividend" id="Fact_aa177dd4d4234be28ff0a94029d74ef8" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="btx:IssuanceOfCommonStockForSeriesAPreferredStockDividend" id="Fact_7bc3c873bbc94ac7855ecfbbcf7f2e03" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
              <div style="margin-left: 9pt;">Issuance of common stock for business combination</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:StockIssued1" id="Fact_277b2369befa4052ae87239f50234b75" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8,178</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:StockIssued1" id="Fact_619d89e3d2ed4e5cad84e99ddd994539" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Issuance of common Stock for Novellus acquisition</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="btx:IssuanceOfCommonStockForAssetAcquisition" id="Fact_4118f1850d014415966884a0a6b83818" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">58,684</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="btx:IssuanceOfCommonStockForAssetAcquisition" id="Fact_73bb896ccdef4a45a88ce5244e14b246" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
              <div style="margin-left: 9pt;">Forfeiture of unvested restricted stock</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div><ix:nonFraction name="btx:ForfeitureOfUnvestedRestrictedStock" id="Fact_74b3505d004f4efcb96651b9a515b230" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div><ix:nonFraction name="btx:ForfeitureOfUnvestedRestrictedStock" id="Fact_0c753636a71c4686b92dc185d755c90c" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Preferred shares issued in connection with reverse merger</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="btx:NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" id="Fact_59e5b1947a7a4bf594d3ef5e79ee573a" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="btx:NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" id="Fact_4ff101d185ee4fa886d495f3759e783c" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
              <div style="margin-left: 9pt;">Initial measurement of ROU assets, net of tenant improvement allowance</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div><ix:nonFraction name="btx:InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance" id="Fact_ffa438e13ad4478aa45d82ff73bc6bc1" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">816</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div><ix:nonFraction name="btx:InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance" id="Fact_697d4394e98a4b6fa702ea9414aab5b9" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Initial measurement of operating lease liabilities</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="btx:InitialMeasurementOfOperatingLeaseLiabilities" id="Fact_622c7bce84fd472c868cec799d22c924" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">866</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="btx:InitialMeasurementOfOperatingLeaseLiabilities" id="Fact_ac4355951cd2491da4681eb6b3c3e288" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
              <div style="margin-left: 9pt;">Investor deposits for sale of members&#8217; equity</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div><ix:nonFraction name="btx:InvestorDepositsForSaleOfMembersEquity" id="Fact_360f531c6b894eef882a333b4a444251" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div><ix:nonFraction name="btx:InvestorDepositsForSaleOfMembersEquity" id="Fact_99354eeee6694fbbbed57480752364a9" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">666</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="margin-left: 9pt;">Right of use assets obtained in exchange for new operating lease liabilities</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" id="Fact_4df912dac606496bac0fde396c9ec33e" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" id="Fact_ecd6a48540374910943b755ec675df9f" contextRef="c20200101to20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,093</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The accompanying notes are an integral part of these consolidated financial statements.</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-6</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

      <!--PROfilePageNumberReset%Num%7%F-%%--> </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">BROOKLYN IMMUNOTHERAPEUTICS, INC. AND SUBSIDIARIES</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><a id="NOTES"><!--Anchor--></a>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">For the Years Ended December 31, 2021 and 2020</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>


      <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Text_e8e4b46423fc459bb75555fc7279ec7b" contextRef="c20210101to20211231" escape="true" continuedAt="Text_e40873b8689c4ba48dac73e4f07362bf1">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">1)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Organization and Description of Business Operations</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <div>
        <ix:continuation id="Text_e40873b8689c4ba48dac73e4f07362bf1" continuedAt="Text_e40873b8689c4ba48dac73e4f07362bf2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold; color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_e40873b8689c4ba48dac73e4f07362bf2" continuedAt="Text_e40873b8689c4ba48dac73e4f07362bf3">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn ImmunoTherapeutics Inc., a Delaware corporation (&#8220;Brooklyn&#8221; or the &#8220;Company&#8221;), together with its subsidiaries including Brooklyn
          ImmunoTherapeutics LLC (&#8220;Brooklyn LLC&#8221;), Novellus, Inc. (&#8220;Novellus&#8221;) and Novellus Therapeutics, Ltd. (&#8220;Novellus, Ltd.&#8221;), is a clinical stage biopharmaceutical company focused on exploring the role that cytokine, gene editing and cell therapy can
          have in treating patients with cancer, blood disorders and monogenic diseases. As used herein, the &#8220;Company&#8221; refers collectively to Brooklyn and its subsidiaries.</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_e40873b8689c4ba48dac73e4f07362bf3" continuedAt="Text_e40873b8689c4ba48dac73e4f07362bf4">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_e40873b8689c4ba48dac73e4f07362bf4" continuedAt="Text_e40873b8689c4ba48dac73e4f07362bf5">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On August 12, 2020, Brooklyn (then known as &#8220;NTN Buzztime, Inc.&#8221;), Brooklyn LLC and BIT Merger Sub, Inc., a wholly owned subsidiary of Brooklyn
          (the &#8220;Merger Sub&#8221;), entered into an agreement and plan of merger and reorganization (the &#8220;Merger Agreement&#8221;) pursuant to which, among other matters, Merger Sub merged with and into Brooklyn LLC, with Brooklyn LLC continuing as a wholly owned
          subsidiary of Brooklyn and as the surviving company of the merger (the &#8220;Merger&#8221;). The Merger closed on March 25, 2021. After the Merger, Brooklyn changed its name from &#8220;NTN Buzztime, Inc.&#8221; to &#8220;Brooklyn ImmunoTherapeutics, Inc.&#8221; The Merger was
          accounted for as a reverse acquisition, in which Brooklyn LLC was deemed the acquiring company for accounting purposes.</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_e40873b8689c4ba48dac73e4f07362bf5" continuedAt="Text_e40873b8689c4ba48dac73e4f07362bf6">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_e40873b8689c4ba48dac73e4f07362bf6" continuedAt="Text_e40873b8689c4ba48dac73e4f07362bf7">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On March 26, 2021, Brooklyn sold (the &#8220;Disposition&#8221;) its rights, title and interest in and to the assets relating to the business operated under
          the name &#8220;NTN Buzztime, Inc.&#8221; prior to the Merger to eGames.com Holdings LLC (&#8220;eGames.com&#8221;) in accordance with the terms of an asset purchase agreement dated September 18, 2020, as amended, between Brooklyn and eGames.com (the &#8220;Asset Purchase
          Agreement&#8221;). (See Note 4.)</div>
</ix:continuation>
        <ix:continuation id="Text_e40873b8689c4ba48dac73e4f07362bf7" continuedAt="Text_e40873b8689c4ba48dac73e4f07362bf8">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_e40873b8689c4ba48dac73e4f07362bf8">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On July 16, 2021, Brooklyn and its newly formed, wholly owned subsidiary Brooklyn Acquisition Sub, Inc. entered into an agreement and plan of
          acquisition (the &#8220;Acquisition Agreement&#8221;) with (a) Novellus LLC, (b) Novellus (the sole equity holder of Novellus, Ltd. and, prior to the closing under the Acquisition Agreement, a wholly owned subsidiary of Novellus, LLC), and (c) a seller
          representative (the &#8220;Acquisition&#8221;), pursuant to which Brooklyn acquired Novellus and its subsidiary, Novellus, Ltd. As part of the Acquisition, Brooklyn also acquired <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" id="Fact_dc56a5c3b3d646b1bea1e964bc31d6a0" contextRef="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember" unitRef="U004" decimals="3" scale="-2" format="ixt:numdotdecimal">25.0</ix:nonFraction>% of the total outstanding equity interests of NoveCite, Inc. (&#8220;NoveCite&#8221;), a corporation focused on developing an allogeneic mesenchymal stem cell product for patients with acute respiratory distress
          syndrome, including from COVID-19. (See Note 4.)</div>
</ix:continuation>

      </div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="btx:LiquidityAndCapitalResourcesTextBlock" id="Text_fc15066e43c442738a9103a62a510e6f" contextRef="c20210101to20211231" escape="true" continuedAt="Text_30c8e91d21b246419a004113cafb2bfd1">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Liquidity and Capital Resources</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <div>
        <ix:continuation id="Text_30c8e91d21b246419a004113cafb2bfd1" continuedAt="Text_30c8e91d21b246419a004113cafb2bfd2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_30c8e91d21b246419a004113cafb2bfd2" continuedAt="Text_30c8e91d21b246419a004113cafb2bfd3">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company has incurred significant operating losses and has an accumulated deficit as a result of ongoing efforts to develop product candidates,
        including conducting clinical trials and providing general and administrative support for these operations. As of December 31, 2021, the Company had a cash balance of approximately $<ix:nonFraction name="us-gaap:Cash" id="Fact_1a3a8058fca940ceb18dab402f895fc3" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">16,985,000</ix:nonFraction> and an accumulated deficit of approximately $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_83a3e652c73e41e5a2b30b34ea1217ef" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">159,703,000</ix:nonFraction>.
        For the year ended December 31, 2021, the Company incurred a net loss of $<ix:nonFraction name="btx:NetIncomeLossAttributableToParentTemporaryElement" id="Fact_0ff5a43588cf440c9675eb33683cf040" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">122,306,000</ix:nonFraction> and the Company used cash in operating activities
        of $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_86d4030bab7a4058b2e51109566a693f" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">23,488,000</ix:nonFraction> (inclusive of $<ix:nonFraction name="btx:ResearchAndDevelopmentInProcessAssetAcquisition" id="Fact_e2e85d239a964c87a53e4c4c1e9ce698" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">80,538,000</ix:nonFraction>
        IPR&amp;D expense related to the Acquisition, $<ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" id="Fact_41e7149e17a64723a94ac57f784cb09c" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">9,648,000</ix:nonFraction> related to the loss on sale of assets in the Disposition and $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" id="Fact_5ba9d91ed23c41a39132272ccdf5104a" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" sign="-" format="ixt:numdotdecimal">180,000</ix:nonFraction> related to the change in fair value of contingent consideration).</div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_30c8e91d21b246419a004113cafb2bfd3" continuedAt="Text_30c8e91d21b246419a004113cafb2bfd4">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_30c8e91d21b246419a004113cafb2bfd4" continuedAt="Text_30c8e91d21b246419a004113cafb2bfd5">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On April 26, 2021, Brooklyn entered into a common stock purchase agreement (the &#8220;First Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC
          (&#8220;Lincoln Park&#8221;), which provided that Brooklyn could offer to Lincoln Park up to an aggregate of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_da37b7bfccdf4db9ac1cef7c2eed65b3" contextRef="c20210426to20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">20,000,000</ix:nonFraction> of common stock over a <ix:nonNumeric name="btx:CommencementPeriodOfCommonStockInPurchaseAgreement" id="Fact_c6178ad7fac04e42a358395dd0dac623" contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember" format="ixt-sec:durmonth">36</ix:nonNumeric>-month period commencing after May 10, 2021, the date that a registration statement covering the resale of shares of common stock issued under the
          First Purchase Agreement was declared effective by the SEC. As of December 31, 2021, Brooklyn had issued and sold an aggregate of approximately <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" id="Fact_f5e3c8448a3c418cb93ed5c29ac3448a" contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,128,000</ix:nonFraction>
          shares of common stock to Lincoln Park pursuant to the First Purchase Agreement, resulting in gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" id="Fact_23c86708c70a49609a27b77d58d06577" contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">20,000,000</ix:nonFraction>.</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_30c8e91d21b246419a004113cafb2bfd5" continuedAt="Text_30c8e91d21b246419a004113cafb2bfd6">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-7</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

      <ix:continuation id="Text_30c8e91d21b246419a004113cafb2bfd6" continuedAt="Text_30c8e91d21b246419a004113cafb2bfd7">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On May 26, 2021, Brooklyn entered into a second common stock purchase agreement (the &#8220;Second Purchase Agreement&#8221;) with Lincoln Park, which
        provides that Brooklyn may offer to Lincoln Park up to an aggregate of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_9ccb30b039f54e75a00b64b10f167e8f" contextRef="c20210526to20210526_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">40,000,000</ix:nonFraction> of common stock over a <ix:nonNumeric name="btx:CommencementPeriodOfCommonStockInPurchaseAgreement" id="Fact_1629b42b72574dabab386a7c680f728c" contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember" format="ixt-sec:durmonth">36</ix:nonNumeric>-month period commencing after June 4, 2021, the date that a registration statement covering the resale of shares of common stock issued under the
        Second Purchase Agreement was declared effective by the SEC. As of December 31, 2021, Brooklyn had issued and sold an aggregate of approximately <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" id="Fact_8d566bc5eb54458f86687f3c5a1b0f28" contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,424,000</ix:nonFraction>
        shares of common stock to Lincoln Park pursuant to the Second Purchase Agreement, resulting in gross proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" id="Fact_3e92bff0a3f04fc2b017b7f0bd229dac" contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">34,106,000</ix:nonFraction>.</div>
</ix:continuation>
      <ix:continuation id="Text_30c8e91d21b246419a004113cafb2bfd7" continuedAt="Text_30c8e91d21b246419a004113cafb2bfd8">
<div> <br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_30c8e91d21b246419a004113cafb2bfd8" continuedAt="Text_30c8e91d21b246419a004113cafb2bfd9">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On July 16, 2021, Brooklyn used approximately $<ix:nonFraction name="btx:PaymentsToAcquireProductiveAssetsNet" id="Fact_3a8f7f1861984ecf831cfe57129b2f2c" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">22,854,000</ix:nonFraction>
        of cash, net of cash acquired, as part of the purchase price of the Acquisition. Brooklyn issued common stock as the remaining portion of the purchase price of the Acquisition.</div>
</ix:continuation>
      <ix:continuation id="Text_30c8e91d21b246419a004113cafb2bfd9" continuedAt="Text_30c8e91d21b246419a004113cafb2bfd10">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br />
        </span></div>
</ix:continuation>
      <ix:continuation id="Text_30c8e91d21b246419a004113cafb2bfd10" continuedAt="Text_30c8e91d21b246419a004113cafb2bfd11">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> On March 9, 2022, we consummated a private placement of equity resulting in net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" id="Fact_a7076d7f22d34b9bab8487616c4d8f37" contextRef="c20220309to20220309_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction> million. See Note 17 for details.</span> </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_30c8e91d21b246419a004113cafb2bfd11" continuedAt="Text_30c8e91d21b246419a004113cafb2bfd12">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_30c8e91d21b246419a004113cafb2bfd12" continuedAt="Text_30c8e91d21b246419a004113cafb2bfd13">
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none;">In connection with
            preparing its financial statements as of and for the year ended December 31, 2021, the Company&#8217;s management concluded that there is substantial doubt regarding the Company&#8217;s ability to continue as a going concern because it does not expect to
            have sufficient cash or working capital resources to fund operations for the twelve-month period subsequent to the issuance date of these financial statements.&#160; The Company will need to raise additional capital, which could be through the
            remaining availability under the Second Purchase Agreement (to the extent the Company is permitted to use such agreement), public or private equity offerings, debt financings, corporate collaborations or other means. The Company may also seek
            governmental grants to support our clinical trials and preclinical trials..&#160; The Company currently has no arrangements for such capital and no assurances can be given that it will be able to raise such capital when needed, on acceptable terms,
            or at all.&#160;</div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_30c8e91d21b246419a004113cafb2bfd13" continuedAt="Text_30c8e91d21b246419a004113cafb2bfd14">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_30c8e91d21b246419a004113cafb2bfd14">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">The accompanying
        consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do
        not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to the Company&#8217;s ability to continue as
        a going concern.</div>
</ix:continuation>

      <div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Text_c553cd7856fc42e9a8ba0aba36ff481f" contextRef="c20210101to20211231" escape="true" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b1">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Basis of Accounting Presentation and Summary of Significant Accounting Policies</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b1" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b2" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b3"><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Text_00959b52567a41a3b8e8cec794fec4cb" contextRef="c20210101to20211231" escape="true" continuedAt="Text_226fbdc03187433fa97822adbaecdef11">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Basis of Accounting Presentation</div>
</ix:nonNumeric></ix:continuation>
      <div>
        <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b3" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b4"><ix:continuation id="Text_226fbdc03187433fa97822adbaecdef11" continuedAt="Text_226fbdc03187433fa97822adbaecdef12">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation></ix:continuation>
      </div>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b4" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b5"><ix:continuation id="Text_226fbdc03187433fa97822adbaecdef12" continuedAt="Text_226fbdc03187433fa97822adbaecdef13">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference
        in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). All significant intercompany
        balances and transactions have been eliminated in consolidation.</div>
</ix:continuation></ix:continuation>
      <div>
        <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b5" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b6"><ix:continuation id="Text_226fbdc03187433fa97822adbaecdef13" continuedAt="Text_226fbdc03187433fa97822adbaecdef14">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation></ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b6" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b7"><ix:continuation id="Text_226fbdc03187433fa97822adbaecdef14" continuedAt="Text_226fbdc03187433fa97822adbaecdef15">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">As described above, the Merger closed on March 25, 2021. The Merger was accounted for as a reverse acquisition, in which Brooklyn LLC was deemed
          the acquiring company for accounting purposes. Brooklyn LLC&#8217;s historical financial statements have replaced Brooklyn&#8217;s historical financial statements with respect to periods prior to the completion of the Merger (when Brooklyn operated under the
          name &#8220;NTN Buzztime, Inc.&#8221;). The Company retrospectively adjusted the weighted average shares used in determining loss per common share to reflect the conversion of the outstanding Class A units, Class B units, Class C units, and common units of
          Brooklyn LLC that converted into shares of Brooklyn&#8217;s common stock upon the Merger and to reflect the effect of a <span style="-sec-ix-hidden:Fact_565a5991ac0445a8b9e9f14506915bfe">2-to-1</span> reverse stock
          split of Brooklyn&#8217;s common stock that occurred immediately prior to the Merger.</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b7" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b8"><ix:continuation id="Text_226fbdc03187433fa97822adbaecdef15" continuedAt="Text_226fbdc03187433fa97822adbaecdef16">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b8" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b9"><ix:continuation id="Text_226fbdc03187433fa97822adbaecdef16">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Also as described above, the Acquisition closed on July 16, 2021. The Acquisition was accounted for as an asset acquisition, and substantially
          all of the value was attributed to in-process research and development (&#8220;IPR&amp;D&#8221;), with the exception of the cash paid for the investment in NoveCite, which is being accounted for as an investment in equity securities. The IPR&amp;D had no
          alternative future uses and no separate economic value from its originally intended purpose and was therefore expensed in the period the cost was incurred.</div>
</ix:continuation></ix:continuation>
         </div>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b9" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b10">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-7</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b10" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b11">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Summary of Significant Accounting Policies</div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b11" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b12">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>


      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b12" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b13"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="Text_c45d270b2b8544d091aa6a102988a144" contextRef="c20210101to20211231" escape="true" continuedAt="Text_f78a7922e807418a9626e653d182b1e11">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Use of Estimates</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b13" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b14"><ix:continuation id="Text_f78a7922e807418a9626e653d182b1e11" continuedAt="Text_f78a7922e807418a9626e653d182b1e12">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b14" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b15"><ix:continuation id="Text_f78a7922e807418a9626e653d182b1e12">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (a)
        the reported amounts of assets and liabilities; (b) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; (c) the reported amounts of revenues and expenses during the reporting period and (d) the
        reported amount of the fair value of assets acquired in connection with business combinations. Actual results could differ from those estimates. The Company&#8217;s significant estimates and assumptions include the recoverability and useful lives of
        long-lived assets and the contingent consideration liability.</div>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b15" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b16">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b16" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b17"><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Text_48422aca8e0b4de1b6a610801a9b8cb8" contextRef="c20210101to20211231" escape="true" continuedAt="Text_2ba596d46f4445689c2b2fb49325795d1">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Cash and Cash Equivalents</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b17" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b18"><ix:continuation id="Text_2ba596d46f4445689c2b2fb49325795d1" continuedAt="Text_2ba596d46f4445689c2b2fb49325795d2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b18" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b19"><ix:continuation id="Text_2ba596d46f4445689c2b2fb49325795d2">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company classifies highly liquid investments with a remaining contractual maturity at date of purchase of three months or less as cash
        equivalents. The Company had <ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" id="Fact_d836cfced2e34b77b8c7c2c64d2977b9" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" id="Fact_f5031621ff6c4308b7a8c24b580c0c65" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> cash equivalents as of December 31, 2021 or 2020.</div>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b19" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b20">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b20" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b21"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Text_2da43536e14c489382ce5eef9701b4b4" contextRef="c20210101to20211231" escape="true" continuedAt="Text_fefd524efda04ab2851b7d2d46691bc71">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Property and Equipment</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b21" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b22"><ix:continuation id="Text_fefd524efda04ab2851b7d2d46691bc71" continuedAt="Text_fefd524efda04ab2851b7d2d46691bc72">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b22" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b23"><ix:continuation id="Text_fefd524efda04ab2851b7d2d46691bc72">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment are recorded at cost and are depreciated over their estimated useful lives using the straight-line method. Laboratory and
        manufacturing equipment are depreciated over an estimated useful life of <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_a951a9e8e05c4662bef15fd639d8de03" contextRef="c20210101to20211231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryAndManufacturingEquipmentMember" format="ixt-sec:durwordsen">seven years</ix:nonNumeric>. Leasehold improvements are depreciated over the
        shorter of their estimated useful life, or the lease term. Computer equipment are depreciated over an estimated useful life of <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_11f6d775c4364a3c9c3e969631e26d5d" contextRef="c20210101to20211231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember" format="ixt-sec:durwordsen">three years</ix:nonNumeric>.
        Upon retirement or other disposition of these assets, the cost and related accumulated depreciation of these assets are removed from the accounts and the resulting gain or losses are reflected in the results of operations. Expenditures for
        maintenance and repairs are charged to operations. Renewals and betterments are capitalized.</div>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b23" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b24">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b24" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b25"><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="Text_c6a6f33ca0aa4d9d911c3133c23c4c45" contextRef="c20210101to20211231" escape="true" continuedAt="Text_253f04e5431c4af09cd51ca0013d36981">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Goodwill</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b25" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b26"><ix:continuation id="Text_253f04e5431c4af09cd51ca0013d36981" continuedAt="Text_253f04e5431c4af09cd51ca0013d36982">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b26" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b27"><ix:continuation id="Text_253f04e5431c4af09cd51ca0013d36982">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in the acquisition of IRX
        Therapeutics, Inc. in November 2018 (the &#8220;IRX Acquisition&#8221;), which was accounted for as a business combination. Goodwill is not amortized but is tested for impairment annually, or if events occur or circumstances change that would reduce the fair
        value of a reporting unit below its carrying value. Because management evaluates the Company as a single reporting unit, goodwill is tested for impairment at the entity level by first performing a qualitative assessment to determine whether it is
        more likely than not that the fair value of the entity is less than its carrying value. Such qualitative factors include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant
        events.&#160; If the entity does not pass the qualitative assessment, then the entity&#8217;s carrying value is compared to its fair value. Goodwill is considered impaired if the carrying value of the entity exceeds its fair value.</div>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b27" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b28">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b28" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b29"><ix:nonNumeric name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="Text_c2367262f15e42dd88fba84a270f0b9e" contextRef="c20210101to20211231" escape="true" continuedAt="Text_ff53e03b75d748bb84ce28de2c56a20e1">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">IPR&amp;D</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b29" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b30"><ix:continuation id="Text_ff53e03b75d748bb84ce28de2c56a20e1" continuedAt="Text_ff53e03b75d748bb84ce28de2c56a20e2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b30" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b31"><ix:continuation id="Text_ff53e03b75d748bb84ce28de2c56a20e2">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">IPR&amp;D assets represent the fair value assigned to technologies that were acquired in connection with the IRX Acquisition, which have not
        reached technological feasibility and have no alternative future use. IPR&amp;D assets are considered to be indefinite lived until the completion or abandonment of the associated research and development projects. During the period that the
        IPR&amp;D assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the
        IPR&amp;D assets are less than their carrying amounts. If and when development is complete, which generally occurs upon regulatory approval, and the Company is able to commercialize products associated with the IPR&amp;D assets, these assets are
        then deemed definite-lived and are amortized based on their estimated useful lives beginning at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&amp;D assets,
        calculated as the excess of carrying value of the IPR&amp;D assets over fair value.</div>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b31" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b32">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-8</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>


      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b32" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b33"><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Text_af5453d836da4141beba2cb0931730e6" contextRef="c20210101to20211231" escape="true" continuedAt="Text_57dfa4e3df9a4079afedbc46f39964e61">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Impairment of Long-Lived Assets</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b33" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b34"><ix:continuation id="Text_57dfa4e3df9a4079afedbc46f39964e61" continuedAt="Text_57dfa4e3df9a4079afedbc46f39964e62">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b34" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b35"><ix:continuation id="Text_57dfa4e3df9a4079afedbc46f39964e62">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company reviews long-lived assets and certain identifiable assets for impairment whenever circumstances and situations change such that there
        is an indication that the carrying amounts may not be recovered. An impairment exists when the carrying value of the long-lived asset is not recoverable and exceeds its fair value. For the years ended December 31, 2021 and 2020, there were no
        qualitative factors that indicated it was more likely than not that the fair value of the long-lived assets exceeded the carrying value.</div>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b35" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b36">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b36" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b37"><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Text_3a7f085e167c4fe3adab4b68b5c77eb4" contextRef="c20210101to20211231" escape="true" continuedAt="Text_2bd4a71fb12245daac39d87b33af048a1">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Research and Development</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b37" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b38"><ix:continuation id="Text_2bd4a71fb12245daac39d87b33af048a1" continuedAt="Text_2bd4a71fb12245daac39d87b33af048a2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b38" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b39"><ix:continuation id="Text_2bd4a71fb12245daac39d87b33af048a2" continuedAt="Text_2bd4a71fb12245daac39d87b33af048a3">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company expenses its research and development costs as incurred. Research and development expenses consist of costs incurred for
        company-sponsored research and development activities, as well as support for selected investigator-sponsored research. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the
        period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. IPR&amp;D that is acquired through an asset acquisition (as
        opposed to a business combination) and has no alternative future uses and, therefore, no separate economic values, is expensed to research and development costs at the time the costs are incurred.</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b39" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b40"><ix:continuation id="Text_2bd4a71fb12245daac39d87b33af048a3" continuedAt="Text_2bd4a71fb12245daac39d87b33af048a4">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b40" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b41"><ix:continuation id="Text_2bd4a71fb12245daac39d87b33af048a4" continuedAt="Text_2bd4a71fb12245daac39d87b33af048a5">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The major components of research and development costs include preclinical study costs, clinical manufacturing costs, clinical study and trial
        expenses, insurance coverage for clinical trials, expensed licensed technology, expensed IPR&amp;D, consulting, scientific advisors and other third-party costs, salaries and employee benefits, stock-based compensation expense, supplies and
        materials and allocations of various overhead costs related to our product development efforts.</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b41" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b42"><ix:continuation id="Text_2bd4a71fb12245daac39d87b33af048a5" continuedAt="Text_2bd4a71fb12245daac39d87b33af048a6">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b42" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b43"><ix:continuation id="Text_2bd4a71fb12245daac39d87b33af048a6">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In the normal course of our business, the Company contracts with third parties to perform various clinical study and trial activities in the
        on-going development and testing of potential products. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors
        such as the achievement of certain events or milestones, the successful enrollment of patients, the allocation of responsibilities among the parties to the agreement, and the completion of portions of the clinical study or trial or similar
        conditions. Preclinical and clinical study and trial associated activities such as production and testing of clinical material require significant up-front expenditures. The Company anticipates paying significant portions of a study&#8217;s or trial&#8217;s
        cost before they begin and incurring additional expenditures as the study or trial progresses and reaches certain milestones.</div>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b43" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b44">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b44" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b45"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="Text_498e5018dea24bdf8cc2b8a498488b16" contextRef="c20210101to20211231" escape="true" continuedAt="Text_882a7ec67f804596b595d020f1c0be291">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Income Taxes</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b45" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b46"><ix:continuation id="Text_882a7ec67f804596b595d020f1c0be291" continuedAt="Text_882a7ec67f804596b595d020f1c0be292">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b46" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b47"><ix:continuation id="Text_882a7ec67f804596b595d020f1c0be292" continuedAt="Text_882a7ec67f804596b595d020f1c0be293">
<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company records deferred tax liabilities and assets based on the differences between the consolidated financial statements carrying amounts
        and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and established a valuation allowance when it was more likely than not that some portion or all of the deferred tax
        assets would not be realized. Income tax expense consists of the tax payable for the period and the change during the period in deferred tax assets and liabilities.</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b47" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b48"><ix:continuation id="Text_882a7ec67f804596b595d020f1c0be293" continuedAt="Text_882a7ec67f804596b595d020f1c0be294">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b48" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b49"><ix:continuation id="Text_882a7ec67f804596b595d020f1c0be294">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Tax benefits from uncertain tax positions are recognized only if it is more likely than not that the tax position will be sustained on examination
        by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of
        being realized upon ultimate resolution. The Company has no material uncertain tax positions for any of the reporting periods presented.</div>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b49" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b50">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b50" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b51"><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" id="Text_7951f8cc83434eda9aa97204d7a1dd30" contextRef="c20210101to20211231" escape="true" continuedAt="Text_3cf7fdf06ebe40018fb62e308c546fb61">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Earnings Per Share</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b51" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b52"><ix:continuation id="Text_3cf7fdf06ebe40018fb62e308c546fb61" continuedAt="Text_3cf7fdf06ebe40018fb62e308c546fb62">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b52" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b53"><ix:continuation id="Text_3cf7fdf06ebe40018fb62e308c546fb62">
<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Basic and diluted loss per common share have been computed by dividing the losses applicable to common stock by the weighted average number of
        common shares outstanding. The Company&#8217;s basic and fully diluted earnings per share (&#8220;EPS&#8221;) calculation are the same since the increased number of shares that would be included in the diluted calculation from assumed exercise of common stock
        equivalents would be anti-dilutive to the net loss in each of the years shown in the consolidated financial statements.</div>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b53" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b54">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-9</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>


      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b54" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b55"><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Text_eed8acfbc096446e81415cdb77dd5376" contextRef="c20210101to20211231" escape="true" continuedAt="Text_e4160deb6a4549a5860dbf0a7fc5a66e1">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Segment Reporting</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b55" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b56"><ix:continuation id="Text_e4160deb6a4549a5860dbf0a7fc5a66e1" continuedAt="Text_e4160deb6a4549a5860dbf0a7fc5a66e2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b56" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b57"><ix:continuation id="Text_e4160deb6a4549a5860dbf0a7fc5a66e2">
<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In accordance with ASC No. 280, <span style="font-style: italic;">Segment Reporting</span>, the Company has determined that it operates as <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" id="Fact_178445ef0fb94c5795b2f78c5d91af5d" contextRef="c20210101to20211231" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> operating segment. Decisions regarding the Company&#8217;s overall operating performance and allocation of its resources are assessed on a consolidated
        basis.</div>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b57" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b58">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b58" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b59"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" id="Text_8b2098fc4dcc48598043cbdf4eb2f4e7" contextRef="c20210101to20211231" escape="true" continuedAt="Text_f69803b8085d4c9b8a14b2d6118f0f851">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Concentration of Credit Risk</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b59" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b60"><ix:continuation id="Text_f69803b8085d4c9b8a14b2d6118f0f851" continuedAt="Text_f69803b8085d4c9b8a14b2d6118f0f852">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b60" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b61"><ix:continuation id="Text_f69803b8085d4c9b8a14b2d6118f0f852" continuedAt="Text_f69803b8085d4c9b8a14b2d6118f0f853">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company maintains its cash balances in financial institutions located in the United States. Accounts at each institution are insured by the
        Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250,000. At times, the Company&#8217;s cash balances may be uninsured for deposit accounts that exceed the FDIC insurance limit.</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b61" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b62"><ix:continuation id="Text_f69803b8085d4c9b8a14b2d6118f0f853" continuedAt="Text_f69803b8085d4c9b8a14b2d6118f0f854">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b62" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b63"><ix:continuation id="Text_f69803b8085d4c9b8a14b2d6118f0f854">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In the Company&#8217;s business, vendor concentrations could be indicative of vulnerabilities in the Company&#8217;s supply chain, which could ultimately
        impact the Company&#8217;s ability to continue its research and development activities. For the years ended December 31, 2021 and 2020, there was no vendor concentration related to the Company&#8217;s research and development activities.</div>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b63" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b64">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b64" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b65"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Text_2791aa3d01e245a0bf8c2ac430d9635d" contextRef="c20210101to20211231" escape="true" continuedAt="Text_bb3d030f36fa442e9cf8ce6287ed44991">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Fair Value of Financial Instruments</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b65" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b66"><ix:continuation id="Text_bb3d030f36fa442e9cf8ce6287ed44991" continuedAt="Text_bb3d030f36fa442e9cf8ce6287ed44992">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b66" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b67"><ix:continuation id="Text_bb3d030f36fa442e9cf8ce6287ed44992" continuedAt="Text_bb3d030f36fa442e9cf8ce6287ed44993">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between
        willing market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The
        fair value hierarchy is as follows:</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b67" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b68"><ix:continuation id="Text_bb3d030f36fa442e9cf8ce6287ed44993" continuedAt="Text_bb3d030f36fa442e9cf8ce6287ed44994">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b68" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b69"><ix:continuation id="Text_bb3d030f36fa442e9cf8ce6287ed44994" continuedAt="Text_bb3d030f36fa442e9cf8ce6287ed44995">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Level 1 Inputs &#8211; Valued based on quoted prices in active markets for identical
          assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b69" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b70"><ix:continuation id="Text_bb3d030f36fa442e9cf8ce6287ed44995" continuedAt="Text_bb3d030f36fa442e9cf8ce6287ed44996">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b70" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b71"><ix:continuation id="Text_bb3d030f36fa442e9cf8ce6287ed44996" continuedAt="Text_bb3d030f36fa442e9cf8ce6287ed44997">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Level 2 Inputs &#8211; Valued based on inputs other than quoted prices included in Level
          1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that
          are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market
          data by correlation or other means.</span></div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b71" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b72"><ix:continuation id="Text_bb3d030f36fa442e9cf8ce6287ed44997" continuedAt="Text_bb3d030f36fa442e9cf8ce6287ed44998">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b72" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b73"><ix:continuation id="Text_bb3d030f36fa442e9cf8ce6287ed44998" continuedAt="Text_bb3d030f36fa442e9cf8ce6287ed44999">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Level 3 Inputs &#8211; Valued based on inputs for which there is little or no market
          value, which require the reporting entity to develop its own assumptions.</span></div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b73" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b74"><ix:continuation id="Text_bb3d030f36fa442e9cf8ce6287ed44999" continuedAt="Text_bb3d030f36fa442e9cf8ce6287ed449910">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b74" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b75"><ix:continuation id="Text_bb3d030f36fa442e9cf8ce6287ed449910">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The carrying amounts reported on the balance sheet for cash and cash equivalents, accounts receivable, prepaid assets and other current assets,
        accounts payable and accrued expenses, other current liabilities and other liabilities approximate fair value based due to their short maturities. The carrying value of loans payable approximates its fair market value because the effective yield on
        this debt, which includes contractual interest rates as well as other finance charges, is comparable to rates of returns for instruments of similar credit risk.</div>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b75" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b76">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b76" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b77"><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" id="Text_50f18a33557b4d308295462934021741" contextRef="c20210101to20211231" escape="true" continuedAt="Text_dc7e483f969a4e0e902cd3785abeeeb21">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Leases</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b77" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b78"><ix:continuation id="Text_dc7e483f969a4e0e902cd3785abeeeb21" continuedAt="Text_dc7e483f969a4e0e902cd3785abeeeb22">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b78" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b79"><ix:continuation id="Text_dc7e483f969a4e0e902cd3785abeeeb22" continuedAt="Text_dc7e483f969a4e0e902cd3785abeeeb23">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company adopted ASC Topic 842, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Leases,</span>
        on December 31, 2020 using the modified transition method without retrospective application to comparative periods. The Company elected the package of three practical expedients allowed for under the transition guidance. Accordingly, the Company
        did not reassess: (1) whether any expired or existing contracts are/or contain leases; (2) the lease classification for any expired or existing leases; or (3) initial direct costs for any existing leases. The Company has also elected not to
        recognize right-of-use assets (&#8220;ROU assets&#8221;) and lease liabilities for short-term leases that have a term of 12 months or less.</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b79" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b80"><ix:continuation id="Text_dc7e483f969a4e0e902cd3785abeeeb23" continuedAt="Text_dc7e483f969a4e0e902cd3785abeeeb24">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>
</ix:continuation></ix:continuation>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
        <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b80" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b81"><ix:continuation id="Text_dc7e483f969a4e0e902cd3785abeeeb24" continuedAt="Text_dc7e483f969a4e0e902cd3785abeeeb25">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Operating lease liabilities represent the present value of lease payments not yet paid. ROU assets represent the Company&#8217;s right to use an
          underlying asset and are based upon the operating lease liabilities adjusted for prepaid or accrued lease payments, initial direct costs, lease incentives and impairment of operating lease assets. If the interest rate implicit in the lease is not
          readily determinable, the Company uses the incremental borrowing rates based on the information available at the lease commencement date in determining the present value of lease payments. To determine the present value of lease payments not yet
          paid, the Company estimates secured borrowing rates corresponding to the maturities of the leases.</div>
</ix:continuation></ix:continuation>
      </div>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b81" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b82"><ix:continuation id="Text_dc7e483f969a4e0e902cd3785abeeeb25" continuedAt="Text_dc7e483f969a4e0e902cd3785abeeeb26">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>
</ix:continuation></ix:continuation>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
        <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b82" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b83"><ix:continuation id="Text_dc7e483f969a4e0e902cd3785abeeeb26">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company has elected the practical expedient to not separate non-lease components from the lease components to which they relate and instead
          account for each as a single lease component for all underlying asset classes. Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as payments for insurance, tax payments and other
          miscellaneous costs. The variable portion of lease payments is not included in the ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are expensed when the obligation for those payments
          is incurred and are included in lease expenses. Accordingly, all expenses associated with a lease contract are accounted for as lease expenses.</div>
</ix:continuation></ix:continuation>
      </div>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b83" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b84">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b84" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b85"><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="Text_4f18285a39af4e629713ec9c7a2a2f1d" contextRef="c20210101to20211231" escape="true" continuedAt="Text_c59c742a222b4be199a904dc0ecb8f061">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Commitment and Contingencies</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b85" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b86"><ix:continuation id="Text_c59c742a222b4be199a904dc0ecb8f061" continuedAt="Text_c59c742a222b4be199a904dc0ecb8f062">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b86" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b87"><ix:continuation id="Text_c59c742a222b4be199a904dc0ecb8f062">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company follows ASC No.450-20, <span style="font-style: italic;">Loss Contingencies</span>, to report accounting for contingencies.
        Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.</div>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b87" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b88">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-10</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>


      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b88" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b89"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Text_326ab3d8fd264d64a32f3ad506798d11" contextRef="c20210101to20211231" escape="true" continuedAt="Text_6ef0a74a9b5f4b1bb32af2ec31ca779f1">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Stock-Based Compensation</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b89" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b90"><ix:continuation id="Text_6ef0a74a9b5f4b1bb32af2ec31ca779f1" continuedAt="Text_6ef0a74a9b5f4b1bb32af2ec31ca779f2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b90" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b91"><ix:continuation id="Text_6ef0a74a9b5f4b1bb32af2ec31ca779f2">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company recognizes stock-based compensation expense for equity awards granted to employees, directors and certain consultants. The Company
        estimates the fair value of stock options using the Black-Scholes option pricing model. The fair value of stock options granted is recognized as expense over the requisite service period. Stock-based compensation expense for share-based payment
        awards is recognized using the straight-line single-option method.</div>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b91" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b92">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b92" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b93"><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Text_072787d7bd454d62baea0d66495e71ff" contextRef="c20210101to20211231" escape="true" continuedAt="Text_47e94999349b498fb116cec0ed04f87b1">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Recent Accounting Standards</span></div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b93" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b94"><ix:continuation id="Text_47e94999349b498fb116cec0ed04f87b1" continuedAt="Text_47e94999349b498fb116cec0ed04f87b2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b94" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b95"><ix:continuation id="Text_47e94999349b498fb116cec0ed04f87b2" continuedAt="Text_47e94999349b498fb116cec0ed04f87b3">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In May 2021, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) <span style="font-style: italic;">2021-04,


























          Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain
          Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span>. ASU 2021-04 addresses the accounting for certain modifications or exchanges of freestanding equity-classified written call options. ASU 2021-04 is effective
        for fiscal years beginning after December 15, 2021 (January 1, 2022 for the Company) and interim periods within those fiscal years, with early adoption permitted. The Company does not expect the adoption of this update to have a significant impact
        on its financial statements.</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b95" continuedAt="Text_4aa62def629c4e9fa7844f124d83fe1b96"><ix:continuation id="Text_47e94999349b498fb116cec0ed04f87b3" continuedAt="Text_47e94999349b498fb116cec0ed04f87b4">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_4aa62def629c4e9fa7844f124d83fe1b96"><ix:continuation id="Text_47e94999349b498fb116cec0ed04f87b4">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In July 2021, the FASB issued ASU 2021-05, <span style="font-style: italic;">Leases (Topic 842) &#8211; Lessors - Certain Leases with Variable Lease
          Payments,</span> which amends the lessor classification guidance to introduce additional criteria when classifying leases with variable lease payments that do not depend on a reference index or a rate. This guidance is effective for annual
        periods beginning after December 15, 2021 (January 1, 2022 for the Company), with early adoption permitted. The Company does not expect the adoption of this update to have a significant impact on its financial statements.</div>
</ix:continuation></ix:continuation>
       </div>


    <div><br />
    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="Text_affbe44113d8430c92fe1e05d1450975" contextRef="c20210101to20211231" escape="true" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb85341">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">4)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Merger, Disposition and Acquisition Transactions</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb85341" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb85342">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb85342" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb85343">
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Merger</div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb85343" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb85344">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb85344" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb85345">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On August 12, 2020, Brooklyn, Brooklyn LLC and the Merger Sub entered into the Merger Agreement. The Merger closed on March 25, 2021. After the
          Merger, Brooklyn changed its name from &#8220;NTN Buzztime, Inc.&#8221; to &#8220;Brooklyn ImmunoTherapeutics, Inc.&#8221; The Merger was accounted for as a reverse acquisition, in which Brooklyn LLC was deemed the acquiring company for accounting purposes. Brooklyn
          LLC, as the accounting acquirer, recorded the assets acquired and liabilities assumed of Brooklyn in the Merger at their fair values as of the acquisition date. Brooklyn&#8217;s common stock trades on the NYSE American stock exchange under the ticker
          symbol &#8220;BTX&#8221;.</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb85345" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb85346">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb85346" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb85347">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn LLC was determined to be the accounting acquirer based upon the terms of the Merger and other factors including that (i) Brooklyn LLC
          members, received common stock in the Merger that represented <ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" id="Fact_6c13ba825ac341bb93291cf7db70904e" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U004" decimals="4" scale="-2" format="ixt:numdotdecimal">96.35</ix:nonFraction>% of Brooklyn&#8217;s outstanding common stock on a fully diluted basis
          as of immediately after the Merger, (ii) all of the directors of Brooklyn immediately after the Merger were designated by Brooklyn LLC under the terms of the Merger Agreement and (iii) existing members of Brooklyn LLC&#8217;s management became the
          management of Brooklyn immediately after the Merger.</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb85347" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb85348">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb85348" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb85349">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">At the closing of the Merger, all the outstanding membership interests of Brooklyn LLC converted into the right to receive an aggregate of
        approximately <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" id="Fact_957debfd09d843b0aabdfcaef3a8b8d6" contextRef="c20210325to20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">39,992,000</ix:nonFraction> shares of common stock, of which <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" id="Fact_a6bf73ead64647b6b817255b94565a75" contextRef="c20210325to20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,068,000</ix:nonFraction> shares were issued as compensation to Maxim Group LLC, Brooklyn LLC&#8217;s financial advisor (the &#8220;Financial Advisor&#8221;) for its services to Brooklyn LLC in connection with the Merger.</div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb85349" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853410">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853410" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853411">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The purchase price of $<ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" id="Fact_8234378c08ff40eba6eba875184e9516" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">8,178,000</ix:nonFraction>,
        which represents the consideration transferred in the Merger to stockholders of Brooklyn immediately before the Merger, was calculated based on the closing price of $<ix:nonFraction name="us-gaap:BusinessAcquisitionSharePrice" id="Fact_f3e87fdcec7544a5bf1efbbb2a514035" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">5.40</ix:nonFraction> per share for approximately <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_73e881825006476cbd5767b7d29ef14d" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,514,000</ix:nonFraction> shares common stock that those stockholders owned on March
        25, 2021 immediately prior to the Merger because that represented a more reliable measure of the fair value of consideration transferred in the Merger.<br />
      </div>
</ix:continuation>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853411" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853412">
<div><br /></div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-12</span></div>

          <div style="page-break-after: always;" class="DSPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853412" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853413">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the acquisition method of accounting, the total purchase price has been allocated to the acquired tangible and intangible assets and assumed
        liabilities of Brooklyn based on their estimated fair values as of March 25, 2021, the Merger closing date. Because the consideration paid by Brooklyn LLC in the Merger is more than the estimated fair values of Brooklyn&#8217;s net assets deemed to be
        acquired, goodwill is equal to the difference of approximately $<ix:nonFraction name="us-gaap:Goodwill" id="Fact_b916da63442e45e38df14bce7699dc35" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">8,589,000</ix:nonFraction>, which has been calculated using the fair values of the net
        assets of Brooklyn as of March 25, 2021.</div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853413" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853414">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853414" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853415"><ix:nonNumeric name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="Text_9d066e9db16c44f0b50877d1ebe9e227" contextRef="c20210101to20211231" escape="true" continuedAt="Text_bd32d8e55ba14c3297333db513398dd11">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The allocation of the estimated purchase price to the tangible and intangible assets acquired and liabilities deemed to be assumed from Brooklyn,
        based on their estimated fair values as of March 25, 2021, is as follows:</div>
</ix:nonNumeric></ix:continuation>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853415" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853416">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853416" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853417"><ix:continuation id="Text_bd32d8e55ba14c3297333db513398dd11">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Historical</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Balance</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Sheet of</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Brooklyn at</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">March 25, 2020</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Fair Value</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Adjustment</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">to Brooklyn</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Pre-Merger</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Assets</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Purchase</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Price</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Allocation Pro</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Forma</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Adjustment</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Cash and cash equivalents</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" id="Fact_54998d49eb4b49a29c98cb8b4fab1987" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">148,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" id="Fact_aa8180708a0c4900864f44dfa0260e4f" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" id="Fact_22e84e427b6649fea8f83050ca84f2b8" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">148,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Accounts receivable</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" id="Fact_b0236b1da76f4d4b8499358ce309026c" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">103,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" id="Fact_0e8ca7bd35d940ecb48bf527ceb040a5" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" id="Fact_eccdbeb6e53445d4bfbb1b0fa16a8f0a" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">103,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Prepaid expense and other current assets</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" id="Fact_4936561c64574d5a9e6f4cac1c5afe83" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">329,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" id="Fact_715cc8ed96524ce3b0324276ba811c1f" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" id="Fact_2d9e5b287201475696a9dee31a9da918" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">329,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Property and equipment, net</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" id="Fact_a1c597e1c427425384a9fc405348929d" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,015,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" id="Fact_397bd43b4306420895e6543dd8f2206f" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" id="Fact_7d16ddfedadf422b83d8f6dc17bcd4d3" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,015,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Software development costs</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" id="Fact_ee4ee2653c6b47ef91678d33e8a40fd8" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,296,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="btx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" id="Fact_74d4dbbef798449d994ae73cacd88940" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">368,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" id="Fact_011221dda6eb4e9c8b0c1a4cfc362183" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">928,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Customers</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" id="Fact_fb2348d3b97f447a9c4d251635dc077d" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" id="Fact_f9d05870a7184910ae9953d7b7b9b0e5" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">548,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" id="Fact_6de3749026fe4c53904c11add09b4a52" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">548,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Trade name</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" id="Fact_3522f30cb3e4424c821194e1e02aaa70" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" id="Fact_22f01bd8f0f847d18416a5dc59f358a0" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">299,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" id="Fact_4cfbaa98f87b4d68a3515332605d2e0b" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">299,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Accounts payable, accrued liabilities and other current liabilities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" id="Fact_28ab7eb468db42aea6fc909f3180b46f" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">3,781,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" id="Fact_05dae0f9b19f4f28b793638cd61abc03" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" id="Fact_a7aef6b0c4ff46708a65da7e4998cfa7" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">3,781,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Net assets acquired, excluding goodwill</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" id="Fact_9d75b62cf359469981764e6382099164" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">890,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" id="Fact_e01db3d2f838489f8b5f509349fc31e9" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">479,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" id="Fact_9be7add69456456e9d886174096b7333" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">411,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Total consideration</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" id="Fact_41bf49aa8aeb4574a155f584fb8224c3" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">8,178,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Net assets acquired, excluding goodwill</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" id="Fact_986edef52f5d4b50a6d69ea5f5b6e45b" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">411,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Goodwill</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:Goodwill" id="Fact_8df92d1288e247bab411f13f70b95732" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">8,589,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853417" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853418">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853418" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853419">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn LLC was obligated under the Merger Agreement to have $<ix:nonFraction name="btx:ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" id="Fact_36492083e3c84d10b33af4efd7ec9714" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction> in cash and cash equivalents on its balance sheet at the effective time of the Merger. To ensure Brooklyn LLC had the required funds, certain beneficial holders of Brooklyn LLC&#8217;s
        Class A membership interests entered into contractual commitments to invest $<ix:nonFraction name="btx:BeneficialHoldersContractualCommitmentsToInvest" id="Fact_19dac027329c40a1b1020b52ac27c387" contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction> into Brooklyn LLC immediately prior to the
        closing of the Merger. During March 2021, Brooklyn offered its Class A unit holders an additional <ix:nonFraction name="btx:PercentageOfAdditionalRightsOffering" id="Fact_801f9923d21047b2936f4ba47a53affb" contextRef="c20210301to20210331_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>% rights offering for an additional $<ix:nonFraction name="btx:ProceedsFromSaleOfRights" id="Fact_6573930294314e7286f2ea3b03fcf569" contextRef="c20210301to20210331_BusinessAcquisitionAxis_NTNBuzztimeIncMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">500,000</ix:nonFraction> to be raised by a rights offering. Brooklyn received funds from the rights offering between February 17, 2021 and April 5, 2021.</div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853419" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853420">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853420" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853421">
<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Disposition</div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853421" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853422">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853422" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853423"><ix:nonNumeric name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="Text_ce7246fb9a084f1d95d792a5effb4108" contextRef="c20210101to20211231" escape="true" continuedAt="Text_1584e4e8620a4457a1054c70d2c4597e1">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On March 26, 2021, Brooklyn sold its rights, title and interest in and to the assets relating to the business it operated (under the name NTN
        Buzztime, Inc.) prior to the Merger to eGames.com in exchange for a purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" id="Fact_8a27c35a36974c4380819c8609bab11f" contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">2,000,000</ix:nonFraction> and assumption of specified liabilities
        relating to that business. The sale was completed in accordance with the terms of the Asset Purchase Agreement. Details of the Disposition are as follows:</div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853423" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853424"><ix:continuation id="Text_1584e4e8620a4457a1054c70d2c4597e1" continuedAt="Text_1584e4e8620a4457a1054c70d2c4597e2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-13</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853424" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853425"><ix:continuation id="Text_1584e4e8620a4457a1054c70d2c4597e2">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Proceeds from sale:</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Cash</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" id="Fact_807b4ce8325946849ee811e699208e1f" contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">132,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
              <div style="color: rgb(0, 0, 0);">Escrow</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" id="Fact_511f779000594abaa922cfb4aba00a88" contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Assume advance/loans</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" id="Fact_2df509ba09dc4f3dacacee5b5af8c95b" contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,700,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
              <div style="color: rgb(0, 0, 0);">Interest on advance/loans</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" id="Fact_696b37c9991c44baa0edf54ef8bb2839" contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">68,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Carrying value of assets sold:</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Cash and cash equivalents</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" id="Fact_3d980b560cd1473399f019af9246f681" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">14,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
              <div style="color: rgb(0, 0, 0);">Accounts receivable</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" id="Fact_0bc2fbba6d4748148784e6a7c9fd3713" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">75,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Prepaids and other current assets</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" id="Fact_ce0ac8ddf8234ef99c2e6875e04ab476" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">124,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
              <div style="color: rgb(0, 0, 0);">Property and equipment, net</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" id="Fact_01f85aaead0444fbbdda7f7093c04b89" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,014,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Software development costs</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="btx:DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" id="Fact_2ec6e288254746a89d3f0625c8a33262" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">927,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
              <div style="color: rgb(0, 0, 0);">Customers</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" id="Fact_6163d7a0b808433a9d1f2b7847c3b03e" contextRef="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">548,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Trade name</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" id="Fact_4e763bb029ee4150a4c80ff3272815b7" contextRef="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">299,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
              <div style="color: rgb(0, 0, 0);">Goodwill</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" id="Fact_49bc7dae4360453b8e82a8d07e33748b" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">8,589,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Other assets</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" id="Fact_b31b37e9da144e8f8b0bf4b5d53f63b9" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">103,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Liabilities transferred upon sale:</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
              <div style="color: rgb(0, 0, 0);">Accounts payable and accrued expenses</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" id="Fact_4360980b9a474b32997a3b4237d39a1f" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">113,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Obligations under finance leases</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" id="Fact_b7dc86c5823743e694926ab1e3bb4638" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">17,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
              <div style="color: rgb(0, 0, 0);">Lease liability</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:DisposalGroupIncludingDiscontinuedOperationLeaseLiability" id="Fact_61d04107ef0047fba451f357980ae856" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">26,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Deferred revenue</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" id="Fact_07726609b4f043a5b4f2e513fcce2822" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">55,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
              <div style="color: rgb(0, 0, 0);">Other current liabilities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" id="Fact_8d2648361c5a41d2b65c22ce1eab6bfb" contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">149,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%;">
              <div style="color: rgb(0, 0, 0);">Transaction costs</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="btx:DisposalGroupIncludingDiscontinuedOperationTransactionCosts" id="Fact_fe92b742c340431ba1ed3c429fc31b66" contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">265,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 4px;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Total loss on sale of assets</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">(<ix:nonFraction name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" id="Fact_1c32dc5e98af428f9cd000c9d03a4540" contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">9,648,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div>
            </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853425" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853426">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853426" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853427">
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Unaudited Pro Forma Disclosure</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853427" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853428">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853428" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853429"><ix:nonNumeric name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="Text_953ffa0af1344c5abd3743b2b53134b4" contextRef="c20210101to20211231" escape="true" continuedAt="Text_12e6d73fa4e74912aa2bc7475fbb0e1c1">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following unaudited pro forma financial information summarizes the results of operations for the years months ended December 31, 2021 and 2020
        as if the Merger and the Disposition had been completed as of January 1, 2020. Pro forma information primarily reflects adjustments relating to the reversal of transaction costs. Assuming that the Merger and the Disposition had been completed as of
        January 1, 2020, the transaction costs would have been expensed in the prior period.</div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853429" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853430"><ix:continuation id="Text_12e6d73fa4e74912aa2bc7475fbb0e1c1" continuedAt="Text_12e6d73fa4e74912aa2bc7475fbb0e1c2">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853430" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853431"><ix:continuation id="Text_12e6d73fa4e74912aa2bc7475fbb0e1c2">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> Years ended December 31,</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2021<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2020<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Net loss attributable to common stockholders</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">(<ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" id="Fact_ac78501bc7fb446abaa1b916847308bf" contextRef="c20210101to20211231" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">122,306,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">(<ix:nonFraction name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" id="Fact_f7065180120142d19e31530219496eba" contextRef="c20200101to20201231" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">26,547,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Basic and diluted net loss per share attributable to common stockholders</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" id="Fact_b952af21f13a49f1831fe0df9a81f0e0" contextRef="c20210101to20211231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" id="Fact_3581ce8e3a11409ab912200210958922" contextRef="c20210101to20211231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">2.82</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted" id="Fact_63c5a07331c842e588190399524b6b4b" contextRef="c20200101to20201231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic" id="Fact_29671fd8a24f4185b523a0bb787f9f9b" contextRef="c20200101to20201231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">1.51</ix:nonFraction></ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853431" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853432">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853432" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853433">
<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Acquisition</div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853433" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853434">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853434" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853435">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On July 16, 2021, Brooklyn and Brooklyn Acquisition Sub, Inc. entered into the Acquisition Agreement. The Acquisition closed contemporaneously
          with the execution and delivery of the Acquisition Agreement. At the closing:</div>
</ix:continuation>
        <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853435" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853436">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853436" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853437">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Brooklyn acquired all of the outstanding equity interests of Novellus, Inc. as
            the result of the merger of Brooklyn Acquisition Sub, Inc. with and into Novellus, Inc., following which, Novellus, Inc., as the surviving corporation, became Brooklyn&#8217;s wholly owned subsidiary and Novellus Ltd. became Brooklyn&#8217;s indirectly
            owned subsidiary; and<br />
          </span></div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853437" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853438">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853438" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853439">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Brooklyn acquired <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" id="Fact_519fdc5024274ce18580023b91cfb123" contextRef="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember" unitRef="U004" decimals="3" scale="-2" format="ixt:numdotdecimal">25.0</ix:nonFraction>% of the total outstanding equity interests of NoveCite.</span></div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853439" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853440">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-14</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

      <div>
        <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853440" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853441">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn delivered consideration for the Acquisition totaling approximately $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" id="Fact_def528c0811440a9bfc8f7eb61d31a4f" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">124,000,000</ix:nonFraction>, which consisted of (a) approximately $<ix:nonFraction name="us-gaap:PaymentsToAcquireOtherProductiveAssets" id="Fact_aaee0dcc04404aa692b45d257934ed5a" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">22,854,000</ix:nonFraction>
          in cash, net of cash acquired, and (b) approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" id="Fact_0ce5f65140514384bc64ab345a332ff4" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,022,000</ix:nonFraction> shares of common stock, which under the terms of the Acquisition
          Agreement were valued at a total of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" id="Fact_8252a903d5b64579a9460ac6f44ac503" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">102,000,000</ix:nonFraction>, based on a price of $<ix:nonFraction name="btx:AssetAcquisitionSharePrice" id="Fact_97a4241c824840fa8583a0bddb045a46" contextRef="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U003" decimals="4" scale="0" format="ixt:numdotdecimal">14.5253</ix:nonFraction> per share.</div>
</ix:continuation>
        <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853441" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853442">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853442" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853443">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Acquisition Agreement contained customary representations, warranties and certain indemnification provisions. Approximately <ix:nonFraction name="btx:EscrowShares" id="Fact_09613d0defbc4769b868462e51085ee9" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">741,000</ix:nonFraction> of the shares issued as consideration were placed in escrow for a period of up to <ix:nonNumeric name="btx:EscrowPeriod" id="Fact_a4627cb4f633453c8fa4f3e6a434d597" contextRef="c20210101to20211231_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember_RangeAxis_MaximumMember" format="ixt-sec:durmonth">12</ix:nonNumeric> months in order to secure indemnification obligations to Brooklyn under the Acquisition Agreement. The Acquisition Agreement also contains certain non-competition and
          non-solicitation provisions pursuant to which Novellus LLC agreed not to engage in certain competitive activities for a period of <ix:nonNumeric name="btx:AcquisitionAgreementNonCompetitivePeriod" id="Fact_5be1e6456b1a4a6da62d0a98d6f03630" contextRef="c20210101to20211231_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric>
          following the closing, including customary restrictions relating to employees. No employees of Novellus Ltd. or Novellus, Inc. prior to the Acquisition continued their employment, or were otherwise engaged by Brooklyn, following the Acquisition.</div>
</ix:continuation>
        <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853443" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853444">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853444" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853445">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In connection with the Acquisition, the co-founders of Novellus, Ltd. entered into lock-up agreements with respect to approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" id="Fact_49aeab7906a748a99a4273e07ac6edd6" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember_RelatedPartyTransactionsByRelatedPartyAxis_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,378,000</ix:nonFraction> of the shares of common stock received in the Acquisition, and Brooklyn&#8217;s Chairman of the Board of Directors and its Chief Executive Officer
          and President entered into identical lock-up agreements with respect to their current holdings of Brooklyn stock. Each lock-up agreement extends for a period of <ix:nonNumeric name="btx:EachLockUpAgreementExtendsTerm" id="Fact_a053df53414c4052975a8785b21a2d16" contextRef="c20210101to20211231_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" format="ixt-sec:durwordsen">three years</ix:nonNumeric>, provided that up to <ix:nonFraction name="btx:PercentageOfCommonStockSubjectToLockUpAgreement" id="Fact_9b3828e5d70143e7a3372bc7515b54ac" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember_RangeAxis_MaximumMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">75</ix:nonFraction>% of the shares of common stock subject to the lock-up agreement
          may be released from the lock-up restrictions earlier if the price of common stock on the Nasdaq exceeds specified thresholds. The lock-up agreements include customary exceptions for transfers during the applicable lock-up period.</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853445" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853446">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853446" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853447">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company expects the Acquisition will advance its evolution into a platform company with a pipeline of next generation engineered cellular,
        gene editing and cytokine programs. In addition, the acquisition of Novellus, Ltd. builds on the License Agreement. (See Note 11). The completion of the acquisition of Novellus, Ltd. relieved Brooklyn LLC from potential obligations to pay Novellus,
        Ltd. certain upfront fees, clinical development milestone fees and post-registration royalties under the License Agreement. The agreement with Factor Bioscience Limited (&#8220;Factor&#8221;) under the License Agreement, which grants Brooklyn LLC exclusive
        rights to develop certain next-generation mRNA gene editing and cell therapy products, remained unchanged.</div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853447" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853448">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853448" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853449">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Although Brooklyn acquired all of the outstanding equity interests of Novellus, Inc., the Company accounted for the Acquisition as an asset
        acquisition (as the assets acquired did not constitute a business as defined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805, <span style="font-style: italic;">Business Combinations</span>)<span style="font-style: italic;">, </span>and was
        measured by the amount of cash paid and by the fair value of the shares of common stock issued. As a result, substantially all of the value acquired was attributed to IPR&amp;D, with the exception of the cash paid for the investment in NoveCite,
        which is being accounted for as an investment in equity securities, as discussed further below.</div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853449" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853450">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853450" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853451">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn paid $<ix:nonFraction name="btx:PaymentsToAcquireProductiveAssetsNet" id="Fact_68e7b3c226814e7da9afa980dedbf2ff" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">22,854,000</ix:nonFraction> in cash,
        net of cash acquired, as part of the consideration for the Acquisition, of which $<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" id="Fact_aeb0cd9994af48bd9dc727c3003b5e6c" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction> was paid in cash for the investment in
        NoveCite. Brooklyn also issued approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" id="Fact_5321dd9ad35140d396df58bf5ecc3489" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,022,000</ix:nonFraction> shares of the Company&#8217;s common stock, of which approximately <ix:nonFraction name="btx:StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" id="Fact_2ddef28330fb4b64b6a811e8e3da88fa" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,644,000</ix:nonFraction> shares are unrestricted and <ix:nonFraction name="btx:StockIssuedDuringPeriodRestrictedSharesAcquisitions" id="Fact_66a3347be3814252866ca9fd850f2378" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,378,000</ix:nonFraction>
        shares are subject to the <ix:nonNumeric name="btx:LockUpPeriodForRestrictedShares" id="Fact_945def94770949bbb3c93bbefb03c69e" contextRef="c20210101to20211231_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" format="ixt-sec:durwordsen">three-year</ix:nonNumeric> lockup. The unrestricted shares were valued at $<ix:nonFraction name="btx:AssetAcquisitionUnrestrictedSharesSharePrice" id="Fact_e86e3a65aab84042901c3100c2043503" contextRef="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">10.05</ix:nonFraction> per share, which was the closing price of Brooklyn&#8217;s common stock on July 16, 2021. The fair value of the restricted shares was discounted by approximately <ix:nonFraction name="btx:PercentageOfDiscountOnFairValueOfRestrictedShares" id="Fact_44aec31945224260bcc90a5980bfc48f" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">35</ix:nonFraction>% to $<ix:nonFraction name="btx:AssetAcquisitionRestrictedSharesSharePrice" id="Fact_bff5f0e568934ede8f2978a4d2a7e072" contextRef="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">6.53</ix:nonFraction> per restricted share, which
        was derived from the average discount rate between the Black Scholes and Finnerty valuation models. <ix:nonNumeric name="us-gaap:AssetAcquisitionTableTextBlock" id="Text_82e0e11bff704f09a63602ac532be334" contextRef="c20210101to20211231" escape="true" continuedAt="Text_a5bace9092a94790ae3faed132259b291"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The resulting fair value of the asset acquired is as follows:</span></ix:nonNumeric></div>
</ix:continuation>
      <ix:continuation id="Text_a5bace9092a94790ae3faed132259b291" continuedAt="Text_a5bace9092a94790ae3faed132259b292"><ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853451" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853452">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_a5bace9092a94790ae3faed132259b292"><ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853452" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853453">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Fair Value of</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Consideration</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Cash paid</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" id="Fact_568c1bcae0c44ad7b75af065fd3129ea" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">22,882,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Cash acquired</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:CashAcquiredFromAcquisition" id="Fact_a097906b1a98425882c2b0e59494eb74" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">28,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 83.46%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Unrestricted shares</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.44%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12.34%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" id="Fact_64ebd0f7a0744579b86b07476a790034" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">36,628,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 83.46%; padding-bottom: 2px; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Restricted shares</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.44%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12.34%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" id="Fact_d674e0bfd14e4324ae6dca8211c83a4a" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">22,056,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 83.46%; background-color: rgb(204, 238, 255);">
              <div style="color: rgb(0, 0, 0);">Total fair value of consideration paid</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.44%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12.34%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:AssetAcquisitionFairValueOfConsiderationPaid" id="Fact_61c0d41cefd2492992860027ba6a4e9c" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">81,538,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 83.46%; padding-bottom: 2px; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Less amount of cash paid for NoveCite investment</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.44%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12.34%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" id="Fact_4e60bf172d644293bb2a13fb279bb4bf" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 83.46%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Fair value of IPR&amp;D acquired</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1.31%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.44%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 12.34%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:ResearchAndDevelopmentInProcessAssetAcquisition" id="Fact_0626b3cea71b4ac1b995e4e7c2781b9b" contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">80,538,000</ix:nonFraction><br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.31%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853453" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853454">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853454" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853455">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">IPR&amp;D that is acquired through an asset purchase that has no alternative future uses and no separate economic values from its original
          intended purpose is expensed in the period the cost is incurred. Accordingly, the Company expensed the fair value of the IPR&amp;D during the third quarter of 2021 in the amount of $<ix:nonFraction name="btx:ResearchAndDevelopmentInProcessAssetAcquisition" id="Fact_0158f27933094ae1bb600509b47259a4" contextRef="c20210701to20210930_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">80,538,000</ix:nonFraction>.</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853455" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853456">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-15</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853456" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853457">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Investment in NoveCite</span></div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853457" continuedAt="Text_672b9debd5eb4dc9906c1c7d44eb853458">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_672b9debd5eb4dc9906c1c7d44eb853458">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">As a result of the Acquisition, Brooklyn acquired and currently owns <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" id="Fact_57b7551c8862493fa90f7dc4a651100b" contextRef="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>% of NoveCite and Citius Pharmaceuticals, Inc. (&#8220;Citius&#8221;) owns the remaining <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" id="Fact_9e7d29a8680b452d8fb0c3b02c03b891" contextRef="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember_OwnershipAxis_CitiusPharmaceuticalsIncMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">75</ix:nonFraction>%.
        A member of the Company&#8217;s management holds one of <ix:nonFraction name="btx:NumberOfBoardSeats" id="Fact_67c787d4883e4e61a3802932c3028e99" contextRef="c20210716to20210716_BusinessAcquisitionAxis_NoveCiteINCMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> board seats on NoveCite&#8217;s board of directors. Citius&#8217; s officers and directors
        hold the other two board seats. Citius also retains the ability, in its sole discretion, to increase the size of the board of directors of NoveCite. Pursuant to a subscription agreement, as amended, between NoveCite and Novellus, LLC (the former
        parent of Novellus, Inc.), which was further amended and assigned to Brooklyn by Novellus, LLC upon the completion of the Acquisition, Citius has complete operational control and financial responsibility for NoveCite. Citrus&#8217;s officers are also the
        officers of NoveCite and oversee the business strategy and operations of NoveCite. Therefore, despite Brooklyn&#8217;s ownership of greater than <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" id="Fact_c77553bd350e48e685df22c4ee9f7709" contextRef="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember_RangeAxis_MinimumMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>%
        of NoveCite, which leads to a presumption that in the absence of predominant evidence to the contrary, an investor has the ability to exercise significant influence over an investee, Brooklyn does not exercise any significant influence over
        NoveCite or its board of directors. Brooklyn also has no contractual rights in the profits or obligations to share in the losses of NoveCite.&#160; Accordingly, the Company is accounting for its interest in NoveCite under ASC Topic 321, <span style="font-style: italic;">Investments &#8211; Equity Securities. </span>Because NoveCite&#8217;s stock is not publicly traded and, therefore, does not have a readily determinable fair value, the Company has elected to account for its investment at cost,
        which was $<ix:nonFraction name="us-gaap:EquityMethodInvestments" id="Fact_11b10af0c54a4f25bee844b2adc37bc5" contextRef="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction>. The Company will make adjustments to this amount when there are observable transactions for the identical or
        similar equity securities of the same issuer that would provide an indicator of fair value. In addition, if qualitative factors indicate a potential impairment, fair value must be estimated and the investment written down to that fair value if it
        is lower than the carrying value. As of December 31, 2021, there were no observable transactions for identical or similar equity securities of NoveCite to provide an indication of fair value, nor were there any indications of impairment of the
        investment.</div>
</ix:continuation>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" id="Text_37da32b66e184899b6d646f65abc294e" contextRef="c20210101to20211231" escape="true" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd51">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5)</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Fair Value of Financial Instruments</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd51" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd52">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd52" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd53">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between
          market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair
          value hierarchy is as follows:</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd53" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd54">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd54" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd55">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Level 1 Inputs &#8211; Valued based on quoted prices in active markets for identical
          assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div>
</ix:continuation>
      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd55" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd56">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd56" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd57">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Level 2 Inputs &#8211; Valued based on inputs other than quoted prices included in
          Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets
          that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by
          market data by correlation or other means.</span></div>
</ix:continuation>
      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd57" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd58">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd58" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd59">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="color: rgb(0, 0, 0);">Level 3 Inputs &#8211; Valued based on inputs for which there is little or no market
          value, which require the reporting entity to develop its own assumptions.</span></div>
</ix:continuation>
      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd59" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd510">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd510" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd511"><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="Text_79d4fefc81c343948d27e680a3111a93" contextRef="c20210101to20211231" escape="true" continuedAt="Text_288d7c7ae1e7463088e30a3742a1b4d91">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following tables summarize the liabilities that are measured at fair value as of December 31, 2021 and 2020:</div>
</ix:nonNumeric></ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd511" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd512"><ix:continuation id="Text_288d7c7ae1e7463088e30a3742a1b4d91" continuedAt="Text_288d7c7ae1e7463088e30a3742a1b4d92">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation></ix:continuation>
      </div>

      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd512" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd513"><ix:continuation id="Text_288d7c7ae1e7463088e30a3742a1b4d92" continuedAt="Text_288d7c7ae1e7463088e30a3742a1b4d93">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of December 31, 2021</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Description</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 1</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 2</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 3</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-style: italic;">Liabilities:</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Contingent consideration</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_f914e9d0445a46d2ad27c91d8ba8ea63" contextRef="c20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_e747e00544d449e59b0e2f613583aaab" contextRef="c20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_8655a12bdb844dbaa0a3d629df436e76" contextRef="c20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">19,930,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;">
              <div style="color: rgb(0, 0, 0);">Total</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_b719c48cd0f640ef9765a87931583671" contextRef="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_ab668a1e78784f50bf20de7bc95bf17c" contextRef="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_0320b25f09404f9787c54244a585376a" contextRef="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">19,930,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd513" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd514"><ix:continuation id="Text_288d7c7ae1e7463088e30a3742a1b4d93" continuedAt="Text_288d7c7ae1e7463088e30a3742a1b4d94">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd514" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd515"><ix:continuation id="Text_288d7c7ae1e7463088e30a3742a1b4d94">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of December 31, 2020</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Description</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 1</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 2</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 3</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-style: italic;">Liabilities:</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Contingent consideration</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_a814f14028e74e57b65911bd3547652c" contextRef="c20201231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_a138cc7dbbc34d64b077e23ed952141a" contextRef="c20201231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_a6d46cd9a48e4beda19002907b58c5b6" contextRef="c20201231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">20,110,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;">
              <div style="color: rgb(0, 0, 0);">Total</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_4bebe546646143408690d47fc4ea0d06" contextRef="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_272f32e1fb6546708505bff33d67c5b4" contextRef="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_5007bcfbe0264bda984400be8ea8414a" contextRef="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">20,110,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd515" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd516">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-16</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

      <div>
        <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd516" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd517">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The contingent consideration is related to an asset purchase agreement entered into between Brooklyn LLC and IRX Therapeutics (&#8220;IRX&#8221;) in
          connection with the IRX Acquisition, according to which, Brooklyn LLC is obligated to pay royalties to certain noteholders and shareholders of IRX based on future revenues from any future IRX-2 product sales.</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd517" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd518">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd518" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd519"><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Text_e93a621590a64b47bb0bb284acb40963" contextRef="c20210101to20211231" escape="true" continuedAt="Text_21c8bb744906425fa66f119e17306c9f1">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Contingent consideration for the IRX Acquisition was initially valued at the transaction price and is subsequently valued at the end of each
        reporting period using third-party valuation services or other market observable data. The third-party valuation services use industry standard valuation models, including discounted cash flow analysis, to determine the value. After completing its
        validation procedures as of December 31, 2021, the Company adjusted the carrying amount of its contingent consideration liabilities as follows:</div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd519" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd520"><ix:continuation id="Text_21c8bb744906425fa66f119e17306c9f1" continuedAt="Text_21c8bb744906425fa66f119e17306c9f2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd520" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd521"><ix:continuation id="Text_21c8bb744906425fa66f119e17306c9f2">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Year ended</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31, 2021 </div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Balance as of beginning of period</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_4af2b171c3394a2f8eb0f84bcf4c2498" contextRef="c20201231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">20,110,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Fair value adjustments included in operating expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" id="Fact_fddf9066c9d6442e9c88e31d61a06f0e" contextRef="c20210101to20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">180,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Balance as of end of period</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" id="Fact_275ad11d1e9e47809ba6eb1f0d2ec4dc" contextRef="c20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">19,930,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd521" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd522">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd522" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd523">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Contingent consideration is measured at fair value and is based on significant inputs not observable in the market, which represents a Level 3
          measurement within the fair value hierarchy. The valuation of contingent consideration uses assumptions the Company believes would be made by a market participant. The Company assesses these estimates on an on-going basis as additional data
          impacting the assumptions is obtained. Future changes in the fair value of contingent consideration related to updated assumptions and estimates are recognized within the statements of operations.</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd523" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd524">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd524" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd525">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Contingent consideration may change significantly as development progresses and additional data are obtained, impacting the Company&#8217;s assumptions
        regarding probabilities of successful achievement of related milestones used to estimate the fair value of the liability and the timing in which the milestones are expected to be achieved. In evaluating the fair value information, considerable
        judgment is required to interpret the market data used to develop the estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange.&#160; Accordingly, the use of different market
        assumptions and/or different valuation techniques could result in materially different fair value estimates.</div>
</ix:continuation>
      <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd525" continuedAt="Text_a1399ec0c19042eabd1b811dc5431dd526">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_a1399ec0c19042eabd1b811dc5431dd526">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">For purposes of this calculation, a royalty equal to <ix:nonFraction name="btx:PercentageOfRoyaltyRevenueAssumedUntil2029" id="Fact_f4e5afa8cffe477f8ff53ca841d33496" contextRef="c20210101to20211231" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction>% of revenue (consisting of the royalty due to University of South Florida and the royalty due to the collaborator) is assumed until 2029 and a royalty of <ix:nonFraction name="btx:PercentageOfRoyaltyRevenueAssumedFrom2030To2038" id="Fact_420d402c2a48446ba15e4ca40297ce35" contextRef="c20210101to20211231" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>% of revenues is assumed from 2030 to 2038. The post patent decline is <ix:nonFraction name="btx:PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" id="Fact_935edbda7b10468abf9ca012fd524282" contextRef="c20210101to20211231" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%
          in the first year and <ix:nonFraction name="btx:PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" id="Fact_03a0d92f2b6640c999272a1451faa03b" contextRef="c20210101to20211231" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>% thereafter. Income taxes were projected to be <ix:nonFraction name="btx:PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" id="Fact_dd760951ba7a427f84050f38df61eb53" contextRef="c20210101to20211231" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction>% of net royalty savings. The cash flows were discounted by the liability specific weighted average cost of capital of <ix:nonFraction name="btx:PercentageOfWeightedAverageCostOfCapital" id="Fact_7ace8c434524451299721408cedfafa7" contextRef="c20210101to20211231" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction>% using the mid-point convention.</div>
</ix:continuation>
      </div>

      <div>  </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Text_04f70f6d71f24cdaa97b8877306a3d65" contextRef="c20210101to20211231" escape="true" continuedAt="Text_b28e9d2527b242eea91246a52d3d11721">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">6)</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Property and Equipment</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <div>
        <ix:continuation id="Text_b28e9d2527b242eea91246a52d3d11721" continuedAt="Text_b28e9d2527b242eea91246a52d3d11722">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>


      <ix:continuation id="Text_b28e9d2527b242eea91246a52d3d11722" continuedAt="Text_b28e9d2527b242eea91246a52d3d11723"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Text_d6baae7027f6405f93a110b8d03de481" contextRef="c20210101to20211231" escape="true" continuedAt="Text_51d54964e7d746d695c1d8e0ed7758211">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment consist of the following:</div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_b28e9d2527b242eea91246a52d3d11723" continuedAt="Text_b28e9d2527b242eea91246a52d3d11724"><ix:continuation id="Text_51d54964e7d746d695c1d8e0ed7758211" continuedAt="Text_51d54964e7d746d695c1d8e0ed7758212">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-17</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

      <ix:continuation id="Text_b28e9d2527b242eea91246a52d3d11724" continuedAt="Text_b28e9d2527b242eea91246a52d3d11725"><ix:continuation id="Text_51d54964e7d746d695c1d8e0ed7758212">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,<br />
              </div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2020</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Laboratory and manufacturing equipment</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_94f7c660e06d4d439c42b087ae705490" contextRef="c20211231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">258,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_3bfff308a54b4e36b1e5add8414f52d5" contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">300,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="color: rgb(0, 0, 0);">Leasehold improvements<br />
              </div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_f825ca80f52541ee8d1fa0a4ea67fe87" contextRef="c20211231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">464,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_071e876e68674c538ca3473c0ec729cc" contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">414,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Computer equipment</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_ea6264ac0e934e2780476484cec9be22" contextRef="c20211231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">154,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_c5a074b1082f44b2a6af1769acd6e4ff" contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_b0f0c0b2738b41babe24f447adb31d12" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">877,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_da0e88c6560042fbb4d408926884f95a" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">714,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Less: accumulated depreciation and amortization</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_8641f66a5d2044e79cfef5fbdb1e640d" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">207,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_b15ef5ffac9248c9b16c94252e814c66" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">120,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
              <div style="color: rgb(0, 0, 0);">Property and equipment, net</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_68373ed130cd4d7db870f2de3bf77b07" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">670,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_84d5f55656994cc98357873026780861" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">594,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_b28e9d2527b242eea91246a52d3d11725" continuedAt="Text_b28e9d2527b242eea91246a52d3d11726">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_b28e9d2527b242eea91246a52d3d11726">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Depreciation expense totaled $<ix:nonFraction name="us-gaap:Depreciation" id="Fact_c1fb583bde7b417eb7f564de58b99d06" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">117,000</ix:nonFraction>
        and $<ix:nonFraction name="us-gaap:Depreciation" id="Fact_2ce52ded9d724dbda7a52bb43d691208" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">98,000</ix:nonFraction> for the years ended December 31, 2021 and 2020, respectively. No depreciation expense is recorded on fixed assets in process
        until such time as the assets are completed and are placed into service.</div>
</ix:continuation>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" id="Text_002652cef29f43bbaa9fcf2ae34220f9" contextRef="c20210101to20211231" escape="true" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c391">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7)</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Leases</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c391" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c392">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c392" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c393">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company has operating leases for office and laboratory space in the boroughs of Brooklyn and Manhattan in New York, New York, which expire
          in 2025 and 2026, respectively. In June 2021, the Company entered into an additional lease agreement to lease approximately <ix:nonFraction name="btx:OperatingLeaseArea" id="Fact_69a68c6b55ff45e580aebf0e2e9ca091" contextRef="c20211231" unitRef="U007" decimals="0" scale="0" format="ixt:numdotdecimal">2,700</ix:nonFraction>
          square feet of office and laboratory space in Cambridge, Massachusetts for approximately $<ix:nonFraction name="btx:AnnualRentPerSquareFoot" id="Fact_97b35a2946714e55a3da62a164067d0d" contextRef="c20210101to20211231" unitRef="U007" decimals="2" scale="0" format="ixt:numdotdecimal">56.00</ix:nonFraction> per square foot annually. The lease
          provides for annual escalation of the base rent based on the year-over-year increase of the consumer price index, as well as the payment of other customary expenses, such as common area maintenance fees, property taxes, and insurance. Upon
          entering into this lease agreement, the Company paid a lease deposit of approximately $<ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_65c5b2d9135f4fd2afd9d71c06e4f109" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">25,000</ix:nonFraction>. The Cambridge, Massachusetts lease
          expires in June 2028. See Note 17 for subsequent event information regarding the Company&#8217;s leases.<br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c393" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c394">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c394" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c395">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company adopted ASC Topic 842, <span style="font-style: italic;">Leases,</span> on December 31, 2020 using the modified transition method
          without retrospective application to comparative periods. The Company elected the package of three practical expedients allowed for under the transition guidance. Accordingly, the Company did not reassess: (1) whether any expired or existing
          contracts are/or contain leases; (2) the lease classification for any expired or existing leases; or (3) initial direct costs for any existing leases. The Company has also elected not to recognize right-of-use assets (&#8220;ROU assets&#8221;) and lease
          liabilities for short-term leases that have a term of 12 months or less.</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c395" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c396">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c396" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c397">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Operating lease liabilities represent the present value of lease payments not yet paid. ROU assets represent the Company&#8217;s right to use an
          underlying asset and are based upon the operating lease liabilities adjusted for prepaid or accrued lease payments, initial direct costs, lease incentives and impairment of operating lease assets. As the rate implicit in the lease is not readily
          determinable, the Company used its incremental borrowing rates based on the information available at the lease commencement date in determining the present value of lease payments. To determine the present value of lease payments not yet paid,
          the Company estimates secured borrowing rates corresponding to the maturities of the leases.</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c397" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c398">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c398" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c399">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company has elected the practical expedient to not separate non-lease components from the lease components to which they relate and instead
          account for each as a single lease component for all underlying asset classes. Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as payments for insurance, tax payments and other
          miscellaneous costs. The variable portion of lease payments is not included in the ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are expensed when the obligation for those payments
          is incurred and are included in lease expenses. Accordingly, all expenses associated with a lease contract are accounted for as lease expenses.</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c399" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3910">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3910" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3911">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Operating leases are included in right of use assets - operating leases and operating lease liabilities, current and long-term, on the balance
          sheet. Lease expense for operating leases is recognized on a straight-line basis over the lease term and is included in general and administrative costs in the statements of operations.</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3911" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3912">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3912" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3913"><ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" id="Text_48e17f2ddd0d43088c17bf4695ba7c4a" contextRef="c20210101to20211231" escape="true" continuedAt="Text_c12851a7229c4898b86c04e46d62a37f1">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company recognizes operating lease expense and lease payments from the sublease on a straight-line basis in its statements of operations
          over the lease terms. During the years ended December 31, 2021 and 2020, the net operating lease expenses were as follows:</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3913" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3914"><ix:continuation id="Text_c12851a7229c4898b86c04e46d62a37f1" continuedAt="Text_c12851a7229c4898b86c04e46d62a37f2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation></ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-18</span></div>

          <div style="page-break-after: always;" class="DSPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3914" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3915"><ix:continuation id="Text_c12851a7229c4898b86c04e46d62a37f2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Years ended December 31,</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;">2021</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; font-weight: bold;">2020</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Operating lease expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_803e9bde990a49219364523cdbf2b03d" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">688,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_3aef8ff3be97431fb7c25397828acfb4" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">591,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Sublease income</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_7d5cb521e0fb4e7987f70037aff7d1a3" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">84,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_aafefb71088945e9b75b5dadd8ba071a" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">77,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Variable lease expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:VariableLeaseCost" id="Fact_3eb80ad87adf45d68c2d9f6b5157e63b" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">19,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:VariableLeaseCost" id="Fact_5aa31e0d3bd543bbaa250915d40d3359" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">21,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Total lease expense</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LeaseCost" id="Fact_e990d483866a420ba19fcb2ac26a7490" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">623,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LeaseCost" id="Fact_01df96d899dc45d1a590fcb0410d0c2e" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">535,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3915" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3916">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>


      <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3916" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3917"><ix:nonNumeric name="btx:OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" id="Text_a21c6faafd8b41f3b40b59e2c3ab2115" contextRef="c20210101to20211231" escape="true" continuedAt="Text_b5cb35070e5f4cfba950e9b766fc2c721">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The tables below show the beginning balances of the operating ROU assets and lease liabilities as of January 1, 2021 and the ending balances as of
        December 31, 2021, including the changes during the period.</div>
</ix:nonNumeric></ix:continuation>
      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3917" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3918"><ix:continuation id="Text_b5cb35070e5f4cfba950e9b766fc2c721" continuedAt="Text_b5cb35070e5f4cfba950e9b766fc2c722">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation></ix:continuation>
      </div>

      <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3918" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3919"><ix:continuation id="Text_b5cb35070e5f4cfba950e9b766fc2c722" continuedAt="Text_b5cb35070e5f4cfba950e9b766fc2c723">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Operating Lease</div>
              <span style="font-weight: bold;"> </span>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ROU Assets</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Operating lease ROU assets at January 1, 2021</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_fb47bd67402c4a65b36457de457c6e92" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">2,093,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Amortization of operating lease ROU assets</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" id="Fact_fb5c87a7f880494ab5b2f8d8c3d0c2df" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">342,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Addition of operating lease ROU assets</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:AdditionOfOperatingLeaseRightofUseAsset" id="Fact_680e6411e628448ab79a8962168c56b4" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">816,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Operating lease ROU assets at December 31, 2021</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_404b483107624f5f8942c3eac5187bb5" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">2,567,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3919" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3920"><ix:continuation id="Text_b5cb35070e5f4cfba950e9b766fc2c723" continuedAt="Text_b5cb35070e5f4cfba950e9b766fc2c724">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation></ix:continuation>
      </div>

      <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3920" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3921"><ix:continuation id="Text_b5cb35070e5f4cfba950e9b766fc2c724">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0);">Operating Lease</div>
              <div style="text-align: center; color: rgb(0, 0, 0);">Liabilities</div>
            </td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Operating lease liabilities at January 1, 2021</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_1fc4ebb213214193a88115f8b09f7ae5" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">2,178,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Principal payments on operating lease liabilities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="btx:PrincipalPaymentsOnOperatingLeaseLiabilities" id="Fact_ec98cb9841204c339deec6d75b145325" contextRef="c20210101to20211231" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">321,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Addition of operating lease liabilities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:AdditionOfOperatingLeaseLiability" id="Fact_709abad0a0294bbbae339b9a1f7ed26f" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">866,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Operating lease liabilities at December 31, 2021</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_65901b52de8344d5beec49a279f9e73a" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">2,723,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Less non-current portion</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_cf0e44f7b3b9482487d5eb3827b293f8" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">2,297,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Current portion at December 31, 2021</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_a3531a7dd8424c458f1cd7ff1a8fc730" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">426,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3921" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3922">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3922" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3923">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">As of December 31, 2021, the Company&#8217;s operating leases had a weighted-average remaining life of <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Fact_1da4e24538b14402b840e8d25a17617f" contextRef="c20211231" format="ixt-sec:duryear">4.9</ix:nonNumeric> years with a weighted-average discount rate of <ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" id="Fact_19b040d559d84f4a91076b511ddf88cb" contextRef="c20211231" unitRef="U004" decimals="4" scale="-2" format="ixt:numdotdecimal">12.76</ix:nonFraction>%. <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Text_9853771db42342d89b7a4218c184b5e2" contextRef="c20210101to20211231" escape="true" continuedAt="Text_d8ca8c4299cb4af4afd43b202d70a71a1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The maturities of the operating
          lease liabilities are as follows:</span></ix:nonNumeric></div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_d8ca8c4299cb4af4afd43b202d70a71a1" continuedAt="Text_d8ca8c4299cb4af4afd43b202d70a71a2"><ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3923" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3924">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation></ix:continuation>
      </div>

      <ix:continuation id="Text_d8ca8c4299cb4af4afd43b202d70a71a2"><ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3924" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3925">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">2022</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" id="Fact_b4e30791d8d748b4b5c22791035f6064" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">750,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">2023</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" id="Fact_105ae1814989432c9483d84e74aad7ef" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">767,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">2024</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" id="Fact_2cdbeedc60ad4641b57d5b10325a32c4" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">785,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">2025</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" id="Fact_885e3cf29a694a90a90dbe9dcb6c937e" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">802,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">2026</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" id="Fact_177bbe0d84ad4a059e77ed3c12cf651c" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">267,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Thereafter</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" id="Fact_9d54781c5f534627a0f9dec706248073" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">246,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Total payments</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" id="Fact_f462dd0117954c208ff69cde83699f3e" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">3,617,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Less imputed interest</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" id="Fact_a7a8b6b5799041d99cdc72d033b0a399" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">894,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Total operating lease liabilities</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_bb85f1f2c0ad4c22ab8ec0acba10dfb7" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">2,723,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3925" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3926">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3926" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3927">
<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Sublease Agreement</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3927" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3928">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3928" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3929">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On April 18, 2019, the Company entered into a sublease agreement with Nezu Asia Capital Management, LLC (the &#8220;Tenant&#8221;), whereby the Tenant
          agreed to sublease approximately <ix:nonFraction name="btx:AreaOfSubleaseSpaceCurrentlyRented" id="Fact_93bbedd9132e4df6b9c07b987ff14d55" contextRef="c20190418" unitRef="U008" decimals="0" scale="0" format="ixt:numdotdecimal">999</ix:nonFraction> square feet of space currently rented by the Company in the borough of Manhattan in New York, New
          York commencing on May 15, 2019. The term of this sublease expires on October 31, 2026 with no option to extend the sublease term. Rent payments provided by the Tenant under the sublease agreement began on September 1, 2019. The sublease
          agreement stipulates an annual rent increase of <ix:nonFraction name="btx:PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments" id="Fact_53112e46bedd45138a86a30edd216570" contextRef="c20190418to20190418" unitRef="U004" decimals="4" scale="-2" format="ixt:numdotdecimal">2.25</ix:nonFraction>%. <ix:nonNumeric name="btx:FutureLeasePaymentsSubleaseAgreementTableTextBlock" id="Text_a352252085424e6ea914f927841c1fde" contextRef="c20210101to20211231" escape="true" continuedAt="Text_9a28b890fbd74b9193ee289d608fbc051"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Tenant is also responsible for paying to the Company all tenant energy costs, annual
          operating costs, and annual tax costs attributable to the subleased space during the term of the sublease.</span></ix:nonNumeric></div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_9a28b890fbd74b9193ee289d608fbc051" continuedAt="Text_9a28b890fbd74b9193ee289d608fbc052"><ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3929" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3930">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation></ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-19</span></div>

          <div style="page-break-after: always;" class="DSPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_9a28b890fbd74b9193ee289d608fbc052"><ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3930" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3931">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2021<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">2022</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" id="Fact_baea99917e33416abc5aabc71e8db730" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">82,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 88%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">2023</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" id="Fact_13982c613ea94d878bae102c8dbae6fe" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">84,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">2024</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" id="Fact_ecef32657e3541f6ae7c98a3e6f66a05" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">86,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 88%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">2025</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" id="Fact_ee8f8ed3222944da88926b85de1d7572" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">88,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">2026</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" id="Fact_f6076712b4044997804ee811ed17801a" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">75,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 88%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentals" id="Fact_c2464a3bf4eb40d696c8402111cea48e" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">415,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <div>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3931" continuedAt="Text_04fbfc4d7cab4334b7b7e17213123c3932">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_04fbfc4d7cab4334b7b7e17213123c3932">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company received sublease payments of approximately $<ix:nonFraction name="us-gaap:ProceedsFromLeasePayments" id="Fact_db76435709ed43b68b73ffaf3d49c711" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">83,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ProceedsFromLeasePayments" id="Fact_05d4a158e613461593e246e2443b2f23" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">79,000</ix:nonFraction> during the years ended December 31, 2021 and 2020,
          respectively. In accordance with ASC Topic 842, the Company treats the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease. The Company continues to account for the Manhattan lease as a
          lessee and in the same manner as prior to the commencement date of the sublease. The Company accounts for the sublease as a lessor of the lease. The sublease is classified as an operating lease, as it does not meet the criteria of a sale-type or
          direct financing lease.</div>
</ix:continuation>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="Text_fbe77a5fc5064a108069e0e7d30c1f76" contextRef="c20210101to20211231" escape="true" continuedAt="Text_99168fc9eb68476f94c5adacbad28ec41">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Goodwill and In-Process Research &amp; Development</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_99168fc9eb68476f94c5adacbad28ec41" continuedAt="Text_99168fc9eb68476f94c5adacbad28ec42">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_99168fc9eb68476f94c5adacbad28ec42" continuedAt="Text_99168fc9eb68476f94c5adacbad28ec43">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company recorded goodwill and IPR&amp;D in the amount of $<ix:nonFraction name="us-gaap:Goodwill" id="Fact_f9e670d9fa874afc9350aefdebff0325" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">2,044,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" id="Fact_76829daa58c14ef89012ef25dfee3122" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">6,860,000</ix:nonFraction>, respectively, in connection with the IRX Acquisition
        in the year ended December 31, 2018. IPR&amp;D assets are considered to be indefinite lived until the completion or abandonment of the associated research and development projects.</div>
</ix:continuation>
      <ix:continuation id="Text_99168fc9eb68476f94c5adacbad28ec43" continuedAt="Text_99168fc9eb68476f94c5adacbad28ec44">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_99168fc9eb68476f94c5adacbad28ec44">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In connection with the Acquisition, the Company expensed the fair value of the IPR&amp;D it acquired in the amount of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" id="Fact_9e68ed253a6149b8a3c6886719880614" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">80,538,000</ix:nonFraction>, as the Company determined there were no future alternative uses or separate economic values from its original intended purpose. (See Note
        4.)</div>
</ix:continuation>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Text_09ff2d1d1d51425899784ee7a9d40e93" contextRef="c20210101to20211231" escape="true" continuedAt="Text_968a2940ddfb417b96f434591d819fa31">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">9)</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Accrued Expenses</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_968a2940ddfb417b96f434591d819fa31" continuedAt="Text_968a2940ddfb417b96f434591d819fa32">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_968a2940ddfb417b96f434591d819fa32" continuedAt="Text_968a2940ddfb417b96f434591d819fa33"><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Text_7d93a6d21dd346b99df188153b132581" contextRef="c20210101to20211231" escape="true" continuedAt="Text_d4d3f676084f481a98b7481318f0e82a1">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Accrued expenses consisted of the following:</div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_968a2940ddfb417b96f434591d819fa33" continuedAt="Text_968a2940ddfb417b96f434591d819fa34"><ix:continuation id="Text_d4d3f676084f481a98b7481318f0e82a1" continuedAt="Text_d4d3f676084f481a98b7481318f0e82a2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_968a2940ddfb417b96f434591d819fa34"><ix:continuation id="Text_d4d3f676084f481a98b7481318f0e82a2">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2021<br />
              </div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2020</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Accrued compensation</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_b1f496e6f81e4e4a89e2dc997a2ced07" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">656,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_1b3f4d5e995741938d8dc724b5c0cad6" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">294,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="color: rgb(0, 0, 0);">Accrued research and development expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:AccruedResearchAndDevelopmentExpenses" id="Fact_6f696b6c42b74f409af47c46519b4c2f" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">222,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:AccruedResearchAndDevelopmentExpenses" id="Fact_50a9411f811e41c6b4a3fd7891a4466e" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">207,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Accrued general and administrative expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:AccruedGeneralAndAdministrativeExpenses" id="Fact_92c2cb4afd1a41c4b5cc318551d9c2fb" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">371,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:AccruedGeneralAndAdministrativeExpenses" id="Fact_934cb73f3a554614a3c319faa2d6c84f" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">400,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">Accrued interest</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:InterestPayableCurrent" id="Fact_01f0bce81d7147168c00e827fc5d3f65" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:InterestPayableCurrent" id="Fact_c7b956167b9b475abc1297117da8e831" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">150,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Total accrued expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_ae35c715a4564728b033530311f71803" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,249,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_5d16ea13a8514c81a94fcaa3f2171ed5" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,051,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
        </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div> <br />
      </div>


      <ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" id="Text_e0a9604a8f0746a2a82ba18894737c70" contextRef="c20210101to20211231" escape="true" continuedAt="Text_95c9161709d6434c8d2f3e730f90c1841">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">10)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Debt</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <div>
        <ix:continuation id="Text_95c9161709d6434c8d2f3e730f90c1841" continuedAt="Text_95c9161709d6434c8d2f3e730f90c1842">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_95c9161709d6434c8d2f3e730f90c1842" continuedAt="Text_95c9161709d6434c8d2f3e730f90c1843">
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Loans Payable</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_95c9161709d6434c8d2f3e730f90c1843" continuedAt="Text_95c9161709d6434c8d2f3e730f90c1844">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_95c9161709d6434c8d2f3e730f90c1844" continuedAt="Text_95c9161709d6434c8d2f3e730f90c1845">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In connection with the IRX Acquisition in 2018, Brooklyn LLC assumed certain notes payable (the &#8220;IRX Notes&#8221;) in the amount of $<ix:nonFraction name="us-gaap:LoansPayableCurrent" id="Fact_38deea82d13d4a0d9e42a7d5d5316f1a" contextRef="c20181231_DebtInstrumentAxis_PaycheckProtectionProgramLoanMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">410,000</ix:nonFraction>. On January 27, 2020, the IRX Notes were amended to extend the maturity date to the earlier of (i) a change of control, as defined in the IRX
          Notes, and (ii) December 31, 2021. On December 31, 2021, the Company paid the outstanding $<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" id="Fact_077a2c37abeb4b1e9a9c3200655b98ab" contextRef="c20210101to20211231_DebtInstrumentAxis_PaycheckProtectionProgramLoanMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">410,000</ix:nonFraction> in principal plus accrued and unpaid
          interest of approximately $<ix:nonFraction name="btx:PaymentOfAccruedAndUnpaidInterest" id="Fact_26dbcfc566464eaca28ca2415fd5530c" contextRef="c20210101to20211231_DebtInstrumentAxis_PaycheckProtectionProgramLoanMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">210,000</ix:nonFraction> under the IRX Notes, and the Company has <ix:nonFraction name="us-gaap:LoansPayableCurrent" id="Fact_833bc4650cc143fb971ebe385944ede7" contextRef="c20211231_DebtInstrumentAxis_PaycheckProtectionProgramLoanMember" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> further obligations thereunder.</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_95c9161709d6434c8d2f3e730f90c1845" continuedAt="Text_95c9161709d6434c8d2f3e730f90c1846">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_95c9161709d6434c8d2f3e730f90c1846" continuedAt="Text_95c9161709d6434c8d2f3e730f90c1847">
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Payment Protection Program Loan</div>
</ix:continuation>
        <ix:continuation id="Text_95c9161709d6434c8d2f3e730f90c1847" continuedAt="Text_95c9161709d6434c8d2f3e730f90c1848">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_95c9161709d6434c8d2f3e730f90c1848" continuedAt="Text_95c9161709d6434c8d2f3e730f90c1849">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Brooklyn LLC PPP Loan.</span></div>
</ix:continuation>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-20</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

      <div><ix:continuation id="Text_95c9161709d6434c8d2f3e730f90c1849" continuedAt="Text_95c9161709d6434c8d2f3e730f90c18410">
<div><br /></div>
</ix:continuation>
        <ix:continuation id="Text_95c9161709d6434c8d2f3e730f90c18410" continuedAt="Text_95c9161709d6434c8d2f3e730f90c18411">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On May 4, 2020, Brooklyn LLC issued a note in the principal amount of approximately $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_1f5acd51e9d64d9f99a17cee027e3fc5" contextRef="c20200504_DebtInstrumentAxis_PaycheckProtectionProgramMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">310,000</ix:nonFraction> to Silicon Valley Bank evidencing a loan (the &#8220;Brooklyn LLC PPP Loan&#8221;) Brooklyn LLC received under the Paycheck Protection Program (the &#8220;PPP&#8221;) of the Coronavirus Aid, Relief, and
          Economic Security Act administered by the U.S. Small Business Administration (the &#8220;CARES Act&#8221;). Brooklyn LLC PPP Loan incurred interest at a rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_300a27c149334a7fbbb3e0d4f4f71832" contextRef="c20200504_DebtInstrumentAxis_PaycheckProtectionProgramMember" unitRef="U004" decimals="3" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction>%
          per annum.</div>
</ix:continuation>
        <ix:continuation id="Text_95c9161709d6434c8d2f3e730f90c18411" continuedAt="Text_95c9161709d6434c8d2f3e730f90c18412">
<div><br /></div>
</ix:continuation>
        <ix:continuation id="Text_95c9161709d6434c8d2f3e730f90c18412">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the terms of the Cares Act, certain amounts of the Brooklyn LLC PPP Loan could be forgiven if they were used for qualifying expenses, as
          described in the CARES Act. In June 2021, Brooklyn LLC submitted its loan forgiveness application for the Brooklyn LLC PPP Loan, and in September 2021, the lender informed Brooklyn LLC that the U.S Small Business Administration approved the
          forgiveness of 100% of the outstanding principal and interest of the Brooklyn LLC PPP Loan. As of December 31, 2021, there was <ix:nonFraction name="us-gaap:LongTermDebt" id="Fact_f827807a5c344da385b145e1fec68c92" contextRef="c20211231_DebtInstrumentAxis_PaycheckProtectionProgramMember" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction>
          outstanding principal balance of the Brooklyn LLC PPP Loan.</div>
</ix:continuation>
      </div>

      <div>  </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Text_f4231dc08ddd4c96a95d47ca8a681279" contextRef="c20210101to20211231" escape="true" continuedAt="Text_5d224fe5eeb847888200e056309ef48b1">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">11)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Commitments and Contingencies</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b1" continuedAt="Text_5d224fe5eeb847888200e056309ef48b2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b2" continuedAt="Text_5d224fe5eeb847888200e056309ef48b3">
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Legal Matters</div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b3" continuedAt="Text_5d224fe5eeb847888200e056309ef48b4">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b4" continuedAt="Text_5d224fe5eeb847888200e056309ef48b5">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company is involved in litigation and arbitrations from time to time in the ordinary course of business. Legal fees and other costs associated
        with such actions are expensed as incurred. In addition, the Company assesses the need to record a liability for litigation and contingencies. The Company reserves for costs relating to these matters when a loss is probable, and the amount can be
        reasonably estimated.</div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b5" continuedAt="Text_5d224fe5eeb847888200e056309ef48b6">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b6" continuedAt="Text_5d224fe5eeb847888200e056309ef48b7">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Merger-Related Shareholder Litigation</span></div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b7" continuedAt="Text_5d224fe5eeb847888200e056309ef48b8">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b8" continuedAt="Text_5d224fe5eeb847888200e056309ef48b9">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn (then known as NTN Buzztime, Inc.) and its former directors were named as defendants in <ix:nonFraction name="us-gaap:LossContingencyNumberOfDefendants" id="Fact_0b4eadcd5aea40409a62a8aa5167dd5f" contextRef="c20210101to20211231_LegalEntityAxis_NTNBuzztimeIncMember" unitRef="U010" decimals="INF" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction> substantially similar actions arising out of the Merger that were brought by purported pre-Merger stockholders of Brooklyn: Henson v. NTN Buzztime, Inc., et al., No.
        1:20-cv-08663-LGS (S.D.N.Y.); Monsour v. NTN Buzztime, Inc., et al., No. 1:20-cv-08755-LGS (S.D.N.Y.); Amanfo v. NTN Buzztime, Inc., et al., No. 1:20-cv-08747-LGS (S.D.N.Y.); Carlson v. NTN Buzztime, Inc., et al., No. 1:21-cv-00047-LGS (S.D.N.Y.);
        Finger v. NTN Buzztime, Inc., et al., No. 1:21-cv-00728-LGS (S.D.N.Y.); Falikman v. NTN Buzztime, Inc., et al., No. 1:20-cv-05106-EK-SJB (E.D.N.Y.); Haas v. NTN Buzztime, Inc., et al., No. 3:20-cv-02123-BAS-JLB (S.D. Cal.); Gallo v. NTN Buzztime,
        Inc., et al., No. 3:21-cv-00157-WQH-AGS (S.D. Cal.); Chinta v. NTN Buzztime, Inc., et al., No. 1:20-cv-01401-CFC (D. Del.); and Nicosia v. NTN Buzztime, Inc., et al., No. 1:21-cv-00125-CFC (D. Del.) (collectively, the &#8220;Stockholder Actions&#8221;).&#160; Only
        <ix:nonFraction name="us-gaap:LossContingencyNewClaimsFiledNumber" id="Fact_baf27639c704486d8a245d04be7c87be" contextRef="c20210101to20211231_LegalEntityAxis_NTNBuzztimeIncMember" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> of the Stockholder Actions (the Chinta and Nicosia cases) also named Brooklyn.&#160; These actions asserted claims alleging violations of
        Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 14a-9 promulgated thereunder and both the Chinta and Nicosia cases alleged that Brooklyn LLC is a controlling person of Brooklyn.&#160; The complaints generally alleged that
        the defendants failed to disclose allegedly material information in a Form S-4 Registration Statement filed on October 2, 2020, including:&#160; (1) certain details regarding any projections or forecasts of Brooklyn or Brooklyn LLC may have made, and
        the analyses performed by Brooklyn&#8217;s financial advisor, Newbridge Securities Corporation; (2) conflicts concerning the sales process; and (3) disclosures regarding whether or not Brooklyn entered into any confidentiality agreements with standstill
        and/or &#8220;don&#8217;t ask, don&#8217;t waive&#8221; provisions.&#160; The complaints generally alleged that these purported failures to disclose rendered the Form S-4 false and misleading.&#160; The complaints requested: preliminary and permanent injunction of the Merger;
        rescission of the Merger if executed and/or rescissory damages in unspecified amounts; direction to the individual directors to disseminate a compliant Form S-4; an accounting by Brooklyn for all alleged damages suffered; a declaration that certain
        federal securities laws had been violated; and reimbursement of costs, including attorneys&#8217; and expert fees and expenses.&#160; On or about February 26, 2021, in order to moot certain of the disclosure claims asserted in the Stockholder Actions, to
        avoid nuisance, potential expense, and delay, and to provide additional information to Brooklyn&#8217;s stockholders, Brooklyn determined to voluntarily supplement the Form S-4 with certain additional disclosures.&#160; In exchange for those disclosures, the
        plaintiffs in each of the Stockholder Actions agreed to voluntarily dismiss their claims.&#160; All ten actions have now been dismissed.&#160; Following the dismissal the parties amicably resolved plaintiffs&#8217; counsel&#8217;s request for an award of attorneys&#8217; fees
        and expenses based on the purported benefit contented to be conferred on Brooklyn&#8217;s stockholders as a result of the supplemental disclosures.</div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b9" continuedAt="Text_5d224fe5eeb847888200e056309ef48b10">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-21</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>

      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b10" continuedAt="Text_5d224fe5eeb847888200e056309ef48b11">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Dhesh Govender v. Brooklyn Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021)</span></div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b11" continuedAt="Text_5d224fe5eeb847888200e056309ef48b12">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b12" continuedAt="Text_5d224fe5eeb847888200e056309ef48b13">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">On or about February 5, 2021, Dhesh Govender, a former short-term consultant of Brooklyn LLC, filed a complaint against Brooklyn
            LLC and certain individuals that plaintiff alleges were directors of Brooklyn LLC. The complaint is captioned, Dhesh Govender v. Brooklyn Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021). Plaintiff alleges
            that Brooklyn LLC and certain of its officers and directors (&#8220;defendants&#8221;) engaged in unlawful and discriminatory conduct based on race, national origin and hostile work environment. Plaintiff also asserts various breach of contract, fraud and
            quantum meruit claims based on an alleged oral agreement pursuant to which he alleges Brooklyn LLC agreed to hire him as an executive once the Merger was completed. In particular, plaintiff alleges that, in exchange for transferring an
            opportunity to obtain an agreement to acquire a license from Novellus for its mRNA-based gene editing and cell reprogramming technology to Brooklyn LLC, he was promised a $<ix:nonFraction name="btx:LossContingencyDamagesSoughtExpectedSalary" id="Fact_49b85533110144d58a40969c7faec51a" contextRef="c20210205to20210205_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">500,000</ix:nonFraction> salary and <ix:nonFraction name="btx:LossContingencyDamagesSoughtExpectedEquityPercentage" id="Fact_243af90267a24dabb448dd1d64e3a0c4" contextRef="c20210205to20210205_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>% of the equity of Brooklyn LLC.&#160; Based on these and
            other allegations, plaintiff seeks damages of not less than $<ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" id="Fact_573de681b8644f37975ff0511a46aba6" contextRef="c20210205to20210205_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million, a permanent injunction enjoining Brooklyn LLC from
            exercising the option to acquire such license from Novellus or completing the proposed Merger. On or about February 19, 2021, an amended complaint was filed asserting the same causes of action but withdrawing the request for injunctive relief.
            On June 6, 2021, defendants filed a motion to compel arbitration or, in the alternative, for partial dismissal of the complaint for failure to state viable fraud, quantum meruit and employment discrimination claims. After obtaining extensions
            of time to respond, plaintiff opposed the defendants&#8217; motion on August 9, 2021. The defendants filed their reply on September 3, 2021. The Court heard oral argument on the motion to compel arbitration and/or dismiss and the motion to seal on
            October 13, 2021. By Order dated November 10, 2021, the Court granted defendants&#8217; motion to compel Govender to arbitrate all of his claims against them, based on the arbitration clause of his consulting agreement with Brooklyn LLC.&#160; Govender
            thereafter filed his Statement of Claim (the &#8220;Demand&#8221;) with the American Arbitration Association (&#8220;AAA&#8221;), Case No. 01-21-0017-9417, on December 15, 2021 against the same defendants, and served it on defendants&#8217; counsel on February 3, 2022.&#160; In
            his Demand, Govender continues to assert statutory discrimination claims against all defendants, claims against Brooklyn LLC premised on the breach of an alleged oral promise to issue Govender<span style="font-family: 'Times New Roman',serif; font-size: 10pt;"> <ix:nonFraction name="btx:LossContingencyDamagesSoughtExpectedEquityPercentage" id="Fact_90c6809196de4f42829468819ea8c915" contextRef="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>% of the equity of Brooklyn LLC and to employ Govender at a $<ix:nonFraction name="btx:LossContingencyDamagesSoughtExpectedSalary" id="Fact_cd40a3b8983e4dd8820f789d7dbb6d4a" contextRef="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">500,000</ix:nonFraction></span> annual salary in exchange for allegedly arranging and negotiating the Novellus license, common law fraud claims against Brooklyn LLC and Cherington based
            on the breach of these same promises and a claim for quantum meruit against the Brooklyn LLC.&#160; In his Demand, Govender now claims that the fair and reasonable value of his services on the quantum meruit claim exceeded<span style="font-family: 'Times New Roman',serif; font-size: 10pt;"> $<ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" id="Fact_977c357d0ce7444a81107a7338e4e56f" contextRef="c20211215to20211215_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction> million</span> and is seeking damages in an amount to be determined at the
            hearing.&#160; Defendants filed an answering statement to the Demand on February 28, 2022 and the parties are in the process of conferring on the selection of a<span style="font-family: 'Times New Roman',serif; font-size: 10pt;"> <ix:nonFraction name="btx:LossContingencyNumberOfArbitrationPanel" id="Fact_f561abfd578549cda233e4209db3a649" contextRef="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction>-member arbitration panel.</span> Defendants intend to vigorously defend themselves against these claims. At this stage in the litigation,
            the Company is not able to predict the probability of a favorable or unfavorable outcome.</div>
</ix:continuation>
        </div>

      </div>

      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b13" continuedAt="Text_5d224fe5eeb847888200e056309ef48b14">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b14" continuedAt="Text_5d224fe5eeb847888200e056309ef48b15">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Carlson v. Allen Wolff, Michael Gottlieb, Richard Simtob, Susan Miller, and NTN Buzztime, Inc., C.A. No. 2021-0193-KSJM (Del. Ch. Ct.)</span></div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b15" continuedAt="Text_5d224fe5eeb847888200e056309ef48b16">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b16" continuedAt="Text_5d224fe5eeb847888200e056309ef48b17">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">On or about March 12, 2021, Douglas Carlson, a purported stockholder of Brooklyn (then known as NTN Buzztime, Inc.), filed a verified class
            action complaint against Brooklyn and its then current members of the board of directors, for allegedly breaching their fiduciary duties and violating Section 211(c) of the Delaware General Corporation Law.&#160; In particular, plaintiff seeks to
            compel the defendants to hold an annual stockholder meeting.&#160; Plaintiff also moved for summary judgment at the same time that he filed his complaint.&#160; In order to moot the claim addressed in the complaint, Brooklyn agreed to hold its annual
            meeting on June 29, 2021, which date was subsequently rescheduled to August 20, 2021.&#160; On or about May 6, 2021, the parties entered into a stipulation, which was &#8220;so ordered&#8221; by the court, extending defendants&#8217; time to respond to the complaint
            and to file their answering brief in opposition to plaintiff&#8217;s motion for summary judgment on or before July 16, 2021 and providing that plaintiff&#8217;s reply brief in support of his motion for summary judgment is due on or before August 20, 2021.
            On or about July 12, 2021, the parties entered in a further amended scheduling order, which provided that defendants were to respond to the complaint and file their answering brief in opposition to plaintiff&#8217;s motion for summary judgment on or
            before September 16, 2021 and plaintiff was to file its reply brief in support of his motion for summary judgment on or before October 20, 2021.&#160; On August 20, 2021, Brooklyn convened its 2021 annual meeting. Due to the lack of a required
            quorum, the meeting was adjourned to September 3, 2021. Thereafter, Brooklyn obtained a quorum, and the annual meeting was held on September 3, 2021. On September 10, 2021, Brooklyn filed a report on Form 8-K with the SEC announcing the results
            of the annual meeting. On September 16, 2021, the parties filed a stipulation seeking voluntary dismissal of the complaint as moot. The Court entered the dismissal on September 16, 2021 with prejudice as to the named plaintiff and without
            prejudice as to other members of the purported class and retained jurisdiction for the purpose of determining any fee application to the extent it cannot be resolved amicably the parties. <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">Thereafter, on or about November 12, 2022, the parties resolved plaintiff&#8217;s counsel&#8217;s request for an award of fees and expenses for the purported benefit that Carlson contended was received by stockholders as a result of his
              action.&#160; </span></div>
</ix:continuation>
          <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b17" continuedAt="Text_5d224fe5eeb847888200e056309ef48b18">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"><span style="font-family: 'Times New Roman', serif; font-size: 10pt;"> <br />
            </span></div>
</ix:continuation>
        </div>

      </div>

      <div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-22</span></div>

          <div style="page-break-after: always;" class="DSPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b18" continuedAt="Text_5d224fe5eeb847888200e056309ef48b19">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Robert Garfield Matter</span></div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b19" continuedAt="Text_5d224fe5eeb847888200e056309ef48b20">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
          <div>
            <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b20" continuedAt="Text_5d224fe5eeb847888200e056309ef48b21">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">On April 29, 2021, Robert Garfield, a purported stockholder of Brooklyn, sent to Brooklyn a demand letter that had purportedly been sent
              to Brooklyn (then known as NTN Buzztime, Inc.) on or about March 16, 2021. The demand letter asserts that, Brooklyn (then known as NTN Buzztime, Inc.) made material misstatements in a prospectus issued in seeking a stockholder vote on March
              15, 2021 with respect to an amendment to Brooklyn&#8217;s certificate of incorporation to increase the number of authorized shares from <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_3a16c8397a2347acbb74089cdb53099a" contextRef="c20210315_LegalEntityAxis_NTNBuzztimeIncMember_RelatedPartyTransactionsByRelatedPartyAxis_RobertGarfieldMember" unitRef="U002" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction>
              million to <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_07b1dcb843f64085b221823fd1760a88" contextRef="c20210316_LegalEntityAxis_NTNBuzztimeIncMember_RelatedPartyTransactionsByRelatedPartyAxis_RobertGarfieldMember" unitRef="U002" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction> million. The demand letter seeks to have Brooklyn deem the amendment to the certificate of incorporation
              ineffective or seek valid stockholder approval of such amendment and for Brooklyn to implement internal controls.</div>
</ix:continuation>
          </div>

        </div>

        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b21" continuedAt="Text_5d224fe5eeb847888200e056309ef48b22">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
          <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">
            <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b22" continuedAt="Text_5d224fe5eeb847888200e056309ef48b23">
<div style="text-align: justify;"><span style="font-family: 'Times New Roman',serif; font-size: 1pt;">&#160;</span><span style="font-family: 'Times New Roman',serif; font-size: 10pt;">Brooklyn decided to seek stockholder ratification of the March
                15, 2021 stockholder vote concerning an amendment to Brooklyn&#8217;s certificate of incorporation to increase the number of authorized shares from</span> <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_c096b9846f6b49afbdafb6ff52839f5e" contextRef="c20210315_LegalEntityAxis_NTNBuzztimeIncMember_RelatedPartyTransactionsByRelatedPartyAxis_RobertGarfieldMember" unitRef="U002" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction> million to <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_2d2fb5f5e49d4a31979aef45d480a8ae" contextRef="c20210316_LegalEntityAxis_NTNBuzztimeIncMember_RelatedPartyTransactionsByRelatedPartyAxis_RobertGarfieldMember" unitRef="U002" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction> million<span style="font-family: 'Times New Roman',serif; font-size: 10pt;"> pursuant to Sections 204 of the Delaware General Corporation Law. &#160;Stockholder ratification was obtained at the annual meeting of stockholders that took place on September 3, 2021. As a result of the
                ratification, Garfield advised that the claims set forth in his demand letter were moot. The parties thereafter resolved Garfield&#8217;s counsel&#8217;s request for an award of attorney&#8217;s fees and expenses for the purported benefit that Garfield
                contented was received by stockholders as a result of the stockholder ratification.</span> </div>
</ix:continuation>
            <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b23" continuedAt="Text_5d224fe5eeb847888200e056309ef48b24">
<div><br />
            </div>
</ix:continuation>
          </div>

        </div>

      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b24" continuedAt="Text_5d224fe5eeb847888200e056309ef48b25">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Edmund Truell Matter</span></div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b25" continuedAt="Text_5d224fe5eeb847888200e056309ef48b26">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b26" continuedAt="Text_5d224fe5eeb847888200e056309ef48b27">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On May 14, 2021, Edmund Truell, a stockholder of Brooklyn, alleged that he sustained a loss because he was unable to sell shares of common stock
          timely due to a delay caused by Brooklyn&#8217;s issuance of stock certificates in lieu of electronic book entry.</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b27" continuedAt="Text_5d224fe5eeb847888200e056309ef48b28">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b28" continuedAt="Text_5d224fe5eeb847888200e056309ef48b29">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Emerald Private Equity Fund, LLC Matter</span></div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b29" continuedAt="Text_5d224fe5eeb847888200e056309ef48b30">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
          <div>
            <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b30" continuedAt="Text_5d224fe5eeb847888200e056309ef48b31">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">By a letter dated July 7, 2021, Emerald Private Equity Fund, LLC (&#8220;Emerald&#8221;), a stockholder of Brooklyn, made a demand pursuant to 8 Del.
              C. 220 to inspect certain books and records of Brooklyn. The stated purpose of the demand is to investigate possible wrongdoing by persons responsible for the implementation of the Merger and the issuance of paper stock certificates,
              including investigating&#160; whether: (i) Brooklyn&#8217;s stock certificates were issued in accordance with the Merger Agreement; (ii) certain restrictions on the sale of Brooklyn common stock following the Merger were proper and applied without
              favor; (iii) anyone received priority in post-Merger issuances of Brooklyn&#8217;s stock certificates that allowed them to benefit from an increase in the trading price of Brooklyn&#8217;s common stock; and (iv) it should pursue remedial measures and/or
              report alleged misconduct to the SEC. Brooklyn has responded to the demand letter and has produced certain information to Emerald in connection with the demand, which is subject to the terms of a confidentiality agreement entered into among
              the parties, including certain additional stockholders who have subsequently joined as parties to such agreement (including Truell noted above).&#160; In October 2021, Emerald requested that Brooklyn produce additional information related to the
              authority, purpose and justification for the restriction imposed on the sale of Brooklyn common stock following the Merger and the timing of share delivery to Brooklyn stockholders, following which request Brooklyn agreed to produce certain
              additional information and emails relating to these topics.<br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b31" continuedAt="Text_5d224fe5eeb847888200e056309ef48b32">
<div><br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b32" continuedAt="Text_5d224fe5eeb847888200e056309ef48b33">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">On March 30, 2022, counsel to Emerald advised the Company that it was prepared to file suit against the Company, certain current and
              former directors of the Company, and the Company&#8217;s financial advisor in connection with the Merger, on behalf of Emerald and a class of similarly situated stockholders with respect to some or all of the foregoing matters, alleging claims for
              breach of fiduciary duty, conversion and aiding and abetting breach of fiduciary duty.&#160; Emerald&#8217;s counsel has expressed a willingness to engage in private pre-suit early resolution discussions with the Company and its financial advisor on
              behalf of individual stockholders whom counsel represents in addition to Emerald; and the Company has agreed to respond to Emerald&#8217;s counsel by April 22, 2022.&#160; The Company can provide no assurance that such pre-suit early resolution
              discussions will be successful or that suit will not ultimately be filed against the Company, nor can the Company currently predict the outcome of any such suit, if filed.&#160; The Company intends to defend itself vigorously against any and all
              claims.&#160; Additionally, on April 7, 2022, the Company received a demand for indemnification from its financial advisor as it relates to the aforementioned potential lawsuit.</div>
</ix:continuation>
          </div>

        </div>

      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b33" continuedAt="Text_5d224fe5eeb847888200e056309ef48b34">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b34" continuedAt="Text_5d224fe5eeb847888200e056309ef48b35">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">John Westman v. Novellus, Inc., Christopher Rohde, and Matthew Angel, Civil Action No. 2181CV01949 (Middlesex County (Massachusetts) Superior
            Court)</span></div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b35" continuedAt="Text_5d224fe5eeb847888200e056309ef48b36">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b36" continuedAt="Text_5d224fe5eeb847888200e056309ef48b37">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">On or about September 7, 2021, John Westman, a former employee of Novellus, Inc. filed a Complaint in Middlesex County (Massachusetts)
            Superior Court against Novellus, Inc. and the company&#8217;s founders and former executives, Christopher Rohde and Matthew Angel (collectively, &#8220;Defendants&#8221;).&#160; Brooklyn acquired Novellus, Inc. on July 16, 2021.&#160; Mr. Westman&#8217;s claims relate to
            alleged conduct that took place before Brooklyn acquired Novellus, Inc.&#160; Pursuant to the July 16, 2021 Agreement and Plan of Acquisition, as well as a separate agreement among Brooklyn, Novellus, Inc., Mr. Rohde, and Mr. Angel, Mr. Rohde and
            Mr. Angel are essentially assuming the defense of and paying the fees associated with defending against these claims.&#160; To that end, on September 10, 2021, Morgan Lewis accepted service on behalf of all defendants. On December 24, 2021, Westman
            dismissed the case without prejudice so the parties could mediate the matter. The parties&#8217; February 2022 mediation was unsuccessful, but Mr. Westman has not refiled suit.</div>
</ix:continuation>
        </div>

      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b37" continuedAt="Text_5d224fe5eeb847888200e056309ef48b38">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-23</span></div>

          <div style="page-break-after: always;" class="DSPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b38" continuedAt="Text_5d224fe5eeb847888200e056309ef48b39">
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Licensing Agreements</div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b39" continuedAt="Text_5d224fe5eeb847888200e056309ef48b40">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b40" continuedAt="Text_5d224fe5eeb847888200e056309ef48b41">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">USF</span></div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b41" continuedAt="Text_5d224fe5eeb847888200e056309ef48b42">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b42" continuedAt="Text_5d224fe5eeb847888200e056309ef48b43">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn LLC has license agreements with University of South Florida Research Association, Inc. (&#8220;USF&#8221;), granting Brooklyn LLC the right to
          sell, market, and distribute IRX-2, subject to a <ix:nonFraction name="btx:LossContingencyPercentageOfRoyaltyPayable" id="Fact_784b26e89e4e4ee6bb4f0e16c18e530a" contextRef="c20210101to20211231_LegalEntityAxis_UniversityOfSouthFloridaMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>% royalty payable to USF based on a percentage of gross product sales. Under the
          license agreement with USF, Brooklyn LLC is obligated to repay patent prosecution expenses incurred by USF. To date, Brooklyn LLC has not recorded any product sales, or obligations related to USF patent prosecution expenses. The license agreement
          terminates upon the expiration of the IRX-2 patents.</div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b43" continuedAt="Text_5d224fe5eeb847888200e056309ef48b44">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;"> <br />
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b44" continuedAt="Text_5d224fe5eeb847888200e056309ef48b45">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Novellus, Ltd. and Factor</span></div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b45" continuedAt="Text_5d224fe5eeb847888200e056309ef48b46">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b46" continuedAt="Text_5d224fe5eeb847888200e056309ef48b47">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In December 2020, Brooklyn LLC entered into option agreements (the &#8220;Option Agreements&#8221;) with Novellus, Ltd. and Factor (together, the
          &#8220;Licensors&#8221;) to obtain the right to exclusively license the Licensors&#8217; intellectual property and mRNA cell reprogramming and gene editing technology for use in the development of certain cell-based therapies to be evaluated and developed for
          treating human diseases, including certain types of cancer, sickle cell disease, and beta thalassemia (the &#8220;Licensed Technology&#8221;). The option was exercisable before February 28, 2021 (or April 30, 2021 if the Merger had not closed by that date)
          and required Brooklyn LLC to pay a non-refundable option fee of $<ix:nonFraction name="btx:LossContingencyNonRefundableOptionFee" id="Fact_86c044aab7c844e6ba5c7c6a5d66083a" contextRef="c20210413to20210413_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">500,000</ix:nonFraction> and then an initial license fee of $<ix:nonFraction name="btx:InitialLicenseFees" id="Fact_84dde60bcdaa42aeabef305e291df51c" contextRef="c20210430to20210430_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">4,000,000</ix:nonFraction> (including the non-refundable fee of $<ix:nonFraction name="btx:LossContingencyNonRefundableOptionFee" id="Fact_8fd4f38edc85491db937cf1408147f60" contextRef="c20210413to20210413_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">500,000</ix:nonFraction>)
          in order to exercise the option.</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b47" continuedAt="Text_5d224fe5eeb847888200e056309ef48b48">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b48" continuedAt="Text_5d224fe5eeb847888200e056309ef48b49">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In April 2021, Brooklyn LLC and the Licensors amended the Option Agreements to extend the exercise period to May 21, 2021 and to require
          Brooklyn, LLC to pay a total $<ix:nonFraction name="btx:AdditionalFeesObligatedToPay" id="Fact_214b5176969f4e50a08d6135fb6dfae3" contextRef="c20210415to20210415_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction> of the $<ix:nonFraction name="btx:AmountRequireToPayInitialLicenseFees" id="Fact_7acb7f51ddc74a1ba3812a028ba34225" contextRef="c20210426_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">4,000,000</ix:nonFraction> initial license fees to the Licensors by April 15, 2021.</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b49" continuedAt="Text_5d224fe5eeb847888200e056309ef48b50">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b50" continuedAt="Text_5d224fe5eeb847888200e056309ef48b51">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In April 2021, Brooklyn LLC and the Licensors entered into an exclusive license agreement (the &#8220;License Agreement&#8221;) pursuant to which Brooklyn
          LLC acquired an exclusive worldwide license to the Licensed Technology.&#160; Under the terms of the License Agreement, Brooklyn LLC is obligated to pay the Licensors a total of $<ix:nonFraction name="btx:AmountRequireToPayInitialLicenseFees" id="Fact_ce3aef6987d444f5b2d004ec03a0de25" contextRef="c20210426_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">4,000,000</ix:nonFraction> in connection with the execution of the License Agreement, all of which had been paid as of June 30, 2021.</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b51" continuedAt="Text_5d224fe5eeb847888200e056309ef48b52">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b52" continuedAt="Text_5d224fe5eeb847888200e056309ef48b53">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The completion of the acquisition of Novellus, Ltd. relieved Brooklyn LLC from potential obligations to pay Novellus, Ltd. certain upfront fees,
          clinical development milestone fees and post-registration royalties under the License Agreement. The agreement with Factor under the License Agreement, which grants Brooklyn LLC exclusive rights to develop certain next-generation mRNA gene
          editing and cell therapy products, remained unchanged. Accordingly, Brooklyn LLC is obligated to pay to Factor a fee of $<ix:nonFraction name="btx:AmountObligatedToPayInYearTwo" id="Fact_c4ee036402964dca94f65c93462cfe8a" contextRef="c20221031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember_StatementScenarioAxis_ScenarioForecastMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">3,500,000</ix:nonFraction> in
          October 2022, which will be in addition to a fee of $<ix:nonFraction name="btx:AmountObligatedToPayInYearOne" id="Fact_a3b2f6b853b64fb8803deffcbe489c76" contextRef="c20211031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">2,500,000</ix:nonFraction> paid to Factor in October 2021.</div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b53" continuedAt="Text_5d224fe5eeb847888200e056309ef48b54">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b54" continuedAt="Text_5d224fe5eeb847888200e056309ef48b55">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn LLC is also required to use commercially reasonably efforts to achieve certain delineated milestones, including specified clinical
          development and regulatory milestones and specified commercialization milestones. In general, upon its achievement of these milestones, Brooklyn LLC will be obligated to pay, in the case of development and regulatory milestones, milestone
          payments to the Licensors in specified amounts and, in the case of commercialization milestones, specified royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers. In the event Brooklyn LLC fails to timely
          achieve certain delineated milestones, the Licensors will have the right to terminate Brooklyn LLC&#8217;s rights under provisions of the License Agreement relating to those milestones.</div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b55" continuedAt="Text_5d224fe5eeb847888200e056309ef48b56">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b56" continuedAt="Text_5d224fe5eeb847888200e056309ef48b57">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Novellus, Ltd. also has a license agreement with Factor, which was entered into in February 2015, amended in June 2018 and March 2020, and then
          amended and restated in November 2020.&#160; This license agreement provides for Novellus, Ltd. to use over <ix:nonFraction name="btx:MinimumNumberOfPatentGranted" id="Fact_39b418ecdd77401d9b3bf836f066cfd0" contextRef="c20210101to20211231_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U011" decimals="0" scale="0" format="ixt:numdotdecimal">70</ix:nonFraction> granted patents owned by
          Factor throughout the world covering synthetic mRNA, RNA-based gene editing, and RNA-based cell reprogramming, in addition to specific patents covering methods for treating specific diseases. There are also more than <ix:nonFraction name="btx:MinimumNumberOfPendingPatents" id="Fact_7b9c77fe840a4f1dba541bbbd510a00c" contextRef="c20210101to20211231_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember" unitRef="U011" decimals="0" scale="0" format="ixt:numdotdecimal">60</ix:nonFraction> pending patent applications throughout the world focused on these and other aspects of the technology. The patent coverage includes granted patents
          and pending patent applications in the United States, Europe, and Japan, along with other major life sciences markets.</div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b57" continuedAt="Text_5d224fe5eeb847888200e056309ef48b58">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-24</span></div>

          <div style="page-break-after: always;" class="DSPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b58" continuedAt="Text_5d224fe5eeb847888200e056309ef48b59">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Novellus, Ltd. is required to use commercially reasonably efforts to achieve certain delineated milestones, including specified clinical
          development and regulatory milestones and specified commercialization milestones. In general, upon its achievement of these milestones, Novellus, Ltd. will be obligated, in the case of development and regulatory milestones, to make milestone
          payments of up to $<ix:nonFraction name="btx:MilestonePayments" id="Fact_ec51d963df074da69282f8416ac40bd2" contextRef="c20210101to20211231_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction> million in aggregate to Factor and, in the case of commercialization milestones, specified royalties with respect
          to product sales, sublicense fees or sales of pediatric review vouchers. In the event Novellus, Ltd. fails to timely achieve certain delineated milestones, Factor may have the right to terminate Novellus, Ltd.&#8217;s rights under provisions of the
          License Agreement relating to those milestones.</div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b59" continuedAt="Text_5d224fe5eeb847888200e056309ef48b60">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b60" continuedAt="Text_5d224fe5eeb847888200e056309ef48b61">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">NoveCite</span></div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b61" continuedAt="Text_5d224fe5eeb847888200e056309ef48b62">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b62" continuedAt="Text_5d224fe5eeb847888200e056309ef48b63">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In October 2020, Novellus, Ltd. (as sublicensor) and NoveCite (as sublicensee) entered into an exclusive license agreement (the &#8220;Sublicense&#8221;) to
          license novel cellular therapy for acute respiratory distress syndrome, which NoveCite is licensing from Factor. Under the sublicense agreement, NoveCite is required to use commercially reasonably efforts to achieve certain delineated milestones,
          including specified clinical development and regulatory milestones and specified commercialization milestones. In general, upon its achievement of these milestones, NoveCite will be obligated, in the case of development and regulatory milestones,
          to make milestone payments to the Novellus, Ltd. in specified amounts and, in the case of commercialization milestones, specified royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers.</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b63" continuedAt="Text_5d224fe5eeb847888200e056309ef48b64">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b64" continuedAt="Text_5d224fe5eeb847888200e056309ef48b65">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the terms of the Sublicense, in the event that Novellus, Ltd. receives any revenue involving the original cell line included in the
          licensed technology, then Novellus, Ltd. shall remit to NoveCite <ix:nonFraction name="btx:PercentageOfRevenue" id="Fact_f4c9ec17fd484c26a47dd6a6bcab77b4" contextRef="c20211231_RelatedPartyTransactionsByRelatedPartyAxis_NoveCiteMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>% of such revenue.</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b65" continuedAt="Text_5d224fe5eeb847888200e056309ef48b66">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b66" continuedAt="Text_5d224fe5eeb847888200e056309ef48b67">
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Royalty Agreements</div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b67" continuedAt="Text_5d224fe5eeb847888200e056309ef48b68">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b68" continuedAt="Text_5d224fe5eeb847888200e056309ef48b69">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Collaborator Royalty Agreement</span></div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b69" continuedAt="Text_5d224fe5eeb847888200e056309ef48b70">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b70" continuedAt="Text_5d224fe5eeb847888200e056309ef48b71">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Effective June 22, 2018, IRX terminated its Research, Development and Option Facilitation Agreement and its Options Agreement (the &#8220;RDO and
        Options Agreements&#8221;) with a collaborative partner (the &#8220;Collaborator&#8221;), pursuant to a termination agreement (the &#8220;Termination Agreement&#8221;). The Termination Agreement was assigned to Brooklyn, LLC in November 2018 when Brooklyn LLC acquired the
        assets of IRX. In connection with the Termination Agreement, all of the rights granted to the Collaborator under the RDO and Options Agreements were terminated, and Brooklyn LLC has no obligation to refund any payments received from the
        Collaborator. As consideration for entering into the Termination Agreement, the Collaborator will receive a royalty equal to <ix:nonFraction name="btx:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" id="Fact_edf47f6512b6439793bb4355914b37dd" contextRef="c20180622to20180622_TypeOfArrangementAxis_CollaboratorRoyaltyAgreementMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>% of
        revenues from the sale of IRX-2, for the period of time beginning with the first sale of IRX-2 through the later of (i) the twelfth anniversary of the first sale of IRX-2 or (ii) the expiration of the last IRX patent, or other exclusivity of IRX-2.</div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b71" continuedAt="Text_5d224fe5eeb847888200e056309ef48b72">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b72" continuedAt="Text_5d224fe5eeb847888200e056309ef48b73">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Investor Royalty Agreement</span></div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b73" continuedAt="Text_5d224fe5eeb847888200e056309ef48b74">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b74" continuedAt="Text_5d224fe5eeb847888200e056309ef48b75">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On March 22, 2021, Brooklyn LLC restated its royalty agreement with certain beneficial holders of Brooklyn ImmunoTherapeutics Investors GP LLC
          and Brooklyn ImmunoTherapeutics Investors LP, whereby such beneficial holders will continue to receive, on an annual basis, royalties in an aggregate amount equal to <ix:nonFraction name="btx:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" id="Fact_68b41008400d4837a779f115649a9748" contextRef="c20210322to20210322_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction>% of the net revenues of IRX-2, a cytokine-based therapy being developed by Brooklyn LLC to treat patients with cancer.</div>
</ix:continuation>
        <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b75" continuedAt="Text_5d224fe5eeb847888200e056309ef48b76">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b76" continuedAt="Text_5d224fe5eeb847888200e056309ef48b77">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Royalty Agreement with certain former IRX Therapeutics Investors</span></div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b77" continuedAt="Text_5d224fe5eeb847888200e056309ef48b78">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_5d224fe5eeb847888200e056309ef48b78">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On May 1, 2012, IRX Therapeutics entered into a royalty agreement (the &#8220;IRX Investor Royalty Agreement&#8221;) with certain investors who participated
        in a financing transaction. The IRX Investor Royalty Agreement was assigned to Brooklyn LLC in November 2018 when Brooklyn LLC acquired the assets of IRX. Pursuant to the IRX Investor Royalty Agreement, when Brooklyn LLC becomes obligated to pay
        royalties to USF under the agreement described above under &#8220;Licensing Agreements-USF,&#8221; it will pay an additional royalty of <ix:nonFraction name="btx:PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" id="Fact_3daaf50710d54edaaab558cd6faa1982" contextRef="c20120501to20120501_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% of gross
        sales to an entity organized by the investors who participated in such financing transaction. There are no termination provisions in the IRX Investor Royalty Agreement. Brooklyn LLC has not recognized any revenues to date, and no royalties are due
        pursuant to any of the above-mentioned royalty agreements.</div>
</ix:continuation>
       </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-25</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>


      <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" id="Text_73a0f143ec0e4578abb3a368832ca6c7" contextRef="c20210101to20211231" escape="true" continuedAt="Text_3694f335dade4124a95f9973731f58991">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Basic and Diluted Earnings per Common Share</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_3694f335dade4124a95f9973731f58991" continuedAt="Text_3694f335dade4124a95f9973731f58992">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_3694f335dade4124a95f9973731f58992" continuedAt="Text_3694f335dade4124a95f9973731f58993">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of
        potential common shares.&#160; Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares.&#160; Stock options, restricted stock units (&#8220;RSUs&#8221;), and other convertible
        securities are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury method when their effect is dilutive. <ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Text_a07923affcd647b7ba6eb50b89054ae0" contextRef="c20210101to20211231" escape="true" continuedAt="Text_a2eace2112724b7b8b599d7ceb949f3f1"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The following table shows the amount of stock options,
        RSUs and convertible preferred stock that were excluded from the computation of diluted net loss per common share for the year ended December 31, 2021, as their effect was anti-dilutive:<br />
      </span></ix:nonNumeric></div>
</ix:continuation>
      <ix:continuation id="Text_a2eace2112724b7b8b599d7ceb949f3f1" continuedAt="Text_a2eace2112724b7b8b599d7ceb949f3f2"><ix:continuation id="Text_3694f335dade4124a95f9973731f58993" continuedAt="Text_3694f335dade4124a95f9973731f58994">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_a2eace2112724b7b8b599d7ceb949f3f2"><ix:continuation id="Text_3694f335dade4124a95f9973731f58994" continuedAt="Text_3694f335dade4124a95f9973731f58995">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">
        <table cellspacing="0" cellpadding="0" border="0" style="width: 100%;">


  <tr>

    <td style="width: 84.65%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;"><br />
              </td>

    <td style="width: 0.98%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 13.45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;" colspan="2">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Year ended</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31, 2021<br />
                </div>
              </td>

    <td style="width: 0.92%; vertical-align: bottom; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 84.65%; vertical-align: middle; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Stock options</div>
              </td>

    <td style="width: 0.98%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 1.1%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td style="width: 12.35%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_b5b2226d5198426cbeeaaa7f7cc38510" contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,988,000</ix:nonFraction></div>
              </td>

    <td style="width: 0.92%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 84.65%; vertical-align: middle; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">RSUs</div>
              </td>

    <td style="width: 0.98%; vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 1.1%; vertical-align: bottom; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 12.35%; vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_27487b984ecf4c8990d175a2feb015c2" contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">240,000</ix:nonFraction></div>
              </td>

    <td style="width: 0.92%; vertical-align: bottom; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 84.65%; vertical-align: middle; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Preferred stock converted into common stock</div>
              </td>

    <td style="width: 0.98%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 1.1%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 12.35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_4662ebac7d3444c1b535cb38c37d6768" contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">42,000</ix:nonFraction></div>
              </td>

    <td style="width: 0.92%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 84.65%; vertical-align: middle; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total potential common shares excluded from computation</div>
              </td>

    <td style="width: 0.98%; vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 1.1%; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td style="width: 12.35%; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_46d9b8182d5d4b80b03fd8f41e302ce3" contextRef="c20210101to20211231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">4,270,000</ix:nonFraction></div>
              </td>

    <td style="width: 0.92%; vertical-align: bottom; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

  </tr>


</table>

      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_3694f335dade4124a95f9973731f58995" continuedAt="Text_3694f335dade4124a95f9973731f58996">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_3694f335dade4124a95f9973731f58996">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">There were <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_344617f1260d4745a3526a3f9edab4aa" contextRef="c20200101to20201231" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> stock options, RSUs or convertible
        preferred stock outstanding prior to the Merger to exclude from diluted net loss per common share for the year ended December 31, 2020.<br />
      </div>
</ix:continuation>

      <div><br />
      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Text_8f9ad6c0936f4457a61165cf0a03b0c4" contextRef="c20210101to20211231" escape="true" continuedAt="Text_e70afbda00ab47bd850adec92f0089041">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Stock-Based Compensation</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f0089041" continuedAt="Text_e70afbda00ab47bd850adec92f0089042">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f0089042" continuedAt="Text_e70afbda00ab47bd850adec92f0089043">
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Equity Incentive Plans</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f0089043" continuedAt="Text_e70afbda00ab47bd850adec92f0089044">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f0089044" continuedAt="Text_e70afbda00ab47bd850adec92f0089045">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn&#8217;s stock-based compensation plans consist of the Restated 2020 Equity Incentive Plan (the &#8220;Restated 2020 Plan&#8221;) and the 2021 Inducement
        Equity Incentive Plan (the &#8220;2021 Inducement Plan&#8221;). Brooklyn&#8217;s board of directors has designated its compensation committee as the administrator of the foregoing plans (the &#8220;Plan Administrator&#8221;). Among other things, the Plan Administrator selects
        persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures, if any, and other provisions of the award.</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f0089045" continuedAt="Text_e70afbda00ab47bd850adec92f0089046">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f0089046" continuedAt="Text_e70afbda00ab47bd850adec92f0089047">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">At Brooklyn&#8217;s special meeting of stockholders held on March 15, 2021, the stockholders approved the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;),
        which provided for the issuance of up to approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_684d810b734745f8b38d1d40fdd623dc" contextRef="c20210315_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,369,000</ix:nonFraction> shares of common stock. At Brooklyn&#8217;s annual meeting of stockholders
        held on September 3, 2021, the stockholders approved the Restated 2020 Plan, which provides for (1) an increase in the number of shares of common stock that can be issued under the Restated 2020 Plan by <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_6085d527935944aa82305096e843a8a4" contextRef="c20210903_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MinimumMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">5,116,000</ix:nonFraction> to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_3f082fd7cdbd46dab3c649daf970b2b3" contextRef="c20210903_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">8,485,000</ix:nonFraction> shares of common stock in total and (2)
        an annual increase in the number of shares reserved for issuance on January 1 of each year from 2022 through 2031 equal to the lesser of (i) <ix:nonFraction name="btx:PercentageOfSharesOfCommonStockOutstanding" id="Fact_c55b85415d784764af9abced847db21d" contextRef="c20210903_PlanNameAxis_EquityIncentivePlan2020Member" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%
        of the number of shares of common stock outstanding on the immediately preceding December 31 and (ii) such smaller number of shares of common stock as may be determine by the board of directors (the &#8220;Annual Evergreen Shares&#8221;). No other provision of
        the 2020 Plan were amended.&#160; Based on the number of shares of common stock outstanding on December 31, 2021, the maximum increase to the number of Annual Evergreen Shares of common stock that can be issued under the Restated 2020 Plan in 2022 is
        approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_3b568119fb8f4d94971dd0c06217a1a0" contextRef="c20211231_PlanNameAxis_EquityIncentivePlan2020Member" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,601,000</ix:nonFraction> shares.</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f0089047" continuedAt="Text_e70afbda00ab47bd850adec92f0089048">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f0089048" continuedAt="Text_e70afbda00ab47bd850adec92f0089049">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Awards under the Restated 2020 Plan may be granted to officers, directors, employees and consultants of the Company.&#160; Stock options granted under
        the Restated 2020 Plan may either be incentive stock options or nonqualified stock options, may have a term of up to <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Fact_9ebfa512c0c44eaf8408486f4ef5635e" contextRef="c20210101to20211231_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember" format="ixt-sec:durwordsen"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Fact_3e7abf0ec74f4014b8f9c1f10f58d7d0" contextRef="c20210101to20211231_AwardTypeAxis_NonQualifiedStockOptionMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric></ix:nonNumeric>, and
        are exercisable at a price per share not less than the fair market value on the date of grant.&#160; As of December 31, 2021, there were approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_afd9d3c5c4f3488aa69638b39e6e813f" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2020Member" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">320,000</ix:nonFraction>
        stock options and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_23f9aaafaf2b4c32bea3ae1f918b33a4" contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">18,000</ix:nonFraction> RSUs outstanding under the Restated 2020 Plan.</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f0089049" continuedAt="Text_e70afbda00ab47bd850adec92f00890410">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890410" continuedAt="Text_e70afbda00ab47bd850adec92f00890411">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In June 2019 Brooklyn adopted the 2019 Performance Incentive Plan (the &#8220;2019 Plan&#8221;), Upon the approval of the 2020 Plan, no future grants could be
        made under the 2019 Plan. As of December 31, 2021, all outstanding options under the 2019 Plan either had been exercised or had expired in accordance with the terms of the applicable award or the 2019 Plan.</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890411" continuedAt="Text_e70afbda00ab47bd850adec92f00890412">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890412" continuedAt="Text_e70afbda00ab47bd850adec92f00890413">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In May 2021, Brooklyn&#8217;s board of directors adopted the 2021 Inducement Plan, which provides for the grant of up to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_a44706259d87499a8af5bb462fc72224" contextRef="c20210531_PlanNameAxis_InducementPlan2021Member_RangeAxis_MaximumMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,500,000</ix:nonFraction> share-based awards as material inducement awards to new employees in accordance with the employment inducement grant rules set forth in
        Section 711(a) of the NYSE American LLC Company Guide. The 2021 Inducement Plan expires in May 2031. As of December 31, 2021, there were approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_3f93dd8301424708aa4bc20b2a764832" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_InducementPlan2021Member" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">443,000</ix:nonFraction>
        nonqualified stock options and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" id="Fact_62c73958ac1e46a496badd47c8f954da" contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_InducementPlan2021Member" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">222,000</ix:nonFraction> RSUs outstanding under the 2021 Inducement Plan.</div>
</ix:continuation>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_e70afbda00ab47bd850adec92f00890413" continuedAt="Text_e70afbda00ab47bd850adec92f00890414">
<div><br /></div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-26</span></div>

          <div style="page-break-after: always;" class="DSPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890414" continuedAt="Text_e70afbda00ab47bd850adec92f00890415">
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Equity Awards</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890415" continuedAt="Text_e70afbda00ab47bd850adec92f00890416">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890416" continuedAt="Text_e70afbda00ab47bd850adec92f00890417">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Stock Options</span></div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890417" continuedAt="Text_e70afbda00ab47bd850adec92f00890418">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890418" continuedAt="Text_e70afbda00ab47bd850adec92f00890419">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company records stock-based compensation in accordance with ASC Topic 718, Compensation &#8211; Stock Compensation.&#160; The Company estimates the fair
        value of each stock option award granted with service-based vesting requirements, using the Black-Scholes option pricing model. The Company recognizes the fair value of stock options granted as expense on a straight-line basis over the requisite
        service period.</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890419" continuedAt="Text_e70afbda00ab47bd850adec92f00890420">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890420" continuedAt="Text_e70afbda00ab47bd850adec92f00890421">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The risk-free rate is based on the observed interest rates appropriate for the expected life. The expected life (estimated period of time
        outstanding) of the stock options granted is estimated using the &#8220;simplified&#8221; method as permitted by the SEC&#8217;s Staff Accounting Bulletin No. 110, Share-Based Payment. Expected volatility is based on the Company&#8217;s historical volatility over the
        expected life of the stock option granted, and the Company assumes no dividends.&#160;&#160; Forfeitures are recognized as incurred.</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890421" continuedAt="Text_e70afbda00ab47bd850adec92f00890422">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890422" continuedAt="Text_e70afbda00ab47bd850adec92f00890423">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_e45a469ca2894dd9b941d2855e3c3c25" contextRef="c20200101to20201231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_7092efef0b774c65ae8918ccd8c88ff7" contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> stock options
        outstanding or granted during the year ended December 31, 2020. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_79d90495a65a437688a20cd2e3b15161" contextRef="c20210101to20211231" escape="true" continuedAt="Text_f484e31e31464f668ff233c178901b0b1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following weighted-average assumptions were used for stock options granted during the year ended December 31, 2021:</span></ix:nonNumeric></div>
</ix:continuation>
      <ix:continuation id="Text_f484e31e31464f668ff233c178901b0b1" continuedAt="Text_f484e31e31464f668ff233c178901b0b2"><ix:continuation id="Text_e70afbda00ab47bd850adec92f00890423" continuedAt="Text_e70afbda00ab47bd850adec92f00890424">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_f484e31e31464f668ff233c178901b0b2"><ix:continuation id="Text_e70afbda00ab47bd850adec92f00890424" continuedAt="Text_e70afbda00ab47bd850adec92f00890425">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Year ended</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31, 2021 </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Weighted average risk-free rate</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_26aa59c06ecc4133b2a887329cd6fcc5" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4" scale="-2" format="ixt:numdotdecimal">1.09</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Weighted average volatility</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_c41b3554989044f6b1351c78b9f2dd47" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="4" scale="-2" format="ixt:numdotdecimal">134.64</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Dividend yield</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_deea928ad16e4488a4d43346e9d4aa65" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">%</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Expected term</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; white-space: nowrap;" colspan="2"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_698ecb9ef45f41e2af4a9f677ad01c3c" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">6.10</ix:nonNumeric> years <br />
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890425" continuedAt="Text_e70afbda00ab47bd850adec92f00890426">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890426" continuedAt="Text_e70afbda00ab47bd850adec92f00890427"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Text_e14ca8bd850640aaa46f800cb8a5947e" contextRef="c20210101to20211231" escape="true" continuedAt="Text_97b948438c944eda935812fc65b8331d1">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes stock option activity for the year ended December 31, 2021:</div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890427" continuedAt="Text_e70afbda00ab47bd850adec92f00890428"><ix:continuation id="Text_97b948438c944eda935812fc65b8331d1" continuedAt="Text_97b948438c944eda935812fc65b8331d2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890428" continuedAt="Text_e70afbda00ab47bd850adec92f00890429"><ix:continuation id="Text_97b948438c944eda935812fc65b8331d2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Outstanding</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Options</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Weighted</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Average</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Exercise</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Price per Share</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Weighted</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Average</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Remaining</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Contractual</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Life (in years)</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Aggregate</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Intrinsic</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Value</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Outstanding January 1, 2021</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_4523fe3d92c44b9c826e0a7009387f96" contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="INF" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_8b40bf42e6f241d7b8c30d3322aa9e14" contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_21b5339388d640458045002e940d42d0" contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Granted</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_90d9014987c149ddad7fb58c99502e08" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,988,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="Fact_cc20655413534735a93fb1aaf0e8b018" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">8.40</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonNumeric name="btx:SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" id="Fact_10e3d91d5a0a4bf496da8a6ca9fd2d05" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">9.38</ix:nonNumeric></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_fcdd0d262f834e888f50b7d0fbd9e3ec" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Outstanding December 31, 2021</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_6b7dffe561a24562a158cfa3c79aaf81" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,988,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_10f5c7efb1a644bc84a3822cd1c48c41" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">8.40</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_937d975cd0f54b9bb40113895cded236" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">9.38</ix:nonNumeric></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_8fdd72d0d8da4f85b143b78e57e76c6a" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Options vested and exercisable at December 31, 2021</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" id="Fact_39e5bdb5ae904b8eb71d13c3f5a0777f" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="INF" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" id="Fact_f880b6aed05449b5a60c197abda8081a" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" id="Fact_8ef0383b1ba949d180a3f72d9e559b2f" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890429" continuedAt="Text_e70afbda00ab47bd850adec92f00890430">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890430" continuedAt="Text_e70afbda00ab47bd850adec92f00890431">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The per-share weighted average grant-date fair value of stock options granted during the year ended December 31, 2021 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_4136f84cca54451e936b0e9d6578512e" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">7.57</ix:nonFraction>.</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890431" continuedAt="Text_e70afbda00ab47bd850adec92f00890432">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890432" continuedAt="Text_e70afbda00ab47bd850adec92f00890433">
<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As of December 31, 2021, the unamortized stock-based compensation expense related to outstanding unvested options was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" id="Fact_1922f5a023344afa8829d89bf9e79d65" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">21,915,000</ix:nonFraction> with a weighted average remaining requisite service period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_83096292d4244d099ff1537fba940251" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">3.30</ix:nonNumeric> years. The Company expects to amortize this expense over the remaining requisite service period of these stock options.<br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890433" continuedAt="Text_e70afbda00ab47bd850adec92f00890434">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890434" continuedAt="Text_e70afbda00ab47bd850adec92f00890435">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Included in the <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_d8d5a04087cd4a33bae4cb87785b34c3" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,988,000</ix:nonFraction> stock
        options granted during the year ended December 31, 2021, the Company issued <ix:nonFraction name="btx:NumberOfStockOptionGrantMade" id="Fact_9dda042451d546eb90b44c0f8836e910" contextRef="c20211231" unitRef="U012" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> stock option grants to Howard J. Federoff, M.D., Ph.D.
        upon his appointment as the Company&#8217;s Chief Executive Officer and President.</div>
</ix:continuation>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_e70afbda00ab47bd850adec92f00890435" continuedAt="Text_e70afbda00ab47bd850adec92f00890436">
<div><span style="color: rgb(0, 0, 0);"> </span><br /></div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-27</span></div>

          <div style="page-break-after: always;" class="DSPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin-top: 4px; margin-bottom: 4px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890436" continuedAt="Text_e70afbda00ab47bd850adec92f00890437">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Dr. Federoff was granted a nonqualified stock option covering approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_b95b796c077e4dc6b38b6b288ac60415" contextRef="c20210101to20211231_AwardTypeAxis_TimeBasedNonQualifiedStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,628,000</ix:nonFraction> shares of common stock (the &#8220;Time-Based Option&#8221;). The Time-Based Option was granted at a per share exercise price equal to the closing price of the common stock on the NYSE
        American stock exchange on the date of grant. Of the shares covered by the Time-Based Option, <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact_2a11d44b73f4449cb41eba02c5179c1a" contextRef="c20210101to20211231_AwardTypeAxis_TimeBasedNonQualifiedStockOptionMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>% will vest on the one-year anniversary
        of the grant date, and the remaining shares will vest in substantially <ix:nonFraction name="btx:ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" id="Fact_04daf038117d4583bd60cab9c67b425e" contextRef="c20210101to20211231_AwardTypeAxis_TimeBasedNonQualifiedStockOptionMember" unitRef="U013" decimals="0" scale="0" format="ixt:numdotdecimal">36</ix:nonFraction> equal monthly installments thereafter, so long as Dr. Federoff
        provides continuous service to the Company throughout the relevant vesting date.</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890437" continuedAt="Text_e70afbda00ab47bd850adec92f00890438">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890438" continuedAt="Text_e70afbda00ab47bd850adec92f00890439">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Dr. Federoff was also granted a performance-based nonqualified stock option covering approximately <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_1122396913fa4a818e93f51d96f0dd4c" contextRef="c20210101to20211231_AwardTypeAxis_PerformanceBasedNonqualifiedStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">597,000</ix:nonFraction> shares of common stock (the &#8220;Milestone Option&#8221;). The Milestone Option was granted at a per share exercise price equal to the closing price of common stock on the NYSE
        American stock exchange on the date of grant, and its fair value is $<ix:nonFraction name="btx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" id="Fact_582b502df4e845dfa9568c1bbc5f0d9f" contextRef="c20210101to20211231_AwardTypeAxis_PerformanceBasedNonqualifiedStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">4,288,738</ix:nonFraction>. The Milestone Option will fully vest upon the first
        concurrence by the U.S. Food and Drug Administration that a proposed investigation may proceed following review of a Company filed investigational new drug application in connection with that the License Agreement. This milestone is subject to Dr.
        Federoff&#8217;s continuous service with the Company through such vesting date.</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890439" continuedAt="Text_e70afbda00ab47bd850adec92f00890440">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890440" continuedAt="Text_e70afbda00ab47bd850adec92f00890441">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Both the Time-Based Option and the Milestone Option were granted outside the Company&#8217;s equity incentive plans discussed above.&#160; The unvested
        portion of the Time-Based Option and the Milestone Option will be cancelled upon the termination of Dr. Federoff&#8217;s employment with the Company for any reason, subject to certain vesting acceleration provisions upon a qualifying termination, as
        described in his employment agreement with the Company. Unless earlier terminated in accordance with their terms, each of the Time-Based Option and the Milestone Option will otherwise expire on the tenth anniversary of their respective grant date
        and be subject to the terms and conditions of the respective option agreement approved by the Company. Each of the Time-Based Option and the Milestone Option was intended to constitute an &#8220;employment inducement grant&#8221; in accordance with the
        employment inducement grant rules set forth in Section 711(a) of the NYSE American LLC Company Guide and was offered as an inducement material to Dr. Federoff in connection with his hiring.</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890441" continuedAt="Text_e70afbda00ab47bd850adec92f00890442">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890442" continuedAt="Text_e70afbda00ab47bd850adec92f00890443">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">During the year ended December 31, 2021, there were <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_e8d9dee8604e4c3ca8d4c6c7dcdbc6c3" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,300</ix:nonFraction>
        options exercised for total cash proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_3866e7b35d17436aa44e85f9bf806fe8" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">10,202</ix:nonFraction>.&#160; The options exercised had a total intrinsic value of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" id="Fact_93b47fabc34f4d519380bbc6d7e004d9" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">47,010</ix:nonFraction>.&#160; There were <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_76a62dbc0e944cf8a0f3948f64860540" contextRef="c20200101to20201231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> options exercised
        during the year ended December 31, 2020.</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890443" continuedAt="Text_e70afbda00ab47bd850adec92f00890444">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890444" continuedAt="Text_e70afbda00ab47bd850adec92f00890445">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">RSUs</span></div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890445" continuedAt="Text_e70afbda00ab47bd850adec92f00890446">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890446" continuedAt="Text_e70afbda00ab47bd850adec92f00890447">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Outstanding RSUs are settled in an equal number of shares of common stock on the vesting date of the award. An RSU award is settled only to the
        extent vested. Vesting generally requires the continued employment or service by the award recipient through the respective vesting date. Because RSUs are settled in an equal number of shares of common stock without any offsetting payment by the
        recipient, the measurement of cost is based on the quoted market price of the stock at the measurement date, which is the grant date.</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890447" continuedAt="Text_e70afbda00ab47bd850adec92f00890448">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890448" continuedAt="Text_e70afbda00ab47bd850adec92f00890449">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_72025a3b05604ae0908f34aaf4104196" contextRef="c20200101to20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> RSUs outstanding or
        granted during the year ended December 31, 2020. <ix:nonNumeric name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="Text_9cd4792e81544e4da3dcf0dcca53502c" contextRef="c20210101to20211231" escape="true" continuedAt="Text_b4e46e7e5fe942eabca105505684df951"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The





















        following table summarizes RSU activity for the years ended December 31, 2021:</span></ix:nonNumeric></div>
</ix:continuation>
      <ix:continuation id="Text_b4e46e7e5fe942eabca105505684df951" continuedAt="Text_b4e46e7e5fe942eabca105505684df952"><ix:continuation id="Text_e70afbda00ab47bd850adec92f00890449" continuedAt="Text_e70afbda00ab47bd850adec92f00890450">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_b4e46e7e5fe942eabca105505684df952"><ix:continuation id="Text_e70afbda00ab47bd850adec92f00890450" continuedAt="Text_e70afbda00ab47bd850adec92f00890451">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Outstanding</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Restricted</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Stock Units</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Weighted</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Average Fair</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Value per Share</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">January 1, 2021</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_317fb2d10b3046fcb58d71b9f32fc367" contextRef="c20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="INF" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_dff02877e10a47bb8222046919b458fd" contextRef="c20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Granted</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_b1f24f9e9fe142938c8068d14f0f5daa" contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">240,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_6ac1a3df030c4532b38aeeeb9d5cad1d" contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">13.80</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">December 31, 2021</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_88b8c78bf9fe427f9e7bd4fd88dc8151" contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">240,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_a35ab63a1fd8452d91dc3ca425a112e4" contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">13.80</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);">Balance expected to vest at December 31, 2021</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" id="Fact_c60ebe3327a14ad698566425a5534172" contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="INF" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890451" continuedAt="Text_e70afbda00ab47bd850adec92f00890452">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890452" continuedAt="Text_e70afbda00ab47bd850adec92f00890453">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_22340cb6df6d4dcab00bfa3556b99d59" contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> RSUs vested during the year
        ended December 31, 2021.</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890453" continuedAt="Text_e70afbda00ab47bd850adec92f00890454">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890454" continuedAt="Text_e70afbda00ab47bd850adec92f00890455">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company recognizes the intrinsic value of RSUs granted as expense on a straight-line basis over the requisite service period. As of December
        31, 2021, the unamortized stock-based compensation expense related to outstanding RSUs was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" id="Fact_cdfbae4b3bea4591a7c0e93cc125e16f" contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">2,935,000</ix:nonFraction> with a weighted
        average remaining requisite service period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_451489021bc242818116d96eac427fc1" contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">3.51</ix:nonNumeric> years. The Company expects to amortize this expense over the remaining requisite
        service period of these stock options.</div>
</ix:continuation>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_e70afbda00ab47bd850adec92f00890455" continuedAt="Text_e70afbda00ab47bd850adec92f00890456">
<div><br /></div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-28</span></div>

          <div style="page-break-after: always;" class="DSPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890456" continuedAt="Text_e70afbda00ab47bd850adec92f00890457">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Restricted Stock</span></div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890457" continuedAt="Text_e70afbda00ab47bd850adec92f00890458">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890458" continuedAt="Text_e70afbda00ab47bd850adec92f00890459">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the Merger, Brooklyn LLC&#8217;s approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" id="Fact_899e66021b534dc1afe111498d166c2b" contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,000</ix:nonFraction>
        outstanding restricted common units were exchanged for approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" id="Fact_6a5816a290474c608a50c72e9aeacde8" contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">630,000</ix:nonFraction> shares of Brooklyn&#8217;s restricted common stock. There were no
        changes to any conditions and requirements of the restricted common stock. The shares vest quarterly beginning on March 31, 2021 and continuing through December 31, 2022. Due to the modification of the restricted common units, the fair value of the
        restricted common stock immediately after the Merger was compared to the fair value of the restricted common units immediately prior to the Merger, and the change in fair value of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_b08c70d2006c4c6cb30f86f45f5c3b26" contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">250,000</ix:nonFraction> was recognized in the statement of operations for year ended December 31, 2021. The Company recognizes the fair value of restricted common stock as an expense on a straight-line
        basis over the requisite service period.</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890459" continuedAt="Text_e70afbda00ab47bd850adec92f00890460">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890460" continuedAt="Text_e70afbda00ab47bd850adec92f00890461">
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Stock-Based Compensation Expense</div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890461" continuedAt="Text_e70afbda00ab47bd850adec92f00890462">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_e70afbda00ab47bd850adec92f00890462">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total stock-based compensation expense for the years ended December 31, 2021 and 2020 was approximately $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_57d6a34e12784ac28e93291bad60f531" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">5,235,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_2e434218917a49edb0180da858e84623" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">91,000</ix:nonFraction>, respectively.&#160; Stock-based compensation is
        recorded in general and administrative expense and research and development expense in the statement of operations.</div>
</ix:continuation>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Text_521b4bd2711b4967be514bf5dae19c4c" contextRef="c20210101to20211231" escape="true" continuedAt="Text_40fc8930add041eaad3b8cde958275461">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Stockholders&#8217; and Members&#8217; Equity (Deficit)</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <div>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde958275461" continuedAt="Text_40fc8930add041eaad3b8cde958275462">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde958275462" continuedAt="Text_40fc8930add041eaad3b8cde958275463">
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Equity Line Offerings</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_40fc8930add041eaad3b8cde958275463" continuedAt="Text_40fc8930add041eaad3b8cde958275464">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_40fc8930add041eaad3b8cde958275464" continuedAt="Text_40fc8930add041eaad3b8cde958275465">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On April 26, 2021, Brooklyn and Lincoln Park executed the First Purchase Agreement and a related registration rights agreement. Pursuant to the
        First Purchase Agreement, Brooklyn had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park would be obligated to purchase, up to $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_83d8420c74a94e228ede7c7fe05909f3" contextRef="c20210426to20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">20,000,000</ix:nonFraction>
        of shares of Brooklyn&#8217;s common stock. Sales of common stock by Brooklyn were subject to certain limitations, and could occur from time to time, at Brooklyn&#8217;s sole discretion. For entering into the First Purchase Agreement, Brooklyn issued to
        Lincoln Park approximately <ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" id="Fact_abcf7cb4e758408c830833cc8d28b643" contextRef="c20210426to20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">56,000</ix:nonFraction> shares of common shares as consideration for Lincoln Park&#8217;s commitment to purchase up to $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_c8e1c5ebebd341f6bd59952751d44e19" contextRef="c20210426to20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">20,000,000</ix:nonFraction> in shares of common stock. As of December 31, 2021, Brooklyn issued and sold to Lincoln Park approximately <ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" id="Fact_6c66ad0ead2c45bebd65ef373b70ea8a" contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,128,000</ix:nonFraction> shares of common stock under the First Purchase Agreement for gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_a608c3f7ccb84bcfbed72260d19b60ef" contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">20,000,000</ix:nonFraction>, and <ix:nonFraction name="btx:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" id="Fact_59664752c3c44d90a29ea629f0016776" contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> further shares may be sold to Lincoln Park under the First
        Purchase Agreement.</div>
</ix:continuation>
      <ix:continuation id="Text_40fc8930add041eaad3b8cde958275465" continuedAt="Text_40fc8930add041eaad3b8cde958275466">
<div><br /></div>
</ix:continuation>
      <ix:continuation id="Text_40fc8930add041eaad3b8cde958275466" continuedAt="Text_40fc8930add041eaad3b8cde958275467">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On May 26, 2021, Brooklyn executed the Second Purchase Agreement and a related registration rights agreement. Pursuant to the Second Purchase
        Agreement, Brooklyn has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park would be obligated to purchase, up to $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_86daa55b20ce4a58bc7ae3065dfb014a" contextRef="c20210526to20210526_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">40,000,000</ix:nonFraction>
        of shares of Brooklyn&#8217;s common stock. Sales of common stock by Brooklyn are subject to certain limitations, and may occur from time to time, at Brooklyn&#8217;s sole discretion. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In consideration of Lincoln Park&#8217;s entry</span> </span>into the Second Purchase Agreement, Brooklyn issued to Lincoln Park <ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" id="Fact_52429417ef714ca890b2823f4e5c88bc" contextRef="c20210526to20210526_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">50,000</ix:nonFraction> shares of common stock.</div>
</ix:continuation>
      <ix:continuation id="Text_40fc8930add041eaad3b8cde958275467" continuedAt="Text_40fc8930add041eaad3b8cde958275468">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde958275468" continuedAt="Text_40fc8930add041eaad3b8cde958275469">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the Second Purchase Agreement, the Company may direct Lincoln Park to purchase up to <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_6a40159838bd47a0ae3460f9fd5457c3" contextRef="c20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">60,000</ix:nonFraction> shares of common stock on any business day (the &#8220;Regular Purchase&#8221;), which amount may be increased up to <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_6c98cedf24cd4471b5e4f1c724b50bc4" contextRef="c20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">120,000</ix:nonFraction> shares based on the closing price of the common stock, provided that Lincoln Park&#8217;s maximum commitment in any single Regular Purchase may not exceed $<ix:nonFraction name="btx:CommitmentAmountToMeetAnySingleRegularPurchase" id="Fact_282d318c6aba4e5db54e3c9603942136" contextRef="c20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction> million. The purchase price per share for each such Regular Purchase is based off of the common stock&#8217;s market immediately preceding the time of
          sale.<br />
        </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_40fc8930add041eaad3b8cde958275469" continuedAt="Text_40fc8930add041eaad3b8cde9582754610">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754610" continuedAt="Text_40fc8930add041eaad3b8cde9582754611">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Second Purchase Agreement also prohibits Brooklyn from directing Lincoln Park to purchase any shares of common stock if those shares, when
          aggregated with all other shares of common stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership, at any single point in time, of more than <ix:nonFraction name="btx:BeneficialOwnershipPercentageOnTotalOutstandingShares" id="Fact_fa5ca2cf3b224541ae90934d90b455aa" contextRef="c20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember" unitRef="U004" decimals="4" scale="-2" format="ixt:numdotdecimal">4.99</ix:nonFraction>% of the then total outstanding shares of common stock. Brooklyn has the right to terminate the Second Purchase Agreement at any time, at no cost
          or penalty.</div>
</ix:continuation>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754611" continuedAt="Text_40fc8930add041eaad3b8cde9582754612">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754612" continuedAt="Text_40fc8930add041eaad3b8cde9582754613">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Actual sales of shares of common stock to Lincoln Park under the Second Purchase Agreements depend on a variety of factors to be determined by
          us from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations.<br />
        </div>
</ix:continuation>
        <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_40fc8930add041eaad3b8cde9582754613" continuedAt="Text_40fc8930add041eaad3b8cde9582754614">
<div><span style="color: rgb(0, 0, 0);"> </span><br /></div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-29</span></div>

            <div style="page-break-after: always;" class="DSPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin-top: 4px; margin-bottom: 4px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
              </div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754614" continuedAt="Text_40fc8930add041eaad3b8cde9582754615">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">As of December 31,
          2021, Brooklyn had issued and sold approximately <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" id="Fact_2cf1f1b4783e42bb88395d315a31734e" contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_PurchaseAgreementMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,424,000</ix:nonFraction> shares of common stock under the Second Purchase Agreement for total gross
          proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" id="Fact_1f88a8fab2004e218172f6555866a55b" contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_PurchaseAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">34,106,000</ix:nonFraction>. As of December 31, 2021, there were approximately <ix:nonFraction name="btx:SaleOfStockNumberOfSharesToIssuedInTransaction" id="Fact_983f585a58644d66bcf662b8c6e015e0" contextRef="c20210101to20211231_TypeOfArrangementAxis_SecondPurchaseAgreementMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">446,000</ix:nonFraction> shares remaining to be sold under the Second Purchase Agreement. <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Pursuant to the securities purchase agreement in respect of the PIPE
            Transaction, the Company is prohibited from issuing additional shares under the Section Purchase Agreement for a period of one-year immediately following the closing of the PIPE Transaction.</span></div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754615" continuedAt="Text_40fc8930add041eaad3b8cde9582754616">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754616" continuedAt="Text_40fc8930add041eaad3b8cde9582754617">
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Reverse Stock-Split</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754617" continuedAt="Text_40fc8930add041eaad3b8cde9582754618">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754618" continuedAt="Text_40fc8930add041eaad3b8cde9582754619">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On March 25, 2021, immediately prior to the Merger, Brooklyn filed an amendment to the Certificate of Incorporation with the Secretary of State
          of the State of Delaware to effect a reverse stock split. As a result of the reverse stock split, the number of issued and outstanding shares of common stock immediately prior to the reverse stock split was reduced into a smaller number of
          shares, such that every two shares of common stock held by a stockholder of Brooklyn immediately prior to the reverse stock split were combined and reclassified into <span style="-sec-ix-hidden:Fact_8f4da43a33f64403a03756802f5c0aae">one</span> share of common stock after the reverse stock split.</div>
</ix:continuation>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754619" continuedAt="Text_40fc8930add041eaad3b8cde9582754620">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754620" continuedAt="Text_40fc8930add041eaad3b8cde9582754621">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Immediately following the reverse stock split there were approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" id="Fact_47366878477f49fa899dc74fc5c5b87e" contextRef="c20210325to20210325" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,514,000</ix:nonFraction> shares of common stock outstanding prior to the Merger. No fractional shares were issued in connection with the reverse stock split.</div>
</ix:continuation>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754621" continuedAt="Text_40fc8930add041eaad3b8cde9582754622">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754622" continuedAt="Text_40fc8930add041eaad3b8cde9582754623">
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Merger</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754623" continuedAt="Text_40fc8930add041eaad3b8cde9582754624">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754624" continuedAt="Text_40fc8930add041eaad3b8cde9582754625">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the terms of the Merger Agreement (see Notes 1 and 4), on March 25, 2021, Brooklyn issued shares of common stock to the equity holders of
          Brooklyn LLC. The <ix:nonFraction name="us-gaap:SharesIssued" id="Fact_eb41f3d832754a8cbd303f04866fdf60" contextRef="c20210325_StatementClassOfStockAxis_CommonClassAMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">87,000</ix:nonFraction> Class A units of Brooklyn LLC were converted into approximately <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" id="Fact_0bec321015ad41ef91bdccf880cb8922" contextRef="c20210325to20210325_StatementClassOfStockAxis_CommonClassAMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">22,275,000</ix:nonFraction> shares of common stock; the <ix:nonFraction name="us-gaap:SharesIssued" id="Fact_2889441a7798483ea1894b99f6cb2069" contextRef="c20210325_StatementClassOfStockAxis_CommonClassBMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">15,000,000</ix:nonFraction> Class B
          units were converted into approximately <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" id="Fact_9757907026a84e4d8a0d6aeddf29dfc9" contextRef="c20210325to20210325_StatementClassOfStockAxis_CommonClassBMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">2,515,000</ix:nonFraction> shares of common stock; the <ix:nonFraction name="us-gaap:SharesIssued" id="Fact_fb60087659d648ccbc0f12d4b52f27d0" contextRef="c20210325_StatementClassOfStockAxis_CommonClassCMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction> Class C units were converted into approximately <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" id="Fact_e31c7e14c82949798ff556550e04d1ed" contextRef="c20210325to20210325_StatementClassOfStockAxis_CommonClassCMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,676,000</ix:nonFraction> shares
          of common stock; approximately <ix:nonFraction name="us-gaap:SharesIssued" id="Fact_f8529d49994d499481b987fecbeb9792" contextRef="c20210325_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">630,000</ix:nonFraction> shares of common units were converted into approximately <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" id="Fact_104ade947f164d63928c4643ebef6886" contextRef="c20210325to20210325_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">630,000</ix:nonFraction> shares of common stock, and <ix:nonFraction name="btx:ClassOfWarrantOrRightIssued" id="Fact_39e1fd7aacbf4968b47c3e9705e0902b" contextRef="c20210325_StatementClassOfStockAxis_CommonClassCMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">10,500,000</ix:nonFraction>
          rights options were converted into approximately <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_3666bedf9da94a789fb33d2f692d9c87" contextRef="c20210325_StatementClassOfStockAxis_CommonClassCMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">11,828,000</ix:nonFraction> shares of common stock.&#160; Brooklyn also issued approximately <ix:nonFraction name="btx:StockIssuedDuringPeriodSharesAcquisitions1" id="Fact_911bbed7a681405cb2a46b62a865a051" contextRef="c20210325to20210325" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">1,068,000</ix:nonFraction> shares of common stock to the Financial Advisor pursuant to the Merger Agreement.</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754625" continuedAt="Text_40fc8930add041eaad3b8cde9582754626">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754626" continuedAt="Text_40fc8930add041eaad3b8cde9582754627">
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Acquisition</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754627" continuedAt="Text_40fc8930add041eaad3b8cde9582754628">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754628" continuedAt="Text_40fc8930add041eaad3b8cde9582754629">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the terms of the Acquisition (see Notes 1 and 4), on July 16, 2021, Brooklyn issued approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" id="Fact_651d78e0329443fab479785d3c3bdad1" contextRef="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">7,022,000</ix:nonFraction> shares of common stock, of which approximately <ix:nonFraction name="btx:StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" id="Fact_64dfc7f5c7254f8aa6a30fb1c3a9997f" contextRef="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,644,000</ix:nonFraction>
          shares are unrestricted and approximately <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" id="Fact_70f38e7a5f4f43e4b575609e1e5d4796" contextRef="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember_RelatedPartyTransactionsByRelatedPartyAxis_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">3,378,000</ix:nonFraction> shares are subject to a <ix:nonNumeric name="btx:EachLockUpAgreementExtendsTerm" id="Fact_63a7615782864160b1a4a1d3f9078672" contextRef="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember" format="ixt-sec:durwordsen">three-year</ix:nonNumeric> lockup agreement, provided that up to <ix:nonFraction name="btx:PercentageOfCommonStockSubjectToLockUpAgreement" id="Fact_931fcd6f51534781bea99f254dc8c061" contextRef="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember_RangeAxis_MaximumMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">75</ix:nonFraction>% of the shares of common
          stock subject to the lock-up agreement may be released from the lock-up restrictions earlier if the price of common stock on the principal market for the common stock exceeds specified thresholds.</div>
</ix:continuation>
        <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754629" continuedAt="Text_40fc8930add041eaad3b8cde9582754630">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754630" continuedAt="Text_40fc8930add041eaad3b8cde9582754631">
<div style="color: rgb(0, 0, 0); font-style: italic; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Cumulative Convertible Preferred Stock</div>
</ix:continuation>
      <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754631" continuedAt="Text_40fc8930add041eaad3b8cde9582754632">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754632" continuedAt="Text_40fc8930add041eaad3b8cde9582754633">
<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As a result of the Merger, the Company has authorized <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_b45c9ea148b4435886432b71c8e66aad" contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_2e9331c7221e4411b7cbd51015c5cc15" contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_2745bfa59cf648cd96d48153d012ce44" contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">156,000</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock, all of which is designated as Series A Cumulative Convertible Preferred Stock (the &#8220;Series A Preferred Stock&#8221;), and all of which were issued and
        outstanding as of December 31, 2021.</div>
</ix:continuation>
      <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754633" continuedAt="Text_40fc8930add041eaad3b8cde9582754634">
<div style="display:none;"><br /></div>
<div style="text-indent: 9pt; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754634" continuedAt="Text_40fc8930add041eaad3b8cde9582754635">
<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Series A Preferred Stock provides for a cumulative annual dividend of $<ix:nonFraction name="us-gaap:DividendsPayableAmountPerShare" id="Fact_6ccd6c27ecbc4d12862d357c82ded341" contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">0.10</ix:nonFraction> per share, payable in semi-annual installments in June and December. Dividends may be paid in cash or with shares of common stock.&#160; The Company paid approximately $<ix:nonFraction name="us-gaap:DividendsPreferredStockCash" id="Fact_80016cfa54a04d98808d0d2455cc200b" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">8,000</ix:nonFraction> in cash and issued approximately <ix:nonFraction name="us-gaap:PreferredStockDividendsShares" id="Fact_2e2ee3aa3b82467eabc1425957bcae4e" contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">202</ix:nonFraction>
        shares of common stock for payment of dividends during the year ended December 31, 2021.</div>
</ix:continuation>
      <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754635" continuedAt="Text_40fc8930add041eaad3b8cde9582754636">
<div style="display:none;"><br /></div>
<div style="text-indent: 9pt; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754636" continuedAt="Text_40fc8930add041eaad3b8cde9582754637">
<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Series A Preferred Stock has no voting rights and has a $<ix:nonFraction name="us-gaap:PreferredStockLiquidationPreference" id="Fact_10987e02d19a458690b29bdce7995199" contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">1.00</ix:nonFraction> per share liquidation preference over common stock. The registered holder has the right at any time to convert shares of Series A Preferred Stock into that number of shares of common
        stock that equals the number of shares of Series A Preferred Stock that are surrendered for conversion divided by the conversion rate.&#160; At December 31, 2021, the conversion rate was <ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionRatio" id="Fact_27107675250b486980059d7439ac0dde" contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="U004" decimals="4" scale="0" format="ixt:numdotdecimal">3.7016</ix:nonFraction> and, based on that conversion rate, one share of Series A Convertible Preferred Stock would have converted into approximately <ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" id="Fact_aac1b7b60c2b4b5a96db6281474251ae" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="2" scale="0" format="ixt:numdotdecimal">0.27</ix:nonFraction> shares of common stock, and all the outstanding shares of the Series A Convertible Preferred Stock would have converted into approximately <ix:nonFraction name="us-gaap:PreferredStockConvertibleSharesIssuable" id="Fact_08b9772dcf15405f8abe237a990450bb" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">42,000</ix:nonFraction> shares of common stock in the aggregate. There were <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" id="Fact_004b576ef6db4f32939bdfd267713232" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction>
        conversions during the year ended December 31, 2021. There is no mandatory conversion term, date or any redemption features associated with the Series A Preferred Stock. The conversion rate will adjust under the following circumstances:</div>
</ix:continuation>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_40fc8930add041eaad3b8cde9582754637" continuedAt="Text_40fc8930add041eaad3b8cde9582754638">
<div><span style="color: rgb(0, 0, 0);"> </span><br /></div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-30</span></div>

          <div style="page-break-after: always;" class="DSPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin-top: 4px; margin-bottom: 4px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754638" continuedAt="Text_40fc8930add041eaad3b8cde9582754639">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">1.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">If the Company (a) pays a dividend or makes a distribution in shares of its common stock, (b) subdivides its outstanding shares of common stock into a greater number of shares, (c) combines its outstanding
                shares of common stock into a smaller number of shares, or (d) issues by reclassification of its shares of common stock any shares of its common stock (other than a change in par value, or from par value to no par value, or from no par
                value to par value), then the conversion rate in effect immediately prior to the applicable event will be adjusted so that the holders of the Series A Convertible Preferred Stock will be entitled to receive the number of shares of common
                stock which they would have owned or have been entitled to receive immediately following the happening of the event, had the Series A Convertible Preferred Stock been converted immediately prior to the record or effective date of the
                applicable event.</div>
            </td>

  </tr>


</table>
</ix:continuation>
      <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754639" continuedAt="Text_40fc8930add041eaad3b8cde9582754640">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754640" continuedAt="Text_40fc8930add041eaad3b8cde9582754641">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">2.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">If the outstanding shares of the Company&#8217;s common stock are reclassified (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of a
                subdivision, combination or stock dividend), or if the Company consolidates with or merge into another corporation and the Company is not the surviving entity, or if the Company sells all or substantially all of its property, assets,
                business and goodwill, then the holders of the Series A Convertible Preferred Stock will thereafter be entitled upon conversion to the kind and amount of shares of stock or other equity securities, or other property or assets which would
                have been receivable by such holders upon such reclassification, consolidation, merger or sale, if the Series A Convertible Preferred Stock had been converted immediately prior thereto.</div>
            </td>

  </tr>


</table>
</ix:continuation>
      <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754641" continuedAt="Text_40fc8930add041eaad3b8cde9582754642">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_40fc8930add041eaad3b8cde9582754642">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">3.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">If the Company issues common stock without consideration or for a consideration per share less than the then applicable Equivalent Preference Amount (as defined below), then the Equivalent Preference Amount
                will immediately be reduced to the amount determined by dividing (A) an amount equal to the sum of (1) the number of shares of common stock outstanding immediately prior to such issuance multiplied by the Equivalent Preference Amount in
                effect immediately prior to such issuance and (2) the consideration, if any, received by the Company upon such issuance, by (B) the total number of shares of common stock outstanding immediately after such issuance. The &#8220;Equivalent
                Preference Amount&#8221; is the value that results when the liquidation preference of one share of Series A Convertible Preferred Stock (which is $1.00) is multiplied by the conversion rate in effect at that time; thus the conversion rate
                applicable after the adjustment in the Equivalent Preference Amount as described herein will be the figure that results when the adjusted Equivalent Preference Amount is divided by the liquidation preference of one share of Series A
                Convertible Preferred Stock.</div>
            </td>

  </tr>


</table>
</ix:continuation>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" id="Text_5e8fbae6b1184b969719cbe3a9c28eb5" contextRef="c20210101to20211231" escape="true" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b1">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.9pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">15)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Income Taxes</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b1" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b2" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b3"><ix:nonNumeric name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="Text_a3f4ee5e0f204eb396b5a3cc7b336925" contextRef="c20210101to20211231" escape="true" continuedAt="Text_4d9647fb2de24ab5870af5bded6fe5c51">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Loss before income taxes consist of the following:</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b3" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b4"><ix:continuation id="Text_4d9647fb2de24ab5870af5bded6fe5c51" continuedAt="Text_4d9647fb2de24ab5870af5bded6fe5c52">
<div><br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b4" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b5"><ix:continuation id="Text_4d9647fb2de24ab5870af5bded6fe5c52">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Years ended December 31,</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> 2021</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2020</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Domestic</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" id="Fact_833423af94694357bfe0341c52eaf1f4" contextRef="c20210101to20211231" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">122,296,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" id="Fact_ea950597f20841a796f9e09a762c4c6c" contextRef="c20200101to20201231" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">26,531,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" id="Fact_65ec4d6b00174310b4097047884f4e5f" contextRef="c20210101to20211231" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">5,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" id="Fact_1a5b6f03d86c44ee81a8a06d8faddf2d" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total tax provision for income taxes</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_75e7b250e6a544b5b6a24e5dd28d7729" contextRef="c20210101to20211231" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">122,301,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_ef4465a9bd1c48f4a43c5cf6cc1bbd15" contextRef="c20200101to20201231" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">26,531,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
        </div>

      <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b5" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b6">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>
</ix:continuation>

      <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b6" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b7"><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Text_d7cc4244179e400cafb6c5f814b5ad21" contextRef="c20210101to20211231" escape="true" continuedAt="Text_2abb786cecb748a9907486ba148d41ab1">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">For each of the years ended December 31, 2021 and 2020, current tax provisions and current deferred tax provisions were recorded as follows:</div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b7" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b8"><ix:continuation id="Text_2abb786cecb748a9907486ba148d41ab1" continuedAt="Text_2abb786cecb748a9907486ba148d41ab2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b8" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b9"><ix:continuation id="Text_2abb786cecb748a9907486ba148d41ab2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Years ended December 31,</div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2020<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Current Tax Provision</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Federal<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" id="Fact_a9e311d8c21e426b9f1b954f442aeae3" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" id="Fact_1f9db864328a47cca7c247c9bcb47d78" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">State<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" id="Fact_2f46506173e64bc281900baec7e423de" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">5,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" id="Fact_8ec0ad7f59724d438e603affa35a6d6d" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="margin-left: 9pt;">Foreign <br />
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" id="Fact_d66347c3c335425dbe0c75d2a388c163" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" id="Fact_57ec5c42f1de4901b4dcd4ae62424b2c" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" id="Fact_5efa7cd0092d4198a72670d2475ad63f" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">5,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" id="Fact_0d6d880701f943148411fae33ae485de" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Deferred Tax Provision<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%;">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Federal<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" id="Fact_fa75863320ca4bf19d6d25a4c019f666" contextRef="c20210101to20211231" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">5,836,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" id="Fact_5f8d79f727604559b815a8580cfa778e" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">State<br />
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" id="Fact_519d796e5d254406844a32a6ce9bd036" contextRef="c20210101to20211231" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">1,433,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" id="Fact_6492cd2700aa42579bd150749ed82589" contextRef="c20200101to20201231" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">322,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="margin-left: 9pt;">Foreign <br />
              </div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">(<ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" id="Fact_718661ba35e8415ea20a3d044179aba6" contextRef="c20210101to20211231" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">1,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" id="Fact_fb6530f5dc2e47bda7d99da4e171801c" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" id="Fact_b5b26c4eb6154ff091162343a4c0605d" contextRef="c20210101to20211231" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">7,270,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" id="Fact_9d156fc9fb8d4f5c8f694d76f63b61e6" contextRef="c20200101to20201231" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">322,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">Change in valuation allowance</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1"><ix:nonFraction name="btx:EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" id="Fact_08362aef754d45cbb42b59d9825b2084" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">7,270,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="btx:EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" id="Fact_820a845a8b4743d2abdcbc0dd272ea74" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">322,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="color: rgb(0, 0, 0);">Total tax provision for income taxes</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_4f2f0e89fbbd420c90ae5f062486bc41" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">5,000</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
              <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_9c69a009813f4468b90a839b7dd70f4c" contextRef="c20200101to20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b9" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b10">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-31</span></div>

        <div style="page-break-after: always;" class="DSPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="DSPFPageHeader">
          <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
          </div>

        </div>

      </div>


      <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b10" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b11"><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Text_ef8831b411254551aae495607bc6a985" contextRef="c20210101to20211231" escape="true" continuedAt="Text_f3e8d1f469514efb89287f1dd0dd45e81">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">Deferred tax assets and liabilities consist of the effects of
        temporary differences as shown in the table below. Deferred tax assets have been fully reserved by a valuation allowance since it is more likely than not that such tax benefits will not be realized.</div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b11" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b12"><ix:continuation id="Text_f3e8d1f469514efb89287f1dd0dd45e81" continuedAt="Text_f3e8d1f469514efb89287f1dd0dd45e82">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_f3e8d1f469514efb89287f1dd0dd45e82"><ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b12" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b13">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of December 31,</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> 2021<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2020<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Deferred Tax Assets:</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Net operating losses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="btx:DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" id="Fact_265b490f71894ace9d8d67ed656927b2" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">5,454,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="btx:DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" id="Fact_332de8e5b93b4a718406c775f84d3bc2" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">747,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Foreign net operating losses<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" id="Fact_d3fa662472b046ed8713a7285a648439" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">595,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" id="Fact_825259e6e47240c2b9e7db4afc812e32" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">R&amp;D credit carryforwards</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" id="Fact_8c9d7a5e53714a13a6b4a198baebbdab" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">288,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" id="Fact_e793d6535a794bd0ba2c734a29a27de0" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Stock compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" id="Fact_89c1ab4ffabe4ef6860208058bf7de52" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,312,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" id="Fact_1178a54aa1034ed880aa62c60e6b25b5" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Vacation accrual</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" id="Fact_ed2397bd9e31421eac162cea64b93b00" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">30,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" id="Fact_a0d10417ec96430e9f4dd3bdec821b1b" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Contingent consideration</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" id="Fact_8f0451b6299d43b792eb01911632d60a" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">5,171,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" id="Fact_e1d75a1db1c84045880f1bc7be9b188f" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Deferred rent</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" id="Fact_f6377f86ebef4cf7a107d12fc0554bd3" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">40,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" id="Fact_03a99684df8c491c9fbe0af554998d98" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total gross deferred tax assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" id="Fact_4ca4711a94414de99ad4819724181b7a" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">12,890,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" id="Fact_8218f21947fa48b29efae722c4c162f0" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">747,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Valuation allowance</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" id="Fact_2a28462b2f6b416e8f96f17c0932ea81" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">12,610,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" id="Fact_d3118da38abe4d9c9fdd83995a9cb1ab" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">747,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net deferred tax assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" id="Fact_83c8ebd7165e4876b833868db35ba4e0" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">280,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" id="Fact_7f41434d42d141bba19654b9c863cea7" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Deferred Tax Liabilities:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Fixed assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" id="Fact_4ac70712dd6a4920a1e2bec6f9d8d83e" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">168,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" id="Fact_d84929e82bea4adfb286eaae71c7811f" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Intangibles - goodwill</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" id="Fact_6ac71cad98814756a41465c7af2f7f45" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">112,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" id="Fact_0c684e3608d24b5cbd5a6223fb2c5936" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total deferred tax liabilities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" id="Fact_d747908da2b54994a0b57b7eee0f984e" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">280,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilities" id="Fact_9f4f627b429c482da9129aa56de0711d" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net deferred taxes</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Fact_3a00dac283ca455b8a46418b9c4a2e49" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Fact_c614b9c36624449881629ea03cca36d4" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:zerodash">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
         </div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b13" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b14">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>
</ix:continuation>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b14" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b15"><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Text_b153d71df5ac49be98073b30e08b0673" contextRef="c20210101to20211231" escape="true" continuedAt="Text_5fe8d9f873584796ae1cdb06e14276db1">
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none;">The reconciliation of
          computed expected income taxes to effective income taxes by applying the federal statutory rate of <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_0c683b942fa0434ba3359d05b4233f9f" contextRef="c20200101to20201231" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_a5b82c74eb5f4209b58e4a310b8c20df" contextRef="c20210101to20211231" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction></ix:nonFraction>% as follows:</div>
</ix:nonNumeric></ix:continuation>
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b15" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b16"><ix:continuation id="Text_5fe8d9f873584796ae1cdb06e14276db1" continuedAt="Text_5fe8d9f873584796ae1cdb06e14276db2">
<div>&#160;<br /></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_5fe8d9f873584796ae1cdb06e14276db2"><ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b16" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b17">
<div>
          <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" rowspan="1" style="vertical-align: bottom; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of December 31,</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;2021</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;2020</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Tax at federal income tax rate</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_fc9a4317f3c14c24873d3ab61a5d3d1b" contextRef="c20210101to20211231" unitRef="U004" decimals="4" scale="-2" format="ixt:numdotdecimal">21.00</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_7efcbef84fcf4719906c1a33e1ae49bb" contextRef="c20200101to20201231" unitRef="U004" decimals="4" scale="-2" format="ixt:numdotdecimal">21.00</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">%</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">State income tax, net of federal tax</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" id="Fact_e7ccea7d0ed1475bb52d9a2fe0eb48fd" contextRef="c20210101to20211231" unitRef="U004" decimals="4" scale="-2" format="ixt:numdotdecimal">1.17</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;"><br />
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" id="Fact_396e3fe1fc504244a8d16490fcd05fe6" contextRef="c20200101to20201231" unitRef="U004" decimals="INF" scale="-2" format="ixt:zerodash">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Non-deductible expenses/excludable items</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" id="Fact_15b6cbbaccd443758ec113ce48f41a4c" contextRef="c20210101to20211231" unitRef="U004" decimals="4" sign="-" scale="-2" format="ixt:numdotdecimal">16.33</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" id="Fact_45231a99f2164df39b62f6414993a18e" contextRef="c20200101to20201231" unitRef="U004" decimals="INF" scale="-2" format="ixt:zerodash">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;">Pass-through loss <br />
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" id="Fact_3188d51d9b65470babdc93991a508bef" contextRef="c20210101to20211231" unitRef="U004" decimals="INF" scale="-2" format="ixt:zerodash">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" id="Fact_1b021e975f914319bf0d33beea9e63f3" contextRef="c20200101to20201231" unitRef="U004" decimals="4" sign="-" scale="-2" format="ixt:numdotdecimal">19.79</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Change in valuation allowance</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_ad0540e1b6a046debaec30767faf2205" contextRef="c20210101to20211231" unitRef="U004" decimals="4" sign="-" scale="-2" format="ixt:numdotdecimal">5.94</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_d1355d9900a1470fb684f0299e19a841" contextRef="c20200101to20201231" unitRef="U004" decimals="4" sign="-" scale="-2" format="ixt:numdotdecimal">1.21</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Credits</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" id="Fact_fbe26a4bc5294adda1226cb3a0302f84" contextRef="c20210101to20211231" unitRef="U004" decimals="4" scale="-2" format="ixt:numdotdecimal">0.24</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" id="Fact_abe6ee74ab154f91bd2a6eda41f726d9" contextRef="c20200101to20201231" unitRef="U004" decimals="INF" scale="-2" format="ixt:zerodash">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" id="Fact_3a46a533321a445aad6262f9a125bb56" contextRef="c20210101to20211231" unitRef="U004" decimals="4" sign="-" scale="-2" format="ixt:numdotdecimal">0.14</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" id="Fact_091e7767b06b43f1a038fdda5caf78b6" contextRef="c20200101to20201231" unitRef="U004" decimals="INF" scale="-2" format="ixt:zerodash">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Provision for income taxes</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_68673ff44a7847209b33d2727eb2d4af" contextRef="c20210101to20211231" unitRef="U004" decimals="4" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>.00</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">% <br />
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_31a1d98b66a940c6ad4e5ce9de2894b7" contextRef="c20200101to20201231" unitRef="U004" decimals="4" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>.00</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">% <br />
                </td>

  </tr>


</table>
          </div>
</ix:continuation></ix:continuation><ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b17" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b18">
<div>
        &#160;</div>
</ix:continuation></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b18" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b19">
<div style="text-align: justify;">The net increase in the total valuation allowance for the year ended December 31, 2021 was an increase of $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" id="Fact_94dac22c18d74dd4b29a91edf77ff5c9" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">11,863,000</ix:nonFraction>
          of which $<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" id="Fact_683ad3e2d37b4cb19766eb3632ffb3b3" contextRef="c20210101to20211231" unitRef="U001" decimals="0" sign="-" scale="0" format="ixt:numdotdecimal">7,270,000</ix:nonFraction> relates to the current year deferred expense and $<ix:nonFraction name="us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" id="Fact_a37f999d19bd48219a7e97c1d46bba7f" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">4,593,000</ix:nonFraction> relates to the purchase accounting related to the 2021 business combinations. In assessing the realizability of deferred tax assets, management considers whether it
          is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary
          difference become deductible. Management considered the scheduled reversal of deferred tax liabilities, projected future taxable income and planning strategies in making this assessment.&#160; Based on the level of historical operating results and
          projections for the taxable income for the future, management has determined that it is more likely than not that the deferred taxes assets will not be utilized. Accordingly, the Company has recorded a full valuation allowance. </div>
</ix:continuation>
        <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b19" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b20">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
          <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-32</span></div>

          <div style="page-break-after: always;" class="DSPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="DSPFPageHeader">
            <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
            </div>

          </div>

        </div>

        <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b20" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b21">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">At December 31, 2021 and 2020 the Company has available net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_e7438b6e622b49699205541c96becbe4" contextRef="c20211231_IncomeTaxAuthorityAxis_DomesticCountryMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">20,679,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_304ff06eec7b4bf9a00d4edd820a54ec" contextRef="c20201231_IncomeTaxAuthorityAxis_DomesticCountryMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction> for federal income
          tax purposes, respectively, of which $<ix:nonFraction name="btx:TaxCutsAndJobsActOperatingLossCarryforwards" id="Fact_925e7d2469d74f06a702b6a8e6f15742" contextRef="c20211231_IncomeTaxAuthorityAxis_DomesticCountryMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">20,679,000</ix:nonFraction> can be carried forward indefinitely. The Company has available $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_77f2805fe58742cfa78431788f5f9ef1" contextRef="c20211231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">1,397,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_d10f092b5f0e43138e499bf82055a7eb" contextRef="c20201231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">747,000</ix:nonFraction> state NOLs for
          the years ended December 31, 2021 and 2020, respectively.&#160; The Company also has foreign NOL carryforwards of $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_f9e7f3c2be814c76a87c8ddb2ec86703" contextRef="c20211231_IncomeTaxAuthorityAxis_ForeignCountryMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">4,759,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_fef5291caedf49cba9b2b983b96bc461" contextRef="c20201231_IncomeTaxAuthorityAxis_ForeignCountryMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction> for the years ended December 31, 2021 and 2020, respectively, which carry forward indefinitely. Section 382 of the Internal Revenue Code (&#8220;IRC&#8221;)
          imposes limits on the ability to use NOL carryforwards that existed prior to a change in control to offset future taxable income. Such limitations would reduce, potentially significantly, the gross deferred tax assets disclosed in the table above
          related to the NOL carryforwards.&#160; The Company continues to disclose the NOL carryforwards at their original amount in the table above as no potential limitation has been quantified. The Company has also established a full valuation allowance for
          all deferred tax assets, including the NOL carryforwards, since the Company could not conclude that it was more likely than not able to generate future taxable income to realize these assets.</div>
</ix:continuation>
        <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b21" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b22">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b22" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b23">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">At December 31, 2021 and 2020 the Company has federal and state income tax credit carryforwards of approximately $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" id="Fact_fdf4876693344d52862178337afadfbc" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">288,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" id="Fact_358c11aaa6704118a31dc96dbffc046d" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction>, respectively. The
          credits begin to expire in <ix:nonNumeric name="btx:TaxCreditCarryforwardExpirationYear" id="Fact_4a976f2722254da5abfb2186d0b01d33" contextRef="c20210101to20211231">2041</ix:nonNumeric>.</div>
</ix:continuation>
        <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b23" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b24">
<div><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b24" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b25">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the
          largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The Company has <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_e91ba18a98a340238b6ef43a5ccefb34" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> uncertain tax positions as of December 31, 2021 or December 31, 2020.</div>
</ix:continuation>
        <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b25" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b26">
<div><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b26" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b27">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">The Company recognizes interest and penalties related to unrecognized tax positions within the income tax expense line in the accompanying
          consolidated statements of operations. There were <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" id="Fact_8002768c28014cc19ce6279bc21c3fc8" contextRef="c20201231" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" id="Fact_6031b02dc475448dbe58cc0f8619fb75" contextRef="c20211231" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> accrued interest and penalties associated with uncertain tax positions as of
          December 31, 2021 or December 31, 2020.</div>
</ix:continuation>
        <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b27" continuedAt="Text_72ab25326c554fa3be0b814c55bd383b28">
<div><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_72ab25326c554fa3be0b814c55bd383b28">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">The Company is subject to U.S. federal, state, and foreign income tax. Tthe Company&#8217;s income tax returns are subject to examination by the
          relevant taxing authorities. As of December 31, 2021, the <span style="-sec-ix-hidden:Fact_145d916fadf245a7a67bdeb44d432d49">2018 &#8211; 2021</span> tax years remain subject to examination in the U.S. federal tax,
          various state, and foreign tax jurisdictions. The Company is not currently under examination by federal state, or foreign jurisdictions.</div>
</ix:continuation>

        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="us-gaap:PostemploymentBenefitsDisclosureTextBlock" id="Text_3178f0d4fceb4ece9409a7bdbe752f2e" contextRef="c20210101to20211231" escape="true" continuedAt="Text_770a911ba57c42778a093703848a5f061">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 35.9pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">16)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Retirement Savings Plan</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_770a911ba57c42778a093703848a5f061" continuedAt="Text_770a911ba57c42778a093703848a5f062">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_770a911ba57c42778a093703848a5f062">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company established a defined contribution plan, organized under Section 401(k) of the Internal Revenue Code, which allows employees to defer
        up to <ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" id="Fact_921a15b29844417ca8afab80d3ab0a6d" contextRef="c20210101to20211231" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">90</ix:nonFraction>% of their pay on a pre-tax basis. The Company does not contribute a match to the employees&#8217; contribution.</div>
</ix:continuation>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" id="Text_70b25e83691d4a44b87beca2cb618a2c" contextRef="c20210101to20211231" escape="true" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b121">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 35.9pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">17)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Subsequent Events</div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b121" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b122">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b122" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b123">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;">Private Placement of
            Equity</div>
</ix:continuation>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b123" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b124">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
          </div>
</ix:continuation>
        </div>

        <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b124" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b125">
<div style="text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On
              March 6, 2022, the Company entered into a certain Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with an investor (the &#8220;PIPE Investor&#8221;) providing for the private placement (the &#8220;PIPE Transaction&#8221;) to a private investor (the &#8220;PIPE
              Investor&#8221;) of approximately <ix:nonFraction name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" id="Fact_7ec1f64bd93b47759ce509844f4e51b4" contextRef="c20220306_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">6,857,000</ix:nonFraction> units (collectively, the &#8220;Units&#8221;), each Unit consisting of (i) <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" id="Fact_6bf13b247fb14e5e9f806b049eabbe0a" contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> share of our common stock (or, in lieu thereof, one pre-funded warrant (the &#8220;Pre-Funded Warrants&#8221;) to purchase one share of common stock) and
              (ii) <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" id="Fact_d78c3ea3487b4a26a3f4c4842fab2bd3" contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> warrant (the &#8220;Common Warrants&#8221;) to purchase one share of common stock, for an aggregate gross purchase price of
              approximately $<ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" id="Fact_b056869187e949c19369d11f518d0238" contextRef="c20220306_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction> million. The PIPE Transaction closed on March 9, 2022.</span></div>
</ix:continuation>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b125" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b126">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></div>

        <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b126" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b127">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b127" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b128">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b128" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b129">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b129" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1210">
<div style="text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Each
              Pre-Funded Warrant has an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_0db429bd91d14f47ab937f536eea849b" contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U003" decimals="3" scale="0" format="ixt:numdotdecimal">0.005</ix:nonFraction> per share of common stock, was immediately exercisable and may be exercised at
              any time and has no expiration date and is subject to customary adjustments. The Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed <ix:nonFraction name="btx:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" id="Fact_cef2cbdb54974f228628f4b8baab6c93" contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="4" scale="-2" format="ixt:numdotdecimal">9.99</ix:nonFraction>% immediately after exercise thereof.</span></div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1210" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1211">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1211" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1212">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1212" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1213">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1213" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1214">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1214" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1215">
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Each Common Warrant
            has an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_9318c99748314d94bb4587d6c0a4abcd" contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U003" decimals="2" scale="0" format="ixt:numdotdecimal">1.91</ix:nonFraction> per share, becomes exercisable <ix:nonNumeric name="btx:ClassOfWarrantOrRightsExercisableTerm" id="Fact_01122293d73f48379714730fea794eb5" contextRef="c20220306to20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember" format="ixt-sec:durwordsen">six months</ix:nonNumeric> following the closing of the PIPE Transaction, and expires <span style="-sec-ix-hidden:Fact_2d5f06641c0a4e39b73cdc701f6abe8c">five-and-one-half years</span> from the date of issuance, and is subject to customary adjustments. The Common Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed <ix:nonFraction name="btx:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" id="Fact_df61f2cf57674aba834a295e5216f1a4" contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="4" scale="-2" format="ixt:numdotdecimal">4.99</ix:nonFraction>% immediately after exercise thereof, subject to increase to <ix:nonFraction name="btx:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" id="Fact_0b546ce7ae2a47129d4c167085f6c26f" contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="4" scale="-2" format="ixt:numdotdecimal">9.99</ix:nonFraction>% at the option of the holder.</div>
</ix:continuation>
        </div>

        <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1215" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1216">
<div><br />
          </div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
            <div style="text-align: center;" class="DSPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-33</span></div>

            <div style="page-break-after: always;" class="DSPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div style="width: 100%;" class="DSPFPageHeader">
              <div><a href="#TABLE"><span style="font-size: 8pt; font-style: italic;">Table of Contents</span></a><br />
              </div>

            </div>

          </div>

        </div>

        <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1216" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1217">
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In connection with
            the PIPE Transaction, the Company and the PIPE Investor also entered into a registration rights agreement, dated March 6, 2022, pursuant to which the Company agreed to prepare and file a registration statement with the SEC no later than 15 days
            following the filing date of this Annual Report on Form 10-K to register the resale of the shares of common stock included in the Units and the shares of common stock issuable upon exercise of the Pre-Funded Warrants and the Common Warrants.
            The Company agreed to use its best efforts to have such registration statement declared effective as promptly as possible after the filing thereof, subject to certain specified penalties if timely effectiveness is not achieved.</div>
</ix:continuation>
        </div>

        <div>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1217" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1218">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1218" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1219">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;">Reduction in Force</div>
</ix:continuation>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1219" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1220">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1220" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1221">
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On January 3, 2022,
            the Company completed a reduction in force (the &#8220;Reduction&#8221;), comprising <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" id="Fact_b396b4ee24f8480795e4003284534eec" contextRef="c20220103to20220103_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U014" decimals="INF" scale="0" format="ixt-sec:numwordsen">eight</ix:nonFraction> employees (<ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" id="Fact_fcff5db4e43b46f6b79a594b3cd4b85e" contextRef="c20220103to20220103_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">53</ix:nonFraction>% of our workforce at that time), effective January 3, 2022, which was the date on which the Company notified such employees of their termination. The Company believes
            the Reduction, which was approved by its Board of Directors, will enable the Company to better align its workforce with the needs of its business and focus more of its capital resources on the Company&#8217;s cell therapy and gene editing platform,
            as it continues to sustain its investment in the prosecution of IRX-2 through the end of the INSPIRE Phase 2B study. In connection with the Reduction, the Company estimates that it will incur approximately $<ix:nonFraction name="us-gaap:SeveranceCosts1" id="Fact_e60bf6063a964fdda11c7a9eb776c19e" contextRef="c20220103to20220103_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">500,000</ix:nonFraction> for severance and termination-related costs, which the Company will record during the first quarter of 2022. The Company may also incur
            additional costs and non-cash charges that are not currently contemplated or determinable, which may occur as a result of the Reduction.</div>
</ix:continuation>
        </div>

        <div>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1221" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1222">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1222" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1223">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;">Lease Assignment</div>
</ix:continuation>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1223" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1224">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1224" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1225">
<div style="text-align: justify;">On March 5, 2022, the Company entered into an Agreement to Assign Space Lease with RegenLab USA LLC<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> (&#8220;Regen&#8221;) pursuant to which the Company agreed to assign its Brooklyn, NY lease (the &#8220;Brooklyn Lease&#8221;) to Regen. The effective date of the
              assignment would be contingent upon, among other things, a consent from BioBat, Inc. (the &#8220;Landlord&#8221;) to assign the Brooklyn Lease. Additionally, Regen agreed to purchase certain equipment from the Company for $<ix:nonFraction name="btx:LesseeCommitmentToPurchaseProperty" id="Fact_d1bfcc27b61d4a26857334469da4dd85" contextRef="c20220305_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">50,000</ix:nonFraction>, partly reimburse the Company $<ix:nonFraction name="btx:UnamortizedLeaseholdImprovements" id="Fact_9fcdb7790346436580b4421281765dca" contextRef="c20220305_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">50,000</ix:nonFraction>
              toward certain existing unamortized leasehold improvements, and to reimburse the Company for the existing security deposit the Company had under the Brooklyn Lease of approximately $<ix:nonFraction name="us-gaap:DepositAssets" id="Fact_adcf3390e51b4672809c7df32dab0bbc" contextRef="c20220305_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">63,000</ix:nonFraction>.</span></div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1225" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1226">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1226" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1227">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1227" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1228">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1228" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1229">
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On March 25, 2022,
            the Company entered into an Assignment and Assumption of Lease Agreement (the &#8220;Assignment Agreement&#8221;) with Regen, the consent of which was provided by the Landlord in the Assignment Agreement. The effective date of the assignment was March 28,
            2022. Under the Assignment Agreement, Regen (i) accepts the assignment of the Brooklyn Lease; (ii) assumes all of the obligations, liabilities, covenants and conditions of the Company&#8217;s as tenant under the Brooklyn Lease; (iii) assumes and
            agrees to perform and observe all of the obligations, terms, requirements, covenants and conditions to be performed or observed by the Company under the Brooklyn Lease; and (iv) makes all of the representations and warranties binding under the
            Brooklyn Lease with the same force and effect as if Regens had executed the Brooklyn Lease originally as the tenant.</div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1229" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1230">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1230" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1231">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1231" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1232">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1232" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1233">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1233" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1234">
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Notwithstanding the
            above assumptions above by Regen, the Company shall be and remain liable and responsible for the due keeping, and full performance and observance, of all the provisions of the Brooklyn Lease on the part of the tenant to be kept, performed and
            observed. As a result of the Assignment Agreement, the Company will write off the remaining ROU asset balance and the corresponding lease liability as of March 25, 2022, and it will record any resulting gain or loss on the termination of the
            Brooklyn lease in its statement of operations.&#160; The Company does not expect to recognize a contingent liability for its ongoing obligation to remain liable and responsible for all the provisions of the Brooklyn Lease, as the Company has
            determined that it is not probable it will recognize a loss under the Assignment Agreement.</div>
</ix:continuation>
        </div>

        <div>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1234" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1235">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1235" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1236">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;">New Lease Agreement</div>
</ix:continuation>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1236" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1237">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
          </div>
</ix:continuation>
        </div>

        <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1237" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1238">
<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On March 31, 2022,
            the Company entered into the Torrey Pines Science Center Lease in San Diego, California (the &#8220;San Diego Lease&#8221;) with Torrey Pines Science Center Limited Partnership for approximately <ix:nonFraction name="btx:OperatingLeaseArea" id="Fact_1529fd58bfd84b4f8277fccffcce884d" contextRef="c20220331_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U007" decimals="0" scale="0" format="ixt:numdotdecimal">5,200</ix:nonFraction> square feet of lab and office space. The term of the San Diego Lease is <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Fact_b3bd67fc49ef48578a2a54c35e69e8ad" contextRef="c20220331_SubsequentEventTypeAxis_SubsequentEventMember" format="ixt-sec:durmonth">62</ix:nonNumeric>
            months and the lease commencement date begins on the earlier to occur of (i) the date the Company first commences to conduct business in the premises or (ii) the possession date, which is anticipated to be August 1, 2022 (or earlier if the
            current tenant terminates its lease early). The lease commencement date was April <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">15</span>, 2022.</div>
</ix:continuation>
        </div>

        <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1238" continuedAt="Text_cc5e82f439a9461193c27f15a2a02b1239">
<div><br />
          </div>
</ix:continuation>
        </div>

        <div>
          <ix:continuation id="Text_cc5e82f439a9461193c27f15a2a02b1239">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;">Base rent is $<ix:nonFraction name="btx:BaseRentPerSquareFoot" id="Fact_02b04f3e1fc94b91bb11946f5f10f373" contextRef="c20220331to20220331_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U007" decimals="2" scale="0" format="ixt:numdotdecimal">6.35</ix:nonFraction> per square foot in the first year of the San Diego Lease, with a rent abatement for the second and third full months of the first year. The
            base rent will increase by approximately <ix:nonFraction name="btx:PercentageBaseRentIncreaseOnEachAnniversary" id="Fact_41b330afb9c74a79a6c33ee94b04e3f5" contextRef="c20220331_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>% on each anniversary of the lease commencement date. The Company is also required to pay
            its share of operating expenses and property taxes. The San Diego Lease provides for a one-time option to extend the lease term for an additional <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact_ff13e4c263c4470b9da9551eabdae1d1" contextRef="c20220331_SubsequentEventTypeAxis_SubsequentEventMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> at the then fair rental value.</div>
</ix:continuation>
           </div>

      </div>

      <div><br />
      </div>

      <div><br />
      </div>

      <div style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" class="DSPFPageNumber">F-34</span> </div>

      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    </div>

  </div>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>brhc10036185_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman';"> </font>
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit 4.1</div>
      <div style="font-family: 'Times New Roman';"><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES REGISTERED</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">General</div>
      <div style="font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">As of the end of the period covered by the most recent Annual Report on Form 10-K of Brooklyn ImmunoTherapeutics, Inc<font style="font-size: 10pt;">.</font> (the &#8220;registrant&#8221;), the common stock, par value $0.005 per share, of the registrant (&#8220;common stock&#8221;) was registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Unless the context
        otherwise requires, all references herein to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; &#8220;Company&#8221; and &#8220;us&#8221; refer to Brooklyn ImmunoTherapeutics, Inc.</div>
      <div style="font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following description of the common stock is a summary and does not purport to be complete and is qualified in its entirety by reference to
        the terms and provisions contained in our restated certificate of incorporation, including the amendments thereto, which we refer to as our certificate of incorporation, and our amended and restated bylaws, which we refer to as our bylaws, which
        are incorporated by reference as exhibits to our most recently filed Annual Report on Form 10-K, of which this exhibit forms a part.</div>
      <div style="font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Our common stock and the rights of the holders of our common stock are subject to the applicable provisions of the General Corporation Law of the
        State of Delaware, which we refer to as the DGCL, our certificate of incorporation and our bylaws. The description below of our common stock and provisions of our certificate of incorporation and our bylaws are summaries and are qualified by
        reference to our certificate of incorporation and our bylaws, as applicable, and by the applicable provisions of the DGCL. We encourage you to read that law and those documents carefully.</div>
      <div style="font-family: 'Times New Roman';">&#160;</div>
      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Common Stock</div>
      </div>
      <div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Our authorized capital stock consists of 100,000,000 shares of common stock, par value $0.005 per share, and 1,000,000 shares of preferred
          stock, par value $0.005 per share (the &#8220;preferred stock&#8221;). A total of 156,112 shares of preferred stock have been designated as Series A Convertible Preferred Stock. As of April 12, 2022, 51,951,937 shares of common stock were outstanding and
          156,112 shares of Series A Convertible Preferred Stock were outstanding.</div>
      </div>
      <div style="font-family: 'Times New Roman';">
        <div><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Voting Rights</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the
          election of directors. Votes may be cast in person or by proxy. Stockholders do not have cumulative voting rights with respect to election of directors.</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Dividends</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The holders of Series A convertible preferred stock are entitled to receive cumulative dividends of $0.10 per share per annum, payable
          semiannually in equal installments of $0.05 per share on June 1 and December 1 of each year. After the requirements with respect to the preferential dividends of the preferred stock have been met, holders of common stock are entitled to receive
          proportionately any dividends as may be declared and paid on common stock from funds lawfully available therefor as and when determined by the board of directors, subject to any preferential dividend rights of outstanding preferred stock.</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Liquidation and Dissolution</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately all assets available for
          distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock.</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Other Rights</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Holders of common stock have no preemptive, subscription, redemption or
            conversion rights and there are no sinking fund provisions with respect to our common stock. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares
            of any series of preferred stock. All of the shares of the common stock currently issued and outstanding are fully-paid and nonassessable.</font></div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Provisions of Our Certificate of Incorporation and Bylaws and Delaware General Corporation Law may have Anti-Takeover Effects</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Our certificate of incorporation and bylaws and the DGCL contain provisions that could have the effect of delaying, deferring or discouraging
          another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids and are designed in part to encourage persons seeking to acquire control
          of us to first negotiate with the board of directors.</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Number of Directors; Vacancies</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Our certificate of incorporation provides that the number of directors is established by the board of directors, which may delay the ability of
          stockholders to change the composition of a majority of the board. The board has the exclusive right to elect a director to fill any vacancy or newly created directorship.</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Removal of Directors</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">A director may be removed only by the affirmative vote of the holders of at least 80% of the voting power of all shares entitled to vote
          generally in the election of directors, voting together as a single class.</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Stockholder Action by Written Consent; Special Meetings</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Our certificate of incorporation provides that any action required or permitted to be taken by our stockholders must be effected at a duly
          called annual or special meeting of such holders and may not be effected by any consent in writing by such holders. Our certificate of incorporation and bylaws also provide that, except as otherwise required by law, special meetings of our
          stockholders can only be called by the board of directors. These provisions may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors.</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Advance Notice Requirements for Stockholder Proposals</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including
          proposed nominations of persons for election to the board of directors. Stockholders at an annual meeting may consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board
          or by a stockholder of record on the record date for the meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder&#8217;s intention to bring such business before the
          meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities.</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Delaware Business Combination Statute</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">We are a Delaware corporation subject to Section 203 of the DGCL. Under Section 203, certain &#8220;business combinations&#8221; between a Delaware
          corporation whose stock is listed on a national securities exchange or held of record by more than 2,000 stockholders and an &#8220;interested stockholder&#8221; are prohibited for a three-year period following the date that such stockholder became an
          interested stockholder, unless:</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze4e20f46eef040c483ab76c6316e8c1f">

            <tr>
              <td style="width: 18pt; font-family: 'Times New Roman';"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman';">
                <div style="color: rgb(0, 0, 0); font-size: 10pt;"> the corporation has elected in its certificate of incorporation not to be governed by Section 203;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-family: 'Times New Roman';">
        <div><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3cdadb66613343dab7ecbcf8f409e7a7">

            <tr>
              <td style="width: 18pt; font-family: 'Times New Roman';"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman';">
                <div style="color: rgb(0, 0, 0); font-size: 10pt;">the business combination or the transaction which resulted in the stockholder becoming an interested stockholder was approved by the board of directors of the corporation before the date of
                  the business combination or the date such stockholder became an interested stockholder, as applicable;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-family: 'Times New Roman';"><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb4563c2ffad74ce69c8be491493ff149">

            <tr>
              <td style="width: 18pt; font-family: 'Times New Roman';"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman';">
                <div style="color: rgb(0, 0, 0); font-size: 10pt;">upon consummation of the transaction that made such stockholder an interested stockholder, the interested stockholder owned at least 85% of the &#8220;voting stock&#8221; (as defined in Section 203) of
                  the corporation outstanding at the commencement of the transaction excluding voting stock owned by directors who are also officers or held in employee benefit plans in which the employees do not have a confidential right to tender stock
                  held by the plan in a tender or exchange offer; or</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-family: 'Times New Roman';">
        <div><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7c2faec6907447239105da8d85702ec2">

            <tr>
              <td style="width: 18pt; font-family: 'Times New Roman';"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman';">
                <div style="color: rgb(0, 0, 0); font-size: 10pt;">the business combination is approved by the board of directors and by the stockholders (acting at a meeting and not by written consent) by the affirmative vote of at least 66-2/3% of the
                  outstanding voting stock which is not &#8220;owned&#8221; (as defined in Section 203) by the interested stockholder.</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The three-year prohibition also does not apply to some business combinations proposed by an interested stockholder following the announcement or
          notification of an extraordinary transaction involving the corporation and a person who had not been an interested stockholder during the previous three years or who became an interested stockholder with the approval of a majority of the
          corporation&#8217;s directors. The term &#8220;business combination&#8221; is defined generally to include mergers or consolidations between a Delaware corporation and an interested stockholder, transactions with an interested stockholder involving the assets or
          stock of the corporation or its majority-owned subsidiaries and transactions which increase an interested stockholder&#8217;s percentage ownership of stock, or other transaction resulting in a financial benefit to the interested stockholder. The term
          &#8220;interested stockholder&#8221; is defined generally as those stockholders who become beneficial owners of 15% or more of a Delaware corporation&#8217;s voting stock, together with the affiliates or associates of that stockholder.</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Certificate of Incorporation or Bylaws</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Any provision of our certificate of incorporation may be amended, altered, changed or repealed in any manner prescribed by law; provided, that
          (a) the affirmative vote of the holders of at least 80% of the voting power of all shares entitled to vote generally in the election of directors, voting together as a single class, is required to alter, amend, or repeal, or adopt any provision
          inconsistent with Article X of the certificate of incorporation, which contains the prohibition on stockholder action by written consent and the requirement that special meetings be called only by the board of directors, and (b) Article XI of the
          certificate of incorporation, provides that, subject to certain exceptions, no purchase by or from any Controlling Person (as defined below) of shares of our stock owned by such Controlling Person shall be made at a price exceeding the average
          price paid by such Controlling Person for all shares of our stock acquired by such Controlling Person during the two-year period preceding the date of such proposed purchase unless such purchase is approved by the affirmative vote of not less
          than a majority of the voting power of the shares of our stock entitled to vote held by Disinterested Stockholders (as defined below), may not be amended without the affirmative vote of not less than a majority of the our stock entitled to vote
          thereon, provided that if, at the time of such vote, there shall be one or more Controlling Persons, such affirmative vote shall include the affirmative vote in favor of such amendment of not less than a majority of the voting power of the shares
          of our stock entitled to vote thereon held by Disinterested Stockholders. &#8220;Controlling Person&#8221; means any individual, corporation, partnership, trust, association or other organization or entity (including any group formed for the purpose of
          acquiring, voting or holding our securities) which either directly, or indirectly through one or more intermediaries, owns, beneficially or of record, or controls by agreement, voting trust or otherwise, at least 10% of the voting power of stock,
          and such term also includes any corporation, partnership, trust, association or other organization or entity in which one or more Controlling Persons have the power, through the ownership of voting securities, by contract, or otherwise, to
          influence significantly any of the management, activities or policies of such corporation, partnership, trust, association, other organization or entity. &#8220;Disinterested Stockholders&#8221; means those holders of stock entitled to vote on any matter,
          none of which is a Controlling Person.</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The board may, by majority vote, amend or repeal our bylaws and may adopt new bylaws.</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Our stockholders may not adopt, amend, or repeal our bylaws or adopt new bylaws except by the vote or written consent of at least 66-2/3% of the
          voting power of our company.</div>
        <div style="font-family: 'Times New Roman';">&#160;</div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exclusive Forum Selection</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the a state court located in the State of
          Delaware (or if no state court has jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (a) any derivative action or proceeding brought on our behalf, (b) any action asserting a claim of
          breach of a fiduciary duty owed by any of our directors or officers to our company or stockholders, (c) any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our certificate of
          incorporation or amended and restated bylaws, or (d) any action asserting a claim against us governed by the internal affairs doctrine. Although our bylaws contain the choice of forum provision described above, it is possible that a court could
          rule that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable.</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Authorized but Unissued Shares</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Our authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval, subject
          to any limitations imposed by the listing requirements of The Nasdaq Global Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but
          unissued and unreserved common stock and preferred stock could make it more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Listing on The Nasdaq Global Market</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The common stock is listed on The Nasdaq Global Market under the symbol &#8220;BTX.&#8221;</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Transfer Agent and Registrar</div>
        <div style="font-family: 'Times New Roman';"><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The transfer agent and registrar for the common stock is Computershare Trust Company, N.A.</div>
        <div style="font-family: 'Times New Roman';">&#160;</div>
      </div>
      <div style="font-family: 'Times New Roman';"><br>
      </div>
      <div style="font-family: 'Times New Roman';">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
  <font style="font-family: 'Times New Roman';"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>3
<FILENAME>brhc10036185_ex10-26.htm
<DESCRIPTION>EXHIBIT 10.26
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div> <font style="color: rgb(0, 0, 0);"> </font>
      <div>
        <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
        <div>
          <div>
            <div style="color: rgb(0, 0, 0); text-align: right;"><font style="font-weight: bold;">Exhibit 10.26</font><br>
            </div>
            <div style="color: rgb(0, 0, 0);">&#160;</div>
            <div style="text-align: center;"><u><font style="color: rgb(0, 0, 0);">TENANT: BROOKLYN IMMUNOTHERAPEUTICS, INC.</font></u></div>
            <div style="color: rgb(0, 0, 0);"><br>
            </div>
            <div style="text-align: center;"><font style="color: rgb(0, 0, 0);"><font style="font-weight: bold;">LEASE</font></font></div>
            <div style="color: rgb(0, 0, 0);">&#160;</div>
            <div style="text-align: justify;"><font style="font-style: italic; color: rgb(0, 0, 0);">LEASE </font><font style="color: rgb(0, 0, 0);">dated as of the 15<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> <font style="color: rgb(0, 0, 0);">day </font>of June 2021, in which the Landlord and the Tenant are the parties hereinafter named, and which relates to the Premises, as defined below, within a building located at 1035 Cambridge Street,
                Cambridge, Massachusetts (the &#8220;Building&#8221;). The undersigned parties do hereby covenant and agree with each other as follows:</font></div>
            <div style="color: rgb(0, 0, 0);">&#160;</div>
            <div style="color: rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE I</div>
            </div>
          </div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <table cellspacing="0" cellpadding="0" id="za421566a07ed4e78aef7a806ddd56271" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.9pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">1.1</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">DEFINITIONS</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div>
            <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Additional Rent: </font><font style="color: rgb(0, 0, 0);">Escalation Charges and other charges due to Landlord from Tenant pursuant to the provisions of this Lease.</font></div>
            <br>
            <div>
              <div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zb2096e7163834302840020f2c99c0953" class="DSPFListTable">

                      <tr style="vertical-align: top;">
                        <td style="vertical-align: top; width: 153pt;">
                          <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Address for Rent Payments:</font></div>
                        </td>
                        <td style="vertical-align: top; width: auto;">
                          <div style="text-align: left;"><font style="color: rgb(0, 0, 0);">Fairlane Columbia, LLC</font></div>
                          <div style="text-align: left;">
                            <div><font style="color: rgb(0, 0, 0);">P.O. Box 844033</font></div>
                            <div><font style="color: rgb(0, 0, 0);">Boston, MA 02284-4033</font></div>
                            <font style="color: rgb(0, 0, 0);"> </font></div>
                        </td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
            <br>
            <div style="color: rgb(75, 79, 82);"><font style="font-weight: bold; color: rgb(0, 0, 0);">Approved Subtenants: </font><font style="color: rgb(0, 0, 0);">None</font></div>
            <br>
            <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Base Rent: </font><font style="color: rgb(0, 0, 0);">$151,984.00 per annum; $12,665.33 per month ($56.00/RSF) for the first Lease Year and increasing as of
                July 1 of each Lease Year by the year-over-year increase of the Consumer Price Index (CPI) multiplied times the prior year&#8217;s Base Rent.</font></div>
            <br>
            <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Base Condominium Fees: </font><font style="color: rgb(0, 0, 0);">Condominium Fees paid, payable or incurred by Landlord in Calendar Year 2021 for the Unit.</font></div>
            <br>
            <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Base Taxes: </font><font style="color: rgb(0, 0, 0);">Real estate taxes assessed by the City of Cambridge against the Unit for the 2021 Fiscal Year ending June 30, 2019.</font></div>
            <br>
            <div style="color: rgb(75, 79, 82);"><font style="font-weight: bold; color: rgb(0, 0, 0);">Broker: </font><font style="color: rgb(0, 0, 0);">None</font></div>
            <br>
            <div style="color: rgb(75, 79, 82);"><font style="font-weight: bold; color: rgb(0, 0, 0);">Building: </font><font style="color: rgb(0, 0, 0);">1035 Cambridge Street, Cambridge, Massachusetts 02141</font></div>
            <br>
            <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Business Days: </font><font style="color: rgb(0, 0, 0);">Monday through Friday excepting legal holidays in Massachusetts as provided in Exhibit F attached
                hereto.</font></div>
            <br>
            <div style="color: rgb(75, 79, 82);"><font style="font-weight: bold; color: rgb(0, 0, 0);">Business Hours: </font><font style="color: rgb(0, 0, 0);">8:00 AM to 5:00 PM</font></div>
            <br>
            <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Commencement Date: </font><font style="color: rgb(0, 0, 0);">June 15, 2021</font></div>
            <br>
            <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Common Areas: </font><font style="color: rgb(0, 0, 0);">Hallways, entryways, stairs, bathrooms, lobby, service areas, driveway, Parking Lot, loading dock,
                freight elevator and all other areas and facilities in the Building and Property which are provided and designated from time to time by the Condominium for the nonexclusive use and convenience of Tenant with other tenants of the Building
                and their respective employees, invitees, licensees or other visitors.</font></div>
            <br>
            <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Condominium: </font><font style="color: rgb(0, 0, 0);">The 432 Columbia Street Condominium, consisting of the land and buildings located at the Property,
                created by the Master Deed.</font></div>
            <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
              </font></div>
          </div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <!--PROfilePageNumberReset%Num%2%%%-->
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Condominium Documents: </font><font style="color: rgb(0, 0, 0);">Master Deed, Condominium Trust, By-Laws, and Rules and Regulations of the Condominium, as
              they may be modified from time to time.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Condominium Fees: </font><font style="color: rgb(0, 0, 0);">Fees charged to the Unit by the Condominium Trust and paid by the Landlord to the Condominium
              Trust for various expenses of the Condominium, as specified in Section 9.2 of the Lease.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Condominium Telephone Closet: </font><font style="color: rgb(0, 0, 0);">Telephone closet located on the Building&#8217;s Lower Level within Suite 9.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Condominium Trust: </font><font style="color: rgb(0, 0, 0);">The 432 Columbia Street Condominium Trust, dated January 22, 1988 and recorded at Book 18837,
              Page 158, including the By-Laws incorporated therein, as the same may be amended from time to time, and the Rules and Regulations incorporated therein, as the same may be amended by the Condominium Trustees from time to time.</font></div>
          <br>
          <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Condominium Trustees: </font><font style="color: rgb(0, 0, 0);">The elected representatives of the Condominium Trust.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Conference Center: </font><font style="color: rgb(0, 0, 0);">The conference room, designated as Suite 5, located in the Building&#8217;s Lower Level.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Consumer Price Index (CPI): </font><font style="color: rgb(0, 0, 0);">The CPI for Urban Wage Earners and Clerical Workers (&#8220;CPI-W&#8221;) as provided by the U.S.
              Bureau of Labor Statistics (&#8220;USBLS&#8221;). In the event that USBLS no longer compiles the CPI-W or the USBLS ceases to exist, then Landlord shall use the Consumer Price Index for All Urban Consumers (&#8220;CPI-U&#8221;) or any other CPI compiled by any
              agency of the United States Government as reasonably selected by Landlord.</font></div>
          <br>
          <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Default by Landlord: </font><font style="color: rgb(0, 0, 0);">As determined in accordance with Section 13.2 of this Lease.</font></div>
          <br>
          <div style="color: rgb(79, 82, 84);"><font style="font-weight: bold; color: rgb(0, 0, 0);">Default by Tenant: </font><font style="color: rgb(0, 0, 0);">As determined in accordance with Section 13.1 of this Lease.</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Escalation Percentage: </font><font style="color: rgb(0, 0, 0);">100% of the Unit</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Escalation Charges: </font><font style="color: rgb(0, 0, 0);">The amounts charged to Tenant for Real Estate Tax Payments and Condominium Fee Payments
              pursuant to Articles VIII and IX.</font></div>
          <br>
          <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Expiration Date: </font><font style="color: rgb(0, 0, 0);">June 30, 2028.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Fair Market Rent: </font><font style="color: rgb(0, 0, 0);">Based on Landlord&#8217;s reasonable analysis of monthly parking charges of garages and parking lots
              within a one (1) mile radius of the Building.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="color: rgb(0, 0, 0);">
            <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Landlord:</font><font style="color: rgb(0, 0, 0);"> Fairlane Columbia, LLC</font></div>
          </div>
          <div style="color: rgb(0, 0, 0);"> <br>
          </div>

          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Landlord&#8217;s Address: </font><font style="color: rgb(0, 0, 0);">c/o Fairlane Properties, Inc., 1035 Cambridge Street, Cambridge, MA 02141</font></div>
          <br>
          <div style="color: rgb(79, 82, 84);"><font style="font-weight: bold; color: rgb(0, 0, 0);">Landlord&#8217;s Numbers: </font><font style="color: rgb(0, 0, 0);">Telephone-(617) 725-1000</font></div>
          <br>
          <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Landlord&#8217;s Agent: </font><font style="color: rgb(0, 0, 0);">LPC Commercial Services, Inc. d/b/a Lincoln Property Company</font></div>
          <div><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Landlord&#8217;s Agent&#8217;s Address: </font><font style="color: rgb(0, 0, 0);">1 Van de Graaf Drive, Burlington, MA 01803</font></div>
          <div><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div><font style="color: rgb(0, 0, 0);"> </font><font style="font-weight: bold; color: rgb(0, 0, 0);">Landlord&#8217;s Agent&#8217;s Numbers: </font><font style="color: rgb(0, 0, 0);">Telephone-(781) 238-4488; Fax-(781) 272-8493<br>
            </font></div>
          <div><font style="font-weight: bold; color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Landlord&#8217;s Work: </font><font style="color: rgb(0, 0, 0);">As provided in Exhibit C.</font></div>
          <div><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Lease Year: </font><font style="color: rgb(0, 0, 0);">The period commencing on the Commencement Date and ending at the end of a calendar month at least
              twelve (12) months from the Commencement Date and the next six (6) twelve (12) month period for the first, second, third, fourth, fifth, sixth and seventh Lease Years, respectively.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Master Deed: </font><font style="color: rgb(0, 0, 0);">The document by which the Condominium was created, dated January 22, 1988 and recorded with the
              Middlesex (South District) Registry of Deeds (&#8220;Registry&#8221;) in Book 18837, Page 122, as amended and restated in its entirety by Master Deed dated April 8, 1988 recorded with said Deeds in Book 1898 0, Page 227, as further amended by Amendment
              to Condominium Master Deed dated April 28, 1988 recorded with said Deeds in Book 19019, Page 382, as further amended by Second Amendment to Condominium Master Deed dated October 3, 1988 recorded with said Deeds in Book 19389, Page 332, as
              further amended by Amendment to Second Amendment to Master Deed dated April 25, 2000 recorded in said Deeds in Book 31369, page 323, as further amended by Amendment to Master Deed dated August 17, 2006 recorded in said Deeds as 45886, Page 24
              (collectively, the &#8220;Master Deed&#8221;).</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Operating Year: </font><font style="color: rgb(0, 0, 0);">Each calendar year in which any part of the Term shall fall after the Commencement Date.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Parking: </font><font style="color: rgb(0, 0, 0);">Tenant shall have three (3) Parking Spaces in the Parking Lot, designated as of the Commencement Date as
              Parking Spaces 21, 95 and 96. Landlord may change the location of the spaces from time to time at its sole discretion. Landlord may also choose to provide Tenant with parking permits for the Parking Lot which must be displayed in authorized
              vehicles.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Parking Lot: </font><font style="color: rgb(0, 0, 0);">The areas in the rear, side and front of the building with access from Columbia and Windsor Streets as
              shown on the attached Exhibit G.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Parking Rent: </font><font style="color: rgb(0, 0, 0);">For each Parking Space, Tenant shall pay $210.00 per space monthly or $2,520.00 annually for the
              first Lease Year and Fair Market Rent for second, third, fourth, fifth, sixth and seventh Lease Years which may be adjusted annually.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Parking Space: </font><font style="color: rgb(0, 0, 0);">A designated area in the Parking Lot where Tenant shall have the exclusive&#160; use to park a vehicle
              and for no other purpose.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Permitted Uses: </font><font style="color: rgb(0, 0, 0);">General offices, research and development and laboratories, and, to the extent permitted by
              applicable law, typical uses ancillary to general office use, research and development and laboratories, including limited manufacturing as provided by the City of Cambridge Zoning Ordinance. The Premises may be used for other uses only with
              the prior written consent of the Landlord.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Premises: </font><font style="color: rgb(0, 0, 0);">2,714 rentable square feet located in Suite 18A comprising the entirety of the Unit on the First Floor of
              the Building as shown on the attached Exhibit B.</font></div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Property: </font><font style="color: rgb(0, 0, 0);">The Building and Parking Lot and the parcels of real property on which they are located which are
              described in Exhibit A of this Lease, also known from time to time as 432 Columbia Street Condominium Trust.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Rent: </font><font style="color: rgb(0, 0, 0);">Base Rent, Parking Rent, Additional Rent, Utility Costs, and all sums due hereunder from Tenant to Landlord.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">RSF: </font><font style="color: rgb(0, 0, 0);">Rentable square feet</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Rules and Regulations: </font><font style="color: rgb(0, 0, 0);">Attached as Exhibit D, originally recorded with the Condominium Trust dated January 22,
              1988, record at the Registry at Book 18837, Page 158, as amended and recorded at the Registry, Book 25255, Page 604 on March 2, 1995 and as amended as of May 1, 2006, October 16, 2008, July 31, 2009, October 28, 2011, December 3, 2014,
              December 2, 2015, December 7, 2016, December 6, 2017, December 5, 2018 and August 7, 2020 by votes of the Trustees of the Condominium Trust.</font><br>
          </div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div style="text-align: justify; color: rgb(79, 84, 86);"><font style="font-weight: bold; color: rgb(0, 0, 0);">Security Deposit: </font><font style="color: rgb(0, 0, 0);">$25,330.66</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Tax Year: </font><font style="color: rgb(0, 0, 0);">Each fiscal year, for the period ending June 301 in which any part of the Term shall fall after the
              Commencement Date.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Taxes: </font><font style="color: rgb(0, 0, 0);">Real estate taxes and any other municipal tax charge or betterment&#160; assessed&#160; with respect to the Unit for
              any Tax Year as determined in accordance with Section 8.1 and as specified in Section 1.1 of this Lease.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Tenant: </font><font style="color: rgb(0, 0, 0);">Brooklyn Immunotherapeutics, Inc.</font></div>
          <br>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z3285b58557a04de38b832337a4beab80">

              <tr>
                <td style="width: 12%;">
                  <div><font style="font-weight: bold; color: rgb(0, 0, 0);">Tenant&#8217;s Address:</font></div>
                </td>
                <td style="width: 88%;">
                  <div>
                    <div><font style="color: rgb(0, 0, 0);">Prior to Commencement Date: 1040 First Ave.# 361, New York, NY 10022</font></div>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 12%;">
                  <div>&#160;</div>
                </td>
                <td style="width: 88%;">
                  <div>&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 12%;">
                  <div>&#160;</div>
                </td>
                <td style="width: 88%;">
                  <div><font style="color: rgb(0, 0, 0);">As of Commencement Date: 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141</font></div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Tenant&#8217;s Early Access: </font><font style="color: rgb(0, 0, 0);">Subject to receipt by Landlord of certificates of insurance required by Section 10.2 of the
              Lease and Section 8 of Exhibit C of the Lease prior to Tenant&#8217;s access, Tenant shall be given access to the Premises and other portions of the Building without payment of Rent in order to install furniture, fixtures, and equipment. Such
              access may be provided by Landlord before completion of Landlord&#8217;s Work.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Tenant&#8217;s Insurance: </font><font style="color: rgb(0, 0, 0);">Insurance as specified in Section l0.2 of this Lease, including commercial general liability
              and property damage liability with a combined single occurrence limit of not less than $2,000,000 and workers&#8217; compensation insurance with a minimum statutory limit of $100,000 for each accident, $500,000 policy limit and $100,000 for each
              employee.</font></div>
          <br>
          <div style="text-align: justify; color: rgb(79, 84, 86);"><font style="font-weight: bold; color: rgb(0, 0, 0);">Tenant&#8217;s Removable Property: </font><font style="color: rgb(0, 0, 0);">As defined in Section 5.2 of this Lease.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Term: </font><font style="color: rgb(0, 0, 0);">Period commencing on the Commencement Date and expiring at 5 p.m. on the Expiration Date.</font></div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Unit: </font><font style="color: rgb(0, 0, 0);">Unit 18A.</font></div>
          <br>
          <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(0, 0, 0);">Utility Costs: </font><font style="color: rgb(0, 0, 0);">For the cost of natural gas and&#160; electricity for the HVAC unit currently servicing the Premises,
              $3,392.50 per annum; $282.71 per month ($1.25/RSF) for the first Lease Year, increasing 3% per annum for the second, third, fourth, fifth, sixth and seventh Lease Years.</font></div>
          <br>
          <table cellspacing="0" cellpadding="0" id="z2e328e904cce4a8f8ab88e27dac4654b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.7pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">1.2</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">EXTENT OF AGREEMENT</div>
                </td>
              </tr>

          </table>
          <br>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">This Lease, together with Exhibits A, B, C, D, E, F and G and the Condominium Documents, contains the complete agreement of the parties concerning the subject matter hereof, and
              there are no oral or written understandings, representations, or agreements pertaining thereto which have not been incorporated herein. This Lease supersedes and replaces all prior understandings, representations, warranties or agreements
              between the parties and shall be the only agreement between the parties with respect to the Premises.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE II</div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zd23805cccf0e415eafdf99fbb7c3fe07" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.5pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.1</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">LEASED PREMISES</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Landlord hereby demises and leases the Premises and Tenant hereby accepts the Premises for the Term, subject to and with the benefit of the terms, covenants, conditions and
              other provisions of this Lease.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z83afa97be3bf48e9808397a6621ed485" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.6pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2.2</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">APPURTENANT RIGHTS AND OBLIGATIONS</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Tenant, its employees, invitees, licensees and other visitors shall have general nonexclusive use of Common Areas of the Building as is necessary for the use and enjoyment of
              the Premises. The Condominium Trust has established Rules and Regulations concerning the maintenance, management, use and operation of the Common Areas as described in Section 1 4.6.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: center; color: rgb(79, 84, 86); font-weight: bold;"><font style="color: rgb(0, 0, 0);">ARTICLE III</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z3f7e98603f41429b92d34f260205049a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.9pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.1</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">RENT</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Tenant agrees to pay the Rent due hereunder to Landlord, or as directed by Landlord (except as otherwise set forth herein), without notice or demand, without deduction or
              offset, and without abatement or reduction. Base Rent shall be payable in equal monthly installments, in advance, on the first day of each and every calendar month during the Term, but in no event shall more than one month&#8217;s Base Rent be paid
              in advance. Additional Rent shall be payable on the first day of each and every calendar month during the Term. All other payments due hereunder shall be due with the next due payment of Rent or, after the termination of this Lease, on the
              first day of the month after such payment is due. All payments shall be paid by check in lawful money of the United States to the order of the Landlord at the Address for Rent Payments listed in Section 1.1. The first full month&#8217;s Base Rent,
              Parking Rent and Utility Costs shall be due at Landlord&#8217;s Address upon Lease execution. If the Commencement Date is on any date other than the first day of the month, the second month&#8217;s Base Rent, Parking Rent and Utility Costs shall be
              prorated&#160; and due&#160; on the first day of the second month of the Term.</font></div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">5</font></div>
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="z82b5d762d0b54ef5906de6adf83e8d53" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.65pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3.2</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">LATE RECEIPT OF RENT</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">If Landlord elects, in its sole discretion and without waiving any other rights under the terms and conditions of this Lease, to accept Rent after the tenth (10th) day of the
              month, Landlord may, at Landlord&#8217;s sole discretion, either charge Tenant the lower of (i) a late payment fee of $50, or (ii) interest on Rent at the rate of 1.5% per month, or any part thereof, (18% per annum) for all sums which are in excess
              of ten (10) days overdue after notice until such time as Rent is paid in full. Such additional payments shall be due and payable with the Rent.</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE IV</div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div>
            <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zb0c47b2f6920427e9b3298b74e47ef76" class="DSPFListTable">

                <tr style="vertical-align: top;">
                  <td style="vertical-align: top; width: 36pt;">
                    <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">4.1</div>
                  </td>
                  <td style="vertical-align: top; width: auto;">
                    <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">CONDITION OF PREMISES</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(a) Tenant acknowledges that it has inspected the Building and the Premises and that the Premises are being leased and the Building is being accepted in their &#8220;as is&#8221; condition,
              except for latent defects and, for the Premises as described in Exhibit C, &#8220;Landlord&#8217;s Work&#8221;. Tenant acknowledges that a central security alarm system is not present at the Premises or the Building. With the keys to the Premises and Building
              passcards, Tenant shall have 24 hour per day access and seven (7) day per week access to the Premises at all times during the Term, except as provided in Sections 12.2 and 12.3. Tenant may install a security system for its Premises and upon
              installation Tenant shall provide the security system code(s) to Landlord and Landlord&#8217;s Agent. Any doors in the Premises which are rekeyed by the Tenant at anytime during the Term shall be on Landlord&#8217;s master key system. Five (5) building
              passcards, with the Tenant providing names for employees using said passcards, shall be provided to Tenant at the Commencement Date. Tenant may request additional or misplaced passcards from Landlord&#8217;s Agent at a cost of $25 for each card.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(b) Within six (6) weeks of the execution of the Lease, Landlord shall include Tenant in its Building directories and First Floor directory and on the front door to the
              Premises, saying &#8220;Brooklyn Immunotherapeutics, Suite 18A&#8221;. The Building directories shall list &#8220;Brooklyn Immunotherapeutics, Suite 18 A&#8221;. Within seven (7) business days of Tenant&#8217;s receipt of notice of substantial completion of &#8220;Landlord&#8217;s
              Work&#8221;, as defined in Exhibit C, Landlord and Tenant shall conduct a walk-through of the Premises to determine compliance with Exhibit C. Tenant shall provide Landlord with a &#8220;Punch List&#8221; which shall include items, if any, requiring further
              work on the part of Landlord to be completed in accordance with Exhibit C. Unless otherwise agreed&#160; by the parties, all Punch List items shall be completed within (30) days of the date of the Punch List.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(c) Tenant&#8217;s telecommunications vendors shall have access to the Premises after the Commencement Date for installation of telecommunications wiring and shall coordinate said
              installation with Landlord so to avoid additional costs by Landlord and delay of completion of Landlord&#8217;s Work. Tenant&#8217;s vendors shall be responsible for any repairs or repainting required after completion of the installation of
              telecommunications wiring. Prior to arranging for any wiring for telecommunications from the Condominium Telephone Closet to the Premises, Tenant must receive Landlord&#8217;s approval for the routing of such wiring prior to installation. Tenant
              shall be responsible for the installation and cost of all telecommunications and data wiring. Tenant&#8217;s telecommunication&#8217;s vendor shall provide a Certificate of Insurance with Certificate Holder and Additional Insureds as provided in Section
              10.2 of this Lease and minimum coverage for such vendor as provided in said section. Tenant agrees to place tags on such wires identifying the Tenant and its wiring. Telecommunications outlets shall be at the height of electrical outlets in
              the space. Any use of wiremold for enclosing telecommunications wiring, loose wiring hung from walls or ceilings or laid on the floor in the Premises will require the approval of Landlord. Land lord must approve in writing all
              telecommunication service providers, not currently servicing the Building or Premises, which require installations or wiring within the Building or Premises. Tenant&#8217;s telecommunications vendor shall receive an electrical permit if necessary
              prior to any electrical work necessary for installation of Tenant&#8217;s telecommunications equipment. In the event that a telecommunication service provider (&#8220;Provider&#8221;) requires installation of equipment in the Building&#8217;s basement, common areas,
              or roof, Landlord may withhold its approval of Provider unless appropriate license agreements have been fully executed between Landlord and Provider. In the event that a Provider requires no equipment in the Building&#8217;s basement, common areas,
              or roof, then such approval shall not be unreasonably delayed or withheld. Tenant shall remove any wall mounted or floor mounted telecommunications equipment at the expiration of the Lease.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(d) In the event that Tenant requests Landlord to coordinate tenant improvements in the Premises, other than those listed in Exhibit C, using Landlord&#8217;s vendors prior to the
              Commencement Date or at any time during the Term (&#8220;Additional Improvements &#8220;), Tenant shall pay for the Additional Improvements within fifteen (15) days of receipt of an invoice from Landlord. As compensation to Landlord for providing
              construction management services to Tenant for the Additional Improvements and for other items listed on Exhibit C completed&#160; by&#160; Landlord&#160; and&#160; paid&#160; for by Tenant, Landlord or an affiliate of Landlord shall charge Tenant a fee of 5% of the
              total of construction and engineering costs. Upon request, Landlord will provide copies of all third-party invoices to Tenant. Failure to pay the abovementioned invoice from Landlord within fifteen (15) days shall have the same consequences
              as a failure to pay Base Rent, pursuant to Section 13.1. In the event that&#160; either&#160; change&#160; orders&#160; requested&#160; by&#160; Tenant&#160; to&#160; Landlord&#8217;s&#160; Work,&#160; Additional Improvements, or other improvements coordinated by Tenant delay completion of
              Landlord&#8217;s Work past the Commencement Date, then the Commencement Date shall be that date by which Landlord reasonably determines that Landlord&#8217;s Work would have been completed but for the change orders to Landlord&#8217;s Work or the Additional
              Improvements.</font></div>
          <br>
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE V</div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z7a8c7982ce1542a682aa399eb4d24398" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.55pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.1</td>
                <td style="width: auto; vertical-align: top; text-align: justify; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">PERMITTED USE OF PREMISES</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(a)&#160; Tenant agrees that the Premises shall be used and occupied by Tenant only for Permitted Uses, and only in accordance with the terms, conditions and restrictions contained
              in the Condominium Documents, and for no other purpose.</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(b)&#160; Tenant shall be solely responsible for obtaining any and all permits, licenses or other consents required to operate its business at the Premises and shall be entirely
              responsible for all costs in connection therewith and shall operate its business in compliance with all applicable laws, rules, regulations and ordinances.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div>
            <div>(c)&#160; <font style="color: rgb(0, 0, 0);">Landlord makes no warranties or representations that the premises are fit for a particular use or purpose, including without limitation the use as specified herein, except as otherwise required by
                law.</font></div>
            <div><font style="color: rgb(0, 0, 0);"> <br>
              </font></div>
          </div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">7</font></div>
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="z5761eae979ce4b9eb68f4e456228787c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 34.7pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5.2</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">ALTERATIONS BY TENANT</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(a) Tenant shall make no alterations, additions or improvements to the Premises or Condominium without Landlord&#8217;s prior written consent, not to be unreasonably withheld&#160; or
              delayed. Any such alterations, additions or improvements shall (i) be performed in a good and workmanlike manner and in compliance with all applicable laws, rules, regulations and ordinances, specifically including City of Cambridge
              Inspectional Services requirements, (ii) be made at Tenant&#8217;s sole cost and expense, (iii) become part of the Premises and the property of Landlord, if permanently affixed to the Premises at the end of the Term.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(b) All articles of personal property and all business fixtures, machinery, equipment (including telecommunications equipment affixed to the Premises) and furniture owned or
              installed in the Premises by Tenant at its expense (&#8220;Tenant&#8217;s Removable Property&#8221;) shall remain the Property of Tenant and may be removed by Tenant at any time prior to the expiration of this Lease, provided that Tenant, at its expense, shall
              repair any damage to the Building caused by such removal.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(c)&#160; Notice is hereby given that Landlord shall not be liable for any labor or materials furnished or to be furnished to Tenant upon credit, and that no mechanic&#8217;s or other lien
              for any such labor or material shall attach to or affect the interest of Landlord in and to the Premises or the Building. In the event any such lien is filed against the Property based upon any act or interest of Tenant or of anyone claiming
              through Tenant, Tenant shall immediately take such action by&#160; bonding, deposit or payment as is necessary to remove or satisfy the lien and hereby indemnifies Landlord and holds&#160;it harmless from any and all loss, cost, damages, expense or
              liability arising there from.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE VI</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div>
            <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z3d83218c71284872b59444b7de69bc9f" class="DSPFListTable">

                <tr style="vertical-align: top;">
                  <td style="vertical-align: top; width: 36pt;">
                    <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">6.1</div>
                  </td>
                  <td style="align: left; vertical-align: top; width: auto;">
                    <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">PROHIBITION AGAINST ASSIGNMENT AND SUBLETTING</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(a) Tenant shall not assign, sublet, mortgage, pledge, encumber or otherwise transfer all or any portion of its interest in the Premises, nor shall Tenant permit the Premises to
              be used or occupied by anyone other than Tenant in whole or in part without the prior written consent of Landlord in each instance which consent shall not be unreasonably conditioned, withheld or delayed.</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(b)&#160; If this Lease is assigned, or if the Premises or any part thereof is sublet or occupied by anyone other than Tenant, Landlord or Landlord&#8217;s Agent may, at any time and from
              time to time, collect Rent and other charges from the assignee, subtenant or occupant, and apply the amount collected to Rent or other charges herein reserved. No such assignment, subletting, occupancy or collection shall be deemed a waiver
              of the covenant against subletting or assignment, or the acceptance&#160; of the assignee, subtenant or occupant as a tenant or a release of Tenant from the further performance by Tenant of its obligations hereunder. At all times Tenant shall
              remain liable for the payment of all Base Rent, Escalation Charges and other charges due hereunder, and for the full performance of the covenants and conditions of this Lease, regardless of whether Premises are occupied by Tenant, vacant
              during the Term of this Lease or occupied pursuant to an assignment or sublease to which the Landlord has consented.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">8</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(i) Tenant&#8217;s request for Landlord&#8217;s consent to subletting or assigning any portion of the Premises shall be submitted in writing. Such written request shall
              state the following information regarding prospective subtenants or assignees: name of individual(s), name of company, occupation or type of business, prior business address. Landlord may request, either verbally or in writing, additional
              reasonable information regarding prospective subtenants. Landlord shall have seven (7) business days after all requested information has been provided to consent to such sublease or assignment. If Landlord has not responded within fourteen
              (14) business days after all requested information has been provided for such consent, it is therefore understood that Landlord has consented. Landlord hereby consents to the Approved Subtenants occupying less than the entire Premises listed
              in Section 1.1 of this Lease. No prior Landlord approval of assigning or subletting shall be required if such assigning or subletting is to any parent company or wholly- owned subsidiary of Tenant.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(ii) Tenant&#8217;s request for Landlord&#8217;s consent to subletting or assigning the entire Premises shall be submitted in writing. Such written request shall state
              the following information regarding prospective assignees or subtenants: name of individual(s), name of company, occupation or type of business, prior business address. Landlord may re quest, either verbally or in writing, additional
              information regarding prospective assignees or subtenants. Landlord&#8217;s consent shall be granted only if the assignee or subtenant shall agree to pay Landlord Rent, including Additional Rent at 100% of that reserved in this Lease. It shall not
              be deemed unreasonable for Landlord to withhold consent to Tenant&#8217;s request to sublet or assign the entire Premises if (y) Landlord is actively negotiating with a prospective assignee or subtenant for another space in the Building or (z) the
              prospective assignee or subtenant is at such time a tenant in the Building. Landlord shall have thirty (30) days after all requested information has been provided to consent to such assignment or sublease. No prior Landlord approval of
              assigning or subletting shall be required if such assigning or subletting is to any parent company, any subsidiary of any parent company, or wholly-owned subsidiary of Tenant or parent company.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(c) If Landlord consents to such assignment or subletting of the Premises, it is understood and agreed that fifty percent (50%) of all amounts, less Tenant&#8217;s reasonable
              subleasing costs (which shall include, but not be limited to attorney fees, brokerage commissions, tenant improvements, and free rent), including any lump sum or installment payments paid to Tenant in excess of the Base Rent, Escalation
              Charges and other charges due to Landlord hereunder shall also be paid to Landlord.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(d) If Landlord consents to such assignment or subletting, Tenant will pay to Landlord all costs associated with signage, parking permits, or any other costs associated with
              Tenant&#8217;s subtenant or assignee. Such costs shall be due as specified in Section 3.l.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(e) Notwithstanding anything contained herein to the contrary and without limiting the generality of Paragraph 6.1 (a), it shall not be deemed unreasonable for Landlord to
              withhold its consent if the Tenant is or has been in default beyond applicable cure periods under the terms of this Lease, has not provided to Landlord information requested by Landlord pursuant to Section 6.1(c), is proposing to assign or
              sublet to any assignee or subtenant or other occupant who is an existing tenant at the Property or is in discussions with Landlord regarding space in the Property being offered by the Landlord for rent to the market, or is proposing to assign
              or sublet to any assignee or subtenant or other occupant whose financial status, character, method of doing business and/or proposed use or occupancy of the Premises or any other part of the Building would adversely affect the character or
              value of the Building, and, in the event of subleasing or assigning the entire Premises, whose financial status is not substantially the same as, or better than, that of the Tenant.</font></div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">9</font></div>
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE VII</div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z843c11c75920465c82c026bc64b3d50f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.1pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.1</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">LANDLORD&#8217;S REPAIRS AND MAINTENANCE</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Landlord shall not be responsible to make any improvements or repairs to the Premises, except for repairs to structural, roof, mechanical, plumbing, life safety and electrical
              systems located within and serving the Premises, including exterior windows, and those specified in&#160; Exhibit C &#8220;Landlord&#8217;s Work.&#8221; Tenant shall be conclusively deemed to have agreed that Landlord has performed all of its obligations under
              Exhibit C unless not later thirty (30) days after the Commencement Date Tenant shall give Landlord written notice specifying the respects in which Landlord has not performed any such obligation.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z40432855a48b4ce1849b38e46f06de90" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.2</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">TENANT&#8217;S REPAIR AND MAINTENANCE</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(a)&#160; Tenant shall keep the Premises neat and clean and maintain the Premises together with all electrical and mechanical fixtures, fittings and appurtenances therein in good
              order, condition and repair (including, without limitation, tenant entry doors, interior window glass and every part thereof, but excepting Landlord&#8217;s responsibilities under Section 7.1), except as a result of reasonable wear and tear of the
              Premises, damage by fire or other casualty or as a consequence of eminent domain. Tenant acknowledges that, subject to the completion of the improvements and repairs specified in Exhibit C &#8220;Landlord&#8217;s Work&#8221; for the Premises, the Premises are
              now in good order and the glass whole. Tenant shall maintain and use the Premises in accordance with all applicable laws, rules, regulations and ordinances and shall, at Tenant&#8217;s expense, obtain all permits, licenses and the like required by
              applicable law in connection with such maintenance and use. Tenant shall be responsible for the cost of any repairs made necessary&#160; by reason of damage&#160; to the Building by Tenant or Tenant&#8217;s independent contractors. Tenant shall be
              responsible for the cost of materials and labor for any repairs pursuant to this Section 7.2 performed by Landlord at the request of Tenant. Tenant shall be responsible for the cost of routine repair of lighting fixtures located within and
              exclusively serving the Premises, including ballasts and bulbs, (the &#8220;Lighting Fixtures&#8221;) after six (6) months following the Commencement Date. All Lighting Fixtures shall be working at the Expiration Date. All such costs due from Tenant
              shall be due and paid&#160; by Tenant as Rent.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(b) If repairs are required to be made by Tenant pursuant to this Lease, Landlord may require that Tenant make such repairs immediately and if Tenant refuses or neglects to
              commence such repairs and complete the same with reasonable diligence after such demand, Landlord shall have the right but not the obligation to make or cause such repairs to be made at Tenant&#8217;s expense and shall not be responsible to Tenant
              for any loss or damage that may accrue to Tenant&#8217;s property or business by reason thereof. Any cost or expense reasonably incurred by Landlord in connection with such repairs shall become part of the Rent and shall&#160; be due and payable in full
              with the next payment of Rent.</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">10</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="z192a8a9f082040f0a622eebe8736fc23" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 32.95pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.3</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">TENANT&#8217;S EQUIPMENT</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Tenant shall not place any fixtures, machinery, equipment or the like (&#8220;Tenant&#8217;s Equipment&#8221;) upon any floor in the Premises exceeding the floor load per square of area which the
              floor was designed to carry and which is permitted by applicable law. Landlord reserves the right to approve the weight or position of any such items so as to properly distribute the weight. Business machines and equipment shall be placed and
              maintained in such settings as are sufficient, in Landlord&#8217;s reasonable judgment, to absorb and prevent vibration, noise and annoyance. Tenant shall provide safety cabinets for any hazardous materials located in the Premises. Any hazardous
              materials must be delivered to the loading dock of the Building and be immediately delivered to the Premises. Pallet movers are not allowed in the Common Areas and pallets must be broken down in the loading dock.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Within thirty (30) days of the final sign-off of the City of Cambridge Inspectional Services building inspector for the completion of improvements in the Premises, Tenant shall
              provide Landlord with a list of the items installed by Tenant with equipment specified by&#160; manufacturer, tonnage or BTU&#8217;s, model number, serial number, location in the Premises or on Building&#8217;s roof and year installed. Tenant shall provide
              Landlord with updated equipment lists throughout the Term as additional HYAC equipment is installed, upgraded or replaced with equipment specified by manufacturer, tonnage or BTU&#8217;s, model number, serial number, location in the Premises or on
              Building&#8217;s roof and year installed.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z431c4bee68dc4336ba424589a0dc70de" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.35pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7.4</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">UTILITIES AND BUILDING SERVICES</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <table cellspacing="0" cellpadding="0" id="z85ec18cb2b43494d9c07256a33c7929b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18.3pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">(a)</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">UTILITIES.</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(i)&#160; <u>Utilit</u><u>i</u><u>es for </u><u>t</u><u>he </u><u>Pr</u><u>em</u><u>i</u><u>ses</u>. For the Premises, Tenant shall pay, as they become due, all
              bills for electricity (whether used for air conditioning, heat, lights, outlets or other purposes) that are furnished to the Premises and separately metered. Tenant agrees to contact the provider of electrical services to the Premises&#8217;
              previous tenant or to Landlord immediately after the Commencement Date and to place the electric meter and its account into the Tenant&#8217;s name. In the event that Tenant fails to transfer the meter to Tenant, then Landlord may transfer the
              account into the Tenant&#8217;s name or should such transfer by Landlord be unsuccessful, Landlord may place Tenant in default under Section 13.1 (ii) of this Lease. Landlord may determine, in its sole discretion, to transfer any or all utilities,
              including those utilities paid for by Tenant, to other public or private vendors of utilities and if such transfer is made, Landlord shall provide advance written notice thereof.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(ii)&#160; Landlord may determine, in its reasonable discretion, to transfer any or all utilities, including those utilities paid for by Tenant, to other public or
              private vendors of utilities and if such transfer is made, Landlord shall provide advance written notice thereof.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(b) <font style="font-weight: bold;">COMMON AREAS. </font>Tenant shall have 24 hours per day, seven days per week and 52 weeks per year access to the Premises, and appropriate
              common areas of the Building, Condominium and Property.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(c) <font style="font-weight: bold;">HEATING AND OTHER SERVICES. </font>Landlord agrees to provide reasonable heat and air conditioning to the Premises during Business Hours
              on Business Days of the heating and air conditioning seasons of each year with the existing 7.5-ton rooftop unit. Land lord shall have no obligation to provide utilities or equipment other than the utilities and equipment within the Premises
              or serving the Premises as of the Commencement Date. The installation of additional heating and air conditioning equipment powered by electricity or gas after the Commencement Date and the maintenance of such equipment located and used wholly
              within the Premises shall be Tenant&#8217;s sole obligation, provided that such installation shall be subject to the written consent of Landlord, which shall not be unreasonably delayed or withheld.</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">11</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE VIII</div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z8e1bbdcef0684c6091171a24ebf677d8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 34.35pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8.1</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">REAL ESTATE TAX PAYMENTS</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">In the event Taxes shall be greater during any Tax Year than Base Taxes, Tenant shall pay to Landlord, as an Escalation Charge, an amount equal to (i) the excess of Taxes over
              Base Taxes, multiplied by (ii) the Escalation Percentage (&#8220;Real Estate Tax Payments&#8221;). Amounts payable by Tenant according to this section will be payable as Rent, without deduction or offset. If Tenant fails to pay any amounts due according
              to this section, Landlord will have all rights and remedies available to it on account of Tenant&#8217;s failure to pay Base Rent. In the event that the Term has expired and Landlord reasonably expects that Tenant shall be required to pay Real
              Estate Tax Payments applicable to the term in excess of Estimated Real Estate Payments, then Landlord may retain that portion of the Security Deposit which Landlord reasonably expects shall be equal to Real Estate Tax Payments for the last
              Lease Year and upon final reconciliation, Landlord shall release any Security Deposit not required for Real Estate Tax Payments. Notwithstanding the previous sentence, Tenant shall remain liable for unpaid Real Estate Tax Payments applicable&#160;
              to the term after the Expiration Date.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z7115c233a34f417db6eb7fbfbe1302ff" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 34.5pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8.2</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">ABATEMENT</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">If Landlord shall receive any tax refund or reimbursement of taxes or sum in lieu thereof with respect to any Tax Year, then, out of any balance remaining after deduction for
              Landlord&#8217;s reasonable expenses incurred in obtaining such abatement, Landlord shall pay to Tenant, provided there does not exist an uncured Default of Tenant, an amount equal to such sum (exclusive of any interest paid on the abatement)
              multiplied by the Escalation Percentage. In no event shall Tenant be entitled to receive more than the payments made by Tenant on account of real estate taxes for such Tax Year pursuant to Section 8.1, or to receive any payment or abatement
              of Base Rent if Taxes for any year are less than Base Taxes or Base Taxes are abated.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z109df61033b84cdeaffb434a3476d761" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 34.35pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8.3</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">ESTIMATED REAL ESTATE TAX PAYMENTS</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Landlord may, from time to time, reasonably estimate Tenant&#8217;s Real Estate Tax Payments with respect to any Tax Year or portion thereof and Tenant shall pay periodically as Land
              lord may determine, but not more frequently than monthly, the amount of Landlord&#8217;s estimate as Rent. Not later than 120 days after the end of each calendar year, Landlord will deliver to Tenant a statement of amounts payable under Section 8.1
              for such calendar year and any amount due from Tenant or any credit due to Tenant hereunder. Payment by Tenant of any amount due shall be made as Rent with Tenant&#8217;s next payment of Base Rent. Landlord shall credit the amount of any
              overpayment against subsequent obligations of Tenant. If the Term has expired and Tenant was not in default, Landlord will refund the overpayment to Tenant.</font></div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">12</font></div>
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE IX</div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z733aa0cc30b042d4aab172cc3fb4d441" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.85pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">9.1</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">CONDOMINIUM FEE PAYMENTS</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">In the event Condominium Fees shall be greater during any Operating Year than Base Condominium Fees, Tenant shall pay to Landlord, as an Escalation Charge, an amount equal to
              (i) the excess of Condominium Fees over Base Condominium Fees, multiplied by (ii) the Escalation Percentage (&#8220;Condominium Fee Payments&#8221;). Amounts payable by Tenant according to this section will be payable as Rent, without deduction or
              offset. If Tenant fails to pay any amounts due according to this section, Landlord will have all rights and remedies available to it on account of Tenant&#8217;s failure to pay Base Rent. In the event that the Term has expired and Landlord
              reasonably expects that Tenant shall be required to pay Condominium Fee Payments in excess of Estimated Condominium Fee Payments, then Landlord may retain that portion of the Security Deposit which Landlord reasonably expects shall be equal
              to Condominium Fee Payments for the last Lease Year and upon final reconciliation, Landlord shall release any Security Deposit not required for Condominium Fee Payments. Notwithstanding the previous sentence, Tenant shall remain liable for
              Condominium Fee Payments applicable to the Term after the Expiration Date. No Condominium Fee Payments shall be due for lease periods prior to the Commencement Date.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z01e06ecad52a4455b1db883db01b0489" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.85pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">9.2</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;"><font style="color: rgb(0, 0, 0);">CONDOMINIUM FEES</font></div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Condominium Fees for purposes of this Lease means: all reasonable costs of management, operation and maintenance of the Building, including without limitation: a) wages,
              salaries, and other compensation (including &#8220;fringe&#8221; benefits) of employees; b) consulting (including tax abatement assistance), accounting, and legal costs incurred in the operation and management&#160; of the Building and Condominium; c)
              services obtained for the benefit of the Building and Condominium such as window washing, trash removal, snow removal, janitorial, maintenance, security, and service contracts with independent contractors for any of the foregoing (including
              fire protection and HVAC); d) management fees (charged&#160; by Landlord,&#160; an affiliate of Landlord, or any other entity managing the Building or Condominium); e) utilities to the extent the same are not separately metered and charged to tenants
              in the Building and Condominium including lighting, heating and hot water for Common Areas, and sewer and water charges; f) materials and supplies, maintenance and repairs, and environmental remediation; g) insurance including building
              insurance, liability insurance, directors and officers insurance, rent loss insurance, umbrella insurance and workers &#8217; compensation insurance; h) alterations and improvements to the Building and Condominium made by reason of the laws and
              requirements of any public authorities promulgated after the Commencement Date, such costs amortized according to the Internal Revenue Code schedules; and i) other costs and expenses which under generally accepted accounting principles would
              be regarded as maintenance and operating expenses. Condominium Fees will not include depreciation, costs of tenant improvements, and leasing commissions, capital expenditures of any </font><font style="font-weight: bold; color: rgb(0, 0, 0);">kind </font><font style="color: rgb(0, 0, 0);">or nature (except as otherwise hereinabove permitted in subsection (h) above, debt service and other financing costs, expenses which are subject to reimbursement by Tenant or other tenants,
              and marketing and advertising expenses.</font></div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">13</font></div>
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="zdfd340af20d94f6d92e70f02cd51e070" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.85pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">9.3</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">ESTIMATED CONDOMINIUM FEE PAYMENTS</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Landlord may, from time to time, reasonably estimate Tenant&#8217;s Condominium Fee Payments with respect to any calendar year or portion thereof and Tenant shall pay periodically as
              Landlord may determine, but not more frequently than monthly, the amount of Landlord&#8217;s estimate as Rent. Not later than 120 days after the end of each calendar year, Landlord will deliver to Tenant a statement of Condominium Fees and any
              amounts payable under Section 9.1 for such calendar year and any amount due from Tenant or any credit due to Tenant hereunder. Payment by Tenant of any amount due shall be made as Rent with Tenant&#8217;s next payment of Base Rent. Landlord shall
              credit the amount of any overpayment against subsequent obligations of Tenant. If the Term has expired and Tenant has no uncured defaults, Landlord will refund the overpayment to Tenant.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE X</div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z72f0bf38f9f04477bb838fa356266120" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 32.85pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">10.1</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">TENANT&#8217;S AND LANDLORD&#8217;S INDEMNITY</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(a) To the maximum extent permitted by law, Tenant agrees to indemnify&#160; and&#160; hold&#160; the Condominium Trustees, Landlord and Land lord&#8217;s Agent harmless from and against all claims
              of whatever nature arising after the earlier&#160; to occur&#160; of&#160; the Commencement&#160; Date or the date on&#160; which the Tenant first takes occupancy of any part of the Premises&#160; until the end of the Term&#160; and&#160; thereafter so long as Tenant is in
              occupancy of any part of the Premises: (i) on account of or based upon any injury to any person, or loss&#160; of or damage&#160; to&#160; property&#160; sustained&#160; or&#160; occurring&#160; or&#160; emanating&#160; from the Premises on account of or based upon the act, omission,
              fault,&#160; negligence, or misconduct arising out of the&#160; use or occupancy of the&#160; Building, Condominium or Premises by the Tenant or by any person claiming by, through&#160; or under Tenant,&#160; except&#160; where&#160; caused&#160; by the negligence,&#160; fault, or
              misconduct of Landlord, Landlord&#8217;s Agent, their employees, agents, and independent contractors, or (ii) on account of or based upon any injury to any person, or loss of or damage to property, sustained or occurring elsewhere in or about the
              Building or Condominium arising out of the use or occupancy of the Building, Condominium or Premises by the Tenant or by any person claiming by, through or under Tenant, except where caused by the negligence, fault, or misconduct of Landlord,
              Landlord&#8217;s Agent, their employees, agents, and independent&#160; contractors;&#160; and&#160; in&#160; addition to and not in&#160; limitation of either the foregoing subsections (i) and (ii); (iii) on account of or based upon&#160; work or thing whatsoever&#160; done on the
              Premises; except where caused by the negligence, fault, or misconduct of Landlord, Landlord&#8217;s Agent, their employees, agents, and independent contractors; and in respect of any of the&#160; foregoing, from and against all costs, expenses
              (including reasonable attorney&#8217;s fees), and liabilities incurred in or in connection with any such claim, or any action or proceedings; and in the case any action or proceeding is brought against Landlord by reason of any claim, Tenant upon
              notice from&#160; Landlord&#160; shall at Tenant&#8217;s expense resist or defend such action or proceeding and employ counsel reasonably satisfactory to Landlord.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">14</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(b) To the maximum extent permitted by law, Landlord agrees to indemnify and hold Tenant harmless from and against all claims of whatever nature arising after the earlier to
              occur of the Commencement Date or the date on which the Tenant first takes occupancy of any part of the Premises until the end of the Term and thereafter so long as Tenant is in occupancy of any part of the Premises: (i) on account of or
              based upon any injury to any person, or loss of or damage to property sustained or occurring or emanating from the Premises on account of or based upon the act, omission, fault, negligence, or misconduct arising out of the use or occupancy of
              the Building, Condominium or Premises by any person claiming by, through or under Landlord, except where caused by the negligence, fault, or misconduct of Tenant or Tenant&#8217;s employees, agents, and independent contractors, or (ii) on account
              of or based upon any injury to any person, or loss of or damage to property, sustained or occurring elsewhere in or about the Building arising out of the use or occupancy of the Building, Condominium or Premises by any person claiming by,
              through or under Landlord, except where caused by the negligence, fault, or misconduct of Tenant, its employees, agents, and independent contractors; and in addition to and not in limitation of either the foregoing subsections (i)and (ii);
              (iii) on account of or based upon work or thing whatsoever done on the Premises; except where caused by the negligence, fault, or misconduct of Tenant, its employees, agents, and independent contractors; and in respect of any of the
              foregoing, from and against all costs, expenses (including reasonable attorney&#8217;s fees), and liabilities incurred in or in connection with any such claim, or any action or proceedings; and in the case any action or proceeding is brought
              against Tenant by reason of any claim, Landlord upon notice from Tenant shall at Landlord&#8217;s expense resist or defend such action or proceeding and employ counsel reasonably satisfactory to Tenant.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zcb3b429426bd4d10881f5d2324a22e4b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.35pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">10.2</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">TENANT&#8217;S INSURANCE</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Tenant agrees to maintain in full force and effect from the date upon which Tenant first enters the Premises for any reason, throughout the Term, and thereafter so long as
              Tenant is in occupancy of any part of the Premises, policies of commercial general liability, property damage liability insurance and workers&#8217; compensation insurance. Such insurance shall be from responsible companies with an A.M. Best rating
              of A- VIII or better and qualified to do business in Massachusetts and in good standing&#160; therein in at least the Tenant&#8217;s Insurance amounts specified in Section 1.1 under which Landlord is the Certificate Holder, and 432 Columbia Street
              Condominium Trust, Landlord and Landlord&#8217;s Agent are named as additional insureds, and under which the insurer agrees to indemnify and hold Landlord and Landlord&#8217;s Agent harmless from and against all cost, expense and/or liability arising out
              of or based upon any claims, accidents, injuries and damages set forth in Section l0.1. Such workers&#8217; compensation coverage must satisfy Tenant&#8217;s obligations and liabilities under the Commonwealth of Massachusetts&#160; workers&#8217;&#160; compensation
              laws. All policies shall be non-cancelable and non-amendable without thirty (30) days prior written notice to Landlord and Landlord&#8217;s mortgagees and a certificate of insurance shall be delivered to Landlord or Landlord&#8217;s Agent prior to the
              Commencement Date and on or prior to each anniversary date of this Lease.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z996e7052be724d608562d23136817afa" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.35pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">10.3</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">TENANT&#8217;S RISK</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">To the maximum extent permitted by law, Tenant agrees to use and occupy Premises and such other portions of the Property or Condominium, as Tenant has right to use, at Tenant&#8217;s
              own risk. The Condominium Trustees, Landlord and Landlord&#8217;s Agent shall have no liability or responsibility for any loss of or damage to Tenant&#8217;s Removable Property. This Section 10.3 shall be applicable from and after the execution of this
              Lease, and during any further period during which Tenant may use or be in occupancy of any part of the Premises. Tenant shall purchase and maintain insurance in an amount adequate to repair or replace its personal property and other Tenant&#8217;s
              Removable Prope1ty.</font></div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">15</font></div>
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="z985d11a1e99042a995331159d45cf5b2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.95pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">10.4</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">INJURY CAUSED BY THIRD PARTIES</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">To the maximum extent permitted by law, Tenant and Landlord each agree that neither party nor its agents, employees, invitees, or independent contractors shall not be
              responsible or liable to the other, or those claiming by, through or under either, for any loss or damage that may be occasioned by or through the acts or omissions of persons occupying adjoining premises or any part of the premises adjacent
              to or connecting with the Premises or any part of the Property or otherwise, except where caused by the gross negligence, or willful misconduct of Landlord, Landlord&#8217;s Agents, their employees, agents and independent contractors or the Tenant,
              its employees, agents and independent contractors.</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE XI</div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div>
            <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z6f535cc9a8a44120919a2b1228b7c671" class="DSPFListTable">

                <tr style="vertical-align: top;">
                  <td style="vertical-align: top; width: 36pt;">
                    <div style="text-align: left;"><font style="font-weight: bold; color: rgb(0, 0, 0);">11.1</font></div>
                  </td>
                  <td style="vertical-align: top; width: auto;">
                    <div style="text-align: left;"><font style="color: rgb(0, 0, 0);"><font style="font-weight: bold;">LANDLORD&#8217;S RIGHT OF ACCESS</font></font></div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Landlord and Landlord&#8217;s Agent shall have the right to enter the Premises upon reasonable oral notice (except in the case of emergency for which no notice shall be required) for
              the purposes of inspecting the Premises and making repairs to the same. Upon reasonable notice, Landlord and Landlord&#8217;s Agent shall also have the right to make access available at all reasonable hours to prospective or existing mortgagees,
              purchasers or tenants of any part of the Property provided, however, that no such entry shall materially interfere with or materially obstruct the Tenant&#8217;s use of the Premises or the conduct of its business from the Premises. Landlord and
              Landlord&#8217;s Agent will at all times have and retain keys with which to unlock all of the doors in the Premises (excluding Tenant&#8217;s vaults, safes, and similar areas designated in writing by Tenant in advance).</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE XII</div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zca1f992ffb614f78a4fb994156f49629" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.6pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.1</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">ABATEMENT OF RENT</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">If the Premises shall be damaged by fire or casualty, Base Rent and Escalation&#160; Charges payable by Tenant shall abate proportionately for the period in which, by reason of such
              damage, there is substantial interference with Tenant&#8217;s use of the Premises, having regard to the extent to which Tenant may be required to discontinue Tenant&#8217;s use of all or a portion of the Premises, but such abatement or reduction shall
              end if when Landlord shall have substantially restored the Premises&#160; to the condition in which they were prior to such damage. If the Premises shall be affected by any exercise of eminent domain, Base Rent and Escalation Charges payable by
              Tenant shall be justly and equitably abated and reduced according to the nature and extent of the loss of use thereof suffered by Tenant.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="za8839599e5ab48eb81b59677ac48e27c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.7pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.2</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">RIGHT TO TERMlNATE</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(a)&#160;&#160; If the Premises or Tenant&#8217;s access to the Premises, or the Building arc substantially damaged by fire or other casualty to the extent that such Premises or Building
              cannot, in the ordinary course, reasonably be expected to be repaired within ninety (90) days from the time of such fire or casualty, or if any part of the Building is taken by the exercise of eminent domain, then Landlord may, at Landlord&#8217;s
              option terminate this Lease by giving written notice to Tenant within sixty (60) days following the occurrence of such fire or other casualty or the effective date of such taking, whereupon this Lease shall terminate thirty (30) days after
              the date of such notice.</font></div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">16</font></div>
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(b)&#160;&#160; In addition to subsection (a) of this Section 12.2, if the Premises or Tenant&#8217;s access to the Premises, are substantially damaged by fire or casualty to the extent that
              such damage cannot for any reason, in the ordinary course, be substantially repaired within ninety (90) days from the time of fire or casualty, or if any substantial portion of the Premises is taken by the exercise of eminent domain, Tenant
              shall have the right to terminate this Lease by giving written notice to Landlord within sixty (60) days following the occurrence of such fire or other casualty or the effective date of such taking, whereupon this Lease shall terminate thirty
              (30) days after the date of such notice.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zde9d676f61204ced8259eaac86770664" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.7pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.3</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">RESTORATION</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">If this lease is not terminated pursuant to Section 12.2, Landlord shall use reasonable diligence to restore the Premises to proper condition for Tenant&#8217;s use provided that
              Landlord&#8217;s obligation shall be limited to the amow1t of insurance proceeds available to Landlord for such restoration. If, for any reason, such restoration shall not be substantially completed, or the Premises is not substantially restored to
              proper condition for Tenant&#8217;s use as it was prior to such damage, within six (6) months subject to any extension for such periods of time as Landlord is prevented from completing such restoration due to any cause beyond Landlord&#8217;s reasonable
              control after the expiration of the ninety (90) day period referred to in Section 12.2, Tenant shall have the right to terminate this Lease by giving written notice to Landlord within thirty (30) days after the termination of such period (as
              such as may have been extended above). Upon the giving of such notice, this Lease shall terminate on the thirtieth (30th) day following Landlord&#8217;s receipt&#160; of Tenant&#8217;s notice without further liability or obligation on the part of either party
              unless, within such thirty (30) day period, Landlord substantially completes such restoration. Such right of termination shall be Tenant&#8217;s sole and exclusive remedy for Landlord&#8217;s failure to complete restoration.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zd89a386372134edfafce445d01597544" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.9pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12.4</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">AWARD</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Landlord hereby reserves and excepts, and Tenant hereby grants and assigns to Landlord, all rights to recover for damages to the Property and the Landlord&#8217;s interest in the
              leasehold interest hereby created, and to compensation accrued or hereafter to accrue by reason of taking, damage or destruction and by way of confirming the foregoing, Tenant hereby grants and assigns, and covenants with Landlord to grant
              and assign to Landlord, all rights to such damages or compensation. Nothing contained herein shall be construed to prevent Tenant from prosecuting in any condemnation proceedings a claim for the value of any of Tenant&#8217;s Removable Property
              installed in Premises by Tenant at Tenant&#8217;s expense and for relocation expenses, provided that such action shall not affect the amount of compensation otherwise recoverable by Landlord from the taking authority. The provisions of this Section
              12.4 shall not apply to any rights of Tenant to recover for damages or compensation relating to Tenant&#8217;s Removable Property.</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE XIII</div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zf725fce13b8042bb96b41d4d4bdebb29" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.8pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13.1</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">TENANT&#8217;S DEFAULT</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z6d6f57715c5b4b759921d675a18c7b1a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 17.5pt; vertical-align: top; color: rgb(0, 0, 0);">(a)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div><font style="color: rgb(0, 0, 0);">If during the Term of this Lease any of the following events shall occur:</font></div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(i)&#160; Tenant shall fail to pay Base Rent, Escalation Charges or other charges hereunder when due, and shall have failed to cure such deficiency within ten (10)
              days of the date that Landlord shall have sent written notice to Tenant via in -hand delivery, receipt from Federal Express (or other express mail service) or the receipt of certified mail of such failure. Notwithstanding the foregoing, if
              Landlord shall have sent to Tenant a notice of any such failure three times during any twelve month period, and even though such failures may have been cured during the ten (10) day cure period, any subsequent failure to make payment during
              such a twelve month period shall be deemed to be a default without any notice from Landlord, and for which the Landlord shall not be required to recognize any period during which such failure may be cured; or</font></div>
          <br>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">17</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(ii)&#160; Tenant shall neglect or fail to perform or observe any other covenant contained in this Lease and Tenant shall fail to remedy the same within thirty
              (30) days after receipt of a written notice to Tenant via Federal Express (or other express mail service) or by certified mail specifying such neglect or failure, or if such failure is of such a nature that Tenant cannot reasonably remedy the
              same within such thirty (30) day period, Tenant shall fail to commence promptly, within such 30 day period, to remedy the same and to prosecute such remedy to completion with diligence and continuity, provided that such cure shall be
              completed in any event within ninety (90) days of written notice, unless such period is extended in writing by Landlord; or</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(iii) Tenant&#8217;s leasehold interest in the Premises shall be taken on execution or by other process of law directed against Tenant; or</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(iv)&#160; Tenant shall make an assignment for the benefit of creditors; or shall file a voluntary petition in bankruptcy; or shall be adjudicated bankrupt or
              insolvent, or shall file any petition or answer seeking any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar relief for itself under any present or future Federal, State or other statute, law or
              regulation for relief of debtors; or shall seek or consent to or acquiesce in the appointment of any trustee, receiver or liquidator of Tenant or of all or a substantial part of its properties; or Tenant shall admit in writing its inability
              to pay its debts generally as they become due; or</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(v)&#160; a petition shall be filed against Tenant in bankruptcy or under any other law seeking any reorganization, arrangement, composition, readjustment,
              liquidation, dissolution or similar relief under any present or future Federal, State or other statute, law or regulation and shall remain undismissed or unstayed for an aggregate of sixty (60) days; or if any debtor in possession, trustee
              receiver or liquidator of Tenant or of all or a substantial part of its properties or of the Premises shall be appointed without the consent or acquiescence of Tenant, and such appointment shall remain unvacated or unstayed for an aggregate
              of sixty (60) days;</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">then in any such case:</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(1) If such Default by Tenant, other than subsection (vi), shall occur prior to the Commencement Date, Landlord may, without further act on the part of
              Landlord, terminate this Lease by written notice to Tenant, and</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(2) If such Default by Tenant shall occur after the Commencement Date, Landlord may terminate this Lease by written notice as provided to Tenant and this
              Lease shall come to an end on the date specified therein and Tenant will then quit and surrender the Premises to Landlord, but Tenant shall remain liable as hereinafter provided.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">18</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div>
            <div>(b) <font style="color: rgb(0, 0, 0);">If this Lease is terminated as provided in this Lease, or if any execution or attachment shall be issued against Tenant or any of Tenant&#8217;s property whereupon the Premises shall be taken or occupied
                by someone other than Tenant, then Landlord may, thereafter, without notice, re-enter the Premises, either by summary proceedings, ejectment or otherwise, and remove and dispossess Tenant and all other persons and any and all property from
                the same, as if this lease had not been made and Tenant hereby waives the service of notice of intention to re-enter or to institute legal proceedings to that end.</font></div>
          </div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(c) In the event of any termination for Default by Tenant, Tenant shall remain responsible for the Base Rent, Escalation Charges and other charges payable hereunder, up to the
              date of the termination, and thereafter Tenant, until the end of what would have been the end of the Term in the absence of such termination whether or not the Premises shall have been re-let, shall be liable to Landlord for and shall pay to
              Landlord, as liquidated current damages, the Base Rent, Escalation Charges and other charges which would be payable hereunder if such termination had not occurred, less the net proceeds, if any, of any re-letting of the Premises, after
              deducting all expenses in connection with such re-letting, including, without limitation, all repossession costs, including attorney fees incurred in seeking possession or unpaid charges, brokerage commissions, legal expenses, reasonable
              alteration costs and expenses of preparation for re-letting Tenant shall pay such Base Rent, Escalation Charges and other charges to Landlord monthly on the days on which the Base Rent would have been payable hereunder if this Lease had not
              been terminated.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(d) At any time after such termination, whether or not Landlord shall have collected any post termination charges, as liquidated final damages and in lieu of all damages beyond
              the date of such demand, at Landlord&#8217;s election, Tenant shall pay to Landlord an amount equal to the excess, if any, of the present value (at a discount rate of 10%) of the Base Rent, Escalation Charges and other charges as herein before
              provided which would be payable hereunder from the date of such demand (assuming that, for the purposes of this paragraph, annual payments by Tenant on account of Taxes and Operating Expenses would be the same as the payments required for the
              immediately preceding Operating Year or Tax Year) for what would be the then unexpired Term of this Lease&#160; if the same remained in effect, over the present value (at a discount rate of 10%) of the then fair net rental value of the Premises
              for the same period. In no event shall Tenant be obligated to pay any more pursuant to this subparagraph (d) than Tenant would have been required to pay under this Lease absent such default.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div>
            <div>
              <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(e) In the case of any Default by Tenant, re-entry, expiration and dispossession of Tenant by summary proceedings or otherwise, Landlord may:</font></div>
            </div>
          </div>
          <br>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(i)&#160; re-let the Premises or any part thereof, either in the name of Landlord or otherwise, for a term or terms which may at Landlord&#8217;s option be equal to or
              less than or exceed the period which would otherwise have constituted the balance of the Term of this Lease and may grant concessions of free rent to the extent that Landlord considers reasonably advisable and necessary to re-let the
              Premises; and</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(ii)&#160; may make such reasonable alterations, repairs and decorations in the Premises as Landlord in its reasonable judgment deems advisable and necessary for
              the re-letting of the Premises. Any such repairs, decorations or alterations shall not operate nor be construed to release Tenant from any liability under this lease.</font></div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">19</font></div>
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Landlord will use best efforts to, but in no event be liable in any way for failure to re-let the Premises, or, in the event that the Premises are re-let, for failure to collect
              the rent under such re-letting. Tenant expressly waives any and all rights of redemption granted by or under any present or future laws in the event of Tenant being evicted or dispossessed, or in the event of Landlord obtaining possession of
              the Premises, by reason of the violation by Tenant of any of the covenants and conditions of this Lease.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(f) The specified remedies to which Landlord may resort are not intended to be exclusive of any remedies or means or redress to which Landlord may at any time be entitled
              lawfully, and Landlord may invoke any remedy (including the remedy of specific performance) allowed at law or in equity as if specific remedies were not herein provided for.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div>
            <div>(g) <font style="color: rgb(0, 0, 0);">Upon Default by Tenant, or the expiration or termination of this Lease, Landlord shall have the right of summary process under any applicable statutes and such other rights to recover possession as
                permitted by law. Tenant and Landlord each hereby waive any and all rights under the law of any state to the right, if any, to trial by jury.</font></div>
          </div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(h) All costs and expenses incurred by or on behalf of Landlord (including reasonable attorneys&#8217; fees and expenses) in enforcing its rights under this Lease or occasioned by any
              Default by Tenant shall be paid by Tenant.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z84bde8b95f00497bb114adb0a8e16189" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.45pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13.2</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">LANDLORD&#8217;S DEFAULT</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Landlord shall in no event be in default in the performance of any of Landlord&#8217;s obligations hereunder unless and until Landlord shall have failed to perform such obligations
              within a reasonable time (given the nature of the obligation and the time reasonably required to correct such default) after written notice by Tenant to Landlord specifying wherein Landlord has failed to perform any such obligations.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE XIV</div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z1073bc4ad0984bb291e9af37498f85b0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.85pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.1</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">WAIVER</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(a)&#160; Failure on the part of Landlord or Tenant to complain of any action or non-action on the part of the other, no matter how long the same may continue, shall never be a
              waiver by Tenant or Landlord, respectively, of any of the other&#8217;s rights hereunder. Further, no express waiver at any time of any of the provisions thereof by Landlord or Tenant shall be construed as a waiver of any of the other provisions
              hereof nor shall it be construed as a waiver at any subsequent time of the same provisions. The consent or approval of Landlord or Tenant to or of any action by the other requiring consent or approval shall not be construed to waive or render
              unnecessary Landlord&#8217;s or Tenant&#8217;s consent or approval to or of any subsequent similar act by the other.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(b) No payment by Tenant, or acceptance by Landlord, of a lesser amount than shall be due from Tenant to Landlord shall be treated otherwise than as a payment on account. The
              acceptance by Landlord of a check for a lesser amount with an endorsement or statement thereon, or upon any letter accompanying such check, that such lesser amount is payment in full, shall be given no effect, and Landlord may accept such
              check without prejudice to any other rights or remedies which Landlord may have against Tenant.</font></div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">20</font></div>
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="z976e3c7a6c2843bcacd5590acb1a4a17" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.5pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.2</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">COVENANT OF QUIET ENJOYMENT</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Tenant, subject to the terms of this Lease, of payment of the Base Rent, Escalation Charges and other charges due hereunder and observing, keeping and performing all of the
              other terms and provisions of this Lease on Tenant&#8217;s part to be observed, kept and performed, shall lawfully, peaceably and quietly have, hold, occupy and enjoy the Premises during the Term, without hindrance or ejection by any persons
              lawfully claiming to have title to the Premises superior to Tenant. This covenant of Quiet Enjoyment is given in lieu of any other covenant, express or implied.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zb46a87bb0804475a90a53688f416a06d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.25pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.3</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">LANDLORD&#8217;S LIABILITY</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(a)&#160; With respect to the Landlord&#8217;s obligations under this Lease, Tenant specifically agrees to look solely to Landlord&#8217;s interest in the Property at the time of award of any
              judgment, for recovery of any such judgment against Landlord. It is specifically understood and agreed that neither Landlord nor any Manager or Member thereof shall ever be personally liable for any such judgment, or for the payment of any
              such monetary obligation to Tenant. This provision is not intended to, and shall not, limit any right Tenant might otherwise have to obtain injunctive relief against Landlord or Landlord&#8217;s successors in interest, or to take any action not
              involving the personal liability of Landlord.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">(b) With respect to any services to be furnished by Landlord to Tenant, Landlord shall in no event be liable for failure to furnish the same when prevented from doing so by
              strike, lockout, breakdown, accident, order or regulation of or by any governmental authority, or failure of supply, or inability by the exercise of reasonable diligence to obtain supplies, parts or employees necessary to furnish such
              services, or because of war, civil disturbance, or other emergency, or for any cause beyond the reasonable control of Landlord, or for any other cause due to any act or neglect of Tenant or Tenant&#8217;s servants, agents, employees, licensees or
              any person claiming by, through or under the Tenant.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z0cc1b60a21564bb5a6dda1b6fe27bb45" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.1pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.4</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">TRANSFER OF TITLE</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">A sale, conveyance or assignment of the Property will operate to release Landlord from liability from and after the effective date of such sale, conveyance or assignment upon
              all of the covenants, terms and conditions of this Lease, express or imp lied, except those liabilities which arose prior to such effective date, and, after the effective date of such sale, conveyance or assignment, Tenant will look solely to
              Landlord&#8217;s successor in interest in and to this Lease.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z223bb86eccdc42e9b894181fa6083cd9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.25pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.5</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">RULES AND REGULATIONS</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">In addition to the Rules and Regulations of the Condominium Trust listed in Exhibit F, Tenant shall abide by rules and regulations reasonably established from time to time by
              Landlord and Landlord&#8217;s Agent, it being agreed that such rules and regulations will be established&#160; and applied by Landlord and Landlord&#8217;s Agent in a non-discriminatory fashion, such that all rules and regulations shall be generally
              applicable to other Tenants of similar nature to Tenant, and do not materially interfere with Tenant&#8217;s use. Landlord and Landlord&#8217;s Agent agrees to use reasonable efforts to ensure that any such rules and regulations are uniformly enforced,
              but Landlord and Landlord&#8217;s Agent shall not be liable to Tenant for violation of the same by any other Tenant or occupant of the Building, or persons having business with them. Initial rules and regulations are attached as Exhibit D, &#8220;Rules
              and Regulations for Fairlane Columbia, LLC.&#8221;</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">21</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="z01f8a6a2f5bc4e78adf626c5a026f4b9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.85pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.6</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">ADDITIONAL CHARGES</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">If Tenant shall fail to pay when due any sums under this Lease, Landlord shall have the same rights and remedies as Landlord has hereunder for failure to pay Base Rent.</div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z8d45b64e994445a7b925d74bc8f53fa9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.65pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.7</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">SEVERABILITY</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">If any term of this Lease, or the application thereof to any person or circumstance shall, to the extent, be invalid or unenforceable, the remainder of this Lease, or the
              application of such term to persons or circumstances other than those to which it is held invalid or unenforceable, shall not be affected thereby, and each terms and provision of this Lease shall be valid and be enforced to the fullest extent
              permitted by law.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zf500045cd0d948349e1a6dbaa0fa9250" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.7pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.8</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">BINDING NATURE</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Except as set forth&#160; herein&#160; to the contrary, the terms of this Lease shall be binding upon and shall inure to the benefit of the successor and assigns, respectively, of
              Landlord and Tenant and, if Tenant shall be an individual, upon and to his heirs, executors, administrators, successors and assigns. Each term to be performed by Tenant shall be construed as both a covenant and a condition. The reference
              contained herein to successors and assigns of Tenant is not intended to constitute a consent to assignment by Tenant, but has reference only to those instances in which Landlord may later give consent to a particular assignment&#160; as required
              by the provisions of Article VI.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z931d67197c2c468e83df348e6ffa6d9b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.55pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.9</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">NOTICES</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Whenever, by the terms of this Lease, notices shall or may be given either to Landlord, Landlord&#8217;s Agent or Tenant, such notice shall be in writing and shall be sent by Federal
              Express (or other similar express mail service), registered or certified mail postage to Landlord at the Landlord&#8217;s Address, Landlord&#8217;s Agent at Landlord&#8217;s Agent&#8217;s address, or to Tenant at Tenant&#8217;s Address, as the case may be. All such
              notices shall be effective upon the mailing thereof.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z147ab79dd24a4dd59e227dc0a366e1b8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.95pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.10</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">COMPLETE AGREEMENT AND AMENDMENT</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">All understandings between Landlord and Tenant are incorporated herein and this Lease expressly supersedes any proposals or other written documents relating hereto. This Lease
              may be modified or amended only by written agreement between Landlord and Tenant, and no act or omission of any employee or agent of Landlord shall alter, change or modify any of the provisions hereof.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z055ccf56e47648e2854010542d78a1ab" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.15pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.11</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">SUBORDINATION</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">This Lease shall be subordinate to Massachusetts General Laws Chapter 183A, the Condominium Documents and any mortgage, or other instrument in the nature of a mortgage, from
              time to time encumbering the Premises or the Condominium, whether executed and delivered prior to or subsequent to the date of this Lease, if the holder of such mortgage shall so elect. Tenant agrees to execute such instruments of
              subordination and provide to Landlord within ten (10) business days of Landlord&#8217;s written request to Tenant in confirmation of the foregoing agreement as the holder of such mortgage may request, and Tenant hereby irrevocably appoints Landlord
              as Tenant&#8217;s attorney-in-fact to execute such subordination agreement upon default of Tenant in complying with the holder of such mortgage&#8217;s request.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">22</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="z2c353c0eaf2e44dda4f5e5fd134a22df" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.5pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.12</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">ESTOPPEL CERTIFICATES</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Tenant, on the request of Landlord made from time to time, will execute and deliver to Landlord within ten (10) business days of Landlord&#8217;s written request to Tenant, a
              statement certifying to the status of any matter pertaining to this Lease, including, without limitation, and if true, (i) that this Lease is unmodified and in full force and effect or, if there have been modifications, (ii) that this Lease
              is in full force and effect as modified, and stating the date and nature of such modifications, (iii) the date, if any, to which Rent and other sums payable under this Lease have been paid, and (iv) such other similar matters as may be
              reasonably requested by Landlord. Tenant agrees to cooperate fully with and to provide such certification to any information requested by Landlord or its lenders in a timely fashion.</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <table cellspacing="0" cellpadding="0" id="ze4c4e4ef4f8f473a9046126d4a342140" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 34pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.13</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">LANDLORD&#8217;S RIGHT TO CURE DEFAULTS</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Landlord shall have the right, but shall not be required, to pay such sums or do any act which requires the expenditure of moneys which may be necessary or appropriate by reason
              of the failure or neglect of Tenant to perform any of the provisions of this Lease (after any applicable notice and cure periods provided in this Lease), and in the event of the exercise of such right by Landlord, Tenant agrees to pay to
              Landlord forthwith upon demand all such sums, together with interest thereon at a rate equal to 2% over the Prime Rate in effect and announced from time to time at Bank of America or successor bank at its principal offices located at 100
              Federal Street, Boston, Massachusetts, or any subsequent location of its principal offices in Massachusetts, as an additional charge here under. Any payment of Base Rent, Escalation charges or other sums payable hereunder not paid when due
              shall, at the option of Landlord, bear interest at the Default Rate from the due date thereof and shall be payable forthwith on demand by Landlord as an additional charge hereunder.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zadca503472eb4ee19cf2afffd0a86e34" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 34pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.14</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">HOLDOVER</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Any holding over by Tenant after the Expiration Date, or after any earlier termination under Article XIII herein, shall be treated as a daily tenancy at sufferance at a rate
              equal to two hundred (200%) percent of the Base Rent plus Escalation Charges and other charges due hereunder and shall othe1wisc be on the terms and conditions set forth in this Lease.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z8219d248411d49578053f7b42369d812" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 34.1pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.15</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">WAIVER OF SUBROGATION</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Insofar as, and to the extent that, this provision may be effective without invalidating or making it impossible to secure insurance coverage obtainable from recognized
              insurance companies doing business in the City of Cambridge, Landlord and Tenant mutually agree that, with respect to any hazard, the loss from which is covered by insurance then being carried by them, respectively, the one carrying such
              insurance and suffering such loss releases the other of and from any and all claims with respect to such loss to the extent of the insurance proceeds paid with respect thereto</font> and that their respective insurance companies shall have no
            right of subrogation against the other on account thereof.</div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">23</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="z839af2a5c23c427480ab358111f45458" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.1pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.16</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">YIELD UP</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">As of the Expiration Date, Termination Date, or earlier termination of the Term of this Lease, Tenant shall peaceably quit and surrender to Landlord the Premises in neat and
              clean&#160; condition and in good order, condition and repair, together with all alterations, additions and improvements which may have been made or installed in on or to the Premises prior to or during the Term, excepting only ordinary wear and
              tear and use and damage by fire or other casualty or by eminent domain for which, under other provisions of this Lease, Tenant has no responsibility of repair or restoration. Tenant shall remove all of Tenant&#8217;s Removable Property and, to the
              extent specified by Landlord at the time they are approved, all alterations and additions made by Tenant and all partitions erected by Tenant wholly within the Premises. For the purposes of this section, telecommunications wiring, but not
              telephone equipment (including PBX boxes, splice boxes, racks, and other telephone system equipment) shall be excluded from the definition of Tenant&#8217;s Removable Property. Tenant shall repair any damages to the Premises or the Building caused
              by such removal. Any of Tenant&#8217;s Removable Property which shall remain in the Building or on the Premises after the Expiration Date, Termination Date, or earlier termination of the Term of this Lease shall be deemed conclusively to have been
              abandoned, and either may be retained by Landlord as its property or may be disposed of in such manner as Landlord may determine, at Tenant&#8217;s sole cost and expense.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Notwithstanding anything to the contrary in the Lease, all of the following items shall remain in the Premises or on the exterior of the Building serving the Premises at the
              expiration or termination of the Term:</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div>
            <div>(a) <font style="color: rgb(0, 0, 0);">All HVAC equipment including ductwork, exhaust fans, heat exchanges and the like;</font></div>
          </div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div><font style="color: rgb(0, 0, 0);">(b) Al1 plumbing for natural gas or water and associated fixtures, sinks, chip tanks and the like; and</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div>
            <div>(c) <font style="color: rgb(0, 0, 0);">All rooftop equipment including electrical generators.</font></div>
          </div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z895fe83f94ea46a4b86df76257134bd5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.25pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.17</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">BROKERAGE</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Tenant and Landlord each warrant and represent to the other they have dealt with no broker in connection with the consummation of this Lease other than the Broker as set forth
              in Section 1.1. Landlord shall pay the brokerage commission, under terms of a separate agreement to Broker. In the event of any brokerage claims against Landlord (other than the Broker) predicated upon prior dealings with Tenant, Tenant
              agrees to defend the same and indemnify Landlord against any such claim. In the event of any brokerage claims against Tenant, predicated upon prior dealings with Landlord, Landlord agrees to defend the same and indemnify Tenant against any
              such claim.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z62b816f3ac064750858f03757e3017bb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.25pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.18</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">CONSTRUCTION</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">The Condominium Trustees, Landlord and the owners of other units of the Condominium shall have the right to make improvements to other premises or spaces in the Condominium. All
              parties making improvements are required to use reasonable effo11s to minimize any disturbance caused by the construction of such improvements.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">24</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="z796fff5744174aeba16345446c4a3faa" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 34pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.19</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">INTENTIONALLY DELETED</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z0296dd72f524443f8a87d01272c2b255" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.85pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.20</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">SECURITY DEPOSIT</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Tenant agrees that the Security Deposit specified in Section 1.1 shall be paid by check in lawful money&#160; of the United States to the order of the Landlord&#160; at Landlord&#8217;s&#160;
              Address&#160; listed&#160; in Section 1.1 upon execution and delivery of this Lease. Landlord shall hold the Security Deposit, throughout the Term of this Lease as security for the performance by Tenant of all obligations on the part of Tenant
              hereunder. Landlord shall have the right, from time to time, without prejudice to any other remedy Landlord may have on account thereof, to apply such Security Deposit, or any part thereof, to Landlord&#8217;s damages arising from any uncured
              Default of Tenant. Provided that there is no uncured Default of Tenant, Landlord shall return the Security Deposit, or so much thereof as shall not have theretofore been applied in accordance with the terms of Section 14.20, to Tenant within
              thirty (30) days of the expiration or earlier termination of the Term and surrender of possession of the Premises by Tenant to Landlord together with an itemized list of deductions, subject to Sections 8.1, 9.1 and 14.16 of the Lease. While
              Landlord holds the Security Deposit, Landlord shall have no obligation to pay interest on the same and shall have the right to commingle the Security Deposit with Landlord&#8217;s other funds. If any part of the Security Deposit is applied as
              herein provided, Tenant shall replace same within thirty (30) days of receiving written notice from the Landlord or Landlord&#8217;s Agent. Landlord shall deliver the Security Deposit, or any part hereof not previously applied, to the purchaser of
              the Building in the event the Building is sold, whereupon Tenant agrees to look solely to such successor in interest for proper application and return in accordance with the terms of this Section 14.20. The Security Deposit shall not be used
              by Tenant as a payment of Rent due for the last month or any month of the Term.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z074603d5723a463783c7e7c434b55284" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.7pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.21</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">PARTIAL INVALIDITY</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">The invalidity of one or more phrases, sentences, clauses, or articles shall not affect the remaining portions of this Lease, and if any part of this Lease should be declared
              invalid by the final order, decree or judgment of a court of competent jurisdiction, this Lease shall be construed as if such invalid phrases, sentences, clauses, or articles had not been inserted.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z5033c853cb2c41cfbb014397a76fad68" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.55pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.22</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">GOVERNING LAW</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">This Lease shall be governed exclusively by the provisions hereof and by the laws of the Commonwealth of Massachusetts.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zdc07cb4d16134c108375fdfc99cd203c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.45pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.23</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">FINANCIAL STATEMENTS</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">In the event that Tenant or any entity purchasing or merging with Tenant is no longer a public company, Tenant shall provide Landlord with annual financial statements of Tenant
              or any entity purchasing or merging with Tenant within ninety (90) days after the close of Tenant&#8217;s fiscal year.</font></div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">25</font></div>
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="z29f0d32f525a4f6d8e4bb669482c3856" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.85pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.24</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;"><font style="color: rgb(0, 0, 0);">SATELLITE DISH/ANTENNA</font></div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Landlord agrees&#160; that&#160; Tenant&#160; may&#160; install&#160; a&#160; satellite&#160; dish/antenna&#160; and&#160; associated&#160; wiring&#160; (the &#8220;Equipment&#8221;) on the Building&#8217;s roof and in the Building&#8217;s risers meeting
              the specifications set forth below, subject to the approval of the Condominium Trustees. The Equipment, which shall be included as Tenant&#8217;s Removable Property, shall be installed, at Tenant&#8217;s sole cost and expense, by a contractor providing
              satisfactory insurance certificates to Landlord and Landlord&#8217;s Agent in a location approved in advance by Landlord. Tenant shall obtain all governmental approval and permits required for the installation and operation of the Equipment and
              otherwise perform all work in a good, workmanlike manner and operate the Equipment in compliance with all applicable Federal, state and&#160; local&#160; laws,&#160; ordinances,&#160; statutes,&#160; codes&#160; and&#160; regulations,&#160; including&#160; without limitation, the rules
              and regulations of the Federal Communications Commission. Upon commencement of installation, Tenant shall pay an additional $200.00 per month for the remaining Term for the use of the roof, risers and other Building areas. No satellite dish
              shall exceed twenty-four (24) inches in diameter. The location of a satellite dish/antenna on the roof and location of wiring on the roof, risers and other Building areas are subject to Landlord&#8217;s approval. Tenant acknowledges that Landlord
              may have provided licenses to telecommunication companies for satellite dishes and antennas and approval to other tenants for rooftop satellite dishes. A satellite dish used by Tenant must not interfere with the placement or use of satellite
              dishes/antenna for the aforesaid telecommunication companies or tenants. In the event that roof maintenance, repair or replacement requires the relocation or movement of a satellite dish/antenna or temporary loss of reception, Tenant agrees
              to cooperate with Landlord and Landlord&#8217;s vendors during the period of such maintenance, repair or replacement.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z9aad3ed88c444ccba9c978828fefdbfa" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.75pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.25</td>
                <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;"><font style="color: rgb(0, 0, 0);">COMPLIANCE WITH CONDOMINIUM DOCUMENTS</font></div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">This Lease is subject to all provisions of the Condominium Documents and Rules and Regulations and Tenant agrees to observe and be bound by all such provisions. Tenant agrees to
              execute any further instruments which may be required of Tenant under the Condominium Documents. The Condominium Trust Rules and Regulations require the following notice to be included in this Lease:</font></div>
          <br>
          <div style="text-align: center; color: rgb(0, 0, 0);">&#8220;IMPORTANT CLAUSE</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">THE BUILDING IN WHICH THE UNIT OR PART OF A UNIT IS BEING LEASED IS LOCATED IS A CONDOMINIUM BUILDING - NOT A RENTAL BUILDING. THE BUILDING MAY BE OCCUPIED BY A COMBINATION OF
              UNIT OWNERS AND TENANTS OR LICENSEES. BY SIGNING THIS LEASE, LICENSE OR OCCUPANCY AGREEMENT, THE TENANT OR LICENSEE ACKNOWLEDGES THAT HE OR SHE HAS BEEN FURNISHED WITH A COPY OF THE MASTER DEED OF THE COND OMINIUM, THE DECLARATION OF TRUST OF
              THE CONDOMINIUM AND THE BY-LAWS AND RULES AND REGULATIONS THERETO AND THAT HE OR SHE HAS READ THEM AND UNDERSTANDS THEM AND THAT HE OR SHE WILL COMPLY IN ALL RESPECTS WITH TH E SAME. THE TENANT OR LICENSEE ALSO UNDERSTANDS TBAT IN THE EVENT
              THAT HE OR SHE FAILS TO COMPLY, THE TENANT OR LICENSEE MAY BE EVICTED BY THE TRUSTEES OF THE CONDOMINIUM TRUST (WHO ARE ELECTED BY THE UNIT OWNERS). THE PROVISIONS OF THIS CLAUSE TAKE PRECEDENCE OVER ANY OTHER PROVISION OF THIS LEASE, LICENSE
              OR OCCUPANCY AGREEMENT.</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">26</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <!--PROfilePageNumberReset%Num%27%%%-->
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Any failure by the Tenant to comply in all respects with the provisions of the Master Deed of the Condominium, the Declaration of Trust and the By-Laws and Rules and Regulations
              thereto shall constitute a material default in this lease, license, or occupancy agreement, and in the event of such default (&#8220;Default&#8221;), the Trustees of the Condominium Trust shall have the following rights and remedies against both the Unit
              Owner and the Tenant, in addition to all other rights and remedies that Trustees and the Unit Owners (other than the owner of the affected Unit) have or may in the future have, against both the owner of the affected Unit and the tenant, all
              rights and remedies of the Trustees and the Unit Owners (other than the owner of the affected Unit) being deemed at all times to be cumulative and not exclusive. In addition,</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(i)&#160; The Trustees shall have the right to give written notice of the Default to both the Tenant and the Unit Owner. Said notice shall be deemed properly given
              if left in any part of the Unit, addressed to the Tenant, and mailed postage pre-paid, registered or certified mail, return receipt requested, addressed to the Unit Owner at such address as appears on the records of the Trustees, or by
              delivering said notice in hand, or be delivering said notice in any other manner permitted by law.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(ii)&#160; If the Default continues for five days after the giving of said notice, then the Trustees shall have the right to levy fines against the Unit Owner in
              accordance with the By-Laws, and terminate the tenancy by giving notice in writing to quit to the Tenant in any manner permitted by the Trustees, or both. A copy of such notice shall be delivered or mailed to the Unit Owner in the manner set
              forth hereinabove. Thereafter, the Trustees may initiate and prosecute a summary process action against the Tenant under the provisions of Massachusetts General Laws, in the name of the Unit Owner or in the name of the Trustees, or both.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(iii) The Trustees shall be entitled to levy a fine or fines, or give a notice or notices to quit, followed by a summary process action or actions, and the
              Trustees&#8217; election to pursue any of the foregoing remedies shall in no way prohibit them from pursuing all of the foregoing remedies, either at the same time, or in the event of any further default.</font></div>
          <div style="color: rgb(0, 0, 0); text-indent: 36pt;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(iv) All of the expenses incurred by the Trustees in giving notices, and notices to quit and maintaining and pursuing summary process actions and appeals
              therefrom, shall be entirely at the expense of the Unit Owner of the affected unit. Such costs and expenses may be enforced and collected against the Unit Owner and Unit as if the same were common charges owed by the Unit Owner.</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(v) The Unit Owner shall make reasonable efforts, at his or her expense and upon his or her initiative, to inform rental agents of the provisions of this
              section and shall, at his or her expense, and upon his or her initiative, furnish copies of the Condominium Documents to the Tenant and cause the lease or occupancy agreement to be prepared in conformity with the provisions of this section.</font></div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">27</font></div>
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(vi)&#160; Any renewal or extension of any lease or occupancy agreement shall be subject to the prior written approval of the Trustees in every in stance. Such
              approval shall not limit any rights or remedies of the Trustees or Unit Owners in the event of a subsequent default.</font></div>
          <div style="color: rgb(0, 0, 0); text-indent: 36pt;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(vii)&#160; A true copy of every lease or occupancy agreement shall be delivered to the Trustees forthwith upon its execution.</font></div>
          <div style="color: rgb(0, 0, 0); text-indent: 36pt;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(viii)&#160; Notwithstanding anything to the contrary herein, and notwithstanding any custom, law or usage to the contrary, it is expressly understood and agreed
              that neither the Trustees, nor the Unit Owners shall ever bear any personal liability with respect to any lease or the use and occupancy of a unit by a Tenant.</font></div>
          <div style="color: rgb(0, 0, 0); text-indent: 36pt;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(ix)&#160;&#160; Every lease, license or occupancy agreement, shall have attached thereto, and incorporated therein by reference, a copy of this section 5.0 of the
              Rules and Regulations.&#8221;</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">The Condominium Trust Rules and Regulations also require that Landlord inform tenants that:</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify; margin-right: 40.6pt; margin-left: 39.4pt;"><font style="color: rgb(0, 0, 0);">&#8220;If a tenant offers any of its employees parking in the Parking Lot, then the tenant has the option of charging such employee market
              rate for parking, or, alternatively, if the tenant charges any of its employees less than the current monthly market rate for parking, then the tenant will offer such employees an equivalent monthly payment to support the employee&#8217;s commute
              by walking, biking, transit or carpool. In the event that an employee chooses to use the equivalent monthly payment for transit, <u>t</u><u>e</u><u>nants </u><u>will </u><u>use be</u><u>s</u><u>t </u><u>e</u><u>fforts to enroll </u><u>in</u>&#160;<u>the

                MBTA pa</u><u>s</u><u>s grogram to provid</u><u>e&#160;an </u><u>e</u><u>mployee&#160;w</u><u>i</u><u>th the ability to purchase a pass using pre</u><u>-</u><u>tax wages</u>. &#8216;Equivalent monthly payment&#8217; means the remainder of the current monthly
              market rate for parking less the fee paid for parking by an employee. For example, if the current monthly market rate is $200 and an employee is being charged $50 per month by the employer, then the equivalent monthly payment equals $150 per
              month. Any tenant may charge certain employees for parking at market rate in the Parking Lot and other employees may be charged at less than the current monthly market rate for parking in the Parking Lot with the tenant providing such
              employees with the equivalent monthly benefit option.&#8221;</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z27887b1b4aaf4dd49b508c1be489bfea" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.15pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.26</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">SUBMISSION NOT OFFER OR OPTION</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">The submission of this Lease for examination and negotiation does not constitute an offer to lease, or a reservation of, or option for, the Premises. This document shall become
              effective and binding only upon the execution and delivery by Landlord and by Tenant, and until such execution and delivery, Landlord shall not in any way be bound to enter into a lease with Tenant for the Premises.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">28</font></div>
            <div style="page-break-after: always;" id="DSPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="z57f6045e3b214f5cbfbd2b062d1d39ed" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.4pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.27</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">AUTHORITY AND ORGANIZATION OF TENANT</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">If Tenant is a corporation or a limited liability company, each person executing this Lease on behalf of the Tenant hereby covenants, represents and warrants that Tenant is a
              duly incorporated or duly qualified (if foreign) corporation or limited liability company and is authorized to do business in the Commonwealth of Massachusetts, a copy of evidence thereof to be supplied to Landlord upon execution of this
              Lease by Tenant; and that each person executing this Lease on behalf of Tenant is an officer or manager of Tenant and that he or she is duly authorized to execute, acknowledge and deliver this Lease to Landlord (if a corporation, a copy of a
              resolution to that effect to be supplied to Landlord upon lease execution&#160; or amendment). If Tenant is a corporation or limited liability company, Tenant shall provide Landlord with a Certificate of Organization or other organizational
              documents required for doing business in the Commonwealth of Massachusetts from the Secretary of the Commonwealth (the &#8220;Secretary&#8221;) at the execution of the Lease and upon filing of an Annual Report </font><font style="font-style: italic; color: rgb(0, 0, 0);">with </font><font style="color: rgb(0, 0, 0);">the Secretary shall also provide a copy to Landlord within thirty (30) days of said filing.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zf0830119681f401abe8a418c1ddd4a8e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.85pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.28</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">NO RECORDING</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">This Lease, any memorandum of this Lease or any short form of this Lease shall not be recorded.</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <table cellspacing="0" cellpadding="0" id="z0582465e961b4752b978a5c10cec39d7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.65pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.29</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">ADDENDUM</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">All Exhibits attached hereto are incorporated herein by this reference.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z07da20231c9a4a4692e4bd37517b4500" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.55pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.30</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">TENANT&#8217;S APPROVALS</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Tenant shall be responsible for any and all public and regulatory approvals regarding its use of hazardous materials (&#8220;Tenant&#8217;s Approvals&#8221;). The Commencement Date shall not be
              delayed due&#160; to the failure of Tenant to receive Tenant&#8217;s Approvals.</font></div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <table cellspacing="0" cellpadding="0" id="zbd45d4d54cc14768b338f11ec60035c7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.4pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.31</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">SIGNATURES</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Authorized signatories for Landlord and Tenant signing this Lease must either personally sign below or provide signatures using DocuSign. Leases signed personally by authorized
              signatories may be submitted via email using a PDF format or with paper copies of the complete document mailed (by USPS or express mail service) to the Landlord&#8217;s Address or Tenant&#8217;s Address.</font></div>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zc63d5e9b6ad24311a773cfd465fb821c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 33.6pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14.32</td>
                <td style="width: auto; vertical-align: top; color: rgb(0, 0, 0);">
                  <div style="font-weight: bold;">NO PERSONAL LIABILITY</div>
                </td>
              </tr>

          </table>
          <div style="color: rgb(0, 0, 0);">&#160;</div>
          <div><font style="color: rgb(0, 0, 0);">Landlord shall&#160; look solely to Tenant&#160; and its assets for the satisfaction of any claims hereunder, the performance of Tenant&#8217;s obligations hereunder, or the collection of any judgment (or other judicial
              process) or the enforcement of any injunctive&#160; relief or specific performance&#160; based thereon, and (i) no other property or assets of any employee, officer, director, shareholder, member, partner or beneficiary of Tenant shall be subject to
              levy, execution or other enforcement procedure for the satisfaction&#160; of any such claim, obligation&#160; or judgment (or other judicial&#160; order or process), and (ii) no employee, officer, director, shareholder, member,&#160; partner or&#160; beneficiary of
              Tenant shall be personally liable for any such claim, obligation or judgment (or other judicial order or process).</font></div>
          <div><font style="color: rgb(0, 0, 0);"> <br>
            </font></div>
          <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">29</font></div>
            <div id="DSPFPageBreak" style="page-break-after:always;">
              <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
          </div>
          <!--PROfilePageNumberReset%Num%30%%%-->
          <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">IN WITNESS WHEREOF, Landlord and Tenant have caused this Lease to be duly executed, under seal, by persons hereunto duly authorized, in multiple copies,
            each to be considered an original hereof, as of the day and year first set forth above.</div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="color: rgb(0, 0, 0);">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z4c4a19294f2e407b8c32b1ad774b0b38">

                <tr>
                  <td style="width: 100%; font-weight: bold;">LANDLORD:<br>
                  </td>
                </tr>
                <tr>
                  <td style="width: 100%; font-weight: bold;"><font style="font-weight: bold;">Fairlane Columbia, LLC</font><br>
                  </td>
                </tr>
                <tr>
                  <td style="width: 100%; font-weight: bold;" rowspan="1">&#160;</td>
                </tr>

            </table>
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z9cc9da0906ed4535b0499f3c495b5219">

                <tr>
                  <td style="width: 3%; padding-bottom: 2px; font-weight: normal;"><font style="font-weight: bold;">By:</font><br>
                  </td>
                  <td style="width: 47%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: normal;">/s/ Michael S. Grill<br>
                  </td>
                  <td style="width: 50%; padding-bottom: 2px;"><br>
                  </td>
                </tr>
                <tr>
                  <td style="font-weight: normal;" colspan="3"><font style="font-weight: bold;">Michael S. Grill, <font style="font-style: italic;">Manager</font> and not individually</font><br>
                  </td>
                </tr>

            </table>
          </div>
          <div style="color: rgb(0, 0, 0);"><br>
          </div>
          <div style="color: rgb(0, 0, 0);">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="ze04e58b9d1d74b42acc8a8a8a39c73d3">

                <tr>
                  <td style="width: 100%; font-weight: bold;">TENANT:</td>
                </tr>
                <tr>
                  <td style="width: 100%; font-weight: bold;"><font style="font-weight: bold;">Brooklyn Immunotherapeutics, Inc.</font><br>
                  </td>
                </tr>
                <tr>
                  <td style="width: 100%; font-weight: bold;" rowspan="1">&#160;</td>
                </tr>

            </table>
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z87020b62d14c4cb2a79da38f68eb72e1">

                <tr>
                  <td style="width: 3%; font-weight: bold; padding-bottom: 2px;" rowspan="1">By:</td>
                  <td style="width: 47%; font-weight: normal; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1">/s/ Howard J. Federoff</td>
                  <td style="width: 50%; font-weight: normal; padding-bottom: 2px;" rowspan="1">&#160;</td>
                </tr>

            </table>
            <div>
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z5c01c0daa571416bbfcfaadcf047de21">

                  <tr>
                    <td style="width: 100%; font-weight: bold;"><font style="font-weight: bold;">Howard J. Federoff, President and CEO and not individually</font><br>
                    </td>
                  </tr>

              </table>
            </div>
            <div><br>
              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">30</font></div>
                <div style="page-break-after: always;" id="DSPFPageBreak">
                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
              </div>
              <div style="text-align: center; font-weight: bold;">EXHIBIT A</div>
              <div style="text-align: center; font-weight: bold;"> <br>
              </div>
              <div style="text-align: center; font-weight: bold;">DESCRIPTION OF PROPERTY</div>
              <div style="text-align: center; font-weight: bold;"> <br>
              </div>
              <div style="text-align: center;">Units B-1, 11, 13, 14, 15/16, 17A, 17B, 18A, 21 and 21A of the 432 Columbia Street</div>
              <div style="text-align: center; font-size: 10.5pt;"><font style="font-size: 10pt;">Condominium established by Master Deed dated January 22, 1988 and recorded with the</font></div>
              <div style="text-align: center; font-size: 10.5pt;"><font style="font-size: 10pt;">Middlesex County South Registry of Deeds in Book 18837 Page 122, as amended and in Book</font></div>
              <div style="text-align: center; font-size: 10.5pt;"><font style="font-size: 10pt;">70488, Page 149.</font></div>
              <div style="text-align: center;"> <br>
              </div>
              <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                <div id="DSPFPageBreak" style="page-break-after: always;">
                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
              </div>
              <div>
                <div style="text-align: center; font-weight: bold;">EXHIBITB </div>
                <div style="text-align: center; font-weight: bold;"> <br>
                </div>
                <div style="text-align: center; font-weight: bold;">PLAN OF PREMISES</div>
                <div style="text-align: center; font-weight: bold;"> <br>
                </div>
                <div style="text-align: center; font-weight: bold;">(See following page)</div>
                <div style="text-align: center; color: rgb(61, 66, 70); font-weight: bold;"> <br>
                </div>
                <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                  <div id="DSPFPageBreak" style="page-break-after: always;">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div style="text-align: center;"> <img src="image00002.jpg">
                  <div><br>
                  </div>
                </div>
                <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                  <div id="DSPFPageBreak" style="page-break-after: always;">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <!--PROfilePageNumberReset%Num%2%%%-->
                <div>
                  <div style="text-align: center; font-weight: bold;">EXHIBIT C<br>
                    <br>
                  </div>
                  <div style="text-align: center; font-weight: bold;">LANDLORD&#8217;S WORK</div>
                  <div style="text-align: center; color: rgb(76, 83, 86); font-weight: bold;"> <br>
                  </div>
                  <div style="text-align: justify;">The Premises is provided to Tenant on an &#8216;as-is&#8217; basis, except that Landlord shall at its cost:</div>
                  <div> <br>
                  </div>
                  <div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc717802ff6d84f66954a32a0fd5c4b0c" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                        <tr style="vertical-align: top;">
                          <td style="width: 18pt;">&#160;</td>
                          <td style="vertical-align: top; width: 18pt;">
                            <div style="text-align: justify;">1)</div>
                          </td>
                          <td style="align: left; vertical-align: top; width: auto;">
                            <div style="text-align: justify;">install 1&#8221; horizontal window blinds for the exterior windows and remove all brown window blinds from the Premises; and</div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div> <br>
                  </div>
                  <div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc81844d40c294eebacdcb3a117d26d95" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                        <tr style="vertical-align: top;">
                          <td style="width: 18pt;">&#160;</td>
                          <td style="vertical-align: top; width: 18pt;">
                            <div style="text-align: justify;">2)</div>
                          </td>
                          <td style="align: left; vertical-align: top; width: auto;">
                            <div style="text-align: justify;">move the 50-amp service providing power to the 7.5-ton HVAC unit servicing the Premises to another electrical panel outside of the Premises.</div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div> <br>
                  </div>
                  <div style="text-align: justify;">Landlord will provide a path for ductwork and gas or vent pipes from Suite 18A through the Building&#8217;s interior to the roof, with the amount of allowable noise from ductwork located in the Building&#8217;s
                    common hallways and shafts subject to Landlord&#8217;s approval. Tenant shall be responsible for the cost of such ductwork and Building work to accommodate a path for such ductwork as well as providing room in the shaftway for potential
                    future ductwork from the lower level. Tenant&#8217;s contractors shall use best efforts to minimize any nuisance or disturbance to nearby tenants from such work in the Building&#8217;s common areas and Landlord may limit certain work to hours
                    outside the business hours of the Building.<br>
                    <br>
                  </div>
                  <div style="text-align: justify;">In addition, Landlord shall provide a tenant allowance of $50,000.00 (the &#8220;Tenant Allowance&#8221;) as described in Section A below. Tenant may enter into a contract with a contractor (the &#8220;Tenant&#8217;s
                    Contractor&#8221;), other than Key Construction, to construct the improvements.</div>
                  <div> <br>
                  </div>
                  <div style="text-align: justify;">In the event that any portion or all of the Premises is converted into biotech lab space during the Term, then Tenant shall comply with Sections B-K below for such construction:</div>
                  <div> <br>
                  </div>
                  <div>
                    <div>
                      <div>
                        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zaffd7d98c26f40cfaac5b55513f52bb6" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                            <tr style="vertical-align: top;">
                              <td style="width: 18pt;">&#160;</td>
                              <td style="vertical-align: top; width: 27pt;">
                                <div style="text-align: justify;">A.</div>
                              </td>
                              <td style="align: left; vertical-align: top; width: auto;">
                                <div style="text-align: justify;">Landlord shall provide Tenant with a check, payable to both Tenant and Tenant&#8217;s Contractor, on a monthly basis up to the amount of the Tenant&#8217;s Allowance within fifteen (15) days of the
                                  receipt of invoices (sent by Tenant to Landlord) from Tenant&#8217;s Contractor. Said invoices, except for the final payment (&#8220;Final Payment&#8221;), must be accompanied by 1) partial lien waivers from Tenant&#8217;s Contractor and 2) a
                                  request by Tenant for payment with a calculation of payments in relation to the total Tenant&#8217;s Allowance. Tenant&#8217;s request for the Final Payment, which shall be in an amount of no less than $5,000.00 and shall also be
                                  Tenant&#8217;s final payment to Tenant&#8217;s Contractor, shall be accompanied by 1) a lien waiver from Tenant&#8217;s Contractor which will be conditional only upon the receipt of the Final Payment, and 2) a copy of the City of Cambridge
                                  building permit signed by the building inspector with his or her final sign-off.</div>
                              </td>
                            </tr>

                        </table>
                      </div>
                    </div>
                  </div>
                  <div><br>
                  </div>
                  <div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3829b91a46444cfdb1e7d133be9f1ef5" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                        <tr style="vertical-align: top;">
                          <td style="width: 18pt;">&#160;</td>
                          <td style="vertical-align: top; width: 27pt;">
                            <div style="text-align: justify;">B.</div>
                          </td>
                          <td style="align: left; vertical-align: top; width: auto;">
                            <div style="text-align: justify;"><u>Plans and Approvals</u>. Tenant shall provide Landlord with one (1) full-scale architectural and engineering sets of plans and one (1) copy of plans emailed to Landlord as a PDF (&#8220;Plans&#8221;)
                              detailing the intended improvements to the Premises (&#8220;New Lab Tenant Improvements&#8221;) prepared by registered architects and engineers, prior to submission of said Plans to the City of Cambridge, for Landlord&#8217;s reasonable
                              approval, which may not be unreasonably withheld, delayed or conditioned, within five (5) business days of the submission of the Plans to Landlord. Landlord shall notify Tenant of any objection to the Plans within the
                              abovementioned five (5) business days. Should Landlord not notify Tenant of any objection to the Plans within the abovementioned five (5) business days, such Plans shall be deemed approved by Landlord. Should Landlord notify
                              Tenant of any objection to the Plans within the abovementioned five (5) business days, Tenant shall make revisions and resubmit the plans for Landlord&#8217;s approval, whereupon the foregoing review and approval shall be repeated
                              until the Plans are approved (or deemed approved) by Landlord in accordance with this Paragraph B. No review or approval by Landlord of the Plans shall constitute any representation or warranty as to the adequacy, correctness,
                              efficiency or compliance with any laws, regulations or ordinances, or any other aspect of such drawings and specifications. The Plans shall be incorporated by reference into this Exhibit C and Tenant shall provide Landlord
                              with a full-sized set and a PDF set of the City of Cambridge approved plans as well as any &#8216; as-built&#8217; plans issued by Tenant&#8217;s architect or Tenant&#8217;s contractor. Tenant shall be responsible for the application, payment and
                              receipt of all governmental permits and approvals for the construction of New Lab Tenant Improvements, including a Certificate of Occupancy (&#8220;C of O&#8221;) that applies to the Premises. Tenant shall provide to Landlord a copy of C
                              of O issued by the City of Cambridge within seven (7) days of the receipt of such C of O by Tenant or Tenant&#8217;s Contractor.</div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div>&#160;</div>
                  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                    <div id="DSPFPageBreak" style="page-break-after: always;">
                      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                  </div>
                  <!--PROfilePageNumberReset%Num%2%%%-->
                  <div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z48901f2472bd47c8a04355daaed02ea0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="width: 18pt;">&#160;</td>
                            <td style="vertical-align: top; width: 27pt;">
                              <div style="text-align: left;">C</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: left;"><u>Tenant&#8217;s Oversight</u>. Oversight of New Lab Tenant Improvements, which shall be made in a good and workmanlike manner and in compliance with all applicable laws and government regulations,
                                shall be the responsibility of Tenant. Tenant shall perform New Lab Tenant Improvements in such a manner as not to interfere with the use and enjoyment of the remainder of the Building by any other tenant or any other
                                construction then being performed by any other tenant or by Landlord. Tenant shall have access to the New Lab Premises as of the date of Lease execution after receipt by Landlord of Tenant&#8217;s and Tenant&#8217;s Contractor&#8217;s
                                Insurance Coverage required under Section H below, provided, however, that Tenant assumes any risks attendant on its entry into the New Lab Premises prior to the completion of the New Lab Tenant Improvements. Tenant&#8217;s entry,
                                as described above, shall not be deemed to be occupancy of the Premises. Tenant shall comply with all of the terms, covenants, and conditions of the Lease after the date of Lease execution. <br>
                              </div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div><br>
                    </div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4c75cf57bc4a454d917af52f7c868567" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="width: 18pt;">&#160;</td>
                            <td style="vertical-align: top; width: 27pt;">
                              <div>D.</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div><u>Tenant&#8217;s Consultants</u>. Tenant shall separately contract with any consultants or engineers for laboratory-specific plumbing, heating, ventilation or air conditioning, or electrical items during construction or during
                                planning of construction. Tenant shall provide Landlord with all specifications and studies provided to Tenant by Tenant&#8217;s Consultants.</div>
                            </td>
                          </tr>

                      </table>
                      <div> <br>
                      </div>
                    </div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z0abbf59d44ba49d8868cb6e1a188d453" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="width: 18pt;">&#160;</td>
                            <td style="vertical-align: top; width: 27pt;">
                              <div style="text-align: left;">E.</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: left;"><u>Landlord&#8217;s Oversight.</u> Landlord and its agents may have unrestricted access at their own risk to the New Lab Premises during construction. Landlord shall provide a punch list containing
                                specific detailed deficiencies to Tenant within thirty (30) days of the substantial completion of the New Lab Tenant Improvements to correct all said deficiencies noted by Landlord in the New Lab Tenant Improvements to the
                                extent that the New Lab Tenant Improvements do not substantially conform to the approved Plans or if Building Common Areas require corrective action. Tenant shall complete such corrections within a reasonable time, but in no
                                event later than thirty (30) days of the presentation of the punch list to Tenant. Landlord&#8217;s punchlist or supervision or approval shall not constitute a warranty that the New Lab Tenant Improvements were properly performed
                                or designed or create any liability for payment for such work by Landlord.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div><br>
                    </div>
                    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
                      <div id="DSPFPageBreak" style="page-break-after: always;">
                        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                    </div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3cf312f934804d7896dbc42ea74061a1" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="width: 18pt;">&#160;</td>
                            <td style="vertical-align: top; width: 27pt;">
                              <div style="text-align: left;">F.</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: left;"><u>Tenant&#8217;s Vendors</u>. New Lab Tenant Improvements may be performed only by licensed contractors or subcontractors approved in advance by Landlord; such approval shall not be unreasonably
                                withheld. Tenant shall provide its contract with its general contractor or construction manager prior to the submission of Plans to the City of Cambridge (the &#8220;Contract&#8221;). With respect to New Lab Tenant Improvements to the
                                life safety system, Landlord reserves the right to require Tenant to use Landlord&#8217;s contractors (&#8220;Landlord&#8217;s Contractors&#8221;) to perform such Tenant Improvements, but in such event the charges of such contractors shall be
                                competitive with the charges of other contractors performing similar work in similar office buildings (i.e. - Tenant&#8217;s Contractor&#8217;s subcontractors (the &#8220;subcontractors&#8221;)) in the City of Cambridge. In the event that the
                                subcontractors provide pricing below that of Landlord&#8217;s Contractors, Tenant shall provide Landlord with the subcontractors&#8217; bids so that Landlord and Tenant&#8217;s general contractor may negotiate competitive pricing from
                                Landlord&#8217;s Contractors. Landlord&#8217;s Contractors will perform all work for Tenant&#8217;s Contractor and will not have any contract, oral or written, express or implied, with Landlord for work according to the Plans. Tenant&#8217;s
                                vendors shall work with Landlord on the timing of work which may unreasonably disrupt tenants of space adjoining, above and below the New Lab Premises so long as access by such vendors is not unduly restricted and the
                                performance of New Lab Tenant Improvements is not materially delayed.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z45c8beebedf64954a85136d317fb4863" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="width: 18pt;">&#160;</td>
                            <td style="vertical-align: top; width: 27pt;">
                              <div style="text-align: left;">G.</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: left;"><u>Use of the Building and Parking Lot</u>. Prior to the Commencement Date and during construction of the New Lab Premises, Tenant&#8217;s Contractor, subcontractors, engineer and architect may park in
                                Tenant&#8217;s Parking Spaces in the Parking Lot and in no other spaces. Tenant&#8217;s contractors, subcontractors, engineer and architect may not park in the Building&#8217;s visitor spaces. Construction dumpsters may be placed in
                                designated areas of the Parking Lot or along Windsor Street. Dumpster pick-up, for dumpsters placed in the Parking Lot, must occur prior to 8AM on Business Days of the Property. Upon receipt of a Certificate of Insurance as
                                provided in Section H below, Tenant&#8217;s Contractor shall be provided with a Building passcard which shall be returned to Landlord upon the later of the receipt of the C of O or completion of Landlord&#8217;s or Tenant&#8217;s punch list.
                                Tenant&#8217;s Contractor must comply with all noise and time regulations of the City of Cambridge for construction including weekend or holiday work.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z1d567d8c07fc49e2bd22ae4719f338bc" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="width: 18pt;">&#160;</td>
                            <td style="vertical-align: top; width: 27pt;">
                              <div style="text-align: left;">H.</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: left;"><u>Insurance and Liability</u>. Tenant&#8217;s general contractor, engineer, consultants and architect shall provide Landlord with insurance certificates with coverages reasonably satisfactory to
                                Landlord, with all certificates naming Landlord as certificate holder and additional insured and Fairlane Columbia, LLC, 432 Columbia Street Condominium Trust and LPC Commercial Services, Inc. as additional insureds
                                (&#8220;Insurance Coverage&#8221;). In the event that Tenant chooses to use a construction manager instead of a general contractor, then all subcontractors shall provide Insurance Coverage to Landlord. Landlord shall have no liability
                                for any loss or damage to any of Tenant&#8217;s fixtures or property installed or left in the Premises, unless such loss or damage is the result of a willful act or gross negligence of Landlord, Landlord&#8217;s Agent or Landlord&#8217;s
                                vendors. Tenant shall hold harmless, indemnify and defend Landlord from and against any and all liabilities arising from or relating to the New Lab Tenant Improvements, unless such loss or damage is the result of a willful
                                act or gross negligence of Landlord, Landlord&#8217;s Agent or Landlord&#8217;s vendors.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
                      <div id="DSPFPageBreak" style="page-break-after: always;">
                        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                    </div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z95aa885f2a9049949ae96725065ecaa2" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="width: 18pt;">&#160;</td>
                            <td style="vertical-align: top; width: 27pt;">
                              <div style="text-align: left;">I.</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: left;"><u>Tenant&#8217;s Cost</u>. Tenant shall be responsible for all architectural, engineering and construction management fees.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zff589616386948678c14f9acfdec54bf" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="width: 18pt;">&#160;</td>
                            <td style="vertical-align: top; width: 27pt;">
                              <div style="text-align: left;">J.</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: left;"><u>Landlord&#8217;s Contractors</u>. Below is a list of Landlord&#8217;s Contractors mentioned in Section F above:</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8ea488492943488eba79617a8d06278d" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="width: 45pt;">&#160;</td>
                            <td style="vertical-align: top; width: 27pt;">
                              <div style="text-align: left;">a)</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: left;">Life Safety: Advanced Signal</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc3cc1a60b0b848b8b8864b8faff68eab" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="width: 45pt;">&#160;</td>
                            <td style="vertical-align: top; width: 27pt;">
                              <div style="text-align: left;">b)</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: left;">Sprinklers: Encore Fire Protection</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb4ebdfca732248c4bb935b749bacd34e" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="width: 18pt;">&#160;</td>
                            <td style="vertical-align: top; width: 27pt;">
                              <div style="text-align: left;">K.</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: left;"><u>Telecommunications.</u> Tenant shall be responsible for the installation and cost of all telecommunications and data wiring. Tenant&#8217;s telecommunication&#8217;s vendor shall provide a Certificate of
                                Insurance with Fairlane Columbia, LLC as the certificate holder and Fairlane Columbia, LLC, 432 Columbia Street Condominium Trust and LPC Commercial Services, Inc. as additional insureds with minimum coverage as provided for
                                Tenant in this Lease. Tenant&#8217;s telecommunications vendor shall receive an electrical permit from the City of Cambridge, if necessary, prior to any electrical work necessary for installation of Tenant&#8217;s telecommunications
                                equipment.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
                      <div id="DSPFPageBreak" style="page-break-after: always;">
                        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                    </div>
                    <div style="text-align: center; font-weight: bold;">EXHIBIT D</div>
                    <div>&#160;</div>
                    <div style="text-align: center; font-weight: bold;">RULES AND REGULATIONS</div>
                    <div style="text-align: center; font-weight: bold;">FOR FAIRLANE COLUMBIA, LLC</div>
                    <div>&#160;</div>
                    <div>1. <font style="font-style: italic;"><u>Tenant Conduct</u> </font>Tenant shall not carry on any practice which is contrary to any law or ordinance or which may damage the Premises or any other part of the Building. Tenant shall
                      not cause any offensive odors, create any loud noise or nuisance to any other tenant or other persons in the Building. As determined by Landlord in its reasonable discretion, Tenant shall not overburden the common areas of the
                      Building, including the hallways, elevator, loading dock and dumpster, with shipments and deliveries of goods. Tenant shall follow Landlord&#8217;s guidelines and instructions to avoid overburdening the common areas of the Building. No
                      electric space heaters shall be used in the Premises or in the Building unless specifically approved by Landlord.</div>
                    <div>&#160;</div>
                    <div>2. <u><font style="font-style: italic;">Smoking</font></u><font style="font-style: italic;"> </font>Smoking or carrying lighted cigars, pipes or cigarettes in the Premises, in the Building, or in front of any tenant&#8217;s entrance at
                      the Property is not permitted. Smoking is permitted in the area designated in the Rules and Regulations of the 432 Columbia Street Condominium Trust. In the event that a Tenant or employee of Tenant is found to be the cause of a fire
                      alarm at the Building because of smoking in the Building, such Tenant shall pay for all costs associated with said fire alarm. Tenant or its employees smoking outside of the Building shall dispose of cigarette or cigar butts in trash
                      receptacles and not on the sidewalk or landscaped areas of the Property, in the Parking Lot or in catch basins of the Parking Lot.</div>
                    <div>&#160;</div>
                    <div>3. <u><font style="font-style: italic;">Animals</font></u><font style="font-style: italic;"> </font>Animals or birds are not allowed in the Building, except for dogs used by the visually or hearing impaired, as
                      except as permitted by Landlord on a case by case basis, in the sole and absolute discretion of Landlord. <br>
                      <br>
                      4. <font style="font-style: italic;"><u>Electronic Devices</u> </font>No televisions, phonographs, radios, compact disc players, or tape players shall be used such that they are heard or seen outside the Premises.</div>
                    <div>&#160;</div>
                    <div>5. <font style="font-style: italic;"><u>Advertising</u> </font>Tenant shall not distribute advertising or promotional materials in the Building or to other tenants and shall not admit into the Building individuals intending to
                      canvas, solicit, or distribute advertising or promotional materials in the Building.</div>
                    <div>&#160;</div>
                    <div><u>6. </u><font style="font-style: italic;"><u>Electrical and HVAC Rooms</u> </font>Tenant shall not use any electrical room or closet in the Premises or in the Building for any additional purpose. Tenant shall not use any room
                      or closet in which an air conditioning unit is located in the Premises or in the Building for any additional purpose, including the storage of any personal property or equipment, unless specifically permitted in writing by Landlord.
                      Landlord may remove any of Tenant&#8217;s personal property or equipment from said rooms or closets without notice to Tenant at no liability to Landlord and may charge the expense incurred by such removal to Tenant. No trash or debris shall
                      be placed in any electrical or air conditioning room or closet in the Premises or in Common Areas.</div>
                    <div>&#160;</div>
                    <div>7. <font style="font-style: italic;"><u>Toilets and Sinks</u> </font>Toilets and sinks shall not be used for any purposes other than those for which they were designed or constructed. No substances or materials other than those
                      intended shall be placed in toilets and sinks, and the resulting expense of any stoppage, breakage, or damage shall be borne by Tenant who, or whose employees, agents, visitors, or invitees, shall have caused same.</div>
                    <div>&#160;</div>
                    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                      <div id="DSPFPageBreak" style="page-break-after: always;">
                        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                    </div>
                    <!--PROfilePageNumberReset%Num%2%%%-->
                    <div>8. <font style="font-style: italic;"><u>Signs</u> </font>Tenant shall not place paper or other signs in Common Areas. Tenant shall not place any sign, symbol, advertisement or the like which may be visible to public view on the
                      exterior of the Premises (including both interior and exterior surfaces of windows) or on any other part of the Building without the prior written consent of Landlord. In the event of a violation of the above rule regarding signs,
                      symbols, advertising and the like by Tenant, Landlord may remove the material without any liability and may charge the expense incurred by such removal to Tenant.</div>
                    <div>&#160;</div>
                    <div>9. <font style="font-style: italic;"><u>Directories</u> </font>Tenant&#8217;s name will be listed on the main lobby directory by Landlord at Landlord&#8217;s expense. Additional names and names of subtenant of Tenant will be
                      listed on the main lobby directory at Tenant&#8217;s request and expense by Landlord if space on the directory is available.</div>
                    <div>&#160;</div>
                    <div>10. <font style="font-style: italic;"><u>Interior Signs</u> </font>Interior signs displaying the Tenant&#8217;s name on Common Area doors or walls are subject to the Rules and Regulations of the 432 Columbia Street Condominium Trust
                      and shall be at the expense of Tenant and shall be of a size, color and style acceptable to Landlord.</div>
                    <div>&#160;</div>
                    <div>11. <font style="font-style: italic;"><u>Locks</u> </font>Landlord shall furnish to Tenant a reasonable number of keys to the Building&#8217;s entrances and Tenant&#8217;s Premises. No additional locks, guards or bolts of any kind may be
                      placed upon any of the doors or windows of Tenant, except with the prior written consent of Landlord. In the event of a violation of the above rule by Tenant, Landlord may remove the additional locks, guards or bolts without any
                      liability and may charge the expense incurred by such removal and repair to Tenant, including the cost for materials and labor for a new door if the existing door is determined by Landlord to be damaged beyond repair. Each Tenant
                      shall, within one day of the termination of its tenancy, return all keys, including bathroom keys to Landlord, whether furnished by Tenant or Landlord. All subtenants shall also return all keys to the Tenant or Landlord. In the event
                      that Tenant does not return all its keys to Landlord or subtenant to Tenant, Tenant shall be responsible for the expense of rekeying the Premises.</div>
                    <div>&#160;<br>
                      12. <font style="font-style: italic;"><u>Hazardous Materials</u> </font>Except for those items necessary for the cleaning, maintenance or operation of Tenant&#8217;s business, including office supplies which shall be properly stored to
                      minimize the risk of fire and explosion, Tenant shall not bring or permit to be brought or kept in or on the Premises any inflammable, combustible or explosive fluid, chemical, or substance. In the event that any inflammable,
                      combustible or explosive fluid, chemical, or substance is stored in the Premises, such materials shall be stored in its original shipping box or container or in a Tenant-supplied cabinet located in the Premises specifically
                      manufactured for such materials.</div>
                    <div>&#160;</div>
                    <div>13. <font style="font-style: italic;"><u>Rules and Regulations of the 432 Columbia Street Condominium: Trust (the &#8220;Trust&#8221;)</u> </font>In the event that any of the above Rules and Regulations for Fairlane Columbia, LLC are in
                      conflict with the Rules and Regulations of the Trust, the Rules and Regulations of the Trust shall prevail.</div>
                    <div>&#160;</div>
                    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
                      <div id="DSPFPageBreak" style="page-break-after: always;">
                        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                    </div>
                    <div>
                      <div style="text-align: center; font-weight: bold;">EXHIBITE</div>
                      <div style="text-align: center; font-weight: bold;">LEGAL HOLIDAYS IN MASSACHUSETTS</div>
                      <div><br>
                      </div>
                      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z3fa9d16ca3b84fc1bbaa0e8b3763e7e6">

                          <tr>
                            <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>*January 1</div>
                            </td>
                            <td style="width: 70%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>- New Year&#8217;s Day</div>
                            </td>
                          </tr>
                          <tr>
                            <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
                            <td rowspan="1" style="width: 70%; vertical-align: top;">&#160;</td>
                          </tr>
                          <tr>
                            <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>Third Monday in January</div>
                            </td>
                            <td style="width: 70%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>- Martin Luther King, Jr. Day</div>
                            </td>
                          </tr>
                          <tr>
                            <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
                            <td rowspan="1" style="width: 70%; vertical-align: top;">&#160;</td>
                          </tr>
                          <tr>
                            <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>Third Monday in February</div>
                            </td>
                            <td style="width: 70%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>- President&#8217;s Day</div>
                            </td>
                          </tr>
                          <tr>
                            <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
                            <td rowspan="1" style="width: 70%; vertical-align: top;">&#160;</td>
                          </tr>
                          <tr>
                            <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>Third Monday in April</div>
                            </td>
                            <td style="width: 70%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>- Patriot&#8217;s Day</div>
                            </td>
                          </tr>
                          <tr>
                            <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
                            <td rowspan="1" style="width: 70%; vertical-align: top;">&#160;</td>
                          </tr>
                          <tr>
                            <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>Last Monday in May</div>
                            </td>
                            <td style="width: 70%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>- Memorial Day</div>
                            </td>
                          </tr>
                          <tr>
                            <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
                            <td rowspan="1" style="width: 70%; vertical-align: top;">&#160;</td>
                          </tr>
                          <tr>
                            <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>*July 4</div>
                            </td>
                            <td style="width: 70%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>- Independence Day</div>
                            </td>
                          </tr>
                          <tr>
                            <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
                            <td rowspan="1" style="width: 70%; vertical-align: top;">&#160;</td>
                          </tr>
                          <tr>
                            <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>First Monday in September</div>
                            </td>
                            <td style="width: 70%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>- Labor Day</div>
                            </td>
                          </tr>
                          <tr>
                            <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
                            <td rowspan="1" style="width: 70%; vertical-align: top;">&#160;</td>
                          </tr>
                          <tr>
                            <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>Second Monday in October</div>
                            </td>
                            <td style="width: 70%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>- Columbus Day</div>
                            </td>
                          </tr>
                          <tr>
                            <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
                            <td rowspan="1" style="width: 70%; vertical-align: top;">&#160;</td>
                          </tr>
                          <tr>
                            <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>*November 11</div>
                            </td>
                            <td style="width: 70%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>- Veteran&#8217;s Day</div>
                            </td>
                          </tr>
                          <tr>
                            <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
                            <td rowspan="1" style="width: 70%; vertical-align: top;">&#160;</td>
                          </tr>
                          <tr>
                            <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>Fourth Thursday in November</div>
                            </td>
                            <td style="width: 70%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>- Thanksgiving Day</div>
                            </td>
                          </tr>
                          <tr>
                            <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
                            <td rowspan="1" style="width: 70%; vertical-align: top;">&#160;</td>
                          </tr>
                          <tr>
                            <td style="width: 30%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>*December 25</div>
                            </td>
                            <td style="width: 70%; vertical-align: top; background-color: rgb(204, 238, 255);">
                              <div>- Christmas Day</div>
                            </td>
                          </tr>

                      </table>
                      <br>
                      <div>*Should any of these dates fall on a Sunday, the Holiday is observed on the following Monday.</div>
                      <div>&#160;</div>
                      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                        <div id="DSPFPageBreak" style="page-break-after: always;">
                          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                      </div>
                    </div>
                    <div>
                      <div style="text-align: center; color: rgb(72, 79, 82); font-weight: bold;">EXHIBIT F</div>
                      <div style="text-align: center; color: rgb(72, 79, 82); font-weight: bold;"> <br>
                      </div>
                      <div style="text-align: center; color: rgb(72, 79, 82); font-weight: bold;">RULES AND REGULATIONS OF</div>
                      <div style="text-align: center; color: rgb(72, 79, 82); font-weight: bold;">432 COLUMBIA STREET CONDOMINIUM TRUST</div>
                      <div style="text-align: center; color: rgb(72, 79, 82); font-weight: bold;"> <br>
                      </div>
                      <div style="text-align: center; font-size: 10.5pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(72, 79, 82);">(See </font><font style="font-size: 10pt; color: rgb(54, 64, 67);">following </font><font style="font-size: 10pt; color: rgb(72, 79, 82);">14 pages)</font></div>
                      <div style="text-align: center; font-size: 10.5pt; font-weight: bold;"><font style="font-size: 10pt; color: rgb(72, 79, 82);"> <br>
                        </font></div>
                      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                        <div id="DSPFPageBreak" style="page-break-after: always;">
                          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                      </div>
                      <!--PROfilePageNumberReset%Num%1%%%-->
                      <div>
                        <div style="text-align: center; font-size: 11.5pt;"><font style="font-size: 10pt;">RULES AND REGULATIONS OF</font></div>
                        <div style="text-align: center;">432 COLUMBIA STREET CONDOMINIUM TRUST</div>
                      </div>
                    </div>
                  </div>
                  <div>
                    <div><br>
                      <div>
                        <div>The following Rules and Regulations constitute an amendment of the Rules and Regulations adopted by the Trustees of the 432 Columbia Street Condominium Trust (the &#8220;Trust&#8221;), dated 2 March 1995 and recorded at the Middlesex South
                          Registry of Deeds, Book 25255 Page 604.</div>
                        <div><br>
                        </div>
                        <div>These Rules and Regulations may, from time to time, be amended, modified, rescinded or otherwise changed by the Trustees. Other Rules and Regulations may be adopted by the Trustees. However, a Unit Owner shall not be bound by
                          such amendment, modification, rescission, change or adoption of a new Rule or Regulation until said Unit Owner has notice or such change. For purposes of these Rules and Regulations, notice conspicuously posted upon the Building
                          shall be deemed notice to all. Alternatively Rules and Regulations sent to Unit Owners by certified mail shall he deemed notice to specific Unit Owner.</div>
                        <div><br>
                        </div>
                        <div>1.0 Statement of Purpose:</div>
                        <div>&#160;</div>
                        <div>These Rules and Regulations are adopted by the Trustees of the Trust for the benefit of the Unit Owners in order to maintain the Building and its grounds in a congenial, dignified and&#160; professional manner.</div>
                        <div>&#160;</div>
                        <div>2.0 Definitions:</div>
                        <div>&#160;</div>
                        <div>
                          <div>Whenever the term Unit Owner is used in these Rules and Regulations it shall be read to mean the unit Owner, his or her employees, agents, servants, invitees, guests, licensees, customers or clients. tenants or subtenants as
                            well as the employees, agents, servants, invitees, guests, licensees, customers or clients of a Unit Owner&#8217;s tenants and their tenants or subtenants, as may be appropriate. It shall also apply in the plural in the event that a
                            Unit is owned by one or more persons or entities. Whenever the term Condominium Documents is used in these Rules and Regulations it shall be read to mean the Master Deed, Declaration of Trust, By-Laws and Rules and Regulations
                            as may be amended from time to time. Whenever the term &#8216;Building&#8217; is used in these Rules and Regulations it shall be read to mean the building itself: including the Common Areas, as well as grounds and any parking areas and is
                            deemed to be interchangeable with and identical in meaning to the word &#8216;Condominium&#8217;. Whenever the term Managing Agent is used in these Rules and Regulations. it shall be read to mean the property manager or property management
                            company for the Trust appointed by the Trustees.</div>
                          <div> <br>
                          </div>
                          <div>
                            <div>3.0 No Obstruction of Common Areas and Facilities:</div>
                          </div>
                          <div>
                            <div><br>
                            </div>
                            <div>
                              <div>
                                <div>
                                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zad23f498561c4cd5ae6fc7698b72821d" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                                      <tr style="vertical-align: top;">
                                        <td style="width: 18pt;">&#160;</td>
                                        <td style="vertical-align: top; width: 18pt;">
                                          <div style="text-align: left;">a.</div>
                                        </td>
                                        <td style="align: left; vertical-align: top; width: auto;">
                                          <div style="text-align: left;">The sidewalks, entrances, passages, public halls, vestibules, corridors and stairways to or appurtenant to the Building shall not be obstructed or used for any purpose other than
                                            ingress&#160;and egress from the Units. No vehicle belonging to a Unit Owner shall impede or prevent&#160;ready access to any entrance to, or exit from, the Building by any person or vehicle, without the prior consent of
                                            the Trustees.</div>
                                        </td>
                                      </tr>

                                  </table>
                                </div>
                              </div>
                            </div>
                            <div><br>
                            </div>
                            <div>
                              <div>
                                <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8d6f2057d3ff48a08070172e8cd5d6bf" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                                    <tr style="vertical-align: top;">
                                      <td style="width: 18pt;">&#160;</td>
                                      <td style="vertical-align: top; width: 18pt;">
                                        <div style="text-align: left;">b.</div>
                                      </td>
                                      <td style="align: left; vertical-align: top; width: auto;">
                                        <div style="text-align: left;">No bicycles, carts, wagons or any other items shall be allowed to stand in the public halls, passageways or other public areas of the Building. Delivery companies must not leave boxes
                                          for Unit Owners or tenants in public hall ways, passageways or other public areas of the Building including in front of suite doorways without first determining that the Unit Owner or tenant is not present.</div>
                                      </td>
                                    </tr>

                                </table>
                              </div>
                              <div> <br>
                              </div>
                              <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                                <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">1</font></div>
                                <div id="DSPFPageBreak" style="page-break-after: always;">
                                  <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                              </div>
                              <div>
                                <div>
                                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z61bf3a3bd7b742e7ae405e7c14297b47" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                                      <tr style="vertical-align: top;">
                                        <td style="width: 18pt;">&#160;</td>
                                        <td style="vertical-align: top; width: 18pt;">
                                          <div style="text-align: left;">c.</div>
                                        </td>
                                        <td style="align: left; vertical-align: top; width: auto;">
                                          <div style="text-align: left;">No article (including but not limited to, garbage cans, bottles or mats) shall be placed or stored in any of the halls or on any of the staircases or landings of the Building, unless
                                            prior written permission is given by the Trustees. No fire exit of the Building shall be blocked in any manner. The Trustees, or their representatives, may remove any article stored in any of the halls,
                                            staircases or landings of the Building without notice to the owner of such article at no liability to the Trustees or their representatives.</div>
                                        </td>
                                      </tr>

                                  </table>
                                  <div> <br>
                                  </div>
                                </div>
                                <div>
                                  <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z3fe2ace79a4a48e2b4a0637bf1298881" class="DSPFListTable">

                                      <tr style="vertical-align: top;">
                                        <td style="width: 18pt;">&#160;</td>
                                        <td style="vertical-align: top; width: 18pt;">
                                          <div style="text-align: left;">d.</div>
                                        </td>
                                        <td style="align: left; vertical-align: top; width: auto;">
                                          <div style="text-align: left;">Unit Owners shall schedule deliveries to their units by vendors at such times, and in such times, and in such manner, as will reasonably minimize traffic congestion adjacent to the
                                            Building. Drivers of vehicles making deliveries to Unit Owners shall not Leave their vehicles unattended except when actually making such deliveries.</div>
                                        </td>
                                      </tr>

                                  </table>
                                </div>
                                <div><br>
                                </div>
                                <div>4.0 Disturbances:</div>
                                <div><br>
                                </div>
                                <div>
                                  <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z762a5f884dd24359be87eebbf32d9705" class="DSPFListTable">

                                      <tr style="vertical-align: top;">
                                        <td style="width: 18pt;">&#160;</td>
                                        <td style="vertical-align: top; width: 18pt;">
                                          <div style="text-align: left;">a.</div>
                                        </td>
                                        <td style="align: left; vertical-align: top; width: auto;">
                                          <div style="text-align: left;">Except as is reasonably required to construct tenant improvements by Unit Owners, no Unit Owner, or tenant or subtenant, shall make, cause or permit any unusual, disturbing or
                                            objectionable noises, odors or vibrations to be produced upon or emanate from his or her Unit or any appurtenant limited common elements or areas or permit anything to be done therein that will interfere with the
                                            right. Comforts or conveniences of any other occupants of the Building. For the Construction of tenant improvements. Unit Owners performing such work shall make reasonable efforts to perform work which may create
                                            objectionable noise, odors or vibrations outside of business hours of adjacent Unit Owners or tenants. No televisions, photographs, radios, compact disc players or tape recorders shall be used such that they are
                                            heard or seen outside of a Unit Owner&#8217;s or tenant&#8217;s premises.</div>
                                        </td>
                                      </tr>

                                  </table>
                                </div>
                                <div><br>
                                </div>
                                <div>
                                  <div>
                                    <div>
                                      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z32409fe03b3c404d800caba16c3caa70" class="DSPFListTable">

                                          <tr style="vertical-align: top;">
                                            <td style="width: 18pt;">&#160;</td>
                                            <td style="vertical-align: top; width: 18pt;">
                                              <div style="text-align: left;">b.</div>
                                            </td>
                                            <td style="align: left; vertical-align: top; width: auto;">
                                              <div style="text-align: left;">No noxious or offensive activity shall be carried on in the Condominium, nor shall anything&#160; be done therein which may be or become an annoyance or nuisance to the other Unit
                                                Owners or occupants. No Common Area shall be decorated or furnished by any Unit Owner, tenant or subtenant in any manner. Unit Owners and tenants shall not distribute advertising or promotional materials in
                                                the Building or to other Unit Owners or tenants of the Building, unless approved in each instance by the Trustees, and shall not admit into the Building individuals intending to canvas, solicit or otherwise
                                                distribute advertising or promotional&#160; materials in the Building.</div>
                                            </td>
                                          </tr>

                                      </table>
                                    </div>
                                  </div>
                                </div>
                                <div><br>
                                </div>
                                <div>5.0 Leases:</div>
                                <div><br>
                                </div>
                                <div>Any Unit Owner may lease or rent his or her Unit, subject to the following conditions and any conditions contained in the Condominium Documents:</div>
                                <div><br>
                                </div>
                                <div>
                                  <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z3e891022da0d4fdda40df54f1753b1c0" class="DSPFListTable">

                                      <tr style="vertical-align: top;">
                                        <td style="width: 18pt;">&#160;</td>
                                        <td style="vertical-align: top; width: 18pt;">
                                          <div style="text-align: left;">a.</div>
                                        </td>
                                        <td style="align: left; vertical-align: top; width: auto;">
                                          <div style="text-align: left;">All leases and occupancy agreements must expressly provide that the lease or occupancy agreement shall be subject to the Master Deed, Declaration of Trust, ByLaws and the Rules and
                                            Regulations of the Condominium, as most recently amended prior to the execution of the lease or occupancy agreement, and contain the following notice, in capital letters :</div>
                                        </td>
                                      </tr>

                                  </table>
                                </div>
                                <div><br>
                                </div>
                                <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                                  <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
                                  <div id="DSPFPageBreak" style="page-break-after: always;">
                                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                                </div>
                                <div style="text-align: center;">&#8216;&#8216;IMPORTANT CLAUSE</div>
                              </div>
                              <div> <br>
                              </div>
                              <div style="font-weight: normal; margin-left: 18pt;">HE BUILDING IN WHICH THIE UNIT OR PART OF A UNIT IS&#160; BEING LEASED IS&#160; LOCATED&#160;IS A CONDOMINIUM BUILDING - NOT A RENTAL BUILDING. THE&#160;BUILDING MAY BE OCCUPIED BY A
                                COMBINATION OF UNIT OWNERS AND TENANTS OR LICENSEES. BY SIGNING THIS LEASE. LICENSE OR OCCUPANCY&#160;AGREEMENT, THE TENANT OR LICENSEE ACKNOWLEDGES THAT HE OR SHE&#160;HAS BEEN FURNISHED WITH A COPY OF THE&#160;MASTER DEED OF
                                THE&#160;CONDOMINIUM, THE DECLARATION OF TRUST OF THE CONDOMINIUM AND&#160;THE BY-LAWS AND RULES AND REGULATIONS THERETO AND THAT HE OR SHE&#160;HAS READ THEM AND UNDERSTAND THEM AND THAT HE OR SHE WILL&#160;COMPLY IN ALL RESPECTS WITH THE
                                SAME. THE TENANT OR LICENSEE ALSO&#160;UNDERSTANDS THAT IN THE EVENT THAT HE OR SHE FAILS TO&#160;COMPLY, THE TENANT OR LICENSEE MAY BE EVICTED BY THE TRUSTEES OF&#160;THE CONDOMINIUM TRUST (WHO ARE ELECTED BY THE UNIT OWNERS).
                                THE&#160;PROVISIONS OF THIS&#160;CLAUSE TAKE PRECEDENCE OVER ANY OTHER PROVISION OF THIS LEASE LICENSE OR OCCUPANCY AGREEMENT.&#8217;&#8217;&#160;</div>
                              <div>&#160;</div>
                            </div>
                            <div>And shall contain the following section in addition to the foregoing notice:</div>
                          </div>
                          <br>
                          <div>
                            <div>&#8220;Any failure by the Tenant to comply in all respects with the provisions of the Master Deed of the Condominium, the Declaration of Trust and the By-Laws and Rules and Regulations thereto shall constitute a material default
                              in this lease, license, or occupancy agreement, and in the event or such default (&#8220;Default&#8221;), the Trusteed of the condominium Trust shall have the following rights and remedies against both the Unit Owner and the Tenant, in
                              addition lo all other rights and remedies that Trustees and the Unit Owners (other than the owner of the affected Unit) have or may in the future have. against both the owner of the affected Unit and the tenant. all rights and
                              remedies of the Trustees and the Unit Owners (other than the owner of the affected Unit) being deemed at all times to be cumulative and not exclusive. In addition, </div>
                            <div>&#160;<br>
                              <div>
                                <div>
                                  <div>
                                    <div>
                                      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zcefeb2f6f8bc4e84ad7d69ad83694947" class="DSPFListTable">

                                          <tr style="vertical-align: top;">
                                            <td style="vertical-align: top; width: 18pt;">
                                              <div>i.</div>
                                            </td>
                                            <td style="align: left; vertical-align: top; width: auto;">
                                              <div>The Trustees shall have the right to give written notice of the Default to both the Tenant, and the&#160;Unit Owner. Said notice shall be deemed properly given if left in any part of the Unit, addressed&#160;to the
                                                Tenant, and mailed postage pre-paid, registered or certified mail. return receipt requested. addressed to the Unit Owner at such address as appears on the records of the Trustees, or by&#160;delivering said notice
                                                in hand, or be delivering said notice in any other manner permitted by&#160;law.</div>
                                            </td>
                                          </tr>

                                      </table>
                                    </div>
                                  </div>
                                </div>
                                <div>&#160;</div>
                                <div>
                                  <div>
                                    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z1796e67dae484e289b424cdcb7b044d7" class="DSPFListTable">

                                        <tr style="vertical-align: top;">
                                          <td style="vertical-align: top; width: 18pt;">
                                            <div>ii.</div>
                                          </td>
                                          <td style="align: left; vertical-align: top; width: auto;">
                                            <div>If the Default continues for five days after the giving of said notice, then the Trustees shall have the right to levy lines against the Unit Owner in accordance with the By-Laws, and terminate the tenancy
                                              by giving notice in writing to quit to the Tenant in any manner permitted by the Trustees, or both. A copy of such notice shall be delivered or mailed to the Unit Owner in the manner set forth here in above.
                                              Thereafter, the Trustees may initiate and prosecute a summary process action against the Tenant under the provisions of Massachusetts General Laws, in the name of the Unit Owner or in the name of the Trustees,
                                              or both.</div>
                                          </td>
                                        </tr>

                                    </table>
                                  </div>
                                  <div>&#160;</div>
                                  <div>
                                    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z9454511f70634bf1b86484e3c420e00c" class="DSPFListTable">

                                        <tr style="vertical-align: top;">
                                          <td style="vertical-align: top; width: 18pt;">
                                            <div style="color: rgb(0, 0, 0);">iii.</div>
                                          </td>
                                          <td style="align: left; vertical-align: top; width: auto;">
                                            <div style="color: rgb(0, 0, 0);">The Trustees shall be entitled to levy a fine or fines, or give a notice or notices to quit, followed by a summary process action or actions, and the Trustees&#8217; election to pursue
                                              any of the foregoing remedies shall in no way prohibit them from pursuing all of the foregoing remedies, either at the same time, or in the event of any further default.</div>
                                          </td>
                                        </tr>

                                    </table>
                                  </div>
                                  <div>&#160;</div>
                                  <div>
                                    <div>
                                      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zd0385db8241542dfbd846e420aec1fe3" class="DSPFListTable">

                                          <tr style="vertical-align: top;">
                                            <td style="vertical-align: top; width: 18pt;">
                                              <div>iv.</div>
                                            </td>
                                            <td style="align: left; vertical-align: top; width: auto;">
                                              <div>All of the expenses incurred by the Trustees in giving notices. and notices to quit and maintaining and pursuing summary&#160;process actions and appeals therefrom. shall be entirely at the expense of the Unit
                                                Owner of the&#160; affected unit. Such costs and expenses may be enforced and collected against the Unit Owner and Unit as if the same were common charges owed by the Unit Owner.</div>
                                            </td>
                                          </tr>

                                      </table>
                                    </div>
                                    <div> <br>
                                    </div>
                                    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                                      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
                                      <div id="DSPFPageBreak" style="page-break-after: always;">
                                        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                                    </div>
                                    <!--PROfilePageNumberReset%Num%4%%%--> </div>
                                </div>
                              </div>
                            </div>
                          </div>
                        </div>
                      </div>
                    </div>
                  </div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf2197206f1cd46faae3422b296a20600">

                      <tr>
                        <td style="width: 18pt; vertical-align: top;">v<br>
                        </td>
                        <td style="width: auto; vertical-align: top;">
                          <div>The Unit Owner shall make reasonable efforts, at his or her expense and upon his or her initiative, to inform rental agents of the provisions of this section and shall, at his or her expense, and upon his or her initiative,
                            furnish copies of the Condominium Documents to the Tenant and cause the lease or occupancy agreement to be prepared in conformity with the provisions of&#8217; this section.</div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;<br>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3b4bab123d4c42208cbb58ff0e1aa5e4" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="vertical-align: top; width: 18pt;">
                              <div>vi</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div>Any renewal or extension of any lease or occupancy agreement shall be subject to the prior&#160;written approval of the Trustees in every instance. Such approval shall not limit any rights or remedies of the Trustees or Unit
                                Owners in the event of a subsequent default.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div><br>
                    </div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z8d57628b956b4a69b9b763af2a553b9b" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="vertical-align: top; width: 18pt;">
                              <div>vii.</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div>A true copy of every lease or occupancy agreement shall be delivered to the Trustees forthwith upon its execution.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <br>
                  </div>
                  <div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb25ab40abcdc458299ea20b651b76b62" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                        <tr style="vertical-align: top;">
                          <td style="vertical-align: top; width: 18pt;">
                            <div style="text-align: left; font-size: 8pt;"><font style="font-size: 10pt;">viii.</font></div>
                          </td>
                          <td style="align: left; vertical-align: top; width: auto;">
                            <div style="text-align: left; font-size: 8pt;"><font style="font-size: 10pt;">Notwithstanding anything to the contrary herein, and notwithstanding any custom, law or usage </font>t<font style="font-size: 10pt;">o the contrary,
                                it is express</font>l<font style="font-size: 10pt;">y understood and agreed that neither the Trustees, nor the Unit Owners shall ever bear any personal liability with respect to any lease or the use and occupancy of a unit
                                by a Tenant.</font></div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div><br>
                  </div>
                  <div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze44f16a7f44c44dd9fd52a4c94a2be91" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                        <tr style="vertical-align: top;">
                          <td style="vertical-align: top; width: 18pt;">
                            <div style="text-align: left; font-size: 8pt;"><font style="font-size: 10pt;">ix.</font></div>
                          </td>
                          <td style="align: left; vertical-align: top; width: auto;">
                            <div style="text-align: left; font-size: 8pt;"><font style="font-size: 10pt;">Every lease, license or occupancy agreement, shall have attached thereto, and incorporated therein by reference, a copy of this section 5.0 of the
                                Rules and Regulations</font>.</div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div>&#160;</div>
                  <div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z02549afb1e394b3eaf2a7fb67948dd59" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="vertical-align: top; width: 18pt;">
                              <div>b.</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div>All leases. lease amendments and occupancy agreements must include the following revised and excerpted language from Section 8.0 (i) from these Rules and Regulations:</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                  </div>
                  <div>&#160;</div>
                  <div style="text-indent: 0.5pt; margin-right: 6.2pt; margin-left: 32.15pt;">&#8220;If a tenant (or, in each case below, a unit owner) offers any of its employees parking in the Parking Lot, then the tenant has the option of charging such
                    employee market rate for parking, or, alternatively, if the tenant charges any of its employees less than the current monthly market rate for parking, then the tenant will offer such employees an equivalent monthly&#160; payment to support
                    the employee&#8217;s commute&#160; by walking, biking. transit or carpool. In the event that an employee chooses to use the equivalent monthly payment for transit, <u>tenants will use best efforts to enroll in the MBTA pass program
                      to provide an employee with the ability to purchase&#160;a pass using pre-tax wages</u>. &#8216;Equivalent monthly payment&#8217; means the remainder of the current monthly market rate for parking less the fee paid for parking&#160; by an employee. For
                    example, if the current monthly market rate is $200 and an employee is being charged $50 per month by the employer, then the equivalent monthly payment equals $150 per month. Any tenant may charge certain&#160; employees&#160; for parking at
                    market rate in the Parking Lot and other employees may be charged at less than the current monthly market rate for parking in the Parking Lot with the tenant providing such employees with the equivalent monthly benefit option.&#8221;</div>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zff9548ee5be84f84b49cd9dcf25c549d">

                      <tr>
                        <td style="width: 18pt; vertical-align: top;">6.0</td>
                        <td style="width: auto; vertical-align: top;">
                          <div style="font-size: 8pt;"><font style="font-size: 10pt;">Use of Premises:</font></div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc46dd35d7f76453299c6485984b27e9a">

                      <tr>
                        <td style="width: 23.9pt;"><br>
                        </td>
                        <td style="width: 17.4pt; vertical-align: top;">a.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div>No window guards, except as may be required by law, or other window decorations shall be used in or about any Unit, except as shall have been approved in writing by the Trustees. <br>
                            <div>Such approval shall not be unreasonably withheld or delayed. In no event shall any exterior glass surfaces of any windows at the Building be colored or painted.</div>
                          </div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
                    <div style="page-break-after:always;" id="DSPFPageBreak">
                      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                  </div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z609c21de31c94866912e747d588efe6c">

                      <tr>
                        <td style="width: 23.05pt;"><br>
                        </td>
                        <td style="width: 17.3pt; vertical-align: top;">b.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div>No radio or television aerial or other object shall be attached to or hung from the exterior of the Building. No sign, notice, advertisement or illumination (including, without limitation. &#8220;For Sale&#8221;, &#8216;&#8216;For Lease&#8221; or &#8220;For
                            Rent&#8221; signs) shall be inscribed or exposed on or at any window or other part of the Building by any unit Owner, tenant or subtenant except as such are permitted by the Condominium Documents or shall have been approved in writing
                            by the Trustees. In the event of a violation of this rule regarding signs, the Trustees or their representatives may remove the material without any liability and may charge the expense incurred by such removal to the owner of
                            such material. See Exhibit A regarding Common&#160; Area Signage.</div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z15279d9c29664c1983564e592d11043c">

                      <tr>
                        <td style="width: 23.05pt;"><br>
                        </td>
                        <td style="width: 17.3pt; vertical-align: top;">c.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div>Nothing, including ventilation ductwork, shall be projected from any window of a Unit or attached to the facade of the Building. without similar approval and, in the case of ventilation ductwork, compliance with all
                            applicable state regulations and approval by all applicable public agencies. In no event shall ductwork be visible from any window on the 1<sup style="color: #777B7B; vertical-align: text-top; line-height: 1; font-size: smaller;">s</sup><sup style="color: #4B4F50; vertical-align: text-top; line-height: 1; font-size: smaller;">t</sup>&#160;and 2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> floors of the
                            Building and in the instance of visibility from any Building penthouse. such ductwork shall be designed for minimal visual impact..</div>
                        </td>
                      </tr>

                  </table>
                  <div><br>
                  </div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z643341a0025b4e9b850b366164aa63e9">

                      <tr>
                        <td style="width: 23.05pt;"><br>
                        </td>
                        <td style="width: 17.3pt; vertical-align: top;">d.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div>Nothing shall be done in any Unit or in, on or to the Common Areas or Facilities which will impair the structural integrity of the Condominium.</div>
                        </td>
                      </tr>

                  </table>
                  <div><br>
                  </div>
                  <div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z67b0ac4251e94fcfba32dc4aa7016119" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                        <tr style="vertical-align: top;">
                          <td style="width: 23.05pt;">&#160;</td>
                          <td style="vertical-align: top; width: 17.3pt;">
                            <div style="text-align: left;">c.</div>
                          </td>
                          <td style="align: left; vertical-align: top; width: auto;">
                            <div style="text-align: left;">Nothing shall be done or kept within any Unit which will increase the rate of insurance on the Building, or the contents thereof; applicable for commercial office usage,&#160;without the prior written
                              approval or the Trustees. No Unit Owner or tenant or subtenant. shall permit or allow anything to be done. or kept in his or her Unit, on in the Common Areas or facilities. which may result in the cancellation of insurance on
                              the Building or the contents thereof or which may be in violation of any law or governmental regulation.</div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z66a9512130bb47eab168278d1309a4c8">

                      <tr>
                        <td style="width: 23.05pt;"><br>
                        </td>
                        <td style="width: 17.3pt; vertical-align: top;">r.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div>Damage by fire or accident affecting any Unit, Common Area, or liability of the Unit Owners of the Condominium Trust (or which may affect their liability) shall be promptly reported to the Trustees immediately following the
                            occurrence or discovery thereof.</div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc6150fc7649f434181ddb5533230cd4e">

                      <tr>
                        <td style="width: 23.05pt;"><br>
                        </td>
                        <td style="width: 17.3pt; vertical-align: top;">g.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div>Any damage to the Building caused by a Unit Owner shall be repaired at the expense of the Unit Owner. The Condominium Trust. at its sole option. may cause the damage to be repaired or may order the Unit Owner to begin
                            immediate repair of the damage. In the event that the Condominium Trust incurs any expense to repair the damage, the reasonable cost of the work to repair such damage plus a 5% construction management fee to the Condominium
                            Trust shall constitute a lien upon the Unit in the event that the Unit Owner&#160;fails to pay the Condominium Trust within thirty (30) days of receiving an invoice.</div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zce30d966720647a6a494bb7e4154856c">

                      <tr>
                        <td style="width: 23.05pt;"><br>
                        </td>
                        <td style="width: 17.3pt; vertical-align: top;">h.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div>Each Unit Owner is responsible to keep his or her Unit in a good state of repair, preservation, condition and cleanliness.</div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3583b425c0b341ee8c1b878327950140">

                      <tr>
                        <td style="width: 23.05pt;"><br>
                        </td>
                        <td style="width: 17.3pt; vertical-align: top;">i.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div>Unit Owners, tenants and subtenants, their employees, agents, servants, invitees, guests, licensees, customer or clients shall at no time enter upon, or attempt to enter upon, the roof of the Building except in an emergency.</div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
                    <div style="page-break-after:always;" id="DSPFPageBreak">
                      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                  </div>
                  <!--PROfilePageNumberReset%Num%6%%%-->
                  <div>
                    <div>
                      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" id="z37c5b172b8c24d64a23ed7c31b7305f1">

                          <tr style="vertical-align: top;">
                            <td style="width: 23.05pt;"><br>
                            </td>
                            <td style="vertical-align: top; width: 17.3pt;">
                              <div style="text-align: left;">j.</div>
                            </td>
                            <td style="vertical-align: top; width: auto;">
                              <div style="text-align: left;">
                                <div>The Trustees, the Superintendent and the agents of the Condominium Trust or of the Managing Agent, and any contractor or workman authorized by the Condominium Trust, or the Managing Agent, may enter into any Unit at any
                                  reasonable time for the purpose of inspecting such Unit for the presence or any vermin. insects or other pests and for purpose of taking such measures as may be necessary to control or exterminate any Such vermin, insects
                                  or other pests; however, such entry. inspection and extermination shall be done in a reasonable manner so as not to unreasonably interfere with the use of such Unit for its permitted purposes. The Trustees may mandate that
                                  a Unit Owner retain the services of a pest control firm until any infestation has been brought under control. No food shall be left accessible in the Condominium common areas or in specific units of the Condominium, i.e.
                                  not in sealed metal or plastic containers.</div>
                              </div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <br>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8bf48bbe227f4372b4178a44262b9db9">

                        <tr>
                          <td style="width: 23.05pt;"><br>
                          </td>
                          <td style="width: 17.3pt; vertical-align: top;">k.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>The Trustees, or their designated agent, shall retain a passkey or access code to all Units for&#160;use in emergency situation or for access to repair or maintain Common Elements. No Unit Owner. tenant or subtenant, shall&#160;alter
                              any lock or install a new lock on any door of a Unit without the prior written consent of the Trustees. If such approval is granted, the Unit Owner shall&#160;supply the Trustees with the key or keys to any altered or new lock.</div>
                          </td>
                        </tr>

                    </table>
                    <div>&#160;</div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zbe886541705443aab5f26890b13ee801">

                        <tr>
                          <td style="width: 23.05pt;"><br>
                          </td>
                          <td style="width: 17.3pt; vertical-align: top;">l.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>
                              <div>All personal property of the Unit Owners, or any other occupant of a unit. whether in a unit, or in the Common Areas and facilities, or in the Parking Spaces. or elsewhere on the Condominium property, shall be kept
                                therein at the sole risk and responsibility of the respective Unit Owner or occupant, and the Trustees shall have no responsibility therefore.</div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <div> <br>
                    </div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zd8bede2fcc6843af88f05c08a935842c">

                          <tr>
                            <td style="width: 23.05pt;"><br>
                            </td>
                            <td style="width: 17.3pt; vertical-align: top;">m.</td>
                            <td style="width: auto; vertical-align: top;">
                              <div>All garbage and trash within every Unit must be placed in scalable or closeable receptacles designated for refuse collection, No garbage. trash, or recycled materials shall be placed elsewhere upon any of the Common Areas
                                and facilities except by the trash compactor and with the approval of the Superintendent.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" id="z63e9e7b1f9b74bdcb584abe3eea1d379">

                          <tr style="vertical-align: top;">
                            <td style="vertical-align: top; width: 18pt;">
                              <div style="text-align: left;">7.0</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: left;">Late Fees:</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" id="z1b63db1ea2a5415ab9aa53e97f141593">

                          <tr style="vertical-align: top;">
                            <td style="width: 17.4pt;">&#160;</td>
                            <td style="vertical-align: top; width: 12.3pt;">
                              <div style="text-align: left;">a.</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: left;">
                                <div>The monthly common area fee is due, in advance, as of the first day of the mon th. Any fee payable by a Unit Owner to the: Condominium Trust received after the I 5<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> clay of the month in which it is payable, or more than 15 days after it is payable, shall he subject to an additional fee. Such additional fee shall be deemed an unpaid common area charge.
                                  The additional fee payable shall be as follows:</div>
                              </div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z367c9dd3f41945f0b6bec25185aad21c">

                        <tr>
                          <td style="width: 33.65pt;"><br>
                          </td>
                          <td style="width: 24.8pt; vertical-align: top; align: right;">1.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>In the event a payment, which is due as of the first of the month, is received after the 15<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> of the month but before the first day of the
                              next month, an additional unpaid common area charge of $200 shall be due and payable. If payment is not received before the first day of the next month. an additional unpaid common area charge of.$200 shall be: due and payable
                              for each calendar month that the amount, or any portion of the amount, remains outstanding.</div>
                          </td>
                        </tr>

                    </table>
                    <div><br>
                    </div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="ze526adfcfb3d46d29bf4671f9f2f424f">

                        <tr>
                          <td style="width: 31.55pt;"><br>
                          </td>
                          <td style="width: 25.45pt; vertical-align: top;">2.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>
                              <div>In the event a payment, which is due on some date other than the first of the month, is received after the 15<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> day from the date it was
                                payable but before the 31<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> day from the date it was payable, an additional unpaid common area charge of $200 shall be due and payable. If
                                payment is not received before the 31<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> day of the date on which it was payable, an additional unpaid common area charge of $200 shall be due
                                and payable for each 30 day period, or any part thereof, during which the amount. or any portion of the amount remains outstanding.</div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <div>&#160;</div>
                    <div>
                      <div>
                        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" id="z984025c84493449fb9030b18f25cd9d7">

                            <tr style="vertical-align: top;">
                              <td style="width: 17.4pt;">&#160;</td>
                              <td style="vertical-align: top; width: 12.3pt;">
                                <div>b.</div>
                              </td>
                              <td style="align: left; vertical-align: top; width: auto;">
                                <div>All payments received by the Condominium Trust will be applied first against the oldest amount due, including any additional fee charges, interest or collection fees (including attorney&#8217;s fees and legal costs) that may
                                  be due.</div>
                              </td>
                            </tr>

                        </table>
                        <div> <br>
                        </div>
                      </div>
                    </div>
                    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></div>
                      <div id="DSPFPageBreak" style="page-break-after:always;">
                        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                    </div>
                    <div>
                      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" id="zc15b0379e00347f7a8970f9d64645495">

                          <tr style="vertical-align: top;">
                            <td style="vertical-align: top; width: 18pt;">
                              <div style="text-align: left;">8.0</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: left;">Miscellaneous:</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z743a479852d54243a5c4f0a4ac58eea6">

                        <tr>
                          <td style="width: 18pt;">&#160;</td>
                          <td style="width: 15.9pt; vertical-align: top;">a.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>
                              <div>Superintendent: No Unit Owner shall attempt to direct. supervise, or in any manner attempt to control or request favors of the building superintendent retained by the Trust&#8217;s property management company or any employee of
                                the Trust. No Unit Owner, tenant or subtenant shall send any employee of the Condominium Trust or of the Managing Agent out of the Building on any private business except as provided under Clause (i) below.</div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <div>&#160;</div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zf0f65acde4614e469858843c8cf3ac10">

                        <tr>
                          <td style="width: 18pt;"><br>
                          </td>
                          <td style="width: 15.9pt; vertical-align: top;">b.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>Moving: The Unit Owner must notify the Trust&#8217;s Managing Agent, at least five (5) business days prior to any unit occupant or tenant moving in or out of a Unit. of the date of the move. All moves must begin and be completed
                              off-hours, before 8AM or after 5PM Monday to Friday except for Building Holidays and weekends. Movers shall put down Masonite boards in Common Area hallways before heavy dollies or carts are operated in Common Areas. Unit
                              Owners must provide the Managing Agent a Certificate of Insurance. from the moving company listing 432 Columbia Street Condominium Trust as the Certificate Holder and the Unit Owner, the Condominium Trust and the Managing
                              Agent as an additional insureds.</div>
                          </td>
                        </tr>

                    </table>
                    <div>&#160;</div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7adb9dbe7cc84468aa4d79fdf4481abd">

                        <tr>
                          <td style="width: 18pt;"><br>
                          </td>
                          <td style="width: 15.9pt; vertical-align: top;">c.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>Moving Fee: The Unit Owner is responsible for paying a move in and move out fee to the Condominium, to be paid within thirty (30) days of the move in. The fee shall be the fee as then most currently set by the Trustees and
                              is subject to change without notice. The fee is initially set at two hundred dollars ($200). The Trustees may, in their discretion, waive this fee.</div>
                          </td>
                        </tr>

                    </table>
                    <div>&#160;</div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z70e9f2c76a9f4bf4bfff001c6c8f9db8">

                        <tr>
                          <td style="width: 18pt;"><br>
                          </td>
                          <td style="width: 15.9pt; vertical-align: top;">d.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>
                              <div>Water Heaters: All new and replacement electric on-line water heaters shall be equipped with an automatic shutoff device (such as Wags valves by Taco) in case of leaks. Such installations shall be capable of automatically
                                closing the water supply line in the event of heater failure or pipe leaks. Unit Owners shall provide to the Managing Agent, when requested, an inventory. including age, presence of an automatic shut-off valve or drain pan,
                                and location of all hot water heaters in their Units. The Building Superintendent may enter the Units of the Building to inspect the Units for hot water heaters if Unit Owners do not provide such an inventory.</div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <div>&#160;</div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z7b8784862cb2415b99776476a33a8b39">

                        <tr>
                          <td style="width: 18pt;"><br>
                          </td>
                          <td style="width: 15.9pt; vertical-align: top;">e.<br>
                          </td>
                          <td style="width: auto; vertical-align: top;">
                            <div>Wires and Cables: No unit owner or tenant may install telephone, data or any other wiring in another Unit without the express prior written approval of that Unit Owner. New connections from any Unit to the Building
                              telephone closet located in Suite 9 of Unit B-1 shall be made only through a surface raceway from the telephone closet to the common areas adjacent to Units 15A, 15B and 17B and then to the common area sub-closets or the Unit
                              the connections will serve. Wiring or cables shall be in a dark color and specifically, not white or yellow and shall be tied to other, wiring or cables following the same route. No wiring or cables shall be hung or
                              intertwined with sprinkler piping or sprinkler heads. The Building Superintendent shall be present during the initial entry by any telecommunications provider into Suite 9. Any such installation shall be paid for by the Unit
                              Owner requiring such service and only after specific details and routes have been submitted to and approved by the Trustees. The Trustees shall have the right, but not obligation. to direct Unit Owners failing to comply with
                              this Rule to make and pay for a properly complying installation and/or correct any non-complying installation at the Unit Owner&#8217;s expense. Installation of new or changed service by any telecommunications provider shall be
                              completed during normal business hours of the. Building Superintendent, which may be changed from time to time. For the purposes of this section, the hours of the Building Superintendent are 8AM to 4PM, Monday to Friday.
                              except for Building Holidays.</div>
                          </td>
                        </tr>

                    </table>
                    <br>
                    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">7</font></div>
                      <div id="DSPFPageBreak" style="page-break-after:always;">
                        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                    </div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z87740adb03cc48fe9ecfbc7c28fab039">

                        <tr>
                          <td style="width: 18pt;"><br>
                          </td>
                          <td style="width: 15.9pt; vertical-align: top;">f.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>
                              <div>Vehicles are to be parked only in the designated areas and shall only park in lined spaces for no more than the designated time frame. No more than one vehicle shall be parked in a single parking space. except for
                                motorcycles and motor scooters but only in spaces designated by the Trustees. No Unit Owner, employee of any Unit owner or his or her tenant shall park at any time in a Visitor&#8217;s Parking Space. The Superintendent shall have
                                standing instructions to have such vehicles towed at the Owner&#8217;s expense. Handicapped-designated spaces shall only be occupied by those vehicles with a handicapped designation visible on or in the vehicle. Vehicles shall not
                                block staircases or the Building&#8217;s loading dock. No vehicles belonging to vendors servicing the Building, a Unit Owner, or a tenant of a Unit Owner shall park in a Visitor&#8217;s Parking Space. In the event of an anticipated snow
                                storm with estimates of over four inches of snow, al I vehicles must be removed from all of the Building&#8217;s parking lots prior to 12AM on the evening of the anticipated storm.</div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <br>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zac08be6e2ccc4e5ea4f5e02e3560feb7">

                        <tr>
                          <td style="width: 18pt;"><br>
                          </td>
                          <td style="width: 15.9pt; vertical-align: top;">g.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>Loading Dock. Only conventional daily office trash shall be disposed of at the loading dock. Unit Owners and their tenants shall make their own arrangements for the disposal of extraordinary trash such as furniture,
                              computers and electronic equipment, at the discretion of the Superintendent. Unit Owners and their tenants must not overburden the loading dock with deliveries or packages being picked up by overnight delivery services, such
                              as the USPS. FedEx. UPS or DHL. Unit Owners, and their tenants must follow procedures provided by the Trustees and may be requested lo remove items from the loading dock if the Trustees determine that the loading dock is
                              overburdened. Unit Owners and their tenants must not block access to the dumpster access panel in the loading dock by deliveries, packages being picked up, recycling materials or other trash. All deliveries that arrive on
                              pallets must be broken down prior to leaving the loading dock. Pallet jacks arc not permitted in Common Area hallways. All pallets must return with delivery driver. Pallets left in the loading clock or elsewhere in the
                              Building from a delivery will be removed by the Trust at the Unit Owner&#8217;s expense.</div>
                          </td>
                        </tr>

                    </table>
                    <div>&#160;</div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z1f80d060e493446b93dc34388f80454d">

                        <tr>
                          <td style="width: 18pt;"><br>
                          </td>
                          <td style="width: 15.9pt; vertical-align: top;">h.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>
                              <div>City of Cambridge Parking and Transportation Demand Management (PTDM) plan (2000 Requirements). To maintain compliance with a City Permit for additional parking spaces, a range of information on employee travel Mode
                                Split, Carpooling, etc. and other information is required by the City on an annual basis, Failure of the Condominium to provide such information on a timely basis may result in withdrawal of the Permit, fines or other
                                serious sanctions. All Unit Owners are obliged to provide the requested information on an urgent basis, on behalf of their or their tenants&#8217; employees. The Condominium Trustees may seek any damages suffered by the
                                Condominium as a result of failure in this regard from a Unit Owner who fails to provide accurate and timely information.</div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <div>&#160;</div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z8184679896b04778988cc57f0d4a506b">

                        <tr>
                          <td style="width: 18pt;"><br>
                          </td>
                          <td style="width: 15.9pt; vertical-align: top;">i.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>
                              <div>City of Cambridge Parking and Transportation Demand Management (PTDM) plan (2020 Requirements). If a tenant (or, in each case below. a unit owner) offers any of its employees parking in the Parking Lot, then the tenant
                                has the option of charging such employee market rate for parking. or, alternatively, if the tenant charges any of its employees less than the current monthly market rate for parking, then the tenant will offer such employees
                                an equivalent monthly payment to support the employee&#8217;s commute by walking, biking, transit or carpool. In the event that an employee chooses to use the equivalent monthly payment for transit,&#160; <u>tenants will use best
                                  efforts to enroll in the MBTA pass program to provide an employee with the ability to purchase a pass using pre-tax wages. </u>&#8216;Equivalent monthly payment&#8217; means the remainder of the current monthly market rate for
                                parking less the fee paid for parking by an employee. For example, if the current monthly market rate is $200 and an employee is being charged $50 per month by the employer, then the equivalent monthly payment equals $150
                                per month. Any tenant may charge certain employees for parking at market rate in the Parking Lot and other employees may be charged at less than the current monthly market rate for parking in the Parking Lot with the tenant
                                providing such employees with the equivalent monthly benefit option.</div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <div>&#160;</div>
                    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">8</font></div>
                      <div id="DSPFPageBreak" style="page-break-after:always;">
                        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                    </div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z0a090ded7b9e4c2ba09fe7b104fabf95">

                        <tr>
                          <td style="width: 18pt;"><br>
                          </td>
                          <td style="width: 15.9pt; vertical-align: top;">j.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>Superintendent. The Superintendent&#8217;s responsibilities are for the maintenance and operation of the Condominium as a whole. Unit Owners or their tenants may request extraordinary services form the Superintendent which he may
                              undertake with the specific approval of the Trustees. Such work will not be commenced without completion of a Maintenance Request. and Work Order form, and shall be billed to the appropriate Owner or tenant&#160; at hourly rates
                              and material mark-ups as established from time to time by the Trustees. The Superintendent has a list of those work items deemed &#8216;extraordinary&#8217;.</div>
                          </td>
                        </tr>

                    </table>
                    <div style="margin-left: 29.85pt;"><br>
                    </div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="za5a709644b764880bc876ce851e07e51">

                        <tr>
                          <td style="width: 18pt;"><br>
                          </td>
                          <td style="width: 15.9pt; vertical-align: top;">k.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>
                              <div>Access Cards. A fee established by the Trustees is levied for the issuance of access cards to employees at the Condominium.</div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <br>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zbaf74d56346643a7a104dc455ac96380">

                        <tr>
                          <td style="width: 18pt;"><br>
                          </td>
                          <td style="width: 15.9pt; vertical-align: top;">l.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>
                              <div>Space Heaters. No electric space heaters shall be used in the Building unless specifically approved by the Trustees.</div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <div> <br>
                    </div>
                    <div>
                      <div>
                        <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" id="z0adc4f901a0a49c384a87cea5f89ed70">

                            <tr style="vertical-align: top;">
                              <td style="width: 18pt;">&#160;</td>
                              <td style="vertical-align: top; width: 15.9pt;">
                                <div style="text-align: left;">m.</div>
                              </td>
                              <td style="align: left; vertical-align: top; width: auto;">
                                <div style="text-align: left;">Smoking. Smoking or carrying lighted cigars. pipes. cigarettes. e-cigarettes, or marijuana or similar products anywhere in the Building or grounds of the Building is not permitted, except in
                                  designated smoking areas of the Building as described below or in parked vehicles with closed windows, except that marijuana or similar products may not be smoked in the designated smoking areas of the Building. In the
                                  event that a Unit Owner, tenant or employee of such Unit Owner or tenant is found to be the cause of a fire alarm at the Building because of smoking in the Building, such Unit Owner or tenant shall pay for all costs
                                  associated with said fire alarm. Unit Owners, tenants or employees of Unit Owners or tenants smoking outside of the Building shall not dispose of cigarette or cigar butts in the parking lot or landscaped areas of the
                                  Building. No smoking is permitted within 50 feet of any entrance or exit of the Building, any driveway entrance of the Building. or any window of the Building. The Trustees of the Condominium have designated the concrete
                                  areas designated on the attached plan dated December 2015 as the smoking areas of the Building.</div>
                              </td>
                            </tr>

                        </table>
                      </div>
                      <div>&#160;</div>
                    </div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z06b90d5448db4c808e9b565a0488b900">

                        <tr>
                          <td style="width: 18pt;"><br>
                          </td>
                          <td style="width: 15.9pt; vertical-align: top;">n.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>
                              <div>Bicycles. Bicycles must be located in the concrete area designated on the attached plan as the location of the Building&#8217;s bicycle area and bicycle racks. No bicycle parking is permitted elsewhere in the parking lot,
                                landscaped areas, sidewalks or attached to fences of the Building, except for the bicycle stands located at the Windsor Street entrance of the Building. Bicycles used by employees and guests of Unit Owners and tenants are
                                permitted inside the Building, but must be lifted above the carpeted areas of the Common Areas of the Building. <br>
                              </div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <div>&#160;</div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z23952d394128425a8e0204e1b9c9ca27">

                        <tr>
                          <td style="width: 18pt;"><br>
                          </td>
                          <td style="width: 15.9pt; vertical-align: top;">o.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>
                              <div>Animals. Animals or birds are not allowed in the Building without the written permission of the Trustees of the Trust, except for dogs used by the visually or hearing impaired. See Exhibit B regarding Pet Visitation.</div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <div>&#160;</div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zbaf2f93aee4a427fbc4671d087491b1d">

                        <tr>
                          <td style="width: 18pt;"><br>
                          </td>
                          <td style="width: 15.9pt; vertical-align: top;">p.</td>
                          <td style="width: auto; vertical-align: top;">
                            <div>
                              <div>Motorcycles. The Rules and Regulations shall apply to motorcycles and motorized scooters in the same manner as other vehicles, except that motorized scooters may park in the hatched area adjacent to Parking Space 115 and
                                two motorcycles may park in Parking Space 124. Prior to parking in the hatched area adjacent to Parking Space 115 and in Parking Space 124, Unit Owners and tenants with employees using motorized scooters and motorcycles must
                                sign a license with the Condominium Trust allowing such parking. The Condominium Trust may charge a monthly fee for such parking. Motorcycles and motorized scooters must not park on any sidewalk of the Building and are
                                subject to towing for failure to comply with this provision.</div>
                            </div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div><br>
                  </div>
                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">9</font></div>
                    <div style="page-break-after: always;" id="DSPFPageBreak">
                      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                  </div>
                  <!--PROfilePageNumberReset%Num%10%%%-->
                  <div>
                    <div>
                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5ea538984ccc4444aedf70e790dc0224">

                          <tr>
                            <td style="width: 18pt;">&#160;</td>
                            <td style="width: 15.9pt; vertical-align: top;">
                              <div>q.</div>
                            </td>
                            <td style="width: auto; vertical-align: top;">
                              <div>
                                <div>Suite/Unit Door Signs: For any entrance door to a suite or unit abutting the Building&#8217;s Common Area, only one sign or no greater than 150 square inches shall be permitted on the entrance door or the walls adjacent to
                                  the entrance doors to a suite or unit, whether the entrance is comprised of single or double doors. Additional or larger signs may be approved by a vote of the Condominium Trustees. Temporary signs or additional entry
                                  equipment at the entrance door or a suite or unit shall be permitted only by the Managing Agent or by a vote of the Condominium Trustees.&#160; See Exhibit A regarding Common Area Signage<br>
                                </div>
                              </div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div><br>
                    </div>
                    <div>
                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc8223f8064b44ad78b6da9d42ebdcdfb">

                          <tr>
                            <td style="width: 18pt;">&#160;</td>
                            <td style="width: 15.9pt; vertical-align: top;">
                              <div>r.</div>
                            </td>
                            <td style="width: auto; vertical-align: top;">
                              <div>Handicapped Parking Spaces: Any employer of a person using a handicapped parking space in the Building&#8217;s parking lot on a regular basis must pay to the Trust the market rent for Trust parking spaces. The employer must
                                enter into a license agreement with the Trust for such space.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd8336986786b414cb420000c8720cee9">

                          <tr>
                            <td style="width: 18pt;">&#160;</td>
                            <td style="width: 15.9pt; vertical-align: top;">
                              <div>s.</div>
                            </td>
                            <td style="width: auto; vertical-align: top;">
                              <div>Vendor, Contractor or Subcontractor: Should a vendor, contractor or subcontractor of a unit Owner fail to follow the instructions of the Property Manager or Building Superintendent or the procedures of the Condominium
                                Trust prescribed in the Rules &amp; Regulations or engage in gross negligence or willful misconduct at the Building, the Condominium Trustees may inform the Unit Owner that the vendor, contractor or subcontractor may not
                                perform any additional services at the Building. Any vendor, contractor or subcontractor&#160;performing fire alarm work or installation, mist coordinate with the Managing Agent, not the Building Superintendent, regarding testing
                                and connecting to the Building&#8217;s main fire alarm panel.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf56ae3aae0364c0eb19c4e393224da30">

                          <tr>
                            <td style="width: 18pt;">&#160;</td>
                            <td style="width: 15.9pt; vertical-align: top;">
                              <div>t.</div>
                            </td>
                            <td style="width: auto; vertical-align: top;">
                              <div>HVAC Units: Unit Owners installing new HVAC units must provide the Trust&#8217;s Managing&#160;Agent with the location on the roof or grounds, serial number and model number. Locations of new HVAC units must be approved by the
                                Managing Agent to ensure that the proposed location does not prevent water from reaching roof drains or block emergency egress paths. Unit Owners must remove old HVAC units from the roof or grounds at the time of installing
                                new units. Evidence or removal must be provided to the Managing Agent. All costs for installing new units and removing old units shall be borne by the Unit Owner installing or removing the units. All roof installations,
                                whether for HVAC or telecommunication purposes must have rubber pads under wooden or plastic blocking.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf7b0252823d34ee89d89a1f5c5b4720e">

                          <tr>
                            <td style="width: 18pt;">&#160;</td>
                            <td style="width: 15.9pt; vertical-align: top;">
                              <div>u.</div>
                            </td>
                            <td style="width: auto; vertical-align: top;">
                              <div>Windows: Unit Owners replacing exterior window frames and windows must use frames with the color &#8216;Hartford Green&#8217; (or an exact match of a window frame manufacturer). matching Hartford Green sealant such as Dow Corning 790
                                &#8220;Blue Spruce&#8221;, Precora 864 Tremco Dymonic FC, and clear glass to match existing window frames and window glass. Prior to installation or sealant maintenance, window frames, sealant. and windows must be approved by the
                                Trustees. The Trustees reserve the right to deny approval of window frames, sealant. and window glass even if said frames, sealant and glass have been purchased by Unit Owners. Unit Owners must replace windows with broken
                                thermopane seals within six (6) months of notification by the Condominium Trustees or Managing Agent. In the event that the Unit Owner has not replaced such windows. the Trust may enter the Unit and replace the window. In
                                the event that Unit Owner&#8217;s failure lo apply sealant or to replace a leaking window causes water damage to another Unit Owner&#8217;s Unit or the personal property of the other Unit Owner or its tenant, the Trust may enter the
                                Unit with the failed window or failed sealant and replace the window or apply sealant. If a window or windows are replaced or sealant applied. the Trust will charge the Unit Owner for the cost of goods and services provided
                                by the window installation company plus a 5% construction management fee and shall constitute a lien upon the Unit in the event that the Unit Owner fails to pay the Condominium Trust within thirty (30) days or receiving an
                                invoice.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div style="text-indent: 0.9pt; margin-right: 33.8pt; margin-left: 25.65pt;"> <br>
                    </div>
                    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">10</font></div>
                      <div style="page-break-after:always;" id="DSPFPageBreak">
                        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                    </div>
                    <div>
                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z90d4a806c09c4d388cc9829a2285cff1">

                          <tr>
                            <td style="width: 18pt;">&#160;</td>
                            <td style="width: 15.9pt; vertical-align: top;">
                              <div>v.</div>
                            </td>
                            <td style="width: auto; vertical-align: top;">
                              <div>Emergency Egress: Unless an emergency has occurred at the Property, occupants of the Property shall not use the exit doors on the first floor. second floor and penthouse which lead via metal staircases into an emergency
                                egress alley located behind the adjacent Shell Station at 1001 Cambridge Street. Construction and telecommunications company personnel may use this emergency egress alley to remove debris from the Building, to service or
                                install HVAC equipment, or to service or install telecommunications equipment with the approval of the Managing Agent.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zded80238012b47fabf4f439cfd908177">

                          <tr>
                            <td style="width: 18pt;">&#160;</td>
                            <td style="width: 15.9pt; vertical-align: top;">
                              <div>w.</div>
                            </td>
                            <td style="width: auto; vertical-align: top;">
                              <div>Skylights and Screens: All new skylights must have protective screens installed on the roof with such screens subject to the approval of the Managing Agent. In the event that a&#160; Unit Owner fails to install a protective
                                screen on the roof within sixty (60) days after receiving notice from the Managing Agent, the Trust may install the protective screen. If a protective screen is installed, the Trust will charge the Unit Owner for the cost of
                                goods and services provided by the screen installation company plus a 5% construction management fee and shall constitute a lien upon the Unit in the event that the Unit Owner fails to pay the Condominium Trust within thirty
                                (30) days of receiving an invoice.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z97c7468236864604875f4e7452d79b3b">

                          <tr>
                            <td style="width: 18pt;">&#160;</td>
                            <td style="width: 15.9pt; vertical-align: top;">
                              <div>x.</div>
                            </td>
                            <td style="width: auto; vertical-align: top;">
                              <div>Building Permit: Any Unit Owner spending over $l0,000 for new construction in a Unit shall be required to receive a building permit from the Inspectional&#160; Services&#160; Department of the City of Cambridge. <font style="font-style: italic;">A </font>copy of such permit shall be provided to the Managing upon receipt of the permit from the City of Cambridge.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za88a7aa3c99f446383ac1b8f606762da">

                          <tr>
                            <td style="width: 18pt;">&#160;</td>
                            <td style="width: 15.9pt; vertical-align: top;">
                              <div>y.</div>
                            </td>
                            <td style="width: auto; vertical-align: top;">
                              <div>Deliveries at Common Area Mailboxes: Unit Owners, tenants and their employees shall not overburden the mailbox area in the Building&#8217;s lobby with personal deliveries. Unit Owners and tenants shall remove boxes from the
                                mailbox area on a daily basis to ensure access to the Building&#8217;s mailboxes and to retain the professional appearance of the Building&#8217;s lobby.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd2aca03729164e39a3a0d08f5a10fe0b">

                          <tr>
                            <td style="width: 18pt;">&#160;</td>
                            <td style="width: 15.9pt; vertical-align: top;">
                              <div>z.</div>
                            </td>
                            <td style="width: auto; vertical-align: top;">
                              <div>Trust&#8217;s Managing Agent: As of the date of these amendments to the Rules and Regulations, the Trust&#8217;s Managing Agent is Lincoln Properly Company, 1 Van de Graaff Drive, Lower Level, Burlington, MA 01803.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="6c6cbd63374340b7bd4a05e6f08b37ba" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                        <tr>
                          <td style="width: 18pt;"><br>
                          </td>
                          <td style="width: 15.9pt; vertical-align: top;">
                            <div>aa.&#160;</div>
                          </td>
                          <td style="width: auto; vertical-align: top;">Within each Unit Owner&#8217;s Unit or each tenant&#8217;s premises, Unit Owners and tenants shall observe and comply with the public health guidelines of the United States Centers for Disease
                            Control and any and all federal, state, and local authorities with jurisdiction over the Building, Units or a tenant&#8217;s premises (collectively, the &#8216;&#8216;Public Health Guidelines&#8221;).</td>
                        </tr>

                    </table>
                    <div> <br>
                    </div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z9cd76380cbe9420eb54605582bb779de" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="width: 18pt;">&#160;</td>
                            <td style="vertical-align: top; width: 15.9pt;">
                              <div style="text-align: left;">bb.</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: left;">Within&#160; all&#160; areas of the Building outside the Units and tenant&#8217;s premises, Unit Owners and tenants shall monitor and cause compliance with Public Health Guidelines and with the Trust&#8217;s
                                regulations and protocols (&#8220;Trust Protocols&#8217;&#8217;) to avoid transmission or COVID-19 and other contagious diseases by every person acting by. through, or on behalf of Unit Owners and tenants, provided that any such Trust
                                Protocols shall have been communicated to Unit Owners and tenants in advance orally, by written correspondence, or by posted signage. Trust Protocols may include, but are not limited to, requiring that individuals wear face
                                masks covering the mouth and nose; requiring that individuals maintain social distancing of at least 6 feet apart; limiting or prohibiting gatherings in common areas; and changing pedestrian traffic patterns in lobbies,
                                stairwells, elevators, and other common areas.</div>
                            </td>
                          </tr>

                      </table>
                      <div> <br>
                      </div>
                    </div>
                    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">11</font></div>
                      <div style="page-break-after:always;" id="DSPFPageBreak">
                        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                    </div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z5159d2f5c0984bda9db7f0bc7e3cf86f" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="width: 18pt;">&#160;</td>
                            <td style="vertical-align: top; width: 15.9pt;">
                              <div style="text-align: justify;">cc.</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: justify;">The Managing Agent shall have the right. but not the obligation, to (a) screen any person seeking entrance to the Building for symptoms of contagious disease (including but not limited to
                                COVID-19), which screening may include, without limitation, a temperature scan, and (b) deny entry lo the Building to any person exhibiting symptoms of contagious disease (including but not limited to COVTD-19), including
                                those persons exhibiting an elevated body&#160; temperature. All persons entering the Building shall cooperate with any such procedures.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zef53ab5814f944e19c13ab7b07c23a02" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="width: 18pt;">&#160;</td>
                            <td style="vertical-align: top; width: 15.9pt;">
                              <div style="text-align: justify;">dd.</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: justify;">Unit Owners and tenants shall immediately report to the Managing Agent (Lincoln Property Company as of the date of these Rules &amp; Regulations) if Unit Owners and tenants becomes aware that
                                any individual present in the Building visiting a Unit Owner or tenant within the last 7 days: (a) had a confirmed case of COVID-19. at the time of such visit. or (b) has since been diagnosed with COVID-19. In each such
                                case. Unit Owners and tenants should use extreme care not to disclose the name or other identifying information of the individual in question. Unit owners and tenants shall cooperate with the Managing Agent and its
                                representatives to identify any areas outside of the Unit or tenant&#8217;s premises that were accessed by such individual during such visit or visits to the Building. such as bathrooms. vending machines and Common Area seating
                                areas.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div>&#160;</div>
                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6f295e10567540e7841ac48d60b253a5" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                          <tr style="vertical-align: top;">
                            <td style="width: 18pt;">&#160;</td>
                            <td style="vertical-align: top; width: 15.9pt;">
                              <div style="text-align: left;">ee.</div>
                            </td>
                            <td style="align: left; vertical-align: top; width: auto;">
                              <div style="text-align: left;">City of Cambridge Parking and Transportation Demand Management (PTDM) plan (Additional 2020 Requirements). Unit owners are required to report to the Managing Agent annually by April 1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> 1) the number of spaces owned, 2) the number of spaces used by&#160; the Unit Owner, 3) the number of spaces leased to tenants of the Unit Owner,
                                and 4) the number of spaces which Unit Owners lease from other Unit Owners.</div>
                            </td>
                          </tr>

                      </table>
                    </div>
                    <div><br>
                    </div>
                    <div style="text-align: center; margin-right: 72.5pt; margin-left: 91.3pt;">REMAINDER OF PAGE LEFT INTENTIONALLY BLANK</div>
                  </div>
                  <div><br>
                  </div>
                  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">12</font></div>
                    <div id="DSPFPageBreak" style="page-break-after: always;">
                      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                  </div>
                  <div>These amendments to the Rules and Regulations are hereby adopted by the consent of the Trustees of the 432 Columbia Street Condominium Trust this 7<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>
                    day of August, 2020.
                    <div>&#160;</div>
                    <div style="text-align: center; font-weight: bold;">VOTE OF TRUSTEES</div>
                    <div>&#160;</div>
                    <div>Reference is made to the 432 Columbia Street Condominium Trust dated 22 January 1988, recorded in the Middlesex County Registry of Deeds Book 18837, Page 158. Pursuant to Section 7 of the By-Laws of the Trust. the Trustees
                      unanimously voted to adopt the above amended Rules and Regulations with Exhibits A and <font style="font-weight: bold;"><font style="font-weight: normal;">B.</font> </font>These Rules and
                      Regulations shall be effective as of the latter of August 31, 2020 or the date a copy is actually received by a Unit Owner or posted in the Condominium.</div>
                    <div>&#160;</div>
                    <div>IN WITNESS HEREOF the parties hereto have signed this vote of trustees this 7<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> of August. 2020,</div>
                    <div><br>
                    </div>
                  </div>
                  <div>
                    <table cellspacing="0" cellpadding="0" border="0" id="zf65ec2c9f0524040a628f310abcca690" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                        <tr>
                          <td style="width: 28%; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Brain Bai</td>
                          <td style="width: 22%; padding-bottom: 2px;"><br>
                          </td>
                          <td style="width: 50%; padding-bottom: 2px;"><br>
                          </td>
                        </tr>
                        <tr>
                          <td style="width: 28%; text-align: left; vertical-align: top;">Brain Bai, Trustee<br>
                          </td>
                          <td style="width: 22%;"><br>
                          </td>
                          <td style="width: 50%;">Witnessed:<img src="image00006.jpg"></td>
                        </tr>
                        <tr>
                          <td style="width: 28%;"><br>
                          </td>
                          <td style="width: 22%;"><br>
                          </td>
                          <td style="width: 50%;"><br>
                          </td>
                        </tr>
                        <tr>
                          <td style="width: 28%; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Michael Grill</td>
                          <td style="width: 22%; padding-bottom: 2px;"><br>
                          </td>
                          <td style="width: 50%; padding-bottom: 2px;"><br>
                          </td>
                        </tr>
                        <tr>
                          <td style="width: 28%; text-align: left; vertical-align: top;">Michael Grill, Trustee<br>
                          </td>
                          <td style="width: 22%;"><br>
                          </td>
                          <td style="width: 50%;">Witnessed:<img src="image00007.jpg"></td>
                        </tr>
                        <tr>
                          <td style="width: 28%;"><br>
                          </td>
                          <td style="width: 22%;"><br>
                          </td>
                          <td style="width: 50%;"><br>
                          </td>
                        </tr>
                        <tr>
                          <td style="width: 28%; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Hillary Brown</td>
                          <td style="width: 22%; padding-bottom: 2px;"><br>
                          </td>
                          <td style="width: 50%; padding-bottom: 2px;"><br>
                          </td>
                        </tr>
                        <tr>
                          <td style="width: 28%; text-align: left; vertical-align: top;">Hillary Brown, Trustee<br>
                          </td>
                          <td style="width: 22%;"><br>
                          </td>
                          <td style="width: 50%;">Witnessed:<img src="image00008.jpg"></td>
                        </tr>

                    </table>
                  </div>
                  <br>
                </div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                  <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">13</font></div>
                  <div style="page-break-after: always;" id="DSPFPageBreak">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div> <img src="image00009.jpg"></div>
                <div> <br>
                </div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                  <div style="page-break-after: always;" id="DSPFPageBreak">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div>
                  <div style="text-align: center;">EXHIBIT A</div>
                  <div style="text-align: center;">RULES AND REGULATIONS</div>
                  <div style="text-align: center;">432 COLUMBIA STREET CONDOMINIUM TRUST</div>
                  <div style="text-align: center;">&#160;</div>
                  <div style="text-align: center; font-weight: bold;">COMMON AREA SIGNAGE<br>
                  </div>
                  <div style="text-align: center; font-weight: bold;">RULES &amp; REGULATIONS</div>
                  <div>&#160;
                    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
                  <div><br>
                  </div>
                  <div style="text-align: justify;">In addition to the rules regarding signage in the existing Rules and Regulations, the Trust prohibits posting signage in the Building common areas without prior written permission of the Trustees. The
                    Trustees hereby provide authority to the Managing Agent to provide permission or denial to Unit Owners. tenant or subtenant for proposed signage. The following Common Area Signage Rules &amp; Regulations are provided below to clarify
                    this building policy.</div>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" id="z1434eb0213c84f8cb8ba86a3cd0d828f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                      <tr>
                        <td style="width: 24.2pt;"><br>
                        </td>
                        <td style="width: 30.55pt; vertical-align: top;">1.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div>All proposed signage must be presented to Trustees or Managing Agent for authorization 24-hours prior to the requested posting date and time.</div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" id="zda3b01dc4c944386b480ce9724731167" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                      <tr>
                        <td style="width: 24.2pt;"><br>
                        </td>
                        <td style="width: 30.55pt; vertical-align: top;">2.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div>Any and all signage must receive <font style="font-weight: bold;">written </font>authorization from Trustees and/or Managing Agent.</div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <div>
                    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z33542c68894840839f5628676c0d95c5" class="DSPFListTable">

                        <tr style="vertical-align: top;">
                          <td style="width: 24.2pt;">&#160;</td>
                          <td style="vertical-align: top; width: 30.55pt;">
                            <div style="text-align: left;">3.</div>
                          </td>
                          <td style="vertical-align: top; width: auto;">
                            <div style="text-align: left;">Any and all signage must be <font style="font-style: italic;">printed, laminated and professional in appearance. <font style="font-style: normal;">Hand</font></font><font style="font-style: normal;">-</font>written and/or non-laminated paper signage will not be authorized.</div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" id="z7f6114b56dde489daaf9cfc90eb6128e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                      <tr>
                        <td style="width: 24.2pt;"><br>
                        </td>
                        <td style="width: 30.55pt; vertical-align: top;">4.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div>Overnight signage must be posted after 5:00pm and removed prior to 8:00am, Monday through Friday.</div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" id="z046a69a6f4544c67979670c45db4c4e2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                      <tr>
                        <td style="width: 24.2pt;"><br>
                        </td>
                        <td style="width: 30.55pt; vertical-align: top;">5.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div>Weekend signage must be posted after 5:00pm on the appropriate Friday and removed prior to 8:00am on the following Monday.</div>
                        </td>
                      </tr>

                  </table>
                  <div><br>
                  </div>
                  <table cellspacing="0" cellpadding="0" id="z6656daee5a864ce49ca96c05a2be19b6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                      <tr>
                        <td style="width: 24.2pt;"><br>
                        </td>
                        <td style="width: 30.55pt; vertical-align: top;">6.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div>Any and all adhesive used to post signage must be completely and appropriately removed immediately upon removal of signage. Any and all damage caused by the installation or removal of signage is the whole responsibility of
                            the corresponding Unit Owner to repair with in 24-hours of damage occurring, to Trustees satisfaction.</div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" id="z6f287514c3314710a9fc1f8bfd1beb56" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                      <tr>
                        <td style="width: 24.2pt;"><br>
                        </td>
                        <td style="width: 30.55pt; vertical-align: top;">7.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div>Signage posted on a floor stand or easel is strictly prohibited from impeding any emergency exit pathways or doorway at any time, for any reason. The Trust reserves&#160;the right to relocate floor stand signage at any time.</div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" id="z3055b4cc93a94fc4bab3bee3b7f464ab" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                      <tr>
                        <td style="width: 24.2pt;"><br>
                        </td>
                        <td style="width: 30.55pt; vertical-align: top;">8.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div>The Trust reserves the right to deny authorization of signage at any time for any reason.</div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <div>
                    <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z5473a175a08d4ca188fb72cda78e3184" class="DSPFListTable">

                        <tr style="vertical-align: top;">
                          <td style="width: 24.2pt;">&#160;</td>
                          <td style="vertical-align: top; width: 30.55pt;">
                            <div style="text-align: left;">9.</div>
                          </td>
                          <td style="vertical-align: top; width: auto;">
                            <div style="text-align: left;">Signage authorization is given on a first come, first serve basis.</div>
                          </td>
                        </tr>

                    </table>
                  </div>
                </div>
                <div> <br>
                </div>
                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                  <div style="page-break-after: always;" id="DSPFPageBreak">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div>
                  <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">EXHIBIT B<br>
                  </div>
                  <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;">RUL</font>E<font style="font-family: 'Times New Roman',Times,serif;">S
                      &amp;&#160; REGULATIONS OF</font></div>
                  <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman',Times,serif;">432 COLUMBlA STREET CONDOMINIUM TRUST<br>
                    </font><br>
                  </div>
                  <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">PET VISITATION</div>
                  <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">RULES &amp; REGULATIONS</div>
                  <div>
                    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
                  <div> <br>
                  </div>
                  <div>Section 8.0 (0) of the Rules and Regulations of the 432 Columbia Street Columbia Street Condominium Trust dated October 16, 2008 prohibits animals at 1035 Cambridge Street without written permission of the Trustees. The following Pet
                    Visitation Rules &amp; Regulations are provided below to clarify this building policy.<br>
                  </div>
                  <div><br>
                  </div>
                  <div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z3c4c56a5e9f5445f989fafbbccb0a60a" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

                        <tr style="vertical-align: top;">
                          <td style="width: 21.6pt;">&#160;</td>
                          <td style="vertical-align: top; width: 31.85pt;">
                            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">l</div>
                          </td>
                          <td style="vertical-align: top; width: auto;">
                            <div style="text-align: justify; font-family: 'Times New Roman',Times,serif;">Any and all non-service dogs brought onto the property&#160; must first receive written authorization from the Trustees or Managing Agent. Service dogs,
                              those used by visually or hearing impaired, are permitted in the building.</div>
                          </td>
                        </tr>

                    </table>
                  </div>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zddf28353a78642baaa00d0db6c82d26e">

                      <tr>
                        <td style="width: 21.6pt;"><br>
                        </td>
                        <td style="width: 31.85pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">2.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman',Times,serif;">Only service dogs will be permitted on the property. Any and all other pets or animals are prohibited.</font></div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb9721b32d8844cbf9ebab6d1cde62358">

                      <tr>
                        <td style="width: 21.65pt;"><br>
                        </td>
                        <td style="width: 31.65pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">3.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman',Times,serif;">Trustees or Managing Agent shall have the authority to revoke dog visitation privileges at the property at any
                              time, with or without reason.<br>
                            </font></div>
                        </td>
                      </tr>

                  </table>
                  <div style="margin-left: 53.4pt; font-family: 'Times New Roman', Times, serif;"><br>
                  </div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfa418cc5322e42fcb86169936a369205">

                      <tr>
                        <td style="width: 21.65pt;"><br>
                        </td>
                        <td style="width: 31.55pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">4.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman',Times,serif;">Only one </font>(<font style="font-family: 'Times New Roman',Times,serif;">1) dog authorization shall be
                              provided PER TENANT SUITE.</font></div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2f893b7b7fd74fc8a5f5eb8c64ca47c9">

                      <tr>
                        <td style="width: 21.8pt;"><br>
                        </td>
                        <td style="width: 31.95pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">5.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman',Times,serif;">Authorized dogs are allowed a maximum of (1) visit per business week.</font></div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7ed53a1394c64698b6289f2ec43fb7f6">

                      <tr>
                        <td style="width: 21.35pt;"><br>
                        </td>
                        <td style="width: 31.85pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">6.</td>
                        <td style="width: auto; vertical-align: top; text-align: justify;">
                          <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman',Times,serif;">Dogs must be kept contained or on a leash at all times while within any and all common areas including, but not
                              limited to: parking lot, landscaping, common lobbies or common hallways.</font></div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf86a8c81d16a4252adb1a5c5241265b3">

                      <tr>
                        <td style="width: 22.15pt;"><br>
                        </td>
                        <td style="width: 31.25pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">7.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman',Times,serif;">Dogs are strictly prohibited from using building common areas including, but not limited to, <u>parking </u><u>lot</u><u>s
                                and </u><u>landscaped</u></font><u> areas</u>, <font style="font-family: 'Times New Roman',Times,serif;">for </font>&#8220;<font style="font-family: 'Times New Roman',Times,serif;">restroom&#8221; purposes.</font></div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc96ad1a4e62346b8bd338b7cc49cb041">

                      <tr>
                        <td style="width: 21.9pt;"><br>
                        </td>
                        <td style="width: 31.8pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">8.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman',Times,serif;">Each individual Unit Owner is wholly responsible for any and all liability related to the pet&#8217;s visitation.<br>
                            </font></div>
                        </td>
                      </tr>

                  </table>
                  <div>&#160;</div>
                  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8729958f4d4b44d58c8e0bd2e5eed3f4">

                      <tr>
                        <td style="width: 21.9pt;"><br>
                        </td>
                        <td style="width: 31.8pt; vertical-align: top; font-family: 'Times New Roman',Times,serif;">9.</td>
                        <td style="width: auto; vertical-align: top;">
                          <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman',Times,serif;">Any and all incidents occurring because of or related to a dog involving additional costs (i.e,: cleaning,
                              carpeting, legal fees) will be the full and complete responsibility of Unit Owner to repair to the satisfaction of the Trustees.<br>
                            </font></div>
                        </td>
                      </tr>

                  </table>
                  <div style="margin-left: 53.75pt; font-family: 'Times New Roman', Times, serif;"><br>
                  </div>
                </div>
                <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                  <div id="DSPFPageBreak" style="page-break-after: always;">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div>
                  <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">EXHIBIT G</div>
                  <div><br>
                  </div>
                  <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">PARKING LOT PLAN OF 1035 CAMBRIDGE STREET</div>
                  <div><br>
                  </div>
                  <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-weight: bold;">(Sec following page)</div>
                  <div style="text-align: center; margin-right: 151.5pt; margin-left: 71.85pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
                  </div>
                  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                    <div id="DSPFPageBreak" style="page-break-after: always;">
                      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                  </div>
                  <div style="text-align: center;"> <img src="image00005.jpg"></div>
                </div>
                <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                  <div id="DSPFPageBreak" style="page-break-after: always;">
                    <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
                </div>
                <div>
                  <div style="text-align: center; margin-right: 178.5pt; margin-left: 180.5pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">INDEX TO LEASE</div>
                  <div style="text-align: center; margin-right: 178.5pt; margin-left: 180.5pt; color: #525657; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> <br>
                  </div>
                  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zbd791437a24e417a977f3dab7a0685d4">

                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">1.1</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">DEFINITIONS</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">1</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">1.2</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">EXTENT OF AGREEMENT</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">5</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">2.1</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">LEASED PREMISES</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">5</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">2.2</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">APPURTENANT RIGHTS AND OBLIGATIONS</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">5</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">3.1</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">RENT</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">5</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">3.2</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">LATE RECEIPT OF RENT</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">6</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">4.1</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">CONDITION OF PREMISES</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">6</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">5.1</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">PERMITTED USE OF PREMISES</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">7</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">5.2</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">ALTERATIONS BY TENANT</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">8</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">6.1</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">PROHIBITION AGAINST ASSIGNMENT AND SUBLETTING</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">8</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">7.1</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">LANDLORD&#8217;S REPAIRS AND MAINTENANCE</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">10</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">7.2</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">TENANT&#8217;S REPAIR AND MAINTENANCE</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">10</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">7.3</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">TENANT&#8217;S EQUIPMENT</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">10</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">7.4</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">UTILITIES AND BUILDING SERVICES</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">11</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">8.1</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">REAL ESTATE TAX PAYMENTS</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">12</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">8.2</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">ABATEMENT</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">12</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">8.3</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">ESTIMATED REAL ESTATE TAX PAYMENTS</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">12</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">9.1</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">CONDOMINIUM FEE PAYMENTS</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">13</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">9.2</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">CONDOMINIUM FEES</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">13</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">9.3</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">ESTIMATED CONDOMINIUM FEE PAYMENTS</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">14</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">10.1</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">TENANT&#8217;S AND LANDLORD&#8217;S INDEMNITY</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">14</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">10.2</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">TENANT&#8217;S INSURANCE</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">15</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">10.3</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">TENANT&#8217;S RISK</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">15</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">10.4</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">INJURY CAUSED BY THIRD PARTIES</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">16</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">l 1.1</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">LANDLORD&#8217;S RIGHT OF ACCESS</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">16</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">12.1</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">ABATEMENT OF RENT</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">16</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">12.2</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">RIGHT TO TERMINATE</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">16</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">12.3</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">RESTORATION</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">17</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">12.4</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">AWARD</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">17</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">13.1</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">TENANT&#8217;S DEFAULT</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">17</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">13.2</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">LANDLORD&#8217;S DEFAULT</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">20</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.1</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">WAIVER</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">20</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.2</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">COVENANT OF QUIET ENJOYMENT</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">21</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.3</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">LANDLORD&#8217;S LIABILITY</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">21</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.4</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">TRANSFER OF TITLE</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">21</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.5</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">RULES AND REGULATIONS</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">21</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.6</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">ADDITIONAL CHARGES</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">22</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.7</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">SEVERABILITY</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">22</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.8</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">BINDING NATURE</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">22</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.9</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">NOTICES</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">22</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.10</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">COMPLETE AGREEMENT AND AMENDMENT</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">22</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.11</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">SUBORDINATION</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">22</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.12</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">ESTOPPEL CERTIFICATES</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">23</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.13</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">LANDLORD&#8217;S RIGHT TO CURE DEFAULTS</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif;">23</div>
                        </td>
                      </tr>

                  </table>
                  <div> <br>
                  </div>
                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
                    <div style="page-break-after:always;" id="DSPFPageBreak">
                      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
                  </div>
                  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zf6c23a66d3c440dd8dae6d0dadb1d305">

                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.14</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">HOLDOVER</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">23</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.15</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">WAIVER OF SUBROGATION</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">23</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.16</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">YIELD UP</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">24</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.17</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">BROKERAGE</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">24</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.18</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">CONSTRUCTION</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">24</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.19</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">INTENTIONALLY DELETED</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">25</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.20</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">SECURITY DEPOSIT</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">25</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.21</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">PARTIAL INVALIDITY</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">25</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.22</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">GOVERNING LAW</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">25</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.23</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">FINANCIAL STATEMENTS</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">25</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.24</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">SATELLITE DISH/ANTENNA</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">26</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.25</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">COMPLIANCE WITH CONDOMINIUM DOCUMENTS</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">26</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.26</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">SUBMISSION NOT OFFER OR OPTION</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">28</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman',Times,serif;">14.27</font></div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">AUTHORITY AND ORGANIZATION OF TENANT</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">28</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.28</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">NO RECORDING</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">29</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.29</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">ADDENDUM</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">29</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.30</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">TENANT&#8217;S APPROVALS</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">29</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.31</div>
                        </td>
                        <td style="width: 83%; vertical-align: top;">
                          <div style="font-family: 'Times New Roman',Times,serif;">SIGNATURES</div>
                        </td>
                        <td style="width: 10%; vertical-align: top;">
                          <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">29</div>
                        </td>
                      </tr>
                      <tr>
                        <td style="width: 7.15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">14.32</div>
                        </td>
                        <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                          <div style="font-family: 'Times New Roman',Times,serif;">NO PERSONAL LIABILITY</div>
                        </td>
                        <td style="width: 10%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255); font-size: 10pt;">29<br>
                        </td>
                      </tr>

                  </table>
                </div>
                <div> <br>
                </div>
              </div>
              <div>
                <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z90d4f90fc17147e1bedaf206eb9eb738">

                    <tr>
                      <td style="width: 20%; vertical-align: top; background-color: rgb(204, 238, 255);">
                        <div style="text-align: justify; margin-right: 1.9pt; font-family: 'Times New Roman',Times,serif;">EXHIBIT A</div>
                      </td>
                      <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
                        <div style="text-align: justify; margin-right: 1.9pt; font-family: 'Times New Roman',Times,serif;">LEGAL DESCRIPTION OF LAND</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 20%; vertical-align: top;">
                        <div style="text-align: justify; margin-right: 1.9pt; font-family: 'Times New Roman',Times,serif;">EXHIBIT B</div>
                      </td>
                      <td style="width: 80%; vertical-align: top;">
                        <div style="text-align: justify; margin-right: 1.9pt; font-family: 'Times New Roman',Times,serif;">LEASE PLAN</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 20%; vertical-align: top; background-color: rgb(204, 238, 255);">
                        <div style="text-align: justify; margin-right: 1.9pt; font-family: 'Times New Roman',Times,serif;">EXHIBIT C</div>
                      </td>
                      <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
                        <div style="text-align: justify; margin-right: 1.9pt; font-family: 'Times New Roman',Times,serif;">LANDLORD&#8217;S WORK</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 20%; vertical-align: top;">
                        <div style="text-align: justify; margin-right: 1.9pt; font-family: 'Times New Roman',Times,serif;">EXHIBIT D</div>
                      </td>
                      <td style="width: 80%; vertical-align: top;">
                        <div style="margin-right: 11.75pt; font-family: 'Times New Roman',Times,serif;">RULES &amp; REGULATIONS FOR FAIRLANE COLUMBIA, LLC</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 20%; vertical-align: top; background-color: rgb(204, 238, 255);">
                        <div style="text-align: justify; margin-right: 1.9pt; font-family: 'Times New Roman',Times,serif;">EXHIBIT E</div>
                      </td>
                      <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
                        <div style="text-align: justify; margin-right: 1.9pt; font-family: 'Times New Roman',Times,serif;">LEGAL HOLIDAYS IN MASSACHUSETTS</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 20%; vertical-align: top;">
                        <div style="text-align: justify; margin-right: 1.9pt; font-family: 'Times New Roman',Times,serif;">EXHIBIT F</div>
                      </td>
                      <td style="width: 80%; vertical-align: top;">
                        <div style="text-align: justify; margin-right: 1.9pt; font-family: 'Times New Roman',Times,serif;">RULES AND REGULATIONS OF 432 COLUMBIA STREET CONDOMINIUM TRUST</div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 20%; vertical-align: top; background-color: rgb(204, 238, 255);">
                        <div style="font-family: 'Times New Roman',Times,serif;">EXHIBIT G</div>
                      </td>
                      <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
                        <div style="font-family: 'Times New Roman',Times,serif;">PARKING LOT PLAN OF 1035 CAMBRIDGE STREET</div>
                      </td>
                    </tr>

                </table>
              </div>
              <div><br>
                <div> <br>
                </div>
                <div>
                  <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>brhc10036185_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">EXHIBIT 21.1</div>
      <div>&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">SUBSIDIARIES OF THE REGISTRANT</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td nowrap="nowrap" style="width: 49%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Subsidiary</div>
            </td>
            <td nowrap="nowrap" style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td nowrap="nowrap" style="width: 49%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">State Or Country of Organization</div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="text-align: justify; text-indent: -12pt; margin-left: 12pt; color: rgb(0, 0, 0);">Brooklyn ImmunoTherapeutics, LLC</div>
            </td>
            <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: justify; margin-left: 8.1pt; color: rgb(0, 0, 0);">Delaware</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div style="color: rgb(0, 0, 0);">*Pursuant to Item 601(b)(21)(ii) of Regulation S-K, the names of other subsidiaries of the registrant are omitted because, considered in the aggregate, they would not constitute a significant subsidiary as of the end
        of the year covered by this report.</div>
      <div style="color: rgb(0, 0, 0);"> <br>
      </div>
      <div style="color: rgb(0, 0, 0);"> <br>
      </div>
      <div style="color: rgb(0, 0, 0);">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>brhc10036185_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">EXHIBIT 23.1</div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#8217;S CONSENT</u></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">We consent to the incorporation by reference in the Registration Statement of Brooklyn ImmunoTherapeutics, Inc. on Form S-8 (File No. 333-260200;
        File No. 333-256760; and File No. 333-232141) of our report dated April 15, 2022, which includes an explanatory paragraph as to the Company&#8217;s ability to continue as a going concern, with respect to our audits of the consolidated financial
        statements of Brooklyn ImmunoTherapeutics, Inc.<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</font>as of December 31, 2021 and 2020 and for each of the two years in the period ended December 31, 2021,
        which report is included in this Annual Report on Form 10-K of Brooklyn ImmunoTherapeutics, Inc.<font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;</font>for the year ended December 31, 2021.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Our report on the consolidated financial statements refers to a change in the method of accounting for leases in 2020 due to the adoption of the
        guidance in ASC Topic 842, Leases (&#8220;Topic 842&#8221;).</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">/s/ Marcum <font style="font-family: 'Times New Roman',Times,serif; font-variant: small-caps;">llp</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Marcum <font style="font-family: 'Times New Roman',Times,serif; font-variant: small-caps;">llp</font></div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">New York, NY</div>
      <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">April 15, 2022</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>brhc10036185_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">EXHIBIT 31.1</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15(d)-14(a), AS ADOPTED PURSUANT TO</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <br>
      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0);">
        <div style="color: rgb(0, 0, 0); text-indent: -18pt; margin-left: 18pt;">I, Howard J. Federoff, certify that:</div>
        <div>&#160;</div>
        <div style="text-indent: 24.5pt; color: rgb(0, 0, 0);">1. I have reviewed this annual report on Form 10-K of Brooklyn ImmunoTherapeutics, Inc. (the &#8220;Company&#8221;);</div>
        <div>&#160;</div>
        <div>
          <div style="text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman', Times, serif;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
            statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
          <br>
        </div>
      </div>
      <div>
        <div style="text-indent: 24.5pt; color: rgb(0, 0, 0);">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of
          operations and cash flows of the registrant as of, and for, the periods presented in this report;</div>
        <div style="text-indent: 24.5pt; color: #000000; font-family: 'Times New Roman', Times, serif;"> <br>
        </div>
      </div>
      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0);">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
        and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 20.55pt; vertical-align: top; color: rgb(0, 0, 0);">(a)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
                including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 20.55pt; vertical-align: top; color: rgb(0, 0, 0);">(b)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the
                reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 20.55pt; vertical-align: top; color: rgb(0, 0, 0);">(c)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end
                of the period covered by this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 20.55pt; vertical-align: top; color: rgb(0, 0, 0);">(d)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in
                the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0);">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit
        committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 20.55pt; vertical-align: top; color: rgb(0, 0, 0);">(a)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record,
                process, summarize and report financial information; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 20.55pt; vertical-align: top; color: rgb(0, 0, 0);">(b)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Dated: April <font style="font-family: 'Times New Roman', serif; font-size: 10pt;">15</font>, 2022</div>
              </div>
            </td>
            <td style="width: 2%; vertical-align: top;"><br>
            </td>
            <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0);">/s<font style="font-style: italic;">/&#160;</font><font style="font-style: italic; font-variant: small-caps;">Howard J. Federoff</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;"><br>
            </td>
            <td style="width: 2%; vertical-align: top;"><br>
            </td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Howard J. Federoff,</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Chief Executive Officer and President</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Brooklyn ImmunoTherapeutics, Inc.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>brhc10036185_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">EXHIBIT 31.2</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15(d)-14(a), AS ADOPTED PURSUANT TO</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div>&#160;</div>
      <div style="color: rgb(0, 0, 0);">I, Sandra Gurrola, certify that:</div>
      <div>&#160;</div>
      <div style="text-indent: 27pt;"><font style="color: rgb(0, 0, 0);">1.</font>&#160; <font style="color: rgb(0, 0, 0);">I have reviewed this annual report on Form 10-K of Brooklyn ImmunoTherapeutics, Inc. (the &#8220;Company&#8221;);</font></div>
      <div>&#160;</div>
      <div style="text-indent: 27pt;"><font style="color: rgb(0, 0, 0);">2.</font>&#160; <font style="color: rgb(0, 0, 0);">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
          to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
      <div>&#160;</div>
      <div style="text-indent: 27pt;"><font style="color: rgb(0, 0, 0);">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results
          of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>
      <div>&#160;</div>
      <div style="text-indent: 27pt;"><font style="color: rgb(0, 0, 0);">4.</font> <font style="color: rgb(0, 0, 0);">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as
          defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 42.45pt;"><br>
            </td>
            <td style="width: 20.55pt; vertical-align: top; color: rgb(0, 0, 0);">(a)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
                including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 42.45pt;"><br>
            </td>
            <td style="width: 20.55pt; vertical-align: top; color: rgb(0, 0, 0);">(b)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the
                reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 42.45pt;"><br>
            </td>
            <td style="width: 20.55pt; vertical-align: top; color: rgb(0, 0, 0);">(c)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end
                of the period covered by this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 42.45pt;"><br>
            </td>
            <td style="width: 20.55pt; vertical-align: top; color: rgb(0, 0, 0);">(d)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in
                the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-indent: 27pt;"><font style="color: rgb(0, 0, 0);">5.</font>&#160; <font style="color: rgb(0, 0, 0);">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
          reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 42.45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">(a)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record,
                process, summarize and report financial information; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 42.45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">(b)</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Dated: April <font style="font-family: 'Times New Roman', serif; font-size: 10pt;">15</font>, 2022</div>
              </div>
            </td>
            <td style="width: 2%; vertical-align: top;"><br>
            </td>
            <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0);">/s/&#160;<font style="font-style: italic; font-variant: small-caps;">Sandra Gurrola</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;"><br>
            </td>
            <td style="width: 2%; vertical-align: top;"><br>
            </td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Sandra Gurrola,</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Vice President of Finance</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Brooklyn ImmunoTherapeutics, Inc.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>brhc10036185_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">EXHIBIT 32.1</div>
      <div>&#160;</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div>&#160;</div>
      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0);">&#160;In connection with the Annual Report of Brooklyn ImmunoTherapeutics, Inc. (the &#8220;Registrant&#8221;) on Form 10-K for the year ended December&#160;31, 2021 (the &#8220;Report&#8221;), I, Howard J. Federoff, Chief
        Executive Officer and President of the Registrant, do hereby certify, pursuant to 18&#160;U.S.C.&#160;&#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</div>
      <div>&#160;</div>
      <div style="text-indent: 27pt;"><font style="color: rgb(0, 0, 0);">(1)</font> <font style="color: rgb(0, 0, 0);">the Report, as filed with the Securities and Exchange Commission, fully complies with the requirements of section 13(a) or 15(d) of the
          Securities Exchange Act of 1934; and</font></div>
      <div>&#160;</div>
      <div style="text-indent: 27pt;"><font style="color: rgb(0, 0, 0);">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div>
      <div style="text-indent: 27pt;"><font style="color: rgb(0, 0, 0);"> <br>
        </font></div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Dated: April <font style="font-family: 'Times New Roman', serif; font-size: 10pt;">15</font>, 2022</div>
              </div>
            </td>
            <td style="width: 2%; vertical-align: top;"><br>
            </td>
            <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0);">/s/&#160;<font style="font-style: italic; font-variant: small-caps;">Howard J. Federoff</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;"><br>
            </td>
            <td style="width: 2%; vertical-align: top;"><br>
            </td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Howard J. Federoff,</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Chief Executive Officer and President</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Brooklyn ImmunoTherapeutics, Inc.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>brhc10036185_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">EXHIBIT 32.2</div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div>&#160;</div>
      <div style="text-indent: 24.5pt; color: rgb(0, 0, 0);">In connection with the Annual Report of Brooklyn ImmunoTherapeutics, Inc. (the &#8220;Registrant&#8221;) on Form 10-K for the year ended December&#160;31, 2021 (the &#8220;Report&#8221;), I, Sandra Gurrola, Vice President of
        Finance of the Registrant, do hereby certify, pursuant to 18&#160;U.S.C.&#160;&#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</div>
      <div>&#160;</div>
      <div style="text-indent: 27pt;"><font style="color: rgb(0, 0, 0);">(1)</font> <font style="color: rgb(0, 0, 0);">the Report, as filed with the Securities and Exchange Commission, fully complies with the requirements of section 13(a) or 15(d) of the
          Securities Exchange Act of 1934; and</font></div>
      <div>&#160;</div>
      <div style="text-indent: 27pt;"><font style="color: rgb(0, 0, 0);">(2)</font> <font style="color: rgb(0, 0, 0);">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of
          the Registrant.</font></div>
      <div style="text-indent: 27pt;"><font style="color: rgb(0, 0, 0);"> <br>
        </font></div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 49%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">Dated: April <font style="font-family: 'Times New Roman', serif; font-size: 10pt;">15</font>, 2022</div>
              </div>
            </td>
            <td style="width: 2%; vertical-align: top;"><br>
            </td>
            <td style="width: 49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0);">/s/&#160;<font style="font-variant: small-caps;">Sandra Gurrola</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%; vertical-align: top;"><br>
            </td>
            <td style="width: 2%; vertical-align: top;"><br>
            </td>
            <td style="width: 49%; vertical-align: bottom;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Sandra Gurrola,</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Vice President of Finance</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Brooklyn ImmunoTherapeutics, Inc.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>btx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<xs:schema targetNamespace="http://brooklynitx.com/20211231" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:btx="http://brooklynitx.com/20211231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://brooklynitx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>010000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <!--Parent Role: CONSOLIDATED BALANCE SHEETS-->
        <link:definition>010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
        <link:definition>020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit" id="ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit">
        <link:definition>030000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>040000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperations" id="OrganizationAndDescriptionOfBusinessOperations">
        <link:definition>060100 - Disclosure - Organization and Description of Business Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/LiquidityAndCapitalResources" id="LiquidityAndCapitalResources">
        <link:definition>060200 - Disclosure - Liquidity and Capital Resources</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPolicies" id="BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>060300 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactions" id="MergerDispositionAndAcquisitionTransactions">
        <link:definition>060400 - Disclosure - Merger, Disposition and Acquisition Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/FairValueOfFinancialInstruments" id="FairValueOfFinancialInstruments">
        <link:definition>060500 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
        <link:definition>060600 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/Leases" id="Leases">
        <link:definition>060700 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopment" id="GoodwillAndInprocessResearchDevelopment">
        <link:definition>060800 - Disclosure - Goodwill and In-Process Research &amp; Development</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/AccruedExpenses" id="AccruedExpenses">
        <link:definition>060900 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/Debt" id="Debt">
        <link:definition>061000 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>061100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShare" id="BasicAndDilutedEarningsPerCommonShare">
        <link:definition>061200 - Disclosure - Basic and Diluted Earnings per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/StockbasedCompensation" id="StockbasedCompensation">
        <link:definition>061300 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficit" id="StockholdersAndMembersEquityDeficit">
        <link:definition>061400 - Disclosure - Stockholders' and Members' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>061500 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/RetirementSavingsPlan" id="RetirementSavingsPlan">
        <link:definition>061600 - Disclosure - Retirement Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>061700 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <!--Parent Role: Basis of Accounting Presentation and Summary of Significant Accounting Policies-->
        <link:definition>070300 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsTables" id="MergerDispositionAndAcquisitionTransactionsTables">
        <!--Parent Role: Merger, Disposition and Acquisition Transactions-->
        <link:definition>080400 - Disclosure - Merger, Disposition and Acquisition Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/FairValueOfFinancialInstrumentsTables" id="FairValueOfFinancialInstrumentsTables">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>080500 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
        <!--Parent Role: Property and Equipment-->
        <link:definition>080600 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/LeasesTables" id="LeasesTables">
        <!--Parent Role: Leases-->
        <link:definition>080700 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
        <!--Parent Role: Accrued Expenses-->
        <link:definition>080900 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareTables" id="BasicAndDilutedEarningsPerCommonShareTables">
        <!--Parent Role: Basic and Diluted Earnings per Common Share-->
        <link:definition>081200 - Disclosure - Basic and Diluted Earnings per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/StockbasedCompensationTables" id="StockbasedCompensationTables">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>081300 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <!--Parent Role: Income Taxes-->
        <link:definition>081500 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperationsDetails" id="OrganizationAndDescriptionOfBusinessOperationsDetails">
        <!--Parent Role: Organization and Description of Business Operations-->
        <link:definition>090100 - Disclosure - Organization and Description of Business Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails" id="LiquidityAndCapitalResourcesDetails">
        <!--Parent Role: Liquidity and Capital Resources-->
        <link:definition>090200 - Disclosure - Liquidity and Capital Resources (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesBasisOfAccountingPresentationDetails" id="BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesBasisOfAccountingPresentationDetails">
        <!--Parent Role: Basis of Accounting Presentation and Summary of Significant Accounting Policies-->
        <link:definition>090300 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies, Basis of Accounting Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" id="BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails">
        <!--Parent Role: Basis of Accounting Presentation and Summary of Significant Accounting Policies-->
        <link:definition>090302 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies, Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <!--Parent Role: Basis of Accounting Presentation and Summary of Significant Accounting Policies-->
        <link:definition>090304 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies, Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesSegmentReportingDetails" id="BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesSegmentReportingDetails">
        <!--Parent Role: Basis of Accounting Presentation and Summary of Significant Accounting Policies-->
        <link:definition>090306 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies, Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails" id="MergerDispositionAndAcquisitionTransactionsMergerDetails">
        <!--Parent Role: Merger, Disposition and Acquisition Transactions-->
        <link:definition>090400 - Disclosure - Merger, Disposition and Acquisition Transactions, Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" id="MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails">
        <!--Parent Role: Merger, Disposition and Acquisition Transactions-->
        <link:definition>090402 - Disclosure - Merger, Disposition and Acquisition Transactions, Fair Value of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails" id="MergerDispositionAndAcquisitionTransactionsDispositionDetails">
        <!--Parent Role: Merger, Disposition and Acquisition Transactions-->
        <link:definition>090404 - Disclosure - Merger, Disposition and Acquisition Transactions, Disposition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsProFormaFinancialInformationDetails" id="MergerDispositionAndAcquisitionTransactionsProFormaFinancialInformationDetails">
        <!--Parent Role: Merger, Disposition and Acquisition Transactions-->
        <link:definition>090406 - Disclosure - Merger, Disposition and Acquisition Transactions, Pro forma Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails" id="MergerDispositionAndAcquisitionTransactionsAcquisitionDetails">
        <!--Parent Role: Merger, Disposition and Acquisition Transactions-->
        <link:definition>090408 - Disclosure - Merger, Disposition and Acquisition Transactions, Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails" id="MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails">
        <!--Parent Role: Merger, Disposition and Acquisition Transactions-->
        <link:definition>090410 - Disclosure - Merger, Disposition and Acquisition Transactions, Investment in NoveCite (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails" id="FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>090500 - Disclosure - Fair Value of Financial Instruments, Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails" id="FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails">
        <!--Parent Role: Fair Value of Financial Instruments-->
        <link:definition>090502 - Disclosure - Fair Value of Financial Instruments, Carrying Amount of Contingent Consideration Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
        <!--Parent Role: Property and Equipment-->
        <link:definition>090600 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/LeasesOperatingLeaseDetails" id="LeasesOperatingLeaseDetails">
        <!--Parent Role: Leases-->
        <link:definition>090700 - Disclosure - Leases, Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails" id="LeasesNetOperatingLeaseExpensesDetails">
        <!--Parent Role: Leases-->
        <link:definition>090702 - Disclosure - Leases, Net Operating Lease Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails" id="LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails">
        <!--Parent Role: Leases-->
        <link:definition>090704 - Disclosure - Leases, Operating Lease Right-of-use Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" id="LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails">
        <!--Parent Role: Leases-->
        <link:definition>090706 - Disclosure - Leases, Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/LeasesSubleaseAgreementDetails" id="LeasesSubleaseAgreementDetails">
        <!--Parent Role: Leases-->
        <link:definition>090708 - Disclosure - Leases, Sublease Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc01" id="LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc01">
        <!--Parent Role: Leases, Maturities of Operating Lease Liabilities (Details)-->
        <link:definition>090708 - Disclosure - LEASES, Maturities of Operating Lease Liabilities (Details) CALC 01</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopmentDetails" id="GoodwillAndInprocessResearchDevelopmentDetails">
        <!--Parent Role: Goodwill and In-Process Research & Development-->
        <link:definition>090800 - Disclosure - Goodwill and In-Process Research &amp; Development (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
        <!--Parent Role: Accrued Expenses-->
        <link:definition>090900 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/DebtDetails" id="DebtDetails">
        <!--Parent Role: Debt-->
        <link:definition>091000 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails" id="CommitmentsAndContingenciesLegalMattersDetails">
        <!--Parent Role: Commitments and Contingencies-->
        <link:definition>091100 - Disclosure - Commitments and Contingencies, Legal Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails" id="CommitmentsAndContingenciesLicensingAgreementsDetails">
        <!--Parent Role: Commitments and Contingencies-->
        <link:definition>091102 - Disclosure - Commitments and Contingencies, Licensing Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails" id="CommitmentsAndContingenciesRoyaltyAgreementsDetails">
        <!--Parent Role: Commitments and Contingencies-->
        <link:definition>091104 - Disclosure - Commitments and Contingencies, Royalty Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails" id="BasicAndDilutedEarningsPerCommonShareDetails">
        <!--Parent Role: Basic and Diluted Earnings per Common Share-->
        <link:definition>091200 - Disclosure - Basic and Diluted Earnings per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails" id="StockbasedCompensationEquityIncentivePlansDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>091300 - Disclosure - Stock-Based Compensation, Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails" id="StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>091302 - Disclosure - Stock-Based Compensation, Weighted-Average Assumptions Used for Grants Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails" id="StockbasedCompensationStockOptionActivityDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>091304 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails" id="StockbasedCompensationSummaryOfStockOptionsDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>091306 - Disclosure - Stock-Based Compensation, Summary of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/StockbasedCompensationRsusDetails" id="StockbasedCompensationRsusDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>091308 - Disclosure - Stock-Based Compensation, RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails" id="StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails">
        <!--Parent Role: Stock-Based Compensation-->
        <link:definition>091310 - Disclosure - Stock-Based Compensation, Restricted Stock and Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails" id="StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails">
        <!--Parent Role: Stockholders' and Members' Equity (Deficit)-->
        <link:definition>091400 - Disclosure - Stockholders' and Members' Equity (Deficit), Private Placement Offerings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitReverseStocksplitDetails" id="StockholdersAndMembersEquityDeficitReverseStocksplitDetails">
        <!--Parent Role: Stockholders' and Members' Equity (Deficit)-->
        <link:definition>091402 - Disclosure - Stockholders' and Members' Equity (Deficit), Reverse Stock-Split (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails" id="StockholdersAndMembersEquityDeficitMergerDetails">
        <!--Parent Role: Stockholders' and Members' Equity (Deficit)-->
        <link:definition>091404 - Disclosure - Stockholders' and Members' Equity (Deficit), Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails" id="StockholdersAndMembersEquityDeficitAcquisitionDetails">
        <!--Parent Role: Stockholders' and Members' Equity (Deficit)-->
        <link:definition>091406 - Disclosure - Stockholders' and Members' Equity (Deficit), Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails" id="StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails">
        <!--Parent Role: Stockholders' and Members' Equity (Deficit)-->
        <link:definition>091408 - Disclosure - Stockholders' and Members' Equity (Deficit), Cumulative Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails" id="IncomeTaxesLossBeforeIncomeTaxesDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>091500 - Disclosure - Income Taxes, Loss before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails" id="IncomeTaxesComponentsOfIncomeTaxProvisionDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>091502 - Disclosure - Income Taxes, Components of Income Tax Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" id="IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>091504 - Disclosure - Income Taxes, Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails" id="IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>091506 - Disclosure - Income Taxes, Reconciliation of Computed Expected Income Taxes to Effective Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/RetirementSavingsPlanDetails" id="RetirementSavingsPlanDetails">
        <!--Parent Role: Retirement Savings Plan-->
        <link:definition>091600 - Disclosure - Retirement Savings Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://brooklynitx.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
        <!--Parent Role: Subsequent Events-->
        <link:definition>091700 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xs:element name="LiquidityAndCapitalResourcesAbstract" id="btx_LiquidityAndCapitalResourcesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LiquidityAndCapitalResourcesTextBlock" id="btx_LiquidityAndCapitalResourcesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PaymentsToAcquireProductiveAssetsNet" id="btx_PaymentsToAcquireProductiveAssetsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="LiquidityAndCapitalResourcesTable" id="btx_LiquidityAndCapitalResourcesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FirstPurchaseAgreementMember" id="btx_FirstPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SecondPurchaseAgreementMember" id="btx_SecondPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NovellusTherapeuticsLimitedMember" id="btx_NovellusTherapeuticsLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LiquidityAndCapitalResourcesLineItems" id="btx_LiquidityAndCapitalResourcesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" id="btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NetIncomeLossAttributableToParentTemporaryElement" id="btx_NetIncomeLossAttributableToParentTemporaryElement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ResearchAndDevelopmentInProcessAssetAcquisition" id="btx_ResearchAndDevelopmentInProcessAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="CommencementPeriodOfCommonStockInPurchaseAgreement" id="btx_CommencementPeriodOfCommonStockInPurchaseAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LincolnParkCapitalFundLLCMember" id="btx_LincolnParkCapitalFundLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" id="btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="RoyaltyAgreementsAbstract" id="btx_RoyaltyAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" id="btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="InvestorRoyaltyAgreementMember" id="btx_InvestorRoyaltyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" id="btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CollaboratorRoyaltyAgreementMember" id="btx_CollaboratorRoyaltyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" id="btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EachLockUpAgreementExtendsTerm" id="btx_EachLockUpAgreementExtendsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfCommonStockSubjectToLockUpAgreement" id="btx_PercentageOfCommonStockSubjectToLockUpAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" id="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommonUnitsMember" id="btx_CommonUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PaycheckProtectionProgramLoanCurrent" id="btx_PaycheckProtectionProgramLoanCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="PaycheckProtectionProgramLoanNonCurrent" id="btx_PaycheckProtectionProgramLoanNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="MembershipEquityMember" id="btx_MembershipEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueStockPurchaseAgreement" id="btx_StockIssuedDuringPeriodValueStockPurchaseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesAcquisitions1" id="btx_StockIssuedDuringPeriodSharesAcquisitions1" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueAcquisitions1" id="btx_StockIssuedDuringPeriodValueAcquisitions1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" id="btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" id="btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" id="btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" id="btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" id="btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueInLieuOfDividends" id="btx_StockIssuedDuringPeriodValueInLieuOfDividends" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" id="btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesInLieuOfDividends" id="btx_StockIssuedDuringPeriodSharesInLieuOfDividends" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodSharesAcquisitions2" id="btx_StockIssuedDuringPeriodSharesAcquisitions2" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueAcquisitions2" id="btx_StockIssuedDuringPeriodValueAcquisitions2" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesStockPurchaseAgreement" id="btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EffectOfImplementationOfNewAccountingPrincipal" id="btx_EffectOfImplementationOfNewAccountingPrincipal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PaymentsOfPaycheckProtectionProgramLoan" id="btx_PaymentsOfPaycheckProtectionProgramLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="GainLossOnDisposalOfFixedAssets" id="btx_GainLossOnDisposalOfFixedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="CashPaidDuringThePeriodForAbstract" id="btx_CashPaidDuringThePeriodForAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" id="btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IssuanceOfCommonStockForSeriesAPreferredStockDividend" id="btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance" id="btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ForfeitureOfUnvestedRestrictedStock" id="btx_ForfeitureOfUnvestedRestrictedStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" id="btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="InvestorDepositsForSaleOfMembersEquity" id="btx_InvestorDepositsForSaleOfMembersEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="InitialMeasurementOfOperatingLeaseLiabilities" id="btx_InitialMeasurementOfOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" id="btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IncreaseDecreaseInOperatingLeaseLiabilities" id="btx_IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="IssuanceOfCommonStockForAssetAcquisition" id="btx_IssuanceOfCommonStockForAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="LaboratoryAndManufacturingEquipmentMember" id="btx_LaboratoryAndManufacturingEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BasisOfPresentationAbstract" id="btx_BasisOfPresentationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NoveCiteINCMember" id="btx_NoveCiteINCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AggregateIntrinsicValueAbstract" id="btx_AggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" id="btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NonQualifiedStockOptionMember" id="btx_NonQualifiedStockOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TimeBasedNonQualifiedStockOptionMember" id="btx_TimeBasedNonQualifiedStockOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PerformanceBasedNonqualifiedStockOptionMember" id="btx_PerformanceBasedNonqualifiedStockOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfStockOptionGrantMade" id="btx_NumberOfStockOptionGrantMade" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" id="btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" id="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" id="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="IncentiveStockOptionsMember" id="btx_IncentiveStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="InducementPlan2021Member" id="btx_InducementPlan2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlan2020Member" id="btx_EquityIncentivePlan2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfSharesOfCommonStockOutstanding" id="btx_PercentageOfSharesOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="PrivatePlacementOfEquityAbstract" id="btx_PrivatePlacementOfEquityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ClassOfWarrantOrRightsExercisableTerm" id="btx_ClassOfWarrantOrRightsExercisableTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NewLeaseAgreementAbstract" id="btx_NewLeaseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BaseRentPerSquareFoot" id="btx_BaseRentPerSquareFoot" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="OperatingLeaseArea" id="btx_OperatingLeaseArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="PercentageBaseRentIncreaseOnEachAnniversary" id="btx_PercentageBaseRentIncreaseOnEachAnniversary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="PIPEInvestorMember" id="btx_PIPEInvestorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" id="btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="LeaseAssignmentAbstract" id="btx_LeaseAssignmentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="UnamortizedLeaseholdImprovements" id="btx_UnamortizedLeaseholdImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="LesseeCommitmentToPurchaseProperty" id="btx_LesseeCommitmentToPurchaseProperty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="PreFundedWarrantsMember" id="btx_PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommonWarrantsMember" id="btx_CommonWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ReverseStockSplitAbstract" id="btx_ReverseStockSplitAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AccruedGeneralAndAdministrativeExpenses" id="btx_AccruedGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="AccruedResearchAndDevelopmentExpenses" id="btx_AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="PrivatePlacementOfferingsAbstract" id="btx_PrivatePlacementOfferingsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" id="btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SaleOfStockNumberOfSharesToIssuedInTransaction" id="btx_SaleOfStockNumberOfSharesToIssuedInTransaction" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="BeneficialOwnershipPercentageOnTotalOutstandingShares" id="btx_BeneficialOwnershipPercentageOnTotalOutstandingShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="CommitmentAmountToMeetAnySingleRegularPurchase" id="btx_CommitmentAmountToMeetAnySingleRegularPurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="PurchaseAgreementMember" id="btx_PurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MergerAbstract" id="btx_MergerAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ClassOfWarrantOrRightIssued" id="btx_ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NTNBuzztimeIncMember" id="btx_NTNBuzztimeIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="UniversityOfSouthFloridaMember" id="btx_UniversityOfSouthFloridaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NovellusLtdAndFactorBioscienceMember" id="btx_NovellusLtdAndFactorBioscienceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NoveCiteMember" id="btx_NoveCiteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LicensingAgreementsAbstract" id="btx_LicensingAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfRevenue" id="btx_PercentageOfRevenue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="LossContingencyPercentageOfRoyaltyPayable" id="btx_LossContingencyPercentageOfRoyaltyPayable" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AmountObligatedToPayInYearTwo" id="btx_AmountObligatedToPayInYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="AdditionalFeesObligatedToPay" id="btx_AdditionalFeesObligatedToPay" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="MinimumNumberOfPatentGranted" id="btx_MinimumNumberOfPatentGranted" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="InitialLicenseFees" id="btx_InitialLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="LossContingencyNonRefundableOptionFee" id="btx_LossContingencyNonRefundableOptionFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="MilestonePayments" id="btx_MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="MinimumNumberOfPendingPatents" id="btx_MinimumNumberOfPendingPatents" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AmountObligatedToPayInYearOne" id="btx_AmountObligatedToPayInYearOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="AmountRequireToPayInitialLicenseFees" id="btx_AmountRequireToPayInitialLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="ContingentConsiderationMember" id="btx_ContingentConsiderationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PaycheckProtectionProgramMember" id="btx_PaycheckProtectionProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BrooklynPaycheckProtectionProgramMember" id="btx_BrooklynPaycheckProtectionProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PaycheckProtectionProgramLoanMember" id="btx_PaycheckProtectionProgramLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentAbstract" id="btx_DebtInstrumentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PaymentOfAccruedAndUnpaidInterest" id="btx_PaymentOfAccruedAndUnpaidInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PercentageOfRoyaltyRevenueAssumedFrom2030To2038" id="btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfWeightedAverageCostOfCapital" id="btx_PercentageOfWeightedAverageCostOfCapital" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" id="btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" id="btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" id="btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfRoyaltyRevenueAssumedUntil2029" id="btx_PercentageOfRoyaltyRevenueAssumedUntil2029" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DheshGovenderMember" id="btx_DheshGovenderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LossContingencyNumberOfArbitrationPanel" id="btx_LossContingencyNumberOfArbitrationPanel" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RobertGarfieldMember" id="btx_RobertGarfieldMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LegalMattersAbstract" id="btx_LegalMattersAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LossContingencyDamagesSoughtExpectedEquityPercentage" id="btx_LossContingencyDamagesSoughtExpectedEquityPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LossContingencyDamagesSoughtExpectedSalary" id="btx_LossContingencyDamagesSoughtExpectedSalary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="AreaOfSubleaseSpaceCurrentlyRented" id="btx_AreaOfSubleaseSpaceCurrentlyRented" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments" id="btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="PrincipalPaymentsOnOperatingLeaseLiabilities" id="btx_PrincipalPaymentsOnOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AdditionOfOperatingLeaseLiability" id="btx_AdditionOfOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="OperatingLeaseAssestAbstract" id="btx_OperatingLeaseAssestAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AdditionOfOperatingLeaseRightofUseAsset" id="btx_AdditionOfOperatingLeaseRightofUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="AnnualRentPerSquareFoot" id="btx_AnnualRentPerSquareFoot" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" id="btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="FutureLeasePaymentsSubleaseAgreementTableTextBlock" id="btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DispositionAbstract" id="btx_DispositionAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ProceedsFromDispositionAbstract" id="btx_ProceedsFromDispositionAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" id="btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" id="btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" id="btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="NTNBusinessMember" id="btx_NTNBusinessMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" id="btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" id="btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="LockUpPeriodForRestrictedShares" id="btx_LockUpPeriodForRestrictedShares" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AcquisitionAgreementNonCompetitivePeriod" id="btx_AcquisitionAgreementNonCompetitivePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfDiscountOnFairValueOfRestrictedShares" id="btx_PercentageOfDiscountOnFairValueOfRestrictedShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AssetAcquisitionRestrictedSharesSharePrice" id="btx_AssetAcquisitionRestrictedSharesSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" id="btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AssetAcquisitionFairValueOfConsiderationPaid" id="btx_AssetAcquisitionFairValueOfConsiderationPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="EscrowPeriod" id="btx_EscrowPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AssetAcquisitionUnrestrictedSharesSharePrice" id="btx_AssetAcquisitionUnrestrictedSharesSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AssetAcquisitionSharePrice" id="btx_AssetAcquisitionSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="StockIssuedDuringPeriodRestrictedSharesAcquisitions" id="btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EscrowShares" id="btx_EscrowShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ObservableTransactionsForIdenticalEquitySecurities" id="btx_ObservableTransactionsForIdenticalEquitySecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="NumberOfBoardSeats" id="btx_NumberOfBoardSeats" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CitiusPharmaceuticalsIncMember" id="btx_CitiusPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" id="btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" id="btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="PercentageOfAdditionalRightsOffering" id="btx_PercentageOfAdditionalRightsOffering" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ProceedsFromSaleOfRights" id="btx_ProceedsFromSaleOfRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" id="btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="BeneficialHoldersContractualCommitmentsToInvest" id="btx_BeneficialHoldersContractualCommitmentsToInvest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ProFormaFairValueAdjustmentToAssetsMember" id="btx_ProFormaFairValueAdjustmentToAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PurchasePriceAllocationProFormaAdjustmentMember" id="btx_PurchasePriceAllocationProFormaAdjustmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" id="btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="IncomeTaxAbstract" id="btx_IncomeTaxAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TaxCutsAndJobsActOperatingLossCarryforwards" id="btx_TaxCutsAndJobsActOperatingLossCarryforwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="TaxCreditCarryforwardExpirationYear" id="btx_TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>btx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxesComponentsOfIncomeTaxProvisionDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxesLossBeforeIncomeTaxesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#AccruedExpensesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc01" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc01" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesSubleaseAgreementDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesSubleaseAgreementDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesNetOperatingLeaseExpensesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactionsAcquisitionDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="btx-20211231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://brooklynitx.com/role/ConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="btx-20211231.xsd#ConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://brooklynitx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="btx-20211231.xsd#ConsolidatedBalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="calculation: Assets to IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="calculation: Assets to OperatingLeaseRightOfUseAsset" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="EquityMethodInvestments" xlink:title="EquityMethodInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="EquityMethodInvestments" xlink:title="calculation: Assets to EquityMethodInvestments" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets" xlink:label="DepositAssets" xlink:title="DepositAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="DepositAssets" xlink:title="calculation: Assets to DepositAssets" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="Cash" xlink:title="calculation: AssetsCurrent to Cash" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="AccountsReceivableNetCurrent" xlink:title="calculation: AssetsCurrent to AccountsReceivableNetCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="Goodwill" xlink:title="calculation: Assets to Goodwill" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="calculation: Liabilities to OtherLiabilitiesNoncurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="calculation: Liabilities to BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaycheckProtectionProgramLoanNonCurrent" xlink:label="PaycheckProtectionProgramLoanNonCurrent" xlink:title="PaycheckProtectionProgramLoanNonCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="PaycheckProtectionProgramLoanNonCurrent" xlink:title="calculation: Liabilities to PaycheckProtectionProgramLoanNonCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaycheckProtectionProgramLoanCurrent" xlink:label="PaycheckProtectionProgramLoanCurrent" xlink:title="PaycheckProtectionProgramLoanCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="PaycheckProtectionProgramLoanCurrent" xlink:title="calculation: LiabilitiesCurrent to PaycheckProtectionProgramLoanCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OtherLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to OtherLiabilitiesCurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to OperatingLeaseLiabilityCurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="LoansPayableCurrent" xlink:title="LoansPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="LoansPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to LoansPayableCurrent" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="calculation: Liabilities to OperatingLeaseLiabilityNoncurrent" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital" xlink:label="MembersCapital" xlink:title="MembersCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="MembersCapital" xlink:title="calculation: StockholdersEquity to MembersCapital" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/ConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="PreferredStockDividendsAndOtherAdjustments" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to PreferredStockDividendsAndOtherAdjustments" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: NetIncomeLoss to IncomeTaxExpenseBenefit" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="calculation: NonoperatingIncomeExpense to OtherNonoperatingIncomeExpense" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="GainLossOnDispositionOfAssets1" xlink:title="calculation: NonoperatingIncomeExpense to GainLossOnDispositionOfAssets1" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to NonoperatingIncomeExpense" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to GeneralAndAdministrativeExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ResearchAndDevelopmentInProcessAssetAcquisition" xlink:label="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="ResearchAndDevelopmentInProcessAssetAcquisition" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentInProcessAssetAcquisition" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:title="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:title="calculation: OperatingExpenses to BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="NoncashMergerRelatedCosts" xlink:title="NoncashMergerRelatedCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="NoncashMergerRelatedCosts" xlink:title="calculation: OperatingExpenses to NoncashMergerRelatedCosts" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="0.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to OperatingIncomeLoss" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="calculation: NetIncomeLoss to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="NetIncomeLoss" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersBasic to NetIncomeLoss" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaymentsOfPaycheckProtectionProgramLoan" xlink:label="PaymentsOfPaycheckProtectionProgramLoan" xlink:title="PaymentsOfPaycheckProtectionProgramLoan" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsOfPaycheckProtectionProgramLoan" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsOfPaycheckProtectionProgramLoan" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromNotesPayable" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromNotesPayable" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="ProceedsFromOtherEquity" xlink:title="ProceedsFromOtherEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromOtherEquity" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromOtherEquity" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromStockOptionsExercised" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="PaymentsOfDividendsPreferredStockAndPreferenceStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsOfDividendsPreferredStockAndPreferenceStock" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="RepaymentsOfNotesPayable" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to RepaymentsOfNotesPayable" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonStock" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaymentsToAcquireProductiveAssetsNet" xlink:label="PaymentsToAcquireProductiveAssetsNet" xlink:title="PaymentsToAcquireProductiveAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquireProductiveAssetsNet" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquireProductiveAssetsNet" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="ProceedsFromDivestitureOfBusinesses" xlink:title="ProceedsFromDivestitureOfBusinesses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromDivestitureOfBusinesses" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromDivestitureOfBusinesses" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSalesOfAssetsInvestingActivities" xlink:label="ProceedsFromSalesOfAssetsInvestingActivities" xlink:title="ProceedsFromSalesOfAssetsInvestingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromSalesOfAssetsInvestingActivities" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromSalesOfAssetsInvestingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInInvestingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:title="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:title="IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOperatingLeaseLiabilities" order="14.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:label="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:title="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnForgivenessOfPaycheckProtectionProgramLoan" order="7.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" xlink:label="IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" xlink:title="IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" order="12.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOtherOperatingLiabilities" order="15.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_GainLossOnDisposalOfFixedAssets" xlink:label="GainLossOnDisposalOfFixedAssets" xlink:title="GainLossOnDisposalOfFixedAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnDisposalOfFixedAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnDisposalOfFixedAssets" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnDispositionOfAssets1" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnDispositionOfAssets1" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsReceivable" order="10.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ResearchAndDevelopmentInProcessAssetAcquisition" xlink:label="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="ResearchAndDevelopmentInProcessAssetAcquisition" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ResearchAndDevelopmentInProcessAssetAcquisition" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to OperatingLeaseRightOfUseAssetAmortizationExpense" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DepreciationDepletionAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DepreciationDepletionAndAmortization" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="NoncashMergerRelatedCosts" xlink:title="NoncashMergerRelatedCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NoncashMergerRelatedCosts" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NoncashMergerRelatedCosts" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AssetAcquisitionFairValueOfConsiderationPaid" xlink:label="AssetAcquisitionFairValueOfConsiderationPaid" xlink:title="AssetAcquisitionFairValueOfConsiderationPaid" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetAcquisitionFairValueOfConsiderationPaid" xlink:to="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:title="calculation: AssetAcquisitionFairValueOfConsiderationPaid to StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetAcquisitionFairValueOfConsiderationPaid" xlink:to="CashAcquiredFromAcquisition" xlink:title="calculation: AssetAcquisitionFairValueOfConsiderationPaid to CashAcquiredFromAcquisition" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetAcquisitionFairValueOfConsiderationPaid" xlink:to="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:title="calculation: AssetAcquisitionFairValueOfConsiderationPaid to StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="PaymentsToAcquireProductiveAssets" xlink:title="PaymentsToAcquireProductiveAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetAcquisitionFairValueOfConsiderationPaid" xlink:to="PaymentsToAcquireProductiveAssets" xlink:title="calculation: AssetAcquisitionFairValueOfConsiderationPaid to PaymentsToAcquireProductiveAssets" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="calculation: PropertyPlantAndEquipmentNet to PropertyPlantAndEquipmentGross" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="calculation: PropertyPlantAndEquipmentNet to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" xlink:title="LeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="SubleaseIncome" xlink:title="calculation: LeaseCost to SubleaseIncome" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="OperatingLeaseCost" xlink:title="calculation: LeaseCost to OperatingLeaseCost" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="VariableLeaseCost" xlink:title="VariableLeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="VariableLeaseCost" xlink:title="calculation: LeaseCost to VariableLeaseCost" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesSubleaseAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" xlink:to="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" xlink:title="calculation: SaleLeasebackTransactionsFutureMinimumSubleaseRentals to SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" xlink:to="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" xlink:title="calculation: SaleLeasebackTransactionsFutureMinimumSubleaseRentals to SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" xlink:to="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" xlink:title="calculation: SaleLeasebackTransactionsFutureMinimumSubleaseRentals to SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" xlink:to="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" xlink:title="calculation: SaleLeasebackTransactionsFutureMinimumSubleaseRentals to SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" xlink:to="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" xlink:title="calculation: SaleLeasebackTransactionsFutureMinimumSubleaseRentals to SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" order="4.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc01">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="OperatingLeaseLiability" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to OperatingLeaseLiability" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/AccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="InterestPayableCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to InterestPayableCurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AccruedResearchAndDevelopmentExpenses" xlink:label="AccruedResearchAndDevelopmentExpenses" xlink:title="AccruedResearchAndDevelopmentExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedResearchAndDevelopmentExpenses" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedResearchAndDevelopmentExpenses" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to EmployeeRelatedLiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AccruedGeneralAndAdministrativeExpenses" xlink:label="AccruedGeneralAndAdministrativeExpenses" xlink:title="AccruedGeneralAndAdministrativeExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedGeneralAndAdministrativeExpenses" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedGeneralAndAdministrativeExpenses" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="CurrentStateAndLocalTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="calculation: CurrentIncomeTaxExpenseBenefit to CurrentStateAndLocalTaxExpenseBenefit" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="CurrentForeignTaxExpenseBenefit" xlink:title="CurrentForeignTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="CurrentForeignTaxExpenseBenefit" xlink:title="calculation: CurrentIncomeTaxExpenseBenefit to CurrentForeignTaxExpenseBenefit" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="CurrentFederalTaxExpenseBenefit" xlink:title="CurrentFederalTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="CurrentFederalTaxExpenseBenefit" xlink:title="calculation: CurrentIncomeTaxExpenseBenefit to CurrentFederalTaxExpenseBenefit" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="CurrentIncomeTaxExpenseBenefit" xlink:title="calculation: IncomeTaxExpenseBenefit to CurrentIncomeTaxExpenseBenefit" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="DeferredForeignIncomeTaxExpenseBenefit" xlink:title="DeferredForeignIncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="DeferredForeignIncomeTaxExpenseBenefit" xlink:title="calculation: DeferredIncomeTaxExpenseBenefit to DeferredForeignIncomeTaxExpenseBenefit" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="DeferredFederalIncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="calculation: DeferredIncomeTaxExpenseBenefit to DeferredFederalIncomeTaxExpenseBenefit" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="calculation: DeferredIncomeTaxExpenseBenefit to DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="DeferredIncomeTaxExpenseBenefit" xlink:title="calculation: IncomeTaxExpenseBenefit to DeferredIncomeTaxExpenseBenefit" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" xlink:label="EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" xlink:title="EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" xlink:title="calculation: IncomeTaxExpenseBenefit to EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsGross" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsGross" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsValuationAllowance" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="DeferredTaxAssetsNet" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNet to DeferredTaxAssetsNet" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="DeferredTaxLiabilities" xlink:title="DeferredTaxLiabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:title="DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxLiabilities" xlink:to="DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:title="calculation: DeferredTaxLiabilities to DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxLiabilities" xlink:to="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="calculation: DeferredTaxLiabilities to DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="DeferredTaxLiabilities" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNet to DeferredTaxLiabilities" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationTaxCredits" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:title="EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="6.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>btx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://brooklynitx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/RetirementSavingsPlanDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#RetirementSavingsPlanDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxesComponentsOfIncomeTaxProvisionDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxesLossBeforeIncomeTaxesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockholdersAndMembersEquityDeficitAcquisitionDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockholdersAndMembersEquityDeficitMergerDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitReverseStocksplitDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockholdersAndMembersEquityDeficitReverseStocksplitDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensationRsusDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensationRsusDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensationSummaryOfStockOptionsDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensationStockOptionActivityDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensationEquityIncentivePlansDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#BasicAndDilutedEarningsPerCommonShareDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#CommitmentsAndContingenciesRoyaltyAgreementsDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#CommitmentsAndContingenciesLicensingAgreementsDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#CommitmentsAndContingenciesLegalMattersDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/DebtDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#DebtDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#AccruedExpensesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopmentDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#GoodwillAndInprocessResearchDevelopmentDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc01" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc01" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesSubleaseAgreementDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesSubleaseAgreementDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesNetOperatingLeaseExpensesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesOperatingLeaseDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesOperatingLeaseDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactionsAcquisitionDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactionsProFormaFinancialInformationDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactionsDispositionDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactionsMergerDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesSegmentReportingDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesSegmentReportingDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesBasisOfAccountingPresentationDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesBasisOfAccountingPresentationDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#LiquidityAndCapitalResourcesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperationsDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#OrganizationAndDescriptionOfBusinessOperationsDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareTables" xlink:type="simple" xlink:href="btx-20211231.xsd#BasicAndDilutedEarningsPerCommonShareTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="btx-20211231.xsd#AccruedExpensesTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesTables" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="btx-20211231.xsd#PropertyAndEquipmentTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="btx-20211231.xsd#FairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsTables" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactionsTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="btx-20211231.xsd#BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://brooklynitx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="btx-20211231.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://brooklynitx.com/role/RetirementSavingsPlan" xlink:type="simple" xlink:href="btx-20211231.xsd#RetirementSavingsPlan" />
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficit" xlink:type="simple" xlink:href="btx-20211231.xsd#StockholdersAndMembersEquityDeficit" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShare" xlink:type="simple" xlink:href="btx-20211231.xsd#BasicAndDilutedEarningsPerCommonShare" />
  <link:roleRef roleURI="http://brooklynitx.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="btx-20211231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://brooklynitx.com/role/Debt" xlink:type="simple" xlink:href="btx-20211231.xsd#Debt" />
  <link:roleRef roleURI="http://brooklynitx.com/role/AccruedExpenses" xlink:type="simple" xlink:href="btx-20211231.xsd#AccruedExpenses" />
  <link:roleRef roleURI="http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopment" xlink:type="simple" xlink:href="btx-20211231.xsd#GoodwillAndInprocessResearchDevelopment" />
  <link:roleRef roleURI="http://brooklynitx.com/role/Leases" xlink:type="simple" xlink:href="btx-20211231.xsd#Leases" />
  <link:roleRef roleURI="http://brooklynitx.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="btx-20211231.xsd#PropertyAndEquipment" />
  <link:roleRef roleURI="http://brooklynitx.com/role/FairValueOfFinancialInstruments" xlink:type="simple" xlink:href="btx-20211231.xsd#FairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactions" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactions" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="btx-20211231.xsd#BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LiquidityAndCapitalResources" xlink:type="simple" xlink:href="btx-20211231.xsd#LiquidityAndCapitalResources" />
  <link:roleRef roleURI="http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperations" xlink:type="simple" xlink:href="btx-20211231.xsd#OrganizationAndDescriptionOfBusinessOperations" />
  <link:roleRef roleURI="http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="btx-20211231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit" xlink:type="simple" xlink:href="btx-20211231.xsd#ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit" />
  <link:roleRef roleURI="http://brooklynitx.com/role/ConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="btx-20211231.xsd#ConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="btx-20211231.xsd#ConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://brooklynitx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="btx-20211231.xsd#ConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://brooklynitx.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="btx-20211231.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AssetsAbstract" xlink:title="definition: StatementLineItems to AssetsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="definition: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesCurrentAbstract" xlink:title="definition: StatementLineItems to LiabilitiesCurrentAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="definition: StatementLineItems to BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="definition: StatementLineItems to OperatingLeaseLiabilityNoncurrent" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaycheckProtectionProgramLoanNonCurrent" xlink:label="PaycheckProtectionProgramLoanNonCurrent" xlink:title="PaycheckProtectionProgramLoanNonCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PaycheckProtectionProgramLoanNonCurrent" xlink:title="definition: StatementLineItems to PaycheckProtectionProgramLoanNonCurrent" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="definition: StatementLineItems to OtherLiabilitiesNoncurrent" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="Liabilities" xlink:title="definition: StatementLineItems to Liabilities" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EquityAbstract" xlink:title="definition: StatementLineItems to EquityAbstract" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="definition: StatementLineItems to LiabilitiesAndStockholdersEquity" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital" xlink:label="MembersCapital" xlink:title="MembersCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="MembersCapital" xlink:title="definition: StatementLineItems to MembersCapital" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockValue" xlink:title="definition: StatementLineItems to PreferredStockValue" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockValue" xlink:title="definition: StatementLineItems to CommonStockValue" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdditionalPaidInCapital" xlink:title="definition: StatementLineItems to AdditionalPaidInCapital" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="definition: StatementLineItems to RetainedEarningsAccumulatedDeficit" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccountsPayableCurrent" xlink:title="definition: StatementLineItems to AccountsPayableCurrent" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccruedLiabilitiesCurrent" xlink:title="definition: StatementLineItems to AccruedLiabilitiesCurrent" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="LoansPayableCurrent" xlink:title="LoansPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LoansPayableCurrent" xlink:title="definition: StatementLineItems to LoansPayableCurrent" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaycheckProtectionProgramLoanCurrent" xlink:label="PaycheckProtectionProgramLoanCurrent" xlink:title="PaycheckProtectionProgramLoanCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PaycheckProtectionProgramLoanCurrent" xlink:title="definition: StatementLineItems to PaycheckProtectionProgramLoanCurrent" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="definition: StatementLineItems to OperatingLeaseLiabilityCurrent" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherLiabilitiesCurrent" xlink:title="definition: StatementLineItems to OtherLiabilitiesCurrent" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesCurrent" xlink:title="definition: StatementLineItems to LiabilitiesCurrent" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AssetsCurrentAbstract" xlink:title="definition: StatementLineItems to AssetsCurrentAbstract" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: StatementLineItems to PropertyPlantAndEquipmentNet" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="definition: StatementLineItems to OperatingLeaseRightOfUseAsset" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="Goodwill" xlink:title="definition: StatementLineItems to Goodwill" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="definition: StatementLineItems to IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="EquityMethodInvestments" xlink:title="EquityMethodInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EquityMethodInvestments" xlink:title="definition: StatementLineItems to EquityMethodInvestments" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets" xlink:label="DepositAssets" xlink:title="DepositAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DepositAssets" xlink:title="definition: StatementLineItems to DepositAssets" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="Assets" xlink:title="definition: StatementLineItems to Assets" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="Cash" xlink:title="definition: StatementLineItems to Cash" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccountsReceivableNetCurrent" xlink:title="definition: StatementLineItems to AccountsReceivableNetCurrent" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="definition: StatementLineItems to PrepaidExpenseAndOtherAssetsCurrent" order="34.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AssetsCurrent" xlink:title="definition: StatementLineItems to AssetsCurrent" order="35.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="36.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassAMember" xlink:title="definition: ClassOfStockDomain to CommonClassAMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassBMember" xlink:title="definition: ClassOfStockDomain to CommonClassBMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="definition: ClassOfStockDomain to CommonClassCMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CommonUnitsMember" xlink:label="CommonUnitsMember" xlink:title="CommonUnitsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonUnitsMember" xlink:title="definition: ClassOfStockDomain to CommonUnitsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesAPreferredStockMember" order="5.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/ConsolidatedStatementsOfOperations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:label="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:title="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:label="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:title="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueAcquisitions1" xlink:label="StockIssuedDuringPeriodValueAcquisitions1" xlink:title="StockIssuedDuringPeriodValueAcquisitions1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueAcquisitions1" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueAcquisitions1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesAcquisitions1" xlink:label="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="StockIssuedDuringPeriodSharesAcquisitions1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesAcquisitions1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:label="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:label="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnersCapitalAccountAcquisitions" xlink:label="PartnersCapitalAccountAcquisitions" xlink:title="PartnersCapitalAccountAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PartnersCapitalAccountAcquisitions" xlink:title="definition: StatementLineItems to PartnersCapitalAccountAcquisitions" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnersCapitalAccountUnitsAcquisitions" xlink:label="PartnersCapitalAccountUnitsAcquisitions" xlink:title="PartnersCapitalAccountUnitsAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PartnersCapitalAccountUnitsAcquisitions" xlink:title="definition: StatementLineItems to PartnersCapitalAccountUnitsAcquisitions" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueAcquisitions" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesAcquisitions" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockOptionsExercised" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodValueStockPurchaseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockPurchaseAgreement" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodSharesStockPurchaseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockPurchaseAgreement" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="StockIssuedDuringPeriodValueAcquisitions2" xlink:title="StockIssuedDuringPeriodValueAcquisitions2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueAcquisitions2" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueAcquisitions2" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="StockIssuedDuringPeriodSharesAcquisitions2" xlink:title="StockIssuedDuringPeriodSharesAcquisitions2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions2" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesAcquisitions2" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="DividendsPreferredStockCash" xlink:title="DividendsPreferredStockCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DividendsPreferredStockCash" xlink:title="definition: StatementLineItems to DividendsPreferredStockCash" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="PreferredStockDividendsShares" xlink:title="PreferredStockDividendsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PreferredStockDividendsShares" xlink:title="definition: StatementLineItems to PreferredStockDividendsShares" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueInLieuOfDividends" xlink:label="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:title="StockIssuedDuringPeriodValueInLieuOfDividends" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueInLieuOfDividends" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:label="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:title="StockIssuedDuringPeriodSharesInLieuOfDividends" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesInLieuOfDividends" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:label="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:title="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:label="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:title="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:title="definition: StatementLineItems to SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EffectOfImplementationOfNewAccountingPrincipal" xlink:label="EffectOfImplementationOfNewAccountingPrincipal" xlink:title="EffectOfImplementationOfNewAccountingPrincipal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EffectOfImplementationOfNewAccountingPrincipal" xlink:title="definition: StatementLineItems to EffectOfImplementationOfNewAccountingPrincipal" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="StockholdersEquityOther" xlink:title="StockholdersEquityOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityOther" xlink:title="definition: StatementLineItems to StockholdersEquityOther" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="30.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_MembershipEquityMember" xlink:label="MembershipEquityMember" xlink:title="MembershipEquityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="MembershipEquityMember" xlink:title="definition: EquityComponentDomain to MembershipEquityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="PreferredStockMember" xlink:title="definition: EquityComponentDomain to PreferredStockMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: StatementTable to StatementClassOfStockAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassAMember" xlink:title="definition: ClassOfStockDomain to CommonClassAMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassBMember" xlink:title="definition: ClassOfStockDomain to CommonClassBMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="definition: ClassOfStockDomain to CommonClassCMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CommonUnitsMember" xlink:label="CommonUnitsMember" xlink:title="CommonUnitsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonUnitsMember" xlink:title="definition: ClassOfStockDomain to CommonUnitsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesAPreferredStockMember" order="5.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LiquidityAndCapitalResources" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactions" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/FairValueOfFinancialInstruments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/PropertyAndEquipment" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/Leases" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopment" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/AccruedExpenses" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/Debt" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/CommitmentsAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShare" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficit" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/RetirementSavingsPlan" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/SubsequentEvents" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/FairValueOfFinancialInstrumentsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/PropertyAndEquipmentTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/AccruedExpensesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationDescriptionAbstract" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="definition: BusinessAcquisitionLineItems to EquityMethodInvestmentOwnershipPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="BusinessAcquisitionLineItems" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="definition: BusinessAcquisitionLineItems to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NoveCiteINCMember" xlink:label="NoveCiteINCMember" xlink:title="NoveCiteINCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NoveCiteINCMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to NoveCiteINCMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails">
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LiquidityAndCapitalResourcesLineItems" xlink:label="LiquidityAndCapitalResourcesLineItems" xlink:title="LiquidityAndCapitalResourcesLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:label="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:title="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="Cash" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to Cash" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to RetainedEarningsAccumulatedDeficit" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NetIncomeLossAttributableToParentTemporaryElement" xlink:label="NetIncomeLossAttributableToParentTemporaryElement" xlink:title="NetIncomeLossAttributableToParentTemporaryElement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="NetIncomeLossAttributableToParentTemporaryElement" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to NetIncomeLossAttributableToParentTemporaryElement" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to NetCashProvidedByUsedInOperatingActivities" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ResearchAndDevelopmentInProcessAssetAcquisition" xlink:label="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="ResearchAndDevelopmentInProcessAssetAcquisition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to ResearchAndDevelopmentInProcessAssetAcquisition" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="GainLossOnDispositionOfAssets1" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to GainLossOnDispositionOfAssets1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:title="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to ProceedsFromIssuanceOfCommonStock" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CommencementPeriodOfCommonStockInPurchaseAgreement" xlink:label="CommencementPeriodOfCommonStockInPurchaseAgreement" xlink:title="CommencementPeriodOfCommonStockInPurchaseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="CommencementPeriodOfCommonStockInPurchaseAgreement" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to CommencementPeriodOfCommonStockInPurchaseAgreement" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to SaleOfStockNumberOfSharesIssuedInTransaction" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to ProceedsFromIssuanceOrSaleOfEquity" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaymentsToAcquireProductiveAssetsNet" xlink:label="PaymentsToAcquireProductiveAssetsNet" xlink:title="PaymentsToAcquireProductiveAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="PaymentsToAcquireProductiveAssetsNet" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to PaymentsToAcquireProductiveAssetsNet" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to ProceedsFromIssuanceOfPrivatePlacement" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LiquidityAndCapitalResourcesTable" xlink:label="LiquidityAndCapitalResourcesTable" xlink:title="LiquidityAndCapitalResourcesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="LiquidityAndCapitalResourcesTable" xlink:title="definition: LiquidityAndCapitalResourcesLineItems to LiquidityAndCapitalResourcesTable" order="15.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LiquidityAndCapitalResourcesTable" xlink:to="LegalEntityAxis" xlink:title="definition: LiquidityAndCapitalResourcesTable to LegalEntityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LincolnParkCapitalFundLLCMember" xlink:label="LincolnParkCapitalFundLLCMember" xlink:title="LincolnParkCapitalFundLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="LincolnParkCapitalFundLLCMember" xlink:title="definition: EntityDomain to LincolnParkCapitalFundLLCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LiquidityAndCapitalResourcesTable" xlink:to="AssetAcquisitionAxis" xlink:title="definition: LiquidityAndCapitalResourcesTable to AssetAcquisitionAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain" xlink:title="definition: AssetAcquisitionAxis to AssetAcquisitionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain_2" xlink:title="AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain_2" xlink:title="definition: AssetAcquisitionAxis to AssetAcquisitionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetAcquisitionDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="definition: AssetAcquisitionDomain to NovellusTherapeuticsLimitedMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LiquidityAndCapitalResourcesTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: LiquidityAndCapitalResourcesTable to TypeOfArrangementAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_FirstPurchaseAgreementMember" xlink:label="FirstPurchaseAgreementMember" xlink:title="FirstPurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="FirstPurchaseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to FirstPurchaseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SecondPurchaseAgreementMember" xlink:label="SecondPurchaseAgreementMember" xlink:title="SecondPurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SecondPurchaseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to SecondPurchaseAgreementMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LiquidityAndCapitalResourcesTable" xlink:to="RangeAxis" xlink:title="definition: LiquidityAndCapitalResourcesTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LiquidityAndCapitalResourcesTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: LiquidityAndCapitalResourcesTable to SubsequentEventTypeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesBasisOfAccountingPresentationDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetByTypeAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LaboratoryAndManufacturingEquipmentMember" xlink:label="LaboratoryAndManufacturingEquipmentMember" xlink:title="LaboratoryAndManufacturingEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LaboratoryAndManufacturingEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LaboratoryAndManufacturingEquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to ComputerEquipmentMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesSegmentReportingDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationDescriptionAbstract" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:title="BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodSharesIssuedForServices" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="BusinessAcquisitionSharePrice" xlink:title="BusinessAcquisitionSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionSharePrice" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionSharePrice" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="definition: BusinessAcquisitionLineItems to CommonStockSharesOutstanding" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="Goodwill" xlink:title="definition: BusinessAcquisitionLineItems to Goodwill" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="BusinessAcquisitionLineItems" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="definition: BusinessAcquisitionLineItems to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NTNBuzztimeIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to NTNBuzztimeIncMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:label="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:title="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:title="definition: BusinessAcquisitionLineItems to ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BeneficialHoldersContractualCommitmentsToInvest" xlink:label="BeneficialHoldersContractualCommitmentsToInvest" xlink:title="BeneficialHoldersContractualCommitmentsToInvest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BeneficialHoldersContractualCommitmentsToInvest" xlink:title="definition: BusinessAcquisitionLineItems to BeneficialHoldersContractualCommitmentsToInvest" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfAdditionalRightsOffering" xlink:label="PercentageOfAdditionalRightsOffering" xlink:title="PercentageOfAdditionalRightsOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="PercentageOfAdditionalRightsOffering" xlink:title="definition: BusinessAcquisitionLineItems to PercentageOfAdditionalRightsOffering" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ProceedsFromSaleOfRights" xlink:label="ProceedsFromSaleOfRights" xlink:title="ProceedsFromSaleOfRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ProceedsFromSaleOfRights" xlink:title="definition: BusinessAcquisitionLineItems to ProceedsFromSaleOfRights" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="definition: BusinessAcquisitionLineItems to BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="Goodwill" xlink:title="definition: BusinessAcquisitionLineItems to Goodwill" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="BusinessAcquisitionLineItems" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="definition: BusinessAcquisitionLineItems to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="16.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NTNBuzztimeIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to NTNBuzztimeIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="NonrecurringAdjustmentAxis" xlink:title="NonrecurringAdjustmentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="NonrecurringAdjustmentAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to NonrecurringAdjustmentAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="NonrecurringAdjustmentDomain" xlink:title="NonrecurringAdjustmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="NonrecurringAdjustmentAxis" xlink:to="NonrecurringAdjustmentDomain" xlink:title="definition: NonrecurringAdjustmentAxis to NonrecurringAdjustmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="NonrecurringAdjustmentDomain_2" xlink:title="NonrecurringAdjustmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NonrecurringAdjustmentAxis" xlink:to="NonrecurringAdjustmentDomain_2" xlink:title="definition: NonrecurringAdjustmentAxis to NonrecurringAdjustmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ProFormaFairValueAdjustmentToAssetsMember" xlink:label="ProFormaFairValueAdjustmentToAssetsMember" xlink:title="ProFormaFairValueAdjustmentToAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonrecurringAdjustmentDomain" xlink:to="ProFormaFairValueAdjustmentToAssetsMember" xlink:title="definition: NonrecurringAdjustmentDomain to ProFormaFairValueAdjustmentToAssetsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PurchasePriceAllocationProFormaAdjustmentMember" xlink:label="PurchasePriceAllocationProFormaAdjustmentMember" xlink:title="PurchasePriceAllocationProFormaAdjustmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonrecurringAdjustmentDomain" xlink:to="PurchasePriceAllocationProFormaAdjustmentMember" xlink:title="definition: NonrecurringAdjustmentDomain to PurchasePriceAllocationProFormaAdjustmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="CustomerRelationshipsMember" xlink:title="CustomerRelationshipsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="CustomerRelationshipsMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to CustomerRelationshipsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="TradeNamesMember" xlink:title="TradeNamesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TradeNamesMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to TradeNamesMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DispositionAbstract" xlink:label="DispositionAbstract" xlink:title="DispositionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DispositionAbstract" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DispositionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:title="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ProceedsFromDispositionAbstract" xlink:label="ProceedsFromDispositionAbstract" xlink:title="ProceedsFromDispositionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ProceedsFromDispositionAbstract" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to ProceedsFromDispositionAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:label="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:title="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationTransactionCosts" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:title="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:label="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:title="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:label="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:title="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:label="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:title="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationLeaseLiability" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:label="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:title="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:title="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:title="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:title="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:title="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:label="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:title="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:title="DisposalGroupIncludingDiscontinuedOperationGoodwill1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationGoodwill1" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationOtherAssets" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="25.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:title="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis to DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" xlink:title="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis to DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NTNBusinessMember" xlink:label="NTNBusinessMember" xlink:title="NTNBusinessMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="NTNBusinessMember" xlink:title="definition: DisposalGroupsIncludingDiscontinuedOperationsNameDomain to NTNBusinessMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="definition: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="CustomerRelationshipsMember" xlink:title="CustomerRelationshipsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="CustomerRelationshipsMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to CustomerRelationshipsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="TradeNamesMember" xlink:title="TradeNamesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TradeNamesMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to TradeNamesMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsProFormaFinancialInformationDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationDescriptionAbstract" xlink:title="definition: BusinessAcquisitionLineItems to BusinessCombinationDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="definition: BusinessAcquisitionLineItems to EquityMethodInvestmentOwnershipPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="AssetAcquisitionConsiderationTransferred" xlink:title="AssetAcquisitionConsiderationTransferred" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="AssetAcquisitionConsiderationTransferred" xlink:title="definition: BusinessAcquisitionLineItems to AssetAcquisitionConsiderationTransferred" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="PaymentsToAcquireOtherProductiveAssets" xlink:title="PaymentsToAcquireOtherProductiveAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="PaymentsToAcquireOtherProductiveAssets" xlink:title="definition: BusinessAcquisitionLineItems to PaymentsToAcquireOtherProductiveAssets" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodSharesAcquisitions" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodValueAcquisitions" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AssetAcquisitionSharePrice" xlink:label="AssetAcquisitionSharePrice" xlink:title="AssetAcquisitionSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="AssetAcquisitionSharePrice" xlink:title="definition: BusinessAcquisitionLineItems to AssetAcquisitionSharePrice" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EscrowShares" xlink:label="EscrowShares" xlink:title="EscrowShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="EscrowShares" xlink:title="definition: BusinessAcquisitionLineItems to EscrowShares" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EscrowPeriod" xlink:label="EscrowPeriod" xlink:title="EscrowPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="EscrowPeriod" xlink:title="definition: BusinessAcquisitionLineItems to EscrowPeriod" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AcquisitionAgreementNonCompetitivePeriod" xlink:label="AcquisitionAgreementNonCompetitivePeriod" xlink:title="AcquisitionAgreementNonCompetitivePeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="AcquisitionAgreementNonCompetitivePeriod" xlink:title="definition: BusinessAcquisitionLineItems to AcquisitionAgreementNonCompetitivePeriod" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodSharesIssuedForServices" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EachLockUpAgreementExtendsTerm" xlink:label="EachLockUpAgreementExtendsTerm" xlink:title="EachLockUpAgreementExtendsTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="EachLockUpAgreementExtendsTerm" xlink:title="definition: BusinessAcquisitionLineItems to EachLockUpAgreementExtendsTerm" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfCommonStockSubjectToLockUpAgreement" xlink:label="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:title="PercentageOfCommonStockSubjectToLockUpAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:title="definition: BusinessAcquisitionLineItems to PercentageOfCommonStockSubjectToLockUpAgreement" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaymentsToAcquireProductiveAssetsNet" xlink:label="PaymentsToAcquireProductiveAssetsNet" xlink:title="PaymentsToAcquireProductiveAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="PaymentsToAcquireProductiveAssetsNet" xlink:title="definition: BusinessAcquisitionLineItems to PaymentsToAcquireProductiveAssetsNet" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LockUpPeriodForRestrictedShares" xlink:label="LockUpPeriodForRestrictedShares" xlink:title="LockUpPeriodForRestrictedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="LockUpPeriodForRestrictedShares" xlink:title="definition: BusinessAcquisitionLineItems to LockUpPeriodForRestrictedShares" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AssetAcquisitionUnrestrictedSharesSharePrice" xlink:label="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:title="AssetAcquisitionUnrestrictedSharesSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:title="definition: BusinessAcquisitionLineItems to AssetAcquisitionUnrestrictedSharesSharePrice" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:label="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:title="StockIssuedDuringPeriodRestrictedSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodRestrictedSharesAcquisitions" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AssetAcquisitionRestrictedSharesSharePrice" xlink:label="AssetAcquisitionRestrictedSharesSharePrice" xlink:title="AssetAcquisitionRestrictedSharesSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="AssetAcquisitionRestrictedSharesSharePrice" xlink:title="definition: BusinessAcquisitionLineItems to AssetAcquisitionRestrictedSharesSharePrice" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:label="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:title="PercentageOfDiscountOnFairValueOfRestrictedShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:title="definition: BusinessAcquisitionLineItems to PercentageOfDiscountOnFairValueOfRestrictedShares" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="PaymentsToAcquireProductiveAssets" xlink:title="PaymentsToAcquireProductiveAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="PaymentsToAcquireProductiveAssets" xlink:title="definition: BusinessAcquisitionLineItems to PaymentsToAcquireProductiveAssets" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="CashAcquiredFromAcquisition" xlink:title="definition: BusinessAcquisitionLineItems to CashAcquiredFromAcquisition" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:title="definition: BusinessAcquisitionLineItems to StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AssetAcquisitionFairValueOfConsiderationPaid" xlink:label="AssetAcquisitionFairValueOfConsiderationPaid" xlink:title="AssetAcquisitionFairValueOfConsiderationPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="AssetAcquisitionFairValueOfConsiderationPaid" xlink:title="definition: BusinessAcquisitionLineItems to AssetAcquisitionFairValueOfConsiderationPaid" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="PaymentsToAcquireInvestments" xlink:title="PaymentsToAcquireInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="PaymentsToAcquireInvestments" xlink:title="definition: BusinessAcquisitionLineItems to PaymentsToAcquireInvestments" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ResearchAndDevelopmentInProcessAssetAcquisition" xlink:label="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="ResearchAndDevelopmentInProcessAssetAcquisition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="definition: BusinessAcquisitionLineItems to ResearchAndDevelopmentInProcessAssetAcquisition" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="BusinessAcquisitionLineItems" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="definition: BusinessAcquisitionLineItems to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="28.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NoveCiteINCMember" xlink:label="NoveCiteINCMember" xlink:title="NoveCiteINCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NoveCiteINCMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to NoveCiteINCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="AssetAcquisitionAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to AssetAcquisitionAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain" xlink:title="definition: AssetAcquisitionAxis to AssetAcquisitionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain_2" xlink:title="AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain_2" xlink:title="definition: AssetAcquisitionAxis to AssetAcquisitionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetAcquisitionDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="definition: AssetAcquisitionDomain to NovellusTherapeuticsLimitedMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:label="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:title="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:title="definition: RelatedPartyDomain to ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAbstract" xlink:label="InvestmentsAbstract" xlink:title="InvestmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="InvestmentsAbstract" xlink:title="definition: BusinessAcquisitionLineItems to InvestmentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="definition: BusinessAcquisitionLineItems to EquityMethodInvestmentOwnershipPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="definition: BusinessAcquisitionLineItems to MinorityInterestOwnershipPercentageByParent" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NumberOfBoardSeats" xlink:label="NumberOfBoardSeats" xlink:title="NumberOfBoardSeats" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="NumberOfBoardSeats" xlink:title="definition: BusinessAcquisitionLineItems to NumberOfBoardSeats" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="EquityMethodInvestments" xlink:title="EquityMethodInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="EquityMethodInvestments" xlink:title="definition: BusinessAcquisitionLineItems to EquityMethodInvestments" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ObservableTransactionsForIdenticalEquitySecurities" xlink:label="ObservableTransactionsForIdenticalEquitySecurities" xlink:title="ObservableTransactionsForIdenticalEquitySecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ObservableTransactionsForIdenticalEquitySecurities" xlink:title="definition: BusinessAcquisitionLineItems to ObservableTransactionsForIdenticalEquitySecurities" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="BusinessAcquisitionLineItems" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="definition: BusinessAcquisitionLineItems to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NoveCiteINCMember" xlink:label="NoveCiteINCMember" xlink:title="NoveCiteINCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NoveCiteINCMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to NoveCiteINCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="OwnershipAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to OwnershipAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="definition: OwnershipAxis to OwnershipDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain_2" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain_2" xlink:title="definition: OwnershipAxis to OwnershipDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CitiusPharmaceuticalsIncMember" xlink:label="CitiusPharmaceuticalsIncMember" xlink:title="CitiusPharmaceuticalsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OwnershipDomain" xlink:to="CitiusPharmaceuticalsIncMember" xlink:title="definition: OwnershipDomain to CitiusPharmaceuticalsIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="LiabilitiesFairValueDisclosureAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to LiabilitiesFairValueDisclosureAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="LiabilitiesFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to LiabilitiesFairValueDisclosure" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="ContingentConsiderationByTypeAxis" xlink:title="ContingentConsiderationByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ContingentConsiderationByTypeAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ContingentConsiderationByTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="ContingentConsiderationTypeDomain" xlink:title="ContingentConsiderationTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ContingentConsiderationByTypeAxis" xlink:to="ContingentConsiderationTypeDomain" xlink:title="definition: ContingentConsiderationByTypeAxis to ContingentConsiderationTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="ContingentConsiderationTypeDomain_2" xlink:title="ContingentConsiderationTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ContingentConsiderationByTypeAxis" xlink:to="ContingentConsiderationTypeDomain_2" xlink:title="definition: ContingentConsiderationByTypeAxis to ContingentConsiderationTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ContingentConsiderationMember" xlink:label="ContingentConsiderationMember" xlink:title="ContingentConsiderationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ContingentConsiderationTypeDomain" xlink:to="ContingentConsiderationMember" xlink:title="definition: ContingentConsiderationTypeDomain to ContingentConsiderationMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="LiabilitiesFairValueDisclosureAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to LiabilitiesFairValueDisclosureAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRoyaltyRevenueAssumedUntil2029" xlink:label="PercentageOfRoyaltyRevenueAssumedUntil2029" xlink:title="PercentageOfRoyaltyRevenueAssumedUntil2029" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="PercentageOfRoyaltyRevenueAssumedUntil2029" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to PercentageOfRoyaltyRevenueAssumedUntil2029" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038" xlink:label="PercentageOfRoyaltyRevenueAssumedFrom2030To2038" xlink:title="PercentageOfRoyaltyRevenueAssumedFrom2030To2038" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="PercentageOfRoyaltyRevenueAssumedFrom2030To2038" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to PercentageOfRoyaltyRevenueAssumedFrom2030To2038" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" xlink:label="PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" xlink:title="PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" xlink:label="PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" xlink:title="PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" xlink:label="PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" xlink:title="PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfWeightedAverageCostOfCapital" xlink:label="PercentageOfWeightedAverageCostOfCapital" xlink:title="PercentageOfWeightedAverageCostOfCapital" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="PercentageOfWeightedAverageCostOfCapital" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to PercentageOfWeightedAverageCostOfCapital" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="LiabilitiesFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to LiabilitiesFairValueDisclosure" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="LiabilitiesFairValueAdjustment" xlink:title="LiabilitiesFairValueAdjustment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="LiabilitiesFairValueAdjustment" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to LiabilitiesFairValueAdjustment" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="ContingentConsiderationByTypeAxis" xlink:title="ContingentConsiderationByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ContingentConsiderationByTypeAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ContingentConsiderationByTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="ContingentConsiderationTypeDomain" xlink:title="ContingentConsiderationTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ContingentConsiderationByTypeAxis" xlink:to="ContingentConsiderationTypeDomain" xlink:title="definition: ContingentConsiderationByTypeAxis to ContingentConsiderationTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="ContingentConsiderationTypeDomain_2" xlink:title="ContingentConsiderationTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ContingentConsiderationByTypeAxis" xlink:to="ContingentConsiderationTypeDomain_2" xlink:title="definition: ContingentConsiderationByTypeAxis to ContingentConsiderationTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ContingentConsiderationMember" xlink:label="ContingentConsiderationMember" xlink:title="ContingentConsiderationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ContingentConsiderationTypeDomain" xlink:to="ContingentConsiderationMember" xlink:title="definition: ContingentConsiderationTypeDomain to ContingentConsiderationMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:label="PropertyPlantAndEquipmentGrossAbstract" xlink:title="PropertyPlantAndEquipmentGrossAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentGrossAbstract" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentGrossAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentGross" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="definition: PropertyPlantAndEquipmentLineItems to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNet" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="Depreciation" xlink:title="definition: PropertyPlantAndEquipmentLineItems to Depreciation" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to EquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LeaseholdImprovementsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to ComputerEquipmentMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesOperatingLeaseDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesSubleaseAgreementDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc01" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopmentDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/AccruedExpensesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/DebtDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DebtInstrumentAbstract" xlink:label="DebtInstrumentAbstract" xlink:title="DebtInstrumentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentAbstract" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="LoansPayableCurrent" xlink:title="LoansPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LoansPayableCurrent" xlink:title="definition: DebtInstrumentLineItems to LoansPayableCurrent" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="RepaymentsOfNotesPayable" xlink:title="definition: DebtInstrumentLineItems to RepaymentsOfNotesPayable" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaymentOfAccruedAndUnpaidInterest" xlink:label="PaymentOfAccruedAndUnpaidInterest" xlink:title="PaymentOfAccruedAndUnpaidInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PaymentOfAccruedAndUnpaidInterest" xlink:title="definition: DebtInstrumentLineItems to PaymentOfAccruedAndUnpaidInterest" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFaceAmount" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebt" xlink:title="definition: DebtInstrumentLineItems to LongTermDebt" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateStatedPercentage" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaycheckProtectionProgramLoanMember" xlink:label="PaycheckProtectionProgramLoanMember" xlink:title="PaycheckProtectionProgramLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="PaycheckProtectionProgramLoanMember" xlink:title="definition: DebtInstrumentNameDomain to PaycheckProtectionProgramLoanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaycheckProtectionProgramMember" xlink:label="PaycheckProtectionProgramMember" xlink:title="PaycheckProtectionProgramMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="PaycheckProtectionProgramMember" xlink:title="definition: DebtInstrumentNameDomain to PaycheckProtectionProgramMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BrooklynPaycheckProtectionProgramMember" xlink:label="BrooklynPaycheckProtectionProgramMember" xlink:title="BrooklynPaycheckProtectionProgramMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="BrooklynPaycheckProtectionProgramMember" xlink:title="definition: DebtInstrumentNameDomain to BrooklynPaycheckProtectionProgramMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LegalMattersAbstract" xlink:label="LegalMattersAbstract" xlink:title="LegalMattersAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LegalMattersAbstract" xlink:title="definition: LossContingenciesLineItems to LegalMattersAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="LossContingencyNewClaimsFiledNumber" xlink:title="LossContingencyNewClaimsFiledNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LossContingencyNewClaimsFiledNumber" xlink:title="definition: LossContingenciesLineItems to LossContingencyNewClaimsFiledNumber" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfDefendants" xlink:label="LossContingencyNumberOfDefendants" xlink:title="LossContingencyNumberOfDefendants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LossContingencyNumberOfDefendants" xlink:title="definition: LossContingenciesLineItems to LossContingencyNumberOfDefendants" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LossContingencyDamagesSoughtExpectedSalary" xlink:label="LossContingencyDamagesSoughtExpectedSalary" xlink:title="LossContingencyDamagesSoughtExpectedSalary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LossContingencyDamagesSoughtExpectedSalary" xlink:title="definition: LossContingenciesLineItems to LossContingencyDamagesSoughtExpectedSalary" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:label="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:title="LossContingencyDamagesSoughtExpectedEquityPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:title="definition: LossContingenciesLineItems to LossContingencyDamagesSoughtExpectedEquityPercentage" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="LossContingencyDamagesSoughtValue" xlink:title="LossContingencyDamagesSoughtValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LossContingencyDamagesSoughtValue" xlink:title="definition: LossContingenciesLineItems to LossContingencyDamagesSoughtValue" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="CommonStockSharesAuthorized" xlink:title="definition: LossContingenciesLineItems to CommonStockSharesAuthorized" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LossContingencyNumberOfArbitrationPanel" xlink:label="LossContingencyNumberOfArbitrationPanel" xlink:title="LossContingencyNumberOfArbitrationPanel" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LossContingencyNumberOfArbitrationPanel" xlink:title="definition: LossContingenciesLineItems to LossContingencyNumberOfArbitrationPanel" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LossContingenciesLineItems" xlink:to="LossContingenciesTable" xlink:title="definition: LossContingenciesLineItems to LossContingenciesTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="LegalEntityAxis" xlink:title="definition: LossContingenciesTable to LegalEntityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="NTNBuzztimeIncMember" xlink:title="definition: EntityDomain to NTNBuzztimeIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: LossContingenciesTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="definition: RelatedPartyDomain to NovellusTherapeuticsLimitedMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_RobertGarfieldMember" xlink:label="RobertGarfieldMember" xlink:title="RobertGarfieldMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="RobertGarfieldMember" xlink:title="definition: RelatedPartyDomain to RobertGarfieldMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DheshGovenderMember" xlink:label="DheshGovenderMember" xlink:title="DheshGovenderMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="DheshGovenderMember" xlink:title="definition: RelatedPartyDomain to DheshGovenderMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="definition: LossContingenciesTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LicensingAgreementsAbstract" xlink:label="LicensingAgreementsAbstract" xlink:title="LicensingAgreementsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LicensingAgreementsAbstract" xlink:title="definition: LossContingenciesLineItems to LicensingAgreementsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LossContingencyPercentageOfRoyaltyPayable" xlink:label="LossContingencyPercentageOfRoyaltyPayable" xlink:title="LossContingencyPercentageOfRoyaltyPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LossContingencyPercentageOfRoyaltyPayable" xlink:title="definition: LossContingenciesLineItems to LossContingencyPercentageOfRoyaltyPayable" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LossContingencyNonRefundableOptionFee" xlink:label="LossContingencyNonRefundableOptionFee" xlink:title="LossContingencyNonRefundableOptionFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="LossContingencyNonRefundableOptionFee" xlink:title="definition: LossContingenciesLineItems to LossContingencyNonRefundableOptionFee" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_InitialLicenseFees" xlink:label="InitialLicenseFees" xlink:title="InitialLicenseFees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="InitialLicenseFees" xlink:title="definition: LossContingenciesLineItems to InitialLicenseFees" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AdditionalFeesObligatedToPay" xlink:label="AdditionalFeesObligatedToPay" xlink:title="AdditionalFeesObligatedToPay" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="AdditionalFeesObligatedToPay" xlink:title="definition: LossContingenciesLineItems to AdditionalFeesObligatedToPay" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AmountRequireToPayInitialLicenseFees" xlink:label="AmountRequireToPayInitialLicenseFees" xlink:title="AmountRequireToPayInitialLicenseFees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="AmountRequireToPayInitialLicenseFees" xlink:title="definition: LossContingenciesLineItems to AmountRequireToPayInitialLicenseFees" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AmountObligatedToPayInYearTwo" xlink:label="AmountObligatedToPayInYearTwo" xlink:title="AmountObligatedToPayInYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="AmountObligatedToPayInYearTwo" xlink:title="definition: LossContingenciesLineItems to AmountObligatedToPayInYearTwo" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AmountObligatedToPayInYearOne" xlink:label="AmountObligatedToPayInYearOne" xlink:title="AmountObligatedToPayInYearOne" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="AmountObligatedToPayInYearOne" xlink:title="definition: LossContingenciesLineItems to AmountObligatedToPayInYearOne" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_MinimumNumberOfPatentGranted" xlink:label="MinimumNumberOfPatentGranted" xlink:title="MinimumNumberOfPatentGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="MinimumNumberOfPatentGranted" xlink:title="definition: LossContingenciesLineItems to MinimumNumberOfPatentGranted" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_MinimumNumberOfPendingPatents" xlink:label="MinimumNumberOfPendingPatents" xlink:title="MinimumNumberOfPendingPatents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="MinimumNumberOfPendingPatents" xlink:title="definition: LossContingenciesLineItems to MinimumNumberOfPendingPatents" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRevenue" xlink:label="PercentageOfRevenue" xlink:title="PercentageOfRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PercentageOfRevenue" xlink:title="definition: LossContingenciesLineItems to PercentageOfRevenue" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_MilestonePayments" xlink:label="MilestonePayments" xlink:title="MilestonePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="MilestonePayments" xlink:title="definition: LossContingenciesLineItems to MilestonePayments" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LossContingenciesLineItems" xlink:to="LossContingenciesTable" xlink:title="definition: LossContingenciesLineItems to LossContingenciesTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="LegalEntityAxis" xlink:title="definition: LossContingenciesTable to LegalEntityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_UniversityOfSouthFloridaMember" xlink:label="UniversityOfSouthFloridaMember" xlink:title="UniversityOfSouthFloridaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="UniversityOfSouthFloridaMember" xlink:title="definition: EntityDomain to UniversityOfSouthFloridaMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: LossContingenciesTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="definition: RelatedPartyDomain to NovellusTherapeuticsLimitedMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NovellusLtdAndFactorBioscienceMember" xlink:label="NovellusLtdAndFactorBioscienceMember" xlink:title="NovellusLtdAndFactorBioscienceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="NovellusLtdAndFactorBioscienceMember" xlink:title="definition: RelatedPartyDomain to NovellusLtdAndFactorBioscienceMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NoveCiteMember" xlink:label="NoveCiteMember" xlink:title="NoveCiteMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="NoveCiteMember" xlink:title="definition: RelatedPartyDomain to NoveCiteMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="StatementScenarioAxis" xlink:title="definition: LossContingenciesTable to StatementScenarioAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="definition: ScenarioUnspecifiedDomain to ScenarioForecastMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="definition: LossContingenciesTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_RoyaltyAgreementsAbstract" xlink:label="RoyaltyAgreementsAbstract" xlink:title="RoyaltyAgreementsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="RoyaltyAgreementsAbstract" xlink:title="definition: LossContingenciesLineItems to RoyaltyAgreementsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:label="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:title="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:title="definition: LossContingenciesLineItems to PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:label="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:title="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:title="definition: LossContingenciesLineItems to PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LossContingenciesLineItems" xlink:to="LossContingenciesTable" xlink:title="definition: LossContingenciesLineItems to LossContingenciesTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: LossContingenciesTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_InvestorRoyaltyAgreementMember" xlink:label="InvestorRoyaltyAgreementMember" xlink:title="InvestorRoyaltyAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="InvestorRoyaltyAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to InvestorRoyaltyAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CollaboratorRoyaltyAgreementMember" xlink:label="CollaboratorRoyaltyAgreementMember" xlink:title="CollaboratorRoyaltyAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaboratorRoyaltyAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaboratorRoyaltyAgreementMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertiblePreferredStockMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to ConvertiblePreferredStockMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfSharesOfCommonStockOutstanding" xlink:label="PercentageOfSharesOfCommonStockOutstanding" xlink:title="PercentageOfSharesOfCommonStockOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PercentageOfSharesOfCommonStockOutstanding" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to PercentageOfSharesOfCommonStockOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EquityIncentivePlan2020Member" xlink:label="EquityIncentivePlan2020Member" xlink:title="EquityIncentivePlan2020Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2020Member" xlink:title="definition: PlanNameDomain to EquityIncentivePlan2020Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_InducementPlan2021Member" xlink:label="InducementPlan2021Member" xlink:title="InducementPlan2021Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="InducementPlan2021Member" xlink:title="definition: PlanNameDomain to InducementPlan2021Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IncentiveStockOptionsMember" xlink:label="IncentiveStockOptionsMember" xlink:title="IncentiveStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeStockOptionMember" xlink:to="IncentiveStockOptionsMember" xlink:title="definition: EmployeeStockOptionMember to IncentiveStockOptionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NonQualifiedStockOptionMember" xlink:label="NonQualifiedStockOptionMember" xlink:title="NonQualifiedStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeStockOptionMember" xlink:to="NonQualifiedStockOptionMember" xlink:title="definition: EmployeeStockOptionMember to NonQualifiedStockOptionMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AggregateIntrinsicValueAbstract" xlink:label="AggregateIntrinsicValueAbstract" xlink:title="AggregateIntrinsicValueAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AggregateIntrinsicValueAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AggregateIntrinsicValueAbstract" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="19.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NumberOfStockOptionGrantMade" xlink:label="NumberOfStockOptionGrantMade" xlink:title="NumberOfStockOptionGrantMade" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfStockOptionGrantMade" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfStockOptionGrantMade" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ProceedsFromStockOptionsExercised" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NonQualifiedStockOptionMember" xlink:label="NonQualifiedStockOptionMember" xlink:title="NonQualifiedStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeStockOptionMember" xlink:to="NonQualifiedStockOptionMember" xlink:title="definition: EmployeeStockOptionMember to NonQualifiedStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_TimeBasedNonQualifiedStockOptionMember" xlink:label="TimeBasedNonQualifiedStockOptionMember" xlink:title="TimeBasedNonQualifiedStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonQualifiedStockOptionMember" xlink:to="TimeBasedNonQualifiedStockOptionMember" xlink:title="definition: NonQualifiedStockOptionMember to TimeBasedNonQualifiedStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PerformanceBasedNonqualifiedStockOptionMember" xlink:label="PerformanceBasedNonqualifiedStockOptionMember" xlink:title="PerformanceBasedNonqualifiedStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NonQualifiedStockOptionMember" xlink:to="PerformanceBasedNonqualifiedStockOptionMember" xlink:title="definition: NonQualifiedStockOptionMember to PerformanceBasedNonqualifiedStockOptionMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="VestingAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to VestingAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="definition: VestingAxis to VestingDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain_2" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VestingAxis" xlink:to="VestingDomain_2" xlink:title="definition: VestingAxis to VestingDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="ShareBasedCompensationAwardTrancheOneMember" xlink:title="ShareBasedCompensationAwardTrancheOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VestingDomain" xlink:to="ShareBasedCompensationAwardTrancheOneMember" xlink:title="definition: VestingDomain to ShareBasedCompensationAwardTrancheOneMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensationRsusDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PrivatePlacementOfferingsAbstract" xlink:label="PrivatePlacementOfferingsAbstract" xlink:title="PrivatePlacementOfferingsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="PrivatePlacementOfferingsAbstract" xlink:title="definition: SubsidiarySaleOfStockLineItems to PrivatePlacementOfferingsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: SubsidiarySaleOfStockLineItems to ProceedsFromIssuanceOfCommonStock" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:label="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:title="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:title="definition: SubsidiarySaleOfStockLineItems to NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" xlink:label="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" xlink:title="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" xlink:title="definition: SubsidiarySaleOfStockLineItems to NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="CommonStockSharesAuthorized" xlink:title="definition: SubsidiarySaleOfStockLineItems to CommonStockSharesAuthorized" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CommitmentAmountToMeetAnySingleRegularPurchase" xlink:label="CommitmentAmountToMeetAnySingleRegularPurchase" xlink:title="CommitmentAmountToMeetAnySingleRegularPurchase" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="CommitmentAmountToMeetAnySingleRegularPurchase" xlink:title="definition: SubsidiarySaleOfStockLineItems to CommitmentAmountToMeetAnySingleRegularPurchase" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BeneficialOwnershipPercentageOnTotalOutstandingShares" xlink:label="BeneficialOwnershipPercentageOnTotalOutstandingShares" xlink:title="BeneficialOwnershipPercentageOnTotalOutstandingShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="BeneficialOwnershipPercentageOnTotalOutstandingShares" xlink:title="definition: SubsidiarySaleOfStockLineItems to BeneficialOwnershipPercentageOnTotalOutstandingShares" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="definition: SubsidiarySaleOfStockLineItems to SaleOfStockNumberOfSharesIssuedInTransaction" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="definition: SubsidiarySaleOfStockLineItems to ProceedsFromIssuanceOrSaleOfEquity" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleOfStockNumberOfSharesToIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesToIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesToIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="SaleOfStockNumberOfSharesToIssuedInTransaction" xlink:title="definition: SubsidiarySaleOfStockLineItems to SaleOfStockNumberOfSharesToIssuedInTransaction" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="definition: SubsidiarySaleOfStockLineItems to SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PurchaseAgreementMember" xlink:label="PurchaseAgreementMember" xlink:title="PurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PurchaseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to PurchaseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_FirstPurchaseAgreementMember" xlink:label="FirstPurchaseAgreementMember" xlink:title="FirstPurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PurchaseAgreementMember" xlink:to="FirstPurchaseAgreementMember" xlink:title="definition: PurchaseAgreementMember to FirstPurchaseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SecondPurchaseAgreementMember" xlink:label="SecondPurchaseAgreementMember" xlink:title="SecondPurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PurchaseAgreementMember" xlink:to="SecondPurchaseAgreementMember" xlink:title="definition: PurchaseAgreementMember to SecondPurchaseAgreementMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="LegalEntityAxis" xlink:title="definition: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to LegalEntityAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="EntityDomain_2" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain_2" xlink:title="definition: LegalEntityAxis to EntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LincolnParkCapitalFundLLCMember" xlink:label="LincolnParkCapitalFundLLCMember" xlink:title="LincolnParkCapitalFundLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityDomain" xlink:to="LincolnParkCapitalFundLLCMember" xlink:title="definition: EntityDomain to LincolnParkCapitalFundLLCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="RangeAxis" xlink:title="definition: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitReverseStocksplitDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_MergerAbstract" xlink:label="MergerAbstract" xlink:title="MergerAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="MergerAbstract" xlink:title="definition: ClassOfStockLineItems to MergerAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="SharesIssued" xlink:title="definition: ClassOfStockLineItems to SharesIssued" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="ConversionOfStockSharesConverted1" xlink:title="ConversionOfStockSharesConverted1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ConversionOfStockSharesConverted1" xlink:title="definition: ClassOfStockLineItems to ConversionOfStockSharesConverted1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ClassOfWarrantOrRightIssued" xlink:label="ClassOfWarrantOrRightIssued" xlink:title="ClassOfWarrantOrRightIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightIssued" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightIssued" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: ClassOfStockLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesAcquisitions1" xlink:label="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="StockIssuedDuringPeriodSharesAcquisitions1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodSharesAcquisitions1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassAMember" xlink:title="definition: ClassOfStockDomain to CommonClassAMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassBMember" xlink:title="definition: ClassOfStockDomain to CommonClassBMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="definition: ClassOfStockDomain to CommonClassCMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfStockByClassTable to BusinessAcquisitionAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NTNBuzztimeIncMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to NTNBuzztimeIncMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="BusinessCombinationDescriptionAbstract" xlink:title="definition: ClassOfStockLineItems to BusinessCombinationDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodSharesAcquisitions" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodSharesIssuedForServices" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EachLockUpAgreementExtendsTerm" xlink:label="EachLockUpAgreementExtendsTerm" xlink:title="EachLockUpAgreementExtendsTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="EachLockUpAgreementExtendsTerm" xlink:title="definition: ClassOfStockLineItems to EachLockUpAgreementExtendsTerm" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfCommonStockSubjectToLockUpAgreement" xlink:label="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:title="PercentageOfCommonStockSubjectToLockUpAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:title="definition: ClassOfStockLineItems to PercentageOfCommonStockSubjectToLockUpAgreement" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfStockByClassTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to NovellusTherapeuticsLimitedMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ScheduleOfStockByClassTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:label="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:title="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:title="definition: RelatedPartyDomain to ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfStockByClassTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:label="FeaturesOfConvertiblePreferredStockAbstract" xlink:title="FeaturesOfConvertiblePreferredStockAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="FeaturesOfConvertiblePreferredStockAbstract" xlink:title="definition: ClassOfStockLineItems to FeaturesOfConvertiblePreferredStockAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockSharesAuthorized" xlink:title="definition: ClassOfStockLineItems to PreferredStockSharesAuthorized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockSharesIssued" xlink:title="definition: ClassOfStockLineItems to PreferredStockSharesIssued" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockSharesOutstanding" xlink:title="definition: ClassOfStockLineItems to PreferredStockSharesOutstanding" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="DividendsPayableAmountPerShare" xlink:title="DividendsPayableAmountPerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="DividendsPayableAmountPerShare" xlink:title="definition: ClassOfStockLineItems to DividendsPayableAmountPerShare" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="DividendsPreferredStockCash" xlink:title="DividendsPreferredStockCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="DividendsPreferredStockCash" xlink:title="definition: ClassOfStockLineItems to DividendsPreferredStockCash" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="PreferredStockDividendsShares" xlink:title="PreferredStockDividendsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockDividendsShares" xlink:title="definition: ClassOfStockLineItems to PreferredStockDividendsShares" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="PreferredStockLiquidationPreference" xlink:title="PreferredStockLiquidationPreference" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockLiquidationPreference" xlink:title="definition: ClassOfStockLineItems to PreferredStockLiquidationPreference" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="PreferredStockConvertibleConversionRatio" xlink:title="PreferredStockConvertibleConversionRatio" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockConvertibleConversionRatio" xlink:title="definition: ClassOfStockLineItems to PreferredStockConvertibleConversionRatio" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="definition: ClassOfStockLineItems to ConvertiblePreferredStockSharesIssuedUponConversion" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="PreferredStockConvertibleSharesIssuable" xlink:title="PreferredStockConvertibleSharesIssuable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockConvertibleSharesIssuable" xlink:title="definition: ClassOfStockLineItems to PreferredStockConvertibleSharesIssuable" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="definition: ClassOfStockDomain to SeriesAPreferredStockMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IncomeTaxAbstract" xlink:label="IncomeTaxAbstract" xlink:title="IncomeTaxAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="IncomeTaxAbstract" xlink:title="definition: OperatingLossCarryforwardsLineItems to IncomeTaxAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="definition: OperatingLossCarryforwardsLineItems to ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="DeferredIncomeTaxExpenseBenefit" xlink:title="definition: OperatingLossCarryforwardsLineItems to DeferredIncomeTaxExpenseBenefit" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:label="DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:title="DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:title="definition: OperatingLossCarryforwardsLineItems to DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwards" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwards" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_TaxCutsAndJobsActOperatingLossCarryforwards" xlink:label="TaxCutsAndJobsActOperatingLossCarryforwards" xlink:title="TaxCutsAndJobsActOperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="TaxCutsAndJobsActOperatingLossCarryforwards" xlink:title="definition: OperatingLossCarryforwardsLineItems to TaxCutsAndJobsActOperatingLossCarryforwards" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="TaxCreditCarryforwardAmount" xlink:title="definition: OperatingLossCarryforwardsLineItems to TaxCreditCarryforwardAmount" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_TaxCreditCarryforwardExpirationYear" xlink:label="TaxCreditCarryforwardExpirationYear" xlink:title="TaxCreditCarryforwardExpirationYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="TaxCreditCarryforwardExpirationYear" xlink:title="definition: OperatingLossCarryforwardsLineItems to TaxCreditCarryforwardExpirationYear" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="UnrecognizedTaxBenefits" xlink:title="definition: OperatingLossCarryforwardsLineItems to UnrecognizedTaxBenefits" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="definition: OperatingLossCarryforwardsLineItems to UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="OpenTaxYear" xlink:title="OpenTaxYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OpenTaxYear" xlink:title="definition: OperatingLossCarryforwardsLineItems to OpenTaxYear" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardsTable" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardsTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="IncomeTaxAuthorityAxis" xlink:title="definition: OperatingLossCarryforwardsTable to IncomeTaxAuthorityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain_2" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain_2" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="DomesticCountryMember" xlink:title="DomesticCountryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxAuthorityDomain" xlink:to="DomesticCountryMember" xlink:title="definition: IncomeTaxAuthorityDomain to DomesticCountryMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxAuthorityDomain" xlink:to="StateAndLocalJurisdictionMember" xlink:title="definition: IncomeTaxAuthorityDomain to StateAndLocalJurisdictionMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="ForeignCountryMember" xlink:title="ForeignCountryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxAuthorityDomain" xlink:to="ForeignCountryMember" xlink:title="definition: IncomeTaxAuthorityDomain to ForeignCountryMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/RetirementSavingsPlanDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PrivatePlacementOfEquityAbstract" xlink:label="PrivatePlacementOfEquityAbstract" xlink:title="PrivatePlacementOfEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="PrivatePlacementOfEquityAbstract" xlink:title="definition: SubsequentEventLineItems to PrivatePlacementOfEquityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostPositionsEliminatedAbstract" xlink:label="RestructuringAndRelatedCostPositionsEliminatedAbstract" xlink:title="RestructuringAndRelatedCostPositionsEliminatedAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="RestructuringAndRelatedCostPositionsEliminatedAbstract" xlink:title="definition: SubsequentEventLineItems to RestructuringAndRelatedCostPositionsEliminatedAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LeaseAssignmentAbstract" xlink:label="LeaseAssignmentAbstract" xlink:title="LeaseAssignmentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="LeaseAssignmentAbstract" xlink:title="definition: SubsequentEventLineItems to LeaseAssignmentAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NewLeaseAgreementAbstract" xlink:label="NewLeaseAgreementAbstract" xlink:title="NewLeaseAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="NewLeaseAgreementAbstract" xlink:title="definition: SubsequentEventLineItems to NewLeaseAgreementAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_OperatingLeaseArea" xlink:label="OperatingLeaseArea" xlink:title="OperatingLeaseArea" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="OperatingLeaseArea" xlink:title="definition: SubsequentEventLineItems to OperatingLeaseArea" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="LesseeOperatingLeaseTermOfContract" xlink:title="definition: SubsequentEventLineItems to LesseeOperatingLeaseTermOfContract" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BaseRentPerSquareFoot" xlink:label="BaseRentPerSquareFoot" xlink:title="BaseRentPerSquareFoot" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="BaseRentPerSquareFoot" xlink:title="definition: SubsequentEventLineItems to BaseRentPerSquareFoot" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageBaseRentIncreaseOnEachAnniversary" xlink:label="PercentageBaseRentIncreaseOnEachAnniversary" xlink:title="PercentageBaseRentIncreaseOnEachAnniversary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="PercentageBaseRentIncreaseOnEachAnniversary" xlink:title="definition: SubsequentEventLineItems to PercentageBaseRentIncreaseOnEachAnniversary" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="LesseeOperatingLeaseRenewalTerm" xlink:title="LesseeOperatingLeaseRenewalTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="LesseeOperatingLeaseRenewalTerm" xlink:title="definition: SubsequentEventLineItems to LesseeOperatingLeaseRenewalTerm" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LesseeCommitmentToPurchaseProperty" xlink:label="LesseeCommitmentToPurchaseProperty" xlink:title="LesseeCommitmentToPurchaseProperty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="LesseeCommitmentToPurchaseProperty" xlink:title="definition: SubsequentEventLineItems to LesseeCommitmentToPurchaseProperty" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_UnamortizedLeaseholdImprovements" xlink:label="UnamortizedLeaseholdImprovements" xlink:title="UnamortizedLeaseholdImprovements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="UnamortizedLeaseholdImprovements" xlink:title="definition: SubsequentEventLineItems to UnamortizedLeaseholdImprovements" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets" xlink:label="DepositAssets" xlink:title="DepositAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="DepositAssets" xlink:title="definition: SubsequentEventLineItems to DepositAssets" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:title="RestructuringAndRelatedCostNumberOfPositionsEliminated" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:title="definition: SubsequentEventLineItems to RestructuringAndRelatedCostNumberOfPositionsEliminated" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="definition: SubsequentEventLineItems to RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="SeveranceCosts1" xlink:title="SeveranceCosts1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="SeveranceCosts1" xlink:title="definition: SubsequentEventLineItems to SeveranceCosts1" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:title="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:title="definition: SubsequentEventLineItems to StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="definition: SubsequentEventLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="StockRepurchaseProgramAuthorizedAmount1" xlink:title="StockRepurchaseProgramAuthorizedAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="StockRepurchaseProgramAuthorizedAmount1" xlink:title="definition: SubsequentEventLineItems to StockRepurchaseProgramAuthorizedAmount1" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: SubsequentEventLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:label="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:title="definition: SubsequentEventLineItems to ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ClassOfWarrantOrRightsExercisableTerm" xlink:label="ClassOfWarrantOrRightsExercisableTerm" xlink:title="ClassOfWarrantOrRightsExercisableTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ClassOfWarrantOrRightsExercisableTerm" xlink:title="definition: SubsequentEventLineItems to ClassOfWarrantOrRightsExercisableTerm" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="definition: SubsequentEventLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventTable" xlink:title="definition: SubsequentEventLineItems to SubsequentEventTable" order="23.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="InvestmentTypeAxis" xlink:title="definition: SubsequentEventTable to InvestmentTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember" xlink:title="definition: InvestmentTypeAxis to InvestmentTypeCategorizationMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember_2" xlink:title="InvestmentTypeCategorizationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember_2" xlink:title="definition: InvestmentTypeAxis to InvestmentTypeCategorizationMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PIPEInvestorMember" xlink:label="PIPEInvestorMember" xlink:title="PIPEInvestorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentTypeCategorizationMember" xlink:to="PIPEInvestorMember" xlink:title="definition: InvestmentTypeCategorizationMember to PIPEInvestorMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: SubsequentEventTable to ClassOfWarrantOrRightAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CommonWarrantsMember" xlink:label="CommonWarrantsMember" xlink:title="CommonWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="CommonWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to CommonWarrantsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PreFundedWarrantsMember" xlink:label="PreFundedWarrantsMember" xlink:title="PreFundedWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PreFundedWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to PreFundedWarrantsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsequentEventTable to SubsequentEventTypeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>btx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="us-gaap_AwardTypeAxis_lbl">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:title="label: ArrangementsAndNonarrangementTransactionsMember to us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="us-gaap_AccountingPoliciesAbstract_lbl">Basis of Accounting Presentation and Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:title="label: AccountingPoliciesAbstract to us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl1">Accounts Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl1" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsReceivableNetCurrent_lbl">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:title="label: AccountsReceivableNetCurrent to us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableNetCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccountsReceivableNetCurrent_lbl1">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl1" xlink:title="label: AccountsReceivableNetCurrent to us-gaap_AccountsReceivableNetCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl">Total accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl1">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl2" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl2">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl">Less: accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl1">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl1" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember_lbl">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember_lbl1">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl1" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl">Stock based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl">Stock based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl">Total potential common shares excluded from computation (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain_lbl">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="AssetAcquisitionConsiderationTransferred" xlink:title="AssetAcquisitionConsiderationTransferred" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US" id="us-gaap_AssetAcquisitionConsiderationTransferred_lbl">Business consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:title="label: AssetAcquisitionConsiderationTransferred to us-gaap_AssetAcquisitionConsiderationTransferred_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetAcquisitionConsiderationTransferred_lbl1" xml:lang="en-US" id="us-gaap_AssetAcquisitionConsiderationTransferred_lbl1">Asset Acquisition, Consideration Transferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl1" xlink:title="label: AssetAcquisitionConsiderationTransferred to us-gaap_AssetAcquisitionConsiderationTransferred_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US" id="us-gaap_AssetAcquisitionAxis_lbl">Asset Acquisition [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xlink:title="label: AssetAcquisitionAxis to us-gaap_AssetAcquisitionAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="AssetAcquisitionTableTextBlock" xlink:title="AssetAcquisitionTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetAcquisitionTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_AssetAcquisitionTableTextBlock_lbl">Fair Value of Asset Acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionTableTextBlock" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_lbl" xlink:title="label: AssetAcquisitionTableTextBlock to us-gaap_AssetAcquisitionTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US" id="us-gaap_AssetAcquisitionDomain_lbl">Asset Acquisition [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl" xlink:title="label: AssetAcquisitionDomain to us-gaap_AssetAcquisitionDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="AssetsAndLiabilitiesLesseeAbstract" xlink:title="AssetsAndLiabilitiesLesseeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAndLiabilitiesLesseeAbstract" xlink:to="us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" xlink:title="label: AssetsAndLiabilitiesLesseeAbstract to us-gaap_AssetsAndLiabilitiesLesseeAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets_lbl" xml:lang="en-US" id="us-gaap_Assets_lbl">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl" xlink:title="label: Assets to us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl1">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl1" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl">Carrying value of assets sold [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" xlink:title="label: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl">Basis of Accounting Presentation and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:title="label: BasisOfPresentationAndSignificantAccountingPoliciesTextBlock to us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl">Basis of Accounting Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl">Contingent consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:title="label: BusinessCombinationContingentConsiderationLiabilityNoncurrent to us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl1">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl1" xlink:title="label: BusinessCombinationContingentConsiderationLiabilityNoncurrent to us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl">Accounts payable, accrued liabilities and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl1" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:title="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl">Change in fair value of contingent consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:title="label: BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 to us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl1">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl1" xlink:title="label: BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 to us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="BusinessAcquisitionSharePrice" xlink:title="BusinessAcquisitionSharePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessAcquisitionSharePrice_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionSharePrice_lbl">Closing price of common stock (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:title="label: BusinessAcquisitionSharePrice to us-gaap_BusinessAcquisitionSharePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionSharePrice_lbl1" xml:lang="en-US" id="us-gaap_BusinessAcquisitionSharePrice_lbl1">Business Acquisition, Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl1" xlink:title="label: BusinessAcquisitionSharePrice to us-gaap_BusinessAcquisitionSharePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl">Prepaid expense and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl">Purchase price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:title="label: BusinessAcquisitionCostOfAcquiredEntityTransactionCosts to us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl1" xml:lang="en-US" id="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl1">Total consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl1" xlink:title="label: BusinessAcquisitionCostOfAcquiredEntityTransactionCosts to us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:title="BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl">Percentage of outstanding common stock received by members and financial adviser</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:title="label: BusinessAcquisitionPercentageOfVotingInterestsAcquired to us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl1" xml:lang="en-US" id="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl1">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl1" xlink:title="label: BusinessAcquisitionPercentageOfVotingInterestsAcquired to us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationsAbstract_lbl">Merger, Disposition and Acquisition Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" xlink:title="label: BusinessCombinationsAbstract to us-gaap_BusinessCombinationsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="BusinessAcquisitionsProFormaNetIncomeLoss" xlink:title="BusinessAcquisitionsProFormaNetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl">Net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:title="label: BusinessAcquisitionsProFormaNetIncomeLoss to us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionAxis_lbl">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:title="label: BusinessAcquisitionAxis to us-gaap_BusinessAcquisitionAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl">Number of common stock issued in exchange of membership interests (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:title="label: BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued to us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl1" xml:lang="en-US" id="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl1">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl1" xlink:title="label: BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued to us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionLineItems_lbl">Business Acquisition [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:title="label: BusinessAcquisitionLineItems to us-gaap_BusinessAcquisitionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionAcquireeDomain_lbl">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:title="label: BusinessAcquisitionAcquireeDomain to us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:title="BusinessAcquisitionProFormaEarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_lbl">Diluted net loss per share attributable to common stockholders (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_lbl" xlink:title="label: BusinessAcquisitionProFormaEarningsPerShareDiluted to us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_lbl1" xml:lang="en-US" id="us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_lbl1">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_lbl1" xlink:title="label: BusinessAcquisitionProFormaEarningsPerShareDiluted to us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="BusinessAcquisitionProFormaInformationAbstract" xlink:title="BusinessAcquisitionProFormaInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionProFormaInformationAbstract_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionProFormaInformationAbstract_lbl">Unaudited Pro Forma Financial Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionProFormaInformationAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationAbstract_lbl" xlink:title="label: BusinessAcquisitionProFormaInformationAbstract to us-gaap_BusinessAcquisitionProFormaInformationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:title="BusinessAcquisitionProFormaEarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl">Basic net loss per share attributable to common stockholders (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl" xlink:title="label: BusinessAcquisitionProFormaEarningsPerShareBasic to us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl1" xml:lang="en-US" id="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl1">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl1" xlink:title="label: BusinessAcquisitionProFormaEarningsPerShareBasic to us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="BusinessAcquisitionProFormaInformationTextBlock" xlink:title="BusinessAcquisitionProFormaInformationTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl">Pro Forma Financial Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:title="label: BusinessAcquisitionProFormaInformationTextBlock to us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl">Net assets acquired, excluding goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl1" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_BusinessCombinationDescriptionAbstract_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationDescriptionAbstract_lbl">Acquisitions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="us-gaap_BusinessCombinationDescriptionAbstract_lbl" xlink:title="label: BusinessCombinationDescriptionAbstract to us-gaap_BusinessCombinationDescriptionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDescriptionAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationDescriptionAbstract_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationDescriptionAbstract_lbl1">Description of Business [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="us-gaap_BusinessCombinationDescriptionAbstract_lbl1" xlink:title="label: BusinessCombinationDescriptionAbstract to us-gaap_BusinessCombinationDescriptionAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDescriptionAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationDescriptionAbstract_lbl2" xml:lang="en-US" id="us-gaap_BusinessCombinationDescriptionAbstract_lbl2">Merger Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="us-gaap_BusinessCombinationDescriptionAbstract_lbl2" xlink:title="label: BusinessCombinationDescriptionAbstract to us-gaap_BusinessCombinationDescriptionAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl1" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl">Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="CashAndCashEquivalentsAtCarryingValueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl">Cash and Cash Equivalents [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" xlink:title="label: CashAndCashEquivalentsAtCarryingValueAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl1">Cash and Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl1" xlink:title="label: CashAndCashEquivalentsAtCarryingValueAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1">Cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_Cash_lbl" xml:lang="en-US" id="us-gaap_Cash_lbl">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Cash" xlink:to="us-gaap_Cash_lbl" xlink:title="label: Cash to us-gaap_Cash_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Cash_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Cash_lbl1" xml:lang="en-US" id="us-gaap_Cash_lbl1">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Cash" xlink:to="us-gaap_Cash_lbl1" xlink:title="label: Cash to us-gaap_Cash_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_CashAcquiredFromAcquisition_lbl" xml:lang="en-US" id="us-gaap_CashAcquiredFromAcquisition_lbl">Cash acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:title="label: CashAcquiredFromAcquisition to us-gaap_CashAcquiredFromAcquisition_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAcquiredFromAcquisition_lbl1" xml:lang="en-US" id="us-gaap_CashAcquiredFromAcquisition_lbl1">Cash Acquired from Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl1" xlink:title="label: CashAcquiredFromAcquisition to us-gaap_CashAcquiredFromAcquisition_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="CashEquivalentsAtCarryingValue" xlink:title="CashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashEquivalentsAtCarryingValue_lbl">Cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashEquivalentsAtCarryingValue to us-gaap_CashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashEquivalentsAtCarryingValue_lbl1">Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashEquivalentsAtCarryingValue to us-gaap_CashEquivalentsAtCarryingValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:title="label: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl1" xml:lang="en-US" id="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl1">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl1" xlink:title="label: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl">Number of rights options converted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightAxis_lbl">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:title="label: ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems_lbl">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockDomain_lbl">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightDomain_lbl">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:title="label: ClassOfWarrantOrRightDomain to us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl">Warrant exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl">Number of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="CommitmentsAndContingenciesPolicyTextBlock" xlink:title="CommitmentsAndContingenciesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl">Commitment and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:title="label: CommitmentsAndContingenciesPolicyTextBlock to us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl1">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl1" xlink:title="label: CommitmentsAndContingenciesPolicyTextBlock to us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl">Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonClassBMember_lbl" xml:lang="en-US" id="us-gaap_CommonClassBMember_lbl">Class B Membership Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" xlink:title="label: CommonClassBMember to us-gaap_CommonClassBMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonClassBMember_lbl1" xml:lang="en-US" id="us-gaap_CommonClassBMember_lbl1">Class B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl1" xlink:title="label: CommonClassBMember to us-gaap_CommonClassBMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonClassBMember_lbl2" xml:lang="en-US" id="us-gaap_CommonClassBMember_lbl2">Common Class B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl2" xlink:title="label: CommonClassBMember to us-gaap_CommonClassBMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonClassCMember_lbl" xml:lang="en-US" id="us-gaap_CommonClassCMember_lbl">Class C Membership Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassCMember" xlink:to="us-gaap_CommonClassCMember_lbl" xlink:title="label: CommonClassCMember to us-gaap_CommonClassCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonClassCMember_lbl1" xml:lang="en-US" id="us-gaap_CommonClassCMember_lbl1">Class C [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassCMember" xlink:to="us-gaap_CommonClassCMember_lbl1" xlink:title="label: CommonClassCMember to us-gaap_CommonClassCMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassCMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonClassCMember_lbl2" xml:lang="en-US" id="us-gaap_CommonClassCMember_lbl2">Common Class C [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassCMember" xlink:to="us-gaap_CommonClassCMember_lbl2" xlink:title="label: CommonClassCMember to us-gaap_CommonClassCMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonClassAMember_lbl" xml:lang="en-US" id="us-gaap_CommonClassAMember_lbl">Class A Membership Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xlink:title="label: CommonClassAMember to us-gaap_CommonClassAMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonClassAMember_lbl1" xml:lang="en-US" id="us-gaap_CommonClassAMember_lbl1">Class A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl1" xlink:title="label: CommonClassAMember to us-gaap_CommonClassAMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonClassAMember_lbl2" xml:lang="en-US" id="us-gaap_CommonClassAMember_lbl2">Common Class A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl2" xlink:title="label: CommonClassAMember to us-gaap_CommonClassAMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember_lbl1" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl1">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl">Common stock, $0.005 par value, 100,000 shares authorized, 52,044 issued and outstanding at December 31, 2021; no shares issued and outstanding at December 31, 2020.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl1" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl1">Common Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl1" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl1">Number of shares authorized to sale in regular purchase (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl2" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl2">Certificate of incorporation to increase the authorized shares (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl2" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl1">Number of shares of common stock owned by stockholders immediately before the Merger (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:title="label: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl">Components of Income Tax Provision [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:title="label: ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xml:lang="en-US" id="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xlink:title="label: ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" id="us-gaap_ComputerEquipmentMember_lbl">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:title="label: ComputerEquipmentMember to us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComputerEquipmentMember_lbl1" xml:lang="en-US" id="us-gaap_ComputerEquipmentMember_lbl1">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl1" xlink:title="label: ComputerEquipmentMember to us-gaap_ComputerEquipmentMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk_lbl">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskCreditRisk_lbl1" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk_lbl1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="ContingentConsiderationTypeDomain" xlink:title="ContingentConsiderationTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContingentConsiderationTypeDomain_lbl" xml:lang="en-US" id="us-gaap_ContingentConsiderationTypeDomain_lbl">Contingent Consideration Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:title="label: ContingentConsiderationTypeDomain to us-gaap_ContingentConsiderationTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="ContingentConsiderationByTypeAxis" xlink:title="ContingentConsiderationByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContingentConsiderationByTypeAxis_lbl" xml:lang="en-US" id="us-gaap_ContingentConsiderationByTypeAxis_lbl">Contingent Consideration by Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:title="label: ContingentConsiderationByTypeAxis to us-gaap_ContingentConsiderationByTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="ConversionOfStockSharesConverted1" xlink:title="ConversionOfStockSharesConverted1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" id="us-gaap_ConversionOfStockSharesConverted1_lbl">Number of shares converted to common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:title="label: ConversionOfStockSharesConverted1 to us-gaap_ConversionOfStockSharesConverted1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConversionOfStockSharesConverted1_lbl1" xml:lang="en-US" id="us-gaap_ConversionOfStockSharesConverted1_lbl1">Conversion of Stock, Shares Converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl1" xlink:title="label: ConversionOfStockSharesConverted1 to us-gaap_ConversionOfStockSharesConverted1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" id="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl">Each preferred stock converted into common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:title="label: ConvertiblePreferredStockSharesIssuedUponConversion to us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_ConvertiblePreferredStockMember_lbl">Preferred Stock Converted into Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:title="label: ConvertiblePreferredStockMember to us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="CurrentForeignTaxExpenseBenefit" xlink:title="CurrentForeignTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_CurrentForeignTaxExpenseBenefit_lbl">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:title="label: CurrentForeignTaxExpenseBenefit to us-gaap_CurrentForeignTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentForeignTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_CurrentForeignTaxExpenseBenefit_lbl1">Current Foreign Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl1" xlink:title="label: CurrentForeignTaxExpenseBenefit to us-gaap_CurrentForeignTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:title="label: CurrentStateAndLocalTaxExpenseBenefit to us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="CurrentFederalTaxExpenseBenefit" xlink:title="CurrentFederalTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_CurrentFederalTaxExpenseBenefit_lbl">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:title="label: CurrentFederalTaxExpenseBenefit to us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentFederalTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_CurrentFederalTaxExpenseBenefit_lbl1">Current Federal Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl1" xlink:title="label: CurrentFederalTaxExpenseBenefit to us-gaap_CurrentFederalTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl">Current income tax provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:title="label: CurrentIncomeTaxExpenseBenefit to us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1">Current Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" xlink:title="label: CurrentIncomeTaxExpenseBenefit to us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl">Current Tax Provision [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:title="label: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xlink:title="label: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="CustomerRelationshipsMember" xlink:title="CustomerRelationshipsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US" id="us-gaap_CustomerRelationshipsMember_lbl">Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl" xlink:title="label: CustomerRelationshipsMember to us-gaap_CustomerRelationshipsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CustomerRelationshipsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CustomerRelationshipsMember_lbl1" xml:lang="en-US" id="us-gaap_CustomerRelationshipsMember_lbl1">Customer Relationships [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl1" xlink:title="label: CustomerRelationshipsMember to us-gaap_CustomerRelationshipsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_DebtDisclosureAbstract_lbl">Debt [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:title="label: DebtDisclosureAbstract to us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_DebtDisclosureTextBlock_lbl">Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:title="label: DebtDisclosureTextBlock to us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentAxis_lbl">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:title="label: DebtInstrumentAxis to us-gaap_DebtInstrumentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount_lbl">Principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFaceAmount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount_lbl1">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl1" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentTable_lbl">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:title="label: DebtInstrumentTable to us-gaap_DebtInstrumentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems_lbl">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl">Interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentNameDomain_lbl">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xlink:title="label: DebtInstrumentNameDomain to us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="DeferredTaxLiabilitiesNetAbstract" xlink:title="DeferredTaxLiabilitiesNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl">Deferred Tax Liabilities: [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:title="label: DeferredTaxLiabilitiesNetAbstract to us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl1">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl1" xlink:title="label: DeferredTaxLiabilitiesNetAbstract to us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl">Deferred Tax Provision [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:title="label: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xlink:title="label: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:title="label: DeferredFederalIncomeTaxExpenseBenefit to us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" xlink:title="label: DeferredFederalIncomeTaxExpenseBenefit to us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl">Deferred Income tax provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:title="label: DeferredIncomeTaxExpenseBenefit to us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1">Current year deferred expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" xlink:title="label: DeferredIncomeTaxExpenseBenefit to us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="DeferredForeignIncomeTaxExpenseBenefit" xlink:title="DeferredForeignIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:title="label: DeferredForeignIncomeTaxExpenseBenefit to us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl1">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl1" xlink:title="label: DeferredForeignIncomeTaxExpenseBenefit to us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:title="label: DeferredStateAndLocalIncomeTaxExpenseBenefit to us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" xlink:title="label: DeferredStateAndLocalIncomeTaxExpenseBenefit to us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="DeferredTaxAssetsNetAbstract" xlink:title="DeferredTaxAssetsNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNetAbstract_lbl">Deferred Tax Assets: [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:title="label: DeferredTaxAssetsNetAbstract to us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsNetAbstract_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNetAbstract_lbl1">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl1" xlink:title="label: DeferredTaxAssetsNetAbstract to us-gaap_DeferredTaxAssetsNetAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNet_lbl">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:title="label: DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNet_lbl1">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl1" xlink:title="label: DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl">Net deferred taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:title="label: DeferredTaxAssetsLiabilitiesNet to us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1">Deferred Tax Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xlink:title="label: DeferredTaxAssetsLiabilitiesNet to us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGross_lbl">Total gross deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:title="label: DeferredTaxAssetsGross to us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsGross_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGross_lbl1">Deferred Tax Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl1" xlink:title="label: DeferredTaxAssetsGross to us-gaap_DeferredTaxAssetsGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl">R&amp;D credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:title="label: DeferredTaxAssetsTaxCreditCarryforwardsResearch to us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl">Stock compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl">Vacation accrual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl">Foreign net operating losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwardsForeign to us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_lbl">Contingent consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_lbl" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies to us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="DeferredTaxLiabilities" xlink:title="DeferredTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:title="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilities_lbl">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:title="label: DeferredTaxLiabilities to us-gaap_DeferredTaxLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilities_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilities_lbl1">Deferred Tax Liabilities, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl1" xlink:title="label: DeferredTaxLiabilities to us-gaap_DeferredTaxLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent to us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance_lbl">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:title="DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_lbl">Intangibles - goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_lbl" xlink:title="label: DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill to us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_lbl1">Deferred Tax Liabilities, Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_lbl1" xlink:title="label: DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill to us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl">Fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:title="label: DeferredTaxLiabilitiesPropertyPlantAndEquipment to us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl1">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl1" xlink:title="label: DeferredTaxLiabilitiesPropertyPlantAndEquipment to us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:label="DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:title="DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense_lbl">Purchase accounting related to 2021 business combination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:to="us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense_lbl" xlink:title="label: DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense to us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:title="DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" id="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl">Percentage of maximum annual contribution to defined contribution plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:title="label: DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent to us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets" xlink:label="DepositAssets" xlink:title="DepositAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepositAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DepositAssets_lbl" xml:lang="en-US" id="us-gaap_DepositAssets_lbl">Security deposits and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositAssets" xlink:to="us-gaap_DepositAssets_lbl" xlink:title="label: DepositAssets to us-gaap_DepositAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepositAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepositAssets_lbl1" xml:lang="en-US" id="us-gaap_DepositAssets_lbl1">Security deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositAssets" xlink:to="us-gaap_DepositAssets_lbl1" xlink:title="label: DepositAssets to us-gaap_DepositAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Depreciation_lbl" xml:lang="en-US" id="us-gaap_Depreciation_lbl">Depreciation expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl1" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl1">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl1" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl">Stock-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1">Share-based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:label="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:title="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities to us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl1">Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities to us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:title="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment to us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl1">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment to us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:label="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:title="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_lbl">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationDeferredRevenue to us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationIntangibleAssets to us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl1">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationIntangibleAssets to us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:title="DisposalGroupIncludingDiscontinuedOperationGoodwill1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationGoodwill1 to us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl1">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationGoodwill1 to us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl">Prepaids and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets to us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl1">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets to us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:title="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents to us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl1">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents to us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:title="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet to us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl1">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet to us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:title="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_lbl">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities to us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationOtherAssets to us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl1">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationOtherAssets to us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:title="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl">Disposal Group Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xlink:title="label: DisposalGroupsIncludingDiscontinuedOperationsNameDomain to us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:title="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl" xml:lang="en-US" id="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl">Total loss on sale of assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl" xlink:title="label: DisposalGroupNotDiscontinuedOperationGainLossOnDisposal to us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="DividendsPayableAmountPerShare" xlink:title="DividendsPayableAmountPerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DividendsPayableAmountPerShare_lbl" xml:lang="en-US" id="us-gaap_DividendsPayableAmountPerShare_lbl">Cumulative annual dividend payable per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:title="label: DividendsPayableAmountPerShare to us-gaap_DividendsPayableAmountPerShare_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="DividendsPreferredStockCash" xlink:title="DividendsPreferredStockCash" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DividendsPreferredStockCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DividendsPreferredStockCash_lbl" xml:lang="en-US" id="us-gaap_DividendsPreferredStockCash_lbl">Dividend paid in cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl" xlink:title="label: DividendsPreferredStockCash to us-gaap_DividendsPreferredStockCash_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DividendsPreferredStockCash_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DividendsPreferredStockCash_lbl1" xml:lang="en-US" id="us-gaap_DividendsPreferredStockCash_lbl1">Cash dividends to Series A preferred stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl1" xlink:title="label: DividendsPreferredStockCash to us-gaap_DividendsPreferredStockCash_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DividendsPreferredStockCash_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DividendsPreferredStockCash_lbl2" xml:lang="en-US" id="us-gaap_DividendsPreferredStockCash_lbl2">Dividends, Preferred Stock, Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl2" xlink:title="label: DividendsPreferredStockCash to us-gaap_DividendsPreferredStockCash_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="DomesticCountryMember" xlink:title="DomesticCountryMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" id="us-gaap_DomesticCountryMember_lbl">Federal [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:title="label: DomesticCountryMember to us-gaap_DomesticCountryMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DomesticCountryMember_lbl1" xml:lang="en-US" id="us-gaap_DomesticCountryMember_lbl1">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl1" xlink:title="label: DomesticCountryMember to us-gaap_DomesticCountryMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareTextBlock_lbl">Basic and Diluted Earnings per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:title="label: EarningsPerShareTextBlock to us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl">Anti-dilutive Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl">Earnings Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl1">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic_lbl">Net loss per common share - basic (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic_lbl1">Earnings Per Share, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract_lbl">Basic and Diluted Earnings per Common Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted_lbl">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl">Non-deductible expenses/excludable items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpense to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl">Pass-through loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationOtherAdjustments to us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:title="EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent to us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl">Federal statutory tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl">Credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationTaxCredits to us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl">Total tax provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl">State income tax, net of federal tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes to us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl">Weighted average remaining requisite service period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl">Unamortized stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:title="label: EmployeeRelatedLiabilitiesCurrent to us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl">Unamortized stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="us-gaap_EquipmentMember_lbl">Laboratory and Manufacturing Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:title="label: EquipmentMember to us-gaap_EquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquipmentMember_lbl1" xml:lang="en-US" id="us-gaap_EquipmentMember_lbl1">Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl1" xlink:title="label: EquipmentMember to us-gaap_EquipmentMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="us-gaap_EquityComponentDomain_lbl">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="us-gaap_EquityAbstract_lbl">Stockholders' and members' equity (deficit):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:title="label: EquityAbstract to us-gaap_EquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_EquityAbstract_lbl1">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl1" xlink:title="label: EquityAbstract to us-gaap_EquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US" id="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl">Percentage of total outstanding equity interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:title="label: EquityMethodInvestmentOwnershipPercentage to us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xml:lang="en-US" id="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1">Ownership percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xlink:title="label: EquityMethodInvestmentOwnershipPercentage to us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="EquityMethodInvestments" xlink:title="EquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US" id="us-gaap_EquityMethodInvestments_lbl">Investment in minority interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl" xlink:title="label: EquityMethodInvestments to us-gaap_EquityMethodInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EquityMethodInvestments_lbl1" xml:lang="en-US" id="us-gaap_EquityMethodInvestments_lbl1">Investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl1" xlink:title="label: EquityMethodInvestments to us-gaap_EquityMethodInvestments_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestments_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityMethodInvestments_lbl2" xml:lang="en-US" id="us-gaap_EquityMethodInvestments_lbl2">Equity Method Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl2" xlink:title="label: EquityMethodInvestments to us-gaap_EquityMethodInvestments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:label="FeaturesOfConvertiblePreferredStockAbstract" xlink:title="FeaturesOfConvertiblePreferredStockAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xml:lang="en-US" id="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl">Cumulative Convertible Preferred Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xlink:title="label: FeaturesOfConvertiblePreferredStockAbstract to us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl1" xml:lang="en-US" id="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl1">Features of Convertible Preferred Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl1" xlink:title="label: FeaturesOfConvertiblePreferredStockAbstract to us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xml:lang="en-US" id="us-gaap_FairValueNetAssetLiabilityAbstract_lbl">Fair Value Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xlink:title="label: FairValueNetAssetLiabilityAbstract to us-gaap_FairValueNetAssetLiabilityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_FairValueDisclosuresAbstract_lbl">Fair Value of Financial Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:title="label: FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl">Liabilities Measured at Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock_lbl">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock_lbl1">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl1" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member_lbl">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member_lbl">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member_lbl">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl">Carrying Amount of Contingent Consideration Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:title="label: FiniteLivedIntangibleAssetsMajorClassNameDomain to us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:title="label: FiniteLivedIntangibleAssetsByMajorClassAxis to us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="ForeignCountryMember" xlink:title="ForeignCountryMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" id="us-gaap_ForeignCountryMember_lbl">Foreign [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:title="label: ForeignCountryMember to us-gaap_ForeignCountryMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ForeignCountryMember_lbl1" xml:lang="en-US" id="us-gaap_ForeignCountryMember_lbl1">Foreign Tax Authority [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl1" xlink:title="label: ForeignCountryMember to us-gaap_ForeignCountryMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets1_lbl">Loss on sales of assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:title="label: GainLossOnDispositionOfAssets1 to us-gaap_GainLossOnDispositionOfAssets1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_GainLossOnDispositionOfAssets1_lbl1" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets1_lbl1">Loss on sale of NTN assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl1" xlink:title="label: GainLossOnDispositionOfAssets1 to us-gaap_GainLossOnDispositionOfAssets1_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_GainLossOnDispositionOfAssets1_lbl2" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets1_lbl2">Loss on sale of NTN assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl2" xlink:title="label: GainLossOnDispositionOfAssets1 to us-gaap_GainLossOnDispositionOfAssets1_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainLossOnDispositionOfAssets1_lbl3" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets1_lbl3">Gain (Loss) on Disposition of Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl3" xlink:title="label: GainLossOnDispositionOfAssets1 to us-gaap_GainLossOnDispositionOfAssets1_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl1">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:title="GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl">Goodwill and In-Process Research &amp; Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureTextBlock to us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl1">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl1" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureTextBlock to us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_Goodwill_lbl" xml:lang="en-US" id="us-gaap_Goodwill_lbl">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:title="label: Goodwill to us-gaap_Goodwill_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Goodwill_lbl1" xml:lang="en-US" id="us-gaap_Goodwill_lbl1">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Goodwill" xlink:to="us-gaap_Goodwill_lbl1" xlink:title="label: Goodwill to us-gaap_Goodwill_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:title="label: GoodwillAndIntangibleAssetsGoodwillPolicy to us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" xlink:title="label: GoodwillAndIntangibleAssetsGoodwillPolicy to us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl">Goodwill and In-Process Research &amp; Development [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureAbstract to us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="InProcessResearchAndDevelopmentPolicy" xlink:title="InProcessResearchAndDevelopmentPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" id="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl">IPR&amp;D</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:title="label: InProcessResearchAndDevelopmentPolicy to us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl1" xml:lang="en-US" id="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl1">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl1" xlink:title="label: InProcessResearchAndDevelopmentPolicy to us-gaap_InProcessResearchAndDevelopmentPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract_lbl">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxAuthorityAxis_lbl">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:title="label: IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl">Loss before Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl1">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl">Domestic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xlink:title="label: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract_lbl">CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl">Disposal Group Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:title="label: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis to us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxAuthorityDomain_lbl">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:title="label: IncomeTaxAuthorityDomain to us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl1">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xlink:title="label: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl">Total tax provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl1">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl2" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl2">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl2" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:title="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl">Reconciliation of Computed Expected Income Taxes to Effective Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:title="label: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl1">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl1" xlink:title="label: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl1">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="IncomeTaxesPaidNet" xlink:title="IncomeTaxesPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxesPaidNet_lbl">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:title="label: IncomeTaxesPaidNet to us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxesPaidNet_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxesPaidNet_lbl1">Income Taxes Paid, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl1" xlink:title="label: IncomeTaxesPaidNet to us-gaap_IncomeTaxesPaidNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl">Account receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1">Increase (Decrease) in Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl">Other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:title="label: IncreaseDecreaseInOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl1">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US" id="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl">In-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:title="label: IndefiniteLivedIntangibleAssetsExcludingGoodwill to us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl1" xml:lang="en-US" id="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl1">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl1" xlink:title="label: IndefiniteLivedIntangibleAssetsExcludingGoodwill to us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_InterestPayableCurrent_lbl">Accrued interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:title="label: InterestPayableCurrent to us-gaap_InterestPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPayableCurrent_lbl1" xml:lang="en-US" id="us-gaap_InterestPayableCurrent_lbl1">Interest Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl1" xlink:title="label: InterestPayableCurrent to us-gaap_InterestPayableCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" id="us-gaap_InterestPaidNet_lbl">Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPaidNet_lbl1" xml:lang="en-US" id="us-gaap_InterestPaidNet_lbl1">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl1" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="us-gaap_InvestmentTypeCategorizationMember_lbl">Investments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:title="label: InvestmentTypeCategorizationMember to us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="us-gaap_InvestmentTypeAxis_lbl">Investment Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:title="label: InvestmentTypeAxis to us-gaap_InvestmentTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAbstract" xlink:label="InvestmentsAbstract" xlink:title="InvestmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsAbstract_lbl" xml:lang="en-US" id="us-gaap_InvestmentsAbstract_lbl">Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsAbstract" xlink:to="us-gaap_InvestmentsAbstract_lbl" xlink:title="label: InvestmentsAbstract to us-gaap_InvestmentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="LesseeLeasesPolicyTextBlock" xlink:title="LesseeLeasesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeLeasesPolicyTextBlock_lbl">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:title="label: LesseeLeasesPolicyTextBlock to us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeasesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LesseeLeasesPolicyTextBlock_lbl1">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl1" xlink:title="label: LesseeLeasesPolicyTextBlock to us-gaap_LesseeLeasesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeasesTextBlock_lbl">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:title="label: LesseeOperatingLeasesTextBlock to us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl">Total payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl">Less: Imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFour to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseTermOfContract_lbl">Lease commencement term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:title="label: LesseeOperatingLeaseTermOfContract to us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="LesseeOperatingLeaseRenewalTerm" xlink:title="LesseeOperatingLeaseRenewalTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl">Extended lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:title="label: LesseeOperatingLeaseRenewalTerm to us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl">Maturities of Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityMaturityTableTextBlock to us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="LeaseCostAbstract" xlink:title="LeaseCostAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" id="us-gaap_LeaseCostAbstract_lbl">Net Operating Lease Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xlink:title="label: LeaseCostAbstract to us-gaap_LeaseCostAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" xlink:title="LeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LeaseCost_lbl" xml:lang="en-US" id="us-gaap_LeaseCost_lbl">Total lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:title="label: LeaseCost to us-gaap_LeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseCost_lbl1" xml:lang="en-US" id="us-gaap_LeaseCost_lbl1">Lease, Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseCost" xlink:to="us-gaap_LeaseCost_lbl1" xlink:title="label: LeaseCost to us-gaap_LeaseCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="LeaseCostTableTextBlock" xlink:title="LeaseCostTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_LeaseCostTableTextBlock_lbl">Net Operating Lease Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:title="label: LeaseCostTableTextBlock to us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="us-gaap_LeaseholdImprovementsMember_lbl">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:title="label: LeaseholdImprovementsMember to us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseholdImprovementsMember_lbl1" xml:lang="en-US" id="us-gaap_LeaseholdImprovementsMember_lbl1">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl1" xlink:title="label: LeaseholdImprovementsMember to us-gaap_LeaseholdImprovementsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" id="us-gaap_LeasesAbstract_lbl">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:title="label: LeasesAbstract to us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="LiabilitiesFairValueAdjustment" xlink:title="LiabilitiesFairValueAdjustment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesFairValueAdjustment_lbl">Fair value adjustment included in operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:title="label: LiabilitiesFairValueAdjustment to us-gaap_LiabilitiesFairValueAdjustment_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl">Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:title="label: LiabilitiesFairValueDisclosureAbstract to us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl1">Other liabilities contingent consideration [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl1" xlink:title="label: LiabilitiesFairValueDisclosureAbstract to us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl">Liabilities transferred upon sale [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" xlink:title="label: LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract to us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities_lbl" xml:lang="en-US" id="us-gaap_Liabilities_lbl">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl">LIABILITIES AND STOCKHOLDERS' AND MEMBERS' EQUITY (DEFICIT)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesFairValueDisclosure_lbl">Fair value liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:title="label: LiabilitiesFairValueDisclosure to us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_LiabilitiesFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesFairValueDisclosure_lbl1">Balance at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl1" xlink:title="label: LiabilitiesFairValueDisclosure to us-gaap_LiabilitiesFairValueDisclosure_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_LiabilitiesFairValueDisclosure_lbl2" xml:lang="en-US" id="us-gaap_LiabilitiesFairValueDisclosure_lbl2">Balance at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl2" xlink:title="label: LiabilitiesFairValueDisclosure to us-gaap_LiabilitiesFairValueDisclosure_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesFairValueDisclosure_lbl3" xml:lang="en-US" id="us-gaap_LiabilitiesFairValueDisclosure_lbl3">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl3" xlink:title="label: LiabilitiesFairValueDisclosure to us-gaap_LiabilitiesFairValueDisclosure_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl">Total liabilities and stockholders' and members' equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="LoansPayableCurrent" xlink:title="LoansPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LoansPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_LoansPayableCurrent_lbl">Loans payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl" xlink:title="label: LoansPayableCurrent to us-gaap_LoansPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LoansPayableCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LoansPayableCurrent_lbl1" xml:lang="en-US" id="us-gaap_LoansPayableCurrent_lbl1">Loans Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl1" xlink:title="label: LoansPayableCurrent to us-gaap_LoansPayableCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LongTermDebt_lbl" xml:lang="en-US" id="us-gaap_LongTermDebt_lbl">Term loan amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:title="label: LongTermDebt to us-gaap_LongTermDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebt_lbl1" xml:lang="en-US" id="us-gaap_LongTermDebt_lbl1">Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl1" xlink:title="label: LongTermDebt to us-gaap_LongTermDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfDefendants" xlink:label="LossContingencyNumberOfDefendants" xlink:title="LossContingencyNumberOfDefendants" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingencyNumberOfDefendants_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingencyNumberOfDefendants_lbl" xml:lang="en-US" id="us-gaap_LossContingencyNumberOfDefendants_lbl">Number of defendant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNumberOfDefendants" xlink:to="us-gaap_LossContingencyNumberOfDefendants_lbl" xlink:title="label: LossContingencyNumberOfDefendants to us-gaap_LossContingencyNumberOfDefendants_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="LossContingencyDamagesSoughtValue" xlink:title="LossContingencyDamagesSoughtValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US" id="us-gaap_LossContingencyDamagesSoughtValue_lbl">Loss contingency, damages sought, value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:title="label: LossContingencyDamagesSoughtValue to us-gaap_LossContingencyDamagesSoughtValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" id="us-gaap_LossContingenciesLineItems_lbl">Loss Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:title="label: LossContingenciesLineItems to us-gaap_LossContingenciesLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" id="us-gaap_LossContingenciesTable_lbl">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:title="label: LossContingenciesTable to us-gaap_LossContingenciesTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="LossContingencyNewClaimsFiledNumber" xlink:title="LossContingencyNewClaimsFiledNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" xml:lang="en-US" id="us-gaap_LossContingencyNewClaimsFiledNumber_lbl">Number of claims filed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNewClaimsFiledNumber" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber_lbl" xlink:title="label: LossContingencyNewClaimsFiledNumber to us-gaap_LossContingencyNewClaimsFiledNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingencyNewClaimsFiledNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingencyNewClaimsFiledNumber_lbl1" xml:lang="en-US" id="us-gaap_LossContingencyNewClaimsFiledNumber_lbl1">Loss Contingency, New Claims Filed, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNewClaimsFiledNumber" xlink:to="us-gaap_LossContingencyNewClaimsFiledNumber_lbl1" xlink:title="label: LossContingencyNewClaimsFiledNumber to us-gaap_LossContingencyNewClaimsFiledNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:title="MergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl">Merger, Disposition and Acquisition Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xlink:title="label: MergersAcquisitionsAndDispositionsDisclosuresTextBlock to us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital" xlink:label="MembersCapital" xlink:title="MembersCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MembersCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_MembersCapital_lbl" xml:lang="en-US" id="us-gaap_MembersCapital_lbl">Common units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MembersCapital" xlink:to="us-gaap_MembersCapital_lbl" xlink:title="label: MembersCapital to us-gaap_MembersCapital_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MembersCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MembersCapital_lbl1" xml:lang="en-US" id="us-gaap_MembersCapital_lbl1">Members' Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MembersCapital" xlink:to="us-gaap_MembersCapital_lbl1" xlink:title="label: MembersCapital to us-gaap_MembersCapital_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" id="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl">Ownership percentage by Citius</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:title="label: MinorityInterestOwnershipPercentageByParent to us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="NonrecurringAdjustmentDomain" xlink:title="NonrecurringAdjustmentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonrecurringAdjustmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonrecurringAdjustmentDomain_lbl" xml:lang="en-US" id="us-gaap_NonrecurringAdjustmentDomain_lbl">Nonrecurring Adjustment [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonrecurringAdjustmentDomain" xlink:to="us-gaap_NonrecurringAdjustmentDomain_lbl" xlink:title="label: NonrecurringAdjustmentDomain to us-gaap_NonrecurringAdjustmentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="NonrecurringAdjustmentAxis" xlink:title="NonrecurringAdjustmentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonrecurringAdjustmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonrecurringAdjustmentAxis_lbl" xml:lang="en-US" id="us-gaap_NonrecurringAdjustmentAxis_lbl">Nonrecurring Adjustment [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonrecurringAdjustmentAxis" xlink:to="us-gaap_NonrecurringAdjustmentAxis_lbl" xlink:title="label: NonrecurringAdjustmentAxis to us-gaap_NonrecurringAdjustmentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl">Cash flows provided by financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl">Cash flows used in investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Cash flows used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl2">Net Income (Loss) Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl">Net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl">Recent Accounting Standards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="NoncashMergerRelatedCosts" xlink:title="NoncashMergerRelatedCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashMergerRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NoncashMergerRelatedCosts_lbl" xml:lang="en-US" id="us-gaap_NoncashMergerRelatedCosts_lbl">Transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashMergerRelatedCosts" xlink:to="us-gaap_NoncashMergerRelatedCosts_lbl" xlink:title="label: NoncashMergerRelatedCosts to us-gaap_NoncashMergerRelatedCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashMergerRelatedCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NoncashMergerRelatedCosts_lbl1" xml:lang="en-US" id="us-gaap_NoncashMergerRelatedCosts_lbl1">Transaction costs - shares to Financial Advisor</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashMergerRelatedCosts" xlink:to="us-gaap_NoncashMergerRelatedCosts_lbl1" xlink:title="label: NoncashMergerRelatedCosts to us-gaap_NoncashMergerRelatedCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashMergerRelatedCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncashMergerRelatedCosts_lbl2" xml:lang="en-US" id="us-gaap_NoncashMergerRelatedCosts_lbl2">Noncash Merger Related Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashMergerRelatedCosts" xlink:to="us-gaap_NoncashMergerRelatedCosts_lbl2" xlink:title="label: NoncashMergerRelatedCosts to us-gaap_NoncashMergerRelatedCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:label="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:title="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_lbl" xml:lang="en-US" id="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_lbl">Common stock, shares issued in consideration for purchase commitment (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_lbl" xlink:title="label: NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1 to us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl">Total other expenses, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl1">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="us-gaap_NumberOfOperatingSegments_lbl">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:title="label: NumberOfOperatingSegments to us-gaap_NumberOfOperatingSegments_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="OpenTaxYear" xlink:title="OpenTaxYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OpenTaxYear_lbl" xml:lang="en-US" id="us-gaap_OpenTaxYear_lbl">Open tax year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl" xlink:title="label: OpenTaxYear to us-gaap_OpenTaxYear_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl">Operating lease liabilities, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl1">Current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl2" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl2">Operating Lease, Liability, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl2" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl">Weighted average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:title="label: OperatingLeaseWeightedAverageDiscountRatePercent to us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl">Operating lease liabilities, non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1">Less non-current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl">Maturities of Operating Lease Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:title="label: OperatingLeaseLiabilitiesPaymentsDueAbstract to us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" id="us-gaap_OperatingLeasePayments_lbl">Operating lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:title="label: OperatingLeasePayments to us-gaap_OperatingLeasePayments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasePayments_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeasePayments_lbl1">Operating Lease, Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl1" xlink:title="label: OperatingLeasePayments to us-gaap_OperatingLeasePayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl">Right-of-use assets - operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl1">Operating lease ROU assets, Beginning</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl2" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl2">Operating lease ROU assets, Ending</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl2" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl3" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl3">Operating Lease, Right-of-Use Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl3" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseCost_lbl">Operating lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:title="label: OperatingLeaseCost to us-gaap_OperatingLeaseCost_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl">Weighted average remaining lease term (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:title="label: OperatingLeaseWeightedAverageRemainingLeaseTerm1 to us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl">Operating lease liabilities, Beginning</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl1">Operating lease liabilities, Ending</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiability_lbl2" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl2">Total operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl2" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="OperatingLeaseLiabilityAbstract" xlink:title="OperatingLeaseLiabilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityAbstract_lbl">Operating Lease, Liability [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xlink:title="label: OperatingLeaseLiabilityAbstract to us-gaap_OperatingLeaseLiabilityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl">Amortization of right-to-use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:title="label: OperatingLeaseRightOfUseAssetAmortizationExpense to us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl1">Amortization of operating lease ROU assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl1" xlink:title="label: OperatingLeaseRightOfUseAssetAmortizationExpense to us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl2" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl2">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl2" xlink:title="label: OperatingLeaseRightOfUseAssetAmortizationExpense to us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpensesAbstract_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl1">Operating Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl1" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsLineItems_lbl">Operating Loss Carryforwards [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:title="label: OperatingLossCarryforwardsLineItems to us-gaap_OperatingLossCarryforwardsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsTable_lbl">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:title="label: OperatingLossCarryforwardsTable to us-gaap_OperatingLossCarryforwardsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwards_lbl">Operating loss carry forward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:title="label: OperatingLossCarryforwards to us-gaap_OperatingLossCarryforwards_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl">Organization and Description of Business Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl">Organization and Description of Business Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="OtherExpensesAbstract" xlink:title="OtherExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_OtherExpensesAbstract_lbl">Other expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl" xlink:title="label: OtherExpensesAbstract to us-gaap_OtherExpensesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherExpensesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherExpensesAbstract_lbl1" xml:lang="en-US" id="us-gaap_OtherExpensesAbstract_lbl1">Other Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl1" xlink:title="label: OtherExpensesAbstract to us-gaap_OtherExpensesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent_lbl">Other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent_lbl1">Other Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl1" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilitiesCurrent_lbl">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:title="label: OtherLiabilitiesCurrent to us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherLiabilitiesCurrent_lbl1">Other Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl1" xlink:title="label: OtherLiabilitiesCurrent to us-gaap_OtherLiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense_lbl">Other income (expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense_lbl1">Other Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnersCapitalAccountUnitsAcquisitions" xlink:label="PartnersCapitalAccountUnitsAcquisitions" xlink:title="PartnersCapitalAccountUnitsAcquisitions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl" xml:lang="en-US" id="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl">Issuance of common stock to Brooklyn members (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PartnersCapitalAccountUnitsAcquisitions" xlink:to="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl" xlink:title="label: PartnersCapitalAccountUnitsAcquisitions to us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl1" xml:lang="en-US" id="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl1">Partners' Capital Account, Units, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PartnersCapitalAccountUnitsAcquisitions" xlink:to="us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl1" xlink:title="label: PartnersCapitalAccountUnitsAcquisitions to us-gaap_PartnersCapitalAccountUnitsAcquisitions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnersCapitalAccountAcquisitions" xlink:label="PartnersCapitalAccountAcquisitions" xlink:title="PartnersCapitalAccountAcquisitions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PartnersCapitalAccountAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PartnersCapitalAccountAcquisitions_lbl" xml:lang="en-US" id="us-gaap_PartnersCapitalAccountAcquisitions_lbl">Issuance of common stock to Brooklyn members</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PartnersCapitalAccountAcquisitions" xlink:to="us-gaap_PartnersCapitalAccountAcquisitions_lbl" xlink:title="label: PartnersCapitalAccountAcquisitions to us-gaap_PartnersCapitalAccountAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PartnersCapitalAccountAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PartnersCapitalAccountAcquisitions_lbl1" xml:lang="en-US" id="us-gaap_PartnersCapitalAccountAcquisitions_lbl1">Partners' Capital Account, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PartnersCapitalAccountAcquisitions" xlink:to="us-gaap_PartnersCapitalAccountAcquisitions_lbl1" xlink:title="label: PartnersCapitalAccountAcquisitions to us-gaap_PartnersCapitalAccountAcquisitions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="us-gaap_PayablesAndAccrualsAbstract_lbl">Accrued Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:title="label: PayablesAndAccrualsAbstract to us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="PaymentsOfDividendsPreferredStockAndPreferenceStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" id="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl">Dividends paid to Series A preferred shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" xlink:title="label: PaymentsOfDividendsPreferredStockAndPreferenceStock to us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl1" xml:lang="en-US" id="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl1">Payments of Ordinary Dividends, Preferred Stock and Preference Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl1" xlink:title="label: PaymentsOfDividendsPreferredStockAndPreferenceStock to us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="PaymentsToAcquireInvestments" xlink:title="PaymentsToAcquireInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquireInvestments_lbl">Less amount of cash paid for NoveCite investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:title="label: PaymentsToAcquireInvestments to us-gaap_PaymentsToAcquireInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquireInvestments_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquireInvestments_lbl1">Payments to Acquire Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl1" xlink:title="label: PaymentsToAcquireInvestments to us-gaap_PaymentsToAcquireInvestments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="PaymentsToAcquireOtherProductiveAssets" xlink:title="PaymentsToAcquireOtherProductiveAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireOtherProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" xlink:title="label: PaymentsToAcquireOtherProductiveAssets to us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl1">Payments to Acquire Other Productive Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireOtherProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl1" xlink:title="label: PaymentsToAcquireOtherProductiveAssets to us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="PaymentsToAcquireProductiveAssets" xlink:title="PaymentsToAcquireProductiveAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquireProductiveAssets_lbl">Cash paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:title="label: PaymentsToAcquireProductiveAssets to us-gaap_PaymentsToAcquireProductiveAssets_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_PlanNameDomain_lbl">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="us-gaap_PlanNameAxis_lbl">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:label="PostemploymentBenefitsDisclosureTextBlock" xlink:title="PostemploymentBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl">Retirement Savings Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostemploymentBenefitsDisclosureTextBlock" xlink:to="us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl" xlink:title="label: PostemploymentBenefitsDisclosureTextBlock to us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl1">Postemployment Benefits Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostemploymentBenefitsDisclosureTextBlock" xlink:to="us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl1" xlink:title="label: PostemploymentBenefitsDisclosureTextBlock to us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="PostemploymentBenefitsAbstract" xlink:title="PostemploymentBenefitsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PostemploymentBenefitsAbstract_lbl" xml:lang="en-US" id="us-gaap_PostemploymentBenefitsAbstract_lbl">Retirement Savings Plan [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostemploymentBenefitsAbstract" xlink:to="us-gaap_PostemploymentBenefitsAbstract_lbl" xlink:title="label: PostemploymentBenefitsAbstract to us-gaap_PostemploymentBenefitsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="PreferredStockConvertibleSharesIssuable" xlink:title="PreferredStockConvertibleSharesIssuable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US" id="us-gaap_PreferredStockConvertibleSharesIssuable_lbl">Aggregate preferred stock to be convert into common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:title="label: PreferredStockConvertibleSharesIssuable to us-gaap_PreferredStockConvertibleSharesIssuable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="PreferredStockLiquidationPreference" xlink:title="PreferredStockLiquidationPreference" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" id="us-gaap_PreferredStockLiquidationPreference_lbl">Preferred stock, liquidation preference per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xlink:title="label: PreferredStockLiquidationPreference to us-gaap_PreferredStockLiquidationPreference_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_PreferredStockMember_lbl">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:title="label: PreferredStockMember to us-gaap_PreferredStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="PreferredStockDividendsShares" xlink:title="PreferredStockDividendsShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockDividendsShares_lbl" xml:lang="en-US" id="us-gaap_PreferredStockDividendsShares_lbl">Cash dividends to Series A preferred stockholders (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsShares" xlink:to="us-gaap_PreferredStockDividendsShares_lbl" xlink:title="label: PreferredStockDividendsShares to us-gaap_PreferredStockDividendsShares_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockDividendsShares_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockDividendsShares_lbl1">Shares issued for payment of dividends (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsShares" xlink:to="us-gaap_PreferredStockDividendsShares_lbl1" xlink:title="label: PreferredStockDividendsShares to us-gaap_PreferredStockDividendsShares_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US" id="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl">Series A preferred stock dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:title="label: PreferredStockDividendsAndOtherAdjustments to us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1">Preferred Stock Dividends and Other Adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" xlink:title="label: PreferredStockDividendsAndOtherAdjustments to us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="PreferredStockLiquidationPreferenceValue" xlink:title="PreferredStockLiquidationPreferenceValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockLiquidationPreferenceValue_lbl">Preferred stock, liquidation preference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:title="label: PreferredStockLiquidationPreferenceValue to us-gaap_PreferredStockLiquidationPreferenceValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="PreferredStockConvertibleConversionRatio" xlink:title="PreferredStockConvertibleConversionRatio" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" id="us-gaap_PreferredStockConvertibleConversionRatio_lbl">Preferred stock, conversion rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:title="label: PreferredStockConvertibleConversionRatio to us-gaap_PreferredStockConvertibleConversionRatio_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockValue_lbl">Series A preferred stock, $0.005 par value, $156 liquidation preference, 156 shares authorized, issued and outstanding at December 31, 2021; no shares issued and outstanding at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockValue_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockValue_lbl1">Preferred Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl1" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl">Preferred stock Series A, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl1">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare_lbl">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl">Preferred stock series A, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl1">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued_lbl">Preferred stock series A, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockSharesIssued_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued_lbl1">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl1" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSalesOfAssetsInvestingActivities" xlink:label="ProceedsFromSalesOfAssetsInvestingActivities" xlink:title="ProceedsFromSalesOfAssetsInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl">Purchase of NTN, net of cash acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSalesOfAssetsInvestingActivities" xlink:to="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl" xlink:title="label: ProceedsFromSalesOfAssetsInvestingActivities to us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl1">Proceeds from Sales of Assets, Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSalesOfAssetsInvestingActivities" xlink:to="us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl1" xlink:title="label: ProceedsFromSalesOfAssetsInvestingActivities to us-gaap_ProceedsFromSalesOfAssetsInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:title="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl">Sale of rights, title and interest in and to the assets relating to the business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" xlink:title="label: ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets to us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl1">Proceeds from Sales of Business, Affiliate and Productive Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:to="us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl1" xlink:title="label: ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets to us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLeasePayments" xlink:label="ProceedsFromLeasePayments" xlink:title="ProceedsFromLeasePayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromLeasePayments_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromLeasePayments_lbl">Sublease payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromLeasePayments" xlink:to="us-gaap_ProceedsFromLeasePayments_lbl" xlink:title="label: ProceedsFromLeasePayments to us-gaap_ProceedsFromLeasePayments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromLeasePayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromLeasePayments_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromLeasePayments_lbl1">Proceeds from Lease Payment, Operating Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromLeasePayments" xlink:to="us-gaap_ProceedsFromLeasePayments_lbl1" xlink:title="label: ProceedsFromLeasePayments to us-gaap_ProceedsFromLeasePayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="ProceedsFromDivestitureOfBusinesses" xlink:title="ProceedsFromDivestitureOfBusinesses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl">Proceeds from the sale of NTN assets, net of cash disposed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDivestitureOfBusinesses" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" xlink:title="label: ProceedsFromDivestitureOfBusinesses to us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl">Net proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:title="label: ProceedsFromIssuanceOfPrivatePlacement to us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl">Gross proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquity to us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl1">Gross proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl1" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquity to us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl">Common stock to be purchased under common stock purchase agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1">Net proceeds of common stock issued to Lincoln Park</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2">Proceeds from sale of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromNotesPayable_lbl">Proceeds from loans payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:title="label: ProceedsFromNotesPayable to us-gaap_ProceedsFromNotesPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromNotesPayable_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromNotesPayable_lbl1">Proceeds from Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl1" xlink:title="label: ProceedsFromNotesPayable to us-gaap_ProceedsFromNotesPayable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="ProceedsFromOtherEquity" xlink:title="ProceedsFromOtherEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromOtherEquity_lbl">Proceeds from sale of members' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl" xlink:title="label: ProceedsFromOtherEquity to us-gaap_ProceedsFromOtherEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromOtherEquity_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromOtherEquity_lbl1">Proceeds from Other Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl1" xlink:title="label: ProceedsFromOtherEquity to us-gaap_ProceedsFromOtherEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl">Proceeds from the exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl1">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentLineItems_lbl">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:title="label: PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl">Estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAbstract_lbl">Property and Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl">Schedule of Property, Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:title="label: PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:label="PropertyPlantAndEquipmentGrossAbstract" xlink:title="PropertyPlantAndEquipmentGrossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentGrossAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGrossAbstract_lbl">Property, Plant and Equipment, Gross [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGrossAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGrossAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentGrossAbstract to us-gaap_PropertyPlantAndEquipmentGrossAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:title="label: PropertyPlantAndEquipmentTypeDomain to us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl1">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl2" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl2">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl2" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross_lbl">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl">Property and Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentNetByTypeAbstract to us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl1">Property, Plant and Equipment, Net, by Type [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl1" xlink:title="label: PropertyPlantAndEquipmentNetByTypeAbstract to us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" id="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl">Right of use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:title="label: RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability to us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xlink:title="label: RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability to us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl">Related Party [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:title="label: RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyDomain_lbl">Related Party [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xlink:title="label: RelatedPartyDomain to us-gaap_RelatedPartyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US" id="us-gaap_RepaymentsOfNotesPayable_lbl">Principal payments on notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:title="label: RepaymentsOfNotesPayable to us-gaap_RepaymentsOfNotesPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RepaymentsOfNotesPayable_lbl1" xml:lang="en-US" id="us-gaap_RepaymentsOfNotesPayable_lbl1">Principal payment of outstanding notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl1" xlink:title="label: RepaymentsOfNotesPayable to us-gaap_RepaymentsOfNotesPayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfNotesPayable_lbl2" xml:lang="en-US" id="us-gaap_RepaymentsOfNotesPayable_lbl2">Repayments of Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl2" xlink:title="label: RepaymentsOfNotesPayable to us-gaap_RepaymentsOfNotesPayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="ResearchAndDevelopmentInProcess" xlink:title="ResearchAndDevelopmentInProcess" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentInProcess_lbl">Acquired in-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:title="label: ResearchAndDevelopmentInProcess to us-gaap_ResearchAndDevelopmentInProcess_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentInProcess_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentInProcess_lbl1">Research and Development in Process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl1" xlink:title="label: ResearchAndDevelopmentInProcess to us-gaap_ResearchAndDevelopmentInProcess_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:title="label: ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost to us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1" xlink:title="label: ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost to us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="us-gaap_RestrictedStockMember_lbl">Restricted Common Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:title="label: RestrictedStockMember to us-gaap_RestrictedStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl">RSU [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl1">Restricted Common Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl2">RSUs [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US" id="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl">Percentage of employees terminated in reduction in force</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:title="label: RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent to us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostPositionsEliminatedAbstract" xlink:label="RestructuringAndRelatedCostPositionsEliminatedAbstract" xlink:title="RestructuringAndRelatedCostPositionsEliminatedAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostPositionsEliminatedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestructuringAndRelatedCostPositionsEliminatedAbstract_lbl" xml:lang="en-US" id="us-gaap_RestructuringAndRelatedCostPositionsEliminatedAbstract_lbl">Reduction in Force [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringAndRelatedCostPositionsEliminatedAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostPositionsEliminatedAbstract_lbl" xlink:title="label: RestructuringAndRelatedCostPositionsEliminatedAbstract to us-gaap_RestructuringAndRelatedCostPositionsEliminatedAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:title="RestructuringAndRelatedCostNumberOfPositionsEliminated" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US" id="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl">Number of employees terminated in reduction in force</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xlink:title="label: RestructuringAndRelatedCostNumberOfPositionsEliminated to us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl1">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl1" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_SubleaseIncome_lbl" xml:lang="en-US" id="us-gaap_SubleaseIncome_lbl">Sublease income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl" xlink:title="label: SubleaseIncome to us-gaap_SubleaseIncome_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubleaseIncome_lbl1" xml:lang="en-US" id="us-gaap_SubleaseIncome_lbl1">Sublease Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl1" xlink:title="label: SubleaseIncome to us-gaap_SubleaseIncome_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl">Warrant expiration term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1">Stock based compensation stock option term period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl">Weighted-average remaining contractual life, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl">Options vested and exercisable, weighted average remaining contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl">Stock-based compensation vesting percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" id="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl">Common stock issued and sold during period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:title="label: SaleOfStockNumberOfSharesIssuedInTransaction to us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US" id="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1">Common stock issued and sold during period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xlink:title="label: SaleOfStockNumberOfSharesIssuedInTransaction to us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl2" xml:lang="en-US" id="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl2">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl2" xlink:title="label: SaleOfStockNumberOfSharesIssuedInTransaction to us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl">Weighted-Average Assumptions Used for Grants Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl">Summarizes of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:title="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl">Tangible and Intangible Assets Acquired And Liabilities Assumed, Based on Estimated Fair Values</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:title="label: ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock to us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl">Summarizes of RSU Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:title="label: ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock to us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:title="ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl">Loss before Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:title="label: ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock to us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl1">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl1" xlink:title="label: ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock to us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl">Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl1">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl">Reconciliation of Computed Expected Income Taxes to Effective Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:title="label: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock to us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl1">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl1" xlink:title="label: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock to us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:title="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl">Income Tax Provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:title="label: ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock to us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl">Computation of Diluted Net Loss per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:title="label: ScheduleOfBusinessAcquisitionsByAcquisitionTable to us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:title="ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl">Disposition Details</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xlink:title="label: ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock to us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:title="label: ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfStockByClassTable_lbl">Schedule of Stock by Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:title="label: ScheduleOfStockByClassTable to us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingAbstract_lbl">Segment Reporting [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:title="label: SegmentReportingAbstract to us-gaap_SegmentReportingAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="SegmentReportingPolicyPolicyTextBlock" xlink:title="SegmentReportingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl">Segment Reporting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:title="label: SegmentReportingPolicyPolicyTextBlock to us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl1">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl1" xlink:title="label: SegmentReportingPolicyPolicyTextBlock to us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_SeriesAPreferredStockMember_lbl">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:title="label: SeriesAPreferredStockMember to us-gaap_SeriesAPreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SeriesAPreferredStockMember_lbl1" xml:lang="en-US" id="us-gaap_SeriesAPreferredStockMember_lbl1">Series A Cumulative Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl1" xlink:title="label: SeriesAPreferredStockMember to us-gaap_SeriesAPreferredStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="SeveranceCosts1" xlink:title="SeveranceCosts1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US" id="us-gaap_SeveranceCosts1_lbl">Severance and termination-related costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xlink:title="label: SeveranceCosts1 to us-gaap_SeveranceCosts1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl">Weighted Average Exercise Price per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl">Number of stock option awards granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl">Weighted Average Fair Value Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl">Stock units outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="ShareBasedCompensationAwardTrancheOneMember" xlink:title="ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl">Vesting on one-year Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:title="label: ShareBasedCompensationAwardTrancheOneMember to us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl1">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl1" xlink:title="label: ShareBasedCompensationAwardTrancheOneMember to us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl1">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl">Weighted Average Fair Value Per Share, Ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1">Weighted Average Fair Value Per Share, Beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl">Outstanding Restricted Stock Units [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl">Stock-based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl">Outstanding, Beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1">Outstanding, Ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl">Assertions Used in Determining Fair Value of Stock Options Granted [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl">Number of shares vested (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl">Weighted average risk-free rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl">Stock-based compensation shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl">Weighted average volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl">Options exercised total intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl">Options vested and exercisable, Weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl">Number of stock option awards outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1">Outstanding, ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2">Outstanding, beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3">Stock option outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1">Outstanding, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl">Outstanding, ending balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1">Outstanding, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl">Options vested and exercisable, Outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl">Number of Option Share [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl">Options vested and exercisable, aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl">Options Vested and Exercisable [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_lbl">Weighted Average Remaining Contractual Life [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_lbl" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="us-gaap_SharesIssued_lbl">Number of shares issued in merger agreement (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:title="label: SharesIssued to us-gaap_SharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesIssued_lbl1" xml:lang="en-US" id="us-gaap_SharesIssued_lbl1">Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1" xlink:title="label: SharesIssued to us-gaap_SharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl1">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" id="us-gaap_StateAndLocalJurisdictionMember_lbl">State [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:title="label: StateAndLocalJurisdictionMember to us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StateAndLocalJurisdictionMember_lbl1" xml:lang="en-US" id="us-gaap_StateAndLocalJurisdictionMember_lbl1">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl1" xlink:title="label: StateAndLocalJurisdictionMember to us-gaap_StateAndLocalJurisdictionMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract_lbl">CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis_lbl">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable_lbl" xml:lang="en-US" id="us-gaap_StatementTable_lbl">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:title="label: StatementTable to us-gaap_StatementTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="us-gaap_StatementLineItems_lbl">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract_lbl">CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis_lbl">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract_lbl">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY (DEFICIT) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="StockIssued1" xlink:title="StockIssued1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssued1_lbl" xml:lang="en-US" id="us-gaap_StockIssued1_lbl">Issuance of common stock for business combination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:title="label: StockIssued1 to us-gaap_StockIssued1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssued1_lbl1" xml:lang="en-US" id="us-gaap_StockIssued1_lbl1">Stock Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssued1" xlink:to="us-gaap_StockIssued1_lbl1" xlink:title="label: StockIssued1 to us-gaap_StockIssued1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl">Issuance of common stock from the exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1">Stock option exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:title="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xml:lang="en-US" id="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl">Private placement (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:title="label: StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased to us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl">Number of shares converted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:title="label: StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities to us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl">Restricted stock replaced during the period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:title="label: StockIssuedDuringPeriodSharesRestrictedStockAwardGross to us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl">Stock outstanding, reverse stock splits (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:title="label: StockIssuedDuringPeriodSharesReverseStockSplits to us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl">Lock-up agreements shares received in acquisition (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1">Number of common stock issued as compensation for services (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2">Lock-up agreements common shares received in acquisition (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl">Acquisition of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions to us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1">Issuance of common stock to Financial Advisor upon consummation of merger (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions to us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="StockRepurchaseProgramAuthorizedAmount1" xlink:title="StockRepurchaseProgramAuthorizedAmount1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xml:lang="en-US" id="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl">Aggregate gross purchase price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockRepurchaseProgramAuthorizedAmount1" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:title="label: StockRepurchaseProgramAuthorizedAmount1 to us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl">Issuance of common stock from the exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl1">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl1" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl">Issuance of common stock to Financial Advisor upon consummation of merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions to us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl1">Acquisition agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl1" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions to us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl2" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl2">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl2" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions to us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl">Stock conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:title="label: StockholdersEquityNoteStockSplitConversionRatio1 to us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1">Reverse stock splits (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" xlink:title="label: StockholdersEquityNoteStockSplitConversionRatio1 to us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl">Total stockholders' and members' equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl2">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl3">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl">Stockholders and Members Equity (Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="StockholdersEquityOther" xlink:title="StockholdersEquityOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityOther_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityOther_lbl">Sale of members' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityOther" xlink:to="us-gaap_StockholdersEquityOther_lbl" xlink:title="label: StockholdersEquityOther to us-gaap_StockholdersEquityOther_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityOther_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityOther_lbl1">Stockholders' Equity, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityOther" xlink:to="us-gaap_StockholdersEquityOther_lbl1" xlink:title="label: StockholdersEquityOther to us-gaap_StockholdersEquityOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteAbstract_lbl">Stockholders and Members Equity (Deficit) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:title="label: StockholdersEquityNoteAbstract to us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventMember_lbl">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeDomain_lbl">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xlink:title="label: SubsequentEventTypeDomain to us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventLineItems_lbl">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:title="label: SubsequentEventLineItems to us-gaap_SubsequentEventLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeAxis_lbl">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:title="label: SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsAbstract_lbl">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:title="label: SubsequentEventsAbstract to us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTable_lbl">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:title="label: SubsequentEventTable to us-gaap_SubsequentEventTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock_lbl">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock_lbl1">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl1" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" id="us-gaap_SubsidiarySaleOfStockLineItems_lbl">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:title="label: SubsidiarySaleOfStockLineItems to us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" id="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:title="label: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract_lbl">Supplemental disclosures of cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract_lbl1" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract_lbl1">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl1" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardAmount_lbl">Federal and state income tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:title="label: TaxCreditCarryforwardAmount to us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="TradeNamesMember" xlink:title="TradeNamesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TradeNamesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TradeNamesMember_lbl" xml:lang="en-US" id="us-gaap_TradeNamesMember_lbl">Trade Names [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeNamesMember" xlink:to="us-gaap_TradeNamesMember_lbl" xlink:title="label: TradeNamesMember to us-gaap_TradeNamesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="us-gaap_TypeOfArrangementAxis_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:title="label: TypeOfArrangementAxis to us-gaap_TypeOfArrangementAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl">Accrued interest and penalties related to uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:title="label: UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued to us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefits_lbl">Uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:title="label: UnrecognizedTaxBenefits to us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates_lbl1" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl1">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl1" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VestingAxis_lbl" xml:lang="en-US" id="us-gaap_VestingAxis_lbl">Vesting [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:title="label: VestingAxis to us-gaap_VestingAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VestingDomain_lbl" xml:lang="en-US" id="us-gaap_VestingDomain_lbl">Vesting [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xlink:title="label: VestingDomain to us-gaap_VestingDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" id="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl">Increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:title="label: ValuationAllowanceDeferredTaxAssetChangeInAmount to us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1" xml:lang="en-US" id="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1" xlink:title="label: ValuationAllowanceDeferredTaxAssetChangeInAmount to us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="VariableLeaseCost" xlink:title="VariableLeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" id="us-gaap_VariableLeaseCost_lbl">Variable lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xlink:title="label: VariableLeaseCost to us-gaap_VariableLeaseCost_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl">Weighted average number of shares outstanding - diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl">Weighted average number of shares outstanding - basic (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MaximumMember_lbl" xml:lang="en-US" id="srt_MaximumMember_lbl">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:title="label: MaximumMember to srt_MaximumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MinimumMember_lbl" xml:lang="en-US" id="srt_MinimumMember_lbl">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:title="label: MinimumMember to srt_MinimumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:label xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_OwnershipDomain_lbl" xml:lang="en-US" id="srt_OwnershipDomain_lbl">Ownership [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xlink:title="label: OwnershipDomain to srt_OwnershipDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:label xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_OwnershipAxis_lbl" xml:lang="en-US" id="srt_OwnershipAxis_lbl">Ownership [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xlink:title="label: OwnershipAxis to srt_OwnershipAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeMember_lbl" xml:lang="en-US" id="srt_RangeMember_lbl">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember_lbl" xlink:title="label: RangeMember to srt_RangeMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_RangeAxis_lbl" xml:lang="en-US" id="srt_RangeAxis_lbl">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:title="label: RangeAxis to srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeAxis_lbl1" xml:lang="en-US" id="srt_RangeAxis_lbl1">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis_lbl1" xlink:title="label: RangeAxis to srt_RangeAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:label xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScenarioForecastMember_lbl" xml:lang="en-US" id="srt_ScenarioForecastMember_lbl">Forecast [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:title="label: ScenarioForecastMember to srt_ScenarioForecastMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="srt_ScenarioUnspecifiedDomain_lbl">Scenario [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xlink:title="label: ScenarioUnspecifiedDomain to srt_ScenarioUnspecifiedDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_StatementScenarioAxis_lbl" xml:lang="en-US" id="srt_StatementScenarioAxis_lbl">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:title="label: StatementScenarioAxis to srt_StatementScenarioAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="DocumentAnnualReport" xlink:title="DocumentAnnualReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentAnnualReport_lbl" xml:lang="en-US" id="dei_DocumentAnnualReport_lbl">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:title="label: DocumentAnnualReport to dei_DocumentAnnualReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentTransitionReport_lbl" xml:lang="en-US" id="dei_DocumentTransitionReport_lbl">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:title="label: DocumentTransitionReport to dei_DocumentTransitionReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" id="dei_EntityInteractiveDataCurrent_lbl">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:title="label: EntityInteractiveDataCurrent to dei_EntityInteractiveDataCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="IcfrAuditorAttestationFlag" xlink:title="IcfrAuditorAttestationFlag" />
    <link:label xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" id="dei_IcfrAuditorAttestationFlag_lbl">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:title="label: IcfrAuditorAttestationFlag to dei_IcfrAuditorAttestationFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:label xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="dei_LegalEntityAxis_lbl">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:title="label: LegalEntityAxis to dei_LegalEntityAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:label xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityDomain_lbl" xml:lang="en-US" id="dei_EntityDomain_lbl">Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityDomain" xlink:to="dei_EntityDomain_lbl" xlink:title="label: EntityDomain to dei_EntityDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="dei_EntityWellKnownSeasonedIssuer_lbl">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:title="label: EntityWellKnownSeasonedIssuer to dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="dei_EntityVoluntaryFilers_lbl">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:title="label: EntityVoluntaryFilers to dei_EntityVoluntaryFilers_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityShellCompany_lbl" xml:lang="en-US" id="dei_EntityShellCompany_lbl">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:title="label: EntityShellCompany to dei_EntityShellCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntitySmallBusiness_lbl" xml:lang="en-US" id="dei_EntitySmallBusiness_lbl">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:title="label: EntitySmallBusiness to dei_EntitySmallBusiness_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="dei_EntityPublicFloat_lbl">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:title="label: EntityPublicFloat to dei_EntityPublicFloat_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="AuditorName" xlink:title="AuditorName" />
    <link:label xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AuditorName_lbl" xml:lang="en-US" id="dei_AuditorName_lbl">Auditor Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AuditorName" xlink:to="dei_AuditorName_lbl" xlink:title="label: AuditorName to dei_AuditorName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="AuditorLocation" xlink:title="AuditorLocation" />
    <link:label xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AuditorLocation_lbl" xml:lang="en-US" id="dei_AuditorLocation_lbl">Auditor Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:title="label: AuditorLocation to dei_AuditorLocation_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="AuditorFirmId" xlink:title="AuditorFirmId" />
    <link:label xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AuditorFirmId_lbl" xml:lang="en-US" id="dei_AuditorFirmId_lbl">Auditor Firm ID</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:title="label: AuditorFirmId to dei_AuditorFirmId_lbl" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LiquidityAndCapitalResourcesAbstract" xlink:label="LiquidityAndCapitalResourcesAbstract" xlink:title="LiquidityAndCapitalResourcesAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_LiquidityAndCapitalResourcesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LiquidityAndCapitalResourcesAbstract_lbl1" xml:lang="en-US" id="btx_LiquidityAndCapitalResourcesAbstract_lbl1">Liquidity and Capital Resources [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesAbstract" xlink:to="btx_LiquidityAndCapitalResourcesAbstract_lbl1" xlink:title="label: LiquidityAndCapitalResourcesAbstract to btx_LiquidityAndCapitalResourcesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LiquidityAndCapitalResourcesTextBlock" xlink:label="LiquidityAndCapitalResourcesTextBlock" xlink:title="LiquidityAndCapitalResourcesTextBlock" />
    <link:label xlink:type="resource" xlink:label="btx_LiquidityAndCapitalResourcesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LiquidityAndCapitalResourcesTextBlock_lbl" xml:lang="en-US" id="btx_LiquidityAndCapitalResourcesTextBlock_lbl">The entire disclosure of liquidity and resource matters when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). going concern.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTextBlock" xlink:to="btx_LiquidityAndCapitalResourcesTextBlock_lbl" xlink:title="label: LiquidityAndCapitalResourcesTextBlock to btx_LiquidityAndCapitalResourcesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LiquidityAndCapitalResourcesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LiquidityAndCapitalResourcesTextBlock_lbl1" xml:lang="en-US" id="btx_LiquidityAndCapitalResourcesTextBlock_lbl1">Liquidity And Capital Resources [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTextBlock" xlink:to="btx_LiquidityAndCapitalResourcesTextBlock_lbl1" xlink:title="label: LiquidityAndCapitalResourcesTextBlock to btx_LiquidityAndCapitalResourcesTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LiquidityAndCapitalResourcesTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LiquidityAndCapitalResourcesTextBlock_lbl2" xml:lang="en-US" id="btx_LiquidityAndCapitalResourcesTextBlock_lbl2">Liquidity and Capital Resources</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTextBlock" xlink:to="btx_LiquidityAndCapitalResourcesTextBlock_lbl2" xlink:title="label: LiquidityAndCapitalResourcesTextBlock to btx_LiquidityAndCapitalResourcesTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaymentsToAcquireProductiveAssetsNet" xlink:label="PaymentsToAcquireProductiveAssetsNet" xlink:title="PaymentsToAcquireProductiveAssetsNet" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentsToAcquireProductiveAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PaymentsToAcquireProductiveAssetsNet_lbl" xml:lang="en-US" id="btx_PaymentsToAcquireProductiveAssetsNet_lbl">The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets excluding cash acquired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireProductiveAssetsNet" xlink:to="btx_PaymentsToAcquireProductiveAssetsNet_lbl" xlink:title="label: PaymentsToAcquireProductiveAssetsNet to btx_PaymentsToAcquireProductiveAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentsToAcquireProductiveAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PaymentsToAcquireProductiveAssetsNet_lbl1" xml:lang="en-US" id="btx_PaymentsToAcquireProductiveAssetsNet_lbl1">Cash paid, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireProductiveAssetsNet" xlink:to="btx_PaymentsToAcquireProductiveAssetsNet_lbl1" xlink:title="label: PaymentsToAcquireProductiveAssetsNet to btx_PaymentsToAcquireProductiveAssetsNet_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentsToAcquireProductiveAssetsNet_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="btx_PaymentsToAcquireProductiveAssetsNet_lbl2" xml:lang="en-US" id="btx_PaymentsToAcquireProductiveAssetsNet_lbl2">Purchase of Novellus, net of common stock issued and cash acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireProductiveAssetsNet" xlink:to="btx_PaymentsToAcquireProductiveAssetsNet_lbl2" xlink:title="label: PaymentsToAcquireProductiveAssetsNet to btx_PaymentsToAcquireProductiveAssetsNet_lbl2" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentsToAcquireProductiveAssetsNet_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PaymentsToAcquireProductiveAssetsNet_lbl3" xml:lang="en-US" id="btx_PaymentsToAcquireProductiveAssetsNet_lbl3">Cash paid, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireProductiveAssetsNet" xlink:to="btx_PaymentsToAcquireProductiveAssetsNet_lbl3" xlink:title="label: PaymentsToAcquireProductiveAssetsNet to btx_PaymentsToAcquireProductiveAssetsNet_lbl3" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LiquidityAndCapitalResourcesTable" xlink:label="LiquidityAndCapitalResourcesTable" xlink:title="LiquidityAndCapitalResourcesTable" />
    <link:label xlink:type="resource" xlink:label="btx_LiquidityAndCapitalResourcesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LiquidityAndCapitalResourcesTable_lbl" xml:lang="en-US" id="btx_LiquidityAndCapitalResourcesTable_lbl">Disclosure of information about liquidity and capital resources.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTable" xlink:to="btx_LiquidityAndCapitalResourcesTable_lbl" xlink:title="label: LiquidityAndCapitalResourcesTable to btx_LiquidityAndCapitalResourcesTable_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LiquidityAndCapitalResourcesTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LiquidityAndCapitalResourcesTable_lbl1" xml:lang="en-US" id="btx_LiquidityAndCapitalResourcesTable_lbl1">Liquidity and Capital Resources [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesTable" xlink:to="btx_LiquidityAndCapitalResourcesTable_lbl1" xlink:title="label: LiquidityAndCapitalResourcesTable to btx_LiquidityAndCapitalResourcesTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_FirstPurchaseAgreementMember" xlink:label="FirstPurchaseAgreementMember" xlink:title="FirstPurchaseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="btx_FirstPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_FirstPurchaseAgreementMember_lbl" xml:lang="en-US" id="btx_FirstPurchaseAgreementMember_lbl">Information about purchase agreement between the entities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstPurchaseAgreementMember" xlink:to="btx_FirstPurchaseAgreementMember_lbl" xlink:title="label: FirstPurchaseAgreementMember to btx_FirstPurchaseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_FirstPurchaseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_FirstPurchaseAgreementMember_lbl1" xml:lang="en-US" id="btx_FirstPurchaseAgreementMember_lbl1">First Purchase Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstPurchaseAgreementMember" xlink:to="btx_FirstPurchaseAgreementMember_lbl1" xlink:title="label: FirstPurchaseAgreementMember to btx_FirstPurchaseAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_FirstPurchaseAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_FirstPurchaseAgreementMember_lbl2" xml:lang="en-US" id="btx_FirstPurchaseAgreementMember_lbl2">First Purchase Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstPurchaseAgreementMember" xlink:to="btx_FirstPurchaseAgreementMember_lbl2" xlink:title="label: FirstPurchaseAgreementMember to btx_FirstPurchaseAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SecondPurchaseAgreementMember" xlink:label="SecondPurchaseAgreementMember" xlink:title="SecondPurchaseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="btx_SecondPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SecondPurchaseAgreementMember_lbl" xml:lang="en-US" id="btx_SecondPurchaseAgreementMember_lbl">Information about second purchase agreement between the entities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondPurchaseAgreementMember" xlink:to="btx_SecondPurchaseAgreementMember_lbl" xlink:title="label: SecondPurchaseAgreementMember to btx_SecondPurchaseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SecondPurchaseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SecondPurchaseAgreementMember_lbl1" xml:lang="en-US" id="btx_SecondPurchaseAgreementMember_lbl1">Second Purchase Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecondPurchaseAgreementMember" xlink:to="btx_SecondPurchaseAgreementMember_lbl1" xlink:title="label: SecondPurchaseAgreementMember to btx_SecondPurchaseAgreementMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:label xlink:type="resource" xlink:label="btx_NovellusTherapeuticsLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NovellusTherapeuticsLimitedMember_lbl" xml:lang="en-US" id="btx_NovellusTherapeuticsLimitedMember_lbl">The name of company involved in licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovellusTherapeuticsLimitedMember" xlink:to="btx_NovellusTherapeuticsLimitedMember_lbl" xlink:title="label: NovellusTherapeuticsLimitedMember to btx_NovellusTherapeuticsLimitedMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NovellusTherapeuticsLimitedMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NovellusTherapeuticsLimitedMember_lbl1" xml:lang="en-US" id="btx_NovellusTherapeuticsLimitedMember_lbl1">Novellus Therapeutics Limited [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovellusTherapeuticsLimitedMember" xlink:to="btx_NovellusTherapeuticsLimitedMember_lbl1" xlink:title="label: NovellusTherapeuticsLimitedMember to btx_NovellusTherapeuticsLimitedMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NovellusTherapeuticsLimitedMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NovellusTherapeuticsLimitedMember_lbl2" xml:lang="en-US" id="btx_NovellusTherapeuticsLimitedMember_lbl2">Novellus, Ltd. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovellusTherapeuticsLimitedMember" xlink:to="btx_NovellusTherapeuticsLimitedMember_lbl2" xlink:title="label: NovellusTherapeuticsLimitedMember to btx_NovellusTherapeuticsLimitedMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LiquidityAndCapitalResourcesLineItems" xlink:label="LiquidityAndCapitalResourcesLineItems" xlink:title="LiquidityAndCapitalResourcesLineItems" />
    <link:label xlink:type="resource" xlink:label="btx_LiquidityAndCapitalResourcesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LiquidityAndCapitalResourcesLineItems_lbl" xml:lang="en-US" id="btx_LiquidityAndCapitalResourcesLineItems_lbl">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="btx_LiquidityAndCapitalResourcesLineItems_lbl" xlink:title="label: LiquidityAndCapitalResourcesLineItems to btx_LiquidityAndCapitalResourcesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LiquidityAndCapitalResourcesLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LiquidityAndCapitalResourcesLineItems_lbl1" xml:lang="en-US" id="btx_LiquidityAndCapitalResourcesLineItems_lbl1">Liquidity and Capital Resources [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="btx_LiquidityAndCapitalResourcesLineItems_lbl1" xlink:title="label: LiquidityAndCapitalResourcesLineItems to btx_LiquidityAndCapitalResourcesLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:label="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:title="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl1" xml:lang="en-US" id="btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl1">Detailed information about Liquidity and Capital Resources [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl1" xlink:title="label: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl2" xml:lang="en-US" id="btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl2">Liquidity and Capital Resources [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl2" xlink:title="label: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NetIncomeLossAttributableToParentTemporaryElement" xlink:label="NetIncomeLossAttributableToParentTemporaryElement" xlink:title="NetIncomeLossAttributableToParentTemporaryElement" />
    <link:label xlink:type="resource" xlink:label="btx_NetIncomeLossAttributableToParentTemporaryElement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NetIncomeLossAttributableToParentTemporaryElement_lbl" xml:lang="en-US" id="btx_NetIncomeLossAttributableToParentTemporaryElement_lbl">The portion of profit or loss for the period, net of income taxes, which is attributable to the parent Temporary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAttributableToParentTemporaryElement" xlink:to="btx_NetIncomeLossAttributableToParentTemporaryElement_lbl" xlink:title="label: NetIncomeLossAttributableToParentTemporaryElement to btx_NetIncomeLossAttributableToParentTemporaryElement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NetIncomeLossAttributableToParentTemporaryElement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NetIncomeLossAttributableToParentTemporaryElement_lbl1" xml:lang="en-US" id="btx_NetIncomeLossAttributableToParentTemporaryElement_lbl1">Net Income (Loss) Attributable to Parent Temporary Element</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAttributableToParentTemporaryElement" xlink:to="btx_NetIncomeLossAttributableToParentTemporaryElement_lbl1" xlink:title="label: NetIncomeLossAttributableToParentTemporaryElement to btx_NetIncomeLossAttributableToParentTemporaryElement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NetIncomeLossAttributableToParentTemporaryElement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NetIncomeLossAttributableToParentTemporaryElement_lbl2" xml:lang="en-US" id="btx_NetIncomeLossAttributableToParentTemporaryElement_lbl2">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAttributableToParentTemporaryElement" xlink:to="btx_NetIncomeLossAttributableToParentTemporaryElement_lbl2" xlink:title="label: NetIncomeLossAttributableToParentTemporaryElement to btx_NetIncomeLossAttributableToParentTemporaryElement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ResearchAndDevelopmentInProcessAssetAcquisition" xlink:label="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="ResearchAndDevelopmentInProcessAssetAcquisition" />
    <link:label xlink:type="resource" xlink:label="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl" xml:lang="en-US" id="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl">The amount of purchased research and development assets that are acquired in a asset acquisition have no alternative future use and are therefore written off in the period of acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:to="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl" xlink:title="label: ResearchAndDevelopmentInProcessAssetAcquisition to btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl1" xml:lang="en-US" id="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl1">Research and Development in Process, Asset Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:to="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl1" xlink:title="label: ResearchAndDevelopmentInProcessAssetAcquisition to btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl2" xml:lang="en-US" id="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl2">IPR&amp;D expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:to="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl2" xlink:title="label: ResearchAndDevelopmentInProcessAssetAcquisition to btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl2" />
    <link:label xlink:type="resource" xlink:label="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl3" xml:lang="en-US" id="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl3">Acquired in-process research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:to="btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl3" xlink:title="label: ResearchAndDevelopmentInProcessAssetAcquisition to btx_ResearchAndDevelopmentInProcessAssetAcquisition_lbl3" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CommencementPeriodOfCommonStockInPurchaseAgreement" xlink:label="CommencementPeriodOfCommonStockInPurchaseAgreement" xlink:title="CommencementPeriodOfCommonStockInPurchaseAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_CommencementPeriodOfCommonStockInPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_CommencementPeriodOfCommonStockInPurchaseAgreement_lbl" xml:lang="en-US" id="btx_CommencementPeriodOfCommonStockInPurchaseAgreement_lbl">Period for common stock purchase agreement commencement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommencementPeriodOfCommonStockInPurchaseAgreement" xlink:to="btx_CommencementPeriodOfCommonStockInPurchaseAgreement_lbl" xlink:title="label: CommencementPeriodOfCommonStockInPurchaseAgreement to btx_CommencementPeriodOfCommonStockInPurchaseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_CommencementPeriodOfCommonStockInPurchaseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CommencementPeriodOfCommonStockInPurchaseAgreement_lbl1" xml:lang="en-US" id="btx_CommencementPeriodOfCommonStockInPurchaseAgreement_lbl1">Commencement Period of Common Stock in Purchase Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommencementPeriodOfCommonStockInPurchaseAgreement" xlink:to="btx_CommencementPeriodOfCommonStockInPurchaseAgreement_lbl1" xlink:title="label: CommencementPeriodOfCommonStockInPurchaseAgreement to btx_CommencementPeriodOfCommonStockInPurchaseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_CommencementPeriodOfCommonStockInPurchaseAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_CommencementPeriodOfCommonStockInPurchaseAgreement_lbl2" xml:lang="en-US" id="btx_CommencementPeriodOfCommonStockInPurchaseAgreement_lbl2">Common stock purchase agreement commencement period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommencementPeriodOfCommonStockInPurchaseAgreement" xlink:to="btx_CommencementPeriodOfCommonStockInPurchaseAgreement_lbl2" xlink:title="label: CommencementPeriodOfCommonStockInPurchaseAgreement to btx_CommencementPeriodOfCommonStockInPurchaseAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LincolnParkCapitalFundLLCMember" xlink:label="LincolnParkCapitalFundLLCMember" xlink:title="LincolnParkCapitalFundLLCMember" />
    <link:label xlink:type="resource" xlink:label="btx_LincolnParkCapitalFundLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US" id="btx_LincolnParkCapitalFundLLCMember_lbl">Name of entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LincolnParkCapitalFundLLCMember" xlink:to="btx_LincolnParkCapitalFundLLCMember_lbl" xlink:title="label: LincolnParkCapitalFundLLCMember to btx_LincolnParkCapitalFundLLCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LincolnParkCapitalFundLLCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LincolnParkCapitalFundLLCMember_lbl1" xml:lang="en-US" id="btx_LincolnParkCapitalFundLLCMember_lbl1">Lincoln Park Capital Fund, LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LincolnParkCapitalFundLLCMember" xlink:to="btx_LincolnParkCapitalFundLLCMember_lbl1" xlink:title="label: LincolnParkCapitalFundLLCMember to btx_LincolnParkCapitalFundLLCMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LincolnParkCapitalFundLLCMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LincolnParkCapitalFundLLCMember_lbl2" xml:lang="en-US" id="btx_LincolnParkCapitalFundLLCMember_lbl2">Lincoln Park [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LincolnParkCapitalFundLLCMember" xlink:to="btx_LincolnParkCapitalFundLLCMember_lbl2" xlink:title="label: LincolnParkCapitalFundLLCMember to btx_LincolnParkCapitalFundLLCMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" xlink:label="EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" xlink:title="EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" />
    <link:label xlink:type="resource" xlink:label="btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount_lbl" xml:lang="en-US" id="btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount_lbl">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to decrease in the valuation allowance for deferred tax assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" xlink:to="btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount to btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount_lbl1" xml:lang="en-US" id="btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount_lbl1">Effective Income Tax Rate Reconciliation, Decrease in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" xlink:to="btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount to btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount_lbl2" xml:lang="en-US" id="btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount_lbl2">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" xlink:to="btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount to btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_RoyaltyAgreementsAbstract" xlink:label="RoyaltyAgreementsAbstract" xlink:title="RoyaltyAgreementsAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_RoyaltyAgreementsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_RoyaltyAgreementsAbstract_lbl1" xml:lang="en-US" id="btx_RoyaltyAgreementsAbstract_lbl1">Royalty Agreements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyAgreementsAbstract" xlink:to="btx_RoyaltyAgreementsAbstract_lbl1" xlink:title="label: RoyaltyAgreementsAbstract to btx_RoyaltyAgreementsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_RoyaltyAgreementsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_RoyaltyAgreementsAbstract_lbl2" xml:lang="en-US" id="btx_RoyaltyAgreementsAbstract_lbl2">Royalty Agreements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyAgreementsAbstract" xlink:to="btx_RoyaltyAgreementsAbstract_lbl2" xlink:title="label: RoyaltyAgreementsAbstract to btx_RoyaltyAgreementsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:label="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:title="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl" xml:lang="en-US" id="btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl">Percentage of additional royalty payable on gross sales by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:to="btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl" xlink:title="label: PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales to btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl1" xml:lang="en-US" id="btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl1">Percentage of Payment Of Additional Royalty On Gross Sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:to="btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl1" xlink:title="label: PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales to btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl2" xml:lang="en-US" id="btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl2">Percentage of payment of additional royalty on gross sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:to="btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl2" xlink:title="label: PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales to btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_InvestorRoyaltyAgreementMember" xlink:label="InvestorRoyaltyAgreementMember" xlink:title="InvestorRoyaltyAgreementMember" />
    <link:label xlink:type="resource" xlink:label="btx_InvestorRoyaltyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_InvestorRoyaltyAgreementMember_lbl" xml:lang="en-US" id="btx_InvestorRoyaltyAgreementMember_lbl">Arrangement other than collaborative applicable to investor royalty.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorRoyaltyAgreementMember" xlink:to="btx_InvestorRoyaltyAgreementMember_lbl" xlink:title="label: InvestorRoyaltyAgreementMember to btx_InvestorRoyaltyAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_InvestorRoyaltyAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_InvestorRoyaltyAgreementMember_lbl1" xml:lang="en-US" id="btx_InvestorRoyaltyAgreementMember_lbl1">Investor Royalty Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorRoyaltyAgreementMember" xlink:to="btx_InvestorRoyaltyAgreementMember_lbl1" xlink:title="label: InvestorRoyaltyAgreementMember to btx_InvestorRoyaltyAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_InvestorRoyaltyAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_InvestorRoyaltyAgreementMember_lbl2" xml:lang="en-US" id="btx_InvestorRoyaltyAgreementMember_lbl2">Investor Royalty Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorRoyaltyAgreementMember" xlink:to="btx_InvestorRoyaltyAgreementMember_lbl2" xlink:title="label: InvestorRoyaltyAgreementMember to btx_InvestorRoyaltyAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:label="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:title="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl" xml:lang="en-US" id="btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl">Percentage of royalty receive equal to revenues generated from disposition of business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:to="btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl" xlink:title="label: PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness to btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl1" xml:lang="en-US" id="btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl1">Percentage of Royalty Receive Equal to Revenues from Sale of Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:to="btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl1" xlink:title="label: PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness to btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl2" xml:lang="en-US" id="btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl2">Percentage of royalty receive equal to revenues from sale of business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:to="btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl2" xlink:title="label: PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness to btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CollaboratorRoyaltyAgreementMember" xlink:label="CollaboratorRoyaltyAgreementMember" xlink:title="CollaboratorRoyaltyAgreementMember" />
    <link:label xlink:type="resource" xlink:label="btx_CollaboratorRoyaltyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_CollaboratorRoyaltyAgreementMember_lbl" xml:lang="en-US" id="btx_CollaboratorRoyaltyAgreementMember_lbl">Collaborative royalty arrangement in licensing deal with the company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaboratorRoyaltyAgreementMember" xlink:to="btx_CollaboratorRoyaltyAgreementMember_lbl" xlink:title="label: CollaboratorRoyaltyAgreementMember to btx_CollaboratorRoyaltyAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_CollaboratorRoyaltyAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CollaboratorRoyaltyAgreementMember_lbl1" xml:lang="en-US" id="btx_CollaboratorRoyaltyAgreementMember_lbl1">Collaborator Royalty Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaboratorRoyaltyAgreementMember" xlink:to="btx_CollaboratorRoyaltyAgreementMember_lbl1" xlink:title="label: CollaboratorRoyaltyAgreementMember to btx_CollaboratorRoyaltyAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_CollaboratorRoyaltyAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_CollaboratorRoyaltyAgreementMember_lbl2" xml:lang="en-US" id="btx_CollaboratorRoyaltyAgreementMember_lbl2">Collaborator Royalty Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaboratorRoyaltyAgreementMember" xlink:to="btx_CollaboratorRoyaltyAgreementMember_lbl2" xlink:title="label: CollaboratorRoyaltyAgreementMember to btx_CollaboratorRoyaltyAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl">Number of shares of stock issued without any restrictions during the period pursuant to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:to="btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl" xlink:title="label: StockIssuedDuringPeriodUnrestrictedSharesAcquisitions to btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl1">Stock Issued During Period, Unrestricted Shares, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:to="btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl1" xlink:title="label: StockIssuedDuringPeriodUnrestrictedSharesAcquisitions to btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl2">Unrestricted shares, issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:to="btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl2" xlink:title="label: StockIssuedDuringPeriodUnrestrictedSharesAcquisitions to btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EachLockUpAgreementExtendsTerm" xlink:label="EachLockUpAgreementExtendsTerm" xlink:title="EachLockUpAgreementExtendsTerm" />
    <link:label xlink:type="resource" xlink:label="btx_EachLockUpAgreementExtendsTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_EachLockUpAgreementExtendsTerm_lbl" xml:lang="en-US" id="btx_EachLockUpAgreementExtendsTerm_lbl">The period of lock-up agreement extend term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EachLockUpAgreementExtendsTerm" xlink:to="btx_EachLockUpAgreementExtendsTerm_lbl" xlink:title="label: EachLockUpAgreementExtendsTerm to btx_EachLockUpAgreementExtendsTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_EachLockUpAgreementExtendsTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_EachLockUpAgreementExtendsTerm_lbl1" xml:lang="en-US" id="btx_EachLockUpAgreementExtendsTerm_lbl1">Each Lock-up Agreement Extends Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EachLockUpAgreementExtendsTerm" xlink:to="btx_EachLockUpAgreementExtendsTerm_lbl1" xlink:title="label: EachLockUpAgreementExtendsTerm to btx_EachLockUpAgreementExtendsTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_EachLockUpAgreementExtendsTerm_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_EachLockUpAgreementExtendsTerm_lbl2" xml:lang="en-US" id="btx_EachLockUpAgreementExtendsTerm_lbl2">Each lock-up agreement extend term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EachLockUpAgreementExtendsTerm" xlink:to="btx_EachLockUpAgreementExtendsTerm_lbl2" xlink:title="label: EachLockUpAgreementExtendsTerm to btx_EachLockUpAgreementExtendsTerm_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfCommonStockSubjectToLockUpAgreement" xlink:label="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:title="PercentageOfCommonStockSubjectToLockUpAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfCommonStockSubjectToLockUpAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageOfCommonStockSubjectToLockUpAgreement_lbl" xml:lang="en-US" id="btx_PercentageOfCommonStockSubjectToLockUpAgreement_lbl">The percentage of shares of common stock subject to the lock-up agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:to="btx_PercentageOfCommonStockSubjectToLockUpAgreement_lbl" xlink:title="label: PercentageOfCommonStockSubjectToLockUpAgreement to btx_PercentageOfCommonStockSubjectToLockUpAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfCommonStockSubjectToLockUpAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageOfCommonStockSubjectToLockUpAgreement_lbl1" xml:lang="en-US" id="btx_PercentageOfCommonStockSubjectToLockUpAgreement_lbl1">Percentage of Common Stock Subject to Lock-up Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:to="btx_PercentageOfCommonStockSubjectToLockUpAgreement_lbl1" xlink:title="label: PercentageOfCommonStockSubjectToLockUpAgreement to btx_PercentageOfCommonStockSubjectToLockUpAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfCommonStockSubjectToLockUpAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageOfCommonStockSubjectToLockUpAgreement_lbl2" xml:lang="en-US" id="btx_PercentageOfCommonStockSubjectToLockUpAgreement_lbl2">Percentage of common stock subject to the lock-up agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:to="btx_PercentageOfCommonStockSubjectToLockUpAgreement_lbl2" xlink:title="label: PercentageOfCommonStockSubjectToLockUpAgreement to btx_PercentageOfCommonStockSubjectToLockUpAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:label="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:title="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" />
    <link:label xlink:type="resource" xlink:label="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl" xml:lang="en-US" id="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl">Person with designation of chairman of the board of directors, chief executive officer and president.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:to="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl" xlink:title="label: ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember to btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl1" xml:lang="en-US" id="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl1">Chairman of the Board of Directors Chief Executive Officer and President [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:to="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl1" xlink:title="label: ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember to btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl2" xml:lang="en-US" id="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl2">Chair of the Board of Directors, Chief Executive Officer and President [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:to="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl2" xlink:title="label: ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember to btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl3" xml:lang="en-US" id="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl3">Chairman of the Board of Directors, Chief Executive Officer and President [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:to="btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl3" xlink:title="label: ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember to btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CommonUnitsMember" xlink:label="CommonUnitsMember" xlink:title="CommonUnitsMember" />
    <link:label xlink:type="resource" xlink:label="btx_CommonUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_CommonUnitsMember_lbl" xml:lang="en-US" id="btx_CommonUnitsMember_lbl">Classification of common stock that has different rights than provided to common units, representing ownership interest in a corporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonUnitsMember" xlink:to="btx_CommonUnitsMember_lbl" xlink:title="label: CommonUnitsMember to btx_CommonUnitsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_CommonUnitsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CommonUnitsMember_lbl1" xml:lang="en-US" id="btx_CommonUnitsMember_lbl1">Common Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonUnitsMember" xlink:to="btx_CommonUnitsMember_lbl1" xlink:title="label: CommonUnitsMember to btx_CommonUnitsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_CommonUnitsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_CommonUnitsMember_lbl2" xml:lang="en-US" id="btx_CommonUnitsMember_lbl2">Common Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonUnitsMember" xlink:to="btx_CommonUnitsMember_lbl2" xlink:title="label: CommonUnitsMember to btx_CommonUnitsMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="btx_CommonUnitsMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_CommonUnitsMember_lbl3" xml:lang="en-US" id="btx_CommonUnitsMember_lbl3">Common [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonUnitsMember" xlink:to="btx_CommonUnitsMember_lbl3" xlink:title="label: CommonUnitsMember to btx_CommonUnitsMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaycheckProtectionProgramLoanCurrent" xlink:label="PaycheckProtectionProgramLoanCurrent" xlink:title="PaycheckProtectionProgramLoanCurrent" />
    <link:label xlink:type="resource" xlink:label="btx_PaycheckProtectionProgramLoanCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PaycheckProtectionProgramLoanCurrent_lbl" xml:lang="en-US" id="btx_PaycheckProtectionProgramLoanCurrent_lbl">The amount of loans related to Paycheck Protection Program classified as current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaycheckProtectionProgramLoanCurrent" xlink:to="btx_PaycheckProtectionProgramLoanCurrent_lbl" xlink:title="label: PaycheckProtectionProgramLoanCurrent to btx_PaycheckProtectionProgramLoanCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PaycheckProtectionProgramLoanCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PaycheckProtectionProgramLoanCurrent_lbl1" xml:lang="en-US" id="btx_PaycheckProtectionProgramLoanCurrent_lbl1">Paycheck Protection Program Loan, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaycheckProtectionProgramLoanCurrent" xlink:to="btx_PaycheckProtectionProgramLoanCurrent_lbl1" xlink:title="label: PaycheckProtectionProgramLoanCurrent to btx_PaycheckProtectionProgramLoanCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PaycheckProtectionProgramLoanCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PaycheckProtectionProgramLoanCurrent_lbl2" xml:lang="en-US" id="btx_PaycheckProtectionProgramLoanCurrent_lbl2">PPP loan, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaycheckProtectionProgramLoanCurrent" xlink:to="btx_PaycheckProtectionProgramLoanCurrent_lbl2" xlink:title="label: PaycheckProtectionProgramLoanCurrent to btx_PaycheckProtectionProgramLoanCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaycheckProtectionProgramLoanNonCurrent" xlink:label="PaycheckProtectionProgramLoanNonCurrent" xlink:title="PaycheckProtectionProgramLoanNonCurrent" />
    <link:label xlink:type="resource" xlink:label="btx_PaycheckProtectionProgramLoanNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PaycheckProtectionProgramLoanNonCurrent_lbl" xml:lang="en-US" id="btx_PaycheckProtectionProgramLoanNonCurrent_lbl">The amount of loans related to Paycheck Protection Program classified as non-current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaycheckProtectionProgramLoanNonCurrent" xlink:to="btx_PaycheckProtectionProgramLoanNonCurrent_lbl" xlink:title="label: PaycheckProtectionProgramLoanNonCurrent to btx_PaycheckProtectionProgramLoanNonCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PaycheckProtectionProgramLoanNonCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PaycheckProtectionProgramLoanNonCurrent_lbl1" xml:lang="en-US" id="btx_PaycheckProtectionProgramLoanNonCurrent_lbl1">Paycheck Protection Program Loan, Non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaycheckProtectionProgramLoanNonCurrent" xlink:to="btx_PaycheckProtectionProgramLoanNonCurrent_lbl1" xlink:title="label: PaycheckProtectionProgramLoanNonCurrent to btx_PaycheckProtectionProgramLoanNonCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PaycheckProtectionProgramLoanNonCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PaycheckProtectionProgramLoanNonCurrent_lbl2" xml:lang="en-US" id="btx_PaycheckProtectionProgramLoanNonCurrent_lbl2">PPP loan, non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaycheckProtectionProgramLoanNonCurrent" xlink:to="btx_PaycheckProtectionProgramLoanNonCurrent_lbl2" xlink:title="label: PaycheckProtectionProgramLoanNonCurrent to btx_PaycheckProtectionProgramLoanNonCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_MembershipEquityMember" xlink:label="MembershipEquityMember" xlink:title="MembershipEquityMember" />
    <link:label xlink:type="resource" xlink:label="btx_MembershipEquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_MembershipEquityMember_lbl" xml:lang="en-US" id="btx_MembershipEquityMember_lbl">Equity membership interest in entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MembershipEquityMember" xlink:to="btx_MembershipEquityMember_lbl" xlink:title="label: MembershipEquityMember to btx_MembershipEquityMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_MembershipEquityMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_MembershipEquityMember_lbl1" xml:lang="en-US" id="btx_MembershipEquityMember_lbl1">Membership Equity [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MembershipEquityMember" xlink:to="btx_MembershipEquityMember_lbl1" xlink:title="label: MembershipEquityMember to btx_MembershipEquityMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_MembershipEquityMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_MembershipEquityMember_lbl2" xml:lang="en-US" id="btx_MembershipEquityMember_lbl2">Membership Equity [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MembershipEquityMember" xlink:to="btx_MembershipEquityMember_lbl2" xlink:title="label: MembershipEquityMember to btx_MembershipEquityMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodValueStockPurchaseAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl">Equity impact of the value of stock that has been issued in a stock purchase agreement during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:to="btx_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" xlink:title="label: StockIssuedDuringPeriodValueStockPurchaseAgreement to btx_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl1">Stock Issued During Period, Value, Stock Purchase Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:to="btx_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl1" xlink:title="label: StockIssuedDuringPeriodValueStockPurchaseAgreement to btx_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl2">Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:to="btx_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl2" xlink:title="label: StockIssuedDuringPeriodValueStockPurchaseAgreement to btx_StockIssuedDuringPeriodValueStockPurchaseAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesAcquisitions1" xlink:label="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="StockIssuedDuringPeriodSharesAcquisitions1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl">Number of shares of stock issued during the period pursuant to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions1" xlink:to="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions1 to btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl1">Stock Issued During Period, Shares, Acquisitions1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions1" xlink:to="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions1 to btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl2">Common stock to be retained by NTN stockholders (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions1" xlink:to="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions1 to btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl2" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl3" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl3">Stock issued, shares, acquisition (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions1" xlink:to="btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl3" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions1 to btx_StockIssuedDuringPeriodSharesAcquisitions1_lbl3" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueAcquisitions1" xlink:label="StockIssuedDuringPeriodValueAcquisitions1" xlink:title="StockIssuedDuringPeriodValueAcquisitions1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueAcquisitions1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodValueAcquisitions1_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueAcquisitions1_lbl">Value of stock issued pursuant to acquisitions during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions1" xlink:to="btx_StockIssuedDuringPeriodValueAcquisitions1_lbl" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions1 to btx_StockIssuedDuringPeriodValueAcquisitions1_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueAcquisitions1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodValueAcquisitions1_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueAcquisitions1_lbl1">Stock Issued During Period, Value, Acquisitions1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions1" xlink:to="btx_StockIssuedDuringPeriodValueAcquisitions1_lbl1" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions1 to btx_StockIssuedDuringPeriodValueAcquisitions1_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueAcquisitions1_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodValueAcquisitions1_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueAcquisitions1_lbl2">Common stock to be retained by NTN stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions1" xlink:to="btx_StockIssuedDuringPeriodValueAcquisitions1_lbl2" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions1 to btx_StockIssuedDuringPeriodValueAcquisitions1_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:label="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl">Equity impact of the shares of new stock issued of preferred stock during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:to="btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl" xlink:title="label: StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders to btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl1">Stock Issued During Period, Shares, New Issues of Preferred Stock, Retained by Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:to="btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders to btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl2">Issuance of Series A preferred stock retained by NTN stockholders (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:to="btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders to btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:label="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:title="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" />
    <link:label xlink:type="resource" xlink:label="btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl" xml:lang="en-US" id="btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl">Amount of decrease (increase) in additional paid in capital (APIC) for the increase in redemption of temporary equity as the result of a triggering event associated with the temporary equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:to="btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity to btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl1" xml:lang="en-US" id="btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl1">Adjustments to Additional Paid in Capital, Elimination Historical Member Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:to="btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity to btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl2" xml:lang="en-US" id="btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl2">Elimination of Brooklyn's historical members' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:to="btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity to btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:label="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:title="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl">Value of stock related to Forfeiture of unvested restricted stock during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:to="btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl" xlink:title="label: StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock to btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl1">Stock Issued During Period, Value, Forfeiture of Unvested Restricted Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:to="btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl1" xlink:title="label: StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock to btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl2">Forfeiture of unvested restricted stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:to="btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl2" xlink:title="label: StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock to btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:label="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl">Equity impact of the value of new stock issued of preferred stock during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:to="btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl" xlink:title="label: StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders to btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl1">Stock Issued During Period, Value, New Issues of Preferred Stock, Retained by Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:to="btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl1" xlink:title="label: StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders to btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl2">Issuance of Series A preferred stock retained by NTN stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:to="btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl2" xlink:title="label: StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders to btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:label="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:title="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" />
    <link:label xlink:type="resource" xlink:label="btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl" xml:lang="en-US" id="btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl">Number of shares Forfeiture of unvested restricted stock during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:to="btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl" xlink:title="label: SharesIssuedSharesForfeitureOfUnvestedRestrictedStock to btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl1" xml:lang="en-US" id="btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl1">Shares Issued, Shares, Forfeiture of unvested restricted stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:to="btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl1" xlink:title="label: SharesIssuedSharesForfeitureOfUnvestedRestrictedStock to btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl2" xml:lang="en-US" id="btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl2">Forfeiture of unvested restricted stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:to="btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl2" xlink:title="label: SharesIssuedSharesForfeitureOfUnvestedRestrictedStock to btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueInLieuOfDividends" xlink:label="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:title="StockIssuedDuringPeriodValueInLieuOfDividends" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueInLieuOfDividends_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodValueInLieuOfDividends_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueInLieuOfDividends_lbl">Value of stock issued during the period in Lieu of Dividends to be paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:to="btx_StockIssuedDuringPeriodValueInLieuOfDividends_lbl" xlink:title="label: StockIssuedDuringPeriodValueInLieuOfDividends to btx_StockIssuedDuringPeriodValueInLieuOfDividends_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueInLieuOfDividends_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodValueInLieuOfDividends_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueInLieuOfDividends_lbl1">Stock Issued During Period, Value, in Lieu of Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:to="btx_StockIssuedDuringPeriodValueInLieuOfDividends_lbl1" xlink:title="label: StockIssuedDuringPeriodValueInLieuOfDividends to btx_StockIssuedDuringPeriodValueInLieuOfDividends_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueInLieuOfDividends_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodValueInLieuOfDividends_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueInLieuOfDividends_lbl2">Issuance of common stock in lieu of cash dividend to Series A convertible preferred stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:to="btx_StockIssuedDuringPeriodValueInLieuOfDividends_lbl2" xlink:title="label: StockIssuedDuringPeriodValueInLieuOfDividends to btx_StockIssuedDuringPeriodValueInLieuOfDividends_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:label="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:title="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl">Value of stock issued pursuant to rights offering membership units during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:to="btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl" xlink:title="label: StockIssuedDuringPeriodValueRightsOfferingMembershipUnits to btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl1">Stock Issued During Period, Value, Rights Offering Membership Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:to="btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl1" xlink:title="label: StockIssuedDuringPeriodValueRightsOfferingMembershipUnits to btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl2">Brooklyn rights offerings membership units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:to="btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl2" xlink:title="label: StockIssuedDuringPeriodValueRightsOfferingMembershipUnits to btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:label="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:title="StockIssuedDuringPeriodSharesInLieuOfDividends" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl">Number of shares issued during the period in lieu of dividends to be paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:to="btx_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl" xlink:title="label: StockIssuedDuringPeriodSharesInLieuOfDividends to btx_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl1">Stock Issued During Period, Shares, in Lieu of Dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:to="btx_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesInLieuOfDividends to btx_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl2">Issuance of common stock in lieu of cash dividend to Series A convertible preferred stockholders (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:to="btx_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesInLieuOfDividends to btx_StockIssuedDuringPeriodSharesInLieuOfDividends_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="StockIssuedDuringPeriodSharesAcquisitions2" xlink:title="StockIssuedDuringPeriodSharesAcquisitions2" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesAcquisitions2_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodSharesAcquisitions2_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesAcquisitions2_lbl">Number of shares of stock issued during the period pursuant to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions2" xlink:to="btx_StockIssuedDuringPeriodSharesAcquisitions2_lbl" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions2 to btx_StockIssuedDuringPeriodSharesAcquisitions2_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesAcquisitions2_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodSharesAcquisitions2_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesAcquisitions2_lbl1">Stock Issued During Period, Shares, Acquisitions2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions2" xlink:to="btx_StockIssuedDuringPeriodSharesAcquisitions2_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions2 to btx_StockIssuedDuringPeriodSharesAcquisitions2_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesAcquisitions2_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodSharesAcquisitions2_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesAcquisitions2_lbl2">Issuance of common stock in connection with the acquisition of Novellus, Inc. (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAcquisitions2" xlink:to="btx_StockIssuedDuringPeriodSharesAcquisitions2_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesAcquisitions2 to btx_StockIssuedDuringPeriodSharesAcquisitions2_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="StockIssuedDuringPeriodValueAcquisitions2" xlink:title="StockIssuedDuringPeriodValueAcquisitions2" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueAcquisitions2_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodValueAcquisitions2_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueAcquisitions2_lbl">Value of stock issued pursuant to acquisitions during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions2" xlink:to="btx_StockIssuedDuringPeriodValueAcquisitions2_lbl" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions2 to btx_StockIssuedDuringPeriodValueAcquisitions2_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueAcquisitions2_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodValueAcquisitions2_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueAcquisitions2_lbl1">Stock Issued During Period, Value, Acquisitions2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions2" xlink:to="btx_StockIssuedDuringPeriodValueAcquisitions2_lbl1" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions2 to btx_StockIssuedDuringPeriodValueAcquisitions2_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodValueAcquisitions2_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodValueAcquisitions2_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodValueAcquisitions2_lbl2">Issuance of common stock in connection with the acquisition of Novellus, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAcquisitions2" xlink:to="btx_StockIssuedDuringPeriodValueAcquisitions2_lbl2" xlink:title="label: StockIssuedDuringPeriodValueAcquisitions2 to btx_StockIssuedDuringPeriodValueAcquisitions2_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodSharesStockPurchaseAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl">Number of shares that have been issued in a stock purchase agreement during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:to="btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" xlink:title="label: StockIssuedDuringPeriodSharesStockPurchaseAgreement to btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl1">Stock Issued During Period, Shares, Stock Purchase Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:to="btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesStockPurchaseAgreement to btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl2">Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:to="btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesStockPurchaseAgreement to btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EffectOfImplementationOfNewAccountingPrincipal" xlink:label="EffectOfImplementationOfNewAccountingPrincipal" xlink:title="EffectOfImplementationOfNewAccountingPrincipal" />
    <link:label xlink:type="resource" xlink:label="btx_EffectOfImplementationOfNewAccountingPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_EffectOfImplementationOfNewAccountingPrincipal_lbl" xml:lang="en-US" id="btx_EffectOfImplementationOfNewAccountingPrincipal_lbl">The effect of implementation of due to new accounting principal.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectOfImplementationOfNewAccountingPrincipal" xlink:to="btx_EffectOfImplementationOfNewAccountingPrincipal_lbl" xlink:title="label: EffectOfImplementationOfNewAccountingPrincipal to btx_EffectOfImplementationOfNewAccountingPrincipal_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_EffectOfImplementationOfNewAccountingPrincipal_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_EffectOfImplementationOfNewAccountingPrincipal_lbl1" xml:lang="en-US" id="btx_EffectOfImplementationOfNewAccountingPrincipal_lbl1">Effect of Implementation of New Accounting Principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectOfImplementationOfNewAccountingPrincipal" xlink:to="btx_EffectOfImplementationOfNewAccountingPrincipal_lbl1" xlink:title="label: EffectOfImplementationOfNewAccountingPrincipal to btx_EffectOfImplementationOfNewAccountingPrincipal_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_EffectOfImplementationOfNewAccountingPrincipal_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_EffectOfImplementationOfNewAccountingPrincipal_lbl2" xml:lang="en-US" id="btx_EffectOfImplementationOfNewAccountingPrincipal_lbl2">Implementation of new accounting principle</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectOfImplementationOfNewAccountingPrincipal" xlink:to="btx_EffectOfImplementationOfNewAccountingPrincipal_lbl2" xlink:title="label: EffectOfImplementationOfNewAccountingPrincipal to btx_EffectOfImplementationOfNewAccountingPrincipal_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaymentsOfPaycheckProtectionProgramLoan" xlink:label="PaymentsOfPaycheckProtectionProgramLoan" xlink:title="PaymentsOfPaycheckProtectionProgramLoan" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentsOfPaycheckProtectionProgramLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PaymentsOfPaycheckProtectionProgramLoan_lbl" xml:lang="en-US" id="btx_PaymentsOfPaycheckProtectionProgramLoan_lbl">The amount of cash outflow for payment of paycheck protection program loans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfPaycheckProtectionProgramLoan" xlink:to="btx_PaymentsOfPaycheckProtectionProgramLoan_lbl" xlink:title="label: PaymentsOfPaycheckProtectionProgramLoan to btx_PaymentsOfPaycheckProtectionProgramLoan_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentsOfPaycheckProtectionProgramLoan_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PaymentsOfPaycheckProtectionProgramLoan_lbl1" xml:lang="en-US" id="btx_PaymentsOfPaycheckProtectionProgramLoan_lbl1">Payments of Paycheck Protection Program Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfPaycheckProtectionProgramLoan" xlink:to="btx_PaymentsOfPaycheckProtectionProgramLoan_lbl1" xlink:title="label: PaymentsOfPaycheckProtectionProgramLoan to btx_PaymentsOfPaycheckProtectionProgramLoan_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentsOfPaycheckProtectionProgramLoan_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="btx_PaymentsOfPaycheckProtectionProgramLoan_lbl2" xml:lang="en-US" id="btx_PaymentsOfPaycheckProtectionProgramLoan_lbl2">Repayment of NTN's PPP loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfPaycheckProtectionProgramLoan" xlink:to="btx_PaymentsOfPaycheckProtectionProgramLoan_lbl2" xlink:title="label: PaymentsOfPaycheckProtectionProgramLoan to btx_PaymentsOfPaycheckProtectionProgramLoan_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_GainLossOnDisposalOfFixedAssets" xlink:label="GainLossOnDisposalOfFixedAssets" xlink:title="GainLossOnDisposalOfFixedAssets" />
    <link:label xlink:type="resource" xlink:label="btx_GainLossOnDisposalOfFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_GainLossOnDisposalOfFixedAssets_lbl" xml:lang="en-US" id="btx_GainLossOnDisposalOfFixedAssets_lbl">Amount of gain (loss) on sale or disposal of fixed assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDisposalOfFixedAssets" xlink:to="btx_GainLossOnDisposalOfFixedAssets_lbl" xlink:title="label: GainLossOnDisposalOfFixedAssets to btx_GainLossOnDisposalOfFixedAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_GainLossOnDisposalOfFixedAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_GainLossOnDisposalOfFixedAssets_lbl1" xml:lang="en-US" id="btx_GainLossOnDisposalOfFixedAssets_lbl1">Gain (Loss) on Disposal of Fixed Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDisposalOfFixedAssets" xlink:to="btx_GainLossOnDisposalOfFixedAssets_lbl1" xlink:title="label: GainLossOnDisposalOfFixedAssets to btx_GainLossOnDisposalOfFixedAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_GainLossOnDisposalOfFixedAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_GainLossOnDisposalOfFixedAssets_lbl2" xml:lang="en-US" id="btx_GainLossOnDisposalOfFixedAssets_lbl2">Loss on disposal of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDisposalOfFixedAssets" xlink:to="btx_GainLossOnDisposalOfFixedAssets_lbl2" xlink:title="label: GainLossOnDisposalOfFixedAssets to btx_GainLossOnDisposalOfFixedAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CashPaidDuringThePeriodForAbstract" xlink:label="CashPaidDuringThePeriodForAbstract" xlink:title="CashPaidDuringThePeriodForAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_CashPaidDuringThePeriodForAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CashPaidDuringThePeriodForAbstract_lbl1" xml:lang="en-US" id="btx_CashPaidDuringThePeriodForAbstract_lbl1">Cash Paid During the Period for [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashPaidDuringThePeriodForAbstract" xlink:to="btx_CashPaidDuringThePeriodForAbstract_lbl1" xlink:title="label: CashPaidDuringThePeriodForAbstract to btx_CashPaidDuringThePeriodForAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_CashPaidDuringThePeriodForAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_CashPaidDuringThePeriodForAbstract_lbl2" xml:lang="en-US" id="btx_CashPaidDuringThePeriodForAbstract_lbl2">Cash paid during the period for:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashPaidDuringThePeriodForAbstract" xlink:to="btx_CashPaidDuringThePeriodForAbstract_lbl2" xlink:title="label: CashPaidDuringThePeriodForAbstract to btx_CashPaidDuringThePeriodForAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:label="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:title="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" />
    <link:label xlink:type="resource" xlink:label="btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl" xml:lang="en-US" id="btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl">Amount of gain (loss) on forgiveness of PPP loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:to="btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl" xlink:title="label: GainLossOnForgivenessOfPaycheckProtectionProgramLoan to btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl1" xml:lang="en-US" id="btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl1">Gain (Loss) on Forgiveness of Paycheck Protection Program Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:to="btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl1" xlink:title="label: GainLossOnForgivenessOfPaycheckProtectionProgramLoan to btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl2" xml:lang="en-US" id="btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl2">Gain on forgiveness of PPP loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:to="btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl2" xlink:title="label: GainLossOnForgivenessOfPaycheckProtectionProgramLoan to btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:label="IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:title="IssuanceOfCommonStockForSeriesAPreferredStockDividend" />
    <link:label xlink:type="resource" xlink:label="btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl" xml:lang="en-US" id="btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl">The fair value of issuance of common stock for Series A preferred stock dividend in non-cash investing and financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:to="btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl" xlink:title="label: IssuanceOfCommonStockForSeriesAPreferredStockDividend to btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl1" xml:lang="en-US" id="btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl1">Issuance of Common Stock for Series A Preferred Stock Dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:to="btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl1" xlink:title="label: IssuanceOfCommonStockForSeriesAPreferredStockDividend to btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl2" xml:lang="en-US" id="btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl2">Issuance of common stock for Series A preferred stock dividend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:to="btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl2" xlink:title="label: IssuanceOfCommonStockForSeriesAPreferredStockDividend to btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance" xlink:label="InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance" xlink:title="InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance" />
    <link:label xlink:type="resource" xlink:label="btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance_lbl" xml:lang="en-US" id="btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance_lbl">The fair value of initial measurement of ROU assets, net of tenant improvement allowance in noncash financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance" xlink:to="btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance_lbl" xlink:title="label: InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance to btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance_lbl1" xml:lang="en-US" id="btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance_lbl1">Initial Measurement of Right-of-Use Assets, Net of Tenant Improvement Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance" xlink:to="btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance_lbl1" xlink:title="label: InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance to btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance_lbl2" xml:lang="en-US" id="btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance_lbl2">Initial measurement of ROU assets, net of tenant improvement allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance" xlink:to="btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance_lbl2" xlink:title="label: InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance to btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ForfeitureOfUnvestedRestrictedStock" xlink:label="ForfeitureOfUnvestedRestrictedStock" xlink:title="ForfeitureOfUnvestedRestrictedStock" />
    <link:label xlink:type="resource" xlink:label="btx_ForfeitureOfUnvestedRestrictedStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ForfeitureOfUnvestedRestrictedStock_lbl" xml:lang="en-US" id="btx_ForfeitureOfUnvestedRestrictedStock_lbl">The Forfeiture of unvested restricted stock issued in noncash financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForfeitureOfUnvestedRestrictedStock" xlink:to="btx_ForfeitureOfUnvestedRestrictedStock_lbl" xlink:title="label: ForfeitureOfUnvestedRestrictedStock to btx_ForfeitureOfUnvestedRestrictedStock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ForfeitureOfUnvestedRestrictedStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ForfeitureOfUnvestedRestrictedStock_lbl1" xml:lang="en-US" id="btx_ForfeitureOfUnvestedRestrictedStock_lbl1">Forfeiture of unvested restricted stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForfeitureOfUnvestedRestrictedStock" xlink:to="btx_ForfeitureOfUnvestedRestrictedStock_lbl1" xlink:title="label: ForfeitureOfUnvestedRestrictedStock to btx_ForfeitureOfUnvestedRestrictedStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ForfeitureOfUnvestedRestrictedStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_ForfeitureOfUnvestedRestrictedStock_lbl2" xml:lang="en-US" id="btx_ForfeitureOfUnvestedRestrictedStock_lbl2">Forfeiture of unvested restricted stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForfeitureOfUnvestedRestrictedStock" xlink:to="btx_ForfeitureOfUnvestedRestrictedStock_lbl2" xlink:title="label: ForfeitureOfUnvestedRestrictedStock to btx_ForfeitureOfUnvestedRestrictedStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:label="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:title="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" />
    <link:label xlink:type="resource" xlink:label="btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl" xml:lang="en-US" id="btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl">The fair value of preferred stock issued in a reverse merger transaction in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:to="btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl" xlink:title="label: NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger to btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl1" xml:lang="en-US" id="btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl1">Noncash or Part Noncash Acquisition, Preferred Shares Issued in Connection with Reverse Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:to="btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl1" xlink:title="label: NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger to btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl2" xml:lang="en-US" id="btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl2">Preferred shares issued in connection with reverse merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:to="btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl2" xlink:title="label: NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger to btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_InvestorDepositsForSaleOfMembersEquity" xlink:label="InvestorDepositsForSaleOfMembersEquity" xlink:title="InvestorDepositsForSaleOfMembersEquity" />
    <link:label xlink:type="resource" xlink:label="btx_InvestorDepositsForSaleOfMembersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_InvestorDepositsForSaleOfMembersEquity_lbl" xml:lang="en-US" id="btx_InvestorDepositsForSaleOfMembersEquity_lbl">The fair value of investor deposits for sale of members' equity in non-cash investing and financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorDepositsForSaleOfMembersEquity" xlink:to="btx_InvestorDepositsForSaleOfMembersEquity_lbl" xlink:title="label: InvestorDepositsForSaleOfMembersEquity to btx_InvestorDepositsForSaleOfMembersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_InvestorDepositsForSaleOfMembersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_InvestorDepositsForSaleOfMembersEquity_lbl1" xml:lang="en-US" id="btx_InvestorDepositsForSaleOfMembersEquity_lbl1">Investor deposits for sale of members' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorDepositsForSaleOfMembersEquity" xlink:to="btx_InvestorDepositsForSaleOfMembersEquity_lbl1" xlink:title="label: InvestorDepositsForSaleOfMembersEquity to btx_InvestorDepositsForSaleOfMembersEquity_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_InvestorDepositsForSaleOfMembersEquity_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_InvestorDepositsForSaleOfMembersEquity_lbl2" xml:lang="en-US" id="btx_InvestorDepositsForSaleOfMembersEquity_lbl2">Investor deposits for sale of members' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorDepositsForSaleOfMembersEquity" xlink:to="btx_InvestorDepositsForSaleOfMembersEquity_lbl2" xlink:title="label: InvestorDepositsForSaleOfMembersEquity to btx_InvestorDepositsForSaleOfMembersEquity_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_InitialMeasurementOfOperatingLeaseLiabilities" xlink:label="InitialMeasurementOfOperatingLeaseLiabilities" xlink:title="InitialMeasurementOfOperatingLeaseLiabilities" />
    <link:label xlink:type="resource" xlink:label="btx_InitialMeasurementOfOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_InitialMeasurementOfOperatingLeaseLiabilities_lbl" xml:lang="en-US" id="btx_InitialMeasurementOfOperatingLeaseLiabilities_lbl">The fair value of initial measurement of operating lease liabilities in noncash financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfOperatingLeaseLiabilities" xlink:to="btx_InitialMeasurementOfOperatingLeaseLiabilities_lbl" xlink:title="label: InitialMeasurementOfOperatingLeaseLiabilities to btx_InitialMeasurementOfOperatingLeaseLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_InitialMeasurementOfOperatingLeaseLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_InitialMeasurementOfOperatingLeaseLiabilities_lbl1" xml:lang="en-US" id="btx_InitialMeasurementOfOperatingLeaseLiabilities_lbl1">Initial Measurement of Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfOperatingLeaseLiabilities" xlink:to="btx_InitialMeasurementOfOperatingLeaseLiabilities_lbl1" xlink:title="label: InitialMeasurementOfOperatingLeaseLiabilities to btx_InitialMeasurementOfOperatingLeaseLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_InitialMeasurementOfOperatingLeaseLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_InitialMeasurementOfOperatingLeaseLiabilities_lbl2" xml:lang="en-US" id="btx_InitialMeasurementOfOperatingLeaseLiabilities_lbl2">Initial measurement of operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialMeasurementOfOperatingLeaseLiabilities" xlink:to="btx_InitialMeasurementOfOperatingLeaseLiabilities_lbl2" xlink:title="label: InitialMeasurementOfOperatingLeaseLiabilities to btx_InitialMeasurementOfOperatingLeaseLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" xlink:label="IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" xlink:title="IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" />
    <link:label xlink:type="resource" xlink:label="btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets_lbl" xml:lang="en-US" id="btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets_lbl">The increase (decrease) during the reporting period in moneys or securities given as security deposits and also includes any other non-current assets which are not separately reported in during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" xlink:to="btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets_lbl" xlink:title="label: IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets to btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets_lbl1" xml:lang="en-US" id="btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets_lbl1">Increase (Decrease) in Deposit Assets and Other Non-current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" xlink:to="btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets_lbl1" xlink:title="label: IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets to btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets_lbl2" xml:lang="en-US" id="btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets_lbl2">Security deposits and other non-current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" xlink:to="btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets_lbl2" xlink:title="label: IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets to btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:title="IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:label xlink:type="resource" xlink:label="btx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US" id="btx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl">The increase (decrease) during the reporting period in the operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="btx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:title="label: IncreaseDecreaseInOperatingLeaseLiabilities to btx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl1" xml:lang="en-US" id="btx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl1">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="btx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInOperatingLeaseLiabilities to btx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl2" xml:lang="en-US" id="btx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl2">Operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="btx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl2" xlink:title="label: IncreaseDecreaseInOperatingLeaseLiabilities to btx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IssuanceOfCommonStockForAssetAcquisition" xlink:label="IssuanceOfCommonStockForAssetAcquisition" xlink:title="IssuanceOfCommonStockForAssetAcquisition" />
    <link:label xlink:type="resource" xlink:label="btx_IssuanceOfCommonStockForAssetAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_IssuanceOfCommonStockForAssetAcquisition_lbl" xml:lang="en-US" id="btx_IssuanceOfCommonStockForAssetAcquisition_lbl">The issuance of common stock for asset acquisition in noncash financing activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockForAssetAcquisition" xlink:to="btx_IssuanceOfCommonStockForAssetAcquisition_lbl" xlink:title="label: IssuanceOfCommonStockForAssetAcquisition to btx_IssuanceOfCommonStockForAssetAcquisition_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_IssuanceOfCommonStockForAssetAcquisition_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_IssuanceOfCommonStockForAssetAcquisition_lbl1" xml:lang="en-US" id="btx_IssuanceOfCommonStockForAssetAcquisition_lbl1">Issuance of Common Stock for Asset Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockForAssetAcquisition" xlink:to="btx_IssuanceOfCommonStockForAssetAcquisition_lbl1" xlink:title="label: IssuanceOfCommonStockForAssetAcquisition to btx_IssuanceOfCommonStockForAssetAcquisition_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_IssuanceOfCommonStockForAssetAcquisition_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_IssuanceOfCommonStockForAssetAcquisition_lbl2" xml:lang="en-US" id="btx_IssuanceOfCommonStockForAssetAcquisition_lbl2">Issuance of common Stock for Novellus acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockForAssetAcquisition" xlink:to="btx_IssuanceOfCommonStockForAssetAcquisition_lbl2" xlink:title="label: IssuanceOfCommonStockForAssetAcquisition to btx_IssuanceOfCommonStockForAssetAcquisition_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LaboratoryAndManufacturingEquipmentMember" xlink:label="LaboratoryAndManufacturingEquipmentMember" xlink:title="LaboratoryAndManufacturingEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="btx_LaboratoryAndManufacturingEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LaboratoryAndManufacturingEquipmentMember_lbl" xml:lang="en-US" id="btx_LaboratoryAndManufacturingEquipmentMember_lbl">Tangible personal property used to produce goods and service.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaboratoryAndManufacturingEquipmentMember" xlink:to="btx_LaboratoryAndManufacturingEquipmentMember_lbl" xlink:title="label: LaboratoryAndManufacturingEquipmentMember to btx_LaboratoryAndManufacturingEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LaboratoryAndManufacturingEquipmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LaboratoryAndManufacturingEquipmentMember_lbl1" xml:lang="en-US" id="btx_LaboratoryAndManufacturingEquipmentMember_lbl1">Laboratory and Manufacturing Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaboratoryAndManufacturingEquipmentMember" xlink:to="btx_LaboratoryAndManufacturingEquipmentMember_lbl1" xlink:title="label: LaboratoryAndManufacturingEquipmentMember to btx_LaboratoryAndManufacturingEquipmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LaboratoryAndManufacturingEquipmentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LaboratoryAndManufacturingEquipmentMember_lbl2" xml:lang="en-US" id="btx_LaboratoryAndManufacturingEquipmentMember_lbl2">Laboratory and Manufacturing Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaboratoryAndManufacturingEquipmentMember" xlink:to="btx_LaboratoryAndManufacturingEquipmentMember_lbl2" xlink:title="label: LaboratoryAndManufacturingEquipmentMember to btx_LaboratoryAndManufacturingEquipmentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BasisOfPresentationAbstract" xlink:label="BasisOfPresentationAbstract" xlink:title="BasisOfPresentationAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_BasisOfPresentationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_BasisOfPresentationAbstract_lbl1" xml:lang="en-US" id="btx_BasisOfPresentationAbstract_lbl1">Basis of Presentation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfPresentationAbstract" xlink:to="btx_BasisOfPresentationAbstract_lbl1" xlink:title="label: BasisOfPresentationAbstract to btx_BasisOfPresentationAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_BasisOfPresentationAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_BasisOfPresentationAbstract_lbl2" xml:lang="en-US" id="btx_BasisOfPresentationAbstract_lbl2">Basis of Presentation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfPresentationAbstract" xlink:to="btx_BasisOfPresentationAbstract_lbl2" xlink:title="label: BasisOfPresentationAbstract to btx_BasisOfPresentationAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NoveCiteINCMember" xlink:label="NoveCiteINCMember" xlink:title="NoveCiteINCMember" />
    <link:label xlink:type="resource" xlink:label="btx_NoveCiteINCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NoveCiteINCMember_lbl" xml:lang="en-US" id="btx_NoveCiteINCMember_lbl">The name of company involved in licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoveCiteINCMember" xlink:to="btx_NoveCiteINCMember_lbl" xlink:title="label: NoveCiteINCMember to btx_NoveCiteINCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NoveCiteINCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NoveCiteINCMember_lbl1" xml:lang="en-US" id="btx_NoveCiteINCMember_lbl1">NoveCite, INC. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoveCiteINCMember" xlink:to="btx_NoveCiteINCMember_lbl1" xlink:title="label: NoveCiteINCMember to btx_NoveCiteINCMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NoveCiteINCMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NoveCiteINCMember_lbl2" xml:lang="en-US" id="btx_NoveCiteINCMember_lbl2">NoveCite, INC. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoveCiteINCMember" xlink:to="btx_NoveCiteINCMember_lbl2" xlink:title="label: NoveCiteINCMember to btx_NoveCiteINCMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AggregateIntrinsicValueAbstract" xlink:label="AggregateIntrinsicValueAbstract" xlink:title="AggregateIntrinsicValueAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_AggregateIntrinsicValueAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AggregateIntrinsicValueAbstract_lbl1" xml:lang="en-US" id="btx_AggregateIntrinsicValueAbstract_lbl1">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateIntrinsicValueAbstract" xlink:to="btx_AggregateIntrinsicValueAbstract_lbl1" xlink:title="label: AggregateIntrinsicValueAbstract to btx_AggregateIntrinsicValueAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2_lbl">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" xlink:to="btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2 to btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US" id="btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2_lbl1">Sharebased Compensation Arrangement By Sharebased Payment Award Granted Weighted Average Remaining Contractual Term2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" xlink:to="btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2 to btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2_lbl2" xml:lang="en-US" id="btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2_lbl2">Weighted-average remaining contractual life, granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" xlink:to="btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2_lbl2" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2 to btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NonQualifiedStockOptionMember" xlink:label="NonQualifiedStockOptionMember" xlink:title="NonQualifiedStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="btx_NonQualifiedStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NonQualifiedStockOptionMember_lbl" xml:lang="en-US" id="btx_NonQualifiedStockOptionMember_lbl">Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonQualifiedStockOptionMember" xlink:to="btx_NonQualifiedStockOptionMember_lbl" xlink:title="label: NonQualifiedStockOptionMember to btx_NonQualifiedStockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NonQualifiedStockOptionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NonQualifiedStockOptionMember_lbl1" xml:lang="en-US" id="btx_NonQualifiedStockOptionMember_lbl1">Non-qualified Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonQualifiedStockOptionMember" xlink:to="btx_NonQualifiedStockOptionMember_lbl1" xlink:title="label: NonQualifiedStockOptionMember to btx_NonQualifiedStockOptionMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NonQualifiedStockOptionMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NonQualifiedStockOptionMember_lbl2" xml:lang="en-US" id="btx_NonQualifiedStockOptionMember_lbl2">Nonqualified Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonQualifiedStockOptionMember" xlink:to="btx_NonQualifiedStockOptionMember_lbl2" xlink:title="label: NonQualifiedStockOptionMember to btx_NonQualifiedStockOptionMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_TimeBasedNonQualifiedStockOptionMember" xlink:label="TimeBasedNonQualifiedStockOptionMember" xlink:title="TimeBasedNonQualifiedStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="btx_TimeBasedNonQualifiedStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TimeBasedNonQualifiedStockOptionMember_lbl" xml:lang="en-US" id="btx_TimeBasedNonQualifiedStockOptionMember_lbl">Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares on time basis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TimeBasedNonQualifiedStockOptionMember" xlink:to="btx_TimeBasedNonQualifiedStockOptionMember_lbl" xlink:title="label: TimeBasedNonQualifiedStockOptionMember to btx_TimeBasedNonQualifiedStockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TimeBasedNonQualifiedStockOptionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TimeBasedNonQualifiedStockOptionMember_lbl1" xml:lang="en-US" id="btx_TimeBasedNonQualifiedStockOptionMember_lbl1">Time-Based Non-qualified Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TimeBasedNonQualifiedStockOptionMember" xlink:to="btx_TimeBasedNonQualifiedStockOptionMember_lbl1" xlink:title="label: TimeBasedNonQualifiedStockOptionMember to btx_TimeBasedNonQualifiedStockOptionMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TimeBasedNonQualifiedStockOptionMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_TimeBasedNonQualifiedStockOptionMember_lbl2" xml:lang="en-US" id="btx_TimeBasedNonQualifiedStockOptionMember_lbl2">Time-Based Non-qualified Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TimeBasedNonQualifiedStockOptionMember" xlink:to="btx_TimeBasedNonQualifiedStockOptionMember_lbl2" xlink:title="label: TimeBasedNonQualifiedStockOptionMember to btx_TimeBasedNonQualifiedStockOptionMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PerformanceBasedNonqualifiedStockOptionMember" xlink:label="PerformanceBasedNonqualifiedStockOptionMember" xlink:title="PerformanceBasedNonqualifiedStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="btx_PerformanceBasedNonqualifiedStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PerformanceBasedNonqualifiedStockOptionMember_lbl" xml:lang="en-US" id="btx_PerformanceBasedNonqualifiedStockOptionMember_lbl">Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares on performance basis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerformanceBasedNonqualifiedStockOptionMember" xlink:to="btx_PerformanceBasedNonqualifiedStockOptionMember_lbl" xlink:title="label: PerformanceBasedNonqualifiedStockOptionMember to btx_PerformanceBasedNonqualifiedStockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PerformanceBasedNonqualifiedStockOptionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PerformanceBasedNonqualifiedStockOptionMember_lbl1" xml:lang="en-US" id="btx_PerformanceBasedNonqualifiedStockOptionMember_lbl1">Performance-Based Nonqualified Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerformanceBasedNonqualifiedStockOptionMember" xlink:to="btx_PerformanceBasedNonqualifiedStockOptionMember_lbl1" xlink:title="label: PerformanceBasedNonqualifiedStockOptionMember to btx_PerformanceBasedNonqualifiedStockOptionMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PerformanceBasedNonqualifiedStockOptionMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PerformanceBasedNonqualifiedStockOptionMember_lbl2" xml:lang="en-US" id="btx_PerformanceBasedNonqualifiedStockOptionMember_lbl2">Performance-Based Nonqualified Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerformanceBasedNonqualifiedStockOptionMember" xlink:to="btx_PerformanceBasedNonqualifiedStockOptionMember_lbl2" xlink:title="label: PerformanceBasedNonqualifiedStockOptionMember to btx_PerformanceBasedNonqualifiedStockOptionMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NumberOfStockOptionGrantMade" xlink:label="NumberOfStockOptionGrantMade" xlink:title="NumberOfStockOptionGrantMade" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfStockOptionGrantMade_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NumberOfStockOptionGrantMade_lbl" xml:lang="en-US" id="btx_NumberOfStockOptionGrantMade_lbl">Number of stock option grants made.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfStockOptionGrantMade" xlink:to="btx_NumberOfStockOptionGrantMade_lbl" xlink:title="label: NumberOfStockOptionGrantMade to btx_NumberOfStockOptionGrantMade_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfStockOptionGrantMade_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NumberOfStockOptionGrantMade_lbl1" xml:lang="en-US" id="btx_NumberOfStockOptionGrantMade_lbl1">Number Of Stock Option Grant Made</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfStockOptionGrantMade" xlink:to="btx_NumberOfStockOptionGrantMade_lbl1" xlink:title="label: NumberOfStockOptionGrantMade to btx_NumberOfStockOptionGrantMade_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfStockOptionGrantMade_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NumberOfStockOptionGrantMade_lbl2" xml:lang="en-US" id="btx_NumberOfStockOptionGrantMade_lbl2">Number of stock option grants made</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfStockOptionGrantMade" xlink:to="btx_NumberOfStockOptionGrantMade_lbl2" xlink:title="label: NumberOfStockOptionGrantMade to btx_NumberOfStockOptionGrantMade_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" />
    <link:label xlink:type="resource" xlink:label="btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl" xml:lang="en-US" id="btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl">The number of monthly installments for vesting of remaining shares in share-based compensation arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:to="btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares to btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl1" xml:lang="en-US" id="btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl1">Share-based Compensation Arrangement by Share-based Payment, Number of Monthly Installments for Vesting of Remaining Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:to="btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares to btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl2" xml:lang="en-US" id="btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl2">Number of monthly installments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:to="btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares to btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />
    <link:label xlink:type="resource" xlink:label="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xml:lang="en-US" id="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl">The amount of fair value of share-based payment arrangement, subject to vesting and other restrictions, to purchase or sell certain number of shares on performance basis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:to="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue to btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl1" xml:lang="en-US" id="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:to="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue to btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl2" xml:lang="en-US" id="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl2">Stock-based compensation grant fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:to="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue to btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" />
    <link:label xlink:type="resource" xlink:label="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_lbl" xml:lang="en-US" id="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_lbl">The number of non-vested equity-based payment instruments, excluding stock (or unit) options expected to vest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:to="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber to btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_lbl1" xml:lang="en-US" id="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:to="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber to btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_lbl2" xml:lang="en-US" id="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_lbl2">Balance expected to vest (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:to="btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber to btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IncentiveStockOptionsMember" xlink:label="IncentiveStockOptionsMember" xlink:title="IncentiveStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="btx_IncentiveStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_IncentiveStockOptionsMember_lbl" xml:lang="en-US" id="btx_IncentiveStockOptionsMember_lbl">Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares on incentive basis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveStockOptionsMember" xlink:to="btx_IncentiveStockOptionsMember_lbl" xlink:title="label: IncentiveStockOptionsMember to btx_IncentiveStockOptionsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_IncentiveStockOptionsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_IncentiveStockOptionsMember_lbl1" xml:lang="en-US" id="btx_IncentiveStockOptionsMember_lbl1">Incentive Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveStockOptionsMember" xlink:to="btx_IncentiveStockOptionsMember_lbl1" xlink:title="label: IncentiveStockOptionsMember to btx_IncentiveStockOptionsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_IncentiveStockOptionsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_IncentiveStockOptionsMember_lbl2" xml:lang="en-US" id="btx_IncentiveStockOptionsMember_lbl2">Incentive Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncentiveStockOptionsMember" xlink:to="btx_IncentiveStockOptionsMember_lbl2" xlink:title="label: IncentiveStockOptionsMember to btx_IncentiveStockOptionsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_InducementPlan2021Member" xlink:label="InducementPlan2021Member" xlink:title="InducementPlan2021Member" />
    <link:label xlink:type="resource" xlink:label="btx_InducementPlan2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_InducementPlan2021Member_lbl" xml:lang="en-US" id="btx_InducementPlan2021Member_lbl">Share-based payment arrangement award inducement plan 2021.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InducementPlan2021Member" xlink:to="btx_InducementPlan2021Member_lbl" xlink:title="label: InducementPlan2021Member to btx_InducementPlan2021Member_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_InducementPlan2021Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_InducementPlan2021Member_lbl1" xml:lang="en-US" id="btx_InducementPlan2021Member_lbl1">Inducement Plan 2021 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InducementPlan2021Member" xlink:to="btx_InducementPlan2021Member_lbl1" xlink:title="label: InducementPlan2021Member to btx_InducementPlan2021Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_InducementPlan2021Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_InducementPlan2021Member_lbl2" xml:lang="en-US" id="btx_InducementPlan2021Member_lbl2">2021 Inducement Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InducementPlan2021Member" xlink:to="btx_InducementPlan2021Member_lbl2" xlink:title="label: InducementPlan2021Member to btx_InducementPlan2021Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EquityIncentivePlan2020Member" xlink:label="EquityIncentivePlan2020Member" xlink:title="EquityIncentivePlan2020Member" />
    <link:label xlink:type="resource" xlink:label="btx_EquityIncentivePlan2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_EquityIncentivePlan2020Member_lbl" xml:lang="en-US" id="btx_EquityIncentivePlan2020Member_lbl">Share-based compensation equity incentive plan 2020.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2020Member" xlink:to="btx_EquityIncentivePlan2020Member_lbl" xlink:title="label: EquityIncentivePlan2020Member to btx_EquityIncentivePlan2020Member_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_EquityIncentivePlan2020Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_EquityIncentivePlan2020Member_lbl1" xml:lang="en-US" id="btx_EquityIncentivePlan2020Member_lbl1">Equity Incentive Plan 2020 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2020Member" xlink:to="btx_EquityIncentivePlan2020Member_lbl1" xlink:title="label: EquityIncentivePlan2020Member to btx_EquityIncentivePlan2020Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_EquityIncentivePlan2020Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_EquityIncentivePlan2020Member_lbl2" xml:lang="en-US" id="btx_EquityIncentivePlan2020Member_lbl2">2020 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2020Member" xlink:to="btx_EquityIncentivePlan2020Member_lbl2" xlink:title="label: EquityIncentivePlan2020Member to btx_EquityIncentivePlan2020Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfSharesOfCommonStockOutstanding" xlink:label="PercentageOfSharesOfCommonStockOutstanding" xlink:title="PercentageOfSharesOfCommonStockOutstanding" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfSharesOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageOfSharesOfCommonStockOutstanding_lbl" xml:lang="en-US" id="btx_PercentageOfSharesOfCommonStockOutstanding_lbl">Percentage of common stock shares outstanding considered for equity number of shares under equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfSharesOfCommonStockOutstanding" xlink:to="btx_PercentageOfSharesOfCommonStockOutstanding_lbl" xlink:title="label: PercentageOfSharesOfCommonStockOutstanding to btx_PercentageOfSharesOfCommonStockOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfSharesOfCommonStockOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageOfSharesOfCommonStockOutstanding_lbl1" xml:lang="en-US" id="btx_PercentageOfSharesOfCommonStockOutstanding_lbl1">Percentage of Shares of Common Stock Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfSharesOfCommonStockOutstanding" xlink:to="btx_PercentageOfSharesOfCommonStockOutstanding_lbl1" xlink:title="label: PercentageOfSharesOfCommonStockOutstanding to btx_PercentageOfSharesOfCommonStockOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfSharesOfCommonStockOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageOfSharesOfCommonStockOutstanding_lbl2" xml:lang="en-US" id="btx_PercentageOfSharesOfCommonStockOutstanding_lbl2">Percentage of number of shares of common stock outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfSharesOfCommonStockOutstanding" xlink:to="btx_PercentageOfSharesOfCommonStockOutstanding_lbl2" xlink:title="label: PercentageOfSharesOfCommonStockOutstanding to btx_PercentageOfSharesOfCommonStockOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PrivatePlacementOfEquityAbstract" xlink:label="PrivatePlacementOfEquityAbstract" xlink:title="PrivatePlacementOfEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_PrivatePlacementOfEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PrivatePlacementOfEquityAbstract_lbl1" xml:lang="en-US" id="btx_PrivatePlacementOfEquityAbstract_lbl1">Private Placement of Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="btx_PrivatePlacementOfEquityAbstract_lbl1" xlink:title="label: PrivatePlacementOfEquityAbstract to btx_PrivatePlacementOfEquityAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PrivatePlacementOfEquityAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PrivatePlacementOfEquityAbstract_lbl2" xml:lang="en-US" id="btx_PrivatePlacementOfEquityAbstract_lbl2">Private Placement of Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="btx_PrivatePlacementOfEquityAbstract_lbl2" xlink:title="label: PrivatePlacementOfEquityAbstract to btx_PrivatePlacementOfEquityAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ClassOfWarrantOrRightsExercisableTerm" xlink:label="ClassOfWarrantOrRightsExercisableTerm" xlink:title="ClassOfWarrantOrRightsExercisableTerm" />
    <link:label xlink:type="resource" xlink:label="btx_ClassOfWarrantOrRightsExercisableTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ClassOfWarrantOrRightsExercisableTerm_lbl" xml:lang="en-US" id="btx_ClassOfWarrantOrRightsExercisableTerm_lbl">Warrants or rights exercisable term, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightsExercisableTerm" xlink:to="btx_ClassOfWarrantOrRightsExercisableTerm_lbl" xlink:title="label: ClassOfWarrantOrRightsExercisableTerm to btx_ClassOfWarrantOrRightsExercisableTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ClassOfWarrantOrRightsExercisableTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ClassOfWarrantOrRightsExercisableTerm_lbl1" xml:lang="en-US" id="btx_ClassOfWarrantOrRightsExercisableTerm_lbl1">Class of Warrant or Rights Exercisable Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightsExercisableTerm" xlink:to="btx_ClassOfWarrantOrRightsExercisableTerm_lbl1" xlink:title="label: ClassOfWarrantOrRightsExercisableTerm to btx_ClassOfWarrantOrRightsExercisableTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ClassOfWarrantOrRightsExercisableTerm_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ClassOfWarrantOrRightsExercisableTerm_lbl2" xml:lang="en-US" id="btx_ClassOfWarrantOrRightsExercisableTerm_lbl2">Warrant exercisable term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightsExercisableTerm" xlink:to="btx_ClassOfWarrantOrRightsExercisableTerm_lbl2" xlink:title="label: ClassOfWarrantOrRightsExercisableTerm to btx_ClassOfWarrantOrRightsExercisableTerm_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NewLeaseAgreementAbstract" xlink:label="NewLeaseAgreementAbstract" xlink:title="NewLeaseAgreementAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_NewLeaseAgreementAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NewLeaseAgreementAbstract_lbl1" xml:lang="en-US" id="btx_NewLeaseAgreementAbstract_lbl1">New Lease Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewLeaseAgreementAbstract" xlink:to="btx_NewLeaseAgreementAbstract_lbl1" xlink:title="label: NewLeaseAgreementAbstract to btx_NewLeaseAgreementAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NewLeaseAgreementAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NewLeaseAgreementAbstract_lbl2" xml:lang="en-US" id="btx_NewLeaseAgreementAbstract_lbl2">New Lease Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewLeaseAgreementAbstract" xlink:to="btx_NewLeaseAgreementAbstract_lbl2" xlink:title="label: NewLeaseAgreementAbstract to btx_NewLeaseAgreementAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BaseRentPerSquareFoot" xlink:label="BaseRentPerSquareFoot" xlink:title="BaseRentPerSquareFoot" />
    <link:label xlink:type="resource" xlink:label="btx_BaseRentPerSquareFoot_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_BaseRentPerSquareFoot_lbl" xml:lang="en-US" id="btx_BaseRentPerSquareFoot_lbl">Amount of base rent expense per square foot for leased asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BaseRentPerSquareFoot" xlink:to="btx_BaseRentPerSquareFoot_lbl" xlink:title="label: BaseRentPerSquareFoot to btx_BaseRentPerSquareFoot_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_BaseRentPerSquareFoot_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_BaseRentPerSquareFoot_lbl1" xml:lang="en-US" id="btx_BaseRentPerSquareFoot_lbl1">Base Rent per Square Foot</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BaseRentPerSquareFoot" xlink:to="btx_BaseRentPerSquareFoot_lbl1" xlink:title="label: BaseRentPerSquareFoot to btx_BaseRentPerSquareFoot_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_BaseRentPerSquareFoot_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_BaseRentPerSquareFoot_lbl2" xml:lang="en-US" id="btx_BaseRentPerSquareFoot_lbl2">Base rent (per square foot)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BaseRentPerSquareFoot" xlink:to="btx_BaseRentPerSquareFoot_lbl2" xlink:title="label: BaseRentPerSquareFoot to btx_BaseRentPerSquareFoot_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_OperatingLeaseArea" xlink:label="OperatingLeaseArea" xlink:title="OperatingLeaseArea" />
    <link:label xlink:type="resource" xlink:label="btx_OperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_OperatingLeaseArea_lbl" xml:lang="en-US" id="btx_OperatingLeaseArea_lbl">Area of leased property under operating lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseArea" xlink:to="btx_OperatingLeaseArea_lbl" xlink:title="label: OperatingLeaseArea to btx_OperatingLeaseArea_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_OperatingLeaseArea_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_OperatingLeaseArea_lbl1" xml:lang="en-US" id="btx_OperatingLeaseArea_lbl1">Operating Lease Area</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseArea" xlink:to="btx_OperatingLeaseArea_lbl1" xlink:title="label: OperatingLeaseArea to btx_OperatingLeaseArea_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_OperatingLeaseArea_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_OperatingLeaseArea_lbl2" xml:lang="en-US" id="btx_OperatingLeaseArea_lbl2">Operating lease area</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseArea" xlink:to="btx_OperatingLeaseArea_lbl2" xlink:title="label: OperatingLeaseArea to btx_OperatingLeaseArea_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageBaseRentIncreaseOnEachAnniversary" xlink:label="PercentageBaseRentIncreaseOnEachAnniversary" xlink:title="PercentageBaseRentIncreaseOnEachAnniversary" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageBaseRentIncreaseOnEachAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageBaseRentIncreaseOnEachAnniversary_lbl" xml:lang="en-US" id="btx_PercentageBaseRentIncreaseOnEachAnniversary_lbl">The percentage of base rent increase on each anniversary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageBaseRentIncreaseOnEachAnniversary" xlink:to="btx_PercentageBaseRentIncreaseOnEachAnniversary_lbl" xlink:title="label: PercentageBaseRentIncreaseOnEachAnniversary to btx_PercentageBaseRentIncreaseOnEachAnniversary_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageBaseRentIncreaseOnEachAnniversary_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageBaseRentIncreaseOnEachAnniversary_lbl1" xml:lang="en-US" id="btx_PercentageBaseRentIncreaseOnEachAnniversary_lbl1">Percentage, Base Rent Increase on each Anniversary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageBaseRentIncreaseOnEachAnniversary" xlink:to="btx_PercentageBaseRentIncreaseOnEachAnniversary_lbl1" xlink:title="label: PercentageBaseRentIncreaseOnEachAnniversary to btx_PercentageBaseRentIncreaseOnEachAnniversary_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageBaseRentIncreaseOnEachAnniversary_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageBaseRentIncreaseOnEachAnniversary_lbl2" xml:lang="en-US" id="btx_PercentageBaseRentIncreaseOnEachAnniversary_lbl2">Percentage of increase in base rent on each year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageBaseRentIncreaseOnEachAnniversary" xlink:to="btx_PercentageBaseRentIncreaseOnEachAnniversary_lbl2" xlink:title="label: PercentageBaseRentIncreaseOnEachAnniversary to btx_PercentageBaseRentIncreaseOnEachAnniversary_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PIPEInvestorMember" xlink:label="PIPEInvestorMember" xlink:title="PIPEInvestorMember" />
    <link:label xlink:type="resource" xlink:label="btx_PIPEInvestorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PIPEInvestorMember_lbl" xml:lang="en-US" id="btx_PIPEInvestorMember_lbl">A private investment in public equity, often called a PIPE deal, involves the selling of publicly traded common shares or some form of preferred stock or convertible security to private investors. It is an allocation of shares in a public company not through a public offering in a stock exchange. PIPE deals are part of the primary market. In the U.S., a PIPE offering may be registered with the Securities and Exchange Commission on a registration statement or may be completed as an unregistered private placement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PIPEInvestorMember" xlink:to="btx_PIPEInvestorMember_lbl" xlink:title="label: PIPEInvestorMember to btx_PIPEInvestorMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PIPEInvestorMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PIPEInvestorMember_lbl1" xml:lang="en-US" id="btx_PIPEInvestorMember_lbl1">PIPE Investor [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PIPEInvestorMember" xlink:to="btx_PIPEInvestorMember_lbl1" xlink:title="label: PIPEInvestorMember to btx_PIPEInvestorMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PIPEInvestorMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PIPEInvestorMember_lbl2" xml:lang="en-US" id="btx_PIPEInvestorMember_lbl2">PIPE Investor [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PIPEInvestorMember" xlink:to="btx_PIPEInvestorMember_lbl2" xlink:title="label: PIPEInvestorMember to btx_PIPEInvestorMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:label="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl" xml:lang="en-US" id="btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl">Percentage of securities that would be issuable upon the exercise of warrants or rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:to="btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl" xlink:title="label: ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights to btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl1" xml:lang="en-US" id="btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl1">Class of Warrant or Right Percent of Securities that Would be Issuable Upon Exercise of Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:to="btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl1" xlink:title="label: ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights to btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl2" xml:lang="en-US" id="btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl2">Percentage of warrants exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:to="btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl2" xlink:title="label: ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights to btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LeaseAssignmentAbstract" xlink:label="LeaseAssignmentAbstract" xlink:title="LeaseAssignmentAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_LeaseAssignmentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LeaseAssignmentAbstract_lbl1" xml:lang="en-US" id="btx_LeaseAssignmentAbstract_lbl1">Lease Assignment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseAssignmentAbstract" xlink:to="btx_LeaseAssignmentAbstract_lbl1" xlink:title="label: LeaseAssignmentAbstract to btx_LeaseAssignmentAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LeaseAssignmentAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LeaseAssignmentAbstract_lbl2" xml:lang="en-US" id="btx_LeaseAssignmentAbstract_lbl2">Lease Assignment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseAssignmentAbstract" xlink:to="btx_LeaseAssignmentAbstract_lbl2" xlink:title="label: LeaseAssignmentAbstract to btx_LeaseAssignmentAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_UnamortizedLeaseholdImprovements" xlink:label="UnamortizedLeaseholdImprovements" xlink:title="UnamortizedLeaseholdImprovements" />
    <link:label xlink:type="resource" xlink:label="btx_UnamortizedLeaseholdImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_UnamortizedLeaseholdImprovements_lbl" xml:lang="en-US" id="btx_UnamortizedLeaseholdImprovements_lbl">The amount of unamortized leasehold improvements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnamortizedLeaseholdImprovements" xlink:to="btx_UnamortizedLeaseholdImprovements_lbl" xlink:title="label: UnamortizedLeaseholdImprovements to btx_UnamortizedLeaseholdImprovements_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_UnamortizedLeaseholdImprovements_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_UnamortizedLeaseholdImprovements_lbl1" xml:lang="en-US" id="btx_UnamortizedLeaseholdImprovements_lbl1">Unamortized Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnamortizedLeaseholdImprovements" xlink:to="btx_UnamortizedLeaseholdImprovements_lbl1" xlink:title="label: UnamortizedLeaseholdImprovements to btx_UnamortizedLeaseholdImprovements_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_UnamortizedLeaseholdImprovements_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_UnamortizedLeaseholdImprovements_lbl2" xml:lang="en-US" id="btx_UnamortizedLeaseholdImprovements_lbl2">Unamortized leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnamortizedLeaseholdImprovements" xlink:to="btx_UnamortizedLeaseholdImprovements_lbl2" xlink:title="label: UnamortizedLeaseholdImprovements to btx_UnamortizedLeaseholdImprovements_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LesseeCommitmentToPurchaseProperty" xlink:label="LesseeCommitmentToPurchaseProperty" xlink:title="LesseeCommitmentToPurchaseProperty" />
    <link:label xlink:type="resource" xlink:label="btx_LesseeCommitmentToPurchaseProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LesseeCommitmentToPurchaseProperty_lbl" xml:lang="en-US" id="btx_LesseeCommitmentToPurchaseProperty_lbl">The amount of property for which lessee committed to purchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeCommitmentToPurchaseProperty" xlink:to="btx_LesseeCommitmentToPurchaseProperty_lbl" xlink:title="label: LesseeCommitmentToPurchaseProperty to btx_LesseeCommitmentToPurchaseProperty_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LesseeCommitmentToPurchaseProperty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LesseeCommitmentToPurchaseProperty_lbl1" xml:lang="en-US" id="btx_LesseeCommitmentToPurchaseProperty_lbl1">Lessee, Commitment to Purchase Property</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeCommitmentToPurchaseProperty" xlink:to="btx_LesseeCommitmentToPurchaseProperty_lbl1" xlink:title="label: LesseeCommitmentToPurchaseProperty to btx_LesseeCommitmentToPurchaseProperty_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LesseeCommitmentToPurchaseProperty_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LesseeCommitmentToPurchaseProperty_lbl2" xml:lang="en-US" id="btx_LesseeCommitmentToPurchaseProperty_lbl2">Commitment to purchase equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeCommitmentToPurchaseProperty" xlink:to="btx_LesseeCommitmentToPurchaseProperty_lbl2" xlink:title="label: LesseeCommitmentToPurchaseProperty to btx_LesseeCommitmentToPurchaseProperty_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PreFundedWarrantsMember" xlink:label="PreFundedWarrantsMember" xlink:title="PreFundedWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="btx_PreFundedWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PreFundedWarrantsMember_lbl" xml:lang="en-US" id="btx_PreFundedWarrantsMember_lbl">A pre-funded warrant that allows the warrant holder to purchase a specified number of a company's securities at a nominal exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreFundedWarrantsMember" xlink:to="btx_PreFundedWarrantsMember_lbl" xlink:title="label: PreFundedWarrantsMember to btx_PreFundedWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PreFundedWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PreFundedWarrantsMember_lbl1" xml:lang="en-US" id="btx_PreFundedWarrantsMember_lbl1">Pre-funded Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreFundedWarrantsMember" xlink:to="btx_PreFundedWarrantsMember_lbl1" xlink:title="label: PreFundedWarrantsMember to btx_PreFundedWarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PreFundedWarrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PreFundedWarrantsMember_lbl2" xml:lang="en-US" id="btx_PreFundedWarrantsMember_lbl2">Pre-funded Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreFundedWarrantsMember" xlink:to="btx_PreFundedWarrantsMember_lbl2" xlink:title="label: PreFundedWarrantsMember to btx_PreFundedWarrantsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CommonWarrantsMember" xlink:label="CommonWarrantsMember" xlink:title="CommonWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="btx_CommonWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_CommonWarrantsMember_lbl" xml:lang="en-US" id="btx_CommonWarrantsMember_lbl">A common warrant represents the right to purchase a company's stock at a specific price and at a specific date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonWarrantsMember" xlink:to="btx_CommonWarrantsMember_lbl" xlink:title="label: CommonWarrantsMember to btx_CommonWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_CommonWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CommonWarrantsMember_lbl1" xml:lang="en-US" id="btx_CommonWarrantsMember_lbl1">Common Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonWarrantsMember" xlink:to="btx_CommonWarrantsMember_lbl1" xlink:title="label: CommonWarrantsMember to btx_CommonWarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_CommonWarrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_CommonWarrantsMember_lbl2" xml:lang="en-US" id="btx_CommonWarrantsMember_lbl2">Common Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonWarrantsMember" xlink:to="btx_CommonWarrantsMember_lbl2" xlink:title="label: CommonWarrantsMember to btx_CommonWarrantsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ReverseStockSplitAbstract" xlink:label="ReverseStockSplitAbstract" xlink:title="ReverseStockSplitAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_ReverseStockSplitAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ReverseStockSplitAbstract_lbl1" xml:lang="en-US" id="btx_ReverseStockSplitAbstract_lbl1">Reverse Stock-Split [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitAbstract" xlink:to="btx_ReverseStockSplitAbstract_lbl1" xlink:title="label: ReverseStockSplitAbstract to btx_ReverseStockSplitAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AccruedGeneralAndAdministrativeExpenses" xlink:label="AccruedGeneralAndAdministrativeExpenses" xlink:title="AccruedGeneralAndAdministrativeExpenses" />
    <link:label xlink:type="resource" xlink:label="btx_AccruedGeneralAndAdministrativeExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AccruedGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" id="btx_AccruedGeneralAndAdministrativeExpenses_lbl">Amount of accrued general and administrative expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedGeneralAndAdministrativeExpenses" xlink:to="btx_AccruedGeneralAndAdministrativeExpenses_lbl" xlink:title="label: AccruedGeneralAndAdministrativeExpenses to btx_AccruedGeneralAndAdministrativeExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AccruedGeneralAndAdministrativeExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AccruedGeneralAndAdministrativeExpenses_lbl1" xml:lang="en-US" id="btx_AccruedGeneralAndAdministrativeExpenses_lbl1">Accrued General and Administrative Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedGeneralAndAdministrativeExpenses" xlink:to="btx_AccruedGeneralAndAdministrativeExpenses_lbl1" xlink:title="label: AccruedGeneralAndAdministrativeExpenses to btx_AccruedGeneralAndAdministrativeExpenses_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AccruedGeneralAndAdministrativeExpenses_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AccruedGeneralAndAdministrativeExpenses_lbl2" xml:lang="en-US" id="btx_AccruedGeneralAndAdministrativeExpenses_lbl2">Accrued general and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedGeneralAndAdministrativeExpenses" xlink:to="btx_AccruedGeneralAndAdministrativeExpenses_lbl2" xlink:title="label: AccruedGeneralAndAdministrativeExpenses to btx_AccruedGeneralAndAdministrativeExpenses_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AccruedResearchAndDevelopmentExpenses" xlink:label="AccruedResearchAndDevelopmentExpenses" xlink:title="AccruedResearchAndDevelopmentExpenses" />
    <link:label xlink:type="resource" xlink:label="btx_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" id="btx_AccruedResearchAndDevelopmentExpenses_lbl">Amount of accrued research and development expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentExpenses" xlink:to="btx_AccruedResearchAndDevelopmentExpenses_lbl" xlink:title="label: AccruedResearchAndDevelopmentExpenses to btx_AccruedResearchAndDevelopmentExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AccruedResearchAndDevelopmentExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AccruedResearchAndDevelopmentExpenses_lbl1" xml:lang="en-US" id="btx_AccruedResearchAndDevelopmentExpenses_lbl1">Accrued Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentExpenses" xlink:to="btx_AccruedResearchAndDevelopmentExpenses_lbl1" xlink:title="label: AccruedResearchAndDevelopmentExpenses to btx_AccruedResearchAndDevelopmentExpenses_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AccruedResearchAndDevelopmentExpenses_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AccruedResearchAndDevelopmentExpenses_lbl2" xml:lang="en-US" id="btx_AccruedResearchAndDevelopmentExpenses_lbl2">Accrued research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentExpenses" xlink:to="btx_AccruedResearchAndDevelopmentExpenses_lbl2" xlink:title="label: AccruedResearchAndDevelopmentExpenses to btx_AccruedResearchAndDevelopmentExpenses_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PrivatePlacementOfferingsAbstract" xlink:label="PrivatePlacementOfferingsAbstract" xlink:title="PrivatePlacementOfferingsAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_PrivatePlacementOfferingsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PrivatePlacementOfferingsAbstract_lbl1" xml:lang="en-US" id="btx_PrivatePlacementOfferingsAbstract_lbl1">Private Placement Offerings [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrivatePlacementOfferingsAbstract" xlink:to="btx_PrivatePlacementOfferingsAbstract_lbl1" xlink:title="label: PrivatePlacementOfferingsAbstract to btx_PrivatePlacementOfferingsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" xlink:label="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" xlink:title="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" />
    <link:label xlink:type="resource" xlink:label="btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1_lbl" xml:lang="en-US" id="btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1_lbl">The number of further shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" xlink:to="btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1_lbl" xlink:title="label: NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1 to btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1_lbl1" xml:lang="en-US" id="btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1_lbl1">Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Further Shares Issued1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" xlink:to="btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1_lbl1" xlink:title="label: NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1 to btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1_lbl2" xml:lang="en-US" id="btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1_lbl2">Number of shares remaining to be sold in purchase commitment (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" xlink:to="btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1_lbl2" xlink:title="label: NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1 to btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleOfStockNumberOfSharesToIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesToIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesToIssuedInTransaction" />
    <link:label xlink:type="resource" xlink:label="btx_SaleOfStockNumberOfSharesToIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SaleOfStockNumberOfSharesToIssuedInTransaction_lbl" xml:lang="en-US" id="btx_SaleOfStockNumberOfSharesToIssuedInTransaction_lbl">The number of shares to be issued by the subsidiary or equity method investee per stock transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesToIssuedInTransaction" xlink:to="btx_SaleOfStockNumberOfSharesToIssuedInTransaction_lbl" xlink:title="label: SaleOfStockNumberOfSharesToIssuedInTransaction to btx_SaleOfStockNumberOfSharesToIssuedInTransaction_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SaleOfStockNumberOfSharesToIssuedInTransaction_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SaleOfStockNumberOfSharesToIssuedInTransaction_lbl1" xml:lang="en-US" id="btx_SaleOfStockNumberOfSharesToIssuedInTransaction_lbl1">Sale of Stock, Number of Shares to Issued in Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesToIssuedInTransaction" xlink:to="btx_SaleOfStockNumberOfSharesToIssuedInTransaction_lbl1" xlink:title="label: SaleOfStockNumberOfSharesToIssuedInTransaction to btx_SaleOfStockNumberOfSharesToIssuedInTransaction_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SaleOfStockNumberOfSharesToIssuedInTransaction_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_SaleOfStockNumberOfSharesToIssuedInTransaction_lbl2" xml:lang="en-US" id="btx_SaleOfStockNumberOfSharesToIssuedInTransaction_lbl2">Number of remaining shares to be sold (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesToIssuedInTransaction" xlink:to="btx_SaleOfStockNumberOfSharesToIssuedInTransaction_lbl2" xlink:title="label: SaleOfStockNumberOfSharesToIssuedInTransaction to btx_SaleOfStockNumberOfSharesToIssuedInTransaction_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BeneficialOwnershipPercentageOnTotalOutstandingShares" xlink:label="BeneficialOwnershipPercentageOnTotalOutstandingShares" xlink:title="BeneficialOwnershipPercentageOnTotalOutstandingShares" />
    <link:label xlink:type="resource" xlink:label="btx_BeneficialOwnershipPercentageOnTotalOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_BeneficialOwnershipPercentageOnTotalOutstandingShares_lbl" xml:lang="en-US" id="btx_BeneficialOwnershipPercentageOnTotalOutstandingShares_lbl">The equity interest of shareholders, partners or other equity holders in consolidated entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeneficialOwnershipPercentageOnTotalOutstandingShares" xlink:to="btx_BeneficialOwnershipPercentageOnTotalOutstandingShares_lbl" xlink:title="label: BeneficialOwnershipPercentageOnTotalOutstandingShares to btx_BeneficialOwnershipPercentageOnTotalOutstandingShares_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_BeneficialOwnershipPercentageOnTotalOutstandingShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_BeneficialOwnershipPercentageOnTotalOutstandingShares_lbl1" xml:lang="en-US" id="btx_BeneficialOwnershipPercentageOnTotalOutstandingShares_lbl1">Beneficial Ownership Percentage on Total Outstanding Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeneficialOwnershipPercentageOnTotalOutstandingShares" xlink:to="btx_BeneficialOwnershipPercentageOnTotalOutstandingShares_lbl1" xlink:title="label: BeneficialOwnershipPercentageOnTotalOutstandingShares to btx_BeneficialOwnershipPercentageOnTotalOutstandingShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_BeneficialOwnershipPercentageOnTotalOutstandingShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_BeneficialOwnershipPercentageOnTotalOutstandingShares_lbl2" xml:lang="en-US" id="btx_BeneficialOwnershipPercentageOnTotalOutstandingShares_lbl2">Beneficial ownership percentage on total outstanding shares that prohibits company to direct share purchases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeneficialOwnershipPercentageOnTotalOutstandingShares" xlink:to="btx_BeneficialOwnershipPercentageOnTotalOutstandingShares_lbl2" xlink:title="label: BeneficialOwnershipPercentageOnTotalOutstandingShares to btx_BeneficialOwnershipPercentageOnTotalOutstandingShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CommitmentAmountToMeetAnySingleRegularPurchase" xlink:label="CommitmentAmountToMeetAnySingleRegularPurchase" xlink:title="CommitmentAmountToMeetAnySingleRegularPurchase" />
    <link:label xlink:type="resource" xlink:label="btx_CommitmentAmountToMeetAnySingleRegularPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_CommitmentAmountToMeetAnySingleRegularPurchase_lbl" xml:lang="en-US" id="btx_CommitmentAmountToMeetAnySingleRegularPurchase_lbl">The amount of purchase price or commitment amount to meet any single regular purchase in share purchase transaction on any business day.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentAmountToMeetAnySingleRegularPurchase" xlink:to="btx_CommitmentAmountToMeetAnySingleRegularPurchase_lbl" xlink:title="label: CommitmentAmountToMeetAnySingleRegularPurchase to btx_CommitmentAmountToMeetAnySingleRegularPurchase_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_CommitmentAmountToMeetAnySingleRegularPurchase_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CommitmentAmountToMeetAnySingleRegularPurchase_lbl1" xml:lang="en-US" id="btx_CommitmentAmountToMeetAnySingleRegularPurchase_lbl1">Commitment Amount to Meet any Single Regular Purchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentAmountToMeetAnySingleRegularPurchase" xlink:to="btx_CommitmentAmountToMeetAnySingleRegularPurchase_lbl1" xlink:title="label: CommitmentAmountToMeetAnySingleRegularPurchase to btx_CommitmentAmountToMeetAnySingleRegularPurchase_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_CommitmentAmountToMeetAnySingleRegularPurchase_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_CommitmentAmountToMeetAnySingleRegularPurchase_lbl2" xml:lang="en-US" id="btx_CommitmentAmountToMeetAnySingleRegularPurchase_lbl2">Maximum commitment in any single regular purchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentAmountToMeetAnySingleRegularPurchase" xlink:to="btx_CommitmentAmountToMeetAnySingleRegularPurchase_lbl2" xlink:title="label: CommitmentAmountToMeetAnySingleRegularPurchase to btx_CommitmentAmountToMeetAnySingleRegularPurchase_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PurchaseAgreementMember" xlink:label="PurchaseAgreementMember" xlink:title="PurchaseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="btx_PurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PurchaseAgreementMember_lbl" xml:lang="en-US" id="btx_PurchaseAgreementMember_lbl">Information about purchase agreement between the entities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseAgreementMember" xlink:to="btx_PurchaseAgreementMember_lbl" xlink:title="label: PurchaseAgreementMember to btx_PurchaseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PurchaseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PurchaseAgreementMember_lbl1" xml:lang="en-US" id="btx_PurchaseAgreementMember_lbl1">Purchase Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseAgreementMember" xlink:to="btx_PurchaseAgreementMember_lbl1" xlink:title="label: PurchaseAgreementMember to btx_PurchaseAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PurchaseAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PurchaseAgreementMember_lbl2" xml:lang="en-US" id="btx_PurchaseAgreementMember_lbl2">Purchase Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchaseAgreementMember" xlink:to="btx_PurchaseAgreementMember_lbl2" xlink:title="label: PurchaseAgreementMember to btx_PurchaseAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_MergerAbstract" xlink:label="MergerAbstract" xlink:title="MergerAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_MergerAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_MergerAbstract_lbl1" xml:lang="en-US" id="btx_MergerAbstract_lbl1">Merger [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergerAbstract" xlink:to="btx_MergerAbstract_lbl1" xlink:title="label: MergerAbstract to btx_MergerAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ClassOfWarrantOrRightIssued" xlink:label="ClassOfWarrantOrRightIssued" xlink:title="ClassOfWarrantOrRightIssued" />
    <link:label xlink:type="resource" xlink:label="btx_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ClassOfWarrantOrRightIssued_lbl" xml:lang="en-US" id="btx_ClassOfWarrantOrRightIssued_lbl">Number of shares issued into which the class of warrant or right may be converted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightIssued" xlink:to="btx_ClassOfWarrantOrRightIssued_lbl" xlink:title="label: ClassOfWarrantOrRightIssued to btx_ClassOfWarrantOrRightIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ClassOfWarrantOrRightIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ClassOfWarrantOrRightIssued_lbl1" xml:lang="en-US" id="btx_ClassOfWarrantOrRightIssued_lbl1">Class of Warrant or Right, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightIssued" xlink:to="btx_ClassOfWarrantOrRightIssued_lbl1" xlink:title="label: ClassOfWarrantOrRightIssued to btx_ClassOfWarrantOrRightIssued_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ClassOfWarrantOrRightIssued_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ClassOfWarrantOrRightIssued_lbl2" xml:lang="en-US" id="btx_ClassOfWarrantOrRightIssued_lbl2">Number of rights options issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightIssued" xlink:to="btx_ClassOfWarrantOrRightIssued_lbl2" xlink:title="label: ClassOfWarrantOrRightIssued to btx_ClassOfWarrantOrRightIssued_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:label xlink:type="resource" xlink:label="btx_NTNBuzztimeIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NTNBuzztimeIncMember_lbl" xml:lang="en-US" id="btx_NTNBuzztimeIncMember_lbl">Name of acquiree entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NTNBuzztimeIncMember" xlink:to="btx_NTNBuzztimeIncMember_lbl" xlink:title="label: NTNBuzztimeIncMember to btx_NTNBuzztimeIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NTNBuzztimeIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NTNBuzztimeIncMember_lbl1" xml:lang="en-US" id="btx_NTNBuzztimeIncMember_lbl1">NTN Buzztime, Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NTNBuzztimeIncMember" xlink:to="btx_NTNBuzztimeIncMember_lbl1" xlink:title="label: NTNBuzztimeIncMember to btx_NTNBuzztimeIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NTNBuzztimeIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NTNBuzztimeIncMember_lbl2" xml:lang="en-US" id="btx_NTNBuzztimeIncMember_lbl2">NTN Buzztime, Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NTNBuzztimeIncMember" xlink:to="btx_NTNBuzztimeIncMember_lbl2" xlink:title="label: NTNBuzztimeIncMember to btx_NTNBuzztimeIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_UniversityOfSouthFloridaMember" xlink:label="UniversityOfSouthFloridaMember" xlink:title="UniversityOfSouthFloridaMember" />
    <link:label xlink:type="resource" xlink:label="btx_UniversityOfSouthFloridaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_UniversityOfSouthFloridaMember_lbl" xml:lang="en-US" id="btx_UniversityOfSouthFloridaMember_lbl">Legal entity involved in litigation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UniversityOfSouthFloridaMember" xlink:to="btx_UniversityOfSouthFloridaMember_lbl" xlink:title="label: UniversityOfSouthFloridaMember to btx_UniversityOfSouthFloridaMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_UniversityOfSouthFloridaMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_UniversityOfSouthFloridaMember_lbl1" xml:lang="en-US" id="btx_UniversityOfSouthFloridaMember_lbl1">University of South Florida [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UniversityOfSouthFloridaMember" xlink:to="btx_UniversityOfSouthFloridaMember_lbl1" xlink:title="label: UniversityOfSouthFloridaMember to btx_UniversityOfSouthFloridaMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_UniversityOfSouthFloridaMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_UniversityOfSouthFloridaMember_lbl2" xml:lang="en-US" id="btx_UniversityOfSouthFloridaMember_lbl2">University of South Florida [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UniversityOfSouthFloridaMember" xlink:to="btx_UniversityOfSouthFloridaMember_lbl2" xlink:title="label: UniversityOfSouthFloridaMember to btx_UniversityOfSouthFloridaMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NovellusLtdAndFactorBioscienceMember" xlink:label="NovellusLtdAndFactorBioscienceMember" xlink:title="NovellusLtdAndFactorBioscienceMember" />
    <link:label xlink:type="resource" xlink:label="btx_NovellusLtdAndFactorBioscienceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NovellusLtdAndFactorBioscienceMember_lbl" xml:lang="en-US" id="btx_NovellusLtdAndFactorBioscienceMember_lbl">The name of companies involved in licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovellusLtdAndFactorBioscienceMember" xlink:to="btx_NovellusLtdAndFactorBioscienceMember_lbl" xlink:title="label: NovellusLtdAndFactorBioscienceMember to btx_NovellusLtdAndFactorBioscienceMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NovellusLtdAndFactorBioscienceMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NovellusLtdAndFactorBioscienceMember_lbl1" xml:lang="en-US" id="btx_NovellusLtdAndFactorBioscienceMember_lbl1">Novellus Ltd. and Factor Bioscience [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovellusLtdAndFactorBioscienceMember" xlink:to="btx_NovellusLtdAndFactorBioscienceMember_lbl1" xlink:title="label: NovellusLtdAndFactorBioscienceMember to btx_NovellusLtdAndFactorBioscienceMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NovellusLtdAndFactorBioscienceMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NovellusLtdAndFactorBioscienceMember_lbl2" xml:lang="en-US" id="btx_NovellusLtdAndFactorBioscienceMember_lbl2">Licensors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovellusLtdAndFactorBioscienceMember" xlink:to="btx_NovellusLtdAndFactorBioscienceMember_lbl2" xlink:title="label: NovellusLtdAndFactorBioscienceMember to btx_NovellusLtdAndFactorBioscienceMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NoveCiteMember" xlink:label="NoveCiteMember" xlink:title="NoveCiteMember" />
    <link:label xlink:type="resource" xlink:label="btx_NoveCiteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NoveCiteMember_lbl" xml:lang="en-US" id="btx_NoveCiteMember_lbl">The name of company involved in licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoveCiteMember" xlink:to="btx_NoveCiteMember_lbl" xlink:title="label: NoveCiteMember to btx_NoveCiteMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NoveCiteMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NoveCiteMember_lbl1" xml:lang="en-US" id="btx_NoveCiteMember_lbl1">NoveCite [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoveCiteMember" xlink:to="btx_NoveCiteMember_lbl1" xlink:title="label: NoveCiteMember to btx_NoveCiteMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NoveCiteMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NoveCiteMember_lbl2" xml:lang="en-US" id="btx_NoveCiteMember_lbl2">NoveCite [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoveCiteMember" xlink:to="btx_NoveCiteMember_lbl2" xlink:title="label: NoveCiteMember to btx_NoveCiteMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LicensingAgreementsAbstract" xlink:label="LicensingAgreementsAbstract" xlink:title="LicensingAgreementsAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_LicensingAgreementsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LicensingAgreementsAbstract_lbl1" xml:lang="en-US" id="btx_LicensingAgreementsAbstract_lbl1">Licensing Agreements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensingAgreementsAbstract" xlink:to="btx_LicensingAgreementsAbstract_lbl1" xlink:title="label: LicensingAgreementsAbstract to btx_LicensingAgreementsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LicensingAgreementsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LicensingAgreementsAbstract_lbl2" xml:lang="en-US" id="btx_LicensingAgreementsAbstract_lbl2">Licensing Agreements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensingAgreementsAbstract" xlink:to="btx_LicensingAgreementsAbstract_lbl2" xlink:title="label: LicensingAgreementsAbstract to btx_LicensingAgreementsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRevenue" xlink:label="PercentageOfRevenue" xlink:title="PercentageOfRevenue" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageOfRevenue_lbl" xml:lang="en-US" id="btx_PercentageOfRevenue_lbl">Percentage of revenue from receives any revenue involving the original cell line included in the licensed technology, then Novellus, Ltd shall remit to NoveCite.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRevenue" xlink:to="btx_PercentageOfRevenue_lbl" xlink:title="label: PercentageOfRevenue to btx_PercentageOfRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageOfRevenue_lbl1" xml:lang="en-US" id="btx_PercentageOfRevenue_lbl1">Percentage of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRevenue" xlink:to="btx_PercentageOfRevenue_lbl1" xlink:title="label: PercentageOfRevenue to btx_PercentageOfRevenue_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRevenue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageOfRevenue_lbl2" xml:lang="en-US" id="btx_PercentageOfRevenue_lbl2">Percentage of revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRevenue" xlink:to="btx_PercentageOfRevenue_lbl2" xlink:title="label: PercentageOfRevenue to btx_PercentageOfRevenue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LossContingencyPercentageOfRoyaltyPayable" xlink:label="LossContingencyPercentageOfRoyaltyPayable" xlink:title="LossContingencyPercentageOfRoyaltyPayable" />
    <link:label xlink:type="resource" xlink:label="btx_LossContingencyPercentageOfRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LossContingencyPercentageOfRoyaltyPayable_lbl" xml:lang="en-US" id="btx_LossContingencyPercentageOfRoyaltyPayable_lbl">Percentage of royalty payable from one party to another in licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyPercentageOfRoyaltyPayable" xlink:to="btx_LossContingencyPercentageOfRoyaltyPayable_lbl" xlink:title="label: LossContingencyPercentageOfRoyaltyPayable to btx_LossContingencyPercentageOfRoyaltyPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LossContingencyPercentageOfRoyaltyPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LossContingencyPercentageOfRoyaltyPayable_lbl1" xml:lang="en-US" id="btx_LossContingencyPercentageOfRoyaltyPayable_lbl1">Loss contingency, Percentage of Royalty Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyPercentageOfRoyaltyPayable" xlink:to="btx_LossContingencyPercentageOfRoyaltyPayable_lbl1" xlink:title="label: LossContingencyPercentageOfRoyaltyPayable to btx_LossContingencyPercentageOfRoyaltyPayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LossContingencyPercentageOfRoyaltyPayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LossContingencyPercentageOfRoyaltyPayable_lbl2" xml:lang="en-US" id="btx_LossContingencyPercentageOfRoyaltyPayable_lbl2">Percentage of royalty payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyPercentageOfRoyaltyPayable" xlink:to="btx_LossContingencyPercentageOfRoyaltyPayable_lbl2" xlink:title="label: LossContingencyPercentageOfRoyaltyPayable to btx_LossContingencyPercentageOfRoyaltyPayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AmountObligatedToPayInYearTwo" xlink:label="AmountObligatedToPayInYearTwo" xlink:title="AmountObligatedToPayInYearTwo" />
    <link:label xlink:type="resource" xlink:label="btx_AmountObligatedToPayInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AmountObligatedToPayInYearTwo_lbl" xml:lang="en-US" id="btx_AmountObligatedToPayInYearTwo_lbl">The entity is obligated to pay additional fees to the Licensors in second year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountObligatedToPayInYearTwo" xlink:to="btx_AmountObligatedToPayInYearTwo_lbl" xlink:title="label: AmountObligatedToPayInYearTwo to btx_AmountObligatedToPayInYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AmountObligatedToPayInYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AmountObligatedToPayInYearTwo_lbl1" xml:lang="en-US" id="btx_AmountObligatedToPayInYearTwo_lbl1">Amount Obligated to Pay in Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountObligatedToPayInYearTwo" xlink:to="btx_AmountObligatedToPayInYearTwo_lbl1" xlink:title="label: AmountObligatedToPayInYearTwo to btx_AmountObligatedToPayInYearTwo_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AmountObligatedToPayInYearTwo_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AmountObligatedToPayInYearTwo_lbl2" xml:lang="en-US" id="btx_AmountObligatedToPayInYearTwo_lbl2">Additional fees obligated to pay in 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountObligatedToPayInYearTwo" xlink:to="btx_AmountObligatedToPayInYearTwo_lbl2" xlink:title="label: AmountObligatedToPayInYearTwo to btx_AmountObligatedToPayInYearTwo_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AdditionalFeesObligatedToPay" xlink:label="AdditionalFeesObligatedToPay" xlink:title="AdditionalFeesObligatedToPay" />
    <link:label xlink:type="resource" xlink:label="btx_AdditionalFeesObligatedToPay_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AdditionalFeesObligatedToPay_lbl" xml:lang="en-US" id="btx_AdditionalFeesObligatedToPay_lbl">The entity is obligated to pay additional fees to Licensors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalFeesObligatedToPay" xlink:to="btx_AdditionalFeesObligatedToPay_lbl" xlink:title="label: AdditionalFeesObligatedToPay to btx_AdditionalFeesObligatedToPay_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AdditionalFeesObligatedToPay_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AdditionalFeesObligatedToPay_lbl1" xml:lang="en-US" id="btx_AdditionalFeesObligatedToPay_lbl1">Additional Fees Obligated to Pay</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalFeesObligatedToPay" xlink:to="btx_AdditionalFeesObligatedToPay_lbl1" xlink:title="label: AdditionalFeesObligatedToPay to btx_AdditionalFeesObligatedToPay_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AdditionalFeesObligatedToPay_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AdditionalFeesObligatedToPay_lbl2" xml:lang="en-US" id="btx_AdditionalFeesObligatedToPay_lbl2">Amount require to pay of initial license fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalFeesObligatedToPay" xlink:to="btx_AdditionalFeesObligatedToPay_lbl2" xlink:title="label: AdditionalFeesObligatedToPay to btx_AdditionalFeesObligatedToPay_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_MinimumNumberOfPatentGranted" xlink:label="MinimumNumberOfPatentGranted" xlink:title="MinimumNumberOfPatentGranted" />
    <link:label xlink:type="resource" xlink:label="btx_MinimumNumberOfPatentGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_MinimumNumberOfPatentGranted_lbl" xml:lang="en-US" id="btx_MinimumNumberOfPatentGranted_lbl">Minimum number of granted patents.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumNumberOfPatentGranted" xlink:to="btx_MinimumNumberOfPatentGranted_lbl" xlink:title="label: MinimumNumberOfPatentGranted to btx_MinimumNumberOfPatentGranted_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_MinimumNumberOfPatentGranted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_MinimumNumberOfPatentGranted_lbl1" xml:lang="en-US" id="btx_MinimumNumberOfPatentGranted_lbl1">Minimum Number of Patent Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumNumberOfPatentGranted" xlink:to="btx_MinimumNumberOfPatentGranted_lbl1" xlink:title="label: MinimumNumberOfPatentGranted to btx_MinimumNumberOfPatentGranted_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_MinimumNumberOfPatentGranted_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="btx_MinimumNumberOfPatentGranted_lbl2" xml:lang="en-US" id="btx_MinimumNumberOfPatentGranted_lbl2">Minimum number of patent granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumNumberOfPatentGranted" xlink:to="btx_MinimumNumberOfPatentGranted_lbl2" xlink:title="label: MinimumNumberOfPatentGranted to btx_MinimumNumberOfPatentGranted_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_InitialLicenseFees" xlink:label="InitialLicenseFees" xlink:title="InitialLicenseFees" />
    <link:label xlink:type="resource" xlink:label="btx_InitialLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_InitialLicenseFees_lbl" xml:lang="en-US" id="btx_InitialLicenseFees_lbl">Initial license fees required to pay including non-refundable fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialLicenseFees" xlink:to="btx_InitialLicenseFees_lbl" xlink:title="label: InitialLicenseFees to btx_InitialLicenseFees_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_InitialLicenseFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_InitialLicenseFees_lbl1" xml:lang="en-US" id="btx_InitialLicenseFees_lbl1">Initial License Fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialLicenseFees" xlink:to="btx_InitialLicenseFees_lbl1" xlink:title="label: InitialLicenseFees to btx_InitialLicenseFees_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_InitialLicenseFees_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_InitialLicenseFees_lbl2" xml:lang="en-US" id="btx_InitialLicenseFees_lbl2">Initial license fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InitialLicenseFees" xlink:to="btx_InitialLicenseFees_lbl2" xlink:title="label: InitialLicenseFees to btx_InitialLicenseFees_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LossContingencyNonRefundableOptionFee" xlink:label="LossContingencyNonRefundableOptionFee" xlink:title="LossContingencyNonRefundableOptionFee" />
    <link:label xlink:type="resource" xlink:label="btx_LossContingencyNonRefundableOptionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LossContingencyNonRefundableOptionFee_lbl" xml:lang="en-US" id="btx_LossContingencyNonRefundableOptionFee_lbl">The amount of Non-refundable option fee in licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNonRefundableOptionFee" xlink:to="btx_LossContingencyNonRefundableOptionFee_lbl" xlink:title="label: LossContingencyNonRefundableOptionFee to btx_LossContingencyNonRefundableOptionFee_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LossContingencyNonRefundableOptionFee_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LossContingencyNonRefundableOptionFee_lbl1" xml:lang="en-US" id="btx_LossContingencyNonRefundableOptionFee_lbl1">Loss Contingency, Non-refundable Option Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNonRefundableOptionFee" xlink:to="btx_LossContingencyNonRefundableOptionFee_lbl1" xlink:title="label: LossContingencyNonRefundableOptionFee to btx_LossContingencyNonRefundableOptionFee_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LossContingencyNonRefundableOptionFee_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LossContingencyNonRefundableOptionFee_lbl2" xml:lang="en-US" id="btx_LossContingencyNonRefundableOptionFee_lbl2">Non-refundable option fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNonRefundableOptionFee" xlink:to="btx_LossContingencyNonRefundableOptionFee_lbl2" xlink:title="label: LossContingencyNonRefundableOptionFee to btx_LossContingencyNonRefundableOptionFee_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_MilestonePayments" xlink:label="MilestonePayments" xlink:title="MilestonePayments" />
    <link:label xlink:type="resource" xlink:label="btx_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_MilestonePayments_lbl" xml:lang="en-US" id="btx_MilestonePayments_lbl">The amount of milestones upfront payment on licenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayments" xlink:to="btx_MilestonePayments_lbl" xlink:title="label: MilestonePayments to btx_MilestonePayments_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_MilestonePayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_MilestonePayments_lbl1" xml:lang="en-US" id="btx_MilestonePayments_lbl1">Milestone Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayments" xlink:to="btx_MilestonePayments_lbl1" xlink:title="label: MilestonePayments to btx_MilestonePayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_MilestonePayments_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_MilestonePayments_lbl2" xml:lang="en-US" id="btx_MilestonePayments_lbl2">Milestone payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayments" xlink:to="btx_MilestonePayments_lbl2" xlink:title="label: MilestonePayments to btx_MilestonePayments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_MinimumNumberOfPendingPatents" xlink:label="MinimumNumberOfPendingPatents" xlink:title="MinimumNumberOfPendingPatents" />
    <link:label xlink:type="resource" xlink:label="btx_MinimumNumberOfPendingPatents_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_MinimumNumberOfPendingPatents_lbl" xml:lang="en-US" id="btx_MinimumNumberOfPendingPatents_lbl">Minimum number of patents pending.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumNumberOfPendingPatents" xlink:to="btx_MinimumNumberOfPendingPatents_lbl" xlink:title="label: MinimumNumberOfPendingPatents to btx_MinimumNumberOfPendingPatents_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_MinimumNumberOfPendingPatents_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_MinimumNumberOfPendingPatents_lbl1" xml:lang="en-US" id="btx_MinimumNumberOfPendingPatents_lbl1">Minimum Number of Pending Patents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumNumberOfPendingPatents" xlink:to="btx_MinimumNumberOfPendingPatents_lbl1" xlink:title="label: MinimumNumberOfPendingPatents to btx_MinimumNumberOfPendingPatents_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_MinimumNumberOfPendingPatents_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_MinimumNumberOfPendingPatents_lbl2" xml:lang="en-US" id="btx_MinimumNumberOfPendingPatents_lbl2">Number of maximum pending patents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumNumberOfPendingPatents" xlink:to="btx_MinimumNumberOfPendingPatents_lbl2" xlink:title="label: MinimumNumberOfPendingPatents to btx_MinimumNumberOfPendingPatents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AmountObligatedToPayInYearOne" xlink:label="AmountObligatedToPayInYearOne" xlink:title="AmountObligatedToPayInYearOne" />
    <link:label xlink:type="resource" xlink:label="btx_AmountObligatedToPayInYearOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AmountObligatedToPayInYearOne_lbl" xml:lang="en-US" id="btx_AmountObligatedToPayInYearOne_lbl">The entity is obligated to pay additional fees to the Licensors in first year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountObligatedToPayInYearOne" xlink:to="btx_AmountObligatedToPayInYearOne_lbl" xlink:title="label: AmountObligatedToPayInYearOne to btx_AmountObligatedToPayInYearOne_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AmountObligatedToPayInYearOne_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AmountObligatedToPayInYearOne_lbl1" xml:lang="en-US" id="btx_AmountObligatedToPayInYearOne_lbl1">Amount Obligated to Pay in Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountObligatedToPayInYearOne" xlink:to="btx_AmountObligatedToPayInYearOne_lbl1" xlink:title="label: AmountObligatedToPayInYearOne to btx_AmountObligatedToPayInYearOne_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AmountObligatedToPayInYearOne_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AmountObligatedToPayInYearOne_lbl2" xml:lang="en-US" id="btx_AmountObligatedToPayInYearOne_lbl2">Additional fees obligated to pay in 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountObligatedToPayInYearOne" xlink:to="btx_AmountObligatedToPayInYearOne_lbl2" xlink:title="label: AmountObligatedToPayInYearOne to btx_AmountObligatedToPayInYearOne_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AmountRequireToPayInitialLicenseFees" xlink:label="AmountRequireToPayInitialLicenseFees" xlink:title="AmountRequireToPayInitialLicenseFees" />
    <link:label xlink:type="resource" xlink:label="btx_AmountRequireToPayInitialLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AmountRequireToPayInitialLicenseFees_lbl" xml:lang="en-US" id="btx_AmountRequireToPayInitialLicenseFees_lbl">Amount require to pay out of the total initial license fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountRequireToPayInitialLicenseFees" xlink:to="btx_AmountRequireToPayInitialLicenseFees_lbl" xlink:title="label: AmountRequireToPayInitialLicenseFees to btx_AmountRequireToPayInitialLicenseFees_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AmountRequireToPayInitialLicenseFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AmountRequireToPayInitialLicenseFees_lbl1" xml:lang="en-US" id="btx_AmountRequireToPayInitialLicenseFees_lbl1">Amount Require to Pay Initial License Fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountRequireToPayInitialLicenseFees" xlink:to="btx_AmountRequireToPayInitialLicenseFees_lbl1" xlink:title="label: AmountRequireToPayInitialLicenseFees to btx_AmountRequireToPayInitialLicenseFees_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AmountRequireToPayInitialLicenseFees_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AmountRequireToPayInitialLicenseFees_lbl2" xml:lang="en-US" id="btx_AmountRequireToPayInitialLicenseFees_lbl2">Amount obligated to pay in license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountRequireToPayInitialLicenseFees" xlink:to="btx_AmountRequireToPayInitialLicenseFees_lbl2" xlink:title="label: AmountRequireToPayInitialLicenseFees to btx_AmountRequireToPayInitialLicenseFees_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ContingentConsiderationMember" xlink:label="ContingentConsiderationMember" xlink:title="ContingentConsiderationMember" />
    <link:label xlink:type="resource" xlink:label="btx_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ContingentConsiderationMember_lbl" xml:lang="en-US" id="btx_ContingentConsiderationMember_lbl">Description of contingent payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentConsiderationMember" xlink:to="btx_ContingentConsiderationMember_lbl" xlink:title="label: ContingentConsiderationMember to btx_ContingentConsiderationMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ContingentConsiderationMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ContingentConsiderationMember_lbl1" xml:lang="en-US" id="btx_ContingentConsiderationMember_lbl1">Contingent Consideration [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentConsiderationMember" xlink:to="btx_ContingentConsiderationMember_lbl1" xlink:title="label: ContingentConsiderationMember to btx_ContingentConsiderationMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaycheckProtectionProgramMember" xlink:label="PaycheckProtectionProgramMember" xlink:title="PaycheckProtectionProgramMember" />
    <link:label xlink:type="resource" xlink:label="btx_PaycheckProtectionProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PaycheckProtectionProgramMember_lbl" xml:lang="en-US" id="btx_PaycheckProtectionProgramMember_lbl">Paycheck Protection Program [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaycheckProtectionProgramMember" xlink:to="btx_PaycheckProtectionProgramMember_lbl" xlink:title="label: PaycheckProtectionProgramMember to btx_PaycheckProtectionProgramMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PaycheckProtectionProgramMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PaycheckProtectionProgramMember_lbl1" xml:lang="en-US" id="btx_PaycheckProtectionProgramMember_lbl1">Paycheck Protection Program [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaycheckProtectionProgramMember" xlink:to="btx_PaycheckProtectionProgramMember_lbl1" xlink:title="label: PaycheckProtectionProgramMember to btx_PaycheckProtectionProgramMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PaycheckProtectionProgramMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PaycheckProtectionProgramMember_lbl2" xml:lang="en-US" id="btx_PaycheckProtectionProgramMember_lbl2">Brooklyn LLC Paycheck Protection Program [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaycheckProtectionProgramMember" xlink:to="btx_PaycheckProtectionProgramMember_lbl2" xlink:title="label: PaycheckProtectionProgramMember to btx_PaycheckProtectionProgramMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BrooklynPaycheckProtectionProgramMember" xlink:label="BrooklynPaycheckProtectionProgramMember" xlink:title="BrooklynPaycheckProtectionProgramMember" />
    <link:label xlink:type="resource" xlink:label="btx_BrooklynPaycheckProtectionProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_BrooklynPaycheckProtectionProgramMember_lbl" xml:lang="en-US" id="btx_BrooklynPaycheckProtectionProgramMember_lbl">Represents the Paycheck Protection Program for Brooklyn.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BrooklynPaycheckProtectionProgramMember" xlink:to="btx_BrooklynPaycheckProtectionProgramMember_lbl" xlink:title="label: BrooklynPaycheckProtectionProgramMember to btx_BrooklynPaycheckProtectionProgramMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_BrooklynPaycheckProtectionProgramMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_BrooklynPaycheckProtectionProgramMember_lbl1" xml:lang="en-US" id="btx_BrooklynPaycheckProtectionProgramMember_lbl1">Brooklyn Paycheck Protection Program [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BrooklynPaycheckProtectionProgramMember" xlink:to="btx_BrooklynPaycheckProtectionProgramMember_lbl1" xlink:title="label: BrooklynPaycheckProtectionProgramMember to btx_BrooklynPaycheckProtectionProgramMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaycheckProtectionProgramLoanMember" xlink:label="PaycheckProtectionProgramLoanMember" xlink:title="PaycheckProtectionProgramLoanMember" />
    <link:label xlink:type="resource" xlink:label="btx_PaycheckProtectionProgramLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PaycheckProtectionProgramLoanMember_lbl" xml:lang="en-US" id="btx_PaycheckProtectionProgramLoanMember_lbl">Name of the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaycheckProtectionProgramLoanMember" xlink:to="btx_PaycheckProtectionProgramLoanMember_lbl" xlink:title="label: PaycheckProtectionProgramLoanMember to btx_PaycheckProtectionProgramLoanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PaycheckProtectionProgramLoanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PaycheckProtectionProgramLoanMember_lbl1" xml:lang="en-US" id="btx_PaycheckProtectionProgramLoanMember_lbl1">Paycheck Protection Program Loan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaycheckProtectionProgramLoanMember" xlink:to="btx_PaycheckProtectionProgramLoanMember_lbl1" xlink:title="label: PaycheckProtectionProgramLoanMember to btx_PaycheckProtectionProgramLoanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PaycheckProtectionProgramLoanMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PaycheckProtectionProgramLoanMember_lbl2" xml:lang="en-US" id="btx_PaycheckProtectionProgramLoanMember_lbl2">IRX Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaycheckProtectionProgramLoanMember" xlink:to="btx_PaycheckProtectionProgramLoanMember_lbl2" xlink:title="label: PaycheckProtectionProgramLoanMember to btx_PaycheckProtectionProgramLoanMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DebtInstrumentAbstract" xlink:label="DebtInstrumentAbstract" xlink:title="DebtInstrumentAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_DebtInstrumentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DebtInstrumentAbstract_lbl1" xml:lang="en-US" id="btx_DebtInstrumentAbstract_lbl1">Debt Instrument [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAbstract" xlink:to="btx_DebtInstrumentAbstract_lbl1" xlink:title="label: DebtInstrumentAbstract to btx_DebtInstrumentAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DebtInstrumentAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DebtInstrumentAbstract_lbl2" xml:lang="en-US" id="btx_DebtInstrumentAbstract_lbl2">Debt Instrument [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAbstract" xlink:to="btx_DebtInstrumentAbstract_lbl2" xlink:title="label: DebtInstrumentAbstract to btx_DebtInstrumentAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaymentOfAccruedAndUnpaidInterest" xlink:label="PaymentOfAccruedAndUnpaidInterest" xlink:title="PaymentOfAccruedAndUnpaidInterest" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentOfAccruedAndUnpaidInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PaymentOfAccruedAndUnpaidInterest_lbl" xml:lang="en-US" id="btx_PaymentOfAccruedAndUnpaidInterest_lbl">Amount of cash paid for accrued and unpaid interest related to notes payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfAccruedAndUnpaidInterest" xlink:to="btx_PaymentOfAccruedAndUnpaidInterest_lbl" xlink:title="label: PaymentOfAccruedAndUnpaidInterest to btx_PaymentOfAccruedAndUnpaidInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentOfAccruedAndUnpaidInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PaymentOfAccruedAndUnpaidInterest_lbl1" xml:lang="en-US" id="btx_PaymentOfAccruedAndUnpaidInterest_lbl1">Payment of Accrued and Unpaid Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfAccruedAndUnpaidInterest" xlink:to="btx_PaymentOfAccruedAndUnpaidInterest_lbl1" xlink:title="label: PaymentOfAccruedAndUnpaidInterest to btx_PaymentOfAccruedAndUnpaidInterest_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PaymentOfAccruedAndUnpaidInterest_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PaymentOfAccruedAndUnpaidInterest_lbl2" xml:lang="en-US" id="btx_PaymentOfAccruedAndUnpaidInterest_lbl2">Payment of accrued and unpaid interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfAccruedAndUnpaidInterest" xlink:to="btx_PaymentOfAccruedAndUnpaidInterest_lbl2" xlink:title="label: PaymentOfAccruedAndUnpaidInterest to btx_PaymentOfAccruedAndUnpaidInterest_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038" xlink:label="PercentageOfRoyaltyRevenueAssumedFrom2030To2038" xlink:title="PercentageOfRoyaltyRevenueAssumedFrom2030To2038" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038_lbl" xml:lang="en-US" id="btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038_lbl">The percentage of royalty revenue assumed from 2030 to 2038 due to use of different market assumptions and/or different valuation techniques.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyRevenueAssumedFrom2030To2038" xlink:to="btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038_lbl" xlink:title="label: PercentageOfRoyaltyRevenueAssumedFrom2030To2038 to btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038_lbl1" xml:lang="en-US" id="btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038_lbl1">Percentage of Royalty Revenue Assumed from 2030 to 2038</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyRevenueAssumedFrom2030To2038" xlink:to="btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038_lbl1" xlink:title="label: PercentageOfRoyaltyRevenueAssumedFrom2030To2038 to btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038_lbl2" xml:lang="en-US" id="btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038_lbl2">Assumed percentage of royalty revenue from 2030 to 2038</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyRevenueAssumedFrom2030To2038" xlink:to="btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038_lbl2" xlink:title="label: PercentageOfRoyaltyRevenueAssumedFrom2030To2038 to btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfWeightedAverageCostOfCapital" xlink:label="PercentageOfWeightedAverageCostOfCapital" xlink:title="PercentageOfWeightedAverageCostOfCapital" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfWeightedAverageCostOfCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageOfWeightedAverageCostOfCapital_lbl" xml:lang="en-US" id="btx_PercentageOfWeightedAverageCostOfCapital_lbl">Cash flows discounted by the liability specific weighted average cost of capital using the mid-point convention.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfWeightedAverageCostOfCapital" xlink:to="btx_PercentageOfWeightedAverageCostOfCapital_lbl" xlink:title="label: PercentageOfWeightedAverageCostOfCapital to btx_PercentageOfWeightedAverageCostOfCapital_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfWeightedAverageCostOfCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageOfWeightedAverageCostOfCapital_lbl1" xml:lang="en-US" id="btx_PercentageOfWeightedAverageCostOfCapital_lbl1">Percentage of Weighted Average Cost of Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfWeightedAverageCostOfCapital" xlink:to="btx_PercentageOfWeightedAverageCostOfCapital_lbl1" xlink:title="label: PercentageOfWeightedAverageCostOfCapital to btx_PercentageOfWeightedAverageCostOfCapital_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfWeightedAverageCostOfCapital_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageOfWeightedAverageCostOfCapital_lbl2" xml:lang="en-US" id="btx_PercentageOfWeightedAverageCostOfCapital_lbl2">Percentage of weighted average cost of capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfWeightedAverageCostOfCapital" xlink:to="btx_PercentageOfWeightedAverageCostOfCapital_lbl2" xlink:title="label: PercentageOfWeightedAverageCostOfCapital to btx_PercentageOfWeightedAverageCostOfCapital_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" xlink:label="PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" xlink:title="PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne_lbl" xml:lang="en-US" id="btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne_lbl">The percentage of royalty revenue after year one post patent decline due to use of different market assumptions and/or different valuation techniques.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" xlink:to="btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne_lbl" xlink:title="label: PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne to btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne_lbl1" xml:lang="en-US" id="btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne_lbl1">Percentage of Royalty Revenue Post Patent Decline After Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" xlink:to="btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne_lbl1" xlink:title="label: PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne to btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne_lbl2" xml:lang="en-US" id="btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne_lbl2">Percentage of royalty revenue post patent decline after year one</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" xlink:to="btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne_lbl2" xlink:title="label: PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne to btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" xlink:label="PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" xlink:title="PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings_lbl" xml:lang="en-US" id="btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings_lbl">Percentage of income taxes projected in terms of royalty savings due to use of different market assumptions and/or different valuation techniques.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" xlink:to="btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings_lbl" xlink:title="label: PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings to btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings_lbl1" xml:lang="en-US" id="btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings_lbl1">Percentage of Income Taxes Projected in terms of Royalty Savings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" xlink:to="btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings_lbl1" xlink:title="label: PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings to btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings_lbl2" xml:lang="en-US" id="btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings_lbl2">Percentage of income taxes projected as royalty savings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" xlink:to="btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings_lbl2" xlink:title="label: PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings to btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" xlink:label="PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" xlink:title="PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne_lbl" xml:lang="en-US" id="btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne_lbl">The percentage of royalty revenue for first year post patent decline due to use of different market assumptions and/or different valuation techniques.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" xlink:to="btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne_lbl" xlink:title="label: PercentageOfRoyaltyRevenuePostPatentDeclineYearOne to btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne_lbl1" xml:lang="en-US" id="btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne_lbl1">Percentage of Royalty Revenue Post Patent Decline Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" xlink:to="btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne_lbl1" xlink:title="label: PercentageOfRoyaltyRevenuePostPatentDeclineYearOne to btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne_lbl2" xml:lang="en-US" id="btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne_lbl2">Percentage of royalty revenue post patent decline for first year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" xlink:to="btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne_lbl2" xlink:title="label: PercentageOfRoyaltyRevenuePostPatentDeclineYearOne to btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRoyaltyRevenueAssumedUntil2029" xlink:label="PercentageOfRoyaltyRevenueAssumedUntil2029" xlink:title="PercentageOfRoyaltyRevenueAssumedUntil2029" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRoyaltyRevenueAssumedUntil2029_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageOfRoyaltyRevenueAssumedUntil2029_lbl" xml:lang="en-US" id="btx_PercentageOfRoyaltyRevenueAssumedUntil2029_lbl">The percentage of royalty revenue assumed until 2029 due to use of different market assumptions and/or different valuation techniques.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyRevenueAssumedUntil2029" xlink:to="btx_PercentageOfRoyaltyRevenueAssumedUntil2029_lbl" xlink:title="label: PercentageOfRoyaltyRevenueAssumedUntil2029 to btx_PercentageOfRoyaltyRevenueAssumedUntil2029_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRoyaltyRevenueAssumedUntil2029_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageOfRoyaltyRevenueAssumedUntil2029_lbl1" xml:lang="en-US" id="btx_PercentageOfRoyaltyRevenueAssumedUntil2029_lbl1">Percentage of Royalty Revenue Assumed Until 2029</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyRevenueAssumedUntil2029" xlink:to="btx_PercentageOfRoyaltyRevenueAssumedUntil2029_lbl1" xlink:title="label: PercentageOfRoyaltyRevenueAssumedUntil2029 to btx_PercentageOfRoyaltyRevenueAssumedUntil2029_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfRoyaltyRevenueAssumedUntil2029_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageOfRoyaltyRevenueAssumedUntil2029_lbl2" xml:lang="en-US" id="btx_PercentageOfRoyaltyRevenueAssumedUntil2029_lbl2">Assumed percentage of royalty revenue until 2029</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyRevenueAssumedUntil2029" xlink:to="btx_PercentageOfRoyaltyRevenueAssumedUntil2029_lbl2" xlink:title="label: PercentageOfRoyaltyRevenueAssumedUntil2029 to btx_PercentageOfRoyaltyRevenueAssumedUntil2029_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DheshGovenderMember" xlink:label="DheshGovenderMember" xlink:title="DheshGovenderMember" />
    <link:label xlink:type="resource" xlink:label="btx_DheshGovenderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DheshGovenderMember_lbl" xml:lang="en-US" id="btx_DheshGovenderMember_lbl">Dhesh Govender, a former short-term consultant of the entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DheshGovenderMember" xlink:to="btx_DheshGovenderMember_lbl" xlink:title="label: DheshGovenderMember to btx_DheshGovenderMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DheshGovenderMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DheshGovenderMember_lbl1" xml:lang="en-US" id="btx_DheshGovenderMember_lbl1">Dhesh Govender [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DheshGovenderMember" xlink:to="btx_DheshGovenderMember_lbl1" xlink:title="label: DheshGovenderMember to btx_DheshGovenderMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DheshGovenderMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DheshGovenderMember_lbl2" xml:lang="en-US" id="btx_DheshGovenderMember_lbl2">Govender [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DheshGovenderMember" xlink:to="btx_DheshGovenderMember_lbl2" xlink:title="label: DheshGovenderMember to btx_DheshGovenderMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LossContingencyNumberOfArbitrationPanel" xlink:label="LossContingencyNumberOfArbitrationPanel" xlink:title="LossContingencyNumberOfArbitrationPanel" />
    <link:label xlink:type="resource" xlink:label="btx_LossContingencyNumberOfArbitrationPanel_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LossContingencyNumberOfArbitrationPanel_lbl" xml:lang="en-US" id="btx_LossContingencyNumberOfArbitrationPanel_lbl">Represents the number member in arbitration panel pertaining to a loss contingency during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNumberOfArbitrationPanel" xlink:to="btx_LossContingencyNumberOfArbitrationPanel_lbl" xlink:title="label: LossContingencyNumberOfArbitrationPanel to btx_LossContingencyNumberOfArbitrationPanel_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LossContingencyNumberOfArbitrationPanel_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LossContingencyNumberOfArbitrationPanel_lbl1" xml:lang="en-US" id="btx_LossContingencyNumberOfArbitrationPanel_lbl1">Loss Contingency, Number of Arbitration Panel Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNumberOfArbitrationPanel" xlink:to="btx_LossContingencyNumberOfArbitrationPanel_lbl1" xlink:title="label: LossContingencyNumberOfArbitrationPanel to btx_LossContingencyNumberOfArbitrationPanel_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LossContingencyNumberOfArbitrationPanel_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LossContingencyNumberOfArbitrationPanel_lbl2" xml:lang="en-US" id="btx_LossContingencyNumberOfArbitrationPanel_lbl2">Number of member arbitration panel</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyNumberOfArbitrationPanel" xlink:to="btx_LossContingencyNumberOfArbitrationPanel_lbl2" xlink:title="label: LossContingencyNumberOfArbitrationPanel to btx_LossContingencyNumberOfArbitrationPanel_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_RobertGarfieldMember" xlink:label="RobertGarfieldMember" xlink:title="RobertGarfieldMember" />
    <link:label xlink:type="resource" xlink:label="btx_RobertGarfieldMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_RobertGarfieldMember_lbl" xml:lang="en-US" id="btx_RobertGarfieldMember_lbl">Robert Garfield, a purported stockholder of the Company forwarded a demand letter (the "Demand")</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RobertGarfieldMember" xlink:to="btx_RobertGarfieldMember_lbl" xlink:title="label: RobertGarfieldMember to btx_RobertGarfieldMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_RobertGarfieldMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_RobertGarfieldMember_lbl1" xml:lang="en-US" id="btx_RobertGarfieldMember_lbl1">Robert Garfield [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RobertGarfieldMember" xlink:to="btx_RobertGarfieldMember_lbl1" xlink:title="label: RobertGarfieldMember to btx_RobertGarfieldMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_RobertGarfieldMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_RobertGarfieldMember_lbl2" xml:lang="en-US" id="btx_RobertGarfieldMember_lbl2">Robert Garfield [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RobertGarfieldMember" xlink:to="btx_RobertGarfieldMember_lbl2" xlink:title="label: RobertGarfieldMember to btx_RobertGarfieldMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LegalMattersAbstract" xlink:label="LegalMattersAbstract" xlink:title="LegalMattersAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_LegalMattersAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LegalMattersAbstract_lbl1" xml:lang="en-US" id="btx_LegalMattersAbstract_lbl1">Legal Matters [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LegalMattersAbstract" xlink:to="btx_LegalMattersAbstract_lbl1" xlink:title="label: LegalMattersAbstract to btx_LegalMattersAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LegalMattersAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LegalMattersAbstract_lbl2" xml:lang="en-US" id="btx_LegalMattersAbstract_lbl2">Legal Matters [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LegalMattersAbstract" xlink:to="btx_LegalMattersAbstract_lbl2" xlink:title="label: LegalMattersAbstract to btx_LegalMattersAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:label="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:title="LossContingencyDamagesSoughtExpectedEquityPercentage" />
    <link:label xlink:type="resource" xlink:label="btx_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl" xml:lang="en-US" id="btx_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl">The percentage of equity promised to the plaintiff seeks in the legal matter.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:to="btx_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl" xlink:title="label: LossContingencyDamagesSoughtExpectedEquityPercentage to btx_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl1" xml:lang="en-US" id="btx_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl1">Loss Contingency, Damages Sought, Expected Equity Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:to="btx_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl1" xlink:title="label: LossContingencyDamagesSoughtExpectedEquityPercentage to btx_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl2" xml:lang="en-US" id="btx_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl2">Percentage of equity promised against plaintiff</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:to="btx_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl2" xlink:title="label: LossContingencyDamagesSoughtExpectedEquityPercentage to btx_LossContingencyDamagesSoughtExpectedEquityPercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LossContingencyDamagesSoughtExpectedSalary" xlink:label="LossContingencyDamagesSoughtExpectedSalary" xlink:title="LossContingencyDamagesSoughtExpectedSalary" />
    <link:label xlink:type="resource" xlink:label="btx_LossContingencyDamagesSoughtExpectedSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LossContingencyDamagesSoughtExpectedSalary_lbl" xml:lang="en-US" id="btx_LossContingencyDamagesSoughtExpectedSalary_lbl">The monetary amount of salary promised to the plaintiff seeks in the legal matter.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyDamagesSoughtExpectedSalary" xlink:to="btx_LossContingencyDamagesSoughtExpectedSalary_lbl" xlink:title="label: LossContingencyDamagesSoughtExpectedSalary to btx_LossContingencyDamagesSoughtExpectedSalary_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LossContingencyDamagesSoughtExpectedSalary_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LossContingencyDamagesSoughtExpectedSalary_lbl1" xml:lang="en-US" id="btx_LossContingencyDamagesSoughtExpectedSalary_lbl1">Loss Contingency, Damages Sought, Expected Salary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyDamagesSoughtExpectedSalary" xlink:to="btx_LossContingencyDamagesSoughtExpectedSalary_lbl1" xlink:title="label: LossContingencyDamagesSoughtExpectedSalary to btx_LossContingencyDamagesSoughtExpectedSalary_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LossContingencyDamagesSoughtExpectedSalary_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LossContingencyDamagesSoughtExpectedSalary_lbl2" xml:lang="en-US" id="btx_LossContingencyDamagesSoughtExpectedSalary_lbl2">Defendants salary promised against plaintiff</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyDamagesSoughtExpectedSalary" xlink:to="btx_LossContingencyDamagesSoughtExpectedSalary_lbl2" xlink:title="label: LossContingencyDamagesSoughtExpectedSalary to btx_LossContingencyDamagesSoughtExpectedSalary_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AreaOfSubleaseSpaceCurrentlyRented" xlink:label="AreaOfSubleaseSpaceCurrentlyRented" xlink:title="AreaOfSubleaseSpaceCurrentlyRented" />
    <link:label xlink:type="resource" xlink:label="btx_AreaOfSubleaseSpaceCurrentlyRented_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AreaOfSubleaseSpaceCurrentlyRented_lbl" xml:lang="en-US" id="btx_AreaOfSubleaseSpaceCurrentlyRented_lbl">The subleases rentable area for properties currently rented.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfSubleaseSpaceCurrentlyRented" xlink:to="btx_AreaOfSubleaseSpaceCurrentlyRented_lbl" xlink:title="label: AreaOfSubleaseSpaceCurrentlyRented to btx_AreaOfSubleaseSpaceCurrentlyRented_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AreaOfSubleaseSpaceCurrentlyRented_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AreaOfSubleaseSpaceCurrentlyRented_lbl1" xml:lang="en-US" id="btx_AreaOfSubleaseSpaceCurrentlyRented_lbl1">Area of Sublease, Space Currently Rented</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfSubleaseSpaceCurrentlyRented" xlink:to="btx_AreaOfSubleaseSpaceCurrentlyRented_lbl1" xlink:title="label: AreaOfSubleaseSpaceCurrentlyRented to btx_AreaOfSubleaseSpaceCurrentlyRented_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AreaOfSubleaseSpaceCurrentlyRented_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AreaOfSubleaseSpaceCurrentlyRented_lbl2" xml:lang="en-US" id="btx_AreaOfSubleaseSpaceCurrentlyRented_lbl2">Currently rented area</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfSubleaseSpaceCurrentlyRented" xlink:to="btx_AreaOfSubleaseSpaceCurrentlyRented_lbl2" xlink:title="label: AreaOfSubleaseSpaceCurrentlyRented to btx_AreaOfSubleaseSpaceCurrentlyRented_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract_lbl1" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract_lbl1">Sale Leaseback Transactions, Future Minimum Sublease Rentals, Fiscal Year Maturity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract_lbl1" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract_lbl2" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract_lbl2">Future Lease Payments, Sublease Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract_lbl2" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths_lbl" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths_lbl">Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths_lbl" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths_lbl1" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths_lbl1">Sale Leaseback Transactions, Future Minimum Sublease Rentals, Next Twelve Months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths_lbl1" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths_lbl2" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths_lbl2">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths_lbl2" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears_lbl" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears_lbl">Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears_lbl" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears_lbl1" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears_lbl1">Sale Leaseback Transactions, Future Minimum Sublease Rentals, within Three Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears_lbl1" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears_lbl2" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears_lbl2">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears_lbl2" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears_lbl" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears_lbl">Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears_lbl" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears_lbl1" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears_lbl1">Sale Leaseback Transactions Future Minimum Sublease Rentals Within Five Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears_lbl1" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears_lbl2" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears_lbl2">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears_lbl2" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears_lbl" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears_lbl">Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears_lbl" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears_lbl1" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears_lbl1">Sale Leaseback Transactions, Future Minimum Sublease Rentals, within Two Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears_lbl1" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears_lbl2" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears_lbl2">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears_lbl2" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments" xlink:label="PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments" xlink:title="PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments_lbl" xml:lang="en-US" id="btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments_lbl">Percentage of increase in annual lease payment for subleases for each year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments" xlink:to="btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments_lbl" xlink:title="label: PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments to btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments_lbl1" xml:lang="en-US" id="btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments_lbl1">Percentage of Lessee Sublease, Increase In Annual Lease Rent Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments" xlink:to="btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments_lbl1" xlink:title="label: PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments to btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments_lbl2" xml:lang="en-US" id="btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments_lbl2">Percentage of annual rent increase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments" xlink:to="btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments_lbl2" xlink:title="label: PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments to btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals_lbl" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals_lbl">Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals_lbl" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentals to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals_lbl1" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals_lbl1">Sale Leaseback Transactions, Future Minimum Sublease Rentals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals_lbl1" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentals to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals_lbl2" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals_lbl2">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals_lbl2" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentals to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears_lbl" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears_lbl">Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears_lbl" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears_lbl1" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears_lbl1">Sale Leaseback Transactions, Future Minimum Sublease Rentals, within Four Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears_lbl1" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears_lbl2" xml:lang="en-US" id="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears_lbl2">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" xlink:to="btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears_lbl2" xlink:title="label: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears to btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PrincipalPaymentsOnOperatingLeaseLiabilities" xlink:label="PrincipalPaymentsOnOperatingLeaseLiabilities" xlink:title="PrincipalPaymentsOnOperatingLeaseLiabilities" />
    <link:label xlink:type="resource" xlink:label="btx_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl" xml:lang="en-US" id="btx_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl">Principal payments on operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrincipalPaymentsOnOperatingLeaseLiabilities" xlink:to="btx_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl" xlink:title="label: PrincipalPaymentsOnOperatingLeaseLiabilities to btx_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl1" xml:lang="en-US" id="btx_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl1">Principal payments on operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrincipalPaymentsOnOperatingLeaseLiabilities" xlink:to="btx_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl1" xlink:title="label: PrincipalPaymentsOnOperatingLeaseLiabilities to btx_PrincipalPaymentsOnOperatingLeaseLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AdditionOfOperatingLeaseLiability" xlink:label="AdditionOfOperatingLeaseLiability" xlink:title="AdditionOfOperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="btx_AdditionOfOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AdditionOfOperatingLeaseLiability_lbl" xml:lang="en-US" id="btx_AdditionOfOperatingLeaseLiability_lbl">Addition of operating lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionOfOperatingLeaseLiability" xlink:to="btx_AdditionOfOperatingLeaseLiability_lbl" xlink:title="label: AdditionOfOperatingLeaseLiability to btx_AdditionOfOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AdditionOfOperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AdditionOfOperatingLeaseLiability_lbl1" xml:lang="en-US" id="btx_AdditionOfOperatingLeaseLiability_lbl1">Addition of operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionOfOperatingLeaseLiability" xlink:to="btx_AdditionOfOperatingLeaseLiability_lbl1" xlink:title="label: AdditionOfOperatingLeaseLiability to btx_AdditionOfOperatingLeaseLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AdditionOfOperatingLeaseLiability_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AdditionOfOperatingLeaseLiability_lbl2" xml:lang="en-US" id="btx_AdditionOfOperatingLeaseLiability_lbl2">Addition of operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionOfOperatingLeaseLiability" xlink:to="btx_AdditionOfOperatingLeaseLiability_lbl2" xlink:title="label: AdditionOfOperatingLeaseLiability to btx_AdditionOfOperatingLeaseLiability_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_OperatingLeaseAssestAbstract" xlink:label="OperatingLeaseAssestAbstract" xlink:title="OperatingLeaseAssestAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_OperatingLeaseAssestAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_OperatingLeaseAssestAbstract_lbl1" xml:lang="en-US" id="btx_OperatingLeaseAssestAbstract_lbl1">Operating Lease, Asset [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseAssestAbstract" xlink:to="btx_OperatingLeaseAssestAbstract_lbl1" xlink:title="label: OperatingLeaseAssestAbstract to btx_OperatingLeaseAssestAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AdditionOfOperatingLeaseRightofUseAsset" xlink:label="AdditionOfOperatingLeaseRightofUseAsset" xlink:title="AdditionOfOperatingLeaseRightofUseAsset" />
    <link:label xlink:type="resource" xlink:label="btx_AdditionOfOperatingLeaseRightofUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AdditionOfOperatingLeaseRightofUseAsset_lbl" xml:lang="en-US" id="btx_AdditionOfOperatingLeaseRightofUseAsset_lbl">Addition of operating lease right-of -use asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionOfOperatingLeaseRightofUseAsset" xlink:to="btx_AdditionOfOperatingLeaseRightofUseAsset_lbl" xlink:title="label: AdditionOfOperatingLeaseRightofUseAsset to btx_AdditionOfOperatingLeaseRightofUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AdditionOfOperatingLeaseRightofUseAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AdditionOfOperatingLeaseRightofUseAsset_lbl1" xml:lang="en-US" id="btx_AdditionOfOperatingLeaseRightofUseAsset_lbl1">Addition of operating lease right-of -use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionOfOperatingLeaseRightofUseAsset" xlink:to="btx_AdditionOfOperatingLeaseRightofUseAsset_lbl1" xlink:title="label: AdditionOfOperatingLeaseRightofUseAsset to btx_AdditionOfOperatingLeaseRightofUseAsset_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AdditionOfOperatingLeaseRightofUseAsset_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AdditionOfOperatingLeaseRightofUseAsset_lbl2" xml:lang="en-US" id="btx_AdditionOfOperatingLeaseRightofUseAsset_lbl2">Addition of operating lease ROU assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionOfOperatingLeaseRightofUseAsset" xlink:to="btx_AdditionOfOperatingLeaseRightofUseAsset_lbl2" xlink:title="label: AdditionOfOperatingLeaseRightofUseAsset to btx_AdditionOfOperatingLeaseRightofUseAsset_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AnnualRentPerSquareFoot" xlink:label="AnnualRentPerSquareFoot" xlink:title="AnnualRentPerSquareFoot" />
    <link:label xlink:type="resource" xlink:label="btx_AnnualRentPerSquareFoot_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AnnualRentPerSquareFoot_lbl" xml:lang="en-US" id="btx_AnnualRentPerSquareFoot_lbl">Amount of rent expense per square foot for leased asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualRentPerSquareFoot" xlink:to="btx_AnnualRentPerSquareFoot_lbl" xlink:title="label: AnnualRentPerSquareFoot to btx_AnnualRentPerSquareFoot_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AnnualRentPerSquareFoot_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AnnualRentPerSquareFoot_lbl1" xml:lang="en-US" id="btx_AnnualRentPerSquareFoot_lbl1">Annual Rent Per Square Foot</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualRentPerSquareFoot" xlink:to="btx_AnnualRentPerSquareFoot_lbl1" xlink:title="label: AnnualRentPerSquareFoot to btx_AnnualRentPerSquareFoot_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AnnualRentPerSquareFoot_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AnnualRentPerSquareFoot_lbl2" xml:lang="en-US" id="btx_AnnualRentPerSquareFoot_lbl2">Annual rent (per square foot)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualRentPerSquareFoot" xlink:to="btx_AnnualRentPerSquareFoot_lbl2" xlink:title="label: AnnualRentPerSquareFoot to btx_AnnualRentPerSquareFoot_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:label="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:title="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl">Tabular disclosure for lessee's operating lease right-of-use assets and liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:to="btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl" xlink:title="label: OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock to btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl1">Operating Lease Right-of-use Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:to="btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl1" xlink:title="label: OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock to btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl2" xml:lang="en-US" id="btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl2">Operating Lease Right-of-use Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:to="btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl2" xlink:title="label: OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock to btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock" xlink:label="FutureLeasePaymentsSubleaseAgreementTableTextBlock" xlink:title="FutureLeasePaymentsSubleaseAgreementTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock_lbl" xml:lang="en-US" id="btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock_lbl">Tabular disclosure of future lease payments of sublease agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FutureLeasePaymentsSubleaseAgreementTableTextBlock" xlink:to="btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock_lbl" xlink:title="label: FutureLeasePaymentsSubleaseAgreementTableTextBlock to btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock_lbl1" xml:lang="en-US" id="btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock_lbl1">Future Lease Payments, Sublease Agreement [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FutureLeasePaymentsSubleaseAgreementTableTextBlock" xlink:to="btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock_lbl1" xlink:title="label: FutureLeasePaymentsSubleaseAgreementTableTextBlock to btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock_lbl2" xml:lang="en-US" id="btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock_lbl2">Future Lease Payments from Sublease Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FutureLeasePaymentsSubleaseAgreementTableTextBlock" xlink:to="btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock_lbl2" xlink:title="label: FutureLeasePaymentsSubleaseAgreementTableTextBlock to btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DispositionAbstract" xlink:label="DispositionAbstract" xlink:title="DispositionAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_DispositionAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DispositionAbstract_lbl1" xml:lang="en-US" id="btx_DispositionAbstract_lbl1">Disposition [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DispositionAbstract" xlink:to="btx_DispositionAbstract_lbl1" xlink:title="label: DispositionAbstract to btx_DispositionAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ProceedsFromDispositionAbstract" xlink:label="ProceedsFromDispositionAbstract" xlink:title="ProceedsFromDispositionAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromDispositionAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ProceedsFromDispositionAbstract_lbl1" xml:lang="en-US" id="btx_ProceedsFromDispositionAbstract_lbl1">Proceeds from Disposition [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDispositionAbstract" xlink:to="btx_ProceedsFromDispositionAbstract_lbl1" xlink:title="label: ProceedsFromDispositionAbstract to btx_ProceedsFromDispositionAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromDispositionAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ProceedsFromDispositionAbstract_lbl2" xml:lang="en-US" id="btx_ProceedsFromDispositionAbstract_lbl2">Proceeds from sale [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDispositionAbstract" xlink:to="btx_ProceedsFromDispositionAbstract_lbl2" xlink:title="label: ProceedsFromDispositionAbstract to btx_ProceedsFromDispositionAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl">Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromCash to btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl1" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl1">Disposal Group, Including Discontinued Operation, Proceeds from Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromCash to btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl2" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl2">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromCash to btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl">Aggregate proceeds received from escrow deposits in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow to btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl1" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl1">Disposal Group, Including Discontinued Operation, Proceeds from Escrow</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow to btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl2" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl2">Escrow</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow to btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl">Aggregate proceeds received from interest on advance/loans in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans to btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl1" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl1">Disposal Group, Including Discontinued Operation, Proceeds from Interest on Advance/Loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans to btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl2" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl2">Interest on advance/loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans to btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:label="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:title="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl">Amount classified as software development cost attributable to disposal group held for sale or disposed of.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts to btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl1" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl1">Disposal Group, Including Discontinued Operation, Software development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts to btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl2" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl2">Software development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts to btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl">Aggregate proceeds received from assume advance/loans in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans to btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl1" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl1">Disposal Group, Including Discontinued Operation, Proceeds from Assume Advance/Loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans to btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl2" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl2">Assume advance/loans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans to btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:label="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:title="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl">Amount classified as Obligations under finance leases attributable to disposal group held for sale or disposed of.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases to btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl1" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl1">Disposal Group, Including Discontinued Operation, Obligations under finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases to btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl2" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl2">Obligations under finance leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases to btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:label="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:title="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl">Amount classified as Lease liability attributable to disposal group held for sale or disposed of.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationLeaseLiability to btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl1" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl1">Disposal Group, Including Discontinued Operation, Lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationLeaseLiability to btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl2" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl2">Lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationLeaseLiability to btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NTNBusinessMember" xlink:label="NTNBusinessMember" xlink:title="NTNBusinessMember" />
    <link:label xlink:type="resource" xlink:label="btx_NTNBusinessMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NTNBusinessMember_lbl" xml:lang="en-US" id="btx_NTNBusinessMember_lbl">Name of the disposal group.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NTNBusinessMember" xlink:to="btx_NTNBusinessMember_lbl" xlink:title="label: NTNBusinessMember to btx_NTNBusinessMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NTNBusinessMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NTNBusinessMember_lbl1" xml:lang="en-US" id="btx_NTNBusinessMember_lbl1">NTN Business [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NTNBusinessMember" xlink:to="btx_NTNBusinessMember_lbl1" xlink:title="label: NTNBusinessMember to btx_NTNBusinessMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NTNBusinessMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NTNBusinessMember_lbl2" xml:lang="en-US" id="btx_NTNBusinessMember_lbl2">NTN Business [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NTNBusinessMember" xlink:to="btx_NTNBusinessMember_lbl2" xlink:title="label: NTNBusinessMember to btx_NTNBusinessMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:label="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:title="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl">Amount of costs of the business disposal including legal, accounting, and other costs incurred to consummate the business disposition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationTransactionCosts to btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl1" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl1">Disposal Group, Including Discontinued Operation, Transaction Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl1" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationTransactionCosts to btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl2" xml:lang="en-US" id="btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl2">Transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:to="btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl2" xlink:title="label: DisposalGroupIncludingDiscontinuedOperationTransactionCosts to btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl">Value of stock issued with restrictions during the period pursuant to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:to="btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl" xlink:title="label: StockIssuedDuringPeriodRestrictedSharesValueAcquisitions to btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl1">Stock Issued During Period, Restricted Shares, Value, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:to="btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl1" xlink:title="label: StockIssuedDuringPeriodRestrictedSharesValueAcquisitions to btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl2">Restricted shares, value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:to="btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl2" xlink:title="label: StockIssuedDuringPeriodRestrictedSharesValueAcquisitions to btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LockUpPeriodForRestrictedShares" xlink:label="LockUpPeriodForRestrictedShares" xlink:title="LockUpPeriodForRestrictedShares" />
    <link:label xlink:type="resource" xlink:label="btx_LockUpPeriodForRestrictedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LockUpPeriodForRestrictedShares_lbl" xml:lang="en-US" id="btx_LockUpPeriodForRestrictedShares_lbl">The period in which shares are locked-up, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LockUpPeriodForRestrictedShares" xlink:to="btx_LockUpPeriodForRestrictedShares_lbl" xlink:title="label: LockUpPeriodForRestrictedShares to btx_LockUpPeriodForRestrictedShares_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LockUpPeriodForRestrictedShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LockUpPeriodForRestrictedShares_lbl1" xml:lang="en-US" id="btx_LockUpPeriodForRestrictedShares_lbl1">Lock-up Period for Restricted Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LockUpPeriodForRestrictedShares" xlink:to="btx_LockUpPeriodForRestrictedShares_lbl1" xlink:title="label: LockUpPeriodForRestrictedShares to btx_LockUpPeriodForRestrictedShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LockUpPeriodForRestrictedShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LockUpPeriodForRestrictedShares_lbl2" xml:lang="en-US" id="btx_LockUpPeriodForRestrictedShares_lbl2">Lock-up period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LockUpPeriodForRestrictedShares" xlink:to="btx_LockUpPeriodForRestrictedShares_lbl2" xlink:title="label: LockUpPeriodForRestrictedShares to btx_LockUpPeriodForRestrictedShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AcquisitionAgreementNonCompetitivePeriod" xlink:label="AcquisitionAgreementNonCompetitivePeriod" xlink:title="AcquisitionAgreementNonCompetitivePeriod" />
    <link:label xlink:type="resource" xlink:label="btx_AcquisitionAgreementNonCompetitivePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AcquisitionAgreementNonCompetitivePeriod_lbl" xml:lang="en-US" id="btx_AcquisitionAgreementNonCompetitivePeriod_lbl">The Acquisition Agreement contains non-competition and non-solicitation provisions pursuant to which the Seller has agreed not to engage in certain competitive activities for a period in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AcquisitionAgreementNonCompetitivePeriod" xlink:to="btx_AcquisitionAgreementNonCompetitivePeriod_lbl" xlink:title="label: AcquisitionAgreementNonCompetitivePeriod to btx_AcquisitionAgreementNonCompetitivePeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AcquisitionAgreementNonCompetitivePeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AcquisitionAgreementNonCompetitivePeriod_lbl1" xml:lang="en-US" id="btx_AcquisitionAgreementNonCompetitivePeriod_lbl1">Acquisition Agreement, Non Competitive Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AcquisitionAgreementNonCompetitivePeriod" xlink:to="btx_AcquisitionAgreementNonCompetitivePeriod_lbl1" xlink:title="label: AcquisitionAgreementNonCompetitivePeriod to btx_AcquisitionAgreementNonCompetitivePeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AcquisitionAgreementNonCompetitivePeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AcquisitionAgreementNonCompetitivePeriod_lbl2" xml:lang="en-US" id="btx_AcquisitionAgreementNonCompetitivePeriod_lbl2">Non-compete period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AcquisitionAgreementNonCompetitivePeriod" xlink:to="btx_AcquisitionAgreementNonCompetitivePeriod_lbl2" xlink:title="label: AcquisitionAgreementNonCompetitivePeriod to btx_AcquisitionAgreementNonCompetitivePeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:label="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:title="PercentageOfDiscountOnFairValueOfRestrictedShares" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl" xml:lang="en-US" id="btx_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl">Percentage of discount on restricted shares, which was derived from the average discount rate between the Black Scholes and Finnerty valuation models.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:to="btx_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl" xlink:title="label: PercentageOfDiscountOnFairValueOfRestrictedShares to btx_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl1" xml:lang="en-US" id="btx_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl1">Percentage of Discount on Fair Value of Restricted Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:to="btx_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl1" xlink:title="label: PercentageOfDiscountOnFairValueOfRestrictedShares to btx_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl2" xml:lang="en-US" id="btx_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl2">Percentage of discount on fair value restricted shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:to="btx_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl2" xlink:title="label: PercentageOfDiscountOnFairValueOfRestrictedShares to btx_PercentageOfDiscountOnFairValueOfRestrictedShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AssetAcquisitionRestrictedSharesSharePrice" xlink:label="AssetAcquisitionRestrictedSharesSharePrice" xlink:title="AssetAcquisitionRestrictedSharesSharePrice" />
    <link:label xlink:type="resource" xlink:label="btx_AssetAcquisitionRestrictedSharesSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AssetAcquisitionRestrictedSharesSharePrice_lbl" xml:lang="en-US" id="btx_AssetAcquisitionRestrictedSharesSharePrice_lbl">Price of a single share of a number of saleable stocks paid or offered with restrictions to be paid in asset acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionRestrictedSharesSharePrice" xlink:to="btx_AssetAcquisitionRestrictedSharesSharePrice_lbl" xlink:title="label: AssetAcquisitionRestrictedSharesSharePrice to btx_AssetAcquisitionRestrictedSharesSharePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AssetAcquisitionRestrictedSharesSharePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AssetAcquisitionRestrictedSharesSharePrice_lbl1" xml:lang="en-US" id="btx_AssetAcquisitionRestrictedSharesSharePrice_lbl1">Asset Acquisition, Restricted Shares, Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionRestrictedSharesSharePrice" xlink:to="btx_AssetAcquisitionRestrictedSharesSharePrice_lbl1" xlink:title="label: AssetAcquisitionRestrictedSharesSharePrice to btx_AssetAcquisitionRestrictedSharesSharePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AssetAcquisitionRestrictedSharesSharePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AssetAcquisitionRestrictedSharesSharePrice_lbl2" xml:lang="en-US" id="btx_AssetAcquisitionRestrictedSharesSharePrice_lbl2">Restricted shares, fair value per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionRestrictedSharesSharePrice" xlink:to="btx_AssetAcquisitionRestrictedSharesSharePrice_lbl2" xlink:title="label: AssetAcquisitionRestrictedSharesSharePrice to btx_AssetAcquisitionRestrictedSharesSharePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl">Value of stock issued without any restrictions during the period pursuant to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:to="btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl" xlink:title="label: StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions to btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl1">Stock Issued During Period, Unrestricted Shares, Value, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:to="btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl1" xlink:title="label: StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions to btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl2">Unrestricted shares, value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:to="btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl2" xlink:title="label: StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions to btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AssetAcquisitionFairValueOfConsiderationPaid" xlink:label="AssetAcquisitionFairValueOfConsiderationPaid" xlink:title="AssetAcquisitionFairValueOfConsiderationPaid" />
    <link:label xlink:type="resource" xlink:label="btx_AssetAcquisitionFairValueOfConsiderationPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AssetAcquisitionFairValueOfConsiderationPaid_lbl" xml:lang="en-US" id="btx_AssetAcquisitionFairValueOfConsiderationPaid_lbl">Amount of fair value of consideration paid in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionFairValueOfConsiderationPaid" xlink:to="btx_AssetAcquisitionFairValueOfConsiderationPaid_lbl" xlink:title="label: AssetAcquisitionFairValueOfConsiderationPaid to btx_AssetAcquisitionFairValueOfConsiderationPaid_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AssetAcquisitionFairValueOfConsiderationPaid_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AssetAcquisitionFairValueOfConsiderationPaid_lbl1" xml:lang="en-US" id="btx_AssetAcquisitionFairValueOfConsiderationPaid_lbl1">Asset Acquisition, Fair Value of Consideration Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionFairValueOfConsiderationPaid" xlink:to="btx_AssetAcquisitionFairValueOfConsiderationPaid_lbl1" xlink:title="label: AssetAcquisitionFairValueOfConsiderationPaid to btx_AssetAcquisitionFairValueOfConsiderationPaid_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AssetAcquisitionFairValueOfConsiderationPaid_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="btx_AssetAcquisitionFairValueOfConsiderationPaid_lbl2" xml:lang="en-US" id="btx_AssetAcquisitionFairValueOfConsiderationPaid_lbl2">Total fair value of consideration paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionFairValueOfConsiderationPaid" xlink:to="btx_AssetAcquisitionFairValueOfConsiderationPaid_lbl2" xlink:title="label: AssetAcquisitionFairValueOfConsiderationPaid to btx_AssetAcquisitionFairValueOfConsiderationPaid_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EscrowPeriod" xlink:label="EscrowPeriod" xlink:title="EscrowPeriod" />
    <link:label xlink:type="resource" xlink:label="btx_EscrowPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_EscrowPeriod_lbl" xml:lang="en-US" id="btx_EscrowPeriod_lbl">The period of secure indemnification obligations to acquisition agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EscrowPeriod" xlink:to="btx_EscrowPeriod_lbl" xlink:title="label: EscrowPeriod to btx_EscrowPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_EscrowPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_EscrowPeriod_lbl1" xml:lang="en-US" id="btx_EscrowPeriod_lbl1">Escrow Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EscrowPeriod" xlink:to="btx_EscrowPeriod_lbl1" xlink:title="label: EscrowPeriod to btx_EscrowPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_EscrowPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_EscrowPeriod_lbl2" xml:lang="en-US" id="btx_EscrowPeriod_lbl2">Period of escrow</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EscrowPeriod" xlink:to="btx_EscrowPeriod_lbl2" xlink:title="label: EscrowPeriod to btx_EscrowPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AssetAcquisitionUnrestrictedSharesSharePrice" xlink:label="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:title="AssetAcquisitionUnrestrictedSharesSharePrice" />
    <link:label xlink:type="resource" xlink:label="btx_AssetAcquisitionUnrestrictedSharesSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AssetAcquisitionUnrestrictedSharesSharePrice_lbl" xml:lang="en-US" id="btx_AssetAcquisitionUnrestrictedSharesSharePrice_lbl">Price of a single share of a number of saleable stocks paid or offered without any restrictions to be paid in asset acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:to="btx_AssetAcquisitionUnrestrictedSharesSharePrice_lbl" xlink:title="label: AssetAcquisitionUnrestrictedSharesSharePrice to btx_AssetAcquisitionUnrestrictedSharesSharePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AssetAcquisitionUnrestrictedSharesSharePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AssetAcquisitionUnrestrictedSharesSharePrice_lbl1" xml:lang="en-US" id="btx_AssetAcquisitionUnrestrictedSharesSharePrice_lbl1">Asset Acquisition, Unrestricted Shares, Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:to="btx_AssetAcquisitionUnrestrictedSharesSharePrice_lbl1" xlink:title="label: AssetAcquisitionUnrestrictedSharesSharePrice to btx_AssetAcquisitionUnrestrictedSharesSharePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AssetAcquisitionUnrestrictedSharesSharePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AssetAcquisitionUnrestrictedSharesSharePrice_lbl2" xml:lang="en-US" id="btx_AssetAcquisitionUnrestrictedSharesSharePrice_lbl2">Unrestricted shares, fair value per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:to="btx_AssetAcquisitionUnrestrictedSharesSharePrice_lbl2" xlink:title="label: AssetAcquisitionUnrestrictedSharesSharePrice to btx_AssetAcquisitionUnrestrictedSharesSharePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AssetAcquisitionSharePrice" xlink:label="AssetAcquisitionSharePrice" xlink:title="AssetAcquisitionSharePrice" />
    <link:label xlink:type="resource" xlink:label="btx_AssetAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_AssetAcquisitionSharePrice_lbl" xml:lang="en-US" id="btx_AssetAcquisitionSharePrice_lbl">Price of a single share of a number of saleable stocks paid or offered to be paid in asset acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionSharePrice" xlink:to="btx_AssetAcquisitionSharePrice_lbl" xlink:title="label: AssetAcquisitionSharePrice to btx_AssetAcquisitionSharePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_AssetAcquisitionSharePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_AssetAcquisitionSharePrice_lbl1" xml:lang="en-US" id="btx_AssetAcquisitionSharePrice_lbl1">Asset Acquisition, Share Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionSharePrice" xlink:to="btx_AssetAcquisitionSharePrice_lbl1" xlink:title="label: AssetAcquisitionSharePrice to btx_AssetAcquisitionSharePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_AssetAcquisitionSharePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_AssetAcquisitionSharePrice_lbl2" xml:lang="en-US" id="btx_AssetAcquisitionSharePrice_lbl2">Share price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetAcquisitionSharePrice" xlink:to="btx_AssetAcquisitionSharePrice_lbl2" xlink:title="label: AssetAcquisitionSharePrice to btx_AssetAcquisitionSharePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:label="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:title="StockIssuedDuringPeriodRestrictedSharesAcquisitions" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl" xml:lang="en-US" id="btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl">Number of shares of stock issued with restrictions during the period pursuant to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:to="btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl" xlink:title="label: StockIssuedDuringPeriodRestrictedSharesAcquisitions to btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl1" xml:lang="en-US" id="btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl1">Stock Issued During Period, Restricted Shares, Acquisitions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:to="btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl1" xlink:title="label: StockIssuedDuringPeriodRestrictedSharesAcquisitions to btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl2" xml:lang="en-US" id="btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl2">Restricted shares, issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:to="btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl2" xlink:title="label: StockIssuedDuringPeriodRestrictedSharesAcquisitions to btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EscrowShares" xlink:label="EscrowShares" xlink:title="EscrowShares" />
    <link:label xlink:type="resource" xlink:label="btx_EscrowShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_EscrowShares_lbl" xml:lang="en-US" id="btx_EscrowShares_lbl">Number of shares have been placed in escrow shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EscrowShares" xlink:to="btx_EscrowShares_lbl" xlink:title="label: EscrowShares to btx_EscrowShares_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_EscrowShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_EscrowShares_lbl1" xml:lang="en-US" id="btx_EscrowShares_lbl1">Escrow Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EscrowShares" xlink:to="btx_EscrowShares_lbl1" xlink:title="label: EscrowShares to btx_EscrowShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_EscrowShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_EscrowShares_lbl2" xml:lang="en-US" id="btx_EscrowShares_lbl2">Escrow shares (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EscrowShares" xlink:to="btx_EscrowShares_lbl2" xlink:title="label: EscrowShares to btx_EscrowShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ObservableTransactionsForIdenticalEquitySecurities" xlink:label="ObservableTransactionsForIdenticalEquitySecurities" xlink:title="ObservableTransactionsForIdenticalEquitySecurities" />
    <link:label xlink:type="resource" xlink:label="btx_ObservableTransactionsForIdenticalEquitySecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ObservableTransactionsForIdenticalEquitySecurities_lbl" xml:lang="en-US" id="btx_ObservableTransactionsForIdenticalEquitySecurities_lbl">The amount for observable transactions for identical or similar equity securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObservableTransactionsForIdenticalEquitySecurities" xlink:to="btx_ObservableTransactionsForIdenticalEquitySecurities_lbl" xlink:title="label: ObservableTransactionsForIdenticalEquitySecurities to btx_ObservableTransactionsForIdenticalEquitySecurities_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ObservableTransactionsForIdenticalEquitySecurities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ObservableTransactionsForIdenticalEquitySecurities_lbl1" xml:lang="en-US" id="btx_ObservableTransactionsForIdenticalEquitySecurities_lbl1">Observable Transactions for Identical Equity Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObservableTransactionsForIdenticalEquitySecurities" xlink:to="btx_ObservableTransactionsForIdenticalEquitySecurities_lbl1" xlink:title="label: ObservableTransactionsForIdenticalEquitySecurities to btx_ObservableTransactionsForIdenticalEquitySecurities_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ObservableTransactionsForIdenticalEquitySecurities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ObservableTransactionsForIdenticalEquitySecurities_lbl2" xml:lang="en-US" id="btx_ObservableTransactionsForIdenticalEquitySecurities_lbl2">Observable transactions for identical or similar equity securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObservableTransactionsForIdenticalEquitySecurities" xlink:to="btx_ObservableTransactionsForIdenticalEquitySecurities_lbl2" xlink:title="label: ObservableTransactionsForIdenticalEquitySecurities to btx_ObservableTransactionsForIdenticalEquitySecurities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NumberOfBoardSeats" xlink:label="NumberOfBoardSeats" xlink:title="NumberOfBoardSeats" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfBoardSeats_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_NumberOfBoardSeats_lbl" xml:lang="en-US" id="btx_NumberOfBoardSeats_lbl">Number of members of the company's management holds board seats on board of directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBoardSeats" xlink:to="btx_NumberOfBoardSeats_lbl" xlink:title="label: NumberOfBoardSeats to btx_NumberOfBoardSeats_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfBoardSeats_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_NumberOfBoardSeats_lbl1" xml:lang="en-US" id="btx_NumberOfBoardSeats_lbl1">Number of Board Seats</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBoardSeats" xlink:to="btx_NumberOfBoardSeats_lbl1" xlink:title="label: NumberOfBoardSeats to btx_NumberOfBoardSeats_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_NumberOfBoardSeats_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_NumberOfBoardSeats_lbl2" xml:lang="en-US" id="btx_NumberOfBoardSeats_lbl2">Number of board seats</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBoardSeats" xlink:to="btx_NumberOfBoardSeats_lbl2" xlink:title="label: NumberOfBoardSeats to btx_NumberOfBoardSeats_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CitiusPharmaceuticalsIncMember" xlink:label="CitiusPharmaceuticalsIncMember" xlink:title="CitiusPharmaceuticalsIncMember" />
    <link:label xlink:type="resource" xlink:label="btx_CitiusPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_CitiusPharmaceuticalsIncMember_lbl" xml:lang="en-US" id="btx_CitiusPharmaceuticalsIncMember_lbl">Represents Citius Pharmaceuticals, Inc. Ownership interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CitiusPharmaceuticalsIncMember" xlink:to="btx_CitiusPharmaceuticalsIncMember_lbl" xlink:title="label: CitiusPharmaceuticalsIncMember to btx_CitiusPharmaceuticalsIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_CitiusPharmaceuticalsIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_CitiusPharmaceuticalsIncMember_lbl1" xml:lang="en-US" id="btx_CitiusPharmaceuticalsIncMember_lbl1">Citius Pharmaceuticals, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CitiusPharmaceuticalsIncMember" xlink:to="btx_CitiusPharmaceuticalsIncMember_lbl1" xlink:title="label: CitiusPharmaceuticalsIncMember to btx_CitiusPharmaceuticalsIncMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:label="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:title="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl" xml:lang="en-US" id="btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl">No definition available.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:to="btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl" xlink:title="label: LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract to btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl1" xml:lang="en-US" id="btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl1">Lessee Operating Lease Weighted Average Remaining Lease Term And Discount Rate Abstract [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:to="btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl1" xlink:title="label: LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract to btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl2" xml:lang="en-US" id="btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl2">Weighted Average Remaining Lease Term and Discount Rate [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:to="btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl2" xlink:title="label: LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract to btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:label="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:title="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" />
    <link:label xlink:type="resource" xlink:label="btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl" xml:lang="en-US" id="btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl">Amount of cash and cash equivalents obligated to maintain under merger agreement on balance sheet at the effective time of the merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:to="btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl" xlink:title="label: ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement to btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl1" xml:lang="en-US" id="btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl1">Obligated to Maintain Cash and Cash Equivalents Under Merger Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:to="btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl1" xlink:title="label: ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement to btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl2" xml:lang="en-US" id="btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl2">Cash and cash equivalents obligated to have under merger agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:to="btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl2" xlink:title="label: ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement to btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfAdditionalRightsOffering" xlink:label="PercentageOfAdditionalRightsOffering" xlink:title="PercentageOfAdditionalRightsOffering" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfAdditionalRightsOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PercentageOfAdditionalRightsOffering_lbl" xml:lang="en-US" id="btx_PercentageOfAdditionalRightsOffering_lbl">Percentage of additional right offering made by the entity for unit holders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfAdditionalRightsOffering" xlink:to="btx_PercentageOfAdditionalRightsOffering_lbl" xlink:title="label: PercentageOfAdditionalRightsOffering to btx_PercentageOfAdditionalRightsOffering_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfAdditionalRightsOffering_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PercentageOfAdditionalRightsOffering_lbl1" xml:lang="en-US" id="btx_PercentageOfAdditionalRightsOffering_lbl1">Percentage of Additional Rights Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfAdditionalRightsOffering" xlink:to="btx_PercentageOfAdditionalRightsOffering_lbl1" xlink:title="label: PercentageOfAdditionalRightsOffering to btx_PercentageOfAdditionalRightsOffering_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PercentageOfAdditionalRightsOffering_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PercentageOfAdditionalRightsOffering_lbl2" xml:lang="en-US" id="btx_PercentageOfAdditionalRightsOffering_lbl2">Percentage of additional rights offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfAdditionalRightsOffering" xlink:to="btx_PercentageOfAdditionalRightsOffering_lbl2" xlink:title="label: PercentageOfAdditionalRightsOffering to btx_PercentageOfAdditionalRightsOffering_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ProceedsFromSaleOfRights" xlink:label="ProceedsFromSaleOfRights" xlink:title="ProceedsFromSaleOfRights" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromSaleOfRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ProceedsFromSaleOfRights_lbl" xml:lang="en-US" id="btx_ProceedsFromSaleOfRights_lbl">The cash inflow from the sale of rights during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfRights" xlink:to="btx_ProceedsFromSaleOfRights_lbl" xlink:title="label: ProceedsFromSaleOfRights to btx_ProceedsFromSaleOfRights_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromSaleOfRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ProceedsFromSaleOfRights_lbl1" xml:lang="en-US" id="btx_ProceedsFromSaleOfRights_lbl1">Proceeds From Sale Of Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfRights" xlink:to="btx_ProceedsFromSaleOfRights_lbl1" xlink:title="label: ProceedsFromSaleOfRights to btx_ProceedsFromSaleOfRights_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ProceedsFromSaleOfRights_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ProceedsFromSaleOfRights_lbl2" xml:lang="en-US" id="btx_ProceedsFromSaleOfRights_lbl2">Proceeds from right offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfRights" xlink:to="btx_ProceedsFromSaleOfRights_lbl2" xlink:title="label: ProceedsFromSaleOfRights to btx_ProceedsFromSaleOfRights_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" />
    <link:label xlink:type="resource" xlink:label="btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl" xml:lang="en-US" id="btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl">The amount of software development costs recognized as of the acquisition date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:to="btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts to btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl1" xml:lang="en-US" id="btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl1">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Software Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:to="btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl1" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts to btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl2" xml:lang="en-US" id="btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl2">Software development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:to="btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl2" xlink:title="label: BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts to btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BeneficialHoldersContractualCommitmentsToInvest" xlink:label="BeneficialHoldersContractualCommitmentsToInvest" xlink:title="BeneficialHoldersContractualCommitmentsToInvest" />
    <link:label xlink:type="resource" xlink:label="btx_BeneficialHoldersContractualCommitmentsToInvest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_BeneficialHoldersContractualCommitmentsToInvest_lbl" xml:lang="en-US" id="btx_BeneficialHoldersContractualCommitmentsToInvest_lbl">Amount of contractual commitment made by beneficial holders to invest in the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeneficialHoldersContractualCommitmentsToInvest" xlink:to="btx_BeneficialHoldersContractualCommitmentsToInvest_lbl" xlink:title="label: BeneficialHoldersContractualCommitmentsToInvest to btx_BeneficialHoldersContractualCommitmentsToInvest_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_BeneficialHoldersContractualCommitmentsToInvest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_BeneficialHoldersContractualCommitmentsToInvest_lbl1" xml:lang="en-US" id="btx_BeneficialHoldersContractualCommitmentsToInvest_lbl1">Beneficial Holders Contractual Commitments To Invest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeneficialHoldersContractualCommitmentsToInvest" xlink:to="btx_BeneficialHoldersContractualCommitmentsToInvest_lbl1" xlink:title="label: BeneficialHoldersContractualCommitmentsToInvest to btx_BeneficialHoldersContractualCommitmentsToInvest_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_BeneficialHoldersContractualCommitmentsToInvest_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_BeneficialHoldersContractualCommitmentsToInvest_lbl2" xml:lang="en-US" id="btx_BeneficialHoldersContractualCommitmentsToInvest_lbl2">Beneficial holders contractual commitments to invest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BeneficialHoldersContractualCommitmentsToInvest" xlink:to="btx_BeneficialHoldersContractualCommitmentsToInvest_lbl2" xlink:title="label: BeneficialHoldersContractualCommitmentsToInvest to btx_BeneficialHoldersContractualCommitmentsToInvest_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ProFormaFairValueAdjustmentToAssetsMember" xlink:label="ProFormaFairValueAdjustmentToAssetsMember" xlink:title="ProFormaFairValueAdjustmentToAssetsMember" />
    <link:label xlink:type="resource" xlink:label="btx_ProFormaFairValueAdjustmentToAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_ProFormaFairValueAdjustmentToAssetsMember_lbl" xml:lang="en-US" id="btx_ProFormaFairValueAdjustmentToAssetsMember_lbl">Fair value adjustment to acquisition-date assets reported in proforma information.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProFormaFairValueAdjustmentToAssetsMember" xlink:to="btx_ProFormaFairValueAdjustmentToAssetsMember_lbl" xlink:title="label: ProFormaFairValueAdjustmentToAssetsMember to btx_ProFormaFairValueAdjustmentToAssetsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_ProFormaFairValueAdjustmentToAssetsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_ProFormaFairValueAdjustmentToAssetsMember_lbl1" xml:lang="en-US" id="btx_ProFormaFairValueAdjustmentToAssetsMember_lbl1">Pro Forma Fair Value Adjustment to Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProFormaFairValueAdjustmentToAssetsMember" xlink:to="btx_ProFormaFairValueAdjustmentToAssetsMember_lbl1" xlink:title="label: ProFormaFairValueAdjustmentToAssetsMember to btx_ProFormaFairValueAdjustmentToAssetsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_ProFormaFairValueAdjustmentToAssetsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_ProFormaFairValueAdjustmentToAssetsMember_lbl2" xml:lang="en-US" id="btx_ProFormaFairValueAdjustmentToAssetsMember_lbl2">Fair Value Adjustment to Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProFormaFairValueAdjustmentToAssetsMember" xlink:to="btx_ProFormaFairValueAdjustmentToAssetsMember_lbl2" xlink:title="label: ProFormaFairValueAdjustmentToAssetsMember to btx_ProFormaFairValueAdjustmentToAssetsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PurchasePriceAllocationProFormaAdjustmentMember" xlink:label="PurchasePriceAllocationProFormaAdjustmentMember" xlink:title="PurchasePriceAllocationProFormaAdjustmentMember" />
    <link:label xlink:type="resource" xlink:label="btx_PurchasePriceAllocationProFormaAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_PurchasePriceAllocationProFormaAdjustmentMember_lbl" xml:lang="en-US" id="btx_PurchasePriceAllocationProFormaAdjustmentMember_lbl">Proforma adjustment of purchase price allocation of acquisition-date assets and liability assumed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchasePriceAllocationProFormaAdjustmentMember" xlink:to="btx_PurchasePriceAllocationProFormaAdjustmentMember_lbl" xlink:title="label: PurchasePriceAllocationProFormaAdjustmentMember to btx_PurchasePriceAllocationProFormaAdjustmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_PurchasePriceAllocationProFormaAdjustmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_PurchasePriceAllocationProFormaAdjustmentMember_lbl1" xml:lang="en-US" id="btx_PurchasePriceAllocationProFormaAdjustmentMember_lbl1">Purchase Price Allocation Pro Forma Adjustment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchasePriceAllocationProFormaAdjustmentMember" xlink:to="btx_PurchasePriceAllocationProFormaAdjustmentMember_lbl1" xlink:title="label: PurchasePriceAllocationProFormaAdjustmentMember to btx_PurchasePriceAllocationProFormaAdjustmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_PurchasePriceAllocationProFormaAdjustmentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_PurchasePriceAllocationProFormaAdjustmentMember_lbl2" xml:lang="en-US" id="btx_PurchasePriceAllocationProFormaAdjustmentMember_lbl2">Purchase Price Allocation Pro Forma Adjustment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PurchasePriceAllocationProFormaAdjustmentMember" xlink:to="btx_PurchasePriceAllocationProFormaAdjustmentMember_lbl2" xlink:title="label: PurchasePriceAllocationProFormaAdjustmentMember to btx_PurchasePriceAllocationProFormaAdjustmentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign_lbl" xml:lang="en-US" id="btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign_lbl">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards excluding foreign purpose.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" xlink:to="btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign_lbl" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign to btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign_lbl1" xml:lang="en-US" id="btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign_lbl1">Deferred Tax Assets, Operating Loss Carryforwards Excluding Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" xlink:to="btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign_lbl1" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign to btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign_lbl2" xml:lang="en-US" id="btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign_lbl2">Net operating losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" xlink:to="btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign_lbl2" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign to btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IncomeTaxAbstract" xlink:label="IncomeTaxAbstract" xlink:title="IncomeTaxAbstract" />
    <link:label xlink:type="resource" xlink:label="btx_IncomeTaxAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_IncomeTaxAbstract_lbl1" xml:lang="en-US" id="btx_IncomeTaxAbstract_lbl1">Income Tax [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAbstract" xlink:to="btx_IncomeTaxAbstract_lbl1" xlink:title="label: IncomeTaxAbstract to btx_IncomeTaxAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_IncomeTaxAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_IncomeTaxAbstract_lbl2" xml:lang="en-US" id="btx_IncomeTaxAbstract_lbl2">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAbstract" xlink:to="btx_IncomeTaxAbstract_lbl2" xlink:title="label: IncomeTaxAbstract to btx_IncomeTaxAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_TaxCutsAndJobsActOperatingLossCarryforwards" xlink:label="TaxCutsAndJobsActOperatingLossCarryforwards" xlink:title="TaxCutsAndJobsActOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="btx_TaxCutsAndJobsActOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TaxCutsAndJobsActOperatingLossCarryforwards_lbl" xml:lang="en-US" id="btx_TaxCutsAndJobsActOperatingLossCarryforwards_lbl">Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws from effect of Tax Cuts and Jobs Act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCutsAndJobsActOperatingLossCarryforwards" xlink:to="btx_TaxCutsAndJobsActOperatingLossCarryforwards_lbl" xlink:title="label: TaxCutsAndJobsActOperatingLossCarryforwards to btx_TaxCutsAndJobsActOperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TaxCutsAndJobsActOperatingLossCarryforwards_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TaxCutsAndJobsActOperatingLossCarryforwards_lbl1" xml:lang="en-US" id="btx_TaxCutsAndJobsActOperatingLossCarryforwards_lbl1">Tax Cuts and Jobs Act, Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCutsAndJobsActOperatingLossCarryforwards" xlink:to="btx_TaxCutsAndJobsActOperatingLossCarryforwards_lbl1" xlink:title="label: TaxCutsAndJobsActOperatingLossCarryforwards to btx_TaxCutsAndJobsActOperatingLossCarryforwards_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TaxCutsAndJobsActOperatingLossCarryforwards_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_TaxCutsAndJobsActOperatingLossCarryforwards_lbl2" xml:lang="en-US" id="btx_TaxCutsAndJobsActOperatingLossCarryforwards_lbl2">Net operating loss carryforwards under Tax Cuts and Jobs Act</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCutsAndJobsActOperatingLossCarryforwards" xlink:to="btx_TaxCutsAndJobsActOperatingLossCarryforwards_lbl2" xlink:title="label: TaxCutsAndJobsActOperatingLossCarryforwards to btx_TaxCutsAndJobsActOperatingLossCarryforwards_lbl2" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_TaxCreditCarryforwardExpirationYear" xlink:label="TaxCreditCarryforwardExpirationYear" xlink:title="TaxCreditCarryforwardExpirationYear" />
    <link:label xlink:type="resource" xlink:label="btx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="btx_TaxCreditCarryforwardExpirationYear_lbl" xml:lang="en-US" id="btx_TaxCreditCarryforwardExpirationYear_lbl">Expiration beginning year of the tax credit carryforward, in YYYY format.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardExpirationYear" xlink:to="btx_TaxCreditCarryforwardExpirationYear_lbl" xlink:title="label: TaxCreditCarryforwardExpirationYear to btx_TaxCreditCarryforwardExpirationYear_lbl" />
    <link:label xlink:type="resource" xlink:label="btx_TaxCreditCarryforwardExpirationYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="btx_TaxCreditCarryforwardExpirationYear_lbl1" xml:lang="en-US" id="btx_TaxCreditCarryforwardExpirationYear_lbl1">Tax Credit Carryforward Expiration Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardExpirationYear" xlink:to="btx_TaxCreditCarryforwardExpirationYear_lbl1" xlink:title="label: TaxCreditCarryforwardExpirationYear to btx_TaxCreditCarryforwardExpirationYear_lbl1" />
    <link:label xlink:type="resource" xlink:label="btx_TaxCreditCarryforwardExpirationYear_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="btx_TaxCreditCarryforwardExpirationYear_lbl2" xml:lang="en-US" id="btx_TaxCreditCarryforwardExpirationYear_lbl2">Tax credits begin to expire</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardExpirationYear" xlink:to="btx_TaxCreditCarryforwardExpirationYear_lbl2" xlink:title="label: TaxCreditCarryforwardExpirationYear to btx_TaxCreditCarryforwardExpirationYear_lbl2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>btx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://brooklynitx.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/RetirementSavingsPlanDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#RetirementSavingsPlanDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxesComponentsOfIncomeTaxProvisionDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxesLossBeforeIncomeTaxesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockholdersAndMembersEquityDeficitAcquisitionDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockholdersAndMembersEquityDeficitMergerDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitReverseStocksplitDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockholdersAndMembersEquityDeficitReverseStocksplitDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensationRsusDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensationRsusDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensationSummaryOfStockOptionsDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensationStockOptionActivityDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensationEquityIncentivePlansDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#BasicAndDilutedEarningsPerCommonShareDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#CommitmentsAndContingenciesRoyaltyAgreementsDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#CommitmentsAndContingenciesLicensingAgreementsDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#CommitmentsAndContingenciesLegalMattersDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/DebtDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#DebtDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#AccruedExpensesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopmentDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#GoodwillAndInprocessResearchDevelopmentDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc01" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc01" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesSubleaseAgreementDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesSubleaseAgreementDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesNetOperatingLeaseExpensesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesOperatingLeaseDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesOperatingLeaseDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactionsAcquisitionDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsProFormaFinancialInformationDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactionsProFormaFinancialInformationDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactionsDispositionDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactionsMergerDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesSegmentReportingDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesSegmentReportingDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesBasisOfAccountingPresentationDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesBasisOfAccountingPresentationDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#LiquidityAndCapitalResourcesDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperationsDetails" xlink:type="simple" xlink:href="btx-20211231.xsd#OrganizationAndDescriptionOfBusinessOperationsDetails" />
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareTables" xlink:type="simple" xlink:href="btx-20211231.xsd#BasicAndDilutedEarningsPerCommonShareTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="btx-20211231.xsd#AccruedExpensesTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LeasesTables" xlink:type="simple" xlink:href="btx-20211231.xsd#LeasesTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="btx-20211231.xsd#PropertyAndEquipmentTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/FairValueOfFinancialInstrumentsTables" xlink:type="simple" xlink:href="btx-20211231.xsd#FairValueOfFinancialInstrumentsTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsTables" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactionsTables" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="btx-20211231.xsd#BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://brooklynitx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="btx-20211231.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://brooklynitx.com/role/RetirementSavingsPlan" xlink:type="simple" xlink:href="btx-20211231.xsd#RetirementSavingsPlan" />
  <link:roleRef roleURI="http://brooklynitx.com/role/IncomeTaxes" xlink:type="simple" xlink:href="btx-20211231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficit" xlink:type="simple" xlink:href="btx-20211231.xsd#StockholdersAndMembersEquityDeficit" />
  <link:roleRef roleURI="http://brooklynitx.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="btx-20211231.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShare" xlink:type="simple" xlink:href="btx-20211231.xsd#BasicAndDilutedEarningsPerCommonShare" />
  <link:roleRef roleURI="http://brooklynitx.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="btx-20211231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://brooklynitx.com/role/Debt" xlink:type="simple" xlink:href="btx-20211231.xsd#Debt" />
  <link:roleRef roleURI="http://brooklynitx.com/role/AccruedExpenses" xlink:type="simple" xlink:href="btx-20211231.xsd#AccruedExpenses" />
  <link:roleRef roleURI="http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopment" xlink:type="simple" xlink:href="btx-20211231.xsd#GoodwillAndInprocessResearchDevelopment" />
  <link:roleRef roleURI="http://brooklynitx.com/role/Leases" xlink:type="simple" xlink:href="btx-20211231.xsd#Leases" />
  <link:roleRef roleURI="http://brooklynitx.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="btx-20211231.xsd#PropertyAndEquipment" />
  <link:roleRef roleURI="http://brooklynitx.com/role/FairValueOfFinancialInstruments" xlink:type="simple" xlink:href="btx-20211231.xsd#FairValueOfFinancialInstruments" />
  <link:roleRef roleURI="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactions" xlink:type="simple" xlink:href="btx-20211231.xsd#MergerDispositionAndAcquisitionTransactions" />
  <link:roleRef roleURI="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="btx-20211231.xsd#BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://brooklynitx.com/role/LiquidityAndCapitalResources" xlink:type="simple" xlink:href="btx-20211231.xsd#LiquidityAndCapitalResources" />
  <link:roleRef roleURI="http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperations" xlink:type="simple" xlink:href="btx-20211231.xsd#OrganizationAndDescriptionOfBusinessOperations" />
  <link:roleRef roleURI="http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="btx-20211231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit" xlink:type="simple" xlink:href="btx-20211231.xsd#ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit" />
  <link:roleRef roleURI="http://brooklynitx.com/role/ConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="btx-20211231.xsd#ConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="btx-20211231.xsd#ConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://brooklynitx.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="btx-20211231.xsd#ConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://brooklynitx.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="btx-20211231.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="DocumentAnnualReport" xlink:title="DocumentAnnualReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentAnnualReport" xlink:title="presentation: CoverAbstract to DocumentAnnualReport" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: CoverAbstract to CurrentFiscalYearEndDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentTransitionReport" xlink:title="presentation: CoverAbstract to DocumentTransitionReport" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: CoverAbstract to EntityWellKnownSeasonedIssuer" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: CoverAbstract to EntityVoluntaryFilers" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: CoverAbstract to EntityCurrentReportingStatus" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityInteractiveDataCurrent" xlink:title="presentation: CoverAbstract to EntityInteractiveDataCurrent" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: CoverAbstract to EntityFilerCategory" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntitySmallBusiness" xlink:title="presentation: CoverAbstract to EntitySmallBusiness" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="IcfrAuditorAttestationFlag" xlink:title="IcfrAuditorAttestationFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="IcfrAuditorAttestationFlag" xlink:title="presentation: CoverAbstract to IcfrAuditorAttestationFlag" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityShellCompany" xlink:title="presentation: CoverAbstract to EntityShellCompany" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityPublicFloat" xlink:title="presentation: CoverAbstract to EntityPublicFloat" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: CoverAbstract to EntityCommonStockSharesOutstanding" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="AuditorName" xlink:title="AuditorName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AuditorName" xlink:title="presentation: CoverAbstract to AuditorName" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="AuditorFirmId" xlink:title="AuditorFirmId" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AuditorFirmId" xlink:title="presentation: CoverAbstract to AuditorFirmId" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="AuditorLocation" xlink:title="AuditorLocation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AuditorLocation" xlink:title="presentation: CoverAbstract to AuditorLocation" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassAMember" xlink:title="presentation: ClassOfStockDomain to CommonClassAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassBMember" xlink:title="presentation: ClassOfStockDomain to CommonClassBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="presentation: ClassOfStockDomain to CommonClassCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CommonUnitsMember" xlink:label="CommonUnitsMember" xlink:title="CommonUnitsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonUnitsMember" xlink:title="presentation: ClassOfStockDomain to CommonUnitsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesAPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="Cash" xlink:title="presentation: AssetsCurrentAbstract to Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AccountsReceivableNetCurrent" xlink:title="presentation: AssetsCurrentAbstract to AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: AssetsAbstract to OperatingLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Goodwill" xlink:title="presentation: AssetsAbstract to Goodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="presentation: AssetsAbstract to IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="EquityMethodInvestments" xlink:title="EquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="EquityMethodInvestments" xlink:title="presentation: AssetsAbstract to EquityMethodInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets" xlink:label="DepositAssets" xlink:title="DepositAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="DepositAssets" xlink:title="presentation: AssetsAbstract to DepositAssets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AssetsAbstract" xlink:title="presentation: StatementLineItems to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="LoansPayableCurrent" xlink:title="LoansPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LoansPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LoansPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaycheckProtectionProgramLoanCurrent" xlink:label="PaycheckProtectionProgramLoanCurrent" xlink:title="PaycheckProtectionProgramLoanCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="PaycheckProtectionProgramLoanCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to PaycheckProtectionProgramLoanCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OperatingLeaseLiabilityCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="OtherLiabilitiesCurrent" xlink:title="OtherLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OtherLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OtherLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OperatingLeaseLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaycheckProtectionProgramLoanNonCurrent" xlink:label="PaycheckProtectionProgramLoanNonCurrent" xlink:title="PaycheckProtectionProgramLoanNonCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="PaycheckProtectionProgramLoanNonCurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to PaycheckProtectionProgramLoanNonCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OtherLiabilitiesNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital" xlink:label="MembersCapital" xlink:title="MembersCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="MembersCapital" xlink:title="presentation: EquityAbstract to MembersCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: EquityAbstract to PreferredStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: EquityAbstract to CommonStockValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: EquityAbstract to AdditionalPaidInCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: EquityAbstract to RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: EquityAbstract to StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="EquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to EquityAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfFinancialPositionAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: EquityAbstract to PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="PreferredStockLiquidationPreferenceValue" xlink:title="PreferredStockLiquidationPreferenceValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="PreferredStockLiquidationPreferenceValue" xlink:title="presentation: EquityAbstract to PreferredStockLiquidationPreferenceValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: EquityAbstract to PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: EquityAbstract to PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: EquityAbstract to PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: EquityAbstract to CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: EquityAbstract to CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: EquityAbstract to CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: EquityAbstract to CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="EquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to EquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/ConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ResearchAndDevelopmentInProcessAssetAcquisition" xlink:label="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="ResearchAndDevelopmentInProcessAssetAcquisition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentInProcessAssetAcquisition" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="NoncashMergerRelatedCosts" xlink:title="NoncashMergerRelatedCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="NoncashMergerRelatedCosts" xlink:title="presentation: OperatingExpensesAbstract to NoncashMergerRelatedCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:title="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:title="presentation: OperatingExpensesAbstract to BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="OtherExpensesAbstract" xlink:title="OtherExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpensesAbstract" xlink:to="GainLossOnDispositionOfAssets1" xlink:title="presentation: OtherExpensesAbstract to GainLossOnDispositionOfAssets1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpensesAbstract" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: OtherExpensesAbstract to OtherNonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpensesAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: OtherExpensesAbstract to NonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OtherExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OtherExpensesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: IncomeStatementAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeStatementAbstract to IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="PreferredStockDividendsAndOtherAdjustments" xlink:title="presentation: IncomeStatementAbstract to PreferredStockDividendsAndOtherAdjustments" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareDiluted" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_MembershipEquityMember" xlink:label="MembershipEquityMember" xlink:title="MembershipEquityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="MembershipEquityMember" xlink:title="presentation: StatementEquityComponentsAxis to MembershipEquityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="PreferredStockMember" xlink:title="presentation: StatementEquityComponentsAxis to PreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassAMember" xlink:title="presentation: ClassOfStockDomain to CommonClassAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassBMember" xlink:title="presentation: ClassOfStockDomain to CommonClassBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="presentation: ClassOfStockDomain to CommonClassCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CommonUnitsMember" xlink:label="CommonUnitsMember" xlink:title="CommonUnitsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonUnitsMember" xlink:title="presentation: ClassOfStockDomain to CommonUnitsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesAPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: StatementTable to StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:label="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:title="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueRightsOfferingMembershipUnits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:label="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:title="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueAcquisitions1" xlink:label="StockIssuedDuringPeriodValueAcquisitions1" xlink:title="StockIssuedDuringPeriodValueAcquisitions1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueAcquisitions1" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueAcquisitions1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesAcquisitions1" xlink:label="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="StockIssuedDuringPeriodSharesAcquisitions1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesAcquisitions1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:label="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:label="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnersCapitalAccountAcquisitions" xlink:label="PartnersCapitalAccountAcquisitions" xlink:title="PartnersCapitalAccountAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="PartnersCapitalAccountAcquisitions" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to PartnersCapitalAccountAcquisitions" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PartnersCapitalAccountUnitsAcquisitions" xlink:label="PartnersCapitalAccountUnitsAcquisitions" xlink:title="PartnersCapitalAccountUnitsAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="PartnersCapitalAccountUnitsAcquisitions" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to PartnersCapitalAccountUnitsAcquisitions" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueAcquisitions" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesAcquisitions" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockOptionsExercised" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodValueStockPurchaseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockPurchaseAgreement" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockPurchaseAgreement" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:label="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="StockIssuedDuringPeriodSharesStockPurchaseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesStockPurchaseAgreement" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesStockPurchaseAgreement" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="StockIssuedDuringPeriodValueAcquisitions2" xlink:title="StockIssuedDuringPeriodValueAcquisitions2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueAcquisitions2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueAcquisitions2" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="StockIssuedDuringPeriodSharesAcquisitions2" xlink:title="StockIssuedDuringPeriodSharesAcquisitions2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesAcquisitions2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesAcquisitions2" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="DividendsPreferredStockCash" xlink:title="DividendsPreferredStockCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="DividendsPreferredStockCash" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to DividendsPreferredStockCash" order="18.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="PreferredStockDividendsShares" xlink:title="PreferredStockDividendsShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="PreferredStockDividendsShares" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to PreferredStockDividendsShares" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueInLieuOfDividends" xlink:label="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:title="StockIssuedDuringPeriodValueInLieuOfDividends" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueInLieuOfDividends" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueInLieuOfDividends" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:label="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:title="StockIssuedDuringPeriodSharesInLieuOfDividends" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesInLieuOfDividends" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesInLieuOfDividends" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:label="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:title="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:label="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:title="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesIssuedSharesForfeitureOfUnvestedRestrictedStock" order="23.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EffectOfImplementationOfNewAccountingPrincipal" xlink:label="EffectOfImplementationOfNewAccountingPrincipal" xlink:title="EffectOfImplementationOfNewAccountingPrincipal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="EffectOfImplementationOfNewAccountingPrincipal" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to EffectOfImplementationOfNewAccountingPrincipal" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="StockholdersEquityOther" xlink:title="StockholdersEquityOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquityOther" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquityOther" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OperatingLeaseRightOfUseAssetAmortizationExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashMergerRelatedCosts" xlink:label="NoncashMergerRelatedCosts" xlink:title="NoncashMergerRelatedCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NoncashMergerRelatedCosts" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to NoncashMergerRelatedCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnDispositionOfAssets1" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnDispositionOfAssets1" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_GainLossOnDisposalOfFixedAssets" xlink:label="GainLossOnDisposalOfFixedAssets" xlink:title="GainLossOnDisposalOfFixedAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnDisposalOfFixedAssets" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnDisposalOfFixedAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:label="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:title="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnForgivenessOfPaycheckProtectionProgramLoan" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnForgivenessOfPaycheckProtectionProgramLoan" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ResearchAndDevelopmentInProcessAssetAcquisition" xlink:label="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="ResearchAndDevelopmentInProcessAssetAcquisition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ResearchAndDevelopmentInProcessAssetAcquisition" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:title="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" xlink:label="IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" xlink:title="IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:title="IncreaseDecreaseInOperatingLeaseLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOperatingLeaseLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOperatingLeaseLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherOperatingLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSalesOfAssetsInvestingActivities" xlink:label="ProceedsFromSalesOfAssetsInvestingActivities" xlink:title="ProceedsFromSalesOfAssetsInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromSalesOfAssetsInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromSalesOfAssetsInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaymentsToAcquireProductiveAssetsNet" xlink:label="PaymentsToAcquireProductiveAssetsNet" xlink:title="PaymentsToAcquireProductiveAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquireProductiveAssetsNet" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquireProductiveAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="ProceedsFromDivestitureOfBusinesses" xlink:title="ProceedsFromDivestitureOfBusinesses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromDivestitureOfBusinesses" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromDivestitureOfBusinesses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="ProceedsFromOtherEquity" xlink:title="ProceedsFromOtherEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromOtherEquity" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromOtherEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromNotesPayable" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromNotesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaymentsOfPaycheckProtectionProgramLoan" xlink:label="PaymentsOfPaycheckProtectionProgramLoan" xlink:title="PaymentsOfPaycheckProtectionProgramLoan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfPaycheckProtectionProgramLoan" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsOfPaycheckProtectionProgramLoan" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentsOfNotesPayable" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to RepaymentsOfNotesPayable" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="PaymentsOfDividendsPreferredStockAndPreferenceStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsOfDividendsPreferredStockAndPreferenceStock" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CashPaidDuringThePeriodForAbstract" xlink:label="CashPaidDuringThePeriodForAbstract" xlink:title="CashPaidDuringThePeriodForAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringThePeriodForAbstract" xlink:to="InterestPaidNet" xlink:title="presentation: CashPaidDuringThePeriodForAbstract to InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="IncomeTaxesPaidNet" xlink:title="IncomeTaxesPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidDuringThePeriodForAbstract" xlink:to="IncomeTaxesPaidNet" xlink:title="presentation: CashPaidDuringThePeriodForAbstract to IncomeTaxesPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="CashPaidDuringThePeriodForAbstract" xlink:title="presentation: SupplementalCashFlowInformationAbstract to CashPaidDuringThePeriodForAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:label="IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:title="IssuanceOfCommonStockForSeriesAPreferredStockDividend" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="IssuanceOfCommonStockForSeriesAPreferredStockDividend" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to IssuanceOfCommonStockForSeriesAPreferredStockDividend" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1" xlink:label="StockIssued1" xlink:title="StockIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="StockIssued1" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to StockIssued1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IssuanceOfCommonStockForAssetAcquisition" xlink:label="IssuanceOfCommonStockForAssetAcquisition" xlink:title="IssuanceOfCommonStockForAssetAcquisition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="IssuanceOfCommonStockForAssetAcquisition" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to IssuanceOfCommonStockForAssetAcquisition" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ForfeitureOfUnvestedRestrictedStock" xlink:label="ForfeitureOfUnvestedRestrictedStock" xlink:title="ForfeitureOfUnvestedRestrictedStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ForfeitureOfUnvestedRestrictedStock" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to ForfeitureOfUnvestedRestrictedStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:label="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:title="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance" xlink:label="InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance" xlink:title="InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_InitialMeasurementOfOperatingLeaseLiabilities" xlink:label="InitialMeasurementOfOperatingLeaseLiabilities" xlink:title="InitialMeasurementOfOperatingLeaseLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="InitialMeasurementOfOperatingLeaseLiabilities" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to InitialMeasurementOfOperatingLeaseLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_InvestorDepositsForSaleOfMembersEquity" xlink:label="InvestorDepositsForSaleOfMembersEquity" xlink:title="InvestorDepositsForSaleOfMembersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="InvestorDepositsForSaleOfMembersEquity" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to InvestorDepositsForSaleOfMembersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LiquidityAndCapitalResources">
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LiquidityAndCapitalResourcesAbstract" xlink:label="LiquidityAndCapitalResourcesAbstract" xlink:title="LiquidityAndCapitalResourcesAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LiquidityAndCapitalResourcesTextBlock" xlink:label="LiquidityAndCapitalResourcesTextBlock" xlink:title="LiquidityAndCapitalResourcesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesAbstract" xlink:to="LiquidityAndCapitalResourcesTextBlock" xlink:title="presentation: LiquidityAndCapitalResourcesAbstract to LiquidityAndCapitalResourcesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactions">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:label="MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:title="MergersAcquisitionsAndDispositionsDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:title="presentation: BusinessCombinationsAbstract to MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/FairValueOfFinancialInstruments">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/PropertyAndEquipment">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/Leases">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeasesTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopment">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:title="GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/AccruedExpenses">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/Debt">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtDisclosureTextBlock" xlink:title="presentation: DebtDisclosureAbstract to DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShare">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareTextBlock" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: StockholdersEquityNoteAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/RetirementSavingsPlan">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="PostemploymentBenefitsAbstract" xlink:title="PostemploymentBenefitsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:label="PostemploymentBenefitsDisclosureTextBlock" xlink:title="PostemploymentBenefitsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PostemploymentBenefitsAbstract" xlink:to="PostemploymentBenefitsDisclosureTextBlock" xlink:title="presentation: PostemploymentBenefitsAbstract to PostemploymentBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/SubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: AccountingPoliciesAbstract to UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CashAndCashEquivalentsPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to PropertyPlantAndEquipmentPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="presentation: AccountingPoliciesAbstract to GoodwillAndIntangibleAssetsGoodwillPolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="InProcessResearchAndDevelopmentPolicy" xlink:title="InProcessResearchAndDevelopmentPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="InProcessResearchAndDevelopmentPolicy" xlink:title="presentation: AccountingPoliciesAbstract to InProcessResearchAndDevelopmentPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentExpensePolicy" xlink:title="presentation: AccountingPoliciesAbstract to ResearchAndDevelopmentExpensePolicy" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to EarningsPerSharePolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="SegmentReportingPolicyPolicyTextBlock" xlink:title="SegmentReportingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SegmentReportingPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SegmentReportingPolicyPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ConcentrationRiskCreditRisk" xlink:title="presentation: AccountingPoliciesAbstract to ConcentrationRiskCreditRisk" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueOfFinancialInstrumentsPolicy" xlink:title="presentation: AccountingPoliciesAbstract to FairValueOfFinancialInstrumentsPolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="LesseeLeasesPolicyTextBlock" xlink:title="LesseeLeasesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="LesseeLeasesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to LesseeLeasesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="CommitmentsAndContingenciesPolicyTextBlock" xlink:title="CommitmentsAndContingenciesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CommitmentsAndContingenciesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CommitmentsAndContingenciesPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:title="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:title="ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="BusinessAcquisitionProFormaInformationTextBlock" xlink:title="BusinessAcquisitionProFormaInformationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="BusinessAcquisitionProFormaInformationTextBlock" xlink:title="presentation: BusinessCombinationsAbstract to BusinessAcquisitionProFormaInformationTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="AssetAcquisitionTableTextBlock" xlink:title="AssetAcquisitionTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="AssetAcquisitionTableTextBlock" xlink:title="presentation: BusinessCombinationsAbstract to AssetAcquisitionTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/FairValueOfFinancialInstrumentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/PropertyAndEquipmentTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="LeaseCostTableTextBlock" xlink:title="LeaseCostTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LeaseCostTableTextBlock" xlink:title="presentation: LeasesAbstract to LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:label="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:title="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:title="presentation: LeasesAbstract to OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock" xlink:label="FutureLeasePaymentsSubleaseAgreementTableTextBlock" xlink:title="FutureLeasePaymentsSubleaseAgreementTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="FutureLeasePaymentsSubleaseAgreementTableTextBlock" xlink:title="presentation: LeasesAbstract to FutureLeasePaymentsSubleaseAgreementTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/AccruedExpensesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:title="ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:title="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NoveCiteINCMember" xlink:label="NoveCiteINCMember" xlink:title="NoveCiteINCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NoveCiteINCMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to NoveCiteINCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="presentation: BusinessCombinationDescriptionAbstract to EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationDescriptionAbstract" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessCombinationDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionLineItems" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails">
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LiquidityAndCapitalResourcesAbstract" xlink:label="LiquidityAndCapitalResourcesAbstract" xlink:title="LiquidityAndCapitalResourcesAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LiquidityAndCapitalResourcesTable" xlink:label="LiquidityAndCapitalResourcesTable" xlink:title="LiquidityAndCapitalResourcesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LincolnParkCapitalFundLLCMember" xlink:label="LincolnParkCapitalFundLLCMember" xlink:title="LincolnParkCapitalFundLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="LincolnParkCapitalFundLLCMember" xlink:title="presentation: EntityDomain to LincolnParkCapitalFundLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesTable" xlink:to="LegalEntityAxis" xlink:title="presentation: LiquidityAndCapitalResourcesTable to LegalEntityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="presentation: AssetAcquisitionDomain to NovellusTherapeuticsLimitedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain" xlink:title="presentation: AssetAcquisitionAxis to AssetAcquisitionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesTable" xlink:to="AssetAcquisitionAxis" xlink:title="presentation: LiquidityAndCapitalResourcesTable to AssetAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_FirstPurchaseAgreementMember" xlink:label="FirstPurchaseAgreementMember" xlink:title="FirstPurchaseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="FirstPurchaseAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to FirstPurchaseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SecondPurchaseAgreementMember" xlink:label="SecondPurchaseAgreementMember" xlink:title="SecondPurchaseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SecondPurchaseAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to SecondPurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: LiquidityAndCapitalResourcesTable to TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesTable" xlink:to="RangeAxis" xlink:title="presentation: LiquidityAndCapitalResourcesTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: LiquidityAndCapitalResourcesTable to SubsequentEventTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LiquidityAndCapitalResourcesLineItems" xlink:label="LiquidityAndCapitalResourcesLineItems" xlink:title="LiquidityAndCapitalResourcesLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:label="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:title="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="Cash" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to RetainedEarningsAccumulatedDeficit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NetIncomeLossAttributableToParentTemporaryElement" xlink:label="NetIncomeLossAttributableToParentTemporaryElement" xlink:title="NetIncomeLossAttributableToParentTemporaryElement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="NetIncomeLossAttributableToParentTemporaryElement" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to NetIncomeLossAttributableToParentTemporaryElement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ResearchAndDevelopmentInProcessAssetAcquisition" xlink:label="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="ResearchAndDevelopmentInProcessAssetAcquisition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to ResearchAndDevelopmentInProcessAssetAcquisition" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="GainLossOnDispositionOfAssets1" xlink:title="GainLossOnDispositionOfAssets1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="GainLossOnDispositionOfAssets1" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to GainLossOnDispositionOfAssets1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:title="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to ProceedsFromIssuanceOfCommonStock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CommencementPeriodOfCommonStockInPurchaseAgreement" xlink:label="CommencementPeriodOfCommonStockInPurchaseAgreement" xlink:title="CommencementPeriodOfCommonStockInPurchaseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="CommencementPeriodOfCommonStockInPurchaseAgreement" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to CommencementPeriodOfCommonStockInPurchaseAgreement" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to SaleOfStockNumberOfSharesIssuedInTransaction" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to ProceedsFromIssuanceOrSaleOfEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaymentsToAcquireProductiveAssetsNet" xlink:label="PaymentsToAcquireProductiveAssetsNet" xlink:title="PaymentsToAcquireProductiveAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="PaymentsToAcquireProductiveAssetsNet" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to PaymentsToAcquireProductiveAssetsNet" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:to="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="presentation: DetailedInformationAboutLiquidityAndCapitalResourcesAbstract to ProceedsFromIssuanceOfPrivatePlacement" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesLineItems" xlink:to="DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" xlink:title="presentation: LiquidityAndCapitalResourcesLineItems to DetailedInformationAboutLiquidityAndCapitalResourcesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesTable" xlink:to="LiquidityAndCapitalResourcesLineItems" xlink:title="presentation: LiquidityAndCapitalResourcesTable to LiquidityAndCapitalResourcesLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndCapitalResourcesAbstract" xlink:to="LiquidityAndCapitalResourcesTable" xlink:title="presentation: LiquidityAndCapitalResourcesAbstract to LiquidityAndCapitalResourcesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesBasisOfAccountingPresentationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BasisOfPresentationAbstract" xlink:label="BasisOfPresentationAbstract" xlink:title="BasisOfPresentationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasisOfPresentationAbstract" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="presentation: BasisOfPresentationAbstract to StockholdersEquityNoteStockSplitConversionRatio1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfPresentationAbstract" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfPresentationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="CashAndCashEquivalentsAtCarryingValueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="CashEquivalentsAtCarryingValue" xlink:title="CashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="CashEquivalentsAtCarryingValue" xlink:title="presentation: CashAndCashEquivalentsAtCarryingValueAbstract to CashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="presentation: AccountingPoliciesAbstract to CashAndCashEquivalentsAtCarryingValueAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LaboratoryAndManufacturingEquipmentMember" xlink:label="LaboratoryAndManufacturingEquipmentMember" xlink:title="LaboratoryAndManufacturingEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LaboratoryAndManufacturingEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LaboratoryAndManufacturingEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="presentation: PropertyPlantAndEquipmentNetByTypeAbstract to PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetByTypeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesSegmentReportingDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="NumberOfOperatingSegments" xlink:title="presentation: SegmentReportingAbstract to NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SegmentReportingAbstract" xlink:title="presentation: AccountingPoliciesAbstract to SegmentReportingAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NTNBuzztimeIncMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to NTNBuzztimeIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:title="BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:title="presentation: BusinessCombinationDescriptionAbstract to BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:title="presentation: BusinessCombinationDescriptionAbstract to BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodSharesIssuedForServices" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="presentation: BusinessCombinationDescriptionAbstract to BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="BusinessAcquisitionSharePrice" xlink:title="BusinessAcquisitionSharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="BusinessAcquisitionSharePrice" xlink:title="presentation: BusinessCombinationDescriptionAbstract to BusinessAcquisitionSharePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: BusinessCombinationDescriptionAbstract to CommonStockSharesOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="Goodwill" xlink:title="presentation: BusinessCombinationDescriptionAbstract to Goodwill" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationDescriptionAbstract" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessCombinationDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionLineItems" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NTNBuzztimeIncMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to NTNBuzztimeIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="NonrecurringAdjustmentAxis" xlink:title="NonrecurringAdjustmentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="NonrecurringAdjustmentDomain" xlink:title="NonrecurringAdjustmentDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ProFormaFairValueAdjustmentToAssetsMember" xlink:label="ProFormaFairValueAdjustmentToAssetsMember" xlink:title="ProFormaFairValueAdjustmentToAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonrecurringAdjustmentDomain" xlink:to="ProFormaFairValueAdjustmentToAssetsMember" xlink:title="presentation: NonrecurringAdjustmentDomain to ProFormaFairValueAdjustmentToAssetsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PurchasePriceAllocationProFormaAdjustmentMember" xlink:label="PurchasePriceAllocationProFormaAdjustmentMember" xlink:title="PurchasePriceAllocationProFormaAdjustmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonrecurringAdjustmentDomain" xlink:to="PurchasePriceAllocationProFormaAdjustmentMember" xlink:title="presentation: NonrecurringAdjustmentDomain to PurchasePriceAllocationProFormaAdjustmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonrecurringAdjustmentAxis" xlink:to="NonrecurringAdjustmentDomain" xlink:title="presentation: NonrecurringAdjustmentAxis to NonrecurringAdjustmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="NonrecurringAdjustmentAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to NonrecurringAdjustmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="CustomerRelationshipsMember" xlink:title="CustomerRelationshipsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="CustomerRelationshipsMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to CustomerRelationshipsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="TradeNamesMember" xlink:title="TradeNamesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TradeNamesMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to TradeNamesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="presentation: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:title="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:to="Goodwill" xlink:title="presentation: BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract to Goodwill" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:label="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:title="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" xlink:title="presentation: BusinessAcquisitionLineItems to ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BeneficialHoldersContractualCommitmentsToInvest" xlink:label="BeneficialHoldersContractualCommitmentsToInvest" xlink:title="BeneficialHoldersContractualCommitmentsToInvest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BeneficialHoldersContractualCommitmentsToInvest" xlink:title="presentation: BusinessAcquisitionLineItems to BeneficialHoldersContractualCommitmentsToInvest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfAdditionalRightsOffering" xlink:label="PercentageOfAdditionalRightsOffering" xlink:title="PercentageOfAdditionalRightsOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="PercentageOfAdditionalRightsOffering" xlink:title="presentation: BusinessAcquisitionLineItems to PercentageOfAdditionalRightsOffering" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ProceedsFromSaleOfRights" xlink:label="ProceedsFromSaleOfRights" xlink:title="ProceedsFromSaleOfRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="ProceedsFromSaleOfRights" xlink:title="presentation: BusinessAcquisitionLineItems to ProceedsFromSaleOfRights" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionLineItems" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:title="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NTNBusinessMember" xlink:label="NTNBusinessMember" xlink:title="NTNBusinessMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="NTNBusinessMember" xlink:title="presentation: DisposalGroupsIncludingDiscontinuedOperationsNameDomain to NTNBusinessMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:title="presentation: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis to DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:title="presentation: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="CustomerRelationshipsMember" xlink:title="CustomerRelationshipsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="CustomerRelationshipsMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to CustomerRelationshipsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="TradeNamesMember" xlink:title="TradeNamesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TradeNamesMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to TradeNamesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="presentation: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="presentation: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:title="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DispositionAbstract" xlink:label="DispositionAbstract" xlink:title="DispositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:label="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:title="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DispositionAbstract" xlink:to="ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" xlink:title="presentation: DispositionAbstract to ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ProceedsFromDispositionAbstract" xlink:label="ProceedsFromDispositionAbstract" xlink:title="ProceedsFromDispositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromDispositionAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" xlink:title="presentation: ProceedsFromDispositionAbstract to DisposalGroupIncludingDiscontinuedOperationProceedsFromCash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromDispositionAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" xlink:title="presentation: ProceedsFromDispositionAbstract to DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromDispositionAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" xlink:title="presentation: ProceedsFromDispositionAbstract to DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:label="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:title="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromDispositionAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" xlink:title="presentation: ProceedsFromDispositionAbstract to DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DispositionAbstract" xlink:to="ProceedsFromDispositionAbstract" xlink:title="presentation: DispositionAbstract to ProceedsFromDispositionAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:title="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:title="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:title="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:label="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:title="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:title="DisposalGroupIncludingDiscontinuedOperationGoodwill1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationGoodwill1" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:title="DisposalGroupIncludingDiscontinuedOperationOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:title="presentation: AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationOtherAssets" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DispositionAbstract" xlink:to="AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="presentation: DispositionAbstract to AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:label="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:title="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" xlink:title="presentation: LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:label="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:title="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" xlink:title="presentation: LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:label="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:title="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationLeaseLiability" xlink:title="presentation: LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:label="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:title="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:title="presentation: LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:title="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:title="presentation: LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract to DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DispositionAbstract" xlink:to="LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:title="presentation: DispositionAbstract to LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:label="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:title="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DispositionAbstract" xlink:to="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:title="presentation: DispositionAbstract to DisposalGroupIncludingDiscontinuedOperationTransactionCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:title="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DispositionAbstract" xlink:to="DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:title="presentation: DispositionAbstract to DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="DispositionAbstract" xlink:title="presentation: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems to DispositionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:title="presentation: IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable to IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:title="presentation: BusinessCombinationsAbstract to IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsProFormaFinancialInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationAbstract" xlink:label="BusinessAcquisitionProFormaInformationAbstract" xlink:title="BusinessAcquisitionProFormaInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="BusinessAcquisitionsProFormaNetIncomeLoss" xlink:title="BusinessAcquisitionsProFormaNetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionProFormaInformationAbstract" xlink:to="BusinessAcquisitionsProFormaNetIncomeLoss" xlink:title="presentation: BusinessAcquisitionProFormaInformationAbstract to BusinessAcquisitionsProFormaNetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:title="BusinessAcquisitionProFormaEarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionProFormaInformationAbstract" xlink:to="BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:title="presentation: BusinessAcquisitionProFormaInformationAbstract to BusinessAcquisitionProFormaEarningsPerShareBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:label="BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:title="BusinessAcquisitionProFormaEarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionProFormaInformationAbstract" xlink:to="BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:title="presentation: BusinessAcquisitionProFormaInformationAbstract to BusinessAcquisitionProFormaEarningsPerShareDiluted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="BusinessAcquisitionProFormaInformationAbstract" xlink:title="presentation: BusinessCombinationsAbstract to BusinessAcquisitionProFormaInformationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NoveCiteINCMember" xlink:label="NoveCiteINCMember" xlink:title="NoveCiteINCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NoveCiteINCMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to NoveCiteINCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="AssetAcquisitionAxis" xlink:title="AssetAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="AssetAcquisitionDomain" xlink:title="AssetAcquisitionDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="presentation: AssetAcquisitionDomain to NovellusTherapeuticsLimitedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetAcquisitionAxis" xlink:to="AssetAcquisitionDomain" xlink:title="presentation: AssetAcquisitionAxis to AssetAcquisitionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="AssetAcquisitionAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to AssetAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:label="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:title="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:title="presentation: RelatedPartyDomain to ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="presentation: BusinessCombinationDescriptionAbstract to EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="AssetAcquisitionConsiderationTransferred" xlink:title="AssetAcquisitionConsiderationTransferred" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="AssetAcquisitionConsiderationTransferred" xlink:title="presentation: BusinessCombinationDescriptionAbstract to AssetAcquisitionConsiderationTransferred" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="PaymentsToAcquireOtherProductiveAssets" xlink:title="PaymentsToAcquireOtherProductiveAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="PaymentsToAcquireOtherProductiveAssets" xlink:title="presentation: BusinessCombinationDescriptionAbstract to PaymentsToAcquireOtherProductiveAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodSharesAcquisitions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="StockIssuedDuringPeriodValueAcquisitions" xlink:title="StockIssuedDuringPeriodValueAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodValueAcquisitions" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodValueAcquisitions" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AssetAcquisitionSharePrice" xlink:label="AssetAcquisitionSharePrice" xlink:title="AssetAcquisitionSharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="AssetAcquisitionSharePrice" xlink:title="presentation: BusinessCombinationDescriptionAbstract to AssetAcquisitionSharePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EscrowShares" xlink:label="EscrowShares" xlink:title="EscrowShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="EscrowShares" xlink:title="presentation: BusinessCombinationDescriptionAbstract to EscrowShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EscrowPeriod" xlink:label="EscrowPeriod" xlink:title="EscrowPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="EscrowPeriod" xlink:title="presentation: BusinessCombinationDescriptionAbstract to EscrowPeriod" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AcquisitionAgreementNonCompetitivePeriod" xlink:label="AcquisitionAgreementNonCompetitivePeriod" xlink:title="AcquisitionAgreementNonCompetitivePeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="AcquisitionAgreementNonCompetitivePeriod" xlink:title="presentation: BusinessCombinationDescriptionAbstract to AcquisitionAgreementNonCompetitivePeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodSharesIssuedForServices" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EachLockUpAgreementExtendsTerm" xlink:label="EachLockUpAgreementExtendsTerm" xlink:title="EachLockUpAgreementExtendsTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="EachLockUpAgreementExtendsTerm" xlink:title="presentation: BusinessCombinationDescriptionAbstract to EachLockUpAgreementExtendsTerm" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfCommonStockSubjectToLockUpAgreement" xlink:label="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:title="PercentageOfCommonStockSubjectToLockUpAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:title="presentation: BusinessCombinationDescriptionAbstract to PercentageOfCommonStockSubjectToLockUpAgreement" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaymentsToAcquireProductiveAssetsNet" xlink:label="PaymentsToAcquireProductiveAssetsNet" xlink:title="PaymentsToAcquireProductiveAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="PaymentsToAcquireProductiveAssetsNet" xlink:title="presentation: BusinessCombinationDescriptionAbstract to PaymentsToAcquireProductiveAssetsNet" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LockUpPeriodForRestrictedShares" xlink:label="LockUpPeriodForRestrictedShares" xlink:title="LockUpPeriodForRestrictedShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="LockUpPeriodForRestrictedShares" xlink:title="presentation: BusinessCombinationDescriptionAbstract to LockUpPeriodForRestrictedShares" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AssetAcquisitionUnrestrictedSharesSharePrice" xlink:label="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:title="AssetAcquisitionUnrestrictedSharesSharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="AssetAcquisitionUnrestrictedSharesSharePrice" xlink:title="presentation: BusinessCombinationDescriptionAbstract to AssetAcquisitionUnrestrictedSharesSharePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:label="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:title="StockIssuedDuringPeriodRestrictedSharesAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodRestrictedSharesAcquisitions" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodRestrictedSharesAcquisitions" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AssetAcquisitionRestrictedSharesSharePrice" xlink:label="AssetAcquisitionRestrictedSharesSharePrice" xlink:title="AssetAcquisitionRestrictedSharesSharePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="AssetAcquisitionRestrictedSharesSharePrice" xlink:title="presentation: BusinessCombinationDescriptionAbstract to AssetAcquisitionRestrictedSharesSharePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:label="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:title="PercentageOfDiscountOnFairValueOfRestrictedShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="PercentageOfDiscountOnFairValueOfRestrictedShares" xlink:title="presentation: BusinessCombinationDescriptionAbstract to PercentageOfDiscountOnFairValueOfRestrictedShares" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="PaymentsToAcquireProductiveAssets" xlink:title="PaymentsToAcquireProductiveAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="PaymentsToAcquireProductiveAssets" xlink:title="presentation: BusinessCombinationDescriptionAbstract to PaymentsToAcquireProductiveAssets" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="CashAcquiredFromAcquisition" xlink:title="CashAcquiredFromAcquisition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="CashAcquiredFromAcquisition" xlink:title="presentation: BusinessCombinationDescriptionAbstract to CashAcquiredFromAcquisition" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:label="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:title="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodRestrictedSharesValueAcquisitions" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AssetAcquisitionFairValueOfConsiderationPaid" xlink:label="AssetAcquisitionFairValueOfConsiderationPaid" xlink:title="AssetAcquisitionFairValueOfConsiderationPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="AssetAcquisitionFairValueOfConsiderationPaid" xlink:title="presentation: BusinessCombinationDescriptionAbstract to AssetAcquisitionFairValueOfConsiderationPaid" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="PaymentsToAcquireInvestments" xlink:title="PaymentsToAcquireInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="PaymentsToAcquireInvestments" xlink:title="presentation: BusinessCombinationDescriptionAbstract to PaymentsToAcquireInvestments" order="24.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ResearchAndDevelopmentInProcessAssetAcquisition" xlink:label="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="ResearchAndDevelopmentInProcessAssetAcquisition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="ResearchAndDevelopmentInProcessAssetAcquisition" xlink:title="presentation: BusinessCombinationDescriptionAbstract to ResearchAndDevelopmentInProcessAssetAcquisition" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="BusinessCombinationDescriptionAbstract" xlink:title="presentation: BusinessAcquisitionLineItems to BusinessCombinationDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionLineItems" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NoveCiteINCMember" xlink:label="NoveCiteINCMember" xlink:title="NoveCiteINCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NoveCiteINCMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to NoveCiteINCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CitiusPharmaceuticalsIncMember" xlink:label="CitiusPharmaceuticalsIncMember" xlink:title="CitiusPharmaceuticalsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipDomain" xlink:to="CitiusPharmaceuticalsIncMember" xlink:title="presentation: OwnershipDomain to CitiusPharmaceuticalsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="presentation: OwnershipAxis to OwnershipDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="OwnershipAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to OwnershipAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAbstract" xlink:label="InvestmentsAbstract" xlink:title="InvestmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="EquityMethodInvestmentOwnershipPercentage" xlink:title="EquityMethodInvestmentOwnershipPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="EquityMethodInvestmentOwnershipPercentage" xlink:title="presentation: InvestmentsAbstract to EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="presentation: InvestmentsAbstract to MinorityInterestOwnershipPercentageByParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NumberOfBoardSeats" xlink:label="NumberOfBoardSeats" xlink:title="NumberOfBoardSeats" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="NumberOfBoardSeats" xlink:title="presentation: InvestmentsAbstract to NumberOfBoardSeats" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="EquityMethodInvestments" xlink:title="EquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="EquityMethodInvestments" xlink:title="presentation: InvestmentsAbstract to EquityMethodInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ObservableTransactionsForIdenticalEquitySecurities" xlink:label="ObservableTransactionsForIdenticalEquitySecurities" xlink:title="ObservableTransactionsForIdenticalEquitySecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="ObservableTransactionsForIdenticalEquitySecurities" xlink:title="presentation: InvestmentsAbstract to ObservableTransactionsForIdenticalEquitySecurities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="InvestmentsAbstract" xlink:title="presentation: BusinessAcquisitionLineItems to InvestmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionLineItems" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="ContingentConsiderationByTypeAxis" xlink:title="ContingentConsiderationByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="ContingentConsiderationTypeDomain" xlink:title="ContingentConsiderationTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ContingentConsiderationMember" xlink:label="ContingentConsiderationMember" xlink:title="ContingentConsiderationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentConsiderationTypeDomain" xlink:to="ContingentConsiderationMember" xlink:title="presentation: ContingentConsiderationTypeDomain to ContingentConsiderationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentConsiderationByTypeAxis" xlink:to="ContingentConsiderationTypeDomain" xlink:title="presentation: ContingentConsiderationByTypeAxis to ContingentConsiderationTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ContingentConsiderationByTypeAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ContingentConsiderationByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="LiabilitiesFairValueDisclosure" xlink:title="presentation: LiabilitiesFairValueDisclosureAbstract to LiabilitiesFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="LiabilitiesFairValueDisclosureAbstract" xlink:title="presentation: FairValueNetAssetLiabilityAbstract to LiabilitiesFairValueDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="ContingentConsiderationByTypeAxis" xlink:title="ContingentConsiderationByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="ContingentConsiderationTypeDomain" xlink:title="ContingentConsiderationTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ContingentConsiderationMember" xlink:label="ContingentConsiderationMember" xlink:title="ContingentConsiderationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentConsiderationTypeDomain" xlink:to="ContingentConsiderationMember" xlink:title="presentation: ContingentConsiderationTypeDomain to ContingentConsiderationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentConsiderationByTypeAxis" xlink:to="ContingentConsiderationTypeDomain" xlink:title="presentation: ContingentConsiderationByTypeAxis to ContingentConsiderationTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="ContingentConsiderationByTypeAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to ContingentConsiderationByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="LiabilitiesFairValueDisclosureAbstract" xlink:title="LiabilitiesFairValueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="LiabilitiesFairValueDisclosure" xlink:title="presentation: LiabilitiesFairValueDisclosureAbstract to LiabilitiesFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="LiabilitiesFairValueAdjustment" xlink:title="LiabilitiesFairValueAdjustment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="LiabilitiesFairValueAdjustment" xlink:title="presentation: LiabilitiesFairValueDisclosureAbstract to LiabilitiesFairValueAdjustment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="LiabilitiesFairValueDisclosure_2" xlink:title="LiabilitiesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesFairValueDisclosureAbstract" xlink:to="LiabilitiesFairValueDisclosure_2" xlink:title="presentation: LiabilitiesFairValueDisclosureAbstract to LiabilitiesFairValueDisclosure" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="LiabilitiesFairValueDisclosureAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to LiabilitiesFairValueDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRoyaltyRevenueAssumedUntil2029" xlink:label="PercentageOfRoyaltyRevenueAssumedUntil2029" xlink:title="PercentageOfRoyaltyRevenueAssumedUntil2029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="PercentageOfRoyaltyRevenueAssumedUntil2029" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to PercentageOfRoyaltyRevenueAssumedUntil2029" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038" xlink:label="PercentageOfRoyaltyRevenueAssumedFrom2030To2038" xlink:title="PercentageOfRoyaltyRevenueAssumedFrom2030To2038" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="PercentageOfRoyaltyRevenueAssumedFrom2030To2038" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to PercentageOfRoyaltyRevenueAssumedFrom2030To2038" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" xlink:label="PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" xlink:title="PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to PercentageOfRoyaltyRevenuePostPatentDeclineYearOne" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" xlink:label="PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" xlink:title="PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" xlink:label="PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" xlink:title="PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfWeightedAverageCostOfCapital" xlink:label="PercentageOfWeightedAverageCostOfCapital" xlink:title="PercentageOfWeightedAverageCostOfCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="PercentageOfWeightedAverageCostOfCapital" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to PercentageOfWeightedAverageCostOfCapital" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to EquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LeaseholdImprovementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to ComputerEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:label="PropertyPlantAndEquipmentGrossAbstract" xlink:title="PropertyPlantAndEquipmentGrossAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentGrossAbstract" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="presentation: PropertyPlantAndEquipmentGrossAbstract to PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentGrossAbstract" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentGrossAbstract to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentGrossAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: PropertyPlantAndEquipmentGrossAbstract to PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentGrossAbstract" xlink:to="Depreciation" xlink:title="presentation: PropertyPlantAndEquipmentGrossAbstract to Depreciation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentGrossAbstract" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentGrossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesOperatingLeaseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_OperatingLeaseArea" xlink:label="OperatingLeaseArea" xlink:title="OperatingLeaseArea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseArea" xlink:title="presentation: LeasesAbstract to OperatingLeaseArea" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AnnualRentPerSquareFoot" xlink:label="AnnualRentPerSquareFoot" xlink:title="AnnualRentPerSquareFoot" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="AnnualRentPerSquareFoot" xlink:title="presentation: LeasesAbstract to AnnualRentPerSquareFoot" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeasePayments" xlink:title="presentation: LeasesAbstract to OperatingLeasePayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="LeaseCostAbstract" xlink:title="LeaseCostAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseCostAbstract" xlink:to="OperatingLeaseCost" xlink:title="presentation: LeaseCostAbstract to OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseCostAbstract" xlink:to="SubleaseIncome" xlink:title="presentation: LeaseCostAbstract to SubleaseIncome" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="VariableLeaseCost" xlink:title="VariableLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseCostAbstract" xlink:to="VariableLeaseCost" xlink:title="presentation: LeaseCostAbstract to VariableLeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" xlink:title="LeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseCostAbstract" xlink:to="LeaseCost" xlink:title="presentation: LeaseCostAbstract to LeaseCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LeaseCostAbstract" xlink:title="presentation: LeasesAbstract to LeaseCostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:label="AssetsAndLiabilitiesLesseeAbstract" xlink:title="AssetsAndLiabilitiesLesseeAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_OperatingLeaseAssestAbstract" xlink:label="OperatingLeaseAssestAbstract" xlink:title="OperatingLeaseAssestAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseAssestAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: OperatingLeaseAssestAbstract to OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseAssestAbstract" xlink:to="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="presentation: OperatingLeaseAssestAbstract to OperatingLeaseRightOfUseAssetAmortizationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AdditionOfOperatingLeaseRightofUseAsset" xlink:label="AdditionOfOperatingLeaseRightofUseAsset" xlink:title="AdditionOfOperatingLeaseRightofUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseAssestAbstract" xlink:to="AdditionOfOperatingLeaseRightofUseAsset" xlink:title="presentation: OperatingLeaseAssestAbstract to AdditionOfOperatingLeaseRightofUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset_2" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseAssestAbstract" xlink:to="OperatingLeaseRightOfUseAsset_2" xlink:title="presentation: OperatingLeaseAssestAbstract to OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAndLiabilitiesLesseeAbstract" xlink:to="OperatingLeaseAssestAbstract" xlink:title="presentation: AssetsAndLiabilitiesLesseeAbstract to OperatingLeaseAssestAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="OperatingLeaseLiabilityAbstract" xlink:title="OperatingLeaseLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilityAbstract" xlink:to="OperatingLeaseLiability" xlink:title="presentation: OperatingLeaseLiabilityAbstract to OperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PrincipalPaymentsOnOperatingLeaseLiabilities" xlink:label="PrincipalPaymentsOnOperatingLeaseLiabilities" xlink:title="PrincipalPaymentsOnOperatingLeaseLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilityAbstract" xlink:to="PrincipalPaymentsOnOperatingLeaseLiabilities" xlink:title="presentation: OperatingLeaseLiabilityAbstract to PrincipalPaymentsOnOperatingLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AdditionOfOperatingLeaseLiability" xlink:label="AdditionOfOperatingLeaseLiability" xlink:title="AdditionOfOperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilityAbstract" xlink:to="AdditionOfOperatingLeaseLiability" xlink:title="presentation: OperatingLeaseLiabilityAbstract to AdditionOfOperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability_2" xlink:title="OperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilityAbstract" xlink:to="OperatingLeaseLiability_2" xlink:title="presentation: OperatingLeaseLiabilityAbstract to OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilityAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: OperatingLeaseLiabilityAbstract to OperatingLeaseLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilityAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: OperatingLeaseLiabilityAbstract to OperatingLeaseLiabilityCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAndLiabilitiesLesseeAbstract" xlink:to="OperatingLeaseLiabilityAbstract" xlink:title="presentation: AssetsAndLiabilitiesLesseeAbstract to OperatingLeaseLiabilityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="AssetsAndLiabilitiesLesseeAbstract" xlink:title="presentation: LeasesAbstract to AssetsAndLiabilitiesLesseeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:label="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:title="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:to="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="presentation: LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract to OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:to="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="presentation: LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract to OperatingLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiability" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="presentation: LeasesAbstract to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesSubleaseAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AreaOfSubleaseSpaceCurrentlyRented" xlink:label="AreaOfSubleaseSpaceCurrentlyRented" xlink:title="AreaOfSubleaseSpaceCurrentlyRented" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="AreaOfSubleaseSpaceCurrentlyRented" xlink:title="presentation: LeasesAbstract to AreaOfSubleaseSpaceCurrentlyRented" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments" xlink:label="PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments" xlink:title="PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments" xlink:title="presentation: LeasesAbstract to PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" xlink:to="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" xlink:title="presentation: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract to SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" xlink:to="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" xlink:title="presentation: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract to SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" xlink:to="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" xlink:title="presentation: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract to SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" xlink:to="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" xlink:title="presentation: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract to SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" xlink:to="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" xlink:title="presentation: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract to SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals" xlink:label="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" xlink:title="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" xlink:to="SaleLeasebackTransactionsFutureMinimumSubleaseRentals" xlink:title="presentation: SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract to SaleLeasebackTransactionsFutureMinimumSubleaseRentals" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" xlink:title="presentation: LeasesAbstract to SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLeasePayments" xlink:label="ProceedsFromLeasePayments" xlink:title="ProceedsFromLeasePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="ProceedsFromLeasePayments" xlink:title="presentation: LeasesAbstract to ProceedsFromLeasePayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc01" />
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="Goodwill" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to Goodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="ResearchAndDevelopmentInProcess" xlink:title="ResearchAndDevelopmentInProcess" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ResearchAndDevelopmentInProcess" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ResearchAndDevelopmentInProcess" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/AccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to EmployeeRelatedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AccruedResearchAndDevelopmentExpenses" xlink:label="AccruedResearchAndDevelopmentExpenses" xlink:title="AccruedResearchAndDevelopmentExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedResearchAndDevelopmentExpenses" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedResearchAndDevelopmentExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AccruedGeneralAndAdministrativeExpenses" xlink:label="AccruedGeneralAndAdministrativeExpenses" xlink:title="AccruedGeneralAndAdministrativeExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedGeneralAndAdministrativeExpenses" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedGeneralAndAdministrativeExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="InterestPayableCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to InterestPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/DebtDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaycheckProtectionProgramLoanMember" xlink:label="PaycheckProtectionProgramLoanMember" xlink:title="PaycheckProtectionProgramLoanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="PaycheckProtectionProgramLoanMember" xlink:title="presentation: DebtInstrumentNameDomain to PaycheckProtectionProgramLoanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaycheckProtectionProgramMember" xlink:label="PaycheckProtectionProgramMember" xlink:title="PaycheckProtectionProgramMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="PaycheckProtectionProgramMember" xlink:title="presentation: DebtInstrumentNameDomain to PaycheckProtectionProgramMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BrooklynPaycheckProtectionProgramMember" xlink:label="BrooklynPaycheckProtectionProgramMember" xlink:title="BrooklynPaycheckProtectionProgramMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="BrooklynPaycheckProtectionProgramMember" xlink:title="presentation: DebtInstrumentNameDomain to BrooklynPaycheckProtectionProgramMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DebtInstrumentAbstract" xlink:label="DebtInstrumentAbstract" xlink:title="DebtInstrumentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="LoansPayableCurrent" xlink:title="LoansPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAbstract" xlink:to="LoansPayableCurrent" xlink:title="presentation: DebtInstrumentAbstract to LoansPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAbstract" xlink:to="RepaymentsOfNotesPayable" xlink:title="presentation: DebtInstrumentAbstract to RepaymentsOfNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PaymentOfAccruedAndUnpaidInterest" xlink:label="PaymentOfAccruedAndUnpaidInterest" xlink:title="PaymentOfAccruedAndUnpaidInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAbstract" xlink:to="PaymentOfAccruedAndUnpaidInterest" xlink:title="presentation: DebtInstrumentAbstract to PaymentOfAccruedAndUnpaidInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAbstract" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: DebtInstrumentAbstract to DebtInstrumentFaceAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAbstract" xlink:to="LongTermDebt" xlink:title="presentation: DebtInstrumentAbstract to LongTermDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: DebtInstrumentAbstract to DebtInstrumentInterestRateStatedPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentAbstract" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="NTNBuzztimeIncMember" xlink:title="presentation: EntityDomain to NTNBuzztimeIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="LegalEntityAxis" xlink:title="presentation: LossContingenciesTable to LegalEntityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="presentation: RelatedPartyDomain to NovellusTherapeuticsLimitedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_RobertGarfieldMember" xlink:label="RobertGarfieldMember" xlink:title="RobertGarfieldMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="RobertGarfieldMember" xlink:title="presentation: RelatedPartyDomain to RobertGarfieldMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DheshGovenderMember" xlink:label="DheshGovenderMember" xlink:title="DheshGovenderMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="DheshGovenderMember" xlink:title="presentation: RelatedPartyDomain to DheshGovenderMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: LossContingenciesTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="presentation: LossContingenciesTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LegalMattersAbstract" xlink:label="LegalMattersAbstract" xlink:title="LegalMattersAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="LossContingencyNewClaimsFiledNumber" xlink:title="LossContingencyNewClaimsFiledNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalMattersAbstract" xlink:to="LossContingencyNewClaimsFiledNumber" xlink:title="presentation: LegalMattersAbstract to LossContingencyNewClaimsFiledNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfDefendants" xlink:label="LossContingencyNumberOfDefendants" xlink:title="LossContingencyNumberOfDefendants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalMattersAbstract" xlink:to="LossContingencyNumberOfDefendants" xlink:title="presentation: LegalMattersAbstract to LossContingencyNumberOfDefendants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LossContingencyDamagesSoughtExpectedSalary" xlink:label="LossContingencyDamagesSoughtExpectedSalary" xlink:title="LossContingencyDamagesSoughtExpectedSalary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalMattersAbstract" xlink:to="LossContingencyDamagesSoughtExpectedSalary" xlink:title="presentation: LegalMattersAbstract to LossContingencyDamagesSoughtExpectedSalary" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:label="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:title="LossContingencyDamagesSoughtExpectedEquityPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalMattersAbstract" xlink:to="LossContingencyDamagesSoughtExpectedEquityPercentage" xlink:title="presentation: LegalMattersAbstract to LossContingencyDamagesSoughtExpectedEquityPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="LossContingencyDamagesSoughtValue" xlink:title="LossContingencyDamagesSoughtValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalMattersAbstract" xlink:to="LossContingencyDamagesSoughtValue" xlink:title="presentation: LegalMattersAbstract to LossContingencyDamagesSoughtValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalMattersAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: LegalMattersAbstract to CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LossContingencyNumberOfArbitrationPanel" xlink:label="LossContingencyNumberOfArbitrationPanel" xlink:title="LossContingencyNumberOfArbitrationPanel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalMattersAbstract" xlink:to="LossContingencyNumberOfArbitrationPanel" xlink:title="presentation: LegalMattersAbstract to LossContingencyNumberOfArbitrationPanel" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesLineItems" xlink:to="LegalMattersAbstract" xlink:title="presentation: LossContingenciesLineItems to LegalMattersAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="LossContingenciesLineItems" xlink:title="presentation: LossContingenciesTable to LossContingenciesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LossContingenciesTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LossContingenciesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_UniversityOfSouthFloridaMember" xlink:label="UniversityOfSouthFloridaMember" xlink:title="UniversityOfSouthFloridaMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="UniversityOfSouthFloridaMember" xlink:title="presentation: EntityDomain to UniversityOfSouthFloridaMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="LegalEntityAxis" xlink:title="presentation: LossContingenciesTable to LegalEntityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="presentation: RelatedPartyDomain to NovellusTherapeuticsLimitedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NovellusLtdAndFactorBioscienceMember" xlink:label="NovellusLtdAndFactorBioscienceMember" xlink:title="NovellusLtdAndFactorBioscienceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="NovellusLtdAndFactorBioscienceMember" xlink:title="presentation: RelatedPartyDomain to NovellusLtdAndFactorBioscienceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NoveCiteMember" xlink:label="NoveCiteMember" xlink:title="NoveCiteMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="NoveCiteMember" xlink:title="presentation: RelatedPartyDomain to NoveCiteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: LossContingenciesTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="presentation: ScenarioUnspecifiedDomain to ScenarioForecastMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: LossContingenciesTable to StatementScenarioAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="presentation: LossContingenciesTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LicensingAgreementsAbstract" xlink:label="LicensingAgreementsAbstract" xlink:title="LicensingAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LossContingencyPercentageOfRoyaltyPayable" xlink:label="LossContingencyPercentageOfRoyaltyPayable" xlink:title="LossContingencyPercentageOfRoyaltyPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="LossContingencyPercentageOfRoyaltyPayable" xlink:title="presentation: LicensingAgreementsAbstract to LossContingencyPercentageOfRoyaltyPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LossContingencyNonRefundableOptionFee" xlink:label="LossContingencyNonRefundableOptionFee" xlink:title="LossContingencyNonRefundableOptionFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="LossContingencyNonRefundableOptionFee" xlink:title="presentation: LicensingAgreementsAbstract to LossContingencyNonRefundableOptionFee" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_InitialLicenseFees" xlink:label="InitialLicenseFees" xlink:title="InitialLicenseFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="InitialLicenseFees" xlink:title="presentation: LicensingAgreementsAbstract to InitialLicenseFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AdditionalFeesObligatedToPay" xlink:label="AdditionalFeesObligatedToPay" xlink:title="AdditionalFeesObligatedToPay" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="AdditionalFeesObligatedToPay" xlink:title="presentation: LicensingAgreementsAbstract to AdditionalFeesObligatedToPay" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AmountRequireToPayInitialLicenseFees" xlink:label="AmountRequireToPayInitialLicenseFees" xlink:title="AmountRequireToPayInitialLicenseFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="AmountRequireToPayInitialLicenseFees" xlink:title="presentation: LicensingAgreementsAbstract to AmountRequireToPayInitialLicenseFees" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AmountObligatedToPayInYearTwo" xlink:label="AmountObligatedToPayInYearTwo" xlink:title="AmountObligatedToPayInYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="AmountObligatedToPayInYearTwo" xlink:title="presentation: LicensingAgreementsAbstract to AmountObligatedToPayInYearTwo" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AmountObligatedToPayInYearOne" xlink:label="AmountObligatedToPayInYearOne" xlink:title="AmountObligatedToPayInYearOne" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="AmountObligatedToPayInYearOne" xlink:title="presentation: LicensingAgreementsAbstract to AmountObligatedToPayInYearOne" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_MinimumNumberOfPatentGranted" xlink:label="MinimumNumberOfPatentGranted" xlink:title="MinimumNumberOfPatentGranted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="MinimumNumberOfPatentGranted" xlink:title="presentation: LicensingAgreementsAbstract to MinimumNumberOfPatentGranted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_MinimumNumberOfPendingPatents" xlink:label="MinimumNumberOfPendingPatents" xlink:title="MinimumNumberOfPendingPatents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="MinimumNumberOfPendingPatents" xlink:title="presentation: LicensingAgreementsAbstract to MinimumNumberOfPendingPatents" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRevenue" xlink:label="PercentageOfRevenue" xlink:title="PercentageOfRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="PercentageOfRevenue" xlink:title="presentation: LicensingAgreementsAbstract to PercentageOfRevenue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_MilestonePayments" xlink:label="MilestonePayments" xlink:title="MilestonePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAgreementsAbstract" xlink:to="MilestonePayments" xlink:title="presentation: LicensingAgreementsAbstract to MilestonePayments" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesLineItems" xlink:to="LicensingAgreementsAbstract" xlink:title="presentation: LossContingenciesLineItems to LicensingAgreementsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="LossContingenciesLineItems" xlink:title="presentation: LossContingenciesTable to LossContingenciesLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LossContingenciesTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LossContingenciesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_InvestorRoyaltyAgreementMember" xlink:label="InvestorRoyaltyAgreementMember" xlink:title="InvestorRoyaltyAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="InvestorRoyaltyAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to InvestorRoyaltyAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CollaboratorRoyaltyAgreementMember" xlink:label="CollaboratorRoyaltyAgreementMember" xlink:title="CollaboratorRoyaltyAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaboratorRoyaltyAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaboratorRoyaltyAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: LossContingenciesTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_RoyaltyAgreementsAbstract" xlink:label="RoyaltyAgreementsAbstract" xlink:title="RoyaltyAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:label="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:title="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAgreementsAbstract" xlink:to="PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" xlink:title="presentation: RoyaltyAgreementsAbstract to PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:label="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:title="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAgreementsAbstract" xlink:to="PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" xlink:title="presentation: RoyaltyAgreementsAbstract to PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesLineItems" xlink:to="RoyaltyAgreementsAbstract" xlink:title="presentation: LossContingenciesLineItems to RoyaltyAgreementsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="LossContingenciesLineItems" xlink:title="presentation: LossContingenciesTable to LossContingenciesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LossContingenciesTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LossContingenciesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="ConvertiblePreferredStockMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to ConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EquityIncentivePlan2020Member" xlink:label="EquityIncentivePlan2020Member" xlink:title="EquityIncentivePlan2020Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2020Member" xlink:title="presentation: PlanNameDomain to EquityIncentivePlan2020Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_InducementPlan2021Member" xlink:label="InducementPlan2021Member" xlink:title="InducementPlan2021Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="InducementPlan2021Member" xlink:title="presentation: PlanNameDomain to InducementPlan2021Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IncentiveStockOptionsMember" xlink:label="IncentiveStockOptionsMember" xlink:title="IncentiveStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeStockOptionMember" xlink:to="IncentiveStockOptionsMember" xlink:title="presentation: EmployeeStockOptionMember to IncentiveStockOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NonQualifiedStockOptionMember" xlink:label="NonQualifiedStockOptionMember" xlink:title="NonQualifiedStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeStockOptionMember" xlink:to="NonQualifiedStockOptionMember" xlink:title="presentation: EmployeeStockOptionMember to NonQualifiedStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfSharesOfCommonStockOutstanding" xlink:label="PercentageOfSharesOfCommonStockOutstanding" xlink:title="PercentageOfSharesOfCommonStockOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="PercentageOfSharesOfCommonStockOutstanding" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to PercentageOfSharesOfCommonStockOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_AggregateIntrinsicValueAbstract" xlink:label="AggregateIntrinsicValueAbstract" xlink:title="AggregateIntrinsicValueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregateIntrinsicValueAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="presentation: AggregateIntrinsicValueAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregateIntrinsicValueAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="presentation: AggregateIntrinsicValueAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AggregateIntrinsicValueAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:title="presentation: AggregateIntrinsicValueAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="AggregateIntrinsicValueAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to AggregateIntrinsicValueAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NonQualifiedStockOptionMember" xlink:label="NonQualifiedStockOptionMember" xlink:title="NonQualifiedStockOptionMember" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_TimeBasedNonQualifiedStockOptionMember" xlink:label="TimeBasedNonQualifiedStockOptionMember" xlink:title="TimeBasedNonQualifiedStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonQualifiedStockOptionMember" xlink:to="TimeBasedNonQualifiedStockOptionMember" xlink:title="presentation: NonQualifiedStockOptionMember to TimeBasedNonQualifiedStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PerformanceBasedNonqualifiedStockOptionMember" xlink:label="PerformanceBasedNonqualifiedStockOptionMember" xlink:title="PerformanceBasedNonqualifiedStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonQualifiedStockOptionMember" xlink:to="PerformanceBasedNonqualifiedStockOptionMember" xlink:title="presentation: NonQualifiedStockOptionMember to PerformanceBasedNonqualifiedStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeStockOptionMember" xlink:to="NonQualifiedStockOptionMember" xlink:title="presentation: EmployeeStockOptionMember to NonQualifiedStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="ShareBasedCompensationAwardTrancheOneMember" xlink:title="ShareBasedCompensationAwardTrancheOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VestingDomain" xlink:to="ShareBasedCompensationAwardTrancheOneMember" xlink:title="presentation: VestingDomain to ShareBasedCompensationAwardTrancheOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="presentation: VestingAxis to VestingDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="VestingAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to VestingAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NumberOfStockOptionGrantMade" xlink:label="NumberOfStockOptionGrantMade" xlink:title="NumberOfStockOptionGrantMade" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="NumberOfStockOptionGrantMade" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to NumberOfStockOptionGrantMade" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to StockIssuedDuringPeriodSharesStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ProceedsFromStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensationRsusDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to AllocatedShareBasedCompensationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PurchaseAgreementMember" xlink:label="PurchaseAgreementMember" xlink:title="PurchaseAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_FirstPurchaseAgreementMember" xlink:label="FirstPurchaseAgreementMember" xlink:title="FirstPurchaseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PurchaseAgreementMember" xlink:to="FirstPurchaseAgreementMember" xlink:title="presentation: PurchaseAgreementMember to FirstPurchaseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SecondPurchaseAgreementMember" xlink:label="SecondPurchaseAgreementMember" xlink:title="SecondPurchaseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PurchaseAgreementMember" xlink:to="SecondPurchaseAgreementMember" xlink:title="presentation: PurchaseAgreementMember to SecondPurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PurchaseAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to PurchaseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LincolnParkCapitalFundLLCMember" xlink:label="LincolnParkCapitalFundLLCMember" xlink:title="LincolnParkCapitalFundLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityDomain" xlink:to="LincolnParkCapitalFundLLCMember" xlink:title="presentation: EntityDomain to LincolnParkCapitalFundLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="presentation: LegalEntityAxis to EntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="LegalEntityAxis" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="RangeAxis" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PrivatePlacementOfferingsAbstract" xlink:label="PrivatePlacementOfferingsAbstract" xlink:title="PrivatePlacementOfferingsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfferingsAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: PrivatePlacementOfferingsAbstract to ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:label="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:title="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfferingsAbstract" xlink:to="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:title="presentation: PrivatePlacementOfferingsAbstract to NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" xlink:label="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" xlink:title="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfferingsAbstract" xlink:to="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" xlink:title="presentation: PrivatePlacementOfferingsAbstract to NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfferingsAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: PrivatePlacementOfferingsAbstract to CommonStockSharesAuthorized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CommitmentAmountToMeetAnySingleRegularPurchase" xlink:label="CommitmentAmountToMeetAnySingleRegularPurchase" xlink:title="CommitmentAmountToMeetAnySingleRegularPurchase" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfferingsAbstract" xlink:to="CommitmentAmountToMeetAnySingleRegularPurchase" xlink:title="presentation: PrivatePlacementOfferingsAbstract to CommitmentAmountToMeetAnySingleRegularPurchase" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BeneficialOwnershipPercentageOnTotalOutstandingShares" xlink:label="BeneficialOwnershipPercentageOnTotalOutstandingShares" xlink:title="BeneficialOwnershipPercentageOnTotalOutstandingShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfferingsAbstract" xlink:to="BeneficialOwnershipPercentageOnTotalOutstandingShares" xlink:title="presentation: PrivatePlacementOfferingsAbstract to BeneficialOwnershipPercentageOnTotalOutstandingShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfferingsAbstract" xlink:to="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="presentation: PrivatePlacementOfferingsAbstract to SaleOfStockNumberOfSharesIssuedInTransaction" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="ProceedsFromIssuanceOrSaleOfEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfferingsAbstract" xlink:to="ProceedsFromIssuanceOrSaleOfEquity" xlink:title="presentation: PrivatePlacementOfferingsAbstract to ProceedsFromIssuanceOrSaleOfEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_SaleOfStockNumberOfSharesToIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesToIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesToIssuedInTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfferingsAbstract" xlink:to="SaleOfStockNumberOfSharesToIssuedInTransaction" xlink:title="presentation: PrivatePlacementOfferingsAbstract to SaleOfStockNumberOfSharesToIssuedInTransaction" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="PrivatePlacementOfferingsAbstract" xlink:title="presentation: SubsidiarySaleOfStockLineItems to PrivatePlacementOfferingsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="SubsidiarySaleOfStockLineItems" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to SubsidiarySaleOfStockLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="presentation: StockholdersEquityNoteAbstract to SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitReverseStocksplitDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ReverseStockSplitAbstract" xlink:label="ReverseStockSplitAbstract" xlink:title="ReverseStockSplitAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseStockSplitAbstract" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="presentation: ReverseStockSplitAbstract to StockholdersEquityNoteStockSplitConversionRatio1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseStockSplitAbstract" xlink:to="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="presentation: ReverseStockSplitAbstract to StockIssuedDuringPeriodSharesReverseStockSplits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ReverseStockSplitAbstract" xlink:title="presentation: StockholdersEquityNoteAbstract to ReverseStockSplitAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="CommonClassAMember" xlink:title="CommonClassAMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassAMember" xlink:title="presentation: ClassOfStockDomain to CommonClassAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="CommonClassBMember" xlink:title="CommonClassBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassBMember" xlink:title="presentation: ClassOfStockDomain to CommonClassBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="CommonClassCMember" xlink:title="CommonClassCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonClassCMember" xlink:title="presentation: ClassOfStockDomain to CommonClassCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NTNBuzztimeIncMember" xlink:label="NTNBuzztimeIncMember" xlink:title="NTNBuzztimeIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NTNBuzztimeIncMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to NTNBuzztimeIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfStockByClassTable to BusinessAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_MergerAbstract" xlink:label="MergerAbstract" xlink:title="MergerAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerAbstract" xlink:to="SharesIssued" xlink:title="presentation: MergerAbstract to SharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="ConversionOfStockSharesConverted1" xlink:title="ConversionOfStockSharesConverted1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerAbstract" xlink:to="ConversionOfStockSharesConverted1" xlink:title="presentation: MergerAbstract to ConversionOfStockSharesConverted1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ClassOfWarrantOrRightIssued" xlink:label="ClassOfWarrantOrRightIssued" xlink:title="ClassOfWarrantOrRightIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerAbstract" xlink:to="ClassOfWarrantOrRightIssued" xlink:title="presentation: MergerAbstract to ClassOfWarrantOrRightIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: MergerAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodSharesAcquisitions1" xlink:label="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="StockIssuedDuringPeriodSharesAcquisitions1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerAbstract" xlink:to="StockIssuedDuringPeriodSharesAcquisitions1" xlink:title="presentation: MergerAbstract to StockIssuedDuringPeriodSharesAcquisitions1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="MergerAbstract" xlink:title="presentation: ClassOfStockLineItems to MergerAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: StockholdersEquityNoteAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NovellusTherapeuticsLimitedMember" xlink:label="NovellusTherapeuticsLimitedMember" xlink:title="NovellusTherapeuticsLimitedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="NovellusTherapeuticsLimitedMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to NovellusTherapeuticsLimitedMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfStockByClassTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:label="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:title="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" xlink:title="presentation: RelatedPartyDomain to ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ScheduleOfStockByClassTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfStockByClassTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDescriptionAbstract" xlink:label="BusinessCombinationDescriptionAbstract" xlink:title="BusinessCombinationDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="StockIssuedDuringPeriodSharesAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodSharesAcquisitions" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodSharesAcquisitions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:label="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:title="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodUnrestrictedSharesAcquisitions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="presentation: BusinessCombinationDescriptionAbstract to StockIssuedDuringPeriodSharesIssuedForServices" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EachLockUpAgreementExtendsTerm" xlink:label="EachLockUpAgreementExtendsTerm" xlink:title="EachLockUpAgreementExtendsTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="EachLockUpAgreementExtendsTerm" xlink:title="presentation: BusinessCombinationDescriptionAbstract to EachLockUpAgreementExtendsTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageOfCommonStockSubjectToLockUpAgreement" xlink:label="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:title="PercentageOfCommonStockSubjectToLockUpAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDescriptionAbstract" xlink:to="PercentageOfCommonStockSubjectToLockUpAgreement" xlink:title="presentation: BusinessCombinationDescriptionAbstract to PercentageOfCommonStockSubjectToLockUpAgreement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="BusinessCombinationDescriptionAbstract" xlink:title="presentation: ClassOfStockLineItems to BusinessCombinationDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: StockholdersEquityNoteAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="SeriesAPreferredStockMember" xlink:title="presentation: ClassOfStockDomain to SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:label="FeaturesOfConvertiblePreferredStockAbstract" xlink:title="FeaturesOfConvertiblePreferredStockAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FeaturesOfConvertiblePreferredStockAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: FeaturesOfConvertiblePreferredStockAbstract to PreferredStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FeaturesOfConvertiblePreferredStockAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: FeaturesOfConvertiblePreferredStockAbstract to PreferredStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FeaturesOfConvertiblePreferredStockAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: FeaturesOfConvertiblePreferredStockAbstract to PreferredStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="DividendsPayableAmountPerShare" xlink:title="DividendsPayableAmountPerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FeaturesOfConvertiblePreferredStockAbstract" xlink:to="DividendsPayableAmountPerShare" xlink:title="presentation: FeaturesOfConvertiblePreferredStockAbstract to DividendsPayableAmountPerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="DividendsPreferredStockCash" xlink:title="DividendsPreferredStockCash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FeaturesOfConvertiblePreferredStockAbstract" xlink:to="DividendsPreferredStockCash" xlink:title="presentation: FeaturesOfConvertiblePreferredStockAbstract to DividendsPreferredStockCash" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsShares" xlink:label="PreferredStockDividendsShares" xlink:title="PreferredStockDividendsShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FeaturesOfConvertiblePreferredStockAbstract" xlink:to="PreferredStockDividendsShares" xlink:title="presentation: FeaturesOfConvertiblePreferredStockAbstract to PreferredStockDividendsShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="PreferredStockLiquidationPreference" xlink:title="PreferredStockLiquidationPreference" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FeaturesOfConvertiblePreferredStockAbstract" xlink:to="PreferredStockLiquidationPreference" xlink:title="presentation: FeaturesOfConvertiblePreferredStockAbstract to PreferredStockLiquidationPreference" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="PreferredStockConvertibleConversionRatio" xlink:title="PreferredStockConvertibleConversionRatio" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FeaturesOfConvertiblePreferredStockAbstract" xlink:to="PreferredStockConvertibleConversionRatio" xlink:title="presentation: FeaturesOfConvertiblePreferredStockAbstract to PreferredStockConvertibleConversionRatio" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FeaturesOfConvertiblePreferredStockAbstract" xlink:to="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="presentation: FeaturesOfConvertiblePreferredStockAbstract to ConvertiblePreferredStockSharesIssuedUponConversion" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="PreferredStockConvertibleSharesIssuable" xlink:title="PreferredStockConvertibleSharesIssuable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FeaturesOfConvertiblePreferredStockAbstract" xlink:to="PreferredStockConvertibleSharesIssuable" xlink:title="presentation: FeaturesOfConvertiblePreferredStockAbstract to PreferredStockConvertibleSharesIssuable" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FeaturesOfConvertiblePreferredStockAbstract" xlink:to="StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="presentation: FeaturesOfConvertiblePreferredStockAbstract to StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="FeaturesOfConvertiblePreferredStockAbstract" xlink:title="presentation: ClassOfStockLineItems to FeaturesOfConvertiblePreferredStockAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: StockholdersEquityNoteAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:title="presentation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:title="presentation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="CurrentFederalTaxExpenseBenefit" xlink:title="CurrentFederalTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentFederalTaxExpenseBenefit" xlink:title="presentation: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="CurrentStateAndLocalTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="presentation: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentStateAndLocalTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="CurrentForeignTaxExpenseBenefit" xlink:title="CurrentForeignTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentForeignTaxExpenseBenefit" xlink:title="presentation: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentForeignTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentIncomeTaxExpenseBenefit" xlink:title="presentation: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="presentation: ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="DeferredFederalIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="presentation: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="presentation: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="DeferredForeignIncomeTaxExpenseBenefit" xlink:title="DeferredForeignIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="DeferredForeignIncomeTaxExpenseBenefit" xlink:title="presentation: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to DeferredForeignIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="DeferredIncomeTaxExpenseBenefit" xlink:title="presentation: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to DeferredIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="presentation: ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract to DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" xlink:label="EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" xlink:title="EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" xlink:title="presentation: ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract to EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract to IncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="DeferredTaxAssetsNetAbstract" xlink:title="DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetAbstract" xlink:to="DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" xlink:title="presentation: DeferredTaxAssetsNetAbstract to DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetAbstract" xlink:to="DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:title="presentation: DeferredTaxAssetsNetAbstract to DeferredTaxAssetsOperatingLossCarryforwardsForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetAbstract" xlink:to="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="presentation: DeferredTaxAssetsNetAbstract to DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetAbstract" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="presentation: DeferredTaxAssetsNetAbstract to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetAbstract" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" xlink:title="presentation: DeferredTaxAssetsNetAbstract to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetAbstract" xlink:to="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" xlink:title="presentation: DeferredTaxAssetsNetAbstract to DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetAbstract" xlink:to="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:title="presentation: DeferredTaxAssetsNetAbstract to DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetAbstract" xlink:to="DeferredTaxAssetsGross" xlink:title="presentation: DeferredTaxAssetsNetAbstract to DeferredTaxAssetsGross" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetAbstract" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="presentation: DeferredTaxAssetsNetAbstract to DeferredTaxAssetsValuationAllowance" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetAbstract" xlink:to="DeferredTaxAssetsNet" xlink:title="presentation: DeferredTaxAssetsNetAbstract to DeferredTaxAssetsNet" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsNetAbstract" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to DeferredTaxAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="DeferredTaxLiabilitiesNetAbstract" xlink:title="DeferredTaxLiabilitiesNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxLiabilitiesNetAbstract" xlink:to="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="presentation: DeferredTaxLiabilitiesNetAbstract to DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:label="DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:title="DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxLiabilitiesNetAbstract" xlink:to="DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:title="presentation: DeferredTaxLiabilitiesNetAbstract to DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="DeferredTaxLiabilities" xlink:title="DeferredTaxLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxLiabilitiesNetAbstract" xlink:to="DeferredTaxLiabilities" xlink:title="presentation: DeferredTaxLiabilitiesNetAbstract to DeferredTaxLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesNetAbstract" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to DeferredTaxLiabilitiesNetAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsLiabilitiesNet" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:title="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to EffectiveIncomeTaxRateReconciliationTaxCredits" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:title="EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateContinuingOperations" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to EffectiveIncomeTaxRateContinuingOperations" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="DomesticCountryMember" xlink:title="DomesticCountryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityDomain" xlink:to="DomesticCountryMember" xlink:title="presentation: IncomeTaxAuthorityDomain to DomesticCountryMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityDomain" xlink:to="StateAndLocalJurisdictionMember" xlink:title="presentation: IncomeTaxAuthorityDomain to StateAndLocalJurisdictionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="ForeignCountryMember" xlink:title="ForeignCountryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityDomain" xlink:to="ForeignCountryMember" xlink:title="presentation: IncomeTaxAuthorityDomain to ForeignCountryMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="presentation: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="IncomeTaxAuthorityAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to IncomeTaxAuthorityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_IncomeTaxAbstract" xlink:label="IncomeTaxAbstract" xlink:title="IncomeTaxAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAbstract" xlink:to="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="presentation: IncomeTaxAbstract to ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAbstract" xlink:to="DeferredIncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxAbstract to DeferredIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:label="DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:title="DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAbstract" xlink:to="DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" xlink:title="presentation: IncomeTaxAbstract to DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAbstract" xlink:to="OperatingLossCarryforwards" xlink:title="presentation: IncomeTaxAbstract to OperatingLossCarryforwards" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_TaxCutsAndJobsActOperatingLossCarryforwards" xlink:label="TaxCutsAndJobsActOperatingLossCarryforwards" xlink:title="TaxCutsAndJobsActOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAbstract" xlink:to="TaxCutsAndJobsActOperatingLossCarryforwards" xlink:title="presentation: IncomeTaxAbstract to TaxCutsAndJobsActOperatingLossCarryforwards" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAbstract" xlink:to="TaxCreditCarryforwardAmount" xlink:title="presentation: IncomeTaxAbstract to TaxCreditCarryforwardAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_TaxCreditCarryforwardExpirationYear" xlink:label="TaxCreditCarryforwardExpirationYear" xlink:title="TaxCreditCarryforwardExpirationYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAbstract" xlink:to="TaxCreditCarryforwardExpirationYear" xlink:title="presentation: IncomeTaxAbstract to TaxCreditCarryforwardExpirationYear" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAbstract" xlink:to="UnrecognizedTaxBenefits" xlink:title="presentation: IncomeTaxAbstract to UnrecognizedTaxBenefits" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAbstract" xlink:to="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:title="presentation: IncomeTaxAbstract to UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="OpenTaxYear" xlink:title="OpenTaxYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAbstract" xlink:to="OpenTaxYear" xlink:title="presentation: IncomeTaxAbstract to OpenTaxYear" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="IncomeTaxAbstract" xlink:title="presentation: OperatingLossCarryforwardsLineItems to IncomeTaxAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="OperatingLossCarryforwardsLineItems" xlink:title="presentation: OperatingLossCarryforwardsTable to OperatingLossCarryforwardsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="OperatingLossCarryforwardsTable" xlink:title="presentation: IncomeTaxDisclosureAbstract to OperatingLossCarryforwardsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/RetirementSavingsPlanDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="PostemploymentBenefitsAbstract" xlink:title="PostemploymentBenefitsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:title="DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PostemploymentBenefitsAbstract" xlink:to="DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:title="presentation: PostemploymentBenefitsAbstract to DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PIPEInvestorMember" xlink:label="PIPEInvestorMember" xlink:title="PIPEInvestorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentTypeCategorizationMember" xlink:to="PIPEInvestorMember" xlink:title="presentation: InvestmentTypeCategorizationMember to PIPEInvestorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember" xlink:title="presentation: InvestmentTypeAxis to InvestmentTypeCategorizationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="InvestmentTypeAxis" xlink:title="presentation: SubsequentEventTable to InvestmentTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_CommonWarrantsMember" xlink:label="CommonWarrantsMember" xlink:title="CommonWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="CommonWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to CommonWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PreFundedWarrantsMember" xlink:label="PreFundedWarrantsMember" xlink:title="PreFundedWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="PreFundedWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to PreFundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: SubsequentEventTable to ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsequentEventTable to SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PrivatePlacementOfEquityAbstract" xlink:label="PrivatePlacementOfEquityAbstract" xlink:title="PrivatePlacementOfEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:title="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:title="presentation: PrivatePlacementOfEquityAbstract to StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:title="presentation: PrivatePlacementOfEquityAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="StockRepurchaseProgramAuthorizedAmount1" xlink:title="StockRepurchaseProgramAuthorizedAmount1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="StockRepurchaseProgramAuthorizedAmount1" xlink:title="presentation: PrivatePlacementOfEquityAbstract to StockRepurchaseProgramAuthorizedAmount1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: PrivatePlacementOfEquityAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:label="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:title="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" xlink:title="presentation: PrivatePlacementOfEquityAbstract to ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_ClassOfWarrantOrRightsExercisableTerm" xlink:label="ClassOfWarrantOrRightsExercisableTerm" xlink:title="ClassOfWarrantOrRightsExercisableTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="ClassOfWarrantOrRightsExercisableTerm" xlink:title="presentation: PrivatePlacementOfEquityAbstract to ClassOfWarrantOrRightsExercisableTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrivatePlacementOfEquityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="presentation: PrivatePlacementOfEquityAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="PrivatePlacementOfEquityAbstract" xlink:title="presentation: SubsequentEventLineItems to PrivatePlacementOfEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostPositionsEliminatedAbstract" xlink:label="RestructuringAndRelatedCostPositionsEliminatedAbstract" xlink:title="RestructuringAndRelatedCostPositionsEliminatedAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:title="RestructuringAndRelatedCostNumberOfPositionsEliminated" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringAndRelatedCostPositionsEliminatedAbstract" xlink:to="RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:title="presentation: RestructuringAndRelatedCostPositionsEliminatedAbstract to RestructuringAndRelatedCostNumberOfPositionsEliminated" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringAndRelatedCostPositionsEliminatedAbstract" xlink:to="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="presentation: RestructuringAndRelatedCostPositionsEliminatedAbstract to RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="SeveranceCosts1" xlink:title="SeveranceCosts1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringAndRelatedCostPositionsEliminatedAbstract" xlink:to="SeveranceCosts1" xlink:title="presentation: RestructuringAndRelatedCostPositionsEliminatedAbstract to SeveranceCosts1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="RestructuringAndRelatedCostPositionsEliminatedAbstract" xlink:title="presentation: SubsequentEventLineItems to RestructuringAndRelatedCostPositionsEliminatedAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LeaseAssignmentAbstract" xlink:label="LeaseAssignmentAbstract" xlink:title="LeaseAssignmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_LesseeCommitmentToPurchaseProperty" xlink:label="LesseeCommitmentToPurchaseProperty" xlink:title="LesseeCommitmentToPurchaseProperty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseAssignmentAbstract" xlink:to="LesseeCommitmentToPurchaseProperty" xlink:title="presentation: LeaseAssignmentAbstract to LesseeCommitmentToPurchaseProperty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_UnamortizedLeaseholdImprovements" xlink:label="UnamortizedLeaseholdImprovements" xlink:title="UnamortizedLeaseholdImprovements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseAssignmentAbstract" xlink:to="UnamortizedLeaseholdImprovements" xlink:title="presentation: LeaseAssignmentAbstract to UnamortizedLeaseholdImprovements" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets" xlink:label="DepositAssets" xlink:title="DepositAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseAssignmentAbstract" xlink:to="DepositAssets" xlink:title="presentation: LeaseAssignmentAbstract to DepositAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="LeaseAssignmentAbstract" xlink:title="presentation: SubsequentEventLineItems to LeaseAssignmentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_NewLeaseAgreementAbstract" xlink:label="NewLeaseAgreementAbstract" xlink:title="NewLeaseAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_OperatingLeaseArea" xlink:label="OperatingLeaseArea" xlink:title="OperatingLeaseArea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewLeaseAgreementAbstract" xlink:to="OperatingLeaseArea" xlink:title="presentation: NewLeaseAgreementAbstract to OperatingLeaseArea" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewLeaseAgreementAbstract" xlink:to="LesseeOperatingLeaseTermOfContract" xlink:title="presentation: NewLeaseAgreementAbstract to LesseeOperatingLeaseTermOfContract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_BaseRentPerSquareFoot" xlink:label="BaseRentPerSquareFoot" xlink:title="BaseRentPerSquareFoot" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewLeaseAgreementAbstract" xlink:to="BaseRentPerSquareFoot" xlink:title="presentation: NewLeaseAgreementAbstract to BaseRentPerSquareFoot" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="btx-20211231.xsd#btx_PercentageBaseRentIncreaseOnEachAnniversary" xlink:label="PercentageBaseRentIncreaseOnEachAnniversary" xlink:title="PercentageBaseRentIncreaseOnEachAnniversary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewLeaseAgreementAbstract" xlink:to="PercentageBaseRentIncreaseOnEachAnniversary" xlink:title="presentation: NewLeaseAgreementAbstract to PercentageBaseRentIncreaseOnEachAnniversary" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="LesseeOperatingLeaseRenewalTerm" xlink:title="LesseeOperatingLeaseRenewalTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewLeaseAgreementAbstract" xlink:to="LesseeOperatingLeaseRenewalTerm" xlink:title="presentation: NewLeaseAgreementAbstract to LesseeOperatingLeaseRenewalTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="NewLeaseAgreementAbstract" xlink:title="presentation: SubsequentEventLineItems to NewLeaseAgreementAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventLineItems" xlink:title="presentation: SubsequentEventTable to SubsequentEventLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventTable" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" 'Y L(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.WMDM+.6[N$MDG6X+-&6YS@ICMC\: (-3@UV3PS<:I:>)YF*6[SQ)%9QHKD
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MAM8XUVK##]Q/8<#C\*N44AG/Z8?^*TUL9'_'M:G'IS+6IK%^NF:?)=.C.$P
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MUF&8-*\9:@2/O+;R0@_JG\J2/6KZ4$6O@/6YLG_E\N(U'_CTA/Z5W!TNY?\
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MJK>ZJF3G.,C<WI5N%?$W+P^%/#NGG/+S7>XC_OE/ZT6&=I)KVEQ[MU_;$KU
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M;C^''A]D+W>DZWJ)/>[OF.?J-X_E7JM&*5QV/-K7P#H=HP-OX,TH>]S+O/\
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M9OKGR1_C7IR_=%-B1CZTN-4T>7.W;<,GU!B?_ 5<U/5;'2X3+J%U% H4L [
M%@!S@=3]!5+Q2QCM[*521LO(<_0L%/\ Z%4'B"+5&U"QGTP0-!&DAFCF0?.<
MIM ;JIQOP1D9QD4AFY:7,-W;1W%M(LL,BAD=#D,#W%2UC>$9[B?1(FNWE>4,
MXW2H5?:&.W.57G&,G&#VK9H **** "BBB@ HHHH YS3V_P"*[U@#_GSM<_\
M?4U='7/:?_R/6L^OV.U_]"FKH: "BBB@ HHHH P/'8SX9N?]^+_T8M;R_=%8
M/CH@>&;G/]^+_P!&+6\O04!U%HHHH .E%%% !1110 V4;HW4]""*S]'D#Z+!
MNX*1[&YZ%>#^H-:5<WJMPVDIJ('$4T;S1$G"B3;ROXXW?G0!9\*Q*^@V\CH
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MUYL+7_T.:NBH **** "BBB@# \=?\BQ=_5/_ $-:WE^Z*P_&XSX;N1_M1_\
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M ]U(_2LFS$UUX0@6S(6:6S4(78K@E/4 FMEQE&'M6;X9Q_PC^GA>BPJOY#%
MNIE>#)+NV:YTB_NX;F2R6,+L4[D4KP&; #=.#@<=<]:ZBFA%#%@!D]3BG4#"
MBBB@ HHHH **** "BBJ]S?6MJRK<W,,+-R!(X7/YT 6**C2:)U#)(C*>A!R#
M4E !1110 4444 %%%% !1110 4444 %%%&: //?C2,:%HTO_ #RUBT;/I\^/
MZUZ"OW17 ?&Y<>!S+WAO+:0?A*M:>I:[J$7B2TTNPBMRDT6\R2AOE.&/0'_9
M_6F+J=;16(VI:E;2?Z9II>'&3+:OYF/JA ;\MU:.GZA;7\1DM9ED4':<<%3Z
M$=0?8TAEJBBB@ HHHH **** "BBB@ HHHH **** "BBB@#C?%L?F>([9#_RT
MTR\3@9ZF.M?P3+YWA#19<@[[.(\=/N"LWQ2H_P"$JT(G&7ANH_PV*?Z5:^'3
M%O ^B9.2+2,9^@Q3Z"ZG1UB:(2-:UN(YP)TD&?\ :B3^H-;=8MH"GBS4 >DE
MM"P'N&<'^E(9M4444 %%%% !1110 4444 <]9_\ (^:I_P!>%M_Z'-70USUG
M_P CYJ?_ &#[;_T9-70TV 4444@"BBB@#"\;G'ANX//WXNG_ %T6MQ?NBL'Q
MW_R+-SCKOB_]&+6\O04 +1110 4444 %%%% %*ZTNPN0?M5G;S=_WD8;^=<W
M!X9T:\U;45^P(D<?EQ;89&C'W=V2%(_O8KL3TK'\.C>VIS\GS;V3OG[H"?\
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M;_\ HR6NBKG(#CXA7@]=-AY_[:25T=-@%%%%( HHHH P/'>?^$9N,=?,A_\
M1JUO+]T5@^.CCPW.?^FL/3_KJE;R\**8"T444@"BBB@ HHIAEC$HC+J)",A<
M\D>N* ',<*3[5D>$3OT&WFR#]H+W&1_ML6_K5S6+C[+I5Y/G!BA=_P E)I-%
M@^RZ39V_>*%$/X 4 7'.%-<K\/3OTV_NB#F[U&ZEY]!(4'Z**Z/4)UMK*>=S
MA8T9R?H,UB?#^/R?!.D$C!DMUF/U?YS^K4 0>#W:?6_%%P1@&_$*\YR$B0?S
MS755R_P^0G19;D\FZO+F<GUS*P'Z 5U% !1110 4444 %%%% !1110 4444
M%%%% !7G=MJ%M'\9[P%\>=IT=L#M.#,K%]F>F=IS7HE>67MM9G5-0GM[K1['
M5[/5A.);PJK.GE+P3PV/F/>@3/4ZS-!DW1WBGC9=2K_X]G^M>3:K\5[NWM[V
MSDMX[BZ681)=:81)%C>5P=S @G''/>J'A'Q?XE@N+ZQM-&U2_M!)OC;,1F7(
M&0V6((Z8[^N:=@N>]T5P,7C#Q,8QL\"ZDW;+W<*$_K2MXJ\8D?)X#D]MVIQ#
M^E*P[G>T5P1\0>.G7]WX-M4SS\^J+Q^2USFNZ_X]%PT=QIDMA^Z9HEL(/M8=
MP/E#/M(&3GL,<<T["N>P45YKIUU\2I;")UL/#R[D!_TB6429_P!I0, ^V>*M
M;OB6<#9X53WS.U%AGH%%<%Y'Q(96S<^%E;MB.<_UI?L7Q%;KJGAQ#[6LI_\
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M!:*** "BBB@ KE-2\&P73O)#=20SR7)EDD"*3)&S!FB;&,J2.">1QVXKJZ*
M,;4CN\0Z3$.@664CZ +_ .SULUADB7Q@W<6]D!GT+O\ _:Q6Y0!SWB9//U+0
M(,D!K[>?HL4C?S J'XA/_P 2."WS@W-]:P >H:9<_IFDU%S+\0-&MQTAM+BX
M8>G*(/YM2>+1]HUKPW:D9S?>:1[)&YS^!V_G30CJ5Z44#@44AA1110 4444
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M=_\ 7,UH+TH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/ NA:KH=I]FU"^M;BW#.Z)% R%6=RQR2QR.2.E=728T%%%% !BBBB@ HHHH
M**** .;D_P"2A0^G]FM_Z,%=)7-2D#XB6_J=,?\ ]&K72T"04444#"BBB@#"
M\;''AZ7_ *ZP_P#HU*W%^Z*PO'"[O#DPX_UL/7_KJE;J_=% A:***!A1110
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M;(3BTA%XT;7&P>88P0I;'.,]J!W)Z*** "BBB@ HHHH **** "BBB@ HHHH
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M&&"'O]1?/<W!!_3% &K1D5DC0H-V3=:D?8WTO_Q5(WA^R=B7-XQ/K>2__%4
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M@B[_ .N3=O:KR_=H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@""^&ZSG'8HP_2H-"8-HUBV<Y@C.?7Y15UQ
ME"/:J.@R"71K)ASF%>?7B@"_1110!YI\31J]U<:C;Z9>+;0VNF-=.A4GS3EA
MC@CL/<5NZ;X*T9K6&7RYSO17 \XC;D9XQBJOBD!O$6H1G_EKH4_Z/_\ 95U'
MAV02Z!IK@YW6T9S_ ,!%/H+J9\7A'2(F#1Q7*L.XNY1_[-5F3PWI<I)EMS)G
MKOE<_P!:UZ*5PLB*TMH;.W2"VC6.%!A57H*EHHH&%%%% !1110 4444 %<MX
MEC#>)-,/=K2[C ['(0_TKJ:YOQ%@>)?#A/5I9T_.%C_04T)DW@-_,\%Z(WK9
MQ?\ H K>KG/AT2?!>E ]4B\L_521_2NCI#04444 %%%% !1110 4444 <U=C
M_BX6FG_J'7'_ *,AKI:YZ[_Y'K3/^O"Y_P#1D-=#0 4444 %%%% '/>/<'PX
M^[I]HM__ $<E= OW16!XZ&[PZX_Z;V__ *.2M]?NBGT%U%HHHI#"BBB@ HHH
MH YGQ7F76_#5M@%6O3,V3V2-S_,K2>/P9-+L;91G[3J%K&W^Z)58_HM)J'^D
M?$+28Q@_9;&>8CT+/&H_0-4OB0^9KWAN 8P;IYF&>H6)_P"K"F(Z)1@4M%%(
M9#>?\>TG?Y37G_@7*WOAG)!+>'P/IAH_\?TKT.89C('I7DOAK5FL]2TB-8XX
MGLM/>TG:ZD\I YD0@# ))P#V%-">YZ[17/6.JWU^6^QG2)PIP?*O&?'Y)5D_
MVZ6.U=-4>[.W]!2&;%5=5)&FW6P MY;8!]<52V:XW_+73D^D;M_44V6UUJ92
MC7FG^6PP5-HYS_Y$H UT;*BJEH?^)A>C/=3T_P!G_P"M6,GAZ\W9>YL/PM9/
M_CM68=)O[52+2^MH=W+;+3J?Q<T ;M%92V.I;B6U9L>BVZ#^>:4Z=>GKJ]T/
M]V.+^JF@#4K,UXD6\&./])A_6114?]EWQ_YCE\/I'!_\;IYTJ21HOM&H7<RH
MROL81@,001G" ]10!IJ>*6BB@ HHHH H:\0NC7F[_GDW;/:KR_=%4-?!.CWF
M.OE,?TJ^O04 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!A1110!@>.AGP\__ %W@_P#1R5O+]T5@>._^1=D/I/!_Z.2M]?NB@.HM%%%
M!1110 4444 <S9!9O'FJS;>;>SMX <^K2,?Z47\?VCQ]I7_3M93R_BSQK_(&
MF>$6^TZUXGNB/^7X0*?9(D'\R:GM<3>.K]\?ZBR@BSCH6:1C_2F(Z*BBBD,*
M3:OH*6B@"AJ.E6M\%,T*F1?N2#*NGT88(_ U0+WNCL/.>6_LLY9R!YL(]3C[
MZCV^8>];U!&: &0RK-&LD;!D895E.01ZBGUB6L9TK51:K_QY76YXLM]R3JR
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MMC9W&H>*+6?4=0FN;:XN[V(6V]U$?ELP&"&]!Z#K0)L]"_MW2?\ H)V7_?\
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MV1_Y>H/^_J_XTO\ :5G_ ,_4'_?Q?\: +=%5/[2L_P#GZ@_[^+_C2_VA:?\
M/S#_ -_%_P : +5%5OM]K_S\0_\ ?P?XTG]H6G_/S#_W\'^- $6O'&C7I](6
M/Z5>7I61KM]:G1[P+<0DF%P,2#TJ\M_:X_X^(?\ OX/\: +5%5OM]K_S\0_]
M_!_C1]OM?^?B+_OL?XT 6:*K?;[7_GXAQ_OC_&C[?:_\]XO^^Q_C0!9HJK_:
M%K_SWB_[['^-+]OMCTGB_P"^Q0!9J"^NHK*TEN;AML4:[F.,_P#ZS[4W[; >
MDT1'LXJKJD6G:I9M:WS12P%E8KYNWE2"#D'(((!H JMXD@_=K':WKO):?;%
MA/*Y4;0>A;YAP,X_*C6/$*Z;,D9L;R?>F4:)5P[;68(,L"3A3T&!QFG:?::?
M81620S?+:0&WC#S!OD)7.2>I^056ATC2[?5(;ZVN1!Y2%$MT,?E $Y; *Y!)
MZD$9P*8C:TN[-]80W+0RP&1=WERKM=?8CL:M55^W6X_Y;1?]]BG?;;?_ )[1
M?]]BD,L457^VVW_/:+_OL?XTW[?;?\]XL_[X_P : +5%5OMUM_SWB_[['^-'
MV^U_Y[Q?]]C_ !H LT56^W6__/:+_OL?XTGV^V_Y[Q?]]C_&@"U15;[=;?\
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MRP_\!D_PH_X1W2/^@78?^ R?X5J>8G]X?G1O7^\/SH R_P#A'-(_Z!=A_P"
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M.>'3_P!O<W_Q%*/!5R/^9;\-^V;F;_XBO2Z*+A8\U_X0JY_A\/>&P/3SYO\
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M%% !116=+K>FQ*6>]@P&V'#9.<L",#W5O^^3Z4 :-%9]OK.G7,PAM[R&20G
M56R3P#_(@_B/6I[J^M;1XDNIXXFE.$#MC<<@?S(_,4 6:*8LJ.H96!4C(.:2
M29(T+NRA5Y)STH DHIOF+_>'YT%U'5@/QH =13?,0#.X8Z9S1YB9QO7KCK0
MZBF>:G]]?SIL=S#(@9)4*D;LY[4 2T5&D\3G"R(QSC ;/-5IM3M8;Y;.1V%P
MR!PH1B-I.,D@8'/J: +M%5UO;=I-@F0MO\O /\6W=C\CFK% '.:F?^*WT/U^
MRW7\XJZ.N<U4?\5KH)X_X][K_P!I5T= !1110 4444 8'CK_ )%FZXS\T?\
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M#@_3O@NFT_PE96=O,%*QM'Y\;A6^94)(W$C'5NC=\"NK70=+57 L+?#J$;*
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M +\)_A2_V3H^/^0?88_ZX)_A0(=_;FE?]!.R_P"_Z_XTC:]I"]=4L1];A/\
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M_P#X[2 L?\(?X;SG^P-)SZ_9(_\ "I8O#&B0VMQ;0Z58Q07  FC2!560#IN
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MQHV^+LGY]#_[YE_QH 0^ _#';1;($=Q$ :L7?A'0KV?S;O2[29]H0%XP< =
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MX=R?^)/9<_\ 3.DV>+>/GT/\I?\ &C;XNYR^A?\ ?$W^-  W@?PXW71K(_\
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MP )8D@55DQTR ,&K>DZ18:3&\>FV=O:QNVYE@C" GUP.]8[6_BXCC4]$'O\
M89?_ ([3?LOB_P#Z"NB_^ $G_P =H WM1T^TU*W^SW]M#<P$Y,<J!E./8UD_
M\(9X9_Z%_2/_  #C_P *K&T\7]M7T;_P7R?_ !VD^Q^+R>-9T8?]PZ3_ ..T
M 7/^$.\-#_F7])_\ X_\*!X/\-CIH&D_^ <?^%4_L7C#MK.C_P#@ND_^.TC6
M/C ]-;T@?337_P#CM %L^"_#)Z^'])SV_P!$C_PK1TG1].TB-TTNQMK-'.66
M",(#]<5B_9/&"L,ZKHK#WL)!_P"U:/*\8 \7^A'MC[+*/_:E $^L?\C=X?\
M]RY_]!6NBKEK32]<GUVPOM7NM.>.T60*EM"ZEBX Y+,?2NII#"BBB@ HHHH
MP_&]]<:;X4U.\LWV7$,#.C;0<'UP>*X/Q5XF3PK-!#KOCBYM9IXA*B#3HW)4
MD^B'TKM/B0,^!=;_ .O5Z\7^/>K6-AXET."_T.RU(26B8DGDD5E!8C VL![\
MTT+J=1HGC>PUF^BM++XB,9Y#A$DL(X]Q[8W(!6CXKUX^%IK>'6O'-Q;O."R?
M\2Z-\@'!Z(>]>7_'OP+X?\,Z%IFI:% +*ZDEV-$LC-O&W.1DG&"/UKHM9\*3
M_$/X-:%J62^NV=KNC;/,J@X*GW( (]Z8'J=MI&NSP++'XLN&1P&4_8H.0?\
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MRH MU'M C88 48 VD#N,]Z .OK$M_%6B7.I"P@U*![HN8U4$X9QG*@]"1@\
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M%%% !1110 5F>)]2?1_#VHZC'&LCVL#S*C' 8J"<9K3K ^( SX(UW_KSE_\
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MZ;J4<MLJW#6:HH*R1MSA3V"C 'L*CL_#&G^&]&E?4-0>2,/;EYY4 "I"1L7
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:"/[3>23*NX8/#$UT5%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %  ED# 2(  A$! Q$!_\0
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M--&>)_\ OX:7MJT_>EN==:AA8S:A)V]"K_PA_A_^ZW_@0W^-'_"'^'_[C?\
M@0W^-6_^$0TW_IO_ -_#1_PB&F^L_P#W]-'/4,?98?\ F?W%/_A#_#_]UO\
MO^?\:S?$7AK0;+1[J>,F.14)1C<'K^=;K>$=,[^?_P!_37&_$[P-]JT'.D.Z
M21MO??(2"M:4I2E-*6Q,Z=+E]QMOT.[\'SK/X<L763S/W8!.<UM9KR[X>>%M
M:LO#4"KJY@5_F5%7=@'WKJ/["UO_ *#S?]^A5SA#FLI+\3'7L=5FDS7+?V%K
M?_0>?_OT*#H6M_\ 0>?_ +]"IY(?S(=S5\1$?V8WU'\ZT8/NK_NBN&UFUO\
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M"LBC =0PKG::W*]G3_E_ I_V/9?\^RT?V/9?\^RUI9HI78_90_E1F_V/9?\
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M?ZE'X@L]+OO#UQ ]PQ"MYBMM4=6(':GCXB$W8E_LR<:,9_LXOMPQNSCIZ9H
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M'_*NNHCL5B4E-671!1115'.%%%% !1110 9HIN:-V* '44S<<T[/- "T444
M%&*** #%)BEHHL F*,"EHH 3&**&IN: '8I<4U3FG"E8 Q1BBBG8 Q1BBBBP
M!BDYI,\]:6@!<4F*6B@!,4N*** "BBB@ HHHH **** "JU\[QVD[Q9+A&*_7
M%6:CD(569CA0,G/84 ?*46MWNOM'H3ZI=_;]0U!VU$9(^SPH3QGMQ7J'P%E*
MR:_8VEW->:1;7&RUEE;=D=P#72MJO@."_N9?M&DQW<@*3.-H9O4$UM^%)M!:
MS:'PT]H;9&Y6WQ@'\* .AJKJA<:?<F-@K^6VTDX .*M5#=0I<6\D4HS&ZE6'
MJ#0!X?H]C?\ A$V5[JECI]PMW,RB>$YD5FZ'/>FQ6=O_ ,*]CUHC.K&_W&8'
MYB=^,?\ UJ]#T[P'IUE>02FXNYX(&+PV\LF4C/L*0> -+-_YPENOLWG>>+3?
M^ZWYZXH R/BAK5]'X8N+5-)N)H984+W*D;4)(SFN\\/G.CV7_7%?Y5A_$Q0O
M@75 !@!!C\Q6]H'_ "!K+_KBO\J +]%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !28'I2T4 -VTN!2T4 -(J&8[8V<G&T9JP:A(#
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MBB@ HHHH *3 I:* "BBB@ HHHH **** "BBB@ HQ110 4444 %%%% !1110
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M%R,G)%=%X?.=&LO^N*_RH T**** "BBB@ HHHH **** "BBB@ HHHH ****
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ME<CJ7B"[;Q,^FZ9%YIM;8SSCU)^ZOXUSG_"4>)-%U;3/^$A-D\%\S VL(^>
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M4 %%%% !1110 W8N[.T9]<4WR(O,\SRD\S^]M&?SITAP,DX%<C_PG^C'5OL
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MK<4R3X>VT$=J=&O)]/N(8C"98^LBGUKI?#.BV^@:7%86F3''DEFZLQY)/N:
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M/0$]Z /H[=S3P<UY'\$?$<NIG4K"]N;Q[RV8%H;H?-'GW'6O6TZ?C0 M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VN:-9:Y
MITECJ<*S6LA!9#T..16C10!S;>"=!:]GNSI\7GS0_9W?')CQC%5K_P"'OAN_
ML;2TN=-B,-HNV';P4'IFNMHH YI?!.@K86=FNGQ"WM)!-$@'W7'>I;CPAHL]
MS?7$ME&TMZGEW!/\:^E=!10!RNC^ ?#^D2VDEC8)'): B$Y)V9Z@4Z?P)X?G
MM;JWETZ)HKJ7SY!ZOZUU%% &#X<\*:1X=$O]E6BPM*<N^<LWU-;JC I:* "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
0* "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image00004.jpg
<TEXT>
begin 644 image00004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" %" GH# 2(  A$! Q$!_\0
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MCTZ,'(D8C.\_["CYB?\ &H=:U+6;1M'T73C#/K%VC-->S1'R8E0#>^T8R22
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M9/-*S'=%ZB@$$ @Y!Y!%%(84444 %%%% !1110 4444 %%%% !1110 4444
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MZC<I9V[3GS.5A#!>G.YOPK7;1=<U[4K"7Q+]@MK"QF%REI9NTAEE7[I=V P
M>< =>]7_  KH5QINH:WJ.HR12WNHW6\&/)"0J-L:<^@Y/N36BG&/O2U:7Y_Y
M$<DI>['1-_E_G_F<;!XC@A^*%E>P66J6EIK$/V*Y-Y9O IF7F)@6X)(W+]*W
M_BD?(M?#]\G$UMK%MM(ZX=MC#\0:U_'.@MXC\-W%C!(L-V&6:VF;I'*A#*WY
MBL;Q5'/JNK>%=%F"-<).FI7GEG*HL(X_ N0!1&492C)=-_1?U8)1E&,HOKMZ
MO^KG<5R \>6IO_LO]B>)-WF^5YG]ER>7G.,[NFWW]*Z^BN6+BOB5SJDI/X78
M*XCX=_\ (<\;?]A<_P#HI*[>N M=%\6Z/K6NSZ-_8<MKJ-X;H?:FE#K\JKCY
M1CM6E*SC*-]_\S.K=2C*VW^1-\9N? TJ+_KWNK=8/7S#*NW]:Q-8O%OOB1>P
MZGHU]K-KI=M"L%O#$LD:2.-S2,I(!., 'G&#706_AK6-6U:SOO%U]:2Q63^=
M;V%E&1$).SNS<L1V' %6-;T+5(/$?]O^&I;7[7+"+>ZM;LL(YU4DJ0R@E6&3
MV.<UM"<8+DOKK^-O\C"<)3?/;33\+_Y_@8.AQSQ^/+:YT7P]J&D:?=6\D5^)
M85CB+@9C<*&/S9R,^AK'MK6PT/2+K3O&GA2ZF+/(TVK06XN%E#,2)"X^=" 1
MUZ8KO-'T_7[C5GU#Q!=PP1K$88;"Q=C&N>KLQ +-V'  K.@LO&VGVCZ=;SZ3
MJ$&66*^O))!,JD\;T"D,1GU&<52J:VNNG5^?43IZ7L^O1>70HZL]J^L?#=M.
MNFN[/SY1#.S[S(HMVP2>YJ7P=IMGXCU37]:UFWBO)Q?2V4"7"!Q!%'\NU0>!
MDY)/?-6;3P4^GIX.@M+A'AT26225I.&DWHP)4#_:;./2F16.I6'B'69O"%YI
MES'<3![VQNW93!.5'S J"1N&#@CZ&DY1<>6#Z;_-C49)WFNNWR7Y&?X?T>WT
M3XF>(;>QREJ^E1RQP@_+#EWRJCL,@G'O2?"KPIHUW\/=.FU&PM[V>[A/F27"
M"1MNX@*">@ Q@"D\'65ZWQ'\427UW'=W7V*"*X>-=L<4C;B(U'7 7'7GDGO7
M8>!](FT#PGINEW3QR36T>QFCSM)R3QGZT5JCBFD]?=_(5&FI--QT][\S)^$D
MDC>#8XI'9UMKFXMHRYR0B2LJC/?  KLJY_P/HD^@:*]G=21R2-=3SYCSC#R%
M@.>^#705S5FI5)-=SJHIQIQ3[!11169H%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !2,H=2K@,K#!!&012T4 5=+L+?2["*S
MLU9+>$;8U+%MHST!/8= .PJU113;;=V)))604444AA1110 4444 %%%% !11
M10 4444 %%%% !5.WTVV@U&ZOHT/VJY"K)(S$G:O11Z#DG [DU<HIIM":3"B
MBBD,**** "BBB@ HHHH *P-:\(Z3J]]]MN(IXKPJ$::VN'@=U'0,4(SCWK?H
MJHR<7>+)E%25I*YG:%HNGZ%9FVTNW$,;,7<Y+,['JS,>2?<UHT44FVW=C245
M9!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)I,UO[(OO^?=OS%']D7W_/NWYBN?'BS31YAEO?+19?*5R20_RJVX8_APPY/
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M@CWH#E*T?@.=?&\OB1H<SM9+9H@4#&&)+$YY)&!TZ"M_^R+[_GW;\Q4/F/\
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M%8+30+S2S.SI<IY;3+&J/@*%&<=3@=36!/?W%G'K=SB]E\113S>3"1*8Q!N
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MSC<3N !R>IQC-)V!7.WL-"2PM[J.TNYXY)X(H!+A2T?EQA%8<8S@9Y[UE?\
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M4445H<@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSDC)XQCO]/>M/[-I=V9_VE6ZI'U+_P ++\&_]#!9_F?\*/\ A9?@W_H8+/\
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M  KQ>BO9_L[#_P OXL\7^TL1_-^"/:/^&@];_P"@'IO_ '^?_"C_ (:#UO\
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MW3AH8I&D\O:.#C)/ (8?G1SN]DPY%:]BA)X9U$ O'&DD>Y@&#CHIY)'4#O\
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M.<=>IQ5H^']6M))?)NU1'!$CB8KE.068=<94BO39_@CXHGB$4FNZ=Y?EK#M
M< HIR!]WUH7X(^*DD$B^(K(.!@',GO[>Y_.M/KE*WQHS^I5;_ SSEM,UG3[I
M+7^TYH[6%W3=%,P\M1N);;GC(4D?AZTL^C:I=1F&WU 2)"/L<R.QB4%"OR]?
MF&9!S7H\GP4\5R0O%+XAL71P58-O.<G)_A]::_P2\5OMW^(K([0%',G3(/I[
M#\A4_6Z7\Z^XKZI5Z0?WGF7]B:Z(6E-T1"RE2YN"%9.I.>Z^W7VI9-,O;B%X
M=7U.X5H#*1&Y,J+M."?O<;F.!CJ:]0M?@MXLM2IB\0:?\N=NX.V,C'&5]*0_
M!7Q868GQ#899-C??^89)Y^7U)/XT_KE+^="^IU?Y&>6/HFKZ=]I>.[\B/:PF
M=9RIVYP-X'J>W--\(7,]UXXT*2ZFDFD^VP#=(Q8X#CC)KU)?@CXJ#LP\0V6Y
M@0Q)D.0?7BM#P7\#;S2O$EEJ&K:I;2P6L@F$=NK;G93D DXP,T2QM'E=Y)L(
MX*MS*T6M3W>BBBOFSZ4**** "BBB@ KP#]JK[WAC_MY_]I5[_7@'[57WO#'_
M &\_^TJZ\#_O$3DQW^[S/!*[35O!A@6R@L;?4GN;F*.5)YPJP2$Q>850XR3V
M'/.*XNNCOO$D4]Y9W]O8?9]3MO)_?B=F#>6H4?+C SM%?2U%.ZY3YBFX6?,1
M6/A74;NWCN,P06\D2RB69\ !F*KG )R2IQQT&>E30^#-5DWJ_P!FAF666!89
M9@'DDC +*H[G!^GO5W_A.9FOM2=[0PVEYY>V"TG:$P"/.P(V#Q@G(([U2M_%
M4T%W83K;AS9W4UROF2,S.9  0S'DXV]:B];L:6HKJ4]>T3^R;'2[G[9;S_;;
M<3^6C?-'R1@_E^>:W=7\&&&XL++3H-0>ZNA&5GN J6[EH]Y"MCM[GM7.ZIJB
M:AINFV[6VR>SB,'G!R0Z9)'RXX(R><U=?Q/.WB*#5C"NZ*-8Q%N.WB/9G^M-
MJI^?_ $G2_+_ ((Z'PAJ%Q&\EO+:3+EUBV2$^>47<X3CG ]<<\#-07/AC4+?
M23?R"+8L:3/$&_>)&Y 5R,8P21WSR,BK.G^*9;;0$TR1+@K"TC0O!=-#C?C(
M8#[PR,]N]+J_BF35-(CM9X[A9EAC@++=,(F5, 'RNF< =\=\4KU;^06HV\SF
MJ^I?V;/^2<'_ *_9O_9:^6J^I?V;/^2<'_K]F_\ 9:X\V_@KU_S.W*/XS]/U
M1ZK1117SQ]$%%%% !1110!R?Q:_Y)GXE_P"O&7^5?&-?9WQ:_P"29^)?^O&7
M^5?&->YE'PS^1X6<?%#YA15C3[.;4+Z"TMEW33,$4?U/M6OXBT>QTC7+6U6^
M>XL98HIFN%CP=K=2!GD#G'K7KN23Y3QU!M<Q@45V%_X'N+1&4W,7F[WD5G8+
M']F& LQ;T9B !WP:SH?"FHRW\]CNM$O8CA8&G4/+\NX;!_$",$'OFH5:#5TR
MW1FG9HP**TK_ $:YL--M+VZ:!4NT$D,8E!D9#GYMHY X(YK?M_"^GMJ-KHLU
MY=+K=S"LB[8U,".Z;UC/.XY! +#H3T--U(I7$J4F[''45TFL:#;Z=X>L;X&\
MFDND5_.1%-NK9(,9;.0PQW_+O7-U49*6J)E!QT9ZC^SA_P E)'_7G+_-:^J:
M^5OV</\ DI(_Z\Y?YK7U37S>9?[P_D?399_NZ^84445P'>%%%% !1110 'H:
M^$-8_P"0M??]=Y/_ $(U]WGH:^$-8_Y"U]_UWD_]"->SE&\_D>+G&T/G^A4K
M7L_$>J68C$%R (P%0-&K;,=,9''05D45[3BI:-'AJ3CJF:T/B+4X1\EPO52-
MT2':0, C(X('&?>F3Z]J$RE7F4(1@JL2J/XN>!U.]L_6LRBER1[#YY;7-G_A
M)M5\S>T\;/N+[F@C)R01UV^A-)_PDFIERS31L6.6W0H0W)/(QSR21Z<>E8]%
M'LX]A^TGW+=]J5W? "[F,F#NY4#G 7L/0"JE%%4DEL2VWN>D? &QMM1\>_9K
MV%9H6M)"5/8C:00>H(/((Y%?1_VB_P##W%\9=1TH=+H+NG@'_30#[ZC^\.?4
M'K7SS^SC_P E(7_KTE_I7U37SN:?Q_D?1Y5_ ^9';SQ7,$<]M*DL,BADD1@R
ML#W!'6I*P+G1[C3[B2\\/-'$[DO-92'$$Q[D8^XQ_O#@]P:NZ1K$&I&2(+);
MWL/^NM9AB2/\.X]&&0?6O-/3,?XE>+1X,\+RZH+?[3-O6**,MM!8^I]*\3_X
M7_K_ /T"]-_\?_QKO_VE/^2?1_\ 7Y'_ "-?._@^#2I]8*Z_)Y=DL+L3NQE@
M.!U&?I7MX##4IT7.<;L\3'XFM"LH0E9'I/\ PO\ U_\ Z!>F_P#C_P#C1_PO
M_7_^@7IO_C_^-8%MX+T._N2MEJS2X265DBFB;: P"J">_(ZCGMBJMWX?\+#S
MMNLE)=K%%62,JI&[ /?JH_[ZKH5'"MVY/S.9UL6E?G.I_P"%_P"O_P#0+TW_
M ,?_ ,:/^%_Z_P#] O3?_'_\:Y#5/#OANUAN_L^N&:5(V:'#QE78(6!X.<-@
M #@@FLG7+/3[?2]#:W:W^TS1EKIH;D2@<C 9<Y5@,YR /3H:N.&PTK6@1+$X
MF*;<ST7_ (7_ *__ - O3?\ Q_\ QH_X7_K_ /T"]-_\?_QKG-1T'0OM)@CD
MMX!Y\PE8WBI)&5)\N-58XPR@'><C)]J@7P]X61I$&LM<N$EVXGCC5F DV<GW
M1<YX.X5"HX6U^0OVV*O;G.J_X7_K_P#T"]-_\?\ \:4?M :]GG2M-(^K_P"-
M<I9:#X8#M+)JX>*.0IMDF0!\!>PYP=S$$<#;@\UR>MP16^I21P#";48KG.UB
MH++^!)'X5<<+AI.R@1/%8F"NYGV9X#\21^+/"]GJ\<)@,P(>(G.Q@<$ ]Q5G
MPU_J+_\ Z_KC_P!#-<=^S[_R3*Q_ZZR_^A5V/AK_ %%__P!?UQ_Z&:^<Q$%"
MNXQV39]3A)N>%<I;OE_4UZRK7_D9;[_KWB_FU:M95K_R,M]_U[Q?S:LI;HUH
M_#/T_5'G/Q$^*&J:)XEN='T#28;MK.)9+B69\?>&<*,C/!'^%<5_PO7Q. 2=
M$LL!!(3LDX4]#UZ>]9'Q=UF?1_BCX@^SHC>?%%&V[/'R*?Q^E<['K6KWL<7E
MVD"K=/((F,NP&1AM?&2.H; 4\ ]*^BHX2G[.+<$[I'R];%U/:22FU9L[U_C?
MXK159] M &SMS')SCKW[4ZU^-OBNZ=T@T.P9D3S&!W*=IZ'D\YSQZUYY'K^J
MR//)#IY.0\;LB$X)(8\XQNW)G-58-3UJ'4+N\2UD\VZB4R9C)'EY'3V.,5K]
M4I?R(S^N5?YV>DK\<_%#_=T.SZ!L[),8/0]>GO2-\=/%"C)T.RQG .V3!.<=
M<UR4VKZK#9RQ7VD3"61O+C,> %=0,@C&1T!/J!65#XGUB,?:A &A#@99"4!R
MAQZ?\LQ^9I+"TGM!?>#Q=5;S?W'H$GQW\31KF31;)!NV999!\WIUZU/>?&[Q
M39Q^9<:-IJIYC1$ARV&'4'#<?C7F-_J>K7K) ]K)\K*438200Y8?^AX^F*74
M;JYN;*:!M*F6W=Y+F,G<2I)^]] ./?K3^IT=/<0OKE;7WV>DS_'3Q-!Y0ET?
M35,H#(NYBQ!Z<!LC\:W/#/QDU:;Q1I^E^(=(MH(KQUC62!R2I8X!ZD$9X/IS
MZ5XSJ-UJ&I1+#=63K/:Q!E=B5*A5YZ]/E3@#T)ZU<\/ZLVJ>,?#OG1!9(KR!
M$8'HN_)'N2S$DU,L'2<7[B*AC*RDO??0^S****^</I HHHH **** "O /VJO
MO>&/^WG_ -I5[_7@'[57WO#'_;S_ .TJZ\#_ +Q$Y,=_N\SP2I+=4>XB69_+
MC9@'?&=HSR:CIT3^7*CE%<*0=K=&]C7U)\F=?X@\+I'?^3I=M)%:B&:>.[DN
M5FCNHXQG<A50 <=5YQD5GV_A:9[0W=S>VUM;+:QW;.^3\KN54  <G*]*EC\7
M26[6\=IIUI!8Q>:6M0699#*H5\DG/0 #'2J^I^)KF^M9+;[/;06[016P2)3A
M4C8LN,GK\QR:YTJMDCI;I7N7+'PA<MJ:17#1/;^9;("KE1-YPRH4X/;.>.,5
M4E\,W**\K2PI:BV6Z$I)*[6?8%Z?>W<?@:=%XMU".WT:$+"5TJ3S8B5Y<YXW
M>N.@^M);^+-0@TNTL4$/EVUV+M&*98D,6"'U4,2<>IIVJW%>C8TH_" M/,EO
M',]O)87$\#!'B.^,#J& ./F'/0UQM=/?>,;NYRJ6T$2&.>,C+.3YV-Y)8DY^
M48KF*NFI[S)JN&T/ZV"OJ7]FS_DG!_Z_9O\ V6OEJOJ7]FS_ ))P?^OV;_V6
MN#-OX*]?\SORC^,_3]4>JT445\\?1!1110 4444 <G\6O^29^)?^O&7^5?&-
M?9WQ:_Y)GXE_Z\9?Y5\8U[F4?#/Y'A9Q\4/F7-)U.ZTF\^U6+HDVQH\O&L@*
ML,$88$<BKGB;7Y_$$]I+<PP1&WMTMP(HU0-M[_*!^7;M6/17KN$6^:VIXZG)
M+EOH=98>,YK:;YH91"UA%8/Y%P8Y,1X(96P<'(Z8(JUI/CMM-FEE2UN97-QY
MX=[P[Y!L"[96VY<#&1TQ7$T5FZ$'NC15ZBV9?U743J$=BK1B/[+;);#!SN"Y
MY_6MV/Q9"MQ;ZD^F[M<@@6%+GS\1DJFQ9#'MY8#'\6,C.*Y.BJ=.+5F2JLD[
MHWTUZWM_#]YIUE92QRWJ(ES(]R70[6#;E3:,,2.N3CG'6L"BBJC%1V)E)RM<
M]1_9P_Y*2/\ KSE_FM?5-?*W[.'_ "4D?]><O\UKZIKYO,O]X?R/ILL_W=?,
M****X#O"BBB@ HHHH *\PUSX)^&-6U6XOO,O[5YW,CQP2*$W'DD J<5Z?16E
M.M.D[P=C.I1A55IJYY#_ ,*"\,?\_P!J_P#W]C_^(H_X4%X8_P"?[5_^_L?_
M ,17KU%;?7:_\[,?J6'_ )$>0_\ "@O#'_/]J_\ W]C_ /B*/^%!>&/^?[5_
M^_L?_P 17KU%'UVO_.P^I8?^1'D/_"@O#'_/]J__ ']C_P#B*/\ A07AC_G^
MU?\ [^Q__$5Z]11]=K_SL/J6'_D1Y#_PH+PQ_P _VK_]_8__ (BC_A07AC_G
M^U?_ +^Q_P#Q%>O44?7:_P#.P^I8?^1'F_A'PKX/^'VN3PV]Y(=7ELWN";IP
MSBW4_,5P ,9'/?BN_>]@33_MN\M;^6) RJ6)4C(P!R:Y/QMX,F\17-Y=6UW'
M:W1LE@M)2A)BE#2$L?52LA4CN":DA\&BSN#?VDD#:A]F$(#0I&"=@4GS57S!
MTZ@YK"=251\TW=F\*<::Y8*R-2#Q9I$_V40W#N]R[HB+"Y8,C;6##&5P>#FK
MFKZ/;:GY;N7ANHN8;F$[9(C['T]0<@]Q7$Q^!]3CTF"UAFLX;A;B65+M)YO-
MLU>0.0C=9.Y)<\D\Y%>CU!9XI\?9=27P#]EU6)':.[C*7</"3#GJO56]1R/0
M]A\X5]1_M*?\D^C_ .OR/^1KY<KZ3*_X'S/FLU_C_(N:;:SW#3-!*L*Q1[Y)
M&?:%4D+R?<D#\:L6V@ZC/,D:VS(&D$6]R H)( Y_$=*?H-OJ,B7,FFK$X.V&
M5)0A5@0S\A_EP/+)R>A K;9/$;V]O(J0H8/*ACC<Q$H4R5?YON\YP3C(( R*
MZYS:=DT<<(*2U3.<;1]06XMX?LDIEN/]4@&2_P!,4RPTZ:]NVM4V1S@$[)3M
M)(ZCZUO&UU>\^P3S7D-O<;]D*E?+<R9P,X').WJ?2J]CI6OV;.UM;(6NH_+;
M<8I"5;U!)V_7CT[T<^FZN'L]=G8S&TJ[:[A@15FEFB$R['!&TC/)[5-<>']3
M@F9/LDD@65H0Z<JS!MIQ^-:7V778[VU:ZCAM]J&VRT4158U#$AT YX5CR.<5
MH2S>(9$.RX@O!-"X.T)'M$F"2V0O)W+@'U&*3J2Z-%*G'JF<;=6TUI.8;F,Q
MRJ 2K=1D9J(DDY/)K0UO[<;I&U(*LWEJH4;054# !"]#['FL^M8NZN8R5G8^
MH/@9K"67PZLHFL]0F/F2'=!;-(OWO45U7A_7XHX;W_B7ZLV;R=OELG.,N>.G
M6L?]GW_DF5C_ -=9?_0J['PU_J+[_K^N/_0S7R6+_P!XEZL^TP/^Y_\ @/ZD
M7_"1Q?\ 0-UC_P  9/\ "LVW\01#Q!>/_9^K<P1C'V)\CENV*ZZLJV_Y&6^_
MZ]XOYM7/+=&]'X9^GZH^5?C?,)_B3J4H21 Z1-MD4JP_=KU!Z&N8T[67L8H4
MCM;=S"[2*[[L[B,9X/;M76?'C_DJ&K?2+_T6M>?U]?ATG1@GV7Y'Q>(DXUYM
M=V:MCKMY8Q&.V*K'DG')_B5OYH*L2>*-0?IY2=2P4'YF(P2>>_ITXIVCC3I[
M2TMKB2"+S)BMRSH/,P2-K(Q' '<9'3WJW"?#J[T.WRI$"AFW%PX<=3CA3CJ.
M<$TWRW^$F/-;214'BJ_$[2;8L,YD9/FP6/7OWR>/PZ56?6Y3I"V"1(@RQ=P3
MD@N'P!T R![\4ET=)5M0$0G+97[,4/R@_P 6<\XST[XK6TV?1H[2U-R+0RB(
M"9?*+9&YMPY'WR"N"/0\BAJ*5U$%S-M.15;Q9?;6V16Z,V1O"G(! !YSWV@Y
MZYJ>Z\87#V<5O;0>2JVZP.3(3NVJ%!&,8X!SUSGGI3M'_P"$=.G6L>HNJR-(
MKS-AB^ '##C@#E<8_&J]]!H<=@QMW;[1);K*FYRVULX*8'?@GGH"*5H7MRCO
M.U^8CD\37,MN8YD#LSSR,V[&6D!'Y+N8@>YJ+P6I;Q?HJHQ1C>1 , "5.\<\
M\5C5M^!_^1ST+_K^A_\ 0Q5RBHP=B(2<IQOW/L/^R=4_Z&*\_P# >#_XBC^R
M=5_Z&*\_\!H/_B*W**^0N?9&'_9.J_\ 0Q7G_@-!_P#$4?V3JO\ T,5Y_P"
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M7-,_[\BC_A77@_\ Z%S3/^_(H_M2C_)^0?V76_G/CF^OKB_E$EW)YD@&-VT
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M7#NR[U91&>2Q#!3\N2,?6EN[KPFZ"\FE=Q;P1PEU\XEHY 60''W^"3WQSG%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image00005.jpg
<TEXT>
begin 644 image00005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" -G I$# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH PO^9V7_L'M_Z,6MVL'(_X3A1W_LYO_1@K>H ****
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M@NI>.O%%YK3BSM/)NX4,#0P6SS,N\!N3]W((&/J:/^$<\?>)#YE])+;HR_\
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MZE=!6%X6&)=9_P"O^3^2T ;M%%% !1110 4444 %%%% !1110 4444 %%%%
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M/05E:>6CT_2;Q(Y%2&TA24KD[T91R?\ =(!]<;O6M[Q'<0Q:#J#.Z ?9W'+
M=5/K7-Z%JT\VDZ1';Z5<GSH8U\QR$CP$&6/)(&<8XR<TP-"T=K;6+ZU./),J
M31JHP<,ASDYY^93TI[/&D<;LH1(XGZMR22>W7MZ=ZYRSUBV7Q')I]^MS:/;Q
M1Q%A(3'\V=F6X)! /)[G%=5<7^G:1%%L1I'9=T<4"F61QZ@#)P/6@#F/$>I+
M/<6]A#'>.+I5WFWB;F-,%L'C /"]>Y[XK0V:L81%IUI9VD0DS#O?.["G^%>,
M=.YS4%WJL%YXILT7S[:\DBDA6.>,C!VAPP['L#C/3!K:M93<K*;K;!=PN8AQ
M@)]WD'N&P#^.* ,73[&6#Q<8KUH;AKW3F61UBVJ"DAX [ B3]*U[#R]%UQ--
M@9?LEU&TD$6[F-UY8>N#G(^AJ+P_;.-=N1)--,+*VCMO,G +LQ)8G</;;3M6
MTVS/BS2;R&%?[0+-OD!.1$J..G3JX'XT =31112&%%%% !1110 4444 %%%%
M !1110!B=/&0'<V!/_D05MUB$?\ %:)_V#V_]&+6W0 4444 %%%% !1110 4
M444 %%%% !1110 C?=.*R/#K[WU0G&?MKC_QU:V*PO"O75\#_F(2_P EH W:
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ****  ]*XW3A++XC,J+^X%Q*H413;5(+ L"6V G')V]SW-=E3(H8X0PB1
M5#,6( ZD\DT /[5$UQ"C;7DC5O0L :EIA1,Y*C/KB@",W-OG'G1Y]-PKEKJ^
ME\."Y*0R7>FEC*OD -)"S$EP1D$CG=D9QR/2NMVIZ"H[A8O)<LBD*I."* 9S
MWA/6-/A\/:7!+?6OG?9@P42C+*!R1STKFK_7K?4+:VTFRE,<]WJ!:.1_ERGG
MG+)DY;VP/?M73>%M&T^3PY8O+86I:6WC+$Q@YXXS5/5])M#Y%XUM$][;ZE$(
MIF0%XU:9<@'TP3^=,D?K5J\'BCPQ:Z?+]F007,>0H;"!8\=?H*VGL=3/W=6*
MCT^SK6=X@#CQ;X=DA4O(JW(VYP-I5<G/Y5KBXOMK9LDW <?OAR?RH&020W"W
M$<<FHMO<'8!$OYUH6D4L49$\QF;/WBH7^59=Q'<37UK=/;Q+/ 6$:_:" <CG
M(V\\5J6K3NA-Q&L;9Z*VX8^N!2&3T444 5;R]6VP#',Y/:.-F_D*JC49W_U=
MFZ'G"S$J3^0-+X@NI+/3GFA$A92H_=H6."1G@ GI[5?4#8N2?Q[T 9S:RD4F
MR>VNEST=86=3^0)'X@5HP3)/&'CSM/JI4_D:?\M"X[4 +1110!S6LVL9UBQ!
ML_,CFD*S.L>[C:<9X.![Y'XUIC1]/&&^QP'V*9K-U_4DT[4+>-UN6:=9&'E@
M[0$4G!P#C/OZU;L0NK:7:W$4UU"LB!@ VUA['^5 CF_$&F6NH7]] EG;K;V5
MIYO,?$DC*V#VSM SCU(-;/AY ^AZ1)(4<-%&REER2VP?X5D7M@]IKVI0"ZO&
MBNK,SJF_(WC*GISC&SCZU;TLV[>"]-M[F23RY+2+:8"P<+L7G(Y!]^*8(L-I
M<$_B*\6XA6>.2%"1( RG:W''L<8^E<]HQ%MX@U.SCG\^.&9$7:^/)BV,1$#G
MC# _@178:2[RWUQ,9HY8'BC,>P=LMWSSVKE]2TNTU'Q.YM)#:R0.J&:W !\X
MK*_S=F&"I(/7-" H^*OM+6C:<]Q''>K/'-:7"_.\;%\; >"#PV#Z9!Z4_6=;
MO(VGCU.&-!&0D%S K2QS2=U<;?E/0]^@H_L&#6O$$BZE=W5Y:VJJJ$2,K-(0
M<L=H P%<8(YZ\UB:@XTJ.>WM[V>&2281X"EED21B!(JG(!4 D].5.<Y%,39T
MOA#69[FV>?3[.YO'OYVN"TIV+#'@*H+$8)X' S_4]7H^F207$]Y?.LMY,<<9
M(B3LBY_4]S^%7-,M(K.Q@MX4"QQ(J*,8P ,5;J2@HHHH **** "BBB@ HHHH
M **** "BBB@#$;_D=8_?3V_#]XM;=8K'_BL8AS_QXO\ 3_6)6U0 4444 %%%
M% !1110 4444 %%%% !1110 5@^$V#'6, C&HRCG_@-;U8/A,8;6> /^)C+T
M/LM &]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %1/ &8DL_/HQ%2U$RRECM=0.WR__ %Z &?9E_O/_
M -]&H+FSC,,GSRYVG_EH?2IW61$+-*H Y.5[?G7.>1=Z]:_:IYQ'IYW-'"BD
M&91C:S'/3C( XP1G- F:7A1D7PSI,>\;A:QC&>?NBJFL>6L$BH>?[1MBWS=R
M\?\ ]:L[P[X6L)_!]@J*T5U+!%)]K7F96PO(9LXZ#CI5.]M[K2KB:V:1+BP%
MU:,'E8F5,O'R6)Y&5/J1GTIB-GQ)>I8^*_#K2@[9%N4R%+$?*IZ#Z5L2ZK;Q
MIN;S<8SQ"Y_D*R/$ SXM\,2Y&U6N5/OF+_ZU=)O'M2*.9U*X$^LZ;/')+'%"
MSF5&MY,OE< #C'6NBM+A+F,O&'V@X^92O\ZPO$5M>2WUK<6=S#!#"DF_<F]M
MQ'RE1WP>V1FMK3I ]G"0Q?*+EBNTGCT[?2F+J6J**HZKJ46G0J\BR.S,$2.-
M"S,3V 'T/Y4AE+Q//;65BUU<11R$%5 8XSD@?UJRFDV#Q+OMH6[].,UA:G%K
M<VGM<R7MK9%L8@-OYJIGC#$\DY([8SVI+[2=9L['[5I^KWEY=@JQ@E$8209&
MX ;1MXSCF@1T']D:>&W?98L^N*M6EM#:0"&V18XEZ*O05Q4&M7M@((?$-^(+
MB6%95"1KD%N"I !Y7U'&!FNTM$9(0KR&0_WB ,_E0,GHHHH Q=:U!-/DB,[N
M!)N"XVXX4G'//:K6E3K?Z;;7<#RK'-&LBAU 89'0CL?455U:\CL'#74^U6W,
MOR \!23^@-3Z7)]OT^VN[2Y;R)HQ(G[L#@C/3M0!3\4:8MWILTQF:.XAC9HY
M0!E..1TZ'&"*X/P3XNCTSP[:KJ\:O>W"HL268\TL H54P#D, ,D' &:ZOQ;<
M74LCZ79W;(_V9KB=U4;ECY  ]V(/X U7\+6;:3HVDK,D3V[01@@1@&&1D )&
M.S$\^YIH3,[PUKUSJ2Q6^CO;1*;5%<WC%9%?YL[8QR<#G)QG@\UH74EK8O:V
M-I%->7$4GF2R+@$NRL<EB0 QZ_2F6/AFSN-0U.V"FVGA,)CN8P/,"@LR8)';
M)7Z 57L96TM=6M+RX9;B&X:<W,P#>8GE'#XSR0%(..Z^],"*\UF:RUR5I();
M?]WMN4N&V+(BDX>%QD%NHVD@X(J6ST_4/$NL6=]?6"6NDQHK1)<#,[<Y)./N
MYVKU.<9]:I_8[_59M$U"_+QW9O(Y(+/:N(H #N+]>2,$^AP/7/IT:[5 I7"P
MZBBBD,**** "BBB@ HHHH **** "BBB@ HHHH Q&_P"1TBZ_\>#_ /HQ*VZQ
M&'_%:1'_ *<''_D1*VZ "BBB@ HHHH **** "BBB@ HHHH **** "L#PEG.L
MY.?^)C+_ "6M\]*P?"7W=7.<YU&;^E &]1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1EI<\(,?6I*J
MS7T44S1LDY8=2L+D?F!B@"AXF:X.@:@JP[MT+*=C\A2,%A[@$G\*LHQ.ECRD
M"Q^5\I!Z#%-N+V"Y@DA>*X*NA5@UO)@@CZ5S\'B"VTJPCTK5)I8[S;]G@:2)
MA]I(7JN1S[CL:8FS1\(2R?V)I<0C9K<64++.2/F)'3'TY_&LCQU#/)8ZM';R
M1HTOV9 SCA<R8)_E6_X3*KX7TGG_ )=8Q_XZ*Y+Q=K=C>W+:9:WL$SWSVR*(
MY5)4>:H9AZGD4('L7Y=FHW'@M[J)&\U7D*$9&3 374'2K%FW/9VY/8F,&N>\
M06IA\0>$;>U=H8EEFCRF,X$#8'/T_2NA:QF8Y-[<=.VW_"@#!\6):Z98/-;:
M?:23;7*J8 VXA20![Y[=ZW]%5?[-MY!"D+R1J[JJXP2.:I:@([&)I+O4+I8U
M4NQVY  Y).%K1TY1]F5UEDE60!U9^N".* ++=*YSPZ%U/4+O594&Z.1K6#(Y
M5$8@G\6!/TQ707 <PR>5CS-IVYZ9QQ6-X+DB?10D2.C0R-%*'ZF4'YSGOELG
MBD,O:Q:P75FT5S@19!)P.,$'O]*RX?$5FSR"T%Q?8/RB"/>!P.0W3'/KZTWQ
M>L4EUI*7TICL6G/F MA)&VG:K^Q/KP3@=ZCTF[>V-ZNL76E):>9LM$BD_P"6
M78-GOCT]*!&1KVLWKZDD+:9&T4BQ@VUR4W.'9EX()'\(JYX.ODM=0N-%99HF
M1?/BCF?>R*<9&>_)SU[^U<OXB;3-2\;Z-J2/-->6Z1"VAM@2DG[QPX!P!QQW
M%:6CZ'J%AXJL-3OIY/M=Z\B21%U<+&L7 W8!ZJ#Q3$>E4444BC$UF.UDEC-^
MMK(HW;1+%N(&WG],_G5C2\2Z=;R6$EO]DD0/$40A2IY!'/XU6UG[#YPEU".U
M)A1RK2/\RJ1\Q QZ5:TQA]@B&GQQ"V P@#$8'XCUH$<W?>='K^L1RB)Y9=/$
MBN >$&X;,9_O9.<]ZU+2&8^%X8TEB$LMM&%:1"55M@[#J,]LU6\7Z?>S6CW]
MGL2ZMH7'W_\ 61D LG(X)QP>QQ7.Z)K-M=:/<+>/+8M9Z?&(UNGV'[O^M7#9
M(X7G^M,#L=%00ZI<1*HR(8RS[C\[;G!XYQT]>]<9XH\/6MWXLA2XEN)ENI8C
M(&E/[L$R?*I'*@C((!Y%;6D:U;#52EEOO7DLHYLPD,!EG(W,3QDYI]SICVOV
M&\N?^/ZZU*%YCN)"CY@J#V ./?D]Z.H'0Z5H]GIF\VL05GQN=B69L=,D\\5H
MT#D44AA1110 4444 %%%% !1110 4444 %%%% !1110!A%L^-E7 RNGL<]^9
M%_PK=KG1_P E!Y'_ ##.O_;6NBIL HHHI %%%% !1110 4444 %%%% !1110
M 5@^$CE-6Z?\A&?^8K>K"\)_=U;I_P A&;^8H$;M%%% PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *C,D8;
M!90?0D5)49AC9MQ5=WKB@!#-".LB#_@0KD]?O8=7^U6%M%:S01JXFN)B"D;!
M> O();/H1C!YS6WXCD^PZ'>7$"KYT<3&,$9RY&%_4@5%#IEO8^'&MO+5EC@;
M=N&2QP<D^Y.3^- CB-)\,ZLWA>VO4O9;FX>!"EDLS+"T6T H23UQD@\<^U5[
MP6/]O6UMJFG06^IV9M$M"D9$8!E7<4)XW$9XY^X<'BN[\'7<3:#I=L94-PME
M%(R9YP1C/TR#7-?$R%=MQ<>5/)/ +66W$2Y/FB5]OX9;]:=Q6-SQ2TH\0^%Q
M;A#)]IFP') QY#T_6M8O=&M9+S49=-AMHU).YW!_#CD^U97B#5T6^\'ZAL=X
MI999, ?-@VSGIZUG^*-._M'5;/5+5M1BOK:92D4L/F0_.H4_*"#Z'KCCF@9V
M%K-J5W:PS)]A,<JAP<OR#R./I6E9"X6/%UY6[/'E@@8Q[UR>F/86<.G1+8ZE
M*UDGD12N".@&?XN?_K'%=%H^JQZEY@CCEB,>TE)5VD CCO0!I'I7-:)(VF:Q
M>Z=<;DCFF::TW+PX(W/\WKN+<'G%=+5/4M/COXU61G1D8.CQMAE8=Q^9]N:0
MR/63*;-OL]FEZV5!A9@H(SSR>..M5M)MHI5<S:7%:M%*R)E%)=0<!P1T!':L
M.:75?#JW,^J7]Q>V!;<LJ(@>/EL@KCD8V].?:HK#Q)=ZC")+&UU*;=(T:#$>
M-RD@[SM^3IGGU]>*8KG:3>5%$6;:JH,DGH!6!HTL>N:HNJQ;FM+>,Q6[$XW,
MWWS@<=E _&JUKHFL:CIWE:]JQQ*H,D5M"J<]2N[&2.W05TUC;?9(?+#E^>I
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MT.*Z31=_]D67FAA)Y*;@Y)(.!USSGZT"+M%%% PHHHH **** "BBB@ HHHH
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MU(RGDX_A(J*RMK:Z20H;Y/+D:,[[B0$D<9'S=/2@1JX%*/:J1TV$G)>Z_P#
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M1110 4444 %%%% !114%Y<+:Q"1_N[@I/IDXH GJ.X\WR7\C;YN#MW=,^]2
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M &[@=3CI6EI%P]UI=K/*5,DD2NVWIDC-8/C6>W1K6.?2UU(MEO+ +/&@*[G
M / !^I. ,YK7\-1M%X?TY'C,3+;Q@H?X?E'%,1I4444AA1110 4444 %%%%
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MP@5"?J%S_P "H ZR/E 13JALQBUB''W1T^E34#"BBB@ HHHH **** "BBB@
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M )%6N@K";/\ PG$?I_9S?^C%K=H **** "BBB@ HHHH **** "BBB@ HHHH
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M7L"V^I:BLMH>)%2/:9EST.,;>..":UK/2+.S??!" ^-I=B68C.<9))QFK]%
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MUXQ:6BOYAMD<EI #\H<]NQ(&?K73J-J@4@([1&CMHT<Y95 )]:EHHH&%%%%
M!1110 4444 %%%% !1110 4444 %%%% & __ "/D7_8-?M_TU6M^N>D;'CZ$
M>NFN?I^]2NAH$@HHHH&%%%% !1110 4444 %%%% !1110 5C^%_^/*Z_Z_;G
M_P!'/6Q6)X2;=I]T1_S_ %U_Z.>@1MT444#"BBB@ JDW[O5,XXECQG'=3_\
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MHH **** "BBB@ HHHH #TK#\(?\ 'A>=?^/ZY_\ 1K5MMPIK$\'_ /(.NO\
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MO_C3?[,B'_+6Z_\  A_\: -"C-9_]E0_\]+K_P "'_QH&E0C^.Y/UN'_ ,:
M-#(HK/.E0D#Y[G@Y'^D/_C2?V3#N!\RZR/\ IX?'\Z -'(HR*S6TB!CDR76?
M:X?_ !J3^S(O[\_7/,S_ .- %ZBJ/]G1\?OKH>PG?_&@Z;&1@R7)7T\]^?UH
M O49%4?[-B' >X"^GGO_ (T?V7!_>G_[_O\ XT 7LT9JC_9D./O3_P#?]_\
M&D&EPC_EI<_]_P!_\: +^:,U1_LR''#W''3]^_\ C0--C# B2XX[>>^/_0J
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MC!;!(S^.*N5GV)\O4+V$\ LLJ\]01@_J#6A0 57OHC+:RJOWBA ],XJQ0>E
M%;3I_M-E!-T\Q%;'U%6:S-$++%+$W!CE=<'TW$C]"*TZ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M85DXW-CKC' % CV*BO/#X1\7IQ%XYG(Q_'9(3G\Z3_A$/&/.?'4OX6*?XT[
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M*>82LV1Z*P)_3-<;\*<6.I>*-(4X2WOVFC4= LG(Q^5/H+J>CT444AA1110
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M/?D5CZHK07FEQQS2A9K@H_[P_,OEN<?F!5N^M_*M9)$DFW(C$'>3SCB@#04
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MG;<6X/MN0_X-^E8GC#P[#XC^V:5<2O MU%'+')&!N1T8\C\UK=U)2E]87 )
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MTK2;A;>*=F !>0[OJT9_GAA^5,8S6FOW;1 LDUN)57'!=>"/K@K^54+W4&N
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MN)YPJRSOO*KT48  _(5H44 %%%% !1110 5GD?\ $ZB//^H?_P!"6M"L]O\
MD.1?]<'_ /0EH T**** "BBB@ HHHH **** "BBB@##D'_%:P'//V"3CU_>)
M6Y6%+D^-;8]A8R_^C$K=H$@HHHH&%%%% !1110 4444 %%%% !1110 'I61X
M7&-.F][NX/\ Y&>M<]*R/"^/[-EQ_P _5Q_Z-:@#7HHHH **** "BBB@ HHH
MH ****  \BLO0_DMY8-^_P F1H^>HYR!^1%:E9MF!%JUVOR@3!91ZDC@_P A
M0!YEJ$EI9-?6$%G_ ,2+1]1#323WOD@2.OFM& %Y3YQ]X@98#H*]:MI5GMXY
M4SMD4,,C!P1FN6UW0K[4]6NEMUTVVLI8HS)-+:"=YW#$X(+ ?+A<$@]?:M?P
MO9:C8:3'!K%]]NNPQS+L"\=AP!V]: )/$,;-I4S1G#QE95)&<%2#_2K%Q"+R
MU3:VWE9$8#.,$$?RJQ.@DA=& *L,$&J6@,S:3;K(29(U\MSC&2IVG^5 &?K5
MM(EAYK3S2>6RR.&;:I4'YA@8XVD_D*UA:V_D&-(D$; Y4#CFIKB-9H7CD&4=
M2I'J"*P;36(['1+5[E9792;?]VA8LR9S_P"@&@"SX9.S35M68E[-VMSGJ0IP
MN??;M/XTU"+;Q3(F,"\MPX..K1G!_1E_*JD#-'K5Z(-JR7D2W$0=>-X&TY[_
M -W\JS8]0N8RMU>W,<\EK<J)/+B*A$?,9!SZ-S^%,#<\4*(X+>^^;_0IEF)7
M^[]UA^1/Y5;NKBTG1[265-\RE F<D@@_T!_*J\.F2/;WR7%V]S#=*RJCCA Q
M8XSWX;'T44_1;$C3[1KZ%?MD2!"Y )R!@D'WY_.D!0T>\GMM#BB2"2XN(6>W
MQZ[,@$D9QG:.OK3FCD.KZA9":2V-Y"MPDL>,JPPC8S[!?SK8LK%+22Y=&8^?
M)YA4XPIP!Q^56#&I8,0,CH<=* ,7^R9+6/2Q;32S-:R?.\K99T((.3CGM^57
M/[(M3:WD0C(6[W&4;B<[A@X]*T:* (XXE1%4#[HP*(H8XBYC4 N=S>Y]:DHH
M CEACE4K*BNIZAAD&LBS,]E=WTNHW,0LMRBW+.%"@#G(P,<\=3TK;K(O-/C%
MTDBVJ7&]_P!X7^8K]-QX'7@4 R.XU*R=UNK6!KV95*H\$>[@]M_3''K5?46U
M&XLUNC;PPK RSA6;>YV]1QP,C<,\]:U-4@M);%X;QQ'!C+?O-G ]\]*I_P!K
MPS0%;"&6\3!4&-?E/;[QP#^=,1KP.)8PZG*MR#[5)67X=9O[-6*12CP,T14D
M$@ \=/;%:E(9YY\6B!>>$MW3^U4S^1KT)#E017G_ ,4^=7\'8_Z"8XP#GY37
MH"_=%,2W8M%%%(84444 >=?$ [O'_@>-ONBZD;\?+.*]%' XKSGQYG_A9'@?
MT\^7C'_3,UZ,*8!1112 **** "BBB@ HHHH **** "BBB@ HHHH *SVXUR$'
MK]G<_P#CRUH50./[:0GKY#8^FX4 7Z*** "BBB@ HHHH **** "BBB@##?'_
M  F</7/V&3_T8E;E8;,/^$TB&?\ EP<_^1%K<H **** "BBB@ HHHH ****
M"BBB@ HHHH #TK(\+Y_LV3/7[3<?^C7K7/2LCPOC^S'Q_P _-Q_Z.>@#7HHH
MH **** "BBB@ HHHH ***CF$C*1&54]B1F@"0UDW9QK5D5SO9)$;!_AX.?S
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MMX][!B,@8523S["@":BJGVB9O]7;O]7(4?UIH2]D W2Q0^H1=WZG_"@"[D4
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M $::WZ "BBB@ HHHH **** "BBB@ HHHH **** $;[IK'\(,6T.,MP?-F_\
M1K5LGI6+X0_Y :9_Y[3?^C7I@;5%%%( HHHH **** "BBB@ HQFBB@ HHHH
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M'QRVW&?PI#):*** "DP,YI:,T %%)D9Q2T %%%,::-95C9U$C D+GD@?_KH
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MKA20/TQ6B>E96GLT6J7\!!VDK,OL&&#^JG\Z -6BBB@#.\00F?2;F- 2^S*
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M_7DG_HQZVJQDS_PE\O/R_8EX_P"VC5LT %%%% !1110 4444 %%%% !1110
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MF4#+!7;@YZ$[.#P>*M?;_%ZX!TZW/KB3_P"QHL*YV](2!UKA?[1\7JNY[&V
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MR3:!;H0IR@;G;],]!["K@10. !7ES>(?%)\QUDLC%'G>?/B^7GN>W>GV.O\
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M4\67BW/%Q#@]B3Q_X]0%SN<T5PD=IXP'#S0L,GJ3G_T*E^R>+R?];!]"Q_\
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M<'&.OX5O4C@%<$9H XSX>Q-%+JT3 ?N[EEZ5VF*Y/P7G^U/$&1_R^OCGW/\
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M\L]:['QLLC^&[\6Z&24Q%0H&3S[5R?@2W:TU^&WD21'CL2I#^H\L'^6?QHZ
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M*SM-US2]38+I]_:W+%2^V*4,< @$X'3DC\ZT: #%%%% !1110 4444 %%%%
M!1110 5D>)!G3F Z^;"?_(JUKUD^),?V<V>1YL/_ *-6@#3C8"-?I3LBOGWX
MR:E9V?BZ2)O%VLZ9+Y*%[>UC+Q@XZ\,.2,5PRZ]8DD'Q_P"(L@?\\&&/_(E
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MY(RI!5?D&1QC!!!R#T.:](N%9XW"?>*D"N M]*N-'U#1;>[:!@+C<K1;N3M
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M!_9$VGV5M!]IU+493#;0D[5X&69CV51R>#3YKG5[.ZLVNA8R6#;OM4JAHS
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MV3]W@'WY/YUU5<_H5P9-7O(APB11!08@,_*#D-WZ].<?C704@1QL1 ^*4O\
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M.V>11ECDG ; R:8&I]LM\9\^+_OL4OVJ#:#YT>#R#N%9*^%=)7I!)_X$2?\
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MD\_Z6G'L?\*/^$ITDG O(\^X(JY_8NFY_P"/"T_[\K_A2MHVFL,&QMO^_0H
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M!%;ILAC6-?11@5)112 **** "BBB@ HHHH **** "BBB@ (!&#1110 4444
M%%%% !1110 4444 !S^%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]JFE:U<7DKVNL+#;
MN,)%Y6"G'J#R?K63)X/O[F8->:C;R@<Y>%Y#_P"//C]***?,T!J:#X0T[2;P
IWNTW%]@@32*HV@]E50 OX"NCQ112N 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image00006.jpg
<TEXT>
begin 644 image00006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  ^ '0# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZIHHH)P*
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M>)AC[) Q6(>Q/5OQXK:L[.WLH1#:0I#$.BHH J>@9#;6T5M D,$:1QH,!57
M%38HH)Q0!'((QEGP..2?2N?LD;7-0:[F7_B6PM_HR'I*P_Y:$>GI^?I4/B[5
M@VG?9[/=-YT\<$K1G 168 Y;I[?C6QI8NE5$EA@AB10H1&+8Q[X%,1H@ =**
M6BD,\VN-2N?%TP33PTFD!P-JDJDN.I=^ZY_@')[XKJ-+\/1(()[UA<SH!L&
M(XO9$' _G6W;6\-O"L4$21Q)PJ(, ?A4W2G<5AL:!!@4ZBBD,**** "BBB@
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H=>);R"\U2"2VT^W=9K:UD&'9QG#R#VX('YUUJC:H I:* "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image00007.jpg
<TEXT>
begin 644 image00007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !# (,# 2(  A$! Q$!_\0
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>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image00008.jpg
<TEXT>
begin 644 image00008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !A ' # 2(  A$! Q$!_\0
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M@"]1110 4444 %5[ZXBM;:2:=ML:#<34[' YKFFG&LZCLDVC3K5LENTS@?\
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1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image00009.jpg
<TEXT>
begin 644 image00009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" -N S@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!&^Z:IZ;&T<EX6((>8L,=A@#^
ME734-O&4+ECG<Q/3% $U%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 TYW#TIU%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !35!
M!.3GGBG44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 444UW"C)('U.* '450AU."XN!#;.)F*E@R<K@''WNF<
MU=C+%?F&#0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *0#%+10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% &?J5^+-HD WSS-MBB'5O
M4_0#DU$-,\Z]DGNYI9D?&V G$:#!!&.^<]ZNM;;KHRLQ(VA50CA3SDCW.:L4
M 1V\,4$82&-8T7@*HP!4E%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRJ%CG>!W&*M4FT=P* %HHHH **** "BBB@ HHHH **** $4DYW+CGCWI:**
M"BBB@!LC[%SM+>PIU!QWHH *BBF\R21-CKL(&2,!OI4M% !5:YNEAEBC97)E
M;:I R!]?2K-&!Z4 (K!AQ2U%A5G']YE_05+0 4444 %%%% ",P7J<5D:GXDT
MO3+J.WO;D1S2'"KL9L_D*T+BU6>:)W+_ +LDA0< _4=ZE,2%LE03UZ4 .# J
M".AZ4M&** *]Y>06B@W$@0,<#/>I()DGC5XSN5N0:<T:N064$CID4JJ$&%
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M %%%% !1110!%*BET+9XSCGC\:EIK$4Z@ HHHH **** "BBB@ HHHH ****
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MK6OVFD7<45Z\<,;Q22^9(^T?*,D#U/>MJO.?B]8:KJO]E66DJK9=YW5L ?(
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MVG7*M=Q2X9YGMCYK$'>C$%0#[J>!]:NZ;J%IJ5N+C3[F*Y@)*[XF##(ZC(H
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MRZQ_::VE^;=K>"!@?WT4C!MV $V\A ,<'\_5DW/3P,=*6BBD4%%%% !1110
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MQDYR* )Z*** "BBB@ I-B[MV!NZ9Q2T4 %%%% !1110 4444 %%%% !1110
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MGW.3S0(VZ*9#$D,2QQC:B@ #T%/H&%%%% !1110!%#YGF2;PH3/R$'DC'?\
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M!'(1^)ICXM:UQ"--,QL5<G#?: @<_A@D?45%?>,IK>TU2]DT_;8V4S6RR/,
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M8J%FNR'+;I=Q!_A^5>/\^M7#TJAIC;I+LD8/G$?7 % %^BBB@ HHHH ****
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M^J:'=V@UBRB,J863S48*V1M.,\C=B@#@/"&J:G+\*O$%_<QW%Q?BX9R9"29
M G\@.GM6]\',RV^JW80K%-,HC"%C$H )VINYZL2>W(QWJWIR:3!I6IV^N:_8
MR2:A<&:9H+A80N0H 7#9'"C//<UH^#$\/Z>9;+0]5%VS?/Y;7?G$8Z[>??G'
MM0(ZNBBB@84444 %(W"FEH/0YZ4 ,A;=&K'/(SS3Z9"RM&#&<KV-/H ****
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M\JFC.4!Y'UH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSP4_AG1[[[%I6LR74]XBE$EF+C"Y^[Q@$Y/%)X:\1Z1J%KJ>I".S32;-8_\
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MYW*7#AY%7Y?E7<.!T/'Y5)XJT&\_MCP\DFO7;>9?[D1@O&$)X^7J,'CW/I3
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M!>*&MKE K6S@MPC<<>WZBL_Q1XQT^ZU7PY,EM>E8+\,2UHZM]Q@,9')YZ=:
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M]DMGMV)VJ!8R1G)[?='H/RIL#I**!12&%%%% !1110!#/=06_P#KY8X^GWF
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MWQP-EI]O;G3D\R- H+2LV"!CT]JS['XU7UM>7EPME;L;E@0I)^7:H'/N0.M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%1RG"DXZ#-24V0@+S0!\URLL/[0L(;@?VCT/(^9<<>E?2PZ5\N3Q2']H"-;D
MB)O[31@"<Y'5?S&*^HEZ4"08&[.!GUI:KW3I;JUQ*[*D:G/)QCZ=S26=REU
MDT6_8XR RD'\C0,LTR8[8G;T!-0/= 7BV^R7)7?NVG;],U),^(V^1FX/ [T
M>-?!^VG&M7E]=VP5-1M)98E$87?&) !@ =>3D>FVI?A2D4WC35IX[#45M8V9
M+=IF)2W.264@]#G/KCD>]>@>%O#MCI3_ &JTANHBZ[%BGE+"%3@E4!Z D#\A
M6RTDD4DJQP$JHRK>K'M3N)%VBJ:WT8N!;2-BYVAMGK]/6KE(84444 %%%% !
M3)03&VW&['!-/HH \[\$S>*XM2@C\21R-#<&4KM4$(.""Y'3G( ]Z]$HHH$D
M11\3/\N!USGK4M5DD3[8\8P'VAL8Y(^M6:!A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !69I4PFGO=C;@L[*?8@#B
MM,]*Q]!<O<:H220MT5&?95H V**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HS17GOQ:U;6='LM.N=)OK>SMWN!!<R2INV*W1OH/\* /0LT9KY8O
M_B?J\%R\2>*;DJK%,QV2MVSFJ\GQ3\31LCQZO=2N$P4:U !<#IQWZ\=\4["N
M?5^>:,U\IVWQ1ULV]O)-XDD6;S-LD?V8$;?[V?J>G:GGXIZRL-RR^)G:7?\
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M/RV%J/3]RO'Z5JXHH SO[(L0N!:P?]^UY_2H#X<TDMG^SK3DY)\E<G]*V**
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M-+6-X1U"35?#]E>S.CR2IEB@XSD@@5LT %%%% !1110 4444 %%%% !1110
M4444 %%%%  >E9^D%2UX%S_Q\/GZ\5H5F:0-MUJ8# _Z3T],HA_K0!IT444
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MG=A5&?T_2M!CA36;HSLSWV[^&Y8#Z8% &G1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '*_$W1VUWP7JFGH0'EA)5B"<,/F''U KQ']F_5%
MM/%EWIQ5PMU"74?W2A[X_P!X]?2OI.X567#D;3P0>]?*<LI\#?&IEMRT4"WN
MUL\_N9"IZ],8;]*: ^L:Q/$4XBC@,DPA_?+@[PF_T7)]>E:\+;T![$<5@^*H
MXG@C:9))%CE! 11P2I&<]NO6A <;97<PLA)9Q37ES>7,A$MI\^U<C(+OTZ#@
M#T],U'?FYGOKB3R%,FU#\N9<!6.""<*O0Y(J?^TK^6&*[GMXK6U27RQ##FYE
M8<J#QP#GFJMY;:G>MY4<4EM:1LRB6YS)(Y)[1CCN>O2F2->]']IYN &9XV@,
M)5IP4Y/*CY03@>M5]'2:[NE6]62&TDAPBO)MQEN/W2?AU)XJXNA:G=S0S:?8
M2(44;)[Q]BKVSY2XY^OX5T=AX*2-Q+?7EQ(W&8X<1)QST'.,\XS0!5N;DQZQ
M:1VZM;)#<!70L(PZX^\%&2PZ"NS2Y)CA,,9='8C/3:.>:6UT^V@50D$0*\*0
MO(JUL7T%*Y1%B9G4E@J8Y4+DY^M(UI$TC.P)+8SD\'%6**0#554    '  IU
M1W">9$0 ">V:>HPH[>U "T444 %%5IKV"%]DDJ*^-VTGG'KBH);Z0IFUMWF)
M4LO\()],GI18+E_/.*:\J)]Y@/J:P-5NKV'5-+B>9(K:Z9X6"+EM^PLN#_P$
M]JTH-*M([E;DQA[D)L\USN8B@!\EZ?,DCCB9GCY;/ QZYJG9WTNH-<1[!!/;
MS^4RGYLKP0?Q4_A6QM%8 D%EXO:/"+'>P!R2<9=#CCUX(_*@#<@1DC"NQ=AU
M8CK46I6JWUA/;.S*LJ%24."/<>]6-P'4BEZB@"II-VM]IUO<K_RT0$CT/<?@
M<BK=9.A6LEB;RWDDWKY[RQ?+C".=V/P):M:@#G_&LC6NDK?H7S93).P7^)0<
M,/R)K=A<21JZG(89%1WT$=S:2PS*'C=2I4]#570[F.>P01N7\HM"Q.<AD.TY
M_*@#1-8>JQO%K6FWBD[0S0.,9RK#C_QX+^M;E9WB"!I](N5C7?($+(/]H<C]
M0*!,T0<T5E0ZK;QZ/'J%Q(L<#1J[.3P,C_'BN>O_ (E>'K>26%+OS9D3=M5"
M >F!D^YH&=M03@<UFZ)=SW=NS7<2PS*[(523>"!T/XBH/%U_/IOA^\NK4 S(
MN%8C(3)QN/L,Y/L* -?>.:YOQ-,8;C3+^)8WBM[M4E8]55P4)_#*UYCJ.K>,
M+G4/LFDW4NK"2)XVD@A\F-,DKN+'@D<'C@UVV@Z1=CP;J%G<Z<EC/)&X6,2%
MR[A?OY]SS3%N;?C+7)M&T/[;9QQR2-(D:>:VU!N.-S'L!UKS/4O'?B>?4[O2
M;"*QNII@(X1:,QV[E))W$=5P>?IUKTW3IK?7/"<)GB2>">!1(D@X/&#G-<'#
MXLM;>YB.B)I]G86]]]CFC==K/E@-RGL,;C^%-"9IP:/-J/@/5K2.TO;61F\V
M-;Q_,<R+A^/;(Q72VAM/%'@^ 7Z,]O=P 2I@H<CJ/48(K<B9+BW+*VY&'##H
M1[5A>'(C;WVK6#OE4N&D5,#A' 8?KNI7'8XT^+K*RU*W?3;&!K#[=]FNYF'[
MQ'Z!_H<=3UXKU*15N+1E;[KJ0?IBN:_X0'PXMV)DTR('S!*5'W2X_B([FNJ
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M6T*** "BBB@ H/2BB@"CI6FP::MP+8,!/,T[ G/S,<G%7J** "BBB@ HHHH
M**** "BBB@ HHHH **** "BB@\B@#(FUN!IOL]F#=SE6.R,C QV8]J;X;BNX
M[>>74$2.>XF:8Q(=P0'  SW. ,T:AX>L;RX2=HS#<Q@A)HFVN,]?KT'6J%T=
M7T2R:1+N&^CB!9A<,(V([#=T]>30(ZBBL?PWK]MKT$LEJDR^4YC<2(1@CT/0
M_A6Q0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!",U\U?M)Z=_
M9_BJPU>/RU^T(J$XR<HW7ZX/\J^EJ\J_:(TYKOP*]PJAC:SQR9QR%S@_S%"
M['X?ZP-<\*Z=? 8\R%21Z<5;\1:9_:=JENT4<D;."^\D;1[8ZG.*\X_9JU,W
M7A"YLG(S:W!V#=D[& /Y9S7K5U&98657*'LPZBGU P-.\-FVD0RW;M$A;;%&
M@C0 ]!@#H/ZUOQ6\<0(C4*"<G ZFG0MNC4MU(!J3I2 3&.F*6BB@ HHHH **
M** "JUS=) &R22 ?E49-6::8UW9VC.<YQ0!3\ZYDWK'"49?NLYX/O@?A56YM
M+ZXM)XYKLH9(@JF ;3&V#D@]^<?E6QBD- '/^$X8YM-MKB=8Y;Q8_*FFP"S.
MO#<_45T.*YW0R+3Q!J]BJA$<I>1C/7>"&_\ 'E/YUO23)'C>RKDX&3C)]*!(
MP_'%M--H;36:YN[21;F'_>7M^(R/QK7L+A+FR@GAP8Y$#J1Z&IIAOB92 0PP
M0:Y/P\E]9^&;C3[+RS=6,TD$(D&0RJV5S]4(Y]33 ZX'-9'B$K!%!=N=OD3(
M=V.Q.TCZ'-97P_U.^UB/5;J]CGAB^UM'##.H#(%50>G4;MV*Z#6K(:AI5U:-
MQYT;(#Z$CB@-T8VK^)X['6H-+,/^D3"-HV9L*ZLQ5L>XP./<5TJ'<H-<_H:V
MFO:;IU_=6T;W,'0NN6BE'RMC/0Y!KH%&.E($4;R=H-2LQ_RSGW1'_>QN'Z*U
M7ZS?$ *Z;)<(!YMO^_0XS@KR?S&1^-0ZKJ?D>'9M2LP9OW!EB5!NWDCY>GOB
M@9KM@C!YKGM'B>QU[58&<-'<2"ZB7G*Y #9_$?K7,:3XCUS5=4TRXCTZ\BM)
M=B/&XVHG42LY(SQQCUKHM9%Q;:OHUY"=J><;>Y !8;7''/;Y@O-%A7ZDWB3Q
M19Z%<6]O=;_.N$D:( ?>*KG;]3V%9_@WQ2_B/[5#(B(\21R$IDKAUSMY[C!!
MI?'#:;:K;WNJ:>]W!O6-Y H981N!#'N,''(JK\//$2ZT^HVJV:VCVKCY%0C:
M#G /OCG\:87U([;0X9]+OM!CE:)[6X6X@EQD+EMZ''0@'(Q[5SSZ'H_]O0MK
M.J3ZC>2;DEC"@1;OF3)';&_ Y].M=H[_ &#QU$K$"/4+0H,YQOC;/YD/_P".
MUC+\,+%M>FU274;QY))FDV9 4*Q!9.G0D _A0*QV>AZ39Z/9_9["/9'N+'/)
M))R23UJ[.H:%PP!!&"".*6*,1J O  P*<PR.#BD4>6KXYF>\U119RQKIU[#'
ME8B3)"S!23^/S9'^->G1D-"&YY&:!!&&+;5R>"<=:D(XXH%8YKPQ;+IUWJ.F
MC:8E?SXAG)".22#_ ,"W8]JTWT+39)!))8VK.K!U)B!P1WJ&33)5\1)J4#(%
M-LT$B')+?,"I';@[OSK87I38"*,#'\JQ+BQN4\56]];@FVDA,4ZYP 0<JV.Y
M[?2MVBD,**** &,N3G.,4JG Y-8&M>*+#1]:LM/OI%B:[5BCL<#((&/UKD9[
MW4?$2ZA+#X@_LNWANS:&%4&Y54XY/4%B./K3L)L]*DGC1@&D0,>BYY-84_BW
M3(]+:_%P#;+<BU+XZ/NV_EFO+-/TB;^U+^2U^VW^NZ->HZ[Y21/ <Y4%B #A
MCTZE16K<>$M3\0HT4MH+'1KG4ENY;1I-K[-@W?=XSOR<?RHL%SN;37KN7Q9/
MILL,2V@MEN()E8DRY.#^7]:Z9&#*"""#W!KQT>%=+TA(CXF\4SDVL3HD/G"-
MDC<]"1\Q'W1^'Y]OX/\ $.BW7EZ1HID*6L*[?W;!=G13D]<XZT,$=91112&%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 C&N:ATFUU/6;ZXO\W1@E"1QR#*1_(I
MX'XUTK=*Q?#A+7&L,5 !O6Q@]0$09H V8T6-0J  #L!3J** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *P/'.GG5?"VJ6*@%IK=U7(S@XXXK?
MIK#(- 'R_P#L\:M+I?C"73IF5$NXRA0\'>@ST]>O'M7U F2OS=>]?)?BY)O
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M">-MR@CH1D4^L?PE<&Y\/V,CY\SRE5\G)W+\I_4&MB@ HHHH **** "BBB@
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M!',89@RR1R+U5E.0:O01E(PK<GN?6I**!A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% # F6RV"1T..E/ P*** "BBB@ HHHH **** "BBB
M@ HHJ*>>.#9YC!=[;5R>I]* ):* <T4 &:*P=3O&M/$&D*7S%<F6!@3C#;=P
M/_CI'XUO YH "0!STK)M=3:37;[3Y(POD)'(C _?5L_R(-:K#(P:Y;5F-EXX
MTB=OEBNX);9F[%U^=0?PWX_&@#JJ#TH%% '*>#4:QU3Q!IS!@D=X;F(D=4E
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ME4?TJV:KVK!I)L8X;!_(4 6**** "BBB@ HHHH **** "BBB@ HHHH ****
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M?:)1%Y;+$C??RN6^GI4?]F)+&PNW>8L0QR<#/MCI6A10 Q8D0850!Z"GT44
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MV*2;[;$V4V_-+GRR,]T^7</>NW9?LWQ+5)&_=WVG953T+1OSV]&'>NN$:A0
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M9],+FLNXU77[N9X]-T<P1YPL]VX'7N%&>GI0%SK-P]15:YO[6W!\ZXB0^A8
MU@V_AZYN$!UC4;F8E65TB?RT8'U Z\5H6>E:9I_,%O;QF,'+8RX'7J>:8C/E
M\23W$\D.C:;<7KQMM9V/E1C/0[FZCZ>E;>D&_:T!U5+=+@DG; Q90.W)[U1T
MOQ)INI:C)9V$RS,B;Q(A!1A[$'MD5MT@"BBB@84444 %%%% !1110 449HH
M***"<"@ HJEI]Z+F2[C. ]O+Y; 'V!!_(BKM ",<"H[:9+B)9(F#QMR&'>I3
MTK"\*,4M[RU*A?L]W*@4= NXE?T(H W:S?$7VC^Q;TV9*W"Q,T9']X#(K2I'
M *D'H: *>BWBZAI5I=H<B>)9.O3(SBKM8/A%3;6$ED[ FVGDB7C'RYW+Q]"!
M^%;U &3XHL9-1T:XMX"HGQOB9N0'4Y7]15G1Y_M.GVTQR&>-6(XX.*N-R*YS
MP.SK87=K(^XVEW- N3SL#$KG_@)%/H!TE9GB:WDNM!OX8&VRO X4XZ''%:6:
MS-1UG3K50+B\MTW/Y0#..6]/\^M("70KL7VD6=T 1YT2O@G)&1TJ_7 Z?JL'
MA/POJIN?,:'3KF4[8^2J,V]1^ < U3N/B9977E6VGDI=7EB]U:M.?+4%<C#9
M/L?KBG85SKO&&GMJGA^\M(SMDD3*G)'(.1_*I]#OEN=/M9&949XD;83SD@9_
M7BO&?"?C'7=1UWP]%+<37*SAX9U3 #E"PD8^P^3!''S'UJ6#PSK.M>(]/NK5
MBD5A+<6\Y$Y'S)(YBW#T^89'H3185SUC7/$VGZ1]C^TS+MNF*1D$8.%))SGI
M@&N7O_$L'B/P?=:A:I-%)I\J3E&!4Y0AP>.Q7GZ&N3L_@W=W1M4UK5I;BVCD
M65HNV6 ,J@]@2JX]!FO0=!\'6F@:'J%C:F687>\LTI!8#;M5?HJA1^%&@SE]
M6\4^)5U[6+33TCN(+:SCFACCC.\M)PO/M@G''%9MOI_C/7M>BNM6TY8K&:U:
MTN87E&P H=Q '/S$C!&<8->A?#J1;CPK82NT<MPD7D2R*N"63Y2#^(KJ,47"
MQYS)I]YI_@;1'U<(+S3'BDFVMD;5.ULG')VD_6MC3?!>@DO<BU69IKIKXF3G
M]XXY./H:W?$%D+[2+NW(SYD3+@],XXJ/PM.+G0K*4!06B7.WID#!Q^5'0!++
M0-+M5 M]/MHPH"#$0&%&<#Z#)K-\;6_DV=A>P(@>TO(6STPA<*V/P-=365XI
MMY+K0+^&!5:9H6\O<,C?@[?UQ2&:<8 4#K3L5G^'[P:AHME=C:#-$KL <X)'
M(_ UH4 <MXN=[/4M%U%0 D-T(9#_ +,@*_SVUU"D%1BN?\;V]S<>&K];&'SK
MI5$D28R692"/QXK7TUVDLH)'C>-G169'&"IQT-,"T:X_QK"+75?#^KKNW6]X
M+=L 'Y)?E/?UV_K785%<6\5S'LG173(.TCC(.1^H%(!+B9;>$N02 ">*;9M(
M\9>0@ACE<#&%[ ^].N83+;R1HY0LN P[4^)2B!222!C)[T 4KK3%GU:RO][*
M]J'4*!PP< '/Y UH444 %(!@YI:* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ K+TG'VS4L+C]^ 3NSGY%_*M2LO2W=M1U-7)PL
MR[<CML7^N: -2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQLR@2WDE&WS9=V"N#Z<Y^G7K@L%SN+6X\KQE?6H9V$]O'.F!D##%6_\ 9?\
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MM8VX!%PN>?\ IFM &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT^-X[5-B/(TI&?XF.35NB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^K6L5[I]Q:W"!XID,;*>A!&"*^6/AH\_A/XLV]G<[HP;IK-T!S]X';^&2#3
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MI8HF=8R<;B!G% %_(-%5M/G2ZM(9XN4D0,I]B,U8)'K0!#)=P1W,=O)*BSR
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M1X()QY2]?\_SK?-96FQJNI:H47!>12Q)Z_(!0(U:***!A1110 4444 %%%%
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M?:M/N8,@>;&R'/N"*EEN(H5W2N$ ZEN!5*ZUNPAAWF;>N[9^Z4OR>@XI 5/
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M%% !4%Q.8I846-G\QL$C^'WJ>C% !1110 4444 %%%% !1110 4444 %%%%
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MI>!;B/SXOM-O*DT:EAN+ \@>Y!/YUSO[,FK;]'U+3)9,M%,)43L%8<X_&GT
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M6-#(?^$KO$*KM^RPL#WSOD!_I0!LT444 %%%% !1110 4444 %%%% !1110
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M4_4UX[I_P>\9WNS[6T%J"23YDN[/OQGFNRT3]G^U3:=;U.2Y .=D(V _CUH
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718444925272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 12, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Brooklyn ImmunoTherapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000748592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-1103425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10355 Science Center Drive, Suite 150,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">582-1199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,451,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Marcum LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York, NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718449276232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 16,985,000<span></span>
</td>
<td class="nump">$ 1,630,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">684,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,097,000<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">18,766,000<span></span>
</td>
<td class="nump">1,732,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">670,000<span></span>
</td>
<td class="nump">594,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating leases</a></td>
<td class="nump">2,567,000<span></span>
</td>
<td class="nump">2,093,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,044,000<span></span>
</td>
<td class="nump">2,044,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">In-process research and development</a></td>
<td class="nump">6,860,000<span></span>
</td>
<td class="nump">6,860,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in minority interest</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Security deposits and other assets</a></td>
<td class="nump">522,000<span></span>
</td>
<td class="nump">453,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">32,429,000<span></span>
</td>
<td class="nump">13,776,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,755,000<span></span>
</td>
<td class="nump">1,275,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,249,000<span></span>
</td>
<td class="nump">1,051,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">410,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PaycheckProtectionProgramLoanCurrent', window );">PPP loan, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">116,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">426,000<span></span>
</td>
<td class="nump">273,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">247,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,677,000<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">19,930,000<span></span>
</td>
<td class="nump">20,110,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">2,297,000<span></span>
</td>
<td class="nump">1,905,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PaycheckProtectionProgramLoanNonCurrent', window );">PPP loan, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">194,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">25,927,000<span></span>
</td>
<td class="nump">25,357,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' and members' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.005 par value, 100,000 shares authorized, 52,044 issued and outstanding at December 31, 2021; no shares issued and outstanding at December 31, 2020.</a></td>
<td class="nump">260,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">165,944,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(159,703,000)<span></span>
</td>
<td class="num">(37,381,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' and members' equity (deficit)</a></td>
<td class="nump">6,502,000<span></span>
</td>
<td class="num">(11,581,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' and members' equity (deficit)</a></td>
<td class="nump">32,429,000<span></span>
</td>
<td class="nump">13,776,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Membership Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' and members' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Common units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,202,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Membership Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' and members' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Common units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Class C Membership Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' and members' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Common units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btx_CommonUnitsMember', window );">Common Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' and members' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Common units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">198,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' and members' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A preferred stock, $0.005 par value, $156 liquidation preference, 156 shares authorized, issued and outstanding at December 31, 2021; no shares issued and outstanding at December 31, 2020</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PaycheckProtectionProgramLoanCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loans related to Paycheck Protection Program classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PaycheckProtectionProgramLoanCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PaycheckProtectionProgramLoanNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loans related to Paycheck Protection Program classified as non-current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PaycheckProtectionProgramLoanNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of member capital in limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btx_CommonUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btx_CommonUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718448037272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders' and members' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred stock, liquidation preference</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">52,021<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">52,021<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718445035400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 12,705,000<span></span>
</td>
<td class="nump">$ 3,951,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ResearchAndDevelopmentInProcessAssetAcquisition', window );">Acquired in-process research and development</a></td>
<td class="nump">80,538,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">14,724,000<span></span>
</td>
<td class="nump">3,297,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashMergerRelatedCosts', window );">Transaction costs</a></td>
<td class="nump">5,765,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(180,000)<span></span>
</td>
<td class="nump">19,240,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">113,552,000<span></span>
</td>
<td class="nump">26,488,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(113,552,000)<span></span>
</td>
<td class="num">(26,488,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on sale of NTN assets</a></td>
<td class="num">(9,648,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">899,000<span></span>
</td>
<td class="num">(43,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expenses, net</a></td>
<td class="num">(8,749,000)<span></span>
</td>
<td class="num">(43,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(122,301,000)<span></span>
</td>
<td class="num">(26,531,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(122,306,000)<span></span>
</td>
<td class="num">(26,531,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Series A preferred stock dividend</a></td>
<td class="num">(16,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (122,322,000)<span></span>
</td>
<td class="num">$ (26,531,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (2.82)<span></span>
</td>
<td class="num">$ (1.51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (2.82)<span></span>
</td>
<td class="num">$ (1.51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding - basic (in shares)</a></td>
<td class="nump">43,306<span></span>
</td>
<td class="nump">17,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted (in shares)</a></td>
<td class="nump">43,306<span></span>
</td>
<td class="nump">17,588<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ResearchAndDevelopmentInProcessAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a asset acquisition have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_ResearchAndDevelopmentInProcessAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718442034296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY (DEFICIT) - USD ($)<br></strong></div></th>
<th class="th">
<div>Membership Equity [Member] </div>
<div>Class A [Member]</div>
</th>
<th class="th">
<div>Membership Equity [Member] </div>
<div>Class B [Member]</div>
</th>
<th class="th">
<div>Membership Equity [Member] </div>
<div>Class C [Member]</div>
</th>
<th class="th">
<div>Membership Equity [Member] </div>
<div>Common [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Preferred Stock [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Preferred Stock [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 18,178,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,942,000)<span></span>
</td>
<td class="nump">$ 9,743,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_EffectOfImplementationOfNewAccountingPrincipal', window );">Implementation of new accounting principle</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,000<span></span>
</td>
<td class="nump">92,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Sale of members' equity</a></td>
<td class="nump">5,024,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,024,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,531,000)<span></span>
</td>
<td class="num">(26,531,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">23,202,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">198,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(37,381,000)<span></span>
</td>
<td class="num">(11,581,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits', window );">Brooklyn rights offerings membership units</a></td>
<td class="nump">10,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity', window );">Elimination of Brooklyn's historical members' equity</a></td>
<td class="num">(33,702,000)<span></span>
</td>
<td class="num">(1,400,000)<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="num">(198,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodValueAcquisitions1', window );">Common stock to be retained by NTN stockholders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8,170,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodSharesAcquisitions1', window );">Common stock to be retained by NTN stockholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,514,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders', window );">Issuance of Series A preferred stock retained by NTN stockholders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders', window );">Issuance of Series A preferred stock retained by NTN stockholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountAcquisitions', window );">Issuance of common stock to Brooklyn members</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 195,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(195,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsAcquisitions', window );">Issuance of common stock to Brooklyn members (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,924,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock to Financial Advisor upon consummation of merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,760,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock to Financial Advisor upon consummation of merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,068,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock from the exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock from the exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodValueStockPurchaseAgreement', window );">Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">52,008,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement', window );">Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,552,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodValueAcquisitions2', window );">Issuance of common stock in connection with the acquisition of Novellus, Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">58,649,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">58,684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodSharesAcquisitions2', window );">Issuance of common stock in connection with the acquisition of Novellus, Inc. (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,022,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Cash dividends to Series A preferred stockholders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="num">$ (8,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsShares', window );">Cash dividends to Series A preferred stockholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodValueInLieuOfDividends', window );">Issuance of common stock in lieu of cash dividend to Series A convertible preferred stockholders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodSharesInLieuOfDividends', window );">Issuance of common stock in lieu of cash dividend to Series A convertible preferred stockholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock', window );">Forfeiture of unvested restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock', window );">Forfeiture of unvested restricted stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,235,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,235,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(122,306,000)<span></span>
</td>
<td class="num">(122,306,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 165,944,000<span></span>
</td>
<td class="num">$ (159,703,000)<span></span>
</td>
<td class="nump">$ 6,502,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,021,000<span></span>
</td>
<td class="nump">156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease (increase) in additional paid in capital (APIC) for the increase in redemption of temporary equity as the result of a triggering event associated with the temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_EffectOfImplementationOfNewAccountingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of implementation of due to new accounting principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_EffectOfImplementationOfNewAccountingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares Forfeiture of unvested restricted stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodSharesAcquisitions1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodSharesAcquisitions1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodSharesAcquisitions2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodSharesAcquisitions2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodSharesInLieuOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period in lieu of dividends to be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodSharesInLieuOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the shares of new stock issued of preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been issued in a stock purchase agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodValueAcquisitions1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodValueAcquisitions1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodValueAcquisitions2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodValueAcquisitions2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Forfeiture of unvested restricted stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodValueInLieuOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period in Lieu of Dividends to be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodValueInLieuOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued of preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to rights offering membership units during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodValueStockPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been issued in a stock purchase agreement during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodValueStockPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the different classes of partners' capital accounts during the year due to acquisitions. Partners include general, limited and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 4.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnitsAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the number of units for each class of partners' capital accounts during the year due to acquisitions.  Partners include general, limited and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=66023778&amp;loc=d3e9334-128500<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=66023778&amp;loc=d3e9337-128500<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=66023778&amp;loc=d3e9298-128500<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 05<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=66006417&amp;loc=d3e8580-128490<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnitsAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718445301064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (122,306,000)<span></span>
</td>
<td class="num">$ (26,531,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">117,000<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,235,000<span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-to-use asset</a></td>
<td class="nump">342,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashMergerRelatedCosts', window );">Transaction costs - shares to Financial Advisor</a></td>
<td class="nump">5,765,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on sale of NTN assets</a></td>
<td class="nump">9,648,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_GainLossOnDisposalOfFixedAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan', window );">Gain on forgiveness of PPP loan</a></td>
<td class="num">(310,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ResearchAndDevelopmentInProcessAssetAcquisition', window );">Acquired in-process research and development</a></td>
<td class="nump">80,538,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(180,000)<span></span>
</td>
<td class="nump">19,240,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Account receivable</a></td>
<td class="num">(659,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(850,000)<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets', window );">Security deposits and other non-current assets</a></td>
<td class="num">(34,000)<span></span>
</td>
<td class="num">(90,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(485,000)<span></span>
</td>
<td class="num">(930,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liability</a></td>
<td class="num">(322,000)<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(23,488,000)<span></span>
</td>
<td class="num">(8,101,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(154,000)<span></span>
</td>
<td class="num">(39,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfAssetsInvestingActivities', window );">Purchase of NTN, net of cash acquired</a></td>
<td class="nump">147,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PaymentsToAcquireProductiveAssetsNet', window );">Purchase of Novellus, net of common stock issued and cash acquired</a></td>
<td class="num">(22,854,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from the sale of NTN assets, net of cash disposed</a></td>
<td class="nump">119,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(22,742,000)<span></span>
</td>
<td class="num">(39,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds of common stock issued to Lincoln Park</a></td>
<td class="nump">52,025,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Proceeds from sale of members' equity</a></td>
<td class="nump">10,500,000<span></span>
</td>
<td class="nump">4,359,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from loans payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PaymentsOfPaycheckProtectionProgramLoan', window );">Repayment of NTN's PPP loan</a></td>
<td class="num">(532,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on notes payable</a></td>
<td class="num">(410,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Dividends paid to Series A preferred shareholders</a></td>
<td class="num">(8,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">61,585,000<span></span>
</td>
<td class="nump">4,669,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">15,355,000<span></span>
</td>
<td class="num">(3,471,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">1,630,000<span></span>
</td>
<td class="nump">5,101,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">16,985,000<span></span>
</td>
<td class="nump">1,630,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_CashPaidDuringThePeriodForAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend', window );">Issuance of common stock for Series A preferred stock dividend</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock for business combination</a></td>
<td class="nump">8,178,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_IssuanceOfCommonStockForAssetAcquisition', window );">Issuance of common Stock for Novellus acquisition</a></td>
<td class="nump">58,684,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ForfeitureOfUnvestedRestrictedStock', window );">Forfeiture of unvested restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger', window );">Preferred shares issued in connection with reverse merger</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance', window );">Initial measurement of ROU assets, net of tenant improvement allowance</a></td>
<td class="nump">816,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_InitialMeasurementOfOperatingLeaseLiabilities', window );">Initial measurement of operating lease liabilities</a></td>
<td class="nump">866,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_InvestorDepositsForSaleOfMembersEquity', window );">Investor deposits for sale of members' equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">666,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,093,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_CashPaidDuringThePeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_CashPaidDuringThePeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ForfeitureOfUnvestedRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Forfeiture of unvested restricted stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_ForfeitureOfUnvestedRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_GainLossOnDisposalOfFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of fixed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_GainLossOnDisposalOfFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on forgiveness of PPP loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security deposits and also includes any other non-current assets which are not separately reported in during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_InitialMeasurementOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of initial measurement of operating lease liabilities in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_InitialMeasurementOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of initial measurement of ROU assets, net of tenant improvement allowance in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_InvestorDepositsForSaleOfMembersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of investor deposits for sale of members' equity in non-cash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_InvestorDepositsForSaleOfMembersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_IssuanceOfCommonStockForAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The issuance of common stock for asset acquisition in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_IssuanceOfCommonStockForAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of issuance of common stock for Series A preferred stock dividend in non-cash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of preferred stock issued in a reverse merger transaction in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PaymentsOfPaycheckProtectionProgramLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for payment of paycheck protection program loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PaymentsOfPaycheckProtectionProgramLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PaymentsToAcquireProductiveAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets excluding cash acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PaymentsToAcquireProductiveAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ResearchAndDevelopmentInProcessAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a asset acquisition have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_ResearchAndDevelopmentInProcessAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfAssetsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions that are classified as investing activities in which assets, which may include one or more investments, are sold to third-party buyers. This element can be used by entities to aggregate proceeds from all asset sales that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfAssetsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446541912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of Business Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business Operations</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">1)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Organization and Description of Business Operations</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold; color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn ImmunoTherapeutics Inc., a Delaware corporation (&#8220;Brooklyn&#8221; or the &#8220;Company&#8221;), together with its subsidiaries including Brooklyn
          ImmunoTherapeutics LLC (&#8220;Brooklyn LLC&#8221;), Novellus, Inc. (&#8220;Novellus&#8221;) and Novellus Therapeutics, Ltd. (&#8220;Novellus, Ltd.&#8221;), is a clinical stage biopharmaceutical company focused on exploring the role that cytokine, gene editing and cell therapy can
          have in treating patients with cancer, blood disorders and monogenic diseases. As used herein, the &#8220;Company&#8221; refers collectively to Brooklyn and its subsidiaries.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On August 12, 2020, Brooklyn (then known as &#8220;NTN Buzztime, Inc.&#8221;), Brooklyn LLC and BIT Merger Sub, Inc., a wholly owned subsidiary of Brooklyn
          (the &#8220;Merger Sub&#8221;), entered into an agreement and plan of merger and reorganization (the &#8220;Merger Agreement&#8221;) pursuant to which, among other matters, Merger Sub merged with and into Brooklyn LLC, with Brooklyn LLC continuing as a wholly owned
          subsidiary of Brooklyn and as the surviving company of the merger (the &#8220;Merger&#8221;). The Merger closed on March 25, 2021. After the Merger, Brooklyn changed its name from &#8220;NTN Buzztime, Inc.&#8221; to &#8220;Brooklyn ImmunoTherapeutics, Inc.&#8221; The Merger was
          accounted for as a reverse acquisition, in which Brooklyn LLC was deemed the acquiring company for accounting purposes.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On March 26, 2021, Brooklyn sold (the &#8220;Disposition&#8221;) its rights, title and interest in and to the assets relating to the business operated under
          the name &#8220;NTN Buzztime, Inc.&#8221; prior to the Merger to eGames.com Holdings LLC (&#8220;eGames.com&#8221;) in accordance with the terms of an asset purchase agreement dated September 18, 2020, as amended, between Brooklyn and eGames.com (the &#8220;Asset Purchase
          Agreement&#8221;). (See Note 4.)</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On July 16, 2021, Brooklyn and its newly formed, wholly owned subsidiary Brooklyn Acquisition Sub, Inc. entered into an agreement and plan of
          acquisition (the &#8220;Acquisition Agreement&#8221;) with (a) Novellus LLC, (b) Novellus (the sole equity holder of Novellus, Ltd. and, prior to the closing under the Acquisition Agreement, a wholly owned subsidiary of Novellus, LLC), and (c) a seller
          representative (the &#8220;Acquisition&#8221;), pursuant to which Brooklyn acquired Novellus and its subsidiary, Novellus, Ltd. As part of the Acquisition, Brooklyn also acquired 25.0% of the total outstanding equity interests of NoveCite, Inc. (&#8220;NoveCite&#8221;), a corporation focused on developing an allogeneic mesenchymal stem cell product for patients with acute respiratory distress
          syndrome, including from COVID-19. (See Note 4.)</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718447450360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LiquidityAndCapitalResourcesAbstract', window );"><strong>Liquidity and Capital Resources [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LiquidityAndCapitalResourcesTextBlock', window );">Liquidity and Capital Resources</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">2)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Liquidity and Capital Resources</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company has incurred significant operating losses and has an accumulated deficit as a result of ongoing efforts to develop product candidates,
        including conducting clinical trials and providing general and administrative support for these operations. As of December 31, 2021, the Company had a cash balance of approximately $16,985,000 and an accumulated deficit of approximately $159,703,000.
        For the year ended December 31, 2021, the Company incurred a net loss of $122,306,000 and the Company used cash in operating activities
        of $23,488,000 (inclusive of $80,538,000
        IPR&amp;D expense related to the Acquisition, $9,648,000 related to the loss on sale of assets in the Disposition and $180,000 related to the change in fair value of contingent consideration).</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On April 26, 2021, Brooklyn entered into a common stock purchase agreement (the &#8220;First Purchase Agreement&#8221;) with Lincoln Park Capital Fund, LLC
          (&#8220;Lincoln Park&#8221;), which provided that Brooklyn could offer to Lincoln Park up to an aggregate of $20,000,000 of common stock over a 36-month period commencing after May 10, 2021, the date that a registration statement covering the resale of shares of common stock issued under the
          First Purchase Agreement was declared effective by the SEC. As of December 31, 2021, Brooklyn had issued and sold an aggregate of approximately 1,128,000
          shares of common stock to Lincoln Park pursuant to the First Purchase Agreement, resulting in gross proceeds of $20,000,000.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On May 26, 2021, Brooklyn entered into a second common stock purchase agreement (the &#8220;Second Purchase Agreement&#8221;) with Lincoln Park, which
        provides that Brooklyn may offer to Lincoln Park up to an aggregate of $40,000,000 of common stock over a 36-month period commencing after June 4, 2021, the date that a registration statement covering the resale of shares of common stock issued under the
        Second Purchase Agreement was declared effective by the SEC. As of December 31, 2021, Brooklyn had issued and sold an aggregate of approximately 2,424,000
        shares of common stock to Lincoln Park pursuant to the Second Purchase Agreement, resulting in gross proceeds of approximately $34,106,000.</div>

<div> <br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On July 16, 2021, Brooklyn used approximately $22,854,000
        of cash, net of cash acquired, as part of the purchase price of the Acquisition. Brooklyn issued common stock as the remaining portion of the purchase price of the Acquisition.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br/>
        </span></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> On March 9, 2022, we consummated a private placement of equity resulting in net proceeds of approximately $11 million. See Note 17 for details.</span> </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none;">In connection with
            preparing its financial statements as of and for the year ended December 31, 2021, the Company&#8217;s management concluded that there is substantial doubt regarding the Company&#8217;s ability to continue as a going concern because it does not expect to
            have sufficient cash or working capital resources to fund operations for the twelve-month period subsequent to the issuance date of these financial statements.&#160; The Company will need to raise additional capital, which could be through the
            remaining availability under the Second Purchase Agreement (to the extent the Company is permitted to use such agreement), public or private equity offerings, debt financings, corporate collaborations or other means. The Company may also seek
            governmental grants to support our clinical trials and preclinical trials..&#160; The Company currently has no arrangements for such capital and no assurances can be given that it will be able to raise such capital when needed, on acceptable terms,
            or at all.&#160;</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">The accompanying
        consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do
        not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to the Company&#8217;s ability to continue as
        a going concern.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LiquidityAndCapitalResourcesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_LiquidityAndCapitalResourcesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LiquidityAndCapitalResourcesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of liquidity and resource matters when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_LiquidityAndCapitalResourcesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446504792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Accounting Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Accounting Presentation and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Accounting Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">3)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Basis of Accounting Presentation and Summary of Significant Accounting Policies</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Basis of Accounting Presentation</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference
        in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). All significant intercompany
        balances and transactions have been eliminated in consolidation.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">As described above, the Merger closed on March 25, 2021. The Merger was accounted for as a reverse acquisition, in which Brooklyn LLC was deemed
          the acquiring company for accounting purposes. Brooklyn LLC&#8217;s historical financial statements have replaced Brooklyn&#8217;s historical financial statements with respect to periods prior to the completion of the Merger (when Brooklyn operated under the
          name &#8220;NTN Buzztime, Inc.&#8221;). The Company retrospectively adjusted the weighted average shares used in determining loss per common share to reflect the conversion of the outstanding Class A units, Class B units, Class C units, and common units of
          Brooklyn LLC that converted into shares of Brooklyn&#8217;s common stock upon the Merger and to reflect the effect of a <span style="-sec-ix-hidden:Fact_565a5991ac0445a8b9e9f14506915bfe">2-to-1</span> reverse stock
          split of Brooklyn&#8217;s common stock that occurred immediately prior to the Merger.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Also as described above, the Acquisition closed on July 16, 2021. The Acquisition was accounted for as an asset acquisition, and substantially
          all of the value was attributed to in-process research and development (&#8220;IPR&amp;D&#8221;), with the exception of the cash paid for the investment in NoveCite, which is being accounted for as an investment in equity securities. The IPR&amp;D had no
          alternative future uses and no separate economic value from its originally intended purpose and was therefore expensed in the period the cost was incurred.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Summary of Significant Accounting Policies</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Use of Estimates</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (a)
        the reported amounts of assets and liabilities; (b) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; (c) the reported amounts of revenues and expenses during the reporting period and (d) the
        reported amount of the fair value of assets acquired in connection with business combinations. Actual results could differ from those estimates. The Company&#8217;s significant estimates and assumptions include the recoverability and useful lives of
        long-lived assets and the contingent consideration liability.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Cash and Cash Equivalents</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company classifies highly liquid investments with a remaining contractual maturity at date of purchase of three months or less as cash
        equivalents. The Company had no cash equivalents as of December 31, 2021 or 2020.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Property and Equipment</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment are recorded at cost and are depreciated over their estimated useful lives using the straight-line method. Laboratory and
        manufacturing equipment are depreciated over an estimated useful life of seven years. Leasehold improvements are depreciated over the
        shorter of their estimated useful life, or the lease term. Computer equipment are depreciated over an estimated useful life of three years.
        Upon retirement or other disposition of these assets, the cost and related accumulated depreciation of these assets are removed from the accounts and the resulting gain or losses are reflected in the results of operations. Expenditures for
        maintenance and repairs are charged to operations. Renewals and betterments are capitalized.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Goodwill</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in the acquisition of IRX
        Therapeutics, Inc. in November 2018 (the &#8220;IRX Acquisition&#8221;), which was accounted for as a business combination. Goodwill is not amortized but is tested for impairment annually, or if events occur or circumstances change that would reduce the fair
        value of a reporting unit below its carrying value. Because management evaluates the Company as a single reporting unit, goodwill is tested for impairment at the entity level by first performing a qualitative assessment to determine whether it is
        more likely than not that the fair value of the entity is less than its carrying value. Such qualitative factors include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant
        events.&#160; If the entity does not pass the qualitative assessment, then the entity&#8217;s carrying value is compared to its fair value. Goodwill is considered impaired if the carrying value of the entity exceeds its fair value.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">IPR&amp;D</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">IPR&amp;D assets represent the fair value assigned to technologies that were acquired in connection with the IRX Acquisition, which have not
        reached technological feasibility and have no alternative future use. IPR&amp;D assets are considered to be indefinite lived until the completion or abandonment of the associated research and development projects. During the period that the
        IPR&amp;D assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the
        IPR&amp;D assets are less than their carrying amounts. If and when development is complete, which generally occurs upon regulatory approval, and the Company is able to commercialize products associated with the IPR&amp;D assets, these assets are
        then deemed definite-lived and are amortized based on their estimated useful lives beginning at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&amp;D assets,
        calculated as the excess of carrying value of the IPR&amp;D assets over fair value.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Impairment of Long-Lived Assets</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company reviews long-lived assets and certain identifiable assets for impairment whenever circumstances and situations change such that there
        is an indication that the carrying amounts may not be recovered. An impairment exists when the carrying value of the long-lived asset is not recoverable and exceeds its fair value. For the years ended December 31, 2021 and 2020, there were no
        qualitative factors that indicated it was more likely than not that the fair value of the long-lived assets exceeded the carrying value.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Research and Development</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company expenses its research and development costs as incurred. Research and development expenses consist of costs incurred for
        company-sponsored research and development activities, as well as support for selected investigator-sponsored research. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the
        period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. IPR&amp;D that is acquired through an asset acquisition (as
        opposed to a business combination) and has no alternative future uses and, therefore, no separate economic values, is expensed to research and development costs at the time the costs are incurred.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The major components of research and development costs include preclinical study costs, clinical manufacturing costs, clinical study and trial
        expenses, insurance coverage for clinical trials, expensed licensed technology, expensed IPR&amp;D, consulting, scientific advisors and other third-party costs, salaries and employee benefits, stock-based compensation expense, supplies and
        materials and allocations of various overhead costs related to our product development efforts.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In the normal course of our business, the Company contracts with third parties to perform various clinical study and trial activities in the
        on-going development and testing of potential products. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors
        such as the achievement of certain events or milestones, the successful enrollment of patients, the allocation of responsibilities among the parties to the agreement, and the completion of portions of the clinical study or trial or similar
        conditions. Preclinical and clinical study and trial associated activities such as production and testing of clinical material require significant up-front expenditures. The Company anticipates paying significant portions of a study&#8217;s or trial&#8217;s
        cost before they begin and incurring additional expenditures as the study or trial progresses and reaches certain milestones.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Income Taxes</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company records deferred tax liabilities and assets based on the differences between the consolidated financial statements carrying amounts
        and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and established a valuation allowance when it was more likely than not that some portion or all of the deferred tax
        assets would not be realized. Income tax expense consists of the tax payable for the period and the change during the period in deferred tax assets and liabilities.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Tax benefits from uncertain tax positions are recognized only if it is more likely than not that the tax position will be sustained on examination
        by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of
        being realized upon ultimate resolution. The Company has no material uncertain tax positions for any of the reporting periods presented.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Earnings Per Share</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Basic and diluted loss per common share have been computed by dividing the losses applicable to common stock by the weighted average number of
        common shares outstanding. The Company&#8217;s basic and fully diluted earnings per share (&#8220;EPS&#8221;) calculation are the same since the increased number of shares that would be included in the diluted calculation from assumed exercise of common stock
        equivalents would be anti-dilutive to the net loss in each of the years shown in the consolidated financial statements.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Segment Reporting</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In accordance with ASC No. 280, <span style="font-style: italic;">Segment Reporting</span>, the Company has determined that it operates as one operating segment. Decisions regarding the Company&#8217;s overall operating performance and allocation of its resources are assessed on a consolidated
        basis.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Concentration of Credit Risk</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company maintains its cash balances in financial institutions located in the United States. Accounts at each institution are insured by the
        Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250,000. At times, the Company&#8217;s cash balances may be uninsured for deposit accounts that exceed the FDIC insurance limit.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In the Company&#8217;s business, vendor concentrations could be indicative of vulnerabilities in the Company&#8217;s supply chain, which could ultimately
        impact the Company&#8217;s ability to continue its research and development activities. For the years ended December 31, 2021 and 2020, there was no vendor concentration related to the Company&#8217;s research and development activities.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Fair Value of Financial Instruments</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between
        willing market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The
        fair value hierarchy is as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Level 1 Inputs &#8211; Valued based on quoted prices in active markets for identical
          assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Level 2 Inputs &#8211; Valued based on inputs other than quoted prices included in Level
          1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that
          are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market
          data by correlation or other means.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Level 3 Inputs &#8211; Valued based on inputs for which there is little or no market
          value, which require the reporting entity to develop its own assumptions.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The carrying amounts reported on the balance sheet for cash and cash equivalents, accounts receivable, prepaid assets and other current assets,
        accounts payable and accrued expenses, other current liabilities and other liabilities approximate fair value based due to their short maturities. The carrying value of loans payable approximates its fair market value because the effective yield on
        this debt, which includes contractual interest rates as well as other finance charges, is comparable to rates of returns for instruments of similar credit risk.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Leases</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company adopted ASC Topic 842, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Leases,</span>
        on December 31, 2020 using the modified transition method without retrospective application to comparative periods. The Company elected the package of three practical expedients allowed for under the transition guidance. Accordingly, the Company
        did not reassess: (1) whether any expired or existing contracts are/or contain leases; (2) the lease classification for any expired or existing leases; or (3) initial direct costs for any existing leases. The Company has also elected not to
        recognize right-of-use assets (&#8220;ROU assets&#8221;) and lease liabilities for short-term leases that have a term of 12 months or less.</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Operating lease liabilities represent the present value of lease payments not yet paid. ROU assets represent the Company&#8217;s right to use an
          underlying asset and are based upon the operating lease liabilities adjusted for prepaid or accrued lease payments, initial direct costs, lease incentives and impairment of operating lease assets. If the interest rate implicit in the lease is not
          readily determinable, the Company uses the incremental borrowing rates based on the information available at the lease commencement date in determining the present value of lease payments. To determine the present value of lease payments not yet
          paid, the Company estimates secured borrowing rates corresponding to the maturities of the leases.</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company has elected the practical expedient to not separate non-lease components from the lease components to which they relate and instead
          account for each as a single lease component for all underlying asset classes. Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as payments for insurance, tax payments and other
          miscellaneous costs. The variable portion of lease payments is not included in the ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are expensed when the obligation for those payments
          is incurred and are included in lease expenses. Accordingly, all expenses associated with a lease contract are accounted for as lease expenses.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Commitment and Contingencies</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company follows ASC No.450-20, <span style="font-style: italic;">Loss Contingencies</span>, to report accounting for contingencies.
        Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Stock-Based Compensation</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company recognizes stock-based compensation expense for equity awards granted to employees, directors and certain consultants. The Company
        estimates the fair value of stock options using the Black-Scholes option pricing model. The fair value of stock options granted is recognized as expense over the requisite service period. Stock-based compensation expense for share-based payment
        awards is recognized using the straight-line single-option method.</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Recent Accounting Standards</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In May 2021, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) <span style="font-style: italic;">2021-04,


























          Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain
          Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span>. ASU 2021-04 addresses the accounting for certain modifications or exchanges of freestanding equity-classified written call options. ASU 2021-04 is effective
        for fiscal years beginning after December 15, 2021 (January 1, 2022 for the Company) and interim periods within those fiscal years, with early adoption permitted. The Company does not expect the adoption of this update to have a significant impact
        on its financial statements.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In July 2021, the FASB issued ASU 2021-05, <span style="font-style: italic;">Leases (Topic 842) &#8211; Lessors - Certain Leases with Variable Lease
          Payments,</span> which amends the lessor classification guidance to introduce additional criteria when classifying leases with variable lease payments that do not depend on a reference index or a rate. This guidance is effective for annual
        periods beginning after December 15, 2021 (January 1, 2022 for the Company), with early adoption permitted. The Company does not expect the adoption of this update to have a significant impact on its financial statements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446332072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger, Disposition and Acquisition Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Merger, Disposition and Acquisition Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Merger, Disposition and Acquisition Transactions</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">4)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Merger, Disposition and Acquisition Transactions</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Merger</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On August 12, 2020, Brooklyn, Brooklyn LLC and the Merger Sub entered into the Merger Agreement. The Merger closed on March 25, 2021. After the
          Merger, Brooklyn changed its name from &#8220;NTN Buzztime, Inc.&#8221; to &#8220;Brooklyn ImmunoTherapeutics, Inc.&#8221; The Merger was accounted for as a reverse acquisition, in which Brooklyn LLC was deemed the acquiring company for accounting purposes. Brooklyn
          LLC, as the accounting acquirer, recorded the assets acquired and liabilities assumed of Brooklyn in the Merger at their fair values as of the acquisition date. Brooklyn&#8217;s common stock trades on the NYSE American stock exchange under the ticker
          symbol &#8220;BTX&#8221;.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn LLC was determined to be the accounting acquirer based upon the terms of the Merger and other factors including that (i) Brooklyn LLC
          members, received common stock in the Merger that represented 96.35% of Brooklyn&#8217;s outstanding common stock on a fully diluted basis
          as of immediately after the Merger, (ii) all of the directors of Brooklyn immediately after the Merger were designated by Brooklyn LLC under the terms of the Merger Agreement and (iii) existing members of Brooklyn LLC&#8217;s management became the
          management of Brooklyn immediately after the Merger.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">At the closing of the Merger, all the outstanding membership interests of Brooklyn LLC converted into the right to receive an aggregate of
        approximately 39,992,000 shares of common stock, of which 1,068,000 shares were issued as compensation to Maxim Group LLC, Brooklyn LLC&#8217;s financial advisor (the &#8220;Financial Advisor&#8221;) for its services to Brooklyn LLC in connection with the Merger.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The purchase price of $8,178,000,
        which represents the consideration transferred in the Merger to stockholders of Brooklyn immediately before the Merger, was calculated based on the closing price of $5.40 per share for approximately 1,514,000 shares common stock that those stockholders owned on March
        25, 2021 immediately prior to the Merger because that represented a more reliable measure of the fair value of consideration transferred in the Merger.<br/>
      </div>

<div><br/></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the acquisition method of accounting, the total purchase price has been allocated to the acquired tangible and intangible assets and assumed
        liabilities of Brooklyn based on their estimated fair values as of March 25, 2021, the Merger closing date. Because the consideration paid by Brooklyn LLC in the Merger is more than the estimated fair values of Brooklyn&#8217;s net assets deemed to be
        acquired, goodwill is equal to the difference of approximately $8,589,000, which has been calculated using the fair values of the net
        assets of Brooklyn as of March 25, 2021.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The allocation of the estimated purchase price to the tangible and intangible assets acquired and liabilities deemed to be assumed from Brooklyn,
        based on their estimated fair values as of March 25, 2021, is as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Historical</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Balance</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Sheet of</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Brooklyn at</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">March 25, 2020</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Fair Value</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Adjustment</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">to Brooklyn</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Pre-Merger</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Assets</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Purchase</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Price</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Allocation Pro</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Forma</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Adjustment</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Cash and cash equivalents</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">148,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">148,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accounts receivable</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">103,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">103,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Prepaid expense and other current assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">329,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">329,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Property and equipment, net</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">1,015,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">1,015,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Software development costs</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">1,296,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(368,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">928,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Customers</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">548,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">548,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Trade name</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">299,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">299,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accounts payable, accrued liabilities and other current liabilities</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(3,781,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(3,781,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Net assets acquired, excluding goodwill</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(890,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">479,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(411,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total consideration</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">8,178,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Net assets acquired, excluding goodwill</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(411,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Goodwill</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">8,589,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn LLC was obligated under the Merger Agreement to have $10,000,000 in cash and cash equivalents on its balance sheet at the effective time of the Merger. To ensure Brooklyn LLC had the required funds, certain beneficial holders of Brooklyn LLC&#8217;s
        Class A membership interests entered into contractual commitments to invest $10,000,000 into Brooklyn LLC immediately prior to the
        closing of the Merger. During March 2021, Brooklyn offered its Class A unit holders an additional 5% rights offering for an additional $500,000 to be raised by a rights offering. Brooklyn received funds from the rights offering between February 17, 2021 and April 5, 2021.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Disposition</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On March 26, 2021, Brooklyn sold its rights, title and interest in and to the assets relating to the business it operated (under the name NTN
        Buzztime, Inc.) prior to the Merger to eGames.com in exchange for a purchase price of $2,000,000 and assumption of specified liabilities
        relating to that business. The sale was completed in accordance with the terms of the Asset Purchase Agreement. Details of the Disposition are as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Proceeds from sale:</div>
            </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Cash</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">132,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Escrow</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">50,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Assume advance/loans</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">1,700,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Interest on advance/loans</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">68,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Carrying value of assets sold:</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Cash and cash equivalents</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(14,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accounts receivable</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(75,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Prepaids and other current assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(124,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Property and equipment, net</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(1,014,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Software development costs</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(927,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Customers</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(548,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Trade name</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(299,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Goodwill</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(8,589,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Other assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(103,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Liabilities transferred upon sale:</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accounts payable and accrued expenses</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">113,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Obligations under finance leases</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">17,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Lease liability</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">26,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Deferred revenue</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">55,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Other current liabilities</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">149,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Transaction costs</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(265,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Total loss on sale of assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">(9,648,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Unaudited Pro Forma Disclosure</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following unaudited pro forma financial information summarizes the results of operations for the years months ended December 31, 2021 and 2020
        as if the Merger and the Disposition had been completed as of January 1, 2020. Pro forma information primarily reflects adjustments relating to the reversal of transaction costs. Assuming that the Merger and the Disposition had been completed as of
        January 1, 2020, the transaction costs would have been expensed in the prior period.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> Years ended December 31,</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2021<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2020<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Net loss attributable to common stockholders</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">(122,306,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">(26,547,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Basic and diluted net loss per share attributable to common stockholders</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(2.82</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(1.51</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Acquisition</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On July 16, 2021, Brooklyn and Brooklyn Acquisition Sub, Inc. entered into the Acquisition Agreement. The Acquisition closed contemporaneously
          with the execution and delivery of the Acquisition Agreement. At the closing:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Brooklyn acquired all of the outstanding equity interests of Novellus, Inc. as
            the result of the merger of Brooklyn Acquisition Sub, Inc. with and into Novellus, Inc., following which, Novellus, Inc., as the surviving corporation, became Brooklyn&#8217;s wholly owned subsidiary and Novellus Ltd. became Brooklyn&#8217;s indirectly
            owned subsidiary; and<br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Brooklyn acquired 25.0% of the total outstanding equity interests of NoveCite.</span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn delivered consideration for the Acquisition totaling approximately $124,000,000, which consisted of (a) approximately $22,854,000
          in cash, net of cash acquired, and (b) approximately 7,022,000 shares of common stock, which under the terms of the Acquisition
          Agreement were valued at a total of $102,000,000, based on a price of $14.5253 per share.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Acquisition Agreement contained customary representations, warranties and certain indemnification provisions. Approximately 741,000 of the shares issued as consideration were placed in escrow for a period of up to 12 months in order to secure indemnification obligations to Brooklyn under the Acquisition Agreement. The Acquisition Agreement also contains certain non-competition and
          non-solicitation provisions pursuant to which Novellus LLC agreed not to engage in certain competitive activities for a period of five years
          following the closing, including customary restrictions relating to employees. No employees of Novellus Ltd. or Novellus, Inc. prior to the Acquisition continued their employment, or were otherwise engaged by Brooklyn, following the Acquisition.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In connection with the Acquisition, the co-founders of Novellus, Ltd. entered into lock-up agreements with respect to approximately 3,378,000 of the shares of common stock received in the Acquisition, and Brooklyn&#8217;s Chairman of the Board of Directors and its Chief Executive Officer
          and President entered into identical lock-up agreements with respect to their current holdings of Brooklyn stock. Each lock-up agreement extends for a period of three years, provided that up to 75% of the shares of common stock subject to the lock-up agreement
          may be released from the lock-up restrictions earlier if the price of common stock on the Nasdaq exceeds specified thresholds. The lock-up agreements include customary exceptions for transfers during the applicable lock-up period.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company expects the Acquisition will advance its evolution into a platform company with a pipeline of next generation engineered cellular,
        gene editing and cytokine programs. In addition, the acquisition of Novellus, Ltd. builds on the License Agreement. (See Note 11). The completion of the acquisition of Novellus, Ltd. relieved Brooklyn LLC from potential obligations to pay Novellus,
        Ltd. certain upfront fees, clinical development milestone fees and post-registration royalties under the License Agreement. The agreement with Factor Bioscience Limited (&#8220;Factor&#8221;) under the License Agreement, which grants Brooklyn LLC exclusive
        rights to develop certain next-generation mRNA gene editing and cell therapy products, remained unchanged.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Although Brooklyn acquired all of the outstanding equity interests of Novellus, Inc., the Company accounted for the Acquisition as an asset
        acquisition (as the assets acquired did not constitute a business as defined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 805, <span style="font-style: italic;">Business Combinations</span>)<span style="font-style: italic;">, </span>and was
        measured by the amount of cash paid and by the fair value of the shares of common stock issued. As a result, substantially all of the value acquired was attributed to IPR&amp;D, with the exception of the cash paid for the investment in NoveCite,
        which is being accounted for as an investment in equity securities, as discussed further below.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn paid $22,854,000 in cash,
        net of cash acquired, as part of the consideration for the Acquisition, of which $1,000,000 was paid in cash for the investment in
        NoveCite. Brooklyn also issued approximately 7,022,000 shares of the Company&#8217;s common stock, of which approximately 3,644,000 shares are unrestricted and 3,378,000
        shares are subject to the three-year lockup. The unrestricted shares were valued at $10.05 per share, which was the closing price of Brooklyn&#8217;s common stock on July 16, 2021. The fair value of the restricted shares was discounted by approximately 35% to $6.53 per restricted share, which
        was derived from the average discount rate between the Black Scholes and Finnerty valuation models. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The resulting fair value of the asset acquired is as follows:</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Fair Value of</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Consideration</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Cash paid</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">22,882,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Cash acquired</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(28,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.46%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Unrestricted shares</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">36,628,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.46%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Restricted shares</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">22,056,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.46%; background-color: rgb(204, 238, 255);" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total fair value of consideration paid</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">81,538,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.46%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Less amount of cash paid for NoveCite investment</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(1,000,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.46%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Fair value of IPR&amp;D acquired</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">80,538,000<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">IPR&amp;D that is acquired through an asset purchase that has no alternative future uses and no separate economic values from its original
          intended purpose is expensed in the period the cost is incurred. Accordingly, the Company expensed the fair value of the IPR&amp;D during the third quarter of 2021 in the amount of $80,538,000.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Investment in NoveCite</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">As a result of the Acquisition, Brooklyn acquired and currently owns 25% of NoveCite and Citius Pharmaceuticals, Inc. (&#8220;Citius&#8221;) owns the remaining 75%.
        A member of the Company&#8217;s management holds one of three board seats on NoveCite&#8217;s board of directors. Citius&#8217; s officers and directors
        hold the other two board seats. Citius also retains the ability, in its sole discretion, to increase the size of the board of directors of NoveCite. Pursuant to a subscription agreement, as amended, between NoveCite and Novellus, LLC (the former
        parent of Novellus, Inc.), which was further amended and assigned to Brooklyn by Novellus, LLC upon the completion of the Acquisition, Citius has complete operational control and financial responsibility for NoveCite. Citrus&#8217;s officers are also the
        officers of NoveCite and oversee the business strategy and operations of NoveCite. Therefore, despite Brooklyn&#8217;s ownership of greater than 20%
        of NoveCite, which leads to a presumption that in the absence of predominant evidence to the contrary, an investor has the ability to exercise significant influence over an investee, Brooklyn does not exercise any significant influence over
        NoveCite or its board of directors. Brooklyn also has no contractual rights in the profits or obligations to share in the losses of NoveCite.&#160; Accordingly, the Company is accounting for its interest in NoveCite under ASC Topic 321, <span style="font-style: italic;">Investments &#8211; Equity Securities. </span>Because NoveCite&#8217;s stock is not publicly traded and, therefore, does not have a readily determinable fair value, the Company has elected to account for its investment at cost,
        which was $1,000,000. The Company will make adjustments to this amount when there are observable transactions for the identical or
        similar equity securities of the same issuer that would provide an indicator of fair value. In addition, if qualitative factors indicate a potential impairment, fair value must be estimated and the investment written down to that fair value if it
        is lower than the carrying value. As of December 31, 2021, there were no observable transactions for identical or similar equity securities of NoveCite to provide an indication of fair value, nor were there any indications of impairment of the
        investment.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446444792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">5)</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Fair Value of Financial Instruments</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between
          market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair
          value hierarchy is as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Level 1 Inputs &#8211; Valued based on quoted prices in active markets for identical
          assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Level 2 Inputs &#8211; Valued based on inputs other than quoted prices included in
          Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets
          that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by
          market data by correlation or other means.</span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="color: rgb(0, 0, 0);">Level 3 Inputs &#8211; Valued based on inputs for which there is little or no market
          value, which require the reporting entity to develop its own assumptions.</span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following tables summarize the liabilities that are measured at fair value as of December 31, 2021 and 2020:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of December 31, 2021</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Description</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 1</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 2</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 3</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-style: italic;">Liabilities:</div>
            </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Contingent consideration</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">19,930,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">19,930,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of December 31, 2020</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Description</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 1</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 2</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 3</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-style: italic;">Liabilities:</div>
            </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Contingent consideration</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">20,110,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">20,110,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The contingent consideration is related to an asset purchase agreement entered into between Brooklyn LLC and IRX Therapeutics (&#8220;IRX&#8221;) in
          connection with the IRX Acquisition, according to which, Brooklyn LLC is obligated to pay royalties to certain noteholders and shareholders of IRX based on future revenues from any future IRX-2 product sales.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Contingent consideration for the IRX Acquisition was initially valued at the transaction price and is subsequently valued at the end of each
        reporting period using third-party valuation services or other market observable data. The third-party valuation services use industry standard valuation models, including discounted cash flow analysis, to determine the value. After completing its
        validation procedures as of December 31, 2021, the Company adjusted the carrying amount of its contingent consideration liabilities as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Year ended</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31, 2021 </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Balance as of beginning of period</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">20,110,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Fair value adjustments included in operating expenses</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(180,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Balance as of end of period</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">19,930,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Contingent consideration is measured at fair value and is based on significant inputs not observable in the market, which represents a Level 3
          measurement within the fair value hierarchy. The valuation of contingent consideration uses assumptions the Company believes would be made by a market participant. The Company assesses these estimates on an on-going basis as additional data
          impacting the assumptions is obtained. Future changes in the fair value of contingent consideration related to updated assumptions and estimates are recognized within the statements of operations.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Contingent consideration may change significantly as development progresses and additional data are obtained, impacting the Company&#8217;s assumptions
        regarding probabilities of successful achievement of related milestones used to estimate the fair value of the liability and the timing in which the milestones are expected to be achieved. In evaluating the fair value information, considerable
        judgment is required to interpret the market data used to develop the estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange.&#160; Accordingly, the use of different market
        assumptions and/or different valuation techniques could result in materially different fair value estimates.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">For purposes of this calculation, a royalty equal to 13% of revenue (consisting of the royalty due to University of South Florida and the royalty due to the collaborator) is assumed until 2029 and a royalty of 7% of revenues is assumed from 2030 to 2038. The post patent decline is 50%
          in the first year and 10% thereafter. Income taxes were projected to be 26% of net royalty savings. The cash flows were discounted by the liability specific weighted average cost of capital of 26% using the mid-point convention.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446533048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">6)</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Property and Equipment</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment consist of the following:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2020</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Laboratory and manufacturing equipment</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">258,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">300,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Leasehold improvements<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">464,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">414,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Computer equipment</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">154,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">877,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">714,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Less: accumulated depreciation and amortization</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(207,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(120,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Property and equipment, net</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">670,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">594,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Depreciation expense totaled $117,000
        and $98,000 for the years ended December 31, 2021 and 2020, respectively. No depreciation expense is recorded on fixed assets in process
        until such time as the assets are completed and are placed into service.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446516472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">7)</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Leases</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company has operating leases for office and laboratory space in the boroughs of Brooklyn and Manhattan in New York, New York, which expire
          in 2025 and 2026, respectively. In June 2021, the Company entered into an additional lease agreement to lease approximately 2,700
          square feet of office and laboratory space in Cambridge, Massachusetts for approximately $56.00 per square foot annually. The lease
          provides for annual escalation of the base rent based on the year-over-year increase of the consumer price index, as well as the payment of other customary expenses, such as common area maintenance fees, property taxes, and insurance. Upon
          entering into this lease agreement, the Company paid a lease deposit of approximately $25,000. The Cambridge, Massachusetts lease
          expires in June 2028. See Note 17 for subsequent event information regarding the Company&#8217;s leases.<br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company adopted ASC Topic 842, <span style="font-style: italic;">Leases,</span> on December 31, 2020 using the modified transition method
          without retrospective application to comparative periods. The Company elected the package of three practical expedients allowed for under the transition guidance. Accordingly, the Company did not reassess: (1) whether any expired or existing
          contracts are/or contain leases; (2) the lease classification for any expired or existing leases; or (3) initial direct costs for any existing leases. The Company has also elected not to recognize right-of-use assets (&#8220;ROU assets&#8221;) and lease
          liabilities for short-term leases that have a term of 12 months or less.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Operating lease liabilities represent the present value of lease payments not yet paid. ROU assets represent the Company&#8217;s right to use an
          underlying asset and are based upon the operating lease liabilities adjusted for prepaid or accrued lease payments, initial direct costs, lease incentives and impairment of operating lease assets. As the rate implicit in the lease is not readily
          determinable, the Company used its incremental borrowing rates based on the information available at the lease commencement date in determining the present value of lease payments. To determine the present value of lease payments not yet paid,
          the Company estimates secured borrowing rates corresponding to the maturities of the leases.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company has elected the practical expedient to not separate non-lease components from the lease components to which they relate and instead
          account for each as a single lease component for all underlying asset classes. Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as payments for insurance, tax payments and other
          miscellaneous costs. The variable portion of lease payments is not included in the ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are expensed when the obligation for those payments
          is incurred and are included in lease expenses. Accordingly, all expenses associated with a lease contract are accounted for as lease expenses.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Operating leases are included in right of use assets - operating leases and operating lease liabilities, current and long-term, on the balance
          sheet. Lease expense for operating leases is recognized on a straight-line basis over the lease term and is included in general and administrative costs in the statements of operations.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company recognizes operating lease expense and lease payments from the sublease on a straight-line basis in its statements of operations
          over the lease terms. During the years ended December 31, 2021 and 2020, the net operating lease expenses were as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Years ended December 31,</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; font-weight: bold;">2021</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; font-weight: bold;">2020</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Operating lease expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">688,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">591,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Sublease income</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(84,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(77,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Variable lease expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">19,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">21,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Total lease expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">623,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">535,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The tables below show the beginning balances of the operating ROU assets and lease liabilities as of January 1, 2021 and the ending balances as of
        December 31, 2021, including the changes during the period.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Operating Lease</div>
              <span style="font-weight: bold;"> </span>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ROU Assets</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Operating lease ROU assets at January 1, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2,093,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Amortization of operating lease ROU assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(342,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Addition of operating lease ROU assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">816,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Operating lease ROU assets at December 31, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2,567,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0);">Operating Lease</div>
              <div style="text-align: center; color: rgb(0, 0, 0);">Liabilities</div>
            </td>

    <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Operating lease liabilities at January 1, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2,178,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Principal payments on operating lease liabilities</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(321,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Addition of operating lease liabilities</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">866,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Operating lease liabilities at December 31, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2,723,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Less non-current portion</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2,297,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Current portion at December 31, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">426,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">As of December 31, 2021, the Company&#8217;s operating leases had a weighted-average remaining life of 4.9 years with a weighted-average discount rate of 12.76%. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The maturities of the operating
          lease liabilities are as follows:</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">750,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2023</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">767,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2024</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">785,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2025</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">802,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2026</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">267,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Thereafter</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">246,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total payments</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">3,617,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Less imputed interest</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(894,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total operating lease liabilities</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2,723,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Sublease Agreement</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On April 18, 2019, the Company entered into a sublease agreement with Nezu Asia Capital Management, LLC (the &#8220;Tenant&#8221;), whereby the Tenant
          agreed to sublease approximately 999 square feet of space currently rented by the Company in the borough of Manhattan in New York, New
          York commencing on May 15, 2019. The term of this sublease expires on October 31, 2026 with no option to extend the sublease term. Rent payments provided by the Tenant under the sublease agreement began on September 1, 2019. The sublease
          agreement stipulates an annual rent increase of 2.25%. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Tenant is also responsible for paying to the Company all tenant energy costs, annual
          operating costs, and annual tax costs attributable to the subleased space during the term of the sublease.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2021<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">82,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2023</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">84,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2024</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">86,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2025</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">88,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2026</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">75,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">415,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company received sublease payments of approximately $83,000 and $79,000 during the years ended December 31, 2021 and 2020,
          respectively. In accordance with ASC Topic 842, the Company treats the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease. The Company continues to account for the Manhattan lease as a
          lessee and in the same manner as prior to the commencement date of the sublease. The Company accounts for the sublease as a lessor of the lease. The sublease is classified as an operating lease, as it does not meet the criteria of a sale-type or
          direct financing lease.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446509688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and In-Process Research &amp; Development<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and In-Process Research &amp; Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and In-Process Research &amp; Development</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">8)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Goodwill and In-Process Research &amp; Development</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company recorded goodwill and IPR&amp;D in the amount of $2,044,000 and $6,860,000, respectively, in connection with the IRX Acquisition
        in the year ended December 31, 2018. IPR&amp;D assets are considered to be indefinite lived until the completion or abandonment of the associated research and development projects.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In connection with the Acquisition, the Company expensed the fair value of the IPR&amp;D it acquired in the amount of $80,538,000, as the Company determined there were no future alternative uses or separate economic values from its original intended purpose. (See Note
        4.)</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446495784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">9)</td>

    <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Accrued Expenses</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Accrued expenses consisted of the following:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of December 31,</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2021<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2020</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accrued compensation</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">656,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">294,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accrued research and development expenses</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">222,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">207,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accrued general and administrative expenses</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">371,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">400,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accrued interest</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">150,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total accrued expenses</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">1,249,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">1,051,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718447445608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">10)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Debt</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Loans Payable</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In connection with the IRX Acquisition in 2018, Brooklyn LLC assumed certain notes payable (the &#8220;IRX Notes&#8221;) in the amount of $410,000. On January 27, 2020, the IRX Notes were amended to extend the maturity date to the earlier of (i) a change of control, as defined in the IRX
          Notes, and (ii) December 31, 2021. On December 31, 2021, the Company paid the outstanding $410,000 in principal plus accrued and unpaid
          interest of approximately $210,000 under the IRX Notes, and the Company has no further obligations thereunder.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Payment Protection Program Loan</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Brooklyn LLC PPP Loan.</span></div>

<div><br/></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On May 4, 2020, Brooklyn LLC issued a note in the principal amount of approximately $310,000 to Silicon Valley Bank evidencing a loan (the &#8220;Brooklyn LLC PPP Loan&#8221;) Brooklyn LLC received under the Paycheck Protection Program (the &#8220;PPP&#8221;) of the Coronavirus Aid, Relief, and
          Economic Security Act administered by the U.S. Small Business Administration (the &#8220;CARES Act&#8221;). Brooklyn LLC PPP Loan incurred interest at a rate of 1.0%
          per annum.</div>

<div><br/></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the terms of the Cares Act, certain amounts of the Brooklyn LLC PPP Loan could be forgiven if they were used for qualifying expenses, as
          described in the CARES Act. In June 2021, Brooklyn LLC submitted its loan forgiveness application for the Brooklyn LLC PPP Loan, and in September 2021, the lender informed Brooklyn LLC that the U.S Small Business Administration approved the
          forgiveness of 100% of the outstanding principal and interest of the Brooklyn LLC PPP Loan. As of December 31, 2021, there was no
          outstanding principal balance of the Brooklyn LLC PPP Loan.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718447446728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">11)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Commitments and Contingencies</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Legal Matters</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company is involved in litigation and arbitrations from time to time in the ordinary course of business. Legal fees and other costs associated
        with such actions are expensed as incurred. In addition, the Company assesses the need to record a liability for litigation and contingencies. The Company reserves for costs relating to these matters when a loss is probable, and the amount can be
        reasonably estimated.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Merger-Related Shareholder Litigation</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn (then known as NTN Buzztime, Inc.) and its former directors were named as defendants in ten substantially similar actions arising out of the Merger that were brought by purported pre-Merger stockholders of Brooklyn: Henson v. NTN Buzztime, Inc., et al., No.
        1:20-cv-08663-LGS (S.D.N.Y.); Monsour v. NTN Buzztime, Inc., et al., No. 1:20-cv-08755-LGS (S.D.N.Y.); Amanfo v. NTN Buzztime, Inc., et al., No. 1:20-cv-08747-LGS (S.D.N.Y.); Carlson v. NTN Buzztime, Inc., et al., No. 1:21-cv-00047-LGS (S.D.N.Y.);
        Finger v. NTN Buzztime, Inc., et al., No. 1:21-cv-00728-LGS (S.D.N.Y.); Falikman v. NTN Buzztime, Inc., et al., No. 1:20-cv-05106-EK-SJB (E.D.N.Y.); Haas v. NTN Buzztime, Inc., et al., No. 3:20-cv-02123-BAS-JLB (S.D. Cal.); Gallo v. NTN Buzztime,
        Inc., et al., No. 3:21-cv-00157-WQH-AGS (S.D. Cal.); Chinta v. NTN Buzztime, Inc., et al., No. 1:20-cv-01401-CFC (D. Del.); and Nicosia v. NTN Buzztime, Inc., et al., No. 1:21-cv-00125-CFC (D. Del.) (collectively, the &#8220;Stockholder Actions&#8221;).&#160; Only
        two of the Stockholder Actions (the Chinta and Nicosia cases) also named Brooklyn.&#160; These actions asserted claims alleging violations of
        Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 14a-9 promulgated thereunder and both the Chinta and Nicosia cases alleged that Brooklyn LLC is a controlling person of Brooklyn.&#160; The complaints generally alleged that
        the defendants failed to disclose allegedly material information in a Form S-4 Registration Statement filed on October 2, 2020, including:&#160; (1) certain details regarding any projections or forecasts of Brooklyn or Brooklyn LLC may have made, and
        the analyses performed by Brooklyn&#8217;s financial advisor, Newbridge Securities Corporation; (2) conflicts concerning the sales process; and (3) disclosures regarding whether or not Brooklyn entered into any confidentiality agreements with standstill
        and/or &#8220;don&#8217;t ask, don&#8217;t waive&#8221; provisions.&#160; The complaints generally alleged that these purported failures to disclose rendered the Form S-4 false and misleading.&#160; The complaints requested: preliminary and permanent injunction of the Merger;
        rescission of the Merger if executed and/or rescissory damages in unspecified amounts; direction to the individual directors to disseminate a compliant Form S-4; an accounting by Brooklyn for all alleged damages suffered; a declaration that certain
        federal securities laws had been violated; and reimbursement of costs, including attorneys&#8217; and expert fees and expenses.&#160; On or about February 26, 2021, in order to moot certain of the disclosure claims asserted in the Stockholder Actions, to
        avoid nuisance, potential expense, and delay, and to provide additional information to Brooklyn&#8217;s stockholders, Brooklyn determined to voluntarily supplement the Form S-4 with certain additional disclosures.&#160; In exchange for those disclosures, the
        plaintiffs in each of the Stockholder Actions agreed to voluntarily dismiss their claims.&#160; All ten actions have now been dismissed.&#160; Following the dismissal the parties amicably resolved plaintiffs&#8217; counsel&#8217;s request for an award of attorneys&#8217; fees
        and expenses based on the purported benefit contented to be conferred on Brooklyn&#8217;s stockholders as a result of the supplemental disclosures.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Dhesh Govender v. Brooklyn Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021)</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;">On or about February 5, 2021, Dhesh Govender, a former short-term consultant of Brooklyn LLC, filed a complaint against Brooklyn
            LLC and certain individuals that plaintiff alleges were directors of Brooklyn LLC. The complaint is captioned, Dhesh Govender v. Brooklyn Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021). Plaintiff alleges
            that Brooklyn LLC and certain of its officers and directors (&#8220;defendants&#8221;) engaged in unlawful and discriminatory conduct based on race, national origin and hostile work environment. Plaintiff also asserts various breach of contract, fraud and
            quantum meruit claims based on an alleged oral agreement pursuant to which he alleges Brooklyn LLC agreed to hire him as an executive once the Merger was completed. In particular, plaintiff alleges that, in exchange for transferring an
            opportunity to obtain an agreement to acquire a license from Novellus for its mRNA-based gene editing and cell reprogramming technology to Brooklyn LLC, he was promised a $500,000 salary and 7% of the equity of Brooklyn LLC.&#160; Based on these and
            other allegations, plaintiff seeks damages of not less than $10 million, a permanent injunction enjoining Brooklyn LLC from
            exercising the option to acquire such license from Novellus or completing the proposed Merger. On or about February 19, 2021, an amended complaint was filed asserting the same causes of action but withdrawing the request for injunctive relief.
            On June 6, 2021, defendants filed a motion to compel arbitration or, in the alternative, for partial dismissal of the complaint for failure to state viable fraud, quantum meruit and employment discrimination claims. After obtaining extensions
            of time to respond, plaintiff opposed the defendants&#8217; motion on August 9, 2021. The defendants filed their reply on September 3, 2021. The Court heard oral argument on the motion to compel arbitration and/or dismiss and the motion to seal on
            October 13, 2021. By Order dated November 10, 2021, the Court granted defendants&#8217; motion to compel Govender to arbitrate all of his claims against them, based on the arbitration clause of his consulting agreement with Brooklyn LLC.&#160; Govender
            thereafter filed his Statement of Claim (the &#8220;Demand&#8221;) with the American Arbitration Association (&#8220;AAA&#8221;), Case No. 01-21-0017-9417, on December 15, 2021 against the same defendants, and served it on defendants&#8217; counsel on February 3, 2022.&#160; In
            his Demand, Govender continues to assert statutory discrimination claims against all defendants, claims against Brooklyn LLC premised on the breach of an alleged oral promise to issue Govender<span style="font-family: 'Times New Roman',serif; font-size: 10pt;"> 7% of the equity of Brooklyn LLC and to employ Govender at a $500,000</span> annual salary in exchange for allegedly arranging and negotiating the Novellus license, common law fraud claims against Brooklyn LLC and Cherington based
            on the breach of these same promises and a claim for quantum meruit against the Brooklyn LLC.&#160; In his Demand, Govender now claims that the fair and reasonable value of his services on the quantum meruit claim exceeded<span style="font-family: 'Times New Roman',serif; font-size: 10pt;"> $100 million</span> and is seeking damages in an amount to be determined at the
            hearing.&#160; Defendants filed an answering statement to the Demand on February 28, 2022 and the parties are in the process of conferring on the selection of a<span style="font-family: 'Times New Roman',serif; font-size: 10pt;"> three-member arbitration panel.</span> Defendants intend to vigorously defend themselves against these claims. At this stage in the litigation,
            the Company is not able to predict the probability of a favorable or unfavorable outcome.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Carlson v. Allen Wolff, Michael Gottlieb, Richard Simtob, Susan Miller, and NTN Buzztime, Inc., C.A. No. 2021-0193-KSJM (Del. Ch. Ct.)</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">On or about March 12, 2021, Douglas Carlson, a purported stockholder of Brooklyn (then known as NTN Buzztime, Inc.), filed a verified class
            action complaint against Brooklyn and its then current members of the board of directors, for allegedly breaching their fiduciary duties and violating Section 211(c) of the Delaware General Corporation Law.&#160; In particular, plaintiff seeks to
            compel the defendants to hold an annual stockholder meeting.&#160; Plaintiff also moved for summary judgment at the same time that he filed his complaint.&#160; In order to moot the claim addressed in the complaint, Brooklyn agreed to hold its annual
            meeting on June 29, 2021, which date was subsequently rescheduled to August 20, 2021.&#160; On or about May 6, 2021, the parties entered into a stipulation, which was &#8220;so ordered&#8221; by the court, extending defendants&#8217; time to respond to the complaint
            and to file their answering brief in opposition to plaintiff&#8217;s motion for summary judgment on or before July 16, 2021 and providing that plaintiff&#8217;s reply brief in support of his motion for summary judgment is due on or before August 20, 2021.
            On or about July 12, 2021, the parties entered in a further amended scheduling order, which provided that defendants were to respond to the complaint and file their answering brief in opposition to plaintiff&#8217;s motion for summary judgment on or
            before September 16, 2021 and plaintiff was to file its reply brief in support of his motion for summary judgment on or before October 20, 2021.&#160; On August 20, 2021, Brooklyn convened its 2021 annual meeting. Due to the lack of a required
            quorum, the meeting was adjourned to September 3, 2021. Thereafter, Brooklyn obtained a quorum, and the annual meeting was held on September 3, 2021. On September 10, 2021, Brooklyn filed a report on Form 8-K with the SEC announcing the results
            of the annual meeting. On September 16, 2021, the parties filed a stipulation seeking voluntary dismissal of the complaint as moot. The Court entered the dismissal on September 16, 2021 with prejudice as to the named plaintiff and without
            prejudice as to other members of the purported class and retained jurisdiction for the purpose of determining any fee application to the extent it cannot be resolved amicably the parties. <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">Thereafter, on or about November 12, 2022, the parties resolved plaintiff&#8217;s counsel&#8217;s request for an award of fees and expenses for the purported benefit that Carlson contended was received by stockholders as a result of his
              action.&#160; </span></div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"><span style="font-family: 'Times New Roman', serif; font-size: 10pt;"> <br/>
            </span></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Robert Garfield Matter</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">On April 29, 2021, Robert Garfield, a purported stockholder of Brooklyn, sent to Brooklyn a demand letter that had purportedly been sent
              to Brooklyn (then known as NTN Buzztime, Inc.) on or about March 16, 2021. The demand letter asserts that, Brooklyn (then known as NTN Buzztime, Inc.) made material misstatements in a prospectus issued in seeking a stockholder vote on March
              15, 2021 with respect to an amendment to Brooklyn&#8217;s certificate of incorporation to increase the number of authorized shares from 15
              million to 100 million. The demand letter seeks to have Brooklyn deem the amendment to the certificate of incorporation
              ineffective or seek valid stockholder approval of such amendment and for Brooklyn to implement internal controls.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify;"><span style="font-family: 'Times New Roman',serif; font-size: 1pt;">&#160;</span><span style="font-family: 'Times New Roman',serif; font-size: 10pt;">Brooklyn decided to seek stockholder ratification of the March
                15, 2021 stockholder vote concerning an amendment to Brooklyn&#8217;s certificate of incorporation to increase the number of authorized shares from</span> 15 million to 100 million<span style="font-family: 'Times New Roman',serif; font-size: 10pt;"> pursuant to Sections 204 of the Delaware General Corporation Law. &#160;Stockholder ratification was obtained at the annual meeting of stockholders that took place on September 3, 2021. As a result of the
                ratification, Garfield advised that the claims set forth in his demand letter were moot. The parties thereafter resolved Garfield&#8217;s counsel&#8217;s request for an award of attorney&#8217;s fees and expenses for the purported benefit that Garfield
                contented was received by stockholders as a result of the stockholder ratification.</span> </div>

<div><br/>
            </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Edmund Truell Matter</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On May 14, 2021, Edmund Truell, a stockholder of Brooklyn, alleged that he sustained a loss because he was unable to sell shares of common stock
          timely due to a delay caused by Brooklyn&#8217;s issuance of stock certificates in lieu of electronic book entry.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Emerald Private Equity Fund, LLC Matter</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">By a letter dated July 7, 2021, Emerald Private Equity Fund, LLC (&#8220;Emerald&#8221;), a stockholder of Brooklyn, made a demand pursuant to 8 Del.
              C. 220 to inspect certain books and records of Brooklyn. The stated purpose of the demand is to investigate possible wrongdoing by persons responsible for the implementation of the Merger and the issuance of paper stock certificates,
              including investigating&#160; whether: (i) Brooklyn&#8217;s stock certificates were issued in accordance with the Merger Agreement; (ii) certain restrictions on the sale of Brooklyn common stock following the Merger were proper and applied without
              favor; (iii) anyone received priority in post-Merger issuances of Brooklyn&#8217;s stock certificates that allowed them to benefit from an increase in the trading price of Brooklyn&#8217;s common stock; and (iv) it should pursue remedial measures and/or
              report alleged misconduct to the SEC. Brooklyn has responded to the demand letter and has produced certain information to Emerald in connection with the demand, which is subject to the terms of a confidentiality agreement entered into among
              the parties, including certain additional stockholders who have subsequently joined as parties to such agreement (including Truell noted above).&#160; In October 2021, Emerald requested that Brooklyn produce additional information related to the
              authority, purpose and justification for the restriction imposed on the sale of Brooklyn common stock following the Merger and the timing of share delivery to Brooklyn stockholders, following which request Brooklyn agreed to produce certain
              additional information and emails relating to these topics.<br/>
            </div>

<div><br/>
            </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">On March 30, 2022, counsel to Emerald advised the Company that it was prepared to file suit against the Company, certain current and
              former directors of the Company, and the Company&#8217;s financial advisor in connection with the Merger, on behalf of Emerald and a class of similarly situated stockholders with respect to some or all of the foregoing matters, alleging claims for
              breach of fiduciary duty, conversion and aiding and abetting breach of fiduciary duty.&#160; Emerald&#8217;s counsel has expressed a willingness to engage in private pre-suit early resolution discussions with the Company and its financial advisor on
              behalf of individual stockholders whom counsel represents in addition to Emerald; and the Company has agreed to respond to Emerald&#8217;s counsel by April 22, 2022.&#160; The Company can provide no assurance that such pre-suit early resolution
              discussions will be successful or that suit will not ultimately be filed against the Company, nor can the Company currently predict the outcome of any such suit, if filed.&#160; The Company intends to defend itself vigorously against any and all
              claims.&#160; Additionally, on April 7, 2022, the Company received a demand for indemnification from its financial advisor as it relates to the aforementioned potential lawsuit.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">John Westman v. Novellus, Inc., Christopher Rohde, and Matthew Angel, Civil Action No. 2181CV01949 (Middlesex County (Massachusetts) Superior
            Court)</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;">On or about September 7, 2021, John Westman, a former employee of Novellus, Inc. filed a Complaint in Middlesex County (Massachusetts)
            Superior Court against Novellus, Inc. and the company&#8217;s founders and former executives, Christopher Rohde and Matthew Angel (collectively, &#8220;Defendants&#8221;).&#160; Brooklyn acquired Novellus, Inc. on July 16, 2021.&#160; Mr. Westman&#8217;s claims relate to
            alleged conduct that took place before Brooklyn acquired Novellus, Inc.&#160; Pursuant to the July 16, 2021 Agreement and Plan of Acquisition, as well as a separate agreement among Brooklyn, Novellus, Inc., Mr. Rohde, and Mr. Angel, Mr. Rohde and
            Mr. Angel are essentially assuming the defense of and paying the fees associated with defending against these claims.&#160; To that end, on September 10, 2021, Morgan Lewis accepted service on behalf of all defendants. On December 24, 2021, Westman
            dismissed the case without prejudice so the parties could mediate the matter. The parties&#8217; February 2022 mediation was unsuccessful, but Mr. Westman has not refiled suit.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Licensing Agreements</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">USF</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn LLC has license agreements with University of South Florida Research Association, Inc. (&#8220;USF&#8221;), granting Brooklyn LLC the right to
          sell, market, and distribute IRX-2, subject to a 7% royalty payable to USF based on a percentage of gross product sales. Under the
          license agreement with USF, Brooklyn LLC is obligated to repay patent prosecution expenses incurred by USF. To date, Brooklyn LLC has not recorded any product sales, or obligations related to USF patent prosecution expenses. The license agreement
          terminates upon the expiration of the IRX-2 patents.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;"> <br/>
          </span></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Novellus, Ltd. and Factor</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In December 2020, Brooklyn LLC entered into option agreements (the &#8220;Option Agreements&#8221;) with Novellus, Ltd. and Factor (together, the
          &#8220;Licensors&#8221;) to obtain the right to exclusively license the Licensors&#8217; intellectual property and mRNA cell reprogramming and gene editing technology for use in the development of certain cell-based therapies to be evaluated and developed for
          treating human diseases, including certain types of cancer, sickle cell disease, and beta thalassemia (the &#8220;Licensed Technology&#8221;). The option was exercisable before February 28, 2021 (or April 30, 2021 if the Merger had not closed by that date)
          and required Brooklyn LLC to pay a non-refundable option fee of $500,000 and then an initial license fee of $4,000,000 (including the non-refundable fee of $500,000)
          in order to exercise the option.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In April 2021, Brooklyn LLC and the Licensors amended the Option Agreements to extend the exercise period to May 21, 2021 and to require
          Brooklyn, LLC to pay a total $1,000,000 of the $4,000,000 initial license fees to the Licensors by April 15, 2021.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In April 2021, Brooklyn LLC and the Licensors entered into an exclusive license agreement (the &#8220;License Agreement&#8221;) pursuant to which Brooklyn
          LLC acquired an exclusive worldwide license to the Licensed Technology.&#160; Under the terms of the License Agreement, Brooklyn LLC is obligated to pay the Licensors a total of $4,000,000 in connection with the execution of the License Agreement, all of which had been paid as of June 30, 2021.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The completion of the acquisition of Novellus, Ltd. relieved Brooklyn LLC from potential obligations to pay Novellus, Ltd. certain upfront fees,
          clinical development milestone fees and post-registration royalties under the License Agreement. The agreement with Factor under the License Agreement, which grants Brooklyn LLC exclusive rights to develop certain next-generation mRNA gene
          editing and cell therapy products, remained unchanged. Accordingly, Brooklyn LLC is obligated to pay to Factor a fee of $3,500,000 in
          October 2022, which will be in addition to a fee of $2,500,000 paid to Factor in October 2021.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn LLC is also required to use commercially reasonably efforts to achieve certain delineated milestones, including specified clinical
          development and regulatory milestones and specified commercialization milestones. In general, upon its achievement of these milestones, Brooklyn LLC will be obligated to pay, in the case of development and regulatory milestones, milestone
          payments to the Licensors in specified amounts and, in the case of commercialization milestones, specified royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers. In the event Brooklyn LLC fails to timely
          achieve certain delineated milestones, the Licensors will have the right to terminate Brooklyn LLC&#8217;s rights under provisions of the License Agreement relating to those milestones.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Novellus, Ltd. also has a license agreement with Factor, which was entered into in February 2015, amended in June 2018 and March 2020, and then
          amended and restated in November 2020.&#160; This license agreement provides for Novellus, Ltd. to use over 70 granted patents owned by
          Factor throughout the world covering synthetic mRNA, RNA-based gene editing, and RNA-based cell reprogramming, in addition to specific patents covering methods for treating specific diseases. There are also more than 60 pending patent applications throughout the world focused on these and other aspects of the technology. The patent coverage includes granted patents
          and pending patent applications in the United States, Europe, and Japan, along with other major life sciences markets.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Novellus, Ltd. is required to use commercially reasonably efforts to achieve certain delineated milestones, including specified clinical
          development and regulatory milestones and specified commercialization milestones. In general, upon its achievement of these milestones, Novellus, Ltd. will be obligated, in the case of development and regulatory milestones, to make milestone
          payments of up to $51 million in aggregate to Factor and, in the case of commercialization milestones, specified royalties with respect
          to product sales, sublicense fees or sales of pediatric review vouchers. In the event Novellus, Ltd. fails to timely achieve certain delineated milestones, Factor may have the right to terminate Novellus, Ltd.&#8217;s rights under provisions of the
          License Agreement relating to those milestones.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">NoveCite</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In October 2020, Novellus, Ltd. (as sublicensor) and NoveCite (as sublicensee) entered into an exclusive license agreement (the &#8220;Sublicense&#8221;) to
          license novel cellular therapy for acute respiratory distress syndrome, which NoveCite is licensing from Factor. Under the sublicense agreement, NoveCite is required to use commercially reasonably efforts to achieve certain delineated milestones,
          including specified clinical development and regulatory milestones and specified commercialization milestones. In general, upon its achievement of these milestones, NoveCite will be obligated, in the case of development and regulatory milestones,
          to make milestone payments to the Novellus, Ltd. in specified amounts and, in the case of commercialization milestones, specified royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the terms of the Sublicense, in the event that Novellus, Ltd. receives any revenue involving the original cell line included in the
          licensed technology, then Novellus, Ltd. shall remit to NoveCite 50% of such revenue.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Royalty Agreements</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Collaborator Royalty Agreement</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Effective June 22, 2018, IRX terminated its Research, Development and Option Facilitation Agreement and its Options Agreement (the &#8220;RDO and
        Options Agreements&#8221;) with a collaborative partner (the &#8220;Collaborator&#8221;), pursuant to a termination agreement (the &#8220;Termination Agreement&#8221;). The Termination Agreement was assigned to Brooklyn, LLC in November 2018 when Brooklyn LLC acquired the
        assets of IRX. In connection with the Termination Agreement, all of the rights granted to the Collaborator under the RDO and Options Agreements were terminated, and Brooklyn LLC has no obligation to refund any payments received from the
        Collaborator. As consideration for entering into the Termination Agreement, the Collaborator will receive a royalty equal to 6% of
        revenues from the sale of IRX-2, for the period of time beginning with the first sale of IRX-2 through the later of (i) the twelfth anniversary of the first sale of IRX-2 or (ii) the expiration of the last IRX patent, or other exclusivity of IRX-2.</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Investor Royalty Agreement</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On March 22, 2021, Brooklyn LLC restated its royalty agreement with certain beneficial holders of Brooklyn ImmunoTherapeutics Investors GP LLC
          and Brooklyn ImmunoTherapeutics Investors LP, whereby such beneficial holders will continue to receive, on an annual basis, royalties in an aggregate amount equal to 4% of the net revenues of IRX-2, a cytokine-based therapy being developed by Brooklyn LLC to treat patients with cancer.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Royalty Agreement with certain former IRX Therapeutics Investors</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On May 1, 2012, IRX Therapeutics entered into a royalty agreement (the &#8220;IRX Investor Royalty Agreement&#8221;) with certain investors who participated
        in a financing transaction. The IRX Investor Royalty Agreement was assigned to Brooklyn LLC in November 2018 when Brooklyn LLC acquired the assets of IRX. Pursuant to the IRX Investor Royalty Agreement, when Brooklyn LLC becomes obligated to pay
        royalties to USF under the agreement described above under &#8220;Licensing Agreements-USF,&#8221; it will pay an additional royalty of 1% of gross
        sales to an entity organized by the investors who participated in such financing transaction. There are no termination provisions in the IRX Investor Royalty Agreement. Brooklyn LLC has not recognized any revenues to date, and no royalties are due
        pursuant to any of the above-mentioned royalty agreements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446519464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Earnings per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Basic and Diluted Earnings per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and Diluted Earnings per Common Share</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">12)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Basic and Diluted Earnings per Common Share</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of
        potential common shares.&#160; Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares.&#160; Stock options, restricted stock units (&#8220;RSUs&#8221;), and other convertible
        securities are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury method when their effect is dilutive. <span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The following table shows the amount of stock options,
        RSUs and convertible preferred stock that were excluded from the computation of diluted net loss per common share for the year ended December 31, 2021, as their effect was anti-dilutive:<br/>
      </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <br/>
      </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">
        <table border="0" cellpadding="0" cellspacing="0" style="width: 100%;">


  <tr>

    <td style="width: 84.65%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;"><br/>
              </td>

    <td style="width: 0.98%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="2" style="width: 13.45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Year ended</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31, 2021<br/>
                </div>
              </td>

    <td style="width: 0.92%; vertical-align: bottom; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 84.65%; vertical-align: middle; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Stock options</div>
              </td>

    <td style="width: 0.98%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 1.1%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td style="width: 12.35%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3,988,000</div>
              </td>

    <td style="width: 0.92%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 84.65%; vertical-align: middle; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">RSUs</div>
              </td>

    <td style="width: 0.98%; vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 1.1%; vertical-align: bottom; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 12.35%; vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">240,000</div>
              </td>

    <td style="width: 0.92%; vertical-align: bottom; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 84.65%; vertical-align: middle; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Preferred stock converted into common stock</div>
              </td>

    <td style="width: 0.98%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 1.1%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 12.35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">42,000</div>
              </td>

    <td style="width: 0.92%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 84.65%; vertical-align: middle; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total potential common shares excluded from computation</div>
              </td>

    <td style="width: 0.98%; vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 1.1%; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td style="width: 12.35%; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4,270,000</div>
              </td>

    <td style="width: 0.92%; vertical-align: bottom; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

  </tr>


</table>

      </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <br/>
      </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">There were no stock options, RSUs or convertible
        preferred stock outstanding prior to the Merger to exclude from diluted net loss per common share for the year ended December 31, 2020.<br/>
      </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446441544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">13)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Stock-Based Compensation</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Equity Incentive Plans</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Brooklyn&#8217;s stock-based compensation plans consist of the Restated 2020 Equity Incentive Plan (the &#8220;Restated 2020 Plan&#8221;) and the 2021 Inducement
        Equity Incentive Plan (the &#8220;2021 Inducement Plan&#8221;). Brooklyn&#8217;s board of directors has designated its compensation committee as the administrator of the foregoing plans (the &#8220;Plan Administrator&#8221;). Among other things, the Plan Administrator selects
        persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures, if any, and other provisions of the award.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">At Brooklyn&#8217;s special meeting of stockholders held on March 15, 2021, the stockholders approved the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;),
        which provided for the issuance of up to approximately 3,369,000 shares of common stock. At Brooklyn&#8217;s annual meeting of stockholders
        held on September 3, 2021, the stockholders approved the Restated 2020 Plan, which provides for (1) an increase in the number of shares of common stock that can be issued under the Restated 2020 Plan by 5,116,000 to 8,485,000 shares of common stock in total and (2)
        an annual increase in the number of shares reserved for issuance on January 1 of each year from 2022 through 2031 equal to the lesser of (i) 5%
        of the number of shares of common stock outstanding on the immediately preceding December 31 and (ii) such smaller number of shares of common stock as may be determine by the board of directors (the &#8220;Annual Evergreen Shares&#8221;). No other provision of
        the 2020 Plan were amended.&#160; Based on the number of shares of common stock outstanding on December 31, 2021, the maximum increase to the number of Annual Evergreen Shares of common stock that can be issued under the Restated 2020 Plan in 2022 is
        approximately 2,601,000 shares.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Awards under the Restated 2020 Plan may be granted to officers, directors, employees and consultants of the Company.&#160; Stock options granted under
        the Restated 2020 Plan may either be incentive stock options or nonqualified stock options, may have a term of up to ten years, and
        are exercisable at a price per share not less than the fair market value on the date of grant.&#160; As of December 31, 2021, there were approximately 320,000
        stock options and 18,000 RSUs outstanding under the Restated 2020 Plan.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In June 2019 Brooklyn adopted the 2019 Performance Incentive Plan (the &#8220;2019 Plan&#8221;), Upon the approval of the 2020 Plan, no future grants could be
        made under the 2019 Plan. As of December 31, 2021, all outstanding options under the 2019 Plan either had been exercised or had expired in accordance with the terms of the applicable award or the 2019 Plan.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In May 2021, Brooklyn&#8217;s board of directors adopted the 2021 Inducement Plan, which provides for the grant of up to 1,500,000 share-based awards as material inducement awards to new employees in accordance with the employment inducement grant rules set forth in
        Section 711(a) of the NYSE American LLC Company Guide. The 2021 Inducement Plan expires in May 2031. As of December 31, 2021, there were approximately 443,000
        nonqualified stock options and 222,000 RSUs outstanding under the 2021 Inducement Plan.</div>

<div><br/></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Equity Awards</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Stock Options</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company records stock-based compensation in accordance with ASC Topic 718, Compensation &#8211; Stock Compensation.&#160; The Company estimates the fair
        value of each stock option award granted with service-based vesting requirements, using the Black-Scholes option pricing model. The Company recognizes the fair value of stock options granted as expense on a straight-line basis over the requisite
        service period.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The risk-free rate is based on the observed interest rates appropriate for the expected life. The expected life (estimated period of time
        outstanding) of the stock options granted is estimated using the &#8220;simplified&#8221; method as permitted by the SEC&#8217;s Staff Accounting Bulletin No. 110, Share-Based Payment. Expected volatility is based on the Company&#8217;s historical volatility over the
        expected life of the stock option granted, and the Company assumes no dividends.&#160;&#160; Forfeitures are recognized as incurred.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">There were no stock options
        outstanding or granted during the year ended December 31, 2020. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following weighted-average assumptions were used for stock options granted during the year ended December 31, 2021:</span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Year ended</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31, 2021 </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Weighted average risk-free rate</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">1.09</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">%</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Weighted average volatility</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">134.64</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">%</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Dividend yield</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">0</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">%</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Expected term</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">6.10 years <br/>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes stock option activity for the year ended December 31, 2021:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Outstanding</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Options</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Weighted</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Average</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Exercise</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Price per Share</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Weighted</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Average</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Remaining</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Contractual</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Life (in years)</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Aggregate</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Intrinsic</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Value</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Outstanding January 1, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Granted</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">3,988,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">8.40</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">9.38</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Outstanding December 31, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">3,988,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">8.40</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">9.38</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Options vested and exercisable at December 31, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The per-share weighted average grant-date fair value of stock options granted during the year ended December 31, 2021 was $7.57.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As of December 31, 2021, the unamortized stock-based compensation expense related to outstanding unvested options was approximately $21,915,000 with a weighted average remaining requisite service period of 3.30 years. The Company expects to amortize this expense over the remaining requisite service period of these stock options.<br/>
      </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Included in the 3,988,000 stock
        options granted during the year ended December 31, 2021, the Company issued two stock option grants to Howard J. Federoff, M.D., Ph.D.
        upon his appointment as the Company&#8217;s Chief Executive Officer and President.</div>

<div><span style="color: rgb(0, 0, 0);"> </span><br/></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Dr. Federoff was granted a nonqualified stock option covering approximately 2,628,000 shares of common stock (the &#8220;Time-Based Option&#8221;). The Time-Based Option was granted at a per share exercise price equal to the closing price of the common stock on the NYSE
        American stock exchange on the date of grant. Of the shares covered by the Time-Based Option, 25% will vest on the one-year anniversary
        of the grant date, and the remaining shares will vest in substantially 36 equal monthly installments thereafter, so long as Dr. Federoff
        provides continuous service to the Company throughout the relevant vesting date.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Dr. Federoff was also granted a performance-based nonqualified stock option covering approximately 597,000 shares of common stock (the &#8220;Milestone Option&#8221;). The Milestone Option was granted at a per share exercise price equal to the closing price of common stock on the NYSE
        American stock exchange on the date of grant, and its fair value is $4,288,738. The Milestone Option will fully vest upon the first
        concurrence by the U.S. Food and Drug Administration that a proposed investigation may proceed following review of a Company filed investigational new drug application in connection with that the License Agreement. This milestone is subject to Dr.
        Federoff&#8217;s continuous service with the Company through such vesting date.</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Both the Time-Based Option and the Milestone Option were granted outside the Company&#8217;s equity incentive plans discussed above.&#160; The unvested
        portion of the Time-Based Option and the Milestone Option will be cancelled upon the termination of Dr. Federoff&#8217;s employment with the Company for any reason, subject to certain vesting acceleration provisions upon a qualifying termination, as
        described in his employment agreement with the Company. Unless earlier terminated in accordance with their terms, each of the Time-Based Option and the Milestone Option will otherwise expire on the tenth anniversary of their respective grant date
        and be subject to the terms and conditions of the respective option agreement approved by the Company. Each of the Time-Based Option and the Milestone Option was intended to constitute an &#8220;employment inducement grant&#8221; in accordance with the
        employment inducement grant rules set forth in Section 711(a) of the NYSE American LLC Company Guide and was offered as an inducement material to Dr. Federoff in connection with his hiring.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">During the year ended December 31, 2021, there were 1,300
        options exercised for total cash proceeds of $10,202.&#160; The options exercised had a total intrinsic value of $47,010.&#160; There were no options exercised
        during the year ended December 31, 2020.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">RSUs</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Outstanding RSUs are settled in an equal number of shares of common stock on the vesting date of the award. An RSU award is settled only to the
        extent vested. Vesting generally requires the continued employment or service by the award recipient through the respective vesting date. Because RSUs are settled in an equal number of shares of common stock without any offsetting payment by the
        recipient, the measurement of cost is based on the quoted market price of the stock at the measurement date, which is the grant date.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">There were no RSUs outstanding or
        granted during the year ended December 31, 2020. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The





















        following table summarizes RSU activity for the years ended December 31, 2021:</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Outstanding</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Restricted</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Stock Units</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Weighted</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Average Fair</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Value per Share</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">January 1, 2021</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Granted</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">240,000</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">13.80</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">December 31, 2021</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">240,000</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">13.80</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Balance expected to vest at December 31, 2021</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">No RSUs vested during the year
        ended December 31, 2021.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company recognizes the intrinsic value of RSUs granted as expense on a straight-line basis over the requisite service period. As of December
        31, 2021, the unamortized stock-based compensation expense related to outstanding RSUs was approximately $2,935,000 with a weighted
        average remaining requisite service period of 3.51 years. The Company expects to amortize this expense over the remaining requisite
        service period of these stock options.</div>

<div><br/></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Restricted Stock</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the Merger, Brooklyn LLC&#8217;s approximately 3,000
        outstanding restricted common units were exchanged for approximately 630,000 shares of Brooklyn&#8217;s restricted common stock. There were no
        changes to any conditions and requirements of the restricted common stock. The shares vest quarterly beginning on March 31, 2021 and continuing through December 31, 2022. Due to the modification of the restricted common units, the fair value of the
        restricted common stock immediately after the Merger was compared to the fair value of the restricted common units immediately prior to the Merger, and the change in fair value of $250,000 was recognized in the statement of operations for year ended December 31, 2021. The Company recognizes the fair value of restricted common stock as an expense on a straight-line
        basis over the requisite service period.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Stock-Based Compensation Expense</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total stock-based compensation expense for the years ended December 31, 2021 and 2020 was approximately $5,235,000 and $91,000, respectively.&#160; Stock-based compensation is
        recorded in general and administrative expense and research and development expense in the statement of operations.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446478024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' and Members' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders and Members Equity (Deficit) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders and Members Equity (Deficit)</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">14)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Stockholders&#8217; and Members&#8217; Equity (Deficit)</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Equity Line Offerings</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On April 26, 2021, Brooklyn and Lincoln Park executed the First Purchase Agreement and a related registration rights agreement. Pursuant to the
        First Purchase Agreement, Brooklyn had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park would be obligated to purchase, up to $20,000,000
        of shares of Brooklyn&#8217;s common stock. Sales of common stock by Brooklyn were subject to certain limitations, and could occur from time to time, at Brooklyn&#8217;s sole discretion. For entering into the First Purchase Agreement, Brooklyn issued to
        Lincoln Park approximately 56,000 shares of common shares as consideration for Lincoln Park&#8217;s commitment to purchase up to $20,000,000 in shares of common stock. As of December 31, 2021, Brooklyn issued and sold to Lincoln Park approximately 1,128,000 shares of common stock under the First Purchase Agreement for gross proceeds of $20,000,000, and no further shares may be sold to Lincoln Park under the First
        Purchase Agreement.</div>

<div><br/></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On May 26, 2021, Brooklyn executed the Second Purchase Agreement and a related registration rights agreement. Pursuant to the Second Purchase
        Agreement, Brooklyn has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park would be obligated to purchase, up to $40,000,000
        of shares of Brooklyn&#8217;s common stock. Sales of common stock by Brooklyn are subject to certain limitations, and may occur from time to time, at Brooklyn&#8217;s sole discretion. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In consideration of Lincoln Park&#8217;s entry</span> </span>into the Second Purchase Agreement, Brooklyn issued to Lincoln Park 50,000 shares of common stock.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the Second Purchase Agreement, the Company may direct Lincoln Park to purchase up to 60,000 shares of common stock on any business day (the &#8220;Regular Purchase&#8221;), which amount may be increased up to 120,000 shares based on the closing price of the common stock, provided that Lincoln Park&#8217;s maximum commitment in any single Regular Purchase may not exceed $2.0 million. The purchase price per share for each such Regular Purchase is based off of the common stock&#8217;s market immediately preceding the time of
          sale.<br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Second Purchase Agreement also prohibits Brooklyn from directing Lincoln Park to purchase any shares of common stock if those shares, when
          aggregated with all other shares of common stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership, at any single point in time, of more than 4.99% of the then total outstanding shares of common stock. Brooklyn has the right to terminate the Second Purchase Agreement at any time, at no cost
          or penalty.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Actual sales of shares of common stock to Lincoln Park under the Second Purchase Agreements depend on a variety of factors to be determined by
          us from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations.<br/>
        </div>

<div><span style="color: rgb(0, 0, 0);"> </span><br/></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">As of December 31,
          2021, Brooklyn had issued and sold approximately 2,424,000 shares of common stock under the Second Purchase Agreement for total gross
          proceeds of approximately $34,106,000. As of December 31, 2021, there were approximately 446,000 shares remaining to be sold under the Second Purchase Agreement. <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Pursuant to the securities purchase agreement in respect of the PIPE
            Transaction, the Company is prohibited from issuing additional shares under the Section Purchase Agreement for a period of one-year immediately following the closing of the PIPE Transaction.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Reverse Stock-Split</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On March 25, 2021, immediately prior to the Merger, Brooklyn filed an amendment to the Certificate of Incorporation with the Secretary of State
          of the State of Delaware to effect a reverse stock split. As a result of the reverse stock split, the number of issued and outstanding shares of common stock immediately prior to the reverse stock split was reduced into a smaller number of
          shares, such that every two shares of common stock held by a stockholder of Brooklyn immediately prior to the reverse stock split were combined and reclassified into <span style="-sec-ix-hidden:Fact_8f4da43a33f64403a03756802f5c0aae">one</span> share of common stock after the reverse stock split.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Immediately following the reverse stock split there were approximately 1,514,000 shares of common stock outstanding prior to the Merger. No fractional shares were issued in connection with the reverse stock split.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Merger</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the terms of the Merger Agreement (see Notes 1 and 4), on March 25, 2021, Brooklyn issued shares of common stock to the equity holders of
          Brooklyn LLC. The 87,000 Class A units of Brooklyn LLC were converted into approximately 22,275,000 shares of common stock; the 15,000,000 Class B
          units were converted into approximately 2,515,000 shares of common stock; the 10,000,000 Class C units were converted into approximately 1,676,000 shares
          of common stock; approximately 630,000 shares of common units were converted into approximately 630,000 shares of common stock, and 10,500,000
          rights options were converted into approximately 11,828,000 shares of common stock.&#160; Brooklyn also issued approximately 1,068,000 shares of common stock to the Financial Advisor pursuant to the Merger Agreement.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Acquisition</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the terms of the Acquisition (see Notes 1 and 4), on July 16, 2021, Brooklyn issued approximately 7,022,000 shares of common stock, of which approximately 3,644,000
          shares are unrestricted and approximately 3,378,000 shares are subject to a three-year lockup agreement, provided that up to 75% of the shares of common
          stock subject to the lock-up agreement may be released from the lock-up restrictions earlier if the price of common stock on the principal market for the common stock exceeds specified thresholds.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="color: rgb(0, 0, 0); font-style: italic; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Cumulative Convertible Preferred Stock</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As a result of the Merger, the Company has authorized 156,000 shares of preferred stock, all of which is designated as Series A Cumulative Convertible Preferred Stock (the &#8220;Series A Preferred Stock&#8221;), and all of which were issued and
        outstanding as of December 31, 2021.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 9pt; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Series A Preferred Stock provides for a cumulative annual dividend of $0.10 per share, payable in semi-annual installments in June and December. Dividends may be paid in cash or with shares of common stock.&#160; The Company paid approximately $8,000 in cash and issued approximately 202
        shares of common stock for payment of dividends during the year ended December 31, 2021.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 9pt; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Series A Preferred Stock has no voting rights and has a $1.00 per share liquidation preference over common stock. The registered holder has the right at any time to convert shares of Series A Preferred Stock into that number of shares of common
        stock that equals the number of shares of Series A Preferred Stock that are surrendered for conversion divided by the conversion rate.&#160; At December 31, 2021, the conversion rate was 3.7016 and, based on that conversion rate, one share of Series A Convertible Preferred Stock would have converted into approximately 0.27 shares of common stock, and all the outstanding shares of the Series A Convertible Preferred Stock would have converted into approximately 42,000 shares of common stock in the aggregate. There were no
        conversions during the year ended December 31, 2021. There is no mandatory conversion term, date or any redemption features associated with the Series A Preferred Stock. The conversion rate will adjust under the following circumstances:</div>

<div><span style="color: rgb(0, 0, 0);"> </span><br/></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">1.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">If the Company (a) pays a dividend or makes a distribution in shares of its common stock, (b) subdivides its outstanding shares of common stock into a greater number of shares, (c) combines its outstanding
                shares of common stock into a smaller number of shares, or (d) issues by reclassification of its shares of common stock any shares of its common stock (other than a change in par value, or from par value to no par value, or from no par
                value to par value), then the conversion rate in effect immediately prior to the applicable event will be adjusted so that the holders of the Series A Convertible Preferred Stock will be entitled to receive the number of shares of common
                stock which they would have owned or have been entitled to receive immediately following the happening of the event, had the Series A Convertible Preferred Stock been converted immediately prior to the record or effective date of the
                applicable event.</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">2.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">If the outstanding shares of the Company&#8217;s common stock are reclassified (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of a
                subdivision, combination or stock dividend), or if the Company consolidates with or merge into another corporation and the Company is not the surviving entity, or if the Company sells all or substantially all of its property, assets,
                business and goodwill, then the holders of the Series A Convertible Preferred Stock will thereafter be entitled upon conversion to the kind and amount of shares of stock or other equity securities, or other property or assets which would
                have been receivable by such holders upon such reclassification, consolidation, merger or sale, if the Series A Convertible Preferred Stock had been converted immediately prior thereto.</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">3.</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">If the Company issues common stock without consideration or for a consideration per share less than the then applicable Equivalent Preference Amount (as defined below), then the Equivalent Preference Amount
                will immediately be reduced to the amount determined by dividing (A) an amount equal to the sum of (1) the number of shares of common stock outstanding immediately prior to such issuance multiplied by the Equivalent Preference Amount in
                effect immediately prior to such issuance and (2) the consideration, if any, received by the Company upon such issuance, by (B) the total number of shares of common stock outstanding immediately after such issuance. The &#8220;Equivalent
                Preference Amount&#8221; is the value that results when the liquidation preference of one share of Series A Convertible Preferred Stock (which is $1.00) is multiplied by the conversion rate in effect at that time; thus the conversion rate
                applicable after the adjustment in the Equivalent Preference Amount as described herein will be the figure that results when the adjusted Equivalent Preference Amount is divided by the liquidation preference of one share of Series A
                Convertible Preferred Stock.</div>
            </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446317976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.9pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">15)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Income Taxes</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Loss before income taxes consist of the following:</div>

<div><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Years ended December 31,</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> 2021</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2020</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Domestic</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(122,296,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(26,531,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total tax provision for income taxes</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(122,301,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(26,531,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">For each of the years ended December 31, 2021 and 2020, current tax provisions and current deferred tax provisions were recorded as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Years ended December 31,</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2020<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Current Tax Provision</div>
            </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Federal<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">State<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">5,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="margin-left: 9pt;">Foreign <br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">5,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Deferred Tax Provision<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Federal<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(5,836,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">State<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(1,433,000</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(322,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
              <div style="margin-left: 9pt;">Foreign <br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">(1,000</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(7,270,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(322,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Change in valuation allowance</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">7,270,000</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">322,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total tax provision for income taxes</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">5,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">Deferred tax assets and liabilities consist of the effects of
        temporary differences as shown in the table below. Deferred tax assets have been fully reserved by a valuation allowance since it is more likely than not that such tax benefits will not be realized.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of December 31,</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> 2021<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2020<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Deferred Tax Assets:</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Net operating losses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5,454,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">747,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Foreign net operating losses<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">595,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">R&amp;D credit carryforwards</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">288,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Stock compensation</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,312,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Vacation accrual</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">30,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Contingent consideration</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5,171,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Deferred rent</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">40,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total gross deferred tax assets</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">12,890,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">747,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Valuation allowance</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(12,610,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(747,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net deferred tax assets</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">280,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Deferred Tax Liabilities:</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Fixed assets</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(168,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Intangibles - goodwill</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(112,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total deferred tax liabilities</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(280,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net deferred taxes</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none;">The reconciliation of
          computed expected income taxes to effective income taxes by applying the federal statutory rate of 21% as follows:</div>

<div>&#160;<br/></div>

<div>
          <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of December 31,</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;2021</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;2020</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Tax at federal income tax rate</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">21.00</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">21.00</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">State income tax, net of federal tax</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1.17</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"><br/>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Non-deductible expenses/excludable items</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(16.33</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Pass-through loss <br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(19.79</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Change in valuation allowance</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(5.94</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(1.21</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Credits</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">0.24</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"/>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.14</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Provision for income taxes</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">0.00</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">% <br/>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">0.00</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">% <br/>
                </td>

  </tr>


</table>
          </div>

<div>
        &#160;</div>

<div style="text-align: justify;">The net increase in the total valuation allowance for the year ended December 31, 2021 was an increase of $11,863,000
          of which $7,270,000 relates to the current year deferred expense and $4,593,000 relates to the purchase accounting related to the 2021 business combinations. In assessing the realizability of deferred tax assets, management considers whether it
          is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary
          difference become deductible. Management considered the scheduled reversal of deferred tax liabilities, projected future taxable income and planning strategies in making this assessment.&#160; Based on the level of historical operating results and
          projections for the taxable income for the future, management has determined that it is more likely than not that the deferred taxes assets will not be utilized. Accordingly, the Company has recorded a full valuation allowance. </div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">At December 31, 2021 and 2020 the Company has available net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $20,679,000 and $0 for federal income
          tax purposes, respectively, of which $20,679,000 can be carried forward indefinitely. The Company has available $1,397,000 and $747,000 state NOLs for
          the years ended December 31, 2021 and 2020, respectively.&#160; The Company also has foreign NOL carryforwards of $4,759,000 and $0 for the years ended December 31, 2021 and 2020, respectively, which carry forward indefinitely. Section 382 of the Internal Revenue Code (&#8220;IRC&#8221;)
          imposes limits on the ability to use NOL carryforwards that existed prior to a change in control to offset future taxable income. Such limitations would reduce, potentially significantly, the gross deferred tax assets disclosed in the table above
          related to the NOL carryforwards.&#160; The Company continues to disclose the NOL carryforwards at their original amount in the table above as no potential limitation has been quantified. The Company has also established a full valuation allowance for
          all deferred tax assets, including the NOL carryforwards, since the Company could not conclude that it was more likely than not able to generate future taxable income to realize these assets.</div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">At December 31, 2021 and 2020 the Company has federal and state income tax credit carryforwards of approximately $288,000 and $0, respectively. The
          credits begin to expire in 2041.</div>

<div><br/>
        </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the
          largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The Company has no uncertain tax positions as of December 31, 2021 or December 31, 2020.</div>

<div><br/>
        </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">The Company recognizes interest and penalties related to unrecognized tax positions within the income tax expense line in the accompanying
          consolidated statements of operations. There were no accrued interest and penalties associated with uncertain tax positions as of
          December 31, 2021 or December 31, 2020.</div>

<div><br/>
        </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">The Company is subject to U.S. federal, state, and foreign income tax. Tthe Company&#8217;s income tax returns are subject to examination by the
          relevant taxing authorities. As of December 31, 2021, the <span style="-sec-ix-hidden:Fact_145d916fadf245a7a67bdeb44d432d49">2018 &#8211; 2021</span> tax years remain subject to examination in the U.S. federal tax,
          various state, and foreign tax jurisdictions. The Company is not currently under examination by federal state, or foreign jurisdictions.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446317976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Retirement Savings Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsDisclosureTextBlock', window );">Retirement Savings Plan</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.9pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">16)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Retirement Savings Plan</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company established a defined contribution plan, organized under Section 401(k) of the Internal Revenue Code, which allows employees to defer
        up to 90% of their pay on a pre-tax basis. The Company does not contribute a match to the employees&#8217; contribution.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for postemployment benefits,  which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6410195&amp;loc=d3e80090-111668<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446507112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.9pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">17)</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Subsequent Events</div>
            </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;">Private Placement of
            Equity</div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </div>

<div style="text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On
              March 6, 2022, the Company entered into a certain Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with an investor (the &#8220;PIPE Investor&#8221;) providing for the private placement (the &#8220;PIPE Transaction&#8221;) to a private investor (the &#8220;PIPE
              Investor&#8221;) of approximately 6,857,000 units (collectively, the &#8220;Units&#8221;), each Unit consisting of (i) one share of our common stock (or, in lieu thereof, one pre-funded warrant (the &#8220;Pre-Funded Warrants&#8221;) to purchase one share of common stock) and
              (ii) one warrant (the &#8220;Common Warrants&#8221;) to purchase one share of common stock, for an aggregate gross purchase price of
              approximately $12.0 million. The PIPE Transaction closed on March 9, 2022.</span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Each
              Pre-Funded Warrant has an exercise price of $0.005 per share of common stock, was immediately exercisable and may be exercised at
              any time and has no expiration date and is subject to customary adjustments. The Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 9.99% immediately after exercise thereof.</span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Each Common Warrant
            has an exercise price of $1.91 per share, becomes exercisable six months following the closing of the PIPE Transaction, and expires <span style="-sec-ix-hidden:Fact_2d5f06641c0a4e39b73cdc701f6abe8c">five-and-one-half years</span> from the date of issuance, and is subject to customary adjustments. The Common Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 4.99% immediately after exercise thereof, subject to increase to 9.99% at the option of the holder.</div>

<div><br/>
          </div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In connection with
            the PIPE Transaction, the Company and the PIPE Investor also entered into a registration rights agreement, dated March 6, 2022, pursuant to which the Company agreed to prepare and file a registration statement with the SEC no later than 15 days
            following the filing date of this Annual Report on Form 10-K to register the resale of the shares of common stock included in the Units and the shares of common stock issuable upon exercise of the Pre-Funded Warrants and the Common Warrants.
            The Company agreed to use its best efforts to have such registration statement declared effective as promptly as possible after the filing thereof, subject to certain specified penalties if timely effectiveness is not achieved.</div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;">Reduction in Force</div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On January 3, 2022,
            the Company completed a reduction in force (the &#8220;Reduction&#8221;), comprising eight employees (53% of our workforce at that time), effective January 3, 2022, which was the date on which the Company notified such employees of their termination. The Company believes
            the Reduction, which was approved by its Board of Directors, will enable the Company to better align its workforce with the needs of its business and focus more of its capital resources on the Company&#8217;s cell therapy and gene editing platform,
            as it continues to sustain its investment in the prosecution of IRX-2 through the end of the INSPIRE Phase 2B study. In connection with the Reduction, the Company estimates that it will incur approximately $500,000 for severance and termination-related costs, which the Company will record during the first quarter of 2022. The Company may also incur
            additional costs and non-cash charges that are not currently contemplated or determinable, which may occur as a result of the Reduction.</div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;">Lease Assignment</div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </div>

<div style="text-align: justify;">On March 5, 2022, the Company entered into an Agreement to Assign Space Lease with RegenLab USA LLC<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> (&#8220;Regen&#8221;) pursuant to which the Company agreed to assign its Brooklyn, NY lease (the &#8220;Brooklyn Lease&#8221;) to Regen. The effective date of the
              assignment would be contingent upon, among other things, a consent from BioBat, Inc. (the &#8220;Landlord&#8221;) to assign the Brooklyn Lease. Additionally, Regen agreed to purchase certain equipment from the Company for $50,000, partly reimburse the Company $50,000
              toward certain existing unamortized leasehold improvements, and to reimburse the Company for the existing security deposit the Company had under the Brooklyn Lease of approximately $63,000.</span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On March 25, 2022,
            the Company entered into an Assignment and Assumption of Lease Agreement (the &#8220;Assignment Agreement&#8221;) with Regen, the consent of which was provided by the Landlord in the Assignment Agreement. The effective date of the assignment was March 28,
            2022. Under the Assignment Agreement, Regen (i) accepts the assignment of the Brooklyn Lease; (ii) assumes all of the obligations, liabilities, covenants and conditions of the Company&#8217;s as tenant under the Brooklyn Lease; (iii) assumes and
            agrees to perform and observe all of the obligations, terms, requirements, covenants and conditions to be performed or observed by the Company under the Brooklyn Lease; and (iv) makes all of the representations and warranties binding under the
            Brooklyn Lease with the same force and effect as if Regens had executed the Brooklyn Lease originally as the tenant.</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Notwithstanding the
            above assumptions above by Regen, the Company shall be and remain liable and responsible for the due keeping, and full performance and observance, of all the provisions of the Brooklyn Lease on the part of the tenant to be kept, performed and
            observed. As a result of the Assignment Agreement, the Company will write off the remaining ROU asset balance and the corresponding lease liability as of March 25, 2022, and it will record any resulting gain or loss on the termination of the
            Brooklyn lease in its statement of operations.&#160; The Company does not expect to recognize a contingent liability for its ongoing obligation to remain liable and responsible for all the provisions of the Brooklyn Lease, as the Company has
            determined that it is not probable it will recognize a loss under the Assignment Agreement.</div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;">New Lease Agreement</div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
          </div>

<div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On March 31, 2022,
            the Company entered into the Torrey Pines Science Center Lease in San Diego, California (the &#8220;San Diego Lease&#8221;) with Torrey Pines Science Center Limited Partnership for approximately 5,200 square feet of lab and office space. The term of the San Diego Lease is 62
            months and the lease commencement date begins on the earlier to occur of (i) the date the Company first commences to conduct business in the premises or (ii) the possession date, which is anticipated to be August 1, 2022 (or earlier if the
            current tenant terminates its lease early). The lease commencement date was April <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">15</span>, 2022.</div>

<div><br/>
          </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;">Base rent is $6.35 per square foot in the first year of the San Diego Lease, with a rent abatement for the second and third full months of the first year. The
            base rent will increase by approximately 3% on each anniversary of the lease commencement date. The Company is also required to pay
            its share of operating expenses and property taxes. The San Diego Lease provides for a one-time option to extend the lease term for an additional five years at the then fair rental value.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718445222744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Accounting Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Accounting Presentation and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting Presentation</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Basis of Accounting Presentation</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference
        in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). All significant intercompany
        balances and transactions have been eliminated in consolidation.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">As described above, the Merger closed on March 25, 2021. The Merger was accounted for as a reverse acquisition, in which Brooklyn LLC was deemed
          the acquiring company for accounting purposes. Brooklyn LLC&#8217;s historical financial statements have replaced Brooklyn&#8217;s historical financial statements with respect to periods prior to the completion of the Merger (when Brooklyn operated under the
          name &#8220;NTN Buzztime, Inc.&#8221;). The Company retrospectively adjusted the weighted average shares used in determining loss per common share to reflect the conversion of the outstanding Class A units, Class B units, Class C units, and common units of
          Brooklyn LLC that converted into shares of Brooklyn&#8217;s common stock upon the Merger and to reflect the effect of a <span style="-sec-ix-hidden:Fact_565a5991ac0445a8b9e9f14506915bfe">2-to-1</span> reverse stock
          split of Brooklyn&#8217;s common stock that occurred immediately prior to the Merger.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Also as described above, the Acquisition closed on July 16, 2021. The Acquisition was accounted for as an asset acquisition, and substantially
          all of the value was attributed to in-process research and development (&#8220;IPR&amp;D&#8221;), with the exception of the cash paid for the investment in NoveCite, which is being accounted for as an investment in equity securities. The IPR&amp;D had no
          alternative future uses and no separate economic value from its originally intended purpose and was therefore expensed in the period the cost was incurred.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Use of Estimates</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (a)
        the reported amounts of assets and liabilities; (b) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; (c) the reported amounts of revenues and expenses during the reporting period and (d) the
        reported amount of the fair value of assets acquired in connection with business combinations. Actual results could differ from those estimates. The Company&#8217;s significant estimates and assumptions include the recoverability and useful lives of
        long-lived assets and the contingent consideration liability.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Cash and Cash Equivalents</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company classifies highly liquid investments with a remaining contractual maturity at date of purchase of three months or less as cash
        equivalents. The Company had no cash equivalents as of December 31, 2021 or 2020.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Property and Equipment</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment are recorded at cost and are depreciated over their estimated useful lives using the straight-line method. Laboratory and
        manufacturing equipment are depreciated over an estimated useful life of seven years. Leasehold improvements are depreciated over the
        shorter of their estimated useful life, or the lease term. Computer equipment are depreciated over an estimated useful life of three years.
        Upon retirement or other disposition of these assets, the cost and related accumulated depreciation of these assets are removed from the accounts and the resulting gain or losses are reflected in the results of operations. Expenditures for
        maintenance and repairs are charged to operations. Renewals and betterments are capitalized.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Goodwill</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in the acquisition of IRX
        Therapeutics, Inc. in November 2018 (the &#8220;IRX Acquisition&#8221;), which was accounted for as a business combination. Goodwill is not amortized but is tested for impairment annually, or if events occur or circumstances change that would reduce the fair
        value of a reporting unit below its carrying value. Because management evaluates the Company as a single reporting unit, goodwill is tested for impairment at the entity level by first performing a qualitative assessment to determine whether it is
        more likely than not that the fair value of the entity is less than its carrying value. Such qualitative factors include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant
        events.&#160; If the entity does not pass the qualitative assessment, then the entity&#8217;s carrying value is compared to its fair value. Goodwill is considered impaired if the carrying value of the entity exceeds its fair value.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">IPR&amp;D</a></td>
<td class="text">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">IPR&amp;D</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">IPR&amp;D assets represent the fair value assigned to technologies that were acquired in connection with the IRX Acquisition, which have not
        reached technological feasibility and have no alternative future use. IPR&amp;D assets are considered to be indefinite lived until the completion or abandonment of the associated research and development projects. During the period that the
        IPR&amp;D assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the
        IPR&amp;D assets are less than their carrying amounts. If and when development is complete, which generally occurs upon regulatory approval, and the Company is able to commercialize products associated with the IPR&amp;D assets, these assets are
        then deemed definite-lived and are amortized based on their estimated useful lives beginning at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&amp;D assets,
        calculated as the excess of carrying value of the IPR&amp;D assets over fair value.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Impairment of Long-Lived Assets</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company reviews long-lived assets and certain identifiable assets for impairment whenever circumstances and situations change such that there
        is an indication that the carrying amounts may not be recovered. An impairment exists when the carrying value of the long-lived asset is not recoverable and exceeds its fair value. For the years ended December 31, 2021 and 2020, there were no
        qualitative factors that indicated it was more likely than not that the fair value of the long-lived assets exceeded the carrying value.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Research and Development</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company expenses its research and development costs as incurred. Research and development expenses consist of costs incurred for
        company-sponsored research and development activities, as well as support for selected investigator-sponsored research. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the
        period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. IPR&amp;D that is acquired through an asset acquisition (as
        opposed to a business combination) and has no alternative future uses and, therefore, no separate economic values, is expensed to research and development costs at the time the costs are incurred.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The major components of research and development costs include preclinical study costs, clinical manufacturing costs, clinical study and trial
        expenses, insurance coverage for clinical trials, expensed licensed technology, expensed IPR&amp;D, consulting, scientific advisors and other third-party costs, salaries and employee benefits, stock-based compensation expense, supplies and
        materials and allocations of various overhead costs related to our product development efforts.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In the normal course of our business, the Company contracts with third parties to perform various clinical study and trial activities in the
        on-going development and testing of potential products. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors
        such as the achievement of certain events or milestones, the successful enrollment of patients, the allocation of responsibilities among the parties to the agreement, and the completion of portions of the clinical study or trial or similar
        conditions. Preclinical and clinical study and trial associated activities such as production and testing of clinical material require significant up-front expenditures. The Company anticipates paying significant portions of a study&#8217;s or trial&#8217;s
        cost before they begin and incurring additional expenditures as the study or trial progresses and reaches certain milestones.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Income Taxes</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company records deferred tax liabilities and assets based on the differences between the consolidated financial statements carrying amounts
        and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and established a valuation allowance when it was more likely than not that some portion or all of the deferred tax
        assets would not be realized. Income tax expense consists of the tax payable for the period and the change during the period in deferred tax assets and liabilities.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Tax benefits from uncertain tax positions are recognized only if it is more likely than not that the tax position will be sustained on examination
        by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of
        being realized upon ultimate resolution. The Company has no material uncertain tax positions for any of the reporting periods presented.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Earnings Per Share</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Basic and diluted loss per common share have been computed by dividing the losses applicable to common stock by the weighted average number of
        common shares outstanding. The Company&#8217;s basic and fully diluted earnings per share (&#8220;EPS&#8221;) calculation are the same since the increased number of shares that would be included in the diluted calculation from assumed exercise of common stock
        equivalents would be anti-dilutive to the net loss in each of the years shown in the consolidated financial statements.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Segment Reporting</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In accordance with ASC No. 280, <span style="font-style: italic;">Segment Reporting</span>, the Company has determined that it operates as one operating segment. Decisions regarding the Company&#8217;s overall operating performance and allocation of its resources are assessed on a consolidated
        basis.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Concentration of Credit Risk</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company maintains its cash balances in financial institutions located in the United States. Accounts at each institution are insured by the
        Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250,000. At times, the Company&#8217;s cash balances may be uninsured for deposit accounts that exceed the FDIC insurance limit.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In the Company&#8217;s business, vendor concentrations could be indicative of vulnerabilities in the Company&#8217;s supply chain, which could ultimately
        impact the Company&#8217;s ability to continue its research and development activities. For the years ended December 31, 2021 and 2020, there was no vendor concentration related to the Company&#8217;s research and development activities.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Fair Value of Financial Instruments</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between
        willing market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The
        fair value hierarchy is as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Level 1 Inputs &#8211; Valued based on quoted prices in active markets for identical
          assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Level 2 Inputs &#8211; Valued based on inputs other than quoted prices included in Level
          1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that
          are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market
          data by correlation or other means.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);">&#8226;</span>&#160;&#160;&#160;&#160; <span style="color: rgb(0, 0, 0);">Level 3 Inputs &#8211; Valued based on inputs for which there is little or no market
          value, which require the reporting entity to develop its own assumptions.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The carrying amounts reported on the balance sheet for cash and cash equivalents, accounts receivable, prepaid assets and other current assets,
        accounts payable and accrued expenses, other current liabilities and other liabilities approximate fair value based due to their short maturities. The carrying value of loans payable approximates its fair market value because the effective yield on
        this debt, which includes contractual interest rates as well as other finance charges, is comparable to rates of returns for instruments of similar credit risk.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Leases</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company adopted ASC Topic 842, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Leases,</span>
        on December 31, 2020 using the modified transition method without retrospective application to comparative periods. The Company elected the package of three practical expedients allowed for under the transition guidance. Accordingly, the Company
        did not reassess: (1) whether any expired or existing contracts are/or contain leases; (2) the lease classification for any expired or existing leases; or (3) initial direct costs for any existing leases. The Company has also elected not to
        recognize right-of-use assets (&#8220;ROU assets&#8221;) and lease liabilities for short-term leases that have a term of 12 months or less.</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Operating lease liabilities represent the present value of lease payments not yet paid. ROU assets represent the Company&#8217;s right to use an
          underlying asset and are based upon the operating lease liabilities adjusted for prepaid or accrued lease payments, initial direct costs, lease incentives and impairment of operating lease assets. If the interest rate implicit in the lease is not
          readily determinable, the Company uses the incremental borrowing rates based on the information available at the lease commencement date in determining the present value of lease payments. To determine the present value of lease payments not yet
          paid, the Company estimates secured borrowing rates corresponding to the maturities of the leases.</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company has elected the practical expedient to not separate non-lease components from the lease components to which they relate and instead
          account for each as a single lease component for all underlying asset classes. Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as payments for insurance, tax payments and other
          miscellaneous costs. The variable portion of lease payments is not included in the ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are expensed when the obligation for those payments
          is incurred and are included in lease expenses. Accordingly, all expenses associated with a lease contract are accounted for as lease expenses.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitment and Contingencies</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Commitment and Contingencies</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company follows ASC No.450-20, <span style="font-style: italic;">Loss Contingencies</span>, to report accounting for contingencies.
        Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Stock-Based Compensation</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company recognizes stock-based compensation expense for equity awards granted to employees, directors and certain consultants. The Company
        estimates the fair value of stock options using the Black-Scholes option pricing model. The fair value of stock options granted is recognized as expense over the requisite service period. Stock-based compensation expense for share-based payment
        awards is recognized using the straight-line single-option method.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Recent Accounting Standards</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In May 2021, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) <span style="font-style: italic;">2021-04,


























          Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain
          Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span>. ASU 2021-04 addresses the accounting for certain modifications or exchanges of freestanding equity-classified written call options. ASU 2021-04 is effective
        for fiscal years beginning after December 15, 2021 (January 1, 2022 for the Company) and interim periods within those fiscal years, with early adoption permitted. The Company does not expect the adoption of this update to have a significant impact
        on its financial statements.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In July 2021, the FASB issued ASU 2021-05, <span style="font-style: italic;">Leases (Topic 842) &#8211; Lessors - Certain Leases with Variable Lease
          Payments,</span> which amends the lessor classification guidance to introduce additional criteria when classifying leases with variable lease payments that do not depend on a reference index or a rate. This guidance is effective for annual
        periods beginning after December 15, 2021 (January 1, 2022 for the Company), with early adoption permitted. The Company does not expect the adoption of this update to have a significant impact on its financial statements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718441945624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger, Disposition and Acquisition Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Merger, Disposition and Acquisition Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Tangible and Intangible Assets Acquired And Liabilities Assumed, Based on Estimated Fair Values</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The allocation of the estimated purchase price to the tangible and intangible assets acquired and liabilities deemed to be assumed from Brooklyn,
        based on their estimated fair values as of March 25, 2021, is as follows:</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Historical</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Balance</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Sheet of</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Brooklyn at</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">March 25, 2020</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Fair Value</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Adjustment</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">to Brooklyn</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Pre-Merger</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Assets</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Purchase</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Price</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Allocation Pro</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Forma</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Adjustment</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Cash and cash equivalents</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">148,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">148,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accounts receivable</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">103,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">103,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Prepaid expense and other current assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">329,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">329,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Property and equipment, net</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">1,015,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">1,015,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Software development costs</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">1,296,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(368,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">928,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Customers</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">548,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">548,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Trade name</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">299,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">299,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accounts payable, accrued liabilities and other current liabilities</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(3,781,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(3,781,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Net assets acquired, excluding goodwill</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(890,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">479,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(411,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total consideration</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">8,178,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Net assets acquired, excluding goodwill</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(411,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Goodwill</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">8,589,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposition Details</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On March 26, 2021, Brooklyn sold its rights, title and interest in and to the assets relating to the business it operated (under the name NTN
        Buzztime, Inc.) prior to the Merger to eGames.com in exchange for a purchase price of $2,000,000 and assumption of specified liabilities
        relating to that business. The sale was completed in accordance with the terms of the Asset Purchase Agreement. Details of the Disposition are as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Proceeds from sale:</div>
            </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Cash</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">132,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Escrow</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">50,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Assume advance/loans</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">1,700,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Interest on advance/loans</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">68,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Carrying value of assets sold:</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Cash and cash equivalents</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(14,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accounts receivable</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(75,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Prepaids and other current assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(124,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Property and equipment, net</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(1,014,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Software development costs</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(927,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Customers</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(548,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Trade name</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(299,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Goodwill</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(8,589,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Other assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(103,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Liabilities transferred upon sale:</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accounts payable and accrued expenses</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">113,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Obligations under finance leases</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">17,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Lease liability</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">26,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Deferred revenue</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">55,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Other current liabilities</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">149,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Transaction costs</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(265,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Total loss on sale of assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">(9,648,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div>
            </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Pro Forma Financial Information</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following unaudited pro forma financial information summarizes the results of operations for the years months ended December 31, 2021 and 2020
        as if the Merger and the Disposition had been completed as of January 1, 2020. Pro forma information primarily reflects adjustments relating to the reversal of transaction costs. Assuming that the Merger and the Disposition had been completed as of
        January 1, 2020, the transaction costs would have been expensed in the prior period.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> Years ended December 31,</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2021<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2020<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Net loss attributable to common stockholders</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">(122,306,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">(26,547,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Basic and diluted net loss per share attributable to common stockholders</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(2.82</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(1.51</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Fair Value of Asset Acquired</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The resulting fair value of the asset acquired is as follows:</span>
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Fair Value of</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Consideration</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Cash paid</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">22,882,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Cash acquired</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(28,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.46%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Unrestricted shares</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">36,628,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.46%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Restricted shares</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">22,056,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.46%; background-color: rgb(204, 238, 255);" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total fair value of consideration paid</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">81,538,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.46%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Less amount of cash paid for NoveCite investment</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(1,000,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 83.46%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Fair value of IPR&amp;D acquired</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">80,538,000<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718528381240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Liabilities Measured at Fair Value</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following tables summarize the liabilities that are measured at fair value as of December 31, 2021 and 2020:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of December 31, 2021</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Description</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 1</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 2</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 3</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-style: italic;">Liabilities:</div>
            </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Contingent consideration</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">19,930,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">19,930,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of December 31, 2020</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Description</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 1</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 2</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Level 3</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-style: italic;">Liabilities:</div>
            </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Contingent consideration</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">20,110,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">20,110,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Carrying Amount of Contingent Consideration Liabilities</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Contingent consideration for the IRX Acquisition was initially valued at the transaction price and is subsequently valued at the end of each
        reporting period using third-party valuation services or other market observable data. The third-party valuation services use industry standard valuation models, including discounted cash flow analysis, to determine the value. After completing its
        validation procedures as of December 31, 2021, the Company adjusted the carrying amount of its contingent consideration liabilities as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Year ended</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31, 2021 </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Balance as of beginning of period</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">20,110,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Fair value adjustments included in operating expenses</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(180,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Balance as of end of period</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">19,930,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446546840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Equipment</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment consist of the following:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2020</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Laboratory and manufacturing equipment</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">258,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">300,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Leasehold improvements<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">464,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">414,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Computer equipment</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">154,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">877,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">714,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Less: accumulated depreciation and amortization</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(207,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(120,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Property and equipment, net</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">670,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">594,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718451333352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Net Operating Lease Expense</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company recognizes operating lease expense and lease payments from the sublease on a straight-line basis in its statements of operations
          over the lease terms. During the years ended December 31, 2021 and 2020, the net operating lease expenses were as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Years ended December 31,</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; font-weight: bold;">2021</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; font-weight: bold;">2020</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Operating lease expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">688,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">591,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Sublease income</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(84,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(77,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Variable lease expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">19,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">21,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Total lease expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">623,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">535,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock', window );">Operating Lease Right-of-use Assets and Liabilities</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The tables below show the beginning balances of the operating ROU assets and lease liabilities as of January 1, 2021 and the ending balances as of
        December 31, 2021, including the changes during the period.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Operating Lease</div>
              <span style="font-weight: bold;"> </span>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ROU Assets</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Operating lease ROU assets at January 1, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2,093,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Amortization of operating lease ROU assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(342,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Addition of operating lease ROU assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">816,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Operating lease ROU assets at December 31, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2,567,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0);">Operating Lease</div>
              <div style="text-align: center; color: rgb(0, 0, 0);">Liabilities</div>
            </td>

    <td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Operating lease liabilities at January 1, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2,178,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Principal payments on operating lease liabilities</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(321,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Addition of operating lease liabilities</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">866,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Operating lease liabilities at December 31, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2,723,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Less non-current portion</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2,297,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Current portion at December 31, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">426,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Liabilities</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The maturities of the operating
          lease liabilities are as follows:</span>
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">750,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2023</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">767,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2024</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">785,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2025</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">802,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2026</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">267,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Thereafter</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">246,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total payments</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">3,617,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Less imputed interest</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(894,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total operating lease liabilities</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2,723,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock', window );">Future Lease Payments from Sublease Agreement</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Tenant is also responsible for paying to the Company all tenant energy costs, annual
          operating costs, and annual tax costs attributable to the subleased space during the term of the sublease.</span>
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2021<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">82,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2023</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">84,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2024</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">86,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2025</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">88,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">2026</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">75,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">415,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future lease payments of sublease agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating lease right-of-use assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446471816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Accrued expenses consisted of the following:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">As of December 31,</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2021<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2020</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accrued compensation</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">656,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">294,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accrued research and development expenses</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">222,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">207,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accrued general and administrative expenses</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">371,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">400,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Accrued interest</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">150,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total accrued expenses</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">1,249,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">1,051,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446322408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Earnings per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Basic and Diluted Earnings per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Computation of Diluted Net Loss per Common Share</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The following table shows the amount of stock options,
        RSUs and convertible preferred stock that were excluded from the computation of diluted net loss per common share for the year ended December 31, 2021, as their effect was anti-dilutive:<br/>
      </span>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <br/>
      </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">
        <table border="0" cellpadding="0" cellspacing="0" style="width: 100%;">


  <tr>

    <td style="width: 84.65%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;"><br/>
              </td>

    <td style="width: 0.98%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="2" style="width: 13.45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Year ended</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31, 2021<br/>
                </div>
              </td>

    <td style="width: 0.92%; vertical-align: bottom; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 84.65%; vertical-align: middle; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Stock options</div>
              </td>

    <td style="width: 0.98%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 1.1%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td style="width: 12.35%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">3,988,000</div>
              </td>

    <td style="width: 0.92%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 84.65%; vertical-align: middle; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">RSUs</div>
              </td>

    <td style="width: 0.98%; vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 1.1%; vertical-align: bottom; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 12.35%; vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">240,000</div>
              </td>

    <td style="width: 0.92%; vertical-align: bottom; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 84.65%; vertical-align: middle; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Preferred stock converted into common stock</div>
              </td>

    <td style="width: 0.98%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 1.1%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 12.35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">42,000</div>
              </td>

    <td style="width: 0.92%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 84.65%; vertical-align: middle; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total potential common shares excluded from computation</div>
              </td>

    <td style="width: 0.98%; vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 1.1%; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;">&#160;</td>

    <td style="width: 12.35%; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">4,270,000</div>
              </td>

    <td style="width: 0.92%; vertical-align: bottom; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

  </tr>


</table>

      </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718448016120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions Used for Grants Issued</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following weighted-average assumptions were used for stock options granted during the year ended December 31, 2021:</span>
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Year ended</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31, 2021 </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Weighted average risk-free rate</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">1.09</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">%</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Weighted average volatility</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">134.64</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">%</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Dividend yield</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">0</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">%</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Expected term</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom">6.10 years <br/>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarizes of Stock Option Activity</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes stock option activity for the year ended December 31, 2021:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Outstanding</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Options</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Weighted</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Average</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Exercise</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Price per Share</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Weighted</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Average</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Remaining</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Contractual</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Life (in years)</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Aggregate</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Intrinsic</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Value</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Outstanding January 1, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Granted</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">3,988,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">8.40</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">9.38</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Outstanding December 31, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">3,988,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">8.40</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">9.38</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Options vested and exercisable at December 31, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summarizes of RSU Activity</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The





















        following table summarizes RSU activity for the years ended December 31, 2021:</span>
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Outstanding</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Restricted</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Stock Units</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Weighted</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Average Fair</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Value per Share</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">January 1, 2021</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Granted</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">240,000</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">13.80</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">December 31, 2021</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">240,000</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">13.80</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Balance expected to vest at December 31, 2021</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718531166296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Loss before Income Taxes</a></td>
<td class="text">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Loss before income taxes consist of the following:</div>

<div><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Years ended December 31,</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> 2021</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2020</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Domestic</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(122,296,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(26,531,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total tax provision for income taxes</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(122,301,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(26,531,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div>
              </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Income Tax Provision</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">For each of the years ended December 31, 2021 and 2020, current tax provisions and current deferred tax provisions were recorded as follows:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Years ended December 31,</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2020<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Current Tax Provision</div>
            </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Federal<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">State<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">5,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="margin-left: 9pt;">Foreign <br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">5,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Deferred Tax Provision<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%;" valign="bottom">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">Federal<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(5,836,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0); margin-left: 9pt;">State<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(1,433,000</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">(322,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
              <div style="margin-left: 9pt;">Foreign <br/>
              </div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">(1,000</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(7,270,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(322,000</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Change in valuation allowance</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">7,270,000</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">322,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">Total tax provision for income taxes</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">5,000</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
              <div style="color: rgb(0, 0, 0);">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">Deferred tax assets and liabilities consist of the effects of
        temporary differences as shown in the table below. Deferred tax assets have been fully reserved by a valuation allowance since it is more likely than not that such tax benefits will not be realized.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
      </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of December 31,</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> 2021<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2020<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Deferred Tax Assets:</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Net operating losses</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5,454,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">747,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Foreign net operating losses<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">595,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">R&amp;D credit carryforwards</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">288,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Stock compensation</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1,312,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Vacation accrual</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">30,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Contingent consideration</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">5,171,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Deferred rent</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">40,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total gross deferred tax assets</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">12,890,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">747,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Valuation allowance</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(12,610,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(747,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net deferred tax assets</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">280,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Deferred Tax Liabilities:</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Fixed assets</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(168,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;">Intangibles - goodwill</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(112,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total deferred tax liabilities</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(280,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net deferred taxes</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">-</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
         </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Computed Expected Income Taxes to Effective Income Taxes</a></td>
<td class="text">
<div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none;">The reconciliation of
          computed expected income taxes to effective income taxes by applying the federal statutory rate of 21% as follows:</div>

<div>&#160;<br/></div>

<div>
          <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of December 31,</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;2021</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;2020</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Tax at federal income tax rate</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">21.00</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">%</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">21.00</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">State income tax, net of federal tax</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">1.17</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"><br/>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Non-deductible expenses/excludable items</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(16.33</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Pass-through loss <br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(19.79</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Change in valuation allowance</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(5.94</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(1.21</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Credits</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">0.24</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"/>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Other</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(0.14</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Provision for income taxes</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">0.00</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">% <br/>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">0.00</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">% <br/>
                </td>

  </tr>


</table>
          </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718528381240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of Business Operations (Details)<br></strong></div></th>
<th class="th"><div>Jul. 16, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NoveCiteINCMember', window );">NoveCite, INC. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Description of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of total outstanding equity interests</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=btx_NoveCiteINCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=btx_NoveCiteINCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718441820376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Capital Resources (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 09, 2022</div></th>
<th class="th"><div>Jul. 16, 2021</div></th>
<th class="th"><div>May 26, 2021</div></th>
<th class="th"><div>Apr. 26, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract', window );"><strong>Liquidity and Capital Resources [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,985,000<span></span>
</td>
<td class="nump">$ 1,630,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(159,703,000)<span></span>
</td>
<td class="num">(37,381,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_NetIncomeLossAttributableToParentTemporaryElement', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122,306,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,488,000)<span></span>
</td>
<td class="num">(8,101,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ResearchAndDevelopmentInProcessAssetAcquisition', window );">IPR&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,538,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on sales of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,648,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,000)<span></span>
</td>
<td class="nump">19,240,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock to be purchased under common stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,025,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PaymentsToAcquireProductiveAssetsNet', window );">Cash paid, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,854,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract', window );"><strong>Liquidity and Capital Resources [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds</a></td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=btx_NovellusTherapeuticsLimitedMember', window );">Novellus, Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract', window );"><strong>Liquidity and Capital Resources [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ResearchAndDevelopmentInProcessAssetAcquisition', window );">IPR&amp;D expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PaymentsToAcquireProductiveAssetsNet', window );">Cash paid, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,854,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_LincolnParkCapitalFundLLCMember', window );">Lincoln Park [Member] | First Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract', window );"><strong>Liquidity and Capital Resources [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock to be purchased under common stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_CommencementPeriodOfCommonStockInPurchaseAgreement', window );">Common stock purchase agreement commencement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock issued and sold during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_LincolnParkCapitalFundLLCMember', window );">Lincoln Park [Member] | First Purchase Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract', window );"><strong>Liquidity and Capital Resources [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock to be purchased under common stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_LincolnParkCapitalFundLLCMember', window );">Lincoln Park [Member] | Second Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract', window );"><strong>Liquidity and Capital Resources [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_CommencementPeriodOfCommonStockInPurchaseAgreement', window );">Common stock purchase agreement commencement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock issued and sold during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,424,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_LincolnParkCapitalFundLLCMember', window );">Lincoln Park [Member] | Second Purchase Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract', window );"><strong>Liquidity and Capital Resources [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock to be purchased under common stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_CommencementPeriodOfCommonStockInPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for common stock purchase agreement commencement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_CommencementPeriodOfCommonStockInPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_NetIncomeLossAttributableToParentTemporaryElement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent Temporary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_NetIncomeLossAttributableToParentTemporaryElement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PaymentsToAcquireProductiveAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets excluding cash acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PaymentsToAcquireProductiveAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ResearchAndDevelopmentInProcessAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a asset acquisition have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_ResearchAndDevelopmentInProcessAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=btx_NovellusTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=btx_NovellusTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=btx_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=btx_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btx_FirstPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btx_FirstPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btx_SecondPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btx_SecondPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446546280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Accounting Presentation and Summary of Significant Accounting Policies, Basis of Accounting Presentation (Details)<br></strong></div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock splits (in shares)</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446448872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Accounting Presentation and Summary of Significant Accounting Policies, Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718451438872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Accounting Presentation and Summary of Significant Accounting Policies, Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=btx_LaboratoryAndManufacturingEquipmentMember', window );">Laboratory and Manufacturing Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=btx_LaboratoryAndManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=btx_LaboratoryAndManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446488840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Accounting Presentation and Summary of Significant Accounting Policies, Segment Reporting (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>Segments</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718445257816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger, Disposition and Acquisition Transactions, Merger (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Merger Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares of common stock owned by stockholders immediately before the Merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,021,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,044,000<span></span>
</td>
<td class="nump">$ 2,044,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Merger Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of outstanding common stock received by members and financial adviser</a></td>
<td class="nump">96.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of common stock issued in exchange of membership interests (in shares)</a></td>
<td class="nump">39,992,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common stock issued as compensation for services (in shares)</a></td>
<td class="nump">1,068,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Purchase price</a></td>
<td class="nump">$ 8,178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Closing price of common stock (in dollars per share)</a></td>
<td class="nump">$ 5.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares of common stock owned by stockholders immediately before the Merger (in shares)</a></td>
<td class="nump">1,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 8,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=btx_NTNBuzztimeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=btx_NTNBuzztimeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718448114936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger, Disposition and Acquisition Transactions, Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,044,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,044,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts', window );">Software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,296,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable, accrued liabilities and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,781,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(890,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement', window );">Cash and cash equivalents obligated to have under merger agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_BeneficialHoldersContractualCommitmentsToInvest', window );">Beneficial holders contractual commitments to invest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfAdditionalRightsOffering', window );">Percentage of additional rights offering</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ProceedsFromSaleOfRights', window );">Proceeds from right offering</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Fair Value Adjustment to Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts', window );">Software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(368,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable, accrued liabilities and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Fair Value Adjustment to Assets [Member] | Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Fair Value Adjustment to Assets [Member] | Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Purchase Price Allocation Pro Forma Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expense and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts', window );">Software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">928,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable, accrued liabilities and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,781,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(411,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Purchase Price Allocation Pro Forma Adjustment [Member] | Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Purchase Price Allocation Pro Forma Adjustment [Member] | Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract', window );"><strong>Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 299,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_BeneficialHoldersContractualCommitmentsToInvest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual commitment made by beneficial holders to invest in the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_BeneficialHoldersContractualCommitmentsToInvest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of software development costs recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents obligated to maintain under merger agreement on balance sheet at the effective time of the merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfAdditionalRightsOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional right offering made by the entity for unit holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageOfAdditionalRightsOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ProceedsFromSaleOfRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of rights during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_ProceedsFromSaleOfRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=btx_NTNBuzztimeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=btx_NTNBuzztimeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonrecurringAdjustmentAxis=btx_ProFormaFairValueAdjustmentToAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonrecurringAdjustmentAxis=btx_ProFormaFairValueAdjustmentToAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonrecurringAdjustmentAxis=btx_PurchasePriceAllocationProFormaAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonrecurringAdjustmentAxis=btx_PurchasePriceAllocationProFormaAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718441863592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger, Disposition and Acquisition Transactions, Disposition (Details) - NTN Business [Member]<br></strong></div></th>
<th class="th">
<div>Mar. 26, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DispositionAbstract', window );"><strong>Disposition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets', window );">Sale of rights, title and interest in and to the assets relating to the business</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ProceedsFromDispositionAbstract', window );"><strong>Proceeds from sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash', window );">Cash</a></td>
<td class="nump">132,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow', window );">Escrow</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans', window );">Assume advance/loans</a></td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans', window );">Interest on advance/loans</a></td>
<td class="nump">68,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Carrying value of assets sold [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="num">(14,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable</a></td>
<td class="num">(75,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets', window );">Prepaids and other current assets</a></td>
<td class="num">(124,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="num">(1,014,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts', window );">Software development costs</a></td>
<td class="num">(927,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="num">(8,589,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other assets</a></td>
<td class="num">(103,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities transferred upon sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">113,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases', window );">Obligations under finance leases</a></td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability', window );">Lease liability</a></td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">149,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts', window );">Transaction costs</a></td>
<td class="num">(265,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Total loss on sale of assets</a></td>
<td class="num">(9,648,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=btx_NTNBusinessMember', window );">Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Carrying value of assets sold [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(548,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=btx_NTNBusinessMember', window );">Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Carrying value of assets sold [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">$ (299,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as Lease liability attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as Obligations under finance leases attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds received from assume advance/loans in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds received from escrow deposits in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate proceeds received from interest on advance/loans in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as software development cost attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of the business disposal including legal, accounting, and other costs incurred to consummate the business disposition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DispositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_DispositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ProceedsFromDispositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_ProceedsFromDispositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred revenue attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=btx_NTNBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=btx_NTNBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718450973416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger, Disposition and Acquisition Transactions, Pro forma Financial Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract', window );"><strong>Unaudited Pro Forma Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (122,306,000)<span></span>
</td>
<td class="num">$ (26,547,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Basic net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (2.82)<span></span>
</td>
<td class="num">$ (1.51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted', window );">Diluted net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (2.82)<span></span>
</td>
<td class="num">$ (1.51)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718447783528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger, Disposition and Acquisition Transactions, Acquisition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 16, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Acquisition agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PaymentsToAcquireProductiveAssetsNet', window );">Cash paid, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,854,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ResearchAndDevelopmentInProcessAssetAcquisition', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,538,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=btx_NovellusTherapeuticsLimitedMember', window );">Novellus, Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Business consideration</a></td>
<td class="nump">$ 124,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Cash</a></td>
<td class="nump">$ 22,854,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Acquisition of common stock (in shares)</a></td>
<td class="nump">7,022,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Acquisition agreement</a></td>
<td class="nump">$ 102,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AssetAcquisitionSharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 14.5253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_EscrowShares', window );">Escrow shares (in shares)</a></td>
<td class="nump">741,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AcquisitionAgreementNonCompetitivePeriod', window );">Non-compete period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_EachLockUpAgreementExtendsTerm', window );">Each lock-up agreement extend term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PaymentsToAcquireProductiveAssetsNet', window );">Cash paid, net</a></td>
<td class="nump">$ 22,854,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LockUpPeriodForRestrictedShares', window );">Lock-up period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions', window );">Unrestricted shares, issued (in shares)</a></td>
<td class="nump">3,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AssetAcquisitionUnrestrictedSharesSharePrice', window );">Unrestricted shares, fair value per share (in dollars per share)</a></td>
<td class="nump">$ 10.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions', window );">Restricted shares, issued (in shares)</a></td>
<td class="nump">3,378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AssetAcquisitionRestrictedSharesSharePrice', window );">Restricted shares, fair value per share (in dollars per share)</a></td>
<td class="nump">$ 6.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfDiscountOnFairValueOfRestrictedShares', window );">Percentage of discount on fair value restricted shares</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Cash paid</a></td>
<td class="nump">$ 22,882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="num">(28,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions', window );">Unrestricted shares, value</a></td>
<td class="nump">36,628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions', window );">Restricted shares, value</a></td>
<td class="nump">22,056,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AssetAcquisitionFairValueOfConsiderationPaid', window );">Total fair value of consideration paid</a></td>
<td class="nump">81,538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Less amount of cash paid for NoveCite investment</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ResearchAndDevelopmentInProcessAssetAcquisition', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 80,538,000<span></span>
</td>
<td class="nump">$ 80,538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=btx_NovellusTherapeuticsLimitedMember', window );">Novellus, Ltd. [Member] | Chairman of the Board of Directors, Chief Executive Officer and President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Lock-up agreements common shares received in acquisition (in shares)</a></td>
<td class="nump">3,378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=btx_NovellusTherapeuticsLimitedMember', window );">Novellus, Ltd. [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_EscrowPeriod', window );">Period of escrow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfCommonStockSubjectToLockUpAgreement', window );">Percentage of common stock subject to the lock-up agreement</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NoveCiteINCMember', window );">NoveCite, INC. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of total outstanding equity interests</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AcquisitionAgreementNonCompetitivePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Acquisition Agreement contains non-competition and non-solicitation provisions pursuant to which the Seller has agreed not to engage in certain competitive activities for a period in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AcquisitionAgreementNonCompetitivePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AssetAcquisitionFairValueOfConsiderationPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fair value of consideration paid in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AssetAcquisitionFairValueOfConsiderationPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AssetAcquisitionRestrictedSharesSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered with restrictions to be paid in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AssetAcquisitionRestrictedSharesSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AssetAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AssetAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AssetAcquisitionUnrestrictedSharesSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered without any restrictions to be paid in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AssetAcquisitionUnrestrictedSharesSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_EachLockUpAgreementExtendsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of lock-up agreement extend term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_EachLockUpAgreementExtendsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_EscrowPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of secure indemnification obligations to acquisition agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_EscrowPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_EscrowShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares have been placed in escrow shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_EscrowShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LockUpPeriodForRestrictedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period in which shares are locked-up, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_LockUpPeriodForRestrictedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PaymentsToAcquireProductiveAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets excluding cash acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PaymentsToAcquireProductiveAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfCommonStockSubjectToLockUpAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of shares of common stock subject to the lock-up agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageOfCommonStockSubjectToLockUpAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfDiscountOnFairValueOfRestrictedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of discount on restricted shares, which was derived from the average discount rate between the Black Scholes and Finnerty valuation models.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageOfDiscountOnFairValueOfRestrictedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ResearchAndDevelopmentInProcessAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a asset acquisition have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_ResearchAndDevelopmentInProcessAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued with restrictions during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued with restrictions during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued without any restrictions during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued without any restrictions during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=btx_NovellusTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=btx_NovellusTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=btx_NoveCiteINCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=btx_NoveCiteINCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718442096888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger, Disposition and Acquisition Transactions, Investment in NoveCite (Details)<br></strong></div></th>
<th class="th">
<div>Jul. 16, 2021 </div>
<div>USD ($) </div>
<div>BoardMember</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NoveCiteINCMember', window );">NoveCite, INC. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_NumberOfBoardSeats', window );">Number of board seats | BoardMember</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NoveCiteINCMember', window );">NoveCite, INC. [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NoveCiteINCMember', window );">NoveCite, INC. [Member] | Citius Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by Citius</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_NumberOfBoardSeats">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of members of the company's management holds board seats on board of directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_NumberOfBoardSeats</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=btx_NoveCiteINCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=btx_NoveCiteINCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=btx_CitiusPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=btx_CitiusPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718441607192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments, Liabilities Measured at Fair Value (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Contingent Consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Contingent Consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value liabilities</a></td>
<td class="nump">19,930,000<span></span>
</td>
<td class="nump">20,110,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Contingent Consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value liabilities</a></td>
<td class="nump">$ 19,930,000<span></span>
</td>
<td class="nump">$ 20,110,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=btx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=btx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718441849240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments, Carrying Amount of Contingent Consideration Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Other liabilities contingent consideration [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfRoyaltyRevenueAssumedUntil2029', window );">Assumed percentage of royalty revenue until 2029</a></td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038', window );">Assumed percentage of royalty revenue from 2030 to 2038</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne', window );">Percentage of royalty revenue post patent decline for first year</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne', window );">Percentage of royalty revenue post patent decline after year one</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings', window );">Percentage of income taxes projected as royalty savings</a></td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfWeightedAverageCostOfCapital', window );">Percentage of weighted average cost of capital</a></td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Other liabilities contingent consideration [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Balance at beginning of period</a></td>
<td class="nump">$ 20,110,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Balance at end of period</a></td>
<td class="nump">19,930,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Contingent Consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Other liabilities contingent consideration [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Balance at beginning of period</a></td>
<td class="nump">20,110,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Fair value adjustment included in operating expenses</a></td>
<td class="num">(180,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Balance at end of period</a></td>
<td class="nump">$ 19,930,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of income taxes projected in terms of royalty savings due to use of different market assumptions and/or different valuation techniques.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalty revenue assumed from 2030 to 2038 due to use of different market assumptions and/or different valuation techniques.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfRoyaltyRevenueAssumedUntil2029">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalty revenue assumed until 2029 due to use of different market assumptions and/or different valuation techniques.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageOfRoyaltyRevenueAssumedUntil2029</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalty revenue after year one post patent decline due to use of different market assumptions and/or different valuation techniques.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalty revenue for first year post patent decline due to use of different market assumptions and/or different valuation techniques.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfWeightedAverageCostOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash flows discounted by the liability specific weighted average cost of capital using the mid-point convention.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageOfWeightedAverageCostOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=btx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=btx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718445263416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property, Plant and Equipment, Gross [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 877,000<span></span>
</td>
<td class="nump">$ 714,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(207,000)<span></span>
</td>
<td class="num">(120,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">670,000<span></span>
</td>
<td class="nump">594,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">117,000<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory and Manufacturing Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property, Plant and Equipment, Gross [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">258,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property, Plant and Equipment, Gross [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">464,000<span></span>
</td>
<td class="nump">414,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property, Plant and Equipment, Gross [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 154,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718444856520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Operating Lease (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_OperatingLeaseArea', window );">Operating lease area</a></td>
<td class="nump">2,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AnnualRentPerSquareFoot', window );">Annual rent (per square foot)</a></td>
<td class="nump">56.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments | $</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AnnualRentPerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense per square foot for leased asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AnnualRentPerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_OperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of leased property under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_OperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718447991304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Net Operating Lease Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Net Operating Lease Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 688,000<span></span>
</td>
<td class="nump">$ 591,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(84,000)<span></span>
</td>
<td class="num">(77,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 623,000<span></span>
</td>
<td class="nump">$ 535,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718442124968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Operating Lease Right-of-use Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_OperatingLeaseAssestAbstract', window );"><strong>Operating Lease, Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets, Beginning</a></td>
<td class="nump">$ 2,093,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease ROU assets</a></td>
<td class="num">(342,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AdditionOfOperatingLeaseRightofUseAsset', window );">Addition of operating lease ROU assets</a></td>
<td class="nump">816,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets, Ending</a></td>
<td class="nump">2,567,000<span></span>
</td>
<td class="nump">2,093,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities, Beginning</a></td>
<td class="nump">2,178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PrincipalPaymentsOnOperatingLeaseLiabilities', window );">Principal payments on operating lease liabilities</a></td>
<td class="num">(321,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AdditionOfOperatingLeaseLiability', window );">Addition of operating lease liabilities</a></td>
<td class="nump">866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities, Ending</a></td>
<td class="nump">2,723,000<span></span>
</td>
<td class="nump">2,178,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Less non-current portion</a></td>
<td class="nump">2,297,000<span></span>
</td>
<td class="nump">1,905,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">$ 426,000<span></span>
</td>
<td class="nump">$ 273,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AdditionOfOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Addition of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AdditionOfOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AdditionOfOperatingLeaseRightofUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Addition of operating lease right-of -use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AdditionOfOperatingLeaseRightofUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_OperatingLeaseAssestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_OperatingLeaseAssestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PrincipalPaymentsOnOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal payments on operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PrincipalPaymentsOnOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718442111144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases, Maturities of Operating Lease Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract', window );"><strong>Weighted Average Remaining Lease Term and Discount Rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">12.76%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturities of Operating Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">767,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">785,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">802,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">267,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">246,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total payments</a></td>
<td class="nump">3,617,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(894,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 2,723,000<span></span>
</td>
<td class="nump">$ 2,178,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718441831320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases, Sublease Agreement (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 18, 2019 </div>
<div>Squarefeet</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AreaOfSubleaseSpaceCurrentlyRented', window );">Currently rented area | Squarefeet</a></td>
<td class="nump">999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments', window );">Percentage of annual rent increase</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract', window );"><strong>Future Lease Payments, Sublease Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLeasePayments', window );">Sublease payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="nump">$ 79,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AreaOfSubleaseSpaceCurrentlyRented">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The subleases rentable area for properties currently rented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AreaOfSubleaseSpaceCurrentlyRented</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in annual lease payment for subleases for each year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from lease payment, classified as operating activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123420820&amp;loc=SL77919320-209978<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123420820&amp;loc=SL77919327-209978<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718447974456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and In-Process Research &amp; Development (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and In-Process Research &amp; Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 2,044,000<span></span>
</td>
<td class="nump">$ 2,044,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">In-process research and development</a></td>
<td class="nump">6,860,000<span></span>
</td>
<td class="nump">$ 6,860,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 80,538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718451231160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 656,000<span></span>
</td>
<td class="nump">$ 294,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">222,000<span></span>
</td>
<td class="nump">207,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AccruedGeneralAndAdministrativeExpenses', window );">Accrued general and administrative expenses</a></td>
<td class="nump">371,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 1,249,000<span></span>
</td>
<td class="nump">$ 1,051,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AccruedGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AccruedGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718447733352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 04, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DebtInstrumentAbstract', window );"><strong>Debt Instrument [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payment of outstanding notes payable</a></td>
<td class="nump">410,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btx_PaycheckProtectionProgramLoanMember', window );">IRX Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DebtInstrumentAbstract', window );"><strong>Debt Instrument [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payment of outstanding notes payable</a></td>
<td class="nump">410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PaymentOfAccruedAndUnpaidInterest', window );">Payment of accrued and unpaid interest</a></td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btx_PaycheckProtectionProgramMember', window );">Brooklyn LLC Paycheck Protection Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DebtInstrumentAbstract', window );"><strong>Debt Instrument [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Term loan amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DebtInstrumentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_DebtInstrumentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PaymentOfAccruedAndUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for accrued and unpaid interest related to notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PaymentOfAccruedAndUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btx_PaycheckProtectionProgramLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btx_PaycheckProtectionProgramLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btx_PaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btx_PaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718447910712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies, Legal Matters (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 15, 2021 </div>
<div>USD ($) </div>
<div>BoardMember</div>
</th>
<th class="th">
<div>Feb. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Defendant </div>
<div>Claim </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 15, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LegalMattersAbstract', window );"><strong>Legal Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Certificate of incorporation to increase the authorized shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_NovellusTherapeuticsLimitedMember', window );">Novellus, Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LegalMattersAbstract', window );"><strong>Legal Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LossContingencyDamagesSoughtExpectedSalary', window );">Defendants salary promised against plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LossContingencyDamagesSoughtExpectedEquityPercentage', window );">Percentage of equity promised against plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_NovellusTherapeuticsLimitedMember', window );">Novellus, Ltd. [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LegalMattersAbstract', window );"><strong>Legal Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_DheshGovenderMember', window );">Govender [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LegalMattersAbstract', window );"><strong>Legal Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LossContingencyDamagesSoughtExpectedSalary', window );">Defendants salary promised against plaintiff</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LossContingencyDamagesSoughtExpectedEquityPercentage', window );">Percentage of equity promised against plaintiff</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LossContingencyNumberOfArbitrationPanel', window );">Number of member arbitration panel | BoardMember</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_DheshGovenderMember', window );">Govender [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LegalMattersAbstract', window );"><strong>Legal Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought, value</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LegalMattersAbstract', window );"><strong>Legal Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of claims filed | Claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Number of defendant | Defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_NTNBuzztimeIncMember', window );">NTN Buzztime, Inc [Member] | Robert Garfield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LegalMattersAbstract', window );"><strong>Legal Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Certificate of incorporation to increase the authorized shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LegalMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_LegalMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LossContingencyDamagesSoughtExpectedEquityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of equity promised to the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_LossContingencyDamagesSoughtExpectedEquityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LossContingencyDamagesSoughtExpectedSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The monetary amount of salary promised to the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_LossContingencyDamagesSoughtExpectedSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LossContingencyNumberOfArbitrationPanel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number member in arbitration panel pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_LossContingencyNumberOfArbitrationPanel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of defendants named in a legal action.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_NovellusTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_NovellusTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_DheshGovenderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_DheshGovenderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=btx_NTNBuzztimeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=btx_NTNBuzztimeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_RobertGarfieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_RobertGarfieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718441782744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies, Licensing Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Patents</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 26, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_NovellusTherapeuticsLimitedMember', window );">Novellus, Ltd. [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LicensingAgreementsAbstract', window );"><strong>Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_NovellusLtdAndFactorBioscienceMember', window );">Licensors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LicensingAgreementsAbstract', window );"><strong>Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LossContingencyNonRefundableOptionFee', window );">Non-refundable option fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_InitialLicenseFees', window );">Initial license fees</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AdditionalFeesObligatedToPay', window );">Amount require to pay of initial license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AmountRequireToPayInitialLicenseFees', window );">Amount obligated to pay in license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AmountObligatedToPayInYearOne', window );">Additional fees obligated to pay in 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_MinimumNumberOfPatentGranted', window );">Minimum number of patent granted | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_MinimumNumberOfPendingPatents', window );">Number of maximum pending patents | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_NovellusLtdAndFactorBioscienceMember', window );">Licensors [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LicensingAgreementsAbstract', window );"><strong>Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AmountObligatedToPayInYearTwo', window );">Additional fees obligated to pay in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_NoveCiteMember', window );">NoveCite [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LicensingAgreementsAbstract', window );"><strong>Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfRevenue', window );">Percentage of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_UniversityOfSouthFloridaMember', window );">University of South Florida [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LicensingAgreementsAbstract', window );"><strong>Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LossContingencyPercentageOfRoyaltyPayable', window );">Percentage of royalty payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AdditionalFeesObligatedToPay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity is obligated to pay additional fees to Licensors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AdditionalFeesObligatedToPay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AmountObligatedToPayInYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity is obligated to pay additional fees to the Licensors in first year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AmountObligatedToPayInYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AmountObligatedToPayInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entity is obligated to pay additional fees to the Licensors in second year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AmountObligatedToPayInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AmountRequireToPayInitialLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount require to pay out of the total initial license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AmountRequireToPayInitialLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_InitialLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial license fees required to pay including non-refundable fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_InitialLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_LicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LossContingencyNonRefundableOptionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of Non-refundable option fee in licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_LossContingencyNonRefundableOptionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LossContingencyPercentageOfRoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payable from one party to another in licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_LossContingencyPercentageOfRoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestones upfront payment on licenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_MinimumNumberOfPatentGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum number of granted patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_MinimumNumberOfPatentGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_MinimumNumberOfPendingPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum number of patents pending.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_MinimumNumberOfPendingPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue from receives any revenue involving the original cell line included in the licensed technology, then Novellus, Ltd shall remit to NoveCite.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_NovellusTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_NovellusTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_NovellusLtdAndFactorBioscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_NovellusLtdAndFactorBioscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_NoveCiteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_NoveCiteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=btx_UniversityOfSouthFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=btx_UniversityOfSouthFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718449526808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies, Royalty Agreements (Details)<br></strong></div></th>
<th class="th"><div>Mar. 22, 2021</div></th>
<th class="th"><div>Jun. 22, 2018</div></th>
<th class="th"><div>May 01, 2012</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=btx_InvestorRoyaltyAgreementMember', window );">Investor Royalty Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_RoyaltyAgreementsAbstract', window );"><strong>Royalty Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness', window );">Percentage of royalty receive equal to revenues from sale of business</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales', window );">Percentage of payment of additional royalty on gross sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=btx_CollaboratorRoyaltyAgreementMember', window );">Collaborator Royalty Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_RoyaltyAgreementsAbstract', window );"><strong>Royalty Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness', window );">Percentage of royalty receive equal to revenues from sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional royalty payable on gross sales by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty receive equal to revenues generated from disposition of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_RoyaltyAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_RoyaltyAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btx_InvestorRoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btx_InvestorRoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btx_CollaboratorRoyaltyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btx_CollaboratorRoyaltyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718441576520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Earnings per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential common shares excluded from computation (in shares)</a></td>
<td class="nump">4,270,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential common shares excluded from computation (in shares)</a></td>
<td class="nump">3,988,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential common shares excluded from computation (in shares)</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Preferred Stock Converted into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Anti-dilutive Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential common shares excluded from computation (in shares)</a></td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718449306392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Equity Incentive Plans (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 03, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 15, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock option outstanding (in shares)</a></td>
<td class="nump">3,988,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btx_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock-based compensation shares authorized (in shares)</a></td>
<td class="nump">2,601,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfSharesOfCommonStockOutstanding', window );">Percentage of number of shares of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btx_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock-based compensation shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,116,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btx_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock-based compensation shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btx_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock option outstanding (in shares)</a></td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btx_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan [Member] | Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock-based compensation shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btx_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan [Member] | Incentive Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock based compensation stock option term period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btx_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan [Member] | Nonqualified Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock based compensation stock option term period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btx_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan [Member] | RSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock option outstanding (in shares)</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btx_InducementPlan2021Member', window );">2021 Inducement Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock-based compensation shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btx_InducementPlan2021Member', window );">2021 Inducement Plan [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock option outstanding (in shares)</a></td>
<td class="nump">443,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btx_InducementPlan2021Member', window );">2021 Inducement Plan [Member] | RSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Stock units outstanding (in shares)</a></td>
<td class="nump">222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfSharesOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock shares outstanding considered for equity number of shares under equity incentive plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageOfSharesOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=btx_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=btx_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btx_IncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btx_IncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btx_NonQualifiedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btx_NonQualifiedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=btx_InducementPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=btx_InducementPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718449524024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Weighted-Average Assumptions Used for Grants Issued (Details) - Stock Options [Member] - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option awards granted (in shares)</a></td>
<td class="nump">3,988,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock option awards outstanding (in shares)</a></td>
<td class="nump">3,988,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assertions Used in Determining Fair Value of Stock Options Granted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free rate</a></td>
<td class="nump">1.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Weighted average volatility</a></td>
<td class="nump">134.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718442093400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Stock Option Activity (Details) - Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Option Share [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3,988,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">3,988,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">8.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract', window );"><strong>Weighted Average Remaining Contractual Life [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life, outstanding</a></td>
<td class="text">9 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life, granted</a></td>
<td class="text">9 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Options Vested and Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options vested and exercisable, Outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options vested and exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718447770168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Summary of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Grant </div>
<div>Installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_NumberOfStockOptionGrantMade', window );">Number of stock option grants made | Grant</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized stock-based compensation expense</a></td>
<td class="nump">$ 21,915,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining requisite service period</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option awards granted (in shares) | shares</a></td>
<td class="nump">3,988,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock option exercised (in shares) | shares</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">$ 10,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised total intrinsic value</a></td>
<td class="nump">$ 47,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btx_TimeBasedNonQualifiedStockOptionMember', window );">Time-Based Non-qualified Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option awards granted (in shares) | shares</a></td>
<td class="nump">2,628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares', window );">Number of monthly installments | Installment</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btx_TimeBasedNonQualifiedStockOptionMember', window );">Time-Based Non-qualified Stock Option [Member] | Vesting on one-year Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock-based compensation vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btx_PerformanceBasedNonqualifiedStockOptionMember', window );">Performance-Based Nonqualified Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option awards granted (in shares) | shares</a></td>
<td class="nump">597,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue', window );">Stock-based compensation grant fair value</a></td>
<td class="nump">$ 4,288,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_NumberOfStockOptionGrantMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock option grants made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_NumberOfStockOptionGrantMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fair value of share-based payment arrangement, subject to vesting and other restrictions, to purchase or sell certain number of shares on performance basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of monthly installments for vesting of remaining shares in share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btx_TimeBasedNonQualifiedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btx_TimeBasedNonQualifiedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btx_PerformanceBasedNonqualifiedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btx_PerformanceBasedNonqualifiedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718442111160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, RSUs (Details) - RSU [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Outstanding Restricted Stock Units [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, Ending balance (in shares)</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber', window );">Balance expected to vest (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Fair Value Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value Per Share, Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">13.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value Per Share, Ending balance (in dollars per share)</a></td>
<td class="nump">$ 13.80<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unamortized stock-based compensation expense</a></td>
<td class="nump">$ 2,935,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average remaining requisite service period</a></td>
<td class="text">3 years 6 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718447979512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation, Restricted Stock and Stock-Based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">$ 5,235,000<span></span>
</td>
<td class="nump">$ 91,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Common Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock replaced during the period (in shares)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock replaced during the period (in shares)</a></td>
<td class="nump">630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718448465720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' and Members' Equity (Deficit), Private Placement Offerings (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 26, 2021</div></th>
<th class="th"><div>Apr. 26, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PrivatePlacementOfferingsAbstract', window );"><strong>Private Placement Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,025,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Number of shares authorized to sale in regular purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=btx_LincolnParkCapitalFundLLCMember', window );">Lincoln Park [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PrivatePlacementOfferingsAbstract', window );"><strong>Private Placement Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_CommitmentAmountToMeetAnySingleRegularPurchase', window );">Maximum commitment in any single regular purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=btx_PurchaseAgreementMember', window );">Purchase Agreements [Member] | Lincoln Park [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PrivatePlacementOfferingsAbstract', window );"><strong>Private Placement Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock issued and sold during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,424,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=btx_FirstPurchaseAgreementMember', window );">First Purchase Agreement [Member] | Lincoln Park [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PrivatePlacementOfferingsAbstract', window );"><strong>Private Placement Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1', window );">Common stock, shares issued in consideration for purchase commitment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
<td class="nump">1,128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1', window );">Number of shares remaining to be sold in purchase commitment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock issued and sold during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=btx_FirstPurchaseAgreementMember', window );">First Purchase Agreement [Member] | Lincoln Park [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PrivatePlacementOfferingsAbstract', window );"><strong>Private Placement Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=btx_SecondPurchaseAgreementMember', window );">Second Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PrivatePlacementOfferingsAbstract', window );"><strong>Private Placement Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_SaleOfStockNumberOfSharesToIssuedInTransaction', window );">Number of remaining shares to be sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=btx_SecondPurchaseAgreementMember', window );">Second Purchase Agreement [Member] | Lincoln Park [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PrivatePlacementOfferingsAbstract', window );"><strong>Private Placement Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1', window );">Common stock, shares issued in consideration for purchase commitment (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock issued and sold during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,424,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=btx_SecondPurchaseAgreementMember', window );">Second Purchase Agreement [Member] | Lincoln Park [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PrivatePlacementOfferingsAbstract', window );"><strong>Private Placement Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Number of shares authorized to sale in regular purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_BeneficialOwnershipPercentageOnTotalOutstandingShares', window );">Beneficial ownership percentage on total outstanding shares that prohibits company to direct share purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_BeneficialOwnershipPercentageOnTotalOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_BeneficialOwnershipPercentageOnTotalOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_CommitmentAmountToMeetAnySingleRegularPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchase price or commitment amount to meet any single regular purchase in share purchase transaction on any business day.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_CommitmentAmountToMeetAnySingleRegularPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of further shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PrivatePlacementOfferingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PrivatePlacementOfferingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_SaleOfStockNumberOfSharesToIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares to be issued by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_SaleOfStockNumberOfSharesToIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=btx_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=btx_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btx_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btx_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btx_FirstPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btx_FirstPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btx_SecondPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btx_SecondPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446816088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' and Members' Equity (Deficit), Reverse Stock-Split (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ReverseStockSplitAbstract', window );"><strong>Reverse Stock-Split [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock conversion ratio</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Stock outstanding, reverse stock splits (in shares)</a></td>
<td class="nump">1,514,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ReverseStockSplitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_ReverseStockSplitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718447800344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' and Members' Equity (Deficit), Merger (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_MergerAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodSharesAcquisitions1', window );">Stock issued, shares, acquisition (in shares)</a></td>
<td class="nump">1,068,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_MergerAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued in merger agreement (in shares)</a></td>
<td class="nump">87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted to common stock (in shares)</a></td>
<td class="nump">22,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_MergerAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued in merger agreement (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted to common stock (in shares)</a></td>
<td class="nump">2,515,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Common Class C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_MergerAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued in merger agreement (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted to common stock (in shares)</a></td>
<td class="nump">1,676,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ClassOfWarrantOrRightIssued', window );">Number of rights options issued (in shares)</a></td>
<td class="nump">10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of rights options converted (in shares)</a></td>
<td class="nump">11,828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_MergerAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued in merger agreement (in shares)</a></td>
<td class="nump">630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted to common stock (in shares)</a></td>
<td class="nump">630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodSharesAcquisitions1', window );">Stock issued, shares, acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,514,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued into which the class of warrant or right may be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_MergerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_MergerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodSharesAcquisitions1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodSharesAcquisitions1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718447780616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' and Members' Equity (Deficit), Acquisition (Details) - Novellus, Ltd. [Member]<br></strong></div></th>
<th class="th">
<div>Jul. 16, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Acquisition of common stock (in shares)</a></td>
<td class="nump">7,022,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions', window );">Unrestricted shares, issued (in shares)</a></td>
<td class="nump">3,644,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_EachLockUpAgreementExtendsTerm', window );">Each lock-up agreement extend term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NovellusTherapeuticsLimitedMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageOfCommonStockSubjectToLockUpAgreement', window );">Percentage of common stock subject to the lock-up agreement</a></td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btx_NovellusTherapeuticsLimitedMember', window );">Chair of the Board of Directors, Chief Executive Officer and President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDescriptionAbstract', window );"><strong>Acquisitions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Lock-up agreements shares received in acquisition (in shares)</a></td>
<td class="nump">3,378,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_EachLockUpAgreementExtendsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of lock-up agreement extend term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_EachLockUpAgreementExtendsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageOfCommonStockSubjectToLockUpAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of shares of common stock subject to the lock-up agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageOfCommonStockSubjectToLockUpAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued without any restrictions during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=btx_NovellusTherapeuticsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=btx_NovellusTherapeuticsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718441691800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' and Members' Equity (Deficit), Cumulative Convertible Preferred Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Cumulative Convertible Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock Series A, shares authorized (in shares)</a></td>
<td class="nump">156,000<span></span>
</td>
<td class="nump">156,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock series A, shares issued (in shares)</a></td>
<td class="nump">156,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock series A, shares outstanding (in shares)</a></td>
<td class="nump">156,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Dividend paid in cash | $</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Cumulative Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Cumulative Convertible Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock Series A, shares authorized (in shares)</a></td>
<td class="nump">156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock series A, shares issued (in shares)</a></td>
<td class="nump">156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock series A, shares outstanding (in shares)</a></td>
<td class="nump">156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Cumulative annual dividend payable per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Dividend paid in cash | $</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsShares', window );">Shares issued for payment of dividends (in shares)</a></td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred stock, conversion rate</a></td>
<td class="nump">3.7016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Cumulative Convertible Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Dividend paid in cash | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsShares', window );">Shares issued for payment of dividends (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Each preferred stock converted into common stock (in shares)</a></td>
<td class="nump">0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Aggregate preferred stock to be convert into common stock (in shares)</a></td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares converted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeaturesOfConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718448530232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes, Loss before Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Loss before Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (122,296,000)<span></span>
</td>
<td class="num">$ (26,531,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (122,301,000)<span></span>
</td>
<td class="num">$ (26,531,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718451407656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes, Components of Income Tax Provision (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current Tax Provision [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax provision</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred Tax Provision [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(5,836,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1,433,000)<span></span>
</td>
<td class="num">(322,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred Income tax provision</a></td>
<td class="num">(7,270,000)<span></span>
</td>
<td class="num">(322,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount', window );">Change in valuation allowance</a></td>
<td class="nump">7,270,000<span></span>
</td>
<td class="nump">322,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax provision for income taxes</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to decrease in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718442096888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes, Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets: [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign', window );">Net operating losses</a></td>
<td class="nump">$ 5,454,000<span></span>
</td>
<td class="nump">$ 747,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign net operating losses</a></td>
<td class="nump">595,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credit carryforwards</a></td>
<td class="nump">288,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,312,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences', window );">Vacation accrual</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies', window );">Contingent consideration</a></td>
<td class="nump">5,171,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">12,890,000<span></span>
</td>
<td class="nump">747,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(12,610,000)<span></span>
</td>
<td class="num">(747,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">280,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities: [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(168,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill', window );">Intangibles - goodwill</a></td>
<td class="num">(112,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(280,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards excluding foreign purpose.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123403335&amp;loc=d3e9972-128506<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123403335&amp;loc=d3e9979-128506<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718448489176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes, Reconciliation of Computed Expected Income Taxes to Effective Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Reconciliation of Computed Expected Income Taxes to Effective Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal tax</a></td>
<td class="nump">1.17%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses/excludable items</a></td>
<td class="num">(16.33%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Pass-through loss</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(19.79%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(5.94%)<span></span>
</td>
<td class="num">(1.21%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits</a></td>
<td class="nump">0.24%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.14%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total tax provision for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_IncomeTaxAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 11,863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Current year deferred expense</a></td>
<td class="num">(7,270,000)<span></span>
</td>
<td class="num">$ (322,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense', window );">Purchase accounting related to 2021 business combination</a></td>
<td class="nump">4,593,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Federal and state income tax credit carryforwards</a></td>
<td class="nump">$ 288,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_TaxCreditCarryforwardExpirationYear', window );">Tax credits begin to expire</a></td>
<td class="text">2041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2018 2019 2020 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_IncomeTaxAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward</a></td>
<td class="nump">$ 20,679,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_TaxCutsAndJobsActOperatingLossCarryforwards', window );">Net operating loss carryforwards under Tax Cuts and Jobs Act</a></td>
<td class="nump">20,679,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_IncomeTaxAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward</a></td>
<td class="nump">1,397,000<span></span>
</td>
<td class="nump">747,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_IncomeTaxAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry forward</a></td>
<td class="nump">$ 4,759,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_IncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_IncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration beginning year of the tax credit carryforward, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_TaxCutsAndJobsActOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws from effect of Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_TaxCutsAndJobsActOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the valuation allowance recorded in a business combination against deductible temporary differences for which related tax benefits will be recorded as a reduction of the acquired entity's income tax expense (after such benefits are first being applied to reduce goodwill and then other noncurrent intangible assets to zero).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123403335&amp;loc=d3e9901-128506<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718446442104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Savings Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Retirement Savings Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of maximum annual contribution to defined contribution plan</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139718441361896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 06, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 03, 2022 </div>
<div>USD ($) </div>
<div>Employee</div>
</th>
<th class="th">
<div>Mar. 05, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LeaseAssignmentAbstract', window );"><strong>Lease Assignment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 522,000<span></span>
</td>
<td class="nump">$ 453,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_NewLeaseAgreementAbstract', window );"><strong>New Lease Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_OperatingLeaseArea', window );">Operating lease area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostPositionsEliminatedAbstract', window );"><strong>Reduction in Force [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees terminated in reduction in force | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of employees terminated in reduction in force</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and termination-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LeaseAssignmentAbstract', window );"><strong>Lease Assignment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_LesseeCommitmentToPurchaseProperty', window );">Commitment to purchase equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_UnamortizedLeaseholdImprovements', window );">Unamortized leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_NewLeaseAgreementAbstract', window );"><strong>New Lease Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_OperatingLeaseArea', window );">Operating lease area | ft&#178;</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease commencement term</a></td>
<td class="text">62 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_BaseRentPerSquareFoot', window );">Base rent (per square foot) | ft&#178;</a></td>
<td class="nump">6.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PercentageBaseRentIncreaseOnEachAnniversary', window );">Percentage of increase in base rent on each year</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extended lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btx_CommonWarrantsMember', window );">Common Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PrivatePlacementOfEquityAbstract', window );"><strong>Private Placement of Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights', window );">Percentage of warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ClassOfWarrantOrRightsExercisableTerm', window );">Warrant exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btx_PreFundedWarrantsMember', window );">Pre-funded Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PrivatePlacementOfEquityAbstract', window );"><strong>Private Placement of Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights', window );">Percentage of warrants exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=btx_PIPEInvestorMember', window );">PIPE Investor [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PrivatePlacementOfEquityAbstract', window );"><strong>Private Placement of Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Private placement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,857,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Aggregate gross purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=btx_PIPEInvestorMember', window );">PIPE Investor [Member] | Common Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PrivatePlacementOfEquityAbstract', window );"><strong>Private Placement of Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Warrant expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=btx_PIPEInvestorMember', window );">PIPE Investor [Member] | Pre-funded Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_btx_PrivatePlacementOfEquityAbstract', window );"><strong>Private Placement of Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_BaseRentPerSquareFoot">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of base rent expense per square foot for leased asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_BaseRentPerSquareFoot</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of securities that would be issuable upon the exercise of warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_ClassOfWarrantOrRightsExercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants or rights exercisable term, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_ClassOfWarrantOrRightsExercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LeaseAssignmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_LeaseAssignmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_LesseeCommitmentToPurchaseProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property for which lessee committed to purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_LesseeCommitmentToPurchaseProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_NewLeaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_NewLeaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_OperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of leased property under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_OperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PercentageBaseRentIncreaseOnEachAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of base rent increase on each anniversary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PercentageBaseRentIncreaseOnEachAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_PrivatePlacementOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_PrivatePlacementOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btx_UnamortizedLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unamortized leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btx_UnamortizedLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostPositionsEliminatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostPositionsEliminatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btx_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btx_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=btx_PIPEInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=btx_PIPEInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>brhc10036185_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:btx="http://brooklynitx.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="btx-20211231.xsd" xlink:type="simple"/>
    <context id="c20210101to20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c20220412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2022-04-12</instant>
        </period>
    </context>
    <context id="c20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementClassOfStockAxis_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementClassOfStockAxis_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementClassOfStockAxis_CommonUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:CommonUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementClassOfStockAxis_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementClassOfStockAxis_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementClassOfStockAxis_CommonUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:CommonUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementClassOfStockAxis_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementClassOfStockAxis_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20200101to20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20191231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20200101to20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c20200101to20201231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c20200101to20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c20200101to20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c20200101to20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btx:CommonUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">btx:MembershipEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NoveCiteINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="c20210426to20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:FirstPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-26</startDate>
            <endDate>2021-04-26</endDate>
        </period>
    </context>
    <context id="c20210526to20210526_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:SecondPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-26</startDate>
            <endDate>2021-05-26</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:SecondPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:FirstPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c20220309to20220309_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-09</startDate>
            <endDate>2022-03-09</endDate>
        </period>
    </context>
    <context id="c20210325to20210325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryAndManufacturingEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">btx:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325to20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">btx:PurchasePriceAllocationProFormaAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">btx:ProFormaFairValueAdjustmentToAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">btx:ProFormaFairValueAdjustmentToAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">btx:ProFormaFairValueAdjustmentToAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">btx:PurchasePriceAllocationProFormaAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">btx:PurchasePriceAllocationProFormaAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210301to20210331_BusinessAcquisitionAxis_NTNBuzztimeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">btx:NTNBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">btx:NTNBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">btx:NTNBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">btx:NTNBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="c20210101to20211231_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember_RelatedPartyTransactionsByRelatedPartyAxis_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c20210701to20210930_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NoveCiteINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember_OwnershipAxis_CitiusPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">btx:CitiusPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NoveCiteINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="c20210716to20210716_BusinessAcquisitionAxis_NoveCiteINCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NoveCiteINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">btx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">btx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20201231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">btx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">btx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20201231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">btx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20201231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">btx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">btx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20211231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20211231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20190418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <instant>2019-04-18</instant>
        </period>
    </context>
    <context id="c20190418to20190418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2019-04-18</startDate>
            <endDate>2019-04-18</endDate>
        </period>
    </context>
    <context id="c20211231_DebtInstrumentAxis_PaycheckProtectionProgramLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btx:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20181231_DebtInstrumentAxis_PaycheckProtectionProgramLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btx:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_DebtInstrumentAxis_PaycheckProtectionProgramLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btx:PaycheckProtectionProgramLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20200504_DebtInstrumentAxis_PaycheckProtectionProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btx:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-04</instant>
        </period>
    </context>
    <context id="c20211231_DebtInstrumentAxis_PaycheckProtectionProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btx:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_LegalEntityAxis_NTNBuzztimeIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210205to20210205_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:DheshGovenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="c20211215to20211215_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:DheshGovenderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="c20210205to20210205_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="c20210315_LegalEntityAxis_NTNBuzztimeIncMember_RelatedPartyTransactionsByRelatedPartyAxis_RobertGarfieldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:RobertGarfieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-15</instant>
        </period>
    </context>
    <context id="c20210316_LegalEntityAxis_NTNBuzztimeIncMember_RelatedPartyTransactionsByRelatedPartyAxis_RobertGarfieldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:RobertGarfieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:NTNBuzztimeIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="c20210101to20211231_LegalEntityAxis_UniversityOfSouthFloridaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:UniversityOfSouthFloridaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210413to20210413_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-13</startDate>
            <endDate>2021-04-13</endDate>
        </period>
    </context>
    <context id="c20210430to20210430_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c20210415to20210415_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-15</startDate>
            <endDate>2021-04-15</endDate>
        </period>
    </context>
    <context id="c20210426_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-26</instant>
        </period>
    </context>
    <context id="c20221031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember_StatementScenarioAxis_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c20211031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusLtdAndFactorBioscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20211231_RelatedPartyTransactionsByRelatedPartyAxis_NoveCiteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NoveCiteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210322to20210322_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:InvestorRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-22</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="c20180622to20180622_TypeOfArrangementAxis_CollaboratorRoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:CollaboratorRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-22</startDate>
            <endDate>2018-06-22</endDate>
        </period>
    </context>
    <context id="c20120501to20120501_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:InvestorRoyaltyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-05-01</startDate>
            <endDate>2012-05-01</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210903_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-03</instant>
        </period>
    </context>
    <context id="c20211231_PlanNameAxis_EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20210315_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-15</instant>
        </period>
    </context>
    <context id="c20210903_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-03</instant>
        </period>
    </context>
    <context id="c20210531_PlanNameAxis_InducementPlan2021Member_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:InducementPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c20210903_PlanNameAxis_EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-03</instant>
        </period>
    </context>
    <context id="c20210101to20211231_AwardTypeAxis_NonQualifiedStockOptionMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btx:NonQualifiedStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btx:IncentiveStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_InducementPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:InducementPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_InducementPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btx:InducementPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20200101to20201231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c20201231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20211231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_AwardTypeAxis_PerformanceBasedNonqualifiedStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btx:PerformanceBasedNonqualifiedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_AwardTypeAxis_TimeBasedNonQualifiedStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btx:TimeBasedNonQualifiedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_AwardTypeAxis_TimeBasedNonQualifiedStockOptionMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btx:TimeBasedNonQualifiedStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20200101to20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210426to20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:FirstPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-26</startDate>
            <endDate>2021-04-26</endDate>
        </period>
    </context>
    <context id="c20210526to20210526_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:SecondPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-26</startDate>
            <endDate>2021-05-26</endDate>
        </period>
    </context>
    <context id="c20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:SecondPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:SecondPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-26</instant>
        </period>
    </context>
    <context id="c20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-26</instant>
        </period>
    </context>
    <context id="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">btx:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_TypeOfArrangementAxis_SecondPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btx:SecondPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210325_StatementClassOfStockAxis_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_StatementClassOfStockAxis_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325_StatementClassOfStockAxis_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c20210325to20210325_StatementClassOfStockAxis_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c20210325to20210325_StatementClassOfStockAxis_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c20210325to20210325_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c20210325to20210325_StatementClassOfStockAxis_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-25</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember_RelatedPartyTransactionsByRelatedPartyAxis_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btx:ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btx:NovellusTherapeuticsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20211231_IncomeTaxAuthorityAxis_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20201231_IncomeTaxAuthorityAxis_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20211231_IncomeTaxAuthorityAxis_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20201231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_IncomeTaxAuthorityAxis_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20220306_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">btx:PIPEInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-06</instant>
        </period>
    </context>
    <context id="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">btx:PIPEInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-06</instant>
        </period>
    </context>
    <context id="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">btx:PIPEInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-06</instant>
        </period>
    </context>
    <context id="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-06</instant>
        </period>
    </context>
    <context id="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-06</instant>
        </period>
    </context>
    <context id="c20220306to20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-06</startDate>
            <endDate>2022-03-06</endDate>
        </period>
    </context>
    <context id="c20220306to20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btx:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">btx:PIPEInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-06</startDate>
            <endDate>2022-03-06</endDate>
        </period>
    </context>
    <context id="c20220103to20220103_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="c20220305_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-05</instant>
        </period>
    </context>
    <context id="c20220331_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20220331to20220331_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="U001">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U002">
        <measure>shares</measure>
    </unit>
    <unit id="U003">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U004">
        <measure>pure</measure>
    </unit>
    <unit id="U005">
        <measure>btx:Segments</measure>
    </unit>
    <unit id="U006">
        <measure>btx:BoardMember</measure>
    </unit>
    <unit id="U007">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U008">
        <measure>btx:Squarefeet</measure>
    </unit>
    <unit id="U009">
        <measure>btx:Claim</measure>
    </unit>
    <unit id="U010">
        <measure>btx:Defendant</measure>
    </unit>
    <unit id="U011">
        <measure>btx:Patents</measure>
    </unit>
    <unit id="U012">
        <measure>btx:Grant</measure>
    </unit>
    <unit id="U013">
        <measure>btx:Installment</measure>
    </unit>
    <unit id="U014">
        <measure>btx:Employee</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="c20210101to20211231"
      id="Fact_0aeff87ffc6c40578b41a362360fa3bb">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="c20210101to20211231"
      id="Fact_cf57cd4aa0524f5a95cee76898f58e27">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="c20210101to20211231"
      id="Fact_8359db28ff634441b860c33e1c52f466">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="c20210101to20211231"
      id="Fact_c8e22448b87c4502a0c0e7993ecb862d">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="c20210101to20211231"
      id="Fact_b75e69355dfb40b7bfe444fe530ec6dc">0000748592</dei:EntityCentralIndexKey>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c20210325to20210325"
      decimals="INF"
      id="Fact_8f4da43a33f64403a03756802f5c0aae"
      unitRef="U004">0.5</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c20210325to20210325"
      decimals="INF"
      id="Fact_565a5991ac0445a8b9e9f14506915bfe"
      unitRef="U004">0.5</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:OpenTaxYear
      contextRef="c20210101to20211231"
      id="Fact_145d916fadf245a7a67bdeb44d432d49">2018 2019 2020 2021</us-gaap:OpenTaxYear>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="c20220306to20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember"
      id="Fact_2d5f06641c0a4e39b73cdc701f6abe8c">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <dei:AuditorFirmId
      contextRef="c20210101to20211231"
      id="Fact_10926fb50ef84807b40df791d25443c8">688</dei:AuditorFirmId>
    <dei:DocumentType
      contextRef="c20210101to20211231"
      id="Fact_40786e39032143f49ec1c5c715117f0a">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="c20210101to20211231"
      id="Fact_a3ee7509a9b84b79bb335d4941a56686">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="c20210101to20211231"
      id="Fact_5fe75f530ac642b1a89755b1beddfec1">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="c20210101to20211231"
      id="Fact_984a68efdb7e4e3d9deff87993ad97ab">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="c20210101to20211231"
      id="Fact_9352634f284e4ab582e4e58276c9ac88">1-11460</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="c20210101to20211231"
      id="Fact_cd3f96f5e576403d8b2314703c5947ea">Brooklyn ImmunoTherapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20210101to20211231"
      id="Fact_7c1ae00d7a2b4a9b9b131acd59a9fa12">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20210101to20211231"
      id="Fact_01a81c45a70f438a982f0c57c3544d12">31-1103425</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20210101to20211231"
      id="Fact_29b3a7f1b50b47ba8505adb0ca504e6d">10355 Science Center Drive, Suite 150,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20210101to20211231"
      id="Fact_e689722e864d445cb322e8a8d5416b09">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20210101to20211231"
      id="Fact_2b95c81f98e44857bef87641b2a2d6e4">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20210101to20211231"
      id="Fact_ac4231873cc14ac889408eed5578a137">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20210101to20211231"
      id="Fact_e071081b1b404701ac38e202ae2338a3">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20210101to20211231"
      id="Fact_cc44cd3c5a5647e79fec2c6d9875f11d">582-1199</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20210101to20211231"
      id="Fact_184666d9ce5f454aa0dc67f625e9d859">Common Stock, $0.005 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20210101to20211231"
      id="Fact_99b1b6df09964b38a368e6e5456ecbba">BTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20210101to20211231"
      id="Fact_6f8352c1c5e8469aad9a0da165511810">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="c20210101to20211231"
      id="Fact_b973370f7f964c6fb1c51dc351d928d2">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="c20210101to20211231"
      id="Fact_a408b42577244608a79da17e4befd01f">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="c20210101to20211231"
      id="Fact_388b14146b9e4e2b8b31c69b50c35574">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="c20210101to20211231"
      id="Fact_063fb241572848a1958206b715d9bfe1">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="c20210101to20211231"
      id="Fact_4b2280f0cdc8430f8af4a80b9e36f752">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="c20210101to20211231"
      id="Fact_2ef58c1927ab4b16ab194ea6e62f0f0b">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20210101to20211231"
      id="Fact_182ace3705764c1199c04c57b56fed72">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="c20210101to20211231"
      id="Fact_e1b25788fee748ffbd3a697076b098b3">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="c20210101to20211231"
      id="Fact_7a66746e02e94e67949571889dfc59a6">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="c20210630"
      decimals="-6"
      id="Fact_d87dab6a29e44ad2b9e9554bbeb4dcda"
      unitRef="U001">694000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c20220412"
      decimals="INF"
      id="Fact_cd0cc4324667410886a80322400d1f81"
      unitRef="U002">57451937</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="c20210101to20211231"
      id="Fact_3c04b56a4cac4e488afbc65aa6a80bc6">Marcum LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="c20210101to20211231"
      id="Fact_f34c495b19774ce6a91361494f7884ff">New York, NY</dei:AuditorLocation>
    <us-gaap:Cash
      contextRef="c20211231"
      decimals="-3"
      id="Fact_3105dd9ccc1b48719f8176a107ccd4f9"
      unitRef="U001">16985000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="c20201231"
      decimals="-3"
      id="Fact_673c5e1322154cf49ed662c412f4516e"
      unitRef="U001">1630000</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_1f71e7118a9c4118a047f2a3cf9ece25"
      unitRef="U001">684000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c20201231"
      decimals="-3"
      id="Fact_dd5037cb9c19485ab72c3eb387cbc862"
      unitRef="U001">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_47f0d14df958408e80f2c1a0ffb1c76e"
      unitRef="U001">1097000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20201231"
      decimals="-3"
      id="Fact_766fa37f6a864ccb965af4dcd9857f0a"
      unitRef="U001">102000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_19ecdd8cc8014c38a47e22bd9230caa6"
      unitRef="U001">18766000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20201231"
      decimals="-3"
      id="Fact_ec8ec10327b44638b5afea22b2522071"
      unitRef="U001">1732000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20211231"
      decimals="-3"
      id="Fact_2b7d2f29bbcd4894a3aedfcdf2e257b8"
      unitRef="U001">670000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20201231"
      decimals="-3"
      id="Fact_f2408597d21546f8a2eb36eb09327d25"
      unitRef="U001">594000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20211231"
      decimals="-3"
      id="Fact_ef93195bea7f44f88df1378682c2c431"
      unitRef="U001">2567000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20201231"
      decimals="-3"
      id="Fact_5764aa5646744e69b1d38aa65921f0d0"
      unitRef="U001">2093000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="c20211231"
      decimals="-3"
      id="Fact_4a4a467136da4654b2cfeb7570353b05"
      unitRef="U001">2044000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="c20201231"
      decimals="-3"
      id="Fact_5d5560f56a1d4f2aacda2fa27f118819"
      unitRef="U001">2044000</us-gaap:Goodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="c20211231"
      decimals="-3"
      id="Fact_deafd1da7f164ab3aa3df12c7e4a01f2"
      unitRef="U001">6860000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="c20201231"
      decimals="-3"
      id="Fact_799857ffe05e4240a7ab761fcb2f79e6"
      unitRef="U001">6860000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:EquityMethodInvestments
      contextRef="c20211231"
      decimals="-3"
      id="Fact_f67cb2ff7e3144f7b5d8c9399bc0e38d"
      unitRef="U001">1000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="c20201231"
      decimals="-3"
      id="Fact_16950d0c24294fbe9f3ab2f983b65702"
      unitRef="U001">0</us-gaap:EquityMethodInvestments>
    <us-gaap:DepositAssets
      contextRef="c20211231"
      decimals="-3"
      id="Fact_7a2c3d2392b648ebaf56d7a1f442b234"
      unitRef="U001">522000</us-gaap:DepositAssets>
    <us-gaap:DepositAssets
      contextRef="c20201231"
      decimals="-3"
      id="Fact_d3cf4ecfdc0a42ba87ade4f7685ef059"
      unitRef="U001">453000</us-gaap:DepositAssets>
    <us-gaap:Assets
      contextRef="c20211231"
      decimals="-3"
      id="Fact_e31cc62ef317439291eb1b61998b9664"
      unitRef="U001">32429000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20201231"
      decimals="-3"
      id="Fact_a61df61a01094ffebbc7e7ba7ec52c31"
      unitRef="U001">13776000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_b760e19c944a493abbe5191e772372a4"
      unitRef="U001">1755000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20201231"
      decimals="-3"
      id="Fact_f0056ea2db3f4ecb9b6c8dd61714d03f"
      unitRef="U001">1275000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_2fc4cf671ba1465cb1f1758cba8dcf9b"
      unitRef="U001">1249000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20201231"
      decimals="-3"
      id="Fact_fd56bb147e664534b60ca33c582f7434"
      unitRef="U001">1051000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_f3c48df9f2724b13a3e91a8b1608fc3f"
      unitRef="U001">0</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="c20201231"
      decimals="-3"
      id="Fact_87f71a6ebf544bd8bda1c917271fe023"
      unitRef="U001">410000</us-gaap:LoansPayableCurrent>
    <btx:PaycheckProtectionProgramLoanCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_6a206d85fcab437baaa5cb6a867b0d8e"
      unitRef="U001">0</btx:PaycheckProtectionProgramLoanCurrent>
    <btx:PaycheckProtectionProgramLoanCurrent
      contextRef="c20201231"
      decimals="-3"
      id="Fact_9c841795ba3b4169875c788672e8f092"
      unitRef="U001">116000</btx:PaycheckProtectionProgramLoanCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_d4ddc7eeaf824fe5bae613c8190ade70"
      unitRef="U001">426000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20201231"
      decimals="-3"
      id="Fact_c81c16e3ba1e4aa1b69980bc8f9aeb91"
      unitRef="U001">273000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_f96ab1f0b0524b49a055eba77a2db23e"
      unitRef="U001">247000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c20201231"
      decimals="-3"
      id="Fact_c1c95cfe984d4911984927197e8a1e68"
      unitRef="U001">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_0c7086dc3d4b4afc82f8c47423757476"
      unitRef="U001">3677000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20201231"
      decimals="-3"
      id="Fact_a71671ee0bc0489dbfef42e7552650c2"
      unitRef="U001">3125000</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_d913d3d63ec24dc1b04a453dbc16f225"
      unitRef="U001">19930000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="c20201231"
      decimals="-3"
      id="Fact_d3f4c963a49d4b40a1bd15e5a7145f7f"
      unitRef="U001">20110000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_4cfd1290738e4a558803aeb3e9f91c3c"
      unitRef="U001">2297000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20201231"
      decimals="-3"
      id="Fact_018badadaf0c497297297d85b2f0c1c6"
      unitRef="U001">1905000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <btx:PaycheckProtectionProgramLoanNonCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_c4a272273dfa48a882f3819cd5c17c72"
      unitRef="U001">0</btx:PaycheckProtectionProgramLoanNonCurrent>
    <btx:PaycheckProtectionProgramLoanNonCurrent
      contextRef="c20201231"
      decimals="-3"
      id="Fact_88cac281a1e044dc900ea5e6032ea42f"
      unitRef="U001">194000</btx:PaycheckProtectionProgramLoanNonCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_ce4df0ca62d34750aed114a1ccd220d2"
      unitRef="U001">23000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20201231"
      decimals="-3"
      id="Fact_313f3ea5530945b693fb4893f851ddf4"
      unitRef="U001">23000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="c20211231"
      decimals="-3"
      id="Fact_4532e8cedd7a4953a92798b7990cf61d"
      unitRef="U001">25927000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20201231"
      decimals="-3"
      id="Fact_81e90baa7a744ef6bdb15cb617cf6e3a"
      unitRef="U001">25357000</us-gaap:Liabilities>
    <us-gaap:MembersCapital
      contextRef="c20211231_StatementClassOfStockAxis_CommonClassAMember"
      decimals="-3"
      id="Fact_f4ec78d7ac71448b80665aa2405f006e"
      unitRef="U001">0</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="c20201231_StatementClassOfStockAxis_CommonClassAMember"
      decimals="-3"
      id="Fact_e01d28cfefc24008802683a7776a6b79"
      unitRef="U001">23202000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="c20211231_StatementClassOfStockAxis_CommonClassBMember"
      decimals="-3"
      id="Fact_66ea54ebda6346eb9a4a4adf65bab5cf"
      unitRef="U001">0</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="c20201231_StatementClassOfStockAxis_CommonClassBMember"
      decimals="-3"
      id="Fact_703249fc98cc4c3fbbd3f949bf4f60ea"
      unitRef="U001">1400000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="c20211231_StatementClassOfStockAxis_CommonClassCMember"
      decimals="-3"
      id="Fact_86628241612c4437ba88eef0cc26b938"
      unitRef="U001">0</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="c20201231_StatementClassOfStockAxis_CommonClassCMember"
      decimals="-3"
      id="Fact_d9e046812df34de7903cc80ce5504010"
      unitRef="U001">1000000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="c20211231_StatementClassOfStockAxis_CommonUnitsMember"
      decimals="-3"
      id="Fact_5373217751c445eb9195986880a81886"
      unitRef="U001">0</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="c20201231_StatementClassOfStockAxis_CommonUnitsMember"
      decimals="-3"
      id="Fact_9eda8889c61b47019aeba69999904d5f"
      unitRef="U001">198000</us-gaap:MembersCapital>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20201231"
      decimals="3"
      id="Fact_513d7a7c3c20471d9937a97ca1595e49"
      unitRef="U003">0.005</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20211231"
      decimals="3"
      id="Fact_d69a1f197156427fb86ed00abb8bb991"
      unitRef="U003">0.005</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="c20201231"
      decimals="-3"
      id="Fact_31acc6e1a27b4b879d7c6e77c5d2eebb"
      unitRef="U001">156000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="c20211231"
      decimals="-3"
      id="Fact_0062360134ea426e9aa6231f32db350e"
      unitRef="U001">156000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20211231"
      decimals="-3"
      id="Fact_27828cf010684758b488d7e640ff8cd4"
      unitRef="U002">156000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20211231"
      decimals="-3"
      id="Fact_ac25dadae31641299c8277d1d79a752e"
      unitRef="U002">156000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20201231"
      decimals="-3"
      id="Fact_4a23f9a7c9fd49babb28fea919462fc5"
      unitRef="U002">156000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20211231"
      decimals="-3"
      id="Fact_7809838da624439daee5a2a3004d3d27"
      unitRef="U002">156000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20201231"
      decimals="-3"
      id="Fact_b0cd673f6d2b4219ae74f9ab038d11b2"
      unitRef="U002">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20201231"
      decimals="-3"
      id="Fact_5c5017f43fdf44898c4327bc317edf68"
      unitRef="U002">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="-3"
      id="Fact_3c06de5a37354e65a8849492f19661e5"
      unitRef="U001">1000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="-3"
      id="Fact_da8e4aba74cf471cb2da0d377787e0c8"
      unitRef="U001">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20201231"
      decimals="3"
      id="Fact_1f122b9d571d4b7394ab907a1165ff63"
      unitRef="U003">0.005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20211231"
      decimals="3"
      id="Fact_68444d60f8f34faab3139f302ed53368"
      unitRef="U003">0.005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20201231"
      decimals="-3"
      id="Fact_121619fbcb214cd5b9cebb3d97d19a41"
      unitRef="U002">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20211231"
      decimals="-3"
      id="Fact_0368c0b5a4c84bd29017461f7d3e964b"
      unitRef="U002">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20211231"
      decimals="-3"
      id="Fact_3aa720625143427ba2468ae58c992ebd"
      unitRef="U002">52021000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20211231"
      decimals="-3"
      id="Fact_cdea0190c7dd4d4b852276540bf1e534"
      unitRef="U002">52021000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20201231"
      decimals="-3"
      id="Fact_624457c789d54559a2ce380257b624c1"
      unitRef="U002">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20201231"
      decimals="-3"
      id="Fact_4fb31baabbd94c719c361d1191b50e17"
      unitRef="U002">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="c20211231"
      decimals="-3"
      id="Fact_acfd183b334c4b448746386881a5f1a3"
      unitRef="U001">260000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c20201231"
      decimals="-3"
      id="Fact_689d2db27711499684fb0c7b75a0d459"
      unitRef="U001">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20211231"
      decimals="-3"
      id="Fact_a7869b86b66f4b18baaf6bfaf956911f"
      unitRef="U001">165944000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20201231"
      decimals="-3"
      id="Fact_4c0e2532c384417fb65f5e588fa602f5"
      unitRef="U001">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20211231"
      decimals="-3"
      id="Fact_21eec3385f8c478985cc0ecea2b3377d"
      unitRef="U001">-159703000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20201231"
      decimals="-3"
      id="Fact_02187ad3624844fb89dae0473c890707"
      unitRef="U001">-37381000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20211231"
      decimals="-3"
      id="Fact_cc15f6d34c78426e9bc1b08534e7519f"
      unitRef="U001">6502000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231"
      decimals="-3"
      id="Fact_560b70cfced84ddcbbe71cfd32cd058b"
      unitRef="U001">-11581000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20211231"
      decimals="-3"
      id="Fact_a554beb328b9406880844da48fcaa972"
      unitRef="U001">32429000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20201231"
      decimals="-3"
      id="Fact_93fc25e31f83417cbdef29d6cc256591"
      unitRef="U001">13776000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_01cd1add88fc4750bcad235a94efb490"
      unitRef="U001">12705000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_9f60c4da0eb34485b5f77e418d695d40"
      unitRef="U001">3951000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <btx:ResearchAndDevelopmentInProcessAssetAcquisition
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_22e1533394354721bfd3abd9fc9d0425"
      unitRef="U001">80538000</btx:ResearchAndDevelopmentInProcessAssetAcquisition>
    <btx:ResearchAndDevelopmentInProcessAssetAcquisition
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_0e4ca1d6a16742dd8ec80d2ffe8f4c20"
      unitRef="U001">0</btx:ResearchAndDevelopmentInProcessAssetAcquisition>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_9bb7d355128b41cd8f3e64942a0a7ce9"
      unitRef="U001">14724000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_a7e884621bb742aeaec523854e3e0f5a"
      unitRef="U001">3297000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_4fe9decad0074dfc8114f574e8770623"
      unitRef="U001">5765000</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_831740ad530b4513831620344ebd3983"
      unitRef="U001">0</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_0639037200664749bb955b54de4293b6"
      unitRef="U001">-180000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_706c088d09204051b8bf41833881a5c0"
      unitRef="U001">19240000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_ee22632000d94bda8131d30d5e89ffa1"
      unitRef="U001">113552000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_35a371f5fdc747be869f455cf3b0ed4d"
      unitRef="U001">26488000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_ee01a084a17d4894a5fee901f69edc19"
      unitRef="U001">-113552000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_db49d649e544483796aa161f552a936e"
      unitRef="U001">-26488000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_0f14b415dd394bf7bea9e9fdc05424d1"
      unitRef="U001">-9648000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_b4846047e43c42fd96a854db46f53b44"
      unitRef="U001">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_51930577dcaa4e00929941d47c4b39c4"
      unitRef="U001">899000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_44c8c72a12214b1b98fce1c598d7771b"
      unitRef="U001">-43000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_16e365f1d7a84174b23759e28903f827"
      unitRef="U001">-8749000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_818ae173b43748fab7a4de732249c7ff"
      unitRef="U001">-43000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_6b46aff3e03f4087ab8344ddf3b8ea6a"
      unitRef="U001">-122301000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_fd1efe4c0a1d42d2ac5958537b1b0dce"
      unitRef="U001">-26531000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_b2a816c57e9545d089a175b99825d599"
      unitRef="U001">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_f7b434f713f4481c8ccb3955f1be9c0a"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_1d9f8c5ef15643feb8c324bcf4f3a1fa"
      unitRef="U001">-122306000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_640000860a8a4a5da53a913a6fb3b5d0"
      unitRef="U001">-26531000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_e7f3e3d50a764e9583536993e4f46de9"
      unitRef="U001">16000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_a57c8da9484e400aba9b04f47ca24bbf"
      unitRef="U001">0</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_21643c30732c41a4bcf8387cda6802c7"
      unitRef="U001">-122322000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_6c5e251e213a4c4e8572d941f2e28915"
      unitRef="U001">-26531000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20210101to20211231"
      decimals="2"
      id="Fact_da70584682314fee83ccae881b51b51b"
      unitRef="U003">-2.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20210101to20211231"
      decimals="2"
      id="Fact_258879fa819845759e6dac5588b1dc7d"
      unitRef="U003">-2.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20200101to20201231"
      decimals="2"
      id="Fact_fa1f379cf4a24dcb891cc244a449dca8"
      unitRef="U003">-1.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20200101to20201231"
      decimals="2"
      id="Fact_bfb2c250f973450592b49220f9770750"
      unitRef="U003">-1.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_ac65a98d7d7646d598e85f0d0209de36"
      unitRef="U002">43306000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_1275f61f6b24471e8ce4b9dd21adf2da"
      unitRef="U002">43306000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_e1a4aed506e44770a46a04fd4c0020cc"
      unitRef="U002">17588000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_665f926370474d579ecdfac1f9e4eab3"
      unitRef="U002">17588000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_e9057aef406f4540a8e10bd6d2ebc88a"
      unitRef="U001">23202000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_11bb31ea454e41c7b767dafaab4e2e24"
      unitRef="U001">1400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_c15ab3d0fd9247198a9038caeff059c1"
      unitRef="U001">1000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_677524bbd5bd48bc93e964949e78f09f"
      unitRef="U001">198000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e0ed04c4c8b7411288b1d8d0388a9b9d"
      unitRef="U002">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_48530363e3db402197a6653f468b5ab2"
      unitRef="U001">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_de4636764472463bbcd85abeb451bb5e"
      unitRef="U002">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_209a8d62e661439699b167019f1d405e"
      unitRef="U001">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_17b3294ce6bb4ad4ab94641a2016e5c7"
      unitRef="U001">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_04d4529069fa462e879e5827688231a0"
      unitRef="U001">-37381000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231"
      decimals="-3"
      id="Fact_2058f28807d84e4990c750ebdb33c397"
      unitRef="U001">-11581000</us-gaap:StockholdersEquity>
    <btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_6bc2fea3802e44f7a1553a513a38f90a"
      unitRef="U001">10500000</btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_0eb4ff0e670344149b893025f2ae5f7c"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_44b44c32a08747a9910d73a91036fc03"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_ee6591acb2de4d4d91421e59f269928f"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_9f89fb60ae534e9494c52ec79088b037"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_713537546d5c4f2bb5ec4f26247fd47f"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_043fbfcf5f5f4025a1da4272070787aa"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_1ec00c3ab32740f2b753d802bd3f0db1"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_8661018aeb94457eb60b4a27468f26f7"
      unitRef="U001">10500000</btx:StockIssuedDuringPeriodValueRightsOfferingMembershipUnits>
    <btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_5901af5b6b76452f99fcb8ded3621b9a"
      unitRef="U001">-33702000</btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_e980d155fca84712867132f44492d443"
      unitRef="U001">-1400000</btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_47a6e2c1a0a648239f1ddd75e4d8e2b0"
      unitRef="U001">-1000000</btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_d4b46b7208374d4890f99ddd6476da09"
      unitRef="U001">-198000</btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e689c2d8413c4de6bf583465a62db3fe"
      unitRef="U001">0</btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_4db05f4df22b4cbeb16439fd5f090d9f"
      unitRef="U001">0</btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_4ac1323a1637498ea3640a61d567a123"
      unitRef="U001">36300000</btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_864ceb5fd7b4495993478ab1e0a25324"
      unitRef="U001">0</btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_f1af653d24b94c7c86f7bdc3dfbb0c68"
      unitRef="U001">0</btx:AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity>
    <btx:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_ebd7c994101f45ee97b5d18edb16c2ca"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueAcquisitions1>
    <btx:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_926807bedaa44b0ea00c6ee53c5fbf50"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueAcquisitions1>
    <btx:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_51fc73cc811747c0b24ce37f2198c98c"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueAcquisitions1>
    <btx:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_b629c00a1a8544e38d50d1276ddab65d"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueAcquisitions1>
    <btx:StockIssuedDuringPeriodSharesAcquisitions1
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_3917805bcfa349639a6050eb86f8f288"
      unitRef="U002">1514000</btx:StockIssuedDuringPeriodSharesAcquisitions1>
    <btx:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_126aec1ff9f2432a94b78fc63345bd3a"
      unitRef="U001">8000</btx:StockIssuedDuringPeriodValueAcquisitions1>
    <btx:StockIssuedDuringPeriodSharesAcquisitions1
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_16a626c199c045309964472161e7be22"
      unitRef="U002">0</btx:StockIssuedDuringPeriodSharesAcquisitions1>
    <btx:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_8f479cd4e89d4a4e8ff8b097135ce5cc"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueAcquisitions1>
    <btx:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_f7bc19ebf16a47189c60f74ca109a691"
      unitRef="U001">8170000</btx:StockIssuedDuringPeriodValueAcquisitions1>
    <btx:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_1dae332b93a64c1a8646fcb94a00a4cb"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueAcquisitions1>
    <btx:StockIssuedDuringPeriodValueAcquisitions1
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_09c895144f9644609faf73b14f54f859"
      unitRef="U001">8178000</btx:StockIssuedDuringPeriodValueAcquisitions1>
    <btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_f8c93cff5d304c7084a5dcdd46ece524"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_bc864b87117648f88be5154d0dea86d8"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_a6ec911f141f4244bc3c99155c1a36ff"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_6da7696f6cfb42c0b274087a58765c7c"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <btx:StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_29f38d6177cc461bbbf8a1a528e43650"
      unitRef="U002">0</btx:StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders>
    <btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_675a51144a6b49ff8c9fccf14c7cff7f"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <btx:StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_5049635531e64128a0269997ebcf6229"
      unitRef="U002">156000</btx:StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders>
    <btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_f067c95e1f2a4f189cfd80ae49b13b64"
      unitRef="U001">1000</btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_ba27fbb9b1b34ce7949f6b3a874cc7c7"
      unitRef="U001">-1000</btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_a6abaee3a9f14e90afa571710c15eb68"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_95fa6183824e4a418a73497c39865254"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_f4d9d7d8c54647bcb622f2e4a6185d86"
      unitRef="U001">0</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_3539a6f3621649b199d3fc1ba795186e"
      unitRef="U001">0</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_1072e0e076724101880bbd4eb9872aa1"
      unitRef="U001">0</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_815c65ccf11249e8a766c33529566ae7"
      unitRef="U001">0</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountUnitsAcquisitions
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_04688469418443cbb52bd82a9acbe208"
      unitRef="U002">38924000</us-gaap:PartnersCapitalAccountUnitsAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_fa5e598c32bc4b1092e053cc378a01ec"
      unitRef="U001">195000</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountUnitsAcquisitions
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_9da31cc18816403ba2f7bff0d434af59"
      unitRef="U002">0</us-gaap:PartnersCapitalAccountUnitsAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_245e48f5fdbd46118ec1e105138e9bc4"
      unitRef="U001">0</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a4ebf914dfbc454a8167a0184da78958"
      unitRef="U001">-195000</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_0ff82ca853cc49878d47fd9cd08ad923"
      unitRef="U001">0</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:PartnersCapitalAccountAcquisitions
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_48783773751346db8e7e2096e4c65163"
      unitRef="U001">0</us-gaap:PartnersCapitalAccountAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_853246f6590849d098d682b9eb8882f0"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_517c643fe2ed40b5a71d6f25f4953e74"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_17a56d1b47c64deaa5a7666b222a7080"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_ea23653c04ef47579ff656013b87f95f"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_131cb9d8ec8b440facc1f0c60184e52c"
      unitRef="U002">1068000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_81c23dac0bd048ad8d28fd653360f807"
      unitRef="U001">5000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_00285ff385534fd99a343e8d68e7b4de"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_06585f5d02844239bfefc7113e0c0814"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a9803d0cdd8e4e9297a3d3c27b0f9c25"
      unitRef="U001">5760000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_f45887c71ab140a19bc987f0accc36f8"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_d3ffbb0c6e014a05be9e07347cc06f43"
      unitRef="U001">5765000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_cfe9179d72a84b1ab3ff67c8971eb684"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_b8a4f20ebb4640bfaca3ade33e077548"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_cc1058827ae44ff89a185af64bb3624e"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_b48f037fd9ea4598b6a8707ce340f68e"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_b124eb9af3934f718bbdad0c73988eab"
      unitRef="U002">1000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_a5173ee1e7294a5e924cebf7d6b6148f"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_62803e9961e14483b0a0c7cf504ca913"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_6622e18e245f4fc290bc40d173f9a44a"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_f845426fe01d40469c842517ec63e7d3"
      unitRef="U001">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_741cc1b93cbf4735aca9306bf65d86d8"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_6e7c4f5952df43c6982f2d12349e907c"
      unitRef="U001">10000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <btx:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_b239475f51314747bcdffd54c714443e"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <btx:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_4f8a8fe506304ca39e8ab0dd1c6b8eae"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <btx:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_580ee6871bb04e2abbf869b40e3dba73"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <btx:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_f0724c3ef06a4237a32f0eea858fb8c0"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <btx:StockIssuedDuringPeriodSharesStockPurchaseAgreement
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_1e4294a6e7fc481f99859dcd1e883abc"
      unitRef="U002">3552000</btx:StockIssuedDuringPeriodSharesStockPurchaseAgreement>
    <btx:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_42bc1ff1f0354f4b958f8a3daa54b899"
      unitRef="U001">17000</btx:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <btx:StockIssuedDuringPeriodSharesStockPurchaseAgreement
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_6dae6c55d2d047d496bb426e7f5ac50d"
      unitRef="U002">0</btx:StockIssuedDuringPeriodSharesStockPurchaseAgreement>
    <btx:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_472e21b517cd4d8993f47f4577f2b544"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <btx:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0a91299e538a4ec1ac595f78bad9704e"
      unitRef="U001">52008000</btx:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <btx:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_b10c51f8b9694942bbad8a65b664067f"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <btx:StockIssuedDuringPeriodValueStockPurchaseAgreement
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_1023cdca45e2443e9a9684960c4593da"
      unitRef="U001">52025000</btx:StockIssuedDuringPeriodValueStockPurchaseAgreement>
    <btx:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_04eceb648cfc42b2bf01fcabb794f405"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueAcquisitions2>
    <btx:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_6c0788d7ae974aea9a9db1abbe1e9dca"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueAcquisitions2>
    <btx:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_9a6e041c235e4771ac11464280b205b6"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueAcquisitions2>
    <btx:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_42584bd8e9464c4d99f86665073720ed"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueAcquisitions2>
    <btx:StockIssuedDuringPeriodSharesAcquisitions2
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_6a0b4d8d75c04b619d6c9852ece19219"
      unitRef="U002">7022000</btx:StockIssuedDuringPeriodSharesAcquisitions2>
    <btx:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f14c50061bfe4359b8ed347fd2d14579"
      unitRef="U001">35000</btx:StockIssuedDuringPeriodValueAcquisitions2>
    <btx:StockIssuedDuringPeriodSharesAcquisitions2
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_71d094568ead401e80c873182235050d"
      unitRef="U002">0</btx:StockIssuedDuringPeriodSharesAcquisitions2>
    <btx:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_fb002ffc514f44209b06fd0f1b22d821"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueAcquisitions2>
    <btx:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_eef41400da1f437f89ef18c59bcabe28"
      unitRef="U001">58649000</btx:StockIssuedDuringPeriodValueAcquisitions2>
    <btx:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_c86675cb978e43c9b54e4dcd3395a527"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueAcquisitions2>
    <btx:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_f3c50affb624422bba231a1faeb244ce"
      unitRef="U001">58684000</btx:StockIssuedDuringPeriodValueAcquisitions2>
    <us-gaap:DividendsPreferredStockCash
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_cfecafce884649fb867fb3f908782630"
      unitRef="U001">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_b73b141de6ca42a696e1a1685798d781"
      unitRef="U001">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_b726225040f8497d82bfc79582f1811c"
      unitRef="U001">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_df27285e62344f56bc6a0798fcc77a0d"
      unitRef="U001">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:PreferredStockDividendsShares
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_b117bb6ef03048c6bd792d71c22c1837"
      unitRef="U002">0</us-gaap:PreferredStockDividendsShares>
    <us-gaap:DividendsPreferredStockCash
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_4672708f17234c5182ba3fe33ec86100"
      unitRef="U001">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:PreferredStockDividendsShares
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_13f72c35c0b94ab78a9e9cc36cc03451"
      unitRef="U002">0</us-gaap:PreferredStockDividendsShares>
    <us-gaap:DividendsPreferredStockCash
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_cd68cc42636b4dceb270c6ccf54169ab"
      unitRef="U001">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_03f5cfc183154ba3919d6f6530ff674c"
      unitRef="U001">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_adb24a6c1447451bb72f3cc2978ad49d"
      unitRef="U001">8000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_5967bd4cb4ec4e9da5d1b9beea186909"
      unitRef="U001">8000</us-gaap:DividendsPreferredStockCash>
    <btx:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_37b6bad68e80472dacf15558212a9ecc"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueInLieuOfDividends>
    <btx:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_57582479cb4a41898ba4b08a0fa01b4b"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueInLieuOfDividends>
    <btx:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_d4ff0eceaab646f3b9986daa49caf661"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueInLieuOfDividends>
    <btx:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_e751749c47254a72aee368eb9c253fec"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueInLieuOfDividends>
    <btx:StockIssuedDuringPeriodSharesInLieuOfDividends
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_5268bc771142419ba9a34c8428576e82"
      unitRef="U002">0</btx:StockIssuedDuringPeriodSharesInLieuOfDividends>
    <btx:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_ae04d87e3a8b4312ba9bdc16c4749bd1"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueInLieuOfDividends>
    <btx:StockIssuedDuringPeriodSharesInLieuOfDividends
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_46e4bc7190d946e4ad915678162eb657"
      unitRef="U002">0</btx:StockIssuedDuringPeriodSharesInLieuOfDividends>
    <btx:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_d6cef9d2fffd4134b047539349e9eec3"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueInLieuOfDividends>
    <btx:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_3852e81fd8224922bc428de3ac4372f3"
      unitRef="U001">8000</btx:StockIssuedDuringPeriodValueInLieuOfDividends>
    <btx:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_8235e431edf74adca64fd35efea92bb0"
      unitRef="U001">-8000</btx:StockIssuedDuringPeriodValueInLieuOfDividends>
    <btx:StockIssuedDuringPeriodValueInLieuOfDividends
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_760d49d64e33409bbf03cb7aa6e2f1a4"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueInLieuOfDividends>
    <btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_e8b3d1916d7e40e297555c0fd0e6db32"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_1f4fc4733a254b638dba757f6f36d93b"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_6af14035cc93498aa39f110ad971f82d"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_81c7607d22644842a86429fef4b12fb6"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <btx:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_7c6ccd089e23448f8a7c1a409925adaa"
      unitRef="U002">60000</btx:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock>
    <btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_efd06e62aa8f412baf0a0e9e7021c620"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <btx:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_13cbb9b313ce45878ac7f391f4ac9b53"
      unitRef="U002">0</btx:SharesIssuedSharesForfeitureOfUnvestedRestrictedStock>
    <btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_835869427fe244d9b8885a5bf58aeaca"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_bb7d32fef0894d11ba5f5ec4a0165e08"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_6bc62ca1f67d45518f559e7f9934a39b"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_4682e55e3f074e6daf356a206796d219"
      unitRef="U001">0</btx:StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_854bd3bcab5740069958bba69a76bd1b"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_2b263290fcf44891b3b24a3a3dd7f2cc"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_3b8d6539abda400aa7c8f2bf28b96c4f"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_bb775edc05c5464f8fd0548b68455ed6"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_b024b986296d4b19b6a003ce86be796d"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_3b29c5b9c98b42719209638e556da009"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_3367ce3a27e44e4f882b5b94b0ccbc80"
      unitRef="U001">5235000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_cfa4a7dbfa5e412fba93a4a36d5beec1"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_dc97804095124bb1934388736d4c687b"
      unitRef="U001">5235000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_5af966f6036a444e9cdc4b9cd5beb98e"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_9f1818df4db948fea4666adcbea8ce77"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_b5138ee5964741b3bc285c28d3764790"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_97c9dcb0984d4a7eb949c527216bfd78"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_d87331a16bfd445c916833ffb69d001e"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_68217bd9e8b04e03b023d27b071f9f75"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_4b67c649fac642c3bde8f3c375cce62c"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_15a678e02208445185ef7dfc60ca5251"
      unitRef="U001">-122306000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_0fedf8022c694e169df2d0b89ad74e3d"
      unitRef="U001">-122306000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_c38614db0b004fdcb28fa11c5b88ff29"
      unitRef="U001">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_157eb086e8914fb588ce9eb92799bf35"
      unitRef="U001">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_3cb6af10e2a94d7b9b25e24a6eb49cca"
      unitRef="U001">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_e835fc162478430db8e38577092cd16a"
      unitRef="U001">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c679a78fdcdf43388c793bb2725da0eb"
      unitRef="U002">52021000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_11a1429d21ea4a02bcebe80e44bff3a1"
      unitRef="U001">260000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_9a7798b5d24042b8832fe30619710036"
      unitRef="U002">156000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementEquityComponentsAxis_PreferredStockMember"
      decimals="-3"
      id="Fact_c7fb04cb885044c985bc449e25a2ca8f"
      unitRef="U001">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_cdeda3a4c74f425f9c98f21d779d6833"
      unitRef="U001">165944000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_e8a81bf47e6e48bcbe8b52769fc5e646"
      unitRef="U001">-159703000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231"
      decimals="-3"
      id="Fact_86c1cd5d9446415dacfc49a9924bba76"
      unitRef="U001">6502000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20191231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_e61085ac93ff4e33833533f8f979ad36"
      unitRef="U001">18178000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20191231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_acfb0d963fa64ad0834405af1c885cf8"
      unitRef="U001">1400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20191231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_9c37ea46b5884cc9abb7d795898e15ae"
      unitRef="U001">1000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20191231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_50c9af9ff8004ef2b3d76c217c7c6075"
      unitRef="U001">107000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20191231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_869a039101154f7c90a83f6bd701bd87"
      unitRef="U001">-10942000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20191231"
      decimals="-3"
      id="Fact_765f4e447ee44887869eec456f9d8167"
      unitRef="U001">9743000</us-gaap:StockholdersEquity>
    <btx:EffectOfImplementationOfNewAccountingPrincipal
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_9f64c0f8a9fe4b68a3c44dac33097b21"
      unitRef="U001">0</btx:EffectOfImplementationOfNewAccountingPrincipal>
    <btx:EffectOfImplementationOfNewAccountingPrincipal
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_121aaf0e589c4cb380eb7d4c3419318a"
      unitRef="U001">0</btx:EffectOfImplementationOfNewAccountingPrincipal>
    <btx:EffectOfImplementationOfNewAccountingPrincipal
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_e4a364d03c594175848b1bfc73ef959c"
      unitRef="U001">0</btx:EffectOfImplementationOfNewAccountingPrincipal>
    <btx:EffectOfImplementationOfNewAccountingPrincipal
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_8b9531da695f4a01b0f955886d67a31b"
      unitRef="U001">0</btx:EffectOfImplementationOfNewAccountingPrincipal>
    <btx:EffectOfImplementationOfNewAccountingPrincipal
      contextRef="c20200101to20201231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_b75f465ff15244589e2b9eab35d557cf"
      unitRef="U001">92000</btx:EffectOfImplementationOfNewAccountingPrincipal>
    <btx:EffectOfImplementationOfNewAccountingPrincipal
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_021c6f9679ff4756af8a98bcadedc21f"
      unitRef="U001">92000</btx:EffectOfImplementationOfNewAccountingPrincipal>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_48cf4e7453e1463a8a972ab555f77bd1"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_fcec746ba92149049b615d97134a3ea8"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_aa650e32a4634d288a57676f14d789b0"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_e1ef2f80d8f54351aae2f62cb5d56729"
      unitRef="U001">91000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20200101to20201231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_860206aca5cb47ccafc9d9d1acf7f134"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_060150b54d364a82a955df68b58ec6ba"
      unitRef="U001">91000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquityOther
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_77ad941c1ab9462c8fa39fba562f4485"
      unitRef="U001">5024000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_e62ce40ed66d4f5c9ef8338e82f06bfc"
      unitRef="U001">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_93d5b119ff7644f28c781bbfd813d1a2"
      unitRef="U001">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_673bba027f9b41db8d376a75d8d131ba"
      unitRef="U001">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="c20200101to20201231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_5b42f611ee2746b081fbe18a3f0565cc"
      unitRef="U001">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_282a5e122595460abf02a44344d39430"
      unitRef="U001">5024000</us-gaap:StockholdersEquityOther>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_e54f148b86554d98ba526e272cc61179"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_15afae84120149489f462a4afc07f092"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_5e3dc1198f0f4838a889911694e8a6a2"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_c4add3e2730c4f468e7a1d5cf752f612"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20201231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_e1b7ca3040ce4e34a07bd1caa4e53663"
      unitRef="U001">-26531000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_d3081d26b3074761b84753e82d4b174b"
      unitRef="U001">-26531000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_e92545ba44f24f4ab74c1ad41ba57152"
      unitRef="U001">23202000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementClassOfStockAxis_CommonClassBMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_27b3dd870326470bafb8565998f83635"
      unitRef="U001">1400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementClassOfStockAxis_CommonClassCMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_aacf393ba30f40e49ab18935b397938f"
      unitRef="U001">1000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementClassOfStockAxis_CommonUnitsMember_StatementEquityComponentsAxis_MembershipEquityMember"
      decimals="-3"
      id="Fact_c9b4d6e388ce4585980595a008fd2c93"
      unitRef="U001">198000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_080f0947c35548d69de0bead320bd64b"
      unitRef="U001">-37381000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231"
      decimals="-3"
      id="Fact_62aac37538bc441db7e935c52d308ce8"
      unitRef="U001">-11581000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_0b5a3c432d8046b5a37eb98349d4b4fa"
      unitRef="U001">-122306000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_a830814c69f0449f9a50e3237e031012"
      unitRef="U001">-26531000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_5c33e67354b047eb91ef682500baf574"
      unitRef="U001">117000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_745109199f584e128dd8269e4568b6c1"
      unitRef="U001">98000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_b0b555adf57241a39b3680277f385d9d"
      unitRef="U001">5235000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_2c4c574744be420390b191ec9a594c03"
      unitRef="U001">91000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_9d819258e20942c9bcea05d188e2823a"
      unitRef="U001">342000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_bd4feec8d43c4448a99c5096ce2fa278"
      unitRef="U001">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_cf3b5a1f6ec0429785154b0b72af6030"
      unitRef="U001">5765000</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:NoncashMergerRelatedCosts
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_b477b5a11ec34b11a1521532f338439e"
      unitRef="U001">0</us-gaap:NoncashMergerRelatedCosts>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_437a2d49a9c64dc7a8b3108c0e5c8e28"
      unitRef="U001">-9648000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_927b253ade6042c99d2843f31ebba262"
      unitRef="U001">0</us-gaap:GainLossOnDispositionOfAssets1>
    <btx:GainLossOnDisposalOfFixedAssets
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_947dc1dd675b4ec7a423300cc67bf0ce"
      unitRef="U001">13000</btx:GainLossOnDisposalOfFixedAssets>
    <btx:GainLossOnDisposalOfFixedAssets
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_433e8ae312d5472b86725ea1e2954526"
      unitRef="U001">0</btx:GainLossOnDisposalOfFixedAssets>
    <btx:GainLossOnForgivenessOfPaycheckProtectionProgramLoan
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_35154077e8e842f9a4ce01ac27a2907c"
      unitRef="U001">310000</btx:GainLossOnForgivenessOfPaycheckProtectionProgramLoan>
    <btx:GainLossOnForgivenessOfPaycheckProtectionProgramLoan
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_47b9bb25d7234c6bba835062f1bca494"
      unitRef="U001">0</btx:GainLossOnForgivenessOfPaycheckProtectionProgramLoan>
    <btx:ResearchAndDevelopmentInProcessAssetAcquisition
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_9ac6c1f2c82140b38fa46b768a733273"
      unitRef="U001">80538000</btx:ResearchAndDevelopmentInProcessAssetAcquisition>
    <btx:ResearchAndDevelopmentInProcessAssetAcquisition
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_56ace37820ff4e8188bbb016ec3d5c5e"
      unitRef="U001">0</btx:ResearchAndDevelopmentInProcessAssetAcquisition>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_33d98d08cb93459f846b7b6c1c72f1ed"
      unitRef="U001">-180000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_76a7f792ac2a4bc5b145dec30f064c25"
      unitRef="U001">19240000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_225670abf0f149bab9d448907897cdf8"
      unitRef="U001">659000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_a7120e5d33544c8497d564d3a4e17db2"
      unitRef="U001">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_1919aa5855084332859a3b6ec5a8534b"
      unitRef="U001">850000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_8d6744c712d2414184a0cce3cf622d88"
      unitRef="U001">16000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <btx:IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_6b3d30abb5e648d0be311ef5d83adfbe"
      unitRef="U001">34000</btx:IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets>
    <btx:IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_02e845cc15fa43c88b4ace796ee9a892"
      unitRef="U001">90000</btx:IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_8ed44ef49a5a4bc0b1d1ad6cfec04dd4"
      unitRef="U001">-485000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_ad0781da627945d8b9d7983777bdecfa"
      unitRef="U001">-930000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <btx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_e8965267f06441ebacef418a75c25652"
      unitRef="U001">-322000</btx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <btx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_34e1931ddb4d40ac80fa693a24171bc4"
      unitRef="U001">12000</btx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_95e16e6ba5814878b8a9622f6b75ea2f"
      unitRef="U001">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_a822f9dd0c1f49e5873248b30300ec58"
      unitRef="U001">25000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_cad32201fde649a6b8af981f82a16314"
      unitRef="U001">-23488000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_3a97e2b36294497a95725561054f3476"
      unitRef="U001">-8101000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_9a4de66d7e454d93a2f47c0127451f37"
      unitRef="U001">154000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_ce093a2bc3b6483aa6b20dbdcc32e373"
      unitRef="U001">39000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSalesOfAssetsInvestingActivities
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_df0cf657cbe24d2e814da5f01ab58bfb"
      unitRef="U001">147000</us-gaap:ProceedsFromSalesOfAssetsInvestingActivities>
    <us-gaap:ProceedsFromSalesOfAssetsInvestingActivities
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_cb443ea34d104be1a8be76127daa0f45"
      unitRef="U001">0</us-gaap:ProceedsFromSalesOfAssetsInvestingActivities>
    <btx:PaymentsToAcquireProductiveAssetsNet
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_4801b1c9ede24365b749275403f2585a"
      unitRef="U001">22854000</btx:PaymentsToAcquireProductiveAssetsNet>
    <btx:PaymentsToAcquireProductiveAssetsNet
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_b418fe559f6847618d36fb6359f2ad66"
      unitRef="U001">0</btx:PaymentsToAcquireProductiveAssetsNet>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_6b9ebb63bdef4aa1b9ae71bb8ba10a49"
      unitRef="U001">119000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_fe636a160af94989ad796574fd0b4f49"
      unitRef="U001">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_daaed406ad5c47a8b49a120f48459289"
      unitRef="U001">-22742000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_16fc34fd977e4fdcb858e4eeb19e43ee"
      unitRef="U001">-39000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_693083d516654772b696f0633cd762a8"
      unitRef="U001">52025000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_a797e2b32d174cdcb0ec3fa07ffb675d"
      unitRef="U001">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_14ceec9784594ad69e4d3c641b936e9a"
      unitRef="U001">10500000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_4dbf15a8123d4a29b43cfec805c988e4"
      unitRef="U001">4359000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_9078d1b9c8b741ed929dcfb8af4825af"
      unitRef="U001">10000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_2d6ca4567e5149fe9b4d408ae2dff3c0"
      unitRef="U001">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_6cec81fcf11042fc925d45f5e898996f"
      unitRef="U001">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_e1d5f4dfd91a434e9533d0de5f4cd770"
      unitRef="U001">310000</us-gaap:ProceedsFromNotesPayable>
    <btx:PaymentsOfPaycheckProtectionProgramLoan
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_7b6a035e4e024ef4957de51997f60208"
      unitRef="U001">532000</btx:PaymentsOfPaycheckProtectionProgramLoan>
    <btx:PaymentsOfPaycheckProtectionProgramLoan
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_3b931b5857e3475797f1b368997f4841"
      unitRef="U001">0</btx:PaymentsOfPaycheckProtectionProgramLoan>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_887c514171964ede9b1c8d46a859f1b4"
      unitRef="U001">410000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_088360d5490d437095487aaed3cb7e4f"
      unitRef="U001">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_00eb0da2c53e4a6180362bcf26acd1b4"
      unitRef="U001">8000</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_388f28b03fc04aba8ef8027d49609d5b"
      unitRef="U001">0</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_c56ff05c922e4a04b1eee06c6665ebeb"
      unitRef="U001">61585000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_62c78fd7f2b04480b22e0d21655cb3ac"
      unitRef="U001">4669000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_dd05c41e92814513b3c7b369969a5ad0"
      unitRef="U001">15355000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_364c734ec0bb4ea4bd38678cd2b09a83"
      unitRef="U001">-3471000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20201231"
      decimals="-3"
      id="Fact_0562eb194f60409e9defa1ffcbaceda3"
      unitRef="U001">1630000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20191231"
      decimals="-3"
      id="Fact_a411d5c8a44d402d8e796ed63b49090f"
      unitRef="U001">5101000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20211231"
      decimals="-3"
      id="Fact_2614eb5fd066456194afe3dc9dcba2be"
      unitRef="U001">16985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20201231"
      decimals="-3"
      id="Fact_bb4ac44cb0ef4b3199f512e94fb09fcf"
      unitRef="U001">1630000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_99b54c3ea1b94232823600d4284cabbb"
      unitRef="U001">225000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_e9cac12a2b6b439d8272f12ed679c001"
      unitRef="U001">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_96344efcd6ae43f3a2eb442c4ccd8b30"
      unitRef="U001">1000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_f750be35366c4f038277a6ec0178f484"
      unitRef="U001">0</us-gaap:IncomeTaxesPaidNet>
    <btx:IssuanceOfCommonStockForSeriesAPreferredStockDividend
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_aa177dd4d4234be28ff0a94029d74ef8"
      unitRef="U001">8000</btx:IssuanceOfCommonStockForSeriesAPreferredStockDividend>
    <btx:IssuanceOfCommonStockForSeriesAPreferredStockDividend
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_7bc3c873bbc94ac7855ecfbbcf7f2e03"
      unitRef="U001">0</btx:IssuanceOfCommonStockForSeriesAPreferredStockDividend>
    <us-gaap:StockIssued1
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_277b2369befa4052ae87239f50234b75"
      unitRef="U001">8178000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_619d89e3d2ed4e5cad84e99ddd994539"
      unitRef="U001">0</us-gaap:StockIssued1>
    <btx:IssuanceOfCommonStockForAssetAcquisition
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_4118f1850d014415966884a0a6b83818"
      unitRef="U001">58684000</btx:IssuanceOfCommonStockForAssetAcquisition>
    <btx:IssuanceOfCommonStockForAssetAcquisition
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_73bb896ccdef4a45a88ce5244e14b246"
      unitRef="U001">0</btx:IssuanceOfCommonStockForAssetAcquisition>
    <btx:ForfeitureOfUnvestedRestrictedStock
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_74b3505d004f4efcb96651b9a515b230"
      unitRef="U001">0</btx:ForfeitureOfUnvestedRestrictedStock>
    <btx:ForfeitureOfUnvestedRestrictedStock
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_0c753636a71c4686b92dc185d755c90c"
      unitRef="U001">0</btx:ForfeitureOfUnvestedRestrictedStock>
    <btx:NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_59e5b1947a7a4bf594d3ef5e79ee573a"
      unitRef="U001">1000</btx:NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger>
    <btx:NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_4ff101d185ee4fa886d495f3759e783c"
      unitRef="U001">0</btx:NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger>
    <btx:InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_ffa438e13ad4478aa45d82ff73bc6bc1"
      unitRef="U001">816000</btx:InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance>
    <btx:InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_697d4394e98a4b6fa702ea9414aab5b9"
      unitRef="U001">0</btx:InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance>
    <btx:InitialMeasurementOfOperatingLeaseLiabilities
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_622c7bce84fd472c868cec799d22c924"
      unitRef="U001">866000</btx:InitialMeasurementOfOperatingLeaseLiabilities>
    <btx:InitialMeasurementOfOperatingLeaseLiabilities
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_ac4355951cd2491da4681eb6b3c3e288"
      unitRef="U001">0</btx:InitialMeasurementOfOperatingLeaseLiabilities>
    <btx:InvestorDepositsForSaleOfMembersEquity
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_360f531c6b894eef882a333b4a444251"
      unitRef="U001">0</btx:InvestorDepositsForSaleOfMembersEquity>
    <btx:InvestorDepositsForSaleOfMembersEquity
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_99354eeee6694fbbbed57480752364a9"
      unitRef="U001">666000</btx:InvestorDepositsForSaleOfMembersEquity>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_4df912dac606496bac0fde396c9ec33e"
      unitRef="U001">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c20200101to20201231"
      decimals="-3"
      id="Fact_ecd6a48540374910943b755ec675df9f"
      unitRef="U001">2093000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="c20210101to20211231"
      id="Text_e8e4b46423fc459bb75555fc7279ec7b">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;1)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Organization and Description of Business Operations&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: bold; color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Brooklyn ImmunoTherapeutics Inc., a Delaware corporation (&#x201c;Brooklyn&#x201d; or the &#x201c;Company&#x201d;), together with its subsidiaries including Brooklyn
          ImmunoTherapeutics LLC (&#x201c;Brooklyn LLC&#x201d;), Novellus, Inc. (&#x201c;Novellus&#x201d;) and Novellus Therapeutics, Ltd. (&#x201c;Novellus, Ltd.&#x201d;), is a clinical stage biopharmaceutical company focused on exploring the role that cytokine, gene editing and cell therapy can
          have in treating patients with cancer, blood disorders and monogenic diseases. As used herein, the &#x201c;Company&#x201d; refers collectively to Brooklyn and its subsidiaries.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On August 12, 2020, Brooklyn (then known as &#x201c;NTN Buzztime, Inc.&#x201d;), Brooklyn LLC and BIT Merger Sub, Inc., a wholly owned subsidiary of Brooklyn
          (the &#x201c;Merger Sub&#x201d;), entered into an agreement and plan of merger and reorganization (the &#x201c;Merger Agreement&#x201d;) pursuant to which, among other matters, Merger Sub merged with and into Brooklyn LLC, with Brooklyn LLC continuing as a wholly owned
          subsidiary of Brooklyn and as the surviving company of the merger (the &#x201c;Merger&#x201d;). The Merger closed on March 25, 2021. After the Merger, Brooklyn changed its name from &#x201c;NTN Buzztime, Inc.&#x201d; to &#x201c;Brooklyn ImmunoTherapeutics, Inc.&#x201d; The Merger was
          accounted for as a reverse acquisition, in which Brooklyn LLC was deemed the acquiring company for accounting purposes.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On March 26, 2021, Brooklyn sold (the &#x201c;Disposition&#x201d;) its rights, title and interest in and to the assets relating to the business operated under
          the name &#x201c;NTN Buzztime, Inc.&#x201d; prior to the Merger to eGames.com Holdings LLC (&#x201c;eGames.com&#x201d;) in accordance with the terms of an asset purchase agreement dated September 18, 2020, as amended, between Brooklyn and eGames.com (the &#x201c;Asset Purchase
          Agreement&#x201d;). (See Note 4.)&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On July 16, 2021, Brooklyn and its newly formed, wholly owned subsidiary Brooklyn Acquisition Sub, Inc. entered into an agreement and plan of
          acquisition (the &#x201c;Acquisition Agreement&#x201d;) with (a) Novellus LLC, (b) Novellus (the sole equity holder of Novellus, Ltd. and, prior to the closing under the Acquisition Agreement, a wholly owned subsidiary of Novellus, LLC), and (c) a seller
          representative (the &#x201c;Acquisition&#x201d;), pursuant to which Brooklyn acquired Novellus and its subsidiary, Novellus, Ltd. As part of the Acquisition, Brooklyn also acquired 25.0% of the total outstanding equity interests of NoveCite, Inc. (&#x201c;NoveCite&#x201d;), a corporation focused on developing an allogeneic mesenchymal stem cell product for patients with acute respiratory distress
          syndrome, including from COVID-19. (See Note 4.)&lt;/div&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember"
      decimals="3"
      id="Fact_dc56a5c3b3d646b1bea1e964bc31d6a0"
      unitRef="U004">0.250</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <btx:LiquidityAndCapitalResourcesTextBlock
      contextRef="c20210101to20211231"
      id="Text_fc15066e43c442738a9103a62a510e6f">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;2)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Liquidity and Capital Resources&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company has incurred significant operating losses and has an accumulated deficit as a result of ongoing efforts to develop product candidates,
        including conducting clinical trials and providing general and administrative support for these operations. As of December 31, 2021, the Company had a cash balance of approximately $16,985,000 and an accumulated deficit of approximately $159,703,000.
        For the year ended December 31, 2021, the Company incurred a net loss of $122,306,000 and the Company used cash in operating activities
        of $23,488,000 (inclusive of $80,538,000
        IPR&amp;amp;D expense related to the Acquisition, $9,648,000 related to the loss on sale of assets in the Disposition and $180,000 related to the change in fair value of contingent consideration).&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On April 26, 2021, Brooklyn entered into a common stock purchase agreement (the &#x201c;First Purchase Agreement&#x201d;) with Lincoln Park Capital Fund, LLC
          (&#x201c;Lincoln Park&#x201d;), which provided that Brooklyn could offer to Lincoln Park up to an aggregate of $20,000,000 of common stock over a 36-month period commencing after May 10, 2021, the date that a registration statement covering the resale of shares of common stock issued under the
          First Purchase Agreement was declared effective by the SEC. As of December 31, 2021, Brooklyn had issued and sold an aggregate of approximately 1,128,000
          shares of common stock to Lincoln Park pursuant to the First Purchase Agreement, resulting in gross proceeds of $20,000,000.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On May 26, 2021, Brooklyn entered into a second common stock purchase agreement (the &#x201c;Second Purchase Agreement&#x201d;) with Lincoln Park, which
        provides that Brooklyn may offer to Lincoln Park up to an aggregate of $40,000,000 of common stock over a 36-month period commencing after June 4, 2021, the date that a registration statement covering the resale of shares of common stock issued under the
        Second Purchase Agreement was declared effective by the SEC. As of December 31, 2021, Brooklyn had issued and sold an aggregate of approximately 2,424,000
        shares of common stock to Lincoln Park pursuant to the Second Purchase Agreement, resulting in gross proceeds of approximately $34,106,000.&lt;/div&gt;

&lt;div&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On July 16, 2021, Brooklyn used approximately $22,854,000
        of cash, net of cash acquired, as part of the purchase price of the Acquisition. Brooklyn issued common stock as the remaining portion of the purchase price of the Acquisition.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; On March 9, 2022, we consummated a private placement of equity resulting in net proceeds of approximately $11 million. See Note 17 for details.&lt;/span&gt; &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none;"&gt;In connection with
            preparing its financial statements as of and for the year ended December 31, 2021, the Company&#x2019;s management concluded that there is substantial doubt regarding the Company&#x2019;s ability to continue as a going concern because it does not expect to
            have sufficient cash or working capital resources to fund operations for the twelve-month period subsequent to the issuance date of these financial statements.&#160; The Company will need to raise additional capital, which could be through the
            remaining availability under the Second Purchase Agreement (to the extent the Company is permitted to use such agreement), public or private equity offerings, debt financings, corporate collaborations or other means. The Company may also seek
            governmental grants to support our clinical trials and preclinical trials..&#160; The Company currently has no arrangements for such capital and no assurances can be given that it will be able to raise such capital when needed, on acceptable terms,
            or at all.&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;The accompanying
        consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do
        not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to the Company&#x2019;s ability to continue as
        a going concern.&lt;/div&gt;
</btx:LiquidityAndCapitalResourcesTextBlock>
    <us-gaap:Cash
      contextRef="c20211231"
      decimals="0"
      id="Fact_1a3a8058fca940ceb18dab402f895fc3"
      unitRef="U001">16985000</us-gaap:Cash>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20211231"
      decimals="0"
      id="Fact_83a3e652c73e41e5a2b30b34ea1217ef"
      unitRef="U001">-159703000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <btx:NetIncomeLossAttributableToParentTemporaryElement
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_0ff5a43588cf440c9675eb33683cf040"
      unitRef="U001">-122306000</btx:NetIncomeLossAttributableToParentTemporaryElement>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_86d4030bab7a4058b2e51109566a693f"
      unitRef="U001">-23488000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <btx:ResearchAndDevelopmentInProcessAssetAcquisition
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_e2e85d239a964c87a53e4c4c1e9ce698"
      unitRef="U001">80538000</btx:ResearchAndDevelopmentInProcessAssetAcquisition>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_41e7149e17a64723a94ac57f784cb09c"
      unitRef="U001">-9648000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_5ba9d91ed23c41a39132272ccdf5104a"
      unitRef="U001">-180000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20210426to20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember"
      decimals="0"
      id="Fact_da37b7bfccdf4db9ac1cef7c2eed65b3"
      unitRef="U001">20000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <btx:CommencementPeriodOfCommonStockInPurchaseAgreement
      contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember"
      id="Fact_c6178ad7fac04e42a358395dd0dac623">P36M</btx:CommencementPeriodOfCommonStockInPurchaseAgreement>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember"
      decimals="0"
      id="Fact_f5e3c8448a3c418cb93ed5c29ac3448a"
      unitRef="U002">1128000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember"
      decimals="0"
      id="Fact_23c86708c70a49609a27b77d58d06577"
      unitRef="U001">20000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20210526to20210526_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember"
      decimals="0"
      id="Fact_9ccb30b039f54e75a00b64b10f167e8f"
      unitRef="U001">40000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <btx:CommencementPeriodOfCommonStockInPurchaseAgreement
      contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember"
      id="Fact_1629b42b72574dabab386a7c680f728c">P36M</btx:CommencementPeriodOfCommonStockInPurchaseAgreement>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember"
      decimals="0"
      id="Fact_8d566bc5eb54458f86687f3c5a1b0f28"
      unitRef="U002">2424000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember"
      decimals="0"
      id="Fact_3e92bff0a3f04fc2b017b7f0bd229dac"
      unitRef="U001">34106000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <btx:PaymentsToAcquireProductiveAssetsNet
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_3a8f7f1861984ecf831cfe57129b2f2c"
      unitRef="U001">22854000</btx:PaymentsToAcquireProductiveAssetsNet>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="c20220309to20220309_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-6"
      id="Fact_a7076d7f22d34b9bab8487616c4d8f37"
      unitRef="U001">11000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="c20210101to20211231"
      id="Text_c553cd7856fc42e9a8ba0aba36ff481f">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;3)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Basis of Accounting Presentation and Summary of Significant Accounting Policies&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Basis of Accounting Presentation&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference
        in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). All significant intercompany
        balances and transactions have been eliminated in consolidation.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;As described above, the Merger closed on March 25, 2021. The Merger was accounted for as a reverse acquisition, in which Brooklyn LLC was deemed
          the acquiring company for accounting purposes. Brooklyn LLC&#x2019;s historical financial statements have replaced Brooklyn&#x2019;s historical financial statements with respect to periods prior to the completion of the Merger (when Brooklyn operated under the
          name &#x201c;NTN Buzztime, Inc.&#x201d;). The Company retrospectively adjusted the weighted average shares used in determining loss per common share to reflect the conversion of the outstanding Class A units, Class B units, Class C units, and common units of
          Brooklyn LLC that converted into shares of Brooklyn&#x2019;s common stock upon the Merger and to reflect the effect of a &lt;span style="-sec-ix-hidden:Fact_565a5991ac0445a8b9e9f14506915bfe"&gt;2-to-1&lt;/span&gt; reverse stock
          split of Brooklyn&#x2019;s common stock that occurred immediately prior to the Merger.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Also as described above, the Acquisition closed on July 16, 2021. The Acquisition was accounted for as an asset acquisition, and substantially
          all of the value was attributed to in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;), with the exception of the cash paid for the investment in NoveCite, which is being accounted for as an investment in equity securities. The IPR&amp;amp;D had no
          alternative future uses and no separate economic value from its originally intended purpose and was therefore expensed in the period the cost was incurred.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Summary of Significant Accounting Policies&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (a)
        the reported amounts of assets and liabilities; (b) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; (c) the reported amounts of revenues and expenses during the reporting period and (d) the
        reported amount of the fair value of assets acquired in connection with business combinations. Actual results could differ from those estimates. The Company&#x2019;s significant estimates and assumptions include the recoverability and useful lives of
        long-lived assets and the contingent consideration liability.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company classifies highly liquid investments with a remaining contractual maturity at date of purchase of three months or less as cash
        equivalents. The Company had no cash equivalents as of December 31, 2021 or 2020.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Property and equipment are recorded at cost and are depreciated over their estimated useful lives using the straight-line method. Laboratory and
        manufacturing equipment are depreciated over an estimated useful life of seven years. Leasehold improvements are depreciated over the
        shorter of their estimated useful life, or the lease term. Computer equipment are depreciated over an estimated useful life of three years.
        Upon retirement or other disposition of these assets, the cost and related accumulated depreciation of these assets are removed from the accounts and the resulting gain or losses are reflected in the results of operations. Expenditures for
        maintenance and repairs are charged to operations. Renewals and betterments are capitalized.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in the acquisition of IRX
        Therapeutics, Inc. in November 2018 (the &#x201c;IRX Acquisition&#x201d;), which was accounted for as a business combination. Goodwill is not amortized but is tested for impairment annually, or if events occur or circumstances change that would reduce the fair
        value of a reporting unit below its carrying value. Because management evaluates the Company as a single reporting unit, goodwill is tested for impairment at the entity level by first performing a qualitative assessment to determine whether it is
        more likely than not that the fair value of the entity is less than its carrying value. Such qualitative factors include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant
        events.&#160; If the entity does not pass the qualitative assessment, then the entity&#x2019;s carrying value is compared to its fair value. Goodwill is considered impaired if the carrying value of the entity exceeds its fair value.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;IPR&amp;amp;D assets represent the fair value assigned to technologies that were acquired in connection with the IRX Acquisition, which have not
        reached technological feasibility and have no alternative future use. IPR&amp;amp;D assets are considered to be indefinite lived until the completion or abandonment of the associated research and development projects. During the period that the
        IPR&amp;amp;D assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the
        IPR&amp;amp;D assets are less than their carrying amounts. If and when development is complete, which generally occurs upon regulatory approval, and the Company is able to commercialize products associated with the IPR&amp;amp;D assets, these assets are
        then deemed definite-lived and are amortized based on their estimated useful lives beginning at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&amp;amp;D assets,
        calculated as the excess of carrying value of the IPR&amp;amp;D assets over fair value.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company reviews long-lived assets and certain identifiable assets for impairment whenever circumstances and situations change such that there
        is an indication that the carrying amounts may not be recovered. An impairment exists when the carrying value of the long-lived asset is not recoverable and exceeds its fair value. For the years ended December 31, 2021 and 2020, there were no
        qualitative factors that indicated it was more likely than not that the fair value of the long-lived assets exceeded the carrying value.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company expenses its research and development costs as incurred. Research and development expenses consist of costs incurred for
        company-sponsored research and development activities, as well as support for selected investigator-sponsored research. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the
        period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. IPR&amp;amp;D that is acquired through an asset acquisition (as
        opposed to a business combination) and has no alternative future uses and, therefore, no separate economic values, is expensed to research and development costs at the time the costs are incurred.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The major components of research and development costs include preclinical study costs, clinical manufacturing costs, clinical study and trial
        expenses, insurance coverage for clinical trials, expensed licensed technology, expensed IPR&amp;amp;D, consulting, scientific advisors and other third-party costs, salaries and employee benefits, stock-based compensation expense, supplies and
        materials and allocations of various overhead costs related to our product development efforts.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In the normal course of our business, the Company contracts with third parties to perform various clinical study and trial activities in the
        on-going development and testing of potential products. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors
        such as the achievement of certain events or milestones, the successful enrollment of patients, the allocation of responsibilities among the parties to the agreement, and the completion of portions of the clinical study or trial or similar
        conditions. Preclinical and clinical study and trial associated activities such as production and testing of clinical material require significant up-front expenditures. The Company anticipates paying significant portions of a study&#x2019;s or trial&#x2019;s
        cost before they begin and incurring additional expenditures as the study or trial progresses and reaches certain milestones.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company records deferred tax liabilities and assets based on the differences between the consolidated financial statements carrying amounts
        and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and established a valuation allowance when it was more likely than not that some portion or all of the deferred tax
        assets would not be realized. Income tax expense consists of the tax payable for the period and the change during the period in deferred tax assets and liabilities.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Tax benefits from uncertain tax positions are recognized only if it is more likely than not that the tax position will be sustained on examination
        by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of
        being realized upon ultimate resolution. The Company has no material uncertain tax positions for any of the reporting periods presented.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Earnings Per Share&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Basic and diluted loss per common share have been computed by dividing the losses applicable to common stock by the weighted average number of
        common shares outstanding. The Company&#x2019;s basic and fully diluted earnings per share (&#x201c;EPS&#x201d;) calculation are the same since the increased number of shares that would be included in the diluted calculation from assumed exercise of common stock
        equivalents would be anti-dilutive to the net loss in each of the years shown in the consolidated financial statements.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In accordance with ASC No. 280, &lt;span style="font-style: italic;"&gt;Segment Reporting&lt;/span&gt;, the Company has determined that it operates as one operating segment. Decisions regarding the Company&#x2019;s overall operating performance and allocation of its resources are assessed on a consolidated
        basis.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company maintains its cash balances in financial institutions located in the United States. Accounts at each institution are insured by the
        Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) up to $250,000. At times, the Company&#x2019;s cash balances may be uninsured for deposit accounts that exceed the FDIC insurance limit.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In the Company&#x2019;s business, vendor concentrations could be indicative of vulnerabilities in the Company&#x2019;s supply chain, which could ultimately
        impact the Company&#x2019;s ability to continue its research and development activities. For the years ended December 31, 2021 and 2020, there was no vendor concentration related to the Company&#x2019;s research and development activities.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between
        willing market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The
        fair value hierarchy is as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;&#x2022;&lt;/span&gt;&#160;&#160;&#160;&#160; &lt;span style="color: rgb(0, 0, 0);"&gt;Level 1 Inputs &#x2013; Valued based on quoted prices in active markets for identical
          assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;&#x2022;&lt;/span&gt;&#160;&#160;&#160;&#160; &lt;span style="color: rgb(0, 0, 0);"&gt;Level 2 Inputs &#x2013; Valued based on inputs other than quoted prices included in Level
          1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that
          are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market
          data by correlation or other means.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;&#x2022;&lt;/span&gt;&#160;&#160;&#160;&#160; &lt;span style="color: rgb(0, 0, 0);"&gt;Level 3 Inputs &#x2013; Valued based on inputs for which there is little or no market
          value, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The carrying amounts reported on the balance sheet for cash and cash equivalents, accounts receivable, prepaid assets and other current assets,
        accounts payable and accrued expenses, other current liabilities and other liabilities approximate fair value based due to their short maturities. The carrying value of loans payable approximates its fair market value because the effective yield on
        this debt, which includes contractual interest rates as well as other finance charges, is comparable to rates of returns for instruments of similar credit risk.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Leases&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company adopted ASC Topic 842, &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Leases,&lt;/span&gt;
        on December 31, 2020 using the modified transition method without retrospective application to comparative periods. The Company elected the package of three practical expedients allowed for under the transition guidance. Accordingly, the Company
        did not reassess: (1) whether any expired or existing contracts are/or contain leases; (2) the lease classification for any expired or existing leases; or (3) initial direct costs for any existing leases. The Company has also elected not to
        recognize right-of-use assets (&#x201c;ROU assets&#x201d;) and lease liabilities for short-term leases that have a term of 12 months or less.&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Operating lease liabilities represent the present value of lease payments not yet paid. ROU assets represent the Company&#x2019;s right to use an
          underlying asset and are based upon the operating lease liabilities adjusted for prepaid or accrued lease payments, initial direct costs, lease incentives and impairment of operating lease assets. If the interest rate implicit in the lease is not
          readily determinable, the Company uses the incremental borrowing rates based on the information available at the lease commencement date in determining the present value of lease payments. To determine the present value of lease payments not yet
          paid, the Company estimates secured borrowing rates corresponding to the maturities of the leases.&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company has elected the practical expedient to not separate non-lease components from the lease components to which they relate and instead
          account for each as a single lease component for all underlying asset classes. Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as payments for insurance, tax payments and other
          miscellaneous costs. The variable portion of lease payments is not included in the ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are expensed when the obligation for those payments
          is incurred and are included in lease expenses. Accordingly, all expenses associated with a lease contract are accounted for as lease expenses.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Commitment and Contingencies&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company follows ASC No.450-20, &lt;span style="font-style: italic;"&gt;Loss Contingencies&lt;/span&gt;, to report accounting for contingencies.
        Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company recognizes stock-based compensation expense for equity awards granted to employees, directors and certain consultants. The Company
        estimates the fair value of stock options using the Black-Scholes option pricing model. The fair value of stock options granted is recognized as expense over the requisite service period. Stock-based compensation expense for share-based payment
        awards is recognized using the straight-line single-option method.&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In May 2021, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;span style="font-style: italic;"&gt;2021-04,


























          Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain
          Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/span&gt;. ASU 2021-04 addresses the accounting for certain modifications or exchanges of freestanding equity-classified written call options. ASU 2021-04 is effective
        for fiscal years beginning after December 15, 2021 (January 1, 2022 for the Company) and interim periods within those fiscal years, with early adoption permitted. The Company does not expect the adoption of this update to have a significant impact
        on its financial statements.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In July 2021, the FASB issued ASU 2021-05, &lt;span style="font-style: italic;"&gt;Leases (Topic 842) &#x2013; Lessors - Certain Leases with Variable Lease
          Payments,&lt;/span&gt; which amends the lessor classification guidance to introduce additional criteria when classifying leases with variable lease payments that do not depend on a reference index or a rate. This guidance is effective for annual
        periods beginning after December 15, 2021 (January 1, 2022 for the Company), with early adoption permitted. The Company does not expect the adoption of this update to have a significant impact on its financial statements.&lt;/div&gt;
</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="c20210101to20211231"
      id="Text_00959b52567a41a3b8e8cec794fec4cb">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Basis of Accounting Presentation&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference
        in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). All significant intercompany
        balances and transactions have been eliminated in consolidation.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;As described above, the Merger closed on March 25, 2021. The Merger was accounted for as a reverse acquisition, in which Brooklyn LLC was deemed
          the acquiring company for accounting purposes. Brooklyn LLC&#x2019;s historical financial statements have replaced Brooklyn&#x2019;s historical financial statements with respect to periods prior to the completion of the Merger (when Brooklyn operated under the
          name &#x201c;NTN Buzztime, Inc.&#x201d;). The Company retrospectively adjusted the weighted average shares used in determining loss per common share to reflect the conversion of the outstanding Class A units, Class B units, Class C units, and common units of
          Brooklyn LLC that converted into shares of Brooklyn&#x2019;s common stock upon the Merger and to reflect the effect of a &lt;span style="-sec-ix-hidden:Fact_565a5991ac0445a8b9e9f14506915bfe"&gt;2-to-1&lt;/span&gt; reverse stock
          split of Brooklyn&#x2019;s common stock that occurred immediately prior to the Merger.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Also as described above, the Acquisition closed on July 16, 2021. The Acquisition was accounted for as an asset acquisition, and substantially
          all of the value was attributed to in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;), with the exception of the cash paid for the investment in NoveCite, which is being accounted for as an investment in equity securities. The IPR&amp;amp;D had no
          alternative future uses and no separate economic value from its originally intended purpose and was therefore expensed in the period the cost was incurred.&lt;/div&gt;
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="c20210101to20211231"
      id="Text_c45d270b2b8544d091aa6a102988a144">
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (a)
        the reported amounts of assets and liabilities; (b) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; (c) the reported amounts of revenues and expenses during the reporting period and (d) the
        reported amount of the fair value of assets acquired in connection with business combinations. Actual results could differ from those estimates. The Company&#x2019;s significant estimates and assumptions include the recoverability and useful lives of
        long-lived assets and the contingent consideration liability.&lt;/div&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="c20210101to20211231"
      id="Text_48422aca8e0b4de1b6a610801a9b8cb8">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company classifies highly liquid investments with a remaining contractual maturity at date of purchase of three months or less as cash
        equivalents. The Company had no cash equivalents as of December 31, 2021 or 2020.&lt;/div&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c20201231"
      decimals="-3"
      id="Fact_d836cfced2e34b77b8c7c2c64d2977b9"
      unitRef="U001">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c20211231"
      decimals="-3"
      id="Fact_f5031621ff6c4308b7a8c24b580c0c65"
      unitRef="U001">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="c20210101to20211231"
      id="Text_2da43536e14c489382ce5eef9701b4b4">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Property and equipment are recorded at cost and are depreciated over their estimated useful lives using the straight-line method. Laboratory and
        manufacturing equipment are depreciated over an estimated useful life of seven years. Leasehold improvements are depreciated over the
        shorter of their estimated useful life, or the lease term. Computer equipment are depreciated over an estimated useful life of three years.
        Upon retirement or other disposition of these assets, the cost and related accumulated depreciation of these assets are removed from the accounts and the resulting gain or losses are reflected in the results of operations. Expenditures for
        maintenance and repairs are charged to operations. Renewals and betterments are capitalized.&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20210101to20211231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryAndManufacturingEquipmentMember"
      id="Fact_a951a9e8e05c4662bef15fd639d8de03">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20210101to20211231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember"
      id="Fact_11f6d775c4364a3c9c3e969631e26d5d">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="c20210101to20211231"
      id="Text_c6a6f33ca0aa4d9d911c3133c23c4c45">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in the acquisition of IRX
        Therapeutics, Inc. in November 2018 (the &#x201c;IRX Acquisition&#x201d;), which was accounted for as a business combination. Goodwill is not amortized but is tested for impairment annually, or if events occur or circumstances change that would reduce the fair
        value of a reporting unit below its carrying value. Because management evaluates the Company as a single reporting unit, goodwill is tested for impairment at the entity level by first performing a qualitative assessment to determine whether it is
        more likely than not that the fair value of the entity is less than its carrying value. Such qualitative factors include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant
        events.&#160; If the entity does not pass the qualitative assessment, then the entity&#x2019;s carrying value is compared to its fair value. Goodwill is considered impaired if the carrying value of the entity exceeds its fair value.&lt;/div&gt;
</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="c20210101to20211231"
      id="Text_c2367262f15e42dd88fba84a270f0b9e">
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;IPR&amp;amp;D assets represent the fair value assigned to technologies that were acquired in connection with the IRX Acquisition, which have not
        reached technological feasibility and have no alternative future use. IPR&amp;amp;D assets are considered to be indefinite lived until the completion or abandonment of the associated research and development projects. During the period that the
        IPR&amp;amp;D assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if the Company becomes aware of any events occurring or changes in circumstances that indicate that the fair value of the
        IPR&amp;amp;D assets are less than their carrying amounts. If and when development is complete, which generally occurs upon regulatory approval, and the Company is able to commercialize products associated with the IPR&amp;amp;D assets, these assets are
        then deemed definite-lived and are amortized based on their estimated useful lives beginning at that point in time. If development is terminated or abandoned, the Company may have a full or partial impairment charge related to the IPR&amp;amp;D assets,
        calculated as the excess of carrying value of the IPR&amp;amp;D assets over fair value.&lt;/div&gt;
</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="c20210101to20211231"
      id="Text_af5453d836da4141beba2cb0931730e6">
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company reviews long-lived assets and certain identifiable assets for impairment whenever circumstances and situations change such that there
        is an indication that the carrying amounts may not be recovered. An impairment exists when the carrying value of the long-lived asset is not recoverable and exceeds its fair value. For the years ended December 31, 2021 and 2020, there were no
        qualitative factors that indicated it was more likely than not that the fair value of the long-lived assets exceeded the carrying value.&lt;/div&gt;
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="c20210101to20211231"
      id="Text_3a7f085e167c4fe3adab4b68b5c77eb4">
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company expenses its research and development costs as incurred. Research and development expenses consist of costs incurred for
        company-sponsored research and development activities, as well as support for selected investigator-sponsored research. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the
        period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. IPR&amp;amp;D that is acquired through an asset acquisition (as
        opposed to a business combination) and has no alternative future uses and, therefore, no separate economic values, is expensed to research and development costs at the time the costs are incurred.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The major components of research and development costs include preclinical study costs, clinical manufacturing costs, clinical study and trial
        expenses, insurance coverage for clinical trials, expensed licensed technology, expensed IPR&amp;amp;D, consulting, scientific advisors and other third-party costs, salaries and employee benefits, stock-based compensation expense, supplies and
        materials and allocations of various overhead costs related to our product development efforts.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In the normal course of our business, the Company contracts with third parties to perform various clinical study and trial activities in the
        on-going development and testing of potential products. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors
        such as the achievement of certain events or milestones, the successful enrollment of patients, the allocation of responsibilities among the parties to the agreement, and the completion of portions of the clinical study or trial or similar
        conditions. Preclinical and clinical study and trial associated activities such as production and testing of clinical material require significant up-front expenditures. The Company anticipates paying significant portions of a study&#x2019;s or trial&#x2019;s
        cost before they begin and incurring additional expenditures as the study or trial progresses and reaches certain milestones.&lt;/div&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="c20210101to20211231"
      id="Text_498e5018dea24bdf8cc2b8a498488b16">
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company records deferred tax liabilities and assets based on the differences between the consolidated financial statements carrying amounts
        and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and established a valuation allowance when it was more likely than not that some portion or all of the deferred tax
        assets would not be realized. Income tax expense consists of the tax payable for the period and the change during the period in deferred tax assets and liabilities.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Tax benefits from uncertain tax positions are recognized only if it is more likely than not that the tax position will be sustained on examination
        by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of
        being realized upon ultimate resolution. The Company has no material uncertain tax positions for any of the reporting periods presented.&lt;/div&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="c20210101to20211231"
      id="Text_7951f8cc83434eda9aa97204d7a1dd30">
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Earnings Per Share&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Basic and diluted loss per common share have been computed by dividing the losses applicable to common stock by the weighted average number of
        common shares outstanding. The Company&#x2019;s basic and fully diluted earnings per share (&#x201c;EPS&#x201d;) calculation are the same since the increased number of shares that would be included in the diluted calculation from assumed exercise of common stock
        equivalents would be anti-dilutive to the net loss in each of the years shown in the consolidated financial statements.&lt;/div&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="c20210101to20211231"
      id="Text_eed8acfbc096446e81415cdb77dd5376">
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In accordance with ASC No. 280, &lt;span style="font-style: italic;"&gt;Segment Reporting&lt;/span&gt;, the Company has determined that it operates as one operating segment. Decisions regarding the Company&#x2019;s overall operating performance and allocation of its resources are assessed on a consolidated
        basis.&lt;/div&gt;
</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c20210101to20211231"
      decimals="INF"
      id="Fact_178445ef0fb94c5795b2f78c5d91af5d"
      unitRef="U005">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="c20210101to20211231"
      id="Text_8b2098fc4dcc48598043cbdf4eb2f4e7">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company maintains its cash balances in financial institutions located in the United States. Accounts at each institution are insured by the
        Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) up to $250,000. At times, the Company&#x2019;s cash balances may be uninsured for deposit accounts that exceed the FDIC insurance limit.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In the Company&#x2019;s business, vendor concentrations could be indicative of vulnerabilities in the Company&#x2019;s supply chain, which could ultimately
        impact the Company&#x2019;s ability to continue its research and development activities. For the years ended December 31, 2021 and 2020, there was no vendor concentration related to the Company&#x2019;s research and development activities.&lt;/div&gt;
</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="c20210101to20211231"
      id="Text_2791aa3d01e245a0bf8c2ac430d9635d">
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between
        willing market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The
        fair value hierarchy is as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;&#x2022;&lt;/span&gt;&#160;&#160;&#160;&#160; &lt;span style="color: rgb(0, 0, 0);"&gt;Level 1 Inputs &#x2013; Valued based on quoted prices in active markets for identical
          assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;&#x2022;&lt;/span&gt;&#160;&#160;&#160;&#160; &lt;span style="color: rgb(0, 0, 0);"&gt;Level 2 Inputs &#x2013; Valued based on inputs other than quoted prices included in Level
          1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that
          are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market
          data by correlation or other means.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;&#x2022;&lt;/span&gt;&#160;&#160;&#160;&#160; &lt;span style="color: rgb(0, 0, 0);"&gt;Level 3 Inputs &#x2013; Valued based on inputs for which there is little or no market
          value, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The carrying amounts reported on the balance sheet for cash and cash equivalents, accounts receivable, prepaid assets and other current assets,
        accounts payable and accrued expenses, other current liabilities and other liabilities approximate fair value based due to their short maturities. The carrying value of loans payable approximates its fair market value because the effective yield on
        this debt, which includes contractual interest rates as well as other finance charges, is comparable to rates of returns for instruments of similar credit risk.&lt;/div&gt;
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="c20210101to20211231"
      id="Text_50f18a33557b4d308295462934021741">
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Leases&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company adopted ASC Topic 842, &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Leases,&lt;/span&gt;
        on December 31, 2020 using the modified transition method without retrospective application to comparative periods. The Company elected the package of three practical expedients allowed for under the transition guidance. Accordingly, the Company
        did not reassess: (1) whether any expired or existing contracts are/or contain leases; (2) the lease classification for any expired or existing leases; or (3) initial direct costs for any existing leases. The Company has also elected not to
        recognize right-of-use assets (&#x201c;ROU assets&#x201d;) and lease liabilities for short-term leases that have a term of 12 months or less.&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Operating lease liabilities represent the present value of lease payments not yet paid. ROU assets represent the Company&#x2019;s right to use an
          underlying asset and are based upon the operating lease liabilities adjusted for prepaid or accrued lease payments, initial direct costs, lease incentives and impairment of operating lease assets. If the interest rate implicit in the lease is not
          readily determinable, the Company uses the incremental borrowing rates based on the information available at the lease commencement date in determining the present value of lease payments. To determine the present value of lease payments not yet
          paid, the Company estimates secured borrowing rates corresponding to the maturities of the leases.&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company has elected the practical expedient to not separate non-lease components from the lease components to which they relate and instead
          account for each as a single lease component for all underlying asset classes. Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as payments for insurance, tax payments and other
          miscellaneous costs. The variable portion of lease payments is not included in the ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are expensed when the obligation for those payments
          is incurred and are included in lease expenses. Accordingly, all expenses associated with a lease contract are accounted for as lease expenses.&lt;/div&gt;
</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="c20210101to20211231"
      id="Text_4f18285a39af4e629713ec9c7a2a2f1d">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Commitment and Contingencies&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company follows ASC No.450-20, &lt;span style="font-style: italic;"&gt;Loss Contingencies&lt;/span&gt;, to report accounting for contingencies.
        Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="c20210101to20211231"
      id="Text_326ab3d8fd264d64a32f3ad506798d11">
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company recognizes stock-based compensation expense for equity awards granted to employees, directors and certain consultants. The Company
        estimates the fair value of stock options using the Black-Scholes option pricing model. The fair value of stock options granted is recognized as expense over the requisite service period. Stock-based compensation expense for share-based payment
        awards is recognized using the straight-line single-option method.&lt;/div&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="c20210101to20211231"
      id="Text_072787d7bd454d62baea0d66495e71ff">
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In May 2021, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;span style="font-style: italic;"&gt;2021-04,


























          Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain
          Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/span&gt;. ASU 2021-04 addresses the accounting for certain modifications or exchanges of freestanding equity-classified written call options. ASU 2021-04 is effective
        for fiscal years beginning after December 15, 2021 (January 1, 2022 for the Company) and interim periods within those fiscal years, with early adoption permitted. The Company does not expect the adoption of this update to have a significant impact
        on its financial statements.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In July 2021, the FASB issued ASU 2021-05, &lt;span style="font-style: italic;"&gt;Leases (Topic 842) &#x2013; Lessors - Certain Leases with Variable Lease
          Payments,&lt;/span&gt; which amends the lessor classification guidance to introduce additional criteria when classifying leases with variable lease payments that do not depend on a reference index or a rate. This guidance is effective for annual
        periods beginning after December 15, 2021 (January 1, 2022 for the Company), with early adoption permitted. The Company does not expect the adoption of this update to have a significant impact on its financial statements.&lt;/div&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="c20210101to20211231"
      id="Text_affbe44113d8430c92fe1e05d1450975">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;4)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Merger, Disposition and Acquisition Transactions&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Merger&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On August 12, 2020, Brooklyn, Brooklyn LLC and the Merger Sub entered into the Merger Agreement. The Merger closed on March 25, 2021. After the
          Merger, Brooklyn changed its name from &#x201c;NTN Buzztime, Inc.&#x201d; to &#x201c;Brooklyn ImmunoTherapeutics, Inc.&#x201d; The Merger was accounted for as a reverse acquisition, in which Brooklyn LLC was deemed the acquiring company for accounting purposes. Brooklyn
          LLC, as the accounting acquirer, recorded the assets acquired and liabilities assumed of Brooklyn in the Merger at their fair values as of the acquisition date. Brooklyn&#x2019;s common stock trades on the NYSE American stock exchange under the ticker
          symbol &#x201c;BTX&#x201d;.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Brooklyn LLC was determined to be the accounting acquirer based upon the terms of the Merger and other factors including that (i) Brooklyn LLC
          members, received common stock in the Merger that represented 96.35% of Brooklyn&#x2019;s outstanding common stock on a fully diluted basis
          as of immediately after the Merger, (ii) all of the directors of Brooklyn immediately after the Merger were designated by Brooklyn LLC under the terms of the Merger Agreement and (iii) existing members of Brooklyn LLC&#x2019;s management became the
          management of Brooklyn immediately after the Merger.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;At the closing of the Merger, all the outstanding membership interests of Brooklyn LLC converted into the right to receive an aggregate of
        approximately 39,992,000 shares of common stock, of which 1,068,000 shares were issued as compensation to Maxim Group LLC, Brooklyn LLC&#x2019;s financial advisor (the &#x201c;Financial Advisor&#x201d;) for its services to Brooklyn LLC in connection with the Merger.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The purchase price of $8,178,000,
        which represents the consideration transferred in the Merger to stockholders of Brooklyn immediately before the Merger, was calculated based on the closing price of $5.40 per share for approximately 1,514,000 shares common stock that those stockholders owned on March
        25, 2021 immediately prior to the Merger because that represented a more reliable measure of the fair value of consideration transferred in the Merger.&lt;br/&gt;
      &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Under the acquisition method of accounting, the total purchase price has been allocated to the acquired tangible and intangible assets and assumed
        liabilities of Brooklyn based on their estimated fair values as of March 25, 2021, the Merger closing date. Because the consideration paid by Brooklyn LLC in the Merger is more than the estimated fair values of Brooklyn&#x2019;s net assets deemed to be
        acquired, goodwill is equal to the difference of approximately $8,589,000, which has been calculated using the fair values of the net
        assets of Brooklyn as of March 25, 2021.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The allocation of the estimated purchase price to the tangible and intangible assets acquired and liabilities deemed to be assumed from Brooklyn,
        based on their estimated fair values as of March 25, 2021, is as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Historical&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Balance&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Sheet of&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Brooklyn at&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;March 25, 2020&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Fair Value&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Adjustment&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;to Brooklyn&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Pre-Merger&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Purchase&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Price&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Allocation Pro&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Forma&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Adjustment&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Cash and cash equivalents&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;148,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;148,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accounts receivable&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;103,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;103,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Prepaid expense and other current assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;329,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;329,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Property and equipment, net&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;1,015,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;1,015,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Software development costs&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;1,296,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(368,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;928,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Customers&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;548,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;548,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Trade name&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;299,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;299,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accounts payable, accrued liabilities and other current liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(3,781,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(3,781,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Net assets acquired, excluding goodwill&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(890,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;479,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(411,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total consideration&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;8,178,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Net assets acquired, excluding goodwill&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(411,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Goodwill&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;8,589,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Brooklyn LLC was obligated under the Merger Agreement to have $10,000,000 in cash and cash equivalents on its balance sheet at the effective time of the Merger. To ensure Brooklyn LLC had the required funds, certain beneficial holders of Brooklyn LLC&#x2019;s
        Class A membership interests entered into contractual commitments to invest $10,000,000 into Brooklyn LLC immediately prior to the
        closing of the Merger. During March 2021, Brooklyn offered its Class A unit holders an additional 5% rights offering for an additional $500,000 to be raised by a rights offering. Brooklyn received funds from the rights offering between February 17, 2021 and April 5, 2021.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Disposition&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On March 26, 2021, Brooklyn sold its rights, title and interest in and to the assets relating to the business it operated (under the name NTN
        Buzztime, Inc.) prior to the Merger to eGames.com in exchange for a purchase price of $2,000,000 and assumption of specified liabilities
        relating to that business. The sale was completed in accordance with the terms of the Asset Purchase Agreement. Details of the Disposition are as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Proceeds from sale:&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Cash&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;132,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Escrow&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;50,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Assume advance/loans&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;1,700,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Interest on advance/loans&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;68,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Carrying value of assets sold:&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Cash and cash equivalents&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(14,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accounts receivable&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(75,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Prepaids and other current assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(124,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Property and equipment, net&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(1,014,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Software development costs&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(927,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Customers&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(548,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Trade name&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(299,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Goodwill&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(8,589,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Other assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(103,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Liabilities transferred upon sale:&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accounts payable and accrued expenses&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;113,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Obligations under finance leases&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;17,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Lease liability&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;26,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Deferred revenue&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;55,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Other current liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;149,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Transaction costs&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(265,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Total loss on sale of assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;(9,648,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Unaudited Pro Forma Disclosure&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following unaudited pro forma financial information summarizes the results of operations for the years months ended December 31, 2021 and 2020
        as if the Merger and the Disposition had been completed as of January 1, 2020. Pro forma information primarily reflects adjustments relating to the reversal of transaction costs. Assuming that the Merger and the Disposition had been completed as of
        January 1, 2020, the transaction costs would have been expensed in the prior period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; Years ended December 31,&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; 2021&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2020&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Net loss attributable to common stockholders&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;(122,306,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;(26,547,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Basic and diluted net loss per share attributable to common stockholders&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(2.82&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(1.51&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Acquisition&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On July 16, 2021, Brooklyn and Brooklyn Acquisition Sub, Inc. entered into the Acquisition Agreement. The Acquisition closed contemporaneously
          with the execution and delivery of the Acquisition Agreement. At the closing:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;&#x2022;&lt;/span&gt;&#160;&#160;&#160;&#160; &lt;span style="color: rgb(0, 0, 0);"&gt;Brooklyn acquired all of the outstanding equity interests of Novellus, Inc. as
            the result of the merger of Brooklyn Acquisition Sub, Inc. with and into Novellus, Inc., following which, Novellus, Inc., as the surviving corporation, became Brooklyn&#x2019;s wholly owned subsidiary and Novellus Ltd. became Brooklyn&#x2019;s indirectly
            owned subsidiary; and&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;&#x2022;&lt;/span&gt;&#160;&#160;&#160;&#160; &lt;span style="color: rgb(0, 0, 0);"&gt;Brooklyn acquired 25.0% of the total outstanding equity interests of NoveCite.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Brooklyn delivered consideration for the Acquisition totaling approximately $124,000,000, which consisted of (a) approximately $22,854,000
          in cash, net of cash acquired, and (b) approximately 7,022,000 shares of common stock, which under the terms of the Acquisition
          Agreement were valued at a total of $102,000,000, based on a price of $14.5253 per share.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Acquisition Agreement contained customary representations, warranties and certain indemnification provisions. Approximately 741,000 of the shares issued as consideration were placed in escrow for a period of up to 12 months in order to secure indemnification obligations to Brooklyn under the Acquisition Agreement. The Acquisition Agreement also contains certain non-competition and
          non-solicitation provisions pursuant to which Novellus LLC agreed not to engage in certain competitive activities for a period of five years
          following the closing, including customary restrictions relating to employees. No employees of Novellus Ltd. or Novellus, Inc. prior to the Acquisition continued their employment, or were otherwise engaged by Brooklyn, following the Acquisition.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In connection with the Acquisition, the co-founders of Novellus, Ltd. entered into lock-up agreements with respect to approximately 3,378,000 of the shares of common stock received in the Acquisition, and Brooklyn&#x2019;s Chairman of the Board of Directors and its Chief Executive Officer
          and President entered into identical lock-up agreements with respect to their current holdings of Brooklyn stock. Each lock-up agreement extends for a period of three years, provided that up to 75% of the shares of common stock subject to the lock-up agreement
          may be released from the lock-up restrictions earlier if the price of common stock on the Nasdaq exceeds specified thresholds. The lock-up agreements include customary exceptions for transfers during the applicable lock-up period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company expects the Acquisition will advance its evolution into a platform company with a pipeline of next generation engineered cellular,
        gene editing and cytokine programs. In addition, the acquisition of Novellus, Ltd. builds on the License Agreement. (See Note 11). The completion of the acquisition of Novellus, Ltd. relieved Brooklyn LLC from potential obligations to pay Novellus,
        Ltd. certain upfront fees, clinical development milestone fees and post-registration royalties under the License Agreement. The agreement with Factor Bioscience Limited (&#x201c;Factor&#x201d;) under the License Agreement, which grants Brooklyn LLC exclusive
        rights to develop certain next-generation mRNA gene editing and cell therapy products, remained unchanged.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Although Brooklyn acquired all of the outstanding equity interests of Novellus, Inc., the Company accounted for the Acquisition as an asset
        acquisition (as the assets acquired did not constitute a business as defined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 805, &lt;span style="font-style: italic;"&gt;Business Combinations&lt;/span&gt;)&lt;span style="font-style: italic;"&gt;, &lt;/span&gt;and was
        measured by the amount of cash paid and by the fair value of the shares of common stock issued. As a result, substantially all of the value acquired was attributed to IPR&amp;amp;D, with the exception of the cash paid for the investment in NoveCite,
        which is being accounted for as an investment in equity securities, as discussed further below.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Brooklyn paid $22,854,000 in cash,
        net of cash acquired, as part of the consideration for the Acquisition, of which $1,000,000 was paid in cash for the investment in
        NoveCite. Brooklyn also issued approximately 7,022,000 shares of the Company&#x2019;s common stock, of which approximately 3,644,000 shares are unrestricted and 3,378,000
        shares are subject to the three-year lockup. The unrestricted shares were valued at $10.05 per share, which was the closing price of Brooklyn&#x2019;s common stock on July 16, 2021. The fair value of the restricted shares was discounted by approximately 35% to $6.53 per restricted share, which
        was derived from the average discount rate between the Black Scholes and Finnerty valuation models. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The resulting fair value of the asset acquired is as follows:&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Fair Value of&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Consideration&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Cash paid&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;22,882,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Cash acquired&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(28,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.46%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Unrestricted shares&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;36,628,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.46%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Restricted shares&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;22,056,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.46%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total fair value of consideration paid&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;81,538,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.46%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Less amount of cash paid for NoveCite investment&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(1,000,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.46%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Fair value of IPR&amp;amp;D acquired&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;80,538,000&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;IPR&amp;amp;D that is acquired through an asset purchase that has no alternative future uses and no separate economic values from its original
          intended purpose is expensed in the period the cost is incurred. Accordingly, the Company expensed the fair value of the IPR&amp;amp;D during the third quarter of 2021 in the amount of $80,538,000.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Investment in NoveCite&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;As a result of the Acquisition, Brooklyn acquired and currently owns 25% of NoveCite and Citius Pharmaceuticals, Inc. (&#x201c;Citius&#x201d;) owns the remaining 75%.
        A member of the Company&#x2019;s management holds one of three board seats on NoveCite&#x2019;s board of directors. Citius&#x2019; s officers and directors
        hold the other two board seats. Citius also retains the ability, in its sole discretion, to increase the size of the board of directors of NoveCite. Pursuant to a subscription agreement, as amended, between NoveCite and Novellus, LLC (the former
        parent of Novellus, Inc.), which was further amended and assigned to Brooklyn by Novellus, LLC upon the completion of the Acquisition, Citius has complete operational control and financial responsibility for NoveCite. Citrus&#x2019;s officers are also the
        officers of NoveCite and oversee the business strategy and operations of NoveCite. Therefore, despite Brooklyn&#x2019;s ownership of greater than 20%
        of NoveCite, which leads to a presumption that in the absence of predominant evidence to the contrary, an investor has the ability to exercise significant influence over an investee, Brooklyn does not exercise any significant influence over
        NoveCite or its board of directors. Brooklyn also has no contractual rights in the profits or obligations to share in the losses of NoveCite.&#160; Accordingly, the Company is accounting for its interest in NoveCite under ASC Topic 321, &lt;span style="font-style: italic;"&gt;Investments &#x2013; Equity Securities. &lt;/span&gt;Because NoveCite&#x2019;s stock is not publicly traded and, therefore, does not have a readily determinable fair value, the Company has elected to account for its investment at cost,
        which was $1,000,000. The Company will make adjustments to this amount when there are observable transactions for the identical or
        similar equity securities of the same issuer that would provide an indicator of fair value. In addition, if qualitative factors indicate a potential impairment, fair value must be estimated and the investment written down to that fair value if it
        is lower than the carrying value. As of December 31, 2021, there were no observable transactions for identical or similar equity securities of NoveCite to provide an indication of fair value, nor were there any indications of impairment of the
        investment.&lt;/div&gt;
</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="4"
      id="Fact_6c13ba825ac341bb93291cf7db70904e"
      unitRef="U004">0.9635</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c20210325to20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_957debfd09d843b0aabdfcaef3a8b8d6"
      unitRef="U002">39992000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c20210325to20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_a6bf73ead64647b6b817255b94565a75"
      unitRef="U002">1068000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_8234378c08ff40eba6eba875184e9516"
      unitRef="U001">8178000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="2"
      id="Fact_f3e87fdcec7544a5bf1efbbb2a514035"
      unitRef="U003">5.40</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_73e881825006476cbd5767b7d29ef14d"
      unitRef="U002">1514000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:Goodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_b916da63442e45e38df14bce7699dc35"
      unitRef="U001">8589000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="c20210101to20211231"
      id="Text_9d066e9db16c44f0b50877d1ebe9e227">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The allocation of the estimated purchase price to the tangible and intangible assets acquired and liabilities deemed to be assumed from Brooklyn,
        based on their estimated fair values as of March 25, 2021, is as follows:&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Historical&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Balance&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Sheet of&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Brooklyn at&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;March 25, 2020&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Fair Value&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Adjustment&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;to Brooklyn&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Pre-Merger&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Purchase&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Price&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Allocation Pro&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Forma&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Adjustment&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Cash and cash equivalents&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;148,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;148,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accounts receivable&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;103,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;103,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Prepaid expense and other current assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;329,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;329,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Property and equipment, net&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;1,015,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;1,015,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Software development costs&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;1,296,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(368,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;928,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Customers&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;548,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;548,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Trade name&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;299,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;299,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accounts payable, accrued liabilities and other current liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(3,781,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(3,781,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Net assets acquired, excluding goodwill&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(890,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;479,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(411,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total consideration&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;8,178,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Net assets acquired, excluding goodwill&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(411,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Goodwill&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;8,589,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_54998d49eb4b49a29c98cb8b4fab1987"
      unitRef="U001">148000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="0"
      id="Fact_aa8180708a0c4900864f44dfa0260e4f"
      unitRef="U001">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember"
      decimals="0"
      id="Fact_22e84e427b6649fea8f83050ca84f2b8"
      unitRef="U001">148000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_b0236b1da76f4d4b8499358ce309026c"
      unitRef="U001">103000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="0"
      id="Fact_0e8ca7bd35d940ecb48bf527ceb040a5"
      unitRef="U001">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember"
      decimals="0"
      id="Fact_eccdbeb6e53445d4bfbb1b0fa16a8f0a"
      unitRef="U001">103000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_4936561c64574d5a9e6f4cac1c5afe83"
      unitRef="U001">329000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="0"
      id="Fact_715cc8ed96524ce3b0324276ba811c1f"
      unitRef="U001">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember"
      decimals="0"
      id="Fact_2d9e5b287201475696a9dee31a9da918"
      unitRef="U001">329000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_a1c597e1c427425384a9fc405348929d"
      unitRef="U001">1015000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="0"
      id="Fact_397bd43b4306420895e6543dd8f2206f"
      unitRef="U001">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember"
      decimals="0"
      id="Fact_7d16ddfedadf422b83d8f6dc17bcd4d3"
      unitRef="U001">1015000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <btx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_ee4ee2653c6b47ef91678d33e8a40fd8"
      unitRef="U001">1296000</btx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts>
    <btx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="0"
      id="Fact_74d4dbbef798449d994ae73cacd88940"
      unitRef="U001">-368000</btx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts>
    <btx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember"
      decimals="0"
      id="Fact_011221dda6eb4e9c8b0c1a4cfc362183"
      unitRef="U001">928000</btx:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember"
      decimals="0"
      id="Fact_fb2348d3b97f447a9c4d251635dc077d"
      unitRef="U001">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="0"
      id="Fact_f9d05870a7184910ae9953d7b7b9b0e5"
      unitRef="U001">548000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember"
      decimals="0"
      id="Fact_6de3749026fe4c53904c11add09b4a52"
      unitRef="U001">548000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember"
      decimals="0"
      id="Fact_3522f30cb3e4424c821194e1e02aaa70"
      unitRef="U001">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="0"
      id="Fact_22f01bd8f0f847d18416a5dc59f358a0"
      unitRef="U001">299000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember"
      decimals="0"
      id="Fact_4cfbaa98f87b4d68a3515332605d2e0b"
      unitRef="U001">299000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_28ab7eb468db42aea6fc909f3180b46f"
      unitRef="U001">3781000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="0"
      id="Fact_05dae0f9b19f4f28b793638cd61abc03"
      unitRef="U001">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember"
      decimals="0"
      id="Fact_a7aef6b0c4ff46708a65da7e4998cfa7"
      unitRef="U001">3781000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_9d75b62cf359469981764e6382099164"
      unitRef="U001">-890000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_ProFormaFairValueAdjustmentToAssetsMember"
      decimals="0"
      id="Fact_e01db3d2f838489f8b5f509349fc31e9"
      unitRef="U001">479000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember"
      decimals="0"
      id="Fact_9be7add69456456e9d886174096b7333"
      unitRef="U001">-411000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_41bf49aa8aeb4574a155f584fb8224c3"
      unitRef="U001">8178000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember_NonrecurringAdjustmentAxis_PurchasePriceAllocationProFormaAdjustmentMember"
      decimals="0"
      id="Fact_986edef52f5d4b50a6d69ea5f5b6e45b"
      unitRef="U001">-411000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_8df92d1288e247bab411f13f70b95732"
      unitRef="U001">8589000</us-gaap:Goodwill>
    <btx:ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_36492083e3c84d10b33af4efd7ec9714"
      unitRef="U001">10000000</btx:ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement>
    <btx:BeneficialHoldersContractualCommitmentsToInvest
      contextRef="c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_19dac027329c40a1b1020b52ac27c387"
      unitRef="U001">10000000</btx:BeneficialHoldersContractualCommitmentsToInvest>
    <btx:PercentageOfAdditionalRightsOffering
      contextRef="c20210301to20210331_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="2"
      id="Fact_801f9923d21047b2936f4ba47a53affb"
      unitRef="U004">0.05</btx:PercentageOfAdditionalRightsOffering>
    <btx:ProceedsFromSaleOfRights
      contextRef="c20210301to20210331_BusinessAcquisitionAxis_NTNBuzztimeIncMember"
      decimals="0"
      id="Fact_6573930294314e7286f2ea3b03fcf569"
      unitRef="U001">500000</btx:ProceedsFromSaleOfRights>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="c20210101to20211231"
      id="Text_ce7246fb9a084f1d95d792a5effb4108">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On March 26, 2021, Brooklyn sold its rights, title and interest in and to the assets relating to the business it operated (under the name NTN
        Buzztime, Inc.) prior to the Merger to eGames.com in exchange for a purchase price of $2,000,000 and assumption of specified liabilities
        relating to that business. The sale was completed in accordance with the terms of the Asset Purchase Agreement. Details of the Disposition are as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Proceeds from sale:&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Cash&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;132,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Escrow&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;50,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Assume advance/loans&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;1,700,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Interest on advance/loans&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;68,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Carrying value of assets sold:&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Cash and cash equivalents&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(14,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accounts receivable&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(75,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Prepaids and other current assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(124,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Property and equipment, net&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(1,014,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Software development costs&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(927,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Customers&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(548,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Trade name&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(299,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Goodwill&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(8,589,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Other assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(103,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Liabilities transferred upon sale:&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accounts payable and accrued expenses&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;113,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Obligations under finance leases&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;17,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Lease liability&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;26,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Deferred revenue&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;55,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Other current liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;149,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Transaction costs&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(265,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Total loss on sale of assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;(9,648,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
      contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_8a27c35a36974c4380819c8609bab11f"
      unitRef="U001">2000000</us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets>
    <btx:DisposalGroupIncludingDiscontinuedOperationProceedsFromCash
      contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_807b4ce8325946849ee811e699208e1f"
      unitRef="U001">132000</btx:DisposalGroupIncludingDiscontinuedOperationProceedsFromCash>
    <btx:DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow
      contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_511f779000594abaa922cfb4aba00a88"
      unitRef="U001">50000</btx:DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow>
    <btx:DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans
      contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_2df509ba09dc4f3dacacee5b5af8c95b"
      unitRef="U001">1700000</btx:DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans>
    <btx:DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans
      contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_696b37c9991c44baa0edf54ef8bb2839"
      unitRef="U001">68000</btx:DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_3d980b560cd1473399f019af9246f681"
      unitRef="U001">14000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_0bc2fbba6d4748148784e6a7c9fd3713"
      unitRef="U001">75000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_ce0ac8ddf8234ef99c2e6875e04ab476"
      unitRef="U001">124000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_01f85aaead0444fbbdda7f7093c04b89"
      unitRef="U001">1014000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <btx:DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_2ec6e288254746a89d3f0625c8a33262"
      unitRef="U001">927000</btx:DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_CustomerRelationshipsMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_6163d7a0b808433a9d1f2b7847c3b03e"
      unitRef="U001">548000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="c20210326_FiniteLivedIntangibleAssetsByMajorClassAxis_TradeNamesMember_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_4e763bb029ee4150a4c80ff3272815b7"
      unitRef="U001">299000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_49bc7dae4360453b8e82a8d07e33748b"
      unitRef="U001">8589000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_b31b37e9da144e8f8b0bf4b5d53f63b9"
      unitRef="U001">103000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_4360980b9a474b32997a3b4237d39a1f"
      unitRef="U001">113000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities>
    <btx:DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_b7dc86c5823743e694926ab1e3bb4638"
      unitRef="U001">17000</btx:DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases>
    <btx:DisposalGroupIncludingDiscontinuedOperationLeaseLiability
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_61d04107ef0047fba451f357980ae856"
      unitRef="U001">26000</btx:DisposalGroupIncludingDiscontinuedOperationLeaseLiability>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_07726609b4f043a5b4f2e513fcce2822"
      unitRef="U001">55000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="c20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_8d2648361c5a41d2b65c22ce1eab6bfb"
      unitRef="U001">149000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <btx:DisposalGroupIncludingDiscontinuedOperationTransactionCosts
      contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_fe92b742c340431ba1ed3c429fc31b66"
      unitRef="U001">-265000</btx:DisposalGroupIncludingDiscontinuedOperationTransactionCosts>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember"
      decimals="0"
      id="Fact_1c32dc5e98af428f9cd000c9d03a4540"
      unitRef="U001">-9648000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="c20210101to20211231"
      id="Text_953ffa0af1344c5abd3743b2b53134b4">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following unaudited pro forma financial information summarizes the results of operations for the years months ended December 31, 2021 and 2020
        as if the Merger and the Disposition had been completed as of January 1, 2020. Pro forma information primarily reflects adjustments relating to the reversal of transaction costs. Assuming that the Merger and the Disposition had been completed as of
        January 1, 2020, the transaction costs would have been expensed in the prior period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; Years ended December 31,&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; 2021&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2020&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Net loss attributable to common stockholders&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;(122,306,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;(26,547,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Basic and diluted net loss per share attributable to common stockholders&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(2.82&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(1.51&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_ac78501bc7fb446abaa1b916847308bf"
      unitRef="U001">-122306000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_f7065180120142d19e31530219496eba"
      unitRef="U001">-26547000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="c20210101to20211231"
      decimals="2"
      id="Fact_b952af21f13a49f1831fe0df9a81f0e0"
      unitRef="U003">-2.82</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="c20210101to20211231"
      decimals="2"
      id="Fact_3581ce8e3a11409ab912200210958922"
      unitRef="U003">-2.82</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted
      contextRef="c20200101to20201231"
      decimals="2"
      id="Fact_63c5a07331c842e588190399524b6b4b"
      unitRef="U003">-1.51</us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted>
    <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic
      contextRef="c20200101to20201231"
      decimals="2"
      id="Fact_29671fd8a24f4185b523a0bb787f9f9b"
      unitRef="U003">-1.51</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember"
      decimals="3"
      id="Fact_519fdc5024274ce18580023b91cfb123"
      unitRef="U004">0.250</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_def528c0811440a9bfc8f7eb61d31a4f"
      unitRef="U001">124000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_aaee0dcc04404aa692b45d257934ed5a"
      unitRef="U001">22854000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_0ce5f65140514384bc64ab345a332ff4"
      unitRef="U002">7022000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_8252a903d5b64579a9460ac6f44ac503"
      unitRef="U001">102000000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <btx:AssetAcquisitionSharePrice
      contextRef="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="4"
      id="Fact_97a4241c824840fa8583a0bddb045a46"
      unitRef="U003">14.5253</btx:AssetAcquisitionSharePrice>
    <btx:EscrowShares
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_09613d0defbc4769b868462e51085ee9"
      unitRef="U002">741000</btx:EscrowShares>
    <btx:EscrowPeriod
      contextRef="c20210101to20211231_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember_RangeAxis_MaximumMember"
      id="Fact_a4627cb4f633453c8fa4f3e6a434d597">P12M</btx:EscrowPeriod>
    <btx:AcquisitionAgreementNonCompetitivePeriod
      contextRef="c20210101to20211231_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      id="Fact_5be1e6456b1a4a6da62d0a98d6f03630">P5Y</btx:AcquisitionAgreementNonCompetitivePeriod>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember_RelatedPartyTransactionsByRelatedPartyAxis_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember"
      decimals="0"
      id="Fact_49aeab7906a748a99a4273e07ac6edd6"
      unitRef="U002">3378000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <btx:EachLockUpAgreementExtendsTerm
      contextRef="c20210101to20211231_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      id="Fact_a053df53414c4052975a8785b21a2d16">P3Y</btx:EachLockUpAgreementExtendsTerm>
    <btx:PercentageOfCommonStockSubjectToLockUpAgreement
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember_RangeAxis_MaximumMember"
      decimals="2"
      id="Fact_9b3828e5d70143e7a3372bc7515b54ac"
      unitRef="U004">0.75</btx:PercentageOfCommonStockSubjectToLockUpAgreement>
    <btx:PaymentsToAcquireProductiveAssetsNet
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_68e7b3c226814e7da9afa980dedbf2ff"
      unitRef="U001">22854000</btx:PaymentsToAcquireProductiveAssetsNet>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_aeb0cd9994af48bd9dc727c3003b5e6c"
      unitRef="U001">1000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_5321dd9ad35140d396df58bf5ecc3489"
      unitRef="U002">7022000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <btx:StockIssuedDuringPeriodUnrestrictedSharesAcquisitions
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_2ddef28330fb4b64b6a811e8e3da88fa"
      unitRef="U002">3644000</btx:StockIssuedDuringPeriodUnrestrictedSharesAcquisitions>
    <btx:StockIssuedDuringPeriodRestrictedSharesAcquisitions
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_66a3347be3814252866ca9fd850f2378"
      unitRef="U002">3378000</btx:StockIssuedDuringPeriodRestrictedSharesAcquisitions>
    <btx:LockUpPeriodForRestrictedShares
      contextRef="c20210101to20211231_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      id="Fact_945def94770949bbb3c93bbefb03c69e">P3Y</btx:LockUpPeriodForRestrictedShares>
    <btx:AssetAcquisitionUnrestrictedSharesSharePrice
      contextRef="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="2"
      id="Fact_e86e3a65aab84042901c3100c2043503"
      unitRef="U003">10.05</btx:AssetAcquisitionUnrestrictedSharesSharePrice>
    <btx:PercentageOfDiscountOnFairValueOfRestrictedShares
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="2"
      id="Fact_44aec31945224260bcc90a5980bfc48f"
      unitRef="U004">0.35</btx:PercentageOfDiscountOnFairValueOfRestrictedShares>
    <btx:AssetAcquisitionRestrictedSharesSharePrice
      contextRef="c20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="2"
      id="Fact_bff5f0e568934ede8f2978a4d2a7e072"
      unitRef="U003">6.53</btx:AssetAcquisitionRestrictedSharesSharePrice>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="c20210101to20211231"
      id="Text_82e0e11bff704f09a63602ac532be334">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The resulting fair value of the asset acquired is as follows:&lt;/span&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Fair Value of&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Consideration&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Cash paid&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;22,882,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Cash acquired&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(28,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.46%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Unrestricted shares&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;36,628,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.46%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Restricted shares&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;22,056,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.46%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total fair value of consideration paid&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;81,538,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.46%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Less amount of cash paid for NoveCite investment&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(1,000,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 83.46%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Fair value of IPR&amp;amp;D acquired&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.31%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.44%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 12.34%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;80,538,000&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.31%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_568c1bcae0c44ad7b75af065fd3129ea"
      unitRef="U001">22882000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_a097906b1a98425882c2b0e59494eb74"
      unitRef="U001">28000</us-gaap:CashAcquiredFromAcquisition>
    <btx:StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_64ebd0f7a0744579b86b07476a790034"
      unitRef="U001">36628000</btx:StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions>
    <btx:StockIssuedDuringPeriodRestrictedSharesValueAcquisitions
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_d674e0bfd14e4324ae6dca8211c83a4a"
      unitRef="U001">22056000</btx:StockIssuedDuringPeriodRestrictedSharesValueAcquisitions>
    <btx:AssetAcquisitionFairValueOfConsiderationPaid
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_61c0d41cefd2492992860027ba6a4e9c"
      unitRef="U001">81538000</btx:AssetAcquisitionFairValueOfConsiderationPaid>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_4e60bf172d644293bb2a13fb279bb4bf"
      unitRef="U001">1000000</us-gaap:PaymentsToAcquireInvestments>
    <btx:ResearchAndDevelopmentInProcessAssetAcquisition
      contextRef="c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_0626b3cea71b4ac1b995e4e7c2781b9b"
      unitRef="U001">80538000</btx:ResearchAndDevelopmentInProcessAssetAcquisition>
    <btx:ResearchAndDevelopmentInProcessAssetAcquisition
      contextRef="c20210701to20210930_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_0158f27933094ae1bb600509b47259a4"
      unitRef="U001">80538000</btx:ResearchAndDevelopmentInProcessAssetAcquisition>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember"
      decimals="2"
      id="Fact_57b7551c8862493fa90f7dc4a651100b"
      unitRef="U004">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember_OwnershipAxis_CitiusPharmaceuticalsIncMember"
      decimals="2"
      id="Fact_9e7d29a8680b452d8fb0c3b02c03b891"
      unitRef="U004">0.75</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <btx:NumberOfBoardSeats
      contextRef="c20210716to20210716_BusinessAcquisitionAxis_NoveCiteINCMember"
      decimals="INF"
      id="Fact_67c787d4883e4e61a3802932c3028e99"
      unitRef="U006">3</btx:NumberOfBoardSeats>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_c77553bd350e48e685df22c4ee9f7709"
      unitRef="U004">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="c20210716_BusinessAcquisitionAxis_NoveCiteINCMember"
      decimals="0"
      id="Fact_11b10af0c54a4f25bee844b2adc37bc5"
      unitRef="U001">1000000</us-gaap:EquityMethodInvestments>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="c20210101to20211231"
      id="Text_37da32b66e184899b6d646f65abc294e">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;5)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Fair Value of Financial Instruments&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair value is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between
          market participants. A fair value hierarchy has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair
          value hierarchy is as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;&#x2022;&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;span style="color: rgb(0, 0, 0);"&gt;Level 1 Inputs &#x2013; Valued based on quoted prices in active markets for identical
          assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;&#x2022;&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;span style="color: rgb(0, 0, 0);"&gt;Level 2 Inputs &#x2013; Valued based on inputs other than quoted prices included in
          Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets
          that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by
          market data by correlation or other means.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;&#x2022;&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="color: rgb(0, 0, 0);"&gt;Level 3 Inputs &#x2013; Valued based on inputs for which there is little or no market
          value, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following tables summarize the liabilities that are measured at fair value as of December 31, 2021 and 2020:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;As of December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Description&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Level 1&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Level 2&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Level 3&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt;Liabilities:&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Contingent consideration&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;19,930,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;19,930,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;As of December 31, 2020&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Description&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Level 1&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Level 2&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Level 3&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt;Liabilities:&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Contingent consideration&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;20,110,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;20,110,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The contingent consideration is related to an asset purchase agreement entered into between Brooklyn LLC and IRX Therapeutics (&#x201c;IRX&#x201d;) in
          connection with the IRX Acquisition, according to which, Brooklyn LLC is obligated to pay royalties to certain noteholders and shareholders of IRX based on future revenues from any future IRX-2 product sales.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Contingent consideration for the IRX Acquisition was initially valued at the transaction price and is subsequently valued at the end of each
        reporting period using third-party valuation services or other market observable data. The third-party valuation services use industry standard valuation models, including discounted cash flow analysis, to determine the value. After completing its
        validation procedures as of December 31, 2021, the Company adjusted the carrying amount of its contingent consideration liabilities as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Year ended&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31, 2021 &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Balance as of beginning of period&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;20,110,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Fair value adjustments included in operating expenses&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(180,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Balance as of end of period&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;19,930,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Contingent consideration is measured at fair value and is based on significant inputs not observable in the market, which represents a Level 3
          measurement within the fair value hierarchy. The valuation of contingent consideration uses assumptions the Company believes would be made by a market participant. The Company assesses these estimates on an on-going basis as additional data
          impacting the assumptions is obtained. Future changes in the fair value of contingent consideration related to updated assumptions and estimates are recognized within the statements of operations.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Contingent consideration may change significantly as development progresses and additional data are obtained, impacting the Company&#x2019;s assumptions
        regarding probabilities of successful achievement of related milestones used to estimate the fair value of the liability and the timing in which the milestones are expected to be achieved. In evaluating the fair value information, considerable
        judgment is required to interpret the market data used to develop the estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange.&#160; Accordingly, the use of different market
        assumptions and/or different valuation techniques could result in materially different fair value estimates.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;For purposes of this calculation, a royalty equal to 13% of revenue (consisting of the royalty due to University of South Florida and the royalty due to the collaborator) is assumed until 2029 and a royalty of 7% of revenues is assumed from 2030 to 2038. The post patent decline is 50%
          in the first year and 10% thereafter. Income taxes were projected to be 26% of net royalty savings. The cash flows were discounted by the liability specific weighted average cost of capital of 26% using the mid-point convention.&lt;/div&gt;
</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="c20210101to20211231"
      id="Text_79d4fefc81c343948d27e680a3111a93">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following tables summarize the liabilities that are measured at fair value as of December 31, 2021 and 2020:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;As of December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Description&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Level 1&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Level 2&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Level 3&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt;Liabilities:&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Contingent consideration&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;19,930,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;19,930,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;As of December 31, 2020&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Description&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Level 1&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Level 2&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Level 3&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt;Liabilities:&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Contingent consideration&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;20,110,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;20,110,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact_f914e9d0445a46d2ad27c91d8ba8ea63"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact_e747e00544d449e59b0e2f613583aaab"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact_8655a12bdb844dbaa0a3d629df436e76"
      unitRef="U001">19930000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact_b719c48cd0f640ef9765a87931583671"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact_ab668a1e78784f50bf20de7bc95bf17c"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact_0320b25f09404f9787c54244a585376a"
      unitRef="U001">19930000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20201231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact_a814f14028e74e57b65911bd3547652c"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20201231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact_a138cc7dbbc34d64b077e23ed952141a"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20201231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact_a6d46cd9a48e4beda19002907b58c5b6"
      unitRef="U001">20110000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact_4bebe546646143408690d47fc4ea0d06"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="0"
      id="Fact_272f32e1fb6546708505bff33d67c5b4"
      unitRef="U001">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact_5007bcfbe0264bda984400be8ea8414a"
      unitRef="U001">20110000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="c20210101to20211231"
      id="Text_e93a621590a64b47bb0bb284acb40963">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Contingent consideration for the IRX Acquisition was initially valued at the transaction price and is subsequently valued at the end of each
        reporting period using third-party valuation services or other market observable data. The third-party valuation services use industry standard valuation models, including discounted cash flow analysis, to determine the value. After completing its
        validation procedures as of December 31, 2021, the Company adjusted the carrying amount of its contingent consideration liabilities as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Year ended&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31, 2021 &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Balance as of beginning of period&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;20,110,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Fair value adjustments included in operating expenses&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(180,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Balance as of end of period&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;19,930,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20201231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact_4af2b171c3394a2f8eb0f84bcf4c2498"
      unitRef="U001">20110000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="c20210101to20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact_fddf9066c9d6442e9c88e31d61a06f0e"
      unitRef="U001">-180000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c20211231_ContingentConsiderationByTypeAxis_ContingentConsiderationMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact_275ad11d1e9e47809ba6eb1f0d2ec4dc"
      unitRef="U001">19930000</us-gaap:LiabilitiesFairValueDisclosure>
    <btx:PercentageOfRoyaltyRevenueAssumedUntil2029
      contextRef="c20210101to20211231"
      decimals="2"
      id="Fact_f4e5afa8cffe477f8ff53ca841d33496"
      unitRef="U004">0.13</btx:PercentageOfRoyaltyRevenueAssumedUntil2029>
    <btx:PercentageOfRoyaltyRevenueAssumedFrom2030To2038
      contextRef="c20210101to20211231"
      decimals="2"
      id="Fact_420d402c2a48446ba15e4ca40297ce35"
      unitRef="U004">0.07</btx:PercentageOfRoyaltyRevenueAssumedFrom2030To2038>
    <btx:PercentageOfRoyaltyRevenuePostPatentDeclineYearOne
      contextRef="c20210101to20211231"
      decimals="2"
      id="Fact_935edbda7b10468abf9ca012fd524282"
      unitRef="U004">0.50</btx:PercentageOfRoyaltyRevenuePostPatentDeclineYearOne>
    <btx:PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne
      contextRef="c20210101to20211231"
      decimals="2"
      id="Fact_03a0d92f2b6640c999272a1451faa03b"
      unitRef="U004">0.10</btx:PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne>
    <btx:PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings
      contextRef="c20210101to20211231"
      decimals="2"
      id="Fact_dd760951ba7a427f84050f38df61eb53"
      unitRef="U004">0.26</btx:PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings>
    <btx:PercentageOfWeightedAverageCostOfCapital
      contextRef="c20210101to20211231"
      decimals="2"
      id="Fact_7ace8c434524451299721408cedfafa7"
      unitRef="U004">0.26</btx:PercentageOfWeightedAverageCostOfCapital>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="c20210101to20211231"
      id="Text_04f70f6d71f24cdaa97b8877306a3d65">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;6)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Property and Equipment&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Property and equipment consist of the following:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31,&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2020&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Laboratory and manufacturing equipment&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;258,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;300,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Leasehold improvements&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;464,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;414,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Computer equipment&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;154,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;877,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;714,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Less: accumulated depreciation and amortization&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(207,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(120,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Property and equipment, net&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;670,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;594,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Depreciation expense totaled $117,000
        and $98,000 for the years ended December 31, 2021 and 2020, respectively. No depreciation expense is recorded on fixed assets in process
        until such time as the assets are completed and are placed into service.&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="c20210101to20211231"
      id="Text_d6baae7027f6405f93a110b8d03de481">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Property and equipment consist of the following:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31,&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2020&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Laboratory and manufacturing equipment&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;258,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;300,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Leasehold improvements&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;464,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;414,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Computer equipment&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;154,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;877,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;714,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Less: accumulated depreciation and amortization&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(207,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(120,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Property and equipment, net&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;670,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;594,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20211231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember"
      decimals="0"
      id="Fact_94f7c660e06d4d439c42b087ae705490"
      unitRef="U001">258000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember"
      decimals="0"
      id="Fact_3bfff308a54b4e36b1e5add8414f52d5"
      unitRef="U001">300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20211231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact_f825ca80f52541ee8d1fa0a4ea67fe87"
      unitRef="U001">464000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact_071e876e68674c538ca3473c0ec729cc"
      unitRef="U001">414000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20211231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember"
      decimals="0"
      id="Fact_ea6264ac0e934e2780476484cec9be22"
      unitRef="U001">154000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20201231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember"
      decimals="0"
      id="Fact_c5a074b1082f44b2a6af1769acd6e4ff"
      unitRef="U001">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20211231"
      decimals="0"
      id="Fact_b0f0c0b2738b41babe24f447adb31d12"
      unitRef="U001">877000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20201231"
      decimals="0"
      id="Fact_da0e88c6560042fbb4d408926884f95a"
      unitRef="U001">714000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20211231"
      decimals="0"
      id="Fact_8641f66a5d2044e79cfef5fbdb1e640d"
      unitRef="U001">207000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20201231"
      decimals="0"
      id="Fact_b15ef5ffac9248c9b16c94252e814c66"
      unitRef="U001">120000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20211231"
      decimals="0"
      id="Fact_68373ed130cd4d7db870f2de3bf77b07"
      unitRef="U001">670000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20201231"
      decimals="0"
      id="Fact_84d5f55656994cc98357873026780861"
      unitRef="U001">594000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_c1fb583bde7b417eb7f564de58b99d06"
      unitRef="U001">117000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_2ce52ded9d724dbda7a52bb43d691208"
      unitRef="U001">98000</us-gaap:Depreciation>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="c20210101to20211231"
      id="Text_002652cef29f43bbaa9fcf2ae34220f9">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;7)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Leases&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company has operating leases for office and laboratory space in the boroughs of Brooklyn and Manhattan in New York, New York, which expire
          in 2025 and 2026, respectively. In June 2021, the Company entered into an additional lease agreement to lease approximately 2,700
          square feet of office and laboratory space in Cambridge, Massachusetts for approximately $56.00 per square foot annually. The lease
          provides for annual escalation of the base rent based on the year-over-year increase of the consumer price index, as well as the payment of other customary expenses, such as common area maintenance fees, property taxes, and insurance. Upon
          entering into this lease agreement, the Company paid a lease deposit of approximately $25,000. The Cambridge, Massachusetts lease
          expires in June 2028. See Note 17 for subsequent event information regarding the Company&#x2019;s leases.&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company adopted ASC Topic 842, &lt;span style="font-style: italic;"&gt;Leases,&lt;/span&gt; on December 31, 2020 using the modified transition method
          without retrospective application to comparative periods. The Company elected the package of three practical expedients allowed for under the transition guidance. Accordingly, the Company did not reassess: (1) whether any expired or existing
          contracts are/or contain leases; (2) the lease classification for any expired or existing leases; or (3) initial direct costs for any existing leases. The Company has also elected not to recognize right-of-use assets (&#x201c;ROU assets&#x201d;) and lease
          liabilities for short-term leases that have a term of 12 months or less.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Operating lease liabilities represent the present value of lease payments not yet paid. ROU assets represent the Company&#x2019;s right to use an
          underlying asset and are based upon the operating lease liabilities adjusted for prepaid or accrued lease payments, initial direct costs, lease incentives and impairment of operating lease assets. As the rate implicit in the lease is not readily
          determinable, the Company used its incremental borrowing rates based on the information available at the lease commencement date in determining the present value of lease payments. To determine the present value of lease payments not yet paid,
          the Company estimates secured borrowing rates corresponding to the maturities of the leases.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company has elected the practical expedient to not separate non-lease components from the lease components to which they relate and instead
          account for each as a single lease component for all underlying asset classes. Some leasing arrangements require variable payments that are dependent on usage or may vary for other reasons, such as payments for insurance, tax payments and other
          miscellaneous costs. The variable portion of lease payments is not included in the ROU assets or lease liabilities. Rather, variable payments, other than those dependent upon an index or rate, are expensed when the obligation for those payments
          is incurred and are included in lease expenses. Accordingly, all expenses associated with a lease contract are accounted for as lease expenses.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Operating leases are included in right of use assets - operating leases and operating lease liabilities, current and long-term, on the balance
          sheet. Lease expense for operating leases is recognized on a straight-line basis over the lease term and is included in general and administrative costs in the statements of operations.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company recognizes operating lease expense and lease payments from the sublease on a straight-line basis in its statements of operations
          over the lease terms. During the years ended December 31, 2021 and 2020, the net operating lease expenses were as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Years ended December 31,&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Operating lease expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;688,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;591,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Sublease income&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(84,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(77,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Variable lease expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;19,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;21,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); margin-left: 9pt;"&gt;Total lease expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;623,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;535,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The tables below show the beginning balances of the operating ROU assets and lease liabilities as of January 1, 2021 and the ending balances as of
        December 31, 2021, including the changes during the period.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Operating Lease&lt;/div&gt;
              &lt;span style="font-weight: bold;"&gt; &lt;/span&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;ROU Assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Operating lease ROU assets at January 1, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2,093,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Amortization of operating lease ROU assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(342,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Addition of operating lease ROU assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;816,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Operating lease ROU assets at December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2,567,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0);"&gt;Operating Lease&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0);"&gt;Liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Operating lease liabilities at January 1, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2,178,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Principal payments on operating lease liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(321,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Addition of operating lease liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;866,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Operating lease liabilities at December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2,723,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Less non-current portion&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2,297,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Current portion at December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;426,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;As of December 31, 2021, the Company&#x2019;s operating leases had a weighted-average remaining life of 4.9 years with a weighted-average discount rate of 12.76%. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The maturities of the operating
          lease liabilities are as follows:&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;As of&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;750,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2023&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;767,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2024&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;785,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2025&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;802,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2026&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;267,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Thereafter&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;246,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total payments&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;3,617,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Less imputed interest&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(894,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total operating lease liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2,723,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Sublease Agreement&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On April 18, 2019, the Company entered into a sublease agreement with Nezu Asia Capital Management, LLC (the &#x201c;Tenant&#x201d;), whereby the Tenant
          agreed to sublease approximately 999 square feet of space currently rented by the Company in the borough of Manhattan in New York, New
          York commencing on May 15, 2019. The term of this sublease expires on October 31, 2026 with no option to extend the sublease term. Rent payments provided by the Tenant under the sublease agreement began on September 1, 2019. The sublease
          agreement stipulates an annual rent increase of 2.25%. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Tenant is also responsible for paying to the Company all tenant energy costs, annual
          operating costs, and annual tax costs attributable to the subleased space during the term of the sublease.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;As of&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31,&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; 2021&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;82,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2023&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;84,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2024&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;86,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2025&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;88,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2026&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;75,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;415,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company received sublease payments of approximately $83,000 and $79,000 during the years ended December 31, 2021 and 2020,
          respectively. In accordance with ASC Topic 842, the Company treats the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease. The Company continues to account for the Manhattan lease as a
          lessee and in the same manner as prior to the commencement date of the sublease. The Company accounts for the sublease as a lessor of the lease. The sublease is classified as an operating lease, as it does not meet the criteria of a sale-type or
          direct financing lease.&lt;/div&gt;
</us-gaap:LesseeOperatingLeasesTextBlock>
    <btx:OperatingLeaseArea
      contextRef="c20211231"
      decimals="0"
      id="Fact_69a68c6b55ff45e580aebf0e2e9ca091"
      unitRef="U007">2700</btx:OperatingLeaseArea>
    <btx:AnnualRentPerSquareFoot
      contextRef="c20210101to20211231"
      decimals="2"
      id="Fact_97b35a2946714e55a3da62a164067d0d"
      unitRef="U007">56.00</btx:AnnualRentPerSquareFoot>
    <us-gaap:OperatingLeasePayments
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_65c5b2d9135f4fd2afd9d71c06e4f109"
      unitRef="U001">25000</us-gaap:OperatingLeasePayments>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="c20210101to20211231"
      id="Text_48e17f2ddd0d43088c17bf4695ba7c4a">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company recognizes operating lease expense and lease payments from the sublease on a straight-line basis in its statements of operations
          over the lease terms. During the years ended December 31, 2021 and 2020, the net operating lease expenses were as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Years ended December 31,&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold;"&gt;2020&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Operating lease expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;688,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;591,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Sublease income&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(84,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(77,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Variable lease expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;19,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;21,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); margin-left: 9pt;"&gt;Total lease expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;623,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;535,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_803e9bde990a49219364523cdbf2b03d"
      unitRef="U001">688000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_3aef8ff3be97431fb7c25397828acfb4"
      unitRef="U001">591000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_7d5cb521e0fb4e7987f70037aff7d1a3"
      unitRef="U001">84000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_aafefb71088945e9b75b5dadd8ba071a"
      unitRef="U001">77000</us-gaap:SubleaseIncome>
    <us-gaap:VariableLeaseCost
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_3eb80ad87adf45d68c2d9f6b5157e63b"
      unitRef="U001">19000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_5aa31e0d3bd543bbaa250915d40d3359"
      unitRef="U001">21000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_e990d483866a420ba19fcb2ac26a7490"
      unitRef="U001">623000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_01df96d899dc45d1a590fcb0410d0c2e"
      unitRef="U001">535000</us-gaap:LeaseCost>
    <btx:OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock
      contextRef="c20210101to20211231"
      id="Text_a21c6faafd8b41f3b40b59e2c3ab2115">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The tables below show the beginning balances of the operating ROU assets and lease liabilities as of January 1, 2021 and the ending balances as of
        December 31, 2021, including the changes during the period.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Operating Lease&lt;/div&gt;
              &lt;span style="font-weight: bold;"&gt; &lt;/span&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;ROU Assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Operating lease ROU assets at January 1, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2,093,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Amortization of operating lease ROU assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(342,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Addition of operating lease ROU assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;816,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Operating lease ROU assets at December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2,567,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0);"&gt;Operating Lease&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0);"&gt;Liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Operating lease liabilities at January 1, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2,178,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Principal payments on operating lease liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(321,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Addition of operating lease liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;866,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Operating lease liabilities at December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2,723,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Less non-current portion&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2,297,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Current portion at December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;426,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</btx:OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20201231"
      decimals="0"
      id="Fact_fb47bd67402c4a65b36457de457c6e92"
      unitRef="U001">2093000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_fb5c87a7f880494ab5b2f8d8c3d0c2df"
      unitRef="U001">342000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <btx:AdditionOfOperatingLeaseRightofUseAsset
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_680e6411e628448ab79a8962168c56b4"
      unitRef="U001">816000</btx:AdditionOfOperatingLeaseRightofUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20211231"
      decimals="0"
      id="Fact_404b483107624f5f8942c3eac5187bb5"
      unitRef="U001">2567000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20201231"
      decimals="0"
      id="Fact_1fc4ebb213214193a88115f8b09f7ae5"
      unitRef="U001">2178000</us-gaap:OperatingLeaseLiability>
    <btx:PrincipalPaymentsOnOperatingLeaseLiabilities
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_ec98cb9841204c339deec6d75b145325"
      unitRef="U001">-321000</btx:PrincipalPaymentsOnOperatingLeaseLiabilities>
    <btx:AdditionOfOperatingLeaseLiability
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_709abad0a0294bbbae339b9a1f7ed26f"
      unitRef="U001">866000</btx:AdditionOfOperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20211231"
      decimals="0"
      id="Fact_65901b52de8344d5beec49a279f9e73a"
      unitRef="U001">2723000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20211231"
      decimals="0"
      id="Fact_cf0e44f7b3b9482487d5eb3827b293f8"
      unitRef="U001">2297000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20211231"
      decimals="0"
      id="Fact_a3531a7dd8424c458f1cd7ff1a8fc730"
      unitRef="U001">426000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="c20211231"
      id="Fact_1da4e24538b14402b840e8d25a17617f">P4Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="c20211231"
      decimals="4"
      id="Fact_19b040d559d84f4a91076b511ddf88cb"
      unitRef="U004">0.1276</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="c20210101to20211231"
      id="Text_9853771db42342d89b7a4218c184b5e2">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The maturities of the operating
          lease liabilities are as follows:&lt;/span&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;As of&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;750,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2023&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;767,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2024&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;785,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2025&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;802,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2026&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;267,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Thereafter&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;246,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total payments&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;3,617,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Less imputed interest&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(894,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total operating lease liabilities&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2,723,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="c20211231"
      decimals="0"
      id="Fact_b4e30791d8d748b4b5c22791035f6064"
      unitRef="U001">750000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="c20211231"
      decimals="0"
      id="Fact_105ae1814989432c9483d84e74aad7ef"
      unitRef="U001">767000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="c20211231"
      decimals="0"
      id="Fact_2cdbeedc60ad4641b57d5b10325a32c4"
      unitRef="U001">785000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="c20211231"
      decimals="0"
      id="Fact_885e3cf29a694a90a90dbe9dcb6c937e"
      unitRef="U001">802000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="c20211231"
      decimals="0"
      id="Fact_177bbe0d84ad4a059e77ed3c12cf651c"
      unitRef="U001">267000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="c20211231"
      decimals="0"
      id="Fact_9d54781c5f534627a0f9dec706248073"
      unitRef="U001">246000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="c20211231"
      decimals="0"
      id="Fact_f462dd0117954c208ff69cde83699f3e"
      unitRef="U001">3617000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="c20211231"
      decimals="0"
      id="Fact_a7a8b6b5799041d99cdc72d033b0a399"
      unitRef="U001">894000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20211231"
      decimals="0"
      id="Fact_bb85f1f2c0ad4c22ab8ec0acba10dfb7"
      unitRef="U001">2723000</us-gaap:OperatingLeaseLiability>
    <btx:AreaOfSubleaseSpaceCurrentlyRented
      contextRef="c20190418"
      decimals="0"
      id="Fact_93bbedd9132e4df6b9c07b987ff14d55"
      unitRef="U008">999</btx:AreaOfSubleaseSpaceCurrentlyRented>
    <btx:PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments
      contextRef="c20190418to20190418"
      decimals="4"
      id="Fact_53112e46bedd45138a86a30edd216570"
      unitRef="U004">0.0225</btx:PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments>
    <btx:FutureLeasePaymentsSubleaseAgreementTableTextBlock
      contextRef="c20210101to20211231"
      id="Text_a352252085424e6ea914f927841c1fde">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Tenant is also responsible for paying to the Company all tenant energy costs, annual
          operating costs, and annual tax costs attributable to the subleased space during the term of the sublease.&lt;/span&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;As of&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31,&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; 2021&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;82,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2023&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;84,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2024&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;86,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2025&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;88,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 88%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;2026&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;75,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;415,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</btx:FutureLeasePaymentsSubleaseAgreementTableTextBlock>
    <btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths
      contextRef="c20211231"
      decimals="0"
      id="Fact_baea99917e33416abc5aabc71e8db730"
      unitRef="U001">82000</btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths>
    <btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears
      contextRef="c20211231"
      decimals="0"
      id="Fact_13982c613ea94d878bae102c8dbae6fe"
      unitRef="U001">84000</btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears>
    <btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears
      contextRef="c20211231"
      decimals="0"
      id="Fact_ecef32657e3541f6ae7c98a3e6f66a05"
      unitRef="U001">86000</btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears>
    <btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears
      contextRef="c20211231"
      decimals="0"
      id="Fact_ee8f8ed3222944da88926b85de1d7572"
      unitRef="U001">88000</btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears>
    <btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears
      contextRef="c20211231"
      decimals="0"
      id="Fact_f6076712b4044997804ee811ed17801a"
      unitRef="U001">75000</btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears>
    <btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentals
      contextRef="c20211231"
      decimals="0"
      id="Fact_c2464a3bf4eb40d696c8402111cea48e"
      unitRef="U001">415000</btx:SaleLeasebackTransactionsFutureMinimumSubleaseRentals>
    <us-gaap:ProceedsFromLeasePayments
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_db76435709ed43b68b73ffaf3d49c711"
      unitRef="U001">83000</us-gaap:ProceedsFromLeasePayments>
    <us-gaap:ProceedsFromLeasePayments
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_05d4a158e613461593e246e2443b2f23"
      unitRef="U001">79000</us-gaap:ProceedsFromLeasePayments>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="c20210101to20211231"
      id="Text_fbe77a5fc5064a108069e0e7d30c1f76">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;8)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Goodwill and In-Process Research &amp;amp; Development&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company recorded goodwill and IPR&amp;amp;D in the amount of $2,044,000 and $6,860,000, respectively, in connection with the IRX Acquisition
        in the year ended December 31, 2018. IPR&amp;amp;D assets are considered to be indefinite lived until the completion or abandonment of the associated research and development projects.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In connection with the Acquisition, the Company expensed the fair value of the IPR&amp;amp;D it acquired in the amount of $80,538,000, as the Company determined there were no future alternative uses or separate economic values from its original intended purpose. (See Note
        4.)&lt;/div&gt;
</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="c20211231"
      decimals="0"
      id="Fact_f9e670d9fa874afc9350aefdebff0325"
      unitRef="U001">2044000</us-gaap:Goodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="c20211231"
      decimals="0"
      id="Fact_76829daa58c14ef89012ef25dfee3122"
      unitRef="U001">6860000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_9e68ed253a6149b8a3c6886719880614"
      unitRef="U001">80538000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="c20210101to20211231"
      id="Text_09ff2d1d1d51425899784ee7a9d40e93">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;9)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Accrued Expenses&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued expenses consisted of the following:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;As of December 31,&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; 2021&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2020&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accrued compensation&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;656,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;294,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accrued research and development expenses&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;222,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;207,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accrued general and administrative expenses&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;371,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;400,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accrued interest&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;150,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total accrued expenses&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;1,249,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;1,051,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="c20210101to20211231"
      id="Text_7d93a6d21dd346b99df188153b132581">
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued expenses consisted of the following:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;As of December 31,&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; 2021&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2020&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accrued compensation&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;656,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;294,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accrued research and development expenses&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;222,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;207,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accrued general and administrative expenses&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;371,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;400,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Accrued interest&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;150,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total accrued expenses&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;1,249,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;1,051,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20211231"
      decimals="0"
      id="Fact_b1f496e6f81e4e4a89e2dc997a2ced07"
      unitRef="U001">656000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_1b3f4d5e995741938d8dc724b5c0cad6"
      unitRef="U001">294000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <btx:AccruedResearchAndDevelopmentExpenses
      contextRef="c20211231"
      decimals="0"
      id="Fact_6f696b6c42b74f409af47c46519b4c2f"
      unitRef="U001">222000</btx:AccruedResearchAndDevelopmentExpenses>
    <btx:AccruedResearchAndDevelopmentExpenses
      contextRef="c20201231"
      decimals="0"
      id="Fact_50a9411f811e41c6b4a3fd7891a4466e"
      unitRef="U001">207000</btx:AccruedResearchAndDevelopmentExpenses>
    <btx:AccruedGeneralAndAdministrativeExpenses
      contextRef="c20211231"
      decimals="0"
      id="Fact_92c2cb4afd1a41c4b5cc318551d9c2fb"
      unitRef="U001">371000</btx:AccruedGeneralAndAdministrativeExpenses>
    <btx:AccruedGeneralAndAdministrativeExpenses
      contextRef="c20201231"
      decimals="0"
      id="Fact_934cb73f3a554614a3c319faa2d6c84f"
      unitRef="U001">400000</btx:AccruedGeneralAndAdministrativeExpenses>
    <us-gaap:InterestPayableCurrent
      contextRef="c20211231"
      decimals="0"
      id="Fact_01f0bce81d7147168c00e827fc5d3f65"
      unitRef="U001">0</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_c7b956167b9b475abc1297117da8e831"
      unitRef="U001">150000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20211231"
      decimals="0"
      id="Fact_ae35c715a4564728b033530311f71803"
      unitRef="U001">1249000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20201231"
      decimals="0"
      id="Fact_5d16ea13a8514c81a94fcaa3f2171ed5"
      unitRef="U001">1051000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="c20210101to20211231"
      id="Text_e0a9604a8f0746a2a82ba18894737c70">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;10)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Debt&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Loans Payable&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In connection with the IRX Acquisition in 2018, Brooklyn LLC assumed certain notes payable (the &#x201c;IRX Notes&#x201d;) in the amount of $410,000. On January 27, 2020, the IRX Notes were amended to extend the maturity date to the earlier of (i) a change of control, as defined in the IRX
          Notes, and (ii) December 31, 2021. On December 31, 2021, the Company paid the outstanding $410,000 in principal plus accrued and unpaid
          interest of approximately $210,000 under the IRX Notes, and the Company has no further obligations thereunder.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Payment Protection Program Loan&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Brooklyn LLC PPP Loan.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On May 4, 2020, Brooklyn LLC issued a note in the principal amount of approximately $310,000 to Silicon Valley Bank evidencing a loan (the &#x201c;Brooklyn LLC PPP Loan&#x201d;) Brooklyn LLC received under the Paycheck Protection Program (the &#x201c;PPP&#x201d;) of the Coronavirus Aid, Relief, and
          Economic Security Act administered by the U.S. Small Business Administration (the &#x201c;CARES Act&#x201d;). Brooklyn LLC PPP Loan incurred interest at a rate of 1.0%
          per annum.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Under the terms of the Cares Act, certain amounts of the Brooklyn LLC PPP Loan could be forgiven if they were used for qualifying expenses, as
          described in the CARES Act. In June 2021, Brooklyn LLC submitted its loan forgiveness application for the Brooklyn LLC PPP Loan, and in September 2021, the lender informed Brooklyn LLC that the U.S Small Business Administration approved the
          forgiveness of 100% of the outstanding principal and interest of the Brooklyn LLC PPP Loan. As of December 31, 2021, there was no
          outstanding principal balance of the Brooklyn LLC PPP Loan.&lt;/div&gt;
</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LoansPayableCurrent
      contextRef="c20181231_DebtInstrumentAxis_PaycheckProtectionProgramLoanMember"
      decimals="0"
      id="Fact_38deea82d13d4a0d9e42a7d5d5316f1a"
      unitRef="U001">410000</us-gaap:LoansPayableCurrent>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c20210101to20211231_DebtInstrumentAxis_PaycheckProtectionProgramLoanMember"
      decimals="0"
      id="Fact_077a2c37abeb4b1e9a9c3200655b98ab"
      unitRef="U001">410000</us-gaap:RepaymentsOfNotesPayable>
    <btx:PaymentOfAccruedAndUnpaidInterest
      contextRef="c20210101to20211231_DebtInstrumentAxis_PaycheckProtectionProgramLoanMember"
      decimals="0"
      id="Fact_26dbcfc566464eaca28ca2415fd5530c"
      unitRef="U001">210000</btx:PaymentOfAccruedAndUnpaidInterest>
    <us-gaap:LoansPayableCurrent
      contextRef="c20211231_DebtInstrumentAxis_PaycheckProtectionProgramLoanMember"
      decimals="-3"
      id="Fact_833bc4650cc143fb971ebe385944ede7"
      unitRef="U001">0</us-gaap:LoansPayableCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20200504_DebtInstrumentAxis_PaycheckProtectionProgramMember"
      decimals="0"
      id="Fact_1f5acd51e9d64d9f99a17cee027e3fc5"
      unitRef="U001">310000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20200504_DebtInstrumentAxis_PaycheckProtectionProgramMember"
      decimals="3"
      id="Fact_300a27c149334a7fbbb3e0d4f4f71832"
      unitRef="U004">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="c20211231_DebtInstrumentAxis_PaycheckProtectionProgramMember"
      decimals="0"
      id="Fact_f827807a5c344da385b145e1fec68c92"
      unitRef="U001">0</us-gaap:LongTermDebt>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20210101to20211231"
      id="Text_f4231dc08ddd4c96a95d47ca8a681279">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;11)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Commitments and Contingencies&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Legal Matters&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company is involved in litigation and arbitrations from time to time in the ordinary course of business. Legal fees and other costs associated
        with such actions are expensed as incurred. In addition, the Company assesses the need to record a liability for litigation and contingencies. The Company reserves for costs relating to these matters when a loss is probable, and the amount can be
        reasonably estimated.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Merger-Related Shareholder Litigation&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Brooklyn (then known as NTN Buzztime, Inc.) and its former directors were named as defendants in ten substantially similar actions arising out of the Merger that were brought by purported pre-Merger stockholders of Brooklyn: Henson v. NTN Buzztime, Inc., et al., No.
        1:20-cv-08663-LGS (S.D.N.Y.); Monsour v. NTN Buzztime, Inc., et al., No. 1:20-cv-08755-LGS (S.D.N.Y.); Amanfo v. NTN Buzztime, Inc., et al., No. 1:20-cv-08747-LGS (S.D.N.Y.); Carlson v. NTN Buzztime, Inc., et al., No. 1:21-cv-00047-LGS (S.D.N.Y.);
        Finger v. NTN Buzztime, Inc., et al., No. 1:21-cv-00728-LGS (S.D.N.Y.); Falikman v. NTN Buzztime, Inc., et al., No. 1:20-cv-05106-EK-SJB (E.D.N.Y.); Haas v. NTN Buzztime, Inc., et al., No. 3:20-cv-02123-BAS-JLB (S.D. Cal.); Gallo v. NTN Buzztime,
        Inc., et al., No. 3:21-cv-00157-WQH-AGS (S.D. Cal.); Chinta v. NTN Buzztime, Inc., et al., No. 1:20-cv-01401-CFC (D. Del.); and Nicosia v. NTN Buzztime, Inc., et al., No. 1:21-cv-00125-CFC (D. Del.) (collectively, the &#x201c;Stockholder Actions&#x201d;).&#160; Only
        two of the Stockholder Actions (the Chinta and Nicosia cases) also named Brooklyn.&#160; These actions asserted claims alleging violations of
        Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 14a-9 promulgated thereunder and both the Chinta and Nicosia cases alleged that Brooklyn LLC is a controlling person of Brooklyn.&#160; The complaints generally alleged that
        the defendants failed to disclose allegedly material information in a Form S-4 Registration Statement filed on October 2, 2020, including:&#160; (1) certain details regarding any projections or forecasts of Brooklyn or Brooklyn LLC may have made, and
        the analyses performed by Brooklyn&#x2019;s financial advisor, Newbridge Securities Corporation; (2) conflicts concerning the sales process; and (3) disclosures regarding whether or not Brooklyn entered into any confidentiality agreements with standstill
        and/or &#x201c;don&#x2019;t ask, don&#x2019;t waive&#x201d; provisions.&#160; The complaints generally alleged that these purported failures to disclose rendered the Form S-4 false and misleading.&#160; The complaints requested: preliminary and permanent injunction of the Merger;
        rescission of the Merger if executed and/or rescissory damages in unspecified amounts; direction to the individual directors to disseminate a compliant Form S-4; an accounting by Brooklyn for all alleged damages suffered; a declaration that certain
        federal securities laws had been violated; and reimbursement of costs, including attorneys&#x2019; and expert fees and expenses.&#160; On or about February 26, 2021, in order to moot certain of the disclosure claims asserted in the Stockholder Actions, to
        avoid nuisance, potential expense, and delay, and to provide additional information to Brooklyn&#x2019;s stockholders, Brooklyn determined to voluntarily supplement the Form S-4 with certain additional disclosures.&#160; In exchange for those disclosures, the
        plaintiffs in each of the Stockholder Actions agreed to voluntarily dismiss their claims.&#160; All ten actions have now been dismissed.&#160; Following the dismissal the parties amicably resolved plaintiffs&#x2019; counsel&#x2019;s request for an award of attorneys&#x2019; fees
        and expenses based on the purported benefit contented to be conferred on Brooklyn&#x2019;s stockholders as a result of the supplemental disclosures.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Dhesh Govender v. Brooklyn Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021)&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"&gt;On or about February 5, 2021, Dhesh Govender, a former short-term consultant of Brooklyn LLC, filed a complaint against Brooklyn
            LLC and certain individuals that plaintiff alleges were directors of Brooklyn LLC. The complaint is captioned, Dhesh Govender v. Brooklyn Immunotherapeutics, LLC, et al., Index No. 650847/2021 (N.Y. Sup. Ct. N.Y. Cty. 2021). Plaintiff alleges
            that Brooklyn LLC and certain of its officers and directors (&#x201c;defendants&#x201d;) engaged in unlawful and discriminatory conduct based on race, national origin and hostile work environment. Plaintiff also asserts various breach of contract, fraud and
            quantum meruit claims based on an alleged oral agreement pursuant to which he alleges Brooklyn LLC agreed to hire him as an executive once the Merger was completed. In particular, plaintiff alleges that, in exchange for transferring an
            opportunity to obtain an agreement to acquire a license from Novellus for its mRNA-based gene editing and cell reprogramming technology to Brooklyn LLC, he was promised a $500,000 salary and 7% of the equity of Brooklyn LLC.&#160; Based on these and
            other allegations, plaintiff seeks damages of not less than $10 million, a permanent injunction enjoining Brooklyn LLC from
            exercising the option to acquire such license from Novellus or completing the proposed Merger. On or about February 19, 2021, an amended complaint was filed asserting the same causes of action but withdrawing the request for injunctive relief.
            On June 6, 2021, defendants filed a motion to compel arbitration or, in the alternative, for partial dismissal of the complaint for failure to state viable fraud, quantum meruit and employment discrimination claims. After obtaining extensions
            of time to respond, plaintiff opposed the defendants&#x2019; motion on August 9, 2021. The defendants filed their reply on September 3, 2021. The Court heard oral argument on the motion to compel arbitration and/or dismiss and the motion to seal on
            October 13, 2021. By Order dated November 10, 2021, the Court granted defendants&#x2019; motion to compel Govender to arbitrate all of his claims against them, based on the arbitration clause of his consulting agreement with Brooklyn LLC.&#160; Govender
            thereafter filed his Statement of Claim (the &#x201c;Demand&#x201d;) with the American Arbitration Association (&#x201c;AAA&#x201d;), Case No. 01-21-0017-9417, on December 15, 2021 against the same defendants, and served it on defendants&#x2019; counsel on February 3, 2022.&#160; In
            his Demand, Govender continues to assert statutory discrimination claims against all defendants, claims against Brooklyn LLC premised on the breach of an alleged oral promise to issue Govender&lt;span style="font-family: 'Times New Roman',serif; font-size: 10pt;"&gt; 7% of the equity of Brooklyn LLC and to employ Govender at a $500,000&lt;/span&gt; annual salary in exchange for allegedly arranging and negotiating the Novellus license, common law fraud claims against Brooklyn LLC and Cherington based
            on the breach of these same promises and a claim for quantum meruit against the Brooklyn LLC.&#160; In his Demand, Govender now claims that the fair and reasonable value of his services on the quantum meruit claim exceeded&lt;span style="font-family: 'Times New Roman',serif; font-size: 10pt;"&gt; $100 million&lt;/span&gt; and is seeking damages in an amount to be determined at the
            hearing.&#160; Defendants filed an answering statement to the Demand on February 28, 2022 and the parties are in the process of conferring on the selection of a&lt;span style="font-family: 'Times New Roman',serif; font-size: 10pt;"&gt; three-member arbitration panel.&lt;/span&gt; Defendants intend to vigorously defend themselves against these claims. At this stage in the litigation,
            the Company is not able to predict the probability of a favorable or unfavorable outcome.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Carlson v. Allen Wolff, Michael Gottlieb, Richard Simtob, Susan Miller, and NTN Buzztime, Inc., C.A. No. 2021-0193-KSJM (Del. Ch. Ct.)&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"&gt;On or about March 12, 2021, Douglas Carlson, a purported stockholder of Brooklyn (then known as NTN Buzztime, Inc.), filed a verified class
            action complaint against Brooklyn and its then current members of the board of directors, for allegedly breaching their fiduciary duties and violating Section 211(c) of the Delaware General Corporation Law.&#160; In particular, plaintiff seeks to
            compel the defendants to hold an annual stockholder meeting.&#160; Plaintiff also moved for summary judgment at the same time that he filed his complaint.&#160; In order to moot the claim addressed in the complaint, Brooklyn agreed to hold its annual
            meeting on June 29, 2021, which date was subsequently rescheduled to August 20, 2021.&#160; On or about May 6, 2021, the parties entered into a stipulation, which was &#x201c;so ordered&#x201d; by the court, extending defendants&#x2019; time to respond to the complaint
            and to file their answering brief in opposition to plaintiff&#x2019;s motion for summary judgment on or before July 16, 2021 and providing that plaintiff&#x2019;s reply brief in support of his motion for summary judgment is due on or before August 20, 2021.
            On or about July 12, 2021, the parties entered in a further amended scheduling order, which provided that defendants were to respond to the complaint and file their answering brief in opposition to plaintiff&#x2019;s motion for summary judgment on or
            before September 16, 2021 and plaintiff was to file its reply brief in support of his motion for summary judgment on or before October 20, 2021.&#160; On August 20, 2021, Brooklyn convened its 2021 annual meeting. Due to the lack of a required
            quorum, the meeting was adjourned to September 3, 2021. Thereafter, Brooklyn obtained a quorum, and the annual meeting was held on September 3, 2021. On September 10, 2021, Brooklyn filed a report on Form 8-K with the SEC announcing the results
            of the annual meeting. On September 16, 2021, the parties filed a stipulation seeking voluntary dismissal of the complaint as moot. The Court entered the dismissal on September 16, 2021 with prejudice as to the named plaintiff and without
            prejudice as to other members of the purported class and retained jurisdiction for the purpose of determining any fee application to the extent it cannot be resolved amicably the parties. &lt;span style="font-family: 'Times New Roman', serif; font-size: 10pt;"&gt;Thereafter, on or about November 12, 2022, the parties resolved plaintiff&#x2019;s counsel&#x2019;s request for an award of fees and expenses for the purported benefit that Carlson contended was received by stockholders as a result of his
              action.&#160; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman', serif; font-size: 10pt;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Robert Garfield Matter&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"&gt;On April 29, 2021, Robert Garfield, a purported stockholder of Brooklyn, sent to Brooklyn a demand letter that had purportedly been sent
              to Brooklyn (then known as NTN Buzztime, Inc.) on or about March 16, 2021. The demand letter asserts that, Brooklyn (then known as NTN Buzztime, Inc.) made material misstatements in a prospectus issued in seeking a stockholder vote on March
              15, 2021 with respect to an amendment to Brooklyn&#x2019;s certificate of incorporation to increase the number of authorized shares from 15
              million to 100 million. The demand letter seeks to have Brooklyn deem the amendment to the certificate of incorporation
              ineffective or seek valid stockholder approval of such amendment and for Brooklyn to implement internal controls.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-family: 'Times New Roman',serif; font-size: 1pt;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman',serif; font-size: 10pt;"&gt;Brooklyn decided to seek stockholder ratification of the March
                15, 2021 stockholder vote concerning an amendment to Brooklyn&#x2019;s certificate of incorporation to increase the number of authorized shares from&lt;/span&gt; 15 million to 100 million&lt;span style="font-family: 'Times New Roman',serif; font-size: 10pt;"&gt; pursuant to Sections 204 of the Delaware General Corporation Law. &#160;Stockholder ratification was obtained at the annual meeting of stockholders that took place on September 3, 2021. As a result of the
                ratification, Garfield advised that the claims set forth in his demand letter were moot. The parties thereafter resolved Garfield&#x2019;s counsel&#x2019;s request for an award of attorney&#x2019;s fees and expenses for the purported benefit that Garfield
                contented was received by stockholders as a result of the stockholder ratification.&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Edmund Truell Matter&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On May 14, 2021, Edmund Truell, a stockholder of Brooklyn, alleged that he sustained a loss because he was unable to sell shares of common stock
          timely due to a delay caused by Brooklyn&#x2019;s issuance of stock certificates in lieu of electronic book entry.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Emerald Private Equity Fund, LLC Matter&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"&gt;By a letter dated July 7, 2021, Emerald Private Equity Fund, LLC (&#x201c;Emerald&#x201d;), a stockholder of Brooklyn, made a demand pursuant to 8 Del.
              C. 220 to inspect certain books and records of Brooklyn. The stated purpose of the demand is to investigate possible wrongdoing by persons responsible for the implementation of the Merger and the issuance of paper stock certificates,
              including investigating&#160; whether: (i) Brooklyn&#x2019;s stock certificates were issued in accordance with the Merger Agreement; (ii) certain restrictions on the sale of Brooklyn common stock following the Merger were proper and applied without
              favor; (iii) anyone received priority in post-Merger issuances of Brooklyn&#x2019;s stock certificates that allowed them to benefit from an increase in the trading price of Brooklyn&#x2019;s common stock; and (iv) it should pursue remedial measures and/or
              report alleged misconduct to the SEC. Brooklyn has responded to the demand letter and has produced certain information to Emerald in connection with the demand, which is subject to the terms of a confidentiality agreement entered into among
              the parties, including certain additional stockholders who have subsequently joined as parties to such agreement (including Truell noted above).&#160; In October 2021, Emerald requested that Brooklyn produce additional information related to the
              authority, purpose and justification for the restriction imposed on the sale of Brooklyn common stock following the Merger and the timing of share delivery to Brooklyn stockholders, following which request Brooklyn agreed to produce certain
              additional information and emails relating to these topics.&lt;br/&gt;
            &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"&gt;On March 30, 2022, counsel to Emerald advised the Company that it was prepared to file suit against the Company, certain current and
              former directors of the Company, and the Company&#x2019;s financial advisor in connection with the Merger, on behalf of Emerald and a class of similarly situated stockholders with respect to some or all of the foregoing matters, alleging claims for
              breach of fiduciary duty, conversion and aiding and abetting breach of fiduciary duty.&#160; Emerald&#x2019;s counsel has expressed a willingness to engage in private pre-suit early resolution discussions with the Company and its financial advisor on
              behalf of individual stockholders whom counsel represents in addition to Emerald; and the Company has agreed to respond to Emerald&#x2019;s counsel by April 22, 2022.&#160; The Company can provide no assurance that such pre-suit early resolution
              discussions will be successful or that suit will not ultimately be filed against the Company, nor can the Company currently predict the outcome of any such suit, if filed.&#160; The Company intends to defend itself vigorously against any and all
              claims.&#160; Additionally, on April 7, 2022, the Company received a demand for indemnification from its financial advisor as it relates to the aforementioned potential lawsuit.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="text-decoration: underline;"&gt;John Westman v. Novellus, Inc., Christopher Rohde, and Matthew Angel, Civil Action No. 2181CV01949 (Middlesex County (Massachusetts) Superior
            Court)&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"&gt;On or about September 7, 2021, John Westman, a former employee of Novellus, Inc. filed a Complaint in Middlesex County (Massachusetts)
            Superior Court against Novellus, Inc. and the company&#x2019;s founders and former executives, Christopher Rohde and Matthew Angel (collectively, &#x201c;Defendants&#x201d;).&#160; Brooklyn acquired Novellus, Inc. on July 16, 2021.&#160; Mr. Westman&#x2019;s claims relate to
            alleged conduct that took place before Brooklyn acquired Novellus, Inc.&#160; Pursuant to the July 16, 2021 Agreement and Plan of Acquisition, as well as a separate agreement among Brooklyn, Novellus, Inc., Mr. Rohde, and Mr. Angel, Mr. Rohde and
            Mr. Angel are essentially assuming the defense of and paying the fees associated with defending against these claims.&#160; To that end, on September 10, 2021, Morgan Lewis accepted service on behalf of all defendants. On December 24, 2021, Westman
            dismissed the case without prejudice so the parties could mediate the matter. The parties&#x2019; February 2022 mediation was unsuccessful, but Mr. Westman has not refiled suit.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Licensing Agreements&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;USF&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Brooklyn LLC has license agreements with University of South Florida Research Association, Inc. (&#x201c;USF&#x201d;), granting Brooklyn LLC the right to
          sell, market, and distribute IRX-2, subject to a 7% royalty payable to USF based on a percentage of gross product sales. Under the
          license agreement with USF, Brooklyn LLC is obligated to repay patent prosecution expenses incurred by USF. To date, Brooklyn LLC has not recorded any product sales, or obligations related to USF patent prosecution expenses. The license agreement
          terminates upon the expiration of the IRX-2 patents.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Novellus, Ltd. and Factor&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In December 2020, Brooklyn LLC entered into option agreements (the &#x201c;Option Agreements&#x201d;) with Novellus, Ltd. and Factor (together, the
          &#x201c;Licensors&#x201d;) to obtain the right to exclusively license the Licensors&#x2019; intellectual property and mRNA cell reprogramming and gene editing technology for use in the development of certain cell-based therapies to be evaluated and developed for
          treating human diseases, including certain types of cancer, sickle cell disease, and beta thalassemia (the &#x201c;Licensed Technology&#x201d;). The option was exercisable before February 28, 2021 (or April 30, 2021 if the Merger had not closed by that date)
          and required Brooklyn LLC to pay a non-refundable option fee of $500,000 and then an initial license fee of $4,000,000 (including the non-refundable fee of $500,000)
          in order to exercise the option.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In April 2021, Brooklyn LLC and the Licensors amended the Option Agreements to extend the exercise period to May 21, 2021 and to require
          Brooklyn, LLC to pay a total $1,000,000 of the $4,000,000 initial license fees to the Licensors by April 15, 2021.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In April 2021, Brooklyn LLC and the Licensors entered into an exclusive license agreement (the &#x201c;License Agreement&#x201d;) pursuant to which Brooklyn
          LLC acquired an exclusive worldwide license to the Licensed Technology.&#160; Under the terms of the License Agreement, Brooklyn LLC is obligated to pay the Licensors a total of $4,000,000 in connection with the execution of the License Agreement, all of which had been paid as of June 30, 2021.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The completion of the acquisition of Novellus, Ltd. relieved Brooklyn LLC from potential obligations to pay Novellus, Ltd. certain upfront fees,
          clinical development milestone fees and post-registration royalties under the License Agreement. The agreement with Factor under the License Agreement, which grants Brooklyn LLC exclusive rights to develop certain next-generation mRNA gene
          editing and cell therapy products, remained unchanged. Accordingly, Brooklyn LLC is obligated to pay to Factor a fee of $3,500,000 in
          October 2022, which will be in addition to a fee of $2,500,000 paid to Factor in October 2021.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Brooklyn LLC is also required to use commercially reasonably efforts to achieve certain delineated milestones, including specified clinical
          development and regulatory milestones and specified commercialization milestones. In general, upon its achievement of these milestones, Brooklyn LLC will be obligated to pay, in the case of development and regulatory milestones, milestone
          payments to the Licensors in specified amounts and, in the case of commercialization milestones, specified royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers. In the event Brooklyn LLC fails to timely
          achieve certain delineated milestones, the Licensors will have the right to terminate Brooklyn LLC&#x2019;s rights under provisions of the License Agreement relating to those milestones.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Novellus, Ltd. also has a license agreement with Factor, which was entered into in February 2015, amended in June 2018 and March 2020, and then
          amended and restated in November 2020.&#160; This license agreement provides for Novellus, Ltd. to use over 70 granted patents owned by
          Factor throughout the world covering synthetic mRNA, RNA-based gene editing, and RNA-based cell reprogramming, in addition to specific patents covering methods for treating specific diseases. There are also more than 60 pending patent applications throughout the world focused on these and other aspects of the technology. The patent coverage includes granted patents
          and pending patent applications in the United States, Europe, and Japan, along with other major life sciences markets.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Novellus, Ltd. is required to use commercially reasonably efforts to achieve certain delineated milestones, including specified clinical
          development and regulatory milestones and specified commercialization milestones. In general, upon its achievement of these milestones, Novellus, Ltd. will be obligated, in the case of development and regulatory milestones, to make milestone
          payments of up to $51 million in aggregate to Factor and, in the case of commercialization milestones, specified royalties with respect
          to product sales, sublicense fees or sales of pediatric review vouchers. In the event Novellus, Ltd. fails to timely achieve certain delineated milestones, Factor may have the right to terminate Novellus, Ltd.&#x2019;s rights under provisions of the
          License Agreement relating to those milestones.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;NoveCite&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In October 2020, Novellus, Ltd. (as sublicensor) and NoveCite (as sublicensee) entered into an exclusive license agreement (the &#x201c;Sublicense&#x201d;) to
          license novel cellular therapy for acute respiratory distress syndrome, which NoveCite is licensing from Factor. Under the sublicense agreement, NoveCite is required to use commercially reasonably efforts to achieve certain delineated milestones,
          including specified clinical development and regulatory milestones and specified commercialization milestones. In general, upon its achievement of these milestones, NoveCite will be obligated, in the case of development and regulatory milestones,
          to make milestone payments to the Novellus, Ltd. in specified amounts and, in the case of commercialization milestones, specified royalties with respect to product sales, sublicense fees or sales of pediatric review vouchers.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Under the terms of the Sublicense, in the event that Novellus, Ltd. receives any revenue involving the original cell line included in the
          licensed technology, then Novellus, Ltd. shall remit to NoveCite 50% of such revenue.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Royalty Agreements&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Collaborator Royalty Agreement&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Effective June 22, 2018, IRX terminated its Research, Development and Option Facilitation Agreement and its Options Agreement (the &#x201c;RDO and
        Options Agreements&#x201d;) with a collaborative partner (the &#x201c;Collaborator&#x201d;), pursuant to a termination agreement (the &#x201c;Termination Agreement&#x201d;). The Termination Agreement was assigned to Brooklyn, LLC in November 2018 when Brooklyn LLC acquired the
        assets of IRX. In connection with the Termination Agreement, all of the rights granted to the Collaborator under the RDO and Options Agreements were terminated, and Brooklyn LLC has no obligation to refund any payments received from the
        Collaborator. As consideration for entering into the Termination Agreement, the Collaborator will receive a royalty equal to 6% of
        revenues from the sale of IRX-2, for the period of time beginning with the first sale of IRX-2 through the later of (i) the twelfth anniversary of the first sale of IRX-2 or (ii) the expiration of the last IRX patent, or other exclusivity of IRX-2.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Investor Royalty Agreement&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On March 22, 2021, Brooklyn LLC restated its royalty agreement with certain beneficial holders of Brooklyn ImmunoTherapeutics Investors GP LLC
          and Brooklyn ImmunoTherapeutics Investors LP, whereby such beneficial holders will continue to receive, on an annual basis, royalties in an aggregate amount equal to 4% of the net revenues of IRX-2, a cytokine-based therapy being developed by Brooklyn LLC to treat patients with cancer.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Royalty Agreement with certain former IRX Therapeutics Investors&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On May 1, 2012, IRX Therapeutics entered into a royalty agreement (the &#x201c;IRX Investor Royalty Agreement&#x201d;) with certain investors who participated
        in a financing transaction. The IRX Investor Royalty Agreement was assigned to Brooklyn LLC in November 2018 when Brooklyn LLC acquired the assets of IRX. Pursuant to the IRX Investor Royalty Agreement, when Brooklyn LLC becomes obligated to pay
        royalties to USF under the agreement described above under &#x201c;Licensing Agreements-USF,&#x201d; it will pay an additional royalty of 1% of gross
        sales to an entity organized by the investors who participated in such financing transaction. There are no termination provisions in the IRX Investor Royalty Agreement. Brooklyn LLC has not recognized any revenues to date, and no royalties are due
        pursuant to any of the above-mentioned royalty agreements.&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyNumberOfDefendants
      contextRef="c20210101to20211231_LegalEntityAxis_NTNBuzztimeIncMember"
      decimals="INF"
      id="Fact_0b4eadcd5aea40409a62a8aa5167dd5f"
      unitRef="U010">10</us-gaap:LossContingencyNumberOfDefendants>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c20210101to20211231_LegalEntityAxis_NTNBuzztimeIncMember"
      decimals="INF"
      id="Fact_baf27639c704486d8a245d04be7c87be"
      unitRef="U009">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <btx:LossContingencyDamagesSoughtExpectedSalary
      contextRef="c20210205to20210205_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_49b85533110144d58a40969c7faec51a"
      unitRef="U001">500000</btx:LossContingencyDamagesSoughtExpectedSalary>
    <btx:LossContingencyDamagesSoughtExpectedEquityPercentage
      contextRef="c20210205to20210205_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember"
      decimals="2"
      id="Fact_243af90267a24dabb448dd1d64e3a0c4"
      unitRef="U004">0.07</btx:LossContingencyDamagesSoughtExpectedEquityPercentage>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="c20210205to20210205_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember"
      decimals="-6"
      id="Fact_573de681b8644f37975ff0511a46aba6"
      unitRef="U001">10000000</us-gaap:LossContingencyDamagesSoughtValue>
    <btx:LossContingencyDamagesSoughtExpectedEquityPercentage
      contextRef="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember"
      decimals="2"
      id="Fact_90c6809196de4f42829468819ea8c915"
      unitRef="U004">0.07</btx:LossContingencyDamagesSoughtExpectedEquityPercentage>
    <btx:LossContingencyDamagesSoughtExpectedSalary
      contextRef="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember"
      decimals="0"
      id="Fact_cd40a3b8983e4dd8820f789d7dbb6d4a"
      unitRef="U001">500000</btx:LossContingencyDamagesSoughtExpectedSalary>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="c20211215to20211215_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember"
      decimals="-6"
      id="Fact_977c357d0ce7444a81107a7338e4e56f"
      unitRef="U001">100000000</us-gaap:LossContingencyDamagesSoughtValue>
    <btx:LossContingencyNumberOfArbitrationPanel
      contextRef="c20211215to20211215_RelatedPartyTransactionsByRelatedPartyAxis_DheshGovenderMember"
      decimals="INF"
      id="Fact_f561abfd578549cda233e4209db3a649"
      unitRef="U006">3</btx:LossContingencyNumberOfArbitrationPanel>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20210315_LegalEntityAxis_NTNBuzztimeIncMember_RelatedPartyTransactionsByRelatedPartyAxis_RobertGarfieldMember"
      decimals="-6"
      id="Fact_3a16c8397a2347acbb74089cdb53099a"
      unitRef="U002">15000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20210316_LegalEntityAxis_NTNBuzztimeIncMember_RelatedPartyTransactionsByRelatedPartyAxis_RobertGarfieldMember"
      decimals="-6"
      id="Fact_07b1dcb843f64085b221823fd1760a88"
      unitRef="U002">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20210315_LegalEntityAxis_NTNBuzztimeIncMember_RelatedPartyTransactionsByRelatedPartyAxis_RobertGarfieldMember"
      decimals="-6"
      id="Fact_c096b9846f6b49afbdafb6ff52839f5e"
      unitRef="U002">15000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20210316_LegalEntityAxis_NTNBuzztimeIncMember_RelatedPartyTransactionsByRelatedPartyAxis_RobertGarfieldMember"
      decimals="-6"
      id="Fact_2d2fb5f5e49d4a31979aef45d480a8ae"
      unitRef="U002">100000000</us-gaap:CommonStockSharesAuthorized>
    <btx:LossContingencyPercentageOfRoyaltyPayable
      contextRef="c20210101to20211231_LegalEntityAxis_UniversityOfSouthFloridaMember"
      decimals="2"
      id="Fact_784b26e89e4e4ee6bb4f0e16c18e530a"
      unitRef="U004">0.07</btx:LossContingencyPercentageOfRoyaltyPayable>
    <btx:LossContingencyNonRefundableOptionFee
      contextRef="c20210413to20210413_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="0"
      id="Fact_86c044aab7c844e6ba5c7c6a5d66083a"
      unitRef="U001">500000</btx:LossContingencyNonRefundableOptionFee>
    <btx:InitialLicenseFees
      contextRef="c20210430to20210430_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="0"
      id="Fact_84dde60bcdaa42aeabef305e291df51c"
      unitRef="U001">4000000</btx:InitialLicenseFees>
    <btx:LossContingencyNonRefundableOptionFee
      contextRef="c20210413to20210413_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="0"
      id="Fact_8fd4f38edc85491db937cf1408147f60"
      unitRef="U001">500000</btx:LossContingencyNonRefundableOptionFee>
    <btx:AdditionalFeesObligatedToPay
      contextRef="c20210415to20210415_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="0"
      id="Fact_214b5176969f4e50a08d6135fb6dfae3"
      unitRef="U001">1000000</btx:AdditionalFeesObligatedToPay>
    <btx:AmountRequireToPayInitialLicenseFees
      contextRef="c20210426_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="0"
      id="Fact_7acb7f51ddc74a1ba3812a028ba34225"
      unitRef="U001">4000000</btx:AmountRequireToPayInitialLicenseFees>
    <btx:AmountRequireToPayInitialLicenseFees
      contextRef="c20210426_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="0"
      id="Fact_ce3aef6987d444f5b2d004ec03a0de25"
      unitRef="U001">4000000</btx:AmountRequireToPayInitialLicenseFees>
    <btx:AmountObligatedToPayInYearTwo
      contextRef="c20221031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember_StatementScenarioAxis_ScenarioForecastMember"
      decimals="0"
      id="Fact_c4ee036402964dca94f65c93462cfe8a"
      unitRef="U001">3500000</btx:AmountObligatedToPayInYearTwo>
    <btx:AmountObligatedToPayInYearOne
      contextRef="c20211031_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="0"
      id="Fact_a3b2f6b853b64fb8803deffcbe489c76"
      unitRef="U001">2500000</btx:AmountObligatedToPayInYearOne>
    <btx:MinimumNumberOfPatentGranted
      contextRef="c20210101to20211231_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="0"
      id="Fact_39b418ecdd77401d9b3bf836f066cfd0"
      unitRef="U011">70</btx:MinimumNumberOfPatentGranted>
    <btx:MinimumNumberOfPendingPatents
      contextRef="c20210101to20211231_RelatedPartyTransactionsByRelatedPartyAxis_NovellusLtdAndFactorBioscienceMember"
      decimals="0"
      id="Fact_7b9c77fe840a4f1dba541bbbd510a00c"
      unitRef="U011">60</btx:MinimumNumberOfPendingPatents>
    <btx:MilestonePayments
      contextRef="c20210101to20211231_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember"
      decimals="-6"
      id="Fact_ec51d963df074da69282f8416ac40bd2"
      unitRef="U001">51000000</btx:MilestonePayments>
    <btx:PercentageOfRevenue
      contextRef="c20211231_RelatedPartyTransactionsByRelatedPartyAxis_NoveCiteMember"
      decimals="2"
      id="Fact_f4c9ec17fd484c26a47dd6a6bcab77b4"
      unitRef="U004">0.50</btx:PercentageOfRevenue>
    <btx:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness
      contextRef="c20180622to20180622_TypeOfArrangementAxis_CollaboratorRoyaltyAgreementMember"
      decimals="2"
      id="Fact_edf47f6512b6439793bb4355914b37dd"
      unitRef="U004">0.06</btx:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness>
    <btx:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness
      contextRef="c20210322to20210322_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember"
      decimals="2"
      id="Fact_68b41008400d4837a779f115649a9748"
      unitRef="U004">0.04</btx:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness>
    <btx:PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales
      contextRef="c20120501to20120501_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember"
      decimals="2"
      id="Fact_3daaf50710d54edaaab558cd6faa1982"
      unitRef="U004">0.01</btx:PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="c20210101to20211231"
      id="Text_73a0f143ec0e4578abb3a368832ca6c7">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;12)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Basic and Diluted Earnings per Common Share&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of
        potential common shares.&#160; Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding plus potential common shares.&#160; Stock options, restricted stock units (&#x201c;RSUs&#x201d;), and other convertible
        securities are considered potential common shares and are included in the calculation of diluted net loss per share using the treasury method when their effect is dilutive. &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;The following table shows the amount of stock options,
        RSUs and convertible preferred stock that were excluded from the computation of diluted net loss per common share for the year ended December 31, 2021, as their effect was anti-dilutive:&lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 84.65%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.98%; vertical-align: bottom;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="2" style="width: 13.45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Year ended&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31, 2021&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.92%; vertical-align: bottom; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 84.65%; vertical-align: middle; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.98%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 1.1%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 12.35%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,988,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.92%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 84.65%; vertical-align: middle; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;RSUs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.98%; vertical-align: bottom; white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 1.1%; vertical-align: bottom; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 12.35%; vertical-align: bottom; white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;240,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.92%; vertical-align: bottom; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 84.65%; vertical-align: middle; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Preferred stock converted into common stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.98%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 1.1%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 12.35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;42,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.92%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 84.65%; vertical-align: middle; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total potential common shares excluded from computation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.98%; vertical-align: bottom; white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 1.1%; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 12.35%; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;4,270,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.92%; vertical-align: bottom; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

      &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;There were no stock options, RSUs or convertible
        preferred stock outstanding prior to the Merger to exclude from diluted net loss per common share for the year ended December 31, 2020.&lt;br/&gt;
      &lt;/div&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20210101to20211231"
      id="Text_a07923affcd647b7ba6eb50b89054ae0">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;The following table shows the amount of stock options,
        RSUs and convertible preferred stock that were excluded from the computation of diluted net loss per common share for the year ended December 31, 2021, as their effect was anti-dilutive:&lt;br/&gt;
      &lt;/span&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 84.65%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.98%; vertical-align: bottom;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="2" style="width: 13.45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Year ended&lt;/div&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31, 2021&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.92%; vertical-align: bottom; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 84.65%; vertical-align: middle; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.98%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 1.1%; vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 12.35%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,988,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.92%; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 84.65%; vertical-align: middle; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;RSUs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.98%; vertical-align: bottom; white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 1.1%; vertical-align: bottom; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 12.35%; vertical-align: bottom; white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;240,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.92%; vertical-align: bottom; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 84.65%; vertical-align: middle; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Preferred stock converted into common stock&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.98%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 1.1%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 12.35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;42,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.92%; vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 84.65%; vertical-align: middle; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total potential common shares excluded from computation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.98%; vertical-align: bottom; white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 1.1%; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 12.35%; vertical-align: bottom; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;"&gt;
                &lt;div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;4,270,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td style="width: 0.92%; vertical-align: bottom; white-space: nowrap;"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

      &lt;/div&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_b5b2226d5198426cbeeaaa7f7cc38510"
      unitRef="U002">3988000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_27487b984ecf4c8990d175a2feb015c2"
      unitRef="U002">240000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember"
      decimals="0"
      id="Fact_4662ebac7d3444c1b535cb38c37d6768"
      unitRef="U002">42000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_46d9b8182d5d4b80b03fd8f41e302ce3"
      unitRef="U002">4270000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_344617f1260d4745a3526a3f9edab4aa"
      unitRef="U002">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="c20210101to20211231"
      id="Text_8f9ad6c0936f4457a61165cf0a03b0c4">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;13)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Stock-Based Compensation&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Equity Incentive Plans&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Brooklyn&#x2019;s stock-based compensation plans consist of the Restated 2020 Equity Incentive Plan (the &#x201c;Restated 2020 Plan&#x201d;) and the 2021 Inducement
        Equity Incentive Plan (the &#x201c;2021 Inducement Plan&#x201d;). Brooklyn&#x2019;s board of directors has designated its compensation committee as the administrator of the foregoing plans (the &#x201c;Plan Administrator&#x201d;). Among other things, the Plan Administrator selects
        persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures, if any, and other provisions of the award.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;At Brooklyn&#x2019;s special meeting of stockholders held on March 15, 2021, the stockholders approved the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;),
        which provided for the issuance of up to approximately 3,369,000 shares of common stock. At Brooklyn&#x2019;s annual meeting of stockholders
        held on September 3, 2021, the stockholders approved the Restated 2020 Plan, which provides for (1) an increase in the number of shares of common stock that can be issued under the Restated 2020 Plan by 5,116,000 to 8,485,000 shares of common stock in total and (2)
        an annual increase in the number of shares reserved for issuance on January 1 of each year from 2022 through 2031 equal to the lesser of (i) 5%
        of the number of shares of common stock outstanding on the immediately preceding December 31 and (ii) such smaller number of shares of common stock as may be determine by the board of directors (the &#x201c;Annual Evergreen Shares&#x201d;). No other provision of
        the 2020 Plan were amended.&#160; Based on the number of shares of common stock outstanding on December 31, 2021, the maximum increase to the number of Annual Evergreen Shares of common stock that can be issued under the Restated 2020 Plan in 2022 is
        approximately 2,601,000 shares.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Awards under the Restated 2020 Plan may be granted to officers, directors, employees and consultants of the Company.&#160; Stock options granted under
        the Restated 2020 Plan may either be incentive stock options or nonqualified stock options, may have a term of up to ten years, and
        are exercisable at a price per share not less than the fair market value on the date of grant.&#160; As of December 31, 2021, there were approximately 320,000
        stock options and 18,000 RSUs outstanding under the Restated 2020 Plan.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In June 2019 Brooklyn adopted the 2019 Performance Incentive Plan (the &#x201c;2019 Plan&#x201d;), Upon the approval of the 2020 Plan, no future grants could be
        made under the 2019 Plan. As of December 31, 2021, all outstanding options under the 2019 Plan either had been exercised or had expired in accordance with the terms of the applicable award or the 2019 Plan.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In May 2021, Brooklyn&#x2019;s board of directors adopted the 2021 Inducement Plan, which provides for the grant of up to 1,500,000 share-based awards as material inducement awards to new employees in accordance with the employment inducement grant rules set forth in
        Section 711(a) of the NYSE American LLC Company Guide. The 2021 Inducement Plan expires in May 2031. As of December 31, 2021, there were approximately 443,000
        nonqualified stock options and 222,000 RSUs outstanding under the 2021 Inducement Plan.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Equity Awards&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company records stock-based compensation in accordance with ASC Topic 718, Compensation &#x2013; Stock Compensation.&#160; The Company estimates the fair
        value of each stock option award granted with service-based vesting requirements, using the Black-Scholes option pricing model. The Company recognizes the fair value of stock options granted as expense on a straight-line basis over the requisite
        service period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The risk-free rate is based on the observed interest rates appropriate for the expected life. The expected life (estimated period of time
        outstanding) of the stock options granted is estimated using the &#x201c;simplified&#x201d; method as permitted by the SEC&#x2019;s Staff Accounting Bulletin No. 110, Share-Based Payment. Expected volatility is based on the Company&#x2019;s historical volatility over the
        expected life of the stock option granted, and the Company assumes no dividends.&#160;&#160; Forfeitures are recognized as incurred.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;There were no stock options
        outstanding or granted during the year ended December 31, 2020. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following weighted-average assumptions were used for stock options granted during the year ended December 31, 2021:&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Year ended&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31, 2021 &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Weighted average risk-free rate&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;1.09&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;%&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Weighted average volatility&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;134.64&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;%&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Dividend yield&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;0&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;%&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Expected term&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;6.10 years &lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table summarizes stock option activity for the year ended December 31, 2021:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Outstanding&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Options&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Weighted&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Average&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Exercise&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Price per Share&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Weighted&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Average&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Remaining&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Contractual&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Life (in years)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Aggregate&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Intrinsic&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Value&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Outstanding January 1, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); margin-left: 9pt;"&gt;Granted&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;3,988,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;8.40&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;9.38&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Outstanding December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;3,988,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;8.40&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;9.38&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Options vested and exercisable at December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The per-share weighted average grant-date fair value of stock options granted during the year ended December 31, 2021 was $7.57.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As of December 31, 2021, the unamortized stock-based compensation expense related to outstanding unvested options was approximately $21,915,000 with a weighted average remaining requisite service period of 3.30 years. The Company expects to amortize this expense over the remaining requisite service period of these stock options.&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Included in the 3,988,000 stock
        options granted during the year ended December 31, 2021, the Company issued two stock option grants to Howard J. Federoff, M.D., Ph.D.
        upon his appointment as the Company&#x2019;s Chief Executive Officer and President.&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Dr. Federoff was granted a nonqualified stock option covering approximately 2,628,000 shares of common stock (the &#x201c;Time-Based Option&#x201d;). The Time-Based Option was granted at a per share exercise price equal to the closing price of the common stock on the NYSE
        American stock exchange on the date of grant. Of the shares covered by the Time-Based Option, 25% will vest on the one-year anniversary
        of the grant date, and the remaining shares will vest in substantially 36 equal monthly installments thereafter, so long as Dr. Federoff
        provides continuous service to the Company throughout the relevant vesting date.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Dr. Federoff was also granted a performance-based nonqualified stock option covering approximately 597,000 shares of common stock (the &#x201c;Milestone Option&#x201d;). The Milestone Option was granted at a per share exercise price equal to the closing price of common stock on the NYSE
        American stock exchange on the date of grant, and its fair value is $4,288,738. The Milestone Option will fully vest upon the first
        concurrence by the U.S. Food and Drug Administration that a proposed investigation may proceed following review of a Company filed investigational new drug application in connection with that the License Agreement. This milestone is subject to Dr.
        Federoff&#x2019;s continuous service with the Company through such vesting date.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Both the Time-Based Option and the Milestone Option were granted outside the Company&#x2019;s equity incentive plans discussed above.&#160; The unvested
        portion of the Time-Based Option and the Milestone Option will be cancelled upon the termination of Dr. Federoff&#x2019;s employment with the Company for any reason, subject to certain vesting acceleration provisions upon a qualifying termination, as
        described in his employment agreement with the Company. Unless earlier terminated in accordance with their terms, each of the Time-Based Option and the Milestone Option will otherwise expire on the tenth anniversary of their respective grant date
        and be subject to the terms and conditions of the respective option agreement approved by the Company. Each of the Time-Based Option and the Milestone Option was intended to constitute an &#x201c;employment inducement grant&#x201d; in accordance with the
        employment inducement grant rules set forth in Section 711(a) of the NYSE American LLC Company Guide and was offered as an inducement material to Dr. Federoff in connection with his hiring.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;During the year ended December 31, 2021, there were 1,300
        options exercised for total cash proceeds of $10,202.&#160; The options exercised had a total intrinsic value of $47,010.&#160; There were no options exercised
        during the year ended December 31, 2020.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;RSUs&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Outstanding RSUs are settled in an equal number of shares of common stock on the vesting date of the award. An RSU award is settled only to the
        extent vested. Vesting generally requires the continued employment or service by the award recipient through the respective vesting date. Because RSUs are settled in an equal number of shares of common stock without any offsetting payment by the
        recipient, the measurement of cost is based on the quoted market price of the stock at the measurement date, which is the grant date.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;There were no RSUs outstanding or
        granted during the year ended December 31, 2020. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The





















        following table summarizes RSU activity for the years ended December 31, 2021:&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Outstanding&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Restricted&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Stock Units&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Weighted&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Average Fair&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Value per Share&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;January 1, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); margin-left: 9pt;"&gt;Granted&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;240,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;13.80&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;240,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;13.80&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Balance expected to vest at December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;No RSUs vested during the year
        ended December 31, 2021.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company recognizes the intrinsic value of RSUs granted as expense on a straight-line basis over the requisite service period. As of December
        31, 2021, the unamortized stock-based compensation expense related to outstanding RSUs was approximately $2,935,000 with a weighted
        average remaining requisite service period of 3.51 years. The Company expects to amortize this expense over the remaining requisite
        service period of these stock options.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Pursuant to the Merger, Brooklyn LLC&#x2019;s approximately 3,000
        outstanding restricted common units were exchanged for approximately 630,000 shares of Brooklyn&#x2019;s restricted common stock. There were no
        changes to any conditions and requirements of the restricted common stock. The shares vest quarterly beginning on March 31, 2021 and continuing through December 31, 2022. Due to the modification of the restricted common units, the fair value of the
        restricted common stock immediately after the Merger was compared to the fair value of the restricted common units immediately prior to the Merger, and the change in fair value of $250,000 was recognized in the statement of operations for year ended December 31, 2021. The Company recognizes the fair value of restricted common stock as an expense on a straight-line
        basis over the requisite service period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock-Based Compensation Expense&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total stock-based compensation expense for the years ended December 31, 2021 and 2020 was approximately $5,235,000 and $91,000, respectively.&#160; Stock-based compensation is
        recorded in general and administrative expense and research and development expense in the statement of operations.&lt;/div&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20210315_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"
      decimals="0"
      id="Fact_684d810b734745f8b38d1d40fdd623dc"
      unitRef="U002">3369000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20210903_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MinimumMember"
      decimals="0"
      id="Fact_6085d527935944aa82305096e843a8a4"
      unitRef="U002">5116000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20210903_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"
      decimals="0"
      id="Fact_3f082fd7cdbd46dab3c649daf970b2b3"
      unitRef="U002">8485000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <btx:PercentageOfSharesOfCommonStockOutstanding
      contextRef="c20210903_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="2"
      id="Fact_c55b85415d784764af9abced847db21d"
      unitRef="U004">0.05</btx:PercentageOfSharesOfCommonStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20211231_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="0"
      id="Fact_3b568119fb8f4d94971dd0c06217a1a0"
      unitRef="U002">2601000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="c20210101to20211231_AwardTypeAxis_IncentiveStockOptionsMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"
      id="Fact_9ebfa512c0c44eaf8408486f4ef5635e">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="c20210101to20211231_AwardTypeAxis_NonQualifiedStockOptionMember_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"
      id="Fact_3e7abf0ec74f4014b8f9c1f10f58d7d0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="0"
      id="Fact_afd9d3c5c4f3488aa69638b39e6e813f"
      unitRef="U002">320000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="0"
      id="Fact_23f9aaafaf2b4c32bea3ae1f918b33a4"
      unitRef="U002">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20210531_PlanNameAxis_InducementPlan2021Member_RangeAxis_MaximumMember"
      decimals="0"
      id="Fact_a44706259d87499a8af5bb462fc72224"
      unitRef="U002">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_InducementPlan2021Member"
      decimals="0"
      id="Fact_3f93dd8301424708aa4bc20b2a764832"
      unitRef="U002">443000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_InducementPlan2021Member"
      decimals="0"
      id="Fact_62c73958ac1e46a496badd47c8f954da"
      unitRef="U002">222000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20200101to20201231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_e45a469ca2894dd9b941d2855e3c3c25"
      unitRef="U002">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_7092efef0b774c65ae8918ccd8c88ff7"
      unitRef="U002">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20210101to20211231"
      id="Text_79d90495a65a437688a20cd2e3b15161">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following weighted-average assumptions were used for stock options granted during the year ended December 31, 2021:&lt;/span&gt;
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Year ended&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31, 2021 &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Weighted average risk-free rate&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;1.09&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;%&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Weighted average volatility&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;134.64&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;%&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Dividend yield&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;0&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;%&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Expected term&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; white-space: nowrap;" valign="bottom"&gt;6.10 years &lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="4"
      id="Fact_26aa59c06ecc4133b2a887329cd6fcc5"
      unitRef="U004">0.0109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="4"
      id="Fact_c41b3554989044f6b1351c78b9f2dd47"
      unitRef="U004">1.3464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_deea928ad16e4488a4d43346e9d4aa65"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_698ecb9ef45f41e2af4a9f677ad01c3c">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="c20210101to20211231"
      id="Text_e14ca8bd850640aaa46f800cb8a5947e">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table summarizes stock option activity for the year ended December 31, 2021:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Outstanding&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Options&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Weighted&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Average&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Exercise&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Price per Share&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Weighted&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Average&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Remaining&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Contractual&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Life (in years)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Aggregate&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Intrinsic&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Value&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Outstanding January 1, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); margin-left: 9pt;"&gt;Granted&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;3,988,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;8.40&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;9.38&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Outstanding December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;3,988,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;8.40&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;9.38&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Options vested and exercisable at December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_4523fe3d92c44b9c826e0a7009387f96"
      unitRef="U002">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_8b40bf42e6f241d7b8c30d3322aa9e14"
      unitRef="U003">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_21b5339388d640458045002e940d42d0"
      unitRef="U001">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_90d9014987c149ddad7fb58c99502e08"
      unitRef="U002">3988000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_cc20655413534735a93fb1aaf0e8b018"
      unitRef="U003">8.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <btx:SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_10e3d91d5a0a4bf496da8a6ca9fd2d05">P9Y4M17D</btx:SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_fcdd0d262f834e888f50b7d0fbd9e3ec"
      unitRef="U001">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_6b7dffe561a24562a158cfa3c79aaf81"
      unitRef="U002">3988000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_10f5c7efb1a644bc84a3822cd1c48c41"
      unitRef="U003">8.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_937d975cd0f54b9bb40113895cded236">P9Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_8fdd72d0d8da4f85b143b78e57e76c6a"
      unitRef="U001">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_39e5bdb5ae904b8eb71d13c3f5a0777f"
      unitRef="U002">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_f880b6aed05449b5a60c197abda8081a"
      unitRef="U003">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_8ef0383b1ba949d180a3f72d9e559b2f"
      unitRef="U001">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_4136f84cca54451e936b0e9d6578512e"
      unitRef="U003">7.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_1922f5a023344afa8829d89bf9e79d65"
      unitRef="U001">21915000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_83096292d4244d099ff1537fba940251">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_d8d5a04087cd4a33bae4cb87785b34c3"
      unitRef="U002">3988000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <btx:NumberOfStockOptionGrantMade
      contextRef="c20211231"
      decimals="INF"
      id="Fact_9dda042451d546eb90b44c0f8836e910"
      unitRef="U012">2</btx:NumberOfStockOptionGrantMade>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20210101to20211231_AwardTypeAxis_TimeBasedNonQualifiedStockOptionMember"
      decimals="0"
      id="Fact_b95b796c077e4dc6b38b6b288ac60415"
      unitRef="U002">2628000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c20210101to20211231_AwardTypeAxis_TimeBasedNonQualifiedStockOptionMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember"
      decimals="2"
      id="Fact_2a11d44b73f4449cb41eba02c5179c1a"
      unitRef="U004">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <btx:ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares
      contextRef="c20210101to20211231_AwardTypeAxis_TimeBasedNonQualifiedStockOptionMember"
      decimals="0"
      id="Fact_04daf038117d4583bd60cab9c67b425e"
      unitRef="U013">36</btx:ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20210101to20211231_AwardTypeAxis_PerformanceBasedNonqualifiedStockOptionMember"
      decimals="0"
      id="Fact_1122396913fa4a818e93f51d96f0dd4c"
      unitRef="U002">597000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <btx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
      contextRef="c20210101to20211231_AwardTypeAxis_PerformanceBasedNonqualifiedStockOptionMember"
      decimals="0"
      id="Fact_582b502df4e845dfa9568c1bbc5f0d9f"
      unitRef="U001">4288738</btx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_e8d9dee8604e4c3ca8d4c6c7dcdbc6c3"
      unitRef="U002">1300</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_3866e7b35d17436aa44e85f9bf806fe8"
      unitRef="U001">10202</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_93b47fabc34f4d519380bbc6d7e004d9"
      unitRef="U001">47010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20200101to20201231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact_76a62dbc0e944cf8a0f3948f64860540"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20200101to20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact_72025a3b05604ae0908f34aaf4104196"
      unitRef="U002">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="c20210101to20211231"
      id="Text_9cd4792e81544e4da3dcf0dcca53502c">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The





















        following table summarizes RSU activity for the years ended December 31, 2021:&lt;/span&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Outstanding&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Restricted&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Stock Units&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Weighted&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Average Fair&lt;/div&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Value per Share&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;January 1, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); margin-left: 9pt;"&gt;Granted&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;240,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;13.80&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;240,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;13.80&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Balance expected to vest at December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact_317fb2d10b3046fcb58d71b9f32fc367"
      unitRef="U002">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_dff02877e10a47bb8222046919b458fd"
      unitRef="U003">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_b1f24f9e9fe142938c8068d14f0f5daa"
      unitRef="U002">240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_6ac1a3df030c4532b38aeeeb9d5cad1d"
      unitRef="U003">13.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_88b8c78bf9fe427f9e7bd4fd88dc8151"
      unitRef="U002">240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_a35ab63a1fd8452d91dc3ca425a112e4"
      unitRef="U003">13.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <btx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber
      contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact_c60ebe3327a14ad698566425a5534172"
      unitRef="U002">0</btx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact_22340cb6df6d4dcab00bfa3556b99d59"
      unitRef="U002">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_cdfbae4b3bea4591a7c0e93cc125e16f"
      unitRef="U001">2935000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      id="Fact_451489021bc242818116d96eac427fc1">P3Y6M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_899e66021b534dc1afe111498d166c2b"
      unitRef="U002">3000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_6a5816a290474c608a50c72e9aeacde8"
      unitRef="U002">630000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_b08c70d2006c4c6cb30f86f45f5c3b26"
      unitRef="U001">250000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_57d6a34e12784ac28e93291bad60f531"
      unitRef="U001">5235000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_2e434218917a49edb0180da858e84623"
      unitRef="U001">91000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="c20210101to20211231"
      id="Text_521b4bd2711b4967be514bf5dae19c4c">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;14)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Stockholders&#x2019; and Members&#x2019; Equity (Deficit)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Equity Line Offerings&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On April 26, 2021, Brooklyn and Lincoln Park executed the First Purchase Agreement and a related registration rights agreement. Pursuant to the
        First Purchase Agreement, Brooklyn had the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park would be obligated to purchase, up to $20,000,000
        of shares of Brooklyn&#x2019;s common stock. Sales of common stock by Brooklyn were subject to certain limitations, and could occur from time to time, at Brooklyn&#x2019;s sole discretion. For entering into the First Purchase Agreement, Brooklyn issued to
        Lincoln Park approximately 56,000 shares of common shares as consideration for Lincoln Park&#x2019;s commitment to purchase up to $20,000,000 in shares of common stock. As of December 31, 2021, Brooklyn issued and sold to Lincoln Park approximately 1,128,000 shares of common stock under the First Purchase Agreement for gross proceeds of $20,000,000, and no further shares may be sold to Lincoln Park under the First
        Purchase Agreement.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On May 26, 2021, Brooklyn executed the Second Purchase Agreement and a related registration rights agreement. Pursuant to the Second Purchase
        Agreement, Brooklyn has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park would be obligated to purchase, up to $40,000,000
        of shares of Brooklyn&#x2019;s common stock. Sales of common stock by Brooklyn are subject to certain limitations, and may occur from time to time, at Brooklyn&#x2019;s sole discretion. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In consideration of Lincoln Park&#x2019;s entry&lt;/span&gt; &lt;/span&gt;into the Second Purchase Agreement, Brooklyn issued to Lincoln Park 50,000 shares of common stock.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Under the Second Purchase Agreement, the Company may direct Lincoln Park to purchase up to 60,000 shares of common stock on any business day (the &#x201c;Regular Purchase&#x201d;), which amount may be increased up to 120,000 shares based on the closing price of the common stock, provided that Lincoln Park&#x2019;s maximum commitment in any single Regular Purchase may not exceed $2.0 million. The purchase price per share for each such Regular Purchase is based off of the common stock&#x2019;s market immediately preceding the time of
          sale.&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Second Purchase Agreement also prohibits Brooklyn from directing Lincoln Park to purchase any shares of common stock if those shares, when
          aggregated with all other shares of common stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership, at any single point in time, of more than 4.99% of the then total outstanding shares of common stock. Brooklyn has the right to terminate the Second Purchase Agreement at any time, at no cost
          or penalty.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Actual sales of shares of common stock to Lincoln Park under the Second Purchase Agreements depend on a variety of factors to be determined by
          us from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations.&lt;br/&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;As of December 31,
          2021, Brooklyn had issued and sold approximately 2,424,000 shares of common stock under the Second Purchase Agreement for total gross
          proceeds of approximately $34,106,000. As of December 31, 2021, there were approximately 446,000 shares remaining to be sold under the Second Purchase Agreement. &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Pursuant to the securities purchase agreement in respect of the PIPE
            Transaction, the Company is prohibited from issuing additional shares under the Section Purchase Agreement for a period of one-year immediately following the closing of the PIPE Transaction.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Reverse Stock-Split&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;On March 25, 2021, immediately prior to the Merger, Brooklyn filed an amendment to the Certificate of Incorporation with the Secretary of State
          of the State of Delaware to effect a reverse stock split. As a result of the reverse stock split, the number of issued and outstanding shares of common stock immediately prior to the reverse stock split was reduced into a smaller number of
          shares, such that every two shares of common stock held by a stockholder of Brooklyn immediately prior to the reverse stock split were combined and reclassified into &lt;span style="-sec-ix-hidden:Fact_8f4da43a33f64403a03756802f5c0aae"&gt;one&lt;/span&gt; share of common stock after the reverse stock split.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Immediately following the reverse stock split there were approximately 1,514,000 shares of common stock outstanding prior to the Merger. No fractional shares were issued in connection with the reverse stock split.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Merger&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Under the terms of the Merger Agreement (see Notes 1 and 4), on March 25, 2021, Brooklyn issued shares of common stock to the equity holders of
          Brooklyn LLC. The 87,000 Class A units of Brooklyn LLC were converted into approximately 22,275,000 shares of common stock; the 15,000,000 Class B
          units were converted into approximately 2,515,000 shares of common stock; the 10,000,000 Class C units were converted into approximately 1,676,000 shares
          of common stock; approximately 630,000 shares of common units were converted into approximately 630,000 shares of common stock, and 10,500,000
          rights options were converted into approximately 11,828,000 shares of common stock.&#160; Brooklyn also issued approximately 1,068,000 shares of common stock to the Financial Advisor pursuant to the Merger Agreement.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Acquisition&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Under the terms of the Acquisition (see Notes 1 and 4), on July 16, 2021, Brooklyn issued approximately 7,022,000 shares of common stock, of which approximately 3,644,000
          shares are unrestricted and approximately 3,378,000 shares are subject to a three-year lockup agreement, provided that up to 75% of the shares of common
          stock subject to the lock-up agreement may be released from the lock-up restrictions earlier if the price of common stock on the principal market for the common stock exceeds specified thresholds.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Cumulative Convertible Preferred Stock&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As a result of the Merger, the Company has authorized 156,000 shares of preferred stock, all of which is designated as Series A Cumulative Convertible Preferred Stock (the &#x201c;Series A Preferred Stock&#x201d;), and all of which were issued and
        outstanding as of December 31, 2021.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 9pt; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Series A Preferred Stock provides for a cumulative annual dividend of $0.10 per share, payable in semi-annual installments in June and December. Dividends may be paid in cash or with shares of common stock.&#160; The Company paid approximately $8,000 in cash and issued approximately 202
        shares of common stock for payment of dividends during the year ended December 31, 2021.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 9pt; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Series A Preferred Stock has no voting rights and has a $1.00 per share liquidation preference over common stock. The registered holder has the right at any time to convert shares of Series A Preferred Stock into that number of shares of common
        stock that equals the number of shares of Series A Preferred Stock that are surrendered for conversion divided by the conversion rate.&#160; At December 31, 2021, the conversion rate was 3.7016 and, based on that conversion rate, one share of Series A Convertible Preferred Stock would have converted into approximately 0.27 shares of common stock, and all the outstanding shares of the Series A Convertible Preferred Stock would have converted into approximately 42,000 shares of common stock in the aggregate. There were no
        conversions during the year ended December 31, 2021. There is no mandatory conversion term, date or any redemption features associated with the Series A Preferred Stock. The conversion rate will adjust under the following circumstances:&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
            &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);"&gt;1.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;If the Company (a) pays a dividend or makes a distribution in shares of its common stock, (b) subdivides its outstanding shares of common stock into a greater number of shares, (c) combines its outstanding
                shares of common stock into a smaller number of shares, or (d) issues by reclassification of its shares of common stock any shares of its common stock (other than a change in par value, or from par value to no par value, or from no par
                value to par value), then the conversion rate in effect immediately prior to the applicable event will be adjusted so that the holders of the Series A Convertible Preferred Stock will be entitled to receive the number of shares of common
                stock which they would have owned or have been entitled to receive immediately following the happening of the event, had the Series A Convertible Preferred Stock been converted immediately prior to the record or effective date of the
                applicable event.&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
            &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);"&gt;2.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;If the outstanding shares of the Company&#x2019;s common stock are reclassified (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of a
                subdivision, combination or stock dividend), or if the Company consolidates with or merge into another corporation and the Company is not the surviving entity, or if the Company sells all or substantially all of its property, assets,
                business and goodwill, then the holders of the Series A Convertible Preferred Stock will thereafter be entitled upon conversion to the kind and amount of shares of stock or other equity securities, or other property or assets which would
                have been receivable by such holders upon such reclassification, consolidation, merger or sale, if the Series A Convertible Preferred Stock had been converted immediately prior thereto.&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
            &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);"&gt;3.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;If the Company issues common stock without consideration or for a consideration per share less than the then applicable Equivalent Preference Amount (as defined below), then the Equivalent Preference Amount
                will immediately be reduced to the amount determined by dividing (A) an amount equal to the sum of (1) the number of shares of common stock outstanding immediately prior to such issuance multiplied by the Equivalent Preference Amount in
                effect immediately prior to such issuance and (2) the consideration, if any, received by the Company upon such issuance, by (B) the total number of shares of common stock outstanding immediately after such issuance. The &#x201c;Equivalent
                Preference Amount&#x201d; is the value that results when the liquidation preference of one share of Series A Convertible Preferred Stock (which is $1.00) is multiplied by the conversion rate in effect at that time; thus the conversion rate
                applicable after the adjustment in the Equivalent Preference Amount as described herein will be the figure that results when the adjusted Equivalent Preference Amount is divided by the liquidation preference of one share of Series A
                Convertible Preferred Stock.&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20210426to20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember"
      decimals="0"
      id="Fact_83d8420c74a94e228ede7c7fe05909f3"
      unitRef="U001">20000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
      contextRef="c20210426to20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember"
      decimals="0"
      id="Fact_abcf7cb4e758408c830833cc8d28b643"
      unitRef="U002">56000</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20210426to20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember"
      decimals="0"
      id="Fact_c8e1c5ebebd341f6bd59952751d44e19"
      unitRef="U001">20000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
      contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember"
      decimals="0"
      id="Fact_6c66ad0ead2c45bebd65ef373b70ea8a"
      unitRef="U002">1128000</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember"
      decimals="0"
      id="Fact_a608c3f7ccb84bcfbed72260d19b60ef"
      unitRef="U001">20000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <btx:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1
      contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_FirstPurchaseAgreementMember"
      decimals="INF"
      id="Fact_59664752c3c44d90a29ea629f0016776"
      unitRef="U002">0</btx:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20210526to20210526_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember"
      decimals="0"
      id="Fact_86daa55b20ce4a58bc7ae3065dfb014a"
      unitRef="U001">40000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
      contextRef="c20210526to20210526_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember"
      decimals="0"
      id="Fact_52429417ef714ca890b2823f4e5c88bc"
      unitRef="U002">50000</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember"
      decimals="0"
      id="Fact_6a40159838bd47a0ae3460f9fd5457c3"
      unitRef="U002">60000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember"
      decimals="0"
      id="Fact_6c98cedf24cd4471b5e4f1c724b50bc4"
      unitRef="U002">120000</us-gaap:CommonStockSharesAuthorized>
    <btx:CommitmentAmountToMeetAnySingleRegularPurchase
      contextRef="c20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember"
      decimals="-5"
      id="Fact_282d318c6aba4e5db54e3c9603942136"
      unitRef="U001">2000000.0</btx:CommitmentAmountToMeetAnySingleRegularPurchase>
    <btx:BeneficialOwnershipPercentageOnTotalOutstandingShares
      contextRef="c20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember_TypeOfArrangementAxis_SecondPurchaseAgreementMember"
      decimals="4"
      id="Fact_fa5ca2cf3b224541ae90934d90b455aa"
      unitRef="U004">0.0499</btx:BeneficialOwnershipPercentageOnTotalOutstandingShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_PurchaseAgreementMember"
      decimals="0"
      id="Fact_2cf1f1b4783e42bb88395d315a31734e"
      unitRef="U002">2424000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="c20210101to20211231_LegalEntityAxis_LincolnParkCapitalFundLLCMember_TypeOfArrangementAxis_PurchaseAgreementMember"
      decimals="0"
      id="Fact_1f88a8fab2004e218172f6555866a55b"
      unitRef="U001">34106000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <btx:SaleOfStockNumberOfSharesToIssuedInTransaction
      contextRef="c20210101to20211231_TypeOfArrangementAxis_SecondPurchaseAgreementMember"
      decimals="0"
      id="Fact_983f585a58644d66bcf662b8c6e015e0"
      unitRef="U002">446000</btx:SaleOfStockNumberOfSharesToIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c20210325to20210325"
      decimals="0"
      id="Fact_47366878477f49fa899dc74fc5c5b87e"
      unitRef="U002">1514000</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:SharesIssued
      contextRef="c20210325_StatementClassOfStockAxis_CommonClassAMember"
      decimals="0"
      id="Fact_eb41f3d832754a8cbd303f04866fdf60"
      unitRef="U002">87000</us-gaap:SharesIssued>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c20210325to20210325_StatementClassOfStockAxis_CommonClassAMember"
      decimals="0"
      id="Fact_0bec321015ad41ef91bdccf880cb8922"
      unitRef="U002">22275000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:SharesIssued
      contextRef="c20210325_StatementClassOfStockAxis_CommonClassBMember"
      decimals="0"
      id="Fact_2889441a7798483ea1894b99f6cb2069"
      unitRef="U002">15000000</us-gaap:SharesIssued>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c20210325to20210325_StatementClassOfStockAxis_CommonClassBMember"
      decimals="0"
      id="Fact_9757907026a84e4d8a0d6aeddf29dfc9"
      unitRef="U002">2515000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:SharesIssued
      contextRef="c20210325_StatementClassOfStockAxis_CommonClassCMember"
      decimals="0"
      id="Fact_fb60087659d648ccbc0f12d4b52f27d0"
      unitRef="U002">10000000</us-gaap:SharesIssued>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c20210325to20210325_StatementClassOfStockAxis_CommonClassCMember"
      decimals="0"
      id="Fact_e31c7e14c82949798ff556550e04d1ed"
      unitRef="U002">1676000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:SharesIssued
      contextRef="c20210325_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f8529d49994d499481b987fecbeb9792"
      unitRef="U002">630000</us-gaap:SharesIssued>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c20210325to20210325_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_104ade947f164d63928c4643ebef6886"
      unitRef="U002">630000</us-gaap:ConversionOfStockSharesConverted1>
    <btx:ClassOfWarrantOrRightIssued
      contextRef="c20210325_StatementClassOfStockAxis_CommonClassCMember"
      decimals="0"
      id="Fact_39e1fd7aacbf4968b47c3e9705e0902b"
      unitRef="U002">10500000</btx:ClassOfWarrantOrRightIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20210325_StatementClassOfStockAxis_CommonClassCMember"
      decimals="0"
      id="Fact_3666bedf9da94a789fb33d2f692d9c87"
      unitRef="U002">11828000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <btx:StockIssuedDuringPeriodSharesAcquisitions1
      contextRef="c20210325to20210325"
      decimals="0"
      id="Fact_911bbed7a681405cb2a46b62a865a051"
      unitRef="U002">1068000</btx:StockIssuedDuringPeriodSharesAcquisitions1>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_651d78e0329443fab479785d3c3bdad1"
      unitRef="U002">7022000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <btx:StockIssuedDuringPeriodUnrestrictedSharesAcquisitions
      contextRef="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      decimals="0"
      id="Fact_64dfc7f5c7254f8aa6a30fb1c3a9997f"
      unitRef="U002">3644000</btx:StockIssuedDuringPeriodUnrestrictedSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember_RelatedPartyTransactionsByRelatedPartyAxis_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember"
      decimals="0"
      id="Fact_70f38e7a5f4f43e4b575609e1e5d4796"
      unitRef="U002">3378000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <btx:EachLockUpAgreementExtendsTerm
      contextRef="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember"
      id="Fact_63a7615782864160b1a4a1d3f9078672">P3Y</btx:EachLockUpAgreementExtendsTerm>
    <btx:PercentageOfCommonStockSubjectToLockUpAgreement
      contextRef="c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember_RangeAxis_MaximumMember"
      decimals="2"
      id="Fact_931fcd6f51534781bea99f254dc8c061"
      unitRef="U004">0.75</btx:PercentageOfCommonStockSubjectToLockUpAgreement>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact_b45c9ea148b4435886432b71c8e66aad"
      unitRef="U002">156000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact_2e9331c7221e4411b7cbd51015c5cc15"
      unitRef="U002">156000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact_2745bfa59cf648cd96d48153d012ce44"
      unitRef="U002">156000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="2"
      id="Fact_6ccd6c27ecbc4d12862d357c82ded341"
      unitRef="U003">0.10</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPreferredStockCash
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact_80016cfa54a04d98808d0d2455cc200b"
      unitRef="U001">8000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:PreferredStockDividendsShares
      contextRef="c20210101to20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact_2e2ee3aa3b82467eabc1425957bcae4e"
      unitRef="U002">202</us-gaap:PreferredStockDividendsShares>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="2"
      id="Fact_10987e02d19a458690b29bdce7995199"
      unitRef="U003">1.00</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember"
      decimals="4"
      id="Fact_27107675250b486980059d7439ac0dde"
      unitRef="U004">3.7016</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="2"
      id="Fact_aac1b7b60c2b4b5a96db6281474251ae"
      unitRef="U002">0.27</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_08b9772dcf15405f8abe237a990450bb"
      unitRef="U002">42000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="INF"
      id="Fact_004b576ef6db4f32939bdfd267713232"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="c20210101to20211231"
      id="Text_5e8fbae6b1184b969719cbe3a9c28eb5">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 35.9pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;15)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Income Taxes&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Loss before income taxes consist of the following:&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Years ended December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt; 2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2020&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Domestic&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(122,296,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(26,531,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Foreign&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total tax provision for income taxes&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(122,301,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(26,531,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;For each of the years ended December 31, 2021 and 2020, current tax provisions and current deferred tax provisions were recorded as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Years ended December 31,&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2020&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Current Tax Provision&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); margin-left: 9pt;"&gt;Federal&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); margin-left: 9pt;"&gt;State&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;5,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="margin-left: 9pt;"&gt;Foreign &lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;5,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Deferred Tax Provision&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); margin-left: 9pt;"&gt;Federal&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(5,836,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); margin-left: 9pt;"&gt;State&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(1,433,000&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(322,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
              &lt;div style="margin-left: 9pt;"&gt;Foreign &lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;(1,000&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(7,270,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(322,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Change in valuation allowance&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;7,270,000&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;322,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total tax provision for income taxes&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;5,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;Deferred tax assets and liabilities consist of the effects of
        temporary differences as shown in the table below. Deferred tax assets have been fully reserved by a valuation allowance since it is more likely than not that such tax benefits will not be realized.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;As of December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt; 2021&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2020&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Deferred Tax Assets:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Net operating losses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,454,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;747,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Foreign net operating losses&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;595,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;R&amp;amp;D credit carryforwards&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;288,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Stock compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,312,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Vacation accrual&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;30,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Contingent consideration&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,171,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Deferred rent&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;40,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total gross deferred tax assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;12,890,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;747,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(12,610,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(747,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Net deferred tax assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;280,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Deferred Tax Liabilities:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Fixed assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(168,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Intangibles - goodwill&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(112,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total deferred tax liabilities&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(280,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Net deferred taxes&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none;"&gt;The reconciliation of
          computed expected income taxes to effective income taxes by applying the federal statutory rate of 21% as follows:&lt;/div&gt;

&lt;div&gt;&#160;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;As of December 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;2021&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;2020&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Tax at federal income tax rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;21.00&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;21.00&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;State income tax, net of federal tax&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1.17&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Non-deductible expenses/excludable items&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(16.33&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;Pass-through loss &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(19.79&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Change in valuation allowance&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(5.94&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(1.21&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Credits&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;0.24&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(0.14&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Provision for income taxes&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;0.00&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;% &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;0.00&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;% &lt;br/&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
          &lt;/div&gt;

&lt;div&gt;
        &#160;&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;The net increase in the total valuation allowance for the year ended December 31, 2021 was an increase of $11,863,000
          of which $7,270,000 relates to the current year deferred expense and $4,593,000 relates to the purchase accounting related to the 2021 business combinations. In assessing the realizability of deferred tax assets, management considers whether it
          is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary
          difference become deductible. Management considered the scheduled reversal of deferred tax liabilities, projected future taxable income and planning strategies in making this assessment.&#160; Based on the level of historical operating results and
          projections for the taxable income for the future, management has determined that it is more likely than not that the deferred taxes assets will not be utilized. Accordingly, the Company has recorded a full valuation allowance. &lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;At December 31, 2021 and 2020 the Company has available net operating loss (&#x201c;NOL&#x201d;) carryforwards of approximately $20,679,000 and $0 for federal income
          tax purposes, respectively, of which $20,679,000 can be carried forward indefinitely. The Company has available $1,397,000 and $747,000 state NOLs for
          the years ended December 31, 2021 and 2020, respectively.&#160; The Company also has foreign NOL carryforwards of $4,759,000 and $0 for the years ended December 31, 2021 and 2020, respectively, which carry forward indefinitely. Section 382 of the Internal Revenue Code (&#x201c;IRC&#x201d;)
          imposes limits on the ability to use NOL carryforwards that existed prior to a change in control to offset future taxable income. Such limitations would reduce, potentially significantly, the gross deferred tax assets disclosed in the table above
          related to the NOL carryforwards.&#160; The Company continues to disclose the NOL carryforwards at their original amount in the table above as no potential limitation has been quantified. The Company has also established a full valuation allowance for
          all deferred tax assets, including the NOL carryforwards, since the Company could not conclude that it was more likely than not able to generate future taxable income to realize these assets.&lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;At December 31, 2021 and 2020 the Company has federal and state income tax credit carryforwards of approximately $288,000 and $0, respectively. The
          credits begin to expire in 2041.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the
          largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. The Company has no uncertain tax positions as of December 31, 2021 or December 31, 2020.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;The Company recognizes interest and penalties related to unrecognized tax positions within the income tax expense line in the accompanying
          consolidated statements of operations. There were no accrued interest and penalties associated with uncertain tax positions as of
          December 31, 2021 or December 31, 2020.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;The Company is subject to U.S. federal, state, and foreign income tax. Tthe Company&#x2019;s income tax returns are subject to examination by the
          relevant taxing authorities. As of December 31, 2021, the &lt;span style="-sec-ix-hidden:Fact_145d916fadf245a7a67bdeb44d432d49"&gt;2018 &#x2013; 2021&lt;/span&gt; tax years remain subject to examination in the U.S. federal tax,
          various state, and foreign tax jurisdictions. The Company is not currently under examination by federal state, or foreign jurisdictions.&lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="c20210101to20211231"
      id="Text_a3f4ee5e0f204eb396b5a3cc7b336925">
&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Loss before income taxes consist of the following:&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Years ended December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt; 2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2020&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Domestic&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(122,296,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(26,531,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Foreign&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total tax provision for income taxes&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(122,301,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(26,531,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_833423af94694357bfe0341c52eaf1f4"
      unitRef="U001">-122296000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_ea950597f20841a796f9e09a762c4c6c"
      unitRef="U001">-26531000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_65ec4d6b00174310b4097047884f4e5f"
      unitRef="U001">-5000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_1a5b6f03d86c44ee81a8a06d8faddf2d"
      unitRef="U001">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_75e7b250e6a544b5b6a24e5dd28d7729"
      unitRef="U001">-122301000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_ef4465a9bd1c48f4a43c5cf6cc1bbd15"
      unitRef="U001">-26531000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="c20210101to20211231"
      id="Text_d7cc4244179e400cafb6c5f814b5ad21">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;For each of the years ended December 31, 2021 and 2020, current tax provisions and current deferred tax provisions were recorded as follows:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;Years ended December 31,&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2020&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Current Tax Provision&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); margin-left: 9pt;"&gt;Federal&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); margin-left: 9pt;"&gt;State&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;5,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="margin-left: 9pt;"&gt;Foreign &lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;5,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Deferred Tax Provision&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); margin-left: 9pt;"&gt;Federal&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(5,836,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); margin-left: 9pt;"&gt;State&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(1,433,000&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;(322,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
              &lt;div style="margin-left: 9pt;"&gt;Foreign &lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;(1,000&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(7,270,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(322,000&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Change in valuation allowance&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;7,270,000&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;322,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;Total tax provision for income taxes&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;5,000&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0);"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_a9e311d8c21e426b9f1b954f442aeae3"
      unitRef="U001">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_1f9db864328a47cca7c247c9bcb47d78"
      unitRef="U001">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_2f46506173e64bc281900baec7e423de"
      unitRef="U001">5000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_8ec0ad7f59724d438e603affa35a6d6d"
      unitRef="U001">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_d66347c3c335425dbe0c75d2a388c163"
      unitRef="U001">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_57ec5c42f1de4901b4dcd4ae62424b2c"
      unitRef="U001">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_5efa7cd0092d4198a72670d2475ad63f"
      unitRef="U001">5000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_0d6d880701f943148411fae33ae485de"
      unitRef="U001">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_fa75863320ca4bf19d6d25a4c019f666"
      unitRef="U001">-5836000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_5f8d79f727604559b815a8580cfa778e"
      unitRef="U001">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_519d796e5d254406844a32a6ce9bd036"
      unitRef="U001">-1433000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_6492cd2700aa42579bd150749ed82589"
      unitRef="U001">-322000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_718661ba35e8415ea20a3d044179aba6"
      unitRef="U001">-1000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_fb6530f5dc2e47bda7d99da4e171801c"
      unitRef="U001">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_b5b26c4eb6154ff091162343a4c0605d"
      unitRef="U001">-7270000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_9d156fc9fb8d4f5c8f694d76f63b61e6"
      unitRef="U001">-322000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <btx:EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_08362aef754d45cbb42b59d9825b2084"
      unitRef="U001">7270000</btx:EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount>
    <btx:EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_820a845a8b4743d2abdcbc0dd272ea74"
      unitRef="U001">322000</btx:EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_4f2f0e89fbbd420c90ae5f062486bc41"
      unitRef="U001">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20200101to20201231"
      decimals="0"
      id="Fact_9c69a009813f4468b90a839b7dd70f4c"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="c20210101to20211231"
      id="Text_ef8831b411254551aae495607bc6a985">
&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;Deferred tax assets and liabilities consist of the effects of
        temporary differences as shown in the table below. Deferred tax assets have been fully reserved by a valuation allowance since it is more likely than not that such tax benefits will not be realized.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;
        &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;As of December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt; 2021&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2020&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Deferred Tax Assets:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Net operating losses&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,454,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;747,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Foreign net operating losses&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;595,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;R&amp;amp;D credit carryforwards&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;288,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Stock compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,312,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Vacation accrual&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;30,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Contingent consideration&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,171,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Deferred rent&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;40,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total gross deferred tax assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;12,890,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;747,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(12,610,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(747,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Net deferred tax assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;280,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Deferred Tax Liabilities:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Fixed assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(168,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"&gt;Intangibles - goodwill&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(112,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total deferred tax liabilities&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(280,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Net deferred taxes&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
         &lt;/div&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <btx:DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign
      contextRef="c20211231"
      decimals="0"
      id="Fact_265b490f71894ace9d8d67ed656927b2"
      unitRef="U001">5454000</btx:DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign>
    <btx:DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign
      contextRef="c20201231"
      decimals="0"
      id="Fact_332de8e5b93b4a718406c775f84d3bc2"
      unitRef="U001">747000</btx:DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="c20211231"
      decimals="0"
      id="Fact_d3fa662472b046ed8713a7285a648439"
      unitRef="U001">595000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="c20201231"
      decimals="0"
      id="Fact_825259e6e47240c2b9e7db4afc812e32"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="c20211231"
      decimals="0"
      id="Fact_8c9d7a5e53714a13a6b4a198baebbdab"
      unitRef="U001">288000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="c20201231"
      decimals="0"
      id="Fact_e793d6535a794bd0ba2c734a29a27de0"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="c20211231"
      decimals="0"
      id="Fact_89c1ab4ffabe4ef6860208058bf7de52"
      unitRef="U001">1312000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="c20201231"
      decimals="0"
      id="Fact_1178a54aa1034ed880aa62c60e6b25b5"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="c20211231"
      decimals="0"
      id="Fact_ed2397bd9e31421eac162cea64b93b00"
      unitRef="U001">30000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
      contextRef="c20201231"
      decimals="0"
      id="Fact_a0d10417ec96430e9f4dd3bdec821b1b"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
      contextRef="c20211231"
      decimals="0"
      id="Fact_8f0451b6299d43b792eb01911632d60a"
      unitRef="U001">5171000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
      contextRef="c20201231"
      decimals="0"
      id="Fact_e1d75a1db1c84045880f1bc7be9b188f"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="c20211231"
      decimals="0"
      id="Fact_f6377f86ebef4cf7a107d12fc0554bd3"
      unitRef="U001">40000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="c20201231"
      decimals="0"
      id="Fact_03a99684df8c491c9fbe0af554998d98"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20211231"
      decimals="0"
      id="Fact_4ca4711a94414de99ad4819724181b7a"
      unitRef="U001">12890000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20201231"
      decimals="0"
      id="Fact_8218f21947fa48b29efae722c4c162f0"
      unitRef="U001">747000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20211231"
      decimals="0"
      id="Fact_2a28462b2f6b416e8f96f17c0932ea81"
      unitRef="U001">12610000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20201231"
      decimals="0"
      id="Fact_d3118da38abe4d9c9fdd83995a9cb1ab"
      unitRef="U001">747000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c20211231"
      decimals="0"
      id="Fact_83c8ebd7165e4876b833868db35ba4e0"
      unitRef="U001">280000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c20201231"
      decimals="0"
      id="Fact_7f41434d42d141bba19654b9c863cea7"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="c20211231"
      decimals="0"
      id="Fact_4ac70712dd6a4920a1e2bec6f9d8d83e"
      unitRef="U001">168000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="c20201231"
      decimals="0"
      id="Fact_d84929e82bea4adfb286eaae71c7811f"
      unitRef="U001">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
      contextRef="c20211231"
      decimals="0"
      id="Fact_6ac71cad98814756a41465c7af2f7f45"
      unitRef="U001">112000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
      contextRef="c20201231"
      decimals="0"
      id="Fact_0c684e3608d24b5cbd5a6223fb2c5936"
      unitRef="U001">0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill>
    <us-gaap:DeferredTaxLiabilities
      contextRef="c20211231"
      decimals="0"
      id="Fact_d747908da2b54994a0b57b7eee0f984e"
      unitRef="U001">280000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="c20201231"
      decimals="0"
      id="Fact_9f4f627b429c482da9129aa56de0711d"
      unitRef="U001">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c20211231"
      decimals="0"
      id="Fact_3a00dac283ca455b8a46418b9c4a2e49"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c20201231"
      decimals="0"
      id="Fact_c614b9c36624449881629ea03cca36d4"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="c20210101to20211231"
      id="Text_b153d71df5ac49be98073b30e08b0673">
&lt;div style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify; text-transform: none;"&gt;The reconciliation of
          computed expected income taxes to effective income taxes by applying the federal statutory rate of 21% as follows:&lt;/div&gt;

&lt;div&gt;&#160;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;As of December 31,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;2021&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;2020&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Tax at federal income tax rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;21.00&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;21.00&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;State income tax, net of federal tax&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;1.17&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Non-deductible expenses/excludable items&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(16.33&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;Pass-through loss &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(19.79&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Change in valuation allowance&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(5.94&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(1.21&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Credits&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;0.24&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;(0.14&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Provision for income taxes&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;0.00&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;% &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;0.00&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;% &lt;br/&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
          &lt;/div&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20200101to20201231"
      decimals="2"
      id="Fact_0c683b942fa0434ba3359d05b4233f9f"
      unitRef="U004">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20210101to20211231"
      decimals="2"
      id="Fact_a5b82c74eb5f4209b58e4a310b8c20df"
      unitRef="U004">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20210101to20211231"
      decimals="4"
      id="Fact_fc9a4317f3c14c24873d3ab61a5d3d1b"
      unitRef="U004">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20200101to20201231"
      decimals="4"
      id="Fact_7efcbef84fcf4719906c1a33e1ae49bb"
      unitRef="U004">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="c20210101to20211231"
      decimals="4"
      id="Fact_e7ccea7d0ed1475bb52d9a2fe0eb48fd"
      unitRef="U004">0.0117</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="c20200101to20201231"
      decimals="INF"
      id="Fact_396e3fe1fc504244a8d16490fcd05fe6"
      unitRef="U004">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="c20210101to20211231"
      decimals="4"
      id="Fact_15b6cbbaccd443758ec113ce48f41a4c"
      unitRef="U004">-0.1633</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="c20200101to20201231"
      decimals="INF"
      id="Fact_45231a99f2164df39b62f6414993a18e"
      unitRef="U004">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c20210101to20211231"
      decimals="INF"
      id="Fact_3188d51d9b65470babdc93991a508bef"
      unitRef="U004">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c20200101to20201231"
      decimals="4"
      id="Fact_1b021e975f914319bf0d33beea9e63f3"
      unitRef="U004">-0.1979</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20210101to20211231"
      decimals="4"
      id="Fact_ad0540e1b6a046debaec30767faf2205"
      unitRef="U004">-0.0594</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20200101to20201231"
      decimals="4"
      id="Fact_d1355d9900a1470fb684f0299e19a841"
      unitRef="U004">-0.0121</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="c20210101to20211231"
      decimals="4"
      id="Fact_fbe26a4bc5294adda1226cb3a0302f84"
      unitRef="U004">0.0024</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="c20200101to20201231"
      decimals="INF"
      id="Fact_abe6ee74ab154f91bd2a6eda41f726d9"
      unitRef="U004">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="c20210101to20211231"
      decimals="4"
      id="Fact_3a46a533321a445aad6262f9a125bb56"
      unitRef="U004">-0.0014</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="c20200101to20201231"
      decimals="INF"
      id="Fact_091e7767b06b43f1a038fdda5caf78b6"
      unitRef="U004">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20210101to20211231"
      decimals="4"
      id="Fact_68673ff44a7847209b33d2727eb2d4af"
      unitRef="U004">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20200101to20201231"
      decimals="4"
      id="Fact_31a1d98b66a940c6ad4e5ce9de2894b7"
      unitRef="U004">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_94dac22c18d74dd4b29a91edf77ff5c9"
      unitRef="U001">11863000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_683ad3e2d37b4cb19766eb3632ffb3b3"
      unitRef="U001">-7270000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_a37f999d19bd48219a7e97c1d46bba7f"
      unitRef="U001">4593000</us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20211231_IncomeTaxAuthorityAxis_DomesticCountryMember"
      decimals="0"
      id="Fact_e7438b6e622b49699205541c96becbe4"
      unitRef="U001">20679000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20201231_IncomeTaxAuthorityAxis_DomesticCountryMember"
      decimals="0"
      id="Fact_304ff06eec7b4bf9a00d4edd820a54ec"
      unitRef="U001">0</us-gaap:OperatingLossCarryforwards>
    <btx:TaxCutsAndJobsActOperatingLossCarryforwards
      contextRef="c20211231_IncomeTaxAuthorityAxis_DomesticCountryMember"
      decimals="0"
      id="Fact_925e7d2469d74f06a702b6a8e6f15742"
      unitRef="U001">20679000</btx:TaxCutsAndJobsActOperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20211231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember"
      decimals="0"
      id="Fact_77f2805fe58742cfa78431788f5f9ef1"
      unitRef="U001">1397000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20201231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember"
      decimals="0"
      id="Fact_d10f092b5f0e43138e499bf82055a7eb"
      unitRef="U001">747000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20211231_IncomeTaxAuthorityAxis_ForeignCountryMember"
      decimals="0"
      id="Fact_f9e7f3c2be814c76a87c8ddb2ec86703"
      unitRef="U001">4759000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20201231_IncomeTaxAuthorityAxis_ForeignCountryMember"
      decimals="0"
      id="Fact_fef5291caedf49cba9b2b983b96bc461"
      unitRef="U001">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="c20211231"
      decimals="0"
      id="Fact_fdf4876693344d52862178337afadfbc"
      unitRef="U001">288000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="c20201231"
      decimals="0"
      id="Fact_358c11aaa6704118a31dc96dbffc046d"
      unitRef="U001">0</us-gaap:TaxCreditCarryforwardAmount>
    <btx:TaxCreditCarryforwardExpirationYear
      contextRef="c20210101to20211231"
      id="Fact_4a976f2722254da5abfb2186d0b01d33">2041</btx:TaxCreditCarryforwardExpirationYear>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20211231"
      decimals="0"
      id="Fact_e91ba18a98a340238b6ef43a5ccefb34"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="c20201231"
      decimals="0"
      id="Fact_8002768c28014cc19ce6279bc21c3fc8"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="c20211231"
      decimals="0"
      id="Fact_6031b02dc475448dbe58cc0f8619fb75"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:PostemploymentBenefitsDisclosureTextBlock
      contextRef="c20210101to20211231"
      id="Text_3178f0d4fceb4ece9409a7bdbe752f2e">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 35.9pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;16)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Retirement Savings Plan&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company established a defined contribution plan, organized under Section 401(k) of the Internal Revenue Code, which allows employees to defer
        up to 90% of their pay on a pre-tax basis. The Company does not contribute a match to the employees&#x2019; contribution.&lt;/div&gt;
</us-gaap:PostemploymentBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="c20210101to20211231"
      decimals="2"
      id="Fact_921a15b29844417ca8afab80d3ab0a6d"
      unitRef="U004">0.90</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="c20210101to20211231"
      id="Text_70b25e83691d4a44b87beca2cb618a2c">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 35.9pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;"&gt;17)&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-weight: bold;"&gt;Subsequent Events&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;"&gt;Private Placement of
            Equity&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On
              March 6, 2022, the Company entered into a certain Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with an investor (the &#x201c;PIPE Investor&#x201d;) providing for the private placement (the &#x201c;PIPE Transaction&#x201d;) to a private investor (the &#x201c;PIPE
              Investor&#x201d;) of approximately 6,857,000 units (collectively, the &#x201c;Units&#x201d;), each Unit consisting of (i) one share of our common stock (or, in lieu thereof, one pre-funded warrant (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase one share of common stock) and
              (ii) one warrant (the &#x201c;Common Warrants&#x201d;) to purchase one share of common stock, for an aggregate gross purchase price of
              approximately $12.0 million. The PIPE Transaction closed on March 9, 2022.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Each
              Pre-Funded Warrant has an exercise price of $0.005 per share of common stock, was immediately exercisable and may be exercised at
              any time and has no expiration date and is subject to customary adjustments. The Pre-Funded Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 9.99% immediately after exercise thereof.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Each Common Warrant
            has an exercise price of $1.91 per share, becomes exercisable six months following the closing of the PIPE Transaction, and expires &lt;span style="-sec-ix-hidden:Fact_2d5f06641c0a4e39b73cdc701f6abe8c"&gt;five-and-one-half years&lt;/span&gt; from the date of issuance, and is subject to customary adjustments. The Common Warrants may not be exercised if the aggregate number of shares of common stock beneficially owned by the holder thereof would exceed 4.99% immediately after exercise thereof, subject to increase to 9.99% at the option of the holder.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In connection with
            the PIPE Transaction, the Company and the PIPE Investor also entered into a registration rights agreement, dated March 6, 2022, pursuant to which the Company agreed to prepare and file a registration statement with the SEC no later than 15 days
            following the filing date of this Annual Report on Form 10-K to register the resale of the shares of common stock included in the Units and the shares of common stock issuable upon exercise of the Pre-Funded Warrants and the Common Warrants.
            The Company agreed to use its best efforts to have such registration statement declared effective as promptly as possible after the filing thereof, subject to certain specified penalties if timely effectiveness is not achieved.&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;"&gt;Reduction in Force&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On January 3, 2022,
            the Company completed a reduction in force (the &#x201c;Reduction&#x201d;), comprising eight employees (53% of our workforce at that time), effective January 3, 2022, which was the date on which the Company notified such employees of their termination. The Company believes
            the Reduction, which was approved by its Board of Directors, will enable the Company to better align its workforce with the needs of its business and focus more of its capital resources on the Company&#x2019;s cell therapy and gene editing platform,
            as it continues to sustain its investment in the prosecution of IRX-2 through the end of the INSPIRE Phase 2B study. In connection with the Reduction, the Company estimates that it will incur approximately $500,000 for severance and termination-related costs, which the Company will record during the first quarter of 2022. The Company may also incur
            additional costs and non-cash charges that are not currently contemplated or determinable, which may occur as a result of the Reduction.&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;"&gt;Lease Assignment&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify;"&gt;On March 5, 2022, the Company entered into an Agreement to Assign Space Lease with RegenLab USA LLC&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; (&#x201c;Regen&#x201d;) pursuant to which the Company agreed to assign its Brooklyn, NY lease (the &#x201c;Brooklyn Lease&#x201d;) to Regen. The effective date of the
              assignment would be contingent upon, among other things, a consent from BioBat, Inc. (the &#x201c;Landlord&#x201d;) to assign the Brooklyn Lease. Additionally, Regen agreed to purchase certain equipment from the Company for $50,000, partly reimburse the Company $50,000
              toward certain existing unamortized leasehold improvements, and to reimburse the Company for the existing security deposit the Company had under the Brooklyn Lease of approximately $63,000.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On March 25, 2022,
            the Company entered into an Assignment and Assumption of Lease Agreement (the &#x201c;Assignment Agreement&#x201d;) with Regen, the consent of which was provided by the Landlord in the Assignment Agreement. The effective date of the assignment was March 28,
            2022. Under the Assignment Agreement, Regen (i) accepts the assignment of the Brooklyn Lease; (ii) assumes all of the obligations, liabilities, covenants and conditions of the Company&#x2019;s as tenant under the Brooklyn Lease; (iii) assumes and
            agrees to perform and observe all of the obligations, terms, requirements, covenants and conditions to be performed or observed by the Company under the Brooklyn Lease; and (iv) makes all of the representations and warranties binding under the
            Brooklyn Lease with the same force and effect as if Regens had executed the Brooklyn Lease originally as the tenant.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Notwithstanding the
            above assumptions above by Regen, the Company shall be and remain liable and responsible for the due keeping, and full performance and observance, of all the provisions of the Brooklyn Lease on the part of the tenant to be kept, performed and
            observed. As a result of the Assignment Agreement, the Company will write off the remaining ROU asset balance and the corresponding lease liability as of March 25, 2022, and it will record any resulting gain or loss on the termination of the
            Brooklyn lease in its statement of operations.&#160; The Company does not expect to recognize a contingent liability for its ongoing obligation to remain liable and responsible for all the provisions of the Brooklyn Lease, as the Company has
            determined that it is not probable it will recognize a loss under the Assignment Agreement.&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;"&gt;New Lease Agreement&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On March 31, 2022,
            the Company entered into the Torrey Pines Science Center Lease in San Diego, California (the &#x201c;San Diego Lease&#x201d;) with Torrey Pines Science Center Limited Partnership for approximately 5,200 square feet of lab and office space. The term of the San Diego Lease is 62
            months and the lease commencement date begins on the earlier to occur of (i) the date the Company first commences to conduct business in the premises or (ii) the possession date, which is anticipated to be August 1, 2022 (or earlier if the
            current tenant terminates its lease early). The lease commencement date was April &lt;span style="font-family: 'Times New Roman', serif; font-size: 10pt;"&gt;15&lt;/span&gt;, 2022.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-variant: normal; text-transform: none;"&gt;Base rent is $6.35 per square foot in the first year of the San Diego Lease, with a rent abatement for the second and third full months of the first year. The
            base rent will increase by approximately 3% on each anniversary of the lease commencement date. The Company is also required to pay
            its share of operating expenses and property taxes. The San Diego Lease provides for a one-time option to extend the lease term for an additional five years at the then fair rental value.&lt;/div&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="c20220306_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_7ec1f64bd93b47759ce509844f4e51b4"
      unitRef="U002">6857000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="INF"
      id="Fact_6bf13b247fb14e5e9f806b049eabbe0a"
      unitRef="U002">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="INF"
      id="Fact_d78c3ea3487b4a26a3f4c4842fab2bd3"
      unitRef="U002">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="c20220306_InvestmentTypeAxis_PIPEInvestorMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_b056869187e949c19369d11f518d0238"
      unitRef="U001">12000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="3"
      id="Fact_0db429bd91d14f47ab937f536eea849b"
      unitRef="U003">0.005</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btx:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights
      contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="4"
      id="Fact_cef2cbdb54974f228628f4b8baab6c93"
      unitRef="U004">0.0999</btx:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="2"
      id="Fact_9318c99748314d94bb4587d6c0a4abcd"
      unitRef="U003">1.91</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btx:ClassOfWarrantOrRightsExercisableTerm
      contextRef="c20220306to20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember"
      id="Fact_01122293d73f48379714730fea794eb5">P6M</btx:ClassOfWarrantOrRightsExercisableTerm>
    <btx:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights
      contextRef="c20220306_ClassOfWarrantOrRightAxis_CommonWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="4"
      id="Fact_df61f2cf57674aba834a295e5216f1a4"
      unitRef="U004">0.0499</btx:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights>
    <btx:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights
      contextRef="c20220306_ClassOfWarrantOrRightAxis_PreFundedWarrantsMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="4"
      id="Fact_0b546ce7ae2a47129d4c167085f6c26f"
      unitRef="U004">0.0999</btx:ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="c20220103to20220103_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="INF"
      id="Fact_b396b4ee24f8480795e4003284534eec"
      unitRef="U014">8</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="c20220103to20220103_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="2"
      id="Fact_fcff5db4e43b46f6b79a594b3cd4b85e"
      unitRef="U004">0.53</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:SeveranceCosts1
      contextRef="c20220103to20220103_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_e60bf6063a964fdda11c7a9eb776c19e"
      unitRef="U001">500000</us-gaap:SeveranceCosts1>
    <btx:LesseeCommitmentToPurchaseProperty
      contextRef="c20220305_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_d1bfcc27b61d4a26857334469da4dd85"
      unitRef="U001">50000</btx:LesseeCommitmentToPurchaseProperty>
    <btx:UnamortizedLeaseholdImprovements
      contextRef="c20220305_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_9fcdb7790346436580b4421281765dca"
      unitRef="U001">50000</btx:UnamortizedLeaseholdImprovements>
    <us-gaap:DepositAssets
      contextRef="c20220305_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_adcf3390e51b4672809c7df32dab0bbc"
      unitRef="U001">63000</us-gaap:DepositAssets>
    <btx:OperatingLeaseArea
      contextRef="c20220331_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_1529fd58bfd84b4f8277fccffcce884d"
      unitRef="U007">5200</btx:OperatingLeaseArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="c20220331_SubsequentEventTypeAxis_SubsequentEventMember"
      id="Fact_b3bd67fc49ef48578a2a54c35e69e8ad">P62M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <btx:BaseRentPerSquareFoot
      contextRef="c20220331to20220331_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="2"
      id="Fact_02b04f3e1fc94b91bb11946f5f10f373"
      unitRef="U007">6.35</btx:BaseRentPerSquareFoot>
    <btx:PercentageBaseRentIncreaseOnEachAnniversary
      contextRef="c20220331_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="2"
      id="Fact_41b330afb9c74a79a6c33ee94b04e3f5"
      unitRef="U004">0.03</btx:PercentageBaseRentIncreaseOnEachAnniversary>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="c20220331_SubsequentEventTypeAxis_SubsequentEventMember"
      id="Fact_ff13e4c263c4470b9da9551eabdae1d1">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MZ+L TQZQU."0NG&H-FMU4>>Q9+K-:N8.>#ID VZ" U7P@'4*V=*(SOHW;=1
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M3!F%I40#X/V2<[6_T1TT'Y2N_P-02P,$%     @ Z8B/5*<U>'#]"   :#4
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M%,7RZX?DUA?+GHC)U%^+7%YKG'J(TR#81)O0SV4';?XH I'KO"WTWNX3V1O
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MY,FZ_#7&0Y+G252^7'%?'F4*0'[^F"3YZT7Q X_ZQU6G?P-02P,$%     @
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MUPNN]"\V">(09DC3-K(EFR?;MTQ9%EYRYCC'XISS(X\_<56(+L%T"R'7II-
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M/QP-*PYM/KPIPK-K83P><>%GBE<S63Z _:6!H_4'&VC?X6=_ U!+ P04
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MVKJ1YEY4T@MEBM8Y*H57:Z-6JI F")2UDT&9M=#6>W"Q+*:67"I%6[=:!O
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M\R>JL0%F +'("7!L//[P(E)<9B;.F)7LH6/3D^HGZB[J$&>Z(1XORH^,=^
M,B[BN"'2Q(V/&]ZQVMDQT;30UD=-*AC <2G'T2[F02R&^1 (QP5V0'.$6W"8
MXFO=#W06$@TE-;@XM&26=@%XPBK:KZ"(6483KYZ=6AG_[Q8GZ64[-":>N79P
M]LSW+=]*5K,86A+&-;O.JG7=\@C?FE)642!)BI"-;4S4T23([;&ZA&?  O[P
MCAA#W&(=+<-2#6=/E!M$U>6*;+"U=&M3^((83X$7D/)*U.\8SH-S=%3XART4
M)RD-F6^]TB$JD#=&K27A(5?30@9DI/!<E1G)FH9+\2WBWHJ;L)#VI'S'K.<D
MH93S8&/Z]^284#,"=N0H3BW.=?*SR3\C=$(2'DZ'PQBY$!8;76@,F3]I.I0/
ML@+K2>F2?'<$!O42=4:J@WA^A,2!("]I$+FBCQ2C2$K.,PT5^8%A 1:R%4PI
MVGLP^>8#3UTP?P.L2VTIIA +/QKB^LJ1"MLU!9SKZ)7N.DT55K M'XWJ\.$6
M%#QB;&FQO0(6.69)#5C[/Z!==$-HK[YLN.C1DP'S;O1,![\/#T;!P!9A#Y&!
M+6(V.GY(S9M6QTQF6 _R.1-T8'F4_]K!QJ*UFQ0:1W,3YP Y+<D 6(D)A)FT
MG+'*&)&2*Z%G"7841_,.CJ^QB(_(=GP%8Z)PQZF1$$]QW,NF9#V$AQ@ZE'M\
MIJ3M1K="V=STD$06<*TWMM>M_0.![Z_.-3>6@$G^X,&'P'<G)!%"\J;98 DB
M$SE)/W:\+/D9\CL+RVE=9_I#;C>G!Z/ /GS^9T6V[?7&#+VM@\#DA$[8CL].
M3E^JQUB;0-#G?Y8 K8!"#&/NR&@.^?B"%P1^*$%%(*%H0VRB^WO\2+XZ;4-F
M0T<6;>ZZ :B$M=\N%.P,8B7=\OBIMIZT##@0^1VQCQRR1.P;#B+$D*$VF8W5
M&*R*@ =(39)LW0UCH5I[O\7O?#-E3Z;69#,E:C"XQ.&E+_PE'Q\>J#4[N\_4
MLCC_'4>-4)ND2RZR!2A5<TKJ2!U[Q&3&,P"-ZG=BB>T%[$'Z(20HDW(4@K\K
MPW9KP=QJ#=36VJ](>H@['8N V;2O8 411"M'"EYRB#57 ^E!20Z\J?-CE%WK
MVKL,.NG?AE4I(,=M*/<21TRW^:]F)X[2/>Q3XI8S-@C _!'\1*YDZQ5710Z(
MY-/UE2C+L?HP.53CC*C@1@>1WV%^LEOKBI5C]C3A KC$&;B/:0;Q:>3H5//3
M 4T3)8\/*8F8;#H5!!R%H>1Y=^\Q#Q@_17^07<VNB($UEIW0VIMZU;G6+:V)
M0/>&B+L7PF&W'<>0' )7#(BS!!=UO<(3\O9<)J# 90NH%6]7AW.7X_TCL8,=
M.4CTSY%J-88T@M(K)3 -.46[5UT@YS2GA[I.PIIPE_9U,4S>F1%2!/^-SD]J
M]'8$RSGA$0NJ'B)U)%*P).O6EN\Z[ RX>AF]'\K_-K '9#M>((^AFY"K+28.
M:$Z6MD9(O-&2:>#'TF7R > VV5%*IC3QH'PBHA8E/G./ASA\XM%9")#).AT3
M$39%3B=A6267HPV1M'*6/!9'F?0@=0IOEL 4C. V0%>ZG66,D/A NW%X) U!
MI<-X> L*-A FQ0.&L%GRHU;O'&FV!U.J7NA&#4Y-)9H!:Q'8=*Q[W M9YX82
M;P;T.KKDC;.2_*.<Q2S;X93X>$%W6:^C4F4>K/56+$R34:$XXLGA>51+2CT3
MC),Q6RS+[7&B(ONM(Y;3N]CEL.?:4Q#&,Q/G5:C[0GU$HO6167DN"Z:5NVLT
MQM3A=*RFK *@<(*-XO4=PX+FH>2ZH_=<4")<*)$G 8F \):,@,1O8X6F217P
M;""[FL[L1Y"9YRP3B/"\*VDQMS8@LTMAYC C=X^<$%1.7EL3D_K#,>)]S!L8
MX2LI[>SG;M@!R=M,CBIQH'/5H> ^<1(-( :@X)_%&/NBE!/$<NPNU/A<.NBW
MA4&4:I(+&[:_I\@'6,%9[%BC^GS7O7E']N:AE_I-Z,?%G$?$$OP1)4E=</Z^
M@,(-82[SS$##C2'CI'_#L %B9'V5[K%)!0"[A,,[L/>Q^K*AC E12F]C$@(T
M9<D1]^02QI_7FL!8JDZVE%YTG"E#%"E&2SC*I3U]#P,EQ:AB%,S=BAS3,FMB
M?"J>$947CZFCQQ$O!?Q\1Q%38%V**PH%?-1Y'HS9?.!8<DU%2:EMEN!"M+E(
MH"@A=L-R=;#TK![K4+G-ADO::+$=3'>>1'P3[H8W+*G96%.=W5.F!5H.HV2X
M-G^_:HO-(7[DW#Q,)".%GK7^S7$/@S3+Y$+AO5LG8(]\OJ7X5W,-<FBV<ITP
M>_IU6ES9O2IKI"%',:E*=H;$( R>(;WXMZ4H;E[)]]-]F1^BSB7<W!97LZ!G
M;,)20YBI4%N)%;72S;4-\&MC"M&OK&^.$"_SN8)NM;>I@$I0Q6T->H<=P0"^
MCE[*D<1\<)2>+C$B4C)C"V_C#A60 !]$@$/;NCK&'I+!-3W)#1(R5T8WD?=%
ME':4_D8P,W57"^(5 RVQE0[I48N*JI=*(!8FE9T"AE1/# D1$0L$,D@W.29;
MF;B[1%DXN.0H7'>T=-""B1_$ G@W\4,;UQMNYF20)CHZ9GN /:&H'BV]*4IK
M89C_%EN-G5FZWHXS -?H/G!E*9U1D&'\+ GH-M:,0//0<3TO>D^U:-T-4?,I
M.=/<A"QXUAA4EH#V8I2L&#Q$L$3ID#77)F&=A%<2-/>CRXY"H<6 5X")IO.N
M;=/2#1T+B^2V46^BZ2)$V+&-L'8I81GER.L2[T;L/&W%<O$B:B-?G0H;@81E
MC6!EB7B-$)B2>Q2 1^_  .U.71EQ>*$VB751$Y(<"VTIO(S846KN3+H P^9(
MPJ,IZG[3&C<:B+7=<"V'Y(WMRQU*/FBA/I<!$A/2#Q67*^;2(N-8R-B>21>_
MRP"Q$2X1R25525-V^$L<(%&%U,J3Q#ID!1K5!A:/Y$_]JF_-+G9&;1TJNC <
ME7M].^TV=1F"E3E+[, 8!LAST]^8A%,?[,#MPN$J:1D>/4]S-H>;7[-8Q3>=
M%H1 2SS+!Q8C?;A8XQ1(NTMJ@C$)7^01"SAN(G+>VH#JA%92Q6/U(D.ZX:##
M:/Q!2!O ZJ@<G(2-[>>2S54\HA0C<SZ0"L119#AAC!()9F;#PS722T;Y";\5
M#3H6AR0KS5YY@H<6"ID?YO<Q5"8',O&30Y<TC)\?"_\AMVK(0/Y@/9$:!!<9
M'T@ RHT4U\/F<',!3Q&5,[=Z'0%4-=^F1:Q%0[]R/FK'1$4YY(LCH#./;$M/
M$F/ORP,6]-MOU6=FBGBE\1!@QMIH='6GR;YJD52S+^!G"A-67!XF:X;'$@:]
M./DW89A=.9*76U0R%Y T1$H>@"QP<_#OKAW&8XU].@::V17>)3TNT7?;Q*/=
MCB_\+5<,H9KOM$=1(JA/1.P5C[=@/JX66&A;'JHX/ 8S#E75TIYJ4,=NR+DW
M24%3ZV8<4(NEFCR4$A5@;RBG&SAO)5:5SPSE:,WA[O \4X]RR#:?P:2#XAQR
M@#0$\N[351Y12P60)'CVU1A!(E\5&PSTP1M6@TQDHJ[H2'#)DC%TUK]$2OD,
MUCCN6X/&6Y2P0AP>&+E4MF['[1'2CGA/I!PQXJ-3Q.*"$Z4@DI1 7&A8N9ON
MF\WA6%V9)0.2SUF%/G3<"_(R9<@(\OSJ4OWLCM79RY/9@167CNX$?$J8XY+L
MB(SELPU?)^K-/3KZ+\061%BI/-%')(\4TBT]15-1=@9&(X^_H%378)J0YP?.
M<WNQ%W84:V.B%.V:];!Z;]"6:-5;P^9$QTU)RJ7S&^>G Y'OWWX8)R*'#63P
MKV<O3F8G)R?TZ)X3LRGZ+GH+Y?$ 2TFB0Y?(@0DWD8;<(F7MDN()[XG'%VD4
M)AO[G!'LV45.!@B,-IP.%G))PQA2:.>RUS6KX?70=FER8D3Z^S,9R'FV"%$V
MMPEDQ^35VFV%DE@<--M=GT8S(EZW'?HM]]5V1A3YWZY\B3<]Q(W=.NDNM=]&
M%2IA?T^5L''FE52J]X/$F_=CM<P&J32/E5=I#T]="@4UPZ4TS/UQ12D6+V92
M^+5",V9?,52CQR$5GC;5 #&DX8C<XWQL GT5PC5,-K;I.)D :&9?<%[6]BC-
M\>" !"69K"T@%]1W!%VVH^@0U7?)Q7 <#R,P")X\*!IE__O@P'8^.>N:O%41
M"8I%7B[^UI)4&$FK=E&NQ)Z;W>V'SLV#\=<<B80J#B+5P9/9(+/2@(SA!VF6
M?_=*?>2.[2G)D4_%2G'Z2B1=X(,_=93J\%$RJ!I#>&P4KE+".=J-YDPRU80B
M8&&MA(<_WJ'_["'ZH]"*FMSNB<;@QEM6IT(OMZ1&-B<P*R6VXH HWMA>9DY(
MK='F DNZ](TE@W8\D$&N1TV)6(QYZ1W:L,?XV8$M1I7ZEOV2!'':2G/Y/%J^
MF3W(MC_'(O4XI<@\Z Y]YA2)G+@#@$B9%(].2A$C;- =F*E:HJRG*(LB6E\?
M/Q'^CK8H(T2>_4E\"8'[<(Q)V"=Z[WB02@*D'+PB==+XBLLFPI@\/X27#L*N
MLCW[1F4;Z[CBHC&78/N>6$07&/DR 6RH*<JD>L!!,^%1"7;/,OUZTY4S@@(@
M]UHZ>0@RHOP8I96\Q<8URC3NMSLR-QN#M7AJR#>*QTY:6<(M+M+F\=!9E5>G
M5)!3]KKV@QFG.6<[BW>=GUR=_(H.ZJTD%X6K$_8W0P*/%L 8O8DX9IC'D/<;
M5JTC,8]4COL7?:D81>*SXG -MQ0YN8=-;JUIP>>J7W'\F_=Y=EKL/4S&'Z=&
M4'95Y,P"$=-$EY33960CY1ZRD&MH=,28*]DB(@/+1P=06% <]IO66W3C^%4>
MX-]?W8:RCI?/SV;QSIGZ16;)\!8!3_*5 ID.;:3/(W=Y06[JP+]L.1Y;M+!^
M^7)X]F,/I;#C1-CCHDC%Y<Q65%WZ';&5+7J07P]P]Q">WZ0 WY):R^LHK*-3
MRN$.+==ZQ:FG&KO<91EQ,1[@TMFD3;Q+A)PXS_A,- %+,5B>ZT5Q_Y"&5"A)
MVN:9*3')LB+.;9J<V8$"#&/ ^=UPELXZ,TG\;2?OJW(6<:U)7=@,^N+I/)!
M)\P1>/?=DF^0/%E?.>OU)W2E@F"FIQQ'I?DM [C?G2.R0T=I6?)WP;ZC+\@-
M75;P_=)$:F8*F0B(=2Q^-C;.K8&ZW/SJ7'>4>94Z4WDP=.\*+2_:CX+08\V5
M-%(WR7FR:G*N5\[I[6PG-9*V57M&P4/:.-X52G98QM>\1_%->)Q"#CHD+/C,
M_2*LHN0;)WR&@(H&JO^4YDF3(L=+5!)X!B[7PM->T3-)<C=+!<*Q^\OKJ[4-
M-?E W1GNU<"^1#(C<:EZN:<KL4>[6Z8H' R/D._X /) &H^>[9]_-FWA8I9_
M9 3[%QFK,+?8&4HPFS:C\XB$HTQB&2LDC(Y<03CF,W+K.3FQ\A1"<XJ74@7P
M4&H,F$+JN=N_.Q^DLZ*DII$W^\.ON_N3%5#JG;M=E^F- 7[7I323F$RDDLGS
M%R='2$@_HF S777%;<8+=CJ799MQM^+/)<[P8%M2K$+>,L+86!/4DC0K)KFI
MSTD2%$^=VJ2IP!A;JGKWW8%J]"K[TQ]2X7/QA8QQ9O^BU43K5;UR>.=5KC,^
MYMS3-::-+<%[=DO$VTFA5^?V^3A6S=8:,#<(P(V46LJ@QY''#_",*WOQIJB
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MPTK<%/D<N@_GP[X4+!R61,"[09S7=1M62(=HF-0(,7'5#4F4I!+&_3S'D*A
MBB!!!#+R@$'K M3(N/MZEW2;%T=[,SCXIGZ%%^P(K 3W#W4SR7Q?TCP-9A,2
MH;6/J':M4KW079Q*NB< 7_)'X*!LP?,X#X::(E=<X5 R5V7D@R&=[U1]%(]$
M"$=16^BM L?*P\).VZI2G< )L2!5RAL#<O*"0A;&HU,Z:?+.II79)#.&P6L*
MY5B^(&LGN8%L%8+ !8LD^>!5B7MUUKC@<"NK:HNR".FO4S/:QXMGPN6 \WI
MQWT!<G Q<T]=8-P7'5Q$'$RF9V'QTZ%P@/'/+WPF @ZNIA=N51OO!C[,'<6!
M;N#C6P3Q@X#P\.MGXC?PZ6+]4?(QBGIQ@4 =%]9:/V2R=;JHZ;($T-2$27[F
MV$'=2G8=+DV5R*%4P85\IH_X+1CS-IERK'^K' /8M2L;E<Q8_)^?C,:3LRL?
M]GV?U,MO>C[KA%) 6 I#Y!?!0##H7@W/O5BA&)(00-%9VKP++!WQ&4,0.A9;
M.1I;$Q9#!BYH1!/5XKKDH0WRQ$,7_;NR+FC9)N?TFK&&)(;8@$^W2E985U#7
M7F'7'GPOI> 4^NZD!\HVP>_T3DNL[Z 8+;D&"&# &?!?9,E8S+GKB([-)XGY
M!YQ"_B%L56J!(QUPA)"-[H(I=UTE-ZWZJAD)\O;0H?L764]ZK+OBM+^;V)@&
M0@1E*T3&&6TH@QF_00O:9*/D[R3[7:$G*/2$!(Z9%QF3K.M*SYN:_(*R@[8I
MX((PFM=D.AV>CL]#N@>6.9R=>>>^D5:G='#?&RP]_;8C\9,[34>74]YB,II-
MP)KC40)$T;\TV,O8#:*X>_@2O_/0S#G,[8X-XF6]V4'\R T0,'%2Q=J =I1I
M;+Y-0O11/U3:A.%'IG+()4"K/ASMWZ;;#'S!K:[SE]&10@79MD[CWB"B,@!T
MIR]X9P"$\\;-&,#*DM97/8V"#35.)?<+C,[GTA#3(SV,,(1J].'. C=$ -!Y
MU(_<4:Y0?#S <+W4G9["!HP!5,R-)]O,H7;0Z"+(A]]!?*RST9,4=,D-9M!0
MG\I+(O.TI*>ST?@7+R=N$OV,Q&]U/)CP!L V$S5C/#C&TJ9-:&+0;8&X2!PW
M08B8K7F:,I!'_5? 1R]G')9='4/AFAIIE#R$&HNZX/,^ 7#GZ?,]8.;CB5Y[
M=*JDK;*H.4P938:UDO1276"9,6V/&#H>,DHH)V>CV71VVJ+(KG.V.Z%_2IK(
M\- ;C29T'CD\85.U O\--;*OM,!D5%%"?IKZ6&$>-=X:0*3O"NF,2E%_:">I
MN/L=:YQ.O\YEREBM*&'T"33!-1)JU@B(DZF/E[ 2)VS</09DP?9ZCT$392EQ
MA=;JYB?!+1J-Y-9X(=H@F=*4Q]31K\-T-\'?("F%RK3NBPO+ MM(+J_97%JG
MQ6DN;@?QP= "52[E4E'5[;8+6^'( @MJSNSZ$EO@<\HQDA:&(C0=1B.TV!HL
MQ" WB8[C/<!Z;K8*YZ!WT;<84!ER@(T>PG9*IT[4,-AO;GA.BCT\HLI)M'$#
M+4K"-U"@.DET6K4QPO:(CV#OO5.-ZWA$S-W@XX4AH^B%!SI.)R+FX.+'8(K2
M6X1ENB UJ-U(7[VAT?"4&SD]9^C!1EM<NVREPV0<MP."WZZDAK0MM&)OC*Q(
M[V_#Y)#"$K8-5EHMQ#L.P& 4GQ?@(ZI*\#D4/.B+8(R=@])/U!']B2.S\GS>
MCHD*Z*/;AZ%3CL0["<:^0Q%R@UI13Z%GPO4*5K -#]F!>*8.(,EX<#'[Y0\$
M"W'M'RV;NWLGA=Q2#T11Z9*U?0V_M.,1P$JN<2"P\$EEJG;V](-U:3/Y'7L"
M5".WU3T>RZ*87 F_1\3LFBIR3"2SC@H(5\=9D7'SB'H>ZS4@#F6/GJ9+>&F?
M6W?! 5/CU WI8G>D(82KN\EPU*/).6<CHY (TS56"^&N!*<_8JW7"N_#H"A*
MT*98JM+C.[@M/.%0CXZ5RVJ8X'.AL"&%81VCS+8VWY "J'E9R<*2__J>U7!G
M;K7KJ/-&@T2]\#^"8LIN8V/P ,9T9VHE)I,CEHBK-:*)QO-[X$A.H9MVVGUD
M,FL@#"Z#<;L;=Z"B;LDD1,8C>;.&5\'^%P"D0\!E79++Q5V"0N=@?P8$@XM(
M5% RU<>56FJ\'46,5F8K<PH";6S;(P":X;19!ZKN/=VF$#?:V%33I.FC+JC4
M'?BQ,JT(L^1G-O"YSQ*S!]L5$76L+8!/XMJ%(!AWS#:,@N$<1X93?+F[%KN&
MHO@*0"77V%PU69/6=,NCX,2F*=V]),A*\GIEFN7JWUDNL"5Z3^K>1.K[D^3F
M+#8@DMBN!O[J4&\*EFF.^I@?07R'*A%<*S0LZ4;-@LZHL1H)]V@>D'L ?P!Z
MD[7ICU?@]<-MT-Y7LX8J]'(\@ZK0TX6SS'7I[#6J%FE %"7,OO$_3)Y(F+%Y
M5(4*Z@_3^NBZQ.$D=$4W1$9G8<S@W^3&.UFN+I,]%07E9C[)_,.D/=+BWDM2
M$7?]B'Y^UKDC@(5[4_HHX8:9(>XGT:I>+*+H=HS1C="Z6;.'=FC%UT?:"@'*
M@M%XUJ;\WO,VSK!VKCX\?Q_,]%H&S$?WFH$KD?M\H5%JZYT )PA=84%\AM,>
MGH]<A=(GX3A/^+Y8Q?,%'X$E%(B8^_H=!';KPWR!DAXH&[Z)AQ2"J0/']QHR
M/NS)(N<.1PP4FR[4<I5/4Y&=XY$[MM[8&Q)'TUY8?]L9V%'?&:TV.4S082ZG
MKEL=.4@RF/J>[F^[&DY.SX?G;L&7G8=HO3/N+'&3\[DK(,3'Y60X.[UT35@$
MCX($Z+V6/&SA,G7TH\B]J'4]]F/+]YV=/MQ_^9,LUB_?ML<Z3"['?J_H.25I
M.@(WL';"8H^([7"$EN+MA1)2C!R0%\$(TM1%4V-9UUBGVA(K/8 8- (%9S8%
M8)F;\Y/-8,IB(+X FN4)8CBU]]S]3;I=T>\)<J;)<&6)7TB\,(_%Z$$C%#"5
M?-L%_4!E]S(._M+*(,K,ZI6&[/Q[ P#);26^(<1LM,HY;&6)^4^$>*VFKOF^
M:]RMZJ#JGF"'89.S<^X:63'EQ#D0Q27P04,1=P\V5T UWE#^[VLX'TUX40@H
M1(RQ >,O'A=R\E'BIZQ/06UT-9 286%*U6;\<ZIEK)(\4?9<AK?GOM8)MR1'
MHF4,E@B:1V*18UW/U:U+<#<.^S1LJ#<FWLV3X6!2*:[S24<\PJ!+Q9H'3@Q,
ME7()*LZ&X9MT=XRL_CV8Q"Z_W:[8?=00D-2*2RO-8T'99E>83A1DT\, @AT%
M1LDJI%QT-Q"3=:CTP&O<+<QN-G,41XY%4_$ B3?Q TJ]=#=XV^M9V]Y6X>KN
M;C[=,4TGW%4TK6P'(WP-HJY,3CNW Q:L-!'A6 ,=V")]54'ML=:QG8Y*Q+%[
M^+5O\H9NC:ON9)C2:K7D=FHTM^FH#())1?<1AWCE=HT$=V\*;TIWSP!>!3U*
MONL*"#@=_Y)$Y+P6<OQ['S8"[,GYT3!CJ<.*N?47PF!)!AA8HN$H+(W+]N(5
MWV"HMM@\<-@.8EO)CC%36^>'JE+LKJ">*7DDN%D H-$VCS2N<224BN E,\I2
MNAI((#@^32;D;,)=1]WGQ=ULS@6%^#J&*Q_"4,<L&/7[51</5-PR'+.HG@*?
MA'=MXTOJ_NYL?,L@'(2+(4BP76)]BN.6%K8M==$GDY?B'=<5#]BHI&[=2.S[
MFY:3Z"^,: *!?T>%O@+,\!\;A5_#GVI=\U\HM<OY[[P^R6J)V)6K!;PZ'EW,
M#EAV_DMMUO3W2G-3UZ:@CRLP/U7A GB^,%#0NB^X0?@#MC?_!U!+ P04
M" #IB(]4L)/>I/X(   #%P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6RM6&EO&SD2_=Z_@M!,%C&@6(>=Q/$%V,D8&R #!,D<NUCL!ZI)J9ETDVV2
M;5GY]?NJV"VU9,O)+ 8QHCY8Q3I>O2KV^=+YKZ'0.HK[JK3A8E#$6)^.1B$O
M="7#H:NUQ9NY\Y6,N/6+4:B]EHJ%JG(T'8]?C2II[.#RG)]]])?GKHFEL?JC
M%Z&I*NE7U[ITRXO!9- ]^&061:0'H\OS6B[T9QU_KS]ZW(W66I2IM W&6>'U
M_&)P-3F]/J;UO. /HY>A=RW(DYES7^GFO;H8C,D@7>H\D@:)GSO]5I<E*8(9
MMZW.P7I+$NQ?=]IOV'?X,I-!OW7EGT;%XF)P,A!*SV53QD]N^4_=^O.2].6N
M#/R_6*:UQZ\'(F]"=%4K# LJ8].OO&_CT!,X&>\1F+8"4[8[;<16OI-17IY[
MMQ2>5D,;7;"K+ WCC*6D?(X>;PWDXN6--%[\(<M&"S<7-\9*FQM9BO<V1-\@
M^C&<CR(VHN6CO%5ZG91.]RB=3,6OSL8BB%^LTFI;P0@6KLV<=F9>3Y_4^$[G
MA^)H,A33\73RA+ZCM=M'K._H_W=;_.=JAAO YK]/;'B\WO"8-SS^>^/\M-*7
M!]F/.,)K[GB-"019J%%"!A$++6IO<HTK&5$_3:G$3*/8<HU:42(Z@0(JA43Y
MA*#C4#@O:FGX#6)CPUQ[(45IY,R4)JZ&PEA:[;S2OERE-3(5X$S'I=8V0_%_
M!=O4TD>3FUK"Q$-Q)>8;*PNCO?1YL1(%K)Q!2.@0Y:PT +H2H")>*%FML743
M0_)@ :N36P6J$3+DGO,PC R^;5R$.'L<V%"F!)$,"JS7*(3,Y(@@.QS(X<X[
M REI%>L'F>VJ;ZR;!>WO8*=NK3H4OV$M>9;M>H9,2-JRA*9P*O[QT\ET^NI,
M?-!WNA03Y(^]HL>3R5G*L&+^40)._R57LL==X8B1+U[7#KFP"T$",46=7K1)
M)>=DCHU@<I*HM R-UP0OH634ASOV3[]G?YLT!V6>#'GH45XVH Y<9%U(V%[I
M ?1-F,E/MI0\[#L()&K#VI4!G".P2"&QW1UG)L 38NUNNQTC2'DPE2FEWX.&
M!X$?/J)B ZD?T=<JRM;>6A?;38;?#=M?"Y%X'IJ\(!@:&[4G/'LD$T[<N1+%
ME8P:0KFNY8J3'6JM%1[E7BN#Y29\Q9V.^>%!BN^F%LD,D #S",RS5.HETC#W
MKJ*UN?/>S1SM"&"L.EH G"1N^;4N4XEC=7(9N+-A%VQ'/P@V"L2R,/"8=#$7
MPL.($.&%=6WD4Z$.VY5>WS9 S.-E@K)09(&KA:&L+)DEFZHFH[O:YP(G(>(O
MI"A-/^9;TOF@'BEJ;74IJK8>*R)/H'AT0EW-$(NN&S(EX6)\FET]OB)[IT/N
M#9O555/[.VU_C[(/&TM.L[?HWK"9,I[#%2#8<R:R%_CW<S9Y,WQS-!Z.Q^/L
M-Q=!,#_SXYU7CULS_MNMF8Z'D\GCUFQ><3+R/8H("@RVU/*Z;B?J!E0-% FY
M\#JQG>9*(5["PK:CB6N/J;-<6?'APUM.Q_M/_Z(-O:QU@](/XCE#=GR&%WPU
M.3L@:H,5MAU/EV KA@3)7N6 73#T8DC4BW;*$'()EL/M'6&]0V]<=/:C6(5W
M*UDF6#F1:Q\QGQ.5Z,*5<#LULE  ;MT#Y(JV7E?-O(D (>)RIVU#5$9U*^VJ
M>X'%+Z:H;*>:',0@ >Y#L2]5:Q;:\4XLF7UPS=QPERJW[3+]X2&-*62TH1H"
MO=TVV.6!C,8*>*)E7F2;@JW!0TZ))G 4"^/5"QH_5KTQ@OB2.71#-HF0>E1*
MW)3*^CLZFD 3@,+X[E<"DXM5TJO>PLHI789AVW?(*&5"[AI+&<QE*,0<K %W
M9;D*!@N9:H \G  2<;#7&)OF>(A05W6IV5,0$3&84;(-F\NU0KK"/OH8LKJW
MT$"YE>H+C-9IQLFE]RM2*BLRC<2)Y_96T=:<M)EMLG]K-#Q-)X%'N.E:EAA9
M.W:;Z86QEO;$3<K:=H7W9MED:QIQ>_."P(&5#"*>OL?9->B0/9^<)/&#G?U:
MN*QWVM#7?B@#@/L8.L%S74+!+*R9H_7;V#4AZN9;8V*:IQAJFZ:#CAO8+]GU
MN*P_<A%7M)*/3<T)HANTP<&].0-20[]K;:%AIDNC::)>GPPJB2D)W5F*AU-\
MVG:-)# H_9%"5 .&"U/1<$%QH0."?;%PE",$*XW"4BFF!,Q)5&>9@9X\IH+5
M6R8RWQ&A:74H;A(;@:?A7A /P_*4]SW2;VK%E_V-*)\;PR6S8>Z0TV]8V$L"
M*CSJ!$3LUN*/1X"](*K T<GF/DI*BELW5'"J4<#H/1Q(LF8G2.VLEV(!.MD*
M69L)GHI>GVUE&=2XD*FG8(/9IFQA/F9"&O7G#8Y >4'Y9T/PIHL6)EA$Q=E$
M=!R]+DJ/!+\_YJS6YR<L9[JRFY&LKY?\HNK-V^P >JTQ2/E[' =;=+>N]G8T
M-GVIXM:YCCEJ+?O2J 6[PMV>YSK6S<,O*B[V2C%%M_.NF_*XP71X2'#OX7K>
M-X/R2[4^XT: Y/(IH0U'XM-VXLLWIV[P]K?$85+D#>9?&-O:H^\36D#YW3A0
MKA)W4[.!8F7F.(QO1+(=)(^<[ZW9L$/4>6'-+;7X9 K@UI0QG440F=29-Y(]
M)WNQN*$/ XVO74BA0&U GRSSIFQS(=N99"40>^ 7<9T</4NXXA%#/.=TA=C2
M/\_<K8C":PC\;A%%'PA(6/#9-9B9;DJ<P)5<(VM'A!L9.I'DHX;S!^GDC= @
MTLB"*:D/O4G5M1:&]M=]VT)?BB>AZ?AH3/KQ>Y*@ -^)#R,?BG5.'VM(ZN7X
M6=:QDO%8LJ)V2-M-QL_24412%R=<HY'#:'E/E$M'%!3GEWX-3%^Q41: Z"P-
M\@[Q:M&X'AU:^=Y4 =+>KD0<Y7*B':RD,S!1'V(K%Q2NP/6>R]I$.K;.>>-N
M>J)"Q>P#]F92NZ/3D+.'CWTD&_4^3%;:+_CS*^/,QO2-<OUT_87W*GW8W"Q/
MGX=_E1ZC 8YL>@[1\>'KEP,</_F3:[J)KN;/G#,7HZOXLM!H5YX6X/W<8?IM
M;VB#]7?OR_\!4$L#!!0    ( .F(CU0> T3-"0,  *T&   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$R+GAM;*55VV[;, Q]]U<(1A]6H(LO29JN2 +T-FQ
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MY4J90F)-;MJ,H%^[Q^E%0'I#Z$F *D09T&T0(\ =TZNS\_0]*;:U499VDUY
M&$]7/"K]Z6>"ZB5I8,%49S9!*"QZ"KGKK].3^6F:T4:1O"02_:= =%HK1.1U
MBO!%ZOSH-HD"& FA257= &OQP4!9I;I)-VJ'N)9+\.)%JTH5-U SZ8Y#20Y8
M=V_"1.>/GY%"B U0(*5%JWQGVKHA7]#7R\;DZX%%7-:(![SN9^G)XA3;LRI,
M1L+13[2LBF,L3=RJ0G,TS2C BQ.>/#AU^NXI1$>KIAC,)(,65=61%9!2R9I
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M;:JZJ-<W<7@2HZ:%8\5(30S7H]*O'LYF$\K*04T=?WK\-X=9!*U8PYZS/8^
M4ZA:(@4QUI.R03>HK]7Z4^MY"@T'0DM4F!5:I5_-9T3U*)U!)4P=YF^Z^E@;
M)M*#/8?*$MK?)I,2#M?QMBXX.Q5S1>ZPEKD8Q@;@7B?M;&NL3VSD"&69/W5X
MB7TM@2QY!$!0LP5"=I.0 92$4ZIO10\2-=,EC8QPGS?*1\@XKCD][/#GPNC5
M-"&A?NK)&CQSBC,YB\!E[10!P701UT%3I#.6,JF"0!U8L"-,P'SL!!*F;)2V
M!A$6B,<LI\<$+?(]XHZH$HK73]*1RW/HI=?K&_: "*$@CN<3JPXY#[L,5*$_
M=W)"TB:0P99M*6YN"=)B&X/3M3:5& (E@K]5!?WOHE_WI%:[?1(X]G0G'(<<
MB[@(LEF]I6P6R>N#^+7+NB>2N]',.!BUFG4O1%D4>^L&V.S"T2I760WOM!J*
MKQ*7.,_]Y,]OTI^9)>=<7H QLW3SF;.&SHM'P, <YJA.@G0^0L)UK*2,M=C^
M#6*JI=PVGM,DY63(HN(%TM.]E-'Y7:$,C%P>!IGC#K'%"9%PT42Q.<BF8)10
M5Z!A+R&.%(ELA'RA"3ER'QUY>'Q\039H4*R^B.2[L'5[_.Q"[,7%A7M[DE[2
MRCCTS^9GBSF*7X_/GI[/'T^PVA<ZLTJWS"E6B_AY4+DD%%R 1P4;[^_OAV6V
M^-##C&SY J$IP?IE@9.P55+Q[R6Q%JQA9^PY[A]T,B\H=C:6<?3Q &@IR9:8
M83<Z1/MQZ+;1!?*07?<ZR/I'@<5E78(2X3UB3E&DHFCAPP4-1J9T5LI.Q,:W
MI0A23.,:-64JE)'\6A>KU21]0T1"L<EW'0'J<I*^QU_(D:],2>XV(7)'B2(]
M1V\ULGV'BJ27TXLIFP@LX&PV?_K@[.]7/[U)3U[P[!OFAT/&_48UI+CYPO/M
MNE\7%"ZLJ!P!?2X2914#;?WQ84D@XCNR?2Y3T/ZVE ))S#E.S_TQ"\_!QU7T
ME.BX=3NXK&V>Y6GJQ!4F;,E0+,2&,P,G)@IJ8-1Y+]D>36/+L/20+<&FB_G\
M)/.%5U(C,CHR(BDSQ<6V]+6ZOH6S">F@S-^BVZC<"9I(>F7SK2H4:&)=EYH)
MP1[I+6MX,!9J3_G3CWV^9D!2D>=+G +EI[\$]/(Z9[&'A0X.KPQHE.LW. #T
M)0W_6E1/B,@N5F'XO!3+2*SH<%1F" O/5(0^(V8P/\&A&$A&U4G&G6UTWML2
ML(V2BYD+.4,+O@F\(\[?AZ5)4JC9]E)E=Y-C7@NUI$W6@'9XC2*7+)?BUD0B
M/Y>8]J%RQ -<M<TK*K%( M5;\R.*3CDDU](:8E!<:0)E,"X(>LOQ*;T-D =W
MFQE4NM0H1).>28/S1RX.H ;)A2,Q_CB?C<H66_81*PJJ ^3Q+EC>-C-]G/=Z
M*,!XNY)XNT2ZQ>T;AC2?U,XDWK)9:Q!L2PV7 F0/;5',%GHCE^(<_99=8<W\
MQ5N26(T$RC;<%^_.L$1G(:;[GVS(8"?\*4?L.:/MB=R8PC<%.2T.;*5D,/(
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M=#:]NC@*77?SX,V6OY1=&N]-P3\W2L)Y: />KXSQS0,A:#^=?O,_4$L#!!0
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MNKV21IHHV,R_2H$--]$"]V3([#S_=+%>.!'5I=S!#E$01,E:4(8-34N:7\7
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M*%C@ ^K*Y\GP!.I<ICD(Q1YV@$6IS!;1 1F?$>U15?KQ^^AUQR,ME&(+WG;
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MA0W!+OCG7$DP(DW ..$K/] &W4?I#_\%4$L#!!0    ( .F(CU0!-5M\KQ@
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MQ6O4J=09]O=Q#H[2ZEV:"15_D/>3N,F9:@&@ /->\+PW7&!BA1W5K&PCOX+
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MMD&;W</A<!]H:6SS*HE:DHJ;_OJ;X8LLIXE1'.Z++8KDS#-O#X>ZV$OU5>\
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M@IY3:+P [:^U=ON)-] ]T!9_ U!+ P04    " #IB(]4CD[',ZL"  ##!0
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M^&P\"HEN1T:[L:KV,ETKBZ+W9H53%K1SP/M2*;O;.()^;B_^ 5!+ P04
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;*U536_;, R]YU<0/FU
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MT<FE15X?GS>8;#CHW!^LHA]]%N*-\H<]_RCO_57A(:_:0T<HDC9"02-4YY*
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M5!8?$GZ8X\L-M"/ _952MIDX!NU;</$_4$L#!!0    ( .F(CU0\4-I*"0(
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MP+@$6B^TQD/@6G-\6-+_4$L#!!0    ( .F(CU2XCII+-P4  , 8   9
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M</;)@M5P3P;'R-:/VDX:.[C>K.W3@LH%V/-22G-PW/1.CU7Z#U!+ P04
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M)!Y[WILWGAGG@S9/M@5 \B*%LJND1>SN*;5E"Y+9F>Y N9-:&\G0F::AMC/
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MMIG#-8?$R>(!N+\40M^=%!4<OD*9_ =02P,$%     @ Z8B/5$:+"GB3!
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MM:&T">;]5@A]"&R![K),_P)02P,$%     @ Z8B/5 @;OP+'!0  "1D  !D
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M+$D6JP>^^0J%0RW#%_)8VG^T*=9Z#@HSJ7A2@+4%"67YE[P60NP! O\ P"\
M_C\ 'Q\ ! 4@.!70+ !6:C=WQ>HP)HH,>H)OD#"K-9MI6#$M6KM/F8G[3 D]
M2S5.#28@5B"NT)C*E$N:QX(MT&WXDM&B_T,0)HF-D[Q"=VP-4NG0*T09NN<Z
M:E0!NAB#(C26ESU7:;L,NQL6-@QS&_P#-GS+X@;"[2OD>SY^G(W1Q:?+(2=B
M,8%D#J*"<%1/.(:P@0+\CK""97PZBU?)XFJQ2\7]4G'?T@8':'?Z2?1T.Y=*
M:&E_UQ ')7%@B9M'B:L4R[$MBS7%8#W GOWUW/6^)O^OVZUX9U:S-*M9:]8V
M0W3FW(\:Z"D/:IW#K9*Y=5XEVR5QN];D[QL&0D8T12F(4//K"EB5UO4L?JOA
M>9]KS.F4YG3J%<R,8H@OT=R<"B1!UWKT!]6?D6%.VMZ+9% =R6YI1_?C"3;L
M'DVP=YM>EYM>?R1]M/L3RFB2):=D%/9VY= [;T[AO4J+SY)51VA\[TA:X5TE
MPOX'M=6C-)-H&A%]MX:0*1J2V!;_\*0CC'=%"P=G%GQ7>'!]Y:D2',W?"N<J
MI:\G[!P\T>[>#6S>2Q,B5I1)%,-2,WF-CCX7(G^"Y!W%4WLIS[G25[QM1OK9
M!L(LT/-+SM6V8^[Y\B$X^ M02P,$%     @ Z8B/5-&*>.S? @  XPL  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#4N>&ULK59=3]LP%/TK5K0'D!B)D[8T
MJ(T$K="00$(@V /:@YO<MA9.W-ENRZ3]^-E.R >E61'I0V,G]QP?G^O<W-&6
MBQ>Y!%#H-669'#M+I5;GKBOC):1$GO(59/K)G(N4*#T5"U>N!)#$@E+F^IXW
M<%-",R<:V7MW(AKQM6(T@SN!Y#I-B?AS"8QOQPYVWF[<T\52F1MN-%J1!3R
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M(J#=!!POE;)/+\Y ^W4S^Q=02P,$%     @ Z8B/5-U(,.1& P  T0L  !D
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M].B!<09T[HJY6[@ _3.:_P502P,$%     @ Z8B/5+J99M*& @  ! <  !D
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M(@(R1/Y-?GP@:^!%X>!0E[MSFPL0:]OD)$IYQ51SL;O5KH^.;?MP7\.;)OR
MQ9HPB2BL--3K7>OTHFELS43QTO:&)5>ZT]AAKO\%($R WE]QKK83DZ#[NR1_
M %!+ P04    " #IB(]4.O7/#'$"   /!P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6R-E5UOFS 4AO^*A7;12EOYAK5*D-IDTW8QJ6K6[6+:A0,G
MP:K!S'8^^N]W; BB(\ER [8Y[^OG'/PQV0GYHDH 3?85K]74*;5N[EQ7Y254
M5-V(!FK\LA*RHAJ[<NVJ1@(MK*CB;N!YB5M15CO9Q(X]RFPB-IJS&AXE49NJ
MHO+U ;C831W?.0P\L76IS8";31JZA@7HY^918L_M70I60:V8J(F$U=2Y]^]F
MJ8FW 3\8[-2@34PF2R%>3.=K,74\ P0<<FT<*+ZV, /.C1%B_.D\G7Y*(QRV
M#^Z?;>Z8RY(JF G^DQ6ZG#H?'5+ BFZX?A*[+]#E$QN_7'!EGV37QD:10_*-
MTJ+JQ$A0L;I]TWU7AX' /R4(.D%PJ2#L!*%-M"6S:<VIIME$BAV1)AK=3,/6
MQJHQ&U:;O[C0$K\RU.GL/L_E!@KR:8_K0H$B5W/0E'%U33Z0Y\6<7+V[GK@:
M9S+Q;MZY/K2NP0G7.>0W)/3?D\ +_"/RV>5R[ZW<Q?SZ)(,^R<#ZA9<F^>M^
MJ;3$)?3[C'O8NX?6/?J/>RXJ8T_-\CQ6LM8EMBYF<VVS)$X\#Q/<#DLS#@MN
MHV'8&\BHAXPN@I2@@,J\)+0N<+EO<1LWN"DU@:XVQ\A;ZV2(% 1C\B-A7GJ2
M/.[)XXO(UU"#I-R"TP*W C._T!P"9]GC$528^F/V<9BI^2GVI&=/+F)GM0:L
MO#X&F(QF_I=M'.''I]G2GBT]R_9=:%/-CO!<"=/1BO2#Z'9<PR-Q7NR/0=W!
M<66NBF]4KEFM"(<5*KV;%"UD>_RV'2T:>X(MA<;ST#9+O+% F@#\OA)"'SKF
M4.SOP.PO4$L#!!0    ( .F(CU1:L-C'.P,  $0+   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4U+GAM;+56;6_:,!#^*U:T29VT-7$"E%: 5*#3*K43:O<F
M3?M@D@.L)G9FF[+^^YV=-$ ++M,V/A#;N>?Q<^?SY7HKJ>[T L"07T4N=#]8
M&%.>A:%.%U P?2Q+$/AF)E7!#$[5/-2E I8Y4)&'<11UPH)Q$0QZ;FVB!CVY
M-#D7,%%$+XN"J8<AY'+5#VCPN'##YPMC%\)!KV1SN 7SN9PHG(4-2\8+$)I+
M013,^L$Y/;N@;0MP%E\XK/3&F%A7IE+>V<EEU@\BJPAR2(VE8/BXAQ'DN65"
M'3]KTJ#9TP(WQX_L[YWSZ,R4:1C)_"O/S*(?= .2P8PM<W,C5Q^@=L@)3&6N
MW3]95;;M*"#I4AM9U&!44'!1/=FO.A ; -K9 XAK0/P4T-H#2&I \A20[ &T
M:D#KT!W:-<"Y'E:^N\"-F6&#GI(KHJPULMF!B[Y#8[RXL(ER:Q2^Y8@S@S%,
M#3D:@V$\UV_(._+Y=DR.7KWIA0;9K4V8UDS#BBG>PT1C<BV%66AR(3+(M@E"
ME-5HBQ^U#6,OXQC28Y+0MR2.8KI#T.AP>+0#/O;#K]D#B5I[T1<';TZ[GE@D
MS3DECB_QG=.ET$8M\9H:\OU\BF.\9C\\Y*V&O.7(6WO(KR03FI3L@4USV'7R
M%;SMX+;TW \P)/>;1_'<HD4C_#5F6\+:C;"V5]A$<9'RDN56G/-;S@B6.VV8
MR+B8$R$->)57_)W]NBKY;8^#6\H[C?*.5_GES3?RT8G[?@W%%)3OG$X:TI-_
MGP3=AKS[=TG0?1;*)U&\Z/Y1$IPVPD[_<Q*<OI0$6[IHM*Z=D5_96@]+4[6$
MC* DLA0EXQGAPH ";7:6TNB9I-@G::.<4Z^DH<)O<OX@R-75B* ^;"S2.S)1
M&*+JRXS#N6+%(6E)X_6N\;]/3+JN?30Y, -8(9=B5T3'-<5F\B6^B*YK(_47
MQT^@"I+CY=B_^9#Z"N3VONO21_VU[[).'Z*8V975XQ?P]#B*7N\*?[C1+12@
MYJY-TR2USE4?YV:U:07/70/T9'U(ST950[>FJ?K+:Z;F'*M)#C.DC(Y/4*JJ
M6K9J8F3I>I*I--CAN.$"VUQ0U@#?SR0F;#VQ&S2-\^ W4$L#!!0    ( .F(
MCU1H^RE>1@0  'T1   9    >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;+U8
MVV[;.!#]%<+8!1(@L$3ZEA2.@=INL@6:(DAZ>2CV@99&-E%)=$DJ;H-^_ XE
M17(2B5%;8_,04S+G<"YG#DE/=U)]U1L 0[XG<:K/>QMCMJ\\3P<;2+CNRRVD
M^$TD5<(-/JJUI[<*>)@;);''?'_L)5RDO=DT?W>M9E.9F5BD<*V(SI*$JQ]S
MB.7NO$=[#R]NQ'IC[ MO-MWR-=R"^;B]5OCD52BA2"#50J9$073>>TU?7;*1
M-<AG?!*PTWMC8D-92?G5/KP-SWN^]0AB"(R%X/AQ!PN(8XN$?GPK07O5FM9P
M?_R ?I$'C\&LN(:%C#^+T&S.>Z<]$D+$L]C<R-T_4 :4.QC(6.?_R:Z<Z_=(
MD&DCD](8/4A$6GSR[V4B]@P&K,6 E0;LB0&C+0:#TF#P=(5AB\&P-!@^7:$M
MAE%I,.IJ,"X-QET-)J7!)"]6D=V\-$MN^&RJY(XH.QO1[""O;VZ-%1&II>*M
M4?BM0#LS6\@D$0:Y933A:4@6,C4B74,:"- GY!VL>4RNN#&@-#E:@N$BUL=$
M;[@"341*/FQDIM%23SV#_EA4+RC7GA=KLY:UEQ#T"1V=$.8S^O%V28[^.IY+
MKL(K2%:@&@ 7;L +6/6)_QBP 679P:T!+5"6$$$:\M0L8BZ2(NP&R#=NR"NN
M,-)Q =D*<M$%9/0"R&7WX/PF$ \)5+&(52QB.>J@!?4Q3;Z\7FFC4&3^=4 /
M*NA!#CUL(R@H(R(1< -$1LBX0*JM5#P7,B/M"Y1@#<1L@/#,;*02]Q ^,/0(
M*5H,C\E/TIJU9>'$.'?"RO?=C/KV;^K=[2?WQ6F/8AQ6,0Z=,;Z7=ZC%F>TW
M$_;)EX+_KNR-*N31H0LSKJ#'3J>KSM!$\QBW,;)5,A$:<\_7N =J0[;8,R@G
M4=34R@7Z:"^5(T<J)Y57$Z=7UZ "%#/<12U;X%LFS*\ZYEY@TO?]OQWI.ZT<
M/?V=FB-)KT0JDBSI0H.S:K&S0]. ^O4.XCLC>2>U)D&U;_PX(2%/L #("YGA
M0>"$W/$X@T8Y]Y^1H.BG-AK0O7V-.KVZQ/RF(:@N::2USM&#"QVME8ZZI>X/
M.VI>PG=M*5K+$W7KTY\WU?R%%5[J*EH+'AVY^RJSU;9^)GG="5<K8<K]8LM3
MB+'%W*>,>;G$OLP/6G)8JR5UR^4S/OY:I]-: .GDX!2M18NZ5>OW>WU>(C?U
M>AM!:WFC9^ZB?WA/YMG]O<%;T@EYFP9=4LIJA6/^H5/*:J%B;J&J"1OD1TP2
MB1B[ZB?)3YQ-9Y42<)^>K#F#;.\ QSIZ$3ZH$+I0*5*C&ZSA,-3B1ZV!S*V!
M[95$=VXD#@RYY"H2$(>=BER+'!L>O,BU*C&W*OT_I]@W[+EP-1UC+YKFC9[W
MH;=WK[0_3. -9(U23V*(T,[O3Q!&%7?]XL'(;7[57$F#%]=\N &.JF<GX/>1
ME.;AP=Y>JU]<9O\!4$L#!!0    ( .F(CU03R=<*_@,  .$/   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4W+GAM;+57T8ZC-A3]%0NUTE;:!FP"R:R22)G,
M3&>E31OM:-J'51\<N$FL!3MK3#(C[<?7!@+I!APJ=>9A@H%S[O'UY=AW<A3R
M:[8#4.@E37@V=79*[3^X;A;M(*790.R!ZR<;(5.J]%!NW6PO@<8%*$U<XGFA
MFU+&G=FDN+>2LXG(5<(XK"3*\C2E\O46$G&<.M@YW?C,MCME;KBSR9YNX0G4
M\WXE]<BM66*6 L^8X$C"9NK,\8='0@R@>.-/!L?L[!J9J:R%^&H&'^.IXQE%
MD$"D# 75/P=80)(8)JWC6T7JU#$-\/SZQ/Y03%Y/9DTS6(CD+Q:KW=09.RB&
M#<T3]5D<'Z&:4&#X(I%DQ7]T+-\-B8.B/%,BK<!:0<IX^4M?JD2< 0CN ) *
M0/H"_ K@]P4,*\#P1\"X Q!4@*!OA+ "A'T!HPHPZ@L85X!QL;KE<A1K>4<5
MG4VD.")IWM9LYJ(HB *MEY!Q4[M/2NJG3./4;"'2E"E=C"I#E,=H(;AB? L\
M8I"]1Y]89.J4;]%\*P'*]][=@:(LR7Z9N$I+,$1N5(6[+<.1CG#SO1P@WWN/
MB$?P\],=>O=3&\NB!PL.KK'<]6'QK['<VUGN(-(SPO]B65%E$M5"]F G^R-2
M-1GIEO1;?Q;+Q!Y[I(>$%A97UUI=<*0N.%+0#CMH?Q<';52YJ2T5#]"7):1K
MD'^C[VA)7UB:I_4M2S"_#N87P?R.8*WE^V6^SI34IFF+,*PC#*W36;($]$?*
M >WI:]JQZO<E1U!PF-WD, NP5_Q-W$-+]*".'EBCE_,3,NN3M+ F#=\H::,Z
MPNA*#?!?]1:5\YBN$T!B7VQC&X"VCWATF3M+YL:UA+%5PD?.%*,)2HK)@@G>
MMG*WXXOH0]O"W=3A;ZSAYZG(N=*;_[><24!*F/)!8H-8/UV+FPM=UH+"7K,?
M>'V4B77"MMK&XI,VQFM-]%06K:;B_;>,X;.="MN5Q3$SA:*S8[+2*M%X5:MA
MX@M5Q%9&N+$S;/>SI5XQXUH\-]^?6<)]X?YH*RDWXKZC[NW@OB(/SW2-NB0U
MIH=]^^=52TDK2]4GW=A\T*6T[(HF_T)3V*6IL4EL]\E+I](B].D3(IJI/NZ%
M&T_$P1OY%VXL$H?_1RV2UB- >%&+OK46&UO%UWQ5MP%,0:]\-DZ)QV^5S\8.
ML=T/5R!U$*6[)5.V$@[ \[;=X/X*3^ -/.]GVS&E,4)B-\)GKILJF3%5^/*3
M[OMVZ"$1DL6T3WY)XVL$OU%^R=FAR^Y2/^17O-)$STL7JMF V_)\A6_4E6;W
MK!4QS>^2RBWC&4I@HXF\P4B7O2S[R7*@Q+[H3M9"Z5ZGN-SI'ARD>4$_WPBA
M3@/3\-1=_>P?4$L#!!0    ( .F(CU3SL,><A (  )D'   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4X+GAM;,556VO;,!3^*\(PV*#$E[A)*$F@31CK8!!:
MMCV4/<CVL2.JBRO)3?/O=R0[)ML2=QN,O=BZG._[SD4ZFN^4?C1; $M>!)=F
M$6RMK:_"T.1;$-2,5 T2=TJE!;4XU55H:@VT\"#!PR2*)J&@3 ;+N5_;Z.5<
M-98S"1M-3",$U?L;X&JW".+@L'#'JJUU"^%R7M,*[L%^KC<:9V'/4C !TC E
MB89R$5S'5^N9L_<&7QCLS-&8N$@RI1[=Y+98!)%S"#CDUC%0_#W#"CAW1.C&
M4\<9])(.>#P^L+_WL6,L&36P4OPK*^QV$<P"4D!)&V[OU.X#=/%<.KY<<>._
M9-?:3J. Y(VQ2G1@]$ PV?[I2Y>'(T"<G@$D'2#Y7<"X XQ_!HS/ -(.D/K,
MM*'X/*RII<NY5CNBG36RN8%/ID=C^$RZLM];C;L,<7:Y4D(PBW6TAE!9D)62
MELD*9,[ 7) [M:?<[LEUI0%:J[=KL)1Q\VX>6G3 T81Y)W;3BB5GQ#Y1/2))
M<D&2*(E/P%?#\(^-/,#CV0GX^C7U/8EBCTY^1(>8M#YS29^YQ-.E9^ANY3-@
M>?2O.2(/GT!DH+\-J(Q[E;%7&9]1.5& A^O,6(T79H@_[?G3P2@VH'-DQ1M.
M5$ETIZ8A![R.!)X:RHE5N/ ,L@%#2JT$,91[\ZPQ2&?,J9,P+)N.HNC-@/N7
MO?N7?^!^3?<^_SBD1<%<8T'W#T%AEZFT,L:[?\KG];!6_(K/D][GR2 /MBA.
M,Z7I7Q^>::\T_2>'9];SS_[+X5D-RT[.%2(\ZH/NT<)^4S%I"(<2B:+1% NL
MVX>@G5A5^]:8*8N-U@^W^':"=@:X7RIE#Q/7;?O7>/D=4$L#!!0    ( .F(
MCU3*49A/YP(  *H)   9    >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;,56
MR6[;,!#]%4*G!FBBS;&=P#;@)45["&K$37LH>J"EL46$(E62LM._[Y"2966Q
MD$L0'RPN,^_-O)&&'.VE>M 9@"&/.1=Z[&7&%->^KY,,<JHO9 $"=S92Y=3@
M5&U]72B@J7/*N1\%0=_/*1/>9.36EFHRDJ7A3,!2$5WF.57_9L#E?NR%WF'A
MCFTS8Q?\R:B@6UB!N2^6"F=^@Y*R'(1F4A %F[$W#:_G86P=G,5/!GO=&A.;
MREK*!SOYEHZ]P$8$'!)C(2@^=C 'SBT2QO&W!O4:3NO8'A_0O[CD,9DUU3"7
M_!=+33;VAAY)84-+;N[D_BO4"5U:O$1R[?[)OK+MHW%2:B/SVADCR)FHGO2Q
M%J+E$/9/.$2U0_3<H7?"(:X=G')^%9E+:T$-G8R4W!-EK1'-#IPVSANS8<*6
M<644[C+T,Y,9U2PA5*1DP7AI("4W5 DFMIH4H,A<YCF*O<JH O)I 88RKL_(
M.=%V18]\@S%8)#^I^6857W2"+XS(K10FT^1&I) ^!? Q^":#Z)#!+.I$7$!R
M0>+P,XF"*'PEH/G;W8..<.)&T-CAQ2?PIL*P\]1JB:\G64%2*F88:/)[NM9&
MX6O[IX.EU[#T'$OO!,L/:2@GA32 =#A*JCI552'PF/ 2U24;)7.[5Y2&NJ_F
M$SL8G;U6NXJT[TAM ]A->M$@P-_(W[4E?6EWM'B2SV63SV5G/BLCDP?RO;!!
MHE2WD*]!=0G5;X#[[UB.0<,R^(AR#%[('%\-A^UR/(EVV$0[[(SV;G7_)HVO
M&KRK=]0X#(ZM*O@(E6O6MLQ1+SBI<MAJK6%GO$L\D4 I#*EZO>=2[$#9'LN$
MD4UO=7MO*$<8'8FC]RS(L=6%\8<4)'ZE#;VLA]\Z]7)06W<9T$A4"E,='\UJ
M<^&8NF/VV?K,7D3<:7J$J6XQMU1M&38D#AN$#"X&V,54=3&H)D86[FQ=2X,G
MM1MF>)D"90UP?R-1G'IB"9KKV>0_4$L#!!0    ( .F(CU1:0,_/?@0  $08
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;+U976_C*!3]*RC22C/2
M3&P@<9-1&JF?VGG(;M5J=A]&^T!BDJ#:D )NVM7^^ 7;->XD)NZ'^]+X@W/O
MY9S+L4TG6R%OU9I2#1[2A*OCWEKKS;<@4(LU38GJBPWEYLY2R)1H<RI7@=I(
M2N(<E"8!"L,H2 GCO>DDOW8EIQ.1Z81Q>B6!RM*4R,=3FHCM<0_VGBY<L]5:
MVPO!=+(A*WI#]8_-E31G014E9BGEB@D.)%T>]T[@MTL\MH!\Q%^,;E7M&-BI
MS(6XM2??X^->:"NB"5UH&X*8GWMZ1I/$1C)UW)5!>U5."ZP?/T6_S"=O)C,G
MBIZ)Y&\6Z_5Q;]0#,5V2+-'78OL[+2<TM/$6(E'Y7[ MQX8]L,B4%FD)-A6D
MC!>_Y*$DH@: 40, E0#T*V#0 , E /\*P V 00D8M,TP+ '#MH"H!$0Y]P59
M.=/G1)/I1(HMD':TB68/<KERM"&8<=M9-UJ:N\S@]/1&B\7MUU.C30S.1&H:
M5A$K^1=P<9<Q_0B^\P7E5GUPE1"NP*=SJ@E+U&?P%:@UD51- FT*L>&"19GT
MM$B*&I)"!&:"Z[4"%SRF\?, @9E!-0WT-(U3Y(UX3A=]@.$7@$($]Q1TYH??
MT$T?A+@1?NZ'S\BC+_G%(;3L SALA%^VGWKHH1)7'8'S> -?1X _-[8+%/@Y
MH^F<RG\\@0=5X$$>&'M;;;[3:N#GR5QI:3S&EV5891FV*%_DY0-CI4H3'C.^
M I\8+QOV\[Z.+:)&>51KQ_=3/!Z-PM!0>E\78W><&_&LX*@J./(6;&7;O]C:
MD']493GJD/Q1E65TF/PRRZ*>I2 >D$ROA63_FML'Y!CMT(RB$-;E>%;@N"IP
M["WPBDK+L'EF K$$/+/TVJ.R/G-DRDYMP44;N?[99RK^7,-^&/[F(16&SJ/#
MM[8(^ _,&&=IEK;I&EA[/, .^P8BEP=]3.><E8GJK3.$,&IL'>B,$?J=L:4,
MY*&U#,XZ89?>"9UYPA;N^3XR[!KE:# :-LO@_!*^V3"-#"]^C$%GI;!++X7.
M3&$+-WW%HPSNFB<V7QJ-S#OSA'Y'>POS+UL9R'DC"CL4 SDC1/!C5L9%F>B9
M/#@:-^J#G(DBOXFVT\?=>1>EG'TBW*52SBO1H,6RV:=4?3UI*E.PH9*)>-\:
M.I #AN"1$JE\!3O317[3;2?;'X+?921A2V;F]2[*.<=%49?*.6-%1Q^@G#]'
M&^6<0R._0[=3[OKF1RL]G ^C<8=Z8.>MV/_>^=H'4!FV[G!PU.AOV'DP]GNP
M_4 V/,?9@J:&Z[>\>F%GJAAU27;ML[O%=_=[/&#.RT3/Z+<O7HT".&O%?ML[
M),"+7[JP,TD\[%(&YW78_W;YZIZ/=D@?#' SY\X4L=^P#G'>TEVP,S4\ZI)I
MYV+8_S99,)UQIM6+B![O;@T@M$MT4-L43:E<Y=O7RBRMC.MB?[2Z6FV1G^0;
MPX$;7NROSXA<,=/0"5T::-@_,JTJBRWKXD2+3;[%.A=:BS0_7%,24VD'F/M+
M(?33B4U0_>-@^C]02P,$%     @ Z8B/5-M?228F P  %0D  !D   !X;"]W
M;W)K<VAE971S+W-H965T-C$N>&ULI5;;;N(P$/V54:25ME(A-Z!0 1*7MMN'
M[E:MVCY4?3!D (LDSMH&RM_OV DI;2';U;Z ;^?,F1F/)]V-D$NU0-3PFL2I
MZCD+K;-SUU73!29,U46&*>W,A$R8IJF<NRJ3R"(+2F(W\+R6FS">.OVN7;N5
M_:Y8Z9BG>"M!K9*$R>T08['I.;ZS6[CC\X4V"VZ_F[$YWJ-^R&XES=R2)>()
MIHJ+%"3.>L[ /Q_YG@'8$X\<-VIO#,:5B1!+,[F.>HYG%&&,4VTH&/VM<81Q
M;)A(Q^^"U"EM&N#^>,=^:9TG9R9,X4C$3SS2BY[3=B#"&5O%^DYL?F#A4-/P
M346L["]LBK.> ].5TB(IP*0@X6G^SUZ+0.P!@O (("@ P0> WS@"" M :!W-
ME5FWQDRS?E>*#4ASFMC,P,;&HLD;GIHTWFM)NYQPNG^OQ719&U(@(AB)A&Z'
M8B:^I_!D(X!1;;!&21F%@:)<9V93P8,Y3Y<(KB1+M8)KVJ.5[V/4C,?J!&I@
MF>%7 7B^P62"\H4VU())5%U7DWPCPIT64H>YU."(5#^ &Y'JA8*+-,+H/8%+
M?I?.!SOGAT$EXQBG=0C]4PB\P#\@:/1UN%<A)RQS$5J^L#(7DT^Y@.?!1&E)
M-_ZEPDJCM-*P5AI'K/Q<F42 F(&R&1)97D\;)B,%<Y-/DTF>%HDZ.92IW$3+
MFC OQ;H?=MIMSZ,PK/<#^/G<VXEWZINE^N9_J*=W2FF61CR=_\V#YA<]^'SN
MB >MTH-699:IC%#N51')I*I!2<5M9%\R+N&1Q2LT3KXOHJLB.5^Z#V>EGK/*
MB.[J'%A1YY*K96TFD49,XZ'851/Z=:_SK4)8NQ36_C=A:Q%3/<1<;P^)JB;S
MPT:]U:B2U2EE=2J9QGS-(TPCV'*,HT-*JO%>W?.J=/C>V]/M53)=O&;4#"E
MYO8<?$^K\2W8(I,*?$C,NPHMB-A6'9+F[C68!.7<]ET%4[%*=?[<EJME;Q_8
MCO9A?6AZOFU<;S3Y!\,-DW-.=SS&&5%Z]3,J/)GWX'RB16;;V$1H:HIVN*#O
M%I3F .W/A-"[B3%0?@GU_P!02P,$%     @ Z8B/5/6!D)CZ P  1P\  !D
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MP/N.- OP_4H(?9P8 \5?*--_ 5!+ P04    " #IB(]4F7%M6XD#  !D"P
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M5EU/VS 4_2M6M >0@'PUY4-M)-HR;0](B(KM >W!36X;B]C.;)?"O]^UDX8
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M4F4\]FUMN\;O C1-:+:M06K=,*SHK0#K%U"^- 9/@>_?X?7)_@!02P,$%
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MS34#]/LUY^K0, &*#R?3?P%02P,$%     @ Z8B/5$#G=+UE @  5 8  !D
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M_0.\OD "BF=$&VX*(]4+,?R9*&[ M8E^+$:[0?#!Y>O3[7;$#!HQ R_0 XH
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M33ZG?IB'+:6)>U?[? ];\!(W>'^PAXO&!C4/^P"Y%A@3"V/R%!@?;6*WZ.B
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M<[;@TCP WYO3R/["_$)>_:LS^0]02P,$%     @ Z8B/5*DT1?$X P  ]A,
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M(0$9GA%ROH"/N_$] $YOQ/1A/$.0$0$970QROI@.$61,0,87@QP.YI\19$)
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M3U(]GL\MU\M?EM\[)_?X!>?ZMF)X^@M02P,$%     @ Z8B/5,X5S%\/ @
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M\=.S[&T[O.2SZ2^^ZS]02P$"% ,4    " #IB(]4!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .F(
MCU2!8!OZ[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( .F(CU297)PC$ 8  )PG   3              "
M <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ Z8B/5 $-&=4A
M!@  ]AD  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( .F(CU2M/0Q4I@8  / ?   8              "
M@64.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #IB(]4
M#+B)._T"  !V"@  &               @(%!%0  >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ Z8B/5"ST9"GR!   7!(  !@
M     ("!=!@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M .F(CU2G-7AP_0@  &@U   8              " @9P=  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " #IB(]4L3.J9/<(   N)P  &
M            @('/)@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ Z8B/5% KX@T7!@  DP\  !@              ("!_"\  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( .F(CU0@I> FOP<  *84
M   8              " @4DV  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " #IB(]4JW+*@Z(7  !@1   &               @($^/@
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ Z8B/5,5ES^!0
M$P  S#8  !D              ("!%E8  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " #IB(]4L)/>I/X(   #%P  &0
M@(&=:0  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .F(
MCU0> T3-"0,  *T&   9              " @=)R  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ Z8B/5 2\J?MK"@  ?AL  !D
M         ("!$G8  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " #IB(]4W.WT(2,#   K!P  &0              @(&T@   >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( .F(CU1\-!IJ?P(  )D%
M   9              " @0Z$  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ Z8B/5-**B2B2!   E0H  !D              ("!Q(8
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #IB(]4SC+X
M-14@  #*8@  &0              @(&-BP  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( .F(CU0'1J JG0,  ',)   9
M  " @=FK  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
MZ8B/5,[.#]G>#@  CR\  !D              ("!K:\  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " #IB(]4!MQ8.YT-  !&+0  &0
M            @('"O@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( .F(CU3WT350K@D  +,9   9              " @9;,  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ Z8B/5)\[!TY[ @
M> 4  !D              ("!>]8  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " #IB(]4RAC+:[\+  "@'@  &0              @($M
MV0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( .F(CU0!
M-5M\KQ@  &I,   9              " @2/E  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ Z8B/5"1!R7)N!P  Z!(  !D
M     ("!"?X  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .F(CU1P1$EZR@(  $0&   9              "
M@984 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ Z8B/
M5*"SYY6] P  K@D  !D              ("!EQ<! 'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " #IB(]4;=U+P7\%   7#@  &0
M        @(&+&P$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( .F(CU0\4-I*"0(  &0$   9              " @4$A 0!X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ Z8B/5+B.FDLW!0  P!@
M !D              ("!@2,! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " #IB(]4'675!?H!   B!   &0              @('O* $
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( .F(CU1'<79(
M& (  +@$   9              " @2 K 0!X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ Z8B/5"?"J_)G @  =08  !D
M ("!;RT! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #I
MB(]40-0+\R0"  ">!   &0              @($-, $ >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( .F(CU3[F\\,@0,  !\+   9
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M970T,RYX;6Q02P$"% ,4    " #IB(]4KP#^=N\"   4"@  &0
M    @(%@2@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M .F(CU31BGCLWP(  .,+   9              " @89- 0!X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ Z8B/5'L<DG&[ P  Z0P  !D
M             ("!G% ! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    " #IB(]4W4@PY$8#  #1"P  &0              @(&.5 $ >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( .F(CU0RCO((1@(
M %(%   9              " @0M8 0!X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ Z8B/5+J99M*& @  ! <  !D              ("!
MB%H! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #IB(]4
M>&U(-T(#  !+"P  &0              @(%%70$ >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;%!+ 0(4 Q0    ( .F(CU1?$D;#( ,  !L*   9
M      " @;Y@ 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%
M  @ Z8B/5!U8/F_4 @  #0D  !D              ("!%60! 'AL+W=O<FMS
M:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #IB(]4_%71&VP"  !I!@
M&0              @($@9P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+
M 0(4 Q0    ( .F(CU0Z]<\,<0(   \'   9              " @<-I 0!X
M;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ Z8B/5%JPV,<[
M P  1 L  !D              ("!:VP! 'AL+W=O<FMS:&5E=',O<VAE970U
M-2YX;6Q02P$"% ,4    " #IB(]4:/LI7D8$  !]$0  &0
M@('=;P$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( .F(
MCU03R=<*_@,  .$/   9              " @5IT 0!X;"]W;W)K<VAE971S
M+W-H965T-3<N>&UL4$L! A0#%     @ Z8B/5/.PQYR$ @  F0<  !D
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M=#8R+GAM;%!+ 0(4 Q0    ( .F(CU2XMK1%D00  $X1   9
M  " @:N* 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @
MZ8B/5)EQ;5N) P  9 L  !D              ("!<X\! 'AL+W=O<FMS:&5E
M=',O<VAE970V-"YX;6Q02P$"% ,4    " #IB(]4Q0L=^,$"  "P"   &0
M            @($SDP$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4
M Q0    ( .F(CU3(C><PX 0   \7   9              " @2N6 0!X;"]W
M;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ Z8B/5#,J=R@= @
MB00  !D              ("!0IL! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX
M;6Q02P$"% ,4    " #IB(]4:>%5J$,#   -#@  &0              @(&6
MG0$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( .F(CU1$
M9]'L]P(  #@(   9              " @1"A 0!X;"]W;W)K<VAE971S+W-H
M965T-CDN>&UL4$L! A0#%     @ Z8B/5 ?&P_ ?!   1!$  !D
M     ("!/J0! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .F(CU3T%U[Y$ (  )$$   9              "
M@=&W 0!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ Z8B/
M5'4'C>2I!0  X1D  !D              ("!&+H! 'AL+W=O<FMS:&5E=',O
M<VAE970W-BYX;6Q02P$"% ,4    " #IB(]4J31%\3@#  #V$P  #0
M        @ 'XOP$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .F(CU27BKL<
MP    !,"   +              "  5O# 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( .F(CU2F+ \BU@4  %TR   /              "  43$ 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " #IB(]4<WQX+%$"  #[+   &@
M    @ %'R@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" #IB(]4SA7,7P\"  #J*P  $P              @ '0S $ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     5 !4  ,7   0SP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>194</ContextCount>
  <ElementCount>464</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>040000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>060100 - Disclosure - Organization and Description of Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperations</Role>
      <ShortName>Organization and Description of Business Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060200 - Disclosure - Liquidity and Capital Resources</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/LiquidityAndCapitalResources</Role>
      <ShortName>Liquidity and Capital Resources</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060300 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Accounting Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060400 - Disclosure - Merger, Disposition and Acquisition Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactions</Role>
      <ShortName>Merger, Disposition and Acquisition Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060500 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/FairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060600 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060700 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060800 - Disclosure - Goodwill and In-Process Research &amp; Development</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopment</Role>
      <ShortName>Goodwill and In-Process Research &amp; Development</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060900 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>061000 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>061100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061200 - Disclosure - Basic and Diluted Earnings per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShare</Role>
      <ShortName>Basic and Diluted Earnings per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>061300 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>061400 - Disclosure - Stockholders' and Members' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/StockholdersAndMembersEquityDeficit</Role>
      <ShortName>Stockholders' and Members' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>061500 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>061600 - Disclosure - Retirement Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/RetirementSavingsPlan</Role>
      <ShortName>Retirement Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>061700 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>070300 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Accounting Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>080400 - Disclosure - Merger, Disposition and Acquisition Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsTables</Role>
      <ShortName>Merger, Disposition and Acquisition Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactions</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>080500 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/FairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/FairValueOfFinancialInstruments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>080600 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/PropertyAndEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>080700 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>080900 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/AccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>081200 - Disclosure - Basic and Diluted Earnings per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareTables</Role>
      <ShortName>Basic and Diluted Earnings per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>081300 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/StockbasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>081500 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>090100 - Disclosure - Organization and Description of Business Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperationsDetails</Role>
      <ShortName>Organization and Description of Business Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperations</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>090200 - Disclosure - Liquidity and Capital Resources (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails</Role>
      <ShortName>Liquidity and Capital Resources (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/LiquidityAndCapitalResources</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>090300 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies, Basis of Accounting Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesBasisOfAccountingPresentationDetails</Role>
      <ShortName>Basis of Accounting Presentation and Summary of Significant Accounting Policies, Basis of Accounting Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>090302 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies, Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails</Role>
      <ShortName>Basis of Accounting Presentation and Summary of Significant Accounting Policies, Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>090304 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies, Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Basis of Accounting Presentation and Summary of Significant Accounting Policies, Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>090306 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies, Segment Reporting (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesSegmentReportingDetails</Role>
      <ShortName>Basis of Accounting Presentation and Summary of Significant Accounting Policies, Segment Reporting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>090400 - Disclosure - Merger, Disposition and Acquisition Transactions, Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails</Role>
      <ShortName>Merger, Disposition and Acquisition Transactions, Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>090402 - Disclosure - Merger, Disposition and Acquisition Transactions, Fair Value of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>Merger, Disposition and Acquisition Transactions, Fair Value of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>090404 - Disclosure - Merger, Disposition and Acquisition Transactions, Disposition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails</Role>
      <ShortName>Merger, Disposition and Acquisition Transactions, Disposition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>090406 - Disclosure - Merger, Disposition and Acquisition Transactions, Pro forma Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsProFormaFinancialInformationDetails</Role>
      <ShortName>Merger, Disposition and Acquisition Transactions, Pro forma Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>090408 - Disclosure - Merger, Disposition and Acquisition Transactions, Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails</Role>
      <ShortName>Merger, Disposition and Acquisition Transactions, Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>090410 - Disclosure - Merger, Disposition and Acquisition Transactions, Investment in NoveCite (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails</Role>
      <ShortName>Merger, Disposition and Acquisition Transactions, Investment in NoveCite (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>090500 - Disclosure - Fair Value of Financial Instruments, Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>Fair Value of Financial Instruments, Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>090502 - Disclosure - Fair Value of Financial Instruments, Carrying Amount of Contingent Consideration Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Instruments, Carrying Amount of Contingent Consideration Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>090600 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>090700 - Disclosure - Leases, Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/LeasesOperatingLeaseDetails</Role>
      <ShortName>Leases, Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>090702 - Disclosure - Leases, Net Operating Lease Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails</Role>
      <ShortName>Leases, Net Operating Lease Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>090704 - Disclosure - Leases, Operating Lease Right-of-use Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails</Role>
      <ShortName>Leases, Operating Lease Right-of-use Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>090706 - Disclosure - Leases, Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases, Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>090708 - Disclosure - Leases, Sublease Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/LeasesSubleaseAgreementDetails</Role>
      <ShortName>Leases, Sublease Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>090800 - Disclosure - Goodwill and In-Process Research &amp; Development (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopmentDetails</Role>
      <ShortName>Goodwill and In-Process Research &amp; Development (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopment</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>090900 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/AccruedExpensesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>091000 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/Debt</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>091100 - Disclosure - Commitments and Contingencies, Legal Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails</Role>
      <ShortName>Commitments and Contingencies, Legal Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>091102 - Disclosure - Commitments and Contingencies, Licensing Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies, Licensing Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>091104 - Disclosure - Commitments and Contingencies, Royalty Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies, Royalty Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>091200 - Disclosure - Basic and Diluted Earnings per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails</Role>
      <ShortName>Basic and Diluted Earnings per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>091300 - Disclosure - Stock-Based Compensation, Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails</Role>
      <ShortName>Stock-Based Compensation, Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>091302 - Disclosure - Stock-Based Compensation, Weighted-Average Assumptions Used for Grants Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails</Role>
      <ShortName>Stock-Based Compensation, Weighted-Average Assumptions Used for Grants Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>091304 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation, Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>091306 - Disclosure - Stock-Based Compensation, Summary of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation, Summary of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>091308 - Disclosure - Stock-Based Compensation, RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/StockbasedCompensationRsusDetails</Role>
      <ShortName>Stock-Based Compensation, RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/StockbasedCompensationTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>091310 - Disclosure - Stock-Based Compensation, Restricted Stock and Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation, Restricted Stock and Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>091400 - Disclosure - Stockholders' and Members' Equity (Deficit), Private Placement Offerings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails</Role>
      <ShortName>Stockholders' and Members' Equity (Deficit), Private Placement Offerings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/StockholdersAndMembersEquityDeficit</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>091402 - Disclosure - Stockholders' and Members' Equity (Deficit), Reverse Stock-Split (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitReverseStocksplitDetails</Role>
      <ShortName>Stockholders' and Members' Equity (Deficit), Reverse Stock-Split (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/StockholdersAndMembersEquityDeficit</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>091404 - Disclosure - Stockholders' and Members' Equity (Deficit), Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails</Role>
      <ShortName>Stockholders' and Members' Equity (Deficit), Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/StockholdersAndMembersEquityDeficit</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>091406 - Disclosure - Stockholders' and Members' Equity (Deficit), Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails</Role>
      <ShortName>Stockholders' and Members' Equity (Deficit), Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/StockholdersAndMembersEquityDeficit</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>091408 - Disclosure - Stockholders' and Members' Equity (Deficit), Cumulative Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails</Role>
      <ShortName>Stockholders' and Members' Equity (Deficit), Cumulative Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/StockholdersAndMembersEquityDeficit</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>091500 - Disclosure - Income Taxes, Loss before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes, Loss before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>091502 - Disclosure - Income Taxes, Components of Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails</Role>
      <ShortName>Income Taxes, Components of Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>091504 - Disclosure - Income Taxes, Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes, Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>091506 - Disclosure - Income Taxes, Reconciliation of Computed Expected Income Taxes to Effective Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails</Role>
      <ShortName>Income Taxes, Reconciliation of Computed Expected Income Taxes to Effective Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>091600 - Disclosure - Retirement Savings Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/RetirementSavingsPlanDetails</Role>
      <ShortName>Retirement Savings Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/RetirementSavingsPlan</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="brhc10036185_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>091700 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://brooklynitx.com/role/SubsequentEvents</ParentRole>
      <Position>76</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="brhc10036185_10k.htm">brhc10036185_10k.htm</File>
    <File>brhc10036185_ex10-26.htm</File>
    <File>brhc10036185_ex21-1.htm</File>
    <File>brhc10036185_ex23-1.htm</File>
    <File>brhc10036185_ex31-1.htm</File>
    <File>brhc10036185_ex31-2.htm</File>
    <File>brhc10036185_ex32-1.htm</File>
    <File>brhc10036185_ex32-2.htm</File>
    <File>brhc10036185_ex4-1.htm</File>
    <File>btx-20211231.xsd</File>
    <File>btx-20211231_cal.xml</File>
    <File>btx-20211231_def.xml</File>
    <File>btx-20211231_lab.xml</File>
    <File>btx-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image00003.jpg</File>
    <File>image00004.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="702">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10036185_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "contextCount": 194,
   "dts": {
    "calculationLink": {
     "local": [
      "btx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "btx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "brhc10036185_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "btx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "btx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "btx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 699,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 4,
    "http://xbrl.sec.gov/dei/2021q4": 6,
    "total": 10
   },
   "keyCustom": 124,
   "keyStandard": 340,
   "memberCustom": 34,
   "memberStandard": 28,
   "nsprefix": "btx",
   "nsuri": "http://brooklynitx.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://brooklynitx.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060400 - Disclosure - Merger, Disposition and Acquisition Transactions",
     "role": "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactions",
     "shortName": "Merger, Disposition and Acquisition Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060500 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://brooklynitx.com/role/FairValueOfFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060600 - Disclosure - Property and Equipment",
     "role": "http://brooklynitx.com/role/PropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060700 - Disclosure - Leases",
     "role": "http://brooklynitx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060800 - Disclosure - Goodwill and In-Process Research & Development",
     "role": "http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopment",
     "shortName": "Goodwill and In-Process Research & Development",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060900 - Disclosure - Accrued Expenses",
     "role": "http://brooklynitx.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061000 - Disclosure - Debt",
     "role": "http://brooklynitx.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061100 - Disclosure - Commitments and Contingencies",
     "role": "http://brooklynitx.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061200 - Disclosure - Basic and Diluted Earnings per Common Share",
     "role": "http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShare",
     "shortName": "Basic and Diluted Earnings per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061300 - Disclosure - Stock-Based Compensation",
     "role": "http://brooklynitx.com/role/StockbasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010000 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061400 - Disclosure - Stockholders' and Members' Equity (Deficit)",
     "role": "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficit",
     "shortName": "Stockholders' and Members' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061500 - Disclosure - Income Taxes",
     "role": "http://brooklynitx.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061600 - Disclosure - Retirement Savings Plan",
     "role": "http://brooklynitx.com/role/RetirementSavingsPlan",
     "shortName": "Retirement Savings Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061700 - Disclosure - Subsequent Events",
     "role": "http://brooklynitx.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070300 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Accounting Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080400 - Disclosure - Merger, Disposition and Acquisition Transactions (Tables)",
     "role": "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsTables",
     "shortName": "Merger, Disposition and Acquisition Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080500 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080600 - Disclosure - Property and Equipment (Tables)",
     "role": "http://brooklynitx.com/role/PropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080700 - Disclosure - Leases (Tables)",
     "role": "http://brooklynitx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080900 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://brooklynitx.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081200 - Disclosure - Basic and Diluted Earnings per Common Share (Tables)",
     "role": "http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareTables",
     "shortName": "Basic and Diluted Earnings per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081300 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://brooklynitx.com/role/StockbasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081500 - Disclosure - Income Taxes (Tables)",
     "role": "http://brooklynitx.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210716_BusinessAcquisitionAxis_NoveCiteINCMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090100 - Disclosure - Organization and Description of Business Operations (Details)",
     "role": "http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperationsDetails",
     "shortName": "Organization and Description of Business Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090200 - Disclosure - Liquidity and Capital Resources (Details)",
     "role": "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
     "shortName": "Liquidity and Capital Resources (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "0",
      "lang": null,
      "name": "btx:NetIncomeLossAttributableToParentTemporaryElement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090300 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies, Basis of Accounting Presentation (Details)",
     "role": "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesBasisOfAccountingPresentationDetails",
     "shortName": "Basis of Accounting Presentation and Summary of Significant Accounting Policies, Basis of Accounting Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashEquivalentsAtCarryingValue",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090302 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies, Cash and Cash Equivalents (Details)",
     "role": "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails",
     "shortName": "Basis of Accounting Presentation and Summary of Significant Accounting Policies, Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashEquivalentsAtCarryingValue",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryAndManufacturingEquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090304 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies, Property and Equipment (Details)",
     "role": "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "shortName": "Basis of Accounting Presentation and Summary of Significant Accounting Policies, Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryAndManufacturingEquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U005",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090306 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies, Segment Reporting (Details)",
     "role": "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesSegmentReportingDetails",
     "shortName": "Basis of Accounting Presentation and Summary of Significant Accounting Policies, Segment Reporting (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U005",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090400 - Disclosure - Merger, Disposition and Acquisition Transactions, Merger (Details)",
     "role": "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails",
     "shortName": "Merger, Disposition and Acquisition Transactions, Merger (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090402 - Disclosure - Merger, Disposition and Acquisition Transactions, Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
     "shortName": "Merger, Disposition and Acquisition Transactions, Fair Value of Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210325_BusinessAcquisitionAxis_NTNBuzztimeIncMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090404 - Disclosure - Merger, Disposition and Acquisition Transactions, Disposition (Details)",
     "role": "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails",
     "shortName": "Merger, Disposition and Acquisition Transactions, Disposition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210326to20210326_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_NTNBusinessMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090406 - Disclosure - Merger, Disposition and Acquisition Transactions, Pro forma Financial Information (Details)",
     "role": "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsProFormaFinancialInformationDetails",
     "shortName": "Merger, Disposition and Acquisition Transactions, Pro forma Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090408 - Disclosure - Merger, Disposition and Acquisition Transactions, Acquisition (Details)",
     "role": "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
     "shortName": "Merger, Disposition and Acquisition Transactions, Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210716to20210716_AssetAcquisitionAxis_NovellusTherapeuticsLimitedMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090410 - Disclosure - Merger, Disposition and Acquisition Transactions, Investment in NoveCite (Details)",
     "role": "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails",
     "shortName": "Merger, Disposition and Acquisition Transactions, Investment in NoveCite (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210716to20210716_BusinessAcquisitionAxis_NoveCiteINCMember",
      "decimals": "INF",
      "lang": null,
      "name": "btx:NumberOfBoardSeats",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U006",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090500 - Disclosure - Fair Value of Financial Instruments, Liabilities Measured at Fair Value (Details)",
     "role": "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails",
     "shortName": "Fair Value of Financial Instruments, Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "btx:PercentageOfRoyaltyRevenueAssumedUntil2029",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090502 - Disclosure - Fair Value of Financial Instruments, Carrying Amount of Contingent Consideration Liabilities (Details)",
     "role": "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails",
     "shortName": "Fair Value of Financial Instruments, Carrying Amount of Contingent Consideration Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "btx:PercentageOfRoyaltyRevenueAssumedUntil2029",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090600 - Disclosure - Property and Equipment (Details)",
     "role": "http://brooklynitx.com/role/PropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "btx:OperatingLeaseArea",
      "reportCount": 1,
      "unitRef": "U007",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090700 - Disclosure - Leases, Operating Lease (Details)",
     "role": "http://brooklynitx.com/role/LeasesOperatingLeaseDetails",
     "shortName": "Leases, Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "2",
      "lang": null,
      "name": "btx:AnnualRentPerSquareFoot",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U007",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090702 - Disclosure - Leases, Net Operating Lease Expenses (Details)",
     "role": "http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails",
     "shortName": "Leases, Net Operating Lease Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20191231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "030000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY (DEFICIT)",
     "role": "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20191231_StatementClassOfStockAxis_CommonClassAMember_StatementEquityComponentsAxis_MembershipEquityMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090704 - Disclosure - Leases, Operating Lease Right-of-use Assets and Liabilities (Details)",
     "role": "http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails",
     "shortName": "Leases, Operating Lease Right-of-use Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "0",
      "lang": null,
      "name": "btx:AdditionOfOperatingLeaseRightofUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090706 - Disclosure - Leases, Maturities of Operating Lease Liabilities (Details)",
     "role": "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases, Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20190418",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "btx:AreaOfSubleaseSpaceCurrentlyRented",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U008",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090708 - Disclosure - Leases, Sublease Agreement (Details)",
     "role": "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails",
     "shortName": "Leases, Sublease Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20190418",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "btx:AreaOfSubleaseSpaceCurrentlyRented",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U008",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090800 - Disclosure - Goodwill and In-Process Research & Development (Details)",
     "role": "http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopmentDetails",
     "shortName": "Goodwill and In-Process Research & Development (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090900 - Disclosure - Accrued Expenses (Details)",
     "role": "http://brooklynitx.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LoansPayableCurrent",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091000 - Disclosure - Debt (Details)",
     "role": "http://brooklynitx.com/role/DebtDetails",
     "shortName": "Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231_DebtInstrumentAxis_PaycheckProtectionProgramLoanMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LoansPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091100 - Disclosure - Commitments and Contingencies, Legal Matters (Details)",
     "role": "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
     "shortName": "Commitments and Contingencies, Legal Matters (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210205to20210205_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember",
      "decimals": "0",
      "lang": null,
      "name": "btx:LossContingencyDamagesSoughtExpectedSalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "btx:MilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091102 - Disclosure - Commitments and Contingencies, Licensing Agreements (Details)",
     "role": "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
     "shortName": "Commitments and Contingencies, Licensing Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_NovellusTherapeuticsLimitedMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "btx:MilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210322to20210322_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "btx:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091104 - Disclosure - Commitments and Contingencies, Royalty Agreements (Details)",
     "role": "http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails",
     "shortName": "Commitments and Contingencies, Royalty Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210322to20210322_TypeOfArrangementAxis_InvestorRoyaltyAgreementMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "btx:PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091200 - Disclosure - Basic and Diluted Earnings per Common Share (Details)",
     "role": "http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails",
     "shortName": "Basic and Diluted Earnings per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "040000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231_AwardTypeAxis_EmployeeStockOptionMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091300 - Disclosure - Stock-Based Compensation, Equity Incentive Plans (Details)",
     "role": "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails",
     "shortName": "Stock-Based Compensation, Equity Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231_PlanNameAxis_EquityIncentivePlan2020Member",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091302 - Disclosure - Stock-Based Compensation, Weighted-Average Assumptions Used for Grants Issued (Details)",
     "role": "http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails",
     "shortName": "Stock-Based Compensation, Weighted-Average Assumptions Used for Grants Issued (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20201231_AwardTypeAxis_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091304 - Disclosure - Stock-Based Compensation, Stock Option Activity (Details)",
     "role": "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation, Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "btx:NumberOfStockOptionGrantMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U012",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091306 - Disclosure - Stock-Based Compensation, Summary of Stock Options (Details)",
     "role": "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
     "shortName": "Stock-Based Compensation, Summary of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "btx:NumberOfStockOptionGrantMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U012",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20201231_AwardTypeAxis_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091308 - Disclosure - Stock-Based Compensation, RSUs (Details)",
     "role": "http://brooklynitx.com/role/StockbasedCompensationRsusDetails",
     "shortName": "Stock-Based Compensation, RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091310 - Disclosure - Stock-Based Compensation, Restricted Stock and Stock-Based Compensation Expense (Details)",
     "role": "http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation, Restricted Stock and Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091400 - Disclosure - Stockholders' and Members' Equity (Deficit), Private Placement Offerings (Details)",
     "role": "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails",
     "shortName": "Stockholders' and Members' Equity (Deficit), Private Placement Offerings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210426_LegalEntityAxis_LincolnParkCapitalFundLLCMember_RangeAxis_MaximumMember",
      "decimals": "-5",
      "lang": null,
      "name": "btx:CommitmentAmountToMeetAnySingleRegularPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210325to20210325",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091402 - Disclosure - Stockholders' and Members' Equity (Deficit), Reverse Stock-Split (Details)",
     "role": "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitReverseStocksplitDetails",
     "shortName": "Stockholders' and Members' Equity (Deficit), Reverse Stock-Split (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210325to20210325",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210325to20210325",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "btx:StockIssuedDuringPeriodSharesAcquisitions1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091404 - Disclosure - Stockholders' and Members' Equity (Deficit), Merger (Details)",
     "role": "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails",
     "shortName": "Stockholders' and Members' Equity (Deficit), Merger (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210325to20210325",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "btx:StockIssuedDuringPeriodSharesAcquisitions1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091406 - Disclosure - Stockholders' and Members' Equity (Deficit), Acquisition (Details)",
     "role": "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails",
     "shortName": "Stockholders' and Members' Equity (Deficit), Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210716to20210716_BusinessAcquisitionAxis_NovellusTherapeuticsLimitedMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesAcquisitions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060100 - Disclosure - Organization and Description of Business Operations",
     "role": "http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperations",
     "shortName": "Organization and Description of Business Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "us-gaap:PreferredStockSharesIssued",
       "us-gaap:PreferredStockSharesOutstanding",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091408 - Disclosure - Stockholders' and Members' Equity (Deficit), Cumulative Convertible Preferred Stock (Details)",
     "role": "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails",
     "shortName": "Stockholders' and Members' Equity (Deficit), Cumulative Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "us-gaap:PreferredStockSharesOutstanding",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231_StatementClassOfStockAxis_SeriesAPreferredStockMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091500 - Disclosure - Income Taxes, Loss before Income Taxes (Details)",
     "role": "http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes, Loss before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091502 - Disclosure - Income Taxes, Components of Income Tax Provision (Details)",
     "role": "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails",
     "shortName": "Income Taxes, Components of Income Tax Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "btx:DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091504 - Disclosure - Income Taxes, Deferred Tax Assets and Liabilities (Details)",
     "role": "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes, Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "btx:DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091506 - Disclosure - Income Taxes, Reconciliation of Computed Expected Income Taxes to Effective Income Taxes (Details)",
     "role": "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails",
     "shortName": "Income Taxes, Reconciliation of Computed Expected Income Taxes to Effective Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091600 - Disclosure - Retirement Savings Plan (Details)",
     "role": "http://brooklynitx.com/role/RetirementSavingsPlanDetails",
     "shortName": "Retirement Savings Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepositAssets",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091700 - Disclosure - Subsequent Events (Details)",
     "role": "http://brooklynitx.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20220103to20220103_SubsequentEventTypeAxis_SubsequentEventMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U014",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "btx:LiquidityAndCapitalResourcesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060200 - Disclosure - Liquidity and Capital Resources",
     "role": "http://brooklynitx.com/role/LiquidityAndCapitalResources",
     "shortName": "Liquidity and Capital Resources",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "btx:LiquidityAndCapitalResourcesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060300 - Disclosure - Basis of Accounting Presentation and Summary of Significant Accounting Policies",
     "role": "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Basis of Accounting Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10036185_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 67,
   "tag": {
    "btx_AccruedGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued general and administrative expenses.",
        "label": "Accrued General and Administrative Expenses",
        "terseLabel": "Accrued general and administrative expenses"
       }
      }
     },
     "localname": "AccruedGeneralAndAdministrativeExpenses",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued research and development expenses.",
        "label": "Accrued Research and Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_AcquisitionAgreementNonCompetitivePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Acquisition Agreement contains non-competition and non-solicitation provisions pursuant to which the Seller has agreed not to engage in certain competitive activities for a period in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquisition Agreement, Non Competitive Period",
        "terseLabel": "Non-compete period"
       }
      }
     },
     "localname": "AcquisitionAgreementNonCompetitivePeriod",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btx_AdditionOfOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Addition of operating lease liability.",
        "label": "Addition of operating lease liability",
        "terseLabel": "Addition of operating lease liabilities"
       }
      }
     },
     "localname": "AdditionOfOperatingLeaseLiability",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_AdditionOfOperatingLeaseRightofUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Addition of operating lease right-of -use asset.",
        "label": "Addition of operating lease right-of -use asset",
        "terseLabel": "Addition of operating lease ROU assets"
       }
      }
     },
     "localname": "AdditionOfOperatingLeaseRightofUseAsset",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_AdditionalFeesObligatedToPay": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entity is obligated to pay additional fees to Licensors.",
        "label": "Additional Fees Obligated to Pay",
        "terseLabel": "Amount require to pay of initial license fees"
       }
      }
     },
     "localname": "AdditionalFeesObligatedToPay",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in redemption of temporary equity as the result of a triggering event associated with the temporary equity.",
        "label": "Adjustments to Additional Paid in Capital, Elimination Historical Member Equity",
        "terseLabel": "Elimination of Brooklyn's historical members' equity"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_AggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "localname": "AggregateIntrinsicValueAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_AmountObligatedToPayInYearOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entity is obligated to pay additional fees to the Licensors in first year.",
        "label": "Amount Obligated to Pay in Year One",
        "terseLabel": "Additional fees obligated to pay in 2021"
       }
      }
     },
     "localname": "AmountObligatedToPayInYearOne",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_AmountObligatedToPayInYearTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entity is obligated to pay additional fees to the Licensors in second year.",
        "label": "Amount Obligated to Pay in Year Two",
        "terseLabel": "Additional fees obligated to pay in 2022"
       }
      }
     },
     "localname": "AmountObligatedToPayInYearTwo",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_AmountRequireToPayInitialLicenseFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount require to pay out of the total initial license fees.",
        "label": "Amount Require to Pay Initial License Fees",
        "terseLabel": "Amount obligated to pay in license agreement"
       }
      }
     },
     "localname": "AmountRequireToPayInitialLicenseFees",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_AnnualRentPerSquareFoot": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense per square foot for leased asset.",
        "label": "Annual Rent Per Square Foot",
        "terseLabel": "Annual rent (per square foot)"
       }
      }
     },
     "localname": "AnnualRentPerSquareFoot",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "btx_AreaOfSubleaseSpaceCurrentlyRented": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The subleases rentable area for properties currently rented.",
        "label": "Area of Sublease, Space Currently Rented",
        "terseLabel": "Currently rented area"
       }
      }
     },
     "localname": "AreaOfSubleaseSpaceCurrentlyRented",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "btx_AssetAcquisitionFairValueOfConsiderationPaid": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fair value of consideration paid in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Fair Value of Consideration Paid",
        "totalLabel": "Total fair value of consideration paid"
       }
      }
     },
     "localname": "AssetAcquisitionFairValueOfConsiderationPaid",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_AssetAcquisitionRestrictedSharesSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered with restrictions to be paid in asset acquisition.",
        "label": "Asset Acquisition, Restricted Shares, Share Price",
        "terseLabel": "Restricted shares, fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "AssetAcquisitionRestrictedSharesSharePrice",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "btx_AssetAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in asset acquisition.",
        "label": "Asset Acquisition, Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "AssetAcquisitionSharePrice",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "btx_AssetAcquisitionUnrestrictedSharesSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered without any restrictions to be paid in asset acquisition.",
        "label": "Asset Acquisition, Unrestricted Shares, Share Price",
        "terseLabel": "Unrestricted shares, fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "AssetAcquisitionUnrestrictedSharesSharePrice",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "btx_BaseRentPerSquareFoot": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of base rent expense per square foot for leased asset.",
        "label": "Base Rent per Square Foot",
        "terseLabel": "Base rent (per square foot)"
       }
      }
     },
     "localname": "BaseRentPerSquareFoot",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "btx_BasisOfPresentationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation [Abstract]",
        "terseLabel": "Basis of Presentation [Abstract]"
       }
      }
     },
     "localname": "BasisOfPresentationAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesBasisOfAccountingPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_BeneficialHoldersContractualCommitmentsToInvest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual commitment made by beneficial holders to invest in the entity.",
        "label": "Beneficial Holders Contractual Commitments To Invest",
        "terseLabel": "Beneficial holders contractual commitments to invest"
       }
      }
     },
     "localname": "BeneficialHoldersContractualCommitmentsToInvest",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_BeneficialOwnershipPercentageOnTotalOutstandingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of shareholders, partners or other equity holders in consolidated entity.",
        "label": "Beneficial Ownership Percentage on Total Outstanding Shares",
        "terseLabel": "Beneficial ownership percentage on total outstanding shares that prohibits company to direct share purchases"
       }
      }
     },
     "localname": "BeneficialOwnershipPercentageOnTotalOutstandingShares",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_BrooklynPaycheckProtectionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Paycheck Protection Program for Brooklyn.",
        "label": "Brooklyn Paycheck Protection Program [Member]"
       }
      }
     },
     "localname": "BrooklynPaycheckProtectionProgramMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of software development costs recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Software Development Costs",
        "terseLabel": "Software development costs"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSoftwareDevelopmentCosts",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_CashPaidDuringThePeriodForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid During the Period for [Abstract]",
        "terseLabel": "Cash paid during the period for:"
       }
      }
     },
     "localname": "CashPaidDuringThePeriodForAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of chairman of the board of directors, chief executive officer and president.",
        "label": "Chairman of the Board of Directors Chief Executive Officer and President [Member]",
        "terseLabel": "Chair of the Board of Directors, Chief Executive Officer and President [Member]",
        "verboseLabel": "Chairman of the Board of Directors, Chief Executive Officer and President [Member]"
       }
      }
     },
     "localname": "ChairmanOfTheBoardOfDirectorsChiefExecutiveOfficerAndPresidentMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_CitiusPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Citius Pharmaceuticals, Inc. Ownership interest.",
        "label": "Citius Pharmaceuticals, Inc. [Member]"
       }
      }
     },
     "localname": "CitiusPharmaceuticalsIncMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued into which the class of warrant or right may be converted.",
        "label": "Class of Warrant or Right, Issued",
        "terseLabel": "Number of rights options issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "btx_ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of securities that would be issuable upon the exercise of warrants or rights.",
        "label": "Class of Warrant or Right Percent of Securities that Would be Issuable Upon Exercise of Warrants or Rights",
        "terseLabel": "Percentage of warrants exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPercentOfSecuritiesThatWouldBeIssuableUponExerciseOfWarrantsOrRights",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_ClassOfWarrantOrRightsExercisableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants or rights exercisable term, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Class of Warrant or Rights Exercisable Term",
        "terseLabel": "Warrant exercisable term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsExercisableTerm",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btx_CollaboratorRoyaltyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative royalty arrangement in licensing deal with the company.",
        "label": "Collaborator Royalty Agreement [Member]",
        "terseLabel": "Collaborator Royalty Agreement [Member]"
       }
      }
     },
     "localname": "CollaboratorRoyaltyAgreementMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_CommencementPeriodOfCommonStockInPurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for common stock purchase agreement commencement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Commencement Period of Common Stock in Purchase Agreement",
        "terseLabel": "Common stock purchase agreement commencement period"
       }
      }
     },
     "localname": "CommencementPeriodOfCommonStockInPurchaseAgreement",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btx_CommitmentAmountToMeetAnySingleRegularPurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchase price or commitment amount to meet any single regular purchase in share purchase transaction on any business day.",
        "label": "Commitment Amount to Meet any Single Regular Purchase",
        "terseLabel": "Maximum commitment in any single regular purchase"
       }
      }
     },
     "localname": "CommitmentAmountToMeetAnySingleRegularPurchase",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_CommonUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than provided to common units, representing ownership interest in a corporation.",
        "label": "Common Units [Member]",
        "terseLabel": "Common Units [Member]",
        "verboseLabel": "Common [Member]"
       }
      }
     },
     "localname": "CommonUnitsMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_CommonWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A common warrant represents the right to purchase a company's stock at a specific price and at a specific date.",
        "label": "Common Warrants [Member]",
        "terseLabel": "Common Warrants [Member]"
       }
      }
     },
     "localname": "CommonWarrantsMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration [Member]"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails",
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_DebtInstrumentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Abstract]",
        "terseLabel": "Debt Instrument [Abstract]"
       }
      }
     },
     "localname": "DebtInstrumentAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards excluding foreign purpose.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards Excluding Foreign",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_DetailedInformationAboutLiquidityAndCapitalResourcesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Detailed information about Liquidity and Capital Resources [Abstract]",
        "verboseLabel": "Liquidity and Capital Resources [Abstract]"
       }
      }
     },
     "localname": "DetailedInformationAboutLiquidityAndCapitalResourcesAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_DheshGovenderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dhesh Govender, a former short-term consultant of the entity",
        "label": "Dhesh Govender [Member]",
        "terseLabel": "Govender [Member]"
       }
      }
     },
     "localname": "DheshGovenderMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_DisposalGroupIncludingDiscontinuedOperationLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as Lease liability attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Lease liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationLeaseLiability",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as Obligations under finance leases attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Obligations under finance leases",
        "terseLabel": "Obligations under finance leases"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationObligationsUnderFinanceLeases",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate proceeds received from assume advance/loans in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Disposal Group, Including Discontinued Operation, Proceeds from Assume Advance/Loans",
        "terseLabel": "Assume advance/loans"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationProceedsFromAssumeAdvanceLoans",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Disposal Group, Including Discontinued Operation, Proceeds from Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationProceedsFromCash",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate proceeds received from escrow deposits in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Disposal Group, Including Discontinued Operation, Proceeds from Escrow",
        "terseLabel": "Escrow"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationProceedsFromEscrow",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate proceeds received from interest on advance/loans in a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Disposal Group, Including Discontinued Operation, Proceeds from Interest on Advance/Loans",
        "terseLabel": "Interest on advance/loans"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationProceedsFromInterestOnAdvanceLoans",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as software development cost attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Software development costs",
        "negatedLabel": "Software development costs"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationSoftwareDevelopmentCosts",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_DisposalGroupIncludingDiscontinuedOperationTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of the business disposal including legal, accounting, and other costs incurred to consummate the business disposition.",
        "label": "Disposal Group, Including Discontinued Operation, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationTransactionCosts",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_DispositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposition [Abstract]"
       }
      }
     },
     "localname": "DispositionAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_EachLockUpAgreementExtendsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of lock-up agreement extend term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Each Lock-up Agreement Extends Term",
        "terseLabel": "Each lock-up agreement extend term"
       }
      }
     },
     "localname": "EachLockUpAgreementExtendsTerm",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btx_EffectOfImplementationOfNewAccountingPrincipal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effect of implementation of due to new accounting principal.",
        "label": "Effect of Implementation of New Accounting Principal",
        "terseLabel": "Implementation of new accounting principle"
       }
      }
     },
     "localname": "EffectOfImplementationOfNewAccountingPrincipal",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to decrease in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Decrease in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_EquityIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation equity incentive plan 2020.",
        "label": "Equity Incentive Plan 2020 [Member]",
        "terseLabel": "2020 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlan2020Member",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_EscrowPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of secure indemnification obligations to acquisition agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Escrow Period",
        "terseLabel": "Period of escrow"
       }
      }
     },
     "localname": "EscrowPeriod",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btx_EscrowShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares have been placed in escrow shares.",
        "label": "Escrow Shares",
        "terseLabel": "Escrow shares (in shares)"
       }
      }
     },
     "localname": "EscrowShares",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "btx_FirstPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about purchase agreement between the entities.",
        "label": "First Purchase Agreement [Member]",
        "terseLabel": "First Purchase Agreement [Member]"
       }
      }
     },
     "localname": "FirstPurchaseAgreementMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_ForfeitureOfUnvestedRestrictedStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Forfeiture of unvested restricted stock issued in noncash financing activities.",
        "label": "Forfeiture of unvested restricted stock",
        "verboseLabel": "Forfeiture of unvested restricted stock"
       }
      }
     },
     "localname": "ForfeitureOfUnvestedRestrictedStock",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_FutureLeasePaymentsSubleaseAgreementTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future lease payments of sublease agreements.",
        "label": "Future Lease Payments, Sublease Agreement [Table Text Block]",
        "terseLabel": "Future Lease Payments from Sublease Agreement"
       }
      }
     },
     "localname": "FutureLeasePaymentsSubleaseAgreementTableTextBlock",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btx_GainLossOnDisposalOfFixedAssets": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of fixed assets.",
        "label": "Gain (Loss) on Disposal of Fixed Assets",
        "terseLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnDisposalOfFixedAssets",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_GainLossOnForgivenessOfPaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on forgiveness of PPP loan.",
        "label": "Gain (Loss) on Forgiveness of Paycheck Protection Program Loan",
        "negatedLabel": "Gain on forgiveness of PPP loan"
       }
      }
     },
     "localname": "GainLossOnForgivenessOfPaycheckProtectionProgramLoan",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_IncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares on incentive basis.",
        "label": "Incentive Stock Options [Member]",
        "terseLabel": "Incentive Stock Options [Member]"
       }
      }
     },
     "localname": "IncentiveStockOptionsMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_IncomeTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax [Abstract]",
        "terseLabel": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security deposits and also includes any other non-current assets which are not separately reported in during the period.",
        "label": "Increase (Decrease) in Deposit Assets and Other Non-current Assets",
        "negatedLabel": "Security deposits and other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInDepositAssetsAndOtherNonCurrentAssets",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the operating lease liabilities.",
        "label": "Increase (Decrease) in Operating Lease Liabilities",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_InducementPlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement award inducement plan 2021.",
        "label": "Inducement Plan 2021 [Member]",
        "terseLabel": "2021 Inducement Plan [Member]"
       }
      }
     },
     "localname": "InducementPlan2021Member",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_InitialLicenseFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial license fees required to pay including non-refundable fee.",
        "label": "Initial License Fees",
        "terseLabel": "Initial license fees"
       }
      }
     },
     "localname": "InitialLicenseFees",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_InitialMeasurementOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of initial measurement of operating lease liabilities in noncash financing activities.",
        "label": "Initial Measurement of Operating Lease Liabilities",
        "terseLabel": "Initial measurement of operating lease liabilities"
       }
      }
     },
     "localname": "InitialMeasurementOfOperatingLeaseLiabilities",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of initial measurement of ROU assets, net of tenant improvement allowance in noncash financing activities.",
        "label": "Initial Measurement of Right-of-Use Assets, Net of Tenant Improvement Allowance",
        "terseLabel": "Initial measurement of ROU assets, net of tenant improvement allowance"
       }
      }
     },
     "localname": "InitialMeasurementOfRightOfUseAssetsNetOfTenantImprovementAllowance",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_InvestorDepositsForSaleOfMembersEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of investor deposits for sale of members' equity in non-cash investing and financing activities.",
        "label": "Investor deposits for sale of members' equity",
        "terseLabel": "Investor deposits for sale of members' equity"
       }
      }
     },
     "localname": "InvestorDepositsForSaleOfMembersEquity",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_InvestorRoyaltyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement other than collaborative applicable to investor royalty.",
        "label": "Investor Royalty Agreement [Member]",
        "terseLabel": "Investor Royalty Agreement [Member]"
       }
      }
     },
     "localname": "InvestorRoyaltyAgreementMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_IssuanceOfCommonStockForAssetAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The issuance of common stock for asset acquisition in noncash financing activities.",
        "label": "Issuance of Common Stock for Asset Acquisition",
        "terseLabel": "Issuance of common Stock for Novellus acquisition"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForAssetAcquisition",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_IssuanceOfCommonStockForSeriesAPreferredStockDividend": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of issuance of common stock for Series A preferred stock dividend in non-cash investing and financing activities.",
        "label": "Issuance of Common Stock for Series A Preferred Stock Dividend",
        "verboseLabel": "Issuance of common stock for Series A preferred stock dividend"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForSeriesAPreferredStockDividend",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_LaboratoryAndManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and service.",
        "label": "Laboratory and Manufacturing Equipment [Member]",
        "terseLabel": "Laboratory and Manufacturing Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryAndManufacturingEquipmentMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_LeaseAssignmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Assignment [Abstract]",
        "terseLabel": "Lease Assignment [Abstract]"
       }
      }
     },
     "localname": "LeaseAssignmentAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_LegalMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Matters [Abstract]",
        "terseLabel": "Legal Matters [Abstract]"
       }
      }
     },
     "localname": "LegalMattersAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_LesseeCommitmentToPurchaseProperty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property for which lessee committed to purchase.",
        "label": "Lessee, Commitment to Purchase Property",
        "terseLabel": "Commitment to purchase equipment"
       }
      }
     },
     "localname": "LesseeCommitmentToPurchaseProperty",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Lessee Operating Lease Weighted Average Remaining Lease Term And Discount Rate Abstract [Abstract]",
        "terseLabel": "Weighted Average Remaining Lease Term and Discount Rate [Abstract]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseWeightedAverageRemainingLeaseTermAndDiscountRateAbstractAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_LicensingAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreements [Abstract]",
        "terseLabel": "Licensing Agreements [Abstract]"
       }
      }
     },
     "localname": "LicensingAgreementsAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_LincolnParkCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity.",
        "label": "Lincoln Park Capital Fund, LLC [Member]",
        "terseLabel": "Lincoln Park [Member]"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLLCMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_LiquidityAndCapitalResourcesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Capital Resources [Abstract]"
       }
      }
     },
     "localname": "LiquidityAndCapitalResourcesAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "btx_LiquidityAndCapitalResourcesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Liquidity and Capital Resources [Line Items]"
       }
      }
     },
     "localname": "LiquidityAndCapitalResourcesLineItems",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_LiquidityAndCapitalResourcesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about liquidity and capital resources.",
        "label": "Liquidity and Capital Resources [Table]"
       }
      }
     },
     "localname": "LiquidityAndCapitalResourcesTable",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_LiquidityAndCapitalResourcesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of liquidity and resource matters when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). going concern.",
        "label": "Liquidity And Capital Resources [Text Block]",
        "terseLabel": "Liquidity and Capital Resources"
       }
      }
     },
     "localname": "LiquidityAndCapitalResourcesTextBlock",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResources"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btx_LockUpPeriodForRestrictedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period in which shares are locked-up, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Lock-up Period for Restricted Shares",
        "terseLabel": "Lock-up period"
       }
      }
     },
     "localname": "LockUpPeriodForRestrictedShares",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btx_LossContingencyDamagesSoughtExpectedEquityPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of equity promised to the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Expected Equity Percentage",
        "terseLabel": "Percentage of equity promised against plaintiff"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtExpectedEquityPercentage",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_LossContingencyDamagesSoughtExpectedSalary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The monetary amount of salary promised to the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Expected Salary",
        "terseLabel": "Defendants salary promised against plaintiff"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtExpectedSalary",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_LossContingencyNonRefundableOptionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of Non-refundable option fee in licensing agreement.",
        "label": "Loss Contingency, Non-refundable Option Fee",
        "terseLabel": "Non-refundable option fee"
       }
      }
     },
     "localname": "LossContingencyNonRefundableOptionFee",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_LossContingencyNumberOfArbitrationPanel": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number member in arbitration panel pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, Number of Arbitration Panel Member",
        "terseLabel": "Number of member arbitration panel"
       }
      }
     },
     "localname": "LossContingencyNumberOfArbitrationPanel",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "btx_LossContingencyPercentageOfRoyaltyPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payable from one party to another in licensing agreement.",
        "label": "Loss contingency, Percentage of Royalty Payable",
        "terseLabel": "Percentage of royalty payable"
       }
      }
     },
     "localname": "LossContingencyPercentageOfRoyaltyPayable",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_MembershipEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity membership interest in entity.",
        "label": "Membership Equity [Member]",
        "terseLabel": "Membership Equity [Member]"
       }
      }
     },
     "localname": "MembershipEquityMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_MergerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger [Abstract]"
       }
      }
     },
     "localname": "MergerAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestones upfront payment on licenses.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_MinimumNumberOfPatentGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum number of granted patents.",
        "label": "Minimum Number of Patent Granted",
        "verboseLabel": "Minimum number of patent granted"
       }
      }
     },
     "localname": "MinimumNumberOfPatentGranted",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "btx_MinimumNumberOfPendingPatents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum number of patents pending.",
        "label": "Minimum Number of Pending Patents",
        "terseLabel": "Number of maximum pending patents"
       }
      }
     },
     "localname": "MinimumNumberOfPendingPatents",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "btx_NTNBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the disposal group.",
        "label": "NTN Business [Member]",
        "terseLabel": "NTN Business [Member]"
       }
      }
     },
     "localname": "NTNBusinessMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_NTNBuzztimeIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of acquiree entity.",
        "label": "NTN Buzztime, Inc [Member]",
        "terseLabel": "NTN Buzztime, Inc [Member]"
       }
      }
     },
     "localname": "NTNBuzztimeIncMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_NetIncomeLossAttributableToParentTemporaryElement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent Temporary.",
        "label": "Net Income (Loss) Attributable to Parent Temporary Element",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToParentTemporaryElement",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_NewLeaseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Lease Agreement [Abstract]",
        "terseLabel": "New Lease Agreement [Abstract]"
       }
      }
     },
     "localname": "NewLeaseAgreementAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_NonQualifiedStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Non-qualified Stock Option [Member]",
        "terseLabel": "Nonqualified Stock Options [Member]"
       }
      }
     },
     "localname": "NonQualifiedStockOptionMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails",
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of further shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Further Shares Issued1",
        "terseLabel": "Number of shares remaining to be sold in purchase commitment (in shares)"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationFurtherSharesIssued1",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "btx_NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of preferred stock issued in a reverse merger transaction in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Preferred Shares Issued in Connection with Reverse Merger",
        "terseLabel": "Preferred shares issued in connection with reverse merger"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_NoveCiteINCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of company involved in licensing agreement.",
        "label": "NoveCite, INC. [Member]",
        "terseLabel": "NoveCite, INC. [Member]"
       }
      }
     },
     "localname": "NoveCiteINCMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails",
      "http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_NoveCiteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of company involved in licensing agreement.",
        "label": "NoveCite [Member]",
        "terseLabel": "NoveCite [Member]"
       }
      }
     },
     "localname": "NoveCiteMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_NovellusLtdAndFactorBioscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of companies involved in licensing agreement.",
        "label": "Novellus Ltd. and Factor Bioscience [Member]",
        "terseLabel": "Licensors [Member]"
       }
      }
     },
     "localname": "NovellusLtdAndFactorBioscienceMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_NovellusTherapeuticsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of company involved in licensing agreement.",
        "label": "Novellus Therapeutics Limited [Member]",
        "terseLabel": "Novellus, Ltd. [Member]"
       }
      }
     },
     "localname": "NovellusTherapeuticsLimitedMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_NumberOfBoardSeats": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of members of the company's management holds board seats on board of directors.",
        "label": "Number of Board Seats",
        "terseLabel": "Number of board seats"
       }
      }
     },
     "localname": "NumberOfBoardSeats",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "btx_NumberOfStockOptionGrantMade": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock option grants made.",
        "label": "Number Of Stock Option Grant Made",
        "terseLabel": "Number of stock option grants made"
       }
      }
     },
     "localname": "NumberOfStockOptionGrantMade",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "btx_ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents obligated to maintain under merger agreement on balance sheet at the effective time of the merger.",
        "label": "Obligated to Maintain Cash and Cash Equivalents Under Merger Agreement",
        "terseLabel": "Cash and cash equivalents obligated to have under merger agreement"
       }
      }
     },
     "localname": "ObligatedToMaintainCashAndCashEquivalentsUnderMergerAgreement",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_ObservableTransactionsForIdenticalEquitySecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for observable transactions for identical or similar equity securities.",
        "label": "Observable Transactions for Identical Equity Securities",
        "terseLabel": "Observable transactions for identical or similar equity securities"
       }
      }
     },
     "localname": "ObservableTransactionsForIdenticalEquitySecurities",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_OperatingLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of leased property under operating lease.",
        "label": "Operating Lease Area",
        "terseLabel": "Operating lease area"
       }
      }
     },
     "localname": "OperatingLeaseArea",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesOperatingLeaseDetails",
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "btx_OperatingLeaseAssestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Asset [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseAssestAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for lessee's operating lease right-of-use assets and liabilities.",
        "label": "Operating Lease Right-of-use Assets and Liabilities [Table Text Block]",
        "terseLabel": "Operating Lease Right-of-use Assets and Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btx_PIPEInvestorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private investment in public equity, often called a PIPE deal, involves the selling of publicly traded common shares or some form of preferred stock or convertible security to private investors. It is an allocation of shares in a public company not through a public offering in a stock exchange. PIPE deals are part of the primary market. In the U.S., a PIPE offering may be registered with the Securities and Exchange Commission on a registration statement or may be completed as an unregistered private placement.",
        "label": "PIPE Investor [Member]",
        "terseLabel": "PIPE Investor [Member]"
       }
      }
     },
     "localname": "PIPEInvestorMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_PaycheckProtectionProgramLoanCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of loans related to Paycheck Protection Program classified as current.",
        "label": "Paycheck Protection Program Loan, Current",
        "terseLabel": "PPP loan, current"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanCurrent",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_PaycheckProtectionProgramLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the debt instrument.",
        "label": "Paycheck Protection Program Loan [Member]",
        "terseLabel": "IRX Notes [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_PaycheckProtectionProgramLoanNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of loans related to Paycheck Protection Program classified as non-current.",
        "label": "Paycheck Protection Program Loan, Non-current",
        "terseLabel": "PPP loan, non-current"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanNonCurrent",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_PaycheckProtectionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program [Member]",
        "label": "Paycheck Protection Program [Member]",
        "terseLabel": "Brooklyn LLC Paycheck Protection Program [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_PaymentOfAccruedAndUnpaidInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for accrued and unpaid interest related to notes payable.",
        "label": "Payment of Accrued and Unpaid Interest",
        "terseLabel": "Payment of accrued and unpaid interest"
       }
      }
     },
     "localname": "PaymentOfAccruedAndUnpaidInterest",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_PaymentsOfPaycheckProtectionProgramLoan": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow for payment of paycheck protection program loans.",
        "label": "Payments of Paycheck Protection Program Loan",
        "negatedLabel": "Repayment of NTN's PPP loan"
       }
      }
     },
     "localname": "PaymentsOfPaycheckProtectionProgramLoan",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_PaymentsToAcquireProductiveAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets excluding cash acquired.",
        "label": "Cash paid, net",
        "negatedLabel": "Purchase of Novellus, net of common stock issued and cash acquired",
        "terseLabel": "Cash paid, net"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssetsNet",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_PercentageBaseRentIncreaseOnEachAnniversary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of base rent increase on each anniversary.",
        "label": "Percentage, Base Rent Increase on each Anniversary",
        "terseLabel": "Percentage of increase in base rent on each year"
       }
      }
     },
     "localname": "PercentageBaseRentIncreaseOnEachAnniversary",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_PercentageOfAdditionalRightsOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of additional right offering made by the entity for unit holders.",
        "label": "Percentage of Additional Rights Offering",
        "terseLabel": "Percentage of additional rights offering"
       }
      }
     },
     "localname": "PercentageOfAdditionalRightsOffering",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_PercentageOfCommonStockSubjectToLockUpAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of shares of common stock subject to the lock-up agreement",
        "label": "Percentage of Common Stock Subject to Lock-up Agreement",
        "terseLabel": "Percentage of common stock subject to the lock-up agreement"
       }
      }
     },
     "localname": "PercentageOfCommonStockSubjectToLockUpAgreement",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_PercentageOfDiscountOnFairValueOfRestrictedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of discount on restricted shares, which was derived from the average discount rate between the Black Scholes and Finnerty valuation models.",
        "label": "Percentage of Discount on Fair Value of Restricted Shares",
        "terseLabel": "Percentage of discount on fair value restricted shares"
       }
      }
     },
     "localname": "PercentageOfDiscountOnFairValueOfRestrictedShares",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of income taxes projected in terms of royalty savings due to use of different market assumptions and/or different valuation techniques.",
        "label": "Percentage of Income Taxes Projected in terms of Royalty Savings",
        "terseLabel": "Percentage of income taxes projected as royalty savings"
       }
      }
     },
     "localname": "PercentageOfIncomeTaxesProjectedInTermsOfRoyaltySavings",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of increase in annual lease payment for subleases for each year.",
        "label": "Percentage of Lessee Sublease, Increase In Annual Lease Rent Payments",
        "terseLabel": "Percentage of annual rent increase"
       }
      }
     },
     "localname": "PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of additional royalty payable on gross sales by the entity.",
        "label": "Percentage of Payment Of Additional Royalty On Gross Sales",
        "terseLabel": "Percentage of payment of additional royalty on gross sales"
       }
      }
     },
     "localname": "PercentageOfPaymentOfAdditionalRoyaltyOnGrossSales",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_PercentageOfRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue from receives any revenue involving the original cell line included in the licensed technology, then Novellus, Ltd shall remit to NoveCite.",
        "label": "Percentage of Revenue",
        "terseLabel": "Percentage of revenue"
       }
      }
     },
     "localname": "PercentageOfRevenue",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty receive equal to revenues generated from disposition of business.",
        "label": "Percentage of Royalty Receive Equal to Revenues from Sale of Business",
        "terseLabel": "Percentage of royalty receive equal to revenues from sale of business"
       }
      }
     },
     "localname": "PercentageOfRoyaltyReceiveEqualToRevenuesFromSaleOfBusiness",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_PercentageOfRoyaltyRevenueAssumedFrom2030To2038": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of royalty revenue assumed from 2030 to 2038 due to use of different market assumptions and/or different valuation techniques.",
        "label": "Percentage of Royalty Revenue Assumed from 2030 to 2038",
        "terseLabel": "Assumed percentage of royalty revenue from 2030 to 2038"
       }
      }
     },
     "localname": "PercentageOfRoyaltyRevenueAssumedFrom2030To2038",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_PercentageOfRoyaltyRevenueAssumedUntil2029": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of royalty revenue assumed until 2029 due to use of different market assumptions and/or different valuation techniques.",
        "label": "Percentage of Royalty Revenue Assumed Until 2029",
        "terseLabel": "Assumed percentage of royalty revenue until 2029"
       }
      }
     },
     "localname": "PercentageOfRoyaltyRevenueAssumedUntil2029",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of royalty revenue after year one post patent decline due to use of different market assumptions and/or different valuation techniques.",
        "label": "Percentage of Royalty Revenue Post Patent Decline After Year One",
        "terseLabel": "Percentage of royalty revenue post patent decline after year one"
       }
      }
     },
     "localname": "PercentageOfRoyaltyRevenuePostPatentDeclineAfterYearOne",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_PercentageOfRoyaltyRevenuePostPatentDeclineYearOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of royalty revenue for first year post patent decline due to use of different market assumptions and/or different valuation techniques.",
        "label": "Percentage of Royalty Revenue Post Patent Decline Year One",
        "terseLabel": "Percentage of royalty revenue post patent decline for first year"
       }
      }
     },
     "localname": "PercentageOfRoyaltyRevenuePostPatentDeclineYearOne",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_PercentageOfSharesOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common stock shares outstanding considered for equity number of shares under equity incentive plan.",
        "label": "Percentage of Shares of Common Stock Outstanding",
        "terseLabel": "Percentage of number of shares of common stock outstanding"
       }
      }
     },
     "localname": "PercentageOfSharesOfCommonStockOutstanding",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_PercentageOfWeightedAverageCostOfCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows discounted by the liability specific weighted average cost of capital using the mid-point convention.",
        "label": "Percentage of Weighted Average Cost of Capital",
        "terseLabel": "Percentage of weighted average cost of capital"
       }
      }
     },
     "localname": "PercentageOfWeightedAverageCostOfCapital",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btx_PerformanceBasedNonqualifiedStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares on performance basis.",
        "label": "Performance-Based Nonqualified Stock Option [Member]",
        "terseLabel": "Performance-Based Nonqualified Stock Option [Member]"
       }
      }
     },
     "localname": "PerformanceBasedNonqualifiedStockOptionMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A pre-funded warrant that allows the warrant holder to purchase a specified number of a company's securities at a nominal exercise price.",
        "label": "Pre-funded Warrants [Member]",
        "terseLabel": "Pre-funded Warrants [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_PrincipalPaymentsOnOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal payments on operating lease liabilities.",
        "label": "Principal payments on operating lease liabilities"
       }
      }
     },
     "localname": "PrincipalPaymentsOnOperatingLeaseLiabilities",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_PrivatePlacementOfEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement of Equity [Abstract]",
        "terseLabel": "Private Placement of Equity [Abstract]"
       }
      }
     },
     "localname": "PrivatePlacementOfEquityAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_PrivatePlacementOfferingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Offerings [Abstract]"
       }
      }
     },
     "localname": "PrivatePlacementOfferingsAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_ProFormaFairValueAdjustmentToAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value adjustment to acquisition-date assets reported in proforma information.",
        "label": "Pro Forma Fair Value Adjustment to Assets [Member]",
        "terseLabel": "Fair Value Adjustment to Assets [Member]"
       }
      }
     },
     "localname": "ProFormaFairValueAdjustmentToAssetsMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_ProceedsFromDispositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Disposition [Abstract]",
        "terseLabel": "Proceeds from sale [Abstract]"
       }
      }
     },
     "localname": "ProceedsFromDispositionAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_ProceedsFromSaleOfRights": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of rights during the period.",
        "label": "Proceeds From Sale Of Rights",
        "terseLabel": "Proceeds from right offering"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRights",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about purchase agreement between the entities.",
        "label": "Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreements [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_PurchasePriceAllocationProFormaAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proforma adjustment of purchase price allocation of acquisition-date assets and liability assumed.",
        "label": "Purchase Price Allocation Pro Forma Adjustment [Member]",
        "terseLabel": "Purchase Price Allocation Pro Forma Adjustment [Member]"
       }
      }
     },
     "localname": "PurchasePriceAllocationProFormaAdjustmentMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_ResearchAndDevelopmentInProcessAssetAcquisition": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a asset acquisition have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process, Asset Acquisition",
        "terseLabel": "Acquired in-process research and development",
        "verboseLabel": "IPR&amp;D expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcessAssetAcquisition",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_ReverseStockSplitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Stock-Split [Abstract]"
       }
      }
     },
     "localname": "ReverseStockSplitAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitReverseStocksplitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_RobertGarfieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Robert Garfield, a purported stockholder of the Company forwarded a demand letter (the \"Demand\")",
        "label": "Robert Garfield [Member]",
        "terseLabel": "Robert Garfield [Member]"
       }
      }
     },
     "localname": "RobertGarfieldMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_RoyaltyAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Agreements [Abstract]",
        "terseLabel": "Royalty Agreements [Abstract]"
       }
      }
     },
     "localname": "RoyaltyAgreementsAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.",
        "label": "Sale Leaseback Transactions, Future Minimum Sublease Rentals",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "SaleLeasebackTransactionsFutureMinimumSubleaseRentals",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale Leaseback Transactions, Future Minimum Sublease Rentals, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future Lease Payments, Sublease Agreement [Abstract]"
       }
      }
     },
     "localname": "SaleLeasebackTransactionsFutureMinimumSubleaseRentalsFiscalYearMaturityAbstract",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails": {
       "order": 2.0,
       "parentTag": "btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Sale Leaseback Transactions, Future Minimum Sublease Rentals, Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails": {
       "order": 4.0,
       "parentTag": "btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Sale Leaseback Transactions Future Minimum Sublease Rentals Within Five Years",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFiveYears",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails": {
       "order": 6.0,
       "parentTag": "btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Sale Leaseback Transactions, Future Minimum Sublease Rentals, within Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinFourYears",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails": {
       "order": 5.0,
       "parentTag": "btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Sale Leaseback Transactions, Future Minimum Sublease Rentals, within Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails": {
       "order": 3.0,
       "parentTag": "btx_SaleLeasebackTransactionsFutureMinimumSubleaseRentals",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Sale Leaseback Transactions, Future Minimum Sublease Rentals, within Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_SaleOfStockNumberOfSharesToIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares to be issued by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares to Issued in Transaction",
        "terseLabel": "Number of remaining shares to be sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesToIssuedInTransaction",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "btx_SecondPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about second purchase agreement between the entities.",
        "label": "Second Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecondPurchaseAgreementMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options expected to vest.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Number",
        "terseLabel": "Balance expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "btx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fair value of share-based payment arrangement, subject to vesting and other restrictions, to purchase or sell certain number of shares on performance basis.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value",
        "terseLabel": "Stock-based compensation grant fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of monthly installments for vesting of remaining shares in share-based compensation arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment, Number of Monthly Installments for Vesting of Remaining Shares",
        "terseLabel": "Number of monthly installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentNumberOfMonthlyInstallmentsForVestingOfRemainingShares",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "btx_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Granted Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted-average remaining contractual life, granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btx_SharesIssuedSharesForfeitureOfUnvestedRestrictedStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares Forfeiture of unvested restricted stock during the period.",
        "label": "Shares Issued, Shares, Forfeiture of unvested restricted stock",
        "negatedLabel": "Forfeiture of unvested restricted stock (in shares)"
       }
      }
     },
     "localname": "SharesIssuedSharesForfeitureOfUnvestedRestrictedStock",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "btx_StockIssuedDuringPeriodRestrictedSharesAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued with restrictions during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Restricted Shares, Acquisitions",
        "terseLabel": "Restricted shares, issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodRestrictedSharesAcquisitions",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "btx_StockIssuedDuringPeriodRestrictedSharesValueAcquisitions": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails": {
       "order": 4.0,
       "parentTag": "btx_AssetAcquisitionFairValueOfConsiderationPaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued with restrictions during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Restricted Shares, Value, Acquisitions",
        "terseLabel": "Restricted shares, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodRestrictedSharesValueAcquisitions",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_StockIssuedDuringPeriodSharesAcquisitions1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions1",
        "terseLabel": "Common stock to be retained by NTN stockholders (in shares)",
        "verboseLabel": "Stock issued, shares, acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions1",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "btx_StockIssuedDuringPeriodSharesAcquisitions2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions2",
        "terseLabel": "Issuance of common stock in connection with the acquisition of Novellus, Inc. (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions2",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "btx_StockIssuedDuringPeriodSharesInLieuOfDividends": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period in lieu of dividends to be paid.",
        "label": "Stock Issued During Period, Shares, in Lieu of Dividends",
        "terseLabel": "Issuance of common stock in lieu of cash dividend to Series A convertible preferred stockholders (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesInLieuOfDividends",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "btx_StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the shares of new stock issued of preferred stock during the period.",
        "label": "Stock Issued During Period, Shares, New Issues of Preferred Stock, Retained by Stockholders",
        "terseLabel": "Issuance of Series A preferred stock retained by NTN stockholders (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssuesOfPreferredStockRetainedByStockholders",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "btx_StockIssuedDuringPeriodSharesStockPurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been issued in a stock purchase agreement during the period.",
        "label": "Stock Issued During Period, Shares, Stock Purchase Agreement",
        "terseLabel": "Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockPurchaseAgreement",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "btx_StockIssuedDuringPeriodUnrestrictedSharesAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued without any restrictions during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Unrestricted Shares, Acquisitions",
        "terseLabel": "Unrestricted shares, issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodUnrestrictedSharesAcquisitions",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "btx_StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails": {
       "order": 3.0,
       "parentTag": "btx_AssetAcquisitionFairValueOfConsiderationPaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued without any restrictions during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Unrestricted Shares, Value, Acquisitions",
        "terseLabel": "Unrestricted shares, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodUnrestrictedSharesValueAcquisitions",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_StockIssuedDuringPeriodValueAcquisitions1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions1",
        "terseLabel": "Common stock to be retained by NTN stockholders"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions1",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_StockIssuedDuringPeriodValueAcquisitions2": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions2",
        "terseLabel": "Issuance of common stock in connection with the acquisition of Novellus, Inc."
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions2",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Forfeiture of unvested restricted stock during the period.",
        "label": "Stock Issued During Period, Value, Forfeiture of Unvested Restricted Stock",
        "terseLabel": "Forfeiture of unvested restricted stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_StockIssuedDuringPeriodValueInLieuOfDividends": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period in Lieu of Dividends to be paid.",
        "label": "Stock Issued During Period, Value, in Lieu of Dividends",
        "terseLabel": "Issuance of common stock in lieu of cash dividend to Series A convertible preferred stockholders"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueInLieuOfDividends",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued of preferred stock during the period.",
        "label": "Stock Issued During Period, Value, New Issues of Preferred Stock, Retained by Stockholders",
        "terseLabel": "Issuance of Series A preferred stock retained by NTN stockholders"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_StockIssuedDuringPeriodValueRightsOfferingMembershipUnits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to rights offering membership units during the period.",
        "label": "Stock Issued During Period, Value, Rights Offering Membership Units",
        "terseLabel": "Brooklyn rights offerings membership units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRightsOfferingMembershipUnits",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_StockIssuedDuringPeriodValueStockPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been issued in a stock purchase agreement during the period.",
        "label": "Stock Issued During Period, Value, Stock Purchase Agreement",
        "terseLabel": "Issuance of common stock related to stock purchase agreement with Lincoln Park Capital Fund, LLC, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockPurchaseAgreement",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration beginning year of the tax credit carryforward, in YYYY format.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credits begin to expire"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "btx_TaxCutsAndJobsActOperatingLossCarryforwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws from effect of Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards under Tax Cuts and Jobs Act"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOperatingLossCarryforwards",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_TimeBasedNonQualifiedStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares on time basis.",
        "label": "Time-Based Non-qualified Stock Option [Member]",
        "terseLabel": "Time-Based Non-qualified Stock Option [Member]"
       }
      }
     },
     "localname": "TimeBasedNonQualifiedStockOptionMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btx_UnamortizedLeaseholdImprovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unamortized leasehold improvements.",
        "label": "Unamortized Leasehold Improvements",
        "terseLabel": "Unamortized leasehold improvements"
       }
      }
     },
     "localname": "UnamortizedLeaseholdImprovements",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btx_UniversityOfSouthFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal entity involved in litigation.",
        "label": "University of South Florida [Member]",
        "terseLabel": "University of South Florida [Member]"
       }
      }
     },
     "localname": "UniversityOfSouthFloridaMember",
     "nsuri": "http://brooklynitx.com/20211231",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r227",
      "r264",
      "r305",
      "r308",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r527",
      "r528",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r227",
      "r264",
      "r305",
      "r308",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r527",
      "r528",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails",
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r227",
      "r264",
      "r294",
      "r305",
      "r308",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r527",
      "r528",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails",
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r227",
      "r264",
      "r294",
      "r305",
      "r308",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r527",
      "r528",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails",
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r112",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r112",
      "r117",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r112",
      "r117",
      "r201",
      "r306",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting Presentation and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r46",
      "r473"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r16",
      "r32",
      "r167",
      "r168"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://brooklynitx.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/AccruedExpensesDetails",
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r44",
      "r189"
     ],
     "calculation": {
      "http://brooklynitx.com/role/PropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r33",
      "r345",
      "r473"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r342",
      "r343",
      "r344",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r309",
      "r311",
      "r348",
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r311",
      "r338",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Stock based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Total potential common shares excluded from computation (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r414"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Business consideration"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of asset acquisition.",
        "label": "Fair Value of Asset Acquired"
       }
      }
     },
     "localname": "AssetAcquisitionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r97",
      "r151",
      "r160",
      "r164",
      "r172",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r420",
      "r422",
      "r437",
      "r471",
      "r473",
      "r505",
      "r518"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r17",
      "r18",
      "r58",
      "r97",
      "r172",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r420",
      "r422",
      "r437",
      "r471",
      "r473"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying value of assets sold [Abstract]"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r312",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails",
      "http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails",
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails",
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
      "http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Accounting Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Accounting Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r304",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails",
      "http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperationsDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r304",
      "r307",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails",
      "http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperationsDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Purchase price",
        "terseLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Number of common stock issued in exchange of membership interests (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails",
      "http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of outstanding common stock received by members and financial adviser"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share attributable to common stockholders (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsProFormaFinancialInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share attributable to common stockholders (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsProFormaFinancialInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Pro Forma Financial Information [Abstract]"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsProFormaFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Pro Forma Financial Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Closing price of common stock (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r392",
      "r393"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsProFormaFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r83",
      "r405"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r402",
      "r403"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger Agreement [Abstract]",
        "terseLabel": "Description of Business [Abstract]",
        "verboseLabel": "Acquisitions [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails",
      "http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperationsDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Prepaid expense and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Accounts payable, accrued liabilities and other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r397",
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Net assets acquired, excluding goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r397",
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Price allocation of Assets Acquired and Liabilities Assumed [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger, Disposition and Acquisition Transactions [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r40",
      "r473",
      "r534",
      "r535"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails": {
       "order": 2.0,
       "parentTag": "btx_AssetAcquisitionFairValueOfConsiderationPaid",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "negatedLabel": "Cash acquired"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r23",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r80",
      "r86",
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r80",
      "r438"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r94",
      "r97",
      "r121",
      "r122",
      "r123",
      "r126",
      "r128",
      "r137",
      "r138",
      "r139",
      "r172",
      "r213",
      "r217",
      "r218",
      "r219",
      "r222",
      "r223",
      "r261",
      "r262",
      "r267",
      "r271",
      "r437",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r290",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Warrant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Number of rights options converted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r209",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r212",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Commitment and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Class A Membership Units [Member]",
        "terseLabel": "Common Class A [Member]",
        "verboseLabel": "Class A [Member]"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Class B Membership Units [Member]",
        "terseLabel": "Common Class B [Member]",
        "verboseLabel": "Class B [Member]"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation.",
        "label": "Class C Membership Units [Member]",
        "terseLabel": "Common Class C [Member]",
        "verboseLabel": "Class C [Member]"
       }
      }
     },
     "localname": "CommonClassCMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r104",
      "r105",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)",
        "terseLabel": "Number of shares authorized to sale in regular purchase (in shares)",
        "verboseLabel": "Certificate of incorporation to increase the authorized shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r31",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in shares)",
        "terseLabel": "Number of shares of common stock owned by stockholders immediately before the Merger (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r31",
      "r473"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.005 par value, 100,000 shares authorized, 52,044 issued and outstanding at December 31, 2021; no shares issued and outstanding at December 31, 2020."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Components of Income Tax Provision [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://brooklynitx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r142",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails",
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails",
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Number of shares converted to common stock (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r261",
      "r262",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Preferred Stock Converted into Common Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r29",
      "r30",
      "r274",
      "r280",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Each preferred stock converted into common stock (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r374",
      "r381"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r374"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r374",
      "r381",
      "r383"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income tax provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current Tax Provision [Abstract]"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r374",
      "r381"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customers [Member]"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r93",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r241",
      "r248",
      "r249",
      "r251",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r96",
      "r102",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r253",
      "r254",
      "r255",
      "r256",
      "r448",
      "r506",
      "r507",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r224",
      "r253",
      "r254",
      "r447",
      "r448",
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r51",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r52",
      "r96",
      "r102",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r253",
      "r254",
      "r255",
      "r256",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r52",
      "r96",
      "r102",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r280",
      "r284",
      "r285",
      "r286",
      "r446",
      "r447",
      "r448",
      "r449",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r375",
      "r381"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r375",
      "r381"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r98",
      "r375",
      "r381",
      "r382",
      "r383"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current year deferred expense",
        "totalLabel": "Deferred Income tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails",
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred Tax Provision [Abstract]"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r375",
      "r381"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred Tax Assets: [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Foreign net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r370",
      "r372",
      "r373"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "R&amp;D credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days).",
        "label": "Vacation accrual"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from contingent liabilities.",
        "label": "Contingent consideration"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.",
        "label": "Deferred rent"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r356",
      "r367"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": {
     "auth_ref": [
      "r372",
      "r373",
      "r416",
      "r417"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill",
        "negatedLabel": "Intangibles - goodwill"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred Tax Liabilities: [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the valuation allowance recorded in a business combination against deductible temporary differences for which related tax benefits will be recorded as a reduction of the acquired entity's income tax expense (after such benefits are first being applied to reduce goodwill and then other noncurrent intangible assets to zero).",
        "label": "Purchase accounting related to 2021 business combination"
       }
      }
     },
     "localname": "DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIncomeTaxExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Percentage of maximum annual contribution to defined contribution plan"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/RetirementSavingsPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepositAssets": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.",
        "label": "Security deposit",
        "terseLabel": "Security deposits and other assets"
       }
      }
     },
     "localname": "DepositAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r84",
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation expenses"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r84",
      "r149"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "negatedLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill",
        "negatedLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r186",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets",
        "negatedLabel": "Prepaids and other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r1",
      "r2",
      "r9",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r84",
      "r185",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Total loss on sale of assets"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r304",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.",
        "label": "Cumulative annual dividend payable per share (in dollars per share)"
       }
      }
     },
     "localname": "DividendsPayableAmountPerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DividendsPreferredStockCash": {
     "auth_ref": [
      "r288",
      "r514"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Preferred Stock, Cash",
        "negatedLabel": "Cash dividends to Series A preferred stockholders",
        "terseLabel": "Dividend paid in cash"
       }
      }
     },
     "localname": "DividendsPreferredStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Earnings per Common Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r67",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r118",
      "r121",
      "r126",
      "r127",
      "r128",
      "r133",
      "r134",
      "r426",
      "r427",
      "r511",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r67",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r121",
      "r126",
      "r127",
      "r128",
      "r133",
      "r134",
      "r426",
      "r427",
      "r511",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive Securities [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Basic and Diluted Earnings per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total tax provision for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r100",
      "r358",
      "r385"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r358",
      "r385"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r358",
      "r385"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Non-deductible expenses/excludable items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r358",
      "r385"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Pass-through loss"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r358",
      "r385"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "State income tax, net of federal tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r358",
      "r385"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://brooklynitx.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average remaining requisite service period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails",
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unamortized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unamortized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails",
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails",
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
      "http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory and Manufacturing Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Stockholders' and members' equity (deficit):"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r62",
      "r63",
      "r64",
      "r104",
      "r105",
      "r106",
      "r108",
      "r114",
      "r116",
      "r136",
      "r173",
      "r279",
      "r288",
      "r342",
      "r343",
      "r344",
      "r377",
      "r378",
      "r425",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r529",
      "r530",
      "r531",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Ownership percentage",
        "terseLabel": "Percentage of total outstanding equity interests"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails",
      "http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r41",
      "r152",
      "r170"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment",
        "verboseLabel": "Investment in minority interest"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails",
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails",
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r239",
      "r253",
      "r254",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r429",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails",
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r239",
      "r295",
      "r296",
      "r301",
      "r303",
      "r429",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r239",
      "r253",
      "r254",
      "r295",
      "r296",
      "r301",
      "r303",
      "r429",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r239",
      "r253",
      "r254",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r429",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails",
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r431",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Carrying Amount of Contingent Consideration Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r239",
      "r253",
      "r254",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails",
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosure [Abstract]"
       }
      }
     },
     "localname": "FairValueNetAssetLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r435",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FeaturesOfConvertiblePreferredStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Features of Convertible Preferred Stock [Abstract]",
        "terseLabel": "Cumulative Convertible Preferred Stock [Abstract]"
       }
      }
     },
     "localname": "FeaturesOfConvertiblePreferredStockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r180",
      "r182",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r177",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Loss on sale of NTN assets",
        "terseLabel": "Loss on sales of assets",
        "verboseLabel": "Loss on sale of NTN assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r174",
      "r175",
      "r473",
      "r504"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopmentDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and In-Process Research &amp; Development [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and In-Process Research &amp; Development"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r184",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r45",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r99",
      "r384"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r151",
      "r159",
      "r162",
      "r163",
      "r165",
      "r503",
      "r509",
      "r512",
      "r525"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations",
      "http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r99",
      "r384"
     ],
     "calculation": {
      "http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Loss before Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r304",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r10",
      "r11",
      "r12",
      "r13",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r359",
      "r363",
      "r369",
      "r379",
      "r386",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r101",
      "r115",
      "r116",
      "r150",
      "r357",
      "r380",
      "r387",
      "r526"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "totalLabel": "Total tax provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations",
      "http://brooklynitx.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Reconciliation of Computed Expected Income Taxes to Effective Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r354",
      "r355",
      "r363",
      "r364",
      "r368",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Account receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r79",
      "r81",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r21",
      "r22",
      "r49"
     ],
     "calculation": {
      "http://brooklynitx.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r462",
      "r464"
     ],
     "calculation": {
      "http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Operating Lease Expense [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Net Operating Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc01": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc01": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Extended lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lease commencement term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r48",
      "r97",
      "r161",
      "r172",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r421",
      "r422",
      "r423",
      "r437",
      "r471",
      "r472"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r37",
      "r97",
      "r172",
      "r437",
      "r473",
      "r508",
      "r521"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' and members' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' AND MEMBERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r50",
      "r97",
      "r172",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r421",
      "r422",
      "r423",
      "r437",
      "r471",
      "r472",
      "r473"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Fair value adjustment included in operating expenses"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Fair value liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails",
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "verboseLabel": "Other liabilities contingent consideration [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsCarryingAmountOfContingentConsiderationLiabilitiesDetails",
      "http://brooklynitx.com/role/FairValueOfFinancialInstrumentsLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities transferred upon sale [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansPayableCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.",
        "label": "Loans Payable, Current",
        "terseLabel": "Loans payable"
       }
      }
     },
     "localname": "LoansPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r28",
      "r238",
      "r252",
      "r253",
      "r254",
      "r507",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Term loan amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r208",
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r200",
      "r203",
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss contingency, damages sought, value"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of claims filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfDefendants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of defendants named in a legal action.",
        "label": "Number of defendant"
       }
      }
     },
     "localname": "LossContingencyNumberOfDefendants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MembersCapital": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of member capital in limited liability company (LLC).",
        "label": "Members' Capital",
        "terseLabel": "Common units"
       }
      }
     },
     "localname": "MembersCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r14",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Merger, Disposition and Acquisition Transactions"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Ownership percentage by Citius"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows provided by financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r80",
      "r82",
      "r85"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r13",
      "r59",
      "r60",
      "r64",
      "r66",
      "r85",
      "r97",
      "r107",
      "r109",
      "r110",
      "r111",
      "r112",
      "r115",
      "r116",
      "r124",
      "r151",
      "r159",
      "r162",
      "r163",
      "r165",
      "r172",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r427",
      "r437",
      "r510",
      "r523"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112",
      "r118",
      "r119",
      "r125",
      "r128",
      "r151",
      "r159",
      "r162",
      "r163",
      "r165"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashMergerRelatedCosts": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to the increase (decrease) in reserve for business combination costs. Includes, but is not limited to, legal, accounting, and other costs incurred to consummate the merger.",
        "label": "Noncash Merger Related Costs",
        "terseLabel": "Transaction costs - shares to Financial Advisor",
        "verboseLabel": "Transaction costs"
       }
      }
     },
     "localname": "NoncashMergerRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Common stock, shares issued in consideration for purchase commitment (in shares)"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expenses, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonrecurringAdjustmentAxis": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about material and nonrecurring adjustment directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).",
        "label": "Nonrecurring Adjustment [Axis]"
       }
      }
     },
     "localname": "NonrecurringAdjustmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonrecurringAdjustmentDomain": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information).",
        "label": "Nonrecurring Adjustment [Domain]"
       }
      }
     },
     "localname": "NonrecurringAdjustmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesSegmentReportingDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open tax year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r151",
      "r159",
      "r162",
      "r163",
      "r165"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r455",
      "r464"
     ],
     "calculation": {
      "http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of Operating Lease Liabilities [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc01": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total operating lease liabilities",
        "periodEndLabel": "Operating lease liabilities, Ending",
        "periodStartLabel": "Operating lease liabilities, Beginning"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "periodEndLabel": "Current portion",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Less non-current portion",
        "terseLabel": "Operating lease liabilities, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r452",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "periodEndLabel": "Operating lease ROU assets, Ending",
        "periodStartLabel": "Operating lease ROU assets, Beginning",
        "terseLabel": "Right-of-use assets - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "negatedLabel": "Amortization of operating lease ROU assets",
        "terseLabel": "Amortization of right-to-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://brooklynitx.com/role/LeasesOperatingLeaseRightofuseAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r461",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r460",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating loss carry forward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business Operations [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r15",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization and Description of Business Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses [Abstract]",
        "terseLabel": "Other expenses:"
       }
      }
     },
     "localname": "OtherExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r49",
      "r473"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PartnersCapitalAccountAcquisitions": {
     "auth_ref": [
      "r287",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the different classes of partners' capital accounts during the year due to acquisitions. Partners include general, limited and preferred partners.",
        "label": "Partners' Capital Account, Acquisitions",
        "terseLabel": "Issuance of common stock to Brooklyn members"
       }
      }
     },
     "localname": "PartnersCapitalAccountAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PartnersCapitalAccountUnitsAcquisitions": {
     "auth_ref": [
      "r288",
      "r406",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the number of units for each class of partners' capital accounts during the year due to acquisitions.  Partners include general, limited and preferred partners.",
        "label": "Partners' Capital Account, Units, Acquisitions",
        "terseLabel": "Issuance of common stock to Brooklyn members (in shares)"
       }
      }
     },
     "localname": "PartnersCapitalAccountUnitsAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Preferred Stock and Preference Stock",
        "negatedLabel": "Dividends paid to Series A preferred shareholders"
       }
      }
     },
     "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Less amount of cash paid for NoveCite investment"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r73",
      "r408",
      "r409",
      "r410"
     ],
     "calculation": {
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails": {
       "order": 1.0,
       "parentTag": "btx_AssetAcquisitionFairValueOfConsiderationPaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Cash paid"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r312",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Savings Plan [Abstract]"
       }
      }
     },
     "localname": "PostemploymentBenefitsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PostemploymentBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r292",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for postemployment benefits,  which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.",
        "label": "Postemployment Benefits Disclosure [Text Block]",
        "terseLabel": "Retirement Savings Plan"
       }
      }
     },
     "localname": "PostemploymentBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/RetirementSavingsPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.",
        "label": "Preferred stock, conversion rate"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionRatio",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion of preferred stock.",
        "label": "Aggregate preferred stock to be convert into common stock (in shares)"
       }
      }
     },
     "localname": "PreferredStockConvertibleSharesIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r119",
      "r129"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "negatedLabel": "Series A preferred stock dividend"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockDividendsShares": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.",
        "label": "Cash dividends to Series A preferred stockholders (in shares)",
        "terseLabel": "Shares issued for payment of dividends (in shares)"
       }
      }
     },
     "localname": "PreferredStockDividendsShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockLiquidationPreference": {
     "auth_ref": [
      "r30",
      "r94",
      "r267",
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.",
        "label": "Preferred stock, liquidation preference per share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "auth_ref": [
      "r94",
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
        "label": "Preferred stock, liquidation preference"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock Series A, shares authorized (in shares)",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r30",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock series A, shares issued (in shares)",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock series A, shares outstanding (in shares)",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r30",
      "r473"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Series A preferred stock, $0.005 par value, $156 liquidation preference, 156 shares authorized, issued and outstanding at December 31, 2021; no shares issued and outstanding at December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r17",
      "r38",
      "r39"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from the sale of NTN assets, net of cash disposed"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from sale of common stock",
        "terseLabel": "Common stock to be purchased under common stock purchase agreement",
        "verboseLabel": "Net proceeds of common stock issued to Lincoln Park"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Gross proceeds",
        "verboseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLeasePayments": {
     "auth_ref": [
      "r466",
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from lease payment, classified as operating activity.",
        "label": "Proceeds from Lease Payment, Operating Activity",
        "terseLabel": "Sublease payments received"
       }
      }
     },
     "localname": "ProceedsFromLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesSubleaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from loans payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the issuance of equity classified as other.",
        "label": "Proceeds from Other Equity",
        "terseLabel": "Proceeds from sale of members' equity"
       }
      }
     },
     "localname": "ProceedsFromOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfAssetsInvestingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions that are classified as investing activities in which assets, which may include one or more investments, are sold to third-party buyers. This element can be used by entities to aggregate proceeds from all asset sales that are classified as investing activities.",
        "label": "Proceeds from Sales of Assets, Investing Activities",
        "verboseLabel": "Purchase of NTN, net of cash acquired"
       }
      }
     },
     "localname": "ProceedsFromSalesOfAssetsInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.",
        "label": "Proceeds from Sales of Business, Affiliate and Productive Assets",
        "terseLabel": "Sale of rights, title and interest in and to the assets relating to the business"
       }
      }
     },
     "localname": "ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r75",
      "r341"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r44",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://brooklynitx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r196",
      "r553",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r43",
      "r188"
     ],
     "calculation": {
      "http://brooklynitx.com/role/PropertyAndEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://brooklynitx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r24",
      "r25",
      "r190",
      "r473",
      "r513",
      "r522"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://brooklynitx.com/role/PropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net, by Type [Abstract]",
        "terseLabel": "Property and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetByTypeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r42",
      "r190",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r24",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of Property, Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r24",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://brooklynitx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r302",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r302",
      "r468",
      "r470",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLegalMattersDetails",
      "http://brooklynitx.com/role/CommitmentsAndContingenciesLicensingAgreementsDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Principal payments on notes payable",
        "terseLabel": "Principal payment of outstanding notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows",
      "http://brooklynitx.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r351"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/GoodwillAndInprocessResearchDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Common Shares [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "RSU [Member]",
        "terseLabel": "Restricted Common Units [Member]",
        "verboseLabel": "RSUs [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails",
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails",
      "http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails",
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities.",
        "label": "Number of employees terminated in reduction in force"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Percentage of employees terminated in reduction in force"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringAndRelatedCostPositionsEliminatedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduction in Force [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostPositionsEliminatedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r34",
      "r288",
      "r345",
      "r473",
      "r520",
      "r532",
      "r533"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r104",
      "r105",
      "r106",
      "r108",
      "r114",
      "r116",
      "r173",
      "r342",
      "r343",
      "r344",
      "r377",
      "r378",
      "r425",
      "r529",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r459",
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Common stock issued and sold during period (in shares)",
        "verboseLabel": "Common stock issued and sold during period (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Computation of Diluted Net Loss per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasicAndDilutedEarningsPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsInvestmentInNoveciteDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails",
      "http://brooklynitx.com/role/OrganizationAndDescriptionOfBusinessOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Income Tax Provision"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r10",
      "r11",
      "r12",
      "r13",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposition Details"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Computed Expected Income Taxes to Effective Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Loss before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r44",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://brooklynitx.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Tangible and Intangible Assets Acquired And Liabilities Assumed, Based on Estimated Fair Values"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r312",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails",
      "http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails",
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails",
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
      "http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r318",
      "r326",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Summarizes of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Weighted-Average Assumptions Used for Grants Issued"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Summarizes of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r54",
      "r94",
      "r137",
      "r138",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r267",
      "r271",
      "r277",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesSegmentReportingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Cumulative Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance and termination-related costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]",
        "terseLabel": "Stock-based Compensation [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails",
      "http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails",
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails",
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
      "http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, Ending balance (in shares)",
        "periodStartLabel": "Outstanding, Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Outstanding Restricted Stock Units [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Fair Value Per Share, Ending balance (in dollars per share)",
        "periodStartLabel": "Weighted Average Fair Value Per Share, Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Weighted Average Fair Value Per Share [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Number of shares vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assertions Used in Determining Fair Value of Stock Options Granted [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Weighted average volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Weighted average risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails",
      "http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails",
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails",
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
      "http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Stock units outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Stock-based compensation shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Options exercised total intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of stock option awards granted (in shares)",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
      "http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding, ending balance",
        "periodStartLabel": "Outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r320",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Stock option outstanding (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "verboseLabel": "Number of stock option awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails",
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Number of Option Share [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price per Share [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Vested and Exercisable [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Options vested and exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options vested and exercisable, Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Options vested and exercisable, Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r310",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails",
      "http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails",
      "http://brooklynitx.com/role/StockbasedCompensationRsusDetails",
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails",
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails",
      "http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting on one-year Anniversary [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r312",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Stock-based compensation vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock based compensation stock option term period",
        "terseLabel": "Warrant expiration term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationEquityIncentivePlansDetails",
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r333",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationWeightedaverageAssumptionsUsedForGrantsIssuedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average remaining contractual life, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Options vested and exercisable, weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Number of shares issued in merger agreement (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r94",
      "r97",
      "r121",
      "r122",
      "r123",
      "r126",
      "r128",
      "r137",
      "r138",
      "r139",
      "r172",
      "r213",
      "r217",
      "r218",
      "r219",
      "r222",
      "r223",
      "r261",
      "r262",
      "r267",
      "r271",
      "r279",
      "r437",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r56",
      "r62",
      "r63",
      "r64",
      "r104",
      "r105",
      "r106",
      "r108",
      "r114",
      "r116",
      "r136",
      "r173",
      "r279",
      "r288",
      "r342",
      "r343",
      "r344",
      "r377",
      "r378",
      "r425",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r529",
      "r530",
      "r531",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' AND MEMBERS' EQUITY (DEFICIT) [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r136",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Issuance of common stock for business combination"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r30",
      "r31",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Acquisition of common stock (in shares)",
        "verboseLabel": "Issuance of common stock to Financial Advisor upon consummation of merger (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r55",
      "r242",
      "r279",
      "r280",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Number of shares converted (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitCumulativeConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Number of common stock issued as compensation for services (in shares)",
        "terseLabel": "Lock-up agreements shares received in acquisition (in shares)",
        "verboseLabel": "Lock-up agreements common shares received in acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsMergerDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitAcquisitionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r279",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Restricted stock replaced during the period (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationRestrictedStockAndStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.",
        "label": "Stock outstanding, reverse stock splits (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitReverseStocksplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r30",
      "r31",
      "r279",
      "r288",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock from the exercise of stock options (in shares)",
        "verboseLabel": "Stock option exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r56",
      "r279",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock to Financial Advisor upon consummation of merger",
        "verboseLabel": "Acquisition agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r56",
      "r279",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock from the exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Aggregate gross purchase price"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Private placement (in shares)"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r31",
      "r35",
      "r36",
      "r97",
      "r169",
      "r172",
      "r437",
      "r473"
     ],
     "calculation": {
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' and members' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedBalanceSheets",
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders and Members Equity (Deficit) [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r262",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r278",
      "r288",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders and Members Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stock conversion ratio",
        "terseLabel": "Reverse stock splits (in shares)"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesBasisOfAccountingPresentationDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitReverseStocksplitDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "terseLabel": "Sale of members' equity"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfStockholdersAndMembersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r457",
      "r464"
     ],
     "calculation": {
      "http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r445",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r445",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r445",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r445",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r474",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Federal and state income tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsDispositionDetails",
      "http://brooklynitx.com/role/MergerDispositionAndAcquisitionTransactionsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/CommitmentsAndContingenciesRoyaltyAgreementsDetails",
      "http://brooklynitx.com/role/LiquidityAndCapitalResourcesDetails",
      "http://brooklynitx.com/role/StockholdersAndMembersEquityDeficitPrivatePlacementOfferingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r353",
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Accrued interest and penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r140",
      "r141",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/BasisOfAccountingPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/IncomeTaxesReconciliationOfComputedExpectedIncomeTaxesToEffectiveIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r456",
      "r464"
     ],
     "calculation": {
      "http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/LeasesNetOperatingLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/StockbasedCompensationSummaryOfStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r120",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average number of shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r118",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average number of shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://brooklynitx.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410195&loc=d3e80090-111668"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=66006417&loc=d3e8580-128490"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=66023778&loc=d3e9298-128500"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=66023778&loc=d3e9334-128500"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=66023778&loc=d3e9337-128500"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123403335&loc=d3e9901-128506"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123403335&loc=d3e9972-128506"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "740",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123403335&loc=d3e9979-128506"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123420820&loc=SL77919320-209978"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123420820&loc=SL77919327-209978"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r558": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r559": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r561": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r562": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r563": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r564": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r565": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r566": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r567": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0001140361-22-014764-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-22-014764-xbrl.zip
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M.KM-7SKWO;CZX.-5\]^MKVNSA5YDV?"JS[8_.4^?A:%W:ZWAH*GS8:?1T=O
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MKS@8$R8L/R".2_AQX=WR$SODYQ<%[^V]9 ,".@N[V!I@]';5:&T*,(U:2\[
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MIRMK.QZUX'/7PI@+UP8SS1QS ,$$B[-LH82G<E[L0&/:'6C%U>^N=P=[Y"P
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MZ"=?O#IF^!,O2(4#T*WIALY,"'2.B@# T'-1;%./,FQ9CG[-PW]$+M?JNN@
M=E2A&Z)0!"2PJ;E/M3H@:&A#CA>0F&<.^DYM,W^K*)F6AZC1/TM^(O&[= L=
MX5WD,\5>917RJK(I:!'W-J AAZW\MR2%S^0<A:OG:>&*A,AGQV-I;ZG5:5ML
MT&*U+F\TF%4#F[+;;#8& SYH6*:5FRW1JNL'&O;XIN]H;@%0L@DK<8*?#JI
M/GB(\/)6MLV:&TTL+Y17'GQL=1N*/-2B/VJ 80Y\ )&U7_P.FP2!KC?U H75
M-K(_0#*:4(  $P,-M &H($,;U0J JG?G"F3C<8V'1S4>?E#1+!L0&21W0)H/
M:*ZHJR)F"T0;>P[H(@$H2W 7A9[X/::&<POPAU*]+(^K,"RH$0'>B3Y:2_76
MR6@BDOK2EH?$^YA>4<$-(]H?X2HL)_!<R;LW[+=\7>[6HTWV@,@=$%K$'N#?
M"UIJW.)P*56*;#!B GV"_V44DID C"330D4WS4:]UD#!9>B=3HMU]'JMUM!U
MRQAV<H(:-;V!9>1I,JVER?3\XG-,I_I*.FVV*XVF4>G6VPODFB"#1%XXE"RO
M2W;S.O!_L8QTU<(OT))J<$&ZUTI.[!$%Y,PR6)LC/Y.79OQ!?T1!: ]GN>T7
MY>.J<"5P)<#._-=5339-_03J &!*508FYM:BSK)>.^[6ZW6J#1G;(:?+4]NY
M\WPK>00-@Z#[@:9DEP!U !25BI^?^EV>:OR[90=3A\WP&P<T'NV_-'N"QAWL
M /:#4CV6-5=HB\I(UQ)]2,7#;E%1\>YGQ+G)1B9'!UJ0R$,TT3A9^\HYF9WP
MP'Y:M #-8[U1!MT3M0BT^G-X:  H4]$,HT*<TJB+G BC046,H&=IY^?GL4B4
M+[R.C7IJ)H^=W8^U/LF4['+3XN@.=(<D901=-//9(?CBV*&2:B*'U]I8*R+R
M+58<G%00L4NL)EQ%"XUBCU6X[(6I_?'/3(7DUAR'LC#Q)%U2M3 KI1#C4.;B
M,@Y CGS+X_A^L7@]54@53W^A<THWQ[UB(_[)Y^P[%M<M:Y<YA8NJ [P*;)D0
M#Y,Y=X!72QZ5#7$L@*(JG>3B$!?7+Z"BIPO5* J:*6%;J*U;6G;W<%NK]%^O
M.LHGU7#Y$16.S\MY9J24W?0^?3F#O_ZK6NVYYMCSJU58 OM(WV//UY/+BYNS
MBYO^DSM]/KR4=;JC[G8=VK,C[2NB2NM5Y\R+]SN?/2WVF]^?!F38!L*GW571
ML_PRIV6)[X^)V3W[<#<5VLT]6^2N+QX@79HLL('S7@7E+9\DZFB;"/.OVL#:
M)[1%6$ULRW+XJO*;1X+G.0]<L<#<D/CJFJ$M8O<R6U!O@#Y<[TA;\&D),\;Q
MMOCCYE:>L0RK8KY;1ED57RW)"&+:V$?_S-_.;\Z^8NV9=&BC-K$EFEM_ZT\2
M?WG,)GM&W84CZJZ;BVAD(T'/'DJP=<[_)*SO;17M7Q*A>\<''Z_MX+N&;DS/
MWSI:YR%?/A+7.GO&*C^],5[YZ>#C-Q<'S#JWW-+Z(1L.R:<C9O 6@7NNCXS-
M]J[PIMJ^L*8::+:^-\5%\*WC2^'D*"+<9L;Z[##+K+\MCED'6?R%CYBC >*;
MG"J[2DZY-4[9V!=.V3CX^!5#3GTVY.%,.[4#S'3!B%IQM+EF]U5<!>O2^(8=
M"EM\[;,WFP$:A68*XMW9%T_<6W+%E?2UEJQ\/>??TT1C<U]$8Q-4*IF[B7D3
M.0U:9;NOLS\C.YQ5X J'$B52:13:5RQ:D%E\H@&-=A7YYIC)7$%Q;RJ/H3AB
M%Z?>[9-%T'I;%D'KX./_=\T#[M]RZ__?-4O@-7#O:5C5WA=VUT9NMU!-A09!
M)!*ID(7U7.;, IM8U^>X1.K$<RU14(?7 -)%3DB77$ZY2'DKV=K6V%I[NP&%
MPO&U=N_@X_]@6:6-!6VWG' .OG#4WRD;5NL-O"A4%1@8J]@U1MC>&4;8V1=&
MV#GXF+"VODI&%2I</YI.'?J;^3/JX%0<QO8:J+)-QM9]6WRM>_#QA)*7 TRN
M1F0#1L9&/I?H1SG//5$FS/ +$+>]I&H8;TC0-N&!)</;%L/K[DTDO]O#UM54
M_2[8',40K&)Y@?>.O;VQF'[WT\%',<'SW!45:3;6#^X8=S)VACN=[ UW.CGX
MF,@S],,QGQI7?O9\#@O*3(0-1.>,*Y_?8L'3N8MSUPMF@0(2E5[XT@O_EL):
M95RKI*@"4=13!*JA[X- O>I=WP YHD25#28J"S-&9;CJ1)7^:C]C2RPT+;=N
M33Y"B-;VRQPPWE Y1(R$">9A(R?N!KMI%+P"*CX1R?8BPS=&'S6+2+N\<X%K
MC>TI!IU.8&7,=K5/<;,=^3MQM23&)8-52V/V):_;&J][0\FY,;(JM"2,0X,4
MT#7(X. -=D,1W7>"BO0 "R$-=JS%I]B3X@5D\!MFCWN1UAMC7#)%/@D;:)^Y
M[)72Y_XM#I1_NVRNM-=VQ5[;?0_(KZ4#I"2HXA#4DZ3CWF3V&DTT/<?VP)9I
M'3GY'EK?'',K<@HE(.M[9@>\L91<HT7-8D7/.ZT?3> YLYU3YYO[I &\(.?I
MG_]\T;OY=GW6/_C8AY>+QI4%XBZMXG*7;8*_6&SBXO3L7S10@-]C#^;EF8A2
M/!6#?6RH!GZM\O;/56.N"^>#^\[%XN3SXFP=L=*UVO"]1 /*AP]N_C$7$?8M
M%<]9;)^[7O>_3MP=?8TVOTM6</#17M(R=7Y7"XTU']%74TMWUES=.7.N[^:3
M6VEFNG7F]=6<WU]Z%0M[^H4S"P]K;E/4 S/F#:HQY0(XY\$E(6.'@"0F4,P-
M=8I$US@V$J<6*A(D+)>SYFYE$?.WU_[RI/?MYOSRHG?];^WB\N9,NS[[N7=]
M>G[QL_;Y\OHW^%C]<GGY3_R[?],#Q6IY-\XEO767KU5UG5["J6]6-S*F5NW,
M=@,U$73H^7?,MZJ.YWV78Z(D%X_'A\J4)1P7H-G)W!0Q;0A;%5_Y]BV&85/-
MCK_ ?T9BM, UQVPZFCA$H["[S7C,Q%7_RW5/39FHQ).+:NW>XG3M-*SC9]6Q
MH3/(FXEHAWR(M\AGIQ8#ER<O$:Y%^2+C[($QWFIZ]]+7I"]6+SG&\UYRJMBR
M&N<@I+_RI7\=IW)'J'1IE!P65. 7*E6JX#0#RDET35[!-M24-4:"-GTNWA0!
MCFWW81\5^:JY]Z=>YD7(DS""/K)-;>HP5TYSP*F>XO6PCHAK(^[*.BEZN17!
MP;!;9CML8#L8W\*[O.&0X_1FN,]D4Z1MS>7<2OW)[S%$8)-:23/3 )7]F1;Z
M\*UX,ZXHF6PU]<08M%7GF=X^=@0?,)R !K"UDR1.S12#FIV96K7#Q>2U"EZ)
M+Y57T!)-,8@*?N1 :CCB!#["P[C)@E &/N 4_I!Y>QJC&A[$";DE6Z3(BSD7
M=\#8J,I,% +) 2P#[MA\*#8-C#::3..NZ<G(L'C?6@X>>2"#W/3N)653__=
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MY0K46) ; ? ,0K4PI.&>LEN$CV3OXE]CX'M !W]B$QTRE<5P5Y<[%:7GX--
MNU":3O)@N,^>R)XH648A79^S]7,\GA*F*[%[T]B]1 X5%N5_4RHM(B:(/_2Z
M)]P>;(D >RT.A4I"CN: <\(:Z<=#8B <1W-&*?&HPDS0:$&?+PB#H1U*;WR)
MSR4^;QF?:=JIU(])$\?4?=0TE+L<E0X9]:&HEHSMI-43TM-(&@Q!NR,U;D#(
MC%3@<F3?J#1*+<8=+6/U:&8X'%U1Z,E);%"AZN!,#A^5(.D?3^ED<TYZ]8\*
M<)EH39/O9[L$5>9Q;"B/HTSD>#N)'*442IW76Y5"0PREQ.H\V-5^-(V[O"KW
M@'#Y"GL6;0D9#^0:X*7%)[:IS'/7 ]&!'CB07K>V'P7:X<GEK^>G5:-[E+&3
MM3'#KIZQ)U-9ZAJ7=GHV6DN)%:5.5E+#-JGA<MX#EFA:VIUP,$44)Y?ZE>@^
M!9@?S +T;Z$*)M)RS!E(TRJ8XB"0R(W/*./+M+EKSE0F@K@HD.7M)7*7R+UE
M5L^R=@8&CV2]>:BBY]+EHUR2F'ODHQV2-@E MQ_Y;)(DFREE?VI/.3DY$ZT_
MMC4ROJ38VD"?*.Y9"U$&D!?6Y-@IQ.>C"$2/![8+FV*,&ZX!,AKPQ:UK"\^.
MC954)/=!'"BI:BU:**EJ062HM$? 3^EK6K1^B0Y$GA/&4 +;)]3!\([4>$A,
MD%(D0K[3>+0AJ$W<U2(,=C#'<\EI!2($$'V 21BHJU&H1]PGR(5;:A&!N/P6
ML_U$$@?EE-YIEA^-TLEA>90U9DXH4]5B4DVQ @R@""$HKA%1#7(]2Z*M:(X]
ML>-GQ+2I33TT;6Q!UDF@).W3<_E(]'K'.!C_,Z+P:$G0)4%O/[2BG&DDJ&:"
MO+@+!HWG4EMXP.LQ!]H0"::!&*OGL+M 6DTDO(2'[HY+@V? ,84CG;"))0!$
MGB"$X6$VE[1J4C P"#.IFV/F3S(F44D))26\A&\@S9*1'H#!Q_X!.XY<T]>8
M42#%@XRWR"BWE$0JKUED) BY!PR^0A3D(_)3H@F5. 2V2(L3>FF.1+V+'=65
M.'PNA4NFA(/\['G";<!C$2/BFY@"7FJ,)5EMFZPP&S).N)6R +-E;"P3HG17
M_)TL,MNW1/*\2 S#')1(9K'$"ED01A;E;XFD0DR(S]ZH;#!9,*%A \9 9 #9
M^*8D[POE'B4_>MJ$<RPS8)9#4DI%5J7I)H) 2XRQL5I224LE+;U,'DR2GBOC
MGT+\J,@^"U4L4QA)Z-=P,+4:D]"DI37##Z$L:D1T3[DV E6O-B>$J'S"%J[O
MP(3'*#_XH]^81TIB*YA %T@?RE#X$#&[;>![S*HLB%^A+*:%<,8ADFQ(U6KA
M!JA\QA1A9GB@JHW"DBI9FSB?#91]Z!HGI3*7YQ/RMBUPU\W5+*/!N='@,AS\
M=L+!_U6M7EU?8GE9@@,X6S3\ 3[_8/SPPP_5ZL=\ZGE>[[S>]8UV_MB$5P9L
MZZ<#:K@$IPIK[[GFV/-AB7@PP O>EGK0:!T;CQ+KN:# X]2P1_E&)/U3A'H>
M#>0N]9-T@VQ=>CR]0F%ESG_^IF*.M?%RB0<*$"Y='* )JGNM6=%J>LVH:)_.
M;[2OW!^!]M*/!DFAS1I%+=3=P5U9<P,&!I5TDF]-E!ND:VJH\(1^2W\%K_-O
M[5OR, ?Q4M( 75UJ0XT]PJ0#<R7I+Q!7H5.K#BYW#A>P((Y7B9IGTP0I1"6G
M<84%MO4(1%:<%D_S$YJ0PRA=;B(.4K@'/7_$7)5+9U&&12\: 8 THT:GKVML
MXJ7K<%:=9WK[LIPI#W3T[O1ABM+\N=V(E@<KMD"&Z0*JQ(5%LKN'34TR9,40
M5@:2!TG4SX*YF:K0PF"X;XFC%QZA]T_'_;?%\TN3<'%A4]_V")?2-,RH"0MF
M%U%QC19,P:@A5 R#3-D-=2K0;ID3<>V_]6-=;Z+31 O&V(P!JV/A28BV%!]W
M>17,Q&IXYU'WB]+742+V%A%[")+.NQ.5R6G,3NKA!3*K<3XNL&*1IR?+]19E
ML*H-32I.'RRTE;?LJM*5UG-:2GB!\ ] _9*U[:".P5Y#.W2X4DLX2C(UKU>R
M%B  KAI!28\IM212Z6.R75&ZPQ=!Y$%@Y# P$HT_,RQO!V:E_0*+Q191Z2,E
M=0E[(,27542+!(D>P\QO^"ZC_2$ ;C>;R!PVIDTC.!<6\*0J\;]KQ[H&;,11
M\9ZD5P"EO4VY*4K)'%LXBM#;G#X2TB:F/J_*C<2QR\=H8J=VH)I8+:ICZ4-X
M4#-#F"7;3+0<H8+U^33D:/0"UQ!:6+IA644;\/".4R:&\-W'Q[GYVN8'^]/%
MJ $[@85QH<A%+NX#84W:L1)ZS/PSLL4!YBFPWUQ;#,<A/YUH4T8M@$SL(()9
M)\D :EEZ[$C7Y\^]WM4Q/$"@.$!TPL.Q9XF^#>JF2E:%!PBF@68A#*QTTQY:
M+C9!4R0A:^"S"NP:%@;B2NAS J[$I<PKN#7_!CRZI.+7I^IDVG8$;#7 ]A*7
M24IH'J6B+UJ$8-+6D.@&()L+P3%AX 7=K?&KT@>2:4^6/;H!-Y&'+'O*LEL)
MRL##5*P)MF![UMP&,H&=U)9>'+G7<9W./R+VZZU6?2I: %L?+FI (I$KJ:OG
M\<@RCX;EB=XPCB=Z6H >:.CU9E/K4T(OUT[(Y:6=^A3,[D= 3YK1A WU@>N<
MVGSD5;23GM:M&34CR9H<8RZ72VXV]/ _PM6[8A^'\(XCK=FI50VCVSW6I+/P
M-YY$0\!LYF >8R^]4+N[NSL>2$2QPWMB9^G9S:DR?MDMBE$8P*9PR]CWHM%8
M1"'40V6P@E'X47#>.(*1F'[4CBBK*\0],(0KX*$^ >OV*GU1!\[E+0[<X7<O
M330RNY?%4>%J0"VC!K8WQ<PA9I(61VT,%*LS(]GED=]/X9E*M?0]1_8C,F<A
M=LOA5=$X*"1M$-,879FH*'(S;-05N4J"Q]QXY+G$-N$_28\=$T4.Z*SH=!<"
M"I2!4;:9&:Q9>AU69#B"5*F*A\DU8:A94PG.G'^7VH>*@IU?_ZM:0UU95J?D
M;HM:6]'*<Y<MGN\$'KTD.;%LJ@DJ+=BNB]J1(:1&\-R!XX%(M.R _!Q"$(#%
MZ<%6;3,C"NV ,XK>RTUIJ"Z-2"17.=:$RJ)^M/MB<(3<'+OT*D6/L%,'F)8;
M2 $O>G1HGVPOD SK"R9EHDX#7XM?E7P2#Z#07TIK "J^P+-SHB#E3$J^^A):
MQPBQ?T2@-TBM>IDZUTN>^\*R)9=B,VR7'F5Q4SJGW@OM'3,@T#F.:+0T'K9=
M^J9W(Q=EH(_?(^3&$4@"6"O*'"O&Z3CR2H"?8+G6U*&.CRJ1%BR;*-5#%U'J
M'*67PR-X -()3J+[4DOWQ_S.9_$;4'>7'68JLKE6_)/H,B9:FI&EA+ECS,EX
M*+D[)OH0GE!48F(.,HQ<$7T/HJEJ,BE:96IA-/'H?:!\<XSU*VZ593Z(951T
M(ZE6>$RH@Y']'44@,#Y^#ZH3WC[/0A3.JF9EHD^K>I&\VJ)A?<[L6(M! DL%
M48>*MZJ*@_5CV02-8LMFR4P]SZ$\;@?)GV/'8(#@%)?@2$:!K,&-*$"IEA]K
MN5>?OIZ@=8K<F5@PJ?[8QS42A7J"83#*,/!M'J(''#Y330<'!<^;B=^EZ0:O
M]Z8R5Q6)G-XG++WD$F 5N-@EQ/H$9"X+M9\?FI^?CE &YO<W,/]$E7!LP_)2
M@B.6$2!!L$P%(SE<><%C"3&9PK<D'P(I!A*%2;!SY" 38&-FY$@% T2,[87
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MV-1_( Z)2X.'W 9:2WR#)_+E_$@;1#+@H]K\SO> D#AD4X2I3SH;)>Z;,DE
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M;0V]M.<A5>O9Z C"469DIHE. 4K$R&8)032@%P45:N<4R7X?0C0&."'*G@S
MDJ2"/;GAP$%6("U8G T'C (Q#$4L=J+,TQ$2%2E6,XZU7^"HR$(3OV9<\8.
M6H-0*S@?-N]-R+HCD\MSX!;:(IRQI[K_I/;(PM"W!Y'T(7TY5R<G+('JG--(
MA!-D\E,E=JA@<%D,6\7S\&!!_JW020408D=RS:A:+.U8T\!X25R HJBQW?PA
M>2;>"=@)"$S&@JI9S&K:*>6:,OU1(0<Q8G&J9L94B"3]X>KL!O /PR^8K.#&
M6/OB5M]O,L62^3&ZSKLW*QJ)$FH:A5[L>4]=OW<6',WY9ZU(- 2*-ZS:E]5U
M.GL\C3@O1'84PZ-(NV(3AV=]GH8Q$,#FYUY,70Z'3^Z2&)SJ^G \8>C3,[D_
M$,07Q"X]K#B9HM\&]5M;^A)35=GS#YM;_!W%*%9=3U$G(!!LHR'0:_X25^-3
MX"Z6H!\'C02'?K)\=H=*ZB7JR090J6@-]\ !$#.0G?$<>TB=MM #[.)A'H)X
M@!<U@.U<R I^! Q"<9Z[*HU9M38B2/)[K!&/%=<'#D/V\<D^5_* F7H![(\4
M>-#F,<='+-# ?)_:$?G-8@,'(WG,A-<>UO4?CBI9 OQ#O+1*?<2F6$)P6*O!
M59J+?)*IOT0;FZGDP483O[/LO_X2G3?E%T/X>13!>PSC!VGG36;,&<'A'K9_
M>'F_:F](%8+H/Z(\9RI_KK>PW4LX)H>-Z/!:C:859&>*U24$!?2,Q8^)NW7.
MNX.6#@Z4\JG'DQ6S58=-X3(AUXX0)A9@PEA^H<L0([P$1_W2.FP_"&4 3-Z=
M!9,$Y3Q1QX$&A)[/12(=2K&:LC[55[%T0L(2L)'76#9-)\8^DD#S3+1<%">1
M403&*'O0/=JB_Z;2V@\-$0]F-.14KDE(\T9\K:PQ0ZQ2:D9U!FHSK%7^%Z^O
MTV?M]'-_SC,U2+J=DDF@?":"A[9K/\"Z&C^(A[3P+VEXTZ2Y>$.U5F9#P;R[
MZ(XREZ0:I1+T4,.J)??1AA2OQN0>@ATM&U_>7'ZE8)_RTO0F5-1([7(^%I1J
MP9_=.RRW6_MA;AD5K5W_8?Z%\F2Z/Z1J:,7WN=Q&UMX"CW5-+_+9B(J&,U9X
MVHQ/M<9$&S#(Q'53L?P7YP#J"&1^;4[4$9VII ,2!@1*MZ6OTF[S.'"$TY<$
M&);&'0'?Y-52%1\##GQ'U9&\I*C>A*EL,M3%,S(\GA&>8=9)'!$M&-R-Y9D1
MRA?*:U/-(8C+&:#;IU>O?$]_<1GH):^0*X;A<>%R3H-:;) \374@,?Z=V"46
MPTBBR,10,X> (C(6U2!W1&<RC#?+BC@[W=9E,,/S$![9:_7EF0CZSHGJ$]_&
M^ ?#_?0]Q[:T&P&RP^NSD_/^S9%FRBM0V15[#Y+-2^?T)'&M46_!@ MUE@">
M  &]>1.,R\5H+!'#Y2- /=+&DS[@X@T6F5MQ34^FK$A8(G&VN_3!9\._\['I
M;/J!#+G$6(,]:+&U@&D'(ISFQDX])C(:57\"C.O!.U3<7"(1IK,0@ <8$+3B
M^GI,GBR]9@7RFC5*KUGI-7LP##G-YO58MJ7:_U*A3)Z#00964CX*D1S@1MA+
M:QIFXY84FOP[FTP_4'!R,90I1\_@,T0%1B"[>0E..$PRIR3'BSL5N%8F]0<8
MM1WK0:L288B+@[7M@]F!4HN[HBS2 _'F^RB95!J1$/CDI9B*1HV)"D,N*FK2
MG#HB.L7-ZRN*VWS,<4<V=M8=>9-*ZY298G$"F29S]Y*SS>;QJ;]<5980=Y7)
MYKI2N1X-.J+BVXQRJ7*Q*O"_<VJF^FLOE<*%5I64KFF_'5HTH,!FTA>2X9E#
MD7 DX\>BR#Z2%CLM!>BF+P;+JT2[!'MJ[PV:(&$3\EU+="7K7/TAXJ-JB?BV
MFJ%9P*^3'O%*S9=^(#?K-P#)+7TE P^^)U^,>/0(?G71U>13?V+.E<6K"G_)
M CD$5N&%V4;X9!)'\'*4:LN"9V4);SD\9ZVN;@+IW\M<%?6%(*69Z7A3L,!!
M;$W YB2KQ\-1%H@M%>TOD%M5F4Q$S2^11V#FX<3&M$.X<NJSOSPY,$:\ *L#
M4T9)IJI.V2;EQ*@2Z5\ Z6OO4TQ_PPA/>28V&H%A41!_NSEVRHL>6^UJ* B*
M2%&@H>2PZ,6-N9<35?ZKXGFAAR.(*!+EC#P?OITDB=2H&OADS(MI.L?:U^PS
ML)1<3->)G?BBB2N6/[H>/7=(7?V%E$U4CF6918<W(L]/I.T(;ZG8C:QOP)RO
M6P_4^#@X&<23'D1X2!R$VB2&7.G.ET^#O,KJ)94$(,(K&1>#HJ?9PK!9C)^8
MKRS3^'Q*._>2;Y2ZSX(D<2EN3Y^N.!8IQ!<G)Q<:& (6=T1Z::PWD:,G7L0G
MJ2[%%)H%D5:;>Z%TG NU3"EY[!6&*1Q\3!1.Q$@J1L( AE0@*4 A_-F55/H]
M'L,93<\083H5HPR.L>H?Z (LP0G"12BB,B(B7H$18-((4654KO?,&2C-VF&)
ML^Q5\G O4BPPJW%0DTT9P,;*^R3TIC1F2DO.,FAD"Z=P@_$H3BURQQ-F+1X2
M:$85!W2(U+:!&0$9< P+TSIS W)$ZV $HTL7VP3#Z1(O< .48)Y+2\?+$/"&
M+BP'E15)KVS(!$R:J":J E6\7;33Q 2Y!_KIEIZ^%_7T-4M/WYOQ]*UG+ @0
M;,YND" % %&0^;VF/JUC4FS0>*@UCG7CAT5]7!!\O$Y%_X!P.# 4&."*R75K
M4?_Z4XIZ.!=K;;5YQ597[G0S;;\:Q3[*4R_@FSC)-WZ,UUXDQKEG6[[LPLFN
M>$$13C:V,4EU>IZMO 5FN"!9<4<UO5'1:G6<F]ML;NY\#CZ>S&G"6^>!ZVYP
MZR3^LN=<QP*WT;M);;L$_$9/]_S7_3G6#2QC4\=J%(PY;A!AQ*S)7=?W-G<@
MM;HN"_0M!M:&=O@I=D>DW!2@CAA&4UQXM NJR(N<73_MY<&NTK[F8M!5.([G
M?3EPAC2A%]V2K@?6LFUYZJI)%, 7Z^LDQ53R-G>R/7>VVM]5, ;UXG(OY:PL
M-;?MG'&M"8J;=G-^NC\J1H%.]Q(DS/X<;)%TMVKAN./F-O>_&)8Y2<(R7]-A
MF5*M2V&!B/^$6BJ&932K=31&41/!^-8N:!LO<EC;YT4[I'H5D'^\N&R*0[NE
M;K4EW0KYT/Z(_P*=;*E7%5:O2CZ_0G[=F,<I40MY,R*5G(5:O:*U*EI75.+7
M5$+Y8=5H8*+:_ZUUR"(_2A6HRGY],H->]>O MG!53;4S>%XJ3OH$GYB58^A+
MDG*69N)8W"&_3#K_IKG4'8'/?W3VS>82[,OT@3)]8)W3+/91END#9?I H4^V
MF.D#5-NPEBJDY:5)/G!@KYT[\-S=;8O@7^/4MYU)4)[U"^05%.&0M[&NIQSR
M$G-JG5LS*;_YEYQ196Q=&C'Q).!"\>W-X>MVTQJ6+W:K1+^QXRE.DL.NGV0F
MY8%:EB\UFG?R!!_WQJ><(*8VK'(EO'FF^-*B_D52*8H@]XNB7&T[L:(\ZQ<)
M!Q3AF(NBRL:.YC?/O3=VI*^4ZK'K"MHK)G[L^M%MFU?NL-):\K?7DM\OD(I2
M!$%>%'V)$E.$EV"/U::BG':IG19!.]V%_)6XYU9%#@43O4V9/\ET^Z[0*!5L
MJBU&S\J1#*+_=Z:M#K9-E<V"Y&SDUVAGHQK3)UV_,[W+[2 [S\V60Q!QOLC\
M*-RSS_TCO#O>9F;F?-*H#)[I>.Y(]1#'S);5M]1$X_IX+$@:)>2ZI?<T63B.
MY3FTCQ96?]G?SA(K\#;QNM10H%3/;<[,^&K1H0>N7[QAKBDMW377=W,S:+*&
MBD289,&ABP#^>PVX!?>QZ14R3FHY>NY:MN@-%BSM*;/)MRYT_\%MKO'>1Q#%
MI9Q7R&0[+M4F5C6>I2ZQ%1K!&7>.E3/B95\XV2W/SS8/JU+3><_G5GPYHI4<
MB\#I>AQR9:LYXMA]4.]^H#9A"5Y3QW4F1@TPU\2.M4$TQ=$^ I5<;,6>/A\Q
M0!B[#",1!3Q^NVS9_&JMF=9^<GX'G:]>TJA9;FE36\E_X3K;*UMSINCR3;;F
M_'0-6HZA5;6>DJ#NK>?04!6C-==/.MU-$]ML!:$:=3/E/C"'23(B[8HX XUQ
MNP):=Y #?.46<9\3TLR.M5,>@M40Q,W,13]KG+] '?QP^A,\+:=7U1RB*[9&
M]P?'(^]6\MC%\]"TPXN3&[W6;>JU9O>H$.T_2QI<=?!O@09/SB^J-4&$Z>;P
M&DIG;.4,*KOL_BYI1&J.::&;FD!XYR7]I#DHNR3Q_XS81$:@?<:GV('=L<6\
MFBF W&9:':OQX^MN(^>6^:LN7TW >;2W"9H6!%ROM=JMCOX"!%SV;WQ^_\96
MV;\QP[CVN7_CYO37$QIC+B=LE@IS*:P??,F&A/4Z@9=/O3[HS0W2FP<L^,Y#
MJ3Y[OCW""63.+)G,@B-/:& F0G9.IY;C);%1^L !%,+)+SYWT61W<?[HA QW
MP"_-B4 G%_IV!47U1?_DRTD%'@#*-2"4<-+@4%/Z0(-BI78^X*C.@P2/U?.O
MWG!HAV&>D-:T$W'7B9Q#$SL)8EV#IEB[?T1N:@C,Y11.SE-<9<D!MML5K6/
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M>ZB'*)]%UO5 3JK8HYO!,M@/)L>)2\2A5_#V.TXA$8FHRGF>E4O8CM6SD*7
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M[69!FV@)X1_?_?>^YH&_,!CJHT_0R?')<\E1"HCT*QV77ZS4]A'O["%+4 Y
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MDVPV>Z3"3NLVFAG#+D&[$S8D"AP!/RP6P!%RW=JU*R1==[1K*_-A,TM!VA3
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M2#7+-X:Z\JNQ1'/H@J%;]!)[2QYIU1'< ,\IFK/-<VWVP1#5L ZGF][M5Q7
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M(B^K_%3$+'TXWLZ]A@0#Q&,15-WX5T3ZT\Z1%5VTEO*%#\Y>B<W/[B!=&G*
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MKZFAQ6,61A;"A& ;I> 6*2=7(P#5DES0#>36_N0YTI]!Z-J @KCWW%AY(H"
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MVOF6[\PLEB,DDHTD$.C2@N 9EU0S)HQ#5$P^GQD^2@-]FTF@7DC!^<H_(3,
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M,S+LQ6#46CZ 0QQZ!.B?G)*,,3AU?UX=[4^>:C31*>(T6N>4;Z:X ?V*=PH
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M*7Z:&,.A3LQ*9K;M3E)TJEZ)D&S,RZ;M59^-]+:)MXLL'KQ5.J?$-YAC%6A
M&>18%5;<XP?F5+<63YL]S"F$[4;.,L&AU_W:$E<W&1)I[H;:;\9NIUAM,AB&
M7X-O0.RF3!D^)]N;#1D.7QILC$.KO=9V5"GMFE_::,&#7T3I=\;KYJ?M5J]7
MPN]*?/P2\XE.?++&I*%N3ZML46,P=&.R1A6CX59#R7WR6*Q^H6L/>'WKB(Y
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M058I$R_Z[A;I??-@,;UXKJ5K/!G:0TKZF\QT[R6LX^?OHIH!6F@!'NW9(-E
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M'HG2@'%7+K280N)NT32WSNV]"%)DF[&H@%@@FO.9%>IQ.;8DIH+0]!T7;[#
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M?*!-=G1IHR_ 6I]S\_S7,,0]2ZK&D"0Y"QVWA?;/L:61='UK>9:RGY[598C
M7>WS%\]LO>YH-9F:PV_'4P0"ZX8,0FX(MH0[,EV3%'M=7.2SG&6)7X%7I SH
M**_;HNOB\'H1J63;@KSS$-D045$KTN-H9[P6>DP<6:;%.)K80Y"!IY$]3!K&
M2:I37V11GY#K:=GN R>BB!N&;^!YZP7'[+C^-8Y?&MWZ%>CWO.WZ)N@<?E'/
M6;G]#H&#N\1LEYTT6TLAS6HD6Q\XW^#4Z:<>DT^@[S$,H2$4VI%[[*);#K3
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MD_8NU;/YI)S]Q[\<OWO^ZN!HGV3M_[.W=[2<GM?-WAZ+R__]O_Y=^MU-:5/
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ML6M(,@OE$2ZM$(2;DVBKFK3U58JY6 ='3.460#%<\6:=Q6BU2@T)B#*%I&6
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M0(9FII?EF/'4H@@P6/_E!%J&]91P !97Y+,K3@WZA<352:%@U_:WG^V@8(0
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M;;=P:"ZF_2M-6RIE/*AG)6)7/G UXG02\=Y^TMJ/VC&M3CK@_O'Y(1>8XP>
M.7ZUP!P7F./=[7E J*.4*Z&@;3@K9Y+U0P(>]N# 148=83@;(B>0C'EDID-!
M<<7IQ^8H!(T*$V1$"[R-#JR%KQF4X$]_>F;S<\_H9?K%>JJ,=S38%T>*A!"X
MQI!>1-;]>!HVUS1)9; Z00G\B<8:VLXX<A@I6 1T_OCBQV]7KR/(95PG7)&.
M C(JJ^;P$8\;9=+7"4]+6O-5:=@,HW^\K=N;^LD^&-LUP1Z:GH$63$]KD,IQ
M/&%<@-7!Z8TTHTPM7,B [,^>T9/GC1V<027(*93G6UTGHQEQ,!$8-M19+H_K
MU558)D$J8>C+_=H,6K2 H;#1(+/4;%H^8U#TLX1%O?K)X^DO@1<@3C')4"3%
M@ZK"[7^K5RI4ZC,!/4Q@EX2.%)K6Q+Q(.0]Y..%BCJ#B'/4RE ]N-Y3K']UI
M$/=.";P])S_BL6_ML;_"P%=.M!(VY?YP%"X\3.P6EP@ &&+H.^K(AT!.COCM
M&&:X&4:@V;;5.1S13[: 1D9X2K=EOA&4A2>(F\(D78)/5!R,>!D#ZHDN:+=-
M)V@F:)CW@.04;W2\"P839U.P@=PHBZQI?SH&,QG7N7?PA$WR6?_PJ4I@]F2^
MOEBBE5*:GL\5HO>R8F1I/MX-A'7P9VZ0U(V71UET&U:F-Z&'DYPN:WB XM75
MSY+[BL"]47K5$#%-7X'H)! M3XB>":,OP$#]B?2ZK>N)1%WO1,:;?DJOFT$.
M646/P5(JV6TZXRRZ5Q\)<L@MDT_-*94P',W[=:('YB'2B/=.*).0M;0T1>JY
MV"]6/X6_MPQA)3_$Q.]@'E80-,W'18(2AT"<,(RE?%*1MXEM@.\!U.QTM_%]
M5N0D+ILNCC8(V0!1@S+'369*ZR+"V^ET3D:(JQBKF !\(A%/HX6]9S_3QY\]
MZ":;R#]\W$_KN'4<G8!C4B!;C?3(R0KK!E1RCSK?I]Q5 ;E76"O"9XSA)%!L
M>=N$^]K*L@Y&N52#I':C./>-J-L//%8AE#MT7B8\&WS?CS\)O"N^A-0CI&^R
M;!U@,)3JU3HM784_S?B1Z6S )%AQWL-HI64-4[(_T(HDP'[9IDKT,Q+X; \5
M6QF$-QZX(@T<XA5$ATXB5(,L ^](@+BK;OHAQEP/#.H$8WI==^)A[/$])@AL
M&PC2 -VD!P"LJ)],%C$SMC_^L\!-EF0:-4CDXI[9%CEA\#66H GRUJ;D8>\V
M!E3Z-LT_C)05?)JC_2'\I-]XFH$7PB']N;%^[*J-FWYSX_.<6O(#<9S)E3<<
M]CK@%7+^;4UJ3AJ9TI17N*<AF.9-,X3#^S?/?OB/%\^??/G'WZ:I%/-1KBAR
M''@>@>FPN9/GC5+*RW:/=$1^"M:] I"\9,-$FGU9UW(@\,.F/)!K76:9O]0U
M:,^3J6TN(!RJ42<C<!W@2T $8650765[(S2&3X3_214!RAM@JI*1<\"PJA'A
M-ZE\CQ%K%26W)7WI1QRJ:!38W4G'8.VGF#!Q3YT#X!\Q=X+9B/!QX1<@#C(Z
M/[M:) FVO&OH^3A%#K>N&E],*#"&0[':HN2DCPHK?'8='!9VG 0,(?\8>-Z2
MGC %-TKL]3RX1% )_BMBIE87\>=^""_KW^J0/5ZO?ABNJDY=V[;>A+6C=;=?
MKZ+QA\M^C\/@JR^^^N)B]?-UT]92G.[HG&NZ^*+L2^36+VO,R#:[H[AM^L=@
MAYC8"$LY*DZ4N3$ UL\H0"8O7O:+?^PD(0J[1T+WJ?2*HE 1!:9(UHOX2U.;
M5LX?V0ZFT<0I"IT[QEX@&%8._EK*L#V@=21A;,3(^1 29@TCDX'_4PZI[?+R
M 95S]&D$UVKL@<:-M_/@P<M^*R-??)#%B1Q24SB%'[]I1HV6X^ (<R/(F"/=
M\>XTP"Q=*2%6$(0^!KPY\C95F8$.5Y($D+=R (.-9O+1!+M(MQ3I]\(;WE"=
MRJ^ D0KQND4*Z;O=<.SMN73$?AZOA+0-W'N)ZC9XNN2_?'WFR(;0@+5+XZ#(
M@R$VPU4D.9&$SY+,)R_JH 8ZCA(H\C(D]:-^&*2^63C$"JZ%3=P[YOB($_8@
MEO:)W&06C_O!=M+0:N:V+)T959)'ZB;OIC_I"5FX%<938IP5;5D:H^FWV0[@
MU)&NQCD'&5>E0ERFD!$+G1/!+Z*G?.V2KUZLJOQ([&"XJG[5]I=4]8TB+^KH
M*<R4Y4>:K(^=E@.RZ20)0#VP1V.+.+KEG]Y-<0G/&#(R5,5.@S0;1TJI=5'&
ML.?JJ<N6%ZY0.*(MZOSC*)'HW)'\';L#(80-N3<D6<PW"5I:)L8%*J<_KK&8
M._A#!C1<)8<2D7E1;28KGDJ"07E0R",P@DLJ?(LVQF?6V?S]TME<.IL?(K'[
M(3\TO#=EF<@3E>XT*N.)?)JG XG72M1,:3CO'$SS20A:PMO%@5P1MIAI3<X:
MJ/&'I/#U:50*"8AW(A8#(W%SL\],3!T>3\D.4^0RM3UQ?#1'^,A:HC=E5-Y6
M>Z)M1<!@OX/TECYYZF34A C#*HP=KZD%6:UHAVZN00=W+2 M6<B$?P"KMQD(
MXE(1I=Q$0]F3JE\3'T]PZ1IAA4>X#NG4FWK\K9--7I..,I]7=5M+-+F)/6_Z
M1ZJ\5ZV]:LQY#W3<2]"!-7I":V3*54*Q:B0;D?Q0WWU,)W'2;B$[)H$&!V'*
M.)Z48JFV'6W.#$PFUW0=.?X 41UJG_:C_($T7%SSZR4I$2*[MCID;L_X!\I"
MP^O,R(N$.!RO^SI\'CT5'37*\V.^CKX!"DDHJN.J/%-W:#\,!IG4X9D);RWR
M?!:$]&0V1WUO],C<O:RW:D=*]</W+H0:%9PP]O4M,EJE?.+?1UV1"3$ZV?A*
MR-L3&Z5+W0 T\.'W)/72VG0,W5TR,25C)!7%N<PTSL=8TX[$DE4A>"V),',T
M=7T7PZ8\6>7=9]N56 E">FT8C]AED2'-_!%BQLJ<IU/U  UEJU1CQKUF209&
M%34$<U)6;AUJ/]U)-UWL<+ F95S*86+X^O[\6]"5HDW!_DO*DE@<VH.4?VWT
M36(X%,]W&!KTI)MQ$ZY!,2CEYU!L(SQ$B'5WO*]YZ7T_SD%KUDQA2PO+=&)*
M)95L?(VH+4].2VQ%CNZ8HN ]S0:QG[RW^[/4<V*WJ%4=7#R?%D18\\ZS35-=
MOR@VHW@E791#<X!6@:]":$<A%_J8<*]D%9ZU(HGFY(XN[Q(/>>RWP*>^)$FZ
MACY1O*ZKFX9/L\(R9X8FC"J.-<06IU#UC7(G6^8=H-<"RF,RXNIP3II(QN^1
MZ*DD*5JJJ+*V%FDD"KE75^4=Q%0:!SJKW](;!/<4Y90'Q1+H'1AH*7X=UU8Z
MM]\B;"CH_WA55T0<#NF1^L"$%D^_OXTOH$;/SI\B+=4+)GYAK6]1G<J^[WI]
M(4*D8BULG8NWGR?$^[%_R-,<^ULB 9Y''Y>E5!P+<OK\!4D74,XRJB^O(25J
M2^&%]UG'/U9R?'E15I<TQ'19L2+E-28.K[)=F]\)MTRN/K;L'JH(Y)_]UQCQ
MO8I 3S<AX*1?I55+BF@1%*HBOF5? 3>0S/<4ZN),JU $2W%T8##%>][Z//75
MC#TQ]X^KWM^M[/3DJ[(C>H#SR?F!UD61HY2F>N$%>K<9CU)MH3AZ\-G.?'Q
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M^;74W\5KRP1'R3X%1/I31YMW]>IHH,0B%.D1W0_\1'\U5'MHUIMAG6=/E5$
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M$FY?QLPCUFX5UR"1]TR-:N6VKL@AK&ZKX1F]S=5WMX]31[R%M-NK"VDQ3-M
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MUZ&AEDDTY[J$PL3!A4<'B[,GM%%>] P>&[HVC(WFI2Y7+:9R,";N]938.&!
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MA'&ATM0:KYABHY!FGVQ (IE;U 4&EWR>I$41'\F7*%7%RTM&IL[P^^#O<)>
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M5Z>O$OK@2T+SE$;#4XV9DBM)WM;23F![RZ#$ A-M[HW!6GH1F6\(R>)[*F(
M&V<5)RZF4(^/+],8M:9VJ4@11<]#8 *1LTDG7?"*:^IHC3' (L^2,7@Y.2()
MJJ*K:\H>B_$<?:5)\*Y(KM!Z?\F!^9]JC!UC!'X[DKW1U+?HNK?K5._-G_]Q
MB:(;XZI),H\LX"?F;-RTXIJAD@_:+-6:8T3=7%'.*=#MPD>>MO4UAU^. W@)
M\P]RGW5%WZ DZ_V+]:0>VHCM"(JP3]P;F+WCN03]Z:E(Y(>!;+AJX" G>&RO
ML?_I)!=D+Y<)E):R,(W-[93,%=37QCH;D\\]J(MHH151WG%MI=T#![EK!PD_
MR?TD4/;O@T?)=RO0B+X^N&9R7&+72!B]7$QH6,92E'%?:);T!WAX8@L*D(6I
MT-Y>FE^(.,CHF.6.@INZ^$\#[.&61T@%P$DDM(!B8X>U%X+2 C26!$O>EDAG
M;&YZ)4RG]@AY66G1F2ZZ)Q;KUH=IK7&\;'/..>W#-@=!3XCR4[@3)4Z![$#<
MD5#(&EMO<M=#RA.2J^_0N"MG0M!,'9*Y;1R9W1$!0SLS;@R%)UM?KZ0Y$BDS
MHDSL1S#X'>S<+%+1G=AF&7(&Y/P3U(S11DC\.'$0?QY@6G5"!U&S?:@ZP$GI
M-CJJ7):):'5]A5K]7<<![\AYKF ?-CY=@'L;<.W;?-BB1*@>->X3(#:)BR0=
MJGBN>M<A.?$KZZBZ*M)41#2*CF0Y5R'0&_U+I/<!4O^+PNK.N?)5H"Z#*B+G
M;%(;;2>O^QE'5#57)7W:IFS!H(&2$&>WBU?S4?/V>2P&:O%WA/%T?=8#Y77W
M[<(Q2$AJFYH$ %6^2,;E<5>&H_LRUVNW,RFR_BOW%GGG@/OIB7I?BLQPSB35
M4XFWK*E8;M]="9(P7D1N XVRF:67;X6VC:UM;=>AE)LEQW+WF:>H#,DO5I>
MK5(G+(ODB8[B690B[XV=KJ(/./$M%<Q4RUS542/O($5;J 5%'3$K?*$0(P(9
MY$5\27>^<$B$MLRQ7;IB%L&!37CY@&7($:JB-#P=R41!'=$(%"^']+J_K#K'
M,:Y<?YJT-;C*$C2/J&<G/(^8YJA)YJ4D[A=BOF$Y-NUX3*M$+CM3\"+VIBX9
M/6?6WL6+4(%Y<]/::^%MDU-RU53!<S,)1,/"D96R=+>GADS[AZ80T;RM G%"
MJ*L6"NRW"UB#-!@.?:#21^>I",32<J&,X$EU$3$<.:I,=\'N]>N A7@+RKU4
MG39.>:&/Q9.)?Z=.@VFEE$\M=D3O6&5,KNBMBJ60<M$6@J'PVOGA2[$A+;^A
M:RVXV6SI]/.#_8]A5Z^2R[S@)I4&F"42 N>DO0P"UI177!C=3CU=,]F5)VX\
M28=@;#OC*3!V%G[(G)N/.FYTR29QTU1ROYI(8(0'?,X=?=!N-#5DTO:ITQ_>
M-"V^OY[S/_)9%OP&-[!6_ M^S&2_9T6"[*X8ZWR?S[2\%_WI&=Q.%]EEG,*G
MX#2G4EG&N?+!T\'S_SH9/#M[%CSZ)9E,4CC)?V#D-@-S[I%'.?8=EF#$:*=S
M9'=-+GT_W?3[S[#;$+=QR-V-=*I_M.,@'G-_;TU0_KDMN$$TQ/J]:AYD?^O,
MT6^\2O7TN'G9YR2+[*?KB+7DH^R0OK;P-3D2#++638:ZM C6TAQ+;J<Q6,H+
M.ZE)_>(OQ;$NL+U'&(K(NJ2K-$2\,.."$681@VS$(:X9KIO&I EX)R*"R^EG
M4(U?3HOT+HTHX'"!3RR%<"M"/Q^+CS&\7:+%%[D](L5_L@&9IC; )7"U0'&L
M&L#\I<L<-)]CCK"RC)5:!N_2N7H7=*&4<B--M&TB&5]QW"8?:[<W9!/?OUD^
MYKSH,;J>>7>^[)>\N(35>AU?4YQ_C!^9*&K4MUQ\L#$EORS[H4:.F_-7_6I*
M7_DP8*"@G5TJ<R][PKSUY/Q77 #%]B>'L.13FO"WP% $A?*7R&BFF+.U,D(J
M17$$FBPG-#2*F-7"NBMO'>?BAE>:968\ZXD9MTO,>'80Q(R_@/D1?(BF,5PQ
M+VRY\QYSL;Z!TW'!V5AX[@WL?SW1WYUAAY_UV.&'CAT6*=U<,;Z[>/\Q>/7J
M\_F#SWO^X"U?4^>'<4U1SQ$*,"CM3U89Z_\Y1\HY]QD&AB_2R6_^(H2S:-"^
MPNQ:@5;\>!9)9;#D32VWU5[<@+?LGN-E#!*L/:-T!_P*;=0W43F)_A7\G.:C
M"#$FM**UUDP&Y7(.BZU^VX\?__M8/+;;GM8O=^?OSYEG0AT.<FT'G#48BA)V
M0F;@;%$VU>>,W\[[SH8#>6&+P%,(G/WZ6VX&EM$M3I J^;S3+D8ZK$CF7B*K
M"#[H,K;N13A^BSDC.#A_' X&0P>H\R&F%M@7P3NX2YGVYX.(/Z70N<%+141P
MAB9MY9<DNLRPMB@8UW-"25X9L"6%RS':"J\>G- %2+1Z/*(0?66ZB1!E&\^3
M(_Z:*]OH((/S.M=X.D'?<93JOAZ#'<XO,=UH%E'"V=RHG'%;0V<%\L;!)PX.
MP='+5WVY^_8IU;GJ\R;F;0RWH&6#[Z]"0R7Z#_M%"8,XHH>#TE5V9]]8< T.
M_,:,Y9ST@344,*D^7P1R]5ZW<1)41H*);#R VD<*EY- 5EVO6;^JBB3@EHFW
M[H#P96*/ 0'3T8PX'7!3*2/B;:"LDR\-;_+FQRP'&#;)3CA90,_L> !7-R.6
M(Z+^@G#O)XM(V. H4_/YUMSCWIC;KC'W^"",N?_W/7<(F/Q_NS.RK! ^Z85P
MNT+XY""$\)<H _\<KV'C1KPP&6%2>A=$FYO0=?"325Z"JRT)<*)#MB49;[E%
M;YX=G.OP\08.203O8V ?K2*L!#A*P3+TJ!$8DJ"]6>,H$S@2_JC(5(<VV&F!
M_1X3+W.BET:3ZMFS<X-8???A]7N'5<74:3ZY,'2:]I'\ '<=!\].3RG3(B5@
MH<?XXG_50<7"IMJ*T)==/-BA)/_PIF2K1?FYJ+?2E'M84X*>,9B6V)C:;1.<
MJO):,\=36 7D3-'N+Z&3+A^KQ(5N!5!NQ V< R+BN93:5G<1X&4$IBF/@__)
M:T(D,)YONERWFU+:.(U,JHRI1NPGI$><2;AA:4:5(UE.RDU#I7B7W>[CX'V$
M?E"X[J7V6:Z5D>LBP[_C*VGZ;=I1@W57L.E3F,7QF<%<OE3XQY+,& 0X'P<_
M2C' 1F/2CC5<6J!6V1([?8VYOT[87B6F_T 'D& ?#M"R2$J!1==>"V;F%J9<
MD[2!K@MUVIRFY9,$J8D-4SD\6Z"O7D&-]/?6[UDD$LKGG.&\NM4KU^ X^(6*
MH"+&CZT8F]]<_.:1BB^JWV%\N.R?;V.N&]E'6G =&D-,/3PF,_2* N/GB0)X
M!0\)!A?TXV#X0_ >-B3XB9^D%;XW\^M2PR,Y"Q1*J:)/W#0Q'Z6JXV 5Z@4)
MX!I)0]J;!178F5I'V)K()#H0_T)O8^2/P4&O/<:QBIRW)KG@3:?H7A0C;H<N
MS.8X9U*\9G'7'8YIJHV+KY+X&AT0RB6O.72[:-;=N/G?7F%".;[>RE!6.F[D
M+8'=EF1DUC!%SRC)%[#D\VA,]*BDW!E,-<W'M81IX)C",TW19YX*P&V\K' +
M8J&NK(AFE5%QI(\DPI,@"2N&\TJ4<+R3L7\\H=_A/Y8;GUK_@D:F7@T,1( /
M21MCQBX0XG,^$KXO5X;H"<)0"<?UB!\F8])&8+@$6EU*.#6Z\()7[__[:(C0
MF Q1#2NF183B-/+.8?/SB5*5NYW)BEG>4,&(1Y,KKNG(QD3A"?,%22:R5ZD#
M)Q[]/,MAULD8?T^% V8FW$[;G3MRAAZU.$-U.URV4&G :/E(:0:L9((?D[P<
MP\1@<*^3>4(]W^'7_%?%Y?(#6,\:_$@'AHA(4\RO7E>38XXMI4L)!0G^W$&A
M;.<H;GSJWL<8+ M>6*NGO.,!-+-E%]TKN*OV<;>KB/0@1MRQ;P5LRA<%1BV)
M@W,]R_$"SJ\S0I:,RF2"4.:P*3H6!D4G3%\T!"?1<.Y5.3*D.Z%59>'31O"E
M+O)SD&T/BN,@J3[24Y#Z,9F(/4L@F6\'P[-CA[26BQ3H<YS2F ;8I>;;X?#X
MJ>&(TXBF5"LY(4^JYQE]U_CMDQ #],35VQGJU-?:'(DIC6F<)0?S18%^8KV;
M,+&@+)3GFWP[.!FZTS,A^LB6*'T[.#L^'YZ?VO!RW^EPGP 0CT]Z ,1#!T!L
M8'PVAZS5E6@)M,FT[KO+A"E:&IX[5XOA<_?J0;M'C-FF38I4"?39?)>]:(2F
MA]EJI"#8J?OD8I6QP\&5>/:H8:R*P=L<5]_?JZ9\6*'BP5/*.Z\JP[M%Y)>>
MM'G$&;DHP"]__,.6PLM!EQA\3LSYF[]1=;,ZUEH0A\0E6%@62R*M!%>^TFX4
MOIVQB IAROWVY/CDY-Q-*9,104)/83_P/< E/ZJN<RJ[NM-8<R_8#UVPN\J.
M4;(E&HZUYR3,K)>9QXD#?!)F:U\8&ER#TZ)8([]_S$>O?XSSE</M&6^O6=>#
M*Y$?D6(\:*AA+#NITE@B+^Q$!=)A1HOCRC)N]U,W60-)"L03QV6A';EQ,SH4
M&-VF/\.WRV-05L'?8;#P2B^V3BU0,$!O/M;N[&+_9MS01;14*GYB("44GN/X
M.*X1^W)8G+)0O]VV$M2^]$QN99?$5(+*1'1Y,*2)="+8:X99I S/(P;)I]+8
M@/A',1FH['VAW^2F87IT&3^60B'C/;/3M$4^3.?BU,$\U4ZA;M)J%%?7"-6H
MA7C++.?.O,%;91:--&%A"V%.I!^C4)8*P1??DVZ,JP/3\^OQAV.WTZ86"#D=
M'D&(LG$"^\1)N)\O+MX=![_*84"NP[B:Y=QXSGPI])L$7%,G[KC!1^>D#CD>
M0A0O?'C&3A7V;=J"$TTCACB9V:+U"DLU:J/$A9,89(81FC8S46 =E$D+=IYI
MC)9R3J35>$QK YU$GGV5$_7W(QG>TB&[UCS>\"GVJ\VJ?ZIDG#0FH$V$FO0]
M.\DH-)VZ5[ ]G,%^_O:_7KTX&CP+WD58")V,[]NC^T@%?#:U+%@VS3J/,5@W
MH8)K/9&\]9+7D_X?3*H38CB\J!?2X-5-XD43.K+X+_*X.%VUB,I*GD;/(58D
M6AM+/*$+M) %$JV<>#=+&L'>XL,=\C]EW#'$*9*ZO,QA*)DD7+D;VP)WAND*
M='2(;^4DO=P&DG4LQ[,\3X5WJ:Q!",D1%;*W?]41(LWQ"Y)X8TH#R2BR4LGK
MBL([PF8%-T\T\62!#")LA1U9PDK2/H7P,L(,?74C4(H70MMA6*AE$7_+"]BL
MO\=1"B?G+19-)O]FMYAA@KCNYNV166HJ+&8[!.Z9X^"WF?#74F05[L4DLQME
MOH0Z8Q3C(]-D2FF*:\GM<&-E7$K3&RS-X>(ON,UA8DY%Y\8+VM"=MBNXBS3*
MI &.8I>E)P6O/XDSH14EQP:Z%&03=*!Y4UNF19[U.*B%P>ELXO4K=>VI$^A2
M.]8RGPXR@_$W,2_$^60<@@O&0) I2UWK3Y8#2=8<G]0 *YC9E!5\5.XQ=_8$
M[+Y$7#*VY!GE$\ET41\GCG!?H? 3G>\"4YV2J7>.OI \TT1XQ,J7/,&),C$%
M AXRR^3#$!7=3:QIE?SEW+3I&^<+8A0R]"1&!+F](BT]E\YB\0&77OO6E+''
MQ)05O2-]S2/;FUT4D 1\#/;5+K<C![0EE,JP^Z(%^:73S$Q_L@]A^#LQGRGV
M Q\F2HFZMY/,<+<OG!]]2TB6TR6'QR:*WXF(-$-Z:1>R#.[TP>#1KMC\#EQ/
M YCH4"U2ENPH9CM%XQ;HU6Z:\;11PC[Q1[+JR,XD47S)#!_(52"'/&N_TK54
M&-HA?++,E1Y/Y*9OPG7(1,*GI0F801,B'J-#6I*9 '\9FX+L48RMER)F'9#!
M8!_*CY:@UW2][)X2*QBF%+KDVAB5=4?1HYLKRT]D,#IM3^3X3Y-X$;/2$OR-
MH]5*]3@B:J]Y.4L]P([! H7B!1*@A;$4=2'4]"5:R[HH)9RYN*VRE<5:6  1
ME9*YTZ&6F[&T!^BXDG]B=1"*V)''-;:Z23AK6#G)+,W+E3#-N?C!Z"LNO4L)
M.Z!BY;XG_ Z-,OIVEB@'=G07=I1!'HB:;]PTK),,/,_HAT^T8_. +%H^E5=U
MBA>XD,WJ*H3BWEHSYUH0_R5Z2F6:7T_ ?^ VXEF1<]G(BM'H==ZX4E^]^?#N
MU?N7_"&BFO+@%"58.'-L14L@AC$8!TF6SR.5*&K!-HZN0-PD8POVSK3&*2UR
MHA GV *> K9J&K<7R7F:?,+#*>*G5W&<L1]8./>N,\F.WMQ&/+<#'.B3FAU)
MS4&?U'R(2<V-83P_1H*(?\><<'0G;>G9=Q6'ZE[F]X@FKN-MX7^Z7W)WH34#
M,71])D89NO$HNDUF$99P49B->GN20:D1 >0=9:0N5G@BKLZPW=&7UWT+ V@I
MQUNIQPWQ&BDQG.NFJ%LBQF<#HMZ(3(0.#U^Z)$,5^T_#NOP[=H,99':32M46
M/HRS:[20)7L+K78UI^K%$<P%_F0_CL1&(0[.6(I%3,C*D4\UN!?1)BR?(B^>
MRT;M]K^4K@R'*]+25X)VN7"GZ4KY."\)YH\;2LC[X^#MNL^;9A6"'V.<5UG9
M!Y!C(L?FB.C#\X)B1BN>Z!8@6"XO5ZJUQPYUU:&:4XH6*$%X7G2\YCCX=<&"
M*1D2=J/@]H=O806F^;72"5L!1A/)(D\%%(NSGC"D?,5$M#<I^6'XDY'_I10O
MR *)1^B\0QJ(FN(,GW2-W7540K8AN7H*W(V=[$5J3^_Y&"N'"H>>BB=P[D)=
MS92Y&I=#7_OHG71977E&M+KHU;OW_QG-%S^\,%V?F8:WM'A'@]_5)(Z;GU R
M;M0.K2EZ/IU$&H4) 'GFD![4TK[%()8Y.D[DGF.8J+2;Q_2I:\\!.W'2WBW6
MWSJ;MQ/?:1[]+F<*)%?"BC?,1/4S.'V>'['DOX?6NP#KM\:JCYHBG<V_\G?(
M!R:G1\\_!N"4,G:,0>-(<I0-3\H#JYJ=$ SWQ#D#Q!TL41JXM!#-38 E93B5
M:))(>E),CI GSDR'6DPGC0B4<ME365<^_B2P>&H;F)4<Y)4QA1J:*KWH?*ED
MK_E8PA*P].AOHYN'TYYA%(.7W"$W=R[652%9B8O<NSR]8AW!S@L&?HK2A+%L
MQ=PU%_H4&)>1$"0LN4L8#VJ.J@UU,59*C%.9)!HRSXXX1.1= _@%U.BL@"U7
MK1HH%(=R5].&Q%PHL9L6YJ/K5(J9SN*B=*Z05Y!L,3-;\:SIWQHOM2'*.D,+
MSF3=IVE^#0-[IW>)A0KH,THWA"6U5<RU7TI4:9; (S6]I#SD7)U'<4V]L8A]
M(?;O1<.P[#C[U'&#PQ(<<K+2*WJ#6WIHMK_57\  )"S<T.4ZM8E#RIC*F:"_
M^B) <;&$:QB%K-P)\!RCUV.^03')E1)D2#)]K("1*UW01B;"$2='VTG,6RK#
MO/BK,69)*<! ,47&Y3&FCDXI/-WON0L1\? -0$-7P:'I+BOE2*6!CY!PO=0@
M9<V]S)T&"NY@5&SH'3YH4Q8+UN"RL"DY(EM'<TT$RXK37IC?FHNC&O$)]HFC
M^EN\_0_< $<K^M*97>3/KF5'+XID#JHTI:24WF:AN<&<VT]N/)L XV*1CLN-
MN_ER;;40$'>-A;O]9$AYF\:7/%Y/MNBU(%A33K<@#B'F>F&P3%/'% B]82J0
MC0;<%USL56QRV,<F'V)L\LNJ?:E;09&4%C?T/[#:9?"2$I"&,_ITX'32173$
M78YI>T4%+(/\)Y:#\;2BKWX^+OM&*+9W#+X,@7U%[_GK-ZS*O@D*L$U!GO[Z
MS<",OXEPYH_^$,@R&"U(I^YZEE3Q$:X8*93K(D(:F1MPU<U!P'3O8!!*VO)Y
M0WE\XU!$'>E(9+,09)Q,UHUK/2S\B^A>5YVTC8'<A[9+NQ^*.4!#9UC#VPH/
MC$H$Q]_D=0.]O1QUJFM"CF]%0#J7X@YV:'O[M->#.R A^E/P-8E19S7+_ERN
MZ[=LDZ;27[0]>Z1[[^NH;.>0D+G[U6[!'@WE(*3!=7EZ8?BLH6Q-3]\PUL\6
M VS-E\&6'STY'CIA)/3QO@_X=]_\30J(,$0GX;[O[ULN=G,(=R-X7\];^Q7N
M5_C0W_J5K/"]W40<!SP?_JDKOHW&R_ $>_&=8F7S^?F7F# ;W5WO5^!+[OT"
MD_CH%R[+G4O5=H;Y[6<Q9GS!N%V;EJ@3S%2>W8D@_FTP#)^<G"-37"])_3 ?
M@,"?AL_.![V\]\-D>6_E*[\Z@7\:/CD_ZP6^'^9#$?CA<'B@HKYB0G_Z,G:P
M._:.[M;ON="*!?C+0@H@5F'M=[CK.]<)NQG ^K-]NVOJ)#P_?;KC>^J!;N/.
M![!%.3KJQ>?!#:!70_T ]DR.WOSYXG $Z*$&U7]>61!RH [$@3BANSW'=Q%%
M/PN?#/L@2S_,KU2^3\/ALR>]>/?#_#K%>S (SX:]?/?#_$KE^_3LR8$*=A\1
M;SDM'VV/!R[E/AP_\VL9P!;C!.?AD\>[AM\\T%W<^0#ZJ'<_@/T0GUX+/=P!
M]$'OAQ7T?F[ZVTVC1'LS$FTHM8QBSD*G:?6!>@Z]K[D;7_/1X.G) 4=25LSJ
MNP.=3G\*=A11?!8.SP[Y'/2"<TC#W(&6?Q:>#0]9P'M%_S4.\]X/PM'@Y-Z9
M1AYR;'UK[#TW.TR#QQIQSRND36ZQ1^QPW_>(7\25QLW(7N1CQ/KZ.4Q:.U,?
M=SV]5<;DX#0\/Q_N^K(]],W=^^.S1Z/:SX,P?!R>/=TU.+L_!P]H5/MY#IX^
M"4\>[QQNVI^#AS.J]>?@BXWROYT.GQV&-7V03M,^I)UVPXMZ(&&+ QGFW457
M^@7NA]F+ZZ$M<#_,7EP/:('[8?;B>A\+O L3_VZ-]]=Y*4W2)0N29WW9P9Z=
MN%OF[_<BIW PJ?E>XKY8XO8B>-\+W'X/8)L"MQ=1\E[@]GL 6Q2XW<:P^W!U
M'Z[^6ARHWD,]C 7NA]F+ZP$M<#_,7EP/:('[8?;BVH>K/ZO18S6+BQTV>=RU
M4[OS 7R.5_W5+TH_@%XL^@'T8M$/X"&*Q4,-I!)T(,^",DJ)9N;-QS=!5);Q
M3GD+'[*YO_?^U*I\WK/P\=FN\\<]XT!_#G9\#G9)];C/&]$/\Z#%NE?O^S6=
M_ASLYASLED.S#S#?(L"<9.-\'@>/)-#\71AD<=^$=,^.Z.T*ZY\]VTN\X%>_
MASL?P#:!IV>G>RE$>VB@],+VI<+V[&P_:SB^^CW<^0"VV3UB.'BV2Q;#!X==
MWB&+H0N-V'M'8X\8<&X]]H/G1]J&Z[LKAJQ'3\,G9[NVY?=[B?8_,+7)E ]9
M0^S1V _ZK._<W]KO]>D/>C^_AZ,,X.(_>=SK@X/6!WMT%@YY[-LXQU].C3D\
M&1Y ^^&OG0+T'D!^HWB:%[%FQ:KHCYUV2-BYNMC',W]+CJ#A,#P]&>QE?'D/
M[[9>XK;!$71^V@O<7N_WS@>P38%[=AX^>;+K-F:]P.WW +;)$?2XS[-]G7DV
M-87?%?E54B9Y%H UO"_&\,&YKG<53-E'!7(/$UQU_9U_38&R@[E&O_[3N$=C
MW].SI\-VWFH>],T!U/CLM;X]9'D]Y+'OZ5GK[[E]GO4>R>\ACWT_DCV'4+VT
MC4W[^E(X.R>\W?F1W\=S^T 7I1] +Q;] 'JQZ ?P$,5B?_,)=VN"O8FK(,W+
M_4\4[%R@]GF8]\^<PCB=PP"]?F7!B_XD[-5)V O\4'\0^H.PZX- N*;#B'KW
M!^'A#//>#\)N\59W,*']1F7U(>JO<0!?5W2A'T O%OT >K'H!]"+11^BOJ4)
M]B$NDK@,+H)%$4_CHH@G\(Q\_"F IR7P_<F!6MN]?[:KV'4?MMZ;Z?2'8#>'
M8/_1WKV\'/XP>]W>Z_8'/\R^G<-AMG/802'OSJ/->U1<X(K4/A=^W7"\]WGH
MA[+$O8#V GHHX]Q/ =VC47T=XKA'"]J/:EO"MT<#W?+R[8/]?(;CWH>$@F+>
M@ZBJBF145]$HC8,JA_V9S[%M-&879GD*BFB7N/BMK]_N;FL8>C#):USF!M'P
M]KW?;^][RVYUH=WG2C!(?[CK9DWWI =V&B;KSVI_5K^",H+^J/9'M3^JFQ0Z
M/.N/Z@'.<8=>V]Z/_7:N\5V)VVZ+)^YKEE]846'__;__%_P1W5?G[_2&OXR*
MX,_N+^6%_L<\WUF6Y?>ZK)+I\H? F:S5I],\JX[H6]\'205?&<,LW\=E'!7C
M61!ED^!%?!6G^6(.?GCPDGL^EG?Z]F"#N;*+/XY3E(HQ;/%?OSGYAGZ6+:>?
M^5+A/Z516?[UF_&THJ\:(:(13*-YDBZ_#_[OQV0>E\&;^#IXG\^C[/_J")-_
MPP ')QB!<">'80@SL_\XH?]9^3LY^5-#8NXX6+.U!&?77NTJF7E_,;RS&\?2
M,%)DQR6@_67I9'G3&$Y97*P[+=<QZG(<4SJ!1_\/'-0R>)E-8CRIXW@^BHO@
M=- \0LVC=$B[=U^QSB]GKOO*3\APCPY(UUD(AB?#>[<V]BC'T N"" +(P;V[
M<KT<[)\</)]%V>6]=RCO)6'_).%/P>'*PBYRO6T?^3^>/W_Y\J>?[CJ7^SH9
MHX<93.,]:W9RP_QWBHW^K+W9NPCPEJ;U.#P_V74WKJ]*?/9Y; ]+M/>KR.N
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M^P>AW45<IW"\#JI]$^#H0B8+:&=URZDT8I5(*Z]X2F3Y>Z/GF+;LF3&-66
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MXH_*DL[/\9H@S4$Y2DS^HA1,GH.F'25NRP33UD7.,P28UZUODAQ-]YI&+C_
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M(FQWU&'9IUQ%.]RD44RB$1YH93&0ZY!_@UOSHX8&II9>=C#%:<!-L^SH^L>
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M] NBJ@R:^I0F0YE=-N'<=EW$X)X(BI+?NP=Z.O\Q3C$7M%&,TZ>+,1MF4'N
M_S)-!@,A\<8L9;52OTZ '!R&%N-(">F>BP//0HC2T H\AIV&@C];C; TS9ZE
M-U7];25]?>BXLA63>W5<&5*#A0P1'1L4F=3$Q/9MS[;<P AT2G8?&VE;!\R4
M^T0)6X1(-VGR+<J 1/G9'2ZN:(6EMBF2;)_5MC%QN86E+21KN0Q5-MH)BUD8
M5>5D8&+/<(CM,M]&-M4]'QNN'?B^9]K4]G=39[2I\-B>R7 S/-4">-,)AS<K
M'-:5#:$;( N%KL$-&^09Q",DL'S;#HV ^1Q9[2.RYU6(A9:$^:R;-7+%QMJ
MX_CV^*Q;YX-NGQMY@YY@-FY,2S.H'WK$9J%A.\@*6> 1RT0!"5%H82/<BT/$
M::\+^#!OASI.:P&G.0@P@N?HV,,(VQ3;%O8-"SMA8 4<S+?$R?%:&>WUQ+U\
MO&-IQ#*MKXU2%K(46I9EXX1\U?B'$64Q;8_D:85!\[J,F+89+JO(R)N<<.^
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MHW><Q)Y?7O4I,ROZC6$*>U5;DM"96'M,07K_SWW_Y/*\Z2RGSTH=2S3F)$6
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MI>^GIGXXL]G%A2_&#2@1!>44%"CG0XQ!@%<4 /BF9"95U%D0Y"H_5'ZX+3]
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MZ2F 2NZ_<XI%[CTS*3((8.Z2U=^VGOB*#/(Q56Y>.KX_5!5@98+=,8$P4KD
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M(4U]U)!@\M\V&"JDTE0R=%+<94-*%;868I,5MGL.V]7I(.DQFL!BC $H!T=
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MH812 5%Y0ZSF4;J@"'5!JY4D\6#[ULB!@<)VLCRZPU$J43PJHK@'3R@I(B"
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MYOJT=/DK"RW]:L>+/913F6>#-BV9YLVV,V?%3A9*\AYD.F\']/(XI)LU(=M
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M;.':V--4K;K)P4R0#(I*)&NC$IOW<P 3[!6NO*F1ZCG@W>;(]<^M-:@>:/I
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M/=_UB"^\5 9>&(#42DD:24:7)9O;2#9WVY+-CT8A.<)JY"<MV/:IYIZ SDY
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MB_?JY;H7U*&22W3O55U:@?@$.H#2U%)"%1(I4IGUMGX0/!D63UU__731PSI
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M$#P+M--*J0U)Z:#TJ_=_>>*=OJG.%ZNK!56@;KS,-1(;;5$G$3WM6MF/HZ9
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M+3F=5W+Y8JD1-M6>3.= !0XJ)]#+2#^UK.9PUYMW1;&+$$@E*D /!B['CHG
M4V@;MBZX+DEP-^18<H/":<ACT:8Q>.A,^?^6H#510&_ X^N7%K;&X'G,<VGF
M\I!0DODADS(AA/E4\"!F/-RRVKOEP+L&'GK3@'6/QZ!1_0%[(=!JT=R@#G/>
M)-/<7FDT%[P,L#D0B(+R1NW4S&H4TF+W-3TL"NOP53D8/+1<ABQMH%MA&S20
M7ZDESVTQ!W7#M&70PD @A&VA5,.621;0P/,,W;)CU?\*_<]4ZPSF862Z%HX[
M!RKDI=80+,?O-5 "&P[ YBN4)7V++^ 2WL+T81Q@Z=N)IAC,V1H$YI%;,+]
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M2\](^ 8<8TGY52MEVN9#4V"!0CC8ZOX2F\B7X@R[IMY9W4]QAU7[LK:YEVX
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MHSKNF&KEA#]W1(F9#7%'93(5O"EI _1P0NIYFL*;L_G8HND]2ALQ(_B+/I!
M"#AXP($BMT$<4'T0>\XW?J)S ![%:D1>1SX1&0J%$K9"_+;CX@+1F98J 0""
M3DT&I,J[PN)*EJHU&V_,"ZFDB9RQAO@@Y-O%_W/.[L2:1.K;O^9Y)5^28Y -
M9/[,N PDO?4RU1;)+!,M>Z24-<1I9LX'=QQOFT0D@<!VS_*'ABXRA0(E,D5.
M42*]XL"6_Y:^16IA]A%.5LV'?Y/\<RW5,.M&I\6-'V72!J:;P/ LSS)N/-@N
M?T&(_E=9&5]N[Z@93^^+_%^8\R9G!OPX'^,-:N$Z*YFMTSYIK+DES5$%P:#L
M;/>)LK,/H[ M3?Z84NPM<,9T7DW+6G(U7*G "W2<SL?J?%&58/EHP3$"X01'
MI-^63&;??OK$*XQCTSO^,?LL'_LLLRIOD",Y^PU(,@:K,#9]EH3[-*-1"FQ&
MPC"+LLSW4BS;8)Y'XKXV8(O)<Z9I1TS3SFU,NRMWO6WG+=ET?Y0"44S?>B'D
M3#U3P5L\A9HN#/X,5/FM@%-?U2@!X0NWY7QV;[V%3<H9;43BPB,BUZH<CVE2
MPN515B^M7 ESD QS)!4&]F-Y/S0/P^A[[,#;JIRXMF=_ ?)YD1F[<VU&;#=U
M*8D("1+J^)RD%#Z*PY1[_DFV(5R["[5)'Y&EBRM!2N):I) &5D8%&1/*<0)C
M3*"#IX90[!,,]4F,](L<"',[/A:F/R3V?,X21L/$L4D0T22+4VH[;H9*C!NY
M)R&:O^R/^&-'DU<Z>5X!:1XQ/P49ZB 4$?F(RV2Q/6JSV,W<) B(G<9Q[(8N
M=8CO9)3:7E\STB,<Z1ZR("'@[L59HY*1EA,XB/0;6EOP.6I*_S05DNUH),?Y
M@L-\T@.\*[[P:E(W!+RE#R Z:H-&C(6!'?M.0D-*7!![Q/;MS(M8%C@\\;?)
M&=Z?1F[0?^ *4$.TO*GEU.7Q:I)5%<6,/%:P4+N*8 W*':J_ELQ<0N,.)"20
M#%96"W4SI5,L!]E>I/U-C70C!WH-XWS,7LM1#-J&-.512CP"IQ"8SHWCT'6(
M':6<97#5A$]'6YV2C*HPNYJ"-2[L!SA=^(4A!BO^VO_Q$WJVE*/3^,W\6?R^
MQP0W)V=J%[FDCJF(KBP1@*,[Y=7L\=,8S+6;@KT!JT%8:JTCO"_UWR99:&<!
M"YW,)2FC- Z3* HQ=16[F6YS;6Y*_4_<B,?,]=TP@4N%<QH[+@FH[S*/.4[H
M.CODQPZE>*<6;3/YS3JR]Z VB5JOH4FRW4(UZ>GH!<+9.G<R>+G6.=]](9W/
MROX7'J@?@^8\<2TW;#<T=KO2(V]DX.]LM6QFP0%\>_!4^*T,M05!N=E(W;R,
M 6OW-A0LK91&?3*(@;9.>6B#%@'JEI_%'G4<.XF8[3%.HKZ^G[O*(-]A/MAB
MA(<L) $+8C]U6,1MSL+0CV"44UJMG0/#-64L9:)I^TR6H8#@.V@ARN:-'< -
M:_MG;2;]@/TZCS*42TG[H4O:PTM)^_=<TCY8+/5&5#8]M+;=W'82YD>NVOJ.
MVLT%Y]MSQZR#6CYCYBGJ?G:IB_K.>/2,^T*AGOW<N?"R[X/V_=+V<DOXXC!8
M6Y\T).GUO0ZL24L1=(9Y1M/9O!*%/#LY6IZX!/-,JRV?>VKV"<'B5SIT_E*5
MM1D7BDD6ID%@<SM@A!$O3HF;V%&(#AY0N.U5*=8K7V D63>?':[HT8_..R'Z
M#&HG+@+@(@!V$ !>DF699T?4)PGA7I XW(=;'&%,,S#->R)*]A,* ,\^\XJ(
MYU#RO*@'#5)V.*T%Q!TFBU:ES.FLG\8BWEKB/:58>]+:XB>4+UGD^BF-;! F
M/G$XCYB349L23H,PXU%?<L36\J5APG<&#QY,UI" G+>L.3N-XG*^3G^^[-"!
M4Q3P( I"DOI>E%*/A%YJ\S1TXW1E2\PS.%_.]W2^3NJX.$FGX,ETCO"/9^BY
M^''ZYYTW'LE9&C2@6+@!H2  8X]P-XQL$@8D(BE/XX2[?4G26PM$?2@.;]@X
M_ID+PTO7S8O4^(ZE1NI3.R2)8T=N1DCBTH!F3AC$-&4!)UFVCQIU0*GQ+'LZ
M/<O^EM(Q<C&F?BAC*K$S.[43-_2BA#@)!7V!@#@(*4L\ASFK=(<#W/]1&)[W
M_7]V]_GE?)S^?#!J\RA* S^P;>)F24(8L:/8#:*(9+&_JN_9 <Y'>'$6G+&S
MX#VOZY^PH<Y\,I>0#@RQ;E+9PT16%$^P6\:_Q0<73\+%)CBF3; !W_2FY=-?
M##:%G['-25F !+PQN'6E=#0$8Q00)PL"ZC/7)H2'<9KQS,\2EC@\(#8[GN+@
MVF>N.!S&&MB=";:#([U(F8N4>392)G%\E"H936.71&F<.$$:$]=W>>20-%C5
MB/X0[DGWS/,NSEO*/*F^-[17<G_=XPC1&LY7M%X:<V^_ON?3F'NE</R5F_(Q
MB+S0X\SQ[)01%K(D"NW,9=Q+LC!,[%6Y)@>0CT'XS.3C[@VU+\?Y<IQ/>YPC
MPOS,]P,_B&.2IG'D^6$4>K8;A)$=!3U  X=2=_SXS+U-^Q_G'I5$_W0\=.W-
M)< #ZH:? G]Q\ I/BK=HVAVZE1#HBS,X <SZ/^O/J/FL&2=ULL2/O(3Q,"%.
MR),P\P/"N!\E<<SL7>$3AQDC3K_+H^5DU%B'K<]-.>P59S$+72*P]F#ODH1X
M+("=M/MZBC7K.Y3TB?N+7)IVQPBJ5\NNC\N-=L7:<3(CQ%=%P-O\@8\?KZU?
MRZY35O.#P*Q%R%?5GCS_)G&QN6A*)5O[U@;2KT2*K.>(L0L\B$##"K(;GT"<
M7=4P&(=!QR\BW8U!)JD^[ZJ-\1;@8\UI.\+95B+Z.4&&H9.=\X^Z-YA(SJQ[
M0<+@AO2!D3,WSHB7))3&69JYE'O$=>TL/@! CTVR)$M!QTXIG V/)&$2<D1F
M\N#YU(LO(&&[@H2%9P42)IGKK$#!-K/< #Y]RKX<6RD:??B+AZ!6+XS8IH=.
MVJ?#[#1QCUVTFJ:(8\&<XCHLLRQ/98..<5M^+51@#40+GY;SNWL!./VJ*LO?
MQX\R(OF!%O=T-H/-@V_B7/Y>5K^/C)\DD#S<DWG%38Z'KX.D]/5-&RS>M.\*
MZZ_S@O?TO1<5_?HBA!<;,/QB41:]J[B$QX<OJ(^F< 5_$_#GX\<UP*7=BT$
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M*8@*./>PK;J_Z4@JE!1; TPFF#( K[$F%#LH%**/'K '?&NJ?=("1GDD._/
M%"K\SK7UV[0LS*6+\R;;0@@ =-!U%\Y9]WQ.:8[8Y_([H"V7=2ZFO15?:3VM
M>Q _R<6;632!G_J)RV+'\S.2,9=F:&XXJ8V9IHZ]C7YV@$KZ7AM#-?A9=<:6
M>$L*1V$H:)$775NWG(.Y,>.6$PJFJ^=)S?\U1QY 9.^9V5/#Z!S2UVQ$ROKK
M,[HY>R$7-SVTU'?G*<!'#T:"7GBW30^=M%].ITT5*Z=HC-[<OK:^E%.PJR+B
MCJP>O+T%?#VI!(^4\H82<=':MDV$[9+E68Y@[B",ZEQVY^&S^Y*9!P;[2)7S
M&7#]K"JUTH#R92PZN:#4+84!32O9V$6V#*V[G;?X6.'&"^F:_HXHYT(B@U0#
M&8F'.44I#]*5Y;+A&**38A\#.(YSD-+2DV!,]6Z>,RE$EQK Z+<R$([8>09O
M@%ID?+UP7H*6Q(50%_,2X@ NCPI^E/TKS,4CT^#DA)L V\3@!R#CU2G_V7KA
MOI2H[D( "X--=#02,Y375^]+F@'@LQ?>2Y OL"CL;01?3&<" +XVGN\\U*4L
M:IH@2,N&Q+A@V)*F%9ATH5^5V17VQ5%>CQ<HKUS[Y\\??U,?B0^<GU]*/691
M;([;#IA20-Z7U>P*[JJ)5FY% Y][BKQAB<]A>QT7F*R8H2I;P??J01W'#B4#
M>EVUFQXZN*OV2<5@,(0$X2G%X,>NS=3ANZ8;H90BZN>FRY9\0*ENLK_AHV@&
MF+-KJ^7SA6$6KV]Q6$3#/3PL'=U,2*'Q(TY.#-4X"Z7^.9\J#;1<LP8JNI(K
ML0;S$/H;'O,TK6!3%A8QZI4+(_4M4&VQ+<*#ZI"&/=#RJM%;%R8A%P^R4FJX
M%78J@R= B.<S;7BJ86LM,QGLFTD QO%@YP4Z2+J"5G0'RX7_-97](&'.8 I5
M F!:O*WNJNFF0D4?:#X6GC<Z,Z4I*-8<UBB6Q,2$BV8.^A+;P 8@*\OF&;XS
MXXS,Y7?LXJ;76<U3T8!S<;5P):&171924RQ51S5$5]-]YIJE/JE<#(<(A>B[
MDHO1$!+$3^E;ZNA3R^H3\AOR<<V%6L;AE^*J.57 E(+318NHSGG3?X''FZ:$
MCZKKH39=9R 8S&,!H@L[W B)QJFTB:F%6N9X:62ITH"AO21+A>J$NLTM]AS"
MQ\3?J@H[_<F#J1H5PL&M<B$MFB,K= ^4Q& !<]'QTQ)M9(6668D&A ]HO L'
MG-#]4",L"\.*;\;"[S0&^@C-]O9O2 'QO+G^25YC@( 6O)S74D+K9K=ZGI@T
M*1T7"[)&R5J0FN,YD^T.<3^,VTHH3@NW"%QG%&<Q6B;%2*T/*()#E;5)$W%#
M">\AX]]P9&2-4=-ILD#Q#,JQNL42X.16CY5CZ==TG(M"ZF.+QC9\9BY(3E_[
M31:T=>0%_2=<<HG!/M6]MO%K:"U<#*W835VAM%X<_PG%2#PH\&1_5Z+4L0<1
MX:3],3XN.N87658J@7!<#8OI:MF?+\3!:F5OU#0N%2956=P)@VFD5:"$CE'&
M=#S+]YS/KJWW)DM+J;7X;A4$5\V>\5P#Y2HJ3#W1U$_VL$9'J"'BA6&FFH.;
M"[[C!8P_5IUV4;W"P80Y+TW1(W22/AC'#8JC';[#Q^!C9QV$"H/B8\ZF/CN"
M$[&-G @^]\7N200#9BYCS&;$LZ,H=<(D(T'L)S1,24^%Y<ZQ^]1Q(]^AH>O&
M*8GB*(F"U"8<NRJXU NSDPH/4Q-K3N!2L*\YO(TWQ= PM-I58\:BB$VL.KYP
M[-"J6G7L3-'1<]+ALOU%@CGODH2#W\7^ABM6I!H;TEHU$*H'M _:B]$'N;.=
MM2V$-C/8 *X\J8!92^M3M!'JON;[;R04K6PDU*7$7JV$K#-M)M1=XL[MA*PG
M:BBT?/_V?S:\S= 68FB(\%K;:&@[.73<S+8=^PHM-30:F-2V9<&93D<_;I./
M@[W<S+D_PD0V5YUNF%5PQ(X@?U^AI.Q=QW#$SB#;[%=/SN&%O<^3O=W=V?MH
M/8V>F&LO_'!0?MB_U]$/(,6V:W=TL'+XQ8"SLG*/L5.'Z'-RU"-TDOX1G;GN
MOE_[%Z(>J2/*45:[2]XF>NG,6E3;XW'">!S;E,2N$WL!\<&<8$GF)K:W:SKP
ML"+SZ$C=CYZ,80]SN"Z2X"()3B<)/,JS*,N\A,<A\9PL"5/7]^(P<B.:9@DY
M186H'SL_AB0XM8IT*#WH5L<B\B(M)T^L_YR=:'L*PV6]^#F&C-F #Z99Y)W@
M$$/ A,Q/$]]UN W2A(=Q%&:A;7LAS;*0.=0[A:H1'0G_XKA<L_L>[0\2>#F9
M/\[)I#3C<-\[=A3%Q =[(/03GV&WQ(3:H=,'?WSPJ_]8..'/\V2>6C]X*IC!
M_]69B6?D5CD(+9[4PMH#,/0,)>61EW-H(TNS=*^-Q9/(IBP**<N(SX(H=5F<
M!8GO^"$/O.0D*$/Q^0G:<SUR%Z%Q$1I/+C1\2CTPFIB7,%_"'KF^'3L^(_"9
MY_>4U1]>.W//T"]SLB/WU,K8&A#$7?E0I^XAD>&@R%15!,X[9P5L]?K/4& :
M */?I3_[:5:]7GKV24V,:#$2>5$04.+:"77B+$U<FKH!#4ELGR2PY7KG+S9/
M>KHN0N B!$XH!&R'97' HCAF*=A;#O5C&Z2 31R;V:G+3Q+3\OHAB;XC(="C
M(.F?]L9</EC]UR!@#^<LD#V:SX>O?A"FAQ.NJ/M:QN7[C$+B8_9;S6]$(>1-
MP=ZW-8XKR\*HZZ1!1FG&L#%EYB7$3OR8NZE'$[B&_0.4A25^FGB^'=K<STB:
M)33V;71Q!T&6NBDL]M1E8>(XU%;"Q^571,CY*LL\.>CE J]"%7PVV ]MA951
M\-T6C'5P0\1#?Z7 ']6C919MX4!<@DPTXXMOMWRY5.TU4L6?NC0LO<<J^]IB
M;;681'&ZWKVVZW#G>A PA1.MJY78S#(#^.Q,"KT.6*4R" _#B?>A?&_YZJ:'
MO$MIRR7W_XESO;<N;6DSC<6]VJ<E6CT8?PNC:&3FHTT3KR)YTU^RU;?P[IWH
MB#W%:=I\5DYBDY_U]DO1'T5/4ZQ@JHVS1>WP4L)P25Q^9HG+"[:FX>_)$A(F
M+ B)[::$!GZ"U0PAX_"/-."Z.0 _0F<M=V3'9^CL?>;A,"$Q#R46S:ZT?=B7
MK9B\)$]>DB=W$D$F:[V1(=2.5/+3**1A%D4VB0E-_,3-(A:E'CJA67:*4)1'
MW/.33C]$?J6084^57WFC&K&<L[R[I$Z=EW!])JE3HMV-8N^/68]X+OLTQ""R
M>4 <AP=N1$A$DS"F41RX3A"E?M!7Y7:$(A0G.#]9_#UF4_6*W@-F4VTRM9<B
M*N<E:"\I%6=D;I]C2L6V9C>Q24(BS['#P"69GT4Q<5./T]1WHC!)^J*X!S.[
M_> ,"X?./KWB<.'706C6KKU/$+ 7VG/30R?M5'6*\*L["$(;TQV&4YY<(JFG
MC*0N!][.']&K9\[G$F_=-K@Z:&@CV^E05T\/*;_K(.G31LDZ>527,-DE3/;<
MPV1:(CT:FKH#N@%/$E '7(<XL4>CR'% 84_L. LI[]'4#Q<@<\(?!.;KN0;(
M/E5YD>93.FZ;$*#G>+6<O,3)+G$RTQW;,)!N#OVQZ!=)P#MFJ58:1VD21\1Q
M;9)Z7LPX3P,6^HE#?,_=)@E\K7@2]+S:-E!VCJ6NET#94P;*SD;B72)EYR5>
MOX-(69^2&-HQ32BSJ>W&)$D2RD$F)S%ULI S-SA)OD(47&)DST^#W&!3GUD\
M[.S$X_E)N'.T80,_MIW$=QF//$*8GX"V2&+JAG$6\]#K:R5W,!LV/,>*_F<C
M9IY*N7O/ZUKT-M:=-E6KW8LV=]'FGITVMT%0_EH6BLL-D9EF-B<D"Q,OB4GD
MDBAD/D^\R T3-_:RZ)@BTXV?08#^N]'DCIKM]+HK/L]0I;ND.)UQJ.3\4YP:
M*?IZ2812S_<<&C(6$9>DQ(\R)V5AECDTRM+0Z\.3.I ()>XS,(7/+L-)__M@
MF4[]J \;GSJ?!N('(<*@_N$*@>%$&"LW @2E!\UDUO;D_L__B%PG_'FI(7=M
MW5-F44MF77!V1>$LT#MN57Q"<P'/,LXST4MV;4/TKECYFQKM1@[V68\E_OB%
M5Q/'#-$R2KA+?"]*'$)L-XF(S2/F^M0) R?L\[Y)06.(D*N:IS^Q>87-O$&
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M&^\.[Q=.%Q)MSU<7V$B"\Y-5V[7"?N[AQ5.O?;V07,Z?7Y:3E'M^&CH^)7Y
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M<^%1[TAQE'O=W03Q7:4R<"ZRR*;:^::%ID@#ZY>;(@-+R'?].,B[:8GL(Z^
MZW[?I!-KK0DEM4*):34/%)Q*'1)78AL7F(""0N>UY"S%00F,C.X\5M'&S64Z
MIS11'O!CK&:[[A+@HZIK:?RE9NQ'*6634E-%]&0>FREY%D8\-%;0&/2\0C0
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M3:129JJF4UR_QL8R&01KYN5=]Y#?E54YKS'C0?Q=J+NPD5C?8TBUFK=6#7Z
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M22V2;#A3G89:CA39"L)ZQAI9?$L#?RX,>W'7F7S=AL,[U]ZLG(%,7B,XVBQ
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MF>!,"Z21_U^#F'IZE+%@4%)"</"DA"=-S0H&I2D$)TU3Z.)/VTOZPPM:M_=
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MLLHQ.4P6I'W@U1T7ORE-0RH:!TDPLZ]W9</FFZ)484V5S)F4]6Q7J_!+7J=
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MJ'S@@'Z\^J^ECMA;!BP.D _0*6,8+V4,]S?<<T!8=<K^Q>DF,FX) #<)NAD
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M.$@Q0D!OYR:A,64<_C_HW%;0V%#<-L5E#[&*KF+UK(Z0'4+..[M JFZO'IA
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ME,V\FD]MXUL3)#4B91K,9T:54(K&"!$NX(HUF+2D.'^#OK6^D/25*5W5K_X
MY/Q)7=P9DV(3&VXD=9PI1(E*N66I31.=;#F^^]OT!!Z-(QS32;BPK^ G/'0K
MD6L?XR-QL&\*1%<LNF+1%8NN6-0'$%VQZ(I%U\CNM/E8F-7M1V$,361G"0>1
M'%^#NQ=FQ5]=B\<UPO\K4,K=T$S[1(_\I4::SE+,EPC+E%%,6A%3Q:U*D4%$
M$\=DG*:I.U[,]Q)[)O25PJ\\ZNII[ ] SLWDMHS_.LYCE4AK8D:I !:8Q!J)
M5"HC><S18=V1%]ZZH:]LX\KXKLK95](JHJ\(>B6QJV[1'X"<6[>8MNU<'>6T
M+B:<**2DH,(@'DOB4FS T&)"X<-:5-<HYR6/]1%=!EV0^'3C/?;?(XD[[7%I
M/,WJXH^=)]$\ D<K/!>(OBR.V?WDBQY?&"#OR,DL][@^L='(1<T1-47Y,[C-
M3/(PT&;#E)KHBRRB?SMEAX@%"RA\^0OL:CI3K-DU$Y'$<:JU!#.((2M(HF(K
M3,)2SA#>/(SHA FQZ2U+ESC8[5'QMW4"S\:[#C""I^9D1]P;[K0WLA5M-N7!
M'K/&[@I/?DLD=1.(;@(T- (A\R^@ND"A+T+6)6QJ1D*1_=/_;:/<#F289CB*
M1HT"L<FPBB_4Q.V)53X^YJ,_ >?&=O"TB72G"&_SSYFV[93\VZAZ3R"6XO?1
M6 Z:W[\:%>/?1N/_MD @>O1IZ/?4G"G6S%L7&'OW+":$4NDDYU@8+I03-O5D
M>P8%8X%,X7P$8JUU.B#]Q_>17&:]>9W]"G_]<Y(5(.BCHH2HY]C U#PBK$W-
M/=I!E$SUS2BO+OG?-4M<.8E%@@4V%%-J8B&<0XRDSFN ,69ME00'S\HEMV3%
M^,7;R$L]OT<Y? KDH,>%)X.:>("6LF)*)R,XD$!=VYT(_!)NFI./MR=4+T@G
M%D8O2H6BG?;(3CGA[^U0#R9>^<F& 7?.V0[+<-]Z@L8\U89*0I2T5"N>@CJC
M"-7D,MIAE20U,U<ZZIZEH*R)/RL*P*$5I^/;A93QP7>NL=< [+\!;C7+$ P@
M'C [A@RCB54B5I3JV'%.$BM02WO&:FQE V!HRVA@8', MB\C8-=V^.SG\9?1
M"FC5,R0#C *+^X^1/\KH/V^C-]: %>S<3?2WVU]N;Z+W]_"?&7@GCW"?9X,@
M^D?9<.Q1+@)-H &]__T7CE'Z8Q&]NL^LBU[_:?5DG'VVT3OG@"?F(4/A?6X+
M/\E[O(U6>H31K-VY3*<9LV0Z8W;WJ;"; ;3@$!H G@<WPOVTK^-X]%B/5ZRN
MU*Z$$B#U$,5?/KY_\Q[4C)>YE7_<P3_SOJ=-4U!V/HC%]Y9T5;YX#E [/)G[
M7<[U.QAZ*AG4/_(/G%Y;L8)G/[]Y@=/Z&*H#6 6)1[CMA?(0>R$=P.&'2 Z^
MR*=B!5@7W7D_W>?UDRH_8N7YB;V79^5I!A_0PF&&:\WIF-%]!8+0(:-5B"V[
MD>:QL8&!JP#0.H^SWO-_6*"$?&G3@11D=)][+O>7W^]>_OJZ[<@7C[0ZO0RT
MT4Q[1T7(<0+]RA>#^59OTS.3/[>/TV[9RM*UQ2M+G[NSCTYCETEZ2B7EEWPF
M!H*95\M2"50S_.<$7NNRVI2L98GV^K"7M/,VX3D5'"682D6BXS2UU.A$$:X2
MA3F7.HDIVKG!EH==6 G81O^GAL(QM!U\D^!5VHX'1[#UP7A_& VK0_C>RU\O
M>''\HU_FB[#.J%Q7N(Y^?%X:.$M?SQ\Q2/,P;+'T_%6)A&#(A"F,UA^^UQ?\
MZ_1@5/@#+[\J39SY58U*)?>W__[X>D9;=\'FDO5O[)_ZWI]V_>/@5(2'A07=
M@LX0KE;;#D@&JU1/X>K25FZVP;<N1:GA'Q_B@ U_\!RU )3S4@\87+,=MT3(
M4*I2XBBE0BN*X%DQU@RE0K>F2AP X_Y1+2S<LH*DPF-AF_K>OAO:-DRE[8[&
M%W@]JK(E'/T.)-!@$-)1ZT,=#>V+H'W+X1 TP;R0^5-#92_/.)QX./^;H"+.
MV]85!LP>#194,5'>/S7.Y& EJYDV]]N1S=0:_M_@P.X'3V^'\*;!('03?3/*
M*XB_<]-BY/" )O>)J9$^PH50:BCC1)DDUE()G:2*8K:SO[@#]T';9=,LVEK)
M,MLI"?^AA 6 ?@8,?TR@U7B]YR8J1M%@Y&5 $36%R.RH031\!K6_J&7@:%),
M?2456ZEML/$]*"6?[D>3<84) _O9(\CG$O0!48[KTNXTQY[P15%MLN)Q()\\
M0.W4(3)=^":9'BYF0V\J_1"19*H([6;N[&ISG,1?TVE^/1%G586 DD8-?0@D
M9:"DH;:53_VB-"3@,YB(1"#B))4<<2N(8\B(Q,7&T+:>@VMYU/L9.&I6]<]C
M*DI,I)W5I+]E ^ D0).M6M+BMP=3D@ZK()62,@,VW(C#9BNCJ%V%X6J,:HN4
M,HX5B[%QU'+*C).")5PCI30#M!)MF1W'PJI.81EZ S;"33KKWC$+H:[ #:^4
MN(E70H)J$IQD_JQ<EA?CV<G"MO4DSRULI%9A_W[[$3C,:%36[?R23SY%=^8!
M-(IBG)?\='Q?HEL^>AP5P7,<)."G\ML'^>2_TA:^<:/!8/2E#$1\SH"O 9;(
MJ3QUL.J%NP%-A_ SX]\*3 DLZHJ%>V8U'%I=[6Y\7Z["+_A7P&,?_KC[E-N
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M2I,(SI+$:XN,$8I2?%PS^+(R3"Z,F*_+/3&WN80=G-'NJ?_J.@QQCQ*23DV
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M6:7-A'W?B$!.NRIMT*FF.-5P_S9:1C1'H5*FA96(<@6V .,@IPE6*=+<)@E
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MM_-V;ABVTUHV/&ZR[>,?TTKJF1U3.11]5D[ E4A3;+1#C,;,<:DL)JD4(J9
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MM<_A%R W;'ML\P? 7U.B339>CU:+^&.+-@R:C+,*@^Z =G*O7PV>;L+-P$Q
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MUV/B!V]4R>?.H[PW!/&&(+Q)J7'//U3?>4EQ@3<I!^^10QV;US&O]_"728P
MC[[YRY[S=%(VW;M7.GT?5LL+&08,O)QN+J*[OCY7R)40+TX3P*\Q\6B64,YI
M$$=9F+J,,IZ.D&XG)9(>*][R[RL1=IP,F[$WX=;,2 E7G;!JIY+!Z,-6'YI#
M/XMRT8YC/<_W_81D$9%@V"B)/!H15PH6)53PD8)#951%.OT9YNUGUK)-66?6
MJOR' Q=8WU1]"B(<AK1Q*W>#"1B3*U^/)&AT/966B:CN+@GS,R3?A]1#QQ,D
MX1%)LS1R/1DR+N+TEU]E_DT<P3F/8$8=W;"YU'5@%IC(LEAHV6*,-^&F<@SG
ME$S @V+<7L+P-<>WF0P]B'!E$(78D9C%A#(_"43@>Z'TV$[*R,];&Z8%MW1J
M<#MK^U#=GF%GF<3/&B>7!S1,1<2$SVCD^4E&4R^,W#B08>J'(WK[?_=]"*-0
M7JRLVGPSD>Y7SOQ&AAPBL2GX;;<"Q?U8J3]-SOQO+FA.;A$T?U1)\Y<K:KZW
MK/GS"9N/2YOO(7C^VA>K20P0;Z _<Z#!YD<E,;HT9:%(F>ZZW3A<;U.X$3'7
MW[+L,".AV65W _[-53,4O)3JC =QK*5MSQPM=-,CBZ\V)4)SA:)L^Y?6M?%H
MI<2S*L4*<V-*F"''O%?W<K5^CJ:%XTFN/IQAE@O%?$JM@.4%<!/;JFN!;B0C
M50OC.G!0;5QT\:IS*;"W#K+,?@<+PP =_5OK;.)M:-2.PGEL+BP*V8'_M51H
MH[BJ6,BUG7<=9)"@U@^KT:B-N$:R<?:$O2CFN/OXGT?-C7*V6N.O6CM"@DNM
M56'P#?N&LB$P3#NL#VAMSE0'*MNK$+5H5A"0K5 ; W\NJBI7F4MIK6:,/H:L
M;<4 ZA$J-=>6& Y&7C"%,"%J+Z::,AE%#I;>Y.*;R/9 @8^U1DWB&GD#^9F7
ML1P];6W27G:>Q!RZO</?H53I7>I&65H.!Q:P5#SY:$QBXPS[++UY_9T6FV+G
M0>.: T5 YTOG7PR,6FX=8E#'$ (UDMR+U5RLE>Q&V9XQ$F=,IYJ@GE!-_1 >
M7>9J)_3VG?I+>*V6<+3J@'>RS"ZUY.!94=5%(!=6R^T#JILO\>,VZ9\D(:="
M^%3&-':C)!#4=8D?TX# GT>D#'S7<XG958:?]MB^\>C$0@WE'\.=^$9YY-U3
M6.U"]1<<2HS(5,H@ R-2PFDH0QXE+$@H)VE&>1R,R#@]G@DG"I($9%R0! NB
MP,I?M9,RV[</)A<6M=5 K#\-#.!&=EFS6;X<@>& IC3V4LBO&:]:"T4W%%3K
M5E< A8LY8K!J../JZ=.^#54J\TWOAR/\/"VPI0.JR^4E/$115C.M> L84 GA
MMRZE=';7""G5&J:.;XQ21P5+0+CJSA6\M7T\M=Y;NC&J^^;CE*WP-8VH'DR<
MBKKQ0U]?#Z4[%'QE*QTPH3R_@WK7JL,EN"F.:F_=05+?NMLCP0CQJHOG=7V.
MC1/ -C"E-G:?\^/E?XY\^ !6YVO];&*9U9(_?UQ=?+S\X%RHTB3_%!;Y3;95
M+4I[\6!_-#KENY5N!%HUC0G0^A# @,<]K*X)^VYB"@9G:R?K*$*7R] -"4M"
M*K.,>5X:L43P* I3+WG:>3A),3UP=[3FQ0JQRCZHCK^:B7%D=653M,!L9)HI
MV^H&F;8YJHZ.2@C"_@=3=ZW32JJVJ3/-,#&E(G(U,CTWRS*U)((?JRNK^X+;
M/DI9=8.=2%#*6H\O!MA=+4-E^L5*WWA1UKU#<?;91\"+%ZGRB$J]-K%OJ?7#
MVK&>/PJ;J'HRD#UY&9#H!>/1232MUZ&5\DEE"4\J;-&#2_N3C\4D"M3K5$79
MR\Z3*$_W51 YMX6MP=T:&\N6D ;\KEW-N5HQ>"-I[U,O_4L!$.43X\Z7JQ/G
MTZ>S0Z.ZO:NC-'C.1O_CGKO-3%M-0="R*+[.MP",_O@O+$-HP'84:#_6MFV7
ME*LKZ]=T \&;?6713PNQ>E$PO ]L!:E<ZMJV5I]APPFDV:C.\*@_?PU @BFU
M"OR.XKV<YL4I6\\ Z:7'G5O]!"]^&)RL(V*B'Q2_U7V28^>DQ@THFJ&>IKT?
M;ZO>[08M *U\M:COHFU7A$6W]/O\! !<"-RESG4Y>G'15+^OX/3;3C-&+E.8
M13Q$#3\_C(,(NP&%2<9HEL4[Z%3!,V#$48@X<U8 X^;8AB!?</#&;@QSBY6^
MP(]%N48- #5 R'#XN%#ADF(LM7E\,LT /2<NH2$E81"[G%+?\V,O"H,LW2$@
M\F)LU)\8ZT(U]JL=[8<19MDT%M$3$TV"/6!JFVBZE\K1C%G;:@#59ZPT!6<+
MSZ*D]'N=L*S(ZG"V/+CAU6_Z B>J*UMKZ%B62D(25\GPA)$?NTD:99+X&>,N
M'VMQ]3Q#%Y+1H7NNBI]I$@RO68/AC4#0\H(IOG.P&A(OJ>)GFDC#X:HTO,WK
M!_C.I&2P?VLR^+#28CJF](,[LV*#"+,)51!@P:^;14V_-5L<HVJ.K0-WZ#FJ
M.$/'MS:J02)\G2'0"HX-8]X&-7:/?.P*MP1AG:@+3F],$O>,H7=<O]3H;^PJ
M-D9"L4"6IF*UKOI7,-?L8L=_:KTXAD;$#D_SN?U>P<'K=!NPF3//=;?I7%28
M: 0T5Y-\P%"9Z?MDCNSG)S##HP[8B6#57;1OHR]KIT(_E:2 D P]25VZ 'A9
M(L=GQUWC;G&%_40A.BPM*-]Y][I5HCF_WG V%ZC'V[KD[N? <[[+O[UW%NQK
MUYZE6)4"7<ITT,9O&ITXI!/Q?)GIN,*<NFN 'N*O4R<5 'N3'E95+LK-5')'
M:H^H5.@@?F#J1F2CT8-I>:T)4JK;M3+0U#WSZ6OF),H&<=_>MV_O6S*)AD(.
M5G7A)>%H,BGU10Y6U>!US.L]_&5:MX,WI85]Y^FD=!T9I.L.-&;YHU@C[*K6
M3".U 49CO%"$<QN/5.8O !Y;@87%D-4-@D.N<9MI(8DP>V[_4JU0!AQ_MUO%
MV48X7X58P=5-D\@-G,(@UIKUH4&K+CC&G6%-#M*Q2]7&Z7T<:'@^K*QC!0/;
M-3+^"D'%K(6/!R#=HF75E+-/Q1@/6@8$E.]EKL(CBYG1+&CLR_,O:%FQ!D>:
M-P07%:B5VE9J4'2.S(8K6]-:NQ=KZCKL=8?RHKLSXQWC::YQ-,#J<]18-H9I
ML6E&DVBU.?4]&")54YS0[:RLF]&,]^O"/LZZ *%N.JSS;#8=USP?N@9>IEA>
M%ZH&OHY_].%WN=5]O6-F8X-6>_;NXUMRC@HR-%W+E$+ N;FZ@;;)[5,I"V]N
MC6V?G[Q#)B78R2#!_C(6P9=+9""3,BDD? WD';RQWN[6DP_'I.0$&50WO@:W
M?ZN-'?&#*=XSJ#L[4#A9;X&;EN7WW@+'#SXCZ-DZ%\@?=Z[27" B.E-?,XL$
M]CF"(.BW7%P7,^<,[ =77^:LLR->?Z-'(%+;B[=>(U_DN)UX 6!Q*<KJ)E]I
M.'&/?D+()SG70&AYK:ZKI T:&H(7^(G,@IC++*:<RMB/(IFF$OZ+.*;C2E#$
MVX>&$$UBD,S\,1YVA61I0%="*,PW9US#<BE12 M[;@J=$T"\9-%6;R00.MW:
M<533EKIF1.VG<XE* '@OG7H=GH5@0IH(2>,@BF&R!30E@0@3$;/',NB(F)/2
M;_KEU]#?U452_],R3S6DUP :"Y#1YW1E+V9-N+C.ES4>%ZR<YP@;"T, -[V2
MZFJ2#MM&T=CM*=5F/V[];P!FUV48=:&#6.05EEN4.CFB_@@P%;YCU8HM^SS'
MFU[G:;Y2''4=*)ULKF&9<LRTQOY ];WF(W&#X;O7P98),[#$&("]M@4>OWVO
MW6:7=3"#=+(J\[GS )&0F0,Q6RZ'"]POOWJ!V7>H^YF\O04GO 4G)8))LJ><
MS=.&0_=+4S_.F/TL?'V*LTI-1)C4MU A\7N7\+4+45ZIE?[WHF@OMF AETHB
M/)DFE"<>YV! &LI >JXDT;@6-_&LY-XCOL?N*U$8'I-=BO#F509/:%='O9"B
MX-V.5]?,M$;4MF3<;G_832QX,\#":];ZO#2;6.8-8$[97$0M>=WUDM<#9<O!
MM/H9W]X;?IAZ3)0>,J/YT9SE?(D"F2?+9?X-8 TKV^Q?ZG%"7"9YDD:410D+
M4T*$@%%VJ2!RG/V[WWA.J]0<+=1<Z@:#K'DT:^T=+Y1ND1>^Z;#&RR33-0V;
M;;M#HS:\ZD9Y%IRH_:QEI?/ZN!ND:-7.FOT01NJPCWX,SZ+2F!+;HAVI]@%&
M9FV-W0/6HH,6%)BR3=*:HK,'@RAP!O&=S7LZFE)Z1-#4#TE*:>3R)&-)$'B"
M\8P)+_.>#D'5]<NH.FF%)GMRF$:$#OXO'<GR4LT.>/AO;+X1]WIOC[PQ!K\/
M7T83OW*;]MGS"YS1?IJT\W2M]VFC3C917\P9,8"CE<[,6\D*S>$>EFTN;_Y4
MZDNJOPV%RMJ_M7]&+^!%ME7N<+->S.&'_P-02P,$%     @ Z8B/5.CWX'"&
M"@$ ?N,& !@   !B<FAC,3 P,S8Q.#5?97@Q,"TR-BYH=&WLO>ERW,:6+OK_
M1MQWP-F]?8X84:)K'NS=.X*2*)O=F@Y)>;?OOP20(&%5 =4 BA3[Z>^:<L!0
M)$NBI#(M1^\662P F8G,-7[K6_^XK%;+?_Z__T\0_.-2JYA^@I^KM%KJ?_[C
M1_Y7/OQ?3Y\&K])(9Z6.@RK_*7A6Y"HNTOA"\S?HOQ=YM%GIK JB0JL*OKDI
MT^PB.'[QR]%IDB[AYS)X=_H6?M3!_'!XV#_L>U<_S]<W17IQ606#Q6(2/ V&
M_>'0>U#P]"F/]D<9[C_"/+X)PHLH7^;%O__MWQ+Z[V]!6=TL];__+<FSZFFB
M5NGRYJ?@_YRG*UT&;_1U<)JO5/9_>@%]T@M*7:3)SP%]NTS_1_\4#/KKZN>@
MTA^KIVJ97F0_!4N=P"?TG)^"?^O3?S__C4<3IU=FE?#'X!]X)S,&N:2X")_T
M>P'^WP%<!U/ +_W33-Z[!_UZ60197EZJ&.X@/_PMH*' '6%]=6$G>:EQQ7X*
MQNN/K0$&H8H^7!3Y)HN?-O_DSXYO^7.P4L5%FCW%R?X4J$V5VX\*?@A_%N9%
MK.%>69YI683.:71\P!_=MCBU@=%CX1&U):47=2W3#O-E#%\X_GB9ABELG/[A
M<"J+^X^P:#[[Q]W'\[=__N]_&TS[/]]U;<=ZPK@W_[S';C@_?G/TYAR.U.G;
MM__YZO<WP<GKU^_?O#W_]?CTZ-WQ^_.3YV>]X.3-\T,SL1_AMI\TE=V7I'M:
M=\_ISC?VZOCH[-A.2/[Y.J_GCTU9I<E-YRCIYY^"M(+O1O9 -1Y)8S=G^!Z+
M$9,L5&60)T%UJ8/!Y!_E9FVNN=)%E49J:89'0ZWR]<\!"$S]U!SP04U$E2NU
M7-++J"[_\2/<[5YR)U8W9M@PE/_89!IE[* 7I%EP?9E&ES2\5RJ+X6H8<1;3
M!^<Z4W!K56CZ=:U@P"!++W6ATTPEL"F"3*UTW*,K^$:%7L*L2] 5=,V[0J_2
M$L4M+$.L$YA9'(1ZF5_W@NNTNH0!J"#<I,L8%<8RCWC)\$2/)L%SM0I9!9Q5
MA=95K_ZB\3_[E5[P6I6EBBXWI:ZJ,GB"C__?_S8?#OL_/Y,'T*^#GP\.@W/X
M(XA'792P]O!$,[<XI^F%-[ %KF3Z,#=U 8^G 0<:'A'D</,"IY3D2YA+^=-7
MV,K=US97Y(Y#W+FS@ZZ#>G0* NC5<7#2.:[69QV?["R6.NY1J1!LAD@OE^5:
M1? *__UO_;_1[VL5Q^;W-/[WO_V/&@\'D^E4]6<Z'NO97.EDIN;]:1S'D^EP
M-H#+EK!#_OUO+\[>O7R5EM4YWON>5D.'G7"=QM4E_M+_X=Y&@_NO]=ZJIHCF
M3V,S/GG<:'2XP*>WI <*CGN_W,'A  R]^%Y/9.5_[^>UMV1S,W0-Z,7QRY,W
M)^<G;]^<=>TWWAT= X8/F^M6WU&T@7;<E]O.XQ:SYBZEMV69CF#_5FF>J65P
M"H?SIQT4RW$);T+AQ<'S2[#48*NBE&*I%,DG\4:C%+92/2GRE1'IZTU1;O '
M$=/K(K]*2[B?Z*JT#%YI5>K#V^1:VZCH>G&='V[]^-Y'OKY'^1#N>H1%<(3#
M_F*J9X/I:#X:C_K#^;C?'_:38;181/W%9+1%<'2.OGVPW;R*K9H?SM*VV_&E
M\6V76DDT&>&D;KG1=O5 ,NM.\VW[3BYTB<JPH*T<O%,WZ [>JA9KH^J613O.
MGP35PTV_>ZXO55HL%1A0S_/E9A6FJA>\>O7\GO.\<P"W7=HE;+K'^.[P[6'P
M+/\8S,?C_FAT[\'=_PG/\K+*,S"YC@+PU>?CI[L^Y_Z^\F?MG0[U8/[KE#T=
MZL+\I5.VW<LTVB8J.^8_F_2"V:(7S(?W<*:VG<8U2G.P:<\V847BOMQ%M[P!
M[WYGJ;^KNW6?>3P#_;.S9OS[8#+H+>;CPWX_6*.)GF6;U<_!WP?#WG0Z.1R-
MZ-,5W.<R>/+WR12^]^/IV<L#DEVH"9.T*"M6?L'O6A6D6-,, UL4TR)OKKT_
M_F.SO D&J#S)/_"N!U<"[WL#/S^%UU(\Q9_,';5Q#9^#ZMVL8&COBC32P0FX
M)A^#)\_?G1P$J\VR2M?+% -PI-)88:<P8+P5^C2#V<]E8-=K=Z7]Q5X?3"O.
M5VF6;E;!2ZUWVHC-:\%'2\'57*L;,A!R6L1-4:!#>>/,'/ HGZNESF)897H!
MZ.G:U_L^2S]A?3YG"<[5Q]WF?:K!(M1E!9YP4.'%L.? @RYYGK19TNH&-XYS
MC]6%2C/8MV:*=KXT^9<IVHN\&K PN(TI!C""1P[[@\6G;Y@'%EW/BOP#1AB_
MDK1ZZ-%+E&&7\7>'.;9'->!UC@?[<;XQQH]6WPMUL]/^?@WG6N%&+O+-Q67P
M$N8)O^J/D5Y7% 32%[!9+_,E?E[B>:XO 4A@<E=B38?=A(!?!JJJX%LZ;DMG
M#.E4^?YL<[-TO^;@A^VR=O.?0*\=O4:W;8(_OGO]M639\WP%)GVD*<WS F33
M+L,F:3.8]$@<[<7NQ>F ]WR$2GB7F?RJELMKV)8]$*15<<,_@JP&JZ$7A HW
M=;Z"'Y=Y&-Y0CND*];G"Y_2"N$BO-%S3 P^I^(";_55>X9<5">4XCSYTA#B3
M@B84Z*6^4E7.)@F,PT0A\=[T60+N\C*E."8<#!3_1B31G]\5.1@_H#HX4HMA
M77N0\.^QQF H!6 I5H#6!@4(\%^C>CRE;'0,YH,^1DO8U%<Z@$-*-XOR[$IG
M*6X95%42=Z (*@];3%-C )F1MJ<OT>BT",#)7.NHPL?HU7J9WV@,+*?955K1
M3TM.5,+T863\%(QJP)*5^V$3>:NWRZ;#8/5X-+0NIZ@)_V7T<,'+M"0)*DNZ
MI'T"_S/Q]=(/L'-TGG=$QZ8SF5QY[R"",=S_0NOXUJ7<;>&V>7ZM%Q)L]P:W
M!)XQLH/QFG?J0C^#N7S HV[#1M$2;"%\5]6ES756^=J$=N43^'.5KTRPJ&NJ
MK:?8)ZSADZ<A?O24,B4_*9(;71'[SJROW(9'0FG>H(^IWEK BS.R3^6S_L^!
M21H-=\P*^^OQM_LM\O]Z^E12^CCY-[ Q=7&J047_ #__,/SAAQ\D;?\5#Y4%
M(NQFD+B]W:L)N/,"AM8+GMT\?:6N2\YRG6Z6$FT]U1<;#L*6GA?G#J0JFV\:
MOG(#>^LF"#6XH'&:I%VB=OOY:N5+OL**[NJUD:?&(>C81)?)(^E0(+2^M);H
MVIEO6$].KO:N:"XHWP#UT)4"AWA3@AFY1A6P[8T$J$!XW4%#GJ$R 2M@<3@T
MW[\CZOTMWL YZ/WU98XAQV4.YVLGS6&OC>A:JP#RNGU@@PBO\FLX"J_TE5Z:
M_.S9!M1K<(N3^$T6!=_\ ^M0<]XY;?\?*MNHXB88#GO!8#&?TSXM=(0BEQ3H
MLSS_$ SF\]&LI3Y1(H*].T?C! PCLL!HN5F2X*=YL<X+>E#%^73:GOBE4H$L
M$"D!/V9QEY#HV21]MT#:^0G;CB<>Y\\440_UNG>41/C&8?M'N *%7H/Q"(I!
MH?78)1WX$7NQR1-X6V@V/Z>4_:Y3CMP-T!?I^68]O'\^S9.>E03IW9)@+U9E
M2WATU^6!:TAAO"]"E07_PH-ZK(I,%WR&GB]U@?FEX%]Y\0$_?"(0$KCNZ;\,
M?J06@Y"3\_[P[+ I!YYMP #<X&Y[I<!6 YD#^P]6(G+W?7_V[-69PZ6<\-N
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M1B3E225?W4;Z@2Y' 5OF2U G:0FZ B]KW%@MRQSNGN<E72B65@WF9\)T:\P
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M)95)<#T9S+W<-:>[;2&BZR&']O1'C)6T[75<,5PO6BU89S@S9([0BHH3L,E
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M7Z%0$QX8.]QCS"*1<%6AUPIT+:=^UPB0P8G:ZE]>N_K3<24;:]:"\&Q;PL/
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M*VY/VPA4E(-L*GC<$<FFX/=!\%7SEYJQC(A5"6^%^MZ&;+/9YZ:(+I7L#<^
M=]5:@2.94#%6UU>:*SVP]LOKTTGQ%HZ6J:6S@5TIR>U;HK'H@_NV9/E>[/%E
M\U^3[\4>9G-\EJ$QG\2#@1KHQ:(_'JK%8C(:#0:313R>1,DD'#X:0V/Q,(;&
MGO5C/7GS'^]/?P^>'[T_.WX1//L]./_UY/1%\ [QS?O0CG6O; Z?O9Y] +1"
MF.DEDU0#JJ8;%#W<)E%B\UZX/LVN4C8$*-K=76'N-_%I5]"ZR(BXOH[FA#02
ML^92\[C;4W(\YE[#B' 6!$X,M3&H8=#!"A..O"QT?[Z9I"2Y9:8I)D7ES"I3
MLK\WI/_C/W*F65Y[K:B;"MW^#;ZNH@YR7\3)%C9+(*0,C1QJ^[:^P6>+26]-
M9($\+<MF8A5+%Y+-<D?T4[D5_G1;VL8DV27QTRHG[\H#W7:_K]?MZ6%J*QZV
MI4^'FK^?GJN+9=8\N^HMT9;39#*:1-%"S=5X/!CV%X.%&H:#X7 >SJ+I;!ME
M8$O6=NF/P@QT!TH:IW0Z]8S1?M,.H^ZNUT[ZN,N$NT_%^&!P>%L'+;,%.S7I
MO:=%"O8AIK7EQ-S5W+!5\'%Z\LNOY\';E\'1\^?'9X[=Y]/6H4,?-S=.IT[^
MJL+ATRHS[^<YH^BT_CL)H0;@"&/ 7L8ZQW2'Q"D-\X"?228.'EV@+F"_F[U6
M<-#EHA;=W$$7:1GI.(^]"'S2M2BRVO#8<?W :77B(S%*OJ3FRN\;P^=![!)?
M4,LR[U@J>*@V34H=U9^JFJQ*W "5(2X\A2NR2&PG2Q?+;>DNXYZ+DF/RA&[W
M7M2VZ;70@^=>(\BB)X:7]$V :14W,C'#\[*4Q@D)*G>R$A!4X?Z8AV55;*+.
M[,VFU,T0@]''GN)''6QS2"TLUV'M9=P/I,[%D;+:%2D6)F,D7AJ*8GS0-Y(*
MD^P+%ELN\^@#72.#CO.<N&/J,^#.$@0H:,SW2HHT2Y48QJH23,<EMTI091#K
M$HZL$K(-C.NS76F3CIEI#'SPYRC=_'8M R,U2!:+89*$T\$XF8$QD(2+Q7@P
MF2;CQ73X>#CYI@_@,P_WK7;3-@%"57WZEV@&5),A+O%&;B+Y2\1OAEZ9*C=J
MB6 !UW\%18DCUI5\)#/]=C'EBFY"%CN*MG+@GJG&#&F<1(]3@5GTZA@MU ?-
M9>>Q]CAWCZEU1 %6\+R4$MNB)*BK>4?U?8<RZ*%89N6,;$Y-OK2\'=-N\-#&
MY$&"$-ULTSTDS4'\-FEDW1"0S:'>LH@#UX8PN),10'//]^L:<ZUG-WDKL\1E
M+<%WY!Y'S?I0F;-MU&Q?"'Y\$V"?9I<UI7'R:[ T NT]I0A0PYL*;0']$?$H
MQOH"/8O,"3D&]+=OL8[-M04H8Q^+!V+)07U\116!ZKCOCVA>6-(N9C&#K">R
ML,ITP$("-$G(X+LT1![E)DE,[^K]0.BI^7RTF"P6>J+"\5R'\T$X64QG,Q7!
M;\-9]&@TT>Q!--&> ?3883Q_&YP?G[Y>O@&U],A5T1-UP/<7 =04(^V: /%C
MY+0ZR2F*Q(/81PW!UZ'=A!Y0=%R+(M.T<O>'\VP+%V2D,G#8>I9Q%84*0DDB
M=*KJ)$.A%C9PUAND1M ?Q-;TW(0^ [F(V)N%P=Y83X28BTR/^[:2QA!TV^>R
MBX((-' &,Q,1O4T85TTB]%X7\KF5,%\SAI_HB2@#Z[A\X:$7*:G8-HC(-,SA
M^9?I1YS^U$X_7R[S:^-1<ZF%%F;?VDHT7JAL"@9UHC=K@#UT447.>(]CQ5*.
M8P?+FJ0VCSH<BC*%7;& VC-XAM\SQ/N0(9Y^SQ";S?&ERB/KPKQ>U./3>:H#
M"Z^S6!70QCV47I^H (3@\W:!?XNH;[Y(S[P5X=["=F^3]6';YMY5OM\FVGU/
M9XLGL9.DYP5NS7]+X'5GT>ZQA.VW<&_5B]5E_><)]R]G\L=Z$4]GTP19PL;@
MT\R'DX56*IJ#V=^?3L??3?Z:R;]GR-#3X[/SMZ='YR=OWSQR6_]$!#XW6TFY
M,Z(]@W%GRV!6"HV@QH8*[6S:(DXEG\]H/XINU(6AK=KU(AM)6[/@?;T.T&V5
MT KP.XR_BSQ0P:JV\2.URJ\'51WI+E6 C<9+=I:6Q9(G0_?'"$NOI8":WZKA
M3!HZ" L&EKK2L?65?&5!+0"VQ(E:5 +W74Q58C<I;(+9%33J>0H!U,$!LY66
M/DLW!XQ G93F*72]:=2#2@_UI?1V-44VV(8([<R8U:I,W'8#]]=+R#Z9M16'
M'.J;O"O-YO9;R_%#/$:^K"%I;2\B4<L-?6_"G85.="'10[^ B#9]+:+U!=1P
MMT/#1HC<.W7A5S/D)^T:-=/( T.B-,Y0ZXQ?&W'B(VW[@:0W"8;#(ZPKT=YM
MZEDNI!&GNKK$05>7O)3.>NAX9Y%.UUZ3DR8%*Z^-*7@Q2.8:.ML[X;GID<Z.
MM8\/:R[))L-Z)[?!R2"IK[<LJ"_<.H]KV2$*J$")=P(U!7!ORTJAQE3+?&EB
MFJ81/36^X A\:^6\'F]F'+41?&N+9[Y0H_ET-!L.1F,=)RJ)]'@\B?N#R6(V
M&3\>BV?Q(!;/GD%4C_YU=/KBD=LZ]E"C]T&Y+.Q8H4T3$H2B2$[>XYE&Z5TH
M@_G#9D\76=EHL.DZ.)*Q0Y6(=(9-7:/UB[VR!OR@=<8I1X85MVDGD1Q9:53B
M:;\H8XRH@6@L5<QYO302O/-BPXPHKKX9-2Q]WF@K(RZ:.-E$FL#X#=-1";Y^
MK6ZXD#D#-W!EO$2/TN*N!>1QXD(Q)H72@?;]P-#HDN;TW0UN>P&>-5,RAM4M
M!7&H7W)#DDQX8J3.V$II;/I5T7J1B<J=,TV).=HNB,2ALAP,WDJ!:TY5N+S<
M'E,&EE8B.-CF5*_4<J,]9I [BX=:>%08' R4\2$^W8S!3V_ECL/52RAQN<PC
M'JEA%^G53>P:08:S7CEK: QHX6JI;337/T9.@<DZ.S/:QE08=&7:$=UP,1<-
MPX*;_5!4<QU0A/IC6Z^7EBU(]H)C,=IR+!N; U>&^:+N5=7U9\/Y?CLD3C(;
M3L :&(S">7\\#,/%-!P/XG$\#F,=AH\(B3-_ --@M&](G$:9[(OCET?O7^TS
M'&>'G3F-I\ED-AM,HDDX#F>3Q6(XB*>SB1K,HUDX>"05W(/9X6YU590#?HA=
MV&VK;=N%]PQ823FK92ZL-R>M]8PT;B@I<0. H6CV3W_ZMJZ\N"D5H-CR@?MD
MA%+)"-6C&>A>MOJ'][H /R[J+Q_8?BP,=XHW4I'LA4GP[FQ18;\2L=%T@CP8
M"/0VX0^X^LF@WVIL2J$0 [GE\(J7]J[!J@C<NRV3?95B_\;@Z2752S.CQ4W/
MQ"38.'FI8Z+D.?X(ME]9!D_L=+5\LL*5DF9W!R9N9^Z!)A&3:>B8OVDS)NR_
M=W?I]FSGM$43N76B?O<>F6QNTE'NB5A%IK7 G+TJ\>I:+^%.%.&SD0_RA>"T
M8&D;5I[Y-VJ&DZ3UC#N.YOU1+(5>M+OMC=_WQHME$!#>]*7A>W4'L[K&Z_.3
M8.A$H!O*],.Q<21\OD\>YSD/8A8[CIW&<DO@UD<5HC%YD8%<-R2/K2K[VOH+
M+I&6"]GZMUN.3;OPK\N<//O.G.SIE:^G&[J5 ]9G$J5EX?2$+N#8K#@>2X&4
MP+5$-IZ]YV:G65U+Q]WJ1R*@I@*G'AB_*QGL"6%UNQ;X!"F/49:Z9&>FL1N;
MQ&BL$AQW@Q"HB8.TM#I!&6@K*309GP ;/'":6Y26:/36Z-:(=N=B1T+$1)V
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MO%P=]/>S!V?D\X,+"DL &H';(,A):)_"ASX7<L66ZB4^HH+<-"2^YES[AUH
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M5Z[KE6EU12VN:@VMC$/O74W>VUJEL5G8'K:A^L -(C#J+12:/9$J#@BWO:9
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M+?4$/(Q]"DKU1U:AL(6#HP;-]JS)P7]/S[X?3P]_F\[$,Y-+ZRNV,1/_?)W
M\DQ/K2_?+DZ/Q">'1/I@'N=_P#)"HR>3V>7TPCJ<BJ_E1[!LEEPWZOEP*@[/
MA9JX=7GQ;799L0+J9;7FN JPJG]\.IY\IU6Y^'8\E;]-?_MVC&W"T*<7T\LS
M^49I&A?3";9$37X[/11K+,[TX2S[L/#6]Z/C8PN)_A]PE";BKXOI['QZ(#8$
M5T'\_]2:34ZF[=JU/9Z=Y?OZ++H0C<'ST]_%MI3GGQO#E\G1\0RQY'$<M9LH
MS]KT]Z.#2SIJ^" LLC@RYJZHA:4-^/#]JUBQ"_'F\=1\TSB('VEVYQ=GOQ_-
M<*6Q-7'NB!I8EY/_PM?3@^GA%)@C.&?%>HKC 5N2O:C?RY_7X@I4']]'+M;P
MU\U]&K[G/FTZ&/_7IT_B  ?AG&>K=L%3OOJ'^/T?O=$__O&/3Y_VS\< $$B5
M(I"^^RR2EXJU6=+^)5$L4T,O+0E@)PPJ05N'G(28@MQ"QIM###C2]@,26%12
MYN>[3U@)L59FJ["90E"UM'Y@+%&X0HD+JLD(18[-=24Z)=/,*4)*&@:H>*+G
MK9<$'*U2XZL+(J $J!K\( 47&3VN[,,T3V5^K37-%B.(,Y$,8XE3:=%:<!]4
M<Y4I#D=5IU&4:-JM,O]E.]DB2Z<$?).RLPSHK^B'/,IJ[*HIZ(Q:3TL9_YA(
MJV9),6IB^^&-CS(]@-"3Y%(&:RRH =^TRK.J;TR/9:4*0Y6S9ZLFI")8]S4E
M0K>5&%0 Q">6<X4Z,XG00C3'PRI5"+#IZ/ 9M*JHO6@] ]H3:>L 0Q )4M8?
MHN>X"5I/^%%Y9,RUK(N!OT*TY'S4N%Q-E6D!BZ4VW0#IR.],VYJ!R:I8VEXN
M/H59"PH%W972(,( S1%X^@O1]-!!2U6+YQH+VBRS#)7<H0M9OWZ9\$]4OVI3
MN?N6"O'&T/GE*BL95=%;-DL"JQ=T13Z#T=K+I>!,:5:B#0+&2X>Y1>"%)1L@
M!=DC3I:Q?F(EKA$R$%[B&Y[*4GZD0X$\'!+3;\YNGP.H[/Y'5Y_=H_P1!#]4
M&*VE[3> ,UN(++FB_ >TM^H50O(>Y8E*W468\QO G8P, E[8^W+^3E5R@.2+
M$KI<INSPC!QZ&)<GAYMM)%Q!"=.&&*.Y@ZYVNFJ/RX=,G >P8GOQ\D[SP?*]
M5!5_D>3C#2J?=LD'9+="Q"DN #D\*8F%N3&0S4OX"_>EP%R)L8A9JMIV@BBD
MTN9B(0Y/<D?(W7"OO!* =LG.DA=JZHLUM[+ZR@MN$A8YRSBI>J"\IJ_K)H4?
MJQ@ 8&!".)?<;SST#(^]A1<KDA-&ML T0TCD;ZDZGRTI ]$9K-T_B"!3:6.2
M9Y346SE :>8G5#65U;5.TC4W*VMEE9>UU$ 3@[BSV!+J!PSA.G1#/#0+RH#"
M=M"I9<(<%EMJ*;Q)F5N+65>4;ID=D1PTD;(32BGS_B>D<I^?_M#< -"?7B$9
M"@"N2 _2"TOD!L&*34(F=[EP5A27CE1I3[S\:DNJ3XYVX7$VK]8D8&-;^5.=
M0-"SW#PY^*KK7I 5 4U&2"^(X21DB-0,@U#5+47S6,#3EU5?YG-ZMX93P$,D
M"*>J/CJE\(&ST,,HZZQ:UVVVL(8X]63&C;V>H!LB.L92T 8A $\! "?!XF<K
M"_0\<;^H*#UM&H)"@ZO?^$ZRCA!T$7&PJ-RG:)."/*Y4)&N5MAN63I $+,ZR
M0VM&TMHZ%$$"(G 2"VX;5FN0F7LCS]/Q)$%^#,7A$^Q<I7XKU94E>#03LOA#
M5?H8I("[>B4_ V9^CZE]"7:UT7M,[=,3)*U1@/U,4 M^B\EQA+JN4N2!EV^\
M@)K-%(+Z"&I0J<_%$#^33W($K  <ZA7H"\1P2OJ$:B#+),2 *AR@M)C$2;W!
M1'QGVDI*(HM9JO*-R"PWF<XXP?+?6N^A%6^VK9DZI&BT6M)"^5,('M1@)&]@
M[?3B-<8-5Z7]I*!7?,GRQ*A ,INS6PJ" J-,H9&61;@(@LN"%65^1UJ=>#$F
M"0NWJ%PP @R>D132\SI:)(.GS.,OP^RPT"&5FK@#U3G%.,!YR&3%AZJ"6OK4
MJ A #)#3)PCO$LB-I/Q(\))7?AK"G_(LR!,QS>Z/ML#7&N -JPI;K80>CA N
M:/!7UGDO3B!0;*6^$=0)2R]#!!T&;#%]=4W9Q1JT.Y+0%<]#I=NA+6W[+Q6@
M?Y<P$*'[Q$8LB!%,J>1?%=((7SX6,/[&TR:EL80D!;O3'AHR&EAUQ1D<M^VF
MIU#%E\ %6RE\I8!"5.]4566^6,[C.Z#.0A[^84"&G,L_C^.58?I;9?5>T&.@
MZQFC"J:+U*E68? _RJ8NC%)$R!#J!(P"+2J^$C%5*D\J>[)'3U<;K1CZ')1=
M[<9 !3N2N![S.SF&BDZ+L[H-46$/L-RS,0NLEPPG1X@39L,*602A498 24 R
M@GQ-!UMBW&DY9E7<6"% T5#<4 XI81& G("1G8D['L^K0E)A.&J%O>LXEG&^
M2O_9,%0,C*4^6M:_U[^N_OW/]:_B7R[_I1L@_\#UD+]#VZYZ*I7_KJS"ZZ2*
MPEAXE,39VV$$O\B+(=X#^E,.WSOY?#D1(RUTDEI"-+Y*V *M6!C?K'JE!L5J
M%(:A-P"^OE5C4(,F#4^Q+#*-(9H.@L6(D[3&Q$S!3N4;G]2;[*?8,7$*X>\V
M)LITAY@H4[W:R@RWX&+!C;AX _.M<%;+<=V51U<=>/$AER!TYK?NG7E"J-80
M_\G$WUQ?JTV71# ,".V78>#941.?RR*7>!E]Z^\#,_A?&E[DXXEQOS8<2"Q%
M+/KK4E.E!8#'J8*/O*1@1)(%R\$-!7DJV3TU5X&M\I,JD34C4C]K0=JHU Q%
M(_<B+E7=&9A'.!.=!519!#0;DGZO8AE=H84%0"^0$#\FO]XE4W/D.".WZ]J,
M!;;OVV-WT'&\KLMM9^P&_.T$9G?W%)C]PJH>SKY]/CF:85 91&*>??D"99/%
M_Y__1;#4A6HOTZ0* $*!I*0*.A 5-WX5HPE3_.W'/$53@QF2$TF9 GU$3(;>
M,%"3>'*C(H(H'H?$J2"6_KZL7!R&A/O2^JEU;2%8E.L^Z;K-&,H=DC:)5011
MZR:#?B4$:*X66&3DZ4C3;;0*93!X=0,E?$'*[$&9[9;H*L65HWRP0NLO*(E2
M133A#U0"CUZ!=TCV?9I/G?>P1(,&/0CL:A0,._: ]]U>UPX&GANX?L_M#'M^
MU^^/N?]F>-U^0-E[+ZP@U.3;Y=<SA+Z&$/6SB]\FIT?_7Q9&CZ'@;YSA'>FT
M&T!7M91I284<D-4<,TJ5RJ3!<K"D%)D!%4O 9,*L]%,DB+Y@!4&&J$GV YYP
M@,V.;\CFTLJ*49'E1M:I4H&9V?A*05]KC-4U#&)83A?+"XO5P""U#T+G@1 %
ML38?B_.KG1U9VE(XAM=Q@@"^4-XHMEQ0#T$GT+5--B!]F98X#IFY$-^TDM!A
MY(H$TP$BVIJ)_06D[AK7*RVR9M/_DG$A4 MQIYTQUA>%E="C4!Y!@]@5*:NY
M8$7P[Z+],KU&K1#7.[]0,@6L928QF\*".19SXK!7N4-HKF!I]\61B>=K%>)"
M,Y=PD5O6ED0.O<(ZJ]]B0L+RL=0M0A)ON!H;+D83%"GK($-U@,F=)5<L"O]7
M-T^::6Q\RDJ1O[[VA^=0&'R,Q=GIH&;PQC. N5RQY"YSP!OOF1 A^DD-$:(#
M1G('ERL<>.7_#\*Y## 4YVU"<%H7' UH2C I"S\DUX0K<:N].A: *UO51/7C
M^>G2;J&=6&V9/'KFZ=D '8W1DC2WY\Z-#CI.O]/MCH=.-[ [7>9RA]E=H83[
M0A]G#G\S8LF^P))>6/&RTS/K8GIP=@&ICF]<_KC,P??>60N^$$0V\M?%,A(2
M0B^]!CJ!'INJ2MD2&)Q"QQ\&AML@^&L7(.^!T[.' SX>=EU[-.BYXY'#!EZW
MXW&O/_9';^9*#O=T)5]8_:;)X>'T]/#;R1N_CA"T.OV)4;]IYG^6^68 89,3
MMC/G,UY$[8%^;O[7&?FLU^GUN]Z8V<P>CGO<=OW^:- =N?:@TWDSEVU/&-3]
M%U:1BC1OZ4";69-SR'.>'+]UE-N<WH!<+!7R<AK"N0\D_T.O'*@5A%QK ( !
M:)P*>X.[>,42*O6Q2A6 TC7[7_%AO$YUGFBJ\SD+6'83U9*2[A7LAH$8=@BZ
MB\EW*W*RV)V@$_Y:P1/*\"65?INIEJM8UEY15H+R2%X.,W=]>^#;_L#VO*X]
M&CINO^\$W2[WAIU.?^"]'6:^'[-?_X55Y0" C\GEMXOI6R<HD\PHDXJW@48H
MU+><JT<1'O%,P5"$$&TR3E!%_$%],_$DH7-:&M"2RS[6@()&0100L#\3'[:I
MM12?X+[9DFN:CDK)!<:@I6L>G7.8L7<3,@L"*N:R,V:='WY!S8!A! U: Y8,
M(A3R*068XL\!@$UYU&3:W@<QF&^S\QE%-6- )7YE@:LN]/A'1;[*H)LRB56\
M6*1>],US2T3>L.\+Y<,=,K]G][M=-AKUO< 7&DG@BI&^'<S_X7XHU@LKRG%Z
M9IU/+V90/=8Z/II\/CI^\:6$=H)"1B%"8Z[FRH[ET)#1*@^:29IR"3])*6$2
M.-?(0A#G.5RD66U(\JF;A2?+X/EFY4GC1=F+3%8S^M"5@#YHBRW6D S+MEJ9
ME/=1-2;3X#0N9 1^C#_7$3KO-5KL/.0!U5,GA&1S_/(AEZ4J#CB6P>0?PH]8
MUX^HM@0Q1@,*+9OL3\48M931OV7YH1#"5A" ('8DX5!,$#Y></ <MQ!/0.;Y
M4NB1F"E9BHNB:Y;=45P(2)1MF39BM7+FBN!J^2 A5FUQ5EH5+4*8;PB[W3(V
M,#/I;]BD#,V7)J4V22TCK>/.ZR2;S59+;55NS8H+4UQ"@TF"C\'0 :IGO&6N
MY5ENYDGOZ6I[B[<8OZ>KJ<.Q(P94O[,[!M0&1E_P(E5Q6L U/+H\G<YFUG<
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MD2R19K;1R&^ JY*S"Y&I:+7V0UZ9Z5*VF1AKOI^#\RC$;UM $[5P'V_EHU/
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M.1FC[@[16 F"#-A)P(40(GA/[&,DJ)F0'*]]&4$G^M9EPU2 00$F3(Y+Z"G
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M!1^*C6E$#O3)15,(K!76JKZ(XT6Z<:N4B&P84K"T+Q#M>0S5$!H(2BI(U[!
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MU@PL3V""BN<$F@2D[4<H*5K]K9."(H(O2/T&[XD^1,0JLMW3YBL-UK5WGM"
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MF&,&_$(829RN(--HF?!/2S%B@(<$($^>D.\T#WC8%M\*6A^A02]<KC#>C@-
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MV#T[>"**VFT/'H^B#MKVH-[ U7NI-OQ&E!9B.N(%9)1 8/B*"A%)U.3GIKU
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MD*+5E$P!A5(.<(,5W@.4QEQ>QY&@0$+W9_E,\-LPD08#%M$G)0@(_A,(5UJ
M@LBG'PJ1SL2N@,/HQ5%$OO,T*T6%#Q6@IK=1.#U^RO)<$;$C57VV!NU_#(/
MIC]_ZF8\98'EV"($F$#@'R& RW+,5B+^<VL&A)5ZD:/,X?PP_T_F(19R+"E>
M=S!IB?]\QEWICCXK[3FJ>!]DYD_4NJH>V<BZ0,UDJXG!#X"$)(3L[[1_:,N
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MRS">;[/SF5#*N3_]*:9Q/H-^#[\>M_/(GC5S(N,<V!P\[B. O8[?K/#X*^.
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MWT*$81#P;%>V3]YL&@Q7:H7%$%6\#\50PHY?L42IJZ82?GL=6UD]6[DV#(J
M4U$?7^VCL4*O52-]:WS(Z3KV<#1VQD.W8X]&SMAQ/&\P"CJ^S0:=H?NV^=#6
M8IUO@P_U2GSH*,AL:A_B!,.%)7A9RF5JFBQI0*;9CZ P<UFX&YB.D&4UE=+<
MJ5#2X#A>M61@!T:+0'?;2=*UU.2HOCETAC@3VIVO&=P";-Y"[@8J0Q'CV"U@
MVK2H[ E81 4/A'#HP!B# JZHGLP<]2%ED9=QWQH-M:;3TCQ)!L=%RP^[$< Y
M*NTW "27]:RPCP21A6C-.)&A1K)=+<6C WV%/G7!'6EP;B@'"2<G7,D\'F#U
M597;F2%%>-<Q>K6AW)DL,;]A;&C>H#Y:1":M?Z]_5:HG+LD:#UC:J*09#T2#
MJY1JR"9".5<G[.3SY00K#P&_N4I83I8PAY]!OZL*%#%XZL4!2+DL7F2M,19V
MF?!/*_93K-D5\-U__W/]*R[I\%_3VODJ?KW@+$JE. #RW?_?WI<VMVTL:_\5
MW+PGM^PJFL&^V#ZNHD1:Y@DEZI*4G=QO V @(:%(7H"TK?SZ=[IGL'$7)2X@
MF4HE%!=@9M#=T]/]]-. 5Q!>R0KY6;T*:?27BR45K*T"&Y-\B@"*=-H<E4!_
M$H!"I,*_;"AL?T<Z*M[C,%N_,#G1<Y7QI7\9,IR.$];(I[P,1CDM6"(D[",(
M OQ+,>0UII_<B^.%<E@]0:3E,4-,PD%.@?/K@DPRN6G.&*B<AYM=(4-]X)RQ
MS' #HS#O=JE KFL.N53/6+]<TZ<Y2^W2 0U ST<GX&R=L2*?[#-6Y'2P(C*1
M'=FGON4Z5/=4E_T90-,,60^(&RPCN#D&G_VO/?CLT^F165Q!ZGT5&EZ% CF2
M9'TP]@-V/T&C8@5U+@\S<QQG9VO(VN>#$=-! Q$8X8P=Q5Q2VOH5SMUS$CT"
MY(@C6UDVA P68\AMI3M/"J&=;JR3@3^P@ EZ)'/O#Q,/'.$-93U^BIH7L,VD
M'H>=9K*EZO#)\6C4-[A6&TP'SJI2A%^S9>_S( TZ?3"L413"OMPNPOV%=\JV
M=H!FLBT3-N^5OCG/^O T!N[Z[R8C['(,?7/=?A@_S .)SH<*3SV*!WS>4+K.
M%Q$@'[AN/)4D6@ (E[3PF(7L'6C8OK@9O /#QDR\4[57D1H?A[$F!K%DQ]1U
MUS)UVY9=S[9,C]J&0F6+&COJ [DO8[V/1K9K!5AJ/+]Y"108[&2!AZJ\#D^G
M>T.("WP/15<T+'Z(XPE)*A-%XULDU(##:NJDBV1;SJZ7U1D_ BR.2P)+]PU3
MTTU3UXA%F,OD>[IA$,\Q-?O(67X.MB$K@O.28FR$#:9UUYCNFJVWGL0\,U\H
MII@,\)">K]=:7*Q34B7<6OO1<E!;RX2I:^#("I&)[GB:K1/;\B@Q MMAYZ$E
M"@S_K'C:6Z"V?A9-X=0UEI*$<D5?EREZ"<GF>MO1&M9H:O3;H;Q>,I'NXY '
M_\4+$>*.L&JM#X$%9@6\\)Z B0'^ O8__)..Q_":OLO^XNV]2!3^Q79X+/Z-
M0R; )()@G#_QQI@YR"-U<I2 D<3#%+/57J)I08HMJB28_' EQ@G^R2/&Q1QY
MM<'T?0C"\;TH=+$S B#:.!!<% D4@>187 OG,.:A_(C3,0D2[F5K .=.<9Z#
M 64F>=V1)KF'M5(!N?3$ M;'?&$!QDJ+/:O%%X'[!IZ/*.? <"Z2,N*Q,PC9
M,R5LFH^)ZY8NJTO3[R6SFGKXE26W39#JHA*S+]C.UYDZ,X=#+\3EY#6]&/Q/
M!SH%;4RB L-\0'L8S(00$LAJHBZ3<0S)DVEA2LL$$FPL)N0254$M@S^@)F2<
M,&;D$>OPC3X[-L<>&:7U,>OUE()_,E%A;D&Z['$.H"=HG@P9?/AQ4E0")<G<
M.X<\2#A#W5GAL E Y_T@^:]/2ZBH_.?J,?MQH>9W3A '*T7R53V\+AW@MVO-
MGZ]7[@("\4_&8^+!005SO#Y^5*<>A7"PI,J*D>!AERM@&7CS5\>TUTD2'$4P
M039=1_8-7;=]5_=LV::.:Y@&D77;9I\<^0%F<*@'F(N0U\I5I>15"D;.\6[D
M59]S6ZQ2:Z'">:*BN05"+K\KORB2D(HW(@ UH^E,WDDSDWD3.HT[SMOO-<B4
MILT[VP;93@+8 ]QITCFQ#3> H.^,&:KD"]?A@V2T6( 7IXLH=N1OS!;'[)N"
MT7.Q[4Z?!IX7W:=\7(:MTCT$E6?V1L2KB<V136>M#'6*%8\36& V-2B63*4A
M#' >[O![XGE$(SJ>VA<+9*JSLUJE=RB6Y3W>'A.Z3M4<0_4U1U=46U<-8E-9
ME76JN([G>$0]\N*OX:':Z]H@?"1]B/OR%V"EW!!BMY"L U^70!W0G!A3GN,I
M875"_8_CG(&>=@CQ[X*1\X?WF57"^MPPGF#$"FN?"2>8>AP1@%BS,RT[U#1^
M/H0NT#4)("Y\XY:9/RQY/6-J#TCK71*H@:,12G6BJU;@>M VU)=M2W<45SGR
MVH[1H6K]=49JP,]MP)/$]_L.O9\4Z34)TF$"B=(\*@0F(7Y&AR",!')Y)6TU
M8H$I2V(M4W&5V8M ,"6I8X>KL:^AT\1]NAR'6J&D75+@I+>:?%A"]N#\7/+W
MF[JDJE>EVZ1P;@K*]KQAS;UX9:&[Q6OJ4Q^-XS+GK%7Z''+.]NH5 %\;,^P>
M%+EE((8Y;.X)11N&<U)8\=Q2C#P4D:3X.T@G!L-HZ@+7JV4IK<[$9R/ZBR3N
M]&RD;^"OYZ/FF*?'?&HPNJ3"H\@QQJL]$'88EW5763R>I9VKE__L)6C"!0#%
M-7 3AP(Q=-: &.;'/8,FE!(XX1P(XN+PSC)\X12"$&&#L\]F$?YP0[CA,H3A
MDD_^Z]V[VTX["/LT6]0.C>GX5_;Z5T7^]==?W[U;++&;Y/2>E;3;NFNT)*UG
M4&)HMF/KP)'!_B'4#RR96H[L>[*JZB_HV+?*;KTX9_=<]V@M5^7_UC2Z&XQN
M<T]K35\KA4R&8_H;[O3U(01KV'WB]UB74(C/^T/1H8?M48)6%:N.""04IJF!
MTHA7+D)2X91)P(J%.SRGU;J/.&DY0O850Y;B_YL0#' A-4_&FY4&;Q(JG<+
M1#R*;;[] I/M.J'[F:O%<^:)=.B<"B'_]1#+>$91*+A(!*47GAPGH-5X/7:
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MN+I+TGFEX29:(7WP? FIKG[<&P]OF6WXQN,GV(9S">8$/T]ZV"0EB<RG"&,
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MRPNAD+8-ZF(*DT+P9;H&]&>Z^[]DIC"1GIA(^KW5T^?];OE0XOQ8 !Z*[@
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MF2J! ;F:ZZ90"C<87[7!X(_4F-2HLQED.K690-J8#GQF0&TQC%7HQ1+U&;(
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ML8MP*VM9MN>MXP.Z6.@;Q17)_P%02P,$%     @ Z8B/5 [$W8CD!   /A
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MW[X-5VQ9C,M1JVZ_M;-!\5^#?P%02P,$%     @ Z8B/5(%@2G',!   .!
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M14CC"= WN8U4SP(3-'93"K,IY,"V/D'4>%\8,RKAZ+&)ZR9F<Y%CYEC9!B/
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M%IS;]IJ9/;=7K#H)KQ)7X]:)V>T5>1>*K %UU=(2$F^L@@67L[T*ZI"]8NU
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M=@>GK#@C%.R2%?*_KDRR^Z@#AM&&A[*RO&D SM#7M0NI74NZ/-DL'E-QLW%
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M*0J>I/W3FS]\7A/5@R*D.ML!1F"=\87X]';NTL]'P!]WE^#Y__)_4$L#!!0
M   ( .F(CU1"ZI?FY!8  +-6 0 4    8G1X+3(P,C$Q,C,Q7V-A;"YX;6SM
M75MSVSJ2?M^J_0]>S[/C.&=W=D[J9*;D6\I53NQRG-G=IRF:@BQ.*,)+4K*]
MOWX!\")><&F D-AT4E-S(DN-1G?C ]  &HT__O:RB@\V),TBFGPZ/'GW_O"
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M UH=QA7AS-5=#,A18J!2+*708P&F%J#YE8P0GKO*8S1?%0T/(I;&4O2)T<+
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MMCT-LBCL]%#'TF536Y?&XGV>1YMHSD"0U9&8\W^NY?>7[ M*?55]P?&ZOBL
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MRE!H6K"RL8 SK R5(!ZD6^Z^';ALBG8@!BLZ*: Y6,,5;K"J@ LU9$Z4G3L
M]:*,7'=^R:IXH2?:;#<'^;L]=R2D21C%5<[6ZMG,2EY&5N0/Y\G'BS:*8_H<
M)"&1AC#NN)8JLF%7M:!&YGYL"T7TSJ3!E:>^=8C>T8&/@(C2+O;D:PC73V /
MI.[,FTKJ\1V)6C2 K@ %L6DE2\JO)U)I)DW"/ZINVV!J)ME9D*:O"YH^!^E<
M$5G@SD!E$P"#\9U!13-3#P:1>H+M^IINC$T]"/?K>VJP#]5WY4S'#R79OT4#
M)_-RXLOJK\E\]I 1-FT9^Z0/WBK8#N,]*41[-*,KV(>)@#!9H4S#,_9WE+>Z
M<A5;#4 ZH+0&R]K24T,KW!0#\*BM!/%FHJ9/<?G3#<G$ZZMAN@[BVO.^ZP?%
M^V,('V.-#*<&U4$&\S>:&NO=>=8E"_^F?@9YL(NJXF3OJ_8Y30J)SB;R[[WV
M*T2\A6[7I8JPP4?FE40NSBN4XZ#AM,-Q4B@>;+*=#JB=BGUF@QE]<2:>5#T-
M,C)O$DA>NMEE%8.7:KHJ)MX1AAIUYPLWG23 &Z2C-DKG>4#0_J#>J.4C?RI.
M4Y@5^T<-IN% 74+5NV4E)H0+H\)N()&Q-3WRB,)>BK,0F>GZ1PEZ6[592\TF
M6.+N60TMU)U)0M3O/RTB;+I]IG3^',7\(O!5D@?)8_00EP]J5S^!U+?@H[40
MB ^*?B1K>^K//*H^UF#:Z5JVU>$^MFAH WUNV;&T%H\H'T]V1:'3Z\BVV#,_
M?XPIZ-QM8E2/^P.FQA939"]%-X)$V@$P-PN^CECGQ;HCS!L!8"2[I_T8&@1A
M)/+ 'MEE4U#LEZZ@-IQ+7G#$=#V @*>;?$G2V?R?ZRP7*>,<HN-4+"Q"W_HL
MQAM!'$ !#'4S&*HUU,"E@(:V]6O'F&$*H,C9DCE L @]!S0[<+< NA7WM]@'
MW,V[X^YA)1C"R B(CK/J B$/AU\S25Y;Q Z]!<C1HH<8.;[%7F%GQAWW!*,P
M"#=Z('K5P2<N3DZ_L 6FFX7?(GR5QMDQ4IOU(CP7A*@@OYC4VZ/TP<H"L&I6
M;Q&^0,/M&,QJ*1!N[$$4^DKYGL2:D3W$51Y*!UCKV%A 6L[F+<(98+ =0UDN
M <+@3O"ZN?XJ>109SVY)&DKR'7MB9[MSHF3W%N%M8<!][*@H)3&$?BHW?,L?
M^'\>@HS\]?\!4$L#!!0    ( .F(CU0N3,I(OUL  (Z(!@ 4    8G1X+3(P
M,C$Q,C,Q7V1E9BYX;6SMO6MSY#;2)OK]1)S_X./];+>[/;,[,_'.;NCJ5QMJ
ME592>\[[R4&Q4"J.680,DNJ6?_T"O%3QDKB#!5!B3(1'74PD,I$/@ 202/S'
M__JV2[][021/</;/[S_^^-/WWZ$LQNLD>_KG]V7^0Y3'2?+]__J?_^__\Q__
MWP\__((R1*("K;][?/WNXOR7D[M-DE+2_+O;NQ7]$WWWMQ]_8O_[[I3@:$V2
M]1/ZX0=6F%+]_@_VG\<H1]_12K/\']_RY)_?;XOB^1\?/GS]^O7'KS__B,G3
MAT\__?3QP___^?H^WJ)=]$.2Y464Q>C[[RC]/_+JQVL<1T4E<:?XMT>2M@Q^
M_K"OBTO!_O5#2_8#^^F'CY]^^/GCC]_R]?>-B.RS0B4M^;<1?:/3Q[___>\?
MJJ][4LHH$;#NJ%W1%Q_WQ%W"OU;_6A??TT;^[KNZF0E.T1W:?,?^_\O=U;[<
M(\'X]_0U2XIO/\9X]X%]_W!?/N;HCQ)EQ<4+_4]^CHHH27-:;<6K>'U&__P^
M3W;/*6I_VQ*T^>?WC\4WVFB?/G[\5#?9?^-R^F JVQTJ$H)VE-E]],)@=IM&
MF;F 8G;&4E[1_K)##]$WE-^A&&<Q[1(5.E>;,[Q[+FEWN?CVC&+Z_QW2!WRQ
MV= ?DQ?4^=5<N4FD<-$FYVB#"$%K^H^3/$=%?I*MKY/HD<I7)(XT5JW#A3ZL
M-7'& +[:['^^)?@E86.H$W44JW"AS37.\U.TP<0Y"L6<C66_+W#\^Q:G:SIG
M42M_1KM'^M?%'V52O%(8)'%2G)6[,HT8IL]P1N>V(GE,T2UI,%(QL!CEW-8_
M93N<Q/1?>5)8P=*PGBGU^HS($R*3JC2H8DIM[A!SOU!%F3_3 6M2Q?BU3:GC
M+4E>J-M(Y]NXFG]7=-(A; :>5%=YK78Z,\]OS<9JE.755'N'\H(D;(JMOE.Q
M8#HV$6<YLE3>6?6N6R$O;>TJYNE8WOMRMXO(ZVI3?5X]L]^<*R"NQ+5&ASI.
MF&]7=0G'^@BJ<*S-OU#RM*6@CNC(%3TAZN"5N[K]OE#*2TQ^(1%UE:[H[VCM
M6D^SRAVW0#VJ43>*#F+4JV#+%N< %=9AK,]IE"<Q'8C.D[1:@40DJQ9>B-"Z
M=Q1&VXA8C(-Z[(VU8,R2@DTA;*JA3EU!:T%TB4776O@U2HO7DR>"JCG&PBY&
MM4RATW5"09#3?TZLE:B>2?1"3U'Z.2H*ZBA,HQ!4@;$FY^C1PA?LE3:6X22.
M25GO'%"/P:+5>(R,)?L%X_77)$VI#:ZR9X)CE.?4 4(1B;?GU,E-\3.SD;G$
MNA48:W*-Z%B<4]B4I-JM6&U6SVR7E<*J^C3>R#B+TOBGCP8ZF5=EJ=U]29?
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M=HN%%FG?24L0>_FRW+$7H)=3;[^GWG<HQD]9\B=:7ZVI&YIL$N:1]$W7+J)
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ME_;G.)M@2@Q%A?;IPE%#  D2X8K#<,"/BL:1ZQHJ'B'/_3B %'KWTT+2P0K
M579DZC_@'2)W**T\BWR;/,.K! 7*-C>RB-*3:V<Z6&$=Q14!!%58Y4\6513&
M&/9 HC5B4L,8X7UNVF?\>7YHD*AH"8$Q=\^ORFGDL^L0>4]6=Y51#=!]$175
M.?]IE$99C.ZW"+%+1X?\(E1F%B)0$D2']5J!*/V%X/(YIRS2DJ4N9S28/9+'
MGH"AKGW=-Z^'L1%-%_!0<P.]H];L:ENBBRPX-YZ HE$<I/ TLO@P/U9II.[
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MOJ&X9.'5J\TFB1$YR=:W!+$ HZR L_H[9-F&/3MAZ<LEX8\3>)+6XN&N\RR
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M^<7E4+0ILH_QA;C%>7$;49^Q.$<Q98/^"T5DE0W#ALP92"'*9_!^4*K8B)Z
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M7.E^(3CGO3.M5TC6#H-"GGJQAEVQ80MT^[.\NNJL6[&:,.9_L;1:&-+"SIO
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M0M7HSZ4*V/!JFJE:ELO-,F@0?GD0?:WK:Y]/YAA/2M>^-,BG"]B JMJIFE#
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MLC.8V57U4YG@!;S"N.8/"BAZS4M$*3*\_X0^<KORC"]-Z\-ES<5 6,E]G*"
M][B;5QQ L[<M$(2SMRD4IIJ]ZZ=!VUU2P6NJ,$GO0=4AB=\'VX1]%"NI)37<
M\(G5(3?+[LM)]8 N2Y9>0V@T"=4^L0.'*FS3J2FG83TNPS!FX:'[ &^B2*@X
M^VCSV$Y1TTW%Y>)R"N.!'D \<**5TO'-[=_5DED3-KC\H5R8+<?J8;E8UG8?
M>1W^+0\^H6MA>O$[N@;&#R>-XD!$.+.>B 8VNN?I7-Z)Q^:63N5<IH"I]1_/
M;7YG_V$G;/_S_P)02P,$%     @ Z8B/5._&[9W-&0$ \3X1 !0   !B='@M
M,C R,3$R,S%?;&%B+GAM;.R]:V_D.+8E^OT"]S]P:@;354!D5]EY^N!VG=,Q
MB+2=-<9DIGUM5Y][D+@8R!&TK>X(*5I2.-/]ZX>DWA(?FR^)X4PTT.4,<>_-
M"*ZU-E\B__U_?-UMT3/.\CA-_O+#R1]_^0'A9)UNXN3Q+S\<\C=1OH[C'_['
M\O_^O_[]O[QY\QM.<!85>(/N7]#%^6^KFX=X2XKFZ/KFBOR)T?_SQU_H_]"[
M+(TV6;QYQ&_>4&-2ZN^_TO^[CW*,2- D__5K'O_EAZ>BV/_Z\\]?OGSYXY>W
M?TRSQY]/?_GEY.?_[^.'V_43WD5OXB0OHF2-?T"D_*\Y^_!#NHX*5N..^=?[
M;%L[>/MS$TM8@O[K35WL#?WHS<GIF[<G?_R:;WZHJD@? X+4Q;^.RE??Z>3/
M?_[SS^QI4Y0XBB6NFZ]-?CV$RM\O2[?X!C\@^M_?;RZ%UG_^F9;X.<'%A^@>
M;TE(9EZ\[/%??LCCW7Z+Z\^>,OS ][/-LL8-_77^3'^=DW^EO\Y_;3W_;%.]
M1PJEN[2(MF[JR?R-ZSH*8U_I3ZY^6EF5/[G\E0G%\02_<B>,?:6O<1:GFXMD
MX[_BPU"N*G];1-D$4!D'L_\"_FO-J>J6?O2!_-6+B[\6.-G@31V9^I9H)PO-
MQ)9Y;GRGZY[7+<TB:3;^.CGQRCP^1/D]<TLRX6,4[8G[TY.?\;;(ZT_>T$_>
M_')2Y8W_6GW\OU=?HFQS1\*LOL9Y'8%]N;_\P'U6Q 7]3H-G/_>_ +7O?84,
MY^DA6^-!!&XM_O?V?JOU _;:OZR>S/%N2\+3;@-.WOQ^^P.*-[+R2_81HI^A
MS_33___??VZ_POAKK[)^XT79NJX;^5/Q?:H2/Z]3DE'WQ9O>5WO(TIVH45+
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ML5VRW28HJ@:D.)2Y&D73IIJM,.()WV1 $IE?G]C14F5(DI>',D;/23O)]]J
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MH=5AR5\T\(*5;&)_%ZN)*/&MJ%5HTW:0;UD?G"Z:CH3/]_F(9M>!A4>;)\M
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MJD:W;.?X99X?\$8L;+Q28WGKEW*'\*Y?]YU\40@@UD>6->#9[OQ%M34?Q:Q
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MB%-$0K?2.8%D*)W83M_ZMS3=?(FW6Y+,+I."8"J^W^)J;V#U"#1/H.%'.I4
M\N-EW B([#??&-5%?P@*];ULG^;H#7JLG@4C!H;@4PY@-7$ &>("7*I'P>!Z
MS<D.SQ,O&K7P1@SI],UOWUG"QT-H- DP%5]G=.6Y>+DFN"U(]2_^<8CW.^GD
MD8ZU-.U*K+W(B3#>9"E650-]_9![7+Z/OQ+%".Q=)2T *44!U*H0)1 Z4O-?
M48?IT>PY)2IC.P:R-/W5EN0O:LL.ZFJLOT70:^4_7Z@/)=?A_-TACQ.<TQV
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MA;Y138*0IMO&K<4#.??W%:"[*<O%]<"3%P"XU\.1>_W6/QF<J$@?+1!Y>+Q
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MR1*)];(I@+HET.>R3 @]3$5K#QFC;A8.:_A&(^;(?/N%E-O>@3R.!9Y.OBE
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M2]2LX)6PI</8I_LE"6$,*0L$5DOV@%Y-1I_,C'M)FZ7@'WF ]''A'L1%OOP
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MH9X7%WEU<<EENKF)HX<XB8L8Y]PKXXVA/P.5/G!N0-+!/!U(>\*X/<BFF?E
M.(VK>ZHM9M=GLP6;Z[2H_BG$-5<A48&H)1&5(L\0MU!$_>>'O(AWO#(*.[V)
M^%;GS#<2AC(6J6<%1ZC*S8(HDOM<P'=8@@.6;QKUZNCS\H[#ROHNT6405?*X
M$U@5;$0*VKB L6J(=EI$L?#J>_$MNPAHD6%M&$-1![S! *D-A4&U:H+D &^W
M!.\MZO"\PUN2E35Y[J/O[^G_:*"QIN_TD?X>/Z:&#MI+VL '.TH#<[-.^N$K
M)H"TQ\QCNFM8W9 \1P^<LZQFA2CO<H)3/VA*O9XW/E2.S4FPW'=YM'%^.X(K
M=@#3EL!&Q H;E%)88%%:T<"FSE EC,\G2W'H3RX0,8F(BYRY$/(R34^5(K H
MVYNWF$'=_O=XB[.,S3R_E_/3SKS4,"9PDC*(!2RE@/DN*[T!QWZ7=IBY*WO)
MJXJ%>:-J$2OJKETMQ?>XH4_J<YRAH'(U5@+E+L:A3?.91H#AW*D-@>RB-WP;
M&,F"Q^PY[69TC)[#<!8R)G_8;C%;4F@"BB]1@=F2<KJF;><K$X8#L[NHP>CL
M(@K,#]DK#SA..S?&S"DYBE]U*9A[8DM9![:15)>$;<_:F='4NA8YG_= K]1+
M^:%(Y:GLI<K=E6OK9C:R ".^>T-"6EAO[)>9#F)R4,\0EQL +,.^1D.!>0UL
M(4$!\^4DQ6F15XL.M/W,KZ<Y?H=3O(T+PYC 6=(@)'"0!.:LK'6'V?YT;8:9
MHW*3OFHYI+N,/,?Y_*<H - G=3E>,% Y'&NA<G_CV+8E>)O+M(@W<7)@WO(K
M7A\R/F/Z\'V='#9X\Y'VJ8@MN<^DGK6\D^@.9WPC==P)02L8^"8X!6 N"ZI)
M83P9<.O,'!RHTE6+EJ_.,,%TTO,9%XAO7>YQALHSEIQ]*3X1W!BDKC($_%0>
M%$J7W+'"OLDB_.UZG1VPP\Z+*>/0/XXRPOF]$54!EVH,51LZ*Q-AJY(*E0/]
M8A93C)$B=QX6?:AT"B,R%,9NI'E2L 98\C!5"X?4WG)&!=OCV+H(#^;158EP
M:%[(BH/O*,O>*UC\WQ8.'OL+X8N)^UESEAGSMUHV3;Q?*^SZKI94U(A%E5S$
MW ?JS0[JRXBI<#$=*/W=<IP<I(T$F1+TD1EJ.L"'H2!3@>8-EN!RWQWR.,6Y
M."24Q_QPYKN7UK_T3M6.?> V3=G!'*.9PC"NSTJWF7.S$-EQ7Q4?:C.>H8>7
M]@]+<TZ66).Z'_O^5SD8,TER%V+3BB4XB?=QOB=YE/R6D<,^OTZ9JZ,^C?[,
MRO+'*0TO;_=87)Z5BW7GK]3_B>*.$<7Q&G]]PKBX3#>7FPU_PRAAW G)#]1V
M#=(]IV[!,%5TNA; Y=)-U>8P#G/JYAMF\$W:JI50)QSR>UQ$<;*8]9WIC5*>
M"3@'RI5)A%,U1I& ..VW6,+@=)<1^D;%RQUM/6OW!SJ*[MG[Z"-7,[;!,##&
M!N:[]8K".%PCG69>TD#4JJ(Y0YR*YS'7=$N+/@WQ(O50YGVI<BMZ"7)?8*)U
M"08LKQ;4J@^>EP7"!P72]!8.)->P>)B%W, UQ(Q;,F4I,=M&^504L]/5F1AS
MXO(V@K9(U);)YLEMPE(NXH*7YK>@K,"B))D3 .TJDQFKL"E09MGN1?A.5A+B
MW<M5$N7YB#=440[]VY 2SF/U90?R00HUAEY%RMWU$^*J^!?$B19G\\J^EENQ
MKE.4=MEG4EB:7/:,MH,?F3%_P7N2L8M%+A]R?O%>WW!&R"JK49+YFHQ",*B]
MZ'5HC47'NBJ?HOHQ^K,BF-M&QKJ5V'5!SSH4'!W3T$I=CEW<D21>OXC_*M=G
M;7@4%J/@ 38?J1;X+# +K3;6I98S-+5EV9<>$1IC&^TPO>5)V75FJ-$W%13A
M<KQL-(+@\%P"Q#,D"-&?Y?^7D]05'*2J5*Y@*)TW@0MGK*#H75:>?N<QWR?,
M[OX8#!BCE/4PH:'TMDBE;-CP:DR-WO;TW"M!@"Y135+.2OX45+,;V7A7$^L^
MZ=N3DJEK12.RP^()^-*P<64>L#IOX>KJL#LD$<]PNR+I,Z8>B$WS7@/<E/X;
M F\S^VIV@0S]C%<D+_+!9>SRI[5/[CWUMIN./%C?*Q.M-XPAQZK^D>]-4=O<
MQ2E?*OPYPPDOF+YFU'-#7]YIQ.A+]Q'>(>RB6B)CYINP=4NXJA7<\@:*VT.1
M%[17:5157:Y4WJU4WOZ-[[)XC;^0)-F2C#'V;66V!K3OT)ZX 1 7;$_:9%"G
M,E?K1Z_FGKY1]8UDJ+J1K")'G)Z??"USW)>R]C>?P?9O]Y[-!"17?T_:EL&]
MX#-\B>,=L\3]?M?I';^1][>,Y#GPH*31 #3J2#7,/*Q(VK2D<4/=O) #@TKK
MJKE#5UP;3<0E;!'CS=$C8\-+NBXZH$D ^O41#,(Z;HDR2,^L?)=EVCGP DVX
M1LY@[N?_MOKMS:*#H.T43'K>M2S7=V*9L,7+=4JG)0>>[75;/.'L_BE*R[?]
MS-8[<PKZ7F#)O\+[J,#LGCQ^31Z++C_"K@^$;9UO&!>J=7,-#6'>9Q'A8]!7
M"S(6!6SQ<,&BN>NR?2#_V!<K GL/B/$QO,D!#:UA&@HR+(?\AD<XHM.W%>\]
M_"[-*I&8N$(-TPXJ?<=>*Y5S#:@6C5S$*&G?WB!#GVTS5F+W_<"N@T2D(3F!
M:9J+94&,2X[(!1IL++2#C"#6;[NX88&?QV%;TD_X-L7RA#-[3KV3EG.&\;4R
M7? YR]:Z'=R?4MKJ#W9M'?5:K$)6BG]^P5&&+M,TIL%*'F4O2\DN<H#1N$<:
MZU\CQR(38N ?U+JGQ3)<TK.]7D @L[PYV8G0Q@V?H9(/4<97"6N[A4]@7"]P
MH=)HJ#(:E0(9[41CC?.PTHJ#2[M;MYXNT;3,K<AV'!@WC8#>?0)'[NZS3=TS
MC8?74?Y45=$^?OA8^5LS_"S0BQK,=&[B%%\7> >6+#,0Z+NPTQ(XU[)-W81%
M+,KT6Q-DR:6KI.,A5+4_1DI_,(F(BUQF9.<";8B5%2FX@-9-:MD@JR*]EB[8
MVRE+E$AW['49DK9N$5ZSJ?^$U!S:T<*U=:HUGX!M]_+?P*WI)#1M2))$F;BH
MB:^:+WW1/(#QV7CX,*BV' K@&F$U9D"_^W%YH- K=2';O2#W<VX6:.J+S)VA
M4O<9$MH1=65"_QD:.9GSYM]FL)G7Z.".<[&@3HNYS//#3KQW=9G]^_@YWN!T
MPRYQAEI+L-7GN]1@KF^NE0C3%BYBH<*RL4'6,:S:L*I^02\Q3C8+'PW K 9B
M%<,%F$"+'*:J0=9 [-[S"'T\8/+D I/^%YCI?Q+I_;;CS9Y'21_239#38O O
MMO2,?HLT_C/T021#/H@[+8YSJ6=*7[&PO/YE)_,O+8-_WL.UP"]BM<XD?.S7
M(LJ*8_"RP0[Q@K?3U,^^PX]QFKZYVN-VM=!GDD_<UP*4OEO(FUS,OH 2X(6.
MP<-> .2;G"'1*-1J%>+-0@5M5[-'4#=-LCG FX=8^UH>_LU;+]E;7[QY:\O/
M==)K5+.6H)BUPL21%9 XWOH0BRO_,*CNT#JSB+Y0DBQFJ]5EB>K?^2'9/QD3
M*KF.-3_3SS*G'<R64IQAOMH+IU!:H;D'^#><TF&V?1VPZO*L*73Y#C-FNN8:
M54Q:-WU>*$!K@PP<QOH[I\4ZDZZC+_QC93L0 X$M1('\OHE:$#=O_GY+=Q+3
MI6Y"M'16#V&8GCFR+M-H0Z4ZU-+WYFO"(_U4G<UQ)E6.1LS:S-(9LVX<VQ5\
M"<2Z78M=';%\D^-8.'%[J7G65%S:>MQ'J";W!I,LNW@8TE0K,I9-G&:QQNF[
MG>(87*]:P=;)=-4[W3;"W!4S;5OJEHBZA"2I\&4TG=K2WCU0I33QD>UH2VHZ
M&^&T.P;!BFO:-F'B?0)-F<U%>R&'7,WY\^&[S5^,%SKON2%)!ON;#YH'W:_-
M"1U%?F/3W&-*8NRV>C'.9ZYT1-&"-X<VL:&\-H=VG"F LG.XE^GF$RZ>R(8D
MY/$%.O_"7F.(<@0JC4LJ2"!OXR)6IZV;.UE1 DTK5I0,9YP*_<Z&%AKNOL<%
MSG8QGXJW3A^1;9G65]H[JA:CCWY;U<'\0M4U&,=WP,H&<N7!:AOHWO4(APW+
M%>^9]E)GVBI=\,RFV]#E)/>Y-7P)FYG#O<H37T%1F-@,^X_S;R_.L7NX\!7<
M86/GSPQT;/12W M,OJ#APDF_UN.;&YO41EZ7'SO13,,_^-+0Y,&O7&WPX+>O
M=K%#4[>A1Q3\2AL^S^@D:<JJ7'@EVS+T16)I]#4$PPJ3FV044<-YJD&DVX)I
M!A'96Q^1QSF"8%C>Z*6XFTF#8:'^](/A9;FQR8/A9?BQXPR&98O=7^+\KX\9
MQM<I#9KH>X:N9:[3%V+S4*YO25N'LA8N=N-0T]C)M@V5;6B*%$9E-:N,DOZ\
MI;0HHT1'.B18FU&H3< QI ;< I2I#K8!J'[/(W3Z8L9WN^5/\\M#\42R^%\8
M;*EC3+ZO4U?+G\N)JUJT"*<]TK@@3EJK4WDA<[4"$=7T)[ *,6H-$+[9!(!
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M<<]8,$G7+*O"2*&K1(XU='+[ONC9]\,)UGV<W<2A2P[-9N+#$D*+,/%?E[*
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M2?*\XZ(ZST%0VI(8LFBO1,\X</L\JW>+O+1 VFL#&"L^M S*[4,Y SP/Y(2
M0:#"J3(UUC X/RD<:'V:#1" BI/TQ<(6%9%)MP; 13.*M9X<*P!T]2VL #!O
M/8DB*M@NR@W5D?P_ARS.-_&:31T^8=DY6S/J:N@;H_;%O5X^? QOI$]K%@82
M5IP(_2E^FGM";]CAQ*E7>I:C9^S8D8F.\.B"FQ^8Z?*$UGF%+9;9Q.E0F_"D
M(:<:KD$Q-^]$A;6/3?]OMQ_CE(99<93<D3SFZ_Z*=7 +EK9/'V6!,+T1):!K
MRN;Z1DW01,SJZO;SU]N;Z_>7]Q_>HW>7-Y>?KSZ@KW_[\.'^ZW+6<FW T3=&
MB\Z3&.0(]\ JC;0MP#*ODBC/;[=\@?;R>YRKS%%%U[?!(1V4X?4E![$VA1(C
M$Y/RKOBO;(U47++V)WNR%#-2=JK,=G3?7V$P?1:IE<CE+L T[EF*M<H>.@_[
M1E ^A$(^%Q<$[FW)1AAO&%;U;^A/_NM20-WM&1F2!]]3 5].)\5L2\("@'H3
MI_B:_JETW@."/F!;!%"@K44& 6Y?NA%XNTQM +,GB#]:"HJ'729#LO0C*]!<
MTTH1W9.T %3?;J^B_.EC0K[EXW,%)>EPCB AA9L;#(0'FA.H]!C.!>3LW3G
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M*UT6118_'(KJEH@[&IDM8I7,$1^_PN'CUV5%2"RD>Q_GZX3DAPS?X^_%.]J
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MQ^M?'LGS?]O@F&/YG_\G^_-G\2<',?WG?UV19YPIRHQ)GY4OUWOF"-9!"R!
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M#Z@ PN^>3.CH6RY^+/B6<36QMWB*V&/$GR\C]E;U(3'^X/+(N\?0#[RE\N;
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M=&V'$;,/+/>6;>J^QQQ*FC1]D^QV[*@,6?\UN -<.K\W8>C,\_4,_@F=&O'
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MF,FM2Y.+=_N,//,[O.FS%-%_T1BG>#E#^X3546:TF"K<\^L1?JS8\/<]3BD
M:826_W2&<K(MOD49/N/TA 5C**;?(WV,6=04\192IG5RX"O9O'V1>)'-S'&0
M%4B)&XBZIF["75FZN:8); (D!+)1YFL-- "Z8E#;1_'F#*5XYE-D(:&F"'!"
M8,TOO#'58A;=_'<!MA0_TAG61A7?V.CTQ1R-;NY*;\N<[6?J79/DD'/XL1_6
M8M,S9SMW=,*:'_"F],@MGWBZ.%6$/R%P.@Q^0N#T5[ HW$:C+TI_?3V>\=?I
M$/?K1&N7;"W*9MVR36^R9BGH0\UAF?1)URI;"ITFKS7_ZGUG83).:6R]$SN4
M8HVQNU191<O5A\J7O.37P8C)I+;?C1;S6;Z6:C*7;72$!F/XY;VV)B\8FNQ)
M<>(EK^@YP\UE)<\:;X";4!_C+"^JB/#R,<-\LOT)2XZ\F)"6;ZTG]3 6G6!H
MIVV@2V4HHZRKZX%SKA9!4%31HP=<?,-B^TAL#L6S.VDC$!"[SNJ:BHZKLI)Q
MR0$Q!N*+392XHHMZ8$Z"ZIE>383^%&0S^UY(%"D\+@2,_)82QJ3#;9"8:'(%
MT\6K I-B_@\!)L#-CJ^8?HZ-V:AM1-L<A-'1>MB"5C+TP&VB3&4.X[R2H3OG
M3$<R@IL!@ECVV^#$C9JM,A@#V2$1!S*,&VEQQMHY/Z'%H+58YPN+)L58#@,G
MP%E3M6Q^_X2S:(\/1;S.;^)=7."-U D;TY?O;4#O81JCTJ$=LJE"E:&8\?.]
MY92="A'[&+S.9IP^D^09;^@?*(G7.,W9#F_MH&?VQ>:X( Y=US6B4=;*D QU
MA 8@B'\VUN0%/>JG*SK4)D0EY4)\=1BT*7PV+-S\9F)&*N"F8\;JO$!WT8#N
M#-T4FU].&F6*B1DLR@"G:+IUW)LXQ=<%WO5+Y5OQ&&R4M7@"[4_4&J;<,.LK
M==FMZ,I8L7^BF/T;97A//P8+L+=Q&J5KEJ=?HCVG003+$1/11(0*MA[_"_/X
M-#"O::(,HT..Q?$LL2&'F522<?KNMER>$ZJ!#1'?XN();<@NHJ)W')$YVF#:
M!J&-E5<B&=JQF";ZCGDA?3:I%&U8[D[*$+<&NRE26)EOJ-3L)ILJ/5U3&$KP
MS;R!-F\3,=G4XT;$.1:\L^>/1X<=/G=  LY9W^,BBA.\:2U?7;+5*X<SGA"B
MRJ_G)\K#6GT4@QDQ1"-4MNTO>U6)D*22',NQ4Q"H$F#(=#V'C]C*H0 T;49;
MLIIZ/>/L@:@G7Q!M"652XT>+WNQ&!X_EV0W@C/$S+J[3-=GA&Y+GET61Q0\'
M'MW?D[N(W:1YCW=T$A%E+Q\2OG;97V-VY:_6G.WY?99D;+6!KTD[-D"Y9N,D
MCZ]9\PM2Z<A*MNR TS8NV$R/3AMS?CB*S?+$P>XZ23_FBNC<CTX$S]"WIWC]
MQ ^7M[16\\,]UXUJY7,O>#N#E #@IK=V9"NJ7DMR:\/4U@*S@.ZJ&=1.V ([
MA;Y@1#\RUI_090_N=SVHHU+ :T2\:E%^4LA[+MJ[J 1<Q'=5#PK\"P%\-AB\
M1ABK5OTGA3%@C$=C2$P_]A.-*M_C9YP0?G#Y.KW+R)K=+\9.Z_ S/'DL*2CH
MR%U^.VMN#]NUU 4=V[FI5QFNBS0>UT4[<DAYP%9EAO'Z0%P8G_YM&G'5*?3B
M*2KX%D)UUE)L-?"GXC>A!3U%SQBE!$4)=6-IQ Y[H>V!'7EGNP]</!/#*P_1
M,!*C;UE<%)A%F2R ;(65_-!](WGF"-$5Y,0;>5T?8RFH\C!.^J>U-)"XT%$O
MH(W1F/!+VYA:? S?)><9XKRHQ?S:\*V(!:<#N%\<Z* 0<CW143T@T&D,>'WW
MY?^(=OO_^[TH;9+/7,%Y>@PK L'I,.QW6M]!(=S!?4?E@ C^]=]6ETTX\_->
M4"ICH=<&;D4)@.G #5@8@!7^Q_3;,IUW/+R\W;8N Z#-Z"=H]\S%74!UV9^#
M  _3ME<'/=MQ;H'*PAT%K@0M7[3NE)&1G(M9MU2<\7 M_4?Z*7U_G_Z-_N_K
M#TALQYQQ8?@['?L2?(9^N#O_QW]\.O_U_0]-FE;.9S(BOXJZERW;W*$3&I8O
MQ4J>4@EL9D0;4SSEH@!8\1134CH3VD0O<Q_&\4 [@<!?[_Y%:UF5TW%MQ>2&
M!S+Y<5<-:W*L@%B+$=W5\_GVW37<O ;GAUXG[A5SH:F![S<C<M,)MS3NKA\6
M_A<"_J;C3+G<]3J!KYA 30U\T S[=$V2]"[*_BHS-#X>TLW-S97T!)XA=9U5
M/T+ME2:LE0V?26^B3IT@/,Z]^ER>N<.\?OWLR>AF'4VL>Z.?[ZME;#)]#>2'
M11-0NKF1'@\<\11S3L5V\O^J<^,8X1FBI LYWP0/,&5&.13"?"N^CRJ K/5N
MI,P#9Q<]G)TJJI25W*%0!3B6?]AN,:]7*7;G[Z/O7Z("?V$G^M=Q$O.Q[3U>
MLZM.*,E[O,59AC>43-2W_"-*#B)W,TG(-W:QR27?>NV!.;"6ZK[54%H\3#A0
MFZ!CE;#-5/F,D%I7EW4. %NFVL145\;"YKHR3+URU21U5IL\Z,<'G.)M7/PD
M"MW37]>CE*SPP8%1/;R@:+]/7OC=K$PWY<F+>(VV>,-N!:*3IJ@X4/M\:0O,
MZ*OS8TK[#+-_EX]^3'C*';\_J+R2B,EEU?CYNP^33S?E%ZMR#9ZKSX2BZCOQ
MQ;U-^3VY=I$$,7,$&=I-D,ELLG>';QB%U8@1]'V6Z?M (NO [9O!Z]%(OI9>
MY>Q21L04H*Z&,_2^Y2<J+9Q:Z$&U(E1K.D-"UYN; (+OJ?@)OWE.P(;!S8\"
M-W(&;\%6<9^H3NX!)%'"FY4#8>]4K!PR'YN\1$GQ4B]1JPZ\C])5.=9J.I_L
M(954N&S.,0W*9" ]XZI\WFP[+N>$ZWB?$IO/W\O=4?'463HC0D/!!6XD&E7C
MA)F+5X 953*C%V8@[U+$%%AI$3WBVVUYM\SM]G*SX?EB45(VXS;]+2-Y_C5*
M<+^0E;N ZIY%!P$^ERE9JX->^7)N@?*F)3>!JX:/'PNI&5!66N4^>N%+/#1$
M>V2\*&?,;+6IKG$\]Q:@!_P(!"!Z-SE9RZKO=7)LQ>26 '/SHK-J6!LX[QM!
MR8INMZAAKKPUNDT1YT=<P.L$ONIVQXF1[WGSHY-.N'C*73\L_B_Z^-^7^)>/
M!]UQX'7B7W5KY,3X!PP!K]-GG%/2?L@IS:TR(RZ_S1BQAP7K14.';$;:5*9I
MP+RZS#*V+"9LCU]:73Q%*5J3A+XSR<217[;%%Z^K3;>X%%M9Y\R!F"$PB&WW
M=<U,SU>9E(GTH-@#"9+,U+BC[IQ=;U)B:# /7TBJ##2J%-$+%*S\HI)Q^7 1
MB)DN=W!=O$)P*4(#*' %6O4I%7[!:TP'F0__/$3)/?F"GW%ZP/E'^J%8S'&[
M?7?(XQ3GNN4?1TF2=2!K24!S 4N](5>&W)IB,CUPD=R;)E03@DS(0)@)84C.
M2C'H$:<L78B=TF-Y1)LXWY/R["KE?RAE+VCQR!6\DLF$!XK4DPI+H;+9A5.[
MYK,L\)4FQS8$LJG!VE,U3)9"T(?*J"HYPI28)$9>R7HSH=QT86H>&X);JG)0
M'F;-RK$A@2QIL(HU/CQQ2\I+2WIXLR0Y9I9F28 1\%6]LF*X\&7.4->F&&?P
M.A@\)AZ^]H2A1O7)7R,!JZO.JE=ES%%KB:QSP=\&4^/F5^JP7<GR,L#9:ST8
MHX6X]&?_9.\8;W.2UTQ+<& "U68P5>4'R?,V)A>\H!$*=<I*"K"P\ZV48*(#
MLC*"J3X_\%V\<O IJQG @@_RRG9>%"'/#WCS_I#1(4K43/@]I>@MLIB=Z_KZ
M%-%_M$IS]=?5O&145[R[R?"YB-M%(W2<XM,(Y?7=SC)7GP\<C'2>D7,*_I>H
MU</E\="%7;/$KONKQ/%C=ANNJ5V]=W_(\D,D,J];97SG7D?S RL!PD[O'G$7
M<?7]XNYMF<-Z8*ZW]]$.;C<TY!(%K00S$MQEU:LSU!: A(2S=MW?F>?R\QJ$
M(ER;QR+\@CIGM7!QGE<3P.V"1H,=[.<E]LNQY$<Z,Q8__?2:+4 1,\YC 9"U
M,Z+UTPUMQN_[.H+]\+W Z2:_Q]FN9S]FQ%4EBQ%BG[.66M'@=25,M"F//HXS
MBUN\ZN*+M._^^OFP;Y6APYP!49^RX]5.?WBEY4X-X4=L0=([VJCEJT\H&D@/
MBG"8Z@%&:MRQS<[R4R)T4V*Z66$H"1&C/"U4J<[% \'*\Y3ZJ'S P^9&NMS!
M=5&"2^LP3PM;JM/80-@*E _6*NSY]?#PO_&ZN">]AFARP"RX)7E?1MQ F^D&
MND+F=YFK-]DU-Y5612^MS?)F5:I3R#T78JJ[10=FNYS-<AO(23;(+7&@WA,W
M$"3;!S?6/RWNP;.O+/0"(GZ09=6IEOZU ?D@Z'EM #?(GPJ+<+@\*4.%87*C
M+)0#XGR0 _7FS$UZ?BZL0V8R/45QMHO2VRT=V]^1*-O<;M_'&=5,LOSJ*<;;
M#]_Q^L!R:6ZWVWB-L\MT<T<M*=XH<YT 15;94" B?=(# !H GE$%UR9EC@&4
M"N9><NI0>*+5ACY_3*,JG7]=*JE*GSXP/>P?FTK3&:6ANNA<KU3&KB9EVOBR
MU;[2-W?6%B3N21C<];(@ *37>1)@+5V F<+DEP$V)K2!GO/2>ATS?%>982T/
M<8&HEHAN6U98"UU*0M&"K5&5$;= <_3,J@-J!6#>'6"+0AOE16F4:HL\>S-)
M:(0MWR3]+IB%:H75K;,C-R=#MBFT4?YJ,E*^V24XS)9OE\!WXY+T]S0N<L5Q
M(L7SULVVO>>>MPAVI,&?#9(KT%T".*1?7251GL>TAYJI97L9JWB*"O04Y?7=
M&@7*XL<GGBA!C7F?D6?:HQL&BY+OP#2<-2D5_"*+;RF-+Y[B/8I3&FG@G)\G
MBBA+MB?BBHNYYZ%*<!"#_AS>^M<A;5_J)Y$!C3*P2UBEDJWP=5[?(<D?+,5W
M.W6VYG)3\][VOYIT(!+VYE&I>*L^OSBA/M?<ZVG>YYZQITPD:""I4F#5Z[_6
MO7[,_:V*G*SZ&S"FN8M>UD]X_===1@K,SZC0OQZS:'=#HO3JD&62U! +EBH?
MQ(C%9Z?00 %XYH>Y3N6FH*D(GN,1U7>1)?1Q3B.@A%?CH5"I!*%&$BI%H749
M@%%*&F:MA=2YJ_388(BX]7%O']" N][\,]8T 61ADC8LE/F"E:5G:.#(J.E,
M7-"?+@I5J1<!8.B99&&H!3"SPD*C+QA9#L7='7>89Y7O.UW0J7(@ H .,E-5
MI_(S<0E#AEPFD4B;*Y1%-3HFC4<&:IT,JR<%+BI)2?KS$40F$EB96*B\SRUL
MM!%@9*9]?=-@.7R@,M0'@&*C<.5S@\]3AZ=+X.*%SX#A2U?11!',4"D 2CMQ
M3/IZT.@2T7BA$3"N$0LV;%?BPS\/<?$BW332$Y5OK2+RL!NY2.B81*M%918:
MII7X!>UJDLZ&#U["]54C/4I,OW\7\7+Z"N Z:4%  C+8Z\7;PX,.Y<U#5$)E
M&:O%OJ!0C,JNJ/ ;<]5RX898O0Y[;%R<+C848Z0K-L)736.W V/^[(XB["G*
ML>H8JKL ?;TTK0#XVC8:== CKG,++,O:C FL1NIXMR]K7+"D+'8_.&ZJI=7)
M'P^LP$59[X8G;HCG^U)TZV3YH(#:,NNDF2!47Q''$#-&U7 TLD9*X8RV8G)C
M"5D8S4 UK)F,E$3CW&?EP=9*P%*.L\Z%?+M2:,&@'Z0(VHC.X!70#/3#&@"[
M4RIG]2_7PQ.NK95DY7# CZ[=Q.F:)"FZB[*_T%6TCXLH01\/*;6@FYNK,Y3B
M5VHJ=C73@IE*^(AR6*7MW"R2U##J(T@I([Q#D*B9*&)4:[;T "I!XU5TC[U8
MK@Y<>KL>Z78C<Y;(&#%CI=;)<!TRN-.HA$'T2# G*VE[_CIP:Q>R@0%W2H\<
M/#33Z(6!;Y-674[.Z2=GI2J+*$XIFA]>T.?[S^+9$TDV]!467YH6',AV 148
MD/T2O.UT069^VVN&@?*OE2<6@<1975*Y%3.\/O J<L]#@Q<P6UTW_7 (_M5\
M!JO'P4/_H98IUXH! G^%G-4?W47@,MA7A?9'M>+K8JWZ?C:?N=N8JDKG5"@.
MOH@+$>:K!)DLV2X_R ?&J\.JK#]@)_2[TRR]0H3W*D&VT?UK0*W# JD_:J=:
M#OV,O_%'^>WVCHK 688WG.%+V>OO7KZV^MMFP=11M,F2JK7H4#,CRX9,NBSK
MUC:GR96+*OGF?[/*F^)OW>"/_K:OA)=/CB3L\[,'DWF<!PXM)GJ66HRF@DXM
M7Y YAU^-=FS45(9LN*)-)0L*;MRU< &X,_2E%62T-;S9LS40C\^@ Z[!.[1F
MHE5ZQY9-9=:]I(NO5!HUW<O!$'P":_\+,V27_8.%&#+@K.5R\[\/><&"W_R>
M7&XV?&X4)7=1O+E.R_R=#TF\BT4YZK_%%'A9O(X2D:0L@LN>MP"56?8.D$P/
M_P?2 NB9"62C5"X/3L?JLCZ@O,'K#+/\,>J[Q%\_\6SC6CS:4_GLIW691/;C
MY=WUU4_\6C\V$:G8& FU&+S;\YTD-K^A?Y,LREX0%E.?J+KI+S\D7'F$BBQ^
M?,0\@L+/+*DJRG.RCGF.&\]C8PQ]03//>F#-B@1"==>;@HBOW"A@6Y?@!T"F
M-*"M">X!Z"2F)8OU:R,-W94&7PH\0RV1J)%9'J8ISPV]F:0!P([!)OTF)V#-
M@)N5@#8IN&6R^R-;YD8'R7<9(7\E+^D/.7IJC*\\[?M#.22^F9\!E([!_"8Z
M:?B19%L<%X<,WVY_3Y]Q3@.N+\T%WXS3(E_$0II!%HF1M$![G :ZI\PX,6^.
MRX:HJ?1^=DKK$$HC@CT^E$)8B%]*.:Z="VLT&VRP6D+*?-?50+#)7JQQ^^8U
MN>#I,1;M"&AL9JDT7;.KQ*%&G@#.FXTI,+14(PN7O&/8@&E2>BP:$]#4:*AM
M.'R]V9$")4NUHXFBZ"#91#Z2#:+K!>02N;1CRJA[DDPB9TTC541.*(_(RQ(,
MO%WH+"(7)29.<"$Y1*YM"1[)3Y-!Y*[*),(_I?RA!=JQPTQ@&88<;H:PQ-0A
MGX9-9,X0B4-O5ALB56A!5@LY'^')2J)IXF^'M7P?&=4<PTV&C_-RT0@^;_!H
MA-(C.<L<UHLYV@5Y+T@2((3T_(J+N-J#N+=E#AN!"<I]M(-;!PNTA5$(YB8Y
M_SB6_6:U"%6 /(M)> :]KFK-PMO_+FPBQ8]L4U09X/HT MPTS)>^%Y33/JL]
MJ$+/6>QAHN7MZ_0FQ@=VQSB[;SK=V"Q@*WD-EJ@EO('FO --4RXSJY2[3%SE
MLA1E10:Q'\OV9/R,LI90'H=GZ=]SQX9..#.8@FJ[WWR..1!C,HM4Z)X2Z,$7
M8I5:P2!NMI@J@_=K@K3#:B<<IL.M6$K53;,FJ50-AFQ=%6B*YZ3$\SK*G]"F
M9&1]5"] 4O0]XZR('Q+<7XQ<_+(CO DX+!W"F<!$\=J7^/&IR&^W6WZ@JKG-
MA%^5;A&[&<DQB.-&Y 3R"EJM4\9W)@UQ<1?C<@W*R65<""414MJWAQV8G.4M
M$'H#UL!U&&/'W(MH19IX%(,VS65)P0-(HQ8$L2&SP%*(096<UOU2B$MZ,QFG
MX#.\S80+2D=53Q.@&C4CB.70P+4ZLM8?9?+!,/-F($ZA:7@#F:H@G^,:XPBS
M25&]2589%:HF+8P'M,ZH$S;<A]8M-59SU\W1+#6.P<VD-([_8J-"CE%UF\F6
M&S7JPM>.@UIPU$HSJO]V-$N.P:#M4J -$-L!BZS-L^XXHAL.X1.L/"YH5WEB
MJW"I=@9H%7-<.W=A$]))&6VOG9OH;IB+2<,XF6;OJV$N%.';Z5\[=V%ER\IN
M=[PWYL+ZWIB+L ';0-6TU\Y=> 5J$DG6U\Y=O [<^EX[YPC<B:Z=NY@P$I/J
MA8'O2 1&893B-:\/5==(;-_B15D^DV><) >*\>MT_<N1A%N ,/>]E,X1YA-M
M]#I$5VH^RWN]@L160RU3;M0"1%8*.:_E7B]3:]7WL]N%,V.FJM(Y%8HGO=?+
M-8Y2";*]UVN9410P7CWO]7(#[#3W>DT30*G5@L 6.GQZ#9CVO/7+#=-3K4;Q
MAW?4-)ZB'%\^9ABS4,%F64HOP61]2B4AU+1(KF_2%2MM$YQF2AJ)PS6LXBDJ
MT%/TC-$#QFD5>['B]J4OV)>"4%1).I8 S B4)A.G<9183*#DPHQF4KIV3&\A
MX=>^]+J!;<-P-4S05!)0+>*U6H#+4ED0$PBX>*96.M$JFKX!P(:@"PQ;18V5
MHP,/%V_B=$V2%-U%V5_5'0GHXR&EEG1S<W6&4EP<R7I;4.MQ68$+8CV 0>:'
M[99.'&ZWU[M]@NNPZ';[&7^[7*_9E3JL5;1IZW@?)3U;=&,NOYXMLX>_L%,%
M'5 Z:5>Y"0=AJWL:^F'.QUQ$W.'D26L'S #)RBQ&M0RTKX3,'"\Z@HSX=GW7
MR.WD5/;MHGU2G(.$A6YJX1!.@\$/-;RO!_!F=0<;3E2SOBY8*T*_J7#M%_#9
MZX.+]=QTPZ&;17@#3,M]=8)?%Z85 =E4F 8,P^ZB%W[3SNV6_K5^PC3PRT@A
MEG3I7X]9M+LA4=HS#4NN\BL9<WD8K*$.Z%#+3JW*1FVD\. JJN^>Y!FDY%!L
M$_*-WR>Y%[)XR>I2&+762AK[DXE#"94W=YZ9+9J(<U=WS=500&6G5OJF@3!(
M%&6I#P"\-&ZJJ'E%Y@J?#0,J.1!C.75T*B*D</#TBXDL%$%6?;-4"P!3&@!]
MP2T_^OG^\P\YNKN[XU[SU%&IB''"H1(PJODMBM,;DN>WZ?LXWY,\2FZW'^/O
M>'.9YWA0O\.0NOP.H]0>IC4B&SIJ,5.GLB03[M;MV(^4'/V84(:?$%LICA*,
M:)RR*7D9R99QLVNK*?O,,8DI)HAUQW7-:82Q,B,C^6&!!Q)K&.KQ@!R-+7[C
M2+NID/:^A3!.C 3UJ0%,$4; (<PO;#!0 +=V8JC, V<T.& 4#& J%W9J %-$
M!'   XP KNA\F-T8+':WZ%Q9;'!])-GE0UYDT;J?LF3.4+Z]"8.'N8R+!W/*
MYJI4]F(J8<4($:.L$B=8=I @YJL6?U;T_VM>X[%  W'JKZX)C3-75F2L)CCT
MX)RUN3X__%V4^&.U,22G,"G^_L=IHD[AN*%1%V0"1W4\QL\XQ;GE&K6/B,%4
MST8$2(QDKC#<I-"Z#>/AE*5(]?1QVPCB2XCEHLQB9HT.F!L$8FX84 5GYM*&
M$9MM2V8P >#IJ;UR:/ /)[(?>YA?]++YG*8P.A.>SA:@YLQV6B'7W7W: &T3
M%Z5-J > UPOZT=GY=* '# 2K'./;[17/,.:YJ;0UHD#29??2P*H\3\^2O&24
M7]-1AH?M.VF$#@9]&J$R?G>9/.=A&\59<T5WK,I!9ZL)R@M$ZU);U)>D)/V9
M9T_$_)(@-BF,Z)-MG%*Y_%\4XL]Q027-'%WZX9@ P:KK7IS$5?[%HRUS&!9(
MB.FE'=RDSKNG. 1W>7JI8T&]6[/K0HROV2(48>8\)N$7:#JKM5H%?,;9 U&O
M WHU MPT= ><C :7UVP:BF!T'M. #$=3&@A$R2<<Y8>,)^O>;GG][]OM[SD6
M.UF?,?W7/:;A0W&]VV?DF=-=)@GYQIK?#T[A)%:A*H1$'U_BKQ\\C 5KDM+-
M &F0A;A"--HULMG/7VY_+_>9Q3E)^E/!9;.#5I5P%%72RU"71[I+C&T!S8 $
MP6'/D_D+K_T:5#OGMUF8"!FN+8&ME47/I7%^ZADG$_8SV?[\.SO]7UKI9V&E
M0B9J"46UU#<C' '6TJW0,PR':03<UCQ@@P+;XD5CBWX#Y9L)CH!JZ28(&.Y;
MW(I>6K'-/>KB.QIQ>/@4PWO0(<-M<Y4JIV J@8?+#3&S[4-)CK*:OELQ=-F!
ML V B%,/=^W7@+FR3V,]X=$*$FA:Z/+$*0T4#4%ZJN!3!'#PZ/,+P R50*YZ
M6JCT1.'%JT>A(H:!1R%@#/)9C%6WV5V4%>4_6M4_FV5/<5,-'^.NTZNZ,.O?
MX^+I"WYF4?XGG#WBK ?[8/++;QQ OH>!@[<&.G8*U4"5[PBC3[*,V=\F:=<0
MS80 .G-C$E"116D>B8PV_KR*UW[DA0VRHOKAIW:QX5]0V7PJ&FTPC>WX29RV
MM+HJ?%0E??/"II$HXI/A-7E,XW_5!WC8^<0DCA[BA$>&Z.%0"(8-H2U@#/DA
M*7@=9*:6\N-X+]C6(M&\/.1.*5IE4-&_W;7>X=\0_S#\G P7OB=956V%,;4_
M1J.4O82MWGF]>C@_0R8P[>Z  :ZJ&EX"O</2'"9(^!ZL99.Z2CHUJ-P6-5_N
M&*I_MV2?M1,P1$GFZ]I_7O6*L)<ZD%#R9O4>^#QFL_>;"05I$MS"=+#F36K\
M=$;6V'7WMF?)Y0K=*.G-KCWP=\QV#9K.PF:P)'N/]X0V*6?9-%%"I[;E+?8?
M:%.+ET'&B@U3G91BQN2U>6:B CZUQ$*K>@_,6(@T041PTTF/8.?Y::+ RI9Z
M"R[B!X2YD"-+>;;#&G%%0G]/RX2_V;8RUS8)O(&R,&S4^0.;YU)8X/BT<:G,
M=P@#3-^L!5,]D(D)-CK]X7GQ!D]9/TX#S\ )O+=[G$5L%+RAO^*;9L'/(%5W
ME%>3E*OA!<XA4FJ:(M%V3+E-8I!>EGGR+*GDH(0)ZJSR+CL_P V$FE0@(VR,
MY_PHQ>BR>T9T3VD%P5)71[6"X5^=CEJS(<Z'6HRO"<T66:3P<(;/#-6J"YL#
M.JH:#-3JO$Z-#W]-H+;(RX0'-6ADMLZ8AO=8_/\Z+0-#D?AYF6YNBR><?2;I
MU2'+6-*GK):OIY0Z6G.4XF7A3CKA(SB?9JC-WETJC^KB4@#Z<5.*^*E=PBW#
M?-><W4@B]O5I$+<C*7[AF^(Y7E-2#G1>Q8)E!92_O32S.;8$%B4Y8;J2PP:S
M7UX08>T2*V:B955NP+>G>/V$H@SS7?D<[R-J)CAY*=LBEO"7=@>JKWD0,*SV
MO963P,9O>;1G'IL%BC>]] >P5AZ#5J;ZOC95:@JEB/(T%+<V+H7MOM2VM83*
MS//;B#).G<M(?&-79\60A:P\FQ' 6&AL^U4Z#*D&G==N&,I8=R[#"!K_FJ]+
M6G,JX]Q0:Y+&>L+'L^[KD7:27.-6]KMF;KNX"-)B:NN$@C%;-YC56NJ=#NF!
MHD"/-4=+4:IH;\$KCE/AUSB*@P8P=+0VV3JCM6(@&-,X[%;A<&??R)T*K<:A
M%31:)R@6RN.U5MY=/WZR9!LI"3ID"U"8K:]DJL*?"KVVU=>D8D3 I*NYQF=!
M[3,_2]^LM4762-TU7:^;55KK2Q@KKB;7.!&@@Q;<5"F$@/)864W.TS[?<?HP
MM2R6"8'3,"4Q99H @R!+K1!HE5>Z;-#ZF3SC)#GD;<=[^H"U+&$) 5C 4(CB
MBV2,]N4RW7R*TL.6#HI\W8&EU>W9T"_2['K(M^8KOXX%GX=-&FN!#H=L%:O,
MTD[.ZI[*B!\2OGF8DS1*V+WM]._B!1URS"NCTA\V!VJXCX1LQ.)QCK/G>(UG
M#GWL@40\^KAKH\8B*B.UU#D5@D'B'VN-(-BE$5!#SV'9X4 U"_I3,,U\X=\T
M<%4$06'QZA<&6:F"BX.LU8*@]N(-M;I>G1*U@+'0NRB/V;4U%.75$*^X!-:
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M#[HU.NXJ="S&6?JC1#G6NL/$=Y152X8<8O5:7,!"!U<.CCYB3@<LRC'5'2R
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MC <)J;7_C=.65ZZPS/(A7@N(1Q-10X$8,G:ZOOMPG;+B2B23'M=5$U21D(3
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MXH;PXIOT/0X)KS3*U5)^'.\%&_]A'[V(4S"Q*"4E=/Z"_NVN]9K_AGC94!X
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M]SAMU-G$KE-Z)=$T7'6!M%') ;$$4Q'/0(DKBLX;&#5%? 05*LE.!T2JPGH
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MK[-8)'7P2Q4JCGK3FU\ _;B$-#BSWB>6G=2[&5O'5M^-/2X[)+Q X@4C+<[
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MA>OS>51V\&&"<Y:7VK8A0-YV$;*0<^OL7[[J\"[CM^]X;%>_4<0SN]0.##'
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MY4H^(=4C&,=O=]F6#^%92/(B#7Y?IW$H>0+:XB;=<&Z\P&#_F68A+( C(=O
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M_\!_GSLNA6Y7TEU7B(P4J\2'LI@+=Q1&T47&L!\E28:JB8UO8I00):LX?2:
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M+&G %DJ_5O -B!I<]+F+& TGN.)%TZ$C!B\E!F4+F,LV$GY;!B79:\7=@/;
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M2S<]Z[KG[QF$.'7;^P^?7E^PJ$3/LC[7:NE_=J]G!2((>K9?NNE9U]U\+VF
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MHN:EHT6R7N8[D':408!(H42M:*D2[D)*76!)9$DQUM\_NP$P'I1X.O0&'@:
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M6E)=B7!P)<+!E3\XH,NBB(.KX7MY!W%P+<+!M0@'U_[@@"Z+(@ZNA^_6!^.
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MQ)TPR97A8>UMAK&I-,%VT]64[ZW2M@5L*F;BFIK*1YC+B3Q""INZF@94TY^
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MNC&!6)7*!QRO7( ?0'Z/:<0/P*WN0OV)=U$2).$ /X $ [Y=X3)P8S6 GQQ
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MV%^D,?:7R\(87? 1,/87 F,:OE7;^S[%)1(<MH)@] &W[H[RY>KTUP]B?@\
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M(<J#F(-YF6(4D/.+73:J%50V(8SYK:IQ^S??[Y7-]V+F>S'SO1A/[\6@Z?4
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MHLAW,(W^Z#U)+$'9"DYB4CJ+'GGYY'##Y3=.>*VQJ;!9!B[2UZC,_P6359
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M&!L\/I_O7LQW+^:[%Z*V^IN[;;Y[,:"=EW7WHA73N0ASM/W*W^<;%O,-"_%
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M8!VJ*V=M'/[F1B"XV17X- =HTQR4S0=BQCO(@U$M)50]A/_N[5(>;U#NLZP
MZYLB1;:IDK"R4&VO?).-;DV.9VT&S5#58/ !1N%0M4X]P#3:6X^=']7'SA&D
MK]"!T;-*80C .KM#X) 9+-+TS1TI,?WE#P55I4V,?(GFU4#_R=M)8N#LV:CB
M-(&6AS:CYJU3J=+0FE&NRLL?KQ:ZSK/5I)R$312$CV'DN@IZF/-_S?F_YOQ?
MRFTUG"EWSO_%[/HY_Q?^U$&$J?Q?3UDQI_N:TWU)C,PYW=><[FM.]V6E5YX
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MK:KM!I5488JZNEGCNN@R[N_+8L]J^] MG_A<VHU)/RJV3**TW7"6(Y <;CL
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M9C9[7<7^%_8/ELKTK_\#4$L#!!0    ( .F(CU2&&P!ZI#L  .I#   .
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MAP2CXZ\U_[[\C*HX-5/ '[*5Q+_>']A_.'BSQN[SP\.P+X2BL9OX,I*#WUA
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M%/"T6Q:_]J6>S[R(U0#=[E>MQ\7N4GO' AS;Y2SYE*N1G9^E'6E\D\(!C[6
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M^B4OTDB\<"O%2?>*'L/*$STB'H4K<)Z0SCNYM]$8ME_0YDX6@&W-W--A<V$
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M ! ! &!08'\\@+\>,'"(7_+"P,+!(_P:T(@"  >#@ "'A(""@H3\U>O]JQ\
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M? Q++(F+)S8GM/FI7JO:7"#%I]U7(B:9GF#][QR3MFZN TEMU4$?EB@&"_A
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M_]*1=,3/MW=H;MKQ^5*,Y S_ZL33]$]CBOU)="AVWN'(%1\OH6AHDDW8DW7
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M;+"&R[5Q4V^>9CKL*&!J#88CH8 >'+[8,#;D0B=%']U+VN6QPTF:^"):#8J
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M"Y<WAY*]=N"_R&QY&^[3D.Y]= B DWT^)'J$>RY-6DIR51PG:+B0 HI9A47
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M0*C?;O&P[/89$A##3-N _JI)FY']YB&D\. >C!K#[0P6MSO>LO1"-TTP8=W
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M97E@\?.C3O]]+G_)2;A"M@_/ 'G-DG[R;9*=2(?\LC)S9538J(&_B4I//VO
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M5SPP>F.:G'=/;SRSQMFDM/]&U'Q#],,0,Z$ =K43.'7X'1+P]YU  EO8WY'
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M4B3PPN+@^H .\<5B_V1H\A=9YZT?K&FW/NV:$&9"OP"E;A]X'3!XRJ@HCHI
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MV]C3;#"FA[I&T-%#?XW7/(M7_E*;ZV<T""Y$C<S54&.NVA7I>D2F^;7SC*Y
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M4$L! A0#%     @ Z8B/5&,$)MN*PP, 57(B !0              ( !
M &)R:&,Q,# S-C$X-5\Q,&LN:'1M4$L! A0#%     @ Z8B/5.CWX'"&"@$
M?N,& !@              ( !O,,# &)R:&,Q,# S-C$X-5]E>#$P+3(V+FAT
M;5!+ 0(4 Q0    ( .F(CU0@%S^%;0,  * +   7              "  7C.
M! !B<FAC,3 P,S8Q.#5?97@R,2TQ+FAT;5!+ 0(4 Q0    ( .F(CU1OOROC
M[0,  *T-   7              "  1K2! !B<FAC,3 P,S8Q.#5?97@R,RTQ
M+FAT;5!+ 0(4 Q0    ( .F(CU2[@5G:SP@  &LI   7              "
M 3S6! !B<FAC,3 P,S8Q.#5?97@S,2TQ+FAT;5!+ 0(4 Q0    ( .F(CU16
MB"R-E @  "LI   7              "  4#?! !B<FAC,3 P,S8Q.#5?97@S
M,2TR+FAT;5!+ 0(4 Q0    ( .F(CU0.Q-V(Y 0  #X0   7
M  "  0GH! !B<FAC,3 P,S8Q.#5?97@S,BTQ+FAT;5!+ 0(4 Q0    ( .F(
MCU2!8$IQS 0  #@0   7              "  2+M! !B<FAC,3 P,S8Q.#5?
M97@S,BTR+FAT;5!+ 0(4 Q0    ( .F(CU2158I:4!<  "5S   6
M      "  2/R! !B<FAC,3 P,S8Q.#5?97@T+3$N:'1M4$L! A0#%     @
MZ8B/5+28@:@6'@  96 ! !               ( !IPD% &)T>"TR,#(Q,3(S
M,2YX<V102P$"% ,4    " #IB(]40NJ7YN06  "S5@$ %
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M2P$"% ,4    " #IB(]4AAL >J0[  #J0P  #@              @ '(/P<
M:6UA9V4P,# P,RYJ<&=02P$"% ,4    " #IB(]4M<S'X$Q[   7B   #@
M            @ &8>P< :6UA9V4P,# P-"YJ<&=02P4&     !  $  H!
&$/<'

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
